<SEC-DOCUMENT>0001055726-21-000040.txt : 20210510
<SEC-HEADER>0001055726-21-000040.hdr.sgml : 20210510
<ACCEPTANCE-DATETIME>20210510155554
ACCESSION NUMBER:		0001055726-21-000040
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		76
CONFORMED PERIOD OF REPORT:	20210331
FILED AS OF DATE:		20210510
DATE AS OF CHANGE:		20210510

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			INOVIO PHARMACEUTICALS, INC.
		CENTRAL INDEX KEY:			0001055726
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		IRS NUMBER:				330969592
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-14888
		FILM NUMBER:		21906854

	BUSINESS ADDRESS:	
		STREET 1:		6769 MESA RIDGE RD.
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92121
		BUSINESS PHONE:		8584103134

	MAIL ADDRESS:	
		STREET 1:		6769 MESA RIDGE RD.
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92121

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	INOVIO BIOMEDICAL CORP
		DATE OF NAME CHANGE:	20050404

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	GENETRONICS BIOMEDICAL CORP
		DATE OF NAME CHANGE:	20011116

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	GENETRONICS BIOMEDICAL LTD
		DATE OF NAME CHANGE:	19980213
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>ino-20210331.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2021 Workiva--><!--r:e9d1bb07-ad73-4929-82ea-6e949ab8c789,g:8e741ee6-3c7b-40cd-9e55-d4abd68b099b,d:1d23d16a69484b63aa007ec686e80337--><html xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns:srt="http://fasb.org/srt/2020-01-31" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:ino="http://www.inovio.com/20210331" xmlns="http://www.w3.org/1999/xhtml" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>ino-20210331</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN180L2ZyYWc6NzRmMDA0NjcwZjM0NDcyNGE2YzY4MTZhYjExMjAyMzQvdGFibGU6MGE1Y2M4MWIwMzIzNDRkNzlkNTA3MjA4MDczNjBlN2MvdGFibGVyYW5nZTowYTVjYzgxYjAzMjM0NGQ3OWQ1MDcyMDgwNzM2MGU3Y180LTEtMS0xLTA_fed92ebf-e68f-4a7f-990a-57133a41bf9d">false</ix:nonNumeric><ix:nonNumeric contextRef="i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN180L2ZyYWc6NzRmMDA0NjcwZjM0NDcyNGE2YzY4MTZhYjExMjAyMzQvdGFibGU6MGE1Y2M4MWIwMzIzNDRkNzlkNTA3MjA4MDczNjBlN2MvdGFibGVyYW5nZTowYTVjYzgxYjAzMjM0NGQ3OWQ1MDcyMDgwNzM2MGU3Y182LTEtMS0xLTA_6196f318-c00a-445c-9fc5-8a756986437c">2021</ix:nonNumeric><ix:nonNumeric contextRef="i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN180L2ZyYWc6NzRmMDA0NjcwZjM0NDcyNGE2YzY4MTZhYjExMjAyMzQvdGFibGU6MGE1Y2M4MWIwMzIzNDRkNzlkNTA3MjA4MDczNjBlN2MvdGFibGVyYW5nZTowYTVjYzgxYjAzMjM0NGQ3OWQ1MDcyMDgwNzM2MGU3Y183LTEtMS0xLTA_926b7462-ecb7-403d-9e62-c13145629fcf">Q1</ix:nonNumeric><ix:nonNumeric contextRef="i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN180L2ZyYWc6NzRmMDA0NjcwZjM0NDcyNGE2YzY4MTZhYjExMjAyMzQvdGFibGU6MGE1Y2M4MWIwMzIzNDRkNzlkNTA3MjA4MDczNjBlN2MvdGFibGVyYW5nZTowYTVjYzgxYjAzMjM0NGQ3OWQ1MDcyMDgwNzM2MGU3Y185LTEtMS0xLTA_25a6b41d-575c-46f3-a33a-e9ab9b432b70">0001055726</ix:nonNumeric><ix:nonNumeric contextRef="i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331" format="ixt:datemonthday" name="dei:CurrentFiscalYearEndDate" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN180L2ZyYWc6NzRmMDA0NjcwZjM0NDcyNGE2YzY4MTZhYjExMjAyMzQvdGFibGU6MGE1Y2M4MWIwMzIzNDRkNzlkNTA3MjA4MDczNjBlN2MvdGFibGVyYW5nZTowYTVjYzgxYjAzMjM0NGQ3OWQ1MDcyMDgwNzM2MGU3Y18xMC0xLTEtMS0w_6f9ccae2-c86e-4b4c-a2d7-7fe6dfe60352">12/31</ix:nonNumeric><ix:nonNumeric contextRef="i9c175399baa843e28de7ed23419b160e_D20210101-20210331" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18zNy9mcmFnOmE0NTZiM2ZhOTA0ZjQ0ZjNiYTUyYzg0OWE5YTIxNGRiL3RleHRyZWdpb246YTQ1NmIzZmE5MDRmNDRmM2JhNTJjODQ5YTlhMjE0ZGJfOTk1Nw_def5a8b0-cb2d-4478-a5a4-79b9dd366f59">P2Y</ix:nonNumeric><ix:nonFraction unitRef="number" contextRef="i50447e531b3c434fb8e3ede17ab45a89_D20190219-20190301" decimals="7" name="us-gaap:DebtInstrumentConvertibleConversionRatio1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN182NC9mcmFnOjkxYjcwZjc3MGM3ZDRiNzdhZTliZDE0ZTdkMzc2NTRlL3RhYmxlOjM3NGI2NmZmOGM4NzRlZWFhNjBhM2ZkNzI4NDRjODIzL3RhYmxlcmFuZ2U6Mzc0YjY2ZmY4Yzg3NGVlYWE2MGEzZmQ3Mjg0NGM4MjNfMi0xLTEtMS0w_4d2fc008-1fa8-4e13-b781-1c928b2384bd">0.1858045</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="ia5769dc297d64d63934b48c24c6fac0a_D20200803-20200803" decimals="10" name="us-gaap:DebtInstrumentConvertibleConversionRatio1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN182NC9mcmFnOjkxYjcwZjc3MGM3ZDRiNzdhZTliZDE0ZTdkMzc2NTRlL3RhYmxlOjM3NGI2NmZmOGM4NzRlZWFhNjBhM2ZkNzI4NDRjODIzL3RhYmxlcmFuZ2U6Mzc0YjY2ZmY4Yzg3NGVlYWE2MGEzZmQ3Mjg0NGM4MjNfNS0yLTEtMS0w_281e617d-beb2-4389-8b3c-44bfb51cccd6">0.0002110595</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="i6b6ee21ba47743bcbf1e8f17210f4948_D20200803-20200803" decimals="10" name="us-gaap:DebtInstrumentConvertibleConversionRatio1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN182NC9mcmFnOjkxYjcwZjc3MGM3ZDRiNzdhZTliZDE0ZTdkMzc2NTRlL3RhYmxlOjM3NGI2NmZmOGM4NzRlZWFhNjBhM2ZkNzI4NDRjODIzL3RhYmxlcmFuZ2U6Mzc0YjY2ZmY4Yzg3NGVlYWE2MGEzZmQ3Mjg0NGM4MjNfNi0yLTEtMS0w_ca3947cc-5a44-4480-9219-98c7bc1aca8b">0.0002756873</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="i2159423bb63f4a1fbf69220efa1f3870_D20191226-20191226" decimals="10" name="us-gaap:DebtInstrumentConvertibleConversionRatio1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN182NC9mcmFnOjkxYjcwZjc3MGM3ZDRiNzdhZTliZDE0ZTdkMzc2NTRlL3RhYmxlOjM3NGI2NmZmOGM4NzRlZWFhNjBhM2ZkNzI4NDRjODIzL3RhYmxlcmFuZ2U6Mzc0YjY2ZmY4Yzg3NGVlYWE2MGEzZmQ3Mjg0NGM4MjNfNy0yLTEtMS0w_afc02c1c-2d80-4fa0-81c4-a9e42cbfa409">0.0002147766</ix:nonFraction></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="ino-20210331.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="i884c8c9ea12c402d9c05f28dee28eb3a_I20210506"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-05-06</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="ic36b9cedad7f41a6b9eb223b09b7186c_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i066bb5b0a9e84c0a878b1e800703d92b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibf1dda891fd044098c213cc6a530fa62_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:A6.50ConvertibleSeniorNotesDue2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i09cc78b6ef5244c28a45a7069619a8b5_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:A6.50ConvertibleSeniorNotesDue2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icda7d72fec364e2ea292b925ab363121_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:ConvertibleBondsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifc2893c2a85c477f8396936402f496e2_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:ConvertibleBondsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i09001f493159423f9996d4b99e003558_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2b0dec7a04644e5da0ed8efcc8dcc6e4_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2e683dd292fa4879b525cd0f84179804_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:LicensewithAffiliatedEntitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i800a1e3bd482439e9d1e93a9ff22ac27_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:LicensewithAffiliatedEntitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ica16a3607c6a4031a1fa37be362346d3_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i72f1fa77c5894104884af93e5e365e2a_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i03bccaa0abfb4733b1e2831ecde4e4e8_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="ib30ce8820d124ee6af51f2c43013f18e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia94bfbadb09f4968b33b4adabfa4233d_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ieaec7233643d498d97b1141ea9dad4c5_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i96283fe249ee4626aab2bf451b2e5efe_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic6306740b10d4a7593195541124d73d5_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5c4f0048d9644ed3b4e12718fd6404f9_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ida491abe9af7462cbd6838e5420a3bdb_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4ede063da1fe4025a2e0bc527b82ca1e_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0f5bad0d4b8641e4b0f54e165e445044_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3f929f0365a3465f8cc7dc1c57314519_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibab5fbbfe0ef465e8c296f3289e726c2_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i33c2b6d1adae4987a8b43311a9b56620_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1541412d9b3c4836ae64bd33efc16e22_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i65691acaad974fca8ed0492dec85d517_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1e99d4dac75643f384514d28d4cd004b_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1b91f37fad654b1d9c8a1e92d45461a0_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id632c5e641ae4912873249f66ba9b746_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i40ec371b74df4b3db7e8d29aaa614a0d_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3d58693671394234b39dd81063245378_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iba11ad45e728416593567d5d5ccc86c8_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib7d8df8a887e444f9147b293456ba26e_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if11b90ef299e496ebeb77cd256ffe8e4_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id25261a874ce40da9cfbcc6297ee52ac_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic68df58c3630416794b34bec56896e49_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iba0cb12c2be843b2bd24ae59f143d7a9_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieac446e98d7241d8a6a13f0e4a3044da_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i344d70813010473f9e5c16b3e01640b5_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie9701f9c982742d69bfc64ed972293c3_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia55b1d91150f431281e2f695e0515501_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i90229a4122af48d0aef6e89c51605f73_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7516614b1b654183b04111cbc3406079_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i94124ab8558d4ae989f26b588119e983_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i54cb3f5e003c480faccd9444adf9d1fe_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i63a61b36187545e5820f6cdb1e65f011_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i98369f585c4549d585af1f9094a77fd9_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic50cd4505b98463e9b947cd4aaebd07b_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ino:UnderwrittenPublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia9f4c44746fd42179d0515c760ec6715_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ino:SalesAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9c175399baa843e28de7ed23419b160e_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2f37abb9631043cc818c2a98efb857df_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia2b43dbe48ac4cd98a40e26498a7f881_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:PlumblineLifeSciencesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i54393acc697d46e9aadd822f4955d2fa_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:OtherCounterpartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibc97cab144454f34933b056f760ee615_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ino:MutualFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4af67d24a9704503878ba27b39ec0b38_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibd7b23cb5c014502a4a19618e0a1c8c8_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4a59d94b00fb4beead53f1520382f2ac_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i07337481fc814fa2a711b1ff37845f55_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i333c95a51d3f4b7595b348f7c6eb52c5_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9038be9382ec4b1694bd9bfd7bcda170_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ino:MutualFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i47be9d2882e243b7ace441a9b9205c92_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7ed17972d6064f0bad14d06c6c595208_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6f07020b0bd84e2b85baecf8191dddd4_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id49e93fcdfff47499add351e50b2b851_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ino:MutualFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibb9d7da2bb9f4083a0f78f4d762e46e4_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ino:MutualFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i08f3093795f1462c897c6cadd1da8aed_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ino:MutualFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib5e1a14b053e47c79b64277a69e380a9_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ino:MutualFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8963e309e7dd4867bea8e9ee34e0a52b_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie4a6d945ad73450191ce911b7e550ccc_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i22850f7499b2483f9428ba6cd51e1702_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie7c31848f0e94bee88a97957caa0dac9_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8576b8faf8064d92a55a1d7a9230294b_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i081a1114c57c4457a6e656fb47caa2fc_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i23aedffa2f0c42b9b43cb0b83beea039_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia2a22ff53c7d437b9e4758ed1dd0655b_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i79f50420241043d0abd5aedb34d9926b_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i700d1959d79f4c7891a22d010cdfd228_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic7b40fbbf0484fb98e57b0b99619b678_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib8736cce87614b07956326c0d9cc3035_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idc037a18dec8422896679a520fe0751f_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i950b0135e402482fae846256144517d6_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i536f602826fe46979bdba143abf2858a_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaef1617b1a33479ebd53313a3c7a7812_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i679e853e6cb64bb9bee2cde9c5fa48ab_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i95f3040264524bd7aafa7c66012a9ed0_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i77ffd233d1de4e33aa7330413610496e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie0d4dc3c347a44199532a6ee4469f31e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i765820c859204f75a1eaeb4f280fd337_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ino:MutualFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i42280087f6b44742aa1b7f2971c27575_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ino:MutualFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifcda11a978e44c92b373b4913520b88b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ino:MutualFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i691500b3ba21482aa5fe5467025f71c3_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ino:MutualFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3b31046c5de349d1937a204cdc2973ae_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaaf44a738a1345828679d9a1b25f8327_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie2357d9b866e4be7afcd9fe0ac4e6a56_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8501b73ca4034d94b92aab9e80a10e2f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2921a4efcf7f4fc1bbbf11dcd4e24dc8_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i165dd8f0bd4343b5b394ee5a10eee714_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibc90ce5aa5c04e718823e5f0bfad97e7_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2a4a04a42ab7478daf3585b30a5dc600_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8b1d59d5ed834f6b91384f272748379f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iea068b74107644b3a5e86a21d960799f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9eeb5e9d4f914f2591ba8b7f2f2631da_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i57bed7dd45b14e9f953dd397ed3bdce9_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0cce4e82b88342c787d49f1a7ed20009_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id00cf7a7665d4381ba225961343d2ea4_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iff289276fdba4033befe45d8c121487e_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i545fa05cd5804fa9a426a541fbe08f6d_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i677b4aa23e734ea1ae840c65c0f2ac0c_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ino:BiojectMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i87af82b668704e509e894f5e917c76ee_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ino:BiojectMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icc09668324be44f4a3c6526161d237ec_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ino:BiojectMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1bf527072286443a829aab2684009143_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i04d8063070ed47dca91d948e0b527543_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9898566a542a49b4bf69010ae439ab9a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i16a35fdf0e8348e0a1ede684610bae3e_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iff75d456dbf843feb55dc8e27df1e4c3_I20190301"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:A6.50ConvertibleSeniorNotesDue2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="i50447e531b3c434fb8e3ede17ab45a89_D20190219-20190301"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:A6.50ConvertibleSeniorNotesDue2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-02-19</xbrli:startDate><xbrli:endDate>2019-03-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="day"><xbrli:measure>ino:day</xbrli:measure></xbrli:unit><xbrli:context id="i334e05b1c2d349408f504085686e16e6_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:A6.50ConvertibleSeniorNotesDue2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibaba303f793542bd8caae6689d64fb35_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:A6.50ConvertibleSeniorNotesDue2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ida7e6795aad44fb38ae767d0d07173d2_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:A6.50ConvertibleSeniorNotesDue2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icdb93151b4be464b9f1281340d4933cc_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:A6.50ConvertibleSeniorNotesDue2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i105fc1ec677d41beb16a21a24c107e45_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:A6.50ConvertibleSeniorNotesDue2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="krw"><xbrli:measure>iso4217:KRW</xbrli:measure></xbrli:unit><xbrli:context id="i700b790825e646eaa141e79f67d14908_I20190801"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:August2019ConvertibleBondsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-08-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibbf41c9c4e33452d8cf96974a53ed0d2_D20190801-20190801"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:August2019ConvertibleBondsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-08-01</xbrli:startDate><xbrli:endDate>2019-08-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6b6ee21ba47743bcbf1e8f17210f4948_D20200803-20200803"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:August2019ConvertibleBondsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-03</xbrli:startDate><xbrli:endDate>2020-08-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie81a2e682215493ab64bdb0c300f4bf3_I20200803"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtConversionByUniqueDescriptionAxis">ino:InitialConversionPriceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:August2019ConvertibleBondsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-08-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7871b982a7494885bca85b1422f54c5a_I20200803"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:August2019ConvertibleBondsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-08-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1db0e391023844c58ee91836f1ff6032_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:August2019ConvertibleBondsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4856d99dc58e4812bb359ff1035109a0_I20200831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:August2019ConvertibleBondsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id61aefb0cd4c41cba239205ade4953a0_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:August2019ConvertibleBondsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic05ddd45fe7a4ed3a38c628d55f5113b_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia9abd9a211df4a149587dd748625eb64_I20191226"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:December2019ConvertibleBondsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i244e899ef7a94a67bec0648d010019b1_D20191226-20191226"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:December2019ConvertibleBondsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-26</xbrli:startDate><xbrli:endDate>2019-12-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if2025599c3af4215ad074b05ca0a1e96_I20191226"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtConversionByUniqueDescriptionAxis">ino:InitialConversionPriceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:December2019ConvertibleBondsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibfeaa89fdfd14b48b6469e81e8224d6e_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:December2019ConvertibleBondsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id6dde602cd3b497f9beb038644f6e0f6_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:December2019ConvertibleBondsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1e80eac2298744338c69ed4a78ebcd6b_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:December2019ConvertibleBondsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia5769dc297d64d63934b48c24c6fac0a_D20200803-20200803"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtConversionByUniqueDescriptionAxis">ino:InitialConversionPriceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:August2019ConvertibleBondsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-03</xbrli:startDate><xbrli:endDate>2020-08-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2159423bb63f4a1fbf69220efa1f3870_D20191226-20191226"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtConversionByUniqueDescriptionAxis">ino:InitialConversionPriceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:December2019ConvertibleBondsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-26</xbrli:startDate><xbrli:endDate>2019-12-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic385c05c2d7e4d79bc77a34f466a4d92_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8080707135874457acfda210b14f8caa_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i25c9bfdd10384a7ea0e5d634721712a4_D20200601-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieee221f2ad874f95afe5bd8f6f749911_D20200601-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1105e820c10e4516b0891db1691036b2_D20210125-20210125"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-25</xbrli:startDate><xbrli:endDate>2021-01-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0aaa3652e67040b09e4bec889642601e_I20210125"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-01-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if1aa2ac57025445591f02f2a2b4a827d_D20180501-20180531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ino:PriorSalesAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-05-01</xbrli:startDate><xbrli:endDate>2018-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie8f61637671d4831a979db68dfe70295_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ino:PriorSalesAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i33021fc5991544e6bdc6d451e0bf882e_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ino:PriorSalesAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if1222ca24d5f4b93a286cd93f4df2429_D20200403-20200512"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ino:NewSalesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-03</xbrli:startDate><xbrli:endDate>2020-05-12</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5bdeced5a8d5445a82941bb4b6c54b39_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ino:NewSalesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic7ebb6cd60ce4e4c84cfe4f6fd8ca6fa_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ino:NewSalesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i20753e05a58f4787ad7efb7458e2f0c5_I20160513"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ino:A2016IncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2016-05-13</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i23432a1ccb974c6d9ef1ec635e8143ed_I20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ino:A2016IncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iddaa5cd4d85f4565b4df009a33385893_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ino:A2016IncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i52e41bdcfa1f4dd5ae13e4662c088e67_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ino:A2016IncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8c0e2d352fcb4b638dd0a198e31e2f72_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ino:A2007IncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6236143f37a74492a26b2b567dd6525a_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ino:A2007IncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i87899c635a3d4f67af30c19682c88a69_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaf2883d0b0f44f8aa8540000815316c3_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6aade12f14664b7bafdd10b536ffc9d1_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">ino:ServiceBasedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iecc10df4b79a45de9ffdafc4389503d2_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">ino:ServiceBasedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i623f1c7b68164c0e86bc10eaa5f5a7e5_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i75ed8cb3d08c4c16a0b40f1f253b731e_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i71ea1499a3b143cb8017808669a7a908_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifb05b300647c4bdb9d4dd1b61fa9ee95_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2d25495c4b6c4835a012eb7bc163fc6b_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:A6.50ConvertibleSeniorNotesDue2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4a3bb7fa3e594f029a6eba07308e9930_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:A6.50ConvertibleSeniorNotesDue2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i18791cf1783e4dcb8bb78a1be1ac89ad_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:August2019ConvertibleBondsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i40ed0775a40148b78eea3a36a21b29b8_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:August2019ConvertibleBondsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia21913e3a96f406eaffea5e037b375df_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:December2019ConvertibleBondsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib6797a8f65df45e284ff859468b7d490_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:December2019ConvertibleBondsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i61f2172601e8451ebb73c4ae7a745dab_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ino:EmployeesAndDirectorsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0c1c04ab89af4b82b4d7131a93f0f86f_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ino:EmployeesAndDirectorsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic3dea0b408c94a5c85d39edf3a8a75da_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ino:EmployeesAndDirectorsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2be4bda68db445b1873dcb33cd2a7408_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ino:EmployeesAndDirectorsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia4defc9758104f38bf6c67e512fbf9c8_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic196d4d46d72427380949ad2f6171b35_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4ac71f8b0252490589829c2ceb42c184_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i16bb9f759a90436abc39b470d3758b82_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iced18e00c26943db86d24ef12f5d945b_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2af01b3faa6342e7982d6aae83905e36_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia74c48fc7c3c456fa308825394481794_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if21238de764544869449deb80f173e01_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ino:NonEmployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i337096debaaf43d88b8dd9f4979cb062_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ino:NonEmployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i76e8a75098d84df7ac61105d88d25844_D20200828-20200828"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ino:A2016IncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-28</xbrli:startDate><xbrli:endDate>2020-08-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie0eb7f9e131f4570be7731825dd8538f_D20200828-20200828"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ino:A2016IncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-28</xbrli:startDate><xbrli:endDate>2020-08-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i21a58deaf4d24bd381a2d83d3a8d9889_D20200828-20200828"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ino:A2016IncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-28</xbrli:startDate><xbrli:endDate>2020-08-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4f1544da548041ab8ee6e7df0bf9ef61_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:PlumblineLifeSciencesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:AvailableforsaleSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4c79f6b4729a4ff692ed11a1379cdfcf_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:PlumblineLifeSciencesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5ee95bf76bdd417884688328e2d20f81_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:PlumblineLifeSciencesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i02eea4d019a94e66ae415d3736f47a49_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:PlumblineLifeSciencesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iad065e9a7d2a4690b34e02a44f8e04ee_D20160301-20160331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:DirectorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-03-01</xbrli:startDate><xbrli:endDate>2016-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i22530cebfa2d4a3587a9140e7fb29bb7_D20161101-20161130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:DirectorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-11-01</xbrli:startDate><xbrli:endDate>2016-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if8801c14501949e385e60e1272378e9f_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ino:TheWistarInstituteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6e8d2f7132dd4ad696314336b323045a_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:DirectorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib9b1dac9eb2f4b86842d7bbf220a3ec9_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:DirectorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iab8d55f8b4464cb1af38f6596cf6b33d_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:DirectorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie31e1b7159e7405fb6b7791df154daf6_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:DirectorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="sqft"><xbrli:measure>utr:sqft</xbrli:measure></xbrli:unit><xbrli:context id="ie67e1db182b94da1b67c475206b65805_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">ino:SanDiegoOfficeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib2743077b3474815ac3d7d4bbcd3dbd9_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">ino:PlymouthMeetingPennsylvaniaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic4e4f4221dec4206a08ffb18e83ff0e2_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i02dc7b8bd133444db127be6bff5fedf5_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i49a24e6bc43d4cd9a7a914b19403f340_D20191001-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">ino:PlymouthMeetingPennsylvaniaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-10-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i16a0d0ea59c14de2b4879a3250ddd093_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:AdvaccineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i218a10d1c62a4a1d8cff8c3442114b71_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:AdvaccineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i43ca7eb4e9604967b950979b7b65da58_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:AdvaccineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iff19a2c26f364894a1393fb4bb5ed788_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:AdvaccineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9e2527d562564d0da42bfadc4214aabf_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ino:AdvaccineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie9a3ac315bd64233b038ae99d2926ee5_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ino:AdvaccineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4ae78b29c7ad4225be2a6e2ef791b855_D20171229-20171229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:ApolloBioMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-12-29</xbrli:startDate><xbrli:endDate>2017-12-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifb1c860482c945d2b8d0a23ea9de9d2b_D20180301-20180331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:ApolloBioMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-03-01</xbrli:startDate><xbrli:endDate>2018-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic48f2b7387c740dda32316adb9b93c55_D20180301-20180331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:ApolloBioMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-03-01</xbrli:startDate><xbrli:endDate>2018-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifcaf1ba492eb44b08dea1762e6aae5a6_I20180331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:ApolloBioMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibfe7179d0c314ec8b6575735e5576485_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:ApolloBioMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i166171f55c2146e6a9bfc1cbda21593f_D20180401-20180630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:ApolloBioMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-04-01</xbrli:startDate><xbrli:endDate>2018-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i312dc53a327b4c2584c0408f7ce3c401_D20150901-20150930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:AstraZenecaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-09-01</xbrli:startDate><xbrli:endDate>2015-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id271d63e442f4a9f8fb4db1a017f1090_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:AstraZenecaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iab8cbd4abffa49939bca24df9e09f682_D20171231-20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:AstraZenecaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-12-31</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1279cb3397f540cf8c03eff95603717f_D20181201-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:AstraZenecaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0a00fce528054fc1b13da4166be4a7f9_D20190302-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:AstraZenecaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-03-02</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i26869d6b62d04f7b965bf3b12a74986b_D20180401-20180430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:LassaFeverAndMERSVaccineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:CoalitionforEpidemicPreparednessInnovationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-04-01</xbrli:startDate><xbrli:endDate>2018-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9e2dfcc4dad04e25a9c9b44b8901a333_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:LassaFeverAndMERSVaccineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:CoalitionforEpidemicPreparednessInnovationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id320f2073edd475b8fd5feeb871b3bb2_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:LassaFeverAndMERSVaccineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:CoalitionforEpidemicPreparednessInnovationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7705f1893eef43a683c986157751b493_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:LassaFeverAndMERSVaccineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:CoalitionforEpidemicPreparednessInnovationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4c2c68f34809458b92b1fe442b05fe04_D20200101-20200131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:CoalitionforEpidemicPreparednessInnovationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:SARSCoV2COVID19VaccineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iefa41d3db8c44b3784e3e21a11b9f57b_D20200401-20200430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:CoalitionforEpidemicPreparednessInnovationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie8d1c12d54e14e8fadc5b66c01656f3f_D20200401-20200430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:CoalitionforEpidemicPreparednessInnovationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:CELLECTRA3PSPProprietarySmartDeviceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4e63edbfeb924628bea29aa126db3731_D20200401-20200430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:CoalitionforEpidemicPreparednessInnovationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:INO4800Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i90e840c675604f9ea05a3d3799146d6a_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:CoalitionforEpidemicPreparednessInnovationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:SARSCoV2COVID19VaccineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9c578a4352674268833b02f441d2630a_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:CoalitionforEpidemicPreparednessInnovationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:SARSCoV2COVID19VaccineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i462daba8e70241fa90cc3d9158a0e6b1_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:CoalitionforEpidemicPreparednessInnovationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:SARSCoV2COVID19VaccineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8914061f84134527886aafd4379342b3_D20181001-20181031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:DNAEncodedMonoclonalAntibodyTechnologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:BillAndMelindaGatesFoundationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-10-01</xbrli:startDate><xbrli:endDate>2018-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id9b959950a9d4883a9e0bbc48e5b75b8_D20190801-20190830"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:DNAEncodedMonoclonalAntibodyTechnologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:BillAndMelindaGatesFoundationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-08-01</xbrli:startDate><xbrli:endDate>2019-08-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia04b81c5769143f2ad65bc25e43bd9ed_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:DNAEncodedMonoclonalAntibodyTechnologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:BillAndMelindaGatesFoundationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i091601a25e604419963010db9959837c_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:DNAEncodedMonoclonalAntibodyTechnologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:BillAndMelindaGatesFoundationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i870d9127e6314fc4aebaa4f4b2a7931e_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:DNAEncodedMonoclonalAntibodyTechnologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:BillAndMelindaGatesFoundationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i752ae0ad316946429cc2310340ed7334_D20200301-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:CELLECTRA3PSPProprietarySmartDeviceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:BillAndMelindaGatesFoundationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-03-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i56915aed723e478494673e49cebb3d4e_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:CELLECTRA3PSPProprietarySmartDeviceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:BillAndMelindaGatesFoundationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i779a998ae097423cbfecbd164c6d6a15_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:CELLECTRA3PSPProprietarySmartDeviceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:BillAndMelindaGatesFoundationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i264c6f79f8444773b5305906e6e512df_D20200601-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:DepartmentOfDefenceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:CELLECTRA3PSPProprietarySmartDeviceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic4269fc3e43a44779c7573901206998d_D20200601-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:DepartmentOfDefenceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:CELLECTRA2000DeviceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iccb3ccc026234192a47e7268051e1700_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:DepartmentOfDefenceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic1b65e61f4594842852e823b554bc0cb_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:DepartmentOfDefenceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia71441f3bf2e4190b91ebcea736fec60_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:DepartmentOfDefenceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i12df974976054802af3d27561d6c09dd_D20190201-20190228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-02-01</xbrli:startDate><xbrli:endDate>2019-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i197c02bfa6fb453089c92b4a206b5240_I20190228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i22e9833894df4c5d90786ba65f0c072a_I20200131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9c60a7b844ef4b0685afab98a626ab57_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icf16dce9089247ddb07885bad1158a5b_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i86c6d642fb404b608772c10c34c2a8fc_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i49cf08539f5f4d268c6222c435b55016_D20200601-20200601"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-01</xbrli:startDate><xbrli:endDate>2020-06-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i11b75bcb273c48128928387d5ceda2d2_I20200601"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8ac1a1cef3df4067985d61a1d1aaf9b8_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idc86dae1ec654c2e8eb6ba13fc81ec0b_I20200601"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib661d85215674c8e93c1385a9ed48322_I20200601"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i496071670fd64b74b11100bd501df568_D20200601-20200601"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-01</xbrli:startDate><xbrli:endDate>2020-06-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i521f37bfc08d4393a839105bd352f62b_I20200601"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idf75b7fb59a640709f8bece075b171dd_I20200601"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5f2d61cc6bd64875b11002017e8003ca_D20201101-20201130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-11-01</xbrli:startDate><xbrli:endDate>2020-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i26487b836039455e8049dc86128e27ea_I20201130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie8cf0b8ea91645f8adbebe6fd2ff82e8_D20200601-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iecead882e1cc4b15851f3a17bd9de72e_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i55de06d621d74ea4af67ec695d2aeb62_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ida22e72ec08c488993f6f37b0a40f441_D20200601-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ino:SeriesAOnePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic39b978122b34ef0b586d2c3f0a20046_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i819679aabd4442d3be1364eba1821db3_D20200601-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib3a8dbbd273043a2a304eb2892a14c8c_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5f89255103014c46a5a9ab71646dba92_I20200601"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ino:SeriesAOnePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9ae4c9aeb5d247e7bef7ede5fd594691_I20210228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-02-28</xbrli:instant></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i1d23d16a69484b63aa007ec686e80337_1"></div><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">WASHINGTON, D.C. 20549</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:33.333%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18xL2ZyYWc6NTM4MmMyNzY1Y2NiNGZiYWExMzNkMGYwZDkwMjNmYzAvdGV4dHJlZ2lvbjo1MzgyYzI3NjVjY2I0ZmJhYTEzM2QwZjBkOTAyM2ZjMF8yMTA2_30e51c43-9d22-4d88-8279-f47d43efb02f">10-Q</ix:nonNumeric> </span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:3.201%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:94.599%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331" format="ixt-sec:boolballotbox" name="dei:DocumentQuarterlyReport" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18xL2ZyYWc6NTM4MmMyNzY1Y2NiNGZiYWExMzNkMGYwZDkwMjNmYzAvdGFibGU6NDQ0NGRhYjE5OTZjNDZlMGIwZGYzZTc2Zjc1MjM2ZTAvdGFibGVyYW5nZTo0NDQ0ZGFiMTk5NmM0NmUwYjBkZjNlNzZmNzUyMzZlMF8wLTAtMS0xLTA_1cef70ae-cfc0-48f2-9aca-be4d17cca9a6">&#9746;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">QUARTERLY REPORT PURSUANT TO SECTION&#160;13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF&#160;1934</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">      </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"> FOR THE QUARTERLY PERIOD ENDED <ix:nonNumeric contextRef="i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18xL2ZyYWc6NTM4MmMyNzY1Y2NiNGZiYWExMzNkMGYwZDkwMjNmYzAvdGV4dHJlZ2lvbjo1MzgyYzI3NjVjY2I0ZmJhYTEzM2QwZjBkOTAyM2ZjMF8xMzI_4df55fc3-6861-4ca7-b4e4-bce077331f19">MARCH 31, 2021</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">OR</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:3.335%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:94.465%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331" format="ixt-sec:boolballotbox" name="dei:DocumentTransitionReport" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18xL2ZyYWc6NTM4MmMyNzY1Y2NiNGZiYWExMzNkMGYwZDkwMjNmYzAvdGFibGU6Yjc2OTY5ZDM5ODM2NGM1MGJmMTcxOTQyMzczYTg3ZmQvdGFibGVyYW5nZTpiNzY5NjlkMzk4MzY0YzUwYmYxNzE5NDIzNzNhODdmZF8wLTAtMS0xLTA_f0a2e97b-e6cb-45c0-8ef5-b121aabf6c2c">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">TRANSITION REPORT PURSUANT TO SECTION&#160;13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF&#160;1934</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">       FOR THE TRANSITION PERIOD FROM&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; TO &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">COMMISSION FILE NO.&#160;<ix:nonNumeric contextRef="i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18xL2ZyYWc6NTM4MmMyNzY1Y2NiNGZiYWExMzNkMGYwZDkwMjNmYzAvdGV4dHJlZ2lvbjo1MzgyYzI3NjVjY2I0ZmJhYTEzM2QwZjBkOTAyM2ZjMF8yMTEw_babe0f0b-1425-4d9c-add5-c018e66647e2">001-14888</ix:nonNumeric> </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:186.00pt"><tr><td style="width:1.0pt"></td><td style="width:184.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><img src="ino-20210331_g1.jpg" alt="ino-20210331_g1.jpg" style="height:64px;margin-bottom:5pt;vertical-align:text-bottom;width:204px"/></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:13pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18xL2ZyYWc6NTM4MmMyNzY1Y2NiNGZiYWExMzNkMGYwZDkwMjNmYzAvdGV4dHJlZ2lvbjo1MzgyYzI3NjVjY2I0ZmJhYTEzM2QwZjBkOTAyM2ZjMF8yMTEx_eb58a84f-7f10-4a9d-ae8a-9b02b6339daf">INOVIO PHARMACEUTICALS, INC.</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:13pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">(EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER)</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:54.276%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.260%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.164%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18xL2ZyYWc6NTM4MmMyNzY1Y2NiNGZiYWExMzNkMGYwZDkwMjNmYzAvdGFibGU6YTM4NmIwNDllMDJlNGIyOGFkYzg0NjM3ZmQ3M2JkYWYvdGFibGVyYW5nZTphMzg2YjA0OWUwMmU0YjI4YWRjODQ2MzdmZDczYmRhZl8wLTAtMS0xLTA_f94abe28-7258-447a-918a-3207f8e35d9e">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18xL2ZyYWc6NTM4MmMyNzY1Y2NiNGZiYWExMzNkMGYwZDkwMjNmYzAvdGFibGU6YTM4NmIwNDllMDJlNGIyOGFkYzg0NjM3ZmQ3M2JkYWYvdGFibGVyYW5nZTphMzg2YjA0OWUwMmU0YjI4YWRjODQ2MzdmZDczYmRhZl8wLTItMS0xLTA_d6bf0eb2-71ac-4f01-9e77-49baa40f0cda">33-0969592</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(State or other jurisdiction of<br/>incorporation or organization)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(I.R.S. Employer<br/>Identification No.)</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18xL2ZyYWc6NTM4MmMyNzY1Y2NiNGZiYWExMzNkMGYwZDkwMjNmYzAvdGV4dHJlZ2lvbjo1MzgyYzI3NjVjY2I0ZmJhYTEzM2QwZjBkOTAyM2ZjMF8yMTEy_45c30210-848b-4071-8741-b2db12f3bd30">660 W. GERMANTOWN PIKE, SUITE 110</ix:nonNumeric>  </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18xL2ZyYWc6NTM4MmMyNzY1Y2NiNGZiYWExMzNkMGYwZDkwMjNmYzAvdGV4dHJlZ2lvbjo1MzgyYzI3NjVjY2I0ZmJhYTEzM2QwZjBkOTAyM2ZjMF8yMTA3_57277e60-a12f-4dce-b1db-09fcf2eb54ad">PLYMOUTH MEETING</ix:nonNumeric>, <ix:nonNumeric contextRef="i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331" name="dei:EntityAddressStateOrProvince" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18xL2ZyYWc6NTM4MmMyNzY1Y2NiNGZiYWExMzNkMGYwZDkwMjNmYzAvdGV4dHJlZ2lvbjo1MzgyYzI3NjVjY2I0ZmJhYTEzM2QwZjBkOTAyM2ZjMF8yMTEz_c132ea97-5d31-4fe0-9c7f-875ca8276678">PA</ix:nonNumeric>  <ix:nonNumeric contextRef="i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18xL2ZyYWc6NTM4MmMyNzY1Y2NiNGZiYWExMzNkMGYwZDkwMjNmYzAvdGV4dHJlZ2lvbjo1MzgyYzI3NjVjY2I0ZmJhYTEzM2QwZjBkOTAyM2ZjMF8yMTE0_76595a9a-87de-4f12-8765-99831b11644c">19462</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Address of principal executive offices)</span></div><div style="text-align:center"><span><br/></span></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">REGISTRANT&#8217;S TELEPHONE NUMBER, INCLUDING AREA CODE: (<ix:nonNumeric contextRef="i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18xL2ZyYWc6NTM4MmMyNzY1Y2NiNGZiYWExMzNkMGYwZDkwMjNmYzAvdGV4dHJlZ2lvbjo1MzgyYzI3NjVjY2I0ZmJhYTEzM2QwZjBkOTAyM2ZjMF8yMTE1_2aa72edc-de18-45d0-8bb9-a202774797a8">267</ix:nonNumeric>)&#160;<ix:nonNumeric contextRef="i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18xL2ZyYWc6NTM4MmMyNzY1Y2NiNGZiYWExMzNkMGYwZDkwMjNmYzAvdGV4dHJlZ2lvbjo1MzgyYzI3NjVjY2I0ZmJhYTEzM2QwZjBkOTAyM2ZjMF8yMTE2_595fdd6f-8618-422d-8b16-31be294f541c">440-4200</ix:nonNumeric> </span></div><div style="text-align:center"><span><br/></span></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">SECURITIES REGISTERED PURSUANT TO SECTION&#160;12(B) OF THE ACT:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:92.069%"><tr><td style="width:1.0%"></td><td style="width:41.965%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.936%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.799%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Title of Each Class</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Trading Symbol(s)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Name of Each Exchange on Which Registered</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18xL2ZyYWc6NTM4MmMyNzY1Y2NiNGZiYWExMzNkMGYwZDkwMjNmYzAvdGFibGU6YWY0Mzk3YjZjZWQ0NDdhMmJiZjc3NTU4MjIyNWYzMzQvdGFibGVyYW5nZTphZjQzOTdiNmNlZDQ0N2EyYmJmNzc1NTgyMjI1ZjMzNF8xLTAtMS0xLTA_765ad9eb-a50a-4bc7-8ede-94832111caf6">COMMON STOCK, $0.001 PAR VALUE</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18xL2ZyYWc6NTM4MmMyNzY1Y2NiNGZiYWExMzNkMGYwZDkwMjNmYzAvdGFibGU6YWY0Mzk3YjZjZWQ0NDdhMmJiZjc3NTU4MjIyNWYzMzQvdGFibGVyYW5nZTphZjQzOTdiNmNlZDQ0N2EyYmJmNzc1NTgyMjI1ZjMzNF8xLTEtMS0xLTA_daa7d5eb-1093-4097-baf8-dc66c419e54f">INO</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18xL2ZyYWc6NTM4MmMyNzY1Y2NiNGZiYWExMzNkMGYwZDkwMjNmYzAvdGFibGU6YWY0Mzk3YjZjZWQ0NDdhMmJiZjc3NTU4MjIyNWYzMzQvdGFibGVyYW5nZTphZjQzOTdiNmNlZDQ0N2EyYmJmNzc1NTgyMjI1ZjMzNF8xLTItMS0xLTA_ad49e61d-80ff-485c-898d-ea9cab024d55">Nasdaq Global Select Market</ix:nonNumeric></span></td></tr></table></div><div style="margin-bottom:5pt;margin-top:15pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:33.333%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12&#160;months (or for such shorter period that the Registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90&#160;days.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18xL2ZyYWc6NTM4MmMyNzY1Y2NiNGZiYWExMzNkMGYwZDkwMjNmYzAvdGV4dHJlZ2lvbjo1MzgyYzI3NjVjY2I0ZmJhYTEzM2QwZjBkOTAyM2ZjMF8yMTE3_1e5e6303-2915-467b-8bbf-01acfdccd22b">Yes</ix:nonNumeric>&#160;&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9746;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;No&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule&#160;405 of Regulation&#160;S-T during the preceding 12&#160;months (or for such shorter period that the registrant was required to submit such files).&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18xL2ZyYWc6NTM4MmMyNzY1Y2NiNGZiYWExMzNkMGYwZDkwMjNmYzAvdGV4dHJlZ2lvbjo1MzgyYzI3NjVjY2I0ZmJhYTEzM2QwZjBkOTAyM2ZjMF8yMTA4_c51b5314-e681-47db-bf61-047e25beb8a4">Yes</ix:nonNumeric>&#160;&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9746;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company&#8221; and "emerging growth company" in Rule&#160;12b-2 of the Exchange Act. (Check one):</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:19.867%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.488%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.378%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.077%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.490%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331" format="ixt-sec:entityfilercategoryen" name="dei:EntityFilerCategory" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18xL2ZyYWc6NTM4MmMyNzY1Y2NiNGZiYWExMzNkMGYwZDkwMjNmYzAvdGFibGU6NzBmYjM5Y2JkMmE3NGFmYjg3NjM4ODZlOWViMDcxZTAvdGFibGVyYW5nZTo3MGZiMzljYmQyYTc0YWZiODc2Mzg4NmU5ZWIwNzFlMF8wLTAtMS0xLTI4NjU_b3d72721-e976-4788-8607-675398411088">Large accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#9746;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#9744;</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-accelerated&#160;filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#9744;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Smaller&#160;reporting&#160;company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331" format="ixt-sec:boolballotbox" name="dei:EntitySmallBusiness" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18xL2ZyYWc6NTM4MmMyNzY1Y2NiNGZiYWExMzNkMGYwZDkwMjNmYzAvdGFibGU6NzBmYjM5Y2JkMmE3NGFmYjg3NjM4ODZlOWViMDcxZTAvdGFibGVyYW5nZTo3MGZiMzljYmQyYTc0YWZiODc2Mzg4NmU5ZWIwNzFlMF8yLTQtMS0xLTA_6aad417a-5e7a-40d3-b153-de5dce677e20">&#9744;</ix:nonNumeric></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Emerging growth company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331" format="ixt-sec:boolballotbox" name="dei:EntityEmergingGrowthCompany" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18xL2ZyYWc6NTM4MmMyNzY1Y2NiNGZiYWExMzNkMGYwZDkwMjNmYzAvdGFibGU6NzBmYjM5Y2JkMmE3NGFmYjg3NjM4ODZlOWViMDcxZTAvdGFibGVyYW5nZTo3MGZiMzljYmQyYTc0YWZiODc2Mzg4NmU5ZWIwNzFlMF80LTQtMS0xLTA_a23721ba-9f35-4c32-a641-178903cd79cb">&#9744;</ix:nonNumeric></span></div></td></tr></table></div><div style="text-indent:24.75pt"><span><br/></span></div><div style="text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-top:3pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule&#160;12b-2 of the Act).&#160;&#160;&#160;&#160;Yes&#160;&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331" format="ixt-sec:boolballotbox" name="dei:EntityShellCompany" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18xL2ZyYWc6NTM4MmMyNzY1Y2NiNGZiYWExMzNkMGYwZDkwMjNmYzAvdGV4dHJlZ2lvbjo1MzgyYzI3NjVjY2I0ZmJhYTEzM2QwZjBkOTAyM2ZjMF8yMTA5_babc02b7-9b34-4120-a668-3059b1628077">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">        &#160;No&#160;&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9746;</span></div><div style="margin-top:3pt;text-indent:24.75pt"><span><br/></span></div><div style="margin-top:3pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The number of shares outstanding of the Registrant&#8217;s Common Stock, $0.001 par value, was <ix:nonFraction unitRef="shares" contextRef="i884c8c9ea12c402d9c05f28dee28eb3a_I20210506" decimals="INF" format="ixt:numdotdecimal" name="dei:EntityCommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18xL2ZyYWc6NTM4MmMyNzY1Y2NiNGZiYWExMzNkMGYwZDkwMjNmYzAvdGV4dHJlZ2lvbjo1MzgyYzI3NjVjY2I0ZmJhYTEzM2QwZjBkOTAyM2ZjMF8yMDky_129e0feb-4152-40ff-b290-1fcaba577ae9">209,399,260</ix:nonFraction> as of May&#160;6, 2021.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:186.00pt"><tr><td style="width:1.0pt"></td><td style="width:184.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="height:27pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i1d23d16a69484b63aa007ec686e80337_7"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INOVIO PHARMACEUTICALS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FORM 10-Q</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the Quarterly Period Ended March&#160;31, 2021</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INDEX</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:81.916%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.884%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i1d23d16a69484b63aa007ec686e80337_10">Part I.  Financial Information</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1d23d16a69484b63aa007ec686e80337_10">1</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:24.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1d23d16a69484b63aa007ec686e80337_10">Item&#160;1. Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1d23d16a69484b63aa007ec686e80337_10">1</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:42.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1d23d16a69484b63aa007ec686e80337_13">a) Condensed Consolidated Balance Sheets</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1d23d16a69484b63aa007ec686e80337_13">2</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:42.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1d23d16a69484b63aa007ec686e80337_16">b) Condensed Consolidated Statements of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1d23d16a69484b63aa007ec686e80337_16">3</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:42.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1d23d16a69484b63aa007ec686e80337_19">c) Condensed Consolidated Statements of Comprehensive </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1d23d16a69484b63aa007ec686e80337_19">Loss</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1d23d16a69484b63aa007ec686e80337_19">4</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:42.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1d23d16a69484b63aa007ec686e80337_22">d) Condensed Consolidated Statements of Stockholders' Equity</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1d23d16a69484b63aa007ec686e80337_22">5</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:42.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1d23d16a69484b63aa007ec686e80337_25">e) Condensed Consolidated Statements of Cash Flows</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1d23d16a69484b63aa007ec686e80337_25">6</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:42.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1d23d16a69484b63aa007ec686e80337_28">f) Notes to Condensed Consolidated Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1d23d16a69484b63aa007ec686e80337_28">8</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:24.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1d23d16a69484b63aa007ec686e80337_103">Item&#160;2. Management's Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1d23d16a69484b63aa007ec686e80337_103">30</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:24.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1d23d16a69484b63aa007ec686e80337_121">Item&#160;3. Quantitative and Qualitative Disclosures About Market Risk</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1d23d16a69484b63aa007ec686e80337_121">34</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:24.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1d23d16a69484b63aa007ec686e80337_124">Item&#160;4. Controls and Procedures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1d23d16a69484b63aa007ec686e80337_124">35</a></span></div></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i1d23d16a69484b63aa007ec686e80337_127">Part II.  Other Information</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1d23d16a69484b63aa007ec686e80337_127">37</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:24.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1d23d16a69484b63aa007ec686e80337_130">Item&#160;1. Legal Proceedings</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1d23d16a69484b63aa007ec686e80337_130">37</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:24.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1d23d16a69484b63aa007ec686e80337_133">Item&#160;1A. Risk Factors</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1d23d16a69484b63aa007ec686e80337_133">38</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:24.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1d23d16a69484b63aa007ec686e80337_136">Item&#160;2. Unregistered Sales of Equity Securities and Use of Proceeds</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1d23d16a69484b63aa007ec686e80337_136">58</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:24.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1d23d16a69484b63aa007ec686e80337_139">Item&#160;3. Defaults Upon Senior Securities</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1d23d16a69484b63aa007ec686e80337_139">58</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:24.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1d23d16a69484b63aa007ec686e80337_142">Item&#160;4. Mine Safety Disclosures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1d23d16a69484b63aa007ec686e80337_145">58</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:24.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1d23d16a69484b63aa007ec686e80337_145">Item&#160;5. Other Information</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1d23d16a69484b63aa007ec686e80337_145">58</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:24.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1d23d16a69484b63aa007ec686e80337_148">Item&#160;6. Exhibits</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1d23d16a69484b63aa007ec686e80337_148">58</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i1d23d16a69484b63aa007ec686e80337_151">Signatures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1d23d16a69484b63aa007ec686e80337_151">60</a></span></div></td></tr></table></div><div><span><br/></span></div><div style="text-indent:24.75pt"><span><br/></span></div><div style="margin-bottom:17pt;margin-top:17pt"><span><br/></span></div><div id="i1d23d16a69484b63aa007ec686e80337_1325"></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">SUMMARY OF THE MATERIAL RISKS ASSOCIATED WITH OUR BUSINESS</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business is subject to a number of risks, including risks that may prevent us from achieving our business objectives or may adversely affect our business, financial condition, results of operations, cash flows and prospects. These risks are discussed more fully in Item 1A. Risk Factors herein. These risks include, but are not limited to, the following:</span></div><div><span><br/></span></div><div style="margin-bottom:5pt;padding-left:31.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">Our business could be adversely affected by the effects of health epidemics, including the global COVID-19 pandemic.</span></div><div style="margin-bottom:5pt;padding-left:31.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">We have incurred significant losses in recent years, expect to incur significant net losses in the foreseeable future and may never become profitable.</span></div><div style="margin-bottom:5pt;padding-left:31.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">We are currently subject to litigation and may become subject to additional litigation, which could harm our business, financial condition and reputation.</span></div><div style="margin-bottom:5pt;padding-left:31.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">Our planned clinical development of INO-4800 as a potential COVID-19 vaccine has been placed on partial clinical hold by the FDA, which may cause delays in the commencement of our planned Phase 3 clinical trial or completion of clinical testing, both of which could result in increased costs to us and delay or limit our ability to proceed to commercialization and generate revenues.</span></div><div style="margin-bottom:5pt;padding-left:31.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">There can be no assurance that the product we are developing for COVID-19 would be granted an Emergency Use Authorization by the FDA or similar authorization by regulatory authorities outside of the United States if we were to decide to apply for such an authorization. If we do not apply for such an authorization or, if we do apply and no authorization is granted or, once granted, it is terminated, we will be unable to sell our product in the near future and instead, will be required to pursue the biologic licensure process in order to sell our product, which is lengthy and expensive.</span></div><div style="margin-bottom:5pt;padding-left:31.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">Delays in the commencement or completion of clinical testing could result in increased costs to us and delay or limit our ability to generate revenues.</span></div><div style="margin-bottom:5pt;padding-left:31.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">None of our human vaccine candidates, including INO-4800, or our immunotherapy and DNA encoded monoclonal antibody product candidates have been approved for sale, and we may never develop commercially successful vaccine, immunotherapy or monoclonal antibody products.</span></div><div style="margin-bottom:5pt;padding-left:31.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">We will need substantial additional capital to develop our DNA vaccines, DNA immunotherapies and dMAb programs and electroporation delivery technology.</span></div><div style="margin-bottom:5pt;padding-left:31.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">If we lose or are unable to secure collaborators or partners, or if our collaborators or partners do not apply adequate resources to their relationships with us, our product development and potential for profitability will suffer.</span></div><div style="margin-bottom:5pt;padding-left:31.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">A small number of licensing partners and government contracts account for a substantial portion of our revenue.</span></div><div style="margin-bottom:5pt;padding-left:31.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">We have agreements with government agencies, which are subject to termination and uncertain future funding.</span></div><div style="margin-bottom:5pt;padding-left:31.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">We face intense and increasing competition and many of our competitors have significantly greater resources and experience.</span></div><div style="margin-bottom:5pt;padding-left:31.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">If we and the contract manufacturers upon whom we rely fail to produce our electroporation devices and product candidates in the volumes that we require on a timely basis, or at all, or fail to comply with their obligations to us or with stringent regulations, we may face delays in the development and commercialization of our electroporation equipment and product candidates.</span></div><div style="margin-bottom:5pt;padding-left:31.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">It is difficult and costly to generate and protect our intellectual property and our proprietary technologies, and we may not be able to ensure their protection.</span></div><div style="margin-bottom:5pt;padding-left:31.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">If we are sued for infringing intellectual property rights of third parties, it will be costly and time-consuming, and an unfavorable outcome in that litigation would have a material adverse effect on our business.</span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i1d23d16a69484b63aa007ec686e80337_10"></div><hr style="page-break-after:always"/><div style="min-height:18pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Part I.  Financial Information</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1.&#160;&#160;&#160;&#160;Financial Statements</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</span></div></div></div><div id="i1d23d16a69484b63aa007ec686e80337_13"></div><hr style="page-break-after:always"/><div style="min-height:31.5pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INOVIO PHARMACEUTICALS, INC.  </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED BALANCE SHEETS</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.855%"><tr><td style="width:1.0%"></td><td style="width:74.516%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.946%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.525%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.513%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">March 31,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31,<br/>2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Unaudited)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">ASSETS</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic36b9cedad7f41a6b9eb223b09b7186c_I20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18xMy9mcmFnOjVkY2JmNGI1ZTM3MzQyM2ZhMWY1NTcyM2Q3MTJlZWE1L3RhYmxlOjg4MmZmMDUyMmQ0NjRkYjdhZTY0MTg5MWY2NGEzODY3L3RhYmxlcmFuZ2U6ODgyZmYwNTIyZDQ2NGRiN2FlNjQxODkxZjY0YTM4NjdfNC0xLTEtMS0w_7d5bcaaa-5d74-4917-a2a2-29f53e5b6fcb">83,634,176</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i066bb5b0a9e84c0a878b1e800703d92b_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18xMy9mcmFnOjVkY2JmNGI1ZTM3MzQyM2ZhMWY1NTcyM2Q3MTJlZWE1L3RhYmxlOjg4MmZmMDUyMmQ0NjRkYjdhZTY0MTg5MWY2NGEzODY3L3RhYmxlcmFuZ2U6ODgyZmYwNTIyZDQ2NGRiN2FlNjQxODkxZjY0YTM4NjdfNC0zLTEtMS0w_fb736d15-4e81-4ce0-a730-5286e18aca52">250,728,118</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic36b9cedad7f41a6b9eb223b09b7186c_I20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShortTermInvestments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18xMy9mcmFnOjVkY2JmNGI1ZTM3MzQyM2ZhMWY1NTcyM2Q3MTJlZWE1L3RhYmxlOjg4MmZmMDUyMmQ0NjRkYjdhZTY0MTg5MWY2NGEzODY3L3RhYmxlcmFuZ2U6ODgyZmYwNTIyZDQ2NGRiN2FlNjQxODkxZjY0YTM4NjdfNS0xLTEtMS0w_c49f4d00-b715-44d2-b0b9-705f09b89a22">434,969,528</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i066bb5b0a9e84c0a878b1e800703d92b_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShortTermInvestments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18xMy9mcmFnOjVkY2JmNGI1ZTM3MzQyM2ZhMWY1NTcyM2Q3MTJlZWE1L3RhYmxlOjg4MmZmMDUyMmQ0NjRkYjdhZTY0MTg5MWY2NGEzODY3L3RhYmxlcmFuZ2U6ODgyZmYwNTIyZDQ2NGRiN2FlNjQxODkxZjY0YTM4NjdfNS0zLTEtMS0w_d63f213a-a549-4415-b258-58e6e1d368ff">160,914,935</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic36b9cedad7f41a6b9eb223b09b7186c_I20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNetCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18xMy9mcmFnOjVkY2JmNGI1ZTM3MzQyM2ZhMWY1NTcyM2Q3MTJlZWE1L3RhYmxlOjg4MmZmMDUyMmQ0NjRkYjdhZTY0MTg5MWY2NGEzODY3L3RhYmxlcmFuZ2U6ODgyZmYwNTIyZDQ2NGRiN2FlNjQxODkxZjY0YTM4NjdfNi0xLTEtMS0w_089361b9-a846-43d0-9131-3f4b08885ae8">9,911,922</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i066bb5b0a9e84c0a878b1e800703d92b_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNetCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18xMy9mcmFnOjVkY2JmNGI1ZTM3MzQyM2ZhMWY1NTcyM2Q3MTJlZWE1L3RhYmxlOjg4MmZmMDUyMmQ0NjRkYjdhZTY0MTg5MWY2NGEzODY3L3RhYmxlcmFuZ2U6ODgyZmYwNTIyZDQ2NGRiN2FlNjQxODkxZjY0YTM4NjdfNi0zLTEtMS0w_9dfae3a7-4962-4724-bae6-f09fcb16538c">18,559,967</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts receivable from affiliated entities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic36b9cedad7f41a6b9eb223b09b7186c_I20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableRelatedPartiesCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18xMy9mcmFnOjVkY2JmNGI1ZTM3MzQyM2ZhMWY1NTcyM2Q3MTJlZWE1L3RhYmxlOjg4MmZmMDUyMmQ0NjRkYjdhZTY0MTg5MWY2NGEzODY3L3RhYmxlcmFuZ2U6ODgyZmYwNTIyZDQ2NGRiN2FlNjQxODkxZjY0YTM4NjdfNy0xLTEtMS0w_6e2a5021-b7e4-45a6-974f-ba5841d2474d">346,974</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i066bb5b0a9e84c0a878b1e800703d92b_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableRelatedPartiesCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18xMy9mcmFnOjVkY2JmNGI1ZTM3MzQyM2ZhMWY1NTcyM2Q3MTJlZWE1L3RhYmxlOjg4MmZmMDUyMmQ0NjRkYjdhZTY0MTg5MWY2NGEzODY3L3RhYmxlcmFuZ2U6ODgyZmYwNTIyZDQ2NGRiN2FlNjQxODkxZjY0YTM4NjdfNy0zLTEtMS0w_76c8dffb-a0a8-4a66-b130-0978fcf55d84">503,782</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic36b9cedad7f41a6b9eb223b09b7186c_I20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18xMy9mcmFnOjVkY2JmNGI1ZTM3MzQyM2ZhMWY1NTcyM2Q3MTJlZWE1L3RhYmxlOjg4MmZmMDUyMmQ0NjRkYjdhZTY0MTg5MWY2NGEzODY3L3RhYmxlcmFuZ2U6ODgyZmYwNTIyZDQ2NGRiN2FlNjQxODkxZjY0YTM4NjdfOC0xLTEtMS0w_91284f6d-a536-4d13-a6d9-135c1a0d28f2">59,572,236</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i066bb5b0a9e84c0a878b1e800703d92b_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18xMy9mcmFnOjVkY2JmNGI1ZTM3MzQyM2ZhMWY1NTcyM2Q3MTJlZWE1L3RhYmxlOjg4MmZmMDUyMmQ0NjRkYjdhZTY0MTg5MWY2NGEzODY3L3RhYmxlcmFuZ2U6ODgyZmYwNTIyZDQ2NGRiN2FlNjQxODkxZjY0YTM4NjdfOC0zLTEtMS0w_b5a2dd86-c0c9-4c93-b68b-e23cb9645cf5">40,357,456</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets from affiliated entities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic36b9cedad7f41a6b9eb223b09b7186c_I20210331" decimals="0" format="ixt:zerodash" name="ino:PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18xMy9mcmFnOjVkY2JmNGI1ZTM3MzQyM2ZhMWY1NTcyM2Q3MTJlZWE1L3RhYmxlOjg4MmZmMDUyMmQ0NjRkYjdhZTY0MTg5MWY2NGEzODY3L3RhYmxlcmFuZ2U6ODgyZmYwNTIyZDQ2NGRiN2FlNjQxODkxZjY0YTM4NjdfOS0xLTEtMS0w_5afb9e1d-4a45-4e9c-84cc-74f5afab7071">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i066bb5b0a9e84c0a878b1e800703d92b_I20201231" decimals="0" format="ixt:numdotdecimal" name="ino:PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18xMy9mcmFnOjVkY2JmNGI1ZTM3MzQyM2ZhMWY1NTcyM2Q3MTJlZWE1L3RhYmxlOjg4MmZmMDUyMmQ0NjRkYjdhZTY0MTg5MWY2NGEzODY3L3RhYmxlcmFuZ2U6ODgyZmYwNTIyZDQ2NGRiN2FlNjQxODkxZjY0YTM4NjdfOS0zLTEtMS0w_a3b1125b-92ae-48bd-9447-5a74dc5ddc6e">106,432</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic36b9cedad7f41a6b9eb223b09b7186c_I20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18xMy9mcmFnOjVkY2JmNGI1ZTM3MzQyM2ZhMWY1NTcyM2Q3MTJlZWE1L3RhYmxlOjg4MmZmMDUyMmQ0NjRkYjdhZTY0MTg5MWY2NGEzODY3L3RhYmxlcmFuZ2U6ODgyZmYwNTIyZDQ2NGRiN2FlNjQxODkxZjY0YTM4NjdfMTEtMS0xLTEtMA_11aac481-36b7-46c6-b431-7eccd9cc52c0">588,434,836</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i066bb5b0a9e84c0a878b1e800703d92b_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18xMy9mcmFnOjVkY2JmNGI1ZTM3MzQyM2ZhMWY1NTcyM2Q3MTJlZWE1L3RhYmxlOjg4MmZmMDUyMmQ0NjRkYjdhZTY0MTg5MWY2NGEzODY3L3RhYmxlcmFuZ2U6ODgyZmYwNTIyZDQ2NGRiN2FlNjQxODkxZjY0YTM4NjdfMTEtMy0xLTEtMA_01c4394c-1be1-4439-aa3f-8cc37f863fe8">471,170,690</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fixed assets, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic36b9cedad7f41a6b9eb223b09b7186c_I20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18xMy9mcmFnOjVkY2JmNGI1ZTM3MzQyM2ZhMWY1NTcyM2Q3MTJlZWE1L3RhYmxlOjg4MmZmMDUyMmQ0NjRkYjdhZTY0MTg5MWY2NGEzODY3L3RhYmxlcmFuZ2U6ODgyZmYwNTIyZDQ2NGRiN2FlNjQxODkxZjY0YTM4NjdfMTItMS0xLTEtMA_508aad03-c705-4570-b103-9a8a571b21b2">10,930,312</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i066bb5b0a9e84c0a878b1e800703d92b_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18xMy9mcmFnOjVkY2JmNGI1ZTM3MzQyM2ZhMWY1NTcyM2Q3MTJlZWE1L3RhYmxlOjg4MmZmMDUyMmQ0NjRkYjdhZTY0MTg5MWY2NGEzODY3L3RhYmxlcmFuZ2U6ODgyZmYwNTIyZDQ2NGRiN2FlNjQxODkxZjY0YTM4NjdfMTItMy0xLTEtMA_8ef2e237-be81-4d62-9cc8-40091527473b">11,348,144</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Investment in affiliated entities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic36b9cedad7f41a6b9eb223b09b7186c_I20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:EquitySecuritiesFvNi" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18xMy9mcmFnOjVkY2JmNGI1ZTM3MzQyM2ZhMWY1NTcyM2Q3MTJlZWE1L3RhYmxlOjg4MmZmMDUyMmQ0NjRkYjdhZTY0MTg5MWY2NGEzODY3L3RhYmxlcmFuZ2U6ODgyZmYwNTIyZDQ2NGRiN2FlNjQxODkxZjY0YTM4NjdfMTMtMS0xLTEtMA_210bc4d8-8313-401f-b7d9-838573e6d94e">3,629,891</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i066bb5b0a9e84c0a878b1e800703d92b_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:EquitySecuritiesFvNi" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18xMy9mcmFnOjVkY2JmNGI1ZTM3MzQyM2ZhMWY1NTcyM2Q3MTJlZWE1L3RhYmxlOjg4MmZmMDUyMmQ0NjRkYjdhZTY0MTg5MWY2NGEzODY3L3RhYmxlcmFuZ2U6ODgyZmYwNTIyZDQ2NGRiN2FlNjQxODkxZjY0YTM4NjdfMTMtMy0xLTEtMA_cee38bc1-4c1d-45c8-b0e4-9358d1070ba1">4,460,366</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Investment in Geneos</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic36b9cedad7f41a6b9eb223b09b7186c_I20210331" decimals="0" format="ixt:zerodash" name="us-gaap:EquityMethodInvestments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18xMy9mcmFnOjVkY2JmNGI1ZTM3MzQyM2ZhMWY1NTcyM2Q3MTJlZWE1L3RhYmxlOjg4MmZmMDUyMmQ0NjRkYjdhZTY0MTg5MWY2NGEzODY3L3RhYmxlcmFuZ2U6ODgyZmYwNTIyZDQ2NGRiN2FlNjQxODkxZjY0YTM4NjdfMTQtMS0xLTEtMA_08a40d4e-1c8d-4a8c-9ac5-3ba3fda3793b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i066bb5b0a9e84c0a878b1e800703d92b_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:EquityMethodInvestments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18xMy9mcmFnOjVkY2JmNGI1ZTM3MzQyM2ZhMWY1NTcyM2Q3MTJlZWE1L3RhYmxlOjg4MmZmMDUyMmQ0NjRkYjdhZTY0MTg5MWY2NGEzODY3L3RhYmxlcmFuZ2U6ODgyZmYwNTIyZDQ2NGRiN2FlNjQxODkxZjY0YTM4NjdfMTQtMy0xLTEtMA_a2c232ed-00bb-4453-be6c-de18266d1ed7">434,387</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Intangible assets, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic36b9cedad7f41a6b9eb223b09b7186c_I20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18xMy9mcmFnOjVkY2JmNGI1ZTM3MzQyM2ZhMWY1NTcyM2Q3MTJlZWE1L3RhYmxlOjg4MmZmMDUyMmQ0NjRkYjdhZTY0MTg5MWY2NGEzODY3L3RhYmxlcmFuZ2U6ODgyZmYwNTIyZDQ2NGRiN2FlNjQxODkxZjY0YTM4NjdfMTUtMS0xLTEtMA_5bf36924-a30d-46ff-b1c5-1e504143acf5">3,010,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i066bb5b0a9e84c0a878b1e800703d92b_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18xMy9mcmFnOjVkY2JmNGI1ZTM3MzQyM2ZhMWY1NTcyM2Q3MTJlZWE1L3RhYmxlOjg4MmZmMDUyMmQ0NjRkYjdhZTY0MTg5MWY2NGEzODY3L3RhYmxlcmFuZ2U6ODgyZmYwNTIyZDQ2NGRiN2FlNjQxODkxZjY0YTM4NjdfMTUtMy0xLTEtMA_6a73ba62-cb7b-4010-b906-ecf5665252b6">3,146,770</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic36b9cedad7f41a6b9eb223b09b7186c_I20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18xMy9mcmFnOjVkY2JmNGI1ZTM3MzQyM2ZhMWY1NTcyM2Q3MTJlZWE1L3RhYmxlOjg4MmZmMDUyMmQ0NjRkYjdhZTY0MTg5MWY2NGEzODY3L3RhYmxlcmFuZ2U6ODgyZmYwNTIyZDQ2NGRiN2FlNjQxODkxZjY0YTM4NjdfMTYtMS0xLTEtMA_634a5bf1-bc61-4e4d-996f-29a620509dc2">10,513,371</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i066bb5b0a9e84c0a878b1e800703d92b_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18xMy9mcmFnOjVkY2JmNGI1ZTM3MzQyM2ZhMWY1NTcyM2Q3MTJlZWE1L3RhYmxlOjg4MmZmMDUyMmQ0NjRkYjdhZTY0MTg5MWY2NGEzODY3L3RhYmxlcmFuZ2U6ODgyZmYwNTIyZDQ2NGRiN2FlNjQxODkxZjY0YTM4NjdfMTYtMy0xLTEtMA_5a8784ff-e583-4350-8f4f-a831df00481f">10,513,371</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic36b9cedad7f41a6b9eb223b09b7186c_I20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18xMy9mcmFnOjVkY2JmNGI1ZTM3MzQyM2ZhMWY1NTcyM2Q3MTJlZWE1L3RhYmxlOjg4MmZmMDUyMmQ0NjRkYjdhZTY0MTg5MWY2NGEzODY3L3RhYmxlcmFuZ2U6ODgyZmYwNTIyZDQ2NGRiN2FlNjQxODkxZjY0YTM4NjdfMTctMS0xLTEtMA_8fabc858-2ce1-4a81-ad3d-aaaea9b08ebf">12,463,006</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i066bb5b0a9e84c0a878b1e800703d92b_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18xMy9mcmFnOjVkY2JmNGI1ZTM3MzQyM2ZhMWY1NTcyM2Q3MTJlZWE1L3RhYmxlOjg4MmZmMDUyMmQ0NjRkYjdhZTY0MTg5MWY2NGEzODY3L3RhYmxlcmFuZ2U6ODgyZmYwNTIyZDQ2NGRiN2FlNjQxODkxZjY0YTM4NjdfMTctMy0xLTEtMA_5ddf24ce-7e17-478a-a727-897e6fb84de9">12,741,296</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic36b9cedad7f41a6b9eb223b09b7186c_I20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsNoncurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18xMy9mcmFnOjVkY2JmNGI1ZTM3MzQyM2ZhMWY1NTcyM2Q3MTJlZWE1L3RhYmxlOjg4MmZmMDUyMmQ0NjRkYjdhZTY0MTg5MWY2NGEzODY3L3RhYmxlcmFuZ2U6ODgyZmYwNTIyZDQ2NGRiN2FlNjQxODkxZjY0YTM4NjdfMTgtMS0xLTEtMA_e34b386a-4967-4db4-ab93-e7be649d6f3d">25,881,934</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i066bb5b0a9e84c0a878b1e800703d92b_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsNoncurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18xMy9mcmFnOjVkY2JmNGI1ZTM3MzQyM2ZhMWY1NTcyM2Q3MTJlZWE1L3RhYmxlOjg4MmZmMDUyMmQ0NjRkYjdhZTY0MTg5MWY2NGEzODY3L3RhYmxlcmFuZ2U6ODgyZmYwNTIyZDQ2NGRiN2FlNjQxODkxZjY0YTM4NjdfMTgtMy0xLTEtMA_47677822-3fb2-4d54-9d3f-256de0ad216b">25,957,448</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic36b9cedad7f41a6b9eb223b09b7186c_I20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18xMy9mcmFnOjVkY2JmNGI1ZTM3MzQyM2ZhMWY1NTcyM2Q3MTJlZWE1L3RhYmxlOjg4MmZmMDUyMmQ0NjRkYjdhZTY0MTg5MWY2NGEzODY3L3RhYmxlcmFuZ2U6ODgyZmYwNTIyZDQ2NGRiN2FlNjQxODkxZjY0YTM4NjdfMTktMS0xLTEtMA_6ef473fc-794d-41f1-8a75-148e0c009369">654,863,350</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i066bb5b0a9e84c0a878b1e800703d92b_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18xMy9mcmFnOjVkY2JmNGI1ZTM3MzQyM2ZhMWY1NTcyM2Q3MTJlZWE1L3RhYmxlOjg4MmZmMDUyMmQ0NjRkYjdhZTY0MTg5MWY2NGEzODY3L3RhYmxlcmFuZ2U6ODgyZmYwNTIyZDQ2NGRiN2FlNjQxODkxZjY0YTM4NjdfMTktMy0xLTEtMA_9906ab90-2485-4f5f-8c46-a9f357b0ac06">539,772,472</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts payable and accrued expenses</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic36b9cedad7f41a6b9eb223b09b7186c_I20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18xMy9mcmFnOjVkY2JmNGI1ZTM3MzQyM2ZhMWY1NTcyM2Q3MTJlZWE1L3RhYmxlOjg4MmZmMDUyMmQ0NjRkYjdhZTY0MTg5MWY2NGEzODY3L3RhYmxlcmFuZ2U6ODgyZmYwNTIyZDQ2NGRiN2FlNjQxODkxZjY0YTM4NjdfMjItMS0xLTEtMA_debee0eb-6698-40a0-8159-c9a79bacc428">25,974,530</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i066bb5b0a9e84c0a878b1e800703d92b_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18xMy9mcmFnOjVkY2JmNGI1ZTM3MzQyM2ZhMWY1NTcyM2Q3MTJlZWE1L3RhYmxlOjg4MmZmMDUyMmQ0NjRkYjdhZTY0MTg5MWY2NGEzODY3L3RhYmxlcmFuZ2U6ODgyZmYwNTIyZDQ2NGRiN2FlNjQxODkxZjY0YTM4NjdfMjItMy0xLTEtMA_c25b21c2-3013-4b22-865c-c19dac7aef90">21,203,808</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts payable and accrued expenses due to affiliated entities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic36b9cedad7f41a6b9eb223b09b7186c_I20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DueToRelatedPartiesCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18xMy9mcmFnOjVkY2JmNGI1ZTM3MzQyM2ZhMWY1NTcyM2Q3MTJlZWE1L3RhYmxlOjg4MmZmMDUyMmQ0NjRkYjdhZTY0MTg5MWY2NGEzODY3L3RhYmxlcmFuZ2U6ODgyZmYwNTIyZDQ2NGRiN2FlNjQxODkxZjY0YTM4NjdfMjMtMS0xLTEtMA_806ce4f8-a5e3-41db-976e-a905db0d1ff3">768,261</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i066bb5b0a9e84c0a878b1e800703d92b_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DueToRelatedPartiesCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18xMy9mcmFnOjVkY2JmNGI1ZTM3MzQyM2ZhMWY1NTcyM2Q3MTJlZWE1L3RhYmxlOjg4MmZmMDUyMmQ0NjRkYjdhZTY0MTg5MWY2NGEzODY3L3RhYmxlcmFuZ2U6ODgyZmYwNTIyZDQ2NGRiN2FlNjQxODkxZjY0YTM4NjdfMjMtMy0xLTEtMA_777f8632-02bc-45ab-8875-2448fdaf93f2">642,969</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued clinical trial expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic36b9cedad7f41a6b9eb223b09b7186c_I20210331" decimals="0" format="ixt:numdotdecimal" name="ino:AccruedClinicalTrialExpenseCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18xMy9mcmFnOjVkY2JmNGI1ZTM3MzQyM2ZhMWY1NTcyM2Q3MTJlZWE1L3RhYmxlOjg4MmZmMDUyMmQ0NjRkYjdhZTY0MTg5MWY2NGEzODY3L3RhYmxlcmFuZ2U6ODgyZmYwNTIyZDQ2NGRiN2FlNjQxODkxZjY0YTM4NjdfMjQtMS0xLTEtMA_b97c2d79-8c29-451b-8503-979c273a7b51">7,370,869</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i066bb5b0a9e84c0a878b1e800703d92b_I20201231" decimals="0" format="ixt:numdotdecimal" name="ino:AccruedClinicalTrialExpenseCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18xMy9mcmFnOjVkY2JmNGI1ZTM3MzQyM2ZhMWY1NTcyM2Q3MTJlZWE1L3RhYmxlOjg4MmZmMDUyMmQ0NjRkYjdhZTY0MTg5MWY2NGEzODY3L3RhYmxlcmFuZ2U6ODgyZmYwNTIyZDQ2NGRiN2FlNjQxODkxZjY0YTM4NjdfMjQtMy0xLTEtMA_58ccd8ba-6e1d-4eb8-8fc9-c24154c5efd7">9,950,345</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic36b9cedad7f41a6b9eb223b09b7186c_I20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18xMy9mcmFnOjVkY2JmNGI1ZTM3MzQyM2ZhMWY1NTcyM2Q3MTJlZWE1L3RhYmxlOjg4MmZmMDUyMmQ0NjRkYjdhZTY0MTg5MWY2NGEzODY3L3RhYmxlcmFuZ2U6ODgyZmYwNTIyZDQ2NGRiN2FlNjQxODkxZjY0YTM4NjdfMjYtMS0xLTEtMA_6b6a0afd-b8bc-479b-8861-be4a4064bfe5">15,378</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i066bb5b0a9e84c0a878b1e800703d92b_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18xMy9mcmFnOjVkY2JmNGI1ZTM3MzQyM2ZhMWY1NTcyM2Q3MTJlZWE1L3RhYmxlOjg4MmZmMDUyMmQ0NjRkYjdhZTY0MTg5MWY2NGEzODY3L3RhYmxlcmFuZ2U6ODgyZmYwNTIyZDQ2NGRiN2FlNjQxODkxZjY0YTM4NjdfMjYtMy0xLTEtMA_ca6aef6f-fa92-48d9-bd09-52e40599248b">46,628</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred revenue from affiliated entities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic36b9cedad7f41a6b9eb223b09b7186c_I20210331" decimals="0" format="ixt:numdotdecimal" name="ino:ContractWithCustomerLiabilityAffiliatedEntityCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18xMy9mcmFnOjVkY2JmNGI1ZTM3MzQyM2ZhMWY1NTcyM2Q3MTJlZWE1L3RhYmxlOjg4MmZmMDUyMmQ0NjRkYjdhZTY0MTg5MWY2NGEzODY3L3RhYmxlcmFuZ2U6ODgyZmYwNTIyZDQ2NGRiN2FlNjQxODkxZjY0YTM4NjdfMjctMS0xLTEtMA_3fd00f3b-0dad-415c-8a39-af9f3491a333">39,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i066bb5b0a9e84c0a878b1e800703d92b_I20201231" decimals="0" format="ixt:zerodash" name="ino:ContractWithCustomerLiabilityAffiliatedEntityCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18xMy9mcmFnOjVkY2JmNGI1ZTM3MzQyM2ZhMWY1NTcyM2Q3MTJlZWE1L3RhYmxlOjg4MmZmMDUyMmQ0NjRkYjdhZTY0MTg5MWY2NGEzODY3L3RhYmxlcmFuZ2U6ODgyZmYwNTIyZDQ2NGRiN2FlNjQxODkxZjY0YTM4NjdfMjctMy0xLTEtMA_629f78ae-634b-4911-932e-4e65e88a0af4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic36b9cedad7f41a6b9eb223b09b7186c_I20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18xMy9mcmFnOjVkY2JmNGI1ZTM3MzQyM2ZhMWY1NTcyM2Q3MTJlZWE1L3RhYmxlOjg4MmZmMDUyMmQ0NjRkYjdhZTY0MTg5MWY2NGEzODY3L3RhYmxlcmFuZ2U6ODgyZmYwNTIyZDQ2NGRiN2FlNjQxODkxZjY0YTM4NjdfMjktMS0xLTEtMA_192a066b-066a-48c2-8637-79938916d9fa">2,395,928</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i066bb5b0a9e84c0a878b1e800703d92b_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18xMy9mcmFnOjVkY2JmNGI1ZTM3MzQyM2ZhMWY1NTcyM2Q3MTJlZWE1L3RhYmxlOjg4MmZmMDUyMmQ0NjRkYjdhZTY0MTg5MWY2NGEzODY3L3RhYmxlcmFuZ2U6ODgyZmYwNTIyZDQ2NGRiN2FlNjQxODkxZjY0YTM4NjdfMjktMy0xLTEtMA_08f133e0-86d8-4576-a5dc-24da4265e0b5">2,329,394</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Grant funding liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic36b9cedad7f41a6b9eb223b09b7186c_I20210331" decimals="0" format="ixt:numdotdecimal" name="ino:DeferredGrantFundingCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18xMy9mcmFnOjVkY2JmNGI1ZTM3MzQyM2ZhMWY1NTcyM2Q3MTJlZWE1L3RhYmxlOjg4MmZmMDUyMmQ0NjRkYjdhZTY0MTg5MWY2NGEzODY3L3RhYmxlcmFuZ2U6ODgyZmYwNTIyZDQ2NGRiN2FlNjQxODkxZjY0YTM4NjdfMzAtMS0xLTEtMA_5be0976e-19ea-43ef-8df5-1b50c8e790b4">4,975,484</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i066bb5b0a9e84c0a878b1e800703d92b_I20201231" decimals="0" format="ixt:numdotdecimal" name="ino:DeferredGrantFundingCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18xMy9mcmFnOjVkY2JmNGI1ZTM3MzQyM2ZhMWY1NTcyM2Q3MTJlZWE1L3RhYmxlOjg4MmZmMDUyMmQ0NjRkYjdhZTY0MTg5MWY2NGEzODY3L3RhYmxlcmFuZ2U6ODgyZmYwNTIyZDQ2NGRiN2FlNjQxODkxZjY0YTM4NjdfMzAtMy0xLTEtMA_fb990ce3-3afc-48e9-bdf9-02bb5cb1fc60">7,474,310</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Grant funding liability from affiliated entities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic36b9cedad7f41a6b9eb223b09b7186c_I20210331" decimals="0" format="ixt:zerodash" name="ino:DeferredGrantFundingFromAffiliateCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18xMy9mcmFnOjVkY2JmNGI1ZTM3MzQyM2ZhMWY1NTcyM2Q3MTJlZWE1L3RhYmxlOjg4MmZmMDUyMmQ0NjRkYjdhZTY0MTg5MWY2NGEzODY3L3RhYmxlcmFuZ2U6ODgyZmYwNTIyZDQ2NGRiN2FlNjQxODkxZjY0YTM4NjdfMzEtMS0xLTEtMA_58c706f7-0f44-4921-a548-084810473676">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i066bb5b0a9e84c0a878b1e800703d92b_I20201231" decimals="0" format="ixt:numdotdecimal" name="ino:DeferredGrantFundingFromAffiliateCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18xMy9mcmFnOjVkY2JmNGI1ZTM3MzQyM2ZhMWY1NTcyM2Q3MTJlZWE1L3RhYmxlOjg4MmZmMDUyMmQ0NjRkYjdhZTY0MTg5MWY2NGEzODY3L3RhYmxlcmFuZ2U6ODgyZmYwNTIyZDQ2NGRiN2FlNjQxODkxZjY0YTM4NjdfMzEtMy0xLTEtMA_f44c6b7d-1b62-49c4-ab6b-d1cddc95bfe2">58,500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic36b9cedad7f41a6b9eb223b09b7186c_I20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18xMy9mcmFnOjVkY2JmNGI1ZTM3MzQyM2ZhMWY1NTcyM2Q3MTJlZWE1L3RhYmxlOjg4MmZmMDUyMmQ0NjRkYjdhZTY0MTg5MWY2NGEzODY3L3RhYmxlcmFuZ2U6ODgyZmYwNTIyZDQ2NGRiN2FlNjQxODkxZjY0YTM4NjdfMzMtMS0xLTEtMA_6850d9d9-a753-40c8-a8b0-22bdf85c3825">41,539,450</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i066bb5b0a9e84c0a878b1e800703d92b_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18xMy9mcmFnOjVkY2JmNGI1ZTM3MzQyM2ZhMWY1NTcyM2Q3MTJlZWE1L3RhYmxlOjg4MmZmMDUyMmQ0NjRkYjdhZTY0MTg5MWY2NGEzODY3L3RhYmxlcmFuZ2U6ODgyZmYwNTIyZDQ2NGRiN2FlNjQxODkxZjY0YTM4NjdfMzMtMy0xLTEtMA_5f2396ff-cc35-4ce5-a975-3d0197364207">41,705,954</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred revenue, net of current portion</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic36b9cedad7f41a6b9eb223b09b7186c_I20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18xMy9mcmFnOjVkY2JmNGI1ZTM3MzQyM2ZhMWY1NTcyM2Q3MTJlZWE1L3RhYmxlOjg4MmZmMDUyMmQ0NjRkYjdhZTY0MTg5MWY2NGEzODY3L3RhYmxlcmFuZ2U6ODgyZmYwNTIyZDQ2NGRiN2FlNjQxODkxZjY0YTM4NjdfMzQtMS0xLTEtMA_ea0f1ed8-0f2d-4c30-a2eb-80501524698c">75,501</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i066bb5b0a9e84c0a878b1e800703d92b_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18xMy9mcmFnOjVkY2JmNGI1ZTM3MzQyM2ZhMWY1NTcyM2Q3MTJlZWE1L3RhYmxlOjg4MmZmMDUyMmQ0NjRkYjdhZTY0MTg5MWY2NGEzODY3L3RhYmxlcmFuZ2U6ODgyZmYwNTIyZDQ2NGRiN2FlNjQxODkxZjY0YTM4NjdfMzQtMy0xLTEtMA_db93c4ca-1f23-49b9-8cba-9cb2f0bfbc03">79,214</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Convertible senior notes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf1dda891fd044098c213cc6a530fa62_I20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ConvertibleDebt" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18xMy9mcmFnOjVkY2JmNGI1ZTM3MzQyM2ZhMWY1NTcyM2Q3MTJlZWE1L3RhYmxlOjg4MmZmMDUyMmQ0NjRkYjdhZTY0MTg5MWY2NGEzODY3L3RhYmxlcmFuZ2U6ODgyZmYwNTIyZDQ2NGRiN2FlNjQxODkxZjY0YTM4NjdfMzYtMS0xLTEtMA_34968e8f-142a-475b-b17b-7c2785d4d234">14,069,722</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i09cc78b6ef5244c28a45a7069619a8b5_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ConvertibleDebt" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18xMy9mcmFnOjVkY2JmNGI1ZTM3MzQyM2ZhMWY1NTcyM2Q3MTJlZWE1L3RhYmxlOjg4MmZmMDUyMmQ0NjRkYjdhZTY0MTg5MWY2NGEzODY3L3RhYmxlcmFuZ2U6ODgyZmYwNTIyZDQ2NGRiN2FlNjQxODkxZjY0YTM4NjdfMzYtMy0xLTEtMA_d5f57b14-d7c9-4460-8157-7d105e8bac1f">14,139,988</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Convertible bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icda7d72fec364e2ea292b925ab363121_I20210331" decimals="0" format="ixt:zerodash" name="us-gaap:ConvertibleDebt" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18xMy9mcmFnOjVkY2JmNGI1ZTM3MzQyM2ZhMWY1NTcyM2Q3MTJlZWE1L3RhYmxlOjg4MmZmMDUyMmQ0NjRkYjdhZTY0MTg5MWY2NGEzODY3L3RhYmxlcmFuZ2U6ODgyZmYwNTIyZDQ2NGRiN2FlNjQxODkxZjY0YTM4NjdfMzctMS0xLTEtMA_be0ee862-b697-44cb-b754-fb641bf396fb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc2893c2a85c477f8396936402f496e2_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ConvertibleDebt" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18xMy9mcmFnOjVkY2JmNGI1ZTM3MzQyM2ZhMWY1NTcyM2Q3MTJlZWE1L3RhYmxlOjg4MmZmMDUyMmQ0NjRkYjdhZTY0MTg5MWY2NGEzODY3L3RhYmxlcmFuZ2U6ODgyZmYwNTIyZDQ2NGRiN2FlNjQxODkxZjY0YTM4NjdfMzctMy0xLTEtMA_de76163a-5a3b-4e0e-b70e-1c7b7471b852">4,515,834</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease liability, net of current portion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic36b9cedad7f41a6b9eb223b09b7186c_I20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18xMy9mcmFnOjVkY2JmNGI1ZTM3MzQyM2ZhMWY1NTcyM2Q3MTJlZWE1L3RhYmxlOjg4MmZmMDUyMmQ0NjRkYjdhZTY0MTg5MWY2NGEzODY3L3RhYmxlcmFuZ2U6ODgyZmYwNTIyZDQ2NGRiN2FlNjQxODkxZjY0YTM4NjdfNDAtMS0xLTEtMA_1355fd6c-f5c6-432d-8310-54a67a3fc222">17,438,841</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i066bb5b0a9e84c0a878b1e800703d92b_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18xMy9mcmFnOjVkY2JmNGI1ZTM3MzQyM2ZhMWY1NTcyM2Q3MTJlZWE1L3RhYmxlOjg4MmZmMDUyMmQ0NjRkYjdhZTY0MTg5MWY2NGEzODY3L3RhYmxlcmFuZ2U6ODgyZmYwNTIyZDQ2NGRiN2FlNjQxODkxZjY0YTM4NjdfNDAtMy0xLTEtMA_d6173114-58a2-44b4-8607-7b85f962b485">18,063,515</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred tax liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic36b9cedad7f41a6b9eb223b09b7186c_I20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18xMy9mcmFnOjVkY2JmNGI1ZTM3MzQyM2ZhMWY1NTcyM2Q3MTJlZWE1L3RhYmxlOjg4MmZmMDUyMmQ0NjRkYjdhZTY0MTg5MWY2NGEzODY3L3RhYmxlcmFuZ2U6ODgyZmYwNTIyZDQ2NGRiN2FlNjQxODkxZjY0YTM4NjdfNDEtMS0xLTEtMA_4ff4e430-12bb-4257-97ea-388c96965bd5">32,046</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i066bb5b0a9e84c0a878b1e800703d92b_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18xMy9mcmFnOjVkY2JmNGI1ZTM3MzQyM2ZhMWY1NTcyM2Q3MTJlZWE1L3RhYmxlOjg4MmZmMDUyMmQ0NjRkYjdhZTY0MTg5MWY2NGEzODY3L3RhYmxlcmFuZ2U6ODgyZmYwNTIyZDQ2NGRiN2FlNjQxODkxZjY0YTM4NjdfNDEtMy0xLTEtMA_03942e07-5127-4c35-bfa9-924e8d4dc0ae">32,046</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Grant funding liability from affiliated entity, net of current portion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic36b9cedad7f41a6b9eb223b09b7186c_I20210331" decimals="0" format="ixt:numdotdecimal" name="ino:DeferredGrantFundingFromAffiliateNoncurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18xMy9mcmFnOjVkY2JmNGI1ZTM3MzQyM2ZhMWY1NTcyM2Q3MTJlZWE1L3RhYmxlOjg4MmZmMDUyMmQ0NjRkYjdhZTY0MTg5MWY2NGEzODY3L3RhYmxlcmFuZ2U6ODgyZmYwNTIyZDQ2NGRiN2FlNjQxODkxZjY0YTM4NjdfNDItMS0xLTEtMA_784f650c-cffd-416f-84ab-54c94d6b7717">37,500</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i066bb5b0a9e84c0a878b1e800703d92b_I20201231" decimals="0" format="ixt:numdotdecimal" name="ino:DeferredGrantFundingFromAffiliateNoncurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18xMy9mcmFnOjVkY2JmNGI1ZTM3MzQyM2ZhMWY1NTcyM2Q3MTJlZWE1L3RhYmxlOjg4MmZmMDUyMmQ0NjRkYjdhZTY0MTg5MWY2NGEzODY3L3RhYmxlcmFuZ2U6ODgyZmYwNTIyZDQ2NGRiN2FlNjQxODkxZjY0YTM4NjdfNDItMy0xLTEtMA_82b26004-e67f-41e7-876d-9f43269df0bb">37,500</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic36b9cedad7f41a6b9eb223b09b7186c_I20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesNoncurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18xMy9mcmFnOjVkY2JmNGI1ZTM3MzQyM2ZhMWY1NTcyM2Q3MTJlZWE1L3RhYmxlOjg4MmZmMDUyMmQ0NjRkYjdhZTY0MTg5MWY2NGEzODY3L3RhYmxlcmFuZ2U6ODgyZmYwNTIyZDQ2NGRiN2FlNjQxODkxZjY0YTM4NjdfNDMtMS0xLTEtMA_251907ce-a3b5-406e-9800-8a5d8541931e">64,141</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i066bb5b0a9e84c0a878b1e800703d92b_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesNoncurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18xMy9mcmFnOjVkY2JmNGI1ZTM3MzQyM2ZhMWY1NTcyM2Q3MTJlZWE1L3RhYmxlOjg4MmZmMDUyMmQ0NjRkYjdhZTY0MTg5MWY2NGEzODY3L3RhYmxlcmFuZ2U6ODgyZmYwNTIyZDQ2NGRiN2FlNjQxODkxZjY0YTM4NjdfNDMtMy0xLTEtMA_1b9f7923-628d-4d22-b2e2-1b0fa18e8ffc">57,663</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic36b9cedad7f41a6b9eb223b09b7186c_I20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18xMy9mcmFnOjVkY2JmNGI1ZTM3MzQyM2ZhMWY1NTcyM2Q3MTJlZWE1L3RhYmxlOjg4MmZmMDUyMmQ0NjRkYjdhZTY0MTg5MWY2NGEzODY3L3RhYmxlcmFuZ2U6ODgyZmYwNTIyZDQ2NGRiN2FlNjQxODkxZjY0YTM4NjdfNDQtMS0xLTEtMA_bfac19d5-cca0-4b3e-bd5f-da668b19718d">73,257,201</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i066bb5b0a9e84c0a878b1e800703d92b_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18xMy9mcmFnOjVkY2JmNGI1ZTM3MzQyM2ZhMWY1NTcyM2Q3MTJlZWE1L3RhYmxlOjg4MmZmMDUyMmQ0NjRkYjdhZTY0MTg5MWY2NGEzODY3L3RhYmxlcmFuZ2U6ODgyZmYwNTIyZDQ2NGRiN2FlNjQxODkxZjY0YTM4NjdfNDQtMy0xLTEtMA_22532fc3-1ef5-4f95-ab2f-0f503f771de6">78,631,714</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Stockholders&#8217; equity:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Preferred stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic36b9cedad7f41a6b9eb223b09b7186c_I20210331" decimals="0" format="ixt:zerodash" name="us-gaap:PreferredStockValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18xMy9mcmFnOjVkY2JmNGI1ZTM3MzQyM2ZhMWY1NTcyM2Q3MTJlZWE1L3RhYmxlOjg4MmZmMDUyMmQ0NjRkYjdhZTY0MTg5MWY2NGEzODY3L3RhYmxlcmFuZ2U6ODgyZmYwNTIyZDQ2NGRiN2FlNjQxODkxZjY0YTM4NjdfNDYtMS0xLTEtMA_8fec68e8-ab69-47f0-bcab-302244ff6d35">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i066bb5b0a9e84c0a878b1e800703d92b_I20201231" decimals="0" format="ixt:zerodash" name="us-gaap:PreferredStockValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18xMy9mcmFnOjVkY2JmNGI1ZTM3MzQyM2ZhMWY1NTcyM2Q3MTJlZWE1L3RhYmxlOjg4MmZmMDUyMmQ0NjRkYjdhZTY0MTg5MWY2NGEzODY3L3RhYmxlcmFuZ2U6ODgyZmYwNTIyZDQ2NGRiN2FlNjQxODkxZjY0YTM4NjdfNDYtMy0xLTEtMA_4fbff785-5bca-4ea5-8c99-ac51fb986e03">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic36b9cedad7f41a6b9eb223b09b7186c_I20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CommonStockValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18xMy9mcmFnOjVkY2JmNGI1ZTM3MzQyM2ZhMWY1NTcyM2Q3MTJlZWE1L3RhYmxlOjg4MmZmMDUyMmQ0NjRkYjdhZTY0MTg5MWY2NGEzODY3L3RhYmxlcmFuZ2U6ODgyZmYwNTIyZDQ2NGRiN2FlNjQxODkxZjY0YTM4NjdfNDctMS0xLTEtMA_9ecd81a0-ad83-475d-bc2f-dbd85ee26659">209,333</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i066bb5b0a9e84c0a878b1e800703d92b_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CommonStockValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18xMy9mcmFnOjVkY2JmNGI1ZTM3MzQyM2ZhMWY1NTcyM2Q3MTJlZWE1L3RhYmxlOjg4MmZmMDUyMmQ0NjRkYjdhZTY0MTg5MWY2NGEzODY3L3RhYmxlcmFuZ2U6ODgyZmYwNTIyZDQ2NGRiN2FlNjQxODkxZjY0YTM4NjdfNDctMy0xLTEtMA_04aaa9ef-c050-4ea2-974c-fbfab7271b8b">186,851</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic36b9cedad7f41a6b9eb223b09b7186c_I20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapital" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18xMy9mcmFnOjVkY2JmNGI1ZTM3MzQyM2ZhMWY1NTcyM2Q3MTJlZWE1L3RhYmxlOjg4MmZmMDUyMmQ0NjRkYjdhZTY0MTg5MWY2NGEzODY3L3RhYmxlcmFuZ2U6ODgyZmYwNTIyZDQ2NGRiN2FlNjQxODkxZjY0YTM4NjdfNDgtMS0xLTEtMA_201efff1-e066-4b9f-95f6-e2c7e7611166">1,542,261,467</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i066bb5b0a9e84c0a878b1e800703d92b_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapital" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18xMy9mcmFnOjVkY2JmNGI1ZTM3MzQyM2ZhMWY1NTcyM2Q3MTJlZWE1L3RhYmxlOjg4MmZmMDUyMmQ0NjRkYjdhZTY0MTg5MWY2NGEzODY3L3RhYmxlcmFuZ2U6ODgyZmYwNTIyZDQ2NGRiN2FlNjQxODkxZjY0YTM4NjdfNDgtMy0xLTEtMA_d6236880-41ae-4875-a816-5e4c2d427c98">1,367,406,869</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accumulated deficit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic36b9cedad7f41a6b9eb223b09b7186c_I20210331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18xMy9mcmFnOjVkY2JmNGI1ZTM3MzQyM2ZhMWY1NTcyM2Q3MTJlZWE1L3RhYmxlOjg4MmZmMDUyMmQ0NjRkYjdhZTY0MTg5MWY2NGEzODY3L3RhYmxlcmFuZ2U6ODgyZmYwNTIyZDQ2NGRiN2FlNjQxODkxZjY0YTM4NjdfNDktMS0xLTEtMA_57528c28-4604-4dd2-bd72-1ca521695f1c">960,598,943</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i066bb5b0a9e84c0a878b1e800703d92b_I20201231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18xMy9mcmFnOjVkY2JmNGI1ZTM3MzQyM2ZhMWY1NTcyM2Q3MTJlZWE1L3RhYmxlOjg4MmZmMDUyMmQ0NjRkYjdhZTY0MTg5MWY2NGEzODY3L3RhYmxlcmFuZ2U6ODgyZmYwNTIyZDQ2NGRiN2FlNjQxODkxZjY0YTM4NjdfNDktMy0xLTEtMA_285d94f8-7501-4948-92ab-288856160940">906,196,812</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accumulated other comprehensive loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic36b9cedad7f41a6b9eb223b09b7186c_I20210331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18xMy9mcmFnOjVkY2JmNGI1ZTM3MzQyM2ZhMWY1NTcyM2Q3MTJlZWE1L3RhYmxlOjg4MmZmMDUyMmQ0NjRkYjdhZTY0MTg5MWY2NGEzODY3L3RhYmxlcmFuZ2U6ODgyZmYwNTIyZDQ2NGRiN2FlNjQxODkxZjY0YTM4NjdfNTAtMS0xLTEtMA_981653ba-bd72-4f3a-97ea-faed00b625d3">265,708</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i066bb5b0a9e84c0a878b1e800703d92b_I20201231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18xMy9mcmFnOjVkY2JmNGI1ZTM3MzQyM2ZhMWY1NTcyM2Q3MTJlZWE1L3RhYmxlOjg4MmZmMDUyMmQ0NjRkYjdhZTY0MTg5MWY2NGEzODY3L3RhYmxlcmFuZ2U6ODgyZmYwNTIyZDQ2NGRiN2FlNjQxODkxZjY0YTM4NjdfNTAtMy0xLTEtMA_1dca97f5-f913-4e4d-bf38-9586bec96fbe">256,150</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total Inovio Pharmaceuticals, Inc. stockholders&#8217; equity</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic36b9cedad7f41a6b9eb223b09b7186c_I20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18xMy9mcmFnOjVkY2JmNGI1ZTM3MzQyM2ZhMWY1NTcyM2Q3MTJlZWE1L3RhYmxlOjg4MmZmMDUyMmQ0NjRkYjdhZTY0MTg5MWY2NGEzODY3L3RhYmxlcmFuZ2U6ODgyZmYwNTIyZDQ2NGRiN2FlNjQxODkxZjY0YTM4NjdfNTEtMS0xLTEtMA_879fbbd5-6af7-4368-a267-9ef16c566846">581,606,149</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i066bb5b0a9e84c0a878b1e800703d92b_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18xMy9mcmFnOjVkY2JmNGI1ZTM3MzQyM2ZhMWY1NTcyM2Q3MTJlZWE1L3RhYmxlOjg4MmZmMDUyMmQ0NjRkYjdhZTY0MTg5MWY2NGEzODY3L3RhYmxlcmFuZ2U6ODgyZmYwNTIyZDQ2NGRiN2FlNjQxODkxZjY0YTM4NjdfNTEtMy0xLTEtMA_88562dfe-16a7-49e3-9b76-754e2ae2eea7">461,140,758</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total liabilities and stockholders&#8217; equity</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic36b9cedad7f41a6b9eb223b09b7186c_I20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18xMy9mcmFnOjVkY2JmNGI1ZTM3MzQyM2ZhMWY1NTcyM2Q3MTJlZWE1L3RhYmxlOjg4MmZmMDUyMmQ0NjRkYjdhZTY0MTg5MWY2NGEzODY3L3RhYmxlcmFuZ2U6ODgyZmYwNTIyZDQ2NGRiN2FlNjQxODkxZjY0YTM4NjdfNTQtMS0xLTEtMA_55a7dcea-5957-4797-b8da-418bfa4b745c">654,863,350</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i066bb5b0a9e84c0a878b1e800703d92b_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18xMy9mcmFnOjVkY2JmNGI1ZTM3MzQyM2ZhMWY1NTcyM2Q3MTJlZWE1L3RhYmxlOjg4MmZmMDUyMmQ0NjRkYjdhZTY0MTg5MWY2NGEzODY3L3RhYmxlcmFuZ2U6ODgyZmYwNTIyZDQ2NGRiN2FlNjQxODkxZjY0YTM4NjdfNTQtMy0xLTEtMA_e9a8b0ef-ac0c-45d9-87a2-1b10c6e6db9a">539,772,472</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to unaudited condensed consolidated financial statements.</span></div><div style="height:31.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><div id="i1d23d16a69484b63aa007ec686e80337_16"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INOVIO PHARMACEUTICALS, INC.</span></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</span></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:75.415%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.960%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.557%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.568%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Revenues:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue under collaborative research and development arrangements</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i09001f493159423f9996d4b99e003558_D20210101-20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18xNi9mcmFnOjAwM2U2NzdhMmJmMDRhYTM4NWVmMjFlNzAzNTYxZmUzL3RhYmxlOmYxNTM5MTVmMTRmMTQ3NzRhY2Y1ZGIzNTcxZmYxM2NhL3RhYmxlcmFuZ2U6ZjE1MzkxNWYxNGYxNDc3NGFjZjVkYjM1NzFmZjEzY2FfMy0xLTEtMS0w_128e5863-2b7e-4bfa-a7f9-bd9ce8b0dd55">39,615</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b0dec7a04644e5da0ed8efcc8dcc6e4_D20200101-20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18xNi9mcmFnOjAwM2U2NzdhMmJmMDRhYTM4NWVmMjFlNzAzNTYxZmUzL3RhYmxlOmYxNTM5MTVmMTRmMTQ3NzRhY2Y1ZGIzNTcxZmYxM2NhL3RhYmxlcmFuZ2U6ZjE1MzkxNWYxNGYxNDc3NGFjZjVkYjM1NzFmZjEzY2FfMy0zLTEtMS0w_1cef2734-cca8-4965-9016-6ef9b8d07ecd">71,500</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue under collaborative research and development arrangements with affiliated entities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e683dd292fa4879b525cd0f84179804_D20210101-20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18xNi9mcmFnOjAwM2U2NzdhMmJmMDRhYTM4NWVmMjFlNzAzNTYxZmUzL3RhYmxlOmYxNTM5MTVmMTRmMTQ3NzRhY2Y1ZGIzNTcxZmYxM2NhL3RhYmxlcmFuZ2U6ZjE1MzkxNWYxNGYxNDc3NGFjZjVkYjM1NzFmZjEzY2FfNC0xLTEtMS0w_f26a804c-eb93-47ae-8fe2-f0594a243364">49,949</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i800a1e3bd482439e9d1e93a9ff22ac27_D20200101-20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18xNi9mcmFnOjAwM2U2NzdhMmJmMDRhYTM4NWVmMjFlNzAzNTYxZmUzL3RhYmxlOmYxNTM5MTVmMTRmMTQ3NzRhY2Y1ZGIzNTcxZmYxM2NhL3RhYmxlcmFuZ2U6ZjE1MzkxNWYxNGYxNDc3NGFjZjVkYjM1NzFmZjEzY2FfNC0zLTEtMS0w_c9984c10-ec9f-4233-905f-6f00bfaf3cbe">1,172,126</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica16a3607c6a4031a1fa37be362346d3_D20210101-20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18xNi9mcmFnOjAwM2U2NzdhMmJmMDRhYTM4NWVmMjFlNzAzNTYxZmUzL3RhYmxlOmYxNTM5MTVmMTRmMTQ3NzRhY2Y1ZGIzNTcxZmYxM2NhL3RhYmxlcmFuZ2U6ZjE1MzkxNWYxNGYxNDc3NGFjZjVkYjM1NzFmZjEzY2FfNS0xLTEtMS0w_f971d145-7c10-4304-a3c3-976196c8a424">281,556</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72f1fa77c5894104884af93e5e365e2a_D20200101-20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18xNi9mcmFnOjAwM2U2NzdhMmJmMDRhYTM4NWVmMjFlNzAzNTYxZmUzL3RhYmxlOmYxNTM5MTVmMTRmMTQ3NzRhY2Y1ZGIzNTcxZmYxM2NhL3RhYmxlcmFuZ2U6ZjE1MzkxNWYxNGYxNDc3NGFjZjVkYjM1NzFmZjEzY2FfNS0zLTEtMS0w_8cd3d54d-3dd7-4939-a69c-9fd411328dbc">83,648</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total revenues</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18xNi9mcmFnOjAwM2U2NzdhMmJmMDRhYTM4NWVmMjFlNzAzNTYxZmUzL3RhYmxlOmYxNTM5MTVmMTRmMTQ3NzRhY2Y1ZGIzNTcxZmYxM2NhL3RhYmxlcmFuZ2U6ZjE1MzkxNWYxNGYxNDc3NGFjZjVkYjM1NzFmZjEzY2FfOC0xLTEtMS0w_725d10bf-d296-4b17-886a-edafb698421e">371,120</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03bccaa0abfb4733b1e2831ecde4e4e8_D20200101-20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18xNi9mcmFnOjAwM2U2NzdhMmJmMDRhYTM4NWVmMjFlNzAzNTYxZmUzL3RhYmxlOmYxNTM5MTVmMTRmMTQ3NzRhY2Y1ZGIzNTcxZmYxM2NhL3RhYmxlcmFuZ2U6ZjE1MzkxNWYxNGYxNDc3NGFjZjVkYjM1NzFmZjEzY2FfOC0zLTEtMS0w_84cb229a-a2f9-4f80-a808-2b05b95f1656">1,327,274</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18xNi9mcmFnOjAwM2U2NzdhMmJmMDRhYTM4NWVmMjFlNzAzNTYxZmUzL3RhYmxlOmYxNTM5MTVmMTRmMTQ3NzRhY2Y1ZGIzNTcxZmYxM2NhL3RhYmxlcmFuZ2U6ZjE1MzkxNWYxNGYxNDc3NGFjZjVkYjM1NzFmZjEzY2FfMTAtMS0xLTEtMA_2795fb7c-01ee-41c6-8e2b-3add1b8f04ff">39,044,418</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03bccaa0abfb4733b1e2831ecde4e4e8_D20200101-20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18xNi9mcmFnOjAwM2U2NzdhMmJmMDRhYTM4NWVmMjFlNzAzNTYxZmUzL3RhYmxlOmYxNTM5MTVmMTRmMTQ3NzRhY2Y1ZGIzNTcxZmYxM2NhL3RhYmxlcmFuZ2U6ZjE1MzkxNWYxNGYxNDc3NGFjZjVkYjM1NzFmZjEzY2FfMTAtMy0xLTEtMA_41b522e9-7305-436d-8c82-ac954c249edd">19,111,188</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18xNi9mcmFnOjAwM2U2NzdhMmJmMDRhYTM4NWVmMjFlNzAzNTYxZmUzL3RhYmxlOmYxNTM5MTVmMTRmMTQ3NzRhY2Y1ZGIzNTcxZmYxM2NhL3RhYmxlcmFuZ2U6ZjE1MzkxNWYxNGYxNDc3NGFjZjVkYjM1NzFmZjEzY2FfMTEtMS0xLTEtMA_663fa66a-a32e-4634-b0e2-d9d74b6746ad">13,881,194</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03bccaa0abfb4733b1e2831ecde4e4e8_D20200101-20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18xNi9mcmFnOjAwM2U2NzdhMmJmMDRhYTM4NWVmMjFlNzAzNTYxZmUzL3RhYmxlOmYxNTM5MTVmMTRmMTQ3NzRhY2Y1ZGIzNTcxZmYxM2NhL3RhYmxlcmFuZ2U6ZjE1MzkxNWYxNGYxNDc3NGFjZjVkYjM1NzFmZjEzY2FfMTEtMy0xLTEtMA_7cdfb58a-160d-4f36-b61c-a9e6752eb6bd">7,448,354</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18xNi9mcmFnOjAwM2U2NzdhMmJmMDRhYTM4NWVmMjFlNzAzNTYxZmUzL3RhYmxlOmYxNTM5MTVmMTRmMTQ3NzRhY2Y1ZGIzNTcxZmYxM2NhL3RhYmxlcmFuZ2U6ZjE1MzkxNWYxNGYxNDc3NGFjZjVkYjM1NzFmZjEzY2FfMTMtMS0xLTEtMA_68cb96e1-40e9-43bf-85f5-3f5df05cc201">52,925,612</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03bccaa0abfb4733b1e2831ecde4e4e8_D20200101-20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18xNi9mcmFnOjAwM2U2NzdhMmJmMDRhYTM4NWVmMjFlNzAzNTYxZmUzL3RhYmxlOmYxNTM5MTVmMTRmMTQ3NzRhY2Y1ZGIzNTcxZmYxM2NhL3RhYmxlcmFuZ2U6ZjE1MzkxNWYxNGYxNDc3NGFjZjVkYjM1NzFmZjEzY2FfMTMtMy0xLTEtMA_96342e63-ed0e-4f0b-9734-f8ceb226a0ab">26,559,542</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Loss from operations</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18xNi9mcmFnOjAwM2U2NzdhMmJmMDRhYTM4NWVmMjFlNzAzNTYxZmUzL3RhYmxlOmYxNTM5MTVmMTRmMTQ3NzRhY2Y1ZGIzNTcxZmYxM2NhL3RhYmxlcmFuZ2U6ZjE1MzkxNWYxNGYxNDc3NGFjZjVkYjM1NzFmZjEzY2FfMTQtMS0xLTEtMA_0e9f9b99-402f-4de5-8c65-73c6bd264e99">52,554,492</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i03bccaa0abfb4733b1e2831ecde4e4e8_D20200101-20200331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18xNi9mcmFnOjAwM2U2NzdhMmJmMDRhYTM4NWVmMjFlNzAzNTYxZmUzL3RhYmxlOmYxNTM5MTVmMTRmMTQ3NzRhY2Y1ZGIzNTcxZmYxM2NhL3RhYmxlcmFuZ2U6ZjE1MzkxNWYxNGYxNDc3NGFjZjVkYjM1NzFmZjEzY2FfMTQtMy0xLTEtMA_ac896295-a1d1-4b7d-8134-92bdd454d146">25,232,268</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other income (expense):</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InterestIncomeOperating" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18xNi9mcmFnOjAwM2U2NzdhMmJmMDRhYTM4NWVmMjFlNzAzNTYxZmUzL3RhYmxlOmYxNTM5MTVmMTRmMTQ3NzRhY2Y1ZGIzNTcxZmYxM2NhL3RhYmxlcmFuZ2U6ZjE1MzkxNWYxNGYxNDc3NGFjZjVkYjM1NzFmZjEzY2FfMTYtMS0xLTEtMA_490f0e8b-92c9-4967-ae6a-ce510152f66b">769,237</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03bccaa0abfb4733b1e2831ecde4e4e8_D20200101-20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InterestIncomeOperating" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18xNi9mcmFnOjAwM2U2NzdhMmJmMDRhYTM4NWVmMjFlNzAzNTYxZmUzL3RhYmxlOmYxNTM5MTVmMTRmMTQ3NzRhY2Y1ZGIzNTcxZmYxM2NhL3RhYmxlcmFuZ2U6ZjE1MzkxNWYxNGYxNDc3NGFjZjVkYjM1NzFmZjEzY2FfMTYtMy0xLTEtMA_ff93a11e-50e6-4a72-b581-66d6a0f4bfbe">416,569</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InterestExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18xNi9mcmFnOjAwM2U2NzdhMmJmMDRhYTM4NWVmMjFlNzAzNTYxZmUzL3RhYmxlOmYxNTM5MTVmMTRmMTQ3NzRhY2Y1ZGIzNTcxZmYxM2NhL3RhYmxlcmFuZ2U6ZjE1MzkxNWYxNGYxNDc3NGFjZjVkYjM1NzFmZjEzY2FfMTctMS0xLTEtMA_5370f412-e08b-4721-b031-7a386832d046">513,034</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i03bccaa0abfb4733b1e2831ecde4e4e8_D20200101-20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InterestExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18xNi9mcmFnOjAwM2U2NzdhMmJmMDRhYTM4NWVmMjFlNzAzNTYxZmUzL3RhYmxlOmYxNTM5MTVmMTRmMTQ3NzRhY2Y1ZGIzNTcxZmYxM2NhL3RhYmxlcmFuZ2U6ZjE1MzkxNWYxNGYxNDc3NGFjZjVkYjM1NzFmZjEzY2FfMTctMy0xLTEtMA_e0fb695e-2378-4783-b634-1929bcf31867">2,803,755</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of derivative liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331" decimals="0" format="ixt:zerodash" name="us-gaap:EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18xNi9mcmFnOjAwM2U2NzdhMmJmMDRhYTM4NWVmMjFlNzAzNTYxZmUzL3RhYmxlOmYxNTM5MTVmMTRmMTQ3NzRhY2Y1ZGIzNTcxZmYxM2NhL3RhYmxlcmFuZ2U6ZjE1MzkxNWYxNGYxNDc3NGFjZjVkYjM1NzFmZjEzY2FfMTktMS0xLTEtMA_ea674d29-d909-4fa6-890f-ab9e165dac47">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i03bccaa0abfb4733b1e2831ecde4e4e8_D20200101-20200331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18xNi9mcmFnOjAwM2U2NzdhMmJmMDRhYTM4NWVmMjFlNzAzNTYxZmUzL3RhYmxlOmYxNTM5MTVmMTRmMTQ3NzRhY2Y1ZGIzNTcxZmYxM2NhL3RhYmxlcmFuZ2U6ZjE1MzkxNWYxNGYxNDc3NGFjZjVkYjM1NzFmZjEzY2FfMTktMy0xLTEtMA_2f494188-82c3-4d26-a34b-0e54b19bacda">13,221,977</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain (loss) on investment in affiliated entities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331" decimals="0" sign="-" format="ixt:numdotdecimal" name="ino:ChangeInValueOfInvestmentsInAffiliatedCompany" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18xNi9mcmFnOjAwM2U2NzdhMmJmMDRhYTM4NWVmMjFlNzAzNTYxZmUzL3RhYmxlOmYxNTM5MTVmMTRmMTQ3NzRhY2Y1ZGIzNTcxZmYxM2NhL3RhYmxlcmFuZ2U6ZjE1MzkxNWYxNGYxNDc3NGFjZjVkYjM1NzFmZjEzY2FfMjAtMS0xLTEtMA_636071a6-3d45-4182-95e0-4224adaa1b8f">830,475</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03bccaa0abfb4733b1e2831ecde4e4e8_D20200101-20200331" decimals="0" format="ixt:numdotdecimal" name="ino:ChangeInValueOfInvestmentsInAffiliatedCompany" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18xNi9mcmFnOjAwM2U2NzdhMmJmMDRhYTM4NWVmMjFlNzAzNTYxZmUzL3RhYmxlOmYxNTM5MTVmMTRmMTQ3NzRhY2Y1ZGIzNTcxZmYxM2NhL3RhYmxlcmFuZ2U6ZjE1MzkxNWYxNGYxNDc3NGFjZjVkYjM1NzFmZjEzY2FfMjAtMy0xLTEtMA_98d42e4b-c21a-468a-8da8-cacf6a4cdc34">13,181,619</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net unrealized loss on available-for-sale equity securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18xNi9mcmFnOjAwM2U2NzdhMmJmMDRhYTM4NWVmMjFlNzAzNTYxZmUzL3RhYmxlOmYxNTM5MTVmMTRmMTQ3NzRhY2Y1ZGIzNTcxZmYxM2NhL3RhYmxlcmFuZ2U6ZjE1MzkxNWYxNGYxNDc3NGFjZjVkYjM1NzFmZjEzY2FfMjEtMS0xLTEtMA_66d4a8d1-1268-4e39-a200-a1cdfa431b1b">847,958</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i03bccaa0abfb4733b1e2831ecde4e4e8_D20200101-20200331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18xNi9mcmFnOjAwM2U2NzdhMmJmMDRhYTM4NWVmMjFlNzAzNTYxZmUzL3RhYmxlOmYxNTM5MTVmMTRmMTQ3NzRhY2Y1ZGIzNTcxZmYxM2NhL3RhYmxlcmFuZ2U6ZjE1MzkxNWYxNGYxNDc3NGFjZjVkYjM1NzFmZjEzY2FfMjEtMy0xLTEtMA_ff5043de-f84a-4ade-b7e4-266a073f51f9">5,050,092</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense), net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingIncomeExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18xNi9mcmFnOjAwM2U2NzdhMmJmMDRhYTM4NWVmMjFlNzAzNTYxZmUzL3RhYmxlOmYxNTM5MTVmMTRmMTQ3NzRhY2Y1ZGIzNTcxZmYxM2NhL3RhYmxlcmFuZ2U6ZjE1MzkxNWYxNGYxNDc3NGFjZjVkYjM1NzFmZjEzY2FfMjItMS0xLTEtMA_7434d35c-c911-40e8-be4b-ebad8347384b">8,978</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i03bccaa0abfb4733b1e2831ecde4e4e8_D20200101-20200331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingIncomeExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18xNi9mcmFnOjAwM2U2NzdhMmJmMDRhYTM4NWVmMjFlNzAzNTYxZmUzL3RhYmxlOmYxNTM5MTVmMTRmMTQ3NzRhY2Y1ZGIzNTcxZmYxM2NhL3RhYmxlcmFuZ2U6ZjE1MzkxNWYxNGYxNDc3NGFjZjVkYjM1NzFmZjEzY2FfMjItMy0xLTEtMA_a7e20eed-fc7a-4c66-8b1a-a788b3c08d21">425,500</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net loss before share in net loss of Geneos</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18xNi9mcmFnOjAwM2U2NzdhMmJmMDRhYTM4NWVmMjFlNzAzNTYxZmUzL3RhYmxlOmYxNTM5MTVmMTRmMTQ3NzRhY2Y1ZGIzNTcxZmYxM2NhL3RhYmxlcmFuZ2U6ZjE1MzkxNWYxNGYxNDc3NGFjZjVkYjM1NzFmZjEzY2FfMjctMS0xLTEtMA_c7d8d3a4-25d3-46c2-89c7-3458b1d1c46f">53,967,744</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i03bccaa0abfb4733b1e2831ecde4e4e8_D20200101-20200331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18xNi9mcmFnOjAwM2U2NzdhMmJmMDRhYTM4NWVmMjFlNzAzNTYxZmUzL3RhYmxlOmYxNTM5MTVmMTRmMTQ3NzRhY2Y1ZGIzNTcxZmYxM2NhL3RhYmxlcmFuZ2U6ZjE1MzkxNWYxNGYxNDc3NGFjZjVkYjM1NzFmZjEzY2FfMjctMy0xLTEtMA_be547f15-4ae2-4220-b947-3624f0fa67c2">33,135,404</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share in net loss of Geneos</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18xNi9mcmFnOjAwM2U2NzdhMmJmMDRhYTM4NWVmMjFlNzAzNTYxZmUzL3RhYmxlOmYxNTM5MTVmMTRmMTQ3NzRhY2Y1ZGIzNTcxZmYxM2NhL3RhYmxlcmFuZ2U6ZjE1MzkxNWYxNGYxNDc3NGFjZjVkYjM1NzFmZjEzY2FfMjktMS0xLTEtMA_bdb4a9ed-61e5-4d7a-aeda-b3b08b2b6aa0">434,387</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03bccaa0abfb4733b1e2831ecde4e4e8_D20200101-20200331" decimals="0" format="ixt:zerodash" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18xNi9mcmFnOjAwM2U2NzdhMmJmMDRhYTM4NWVmMjFlNzAzNTYxZmUzL3RhYmxlOmYxNTM5MTVmMTRmMTQ3NzRhY2Y1ZGIzNTcxZmYxM2NhL3RhYmxlcmFuZ2U6ZjE1MzkxNWYxNGYxNDc3NGFjZjVkYjM1NzFmZjEzY2FfMjktMy0xLTEtMA_f97650a2-2557-433a-8f84-f0182ba11055">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18xNi9mcmFnOjAwM2U2NzdhMmJmMDRhYTM4NWVmMjFlNzAzNTYxZmUzL3RhYmxlOmYxNTM5MTVmMTRmMTQ3NzRhY2Y1ZGIzNTcxZmYxM2NhL3RhYmxlcmFuZ2U6ZjE1MzkxNWYxNGYxNDc3NGFjZjVkYjM1NzFmZjEzY2FfMzAtMS0xLTEtMA_ef26fe6c-4fe6-4acb-adc4-f5625422c78f">54,402,131</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i03bccaa0abfb4733b1e2831ecde4e4e8_D20200101-20200331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18xNi9mcmFnOjAwM2U2NzdhMmJmMDRhYTM4NWVmMjFlNzAzNTYxZmUzL3RhYmxlOmYxNTM5MTVmMTRmMTQ3NzRhY2Y1ZGIzNTcxZmYxM2NhL3RhYmxlcmFuZ2U6ZjE1MzkxNWYxNGYxNDc3NGFjZjVkYjM1NzFmZjEzY2FfMzAtMy0xLTEtMA_57ceb320-113d-4a44-b4af-e43c56a14692">33,135,404</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to non-controlling interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331" decimals="0" format="ixt:zerodash" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18xNi9mcmFnOjAwM2U2NzdhMmJmMDRhYTM4NWVmMjFlNzAzNTYxZmUzL3RhYmxlOmYxNTM5MTVmMTRmMTQ3NzRhY2Y1ZGIzNTcxZmYxM2NhL3RhYmxlcmFuZ2U6ZjE1MzkxNWYxNGYxNDc3NGFjZjVkYjM1NzFmZjEzY2FfMzEtMS0xLTEtMA_9596f5bc-84d1-426a-8905-0ca0a60984e4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03bccaa0abfb4733b1e2831ecde4e4e8_D20200101-20200331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18xNi9mcmFnOjAwM2U2NzdhMmJmMDRhYTM4NWVmMjFlNzAzNTYxZmUzL3RhYmxlOmYxNTM5MTVmMTRmMTQ3NzRhY2Y1ZGIzNTcxZmYxM2NhL3RhYmxlcmFuZ2U6ZjE1MzkxNWYxNGYxNDc3NGFjZjVkYjM1NzFmZjEzY2FfMzEtMy0xLTEtMA_8cdc640b-4db3-4954-b729-b4071dccc0cd">594,350</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net loss attributable to Inovio Pharmaceuticals, Inc.</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18xNi9mcmFnOjAwM2U2NzdhMmJmMDRhYTM4NWVmMjFlNzAzNTYxZmUzL3RhYmxlOmYxNTM5MTVmMTRmMTQ3NzRhY2Y1ZGIzNTcxZmYxM2NhL3RhYmxlcmFuZ2U6ZjE1MzkxNWYxNGYxNDc3NGFjZjVkYjM1NzFmZjEzY2FfMzItMS0xLTEtMA_05d2ee85-5c22-43c6-9e13-45138d9bf877">54,402,131</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i03bccaa0abfb4733b1e2831ecde4e4e8_D20200101-20200331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18xNi9mcmFnOjAwM2U2NzdhMmJmMDRhYTM4NWVmMjFlNzAzNTYxZmUzL3RhYmxlOmYxNTM5MTVmMTRmMTQ3NzRhY2Y1ZGIzNTcxZmYxM2NhL3RhYmxlcmFuZ2U6ZjE1MzkxNWYxNGYxNDc3NGFjZjVkYjM1NzFmZjEzY2FfMzItMy0xLTEtMA_c5e6bdb4-d794-4960-8191-8abc10f1074d">32,541,054</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net loss per share attributable to Inovio Pharmaceuticals, Inc. stockholders</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Basic and diluted</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18xNi9mcmFnOjAwM2U2NzdhMmJmMDRhYTM4NWVmMjFlNzAzNTYxZmUzL3RhYmxlOmYxNTM5MTVmMTRmMTQ3NzRhY2Y1ZGIzNTcxZmYxM2NhL3RhYmxlcmFuZ2U6ZjE1MzkxNWYxNGYxNDc3NGFjZjVkYjM1NzFmZjEzY2FfMzQtMS0xLTEtMA_6e5d26ec-1af9-40b0-8f75-e1d0d2ba453a">0.27</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i03bccaa0abfb4733b1e2831ecde4e4e8_D20200101-20200331" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18xNi9mcmFnOjAwM2U2NzdhMmJmMDRhYTM4NWVmMjFlNzAzNTYxZmUzL3RhYmxlOmYxNTM5MTVmMTRmMTQ3NzRhY2Y1ZGIzNTcxZmYxM2NhL3RhYmxlcmFuZ2U6ZjE1MzkxNWYxNGYxNDc3NGFjZjVkYjM1NzFmZjEzY2FfMzQtMy0xLTEtMA_2afbc78a-5e44-4c23-8b69-c841e6691f3a">0.26</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted average number of common shares outstanding </span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Basic and diluted</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18xNi9mcmFnOjAwM2U2NzdhMmJmMDRhYTM4NWVmMjFlNzAzNTYxZmUzL3RhYmxlOmYxNTM5MTVmMTRmMTQ3NzRhY2Y1ZGIzNTcxZmYxM2NhL3RhYmxlcmFuZ2U6ZjE1MzkxNWYxNGYxNDc3NGFjZjVkYjM1NzFmZjEzY2FfMzctMS0xLTEtMA_31f947c6-8dae-41bc-84ea-c90a9d59f2b9">202,414,445</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i03bccaa0abfb4733b1e2831ecde4e4e8_D20200101-20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18xNi9mcmFnOjAwM2U2NzdhMmJmMDRhYTM4NWVmMjFlNzAzNTYxZmUzL3RhYmxlOmYxNTM5MTVmMTRmMTQ3NzRhY2Y1ZGIzNTcxZmYxM2NhL3RhYmxlcmFuZ2U6ZjE1MzkxNWYxNGYxNDc3NGFjZjVkYjM1NzFmZjEzY2FfMzctMy0xLTEtMA_7ee9e29c-47ee-41c7-8905-b8c865538ee2">124,623,263</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span><br/></span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to unaudited condensed consolidated financial statements.</span></div><div style="margin-top:6pt;text-align:center"><span><br/></span></div><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><div id="i1d23d16a69484b63aa007ec686e80337_19"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INOVIO PHARMACEUTICALS, INC.</span></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS</span></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:75.654%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.280%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.743%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18xOS9mcmFnOjRkZDg5N2JmYWY5NDQ4NzlhZjljNGQwYTI5MDk1ZGYzL3RhYmxlOjUwNWE2M2JmODQ3ZTQxMDE5N2ZmNWZiMjg5YWI4ZGU5L3RhYmxlcmFuZ2U6NTA1YTYzYmY4NDdlNDEwMTk3ZmY1ZmIyODlhYjhkZTlfMi0xLTEtMS0w_5063ccd2-23c7-49b9-8683-ac116b7d030f">54,402,131</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i03bccaa0abfb4733b1e2831ecde4e4e8_D20200101-20200331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18xOS9mcmFnOjRkZDg5N2JmYWY5NDQ4NzlhZjljNGQwYTI5MDk1ZGYzL3RhYmxlOjUwNWE2M2JmODQ3ZTQxMDE5N2ZmNWZiMjg5YWI4ZGU5L3RhYmxlcmFuZ2U6NTA1YTYzYmY4NDdlNDEwMTk3ZmY1ZmIyODlhYjhkZTlfMi0zLTEtMS0w_37940248-8ba8-4ed5-a0eb-f447f2212543">33,135,404</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other comprehensive income (loss):</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Foreign currency translation </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18xOS9mcmFnOjRkZDg5N2JmYWY5NDQ4NzlhZjljNGQwYTI5MDk1ZGYzL3RhYmxlOjUwNWE2M2JmODQ3ZTQxMDE5N2ZmNWZiMjg5YWI4ZGU5L3RhYmxlcmFuZ2U6NTA1YTYzYmY4NDdlNDEwMTk3ZmY1ZmIyODlhYjhkZTlfNS0xLTEtMS0w_4e290744-4b8d-4306-8cbe-a8033b8e3743">14,419</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03bccaa0abfb4733b1e2831ecde4e4e8_D20200101-20200331" decimals="0" format="ixt:zerodash" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18xOS9mcmFnOjRkZDg5N2JmYWY5NDQ4NzlhZjljNGQwYTI5MDk1ZGYzL3RhYmxlOjUwNWE2M2JmODQ3ZTQxMDE5N2ZmNWZiMjg5YWI4ZGU5L3RhYmxlcmFuZ2U6NTA1YTYzYmY4NDdlNDEwMTk3ZmY1ZmIyODlhYjhkZTlfNS0zLTEtMS0w_636ddcb8-6dc1-47a7-bb1b-07f4b874d53e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Unrealized gain (loss) on short-term investments, net of tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18xOS9mcmFnOjRkZDg5N2JmYWY5NDQ4NzlhZjljNGQwYTI5MDk1ZGYzL3RhYmxlOjUwNWE2M2JmODQ3ZTQxMDE5N2ZmNWZiMjg5YWI4ZGU5L3RhYmxlcmFuZ2U6NTA1YTYzYmY4NDdlNDEwMTk3ZmY1ZmIyODlhYjhkZTlfNi0xLTEtMS0w_af5e2f15-60e3-4bb9-a396-e432f6a6c902">4,861</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i03bccaa0abfb4733b1e2831ecde4e4e8_D20200101-20200331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18xOS9mcmFnOjRkZDg5N2JmYWY5NDQ4NzlhZjljNGQwYTI5MDk1ZGYzL3RhYmxlOjUwNWE2M2JmODQ3ZTQxMDE5N2ZmNWZiMjg5YWI4ZGU5L3RhYmxlcmFuZ2U6NTA1YTYzYmY4NDdlNDEwMTk3ZmY1ZmIyODlhYjhkZTlfNi0zLTEtMS0w_851f6f5a-ed0a-4154-949a-32abb06b0f1d">1,929,538</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Comprehensive loss</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18xOS9mcmFnOjRkZDg5N2JmYWY5NDQ4NzlhZjljNGQwYTI5MDk1ZGYzL3RhYmxlOjUwNWE2M2JmODQ3ZTQxMDE5N2ZmNWZiMjg5YWI4ZGU5L3RhYmxlcmFuZ2U6NTA1YTYzYmY4NDdlNDEwMTk3ZmY1ZmIyODlhYjhkZTlfOS0xLTEtMS0w_0eaf0268-8c74-47f8-a4c9-50524a021fdd">54,411,689</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i03bccaa0abfb4733b1e2831ecde4e4e8_D20200101-20200331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18xOS9mcmFnOjRkZDg5N2JmYWY5NDQ4NzlhZjljNGQwYTI5MDk1ZGYzL3RhYmxlOjUwNWE2M2JmODQ3ZTQxMDE5N2ZmNWZiMjg5YWI4ZGU5L3RhYmxlcmFuZ2U6NTA1YTYzYmY4NDdlNDEwMTk3ZmY1ZmIyODlhYjhkZTlfOS0zLTEtMS0w_290997da-c7c2-4f73-9eef-9a496d158e6a">35,064,942</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Comprehensive loss attributable to non-controlling interest</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331" decimals="0" format="ixt:zerodash" name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18xOS9mcmFnOjRkZDg5N2JmYWY5NDQ4NzlhZjljNGQwYTI5MDk1ZGYzL3RhYmxlOjUwNWE2M2JmODQ3ZTQxMDE5N2ZmNWZiMjg5YWI4ZGU5L3RhYmxlcmFuZ2U6NTA1YTYzYmY4NDdlNDEwMTk3ZmY1ZmIyODlhYjhkZTlfMTAtMS0xLTEtMA_408968fa-1a97-4123-b657-34a4677558a5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03bccaa0abfb4733b1e2831ecde4e4e8_D20200101-20200331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18xOS9mcmFnOjRkZDg5N2JmYWY5NDQ4NzlhZjljNGQwYTI5MDk1ZGYzL3RhYmxlOjUwNWE2M2JmODQ3ZTQxMDE5N2ZmNWZiMjg5YWI4ZGU5L3RhYmxlcmFuZ2U6NTA1YTYzYmY4NDdlNDEwMTk3ZmY1ZmIyODlhYjhkZTlfMTAtMy0xLTEtMA_39dee4b4-09e2-4998-b0d4-023916141c9d">594,350</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Comprehensive loss attributable to Inovio Pharmaceuticals, Inc.</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18xOS9mcmFnOjRkZDg5N2JmYWY5NDQ4NzlhZjljNGQwYTI5MDk1ZGYzL3RhYmxlOjUwNWE2M2JmODQ3ZTQxMDE5N2ZmNWZiMjg5YWI4ZGU5L3RhYmxlcmFuZ2U6NTA1YTYzYmY4NDdlNDEwMTk3ZmY1ZmIyODlhYjhkZTlfMTEtMS0xLTEtMA_88882b8f-1f1b-46f3-8c9e-081dbc1173aa">54,411,689</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i03bccaa0abfb4733b1e2831ecde4e4e8_D20200101-20200331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18xOS9mcmFnOjRkZDg5N2JmYWY5NDQ4NzlhZjljNGQwYTI5MDk1ZGYzL3RhYmxlOjUwNWE2M2JmODQ3ZTQxMDE5N2ZmNWZiMjg5YWI4ZGU5L3RhYmxlcmFuZ2U6NTA1YTYzYmY4NDdlNDEwMTk3ZmY1ZmIyODlhYjhkZTlfMTEtMy0xLTEtMA_fb0c5e0f-2122-4304-97f4-c9754f662211">34,470,592</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span><br/></span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to unaudited condensed consolidated financial statements.</span></div><div style="margin-top:6pt;text-align:center"><span><br/></span></div><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><div id="i1d23d16a69484b63aa007ec686e80337_22"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INOVIO PHARMACEUTICALS, INC.</span></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</span></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:27.579%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.285%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.341%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.718%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.341%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.285%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.341%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.285%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.341%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.558%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.341%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.558%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.341%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.558%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.341%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.259%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.341%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.587%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="51" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Preferred stock</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common stock</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number<br/>of&#160;shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number<br/>of shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additional<br/>paid-in<br/>capital</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>deficit</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>other<br/>comprehensive<br/>income (loss)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Non-<br/>controlling<br/>interest</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total<br/>stockholders&#8217;<br/>equity</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib30ce8820d124ee6af51f2c43013f18e_I20201231" decimals="INF" name="us-gaap:SharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18yMi9mcmFnOjg2MjFjNDJiNjI3NDRkMmNhMzQ1NDQwN2UzZjI0N2QzL3RhYmxlOmQwOWRlNWFiMWM0MjQ1ODk5YzUwNzc4YjIzZWI0ZWNjL3RhYmxlcmFuZ2U6ZDA5ZGU1YWIxYzQyNDU4OTljNTA3NzhiMjNlYjRlY2NfMy0xLTEtMS0yNzM_8e554740-6e78-4a11-b836-d38523533841">9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib30ce8820d124ee6af51f2c43013f18e_I20201231" decimals="0" format="ixt:zerodash" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18yMi9mcmFnOjg2MjFjNDJiNjI3NDRkMmNhMzQ1NDQwN2UzZjI0N2QzL3RhYmxlOmQwOWRlNWFiMWM0MjQ1ODk5YzUwNzc4YjIzZWI0ZWNjL3RhYmxlcmFuZ2U6ZDA5ZGU1YWIxYzQyNDU4OTljNTA3NzhiMjNlYjRlY2NfMy0zLTEtMS0yNzM_298256a5-0982-4ea9-a258-403098870e9c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia94bfbadb09f4968b33b4adabfa4233d_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18yMi9mcmFnOjg2MjFjNDJiNjI3NDRkMmNhMzQ1NDQwN2UzZjI0N2QzL3RhYmxlOmQwOWRlNWFiMWM0MjQ1ODk5YzUwNzc4YjIzZWI0ZWNjL3RhYmxlcmFuZ2U6ZDA5ZGU1YWIxYzQyNDU4OTljNTA3NzhiMjNlYjRlY2NfMy01LTEtMS0yNzM_bef19972-8d0c-49f0-a1e8-97486619ec55">186,851,493</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia94bfbadb09f4968b33b4adabfa4233d_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18yMi9mcmFnOjg2MjFjNDJiNjI3NDRkMmNhMzQ1NDQwN2UzZjI0N2QzL3RhYmxlOmQwOWRlNWFiMWM0MjQ1ODk5YzUwNzc4YjIzZWI0ZWNjL3RhYmxlcmFuZ2U6ZDA5ZGU1YWIxYzQyNDU4OTljNTA3NzhiMjNlYjRlY2NfMy03LTEtMS0yNzM_2b5f850f-2498-4073-b587-d1799dfcdf9e">186,851</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieaec7233643d498d97b1141ea9dad4c5_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18yMi9mcmFnOjg2MjFjNDJiNjI3NDRkMmNhMzQ1NDQwN2UzZjI0N2QzL3RhYmxlOmQwOWRlNWFiMWM0MjQ1ODk5YzUwNzc4YjIzZWI0ZWNjL3RhYmxlcmFuZ2U6ZDA5ZGU1YWIxYzQyNDU4OTljNTA3NzhiMjNlYjRlY2NfMy05LTEtMS0yNzM_c4065e49-f0ee-4907-ad0c-28f112e8a81f">1,367,406,869</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i96283fe249ee4626aab2bf451b2e5efe_I20201231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18yMi9mcmFnOjg2MjFjNDJiNjI3NDRkMmNhMzQ1NDQwN2UzZjI0N2QzL3RhYmxlOmQwOWRlNWFiMWM0MjQ1ODk5YzUwNzc4YjIzZWI0ZWNjL3RhYmxlcmFuZ2U6ZDA5ZGU1YWIxYzQyNDU4OTljNTA3NzhiMjNlYjRlY2NfMy0xMS0xLTEtMjcz_4605668a-1ee9-4de2-8341-e908e8daeaa2">906,196,812</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic6306740b10d4a7593195541124d73d5_I20201231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18yMi9mcmFnOjg2MjFjNDJiNjI3NDRkMmNhMzQ1NDQwN2UzZjI0N2QzL3RhYmxlOmQwOWRlNWFiMWM0MjQ1ODk5YzUwNzc4YjIzZWI0ZWNjL3RhYmxlcmFuZ2U6ZDA5ZGU1YWIxYzQyNDU4OTljNTA3NzhiMjNlYjRlY2NfMy0xMy0xLTEtMjcz_bf0082fd-e8a5-46d7-95f4-ba73706c09a2">256,150</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c4f0048d9644ed3b4e12718fd6404f9_I20201231" decimals="0" format="ixt:zerodash" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18yMi9mcmFnOjg2MjFjNDJiNjI3NDRkMmNhMzQ1NDQwN2UzZjI0N2QzL3RhYmxlOmQwOWRlNWFiMWM0MjQ1ODk5YzUwNzc4YjIzZWI0ZWNjL3RhYmxlcmFuZ2U6ZDA5ZGU1YWIxYzQyNDU4OTljNTA3NzhiMjNlYjRlY2NfMy0xNS0xLTEtMjcz_77b147d7-51e1-4bb2-b732-29cffefede0d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i066bb5b0a9e84c0a878b1e800703d92b_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18yMi9mcmFnOjg2MjFjNDJiNjI3NDRkMmNhMzQ1NDQwN2UzZjI0N2QzL3RhYmxlOmQwOWRlNWFiMWM0MjQ1ODk5YzUwNzc4YjIzZWI0ZWNjL3RhYmxlcmFuZ2U6ZDA5ZGU1YWIxYzQyNDU4OTljNTA3NzhiMjNlYjRlY2NfMy0xNy0xLTEtMjcz_0ab6deed-5208-4658-8734-0e88359b36c5">461,140,758</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock for cash, net of financing costs of $<ix:nonFraction unitRef="usd" contextRef="i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18yMi9mcmFnOjg2MjFjNDJiNjI3NDRkMmNhMzQ1NDQwN2UzZjI0N2QzL3RhYmxlOmQwOWRlNWFiMWM0MjQ1ODk5YzUwNzc4YjIzZWI0ZWNjL3RhYmxlcmFuZ2U6ZDA5ZGU1YWIxYzQyNDU4OTljNTA3NzhiMjNlYjRlY2NfNC0wLTEtMS0zNjc0L3RleHRyZWdpb246YmFiM2YxNzg0NjMyNDAzZjgxZGU4ZGM0NWVlODUwYjdfMzI5ODUzNDg4MzQwOQ_6663ed19-bd26-4210-be6d-1e4b3ea29048">531,000</ix:nonFraction></span></div></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ida491abe9af7462cbd6838e5420a3bdb_D20210101-20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18yMi9mcmFnOjg2MjFjNDJiNjI3NDRkMmNhMzQ1NDQwN2UzZjI0N2QzL3RhYmxlOmQwOWRlNWFiMWM0MjQ1ODk5YzUwNzc4YjIzZWI0ZWNjL3RhYmxlcmFuZ2U6ZDA5ZGU1YWIxYzQyNDU4OTljNTA3NzhiMjNlYjRlY2NfNC01LTEtMS0yNTM5_984e6e8b-67ee-4467-87ac-30c45e0d07d6">20,355,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ida491abe9af7462cbd6838e5420a3bdb_D20210101-20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18yMi9mcmFnOjg2MjFjNDJiNjI3NDRkMmNhMzQ1NDQwN2UzZjI0N2QzL3RhYmxlOmQwOWRlNWFiMWM0MjQ1ODk5YzUwNzc4YjIzZWI0ZWNjL3RhYmxlcmFuZ2U6ZDA5ZGU1YWIxYzQyNDU4OTljNTA3NzhiMjNlYjRlY2NfNC03LTEtMS0yNTM5_82a90eac-8019-4e89-ac34-6af447e949c2">20,355</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ede063da1fe4025a2e0bc527b82ca1e_D20210101-20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18yMi9mcmFnOjg2MjFjNDJiNjI3NDRkMmNhMzQ1NDQwN2UzZjI0N2QzL3RhYmxlOmQwOWRlNWFiMWM0MjQ1ODk5YzUwNzc4YjIzZWI0ZWNjL3RhYmxlcmFuZ2U6ZDA5ZGU1YWIxYzQyNDU4OTljNTA3NzhiMjNlYjRlY2NfNC05LTEtMS0yNTM5_8c156153-7223-438b-bdb7-2045415c1adf">162,084,675</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18yMi9mcmFnOjg2MjFjNDJiNjI3NDRkMmNhMzQ1NDQwN2UzZjI0N2QzL3RhYmxlOmQwOWRlNWFiMWM0MjQ1ODk5YzUwNzc4YjIzZWI0ZWNjL3RhYmxlcmFuZ2U6ZDA5ZGU1YWIxYzQyNDU4OTljNTA3NzhiMjNlYjRlY2NfNC0xNy0xLTEtMjUzOQ_d926f72e-ec50-4ece-9887-55b73d119894">162,105,030</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Conversion of December 2019 Bonds to common stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ida491abe9af7462cbd6838e5420a3bdb_D20210101-20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18yMi9mcmFnOjg2MjFjNDJiNjI3NDRkMmNhMzQ1NDQwN2UzZjI0N2QzL3RhYmxlOmQwOWRlNWFiMWM0MjQ1ODk5YzUwNzc4YjIzZWI0ZWNjL3RhYmxlcmFuZ2U6ZDA5ZGU1YWIxYzQyNDU4OTljNTA3NzhiMjNlYjRlY2NfNC01LTEtMS0yNzM_ee93ae6c-e3fe-45ea-87eb-051571eb043f">1,009,450</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ida491abe9af7462cbd6838e5420a3bdb_D20210101-20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18yMi9mcmFnOjg2MjFjNDJiNjI3NDRkMmNhMzQ1NDQwN2UzZjI0N2QzL3RhYmxlOmQwOWRlNWFiMWM0MjQ1ODk5YzUwNzc4YjIzZWI0ZWNjL3RhYmxlcmFuZ2U6ZDA5ZGU1YWIxYzQyNDU4OTljNTA3NzhiMjNlYjRlY2NfNC03LTEtMS0yNzM_1bacef74-7cbf-4ec6-8467-50d1b232b4c7">1,009</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ede063da1fe4025a2e0bc527b82ca1e_D20210101-20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18yMi9mcmFnOjg2MjFjNDJiNjI3NDRkMmNhMzQ1NDQwN2UzZjI0N2QzL3RhYmxlOmQwOWRlNWFiMWM0MjQ1ODk5YzUwNzc4YjIzZWI0ZWNjL3RhYmxlcmFuZ2U6ZDA5ZGU1YWIxYzQyNDU4OTljNTA3NzhiMjNlYjRlY2NfNC05LTEtMS0yNzM_f669c872-3d40-452a-82e2-74c716c79421">4,376,883</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18yMi9mcmFnOjg2MjFjNDJiNjI3NDRkMmNhMzQ1NDQwN2UzZjI0N2QzL3RhYmxlOmQwOWRlNWFiMWM0MjQ1ODk5YzUwNzc4YjIzZWI0ZWNjL3RhYmxlcmFuZ2U6ZDA5ZGU1YWIxYzQyNDU4OTljNTA3NzhiMjNlYjRlY2NfNC0xNy0xLTEtMjcz_b2d6d8b8-2aa6-41e4-bee2-d7c29395c712">4,377,892</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Exercise of stock options for cash and vesting of RSUs, net of tax payments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ida491abe9af7462cbd6838e5420a3bdb_D20210101-20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18yMi9mcmFnOjg2MjFjNDJiNjI3NDRkMmNhMzQ1NDQwN2UzZjI0N2QzL3RhYmxlOmQwOWRlNWFiMWM0MjQ1ODk5YzUwNzc4YjIzZWI0ZWNjL3RhYmxlcmFuZ2U6ZDA5ZGU1YWIxYzQyNDU4OTljNTA3NzhiMjNlYjRlY2NfNS01LTEtMS0yNzM_ffa0ddb7-489a-4fa6-b00f-487c960df0b1">1,118,093</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ida491abe9af7462cbd6838e5420a3bdb_D20210101-20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18yMi9mcmFnOjg2MjFjNDJiNjI3NDRkMmNhMzQ1NDQwN2UzZjI0N2QzL3RhYmxlOmQwOWRlNWFiMWM0MjQ1ODk5YzUwNzc4YjIzZWI0ZWNjL3RhYmxlcmFuZ2U6ZDA5ZGU1YWIxYzQyNDU4OTljNTA3NzhiMjNlYjRlY2NfNS03LTEtMS0yNzM_58723cd7-9bce-4952-89ec-f5145693345b">1,118</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4ede063da1fe4025a2e0bc527b82ca1e_D20210101-20210331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18yMi9mcmFnOjg2MjFjNDJiNjI3NDRkMmNhMzQ1NDQwN2UzZjI0N2QzL3RhYmxlOmQwOWRlNWFiMWM0MjQ1ODk5YzUwNzc4YjIzZWI0ZWNjL3RhYmxlcmFuZ2U6ZDA5ZGU1YWIxYzQyNDU4OTljNTA3NzhiMjNlYjRlY2NfNS05LTEtMS0yNzM_44a28e5a-84c9-48f3-955d-373ddf5d8e8a">1,202,907</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18yMi9mcmFnOjg2MjFjNDJiNjI3NDRkMmNhMzQ1NDQwN2UzZjI0N2QzL3RhYmxlOmQwOWRlNWFiMWM0MjQ1ODk5YzUwNzc4YjIzZWI0ZWNjL3RhYmxlcmFuZ2U6ZDA5ZGU1YWIxYzQyNDU4OTljNTA3NzhiMjNlYjRlY2NfNS0xNy0xLTEtMjcz_a0b06db3-d986-4699-8e50-5d00adb3603c">1,201,789</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ede063da1fe4025a2e0bc527b82ca1e_D20210101-20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18yMi9mcmFnOjg2MjFjNDJiNjI3NDRkMmNhMzQ1NDQwN2UzZjI0N2QzL3RhYmxlOmQwOWRlNWFiMWM0MjQ1ODk5YzUwNzc4YjIzZWI0ZWNjL3RhYmxlcmFuZ2U6ZDA5ZGU1YWIxYzQyNDU4OTljNTA3NzhiMjNlYjRlY2NfNi05LTEtMS0yNzM_54f64bad-335b-483c-8ff3-bd8f15db358a">9,595,947</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18yMi9mcmFnOjg2MjFjNDJiNjI3NDRkMmNhMzQ1NDQwN2UzZjI0N2QzL3RhYmxlOmQwOWRlNWFiMWM0MjQ1ODk5YzUwNzc4YjIzZWI0ZWNjL3RhYmxlcmFuZ2U6ZDA5ZGU1YWIxYzQyNDU4OTljNTA3NzhiMjNlYjRlY2NfNi0xNy0xLTEtMjcz_0a7ace5a-c481-4fac-99e4-f3347c07f5fa">9,595,947</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss attributable to common stockholders</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0f5bad0d4b8641e4b0f54e165e445044_D20210101-20210331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18yMi9mcmFnOjg2MjFjNDJiNjI3NDRkMmNhMzQ1NDQwN2UzZjI0N2QzL3RhYmxlOmQwOWRlNWFiMWM0MjQ1ODk5YzUwNzc4YjIzZWI0ZWNjL3RhYmxlcmFuZ2U6ZDA5ZGU1YWIxYzQyNDU4OTljNTA3NzhiMjNlYjRlY2NfNy0xMS0xLTEtMjcz_065c2120-6030-40c6-b64a-c4c1f4ad3c01">54,402,131</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18yMi9mcmFnOjg2MjFjNDJiNjI3NDRkMmNhMzQ1NDQwN2UzZjI0N2QzL3RhYmxlOmQwOWRlNWFiMWM0MjQ1ODk5YzUwNzc4YjIzZWI0ZWNjL3RhYmxlcmFuZ2U6ZDA5ZGU1YWIxYzQyNDU4OTljNTA3NzhiMjNlYjRlY2NfNy0xNy0xLTEtMjcz_eeb619f0-8f9a-445e-abe9-c6b4d3b26d33">54,402,131</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unrealized gain on short-term investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f929f0365a3465f8cc7dc1c57314519_D20210101-20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18yMi9mcmFnOjg2MjFjNDJiNjI3NDRkMmNhMzQ1NDQwN2UzZjI0N2QzL3RhYmxlOmQwOWRlNWFiMWM0MjQ1ODk5YzUwNzc4YjIzZWI0ZWNjL3RhYmxlcmFuZ2U6ZDA5ZGU1YWIxYzQyNDU4OTljNTA3NzhiMjNlYjRlY2NfOC0xMy0xLTEtMjcz_27f6818a-8087-40f9-a3be-35ad673555db">4,861</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18yMi9mcmFnOjg2MjFjNDJiNjI3NDRkMmNhMzQ1NDQwN2UzZjI0N2QzL3RhYmxlOmQwOWRlNWFiMWM0MjQ1ODk5YzUwNzc4YjIzZWI0ZWNjL3RhYmxlcmFuZ2U6ZDA5ZGU1YWIxYzQyNDU4OTljNTA3NzhiMjNlYjRlY2NfOC0xNy0xLTEtMjcz_2af0f985-c0e3-4d72-b1ef-2da942261cb9">4,861</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign currency translation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3f929f0365a3465f8cc7dc1c57314519_D20210101-20210331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18yMi9mcmFnOjg2MjFjNDJiNjI3NDRkMmNhMzQ1NDQwN2UzZjI0N2QzL3RhYmxlOmQwOWRlNWFiMWM0MjQ1ODk5YzUwNzc4YjIzZWI0ZWNjL3RhYmxlcmFuZ2U6ZDA5ZGU1YWIxYzQyNDU4OTljNTA3NzhiMjNlYjRlY2NfOS0xMy0xLTEtMjcz_2a1d7139-7b7b-488e-97dd-79f20f1c75e1">14,419</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18yMi9mcmFnOjg2MjFjNDJiNjI3NDRkMmNhMzQ1NDQwN2UzZjI0N2QzL3RhYmxlOmQwOWRlNWFiMWM0MjQ1ODk5YzUwNzc4YjIzZWI0ZWNjL3RhYmxlcmFuZ2U6ZDA5ZGU1YWIxYzQyNDU4OTljNTA3NzhiMjNlYjRlY2NfOS0xNy0xLTEtMjcz_9370e38f-5ea0-4b7d-9642-81b8d4e07332">14,419</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at March 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ibab5fbbfe0ef465e8c296f3289e726c2_I20210331" decimals="INF" name="us-gaap:SharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18yMi9mcmFnOjg2MjFjNDJiNjI3NDRkMmNhMzQ1NDQwN2UzZjI0N2QzL3RhYmxlOmQwOWRlNWFiMWM0MjQ1ODk5YzUwNzc4YjIzZWI0ZWNjL3RhYmxlcmFuZ2U6ZDA5ZGU1YWIxYzQyNDU4OTljNTA3NzhiMjNlYjRlY2NfMTAtMS0xLTEtMjcz_d2df84dc-edc4-450b-9ae4-90e9b356c1e8">9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibab5fbbfe0ef465e8c296f3289e726c2_I20210331" decimals="0" format="ixt:zerodash" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18yMi9mcmFnOjg2MjFjNDJiNjI3NDRkMmNhMzQ1NDQwN2UzZjI0N2QzL3RhYmxlOmQwOWRlNWFiMWM0MjQ1ODk5YzUwNzc4YjIzZWI0ZWNjL3RhYmxlcmFuZ2U6ZDA5ZGU1YWIxYzQyNDU4OTljNTA3NzhiMjNlYjRlY2NfMTAtMy0xLTEtMjcz_9c04b931-df82-4c7c-9cb2-41b0c6e43c4e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i33c2b6d1adae4987a8b43311a9b56620_I20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18yMi9mcmFnOjg2MjFjNDJiNjI3NDRkMmNhMzQ1NDQwN2UzZjI0N2QzL3RhYmxlOmQwOWRlNWFiMWM0MjQ1ODk5YzUwNzc4YjIzZWI0ZWNjL3RhYmxlcmFuZ2U6ZDA5ZGU1YWIxYzQyNDU4OTljNTA3NzhiMjNlYjRlY2NfMTAtNS0xLTEtMjcz_69dbfa89-a470-4ac9-9672-287afccedafb">209,334,036</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i33c2b6d1adae4987a8b43311a9b56620_I20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18yMi9mcmFnOjg2MjFjNDJiNjI3NDRkMmNhMzQ1NDQwN2UzZjI0N2QzL3RhYmxlOmQwOWRlNWFiMWM0MjQ1ODk5YzUwNzc4YjIzZWI0ZWNjL3RhYmxlcmFuZ2U6ZDA5ZGU1YWIxYzQyNDU4OTljNTA3NzhiMjNlYjRlY2NfMTAtNy0xLTEtMjcz_7ef5cd7a-391d-4061-aacb-5a552ca692b3">209,333</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1541412d9b3c4836ae64bd33efc16e22_I20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18yMi9mcmFnOjg2MjFjNDJiNjI3NDRkMmNhMzQ1NDQwN2UzZjI0N2QzL3RhYmxlOmQwOWRlNWFiMWM0MjQ1ODk5YzUwNzc4YjIzZWI0ZWNjL3RhYmxlcmFuZ2U6ZDA5ZGU1YWIxYzQyNDU4OTljNTA3NzhiMjNlYjRlY2NfMTAtOS0xLTEtMjcz_2bd36c9b-7a4d-4ed1-8fe8-29e110e60f2f">1,542,261,467</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i65691acaad974fca8ed0492dec85d517_I20210331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18yMi9mcmFnOjg2MjFjNDJiNjI3NDRkMmNhMzQ1NDQwN2UzZjI0N2QzL3RhYmxlOmQwOWRlNWFiMWM0MjQ1ODk5YzUwNzc4YjIzZWI0ZWNjL3RhYmxlcmFuZ2U6ZDA5ZGU1YWIxYzQyNDU4OTljNTA3NzhiMjNlYjRlY2NfMTAtMTEtMS0xLTI3Mw_f3267ada-7964-4cca-9f9a-b27ef1caa0f1">960,598,943</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1e99d4dac75643f384514d28d4cd004b_I20210331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18yMi9mcmFnOjg2MjFjNDJiNjI3NDRkMmNhMzQ1NDQwN2UzZjI0N2QzL3RhYmxlOmQwOWRlNWFiMWM0MjQ1ODk5YzUwNzc4YjIzZWI0ZWNjL3RhYmxlcmFuZ2U6ZDA5ZGU1YWIxYzQyNDU4OTljNTA3NzhiMjNlYjRlY2NfMTAtMTMtMS0xLTI3Mw_2b4819ac-47a5-4903-9dce-602d400d1505">265,708</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b91f37fad654b1d9c8a1e92d45461a0_I20210331" decimals="0" format="ixt:zerodash" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18yMi9mcmFnOjg2MjFjNDJiNjI3NDRkMmNhMzQ1NDQwN2UzZjI0N2QzL3RhYmxlOmQwOWRlNWFiMWM0MjQ1ODk5YzUwNzc4YjIzZWI0ZWNjL3RhYmxlcmFuZ2U6ZDA5ZGU1YWIxYzQyNDU4OTljNTA3NzhiMjNlYjRlY2NfMTAtMTUtMS0xLTI3Mw_3b19e452-f7aa-47b8-ae06-54366dcc078d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic36b9cedad7f41a6b9eb223b09b7186c_I20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18yMi9mcmFnOjg2MjFjNDJiNjI3NDRkMmNhMzQ1NDQwN2UzZjI0N2QzL3RhYmxlOmQwOWRlNWFiMWM0MjQ1ODk5YzUwNzc4YjIzZWI0ZWNjL3RhYmxlcmFuZ2U6ZDA5ZGU1YWIxYzQyNDU4OTljNTA3NzhiMjNlYjRlY2NfMTAtMTctMS0xLTI3Mw_6a6b5a6d-120c-4e03-8a3f-c12379b8d1c1">581,606,149</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:5pt;margin-top:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.567%"><tr><td style="width:1.0%"></td><td style="width:27.704%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.747%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.343%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.095%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.343%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.856%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.343%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.421%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.343%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.160%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.343%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.343%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.160%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.343%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.291%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.343%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.627%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="51" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Preferred stock</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common stock</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number<br/>of&#160;shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number<br/>of shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additional<br/>paid-in<br/>capital</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>deficit</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>other<br/>comprehensive<br/>income (loss)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Non-<br/>controlling<br/>interest</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total<br/>stockholders&#8217;<br/>equity</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at December 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id632c5e641ae4912873249f66ba9b746_I20191231" decimals="INF" name="us-gaap:SharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18yMi9mcmFnOjg2MjFjNDJiNjI3NDRkMmNhMzQ1NDQwN2UzZjI0N2QzL3RhYmxlOjM0YjQ5NWMwODljMzRkMmI4OWRhYTVlMmI3NTRmNmM5L3RhYmxlcmFuZ2U6MzRiNDk1YzA4OWMzNGQyYjg5ZGFhNWUyYjc1NGY2YzlfMzMtMS0xLTEtMA_edd60230-d7e6-42fd-8f3a-dbe03521d40a">23</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id632c5e641ae4912873249f66ba9b746_I20191231" decimals="0" format="ixt:zerodash" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18yMi9mcmFnOjg2MjFjNDJiNjI3NDRkMmNhMzQ1NDQwN2UzZjI0N2QzL3RhYmxlOjM0YjQ5NWMwODljMzRkMmI4OWRhYTVlMmI3NTRmNmM5L3RhYmxlcmFuZ2U6MzRiNDk1YzA4OWMzNGQyYjg5ZGFhNWUyYjc1NGY2YzlfMzMtMy0xLTEtMA_c2512b68-20f2-44ce-8cfa-e7a47025f31e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i40ec371b74df4b3db7e8d29aaa614a0d_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18yMi9mcmFnOjg2MjFjNDJiNjI3NDRkMmNhMzQ1NDQwN2UzZjI0N2QzL3RhYmxlOjM0YjQ5NWMwODljMzRkMmI4OWRhYTVlMmI3NTRmNmM5L3RhYmxlcmFuZ2U6MzRiNDk1YzA4OWMzNGQyYjg5ZGFhNWUyYjc1NGY2YzlfMzMtNS0xLTEtMA_a7ef673a-138c-475b-b832-1d870ff02059">101,361,034</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i40ec371b74df4b3db7e8d29aaa614a0d_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18yMi9mcmFnOjg2MjFjNDJiNjI3NDRkMmNhMzQ1NDQwN2UzZjI0N2QzL3RhYmxlOjM0YjQ5NWMwODljMzRkMmI4OWRhYTVlMmI3NTRmNmM5L3RhYmxlcmFuZ2U6MzRiNDk1YzA4OWMzNGQyYjg5ZGFhNWUyYjc1NGY2YzlfMzMtNy0xLTEtMA_7754fe4a-b7ab-4a36-8936-91418d085fec">101,361</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3d58693671394234b39dd81063245378_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18yMi9mcmFnOjg2MjFjNDJiNjI3NDRkMmNhMzQ1NDQwN2UzZjI0N2QzL3RhYmxlOjM0YjQ5NWMwODljMzRkMmI4OWRhYTVlMmI3NTRmNmM5L3RhYmxlcmFuZ2U6MzRiNDk1YzA4OWMzNGQyYjg5ZGFhNWUyYjc1NGY2YzlfMzMtOS0xLTEtMA_091259c8-7915-463f-812c-234e90b9358a">742,646,785</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iba11ad45e728416593567d5d5ccc86c8_I20191231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18yMi9mcmFnOjg2MjFjNDJiNjI3NDRkMmNhMzQ1NDQwN2UzZjI0N2QzL3RhYmxlOjM0YjQ5NWMwODljMzRkMmI4OWRhYTVlMmI3NTRmNmM5L3RhYmxlcmFuZ2U6MzRiNDk1YzA4OWMzNGQyYjg5ZGFhNWUyYjc1NGY2YzlfMzMtMTEtMS0xLTA_91f4e64b-038b-45c9-bdd6-7ad7d357606c">739,785,655</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7d8df8a887e444f9147b293456ba26e_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18yMi9mcmFnOjg2MjFjNDJiNjI3NDRkMmNhMzQ1NDQwN2UzZjI0N2QzL3RhYmxlOjM0YjQ5NWMwODljMzRkMmI4OWRhYTVlMmI3NTRmNmM5L3RhYmxlcmFuZ2U6MzRiNDk1YzA4OWMzNGQyYjg5ZGFhNWUyYjc1NGY2YzlfMzMtMTMtMS0xLTA_3961b1c3-0877-4094-ba96-a3f8820d326e">472,608</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if11b90ef299e496ebeb77cd256ffe8e4_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18yMi9mcmFnOjg2MjFjNDJiNjI3NDRkMmNhMzQ1NDQwN2UzZjI0N2QzL3RhYmxlOjM0YjQ5NWMwODljMzRkMmI4OWRhYTVlMmI3NTRmNmM5L3RhYmxlcmFuZ2U6MzRiNDk1YzA4OWMzNGQyYjg5ZGFhNWUyYjc1NGY2YzlfMzMtMTUtMS0xLTA_f28dea85-4fde-4a32-9eaa-ad04e0fe631a">1,969,759</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id25261a874ce40da9cfbcc6297ee52ac_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18yMi9mcmFnOjg2MjFjNDJiNjI3NDRkMmNhMzQ1NDQwN2UzZjI0N2QzL3RhYmxlOjM0YjQ5NWMwODljMzRkMmI4OWRhYTVlMmI3NTRmNmM5L3RhYmxlcmFuZ2U6MzRiNDk1YzA4OWMzNGQyYjg5ZGFhNWUyYjc1NGY2YzlfMzMtMTctMS0xLTA_fb93c5d4-d7fc-4f3f-b11b-df4fb2c80680">5,404,858</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock for cash</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic68df58c3630416794b34bec56896e49_D20200101-20200331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18yMi9mcmFnOjg2MjFjNDJiNjI3NDRkMmNhMzQ1NDQwN2UzZjI0N2QzL3RhYmxlOjM0YjQ5NWMwODljMzRkMmI4OWRhYTVlMmI3NTRmNmM5L3RhYmxlcmFuZ2U6MzRiNDk1YzA4OWMzNGQyYjg5ZGFhNWUyYjc1NGY2YzlfMzQtNS0xLTEtMA_b0505937-2fc8-42e3-b7f5-4b99f2ee7a11">43,148,952</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic68df58c3630416794b34bec56896e49_D20200101-20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18yMi9mcmFnOjg2MjFjNDJiNjI3NDRkMmNhMzQ1NDQwN2UzZjI0N2QzL3RhYmxlOjM0YjQ5NWMwODljMzRkMmI4OWRhYTVlMmI3NTRmNmM5L3RhYmxlcmFuZ2U6MzRiNDk1YzA4OWMzNGQyYjg5ZGFhNWUyYjc1NGY2YzlfMzQtNy0xLTEtMA_94fbd435-e786-4576-ba92-162862a297ce">43,149</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba0cb12c2be843b2bd24ae59f143d7a9_D20200101-20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18yMi9mcmFnOjg2MjFjNDJiNjI3NDRkMmNhMzQ1NDQwN2UzZjI0N2QzL3RhYmxlOjM0YjQ5NWMwODljMzRkMmI4OWRhYTVlMmI3NTRmNmM5L3RhYmxlcmFuZ2U6MzRiNDk1YzA4OWMzNGQyYjg5ZGFhNWUyYjc1NGY2YzlfMzQtOS0xLTEtMA_0b865750-1315-4a86-8a90-7af69345d1c0">208,198,784</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03bccaa0abfb4733b1e2831ecde4e4e8_D20200101-20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18yMi9mcmFnOjg2MjFjNDJiNjI3NDRkMmNhMzQ1NDQwN2UzZjI0N2QzL3RhYmxlOjM0YjQ5NWMwODljMzRkMmI4OWRhYTVlMmI3NTRmNmM5L3RhYmxlcmFuZ2U6MzRiNDk1YzA4OWMzNGQyYjg5ZGFhNWUyYjc1NGY2YzlfMzQtMTctMS0xLTA_49536127-c202-4549-8eda-dedcd1f8d552">208,241,933</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Exercise of stock options for cash and vesting of RSUs, net of tax payments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic68df58c3630416794b34bec56896e49_D20200101-20200331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18yMi9mcmFnOjg2MjFjNDJiNjI3NDRkMmNhMzQ1NDQwN2UzZjI0N2QzL3RhYmxlOjM0YjQ5NWMwODljMzRkMmI4OWRhYTVlMmI3NTRmNmM5L3RhYmxlcmFuZ2U6MzRiNDk1YzA4OWMzNGQyYjg5ZGFhNWUyYjc1NGY2YzlfMzUtNS0xLTEtMA_f63d858c-577f-4053-a6d2-03e8f00d8968">1,405,114</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic68df58c3630416794b34bec56896e49_D20200101-20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18yMi9mcmFnOjg2MjFjNDJiNjI3NDRkMmNhMzQ1NDQwN2UzZjI0N2QzL3RhYmxlOjM0YjQ5NWMwODljMzRkMmI4OWRhYTVlMmI3NTRmNmM5L3RhYmxlcmFuZ2U6MzRiNDk1YzA4OWMzNGQyYjg5ZGFhNWUyYjc1NGY2YzlfMzUtNy0xLTEtMA_388566b7-7843-4cef-9deb-e940f35ee027">1,405</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba0cb12c2be843b2bd24ae59f143d7a9_D20200101-20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18yMi9mcmFnOjg2MjFjNDJiNjI3NDRkMmNhMzQ1NDQwN2UzZjI0N2QzL3RhYmxlOjM0YjQ5NWMwODljMzRkMmI4OWRhYTVlMmI3NTRmNmM5L3RhYmxlcmFuZ2U6MzRiNDk1YzA4OWMzNGQyYjg5ZGFhNWUyYjc1NGY2YzlfMzUtOS0xLTEtMA_22512618-e891-46a2-9cb9-6eea272df22a">3,099,298</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03bccaa0abfb4733b1e2831ecde4e4e8_D20200101-20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18yMi9mcmFnOjg2MjFjNDJiNjI3NDRkMmNhMzQ1NDQwN2UzZjI0N2QzL3RhYmxlOjM0YjQ5NWMwODljMzRkMmI4OWRhYTVlMmI3NTRmNmM5L3RhYmxlcmFuZ2U6MzRiNDk1YzA4OWMzNGQyYjg5ZGFhNWUyYjc1NGY2YzlfMzUtMTctMS0xLTA_4de04d29-9f42-4000-8c53-5ab5764ce1df">3,100,703</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba0cb12c2be843b2bd24ae59f143d7a9_D20200101-20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18yMi9mcmFnOjg2MjFjNDJiNjI3NDRkMmNhMzQ1NDQwN2UzZjI0N2QzL3RhYmxlOjM0YjQ5NWMwODljMzRkMmI4OWRhYTVlMmI3NTRmNmM5L3RhYmxlcmFuZ2U6MzRiNDk1YzA4OWMzNGQyYjg5ZGFhNWUyYjc1NGY2YzlfMzYtOS0xLTEtMA_507da46e-72f3-4c56-9308-b6d1c0c82229">4,017,761</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ieac446e98d7241d8a6a13f0e4a3044da_D20200101-20200331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18yMi9mcmFnOjg2MjFjNDJiNjI3NDRkMmNhMzQ1NDQwN2UzZjI0N2QzL3RhYmxlOjM0YjQ5NWMwODljMzRkMmI4OWRhYTVlMmI3NTRmNmM5L3RhYmxlcmFuZ2U6MzRiNDk1YzA4OWMzNGQyYjg5ZGFhNWUyYjc1NGY2YzlfMzYtMTUtMS0xLTA_995c682f-5e6a-4649-8150-17f92ee12c48">16,208</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03bccaa0abfb4733b1e2831ecde4e4e8_D20200101-20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18yMi9mcmFnOjg2MjFjNDJiNjI3NDRkMmNhMzQ1NDQwN2UzZjI0N2QzL3RhYmxlOjM0YjQ5NWMwODljMzRkMmI4OWRhYTVlMmI3NTRmNmM5L3RhYmxlcmFuZ2U6MzRiNDk1YzA4OWMzNGQyYjg5ZGFhNWUyYjc1NGY2YzlfMzYtMTctMS0xLTA_893f4c79-8506-4dc4-ad82-bd1f54870eb2">4,001,553</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Acquisition of non-controlling interest in Geneos</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieac446e98d7241d8a6a13f0e4a3044da_D20200101-20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18yMi9mcmFnOjg2MjFjNDJiNjI3NDRkMmNhMzQ1NDQwN2UzZjI0N2QzL3RhYmxlOjM0YjQ5NWMwODljMzRkMmI4OWRhYTVlMmI3NTRmNmM5L3RhYmxlcmFuZ2U6MzRiNDk1YzA4OWMzNGQyYjg5ZGFhNWUyYjc1NGY2YzlfMzctMTUtMS0xLTA_cfd55fdf-a6fb-4fc9-a007-5c32cd949cc2">2,169,998</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03bccaa0abfb4733b1e2831ecde4e4e8_D20200101-20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18yMi9mcmFnOjg2MjFjNDJiNjI3NDRkMmNhMzQ1NDQwN2UzZjI0N2QzL3RhYmxlOjM0YjQ5NWMwODljMzRkMmI4OWRhYTVlMmI3NTRmNmM5L3RhYmxlcmFuZ2U6MzRiNDk1YzA4OWMzNGQyYjg5ZGFhNWUyYjc1NGY2YzlfMzctMTctMS0xLTA_288afeb8-49b0-4337-bb65-67ec040f327f">2,169,998</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss attributable to common stockholders</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i344d70813010473f9e5c16b3e01640b5_D20200101-20200331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18yMi9mcmFnOjg2MjFjNDJiNjI3NDRkMmNhMzQ1NDQwN2UzZjI0N2QzL3RhYmxlOjM0YjQ5NWMwODljMzRkMmI4OWRhYTVlMmI3NTRmNmM5L3RhYmxlcmFuZ2U6MzRiNDk1YzA4OWMzNGQyYjg5ZGFhNWUyYjc1NGY2YzlfMzgtMTEtMS0xLTA_60e05fc3-018b-4b2c-af95-941c7002dc2d">32,541,054</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ieac446e98d7241d8a6a13f0e4a3044da_D20200101-20200331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18yMi9mcmFnOjg2MjFjNDJiNjI3NDRkMmNhMzQ1NDQwN2UzZjI0N2QzL3RhYmxlOjM0YjQ5NWMwODljMzRkMmI4OWRhYTVlMmI3NTRmNmM5L3RhYmxlcmFuZ2U6MzRiNDk1YzA4OWMzNGQyYjg5ZGFhNWUyYjc1NGY2YzlfMzgtMTUtMS0xLTA_5dac852a-e06d-4a2e-97f4-9c6aad66d145">594,350</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i03bccaa0abfb4733b1e2831ecde4e4e8_D20200101-20200331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18yMi9mcmFnOjg2MjFjNDJiNjI3NDRkMmNhMzQ1NDQwN2UzZjI0N2QzL3RhYmxlOjM0YjQ5NWMwODljMzRkMmI4OWRhYTVlMmI3NTRmNmM5L3RhYmxlcmFuZ2U6MzRiNDk1YzA4OWMzNGQyYjg5ZGFhNWUyYjc1NGY2YzlfMzgtMTctMS0xLTA_786db85d-0e59-4fcc-8b92-218f37e99622">33,135,404</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unrealized loss on short-term investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie9701f9c982742d69bfc64ed972293c3_D20200101-20200331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18yMi9mcmFnOjg2MjFjNDJiNjI3NDRkMmNhMzQ1NDQwN2UzZjI0N2QzL3RhYmxlOjM0YjQ5NWMwODljMzRkMmI4OWRhYTVlMmI3NTRmNmM5L3RhYmxlcmFuZ2U6MzRiNDk1YzA4OWMzNGQyYjg5ZGFhNWUyYjc1NGY2YzlfMzktMTMtMS0xLTA_7fe5fe14-83c3-42db-8091-c34b4e647ccf">1,929,538</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i03bccaa0abfb4733b1e2831ecde4e4e8_D20200101-20200331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18yMi9mcmFnOjg2MjFjNDJiNjI3NDRkMmNhMzQ1NDQwN2UzZjI0N2QzL3RhYmxlOjM0YjQ5NWMwODljMzRkMmI4OWRhYTVlMmI3NTRmNmM5L3RhYmxlcmFuZ2U6MzRiNDk1YzA4OWMzNGQyYjg5ZGFhNWUyYjc1NGY2YzlfMzktMTctMS0xLTA_753f8953-8a12-40d5-8fd7-0ba8397cc826">1,929,538</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at March 31, 2020</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia55b1d91150f431281e2f695e0515501_I20200331" decimals="INF" name="us-gaap:SharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18yMi9mcmFnOjg2MjFjNDJiNjI3NDRkMmNhMzQ1NDQwN2UzZjI0N2QzL3RhYmxlOjM0YjQ5NWMwODljMzRkMmI4OWRhYTVlMmI3NTRmNmM5L3RhYmxlcmFuZ2U6MzRiNDk1YzA4OWMzNGQyYjg5ZGFhNWUyYjc1NGY2YzlfNDAtMS0xLTEtMA_981cfb9f-f794-46e9-b076-25fac3142cc8">23</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia55b1d91150f431281e2f695e0515501_I20200331" decimals="0" format="ixt:zerodash" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18yMi9mcmFnOjg2MjFjNDJiNjI3NDRkMmNhMzQ1NDQwN2UzZjI0N2QzL3RhYmxlOjM0YjQ5NWMwODljMzRkMmI4OWRhYTVlMmI3NTRmNmM5L3RhYmxlcmFuZ2U6MzRiNDk1YzA4OWMzNGQyYjg5ZGFhNWUyYjc1NGY2YzlfNDAtMy0xLTEtMA_8da14004-7f43-438e-8a14-fd85653a5ba4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i90229a4122af48d0aef6e89c51605f73_I20200331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18yMi9mcmFnOjg2MjFjNDJiNjI3NDRkMmNhMzQ1NDQwN2UzZjI0N2QzL3RhYmxlOjM0YjQ5NWMwODljMzRkMmI4OWRhYTVlMmI3NTRmNmM5L3RhYmxlcmFuZ2U6MzRiNDk1YzA4OWMzNGQyYjg5ZGFhNWUyYjc1NGY2YzlfNDAtNS0xLTEtMA_2f7bfcff-db59-461f-967f-43ec566ea54e">145,915,100</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i90229a4122af48d0aef6e89c51605f73_I20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18yMi9mcmFnOjg2MjFjNDJiNjI3NDRkMmNhMzQ1NDQwN2UzZjI0N2QzL3RhYmxlOjM0YjQ5NWMwODljMzRkMmI4OWRhYTVlMmI3NTRmNmM5L3RhYmxlcmFuZ2U6MzRiNDk1YzA4OWMzNGQyYjg5ZGFhNWUyYjc1NGY2YzlfNDAtNy0xLTEtMA_f304817d-3944-47d9-b37a-0ac49c3e8d6c">145,915</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7516614b1b654183b04111cbc3406079_I20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18yMi9mcmFnOjg2MjFjNDJiNjI3NDRkMmNhMzQ1NDQwN2UzZjI0N2QzL3RhYmxlOjM0YjQ5NWMwODljMzRkMmI4OWRhYTVlMmI3NTRmNmM5L3RhYmxlcmFuZ2U6MzRiNDk1YzA4OWMzNGQyYjg5ZGFhNWUyYjc1NGY2YzlfNDAtOS0xLTEtMA_675236e0-5376-49a1-9673-a05bf9a7080b">957,962,628</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i94124ab8558d4ae989f26b588119e983_I20200331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18yMi9mcmFnOjg2MjFjNDJiNjI3NDRkMmNhMzQ1NDQwN2UzZjI0N2QzL3RhYmxlOjM0YjQ5NWMwODljMzRkMmI4OWRhYTVlMmI3NTRmNmM5L3RhYmxlcmFuZ2U6MzRiNDk1YzA4OWMzNGQyYjg5ZGFhNWUyYjc1NGY2YzlfNDAtMTEtMS0xLTA_2536a6e5-a940-4e2a-ac04-b8cad08016e4">772,326,709</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i54cb3f5e003c480faccd9444adf9d1fe_I20200331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18yMi9mcmFnOjg2MjFjNDJiNjI3NDRkMmNhMzQ1NDQwN2UzZjI0N2QzL3RhYmxlOjM0YjQ5NWMwODljMzRkMmI4OWRhYTVlMmI3NTRmNmM5L3RhYmxlcmFuZ2U6MzRiNDk1YzA4OWMzNGQyYjg5ZGFhNWUyYjc1NGY2YzlfNDAtMTMtMS0xLTA_5b18c428-39ae-410f-af8e-71220a381c4c">1,456,930</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63a61b36187545e5820f6cdb1e65f011_I20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18yMi9mcmFnOjg2MjFjNDJiNjI3NDRkMmNhMzQ1NDQwN2UzZjI0N2QzL3RhYmxlOjM0YjQ5NWMwODljMzRkMmI4OWRhYTVlMmI3NTRmNmM5L3RhYmxlcmFuZ2U6MzRiNDk1YzA4OWMzNGQyYjg5ZGFhNWUyYjc1NGY2YzlfNDAtMTUtMS0xLTA_5bd909d5-0da6-459c-b0f7-aff41dfd6cf6">3,529,199</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98369f585c4549d585af1f9094a77fd9_I20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18yMi9mcmFnOjg2MjFjNDJiNjI3NDRkMmNhMzQ1NDQwN2UzZjI0N2QzL3RhYmxlOjM0YjQ5NWMwODljMzRkMmI4OWRhYTVlMmI3NTRmNmM5L3RhYmxlcmFuZ2U6MzRiNDk1YzA4OWMzNGQyYjg5ZGFhNWUyYjc1NGY2YzlfNDAtMTctMS0xLTA_2d1b5251-53c2-466e-98d7-8261227bf881">187,854,103</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:5pt;text-align:center"><span><br/></span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to unaudited condensed consolidated financial statements.</span></div><div style="margin-top:5pt;text-align:center"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><div id="i1d23d16a69484b63aa007ec686e80337_25"></div><hr style="page-break-after:always"/><div style="min-height:31.5pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INOVIO PHARMACEUTICALS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.696%"><tr><td style="width:1.0%"></td><td style="width:71.696%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.121%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.559%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.124%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash flows from operating activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18yNS9mcmFnOjdiNjAzZGI3ZTMwMDRhOGNiOWVkMDQ4YTYzYjhhMjQxL3RhYmxlOmMxOTk4MmY4NGY5NzRmYjQ5ZGE5YjIzMjFmZmQzNWRiL3RhYmxlcmFuZ2U6YzE5OTgyZjg0Zjk3NGZiNDlkYTliMjMyMWZmZDM1ZGJfMy0xLTEtMS0w_c65d7472-c0bb-43c3-9f49-05b12ee2cb0f">54,402,131</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i03bccaa0abfb4733b1e2831ecde4e4e8_D20200101-20200331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18yNS9mcmFnOjdiNjAzZGI3ZTMwMDRhOGNiOWVkMDQ4YTYzYjhhMjQxL3RhYmxlOmMxOTk4MmY4NGY5NzRmYjQ5ZGE5YjIzMjFmZmQzNWRiL3RhYmxlcmFuZ2U6YzE5OTgyZjg0Zjk3NGZiNDlkYTliMjMyMWZmZDM1ZGJfMy0zLTEtMS0w_049102d1-fb87-4249-9612-08715200312f">33,135,404</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments to reconcile net loss to net cash used in operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Depreciation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18yNS9mcmFnOjdiNjAzZGI3ZTMwMDRhOGNiOWVkMDQ4YTYzYjhhMjQxL3RhYmxlOmMxOTk4MmY4NGY5NzRmYjQ5ZGE5YjIzMjFmZmQzNWRiL3RhYmxlcmFuZ2U6YzE5OTgyZjg0Zjk3NGZiNDlkYTliMjMyMWZmZDM1ZGJfNS0xLTEtMS0w_c3e95a0d-778e-45c8-ac11-94a31e6ced1d">660,697</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03bccaa0abfb4733b1e2831ecde4e4e8_D20200101-20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Depreciation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18yNS9mcmFnOjdiNjAzZGI3ZTMwMDRhOGNiOWVkMDQ4YTYzYjhhMjQxL3RhYmxlOmMxOTk4MmY4NGY5NzRmYjQ5ZGE5YjIzMjFmZmQzNWRiL3RhYmxlcmFuZ2U6YzE5OTgyZjg0Zjk3NGZiNDlkYTliMjMyMWZmZDM1ZGJfNS0zLTEtMS0w_c9070867-e5c1-4adc-ae58-e929f72df9f8">809,559</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of intangible assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfIntangibleAssets" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18yNS9mcmFnOjdiNjAzZGI3ZTMwMDRhOGNiOWVkMDQ4YTYzYjhhMjQxL3RhYmxlOmMxOTk4MmY4NGY5NzRmYjQ5ZGE5YjIzMjFmZmQzNWRiL3RhYmxlcmFuZ2U6YzE5OTgyZjg0Zjk3NGZiNDlkYTliMjMyMWZmZDM1ZGJfNi0xLTEtMS0w_be0b0e12-6417-4433-8095-ab6df28b0da3">136,770</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03bccaa0abfb4733b1e2831ecde4e4e8_D20200101-20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfIntangibleAssets" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18yNS9mcmFnOjdiNjAzZGI3ZTMwMDRhOGNiOWVkMDQ4YTYzYjhhMjQxL3RhYmxlOmMxOTk4MmY4NGY5NzRmYjQ5ZGE5YjIzMjFmZmQzNWRiL3RhYmxlcmFuZ2U6YzE5OTgyZjg0Zjk3NGZiNDlkYTliMjMyMWZmZDM1ZGJfNi0zLTEtMS0w_1f090676-ddba-444c-af8c-9a2f28b62843">136,770</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of operating lease right-of-use assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331" decimals="0" format="ixt:zerodash" name="ino:AmortizationOfOperatingLeaseRightOfUseAssets" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18yNS9mcmFnOjdiNjAzZGI3ZTMwMDRhOGNiOWVkMDQ4YTYzYjhhMjQxL3RhYmxlOmMxOTk4MmY4NGY5NzRmYjQ5ZGE5YjIzMjFmZmQzNWRiL3RhYmxlcmFuZ2U6YzE5OTgyZjg0Zjk3NGZiNDlkYTliMjMyMWZmZDM1ZGJfNy0xLTEtMS0w_627a02b9-7051-4889-8f8f-8e9175fde8ba">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03bccaa0abfb4733b1e2831ecde4e4e8_D20200101-20200331" decimals="0" format="ixt:numdotdecimal" name="ino:AmortizationOfOperatingLeaseRightOfUseAssets" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18yNS9mcmFnOjdiNjAzZGI3ZTMwMDRhOGNiOWVkMDQ4YTYzYjhhMjQxL3RhYmxlOmMxOTk4MmY4NGY5NzRmYjQ5ZGE5YjIzMjFmZmQzNWRiL3RhYmxlcmFuZ2U6YzE5OTgyZjg0Zjk3NGZiNDlkYTliMjMyMWZmZDM1ZGJfNy0zLTEtMS0w_b2413ab5-943e-447c-8cd6-51a681861879">271,628</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of derivative liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331" decimals="0" format="ixt:zerodash" name="us-gaap:IncreaseDecreaseInDerivativeLiabilities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18yNS9mcmFnOjdiNjAzZGI3ZTMwMDRhOGNiOWVkMDQ4YTYzYjhhMjQxL3RhYmxlOmMxOTk4MmY4NGY5NzRmYjQ5ZGE5YjIzMjFmZmQzNWRiL3RhYmxlcmFuZ2U6YzE5OTgyZjg0Zjk3NGZiNDlkYTliMjMyMWZmZDM1ZGJfOC0xLTEtMS0w_0a7326ca-5758-4301-923d-c6dfc46fbaf2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03bccaa0abfb4733b1e2831ecde4e4e8_D20200101-20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInDerivativeLiabilities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18yNS9mcmFnOjdiNjAzZGI3ZTMwMDRhOGNiOWVkMDQ4YTYzYjhhMjQxL3RhYmxlOmMxOTk4MmY4NGY5NzRmYjQ5ZGE5YjIzMjFmZmQzNWRiL3RhYmxlcmFuZ2U6YzE5OTgyZjg0Zjk3NGZiNDlkYTliMjMyMWZmZDM1ZGJfOC0zLTEtMS0w_03237f4d-c1c2-44a6-8084-cfaf5a9f8353">13,221,977</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18yNS9mcmFnOjdiNjAzZGI3ZTMwMDRhOGNiOWVkMDQ4YTYzYjhhMjQxL3RhYmxlOmMxOTk4MmY4NGY5NzRmYjQ5ZGE5YjIzMjFmZmQzNWRiL3RhYmxlcmFuZ2U6YzE5OTgyZjg0Zjk3NGZiNDlkYTliMjMyMWZmZDM1ZGJfOS0xLTEtMS0w_1248d920-e6bd-4a8a-8975-1c4e280d94a2">9,595,947</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03bccaa0abfb4733b1e2831ecde4e4e8_D20200101-20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18yNS9mcmFnOjdiNjAzZGI3ZTMwMDRhOGNiOWVkMDQ4YTYzYjhhMjQxL3RhYmxlOmMxOTk4MmY4NGY5NzRmYjQ5ZGE5YjIzMjFmZmQzNWRiL3RhYmxlcmFuZ2U6YzE5OTgyZjg0Zjk3NGZiNDlkYTliMjMyMWZmZDM1ZGJfOS0zLTEtMS0w_8316d8b3-53c2-44e9-8c1b-f91e7e739d0d">4,001,553</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash interest expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331" decimals="0" format="ixt:numdotdecimal" name="ino:NonCashInterestIncomeExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18yNS9mcmFnOjdiNjAzZGI3ZTMwMDRhOGNiOWVkMDQ4YTYzYjhhMjQxL3RhYmxlOmMxOTk4MmY4NGY5NzRmYjQ5ZGE5YjIzMjFmZmQzNWRiL3RhYmxlcmFuZ2U6YzE5OTgyZjg0Zjk3NGZiNDlkYTliMjMyMWZmZDM1ZGJfMTItMS0xLTEtMA_211ea232-73b2-45d5-9126-9659abdc1725">31,281</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03bccaa0abfb4733b1e2831ecde4e4e8_D20200101-20200331" decimals="0" sign="-" format="ixt:numdotdecimal" name="ino:NonCashInterestIncomeExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18yNS9mcmFnOjdiNjAzZGI3ZTMwMDRhOGNiOWVkMDQ4YTYzYjhhMjQxL3RhYmxlOmMxOTk4MmY4NGY5NzRmYjQ5ZGE5YjIzMjFmZmQzNWRiL3RhYmxlcmFuZ2U6YzE5OTgyZjg0Zjk3NGZiNDlkYTliMjMyMWZmZDM1ZGJfMTItMy0xLTEtMA_1a54bb72-d289-4e6e-a583-cf763d3b9f31">213,559</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on short-term investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:GainLossOnInvestments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18yNS9mcmFnOjdiNjAzZGI3ZTMwMDRhOGNiOWVkMDQ4YTYzYjhhMjQxL3RhYmxlOmMxOTk4MmY4NGY5NzRmYjQ5ZGE5YjIzMjFmZmQzNWRiL3RhYmxlcmFuZ2U6YzE5OTgyZjg0Zjk3NGZiNDlkYTliMjMyMWZmZDM1ZGJfMTQtMS0xLTEtMA_6fa1c4a8-0dd7-45de-bc9a-37ce79f9d577">10,151</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03bccaa0abfb4733b1e2831ecde4e4e8_D20200101-20200331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:GainLossOnInvestments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18yNS9mcmFnOjdiNjAzZGI3ZTMwMDRhOGNiOWVkMDQ4YTYzYjhhMjQxL3RhYmxlOmMxOTk4MmY4NGY5NzRmYjQ5ZGE5YjIzMjFmZmQzNWRiL3RhYmxlcmFuZ2U6YzE5OTgyZjg0Zjk3NGZiNDlkYTliMjMyMWZmZDM1ZGJfMTQtMy0xLTEtMA_84c991b6-3518-46ae-b530-b08b7fa1f26b">475,490</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Settlement of receivable with shares of common stock from affiliated entity (PLS)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331" decimals="0" format="ixt:zerodash" name="ino:SettlementOfReceivableWithSharesOfCommonStockFromEquitySecurity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18yNS9mcmFnOjdiNjAzZGI3ZTMwMDRhOGNiOWVkMDQ4YTYzYjhhMjQxL3RhYmxlOmMxOTk4MmY4NGY5NzRmYjQ5ZGE5YjIzMjFmZmQzNWRiL3RhYmxlcmFuZ2U6YzE5OTgyZjg0Zjk3NGZiNDlkYTliMjMyMWZmZDM1ZGJfMTYtMS0xLTEtMA_eccbc1a1-7eb2-4d77-a6b0-b94c5aa2e17d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i03bccaa0abfb4733b1e2831ecde4e4e8_D20200101-20200331" decimals="0" format="ixt:numdotdecimal" name="ino:SettlementOfReceivableWithSharesOfCommonStockFromEquitySecurity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18yNS9mcmFnOjdiNjAzZGI3ZTMwMDRhOGNiOWVkMDQ4YTYzYjhhMjQxL3RhYmxlOmMxOTk4MmY4NGY5NzRmYjQ5ZGE5YjIzMjFmZmQzNWRiL3RhYmxlcmFuZ2U6YzE5OTgyZjg0Zjk3NGZiNDlkYTliMjMyMWZmZDM1ZGJfMTYtMy0xLTEtMA_7668159b-00f9-4616-ae2b-81c1ce975fbe">1,713,770</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Gain) loss on equity investment in affiliated entities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331" decimals="0" sign="-" format="ixt:numdotdecimal" name="ino:ChangeInValueOfInvestmentsInAffiliatedCompany" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18yNS9mcmFnOjdiNjAzZGI3ZTMwMDRhOGNiOWVkMDQ4YTYzYjhhMjQxL3RhYmxlOmMxOTk4MmY4NGY5NzRmYjQ5ZGE5YjIzMjFmZmQzNWRiL3RhYmxlcmFuZ2U6YzE5OTgyZjg0Zjk3NGZiNDlkYTliMjMyMWZmZDM1ZGJfMTgtMS0xLTEtMA_742d9f1d-ddca-4134-a931-4e7c90c53790">830,475</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i03bccaa0abfb4733b1e2831ecde4e4e8_D20200101-20200331" decimals="0" format="ixt:numdotdecimal" name="ino:ChangeInValueOfInvestmentsInAffiliatedCompany" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18yNS9mcmFnOjdiNjAzZGI3ZTMwMDRhOGNiOWVkMDQ4YTYzYjhhMjQxL3RhYmxlOmMxOTk4MmY4NGY5NzRmYjQ5ZGE5YjIzMjFmZmQzNWRiL3RhYmxlcmFuZ2U6YzE5OTgyZjg0Zjk3NGZiNDlkYTliMjMyMWZmZDM1ZGJfMTgtMy0xLTEtMA_804fad50-34a8-4746-993e-568482fe11de">13,181,619</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share of net loss in Geneos</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18yNS9mcmFnOjdiNjAzZGI3ZTMwMDRhOGNiOWVkMDQ4YTYzYjhhMjQxL3RhYmxlOmMxOTk4MmY4NGY5NzRmYjQ5ZGE5YjIzMjFmZmQzNWRiL3RhYmxlcmFuZ2U6YzE5OTgyZjg0Zjk3NGZiNDlkYTliMjMyMWZmZDM1ZGJfMTktMS0xLTEtMA_86bb4980-b538-4be1-9507-ceda461dab1a">434,387</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03bccaa0abfb4733b1e2831ecde4e4e8_D20200101-20200331" decimals="0" format="ixt:zerodash" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18yNS9mcmFnOjdiNjAzZGI3ZTMwMDRhOGNiOWVkMDQ4YTYzYjhhMjQxL3RhYmxlOmMxOTk4MmY4NGY5NzRmYjQ5ZGE5YjIzMjFmZmQzNWRiL3RhYmxlcmFuZ2U6YzE5OTgyZjg0Zjk3NGZiNDlkYTliMjMyMWZmZDM1ZGJfMTktMy0xLTEtMA_cb5dbf65-2295-40e8-8e70-3d794cf9743e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net unrealized loss on available-for-sale equity securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:EquitySecuritiesFvNiUnrealizedLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18yNS9mcmFnOjdiNjAzZGI3ZTMwMDRhOGNiOWVkMDQ4YTYzYjhhMjQxL3RhYmxlOmMxOTk4MmY4NGY5NzRmYjQ5ZGE5YjIzMjFmZmQzNWRiL3RhYmxlcmFuZ2U6YzE5OTgyZjg0Zjk3NGZiNDlkYTliMjMyMWZmZDM1ZGJfMjItMS0xLTEtMA_e4cd1084-2fd4-4ac3-8773-67b665d22108">847,958</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03bccaa0abfb4733b1e2831ecde4e4e8_D20200101-20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:EquitySecuritiesFvNiUnrealizedLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18yNS9mcmFnOjdiNjAzZGI3ZTMwMDRhOGNiOWVkMDQ4YTYzYjhhMjQxL3RhYmxlOmMxOTk4MmY4NGY5NzRmYjQ5ZGE5YjIzMjFmZmQzNWRiL3RhYmxlcmFuZ2U6YzE5OTgyZjg0Zjk3NGZiNDlkYTliMjMyMWZmZDM1ZGJfMjItMy0xLTEtMA_91c54c69-7c46-40e4-9936-7cccf323d582">5,050,092</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash lease expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331" decimals="0" format="ixt:numdotdecimal" name="ino:OperatingLeaseNonCashLeaseExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18yNS9mcmFnOjdiNjAzZGI3ZTMwMDRhOGNiOWVkMDQ4YTYzYjhhMjQxL3RhYmxlOmMxOTk4MmY4NGY5NzRmYjQ5ZGE5YjIzMjFmZmQzNWRiL3RhYmxlcmFuZ2U6YzE5OTgyZjg0Zjk3NGZiNDlkYTliMjMyMWZmZDM1ZGJfMjMtMS0xLTEtMA_f6061e4a-cf36-4447-b16c-051dfba6ec54">278,290</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03bccaa0abfb4733b1e2831ecde4e4e8_D20200101-20200331" decimals="0" format="ixt:zerodash" name="ino:OperatingLeaseNonCashLeaseExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18yNS9mcmFnOjdiNjAzZGI3ZTMwMDRhOGNiOWVkMDQ4YTYzYjhhMjQxL3RhYmxlOmMxOTk4MmY4NGY5NzRmYjQ5ZGE5YjIzMjFmZmQzNWRiL3RhYmxlcmFuZ2U6YzE5OTgyZjg0Zjk3NGZiNDlkYTliMjMyMWZmZDM1ZGJfMjMtMy0xLTEtMA_180f63c4-0ba7-4780-90a3-3202429dd9fc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized transaction loss on foreign-currency denominated debt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18yNS9mcmFnOjdiNjAzZGI3ZTMwMDRhOGNiOWVkMDQ4YTYzYjhhMjQxL3RhYmxlOmMxOTk4MmY4NGY5NzRmYjQ5ZGE5YjIzMjFmZmQzNWRiL3RhYmxlcmFuZ2U6YzE5OTgyZjg0Zjk3NGZiNDlkYTliMjMyMWZmZDM1ZGJfMjUtMS0xLTEtMA_cd0456a1-b8b2-4a2f-9450-459b6f979d08">176,927</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i03bccaa0abfb4733b1e2831ecde4e4e8_D20200101-20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18yNS9mcmFnOjdiNjAzZGI3ZTMwMDRhOGNiOWVkMDQ4YTYzYjhhMjQxL3RhYmxlOmMxOTk4MmY4NGY5NzRmYjQ5ZGE5YjIzMjFmZmQzNWRiL3RhYmxlcmFuZ2U6YzE5OTgyZjg0Zjk3NGZiNDlkYTliMjMyMWZmZDM1ZGJfMjUtMy0xLTEtMA_53853ba1-63ed-4cd5-8fe9-2767b2567981">681,151</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in operating assets and liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18yNS9mcmFnOjdiNjAzZGI3ZTMwMDRhOGNiOWVkMDQ4YTYzYjhhMjQxL3RhYmxlOmMxOTk4MmY4NGY5NzRmYjQ5ZGE5YjIzMjFmZmQzNWRiL3RhYmxlcmFuZ2U6YzE5OTgyZjg0Zjk3NGZiNDlkYTliMjMyMWZmZDM1ZGJfMjctMS0xLTEtMA_afaa8645-3f41-4529-ba5a-0f5ff4cc22ef">8,648,045</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03bccaa0abfb4733b1e2831ecde4e4e8_D20200101-20200331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18yNS9mcmFnOjdiNjAzZGI3ZTMwMDRhOGNiOWVkMDQ4YTYzYjhhMjQxL3RhYmxlOmMxOTk4MmY4NGY5NzRmYjQ5ZGE5YjIzMjFmZmQzNWRiL3RhYmxlcmFuZ2U6YzE5OTgyZjg0Zjk3NGZiNDlkYTliMjMyMWZmZDM1ZGJfMjctMy0xLTEtMA_330c63ed-9bcd-4a9a-9704-14fe9523f658">58,430</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable from affiliated entities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsReceivableRelatedParties" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18yNS9mcmFnOjdiNjAzZGI3ZTMwMDRhOGNiOWVkMDQ4YTYzYjhhMjQxL3RhYmxlOmMxOTk4MmY4NGY5NzRmYjQ5ZGE5YjIzMjFmZmQzNWRiL3RhYmxlcmFuZ2U6YzE5OTgyZjg0Zjk3NGZiNDlkYTliMjMyMWZmZDM1ZGJfMjgtMS0xLTEtMA_83a7a8f7-cd48-4a04-8a48-37a44c0bf2ac">156,808</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03bccaa0abfb4733b1e2831ecde4e4e8_D20200101-20200331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsReceivableRelatedParties" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18yNS9mcmFnOjdiNjAzZGI3ZTMwMDRhOGNiOWVkMDQ4YTYzYjhhMjQxL3RhYmxlOmMxOTk4MmY4NGY5NzRmYjQ5ZGE5YjIzMjFmZmQzNWRiL3RhYmxlcmFuZ2U6YzE5OTgyZjg0Zjk3NGZiNDlkYTliMjMyMWZmZDM1ZGJfMjgtMy0xLTEtMA_3a77829e-e950-47f4-8acc-8413c6eb9e5d">697,846</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18yNS9mcmFnOjdiNjAzZGI3ZTMwMDRhOGNiOWVkMDQ4YTYzYjhhMjQxL3RhYmxlOmMxOTk4MmY4NGY5NzRmYjQ5ZGE5YjIzMjFmZmQzNWRiL3RhYmxlcmFuZ2U6YzE5OTgyZjg0Zjk3NGZiNDlkYTliMjMyMWZmZDM1ZGJfMjktMS0xLTEtMA_4c8928e9-440e-4468-9ec2-d5ac24d43691">19,214,780</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i03bccaa0abfb4733b1e2831ecde4e4e8_D20200101-20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18yNS9mcmFnOjdiNjAzZGI3ZTMwMDRhOGNiOWVkMDQ4YTYzYjhhMjQxL3RhYmxlOmMxOTk4MmY4NGY5NzRmYjQ5ZGE5YjIzMjFmZmQzNWRiL3RhYmxlcmFuZ2U6YzE5OTgyZjg0Zjk3NGZiNDlkYTliMjMyMWZmZDM1ZGJfMjktMy0xLTEtMA_0d85c6d6-c64f-4279-84f4-73fa64ba3d1d">894,606</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets from affiliated entities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331" decimals="0" sign="-" format="ixt:numdotdecimal" name="ino:IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18yNS9mcmFnOjdiNjAzZGI3ZTMwMDRhOGNiOWVkMDQ4YTYzYjhhMjQxL3RhYmxlOmMxOTk4MmY4NGY5NzRmYjQ5ZGE5YjIzMjFmZmQzNWRiL3RhYmxlcmFuZ2U6YzE5OTgyZjg0Zjk3NGZiNDlkYTliMjMyMWZmZDM1ZGJfMzAtMS0xLTEtMA_e3505883-668e-417e-824c-474dc88d435e">106,432</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i03bccaa0abfb4733b1e2831ecde4e4e8_D20200101-20200331" decimals="0" format="ixt:numdotdecimal" name="ino:IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18yNS9mcmFnOjdiNjAzZGI3ZTMwMDRhOGNiOWVkMDQ4YTYzYjhhMjQxL3RhYmxlOmMxOTk4MmY4NGY5NzRmYjQ5ZGE5YjIzMjFmZmQzNWRiL3RhYmxlcmFuZ2U6YzE5OTgyZjg0Zjk3NGZiNDlkYTliMjMyMWZmZDM1ZGJfMzAtMy0xLTEtMA_cff363ba-72e2-4c77-a7df-a002546ca618">740,469</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18yNS9mcmFnOjdiNjAzZGI3ZTMwMDRhOGNiOWVkMDQ4YTYzYjhhMjQxL3RhYmxlOmMxOTk4MmY4NGY5NzRmYjQ5ZGE5YjIzMjFmZmQzNWRiL3RhYmxlcmFuZ2U6YzE5OTgyZjg0Zjk3NGZiNDlkYTliMjMyMWZmZDM1ZGJfMzItMS0xLTEtMA_5e192ee9-7d1e-49ae-bc8c-ea47f9df0fab">75,514</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03bccaa0abfb4733b1e2831ecde4e4e8_D20200101-20200331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18yNS9mcmFnOjdiNjAzZGI3ZTMwMDRhOGNiOWVkMDQ4YTYzYjhhMjQxL3RhYmxlOmMxOTk4MmY4NGY5NzRmYjQ5ZGE5YjIzMjFmZmQzNWRiL3RhYmxlcmFuZ2U6YzE5OTgyZjg0Zjk3NGZiNDlkYTliMjMyMWZmZDM1ZGJfMzItMy0xLTEtMA_8c519b27-7103-423f-91bf-fe901c84ccca">191,937</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable and accrued expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18yNS9mcmFnOjdiNjAzZGI3ZTMwMDRhOGNiOWVkMDQ4YTYzYjhhMjQxL3RhYmxlOmMxOTk4MmY4NGY5NzRmYjQ5ZGE5YjIzMjFmZmQzNWRiL3RhYmxlcmFuZ2U6YzE5OTgyZjg0Zjk3NGZiNDlkYTliMjMyMWZmZDM1ZGJfMzMtMS0xLTEtMA_587d4808-2357-4d76-9dc8-f6e9cf2cd7e9">4,735,352</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i03bccaa0abfb4733b1e2831ecde4e4e8_D20200101-20200331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18yNS9mcmFnOjdiNjAzZGI3ZTMwMDRhOGNiOWVkMDQ4YTYzYjhhMjQxL3RhYmxlOmMxOTk4MmY4NGY5NzRmYjQ5ZGE5YjIzMjFmZmQzNWRiL3RhYmxlcmFuZ2U6YzE5OTgyZjg0Zjk3NGZiNDlkYTliMjMyMWZmZDM1ZGJfMzMtMy0xLTEtMA_52d267aa-e42a-4c13-b746-daed2986a427">7,217,676</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued clinical trial expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331" decimals="0" sign="-" format="ixt:numdotdecimal" name="ino:IncreaseDecreaseInAccruedClinicalTrialExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18yNS9mcmFnOjdiNjAzZGI3ZTMwMDRhOGNiOWVkMDQ4YTYzYjhhMjQxL3RhYmxlOmMxOTk4MmY4NGY5NzRmYjQ5ZGE5YjIzMjFmZmQzNWRiL3RhYmxlcmFuZ2U6YzE5OTgyZjg0Zjk3NGZiNDlkYTliMjMyMWZmZDM1ZGJfMzQtMS0xLTEtMA_1d9b12f8-e513-4d11-9f49-400c383c0398">2,579,476</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03bccaa0abfb4733b1e2831ecde4e4e8_D20200101-20200331" decimals="0" format="ixt:numdotdecimal" name="ino:IncreaseDecreaseInAccruedClinicalTrialExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18yNS9mcmFnOjdiNjAzZGI3ZTMwMDRhOGNiOWVkMDQ4YTYzYjhhMjQxL3RhYmxlOmMxOTk4MmY4NGY5NzRmYjQ5ZGE5YjIzMjFmZmQzNWRiL3RhYmxlcmFuZ2U6YzE5OTgyZjg0Zjk3NGZiNDlkYTliMjMyMWZmZDM1ZGJfMzQtMy0xLTEtMA_20d89914-ed4d-466e-9d6c-aaaebd52013c">1,011,439</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable and accrued expenses due to affiliated entities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayableRelatedParties" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18yNS9mcmFnOjdiNjAzZGI3ZTMwMDRhOGNiOWVkMDQ4YTYzYjhhMjQxL3RhYmxlOmMxOTk4MmY4NGY5NzRmYjQ5ZGE5YjIzMjFmZmQzNWRiL3RhYmxlcmFuZ2U6YzE5OTgyZjg0Zjk3NGZiNDlkYTliMjMyMWZmZDM1ZGJfMzUtMS0xLTEtMA_8ef9d71c-7081-4f38-80b1-22eec39d4525">125,292</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i03bccaa0abfb4733b1e2831ecde4e4e8_D20200101-20200331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayableRelatedParties" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18yNS9mcmFnOjdiNjAzZGI3ZTMwMDRhOGNiOWVkMDQ4YTYzYjhhMjQxL3RhYmxlOmMxOTk4MmY4NGY5NzRmYjQ5ZGE5YjIzMjFmZmQzNWRiL3RhYmxlcmFuZ2U6YzE5OTgyZjg0Zjk3NGZiNDlkYTliMjMyMWZmZDM1ZGJfMzUtMy0xLTEtMA_c68fdf8e-e63a-4a95-83d0-0b67c494ba43">466,273</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18yNS9mcmFnOjdiNjAzZGI3ZTMwMDRhOGNiOWVkMDQ4YTYzYjhhMjQxL3RhYmxlOmMxOTk4MmY4NGY5NzRmYjQ5ZGE5YjIzMjFmZmQzNWRiL3RhYmxlcmFuZ2U6YzE5OTgyZjg0Zjk3NGZiNDlkYTliMjMyMWZmZDM1ZGJfMzYtMS0xLTEtMA_be5e4f30-0bd1-4501-b1d4-a302dfb455db">34,963</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i03bccaa0abfb4733b1e2831ecde4e4e8_D20200101-20200331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18yNS9mcmFnOjdiNjAzZGI3ZTMwMDRhOGNiOWVkMDQ4YTYzYjhhMjQxL3RhYmxlOmMxOTk4MmY4NGY5NzRmYjQ5ZGE5YjIzMjFmZmQzNWRiL3RhYmxlcmFuZ2U6YzE5OTgyZjg0Zjk3NGZiNDlkYTliMjMyMWZmZDM1ZGJfMzYtMy0xLTEtMA_3bb4aa12-3fc6-472a-ba5d-4d2ba7848d86">26,297</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue from affiliated entities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331" decimals="0" sign="-" format="ixt:numdotdecimal" name="ino:IncreaseDecreaseInDeferredRevenueFromRelatedParties" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18yNS9mcmFnOjdiNjAzZGI3ZTMwMDRhOGNiOWVkMDQ4YTYzYjhhMjQxL3RhYmxlOmMxOTk4MmY4NGY5NzRmYjQ5ZGE5YjIzMjFmZmQzNWRiL3RhYmxlcmFuZ2U6YzE5OTgyZjg0Zjk3NGZiNDlkYTliMjMyMWZmZDM1ZGJfMzctMS0xLTEtMA_87e59cd4-2436-4f5a-bf38-6cd7e9e2626f">37,500</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i03bccaa0abfb4733b1e2831ecde4e4e8_D20200101-20200331" decimals="0" sign="-" format="ixt:numdotdecimal" name="ino:IncreaseDecreaseInDeferredRevenueFromRelatedParties" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18yNS9mcmFnOjdiNjAzZGI3ZTMwMDRhOGNiOWVkMDQ4YTYzYjhhMjQxL3RhYmxlOmMxOTk4MmY4NGY5NzRmYjQ5ZGE5YjIzMjFmZmQzNWRiL3RhYmxlcmFuZ2U6YzE5OTgyZjg0Zjk3NGZiNDlkYTliMjMyMWZmZDM1ZGJfMzctMy0xLTEtMA_c84a5793-b204-4aa6-8e9c-c85284e8d7ca">31,250</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets and liabilities, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331" decimals="0" sign="-" format="ixt:numdotdecimal" name="ino:IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18yNS9mcmFnOjdiNjAzZGI3ZTMwMDRhOGNiOWVkMDQ4YTYzYjhhMjQxL3RhYmxlOmMxOTk4MmY4NGY5NzRmYjQ5ZGE5YjIzMjFmZmQzNWRiL3RhYmxlcmFuZ2U6YzE5OTgyZjg0Zjk3NGZiNDlkYTliMjMyMWZmZDM1ZGJfMzktMS0xLTEtMA_ee5f18fc-c460-4941-a77a-df7b5ab08fca">558,140</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i03bccaa0abfb4733b1e2831ecde4e4e8_D20200101-20200331" decimals="0" sign="-" format="ixt:numdotdecimal" name="ino:IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18yNS9mcmFnOjdiNjAzZGI3ZTMwMDRhOGNiOWVkMDQ4YTYzYjhhMjQxL3RhYmxlOmMxOTk4MmY4NGY5NzRmYjQ5ZGE5YjIzMjFmZmQzNWRiL3RhYmxlcmFuZ2U6YzE5OTgyZjg0Zjk3NGZiNDlkYTliMjMyMWZmZDM1ZGJfMzktMy0xLTEtMA_3d36aab6-0b6e-42ad-9039-35fc8adc7200">517,949</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Grant funding liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331" decimals="0" sign="-" format="ixt:numdotdecimal" name="ino:IncreaseDecreaseinDeferredGrantFundingCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18yNS9mcmFnOjdiNjAzZGI3ZTMwMDRhOGNiOWVkMDQ4YTYzYjhhMjQxL3RhYmxlOmMxOTk4MmY4NGY5NzRmYjQ5ZGE5YjIzMjFmZmQzNWRiL3RhYmxlcmFuZ2U6YzE5OTgyZjg0Zjk3NGZiNDlkYTliMjMyMWZmZDM1ZGJfNDAtMS0xLTEtMA_1e438d09-7828-450a-9779-5a937421db0d">2,461,326</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03bccaa0abfb4733b1e2831ecde4e4e8_D20200101-20200331" decimals="0" format="ixt:numdotdecimal" name="ino:IncreaseDecreaseinDeferredGrantFundingCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18yNS9mcmFnOjdiNjAzZGI3ZTMwMDRhOGNiOWVkMDQ4YTYzYjhhMjQxL3RhYmxlOmMxOTk4MmY4NGY5NzRmYjQ5ZGE5YjIzMjFmZmQzNWRiL3RhYmxlcmFuZ2U6YzE5OTgyZjg0Zjk3NGZiNDlkYTliMjMyMWZmZDM1ZGJfNDAtMy0xLTEtMA_be378474-e5b7-40d2-ac51-4419a8797d63">7,026,212</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Grant funding liability from affiliated entities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331" decimals="0" sign="-" format="ixt:numdotdecimal" name="ino:IncreaseDecreaseinDeferredGrantFundingFromAffiliateCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18yNS9mcmFnOjdiNjAzZGI3ZTMwMDRhOGNiOWVkMDQ4YTYzYjhhMjQxL3RhYmxlOmMxOTk4MmY4NGY5NzRmYjQ5ZGE5YjIzMjFmZmQzNWRiL3RhYmxlcmFuZ2U6YzE5OTgyZjg0Zjk3NGZiNDlkYTliMjMyMWZmZDM1ZGJfNDEtMS0xLTEtMA_52ca6ac5-035a-4143-b7d1-a47452f13f99">19,500</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i03bccaa0abfb4733b1e2831ecde4e4e8_D20200101-20200331" decimals="0" sign="-" format="ixt:numdotdecimal" name="ino:IncreaseDecreaseinDeferredGrantFundingFromAffiliateCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18yNS9mcmFnOjdiNjAzZGI3ZTMwMDRhOGNiOWVkMDQ4YTYzYjhhMjQxL3RhYmxlOmMxOTk4MmY4NGY5NzRmYjQ5ZGE5YjIzMjFmZmQzNWRiL3RhYmxlcmFuZ2U6YzE5OTgyZjg0Zjk3NGZiNDlkYTliMjMyMWZmZDM1ZGJfNDEtMy0xLTEtMA_fe0d4a59-1d71-4720-81f0-eb5978b159cf">49,250</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18yNS9mcmFnOjdiNjAzZGI3ZTMwMDRhOGNiOWVkMDQ4YTYzYjhhMjQxL3RhYmxlOmMxOTk4MmY4NGY5NzRmYjQ5ZGE5YjIzMjFmZmQzNWRiL3RhYmxlcmFuZ2U6YzE5OTgyZjg0Zjk3NGZiNDlkYTliMjMyMWZmZDM1ZGJfNDMtMS0xLTEtMA_31379712-37fe-40b8-9a71-f12421c5433b">6,478</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03bccaa0abfb4733b1e2831ecde4e4e8_D20200101-20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18yNS9mcmFnOjdiNjAzZGI3ZTMwMDRhOGNiOWVkMDQ4YTYzYjhhMjQxL3RhYmxlOmMxOTk4MmY4NGY5NzRmYjQ5ZGE5YjIzMjFmZmQzNWRiL3RhYmxlcmFuZ2U6YzE5OTgyZjg0Zjk3NGZiNDlkYTliMjMyMWZmZDM1ZGJfNDMtMy0xLTEtMA_db095ed3-18ed-4f76-9413-7654791720dc">36,501</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net cash used in operating activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18yNS9mcmFnOjdiNjAzZGI3ZTMwMDRhOGNiOWVkMDQ4YTYzYjhhMjQxL3RhYmxlOmMxOTk4MmY4NGY5NzRmYjQ5ZGE5YjIzMjFmZmQzNWRiL3RhYmxlcmFuZ2U6YzE5OTgyZjg0Zjk3NGZiNDlkYTliMjMyMWZmZDM1ZGJfNDQtMS0xLTEtMA_8b58543c-8e0f-4b8c-9837-544989a518d9">52,867,428</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i03bccaa0abfb4733b1e2831ecde4e4e8_D20200101-20200331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18yNS9mcmFnOjdiNjAzZGI3ZTMwMDRhOGNiOWVkMDQ4YTYzYjhhMjQxL3RhYmxlOmMxOTk4MmY4NGY5NzRmYjQ5ZGE5YjIzMjFmZmQzNWRiL3RhYmxlcmFuZ2U6YzE5OTgyZjg0Zjk3NGZiNDlkYTliMjMyMWZmZDM1ZGJfNDQtMy0xLTEtMA_46ef2b75-5a49-4f5c-a36d-a7cf184c96da">25,452,721</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash flows from investing activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireShortTermInvestments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18yNS9mcmFnOjdiNjAzZGI3ZTMwMDRhOGNiOWVkMDQ4YTYzYjhhMjQxL3RhYmxlOmMxOTk4MmY4NGY5NzRmYjQ5ZGE5YjIzMjFmZmQzNWRiL3RhYmxlcmFuZ2U6YzE5OTgyZjg0Zjk3NGZiNDlkYTliMjMyMWZmZDM1ZGJfNDYtMS0xLTEtMA_82f3d105-ac39-44ad-8a7b-de7b44ee401e">275,408,976</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i03bccaa0abfb4733b1e2831ecde4e4e8_D20200101-20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireShortTermInvestments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18yNS9mcmFnOjdiNjAzZGI3ZTMwMDRhOGNiOWVkMDQ4YTYzYjhhMjQxL3RhYmxlOmMxOTk4MmY4NGY5NzRmYjQ5ZGE5YjIzMjFmZmQzNWRiL3RhYmxlcmFuZ2U6YzE5OTgyZjg0Zjk3NGZiNDlkYTliMjMyMWZmZDM1ZGJfNDYtMy0xLTEtMA_3ea0e8a9-25ec-4511-b6fe-47ac790be514">56,698,250</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from sale or maturity of investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromSaleOfShortTermInvestments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18yNS9mcmFnOjdiNjAzZGI3ZTMwMDRhOGNiOWVkMDQ4YTYzYjhhMjQxL3RhYmxlOmMxOTk4MmY4NGY5NzRmYjQ5ZGE5YjIzMjFmZmQzNWRiL3RhYmxlcmFuZ2U6YzE5OTgyZjg0Zjk3NGZiNDlkYTliMjMyMWZmZDM1ZGJfNDctMS0xLTEtMA_fa616ff2-c67a-4468-bc0a-5e2449fa9ffa">504,464</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03bccaa0abfb4733b1e2831ecde4e4e8_D20200101-20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromSaleOfShortTermInvestments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18yNS9mcmFnOjdiNjAzZGI3ZTMwMDRhOGNiOWVkMDQ4YTYzYjhhMjQxL3RhYmxlOmMxOTk4MmY4NGY5NzRmYjQ5ZGE5YjIzMjFmZmQzNWRiL3RhYmxlcmFuZ2U6YzE5OTgyZjg0Zjk3NGZiNDlkYTliMjMyMWZmZDM1ZGJfNDctMy0xLTEtMA_fc9e4a4c-33a8-47c9-b07a-2f8ab6358e04">5,030,257</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of capital assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18yNS9mcmFnOjdiNjAzZGI3ZTMwMDRhOGNiOWVkMDQ4YTYzYjhhMjQxL3RhYmxlOmMxOTk4MmY4NGY5NzRmYjQ5ZGE5YjIzMjFmZmQzNWRiL3RhYmxlcmFuZ2U6YzE5OTgyZjg0Zjk3NGZiNDlkYTliMjMyMWZmZDM1ZGJfNDgtMS0xLTEtMA_e6e50700-6d00-497c-be29-7c483617b18b">210,824</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i03bccaa0abfb4733b1e2831ecde4e4e8_D20200101-20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18yNS9mcmFnOjdiNjAzZGI3ZTMwMDRhOGNiOWVkMDQ4YTYzYjhhMjQxL3RhYmxlOmMxOTk4MmY4NGY5NzRmYjQ5ZGE5YjIzMjFmZmQzNWRiL3RhYmxlcmFuZ2U6YzE5OTgyZjg0Zjk3NGZiNDlkYTliMjMyMWZmZDM1ZGJfNDgtMy0xLTEtMA_3fdbbd28-65b7-4dd2-80ab-989229b4fcaf">140,952</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net cash used in investing activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18yNS9mcmFnOjdiNjAzZGI3ZTMwMDRhOGNiOWVkMDQ4YTYzYjhhMjQxL3RhYmxlOmMxOTk4MmY4NGY5NzRmYjQ5ZGE5YjIzMjFmZmQzNWRiL3RhYmxlcmFuZ2U6YzE5OTgyZjg0Zjk3NGZiNDlkYTliMjMyMWZmZDM1ZGJfNTQtMS0xLTEtMA_81800181-c84b-45d2-af60-6bb165e6f327">275,115,336</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i03bccaa0abfb4733b1e2831ecde4e4e8_D20200101-20200331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18yNS9mcmFnOjdiNjAzZGI3ZTMwMDRhOGNiOWVkMDQ4YTYzYjhhMjQxL3RhYmxlOmMxOTk4MmY4NGY5NzRmYjQ5ZGE5YjIzMjFmZmQzNWRiL3RhYmxlcmFuZ2U6YzE5OTgyZjg0Zjk3NGZiNDlkYTliMjMyMWZmZDM1ZGJfNTQtMy0xLTEtMA_3eaa27e5-2c5e-4cbf-9ce3-4b8b0255da02">51,808,945</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash flows from financing activities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from issuance of common stock, net of issuance costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18yNS9mcmFnOjdiNjAzZGI3ZTMwMDRhOGNiOWVkMDQ4YTYzYjhhMjQxL3RhYmxlOmMxOTk4MmY4NGY5NzRmYjQ5ZGE5YjIzMjFmZmQzNWRiL3RhYmxlcmFuZ2U6YzE5OTgyZjg0Zjk3NGZiNDlkYTliMjMyMWZmZDM1ZGJfNTgtMS0xLTEtMA_21ff07d5-c8a9-4e8b-a20e-a91538eeed0b">162,105,030</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03bccaa0abfb4733b1e2831ecde4e4e8_D20200101-20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18yNS9mcmFnOjdiNjAzZGI3ZTMwMDRhOGNiOWVkMDQ4YTYzYjhhMjQxL3RhYmxlOmMxOTk4MmY4NGY5NzRmYjQ5ZGE5YjIzMjFmZmQzNWRiL3RhYmxlcmFuZ2U6YzE5OTgyZjg0Zjk3NGZiNDlkYTliMjMyMWZmZDM1ZGJfNTgtMy0xLTEtMA_83d760ff-8027-4561-b1c9-be0f2ca56c54">208,241,933</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from stock option exercises</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromStockOptionsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18yNS9mcmFnOjdiNjAzZGI3ZTMwMDRhOGNiOWVkMDQ4YTYzYjhhMjQxL3RhYmxlOmMxOTk4MmY4NGY5NzRmYjQ5ZGE5YjIzMjFmZmQzNWRiL3RhYmxlcmFuZ2U6YzE5OTgyZjg0Zjk3NGZiNDlkYTliMjMyMWZmZDM1ZGJfNTktMS0xLTEtMA_70a545df-247f-4caa-bdde-43860902e6b0">2,632,996</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03bccaa0abfb4733b1e2831ecde4e4e8_D20200101-20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromStockOptionsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18yNS9mcmFnOjdiNjAzZGI3ZTMwMDRhOGNiOWVkMDQ4YTYzYjhhMjQxL3RhYmxlOmMxOTk4MmY4NGY5NzRmYjQ5ZGE5YjIzMjFmZmQzNWRiL3RhYmxlcmFuZ2U6YzE5OTgyZjg0Zjk3NGZiNDlkYTliMjMyMWZmZDM1ZGJfNTktMy0xLTEtMA_b1587735-6897-4c84-90b8-e4193f9d2f43">5,173,534</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Taxes paid related to net share settlement of equity awards </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18yNS9mcmFnOjdiNjAzZGI3ZTMwMDRhOGNiOWVkMDQ4YTYzYjhhMjQxL3RhYmxlOmMxOTk4MmY4NGY5NzRmYjQ5ZGE5YjIzMjFmZmQzNWRiL3RhYmxlcmFuZ2U6YzE5OTgyZjg0Zjk3NGZiNDlkYTliMjMyMWZmZDM1ZGJfNjAtMS0xLTEtMA_7f110d59-17c2-4c08-be93-b7cfd070605d">3,834,785</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i03bccaa0abfb4733b1e2831ecde4e4e8_D20200101-20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18yNS9mcmFnOjdiNjAzZGI3ZTMwMDRhOGNiOWVkMDQ4YTYzYjhhMjQxL3RhYmxlOmMxOTk4MmY4NGY5NzRmYjQ5ZGE5YjIzMjFmZmQzNWRiL3RhYmxlcmFuZ2U6YzE5OTgyZjg0Zjk3NGZiNDlkYTliMjMyMWZmZDM1ZGJfNjAtMy0xLTEtMA_b00b81c7-9ffd-478c-a30f-f8ea741a50ed">2,072,831</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition of non-controlling interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331" decimals="0" format="ixt:zerodash" name="us-gaap:ProceedsFromMinorityShareholders" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18yNS9mcmFnOjdiNjAzZGI3ZTMwMDRhOGNiOWVkMDQ4YTYzYjhhMjQxL3RhYmxlOmMxOTk4MmY4NGY5NzRmYjQ5ZGE5YjIzMjFmZmQzNWRiL3RhYmxlcmFuZ2U6YzE5OTgyZjg0Zjk3NGZiNDlkYTliMjMyMWZmZDM1ZGJfNjEtMS0xLTEtMA_5cc86311-934f-417a-bb04-7b05a8d0433f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03bccaa0abfb4733b1e2831ecde4e4e8_D20200101-20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromMinorityShareholders" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18yNS9mcmFnOjdiNjAzZGI3ZTMwMDRhOGNiOWVkMDQ4YTYzYjhhMjQxL3RhYmxlOmMxOTk4MmY4NGY5NzRmYjQ5ZGE5YjIzMjFmZmQzNWRiL3RhYmxlcmFuZ2U6YzE5OTgyZjg0Zjk3NGZiNDlkYTliMjMyMWZmZDM1ZGJfNjEtMy0xLTEtMA_b543f67e-753c-4f88-ba5f-cd6a4b82f9a9">2,169,998</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net cash provided by financing activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18yNS9mcmFnOjdiNjAzZGI3ZTMwMDRhOGNiOWVkMDQ4YTYzYjhhMjQxL3RhYmxlOmMxOTk4MmY4NGY5NzRmYjQ5ZGE5YjIzMjFmZmQzNWRiL3RhYmxlcmFuZ2U6YzE5OTgyZjg0Zjk3NGZiNDlkYTliMjMyMWZmZDM1ZGJfNjMtMS0xLTEtMA_2f8509d7-f7ed-49d6-b18d-b6205d6fc963">160,903,241</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03bccaa0abfb4733b1e2831ecde4e4e8_D20200101-20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18yNS9mcmFnOjdiNjAzZGI3ZTMwMDRhOGNiOWVkMDQ4YTYzYjhhMjQxL3RhYmxlOmMxOTk4MmY4NGY5NzRmYjQ5ZGE5YjIzMjFmZmQzNWRiL3RhYmxlcmFuZ2U6YzE5OTgyZjg0Zjk3NGZiNDlkYTliMjMyMWZmZDM1ZGJfNjMtMy0xLTEtMA_97544c99-9106-457b-90a7-787ff8ca7928">213,512,634</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of exchange rate changes on cash and cash equivalents</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18yNS9mcmFnOjdiNjAzZGI3ZTMwMDRhOGNiOWVkMDQ4YTYzYjhhMjQxL3RhYmxlOmMxOTk4MmY4NGY5NzRmYjQ5ZGE5YjIzMjFmZmQzNWRiL3RhYmxlcmFuZ2U6YzE5OTgyZjg0Zjk3NGZiNDlkYTliMjMyMWZmZDM1ZGJfNjQtMS0xLTEtMA_2ae28c6f-a476-498e-b130-d7dce2a5ce48">14,419</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03bccaa0abfb4733b1e2831ecde4e4e8_D20200101-20200331" decimals="0" format="ixt:zerodash" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18yNS9mcmFnOjdiNjAzZGI3ZTMwMDRhOGNiOWVkMDQ4YTYzYjhhMjQxL3RhYmxlOmMxOTk4MmY4NGY5NzRmYjQ5ZGE5YjIzMjFmZmQzNWRiL3RhYmxlcmFuZ2U6YzE5OTgyZjg0Zjk3NGZiNDlkYTliMjMyMWZmZDM1ZGJfNjQtMy0xLTEtMA_b6c29df9-23e9-46cc-a988-2f5d9b45007f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Increase (Decrease) in cash and cash equivalents</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18yNS9mcmFnOjdiNjAzZGI3ZTMwMDRhOGNiOWVkMDQ4YTYzYjhhMjQxL3RhYmxlOmMxOTk4MmY4NGY5NzRmYjQ5ZGE5YjIzMjFmZmQzNWRiL3RhYmxlcmFuZ2U6YzE5OTgyZjg0Zjk3NGZiNDlkYTliMjMyMWZmZDM1ZGJfNjUtMS0xLTEtMA_670b2960-6de0-43f3-b66c-9ec1ab58062e">167,093,942</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03bccaa0abfb4733b1e2831ecde4e4e8_D20200101-20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18yNS9mcmFnOjdiNjAzZGI3ZTMwMDRhOGNiOWVkMDQ4YTYzYjhhMjQxL3RhYmxlOmMxOTk4MmY4NGY5NzRmYjQ5ZGE5YjIzMjFmZmQzNWRiL3RhYmxlcmFuZ2U6YzE5OTgyZjg0Zjk3NGZiNDlkYTliMjMyMWZmZDM1ZGJfNjUtMy0xLTEtMA_c29464af-b260-4ae9-b56d-c421f9fe7a21">136,250,968</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents, beginning of period</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i066bb5b0a9e84c0a878b1e800703d92b_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18yNS9mcmFnOjdiNjAzZGI3ZTMwMDRhOGNiOWVkMDQ4YTYzYjhhMjQxL3RhYmxlOmMxOTk4MmY4NGY5NzRmYjQ5ZGE5YjIzMjFmZmQzNWRiL3RhYmxlcmFuZ2U6YzE5OTgyZjg0Zjk3NGZiNDlkYTliMjMyMWZmZDM1ZGJfNjYtMS0xLTEtMA_9c89181b-befe-468b-a178-89c583a7a54e">250,728,118</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id25261a874ce40da9cfbcc6297ee52ac_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18yNS9mcmFnOjdiNjAzZGI3ZTMwMDRhOGNiOWVkMDQ4YTYzYjhhMjQxL3RhYmxlOmMxOTk4MmY4NGY5NzRmYjQ5ZGE5YjIzMjFmZmQzNWRiL3RhYmxlcmFuZ2U6YzE5OTgyZjg0Zjk3NGZiNDlkYTliMjMyMWZmZDM1ZGJfNjYtMy0xLTEtMA_337321b9-d94e-4edc-893f-cf8ae5d37771">22,196,097</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="height:31.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:31.5pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.696%"><tr><td style="width:1.0%"></td><td style="width:71.696%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.121%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.559%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.124%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash and cash equivalents, end of period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic36b9cedad7f41a6b9eb223b09b7186c_I20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18yNS9mcmFnOjdiNjAzZGI3ZTMwMDRhOGNiOWVkMDQ4YTYzYjhhMjQxL3RhYmxlOmMxOTk4MmY4NGY5NzRmYjQ5ZGE5YjIzMjFmZmQzNWRiL3RhYmxlcmFuZ2U6YzE5OTgyZjg0Zjk3NGZiNDlkYTliMjMyMWZmZDM1ZGJfNjctMS0xLTEtMA_ef961c90-3401-4c5b-a50f-28de262911b4">83,634,176</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98369f585c4549d585af1f9094a77fd9_I20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18yNS9mcmFnOjdiNjAzZGI3ZTMwMDRhOGNiOWVkMDQ4YTYzYjhhMjQxL3RhYmxlOmMxOTk4MmY4NGY5NzRmYjQ5ZGE5YjIzMjFmZmQzNWRiL3RhYmxlcmFuZ2U6YzE5OTgyZjg0Zjk3NGZiNDlkYTliMjMyMWZmZDM1ZGJfNjctMy0xLTEtMA_86ef5b2b-3a57-4d75-9606-af670384721e">158,447,065</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Supplemental disclosures:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts accrued for purchases of property and equipment</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInOtherAccruedLiabilities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18yNS9mcmFnOjdiNjAzZGI3ZTMwMDRhOGNiOWVkMDQ4YTYzYjhhMjQxL3RhYmxlOmMxOTk4MmY4NGY5NzRmYjQ5ZGE5YjIzMjFmZmQzNWRiL3RhYmxlcmFuZ2U6YzE5OTgyZjg0Zjk3NGZiNDlkYTliMjMyMWZmZDM1ZGJfNzAtMS0xLTEtMA_29f57291-ad7e-498c-812d-bdcdcebea8ce">35,370</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03bccaa0abfb4733b1e2831ecde4e4e8_D20200101-20200331" decimals="0" format="ixt:zerodash" name="us-gaap:IncreaseDecreaseInOtherAccruedLiabilities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18yNS9mcmFnOjdiNjAzZGI3ZTMwMDRhOGNiOWVkMDQ4YTYzYjhhMjQxL3RhYmxlOmMxOTk4MmY4NGY5NzRmYjQ5ZGE5YjIzMjFmZmQzNWRiL3RhYmxlcmFuZ2U6YzE5OTgyZjg0Zjk3NGZiNDlkYTliMjMyMWZmZDM1ZGJfNzAtMy0xLTEtMA_4f5b4806-3f83-4408-94f1-0cc64e1bd6b7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest paid</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InterestPaidNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18yNS9mcmFnOjdiNjAzZGI3ZTMwMDRhOGNiOWVkMDQ4YTYzYjhhMjQxL3RhYmxlOmMxOTk4MmY4NGY5NzRmYjQ5ZGE5YjIzMjFmZmQzNWRiL3RhYmxlcmFuZ2U6YzE5OTgyZjg0Zjk3NGZiNDlkYTliMjMyMWZmZDM1ZGJfNzEtMS0xLTEtMA_ee6c699b-ff46-4fde-a3c3-27c60de4d8cb">544,315</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03bccaa0abfb4733b1e2831ecde4e4e8_D20200101-20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InterestPaidNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18yNS9mcmFnOjdiNjAzZGI3ZTMwMDRhOGNiOWVkMDQ4YTYzYjhhMjQxL3RhYmxlOmMxOTk4MmY4NGY5NzRmYjQ5ZGE5YjIzMjFmZmQzNWRiL3RhYmxlcmFuZ2U6YzE5OTgyZjg0Zjk3NGZiNDlkYTliMjMyMWZmZDM1ZGJfNzEtMy0xLTEtMA_562c01f8-5888-4eb0-839e-8366eb84be1e">2,590,196</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:center;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to unaudited condensed consolidated financial statements.</span></div><div style="height:31.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><div id="i1d23d16a69484b63aa007ec686e80337_28"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INOVIO PHARMACEUTICALS, INC.</span></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div id="i1d23d16a69484b63aa007ec686e80337_31"></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:174%">1. <ix:nonNumeric contextRef="i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331" name="us-gaap:NatureOfOperations" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18zMS9mcmFnOjBjMjUzMjIzY2VmYzQzYjg5OWYxNGQ1ZmM0MzI4YzU5L3RleHRyZWdpb246MGMyNTMyMjNjZWZjNDNiODk5ZjE0ZDVmYzQzMjhjNTlfMzQ3Nw_c74723c0-3775-4c18-927c-8ff9548d9fc8" continuedAt="i0ba5c5339e9b4716b45338294c1b0013" escape="true">Organization and Operations</ix:nonNumeric></span></div><ix:continuation id="i0ba5c5339e9b4716b45338294c1b0013"><div style="margin-top:5pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inovio Pharmaceuticals, Inc. (the &#8220;Company&#8221; or &#8220;INOVIO&#8221;), is a biotechnology company focused on rapidly bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases, cancer, and diseases associated with human papillomavirus ("HPV"). INOVIO's DNA medicines pipeline is comprised of three types of product candidates: DNA vaccines, DNA immunotherapies and DNA encoded monoclonal antibodies ("dMAbs"). In clinical trials, INOVIO has demonstrated that DNA medicines can be delivered directly into cells in the body through its proprietary smart device to consistently activate robust and fully functional T cell and antibody responses against targeted pathogens and cancers. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's novel DNA medicine candidates are made using its proprietary SynCon</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> technology that creates optimized plasmids, which are circular strands of DNA that instruct a cell to produce antigens to help the person&#8217;s immune system recognize and destroy cancerous or virally infected cells.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">INOVIO's patented CELLECTRA</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> smart delivery devices provide optimized uptake of its DNA medicines within the cell, overcoming a key limitation of other DNA-based technology approaches. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Human clinical trial data to date have shown a favorable safety profile of INOVIO's DNA medicines delivered directly into cells in the body using the CELLECTRA</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> smart device in more than 7,000 administrations across more than 3,000 patients.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> INOVIO's corporate strategy is to advance, protect and, once approved, commercialize its novel DNA medicines to meet urgent and emerging global health needs. The Company continues to advance and clinically validate an array of DNA medicine candidates that target HPV-associated diseases, cancer, and infectious diseases, such as COVID-19. The Company aims to advance these candidates through commercialization and continue to leverage third-party resources through collaborations and partnerships, including product license agreements. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company's partners and collaborators include ApolloBio Corporation.,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> AstraZeneca, Beijing Advaccine, The Bill &amp; Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations ("CEPI"), The U.S. Department of Defense ("DoD"), Defense Advanced Research Projects Agency ("DARPA"), GeneOne Life Science, HIV Vaccines Trial Network, the U.S. Defense Threat Reduction Agency&#8217;s Medical CBRN Defense Consortium ("MCDC"), International Vaccine Institute ("IVI"), National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Ology Bioservices, the Parker Institute for Cancer Immunotherapy, Plumbline Life Sciences, Regeneron Pharmaceuticals, Inc., Richter-Helm BioLogics, Thermo Fisher Scientific, the University of Pennsylvania, the Walter Reed Army Institute of Research, and The Wistar Institute.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company and its collaborators are currently conducting or planning clinical studies of its DNA medicines for HPV-associated precancers, including cervical, vulvar, and anal dysplasia; HPV-associated cancers, including head &amp; neck, cervical, anal, penile, vulvar, and vaginal; other HPV-associated disorders, such as recurrent respiratory papillomatosis ("RRP"); glioblastoma multiforme ("GBM"); prostate cancer; HIV; Ebola; Middle East Respiratory Syndrome ("MERS"); Lassa fever; Zika virus; and COVID-19.  </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">INOVIO was incorporated in Delaware in June 2001 and has its principal executive offices in Plymouth Meeting, Pennsylvania.</span></div></ix:continuation><div style="margin-top:5pt;text-indent:22.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:120%">&#160;</span></div><div id="i1d23d16a69484b63aa007ec686e80337_34"></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2. <ix:nonNumeric contextRef="i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331" name="us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18zNC9mcmFnOjZhYmNjYjdmMmEyYzRiYWE5NWQ0OTMzN2M2MzBhYzdmL3RleHRyZWdpb246NmFiY2NiN2YyYTJjNGJhYTk1ZDQ5MzM3YzYzMGFjN2ZfODEzMw_05abfb94-b003-47bb-bb99-c47df79c18ee" continuedAt="i53d20a59856346b684bba6b007ad3bf5" escape="true">Basis of Presentation, Liquidity and Risks and Uncertainties</ix:nonNumeric></span></div><ix:continuation id="i53d20a59856346b684bba6b007ad3bf5" continuedAt="i80c7bbeb93314f4f82c938b7063fb4b3"><ix:nonNumeric contextRef="i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18zNC9mcmFnOjZhYmNjYjdmMmEyYzRiYWE5NWQ0OTMzN2M2MzBhYzdmL3RleHRyZWdpb246NmFiY2NiN2YyYTJjNGJhYTk1ZDQ5MzM3YzYzMGFjN2ZfODE0MA_87581140-801b-4c16-b507-1c36f9a1f1b1" continuedAt="i893191e6dd8b4b52b7795eae7328f18a" escape="true"><div style="margin-bottom:3pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Basis of Presentation</span></div><div style="margin-top:4.5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited condensed consolidated financial statements of Inovio have been prepared in accordance with U.S. generally accepted accounting principles (&#8220;U.S. GAAP&#8221;) as contained in the Financial Accounting Standards Board ("FASB") Accounting Standards Codification ("ASC") for interim financial information and with instructions to Form&#160;10-Q and Article&#160;10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. The condensed consolidated balance sheet as of March&#160;31, 2021, the condensed consolidated statements of operations, the condensed consolidated statements of comprehensive loss, the condensed consolidated statements of stockholders' equity and the condensed consolidated statements of cash flows for the three months ended March 31, 2021 and 2020 are unaudited, but include all adjustments (consisting of normal recurring adjustments) that the Company considers necessary for a fair presentation of the financial position, results of operations, cash flows and changes in stockholders' equity for the periods presented. The results of operations for the three months ended March 31, 2021 shown herein are not necessarily indicative of the results that may be expected for the year ending December&#160;31, 2021, or for any other period. These unaudited financial statements, and notes thereto, should be read in conjunction with the audited consolidated financial statements for the </span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1d23d16a69484b63aa007ec686e80337_7">Table of Contents</a></span></div></div><ix:continuation id="i80c7bbeb93314f4f82c938b7063fb4b3" continuedAt="i9a8b4987dfef456488e8f04d97dd4f4e"><ix:continuation id="i893191e6dd8b4b52b7795eae7328f18a" continuedAt="i57a0bd53e72b41c081069390f0296766"><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">year ended December&#160;31, 2020, included in the Company's Annual Report on Form&#160;10-K filed with the U.S. Securities and Exchange Commission (&#8220;SEC&#8221;) on March&#160;1, 2021. The balance sheet at December&#160;31, 2020 has been derived from the audited financial statements at that date, but does not include all of the information and footnotes required by U.S. GAAP for complete financial statements. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2020, the Company formed a wholly-owned subsidiary, Inovio Asia LLC, under the laws of South Korea, through which the Company intends to advance its corporate development projects and other functions in South Korea and other Asian countries.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These unaudited condensed consolidated financial statements include the accounts of Inovio Pharmaceuticals, Inc. and its subsidiarie</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s. As of March 31, 2021, the Company consolidated its wholly-owned subsidiary Inovio Asia LLC. On December 31, 2020, former wholly-owned subsidiaries Genetronics, Inc. and VGX Pharmaceuticals Inc. and former majority -owned subsidiary VGX Animal Health, Inc. were merged into Inovio Pharmaceuticals, Inc. All intercompany accounts and transactions were eliminated upon consolidation. As of June 1, 2020, the Company deconsolidated its former subsidiary Geneos Therapeutics, Inc. ("Geneos"), as the Company no longer held a controlling financial interest.  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Refer to Footnote 17 for further discussion.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Liquidity </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company incurred a net loss attributable to common stockholders of $<ix:nonFraction unitRef="usd" contextRef="i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18zNC9mcmFnOjZhYmNjYjdmMmEyYzRiYWE5NWQ0OTMzN2M2MzBhYzdmL3RleHRyZWdpb246NmFiY2NiN2YyYTJjNGJhYTk1ZDQ5MzM3YzYzMGFjN2ZfMjk5Ng_67ea475c-0b05-4f12-a037-9e74d86f978b">54.4</ix:nonFraction> million for the three months ended March 31, 2021. The Company had working capital of $<ix:nonFraction unitRef="usd" contextRef="ic36b9cedad7f41a6b9eb223b09b7186c_I20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Capital" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18zNC9mcmFnOjZhYmNjYjdmMmEyYzRiYWE5NWQ0OTMzN2M2MzBhYzdmL3RleHRyZWdpb246NmFiY2NiN2YyYTJjNGJhYTk1ZDQ5MzM3YzYzMGFjN2ZfMzA2Mg_4da33738-ce24-4564-9282-d1fbaec2a4f3">546.9</ix:nonFraction> million and an accumulated deficit of $<ix:nonFraction unitRef="usd" contextRef="ic36b9cedad7f41a6b9eb223b09b7186c_I20210331" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18zNC9mcmFnOjZhYmNjYjdmMmEyYzRiYWE5NWQ0OTMzN2M2MzBhYzdmL3RleHRyZWdpb246NmFiY2NiN2YyYTJjNGJhYTk1ZDQ5MzM3YzYzMGFjN2ZfMzA5Ng_7d88d62d-b255-4ae0-b476-26e49d47b9ac">960.6</ix:nonFraction> million as of March&#160;31, 2021. The Company has incurred losses in each year since its inception and expects to continue to incur significant expenses and operating losses for the foreseeable future in connection with the research and preclinical and clinical development of its product candidates. The Company&#8217;s cash, cash equivalents and short-term investments of $<ix:nonFraction unitRef="usd" contextRef="ic36b9cedad7f41a6b9eb223b09b7186c_I20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsAndShortTermInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18zNC9mcmFnOjZhYmNjYjdmMmEyYzRiYWE5NWQ0OTMzN2M2MzBhYzdmL3RleHRyZWdpb246NmFiY2NiN2YyYTJjNGJhYTk1ZDQ5MzM3YzYzMGFjN2ZfMzQ0Mw_b90a4a35-28dc-40a8-a69e-7fdaa790ee2a">518.6</ix:nonFraction> million as of March&#160;31, 2021 are sufficient to support the Company's operations for a period of at least 12 months from the date of issuance of these financial statements. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to continue to fund future research and development activit</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ies, the Company will need to seek additional capital. This may occur through strategic alliance and licensing arrangements, grant agreements and/or future public or private debt or equity financings including use of potential future At-the-Market Equity Offering Sales Agreements (&#8220;Sales Agreements&#8221;). The Company</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> has a history of conducting debt and equity financings, including the receipt of net proceeds of $<ix:nonFraction unitRef="usd" contextRef="ic50cd4505b98463e9b947cd4aaebd07b_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18zNC9mcmFnOjZhYmNjYjdmMmEyYzRiYWE5NWQ0OTMzN2M2MzBhYzdmL3RleHRyZWdpb246NmFiY2NiN2YyYTJjNGJhYTk1ZDQ5MzM3YzYzMGFjN2ZfMTA5OTUxMTYzOTQ4Ng_e1906a4e-93c0-491e-9bd4-1f35fc320362">162.1</ix:nonFraction>&#160;million from a January 2021 underwritten public offering and net proceeds of $<ix:nonFraction unitRef="usd" contextRef="ia9f4c44746fd42179d0515c760ec6715_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18zNC9mcmFnOjZhYmNjYjdmMmEyYzRiYWE5NWQ0OTMzN2M2MzBhYzdmL3RleHRyZWdpb246NmFiY2NiN2YyYTJjNGJhYTk1ZDQ5MzM3YzYzMGFjN2ZfNDE2OQ_c2094c0d-a3a0-4388-8006-27cb395c3ce9">454.5</ix:nonFraction> million under past Sales Agreements </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for the year ended December 31, 2020. However, sufficient funding may not be available in the future, or if available, may be on terms that significantly dilute or otherwise adversely affect the rights of existing stockholders. If adequate funds are not available, the Company may need to delay, reduce the scope of or put on hold one or more of its clinical and/or preclinical programs.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s ability to continue its operations is dependent upon its ability to obtain additional capital in the future and achieve profitable operations. The Company expects to continue to rely on outside sources of financing to meet its capital needs and the Company may never achieve positive cash flow. These condensed consolidated financial statements do not include any adjustments to the specific amounts and classifications of assets and liabilities, which might be necessary should Inovio be unable to continue as a going concern. The Company's condensed consolidated financial statements as of and for the three months ended March 31, 2021 have been prepared on a going concern basis, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business for the foreseeable future. The Company has evaluated subsequent events after the balance sheet date through the date it issued these condensed consolidated financial statements.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is and, from time to time,&#160;may in the future be subject to various legal proceedings and claims arising in the ordinary course of business. The Company assesses contingencies to determine the degree of probability and range of possible loss for potential accrual in its consolidated financial statements. An estimated loss contingency is accrued in the consolidated financial statements if it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated. Legal proceedings, including litigation, government investigations and enforcement actions, could result in material costs, occupy significant management resources and entail civil and criminal penalties, even if the Company ultimately prevails.&#160;Any of the foregoing consequences could result in serious harm to the Company&#8217;s business, results of operations and financial condition. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risks and Uncertainties</span></div><div style="margin-top:5pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The global pandemic resulting from COVID-19, caused by a novel strain of coronavirus, SARS-CoV-2, has caused national and global economic and financial market disruptions. The impact of this pandemic has been and will likely continue to be extensive in many aspects of society, which has resulted in and will continue to cause significant disruptions to the global economy, as well as businesses and capital markets around the world. </span></div><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company is closely monitoring the impact of the COVID-19 pandemic on its employees, collaborators and service providers. The extent to which the pandemic will continue to impact the Company's business and operations will depend on future developments, including travel restrictions and social distancing in the United States and other countries, and the </span></div></ix:continuation></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1d23d16a69484b63aa007ec686e80337_7">Table of Contents</a></span></div></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:continuation id="i9a8b4987dfef456488e8f04d97dd4f4e"><ix:continuation id="i57a0bd53e72b41c081069390f0296766">effectiveness of actions taken in the United States and other countries to contain and treat the disease, including mass vaccination efforts, that are highly uncertain as of the date the Company is issuing these financial statements.</ix:continuation></ix:continuation> </span></div><div style="text-align:justify;text-indent:27pt"><span><br/></span></div><div id="i1d23d16a69484b63aa007ec686e80337_37"></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3. <ix:nonNumeric contextRef="i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18zNy9mcmFnOmE0NTZiM2ZhOTA0ZjQ0ZjNiYTUyYzg0OWE5YTIxNGRiL3RleHRyZWdpb246YTQ1NmIzZmE5MDRmNDRmM2JhNTJjODQ5YTlhMjE0ZGJfMTgxNDA_943113d0-2941-48c8-a34e-6f1fb58a0fb2" continuedAt="i89493891d9e5430590b9c31f6446efd9" escape="true">Critical Accounting Policies</ix:nonNumeric></span></div><ix:continuation id="i89493891d9e5430590b9c31f6446efd9" continuedAt="iab021b9f13f04c15a1f28dc1c0888455"><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331" name="us-gaap:CollaborativeArrangementAccountingPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18zNy9mcmFnOmE0NTZiM2ZhOTA0ZjQ0ZjNiYTUyYzg0OWE5YTIxNGRiL3RleHRyZWdpb246YTQ1NmIzZmE5MDRmNDRmM2JhNTJjODQ5YTlhMjE0ZGJfMTgxNTY_48e13594-6f19-4841-abe4-2d336663dbbd" continuedAt="ie3608c6a024b49ee9f7247cac1c54621" escape="true">Collaboration Agreements </ix:nonNumeric></span></div><div style="margin-top:5pt;text-indent:27pt"><ix:continuation id="ie3608c6a024b49ee9f7247cac1c54621" continuedAt="ia023f838ab4e4cd1886970662566b01e"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company assesses whether its collaboration agreements are subject to ASC Topic 808:&#160;Collaborative Arrangements&#160;(&#8220;Topic 808&#8221;) based on whether they involve joint operating activities and whether both parties have active participation in the arrangement and are exposed to significant risks and rewards. To the extent that the arrangement falls within the scope of Topic 808 and the Company concludes that its collaboration partner is not a customer, the Company presents such payments as a reduction of research and development expense. If payments from the collaboration partner to the Company represent consideration from a customer, then the Company accounts for those payments within the scope of Accounting Standards Update (&#8220;ASU&#8221;) 2014-09, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span></ix:continuation><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ia023f838ab4e4cd1886970662566b01e"> (&#8220;Topic 606&#8221;).</ix:continuation> </span></div><ix:nonNumeric contextRef="i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18zNy9mcmFnOmE0NTZiM2ZhOTA0ZjQ0ZjNiYTUyYzg0OWE5YTIxNGRiL3RleHRyZWdpb246YTQ1NmIzZmE5MDRmNDRmM2JhNTJjODQ5YTlhMjE0ZGJfMTgxMzQ_80aefc09-d61e-4f0d-a387-56eb7a76d4cf" continuedAt="ic504b8c92cae4661b609b2a8efa53f03" escape="true"><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue Recognition </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which it expects to be entitled in exchange for those goods or services. To determine revenue recognition for contracts with customers, the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the Company satisfies its performance obligations. At contract inception, the Company assesses the goods or services agreed upon within each contract and assess whether each good or service is distinct and determine those that are</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">performance obligations. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Arrangements</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company enters into collaborative arrangements with partners that typically include payment of one or more of the following: (i) license fees; (ii) product supply services; (iii) milestone payments related to the achievement of developmental, regulatory, or commercial goals; and (iv) royalties on net sales of licensed products. Where a portion of non-refundable, upfront fees or other payments received are allocated to continuing performance obligations under the terms of a collaborative arrangement, they are recorded as deferred revenue and recognized as revenue when (or as) the underlying performance obligation is satisfied.  </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the accounting for these arrangements, the Company must develop estimates and assumptions that require judgment of management to determine the underlying stand-alone selling price for each performance obligation which determines how the transaction price is allocated among the performance obligation. The standalone selling price may include items such as forecasted revenues, development timelines, discount rates and probabilities of technical and regulatory success. The Company evaluates each performance obligation to determine if it can be satisfied at a point in time or over time. In addition, variable consideration must be evaluated to determine if it is constrained and, therefore, excluded from the transaction price.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">License Fees</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If a license to intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company will recognize revenues from non-refundable, upfront fees allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license. For licenses that are bundled with other promises, the Company will utilize judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Product Supply Services</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Arrangements that include a promise for future supply of drug product for either clinical development or commercial supply at the licensee&#8217;s discretion are generally considered as options. The Company will assess if these options provide a material right to the licensee and if so, they will be accounted for as separate performance obligations. The Company evaluates whether it is the principal or agent in the arrangement. The Company had determined that it is the principal in the current arrangements as the Company controls the product supply before it is transferred to the customer. </span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1d23d16a69484b63aa007ec686e80337_7">Table of Contents</a></span></div></div><ix:continuation id="iab021b9f13f04c15a1f28dc1c0888455" continuedAt="idad44beb1e16434fb00cad66036a6c31"><ix:continuation id="ic504b8c92cae4661b609b2a8efa53f03"><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Milestone Payments</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the inception of each arrangement that includes milestone payments (variable consideration), the Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the Company's or its collaboration partner&#8217;s control, such as regulatory approvals, are generally not considered probable of being achieved until those approvals are received. The transaction price is then allocated to each performance obligation on a relative stand-alone selling price basis, for which the Company recognizes revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, the Company re-evaluates the probability of achieving such milestones and any related constraint, and if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect license, collaboration or other revenues and earnings in the period of adjustment.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Royalties</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and for which the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). To date, the Company has not recognized any royalty revenue resulting from any of its collaborative arrangements.</span></div></ix:continuation><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331" name="ino:GrantPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18zNy9mcmFnOmE0NTZiM2ZhOTA0ZjQ0ZjNiYTUyYzg0OWE5YTIxNGRiL3RleHRyZWdpb246YTQ1NmIzZmE5MDRmNDRmM2JhNTJjODQ5YTlhMjE0ZGJfMTgxNDI_5e828c14-01f2-44bf-bc9a-bc310359b630" continuedAt="i5262a1476293401f8644e682c68961a2" escape="true">Grants</ix:nonNumeric></span></div><div style="margin-top:5pt;text-indent:27pt"><ix:continuation id="i5262a1476293401f8644e682c68961a2" continuedAt="i5eadb9adde4345aaa5fa4c765387593f"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for various grant agreements under the contributions guidance under Subtopic 958-605, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Not-for-Profit Entities-Revenue Recognition</span></ix:continuation><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i5eadb9adde4345aaa5fa4c765387593f">, which is outside the scope of Topic 606, as the government agencies granting the Company funds are not receiving reciprocal value for their contributions. All contributions received from current grant agreements are recorded as a contra-expense as opposed to revenue on the condensed consolidated statement of operations.</ix:continuation> </span></div><ix:nonNumeric contextRef="i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331" name="us-gaap:LesseeLeasesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18zNy9mcmFnOmE0NTZiM2ZhOTA0ZjQ0ZjNiYTUyYzg0OWE5YTIxNGRiL3RleHRyZWdpb246YTQ1NmIzZmE5MDRmNDRmM2JhNTJjODQ5YTlhMjE0ZGJfMTgxMjg_d6a73699-8462-4341-b402-467c9a232eea" escape="true"><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For its long-term operating leases, the Company recognizes an operating lease right-of-use asset and an operating lease liability on its condensed consolidated balance sheets. The lease liability is determined as the present value of future lease payments using an estimated rate of interest that the Company would pay to borrow equivalent funds on a collateralized basis at the lease commencement date. The right-of-use asset is based on the liability adjusted for any prepaid or deferred rent. The Company determines the lease term at the commencement date by considering whether renewal options and termination options are reasonably assured of exercise. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fixed rent expense for the Company's operating leases is recognized on a straight-line basis over the term of the lease and is included in operating expenses on the condensed consolidated statements of operations. Variable lease payments including lease operating expenses are recorded as incurred.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18zNy9mcmFnOmE0NTZiM2ZhOTA0ZjQ0ZjNiYTUyYzg0OWE5YTIxNGRiL3RleHRyZWdpb246YTQ1NmIzZmE5MDRmNDRmM2JhNTJjODQ5YTlhMjE0ZGJfMTgxMzg_48c1f157-4f63-4b58-bdc8-c2cc6004dc88" escape="true"><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development Expenses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s activities have largely consisted of research and development efforts related to developing electroporation delivery technologies, DNA vaccines, DNA immunotherapies and dMABs. Research and development expenses consist of expenses incurred in performing research and development activities including salaries and benefits, facilities and other overhead expenses, clinical trials, contract services and other outside expenses. Research and development expenses are charged to operations as they are incurred. These expenses result from the Company's independent research and development efforts as well as efforts associated with collaborations and licensing arrangements. The Company reviews and accrues clinical trial expense based on work performed, which relies on estimates of total costs incurred based on patient enrollment, completion of studies and other events. Accrued clinical trial costs are subject to revisions as trials progress. Revisions are charged to expense in the period in which the facts that give rise to the revision become known. Historically, revisions have not resulted in material changes to research and development expense; however, a modification in the protocol of a clinical trial or cancellation of a trial could result in a charge to the Company's results of operations.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331" name="us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18zNy9mcmFnOmE0NTZiM2ZhOTA0ZjQ0ZjNiYTUyYzg0OWE5YTIxNGRiL3RleHRyZWdpb246YTQ1NmIzZmE5MDRmNDRmM2JhNTJjODQ5YTlhMjE0ZGJfMTgxNDU_6ac83c48-21af-4983-9c6a-ac76d6472d53" continuedAt="if0ca59c1553c43cdb9cd45cd3b20d662" escape="true"><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Valuation of Intangible Assets and Goodwill</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets are amortized over their estimated useful lives ranging from <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18zNy9mcmFnOmE0NTZiM2ZhOTA0ZjQ0ZjNiYTUyYzg0OWE5YTIxNGRiL3RleHRyZWdpb246YTQ1NmIzZmE5MDRmNDRmM2JhNTJjODQ5YTlhMjE0ZGJfOTk1Nw_def5a8b0-cb2d-4478-a5a4-79b9dd366f59">two</span> to <ix:nonNumeric contextRef="i2f37abb9631043cc818c2a98efb857df_D20210101-20210331" format="ixt-sec:duryear" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18zNy9mcmFnOmE0NTZiM2ZhOTA0ZjQ0ZjNiYTUyYzg0OWE5YTIxNGRiL3RleHRyZWdpb246YTQ1NmIzZmE5MDRmNDRmM2JhNTJjODQ5YTlhMjE0ZGJfOTk2Mw_f14e3e3d-2647-408f-b931-b0e0cc74946d">18</ix:nonNumeric>&#160;years. Acquired intangible assets are continuously being developed for the future economic viability contemplated at the time of acquisition. The Company is concurrently conducting preclinical studies and clinical trials using the acquired intangibles and has entered into licensing agreements for the use of these acquired intangibles.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">License costs are recorded based on the fair value of consideration paid and are amortized using the straight-line method over the shorter of the expected useful life of the underlying patents or the term of the related license agreement to the extent the license has an alternative future use. As of March&#160;31, 2021 and December&#160;31, 2020, the Company&#8217;s intangible assets </span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1d23d16a69484b63aa007ec686e80337_7">Table of Contents</a></span></div></div><ix:continuation id="idad44beb1e16434fb00cad66036a6c31" continuedAt="i1234a6a72be34b55a21f5b4d32bebc6e"><ix:continuation id="if0ca59c1553c43cdb9cd45cd3b20d662" continuedAt="id68de4311aae4af68c842a515bb58204"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">resulting from the acquisition of Inovio AS and Bioject Medical Technologies, Inc. ("Bioject"), and additional intangibles including license costs, net of accumulated amortization, totaled $<ix:nonFraction unitRef="usd" contextRef="ic36b9cedad7f41a6b9eb223b09b7186c_I20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18zNy9mcmFnOmE0NTZiM2ZhOTA0ZjQ0ZjNiYTUyYzg0OWE5YTIxNGRiL3RleHRyZWdpb246YTQ1NmIzZmE5MDRmNDRmM2JhNTJjODQ5YTlhMjE0ZGJfMTA4Mzc_56c6b5c0-0110-4314-89e2-db24f83fa681">3.0</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i066bb5b0a9e84c0a878b1e800703d92b_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18zNy9mcmFnOmE0NTZiM2ZhOTA0ZjQ0ZjNiYTUyYzg0OWE5YTIxNGRiL3RleHRyZWdpb246YTQ1NmIzZmE5MDRmNDRmM2JhNTJjODQ5YTlhMjE0ZGJfMTA4NDU_bc0c2b55-8d4d-4263-92c4-2193b2f4d249">3.1</ix:nonFraction> million, respectively.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The determination of the value of intangible assets requires management to make estimates and assumptions that affect the Company&#8217;s condensed consolidated financial statements. The Company assesses potential impairments to intangible assets when there is evidence that events or changes in circumstances indicate that the carrying amount of an asset may not be recovered. The Company&#8217;s judgments regarding the existence of impairment indicators and future cash flows related to intangible assets are based on operational performance of its acquired businesses, market conditions and other factors. If impairment is indicated, the Company will reduce the carrying value of the intangible asset to fair value. While current and historical operating and cash flow losses are potential indicators of impairment, the Company believes the future cash flows to be received from its intangible assets will exceed the intangible assets&#8217; carrying value, and accordingly, the Company has not recognized any impairment losses through March&#160;31, 2021.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill represents the excess of acquisition cost over the fair value of the net assets of acquired businesses. Goodwill is reviewed for impairment at least annually at November 30, or more frequently if an event occurs indicating the potential for impairment. During its goodwill impairment review, the Company may assess qualitative factors to determine whether it is more likely than not that the fair value of its reporting unit is less than its carrying amount, including goodwill. The qualitative factors include, but are not limited to, macroeconomic conditions, industry and market considerations, and the overall financial performance of the Company. If, after assessing the totality of these qualitative factors, the Company determines that it is not likely that the fair value of its reporting unit is less than its carrying amount, then no additional assessment is deemed necessary. Otherwise, the Company will proceed to perform the impairment test in which the fair value of the reporting unit is compared with its carrying amount, and an impairment charge will be recorded for the amount by which the carrying amount exceeds the reporting unit's fair value, if any. The Company performed its annual assessment for goodwill impairment as of November 30, 2020, identifying no impairment.</span></div></ix:continuation><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="id68de4311aae4af68c842a515bb58204">Although there are inherent uncertainties in this assessment process, the estimates and assumptions the Company is using are consistent with its internal planning. If these estimates or their related assumptions change in the future, the Company may be required to record an impairment charge on all or a portion of its goodwill and intangible assets. Furthermore, the Company cannot predict the occurrence of future impairment triggering events nor the impact such events might have on its reported asset values. Future events could cause the Company to conclude that impairment indicators exist and that goodwill or other intangible assets associated with its acquired businesses are impaired. Any resulting impairment loss could have an adverse impact on the Company&#8217;s results of operations.</ix:continuation> See Note&#160;8 for further discussion of the Company&#8217;s goodwill and intangible assets.</span></div><ix:nonNumeric contextRef="i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331" name="us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18zNy9mcmFnOmE0NTZiM2ZhOTA0ZjQ0ZjNiYTUyYzg0OWE5YTIxNGRiL3RleHRyZWdpb246YTQ1NmIzZmE5MDRmNDRmM2JhNTJjODQ5YTlhMjE0ZGJfMTgxMzk_63ab33ce-9c5d-420e-a875-c4aee6e9b6ce" escape="true"><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Foreign Currency Translation</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The functional and presentation currency of the Company is the U.S. dollar. Transactions denominated in a currency other than the functional currency are recorded on the initial recognition at the exchange rate at the date of the transaction. After initial recognition monetary assets and liabilities denominated in foreign currency are translated at the end of each reporting period into the functional currency at the exchange rate at that date. The cumulative translation adjustment is included in the accumulated other comprehensive income (loss) within the statement of stockholders' equity. Exchange differences are included in general and administrative expenses in the condensed consolidated statement of operations. Non- monetary assets and liabilities measured at cost are translated at the exchange rate at the date of the transaction.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331" name="us-gaap:ConsolidationVariableInterestEntityPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18zNy9mcmFnOmE0NTZiM2ZhOTA0ZjQ0ZjNiYTUyYzg0OWE5YTIxNGRiL3RleHRyZWdpb246YTQ1NmIzZmE5MDRmNDRmM2JhNTJjODQ5YTlhMjE0ZGJfMTgxNTg_45d6da93-23cf-49dd-b3f3-9e7cc0b25bb8" escape="true"><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Variable Interest Entities (VIE)</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates its ownership, contractual and other interests in entities that are not wholly-owned to determine if these entities are VIEs, and, if so, whether the Company is the primary beneficiary of the VIE. In determining whether the Company is the primary beneficiary of a VIE and therefore required to consolidate the VIE, the Company applies a qualitative approach that determines whether it has both (1) the power to direct the activities of the VIE that most significantly impact the VIE&#8217;s economic performance and (2) the obligation to absorb losses of, or the rights to receive benefits from, the VIE that could potentially be significant to that VIE. The Company will continuously perform this assessment, as changes to existing relationships or future transactions may result in the consolidation or deconsolidation of a VIE.</span></div></ix:nonNumeric><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331" name="us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValuePolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18zNy9mcmFnOmE0NTZiM2ZhOTA0ZjQ0ZjNiYTUyYzg0OWE5YTIxNGRiL3RleHRyZWdpb246YTQ1NmIzZmE5MDRmNDRmM2JhNTJjODQ5YTlhMjE0ZGJfMTgxMzE_d7a5d973-10ec-46b0-85e4-8c6037e72a96" continuedAt="i7ab49f3412944ee5b384767fb3352334" escape="true">Equity Investments</ix:nonNumeric></span></div></ix:continuation><div style="margin-top:5pt;text-indent:27pt"><ix:continuation id="i1234a6a72be34b55a21f5b4d32bebc6e" continuedAt="i595455abf0814d3ba5114ebcd5963b67"><ix:continuation id="i7ab49f3412944ee5b384767fb3352334" continuedAt="i462aafe6316046658a54e885aa62dad3"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under ASC Topic 321, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investments - Equity Securities,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> the Company must measure equity investments (except those accounted for under the equity method, those that result in consolidation of the investee and certain other investments) at fair value and recognize any changes in fair value in the condensed consolidated statement of operations. The Company can elect a measurement alternative for equity investments that do not have readily determinable fair values and do not qualify for the practical expedient in ASC 820, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurement,</span></ix:continuation></ix:continuation><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i595455abf0814d3ba5114ebcd5963b67"><ix:continuation id="i462aafe6316046658a54e885aa62dad3"> to estimate fair value using the net asset value per share (or its equivalent).&#160;The Company's equity investments that do not have readily determinable fair values and do not qualify for the net asset value practical expedient for estimating fair value are measured at cost, less any impairments, plus or minus changes resulting from observable price changes in orderly transactions for identifiable or similar investments of the same issuer.</ix:continuation></ix:continuation>&#160;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1d23d16a69484b63aa007ec686e80337_7">Table of Contents</a></span></div></div><div style="margin-top:5pt"><span><br/></span></div><div id="i1d23d16a69484b63aa007ec686e80337_43"></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4. <ix:nonNumeric contextRef="i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331" name="us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN180My9mcmFnOjE2YjBmNmZlNjlhZTQwNjdhYmQ0N2RlNGM4M2ZhYTg3L3RleHRyZWdpb246MTZiMGY2ZmU2OWFlNDA2N2FiZDQ3ZGU0YzgzZmFhODdfNTE5MA_2f95db5e-3729-45b5-9d39-aa3f7be4be49" continuedAt="id6cb0d8c983d40ae88283625ff09c56f" escape="true">Impact of Recently Issued Accounting Standards </ix:nonNumeric></span></div><ix:continuation id="id6cb0d8c983d40ae88283625ff09c56f"><ix:nonNumeric contextRef="i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN180My9mcmFnOjE2YjBmNmZlNjlhZTQwNjdhYmQ0N2RlNGM4M2ZhYTg3L3RleHRyZWdpb246MTZiMGY2ZmU2OWFlNDA2N2FiZDQ3ZGU0YzgzZmFhODdfNTE5Mw_ac7d4575-738b-4177-9217-db5de1d75f44" escape="true"><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The recent accounting pronouncements below may have a significant effect on the Company's financial statements. Recent accounting pronouncements that are not anticipated to have an impact on or are unrelated to the Company's financial condition, results of operations, or related disclosures are not discussed. </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accounting Standards Pending Adoption</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">ASU No. 2020-06.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In August 2020, the FASB issued ASU No. 2020-06, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Debt&#8212;Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging&#8212;Contracts in Entity&#8217;s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity&#8217;s Own Equity</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;ASU 2020-06&#8221;), which simplifies the guidance on an issuer&#8217;s accounting for convertible instruments and contracts in its own equity. The standard is effective for the Company beginning in the first quarter of 2022, with early adoption permitted in the first quarter of 2021. The Company did not elect to early adopt the standard and does not expect ASU 2020-06 to have a material impact to its condensed consolidated financial statements.</span></div></ix:nonNumeric></ix:continuation><div id="i1d23d16a69484b63aa007ec686e80337_46"></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5. <ix:nonNumeric contextRef="i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331" name="us-gaap:RevenueFromContractWithCustomerTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN180Ni9mcmFnOjZkOWI0OTc4YjgwMDQ3ZjhiOTg3ZGRlODJmM2MyNzk2L3RleHRyZWdpb246NmQ5YjQ5NzhiODAwNDdmOGI5ODdkZGU4MmYzYzI3OTZfNTU3_ebad08c6-6373-45e0-bbf8-02b7cf279f70" continuedAt="i55a2a1e82f9b48adafc1f65101beab2b" escape="true">Revenue Recognition  </ix:nonNumeric></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i55a2a1e82f9b48adafc1f65101beab2b">During the three months ended March 31, 2021, the Company recognized total revenue under collaborative research and development and other agreements of $<ix:nonFraction unitRef="usd" contextRef="ia2b43dbe48ac4cd98a40e26498a7f881_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN180Ni9mcmFnOjZkOWI0OTc4YjgwMDQ3ZjhiOTg3ZGRlODJmM2MyNzk2L3RleHRyZWdpb246NmQ5YjQ5NzhiODAwNDdmOGI5ODdkZGU4MmYzYzI3OTZfMTUx_a91ec5f4-d52b-4b79-b092-0076f45552f9">50,000</ix:nonFraction> from its affiliated entity Plumbline Life Sciences, Inc. ("PLS") and $<ix:nonFraction unitRef="usd" contextRef="i54393acc697d46e9aadd822f4955d2fa_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN180Ni9mcmFnOjZkOWI0OTc4YjgwMDQ3ZjhiOTg3ZGRlODJmM2MyNzk2L3RleHRyZWdpb246NmQ5YjQ5NzhiODAwNDdmOGI5ODdkZGU4MmYzYzI3OTZfMjg4_69f38cf3-ec0c-4051-a01a-71147105f0c8">321,000</ix:nonFraction> from various other contracts as a result of performance obligations being satisfied. Of the total revenue recognized during the three months ended March 31, 2021, $<ix:nonFraction unitRef="usd" contextRef="i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN180Ni9mcmFnOjZkOWI0OTc4YjgwMDQ3ZjhiOTg3ZGRlODJmM2MyNzk2L3RleHRyZWdpb246NmQ5YjQ5NzhiODAwNDdmOGI5ODdkZGU4MmYzYzI3OTZfMzkw_75f2d893-48bc-4c01-b2e6-6a44ef7d31d7">4,000</ix:nonFraction> was in deferred revenue as of December 31, 2020.</ix:continuation> </span></div><div style="margin-top:5pt;text-indent:27pt"><span><br/></span></div><div id="i1d23d16a69484b63aa007ec686e80337_49"></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6. <ix:nonNumeric contextRef="i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331" name="us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN180OS9mcmFnOjBmMTE0ZmJjNDQ1ZDRiYTBiODFjMjhjYWE3YzZjNmE2L3RleHRyZWdpb246MGYxMTRmYmM0NDVkNGJhMGI4MWMyOGNhYTdjNmM2YTZfMzQyNg_3b2b1ee2-19e7-4a7d-ab44-ca25330d80fc" continuedAt="ie1fc7aabcd1d4e04a08b8bc974c9ce93" escape="true">Short-term Investments</ix:nonNumeric></span></div><ix:continuation id="ie1fc7aabcd1d4e04a08b8bc974c9ce93" continuedAt="i44d7bf103fe945c19b93653d94721884"><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Short-term investments at March&#160;31, 2021 consisted of mutual funds, U.S. treasury securities, certificates of deposit and U.S. agency mortgage-backed securities. Short-term investments at December&#160;31, 2020 consisted of mutual funds, certificates of deposit and U.S. agency mortgage-backed securities. Short-term investments are recorded at fair value, based on current market valuations. Unrealized gains and losses on the Company's short-term debt investments are excluded from earnings and reported as a separate component of other comprehensive loss until realized. Realized gains and losses and unrealized gains and losses on available-for-sale equity securities are included in non-operating other income (expense) on the condensed consolidated statements of operations and are derived using the specific identification method for determining the cost of the securities sold. During the three months ended March 31, 2021 and 2020, the Company recorded gross realized gain on investments of $<ix:nonFraction unitRef="usd" contextRef="i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedGain" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN180OS9mcmFnOjBmMTE0ZmJjNDQ1ZDRiYTBiODFjMjhjYWE3YzZjNmE2L3RleHRyZWdpb246MGYxMTRmYmM0NDVkNGJhMGI4MWMyOGNhYTdjNmM2YTZfOTE4_8ba9db78-59d4-4d00-a553-f98ac68eeb1c">0</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i03bccaa0abfb4733b1e2831ecde4e4e8_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedGain" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN180OS9mcmFnOjBmMTE0ZmJjNDQ1ZDRiYTBiODFjMjhjYWE3YzZjNmE2L3RleHRyZWdpb246MGYxMTRmYmM0NDVkNGJhMGI4MWMyOGNhYTdjNmM2YTZfOTI1_32a3772d-fda7-4e6f-b442-d3942a8d5870">50,000</ix:nonFraction>, respectively, and gross realized loss on investments of $<ix:nonFraction unitRef="usd" contextRef="i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN180OS9mcmFnOjBmMTE0ZmJjNDQ1ZDRiYTBiODFjMjhjYWE3YzZjNmE2L3RleHRyZWdpb246MGYxMTRmYmM0NDVkNGJhMGI4MWMyOGNhYTdjNmM2YTZfOTg1_83f96af7-5a8e-4174-a658-f7d161a450d7">10,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i03bccaa0abfb4733b1e2831ecde4e4e8_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN180OS9mcmFnOjBmMTE0ZmJjNDQ1ZDRiYTBiODFjMjhjYWE3YzZjNmE2L3RleHRyZWdpb246MGYxMTRmYmM0NDVkNGJhMGI4MWMyOGNhYTdjNmM2YTZfOTky_9c16a836-63d0-480e-9d86-4ed28ec0ef5c">525,000</ix:nonFraction>, respectively. During the three months ended March 31, 2021 and 2020, the Company recorded net unrealized loss on available-for-sale equity securities of $(<ix:nonFraction unitRef="usd" contextRef="i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN180OS9mcmFnOjBmMTE0ZmJjNDQ1ZDRiYTBiODFjMjhjYWE3YzZjNmE2L3RleHRyZWdpb246MGYxMTRmYmM0NDVkNGJhMGI4MWMyOGNhYTdjNmM2YTZfMTI4Mw_9878f61d-85ba-4892-92a4-331882da994a">848,000</ix:nonFraction>) and $(<ix:nonFraction unitRef="usd" contextRef="i03bccaa0abfb4733b1e2831ecde4e4e8_D20200101-20200331" decimals="-5" sign="-" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN180OS9mcmFnOjBmMTE0ZmJjNDQ1ZDRiYTBiODFjMjhjYWE3YzZjNmE2L3RleHRyZWdpb246MGYxMTRmYmM0NDVkNGJhMGI4MWMyOGNhYTdjNmM2YTZfMTI5MA_abb51152-d72f-4948-9213-ed318b1faca9">5.1</ix:nonFraction>) million, respectively. No&#160;material balances were&#160;reclassified out of accumulated&#160;other comprehensive income (loss) for the three months ended March 31, 2021 and 2020. Interest and dividends on investments classified as available-for-sale are included in interest income in the condensed consolidated statements of operations. </span></div><ix:nonNumeric contextRef="i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331" name="us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN180OS9mcmFnOjBmMTE0ZmJjNDQ1ZDRiYTBiODFjMjhjYWE3YzZjNmE2L3RleHRyZWdpb246MGYxMTRmYmM0NDVkNGJhMGI4MWMyOGNhYTdjNmM2YTZfMzQzNw_b45b3444-e6b7-43f0-b385-b0f37edcd6fb" continuedAt="i4409dbf0209a44cd9472ebafc8dda9ee" escape="true"><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of available-for-sale securities as of March&#160;31, 2021 and December&#160;31, 2020:</span></div><div style="margin-top:5pt;text-indent:27pt"><span><br/></span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:25.839%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.394%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.809%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.809%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.809%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.812%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of March 31, 2021</span></td></tr><tr style="height:21pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Contractual<br/>Maturity&#160;(in&#160;years)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross&#160;Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross&#160;Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair&#160;Market&#160;Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mutual funds</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">---</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc97cab144454f34933b056f760ee615_I20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN180OS9mcmFnOjBmMTE0ZmJjNDQ1ZDRiYTBiODFjMjhjYWE3YzZjNmE2L3RhYmxlOmU2NGMxMTM5YTU3YTRhOTE4NTliNDUzM2EzNGJkNWQxL3RhYmxlcmFuZ2U6ZTY0YzExMzlhNTdhNGE5MTg1OWI0NTMzYTM0YmQ1ZDFfMi0zLTEtMS0w_11e3aa3c-5205-4c10-844c-f085b919b947">228,101,615</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc97cab144454f34933b056f760ee615_I20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN180OS9mcmFnOjBmMTE0ZmJjNDQ1ZDRiYTBiODFjMjhjYWE3YzZjNmE2L3RhYmxlOmU2NGMxMTM5YTU3YTRhOTE4NTliNDUzM2EzNGJkNWQxL3RhYmxlcmFuZ2U6ZTY0YzExMzlhNTdhNGE5MTg1OWI0NTMzYTM0YmQ1ZDFfMi01LTEtMS0w_158701ef-6c45-4fd3-921c-decb100a170b">1,562,498</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibc97cab144454f34933b056f760ee615_I20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN180OS9mcmFnOjBmMTE0ZmJjNDQ1ZDRiYTBiODFjMjhjYWE3YzZjNmE2L3RhYmxlOmU2NGMxMTM5YTU3YTRhOTE4NTliNDUzM2EzNGJkNWQxL3RhYmxlcmFuZ2U6ZTY0YzExMzlhNTdhNGE5MTg1OWI0NTMzYTM0YmQ1ZDFfMi03LTEtMS0w_601c2a28-389b-4ab4-9e32-9cc8db53a793">714,957</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc97cab144454f34933b056f760ee615_I20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN180OS9mcmFnOjBmMTE0ZmJjNDQ1ZDRiYTBiODFjMjhjYWE3YzZjNmE2L3RhYmxlOmU2NGMxMTM5YTU3YTRhOTE4NTliNDUzM2EzNGJkNWQxL3RhYmxlcmFuZ2U6ZTY0YzExMzlhNTdhNGE5MTg1OWI0NTMzYTM0YmQ1ZDFfMi05LTEtMS0w_3eb8d915-8ab7-4eaa-87f1-60ca70c2cc05">228,949,156</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less than <ix:nonNumeric contextRef="i4af67d24a9704503878ba27b39ec0b38_D20210101-20210331" format="ixt-sec:duryear" name="ino:DebtSecuritiesAvailableforSaleContractualMaturity" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN180OS9mcmFnOjBmMTE0ZmJjNDQ1ZDRiYTBiODFjMjhjYWE3YzZjNmE2L3RhYmxlOmU2NGMxMTM5YTU3YTRhOTE4NTliNDUzM2EzNGJkNWQxL3RhYmxlcmFuZ2U6ZTY0YzExMzlhNTdhNGE5MTg1OWI0NTMzYTM0YmQ1ZDFfMy0xLTEtMS00NDE3L3RleHRyZWdpb246OWJmYmExMGI3YzAyNGI2ZGE4ZWJiNGVhNmZkN2E5ZWZfMzI5ODUzNDg4MzM0NA_5ce133e6-797b-41ff-82ce-b9c3c30a53cc">1</ix:nonNumeric></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd7b23cb5c014502a4a19618e0a1c8c8_I20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN180OS9mcmFnOjBmMTE0ZmJjNDQ1ZDRiYTBiODFjMjhjYWE3YzZjNmE2L3RhYmxlOmU2NGMxMTM5YTU3YTRhOTE4NTliNDUzM2EzNGJkNWQxL3RhYmxlcmFuZ2U6ZTY0YzExMzlhNTdhNGE5MTg1OWI0NTMzYTM0YmQ1ZDFfMy0zLTEtMS0w_fb861b6c-2d28-49e0-917f-76b5d7a3a6b4">200,408,976</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd7b23cb5c014502a4a19618e0a1c8c8_I20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN180OS9mcmFnOjBmMTE0ZmJjNDQ1ZDRiYTBiODFjMjhjYWE3YzZjNmE2L3RhYmxlOmU2NGMxMTM5YTU3YTRhOTE4NTliNDUzM2EzNGJkNWQxL3RhYmxlcmFuZ2U6ZTY0YzExMzlhNTdhNGE5MTg1OWI0NTMzYTM0YmQ1ZDFfMy01LTEtMS0w_7c609be1-17c8-4bca-9b35-9784a76af0b7">14,404</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibd7b23cb5c014502a4a19618e0a1c8c8_I20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN180OS9mcmFnOjBmMTE0ZmJjNDQ1ZDRiYTBiODFjMjhjYWE3YzZjNmE2L3RhYmxlOmU2NGMxMTM5YTU3YTRhOTE4NTliNDUzM2EzNGJkNWQxL3RhYmxlcmFuZ2U6ZTY0YzExMzlhNTdhNGE5MTg1OWI0NTMzYTM0YmQ1ZDFfMy03LTEtMS0w_7a1aa932-5a75-4d90-8f80-20c3cf275718">9,380</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd7b23cb5c014502a4a19618e0a1c8c8_I20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN180OS9mcmFnOjBmMTE0ZmJjNDQ1ZDRiYTBiODFjMjhjYWE3YzZjNmE2L3RhYmxlOmU2NGMxMTM5YTU3YTRhOTE4NTliNDUzM2EzNGJkNWQxL3RhYmxlcmFuZ2U6ZTY0YzExMzlhNTdhNGE5MTg1OWI0NTMzYTM0YmQ1ZDFfMy05LTEtMS0w_54ff1078-4504-4bd6-a0a3-bf4abe712f7e">200,414,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less than <ix:nonNumeric contextRef="i4a59d94b00fb4beead53f1520382f2ac_D20210101-20210331" format="ixt-sec:duryear" name="ino:DebtSecuritiesAvailableforSaleContractualMaturity" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN180OS9mcmFnOjBmMTE0ZmJjNDQ1ZDRiYTBiODFjMjhjYWE3YzZjNmE2L3RhYmxlOmU2NGMxMTM5YTU3YTRhOTE4NTliNDUzM2EzNGJkNWQxL3RhYmxlcmFuZ2U6ZTY0YzExMzlhNTdhNGE5MTg1OWI0NTMzYTM0YmQ1ZDFfNS0xLTEtMS00NDEzL3RleHRyZWdpb246NTNlNGY4YzIzYWRhNDgwOWFlMmJhM2ZkNTAzNWYzY2VfMzI5ODUzNDg4MzM0NA_3294376a-e729-44bb-bbea-9c0b4d772ce7">1</ix:nonNumeric></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07337481fc814fa2a711b1ff37845f55_I20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN180OS9mcmFnOjBmMTE0ZmJjNDQ1ZDRiYTBiODFjMjhjYWE3YzZjNmE2L3RhYmxlOmU2NGMxMTM5YTU3YTRhOTE4NTliNDUzM2EzNGJkNWQxL3RhYmxlcmFuZ2U6ZTY0YzExMzlhNTdhNGE5MTg1OWI0NTMzYTM0YmQ1ZDFfNS0zLTEtMS0w_dcbd43ba-6924-424d-ba09-beddf4f672dd">2,977,623</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07337481fc814fa2a711b1ff37845f55_I20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN180OS9mcmFnOjBmMTE0ZmJjNDQ1ZDRiYTBiODFjMjhjYWE3YzZjNmE2L3RhYmxlOmU2NGMxMTM5YTU3YTRhOTE4NTliNDUzM2EzNGJkNWQxL3RhYmxlcmFuZ2U6ZTY0YzExMzlhNTdhNGE5MTg1OWI0NTMzYTM0YmQ1ZDFfNS01LTEtMS0w_299b1057-e3b6-4c23-9563-1346c88a76ca">19,700</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i07337481fc814fa2a711b1ff37845f55_I20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN180OS9mcmFnOjBmMTE0ZmJjNDQ1ZDRiYTBiODFjMjhjYWE3YzZjNmE2L3RhYmxlOmU2NGMxMTM5YTU3YTRhOTE4NTliNDUzM2EzNGJkNWQxL3RhYmxlcmFuZ2U6ZTY0YzExMzlhNTdhNGE5MTg1OWI0NTMzYTM0YmQ1ZDFfNS03LTEtMS0w_c4e3c037-b905-4e33-81f5-d8fbacf8d33d">5,123</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07337481fc814fa2a711b1ff37845f55_I20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN180OS9mcmFnOjBmMTE0ZmJjNDQ1ZDRiYTBiODFjMjhjYWE3YzZjNmE2L3RhYmxlOmU2NGMxMTM5YTU3YTRhOTE4NTliNDUzM2EzNGJkNWQxL3RhYmxlcmFuZ2U6ZTY0YzExMzlhNTdhNGE5MTg1OWI0NTMzYTM0YmQ1ZDFfNS05LTEtMS0w_4a9b0030-9614-4af6-80b7-592de93d7005">2,992,200</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. agency mortgage-backed securities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i333c95a51d3f4b7595b348f7c6eb52c5_I20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN180OS9mcmFnOjBmMTE0ZmJjNDQ1ZDRiYTBiODFjMjhjYWE3YzZjNmE2L3RhYmxlOmU2NGMxMTM5YTU3YTRhOTE4NTliNDUzM2EzNGJkNWQxL3RhYmxlcmFuZ2U6ZTY0YzExMzlhNTdhNGE5MTg1OWI0NTMzYTM0YmQ1ZDFfNi0zLTEtMS0w_f58c7f34-1043-409f-9575-f9971b0fd103">2,646,077</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i333c95a51d3f4b7595b348f7c6eb52c5_I20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN180OS9mcmFnOjBmMTE0ZmJjNDQ1ZDRiYTBiODFjMjhjYWE3YzZjNmE2L3RhYmxlOmU2NGMxMTM5YTU3YTRhOTE4NTliNDUzM2EzNGJkNWQxL3RhYmxlcmFuZ2U6ZTY0YzExMzlhNTdhNGE5MTg1OWI0NTMzYTM0YmQ1ZDFfNi01LTEtMS0w_1b17bb36-07cb-4cbe-aa13-37d240474b59">1,100</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i333c95a51d3f4b7595b348f7c6eb52c5_I20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN180OS9mcmFnOjBmMTE0ZmJjNDQ1ZDRiYTBiODFjMjhjYWE3YzZjNmE2L3RhYmxlOmU2NGMxMTM5YTU3YTRhOTE4NTliNDUzM2EzNGJkNWQxL3RhYmxlcmFuZ2U6ZTY0YzExMzlhNTdhNGE5MTg1OWI0NTMzYTM0YmQ1ZDFfNi03LTEtMS0w_6a152d11-e360-49ab-bf52-c6d8605148bd">33,005</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i333c95a51d3f4b7595b348f7c6eb52c5_I20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN180OS9mcmFnOjBmMTE0ZmJjNDQ1ZDRiYTBiODFjMjhjYWE3YzZjNmE2L3RhYmxlOmU2NGMxMTM5YTU3YTRhOTE4NTliNDUzM2EzNGJkNWQxL3RhYmxlcmFuZ2U6ZTY0YzExMzlhNTdhNGE5MTg1OWI0NTMzYTM0YmQ1ZDFfNi05LTEtMS0w_d48c06f1-c56d-4780-9497-4ed31154d03a">2,614,172</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic36b9cedad7f41a6b9eb223b09b7186c_I20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN180OS9mcmFnOjBmMTE0ZmJjNDQ1ZDRiYTBiODFjMjhjYWE3YzZjNmE2L3RhYmxlOmU2NGMxMTM5YTU3YTRhOTE4NTliNDUzM2EzNGJkNWQxL3RhYmxlcmFuZ2U6ZTY0YzExMzlhNTdhNGE5MTg1OWI0NTMzYTM0YmQ1ZDFfOC0zLTEtMS0w_d5914599-2a3b-4da3-b423-bbcc2ac9a5df">434,134,291</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic36b9cedad7f41a6b9eb223b09b7186c_I20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN180OS9mcmFnOjBmMTE0ZmJjNDQ1ZDRiYTBiODFjMjhjYWE3YzZjNmE2L3RhYmxlOmU2NGMxMTM5YTU3YTRhOTE4NTliNDUzM2EzNGJkNWQxL3RhYmxlcmFuZ2U6ZTY0YzExMzlhNTdhNGE5MTg1OWI0NTMzYTM0YmQ1ZDFfOC01LTEtMS0w_7ca681dc-4f88-42a5-a16a-a8f739f5e495">1,597,702</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic36b9cedad7f41a6b9eb223b09b7186c_I20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN180OS9mcmFnOjBmMTE0ZmJjNDQ1ZDRiYTBiODFjMjhjYWE3YzZjNmE2L3RhYmxlOmU2NGMxMTM5YTU3YTRhOTE4NTliNDUzM2EzNGJkNWQxL3RhYmxlcmFuZ2U6ZTY0YzExMzlhNTdhNGE5MTg1OWI0NTMzYTM0YmQ1ZDFfOC03LTEtMS0w_741d30be-9edb-4ed8-b270-063f1077f4be">762,465</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic36b9cedad7f41a6b9eb223b09b7186c_I20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN180OS9mcmFnOjBmMTE0ZmJjNDQ1ZDRiYTBiODFjMjhjYWE3YzZjNmE2L3RhYmxlOmU2NGMxMTM5YTU3YTRhOTE4NTliNDUzM2EzNGJkNWQxL3RhYmxlcmFuZ2U6ZTY0YzExMzlhNTdhNGE5MTg1OWI0NTMzYTM0YmQ1ZDFfOC05LTEtMS0w_cfe05cf7-5181-4511-9aee-c90ce0cc5bcd">434,969,528</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="text-align:center"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i44d7bf103fe945c19b93653d94721884"><ix:continuation id="i4409dbf0209a44cd9472ebafc8dda9ee"><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:25.839%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.394%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.809%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.809%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.809%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.812%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2020</span></td></tr><tr style="height:21pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Contractual<br/>Maturity&#160;(in&#160;years)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross&#160;Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross&#160;Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair&#160;Market&#160;Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mutual funds</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">---</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9038be9382ec4b1694bd9bfd7bcda170_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN180OS9mcmFnOjBmMTE0ZmJjNDQ1ZDRiYTBiODFjMjhjYWE3YzZjNmE2L3RhYmxlOjk2YjEwY2MxZTI2ZDQyMGFiNTE3NGRkYjU4Zjk0YTY4L3RhYmxlcmFuZ2U6OTZiMTBjYzFlMjZkNDIwYWI1MTc0ZGRiNThmOTRhNjhfMi0zLTEtMS0w_5a50ad23-acfb-481b-934a-741b25ce7f78">153,177,675</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9038be9382ec4b1694bd9bfd7bcda170_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN180OS9mcmFnOjBmMTE0ZmJjNDQ1ZDRiYTBiODFjMjhjYWE3YzZjNmE2L3RhYmxlOjk2YjEwY2MxZTI2ZDQyMGFiNTE3NGRkYjU4Zjk0YTY4L3RhYmxlcmFuZ2U6OTZiMTBjYzFlMjZkNDIwYWI1MTc0ZGRiNThmOTRhNjhfMi01LTEtMS0w_937f9021-4650-4365-8179-0756d749ce91">2,339,639</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9038be9382ec4b1694bd9bfd7bcda170_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN180OS9mcmFnOjBmMTE0ZmJjNDQ1ZDRiYTBiODFjMjhjYWE3YzZjNmE2L3RhYmxlOjk2YjEwY2MxZTI2ZDQyMGFiNTE3NGRkYjU4Zjk0YTY4L3RhYmxlcmFuZ2U6OTZiMTBjYzFlMjZkNDIwYWI1MTc0ZGRiNThmOTRhNjhfMi03LTEtMS0w_e1907c58-a1bc-40e3-9d45-bdb5bd9c754a">644,140</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9038be9382ec4b1694bd9bfd7bcda170_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN180OS9mcmFnOjBmMTE0ZmJjNDQ1ZDRiYTBiODFjMjhjYWE3YzZjNmE2L3RhYmxlOjk2YjEwY2MxZTI2ZDQyMGFiNTE3NGRkYjU4Zjk0YTY4L3RhYmxlcmFuZ2U6OTZiMTBjYzFlMjZkNDIwYWI1MTc0ZGRiNThmOTRhNjhfMi05LTEtMS0w_4664b182-2cdd-474a-b065-67245baefd8b">154,873,174</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less&#160;than&#160;<ix:nonNumeric contextRef="i47be9d2882e243b7ace441a9b9205c92_D20200101-20200331" format="ixt-sec:duryear" name="ino:DebtSecuritiesAvailableforSaleContractualMaturity" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN180OS9mcmFnOjBmMTE0ZmJjNDQ1ZDRiYTBiODFjMjhjYWE3YzZjNmE2L3RhYmxlOjk2YjEwY2MxZTI2ZDQyMGFiNTE3NGRkYjU4Zjk0YTY4L3RhYmxlcmFuZ2U6OTZiMTBjYzFlMjZkNDIwYWI1MTc0ZGRiNThmOTRhNjhfMy0xLTEtMS00NDIxL3RleHRyZWdpb246ODg1OWRjMzFmNzJiNDU2Mzg0MzI0YzExYTdjZjkzZmJfMzI5ODUzNDg4MzM0OA_e5010b9c-39c8-4b0a-80c7-a425adf41367">1</ix:nonNumeric></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ed17972d6064f0bad14d06c6c595208_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN180OS9mcmFnOjBmMTE0ZmJjNDQ1ZDRiYTBiODFjMjhjYWE3YzZjNmE2L3RhYmxlOjk2YjEwY2MxZTI2ZDQyMGFiNTE3NGRkYjU4Zjk0YTY4L3RhYmxlcmFuZ2U6OTZiMTBjYzFlMjZkNDIwYWI1MTc0ZGRiNThmOTRhNjhfMy0zLTEtMS0w_2f147ad7-a0dc-4c6d-88e2-25ba1f7aa826">3,000,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ed17972d6064f0bad14d06c6c595208_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN180OS9mcmFnOjBmMTE0ZmJjNDQ1ZDRiYTBiODFjMjhjYWE3YzZjNmE2L3RhYmxlOjk2YjEwY2MxZTI2ZDQyMGFiNTE3NGRkYjU4Zjk0YTY4L3RhYmxlcmFuZ2U6OTZiMTBjYzFlMjZkNDIwYWI1MTc0ZGRiNThmOTRhNjhfMy01LTEtMS0w_42e19b17-31c5-42ac-8553-ffd96ec23acd">26,260</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7ed17972d6064f0bad14d06c6c595208_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN180OS9mcmFnOjBmMTE0ZmJjNDQ1ZDRiYTBiODFjMjhjYWE3YzZjNmE2L3RhYmxlOjk2YjEwY2MxZTI2ZDQyMGFiNTE3NGRkYjU4Zjk0YTY4L3RhYmxlcmFuZ2U6OTZiMTBjYzFlMjZkNDIwYWI1MTc0ZGRiNThmOTRhNjhfMy03LTEtMS0w_93fc5601-5f9d-45b8-9acc-32b0c34480c8">10,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ed17972d6064f0bad14d06c6c595208_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN180OS9mcmFnOjBmMTE0ZmJjNDQ1ZDRiYTBiODFjMjhjYWE3YzZjNmE2L3RhYmxlOjk2YjEwY2MxZTI2ZDQyMGFiNTE3NGRkYjU4Zjk0YTY4L3RhYmxlcmFuZ2U6OTZiMTBjYzFlMjZkNDIwYWI1MTc0ZGRiNThmOTRhNjhfMy05LTEtMS0w_93dd794d-442b-43b8-9d68-098732e8bd62">3,016,260</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. agency mortgage-backed securities</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f07020b0bd84e2b85baecf8191dddd4_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN180OS9mcmFnOjBmMTE0ZmJjNDQ1ZDRiYTBiODFjMjhjYWE3YzZjNmE2L3RhYmxlOjk2YjEwY2MxZTI2ZDQyMGFiNTE3NGRkYjU4Zjk0YTY4L3RhYmxlcmFuZ2U6OTZiMTBjYzFlMjZkNDIwYWI1MTc0ZGRiNThmOTRhNjhfNC0zLTEtMS0w_b08b7270-592b-458e-8186-8a0fa2bb7252">3,062,256</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f07020b0bd84e2b85baecf8191dddd4_I20201231" decimals="0" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN180OS9mcmFnOjBmMTE0ZmJjNDQ1ZDRiYTBiODFjMjhjYWE3YzZjNmE2L3RhYmxlOjk2YjEwY2MxZTI2ZDQyMGFiNTE3NGRkYjU4Zjk0YTY4L3RhYmxlcmFuZ2U6OTZiMTBjYzFlMjZkNDIwYWI1MTc0ZGRiNThmOTRhNjhfNC01LTEtMS0w_591286c4-3a20-4ead-8a6b-8594de7776fa">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6f07020b0bd84e2b85baecf8191dddd4_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN180OS9mcmFnOjBmMTE0ZmJjNDQ1ZDRiYTBiODFjMjhjYWE3YzZjNmE2L3RhYmxlOjk2YjEwY2MxZTI2ZDQyMGFiNTE3NGRkYjU4Zjk0YTY4L3RhYmxlcmFuZ2U6OTZiMTBjYzFlMjZkNDIwYWI1MTc0ZGRiNThmOTRhNjhfNC03LTEtMS0w_fc93d80b-4ff4-4cf3-b4c9-dc57ff49f1d2">36,755</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f07020b0bd84e2b85baecf8191dddd4_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN180OS9mcmFnOjBmMTE0ZmJjNDQ1ZDRiYTBiODFjMjhjYWE3YzZjNmE2L3RhYmxlOjk2YjEwY2MxZTI2ZDQyMGFiNTE3NGRkYjU4Zjk0YTY4L3RhYmxlcmFuZ2U6OTZiMTBjYzFlMjZkNDIwYWI1MTc0ZGRiNThmOTRhNjhfNC05LTEtMS0w_2c6d6095-3c23-4110-bcfe-60467d752c84">3,025,501</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i066bb5b0a9e84c0a878b1e800703d92b_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN180OS9mcmFnOjBmMTE0ZmJjNDQ1ZDRiYTBiODFjMjhjYWE3YzZjNmE2L3RhYmxlOjk2YjEwY2MxZTI2ZDQyMGFiNTE3NGRkYjU4Zjk0YTY4L3RhYmxlcmFuZ2U6OTZiMTBjYzFlMjZkNDIwYWI1MTc0ZGRiNThmOTRhNjhfNy0zLTEtMS0yODk1_74cc3ac2-070d-4483-88fc-99cc13501f3f">159,239,931</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i066bb5b0a9e84c0a878b1e800703d92b_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN180OS9mcmFnOjBmMTE0ZmJjNDQ1ZDRiYTBiODFjMjhjYWE3YzZjNmE2L3RhYmxlOjk2YjEwY2MxZTI2ZDQyMGFiNTE3NGRkYjU4Zjk0YTY4L3RhYmxlcmFuZ2U6OTZiMTBjYzFlMjZkNDIwYWI1MTc0ZGRiNThmOTRhNjhfNy01LTEtMS0yODk1_e248bc47-c5dc-4136-8c82-489d8846641e">2,365,899</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i066bb5b0a9e84c0a878b1e800703d92b_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN180OS9mcmFnOjBmMTE0ZmJjNDQ1ZDRiYTBiODFjMjhjYWE3YzZjNmE2L3RhYmxlOjk2YjEwY2MxZTI2ZDQyMGFiNTE3NGRkYjU4Zjk0YTY4L3RhYmxlcmFuZ2U6OTZiMTBjYzFlMjZkNDIwYWI1MTc0ZGRiNThmOTRhNjhfNy03LTEtMS0yODk1_73d7c811-c013-4540-b283-65487b4d8614">690,895</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i066bb5b0a9e84c0a878b1e800703d92b_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN180OS9mcmFnOjBmMTE0ZmJjNDQ1ZDRiYTBiODFjMjhjYWE3YzZjNmE2L3RhYmxlOjk2YjEwY2MxZTI2ZDQyMGFiNTE3NGRkYjU4Zjk0YTY4L3RhYmxlcmFuZ2U6OTZiMTBjYzFlMjZkNDIwYWI1MTc0ZGRiNThmOTRhNjhfNy05LTEtMS0yODk1_a1c6352b-e793-4fa9-879f-c3a0e22f8a69">160,914,935</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*No single maturity date.</span></div></ix:continuation><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company periodically reviews its portfolio of available-for-sale debt securities to determine if any investment is impaired due to credit loss or other potential valuation concerns. For the debt securities where the fair value of the investment is less than the amortized cost basis, the Company has assessed at the individual security level for various quantitative factors including, but not limited to, the nature of the investments, changes in credit ratings, interest rate fluctuations, industry analyst reports, and the severity of impairment. Unrealized losses on available-for-sale debt securities as of&#160;March&#160;31, 2021&#160;were primarily due to changes in interest rates, including credit spreads from perceived increased credit risks as a result of the COVID-19 global pandemic, and not due to increased credit risks associated with specific securities. The Company does not intend to sell these investments and it is not more likely than not that the Company will be required to sell the investments before recovery of their amortized cost basis, which may be at maturity. Based on the credit quality of the available-for-sale debt securities that are in an unrealized loss position, and the Company&#8217;s estimates of future cash flows to be collected from those securities, the Company believes the unrealized losses are not credit losses. Accordingly, at March&#160;31, 2021, the Company has not recorded an allowance for credit losses related to its available-for-sale debt securities.</span></div></ix:continuation><div><span><br/></span></div><div id="i1d23d16a69484b63aa007ec686e80337_55"></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7. <ix:nonNumeric contextRef="i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331" name="us-gaap:FairValueDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN181NS9mcmFnOjRiYWIyMmQ4MWJlYjQzNGQ4YzRkYjQwOTE5NTc4MGE4L3RleHRyZWdpb246NGJhYjIyZDgxYmViNDM0ZDhjNGRiNDA5MTk1NzgwYThfNTgzNA_5ae9547b-64a2-45ae-b0d4-7f783abf3a96" continuedAt="i78d9622d22654683822687e103fc10ad" escape="true">Fair Value Measurements</ix:nonNumeric></span></div><ix:continuation id="i78d9622d22654683822687e103fc10ad" continuedAt="i97a6faf06d054771be82c148441cde0a"><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The guidance regarding fair value measurements establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value. These tiers include: Level&#160;1, defined as observable inputs such as quoted prices in active markets that are accessible at the measurement date; Level&#160;2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable; and Level&#160;3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assets are classified based on the lowest level of input that is significant to the fair value measurements. The Company reviews the fair value hierarchy classification on a quarterly basis. Changes in the ability to observe valuation inputs may result in a reclassification of levels for certain securities within the fair value hierarchy. The Company does not have any liabilities measured at fair value on a recurring basis and did not have any transfer of assets or liabilities between Level 1, Level 2 and Level 3 of the fair value hierarchy during the three months ended March 31, 2021 or 2020. </span></div><ix:nonNumeric contextRef="i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN181NS9mcmFnOjRiYWIyMmQ4MWJlYjQzNGQ4YzRkYjQwOTE5NTc4MGE4L3RleHRyZWdpb246NGJhYjIyZDgxYmViNDM0ZDhjNGRiNDA5MTk1NzgwYThfNTgxNg_9cd6b261-7545-4212-aa1b-1d7fc154eeb5" continuedAt="iad233f50287545b698bc3c703e8fbb8e" escape="true"><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the Company&#8217;s assets that were measured at fair value on a recurring basis, determined using the following inputs as of March&#160;31, 2021:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:35.796%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.541%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.541%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.737%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.689%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements at</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted Prices<br/>in Active Markets<br/>(Level&#160;1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Other Unobservable<br/>Inputs<br/>(Level&#160;2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Unobservable<br/>Inputs<br/>(Level&#160;3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Mutual funds</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id49e93fcdfff47499add351e50b2b851_I20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN181NS9mcmFnOjRiYWIyMmQ4MWJlYjQzNGQ4YzRkYjQwOTE5NTc4MGE4L3RhYmxlOmJjYzNkM2MwZTdmMjRiMjhhZTgxNTljYzc4MzViNDU3L3RhYmxlcmFuZ2U6YmNjM2QzYzBlN2YyNGIyOGFlODE1OWNjNzgzNWI0NTdfOS0xLTEtMS0w_19273a7c-18fa-49c8-a628-8669c99cc33a">228,949,156</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibb9d7da2bb9f4083a0f78f4d762e46e4_I20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN181NS9mcmFnOjRiYWIyMmQ4MWJlYjQzNGQ4YzRkYjQwOTE5NTc4MGE4L3RhYmxlOmJjYzNkM2MwZTdmMjRiMjhhZTgxNTljYzc4MzViNDU3L3RhYmxlcmFuZ2U6YmNjM2QzYzBlN2YyNGIyOGFlODE1OWNjNzgzNWI0NTdfOS0zLTEtMS0w_1cdfdba6-258b-456f-9622-c014ef201e56">228,949,156</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08f3093795f1462c897c6cadd1da8aed_I20210331" decimals="0" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN181NS9mcmFnOjRiYWIyMmQ4MWJlYjQzNGQ4YzRkYjQwOTE5NTc4MGE4L3RhYmxlOmJjYzNkM2MwZTdmMjRiMjhhZTgxNTljYzc4MzViNDU3L3RhYmxlcmFuZ2U6YmNjM2QzYzBlN2YyNGIyOGFlODE1OWNjNzgzNWI0NTdfOS01LTEtMS0w_3698d466-fcab-44f4-85ec-3fef9e6193b5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5e1a14b053e47c79b64277a69e380a9_I20210331" decimals="0" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN181NS9mcmFnOjRiYWIyMmQ4MWJlYjQzNGQ4YzRkYjQwOTE5NTc4MGE4L3RhYmxlOmJjYzNkM2MwZTdmMjRiMjhhZTgxNTljYzc4MzViNDU3L3RhYmxlcmFuZ2U6YmNjM2QzYzBlN2YyNGIyOGFlODE1OWNjNzgzNWI0NTdfOS03LTEtMS0w_3c9b3c4a-c9fd-4994-9ef7-dba5022ec50d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S. treasury securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8963e309e7dd4867bea8e9ee34e0a52b_I20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN181NS9mcmFnOjRiYWIyMmQ4MWJlYjQzNGQ4YzRkYjQwOTE5NTc4MGE4L3RhYmxlOmJjYzNkM2MwZTdmMjRiMjhhZTgxNTljYzc4MzViNDU3L3RhYmxlcmFuZ2U6YmNjM2QzYzBlN2YyNGIyOGFlODE1OWNjNzgzNWI0NTdfMTAtMS0xLTEtMjU2Mg_5a5dc029-fe7c-48fd-aad5-8597a2692c77">200,414,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4a6d945ad73450191ce911b7e550ccc_I20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN181NS9mcmFnOjRiYWIyMmQ4MWJlYjQzNGQ4YzRkYjQwOTE5NTc4MGE4L3RhYmxlOmJjYzNkM2MwZTdmMjRiMjhhZTgxNTljYzc4MzViNDU3L3RhYmxlcmFuZ2U6YmNjM2QzYzBlN2YyNGIyOGFlODE1OWNjNzgzNWI0NTdfMTAtMy0xLTEtMjU2Mg_e20c17e7-a74e-4d6a-bab0-68765af52bd7">200,414,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i22850f7499b2483f9428ba6cd51e1702_I20210331" decimals="0" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN181NS9mcmFnOjRiYWIyMmQ4MWJlYjQzNGQ4YzRkYjQwOTE5NTc4MGE4L3RhYmxlOmJjYzNkM2MwZTdmMjRiMjhhZTgxNTljYzc4MzViNDU3L3RhYmxlcmFuZ2U6YmNjM2QzYzBlN2YyNGIyOGFlODE1OWNjNzgzNWI0NTdfMTAtNS0xLTEtMjU2Mg_bf5220a6-f11a-4020-ab1b-649c1b742100">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7c31848f0e94bee88a97957caa0dac9_I20210331" decimals="0" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN181NS9mcmFnOjRiYWIyMmQ4MWJlYjQzNGQ4YzRkYjQwOTE5NTc4MGE4L3RhYmxlOmJjYzNkM2MwZTdmMjRiMjhhZTgxNTljYzc4MzViNDU3L3RhYmxlcmFuZ2U6YmNjM2QzYzBlN2YyNGIyOGFlODE1OWNjNzgzNWI0NTdfMTAtNy0xLTEtMjU2Mg_c325764d-e597-4db4-8525-057dd38dfaac">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Certificates of deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8576b8faf8064d92a55a1d7a9230294b_I20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN181NS9mcmFnOjRiYWIyMmQ4MWJlYjQzNGQ4YzRkYjQwOTE5NTc4MGE4L3RhYmxlOmJjYzNkM2MwZTdmMjRiMjhhZTgxNTljYzc4MzViNDU3L3RhYmxlcmFuZ2U6YmNjM2QzYzBlN2YyNGIyOGFlODE1OWNjNzgzNWI0NTdfMTEtMS0xLTEtMA_121d0d85-3895-4d10-8a82-bc15e6e23ec0">2,992,200</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i081a1114c57c4457a6e656fb47caa2fc_I20210331" decimals="0" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN181NS9mcmFnOjRiYWIyMmQ4MWJlYjQzNGQ4YzRkYjQwOTE5NTc4MGE4L3RhYmxlOmJjYzNkM2MwZTdmMjRiMjhhZTgxNTljYzc4MzViNDU3L3RhYmxlcmFuZ2U6YmNjM2QzYzBlN2YyNGIyOGFlODE1OWNjNzgzNWI0NTdfMTEtMy0xLTEtMA_6281a613-0329-4e5e-a5cb-9cc9cc8b484e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23aedffa2f0c42b9b43cb0b83beea039_I20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN181NS9mcmFnOjRiYWIyMmQ4MWJlYjQzNGQ4YzRkYjQwOTE5NTc4MGE4L3RhYmxlOmJjYzNkM2MwZTdmMjRiMjhhZTgxNTljYzc4MzViNDU3L3RhYmxlcmFuZ2U6YmNjM2QzYzBlN2YyNGIyOGFlODE1OWNjNzgzNWI0NTdfMTEtNS0xLTEtMA_8ed13903-9615-491e-8305-e2cc53232576">2,992,200</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia2a22ff53c7d437b9e4758ed1dd0655b_I20210331" decimals="0" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN181NS9mcmFnOjRiYWIyMmQ4MWJlYjQzNGQ4YzRkYjQwOTE5NTc4MGE4L3RhYmxlOmJjYzNkM2MwZTdmMjRiMjhhZTgxNTljYzc4MzViNDU3L3RhYmxlcmFuZ2U6YmNjM2QzYzBlN2YyNGIyOGFlODE1OWNjNzgzNWI0NTdfMTEtNy0xLTEtMA_260b1ab5-b817-439e-accc-c4abe472bfe9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S. agency mortgage-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i79f50420241043d0abd5aedb34d9926b_I20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN181NS9mcmFnOjRiYWIyMmQ4MWJlYjQzNGQ4YzRkYjQwOTE5NTc4MGE4L3RhYmxlOmJjYzNkM2MwZTdmMjRiMjhhZTgxNTljYzc4MzViNDU3L3RhYmxlcmFuZ2U6YmNjM2QzYzBlN2YyNGIyOGFlODE1OWNjNzgzNWI0NTdfMTItMS0xLTEtMA_96999ca8-9a5e-40a8-a434-167a5d29f838">2,614,172</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i700d1959d79f4c7891a22d010cdfd228_I20210331" decimals="0" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN181NS9mcmFnOjRiYWIyMmQ4MWJlYjQzNGQ4YzRkYjQwOTE5NTc4MGE4L3RhYmxlOmJjYzNkM2MwZTdmMjRiMjhhZTgxNTljYzc4MzViNDU3L3RhYmxlcmFuZ2U6YmNjM2QzYzBlN2YyNGIyOGFlODE1OWNjNzgzNWI0NTdfMTItMy0xLTEtMA_7040c3fa-75ea-46bc-a13b-9adf12a87ab9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic7b40fbbf0484fb98e57b0b99619b678_I20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN181NS9mcmFnOjRiYWIyMmQ4MWJlYjQzNGQ4YzRkYjQwOTE5NTc4MGE4L3RhYmxlOmJjYzNkM2MwZTdmMjRiMjhhZTgxNTljYzc4MzViNDU3L3RhYmxlcmFuZ2U6YmNjM2QzYzBlN2YyNGIyOGFlODE1OWNjNzgzNWI0NTdfMTItNS0xLTEtMA_51695ef9-3514-4875-ab8b-92afbf1aa8ca">2,614,172</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8736cce87614b07956326c0d9cc3035_I20210331" decimals="0" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN181NS9mcmFnOjRiYWIyMmQ4MWJlYjQzNGQ4YzRkYjQwOTE5NTc4MGE4L3RhYmxlOmJjYzNkM2MwZTdmMjRiMjhhZTgxNTljYzc4MzViNDU3L3RhYmxlcmFuZ2U6YmNjM2QzYzBlN2YyNGIyOGFlODE1OWNjNzgzNWI0NTdfMTItNy0xLTEtMA_07ed362a-2e63-40a2-8ef5-9487bc66e410">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total short-term investments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc037a18dec8422896679a520fe0751f_I20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN181NS9mcmFnOjRiYWIyMmQ4MWJlYjQzNGQ4YzRkYjQwOTE5NTc4MGE4L3RhYmxlOmJjYzNkM2MwZTdmMjRiMjhhZTgxNTljYzc4MzViNDU3L3RhYmxlcmFuZ2U6YmNjM2QzYzBlN2YyNGIyOGFlODE1OWNjNzgzNWI0NTdfMTMtMS0xLTEtMA_6fc6dc15-6a29-4326-892b-271bd0d7a9b4">434,969,528</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i950b0135e402482fae846256144517d6_I20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN181NS9mcmFnOjRiYWIyMmQ4MWJlYjQzNGQ4YzRkYjQwOTE5NTc4MGE4L3RhYmxlOmJjYzNkM2MwZTdmMjRiMjhhZTgxNTljYzc4MzViNDU3L3RhYmxlcmFuZ2U6YmNjM2QzYzBlN2YyNGIyOGFlODE1OWNjNzgzNWI0NTdfMTMtMy0xLTEtMA_ca5a4aa3-75f2-47c1-a1da-453bd9bafd58">429,363,156</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i536f602826fe46979bdba143abf2858a_I20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN181NS9mcmFnOjRiYWIyMmQ4MWJlYjQzNGQ4YzRkYjQwOTE5NTc4MGE4L3RhYmxlOmJjYzNkM2MwZTdmMjRiMjhhZTgxNTljYzc4MzViNDU3L3RhYmxlcmFuZ2U6YmNjM2QzYzBlN2YyNGIyOGFlODE1OWNjNzgzNWI0NTdfMTMtNS0xLTEtMA_ca083690-b187-4c39-be5c-a51063a6b2ae">5,606,372</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaef1617b1a33479ebd53313a3c7a7812_I20210331" decimals="0" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN181NS9mcmFnOjRiYWIyMmQ4MWJlYjQzNGQ4YzRkYjQwOTE5NTc4MGE4L3RhYmxlOmJjYzNkM2MwZTdmMjRiMjhhZTgxNTljYzc4MzViNDU3L3RhYmxlcmFuZ2U6YmNjM2QzYzBlN2YyNGIyOGFlODE1OWNjNzgzNWI0NTdfMTMtNy0xLTEtMA_5453be7d-c550-462c-9207-737a92755678">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment in affiliated entity</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc037a18dec8422896679a520fe0751f_I20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:EquitySecuritiesFvNi" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN181NS9mcmFnOjRiYWIyMmQ4MWJlYjQzNGQ4YzRkYjQwOTE5NTc4MGE4L3RhYmxlOmJjYzNkM2MwZTdmMjRiMjhhZTgxNTljYzc4MzViNDU3L3RhYmxlcmFuZ2U6YmNjM2QzYzBlN2YyNGIyOGFlODE1OWNjNzgzNWI0NTdfMTUtMS0xLTEtMA_f63c1fec-9ace-497e-bb6a-240b20f643df">3,629,891</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i950b0135e402482fae846256144517d6_I20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:EquitySecuritiesFvNi" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN181NS9mcmFnOjRiYWIyMmQ4MWJlYjQzNGQ4YzRkYjQwOTE5NTc4MGE4L3RhYmxlOmJjYzNkM2MwZTdmMjRiMjhhZTgxNTljYzc4MzViNDU3L3RhYmxlcmFuZ2U6YmNjM2QzYzBlN2YyNGIyOGFlODE1OWNjNzgzNWI0NTdfMTUtMy0xLTEtMA_0cb4c52e-7a26-4442-9a06-8a08c571aee1">3,629,891</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i536f602826fe46979bdba143abf2858a_I20210331" decimals="0" format="ixt:zerodash" name="us-gaap:EquitySecuritiesFvNi" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN181NS9mcmFnOjRiYWIyMmQ4MWJlYjQzNGQ4YzRkYjQwOTE5NTc4MGE4L3RhYmxlOmJjYzNkM2MwZTdmMjRiMjhhZTgxNTljYzc4MzViNDU3L3RhYmxlcmFuZ2U6YmNjM2QzYzBlN2YyNGIyOGFlODE1OWNjNzgzNWI0NTdfMTUtNS0xLTEtMA_07c7036e-8740-4f34-b5d1-5f260b31ee5e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaef1617b1a33479ebd53313a3c7a7812_I20210331" decimals="0" format="ixt:zerodash" name="us-gaap:EquitySecuritiesFvNi" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN181NS9mcmFnOjRiYWIyMmQ4MWJlYjQzNGQ4YzRkYjQwOTE5NTc4MGE4L3RhYmxlOmJjYzNkM2MwZTdmMjRiMjhhZTgxNTljYzc4MzViNDU3L3RhYmxlcmFuZ2U6YmNjM2QzYzBlN2YyNGIyOGFlODE1OWNjNzgzNWI0NTdfMTUtNy0xLTEtMA_ce037b0f-5e2c-4fe0-8154-bc6205eaace4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets measured at fair value</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc037a18dec8422896679a520fe0751f_I20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN181NS9mcmFnOjRiYWIyMmQ4MWJlYjQzNGQ4YzRkYjQwOTE5NTc4MGE4L3RhYmxlOmJjYzNkM2MwZTdmMjRiMjhhZTgxNTljYzc4MzViNDU3L3RhYmxlcmFuZ2U6YmNjM2QzYzBlN2YyNGIyOGFlODE1OWNjNzgzNWI0NTdfMTctMS0xLTEtMA_a5255c8a-b299-4728-b6c4-d200be455487">438,599,419</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i950b0135e402482fae846256144517d6_I20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN181NS9mcmFnOjRiYWIyMmQ4MWJlYjQzNGQ4YzRkYjQwOTE5NTc4MGE4L3RhYmxlOmJjYzNkM2MwZTdmMjRiMjhhZTgxNTljYzc4MzViNDU3L3RhYmxlcmFuZ2U6YmNjM2QzYzBlN2YyNGIyOGFlODE1OWNjNzgzNWI0NTdfMTctMy0xLTEtMA_fcc0fe07-e5e1-4603-80a8-7960e8656113">432,993,047</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i536f602826fe46979bdba143abf2858a_I20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN181NS9mcmFnOjRiYWIyMmQ4MWJlYjQzNGQ4YzRkYjQwOTE5NTc4MGE4L3RhYmxlOmJjYzNkM2MwZTdmMjRiMjhhZTgxNTljYzc4MzViNDU3L3RhYmxlcmFuZ2U6YmNjM2QzYzBlN2YyNGIyOGFlODE1OWNjNzgzNWI0NTdfMTctNS0xLTEtMA_6ed4ee92-1fd3-477d-b134-d44988ad55b4">5,606,372</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaef1617b1a33479ebd53313a3c7a7812_I20210331" decimals="0" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN181NS9mcmFnOjRiYWIyMmQ4MWJlYjQzNGQ4YzRkYjQwOTE5NTc4MGE4L3RhYmxlOmJjYzNkM2MwZTdmMjRiMjhhZTgxNTljYzc4MzViNDU3L3RhYmxlcmFuZ2U6YmNjM2QzYzBlN2YyNGIyOGFlODE1OWNjNzgzNWI0NTdfMTctNy0xLTEtMA_f77f1cd4-98f3-4e22-99b1-82db1537d935">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i97a6faf06d054771be82c148441cde0a"><ix:continuation id="iad233f50287545b698bc3c703e8fbb8e"><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the Company&#8217;s assets that were measured at fair value on a recurring basis, determined using the following inputs as of December&#160;31, 2020:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:35.796%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.541%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.541%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.737%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.689%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements at</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted Prices<br/>in Active Markets<br/>(Level&#160;1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Other Unobservable<br/>Inputs<br/>(Level&#160;2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Unobservable<br/>Inputs<br/>(Level&#160;3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S. treasury securities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i679e853e6cb64bb9bee2cde9c5fa48ab_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN181NS9mcmFnOjRiYWIyMmQ4MWJlYjQzNGQ4YzRkYjQwOTE5NTc4MGE4L3RhYmxlOjM3OThiYWExNDZkZTQ4OWVhOGUwOTU3OTUyNzRhOGE4L3RhYmxlcmFuZ2U6Mzc5OGJhYTE0NmRlNDg5ZWE4ZTA5NTc5NTI3NGE4YThfNS0xLTEtMS0w_63c34413-322e-428f-8e5d-fdf28ab944da">59,996,800</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i95f3040264524bd7aafa7c66012a9ed0_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN181NS9mcmFnOjRiYWIyMmQ4MWJlYjQzNGQ4YzRkYjQwOTE5NTc4MGE4L3RhYmxlOjM3OThiYWExNDZkZTQ4OWVhOGUwOTU3OTUyNzRhOGE4L3RhYmxlcmFuZ2U6Mzc5OGJhYTE0NmRlNDg5ZWE4ZTA5NTc5NTI3NGE4YThfNS0zLTEtMS0w_e0bc58ab-2ef5-4db2-bcb2-0f96adca727a">59,996,800</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i77ffd233d1de4e33aa7330413610496e_I20201231" decimals="0" format="ixt:zerodash" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN181NS9mcmFnOjRiYWIyMmQ4MWJlYjQzNGQ4YzRkYjQwOTE5NTc4MGE4L3RhYmxlOjM3OThiYWExNDZkZTQ4OWVhOGUwOTU3OTUyNzRhOGE4L3RhYmxlcmFuZ2U6Mzc5OGJhYTE0NmRlNDg5ZWE4ZTA5NTc5NTI3NGE4YThfNS01LTEtMS0w_83a88f8a-8495-4eca-8c34-01126a033c38">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0d4dc3c347a44199532a6ee4469f31e_I20201231" decimals="0" format="ixt:zerodash" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN181NS9mcmFnOjRiYWIyMmQ4MWJlYjQzNGQ4YzRkYjQwOTE5NTc4MGE4L3RhYmxlOjM3OThiYWExNDZkZTQ4OWVhOGUwOTU3OTUyNzRhOGE4L3RhYmxlcmFuZ2U6Mzc5OGJhYTE0NmRlNDg5ZWE4ZTA5NTc5NTI3NGE4YThfNS03LTEtMS0w_ee548533-54db-4538-8814-346fd3c77fa4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Mutual funds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i765820c859204f75a1eaeb4f280fd337_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN181NS9mcmFnOjRiYWIyMmQ4MWJlYjQzNGQ4YzRkYjQwOTE5NTc4MGE4L3RhYmxlOjM3OThiYWExNDZkZTQ4OWVhOGUwOTU3OTUyNzRhOGE4L3RhYmxlcmFuZ2U6Mzc5OGJhYTE0NmRlNDg5ZWE4ZTA5NTc5NTI3NGE4YThfOC0xLTEtMS0w_166dc0b0-2f8c-4f02-9122-01c383d905d8">154,873,174</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i42280087f6b44742aa1b7f2971c27575_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN181NS9mcmFnOjRiYWIyMmQ4MWJlYjQzNGQ4YzRkYjQwOTE5NTc4MGE4L3RhYmxlOjM3OThiYWExNDZkZTQ4OWVhOGUwOTU3OTUyNzRhOGE4L3RhYmxlcmFuZ2U6Mzc5OGJhYTE0NmRlNDg5ZWE4ZTA5NTc5NTI3NGE4YThfOC0zLTEtMS0w_9c7a773a-87c7-439b-b7b1-d6da3c611410">154,873,174</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifcda11a978e44c92b373b4913520b88b_I20201231" decimals="0" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN181NS9mcmFnOjRiYWIyMmQ4MWJlYjQzNGQ4YzRkYjQwOTE5NTc4MGE4L3RhYmxlOjM3OThiYWExNDZkZTQ4OWVhOGUwOTU3OTUyNzRhOGE4L3RhYmxlcmFuZ2U6Mzc5OGJhYTE0NmRlNDg5ZWE4ZTA5NTc5NTI3NGE4YThfOC01LTEtMS0w_97a47f84-f7bb-498e-ac01-5895375cc158">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i691500b3ba21482aa5fe5467025f71c3_I20201231" decimals="0" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN181NS9mcmFnOjRiYWIyMmQ4MWJlYjQzNGQ4YzRkYjQwOTE5NTc4MGE4L3RhYmxlOjM3OThiYWExNDZkZTQ4OWVhOGUwOTU3OTUyNzRhOGE4L3RhYmxlcmFuZ2U6Mzc5OGJhYTE0NmRlNDg5ZWE4ZTA5NTc5NTI3NGE4YThfOC03LTEtMS0w_1abc2501-6e0b-4735-8c14-d4cce2bea89c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Certificates of deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b31046c5de349d1937a204cdc2973ae_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN181NS9mcmFnOjRiYWIyMmQ4MWJlYjQzNGQ4YzRkYjQwOTE5NTc4MGE4L3RhYmxlOjM3OThiYWExNDZkZTQ4OWVhOGUwOTU3OTUyNzRhOGE4L3RhYmxlcmFuZ2U6Mzc5OGJhYTE0NmRlNDg5ZWE4ZTA5NTc5NTI3NGE4YThfOS0xLTEtMS0w_dc45ee87-dda7-409b-8021-fdbae94f34d2">3,016,260</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="iaaf44a738a1345828679d9a1b25f8327_I20201231" xsi:nil="true" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN181NS9mcmFnOjRiYWIyMmQ4MWJlYjQzNGQ4YzRkYjQwOTE5NTc4MGE4L3RhYmxlOjM3OThiYWExNDZkZTQ4OWVhOGUwOTU3OTUyNzRhOGE4L3RhYmxlcmFuZ2U6Mzc5OGJhYTE0NmRlNDg5ZWE4ZTA5NTc5NTI3NGE4YThfOS0zLTEtMS0w_729c3015-8899-42ab-bd58-248f719b49ce"></ix:nonFraction></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie2357d9b866e4be7afcd9fe0ac4e6a56_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN181NS9mcmFnOjRiYWIyMmQ4MWJlYjQzNGQ4YzRkYjQwOTE5NTc4MGE4L3RhYmxlOjM3OThiYWExNDZkZTQ4OWVhOGUwOTU3OTUyNzRhOGE4L3RhYmxlcmFuZ2U6Mzc5OGJhYTE0NmRlNDg5ZWE4ZTA5NTc5NTI3NGE4YThfOS01LTEtMS0w_e093fd3c-8ed1-45e6-981d-3622a647543b">3,016,260</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8501b73ca4034d94b92aab9e80a10e2f_I20201231" decimals="0" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN181NS9mcmFnOjRiYWIyMmQ4MWJlYjQzNGQ4YzRkYjQwOTE5NTc4MGE4L3RhYmxlOjM3OThiYWExNDZkZTQ4OWVhOGUwOTU3OTUyNzRhOGE4L3RhYmxlcmFuZ2U6Mzc5OGJhYTE0NmRlNDg5ZWE4ZTA5NTc5NTI3NGE4YThfOS03LTEtMS0w_11361dbb-6010-4498-9779-139f342df847">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S. agency mortgage-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2921a4efcf7f4fc1bbbf11dcd4e24dc8_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN181NS9mcmFnOjRiYWIyMmQ4MWJlYjQzNGQ4YzRkYjQwOTE5NTc4MGE4L3RhYmxlOjM3OThiYWExNDZkZTQ4OWVhOGUwOTU3OTUyNzRhOGE4L3RhYmxlcmFuZ2U6Mzc5OGJhYTE0NmRlNDg5ZWE4ZTA5NTc5NTI3NGE4YThfMTAtMS0xLTEtMA_c9725b3c-732e-4a7a-908d-a323fed96a7c">3,025,501</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i165dd8f0bd4343b5b394ee5a10eee714_I20201231" decimals="0" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN181NS9mcmFnOjRiYWIyMmQ4MWJlYjQzNGQ4YzRkYjQwOTE5NTc4MGE4L3RhYmxlOjM3OThiYWExNDZkZTQ4OWVhOGUwOTU3OTUyNzRhOGE4L3RhYmxlcmFuZ2U6Mzc5OGJhYTE0NmRlNDg5ZWE4ZTA5NTc5NTI3NGE4YThfMTAtMy0xLTEtMA_49096d96-3e0d-4c2f-b84b-d3f019356447">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc90ce5aa5c04e718823e5f0bfad97e7_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN181NS9mcmFnOjRiYWIyMmQ4MWJlYjQzNGQ4YzRkYjQwOTE5NTc4MGE4L3RhYmxlOjM3OThiYWExNDZkZTQ4OWVhOGUwOTU3OTUyNzRhOGE4L3RhYmxlcmFuZ2U6Mzc5OGJhYTE0NmRlNDg5ZWE4ZTA5NTc5NTI3NGE4YThfMTAtNS0xLTEtMA_5cc43ef4-7821-4682-967c-2fafce8e8b7c">3,025,501</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a4a04a42ab7478daf3585b30a5dc600_I20201231" decimals="0" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN181NS9mcmFnOjRiYWIyMmQ4MWJlYjQzNGQ4YzRkYjQwOTE5NTc4MGE4L3RhYmxlOjM3OThiYWExNDZkZTQ4OWVhOGUwOTU3OTUyNzRhOGE4L3RhYmxlcmFuZ2U6Mzc5OGJhYTE0NmRlNDg5ZWE4ZTA5NTc5NTI3NGE4YThfMTAtNy0xLTEtMA_ca832da8-e6b7-438b-9f0a-58412e9f77bc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total short-term investments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b1d59d5ed834f6b91384f272748379f_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN181NS9mcmFnOjRiYWIyMmQ4MWJlYjQzNGQ4YzRkYjQwOTE5NTc4MGE4L3RhYmxlOjM3OThiYWExNDZkZTQ4OWVhOGUwOTU3OTUyNzRhOGE4L3RhYmxlcmFuZ2U6Mzc5OGJhYTE0NmRlNDg5ZWE4ZTA5NTc5NTI3NGE4YThfMTItMS0xLTEtMjg5OA_99ca1117-6176-4d59-bc8a-41af82f705de">160,914,935</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea068b74107644b3a5e86a21d960799f_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN181NS9mcmFnOjRiYWIyMmQ4MWJlYjQzNGQ4YzRkYjQwOTE5NTc4MGE4L3RhYmxlOjM3OThiYWExNDZkZTQ4OWVhOGUwOTU3OTUyNzRhOGE4L3RhYmxlcmFuZ2U6Mzc5OGJhYTE0NmRlNDg5ZWE4ZTA5NTc5NTI3NGE4YThfMTItMy0xLTEtMjg5OA_8e210a4b-429d-477b-8559-23c3aba92350">154,873,174</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9eeb5e9d4f914f2591ba8b7f2f2631da_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN181NS9mcmFnOjRiYWIyMmQ4MWJlYjQzNGQ4YzRkYjQwOTE5NTc4MGE4L3RhYmxlOjM3OThiYWExNDZkZTQ4OWVhOGUwOTU3OTUyNzRhOGE4L3RhYmxlcmFuZ2U6Mzc5OGJhYTE0NmRlNDg5ZWE4ZTA5NTc5NTI3NGE4YThfMTItNS0xLTEtMjg5OA_e24bdda8-3ff3-4f7e-8629-0dd7aa78d8ac">6,041,761</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57bed7dd45b14e9f953dd397ed3bdce9_I20201231" decimals="0" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN181NS9mcmFnOjRiYWIyMmQ4MWJlYjQzNGQ4YzRkYjQwOTE5NTc4MGE4L3RhYmxlOjM3OThiYWExNDZkZTQ4OWVhOGUwOTU3OTUyNzRhOGE4L3RhYmxlcmFuZ2U6Mzc5OGJhYTE0NmRlNDg5ZWE4ZTA5NTc5NTI3NGE4YThfMTItNy0xLTEtMjg5OA_6b8c92d5-1f9f-42e3-863d-e8139c668810">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment in affiliated entities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b1d59d5ed834f6b91384f272748379f_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:EquitySecuritiesFvNi" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN181NS9mcmFnOjRiYWIyMmQ4MWJlYjQzNGQ4YzRkYjQwOTE5NTc4MGE4L3RhYmxlOjM3OThiYWExNDZkZTQ4OWVhOGUwOTU3OTUyNzRhOGE4L3RhYmxlcmFuZ2U6Mzc5OGJhYTE0NmRlNDg5ZWE4ZTA5NTc5NTI3NGE4YThfMTMtMS0xLTEtMA_45ba6e3e-08f1-482f-84d2-00017a640560">4,460,366</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea068b74107644b3a5e86a21d960799f_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:EquitySecuritiesFvNi" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN181NS9mcmFnOjRiYWIyMmQ4MWJlYjQzNGQ4YzRkYjQwOTE5NTc4MGE4L3RhYmxlOjM3OThiYWExNDZkZTQ4OWVhOGUwOTU3OTUyNzRhOGE4L3RhYmxlcmFuZ2U6Mzc5OGJhYTE0NmRlNDg5ZWE4ZTA5NTc5NTI3NGE4YThfMTMtMy0xLTEtMA_46cddb5c-6524-44e0-9c88-c46d9bb83d99">4,460,366</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9eeb5e9d4f914f2591ba8b7f2f2631da_I20201231" decimals="0" format="ixt:zerodash" name="us-gaap:EquitySecuritiesFvNi" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN181NS9mcmFnOjRiYWIyMmQ4MWJlYjQzNGQ4YzRkYjQwOTE5NTc4MGE4L3RhYmxlOjM3OThiYWExNDZkZTQ4OWVhOGUwOTU3OTUyNzRhOGE4L3RhYmxlcmFuZ2U6Mzc5OGJhYTE0NmRlNDg5ZWE4ZTA5NTc5NTI3NGE4YThfMTMtNS0xLTEtMA_a43ad605-1376-4055-986b-817f02095481">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57bed7dd45b14e9f953dd397ed3bdce9_I20201231" decimals="0" format="ixt:zerodash" name="us-gaap:EquitySecuritiesFvNi" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN181NS9mcmFnOjRiYWIyMmQ4MWJlYjQzNGQ4YzRkYjQwOTE5NTc4MGE4L3RhYmxlOjM3OThiYWExNDZkZTQ4OWVhOGUwOTU3OTUyNzRhOGE4L3RhYmxlcmFuZ2U6Mzc5OGJhYTE0NmRlNDg5ZWE4ZTA5NTc5NTI3NGE4YThfMTMtNy0xLTEtMA_278de89e-41bf-4ecc-b7a8-48b654f12163">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets measured at fair value</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b1d59d5ed834f6b91384f272748379f_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN181NS9mcmFnOjRiYWIyMmQ4MWJlYjQzNGQ4YzRkYjQwOTE5NTc4MGE4L3RhYmxlOjM3OThiYWExNDZkZTQ4OWVhOGUwOTU3OTUyNzRhOGE4L3RhYmxlcmFuZ2U6Mzc5OGJhYTE0NmRlNDg5ZWE4ZTA5NTc5NTI3NGE4YThfMTUtMS0xLTEtMA_af842d24-848c-49f5-885e-f829456cf057">225,372,101</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea068b74107644b3a5e86a21d960799f_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN181NS9mcmFnOjRiYWIyMmQ4MWJlYjQzNGQ4YzRkYjQwOTE5NTc4MGE4L3RhYmxlOjM3OThiYWExNDZkZTQ4OWVhOGUwOTU3OTUyNzRhOGE4L3RhYmxlcmFuZ2U6Mzc5OGJhYTE0NmRlNDg5ZWE4ZTA5NTc5NTI3NGE4YThfMTUtMy0xLTEtMA_5f3c7968-a506-4cf6-9b8d-eacb35480be9">219,330,340</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9eeb5e9d4f914f2591ba8b7f2f2631da_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN181NS9mcmFnOjRiYWIyMmQ4MWJlYjQzNGQ4YzRkYjQwOTE5NTc4MGE4L3RhYmxlOjM3OThiYWExNDZkZTQ4OWVhOGUwOTU3OTUyNzRhOGE4L3RhYmxlcmFuZ2U6Mzc5OGJhYTE0NmRlNDg5ZWE4ZTA5NTc5NTI3NGE4YThfMTUtNS0xLTEtMA_f6f55f44-d167-48f8-9fc1-f9fd007ff4d5">6,041,761</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57bed7dd45b14e9f953dd397ed3bdce9_I20201231" decimals="0" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN181NS9mcmFnOjRiYWIyMmQ4MWJlYjQzNGQ4YzRkYjQwOTE5NTc4MGE4L3RhYmxlOjM3OThiYWExNDZkZTQ4OWVhOGUwOTU3OTUyNzRhOGE4L3RhYmxlcmFuZ2U6Mzc5OGJhYTE0NmRlNDg5ZWE4ZTA5NTc5NTI3NGE4YThfMTUtNy0xLTEtMA_18738026-131c-40c4-8645-d6ae37f95e5e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:continuation><div><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Level 1 assets at March&#160;31, 2021 consisted of mutual funds and U.S. treasury securities held by the Company that are valued at quoted market prices, as well as the Company&#8217;s investment in its affiliated entity, PLS. The Company accounts for its investment in <ix:nonFraction unitRef="shares" contextRef="i0cce4e82b88342c787d49f1a7ed20009_I20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:InvestmentOwnedBalanceShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN181NS9mcmFnOjRiYWIyMmQ4MWJlYjQzNGQ4YzRkYjQwOTE5NTc4MGE4L3RleHRyZWdpb246NGJhYjIyZDgxYmViNDM0ZDhjNGRiNDA5MTk1NzgwYThfMTg2Nw_56f50889-8ff4-43eb-9b4e-25ba72fa7570">597,808</ix:nonFraction> common shares of PLS based on the closing price of the shares on the Korea New Exchange Market on the applicable balance sheet date. Unrealized gains and losses on the Company's equity securities are reported in the condensed consolidated statement of ope</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">rations as unrealized gain (loss) on available-for-sale equity securities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">or as a gain (loss) on investment in affiliated entities.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 2 assets at March&#160;31, 2021 consisted of certificates of deposit and U.S. agency mortgage-backed securities held by the Company that are initially valued at the transaction price and subsequently valued, at the end of each reporting period, typically utilizing market observable data. The Company obtains the fair value of its Level 2 assets from a professional pricing service, which may use quoted market prices for identical or comparable instruments, or inputs other than quoted prices that are observable either directly or indirectly. The professional pricing service gathers quoted market prices and observable inputs from a variety of industry data providers. The valuation techniques used to measure the fair value of the Company's Level 2 financial instruments were derived from non-binding market consensus prices that are corroborated by observable market data, quoted market prices for similar instruments, or pricing models such as discounted cash flow techniques. The Company validates the quoted market prices provided by the primary pricing service by comparing the service's assessment of the fair values of the Company's investment portfolio balance against the fair values of the Company's investment portfolio balance obtained from an independent source.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no Level 3 assets held as of March&#160;31, 2021.</span></div></ix:continuation><div style="margin-bottom:10pt;margin-top:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:79.455%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.345%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div id="i1d23d16a69484b63aa007ec686e80337_58"></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">8. <ix:nonNumeric contextRef="i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331" name="us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN181OC9mcmFnOjI1NjFhMjhkNjFlNTRlMDBhYzE0ZDI2YWM3ODA3OTY2L3RleHRyZWdpb246MjU2MWEyOGQ2MWU1NGUwMGFjMTRkMjZhYzc4MDc5NjZfOTg2_d3d089f0-c854-457b-a8a0-2dbcbd87bfff" continuedAt="i6ec1126b18ec43038abf48f257535ca6" escape="true">Goodwill and Intangible Assets</ix:nonNumeric></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i6ec1126b18ec43038abf48f257535ca6" continuedAt="i9f53d65f20be4727ad71f4283c5a130a"><ix:nonNumeric contextRef="i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331" name="us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN181OC9mcmFnOjI1NjFhMjhkNjFlNTRlMDBhYzE0ZDI2YWM3ODA3OTY2L3RleHRyZWdpb246MjU2MWEyOGQ2MWU1NGUwMGFjMTRkMjZhYzc4MDc5NjZfOTY4_b01319bd-0823-4539-bfa6-827bfc4266e4" continuedAt="i86509a9534ae44d6a6a94d598d85a7e7" escape="true"><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following sets forth the goodwill and intangible assets by major asset class:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:18.870%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.535%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.206%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.060%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.060%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.918%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr style="height:45pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average Useful<br/>Life<br/>(Yrs)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Book<br/>Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Book<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indefinite lived:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill(a)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic36b9cedad7f41a6b9eb223b09b7186c_I20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:GoodwillGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN181OC9mcmFnOjI1NjFhMjhkNjFlNTRlMDBhYzE0ZDI2YWM3ODA3OTY2L3RhYmxlOjZhN2QxMDQ5OTk3YjQyNTNiMmJhOGVlYmI4M2VlOTVkL3RhYmxlcmFuZ2U6NmE3ZDEwNDk5OTdiNDI1M2IyYmE4ZWViYjgzZWU5NWRfMy0zLTEtMS0w_71569106-35fb-4ebf-9f16-7abf2dbf610c">10,513,371</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic36b9cedad7f41a6b9eb223b09b7186c_I20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN181OC9mcmFnOjI1NjFhMjhkNjFlNTRlMDBhYzE0ZDI2YWM3ODA3OTY2L3RhYmxlOjZhN2QxMDQ5OTk3YjQyNTNiMmJhOGVlYmI4M2VlOTVkL3RhYmxlcmFuZ2U6NmE3ZDEwNDk5OTdiNDI1M2IyYmE4ZWViYjgzZWU5NWRfMy03LTEtMS0w_7691b035-c856-47c6-8ad9-7d7d0cce9fd5">10,513,371</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i066bb5b0a9e84c0a878b1e800703d92b_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:GoodwillGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN181OC9mcmFnOjI1NjFhMjhkNjFlNTRlMDBhYzE0ZDI2YWM3ODA3OTY2L3RhYmxlOjZhN2QxMDQ5OTk3YjQyNTNiMmJhOGVlYmI4M2VlOTVkL3RhYmxlcmFuZ2U6NmE3ZDEwNDk5OTdiNDI1M2IyYmE4ZWViYjgzZWU5NWRfMy05LTEtMS0w_86e91bab-0d48-4f64-a3f9-63243e5e55fc">10,513,371</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i066bb5b0a9e84c0a878b1e800703d92b_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN181OC9mcmFnOjI1NjFhMjhkNjFlNTRlMDBhYzE0ZDI2YWM3ODA3OTY2L3RhYmxlOjZhN2QxMDQ5OTk3YjQyNTNiMmJhOGVlYmI4M2VlOTVkL3RhYmxlcmFuZ2U6NmE3ZDEwNDk5OTdiNDI1M2IyYmE4ZWViYjgzZWU5NWRfMy0xMy0xLTEtMA_2d478d11-59ab-4ecb-9168-4cf06f4adb66">10,513,371</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Definite lived:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Licenses</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="id00cf7a7665d4381ba225961343d2ea4_D20210101-20210331" format="ixt-sec:duryear" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN181OC9mcmFnOjI1NjFhMjhkNjFlNTRlMDBhYzE0ZDI2YWM3ODA3OTY2L3RhYmxlOjZhN2QxMDQ5OTk3YjQyNTNiMmJhOGVlYmI4M2VlOTVkL3RhYmxlcmFuZ2U6NmE3ZDEwNDk5OTdiNDI1M2IyYmE4ZWViYjgzZWU5NWRfNi0xLTEtMS0w_51f727d4-c337-4839-b94e-ce84d7fc3361">10</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff289276fdba4033befe45d8c121487e_I20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN181OC9mcmFnOjI1NjFhMjhkNjFlNTRlMDBhYzE0ZDI2YWM3ODA3OTY2L3RhYmxlOjZhN2QxMDQ5OTk3YjQyNTNiMmJhOGVlYmI4M2VlOTVkL3RhYmxlcmFuZ2U6NmE3ZDEwNDk5OTdiNDI1M2IyYmE4ZWViYjgzZWU5NWRfNi0zLTEtMS0w_6c1a4ebc-08dc-466d-a462-5d57d6af6e9a">1,323,761</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iff289276fdba4033befe45d8c121487e_I20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN181OC9mcmFnOjI1NjFhMjhkNjFlNTRlMDBhYzE0ZDI2YWM3ODA3OTY2L3RhYmxlOjZhN2QxMDQ5OTk3YjQyNTNiMmJhOGVlYmI4M2VlOTVkL3RhYmxlcmFuZ2U6NmE3ZDEwNDk5OTdiNDI1M2IyYmE4ZWViYjgzZWU5NWRfNi01LTEtMS0w_3ddd97a2-bce1-499a-8e47-b618d49f2e43">1,284,039</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff289276fdba4033befe45d8c121487e_I20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN181OC9mcmFnOjI1NjFhMjhkNjFlNTRlMDBhYzE0ZDI2YWM3ODA3OTY2L3RhYmxlOjZhN2QxMDQ5OTk3YjQyNTNiMmJhOGVlYmI4M2VlOTVkL3RhYmxlcmFuZ2U6NmE3ZDEwNDk5OTdiNDI1M2IyYmE4ZWViYjgzZWU5NWRfNi03LTEtMS0w_826771ed-27ef-4e85-85c0-f1bbd220c741">39,722</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i545fa05cd5804fa9a426a541fbe08f6d_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN181OC9mcmFnOjI1NjFhMjhkNjFlNTRlMDBhYzE0ZDI2YWM3ODA3OTY2L3RhYmxlOjZhN2QxMDQ5OTk3YjQyNTNiMmJhOGVlYmI4M2VlOTVkL3RhYmxlcmFuZ2U6NmE3ZDEwNDk5OTdiNDI1M2IyYmE4ZWViYjgzZWU5NWRfNi05LTEtMS0w_7a0326ab-7542-4f66-bc9f-87e441fd1cd2">1,323,761</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i545fa05cd5804fa9a426a541fbe08f6d_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN181OC9mcmFnOjI1NjFhMjhkNjFlNTRlMDBhYzE0ZDI2YWM3ODA3OTY2L3RhYmxlOjZhN2QxMDQ5OTk3YjQyNTNiMmJhOGVlYmI4M2VlOTVkL3RhYmxlcmFuZ2U6NmE3ZDEwNDk5OTdiNDI1M2IyYmE4ZWViYjgzZWU5NWRfNi0xMS0xLTEtMA_d1484422-1cb1-49b7-8dfd-4567196cded7">1,276,852</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i545fa05cd5804fa9a426a541fbe08f6d_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN181OC9mcmFnOjI1NjFhMjhkNjFlNTRlMDBhYzE0ZDI2YWM3ODA3OTY2L3RhYmxlOjZhN2QxMDQ5OTk3YjQyNTNiMmJhOGVlYmI4M2VlOTVkL3RhYmxlcmFuZ2U6NmE3ZDEwNDk5OTdiNDI1M2IyYmE4ZWViYjgzZWU5NWRfNi0xMy0xLTEtMA_dace161a-8723-444a-82b8-0fc7beef0aee">46,909</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bioject(b)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i677b4aa23e734ea1ae840c65c0f2ac0c_D20210101-20210331" format="ixt-sec:duryear" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN181OC9mcmFnOjI1NjFhMjhkNjFlNTRlMDBhYzE0ZDI2YWM3ODA3OTY2L3RhYmxlOjZhN2QxMDQ5OTk3YjQyNTNiMmJhOGVlYmI4M2VlOTVkL3RhYmxlcmFuZ2U6NmE3ZDEwNDk5OTdiNDI1M2IyYmE4ZWViYjgzZWU5NWRfOS0xLTEtMS0w_95419027-e188-4635-895e-e95d46110996">12</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87af82b668704e509e894f5e917c76ee_I20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN181OC9mcmFnOjI1NjFhMjhkNjFlNTRlMDBhYzE0ZDI2YWM3ODA3OTY2L3RhYmxlOjZhN2QxMDQ5OTk3YjQyNTNiMmJhOGVlYmI4M2VlOTVkL3RhYmxlcmFuZ2U6NmE3ZDEwNDk5OTdiNDI1M2IyYmE4ZWViYjgzZWU5NWRfOS0zLTEtMS0w_a6fe5c66-b585-4242-9450-45b5f3adb86d">5,100,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i87af82b668704e509e894f5e917c76ee_I20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN181OC9mcmFnOjI1NjFhMjhkNjFlNTRlMDBhYzE0ZDI2YWM3ODA3OTY2L3RhYmxlOjZhN2QxMDQ5OTk3YjQyNTNiMmJhOGVlYmI4M2VlOTVkL3RhYmxlcmFuZ2U6NmE3ZDEwNDk5OTdiNDI1M2IyYmE4ZWViYjgzZWU5NWRfOS01LTEtMS0w_d77e5094-260f-4041-bf13-784c359f5d5d">2,542,222</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87af82b668704e509e894f5e917c76ee_I20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN181OC9mcmFnOjI1NjFhMjhkNjFlNTRlMDBhYzE0ZDI2YWM3ODA3OTY2L3RhYmxlOjZhN2QxMDQ5OTk3YjQyNTNiMmJhOGVlYmI4M2VlOTVkL3RhYmxlcmFuZ2U6NmE3ZDEwNDk5OTdiNDI1M2IyYmE4ZWViYjgzZWU5NWRfOS03LTEtMS0w_389c8307-cedc-46cf-9202-edc941c22d68">2,557,778</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icc09668324be44f4a3c6526161d237ec_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN181OC9mcmFnOjI1NjFhMjhkNjFlNTRlMDBhYzE0ZDI2YWM3ODA3OTY2L3RhYmxlOjZhN2QxMDQ5OTk3YjQyNTNiMmJhOGVlYmI4M2VlOTVkL3RhYmxlcmFuZ2U6NmE3ZDEwNDk5OTdiNDI1M2IyYmE4ZWViYjgzZWU5NWRfOS05LTEtMS0w_22867cd1-5ccb-4234-95ad-ae4025777d4a">5,100,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icc09668324be44f4a3c6526161d237ec_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN181OC9mcmFnOjI1NjFhMjhkNjFlNTRlMDBhYzE0ZDI2YWM3ODA3OTY2L3RhYmxlOjZhN2QxMDQ5OTk3YjQyNTNiMmJhOGVlYmI4M2VlOTVkL3RhYmxlcmFuZ2U6NmE3ZDEwNDk5OTdiNDI1M2IyYmE4ZWViYjgzZWU5NWRfOS0xMS0xLTEtMA_5f37f3ab-dfa5-44c3-b337-092063faa5a5">2,468,889</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icc09668324be44f4a3c6526161d237ec_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN181OC9mcmFnOjI1NjFhMjhkNjFlNTRlMDBhYzE0ZDI2YWM3ODA3OTY2L3RhYmxlOjZhN2QxMDQ5OTk3YjQyNTNiMmJhOGVlYmI4M2VlOTVkL3RhYmxlcmFuZ2U6NmE3ZDEwNDk5OTdiNDI1M2IyYmE4ZWViYjgzZWU5NWRfOS0xMy0xLTEtMA_c8601ae0-3a59-4273-98ea-05481cc3deed">2,631,111</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other(c)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i1bf527072286443a829aab2684009143_D20210101-20210331" format="ixt-sec:duryear" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN181OC9mcmFnOjI1NjFhMjhkNjFlNTRlMDBhYzE0ZDI2YWM3ODA3OTY2L3RhYmxlOjZhN2QxMDQ5OTk3YjQyNTNiMmJhOGVlYmI4M2VlOTVkL3RhYmxlcmFuZ2U6NmE3ZDEwNDk5OTdiNDI1M2IyYmE4ZWViYjgzZWU5NWRfMTAtMS0xLTEtMA_fa1f74fa-bb3d-4e9a-9993-50d4759f7853">18</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i04d8063070ed47dca91d948e0b527543_I20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN181OC9mcmFnOjI1NjFhMjhkNjFlNTRlMDBhYzE0ZDI2YWM3ODA3OTY2L3RhYmxlOjZhN2QxMDQ5OTk3YjQyNTNiMmJhOGVlYmI4M2VlOTVkL3RhYmxlcmFuZ2U6NmE3ZDEwNDk5OTdiNDI1M2IyYmE4ZWViYjgzZWU5NWRfMTAtMy0xLTEtMA_af581e90-0a6c-4cef-84f3-c95313c75573">4,050,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i04d8063070ed47dca91d948e0b527543_I20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN181OC9mcmFnOjI1NjFhMjhkNjFlNTRlMDBhYzE0ZDI2YWM3ODA3OTY2L3RhYmxlOjZhN2QxMDQ5OTk3YjQyNTNiMmJhOGVlYmI4M2VlOTVkL3RhYmxlcmFuZ2U6NmE3ZDEwNDk5OTdiNDI1M2IyYmE4ZWViYjgzZWU5NWRfMTAtNS0xLTEtMA_ab30542e-2260-4ed7-b911-44b7407ed703">3,637,500</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i04d8063070ed47dca91d948e0b527543_I20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN181OC9mcmFnOjI1NjFhMjhkNjFlNTRlMDBhYzE0ZDI2YWM3ODA3OTY2L3RhYmxlOjZhN2QxMDQ5OTk3YjQyNTNiMmJhOGVlYmI4M2VlOTVkL3RhYmxlcmFuZ2U6NmE3ZDEwNDk5OTdiNDI1M2IyYmE4ZWViYjgzZWU5NWRfMTAtNy0xLTEtMA_07fb123b-2668-467a-b646-1642ccb24da3">412,500</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9898566a542a49b4bf69010ae439ab9a_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN181OC9mcmFnOjI1NjFhMjhkNjFlNTRlMDBhYzE0ZDI2YWM3ODA3OTY2L3RhYmxlOjZhN2QxMDQ5OTk3YjQyNTNiMmJhOGVlYmI4M2VlOTVkL3RhYmxlcmFuZ2U6NmE3ZDEwNDk5OTdiNDI1M2IyYmE4ZWViYjgzZWU5NWRfMTAtOS0xLTEtMA_9e46a0bc-0e61-4669-b41c-1087df2f50bf">4,050,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9898566a542a49b4bf69010ae439ab9a_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN181OC9mcmFnOjI1NjFhMjhkNjFlNTRlMDBhYzE0ZDI2YWM3ODA3OTY2L3RhYmxlOjZhN2QxMDQ5OTk3YjQyNTNiMmJhOGVlYmI4M2VlOTVkL3RhYmxlcmFuZ2U6NmE3ZDEwNDk5OTdiNDI1M2IyYmE4ZWViYjgzZWU5NWRfMTAtMTEtMS0xLTA_de1c81df-380e-4dc1-97c6-700bc6f65dc3">3,581,250</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9898566a542a49b4bf69010ae439ab9a_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN181OC9mcmFnOjI1NjFhMjhkNjFlNTRlMDBhYzE0ZDI2YWM3ODA3OTY2L3RhYmxlOjZhN2QxMDQ5OTk3YjQyNTNiMmJhOGVlYmI4M2VlOTVkL3RhYmxlcmFuZ2U6NmE3ZDEwNDk5OTdiNDI1M2IyYmE4ZWViYjgzZWU5NWRfMTAtMTMtMS0xLTA_81e5212f-fb78-4201-aaea-7046f3ea6003">468,750</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total intangible assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i16a35fdf0e8348e0a1ede684610bae3e_D20210101-20210331" format="ixt-sec:duryear" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN181OC9mcmFnOjI1NjFhMjhkNjFlNTRlMDBhYzE0ZDI2YWM3ODA3OTY2L3RhYmxlOjZhN2QxMDQ5OTk3YjQyNTNiMmJhOGVlYmI4M2VlOTVkL3RhYmxlcmFuZ2U6NmE3ZDEwNDk5OTdiNDI1M2IyYmE4ZWViYjgzZWU5NWRfMTEtMS0xLTEtMA_6c42b062-8ad9-4ae1-a733-e191a44dbde2">11</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic36b9cedad7f41a6b9eb223b09b7186c_I20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN181OC9mcmFnOjI1NjFhMjhkNjFlNTRlMDBhYzE0ZDI2YWM3ODA3OTY2L3RhYmxlOjZhN2QxMDQ5OTk3YjQyNTNiMmJhOGVlYmI4M2VlOTVkL3RhYmxlcmFuZ2U6NmE3ZDEwNDk5OTdiNDI1M2IyYmE4ZWViYjgzZWU5NWRfMTEtMy0xLTEtMA_a4ec42d0-edfc-4212-a33f-e9fd90ae74a5">10,473,761</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic36b9cedad7f41a6b9eb223b09b7186c_I20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN181OC9mcmFnOjI1NjFhMjhkNjFlNTRlMDBhYzE0ZDI2YWM3ODA3OTY2L3RhYmxlOjZhN2QxMDQ5OTk3YjQyNTNiMmJhOGVlYmI4M2VlOTVkL3RhYmxlcmFuZ2U6NmE3ZDEwNDk5OTdiNDI1M2IyYmE4ZWViYjgzZWU5NWRfMTEtNS0xLTEtMA_d2790499-f032-48ed-9bce-23bad1b5e5d0">7,463,761</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic36b9cedad7f41a6b9eb223b09b7186c_I20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN181OC9mcmFnOjI1NjFhMjhkNjFlNTRlMDBhYzE0ZDI2YWM3ODA3OTY2L3RhYmxlOjZhN2QxMDQ5OTk3YjQyNTNiMmJhOGVlYmI4M2VlOTVkL3RhYmxlcmFuZ2U6NmE3ZDEwNDk5OTdiNDI1M2IyYmE4ZWViYjgzZWU5NWRfMTEtNy0xLTEtMA_96d8a06c-7b1d-411a-87fb-11ae758b1309">3,010,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i066bb5b0a9e84c0a878b1e800703d92b_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN181OC9mcmFnOjI1NjFhMjhkNjFlNTRlMDBhYzE0ZDI2YWM3ODA3OTY2L3RhYmxlOjZhN2QxMDQ5OTk3YjQyNTNiMmJhOGVlYmI4M2VlOTVkL3RhYmxlcmFuZ2U6NmE3ZDEwNDk5OTdiNDI1M2IyYmE4ZWViYjgzZWU5NWRfMTEtOS0xLTEtMA_88693b7b-9eb0-4249-babb-43bc3bad9723">10,473,761</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i066bb5b0a9e84c0a878b1e800703d92b_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN181OC9mcmFnOjI1NjFhMjhkNjFlNTRlMDBhYzE0ZDI2YWM3ODA3OTY2L3RhYmxlOjZhN2QxMDQ5OTk3YjQyNTNiMmJhOGVlYmI4M2VlOTVkL3RhYmxlcmFuZ2U6NmE3ZDEwNDk5OTdiNDI1M2IyYmE4ZWViYjgzZWU5NWRfMTEtMTEtMS0xLTA_d275a010-5ee2-45be-b658-bf5165d19a6b">7,326,991</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i066bb5b0a9e84c0a878b1e800703d92b_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN181OC9mcmFnOjI1NjFhMjhkNjFlNTRlMDBhYzE0ZDI2YWM3ODA3OTY2L3RhYmxlOjZhN2QxMDQ5OTk3YjQyNTNiMmJhOGVlYmI4M2VlOTVkL3RhYmxlcmFuZ2U6NmE3ZDEwNDk5OTdiNDI1M2IyYmE4ZWViYjgzZWU5NWRfMTEtMTMtMS0xLTA_bab3d57f-c94d-4f3c-8a6e-94cd79e8892a">3,146,770</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total goodwill and intangible assets</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic36b9cedad7f41a6b9eb223b09b7186c_I20210331" decimals="0" format="ixt:numdotdecimal" name="ino:GoodwillAndIntangibleAssetsGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN181OC9mcmFnOjI1NjFhMjhkNjFlNTRlMDBhYzE0ZDI2YWM3ODA3OTY2L3RhYmxlOjZhN2QxMDQ5OTk3YjQyNTNiMmJhOGVlYmI4M2VlOTVkL3RhYmxlcmFuZ2U6NmE3ZDEwNDk5OTdiNDI1M2IyYmE4ZWViYjgzZWU5NWRfMTItMy0xLTEtMA_027ce404-c292-474c-8598-ae91eb4a98fd">20,987,132</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic36b9cedad7f41a6b9eb223b09b7186c_I20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN181OC9mcmFnOjI1NjFhMjhkNjFlNTRlMDBhYzE0ZDI2YWM3ODA3OTY2L3RhYmxlOjZhN2QxMDQ5OTk3YjQyNTNiMmJhOGVlYmI4M2VlOTVkL3RhYmxlcmFuZ2U6NmE3ZDEwNDk5OTdiNDI1M2IyYmE4ZWViYjgzZWU5NWRfMTItNS0xLTEtMA_dd0ede93-22f0-4330-8020-ff2d0521a691">7,463,761</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic36b9cedad7f41a6b9eb223b09b7186c_I20210331" decimals="0" format="ixt:numdotdecimal" name="ino:GoodwillAndIntangibleAssetsNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN181OC9mcmFnOjI1NjFhMjhkNjFlNTRlMDBhYzE0ZDI2YWM3ODA3OTY2L3RhYmxlOjZhN2QxMDQ5OTk3YjQyNTNiMmJhOGVlYmI4M2VlOTVkL3RhYmxlcmFuZ2U6NmE3ZDEwNDk5OTdiNDI1M2IyYmE4ZWViYjgzZWU5NWRfMTItNy0xLTEtMA_7cd9285a-7ceb-4160-a451-95b369b93e07">13,523,371</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i066bb5b0a9e84c0a878b1e800703d92b_I20201231" decimals="0" format="ixt:numdotdecimal" name="ino:GoodwillAndIntangibleAssetsGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN181OC9mcmFnOjI1NjFhMjhkNjFlNTRlMDBhYzE0ZDI2YWM3ODA3OTY2L3RhYmxlOjZhN2QxMDQ5OTk3YjQyNTNiMmJhOGVlYmI4M2VlOTVkL3RhYmxlcmFuZ2U6NmE3ZDEwNDk5OTdiNDI1M2IyYmE4ZWViYjgzZWU5NWRfMTItOS0xLTEtMA_1124b1eb-18fb-4e8f-8007-eb0c41ac3b2f">20,987,132</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i066bb5b0a9e84c0a878b1e800703d92b_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN181OC9mcmFnOjI1NjFhMjhkNjFlNTRlMDBhYzE0ZDI2YWM3ODA3OTY2L3RhYmxlOjZhN2QxMDQ5OTk3YjQyNTNiMmJhOGVlYmI4M2VlOTVkL3RhYmxlcmFuZ2U6NmE3ZDEwNDk5OTdiNDI1M2IyYmE4ZWViYjgzZWU5NWRfMTItMTEtMS0xLTA_8aff7276-3f1d-4c7d-a5df-56d080cd0865">7,326,991</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i066bb5b0a9e84c0a878b1e800703d92b_I20201231" decimals="0" format="ixt:numdotdecimal" name="ino:GoodwillAndIntangibleAssetsNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN181OC9mcmFnOjI1NjFhMjhkNjFlNTRlMDBhYzE0ZDI2YWM3ODA3OTY2L3RhYmxlOjZhN2QxMDQ5OTk3YjQyNTNiMmJhOGVlYmI4M2VlOTVkL3RhYmxlcmFuZ2U6NmE3ZDEwNDk5OTdiNDI1M2IyYmE4ZWViYjgzZWU5NWRfMTItMTMtMS0xLTA_f8a1124b-93e5-4196-aa8f-574ecbd8580e">13,660,141</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">Goodwill was recorded from the acquisition of other companies. </span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">Bioject intangible assets represent the estimated fair value of developed technology and intellectual property which were recorded from an asset acquisition.</span></div></ix:nonNumeric><div style="margin-top:5pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i86509a9534ae44d6a6a94d598d85a7e7" continuedAt="if2eeabb231ce44e3b94423078fad9ec7">(c)</ix:continuation></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt"><ix:continuation id="if2eeabb231ce44e3b94423078fad9ec7">Other intangible assets represent the estimated fair value of acquired intellectual property.</ix:continuation> </span></div></ix:continuation><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i9f53d65f20be4727ad71f4283c5a130a">Aggregate amortization expense on intangible assets for each of the three months ended March 31, 2021 and 2020 was $<ix:nonFraction unitRef="usd" contextRef="i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfIntangibleAssets" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN181OC9mcmFnOjI1NjFhMjhkNjFlNTRlMDBhYzE0ZDI2YWM3ODA3OTY2L3RleHRyZWdpb246MjU2MWEyOGQ2MWU1NGUwMGFjMTRkMjZhYzc4MDc5NjZfNjcx_0dbfb1dd-42b4-47b1-84fa-5e9c7f3208a3"><ix:nonFraction unitRef="usd" contextRef="i03bccaa0abfb4733b1e2831ecde4e4e8_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfIntangibleAssets" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN181OC9mcmFnOjI1NjFhMjhkNjFlNTRlMDBhYzE0ZDI2YWM3ODA3OTY2L3RleHRyZWdpb246MjU2MWEyOGQ2MWU1NGUwMGFjMTRkMjZhYzc4MDc5NjZfNjcx_ad109319-9a0d-40a4-8b96-1d0e48870c3f">137,000</ix:nonFraction></ix:nonFraction>. Estimated aggregate amortization expense is $<ix:nonFraction unitRef="usd" contextRef="ic36b9cedad7f41a6b9eb223b09b7186c_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN181OC9mcmFnOjI1NjFhMjhkNjFlNTRlMDBhYzE0ZDI2YWM3ODA3OTY2L3RleHRyZWdpb246MjU2MWEyOGQ2MWU1NGUwMGFjMTRkMjZhYzc4MDc5NjZfODMz_8b4897c3-e15f-4b7f-8921-a0a6f59c032f">384,000</ix:nonFraction> for the remainder of fiscal year 2021, $<ix:nonFraction unitRef="usd" contextRef="ic36b9cedad7f41a6b9eb223b09b7186c_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN181OC9mcmFnOjI1NjFhMjhkNjFlNTRlMDBhYzE0ZDI2YWM3ODA3OTY2L3RleHRyZWdpb246MjU2MWEyOGQ2MWU1NGUwMGFjMTRkMjZhYzc4MDc5NjZfODcz_155ca0b9-e1ad-4a5f-8dcd-3e1524864a41">493,000</ix:nonFraction> for 2022, $<ix:nonFraction unitRef="usd" contextRef="ic36b9cedad7f41a6b9eb223b09b7186c_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN181OC9mcmFnOjI1NjFhMjhkNjFlNTRlMDBhYzE0ZDI2YWM3ODA3OTY2L3RleHRyZWdpb246MjU2MWEyOGQ2MWU1NGUwMGFjMTRkMjZhYzc4MDc5NjZfODg1_c7d6664a-7e02-49c5-ba50-bd3e9897f873">276,000</ix:nonFraction> for 2023, $<ix:nonFraction unitRef="usd" contextRef="ic36b9cedad7f41a6b9eb223b09b7186c_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN181OC9mcmFnOjI1NjFhMjhkNjFlNTRlMDBhYzE0ZDI2YWM3ODA3OTY2L3RleHRyZWdpb246MjU2MWEyOGQ2MWU1NGUwMGFjMTRkMjZhYzc4MDc5NjZfODk3_037a3970-4123-442f-83a2-cbb5ff175112">253,000</ix:nonFraction> for 2024, $<ix:nonFraction unitRef="usd" contextRef="ic36b9cedad7f41a6b9eb223b09b7186c_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN181OC9mcmFnOjI1NjFhMjhkNjFlNTRlMDBhYzE0ZDI2YWM3ODA3OTY2L3RleHRyZWdpb246MjU2MWEyOGQ2MWU1NGUwMGFjMTRkMjZhYzc4MDc5NjZfOTA5_32037b38-f268-4864-be4e-11afa7f78435">253,000</ix:nonFraction> for 2025 and $<ix:nonFraction unitRef="usd" contextRef="ic36b9cedad7f41a6b9eb223b09b7186c_I20210331" decimals="-5" format="ixt:numdotdecimal" name="ino:FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN181OC9mcmFnOjI1NjFhMjhkNjFlNTRlMDBhYzE0ZDI2YWM3ODA3OTY2L3RleHRyZWdpb246MjU2MWEyOGQ2MWU1NGUwMGFjMTRkMjZhYzc4MDc5NjZfOTI0_9d79a5ff-defa-4bc5-98b1-20f1113bf36e">1.4</ix:nonFraction> million for 2026 and subsequent years combined.</ix:continuation> </span></div><div style="margin-top:5pt;text-indent:27pt"><span><br/></span></div><div id="i1d23d16a69484b63aa007ec686e80337_61"></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">9. <ix:nonNumeric contextRef="i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331" name="us-gaap:DebtDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN182MS9mcmFnOmQ0ODcwNjAzNDk5MTQ0YTNhOThhZjIwMGM2ODZjM2FlL3RleHRyZWdpb246ZDQ4NzA2MDM0OTkxNDRhM2E5OGFmMjAwYzY4NmMzYWVfMTU4ODE_cfbb5a74-c531-4477-a87e-fecd9a957683" continuedAt="idb8c882eba4c43a188002d2d46f34f85" escape="true">Convertible Debt</ix:nonNumeric></span></div><ix:continuation id="idb8c882eba4c43a188002d2d46f34f85" continuedAt="icb67341b6a264f5f9639cc943eba5afc"><div style="margin-bottom:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Convertible Senior Notes </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 19, 2019 and March 1, 2019, the Company completed a private placement of $<ix:nonFraction unitRef="usd" contextRef="iff75d456dbf843feb55dc8e27df1e4c3_I20190301" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN182MS9mcmFnOmQ0ODcwNjAzNDk5MTQ0YTNhOThhZjIwMGM2ODZjM2FlL3RleHRyZWdpb246ZDQ4NzA2MDM0OTkxNDRhM2E5OGFmMjAwYzY4NmMzYWVfMTM2_51dbddae-93c7-49a1-a168-8e8d519a7341">78.5</ix:nonFraction> million aggregate principal amount of its <ix:nonFraction unitRef="number" contextRef="iff75d456dbf843feb55dc8e27df1e4c3_I20190301" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN182MS9mcmFnOmQ0ODcwNjAzNDk5MTQ0YTNhOThhZjIwMGM2ODZjM2FlL3RleHRyZWdpb246ZDQ4NzA2MDM0OTkxNDRhM2E5OGFmMjAwYzY4NmMzYWVfMjE5OTAyMzI3NDY4Mg_b30c308f-2649-42a1-90de-857adde10cde">6.50</ix:nonFraction>% convertible senior notes due 2024 (the &#8220;Notes&#8221;). The Notes were sold in a private offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended. Net proceeds from the offering were approximately $<ix:nonFraction unitRef="usd" contextRef="i50447e531b3c434fb8e3ede17ab45a89_D20190219-20190301" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN182MS9mcmFnOmQ0ODcwNjAzNDk5MTQ0YTNhOThhZjIwMGM2ODZjM2FlL3RleHRyZWdpb246ZDQ4NzA2MDM0OTkxNDRhM2E5OGFmMjAwYzY4NmMzYWVfMzMx_d76f8976-c93a-493a-aca4-8b6ff2daa3f9">75.7</ix:nonFraction> million.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Notes are senior unsecured obligations of the Company and accrue interest payable in cash semi-annually in arrears on March 1 and September 1 of each year, beginning on September 1, 2019, at a rate of <ix:nonFraction unitRef="number" contextRef="iff75d456dbf843feb55dc8e27df1e4c3_I20190301" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN182MS9mcmFnOmQ0ODcwNjAzNDk5MTQ0YTNhOThhZjIwMGM2ODZjM2FlL3RleHRyZWdpb246ZDQ4NzA2MDM0OTkxNDRhM2E5OGFmMjAwYzY4NmMzYWVfNTQw_657a9090-b39e-4fd5-ac29-84cfabcdcff0">6.50</ix:nonFraction>% per annum. The Notes will mature on March 1, 2024, unless earlier converted, redeemed or repurchased.&#160;Prior to the close of business on the business day immediately preceding November 1, 2023, the Notes will be convertible at the option of the holders only upon the satisfaction of certain circumstances. Thereafter, the Notes will be convertible at the option of the holders at any time until the close of business on the scheduled trading day immediately before the maturity date. Upon conversion, the Company will pay or deliver, as the case may be, cash, shares of its common stock or a combination of cash and shares of its common stock, at its election. The initial conversion rate will be 185.8045 shares per $1,000 principal amount of Notes (equivalent to an initial conversion price of approximately $<ix:nonFraction unitRef="usdPerShare" contextRef="iff75d456dbf843feb55dc8e27df1e4c3_I20190301" decimals="2" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN182MS9mcmFnOmQ0ODcwNjAzNDk5MTQ0YTNhOThhZjIwMGM2ODZjM2FlL3RleHRyZWdpb246ZDQ4NzA2MDM0OTkxNDRhM2E5OGFmMjAwYzY4NmMzYWVfMTM1Mg_4509fe42-e04d-42f7-8ef1-0bca1d1b1d7a">5.38</ix:nonFraction> per share), subject to adjustment upon the occurrence of specified events.  </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company may not redeem the Notes prior to March 1, 2022. On or after March 1, 2022, the Company may redeem all, or any portion, of the Notes for cash if the last reported sale price per share of the Company's common stock exceeds <ix:nonFraction unitRef="number" contextRef="i50447e531b3c434fb8e3ede17ab45a89_D20190219-20190301" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN182MS9mcmFnOmQ0ODcwNjAzNDk5MTQ0YTNhOThhZjIwMGM2ODZjM2FlL3RleHRyZWdpb246ZDQ4NzA2MDM0OTkxNDRhM2E5OGFmMjAwYzY4NmMzYWVfMTY2Ng_0b69674a-1c2a-4d0f-b1a5-2407981b9c24">130</ix:nonFraction>% of the conversion price on (i) each of at least <ix:nonFraction unitRef="day" contextRef="i50447e531b3c434fb8e3ede17ab45a89_D20190219-20190301" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdTradingDays" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN182MS9mcmFnOmQ0ODcwNjAzNDk5MTQ0YTNhOThhZjIwMGM2ODZjM2FlL3RleHRyZWdpb246ZDQ4NzA2MDM0OTkxNDRhM2E5OGFmMjAwYzY4NmMzYWVfMTcxNw_367541ee-7c21-445f-a308-bca35781e09b">20</ix:nonFraction> trading days (whether or not consecutive) during the <ix:nonFraction unitRef="day" contextRef="i50447e531b3c434fb8e3ede17ab45a89_D20190219-20190301" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN182MS9mcmFnOmQ0ODcwNjAzNDk5MTQ0YTNhOThhZjIwMGM2ODZjM2FlL3RleHRyZWdpb246ZDQ4NzA2MDM0OTkxNDRhM2E5OGFmMjAwYzY4NmMzYWVfMTc3Mw_749106ac-248e-45a4-a90a-850d6f1609c2">30</ix:nonFraction> consecutive trading days ending on, and including, the trading day immediately before the Company sends the related redemption notice; and (ii) the trading day immediately before the date the Company sends such redemption notice.&#160;The redemption price will be equal to <ix:nonFraction unitRef="number" contextRef="i50447e531b3c434fb8e3ede17ab45a89_D20190219-20190301" decimals="INF" name="us-gaap:DebtInstrumentRedemptionPricePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN182MS9mcmFnOmQ0ODcwNjAzNDk5MTQ0YTNhOThhZjIwMGM2ODZjM2FlL3RleHRyZWdpb246ZDQ4NzA2MDM0OTkxNDRhM2E5OGFmMjAwYzY4NmMzYWVfMjA0NA_4fe4910b-0b3c-4230-9440-d646985d1e4a">100</ix:nonFraction>% of the principal amount of the Notes to be redeemed, plus accrued and unpaid interest to, but excluding, the redemption date.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluated the accounting for the issuance of the Notes and concluded that the embedded conversion features meet the requirements for a derivative scope exception for instruments that are both indexed to an entity&#8217;s own stock and classified in stockholders&#8217; equity in its condensed consolidated balance sheet, and that the cash conversion guidance applies. Therefore, the Notes issuance proceeds of $<ix:nonFraction unitRef="usd" contextRef="iff75d456dbf843feb55dc8e27df1e4c3_I20190301" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN182MS9mcmFnOmQ0ODcwNjAzNDk5MTQ0YTNhOThhZjIwMGM2ODZjM2FlL3RleHRyZWdpb246ZDQ4NzA2MDM0OTkxNDRhM2E5OGFmMjAwYzY4NmMzYWVfMjU4Mw_8b183c79-2758-4106-b403-fcba67f44434">78.5</ix:nonFraction> million are allocated first to the liability component based on the fair </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="icb67341b6a264f5f9639cc943eba5afc" continuedAt="ibfe2f28953a24b47946c610b14172355"><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">value of non-convertible debt with otherwise identical residual terms with the residual proceeds allocated to equity for the conversion featu</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">res. The Company determined that the fair value of the non-convertible debt upon issuance of the Notes was $<ix:nonFraction unitRef="usd" contextRef="iff75d456dbf843feb55dc8e27df1e4c3_I20190301" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN182MS9mcmFnOmQ0ODcwNjAzNDk5MTQ0YTNhOThhZjIwMGM2ODZjM2FlL3RleHRyZWdpb246ZDQ4NzA2MDM0OTkxNDRhM2E5OGFmMjAwYzY4NmMzYWVfMjg5OQ_8df0a64d-241e-4242-93ba-efcb0a4e344b">62.2</ix:nonFraction> million and recorded this amount as a liability and the offsetting amount as a debt discount as a reduction to the carrying value of the Notes on the closing date. The debt issuance costs associated with the Notes of $<ix:nonFraction unitRef="usd" contextRef="iff75d456dbf843feb55dc8e27df1e4c3_I20190301" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DeferredFinanceCostsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN182MS9mcmFnOmQ0ODcwNjAzNDk5MTQ0YTNhOThhZjIwMGM2ODZjM2FlL3RleHRyZWdpb246ZDQ4NzA2MDM0OTkxNDRhM2E5OGFmMjAwYzY4NmMzYWVfMzExMQ_ff88efd4-ddb5-4a34-aba0-0c66d4905a06">2.8</ix:nonFraction> million are allocated to the liability and equity component in the same proportion as the issuance proceeds. </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determined that all other features of the Notes were clearly and closely associated with a debt host and did not require bifurcation as a derivative liability, or the fair value of the feature was immaterial to the Company's condensed consolidated financial statements.</span></div><div style="margin-bottom:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determined that the expected life of the Notes was equal to the period through November 1, 2023 as this represents the point at which the Notes are initially subject to repurchase by the Company at the option of the holders. Accordingly, the total debt discount of $<ix:nonFraction unitRef="usd" contextRef="iff75d456dbf843feb55dc8e27df1e4c3_I20190301" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentUnamortizedDiscount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN182MS9mcmFnOmQ0ODcwNjAzNDk5MTQ0YTNhOThhZjIwMGM2ODZjM2FlL3RleHRyZWdpb246ZDQ4NzA2MDM0OTkxNDRhM2E5OGFmMjAwYzY4NmMzYWVfMzc3NQ_c048deb3-abef-491a-b6a5-1104241645b8">18.6</ix:nonFraction> million, inclusive of the fair value of the embedded conversion feature derivative at issuance, is being amortized using the effective interest method through November 1, 2023.&#160;The effective interest rate of the liability component is <ix:nonFraction unitRef="number" contextRef="i334e05b1c2d349408f504085686e16e6_I20210331" decimals="3" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN182MS9mcmFnOmQ0ODcwNjAzNDk5MTQ0YTNhOThhZjIwMGM2ODZjM2FlL3RleHRyZWdpb246ZDQ4NzA2MDM0OTkxNDRhM2E5OGFmMjAwYzY4NmMzYWVfNDAwNQ_18886e67-d486-4d71-9ec1-263ce2049976">13.1</ix:nonFraction>%. </span></div><div style="margin-bottom:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">During the year ended December 31, 2020, the Company received notices for the conversion of $<ix:nonFraction unitRef="usd" contextRef="ibaba303f793542bd8caae6689d64fb35_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DebtConversionConvertedInstrumentAmount1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN182MS9mcmFnOmQ0ODcwNjAzNDk5MTQ0YTNhOThhZjIwMGM2ODZjM2FlL3RleHRyZWdpb246ZDQ4NzA2MDM0OTkxNDRhM2E5OGFmMjAwYzY4NmMzYWVfNDA3NQ_88d9733a-6f57-4680-9482-2b0546e77c2b">62.1</ix:nonFraction>&#160;million of principal amount of the Notes, which were settled for</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> an aggregate of <ix:nonFraction unitRef="shares" contextRef="ibaba303f793542bd8caae6689d64fb35_D20200101-20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DebtConversionConvertedInstrumentSharesIssued1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN182MS9mcmFnOmQ0ODcwNjAzNDk5MTQ0YTNhOThhZjIwMGM2ODZjM2FlL3RleHRyZWdpb246ZDQ4NzA2MDM0OTkxNDRhM2E5OGFmMjAwYzY4NmMzYWVfNDE2NQ_ec248693-80cb-42af-8a62-f27c74535b3e">11,535,660</ix:nonFraction> shares of the Company's common stock</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">. The fair value of the Notes at the date of conversion was $<ix:nonFraction unitRef="usd" contextRef="ida7e6795aad44fb38ae767d0d07173d2_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN182MS9mcmFnOmQ0ODcwNjAzNDk5MTQ0YTNhOThhZjIwMGM2ODZjM2FlL3RleHRyZWdpb246ZDQ4NzA2MDM0OTkxNDRhM2E5OGFmMjAwYzY4NmMzYWVfNDI2NA_f96d2e9c-62ba-42d1-8025-83600b2a0b8f">43.7</ix:nonFraction>&#160;million compared to the carrying value of $<ix:nonFraction unitRef="usd" contextRef="ida7e6795aad44fb38ae767d0d07173d2_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN182MS9mcmFnOmQ0ODcwNjAzNDk5MTQ0YTNhOThhZjIwMGM2ODZjM2FlL3RleHRyZWdpb246ZDQ4NzA2MDM0OTkxNDRhM2E5OGFmMjAwYzY4NmMzYWVfNDMwMQ_0867e707-ad70-454f-a86a-bff839a32829">52.5</ix:nonFraction>&#160;million, resulting in a $<ix:nonFraction unitRef="usd" contextRef="ibaba303f793542bd8caae6689d64fb35_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN182MS9mcmFnOmQ0ODcwNjAzNDk5MTQ0YTNhOThhZjIwMGM2ODZjM2FlL3RleHRyZWdpb246ZDQ4NzA2MDM0OTkxNDRhM2E5OGFmMjAwYzY4NmMzYWVfNDMyMA_5374bd15-a2e2-4874-b7aa-526afc769ecc">8.8</ix:nonFraction> million gain on extinguishment of debt. This gain was recorded in the condensed consolidated statement of operations. To measure the fair value of the converted Notes as of the conversion dates, the Company engaged a third-party valuation expert and utilized a binomial lattice model.</span></div><ix:nonNumeric contextRef="i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331" name="us-gaap:ConvertibleDebtTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN182MS9mcmFnOmQ0ODcwNjAzNDk5MTQ0YTNhOThhZjIwMGM2ODZjM2FlL3RleHRyZWdpb246ZDQ4NzA2MDM0OTkxNDRhM2E5OGFmMjAwYzY4NmMzYWVfMTU4ODk_5f1dfe80-322a-4111-8e62-44a38da3ba2a" escape="true"><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The balance of the Notes at March&#160;31, 2021 is as follows:</span></div><div style="margin-bottom:5pt;margin-top:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:69.617%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:28.183%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Original principal amount</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf1dda891fd044098c213cc6a530fa62_I20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN182MS9mcmFnOmQ0ODcwNjAzNDk5MTQ0YTNhOThhZjIwMGM2ODZjM2FlL3RhYmxlOjAzNTA3YjU4ZGU5ODQ5YmE5NzhiMDg1ZmQwZWE0NzU1L3RhYmxlcmFuZ2U6MDM1MDdiNThkZTk4NDliYTk3OGIwODVmZDBlYTQ3NTVfMC0xLTEtMS0w_ca5f838b-8e50-4504-a2d1-1764fb0f00e6">78,500,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Principal amount converted into common shares</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibf1dda891fd044098c213cc6a530fa62_I20210331" decimals="0" format="ixt:numdotdecimal" name="ino:DebtInstrumentConvertibleDebtConvertedAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN182MS9mcmFnOmQ0ODcwNjAzNDk5MTQ0YTNhOThhZjIwMGM2ODZjM2FlL3RhYmxlOjAzNTA3YjU4ZGU5ODQ5YmE5NzhiMDg1ZmQwZWE0NzU1L3RhYmxlcmFuZ2U6MDM1MDdiNThkZTk4NDliYTk3OGIwODVmZDBlYTQ3NTVfMS0xLTEtMS0w_a7550380-ea68-4c70-a4fe-c16ad455efaf">62,085,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unamortized debt discount on the liability component</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibf1dda891fd044098c213cc6a530fa62_I20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentUnamortizedDiscount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN182MS9mcmFnOmQ0ODcwNjAzNDk5MTQ0YTNhOThhZjIwMGM2ODZjM2FlL3RhYmxlOjAzNTA3YjU4ZGU5ODQ5YmE5NzhiMDg1ZmQwZWE0NzU1L3RhYmxlcmFuZ2U6MDM1MDdiNThkZTk4NDliYTk3OGIwODVmZDBlYTQ3NTVfMi0xLTEtMS0w_f5b67f53-244e-4fc1-b8a5-5d6f734be01d">2,139,698</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unamortized debt issuance cost</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibf1dda891fd044098c213cc6a530fa62_I20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredFinanceCostsNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN182MS9mcmFnOmQ0ODcwNjAzNDk5MTQ0YTNhOThhZjIwMGM2ODZjM2FlL3RhYmxlOjAzNTA3YjU4ZGU5ODQ5YmE5NzhiMDg1ZmQwZWE0NzU1L3RhYmxlcmFuZ2U6MDM1MDdiNThkZTk4NDliYTk3OGIwODVmZDBlYTQ3NTVfMy0xLTEtMS0w_bf4ccfe9-fb08-4879-afb0-93a98959203f">294,495</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf1dda891fd044098c213cc6a530fa62_I20210331" decimals="0" format="ixt:numdotdecimal" name="ino:DebtInstrumentAccruedInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN182MS9mcmFnOmQ0ODcwNjAzNDk5MTQ0YTNhOThhZjIwMGM2ODZjM2FlL3RhYmxlOjAzNTA3YjU4ZGU5ODQ5YmE5NzhiMDg1ZmQwZWE0NzU1L3RhYmxlcmFuZ2U6MDM1MDdiNThkZTk4NDliYTk3OGIwODVmZDBlYTQ3NTVfNC0xLTEtMS0w_1b0ec873-2801-4d12-ad61-0060b02783dc">88,915</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Net carrying amount </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf1dda891fd044098c213cc6a530fa62_I20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LongTermDebt" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN182MS9mcmFnOmQ0ODcwNjAzNDk5MTQ0YTNhOThhZjIwMGM2ODZjM2FlL3RhYmxlOjAzNTA3YjU4ZGU5ODQ5YmE5NzhiMDg1ZmQwZWE0NzU1L3RhYmxlcmFuZ2U6MDM1MDdiNThkZTk4NDliYTk3OGIwODVmZDBlYTQ3NTVfNS0xLTEtMS0w_b6f67642-e36a-40b5-97c9-0a885df2a7ae">14,069,722</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March 31, 2021 and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2020</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,&#160;the Company recognized $<ix:nonFraction unitRef="usd" contextRef="icdb93151b4be464b9f1281340d4933cc_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN182MS9mcmFnOmQ0ODcwNjAzNDk5MTQ0YTNhOThhZjIwMGM2ODZjM2FlL3RleHRyZWdpb246ZDQ4NzA2MDM0OTkxNDRhM2E5OGFmMjAwYzY4NmMzYWVfNDY4NQ_790f59d8-b645-4d8e-8e06-883fd6f5019a">463,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i105fc1ec677d41beb16a21a24c107e45_D20200101-20200331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN182MS9mcmFnOmQ0ODcwNjAzNDk5MTQ0YTNhOThhZjIwMGM2ODZjM2FlL3RleHRyZWdpb246ZDQ4NzA2MDM0OTkxNDRhM2E5OGFmMjAwYzY4NmMzYWVfNDY5Mg_5ac2d6b3-9f77-4ca1-95ab-66c6e5159cc4">2.1</ix:nonFraction> million, respectively, of interest expense related to the Notes, of which $<ix:nonFraction unitRef="usd" contextRef="icdb93151b4be464b9f1281340d4933cc_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestExpenseDebt" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN182MS9mcmFnOmQ0ODcwNjAzNDk5MTQ0YTNhOThhZjIwMGM2ODZjM2FlL3RleHRyZWdpb246ZDQ4NzA2MDM0OTkxNDRhM2E5OGFmMjAwYzY4NmMzYWVfNDc2MQ_6be75159-cfa3-491a-857c-3201ea09360e">267,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i105fc1ec677d41beb16a21a24c107e45_D20200101-20200331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:InterestExpenseDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN182MS9mcmFnOmQ0ODcwNjAzNDk5MTQ0YTNhOThhZjIwMGM2ODZjM2FlL3RleHRyZWdpb246ZDQ4NzA2MDM0OTkxNDRhM2E5OGFmMjAwYzY4NmMzYWVfNDc2OA_f9f60eef-6c15-4c3b-bf87-aa27957f8ad3">1.3</ix:nonFraction> million, respectively, related to the contractual interest coupon.</span></div><ix:nonNumeric contextRef="i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331" name="us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN182MS9mcmFnOmQ0ODcwNjAzNDk5MTQ0YTNhOThhZjIwMGM2ODZjM2FlL3RleHRyZWdpb246ZDQ4NzA2MDM0OTkxNDRhM2E5OGFmMjAwYzY4NmMzYWVfMzI5ODUzNDkxMjI2MA_878e1f86-97ac-4fd0-b7c0-bbf19dee6e49" escape="true"><div style="margin-top:5pt;text-indent:24.75pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2021, future minimum payments due under the Notes, representing contractual amounts due, including interest based on the fixed rate of <ix:nonFraction unitRef="number" contextRef="i334e05b1c2d349408f504085686e16e6_I20210331" decimals="3" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN182MS9mcmFnOmQ0ODcwNjAzNDk5MTQ0YTNhOThhZjIwMGM2ODZjM2FlL3RleHRyZWdpb246ZDQ4NzA2MDM0OTkxNDRhM2E5OGFmMjAwYzY4NmMzYWVfMzI5ODUzNDkxMjI1NQ_99dc7d24-af10-4c3d-a9d4-3101a391676e">6.5</ix:nonFraction>% per annum, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">are as follows:</span></div><div style="margin-bottom:5pt;margin-top:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.742%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.328%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Remainder of 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i334e05b1c2d349408f504085686e16e6_I20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN182MS9mcmFnOmQ0ODcwNjAzNDk5MTQ0YTNhOThhZjIwMGM2ODZjM2FlL3RhYmxlOjVhYzU2YTc5ZDk2NzRhY2Y5ZTdkZWRiZWVmZWQxNDcxL3RhYmxlcmFuZ2U6NWFjNTZhNzlkOTY3NGFjZjllN2RlZGJlZWZlZDE0NzFfMi0yLTEtMS0zODk3_701c6978-520d-476f-83da-5236ce589ba9">534,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i334e05b1c2d349408f504085686e16e6_I20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN182MS9mcmFnOmQ0ODcwNjAzNDk5MTQ0YTNhOThhZjIwMGM2ODZjM2FlL3RhYmxlOjVhYzU2YTc5ZDk2NzRhY2Y5ZTdkZWRiZWVmZWQxNDcxL3RhYmxlcmFuZ2U6NWFjNTZhNzlkOTY3NGFjZjllN2RlZGJlZWZlZDE0NzFfMy0yLTEtMS0zODk3_d187a090-87dc-4124-8188-cec169000829">1,067,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i334e05b1c2d349408f504085686e16e6_I20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN182MS9mcmFnOmQ0ODcwNjAzNDk5MTQ0YTNhOThhZjIwMGM2ODZjM2FlL3RhYmxlOjVhYzU2YTc5ZDk2NzRhY2Y5ZTdkZWRiZWVmZWQxNDcxL3RhYmxlcmFuZ2U6NWFjNTZhNzlkOTY3NGFjZjllN2RlZGJlZWZlZDE0NzFfNC0yLTEtMS0zODk3_23f2eeb6-e623-4521-8703-40fccb149aab">1,067,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i334e05b1c2d349408f504085686e16e6_I20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN182MS9mcmFnOmQ0ODcwNjAzNDk5MTQ0YTNhOThhZjIwMGM2ODZjM2FlL3RhYmxlOjVhYzU2YTc5ZDk2NzRhY2Y5ZTdkZWRiZWVmZWQxNDcxL3RhYmxlcmFuZ2U6NWFjNTZhNzlkOTY3NGFjZjllN2RlZGJlZWZlZDE0NzFfNS0yLTEtMS0zODk3_4e98c208-8b88-4a26-951e-4847497bfae2">16,948,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i334e05b1c2d349408f504085686e16e6_I20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LongTermDebt" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN182MS9mcmFnOmQ0ODcwNjAzNDk5MTQ0YTNhOThhZjIwMGM2ODZjM2FlL3RhYmxlOjVhYzU2YTc5ZDk2NzRhY2Y5ZTdkZWRiZWVmZWQxNDcxL3RhYmxlcmFuZ2U6NWFjNTZhNzlkOTY3NGFjZjllN2RlZGJlZWZlZDE0NzFfNi0yLTEtMS00Mzgz_70b9d0e3-980e-4ef4-996d-9160f3ce93b5">19,616,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><div style="margin-top:5pt;padding-left:22.5pt"><span><br/></span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">August 2019 Convertible Bonds</span></div><div style="margin-top:5pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 1, 2019, the Company closed a private placem</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ent of the August 2019 Bonds with an aggregate principal amount of <ix:nonFraction unitRef="krw" contextRef="i700b790825e646eaa141e79f67d14908_I20190801" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN182MS9mcmFnOmQ0ODcwNjAzNDk5MTQ0YTNhOThhZjIwMGM2ODZjM2FlL3RleHRyZWdpb246ZDQ4NzA2MDM0OTkxNDRhM2E5OGFmMjAwYzY4NmMzYWVfNTMzMw_0cd35b1c-d2cc-4331-956b-558aaf48e54e">18</ix:nonFraction> billion Korean Won (KRW) (approximately USD $<ix:nonFraction unitRef="usd" contextRef="i700b790825e646eaa141e79f67d14908_I20190801" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN182MS9mcmFnOmQ0ODcwNjAzNDk5MTQ0YTNhOThhZjIwMGM2ODZjM2FlL3RleHRyZWdpb246ZDQ4NzA2MDM0OTkxNDRhM2E5OGFmMjAwYzY4NmMzYWVfNTM1OQ_70dd5d16-3a12-4a51-86a1-91aa0703857c">15.0</ix:nonFraction> million based on the exchange rate on the date of issuance) issued to institutional investors led by Korea Investment Partners (KIP), a global venture capital and private equity firm based in Seoul, Korea. Net proceeds from the offering were approximately $<ix:nonFraction unitRef="usd" contextRef="ibbf41c9c4e33452d8cf96974a53ed0d2_D20190801-20190801" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN182MS9mcmFnOmQ0ODcwNjAzNDk5MTQ0YTNhOThhZjIwMGM2ODZjM2FlL3RleHRyZWdpb246ZDQ4NzA2MDM0OTkxNDRhM2E5OGFmMjAwYzY4NmMzYWVfNTYxMA_fd3fc873-c9d1-4b72-8e54-528028856d55">14.5</ix:nonFraction> million. </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The August 2019 Bonds, which were unsecured obligations of the Company, were issued on August 1, 2019 and accrued interest at a coupon rate of <ix:nonFraction unitRef="number" contextRef="i700b790825e646eaa141e79f67d14908_I20190801" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN182MS9mcmFnOmQ0ODcwNjAzNDk5MTQ0YTNhOThhZjIwMGM2ODZjM2FlL3RleHRyZWdpb246ZDQ4NzA2MDM0OTkxNDRhM2E5OGFmMjAwYzY4NmMzYWVfNTkzNA_8d556462-b0f3-4d0f-a834-03603a38c78c">1.00</ix:nonFraction>% per annum, payable quarterly. The August 2019 Bonds were scheduled to mature on July 31, 2024, unless earlier converted or repurchased. On August 3, 2020 the August 2019 Bonds were converted in full into an aggregate of <ix:nonFraction unitRef="shares" contextRef="i6b6ee21ba47743bcbf1e8f17210f4948_D20200803-20200803" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DebtConversionConvertedInstrumentSharesIssued1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN182MS9mcmFnOmQ0ODcwNjAzNDk5MTQ0YTNhOThhZjIwMGM2ODZjM2FlL3RleHRyZWdpb246ZDQ4NzA2MDM0OTkxNDRhM2E5OGFmMjAwYzY4NmMzYWVfNjE1Nw_4ef7f676-00c4-45da-8dd7-085dea105616">4,962,364</ix:nonFraction> shares of the Company's common stock, leaving no further August 2019 Bonds outstanding. The initial conversion rate was 211.0595 shares per KRW1,000,000 in principal amount (equivalent to an initial conversion price of approximately USD $<ix:nonFraction unitRef="usdPerShare" contextRef="ie81a2e682215493ab64bdb0c300f4bf3_I20200803" decimals="2" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN182MS9mcmFnOmQ0ODcwNjAzNDk5MTQ0YTNhOThhZjIwMGM2ODZjM2FlL3RleHRyZWdpb246ZDQ4NzA2MDM0OTkxNDRhM2E5OGFmMjAwYzY4NmMzYWVfNjM4NA_4065c985-0303-4be3-b1ee-bdfa5b022afe">4.00</ix:nonFraction> per share based on the exchange rate as of July 30, 2019), subject to adjustment upon the occurrence of specified events. The conversion rate was reset on January 2, 2020 and was subject to reset quarterly thereafter if the current </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="ibfe2f28953a24b47946c610b14172355" continuedAt="i8d4f6153ebc8493ba3657d807367121e"><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">market price was lower than the conversion price then in effect. The conversion rate as of the date of conversion on August 1, 2020 was 275.6873 shares per KRW 1,000,000 in principal amount (equivalent to a conversion price of approximately USD $<ix:nonFraction unitRef="usdPerShare" contextRef="i7871b982a7494885bca85b1422f54c5a_I20200803" decimals="2" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN182MS9mcmFnOmQ0ODcwNjAzNDk5MTQ0YTNhOThhZjIwMGM2ODZjM2FlL3RleHRyZWdpb246ZDQ4NzA2MDM0OTkxNDRhM2E5OGFmMjAwYzY4NmMzYWVfNjg2NA_78997f8e-0aab-4631-a64b-ad3d030399a1">3.14</ix:nonFraction> per share).</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluated the accounting for the issuance of the August 2019 Bonds and concluded that the embedded conversion feature was considered a derivative requiring bifurcation from the August 2019 Bonds as it did not meet the equity scope exception due to the fact that it was denominated in a currency other than the Company's functional currency. The fair value of the conversion feature at August 1, 2019 was $<ix:nonFraction unitRef="usd" contextRef="i700b790825e646eaa141e79f67d14908_I20190801" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN182MS9mcmFnOmQ0ODcwNjAzNDk5MTQ0YTNhOThhZjIwMGM2ODZjM2FlL3RleHRyZWdpb246ZDQ4NzA2MDM0OTkxNDRhM2E5OGFmMjAwYzY4NmMzYWVfNzM0Mw_951eb676-d0e6-44e0-ae05-509f3732b317">7.1</ix:nonFraction> million, which was recorded as a reduction to the carrying value of the debt. This debt discount was being amortized to&#160;interest expense over the term of the debt using the effective interest method. The conversion option was accounted for as a derivative liability, which was revalued each reporting period with&#160;the resulting change in fair value reflected in other income (expense), net, in the condensed consolidated&#160;statements of operations.  </span></div><div style="margin-bottom:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determined that all other features of the August 2019 Bonds were clearly and closely associated with a debt host and did not require bifurcation as a derivative liability, or the fair value of the feature was immaterial to the Company's condensed consolidated financial statements.</span></div><div style="margin-bottom:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At their issuance, the Company determined that the expected life of the August 2019 Bonds was equal to the period through August 1, 2022 as this represented the point at which the August 2019 Bonds were initially subject to repurchase by the Company at the option of the holders. Accordingly, the total debt discount of $<ix:nonFraction unitRef="usd" contextRef="i700b790825e646eaa141e79f67d14908_I20190801" decimals="-5" name="us-gaap:DebtInstrumentUnamortizedDiscount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN182MS9mcmFnOmQ0ODcwNjAzNDk5MTQ0YTNhOThhZjIwMGM2ODZjM2FlL3RleHRyZWdpb246ZDQ4NzA2MDM0OTkxNDRhM2E5OGFmMjAwYzY4NmMzYWVfODQwMA_7535496a-9767-4b0b-b102-0c0d96380b09">7.3</ix:nonFraction> million, inclusive of the fair value of the embedded conversion feature derivative at issuance, was being amortized using the effective interest method through August 1, 2022</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. For the three months ended March 31, 2020, the Company recognized $<ix:nonFraction unitRef="usd" contextRef="i1db0e391023844c58ee91836f1ff6032_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN182MS9mcmFnOmQ0ODcwNjAzNDk5MTQ0YTNhOThhZjIwMGM2ODZjM2FlL3RleHRyZWdpb246ZDQ4NzA2MDM0OTkxNDRhM2E5OGFmMjAwYzY4NmMzYWVfODkwOQ_25e4ac10-76b9-4271-9db7-471cee56e7da">641,000</ix:nonFraction> of interest expense related to the August 2019 Bonds, of which $<ix:nonFraction unitRef="usd" contextRef="i1db0e391023844c58ee91836f1ff6032_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestExpenseDebt" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN182MS9mcmFnOmQ0ODcwNjAzNDk5MTQ0YTNhOThhZjIwMGM2ODZjM2FlL3RleHRyZWdpb246ZDQ4NzA2MDM0OTkxNDRhM2E5OGFmMjAwYzY4NmMzYWVfODk3NQ_f5fe9660-bb47-45ad-a45f-4bacb43c0326">38,000</ix:nonFraction> related to the contractual interest coupon.</span></div><div style="margin-bottom:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Immediately prior to the August 2020 conversion, the derivative liability associated with the August 2019 Bonds was revalued at $<ix:nonFraction unitRef="usd" contextRef="i4856d99dc58e4812bb359ff1035109a0_I20200831" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN182MS9mcmFnOmQ0ODcwNjAzNDk5MTQ0YTNhOThhZjIwMGM2ODZjM2FlL3RleHRyZWdpb246ZDQ4NzA2MDM0OTkxNDRhM2E5OGFmMjAwYzY4NmMzYWVfOTE4NA_6cab8325-f8bb-4960-91c4-a64ebbaea430">84.5</ix:nonFraction> million. The change in fair value of the derivative liability was an increase of $<ix:nonFraction unitRef="usd" contextRef="id61aefb0cd4c41cba239205ade4953a0_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN182MS9mcmFnOmQ0ODcwNjAzNDk5MTQ0YTNhOThhZjIwMGM2ODZjM2FlL3RleHRyZWdpb246ZDQ4NzA2MDM0OTkxNDRhM2E5OGFmMjAwYzY4NmMzYWVfOTI4Mw_53716e10-3dce-47cf-8d50-179fb92c3967">75.7</ix:nonFraction> million, which was recorded on the consolidated statement of operations for the year ended December 31, 2020. To measure the fair value of the derivative liability as of the conversion date, the Company engaged a third-party valuation expert.</span></div><div style="margin-bottom:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon conversion, a loss on extinguishment of $<ix:nonFraction unitRef="usd" contextRef="id61aefb0cd4c41cba239205ade4953a0_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN182MS9mcmFnOmQ0ODcwNjAzNDk5MTQ0YTNhOThhZjIwMGM2ODZjM2FlL3RleHRyZWdpb246ZDQ4NzA2MDM0OTkxNDRhM2E5OGFmMjAwYzY4NmMzYWVfOTU2NQ_b9d1d8df-91a4-44be-9243-1981706b1f7f">8.2</ix:nonFraction>&#160;million was recorded on the consolidated statement of operations for the year ended December 31, 2020. This loss represents the difference between (a) the calculated fair value of the derivative liability immediately prior to its derecognition plus the carrying amount of the debt component including any unamortized debt discount and issuance costs and (b) the fair value of the <ix:nonFraction unitRef="shares" contextRef="ic05ddd45fe7a4ed3a38c628d55f5113b_D20200101-20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DebtConversionConvertedInstrumentSharesIssued1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN182MS9mcmFnOmQ0ODcwNjAzNDk5MTQ0YTNhOThhZjIwMGM2ODZjM2FlL3RleHRyZWdpb246ZDQ4NzA2MDM0OTkxNDRhM2E5OGFmMjAwYzY4NmMzYWVfOTk1OQ_a4edced3-0677-4370-a4b8-c8bec60859e5">4,692,364</ix:nonFraction> shares of the Company's common stock issued upon conversion.</span></div><div style="margin-bottom:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">December 2019 Convertible Bonds </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December&#160;26, 2019, the Company closed a private placement of convertible promissory notes (the &#8220;December 2019 Bonds&#8221;) with an aggregate principal amount of <ix:nonFraction unitRef="krw" contextRef="ia9abd9a211df4a149587dd748625eb64_I20191226" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN182MS9mcmFnOmQ0ODcwNjAzNDk5MTQ0YTNhOThhZjIwMGM2ODZjM2FlL3RleHRyZWdpb246ZDQ4NzA2MDM0OTkxNDRhM2E5OGFmMjAwYzY4NmMzYWVfMTAyMTU_f7ebd97f-000d-4918-a3d2-98de7fd9ab41">4.7</ix:nonFraction> billion KRW (approximately USD $<ix:nonFraction unitRef="usd" contextRef="ia9abd9a211df4a149587dd748625eb64_I20191226" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN182MS9mcmFnOmQ0ODcwNjAzNDk5MTQ0YTNhOThhZjIwMGM2ODZjM2FlL3RleHRyZWdpb246ZDQ4NzA2MDM0OTkxNDRhM2E5OGFmMjAwYzY4NmMzYWVfMTAyNDE_901e7ef1-2b05-4d40-826a-82f2225013a7">4.1</ix:nonFraction> million based on the exchange rate on the date of issuance) issued to a Korea-based institutional investor. Net proceeds from the offering were approximately $<ix:nonFraction unitRef="usd" contextRef="i244e899ef7a94a67bec0648d010019b1_D20191226-20191226" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN182MS9mcmFnOmQ0ODcwNjAzNDk5MTQ0YTNhOThhZjIwMGM2ODZjM2FlL3RleHRyZWdpb246ZDQ4NzA2MDM0OTkxNDRhM2E5OGFmMjAwYzY4NmMzYWVfMTAzOTQ_f6c7ff00-26ce-4d59-9325-f73af2b161c3">4.0</ix:nonFraction> million.  </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The December 2019 Bonds, which were unsecured obligations of the Company, were issued on December&#160;31, 2019 and accrued interest at a coupon rate of <ix:nonFraction unitRef="number" contextRef="ia9abd9a211df4a149587dd748625eb64_I20191226" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN182MS9mcmFnOmQ0ODcwNjAzNDk5MTQ0YTNhOThhZjIwMGM2ODZjM2FlL3RleHRyZWdpb246ZDQ4NzA2MDM0OTkxNDRhM2E5OGFmMjAwYzY4NmMzYWVfMTA1NTE_6ea3c298-82b9-4f23-aa6e-0d2ffd425e2b">1.00</ix:nonFraction>% per annum, payable quarterly. The December 2019 Bonds were scheduled to mature on December&#160;31, 2024, unless earlier converted or repurchased. On March 17, 2021, the December 2019 Bonds were converted in full into an aggregate of <ix:nonFraction unitRef="shares" contextRef="i244e899ef7a94a67bec0648d010019b1_D20191226-20191226" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DebtConversionConvertedInstrumentSharesIssued1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN182MS9mcmFnOmQ0ODcwNjAzNDk5MTQ0YTNhOThhZjIwMGM2ODZjM2FlL3RleHRyZWdpb246ZDQ4NzA2MDM0OTkxNDRhM2E5OGFmMjAwYzY4NmMzYWVfNTQ5NzU1ODE2NjYzMA_e8f73c78-a6f2-46e3-8cef-07cdcc7ffa7b">1,009,450</ix:nonFraction> shares of the Company's common stock, leaving no further December 2019 Bonds outstanding. The initial conversion rate was 214.7766 shares per KRW1,000,000 principal amount of Bonds (equivalent to an initial conversion price of approximately USD $<ix:nonFraction unitRef="usdPerShare" contextRef="if2025599c3af4215ad074b05ca0a1e96_I20191226" decimals="2" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN182MS9mcmFnOmQ0ODcwNjAzNDk5MTQ0YTNhOThhZjIwMGM2ODZjM2FlL3RleHRyZWdpb246ZDQ4NzA2MDM0OTkxNDRhM2E5OGFmMjAwYzY4NmMzYWVfMTEzNjg_165e4005-5121-4cd5-88d3-fdb073d467ed">4.00</ix:nonFraction> per share based on the exchange rate as of December&#160;19, 2019), subject to adjustment upon the occurrence of certain events. As of the conversion date of March 17, 2021, the conversion rate had not been reset from the initial conversion rate.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluated the accounting for the issuance of the December 2019 Bonds and concluded that the embedded conversion feature does not require bifurcation from the December 2019 Bonds. Although the embedded conversion feature meets the definition of a derivative, it qualifies for the equity scope exception for instruments that are both indexed to an entity&#8217;s own stock and classified in stockholders&#8217; equity in its consolidated balance sheet. The December 2019 Bonds were denominated in a foreign currency other than the Company&#8217;s functional currency, which would typically violate the settlement provision criteria when analyzing whether the conversion option is indexed to an entity&#8217;s own stock. However, per the terms of the agreement, the functional currency rate required to be used in a conversion scenario was fixed as of the date preceding the date of issuance of the Bonds. Therefore, the fluctuation in functional currency did not impact the settlement of the conversion option. Further, as there was no cash conversion feature or beneficial conversion feature on the date of issuance, and the Bonds were not issued at a substantial premium, all of the proceeds were recorded as a liability. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determined that all other features of the December 2019 Bonds were clearly and closely associated with a debt host and did not require bifurcation as a derivative liability, or the fair value of the feature was immaterial to the Company's condensed consolidated financial statements.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt;text-indent:27pt"><ix:continuation id="i8d4f6153ebc8493ba3657d807367121e" continuedAt="id31fcccf07424442bcda6dd822d3e2b4"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At their issuance, the Company determined that the expected life of the December 2019 Bonds was equal to the period through December 31, 2022 as this represented the point at which the December 2019 Bonds were initially subject to repurchase by the Company at the option of the holders. The effective interest rate of the December 2019 Bonds was <ix:nonFraction unitRef="number" contextRef="ibfeaa89fdfd14b48b6469e81e8224d6e_I20210331" decimals="3" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN182MS9mcmFnOmQ0ODcwNjAzNDk5MTQ0YTNhOThhZjIwMGM2ODZjM2FlL3RleHRyZWdpb246ZDQ4NzA2MDM0OTkxNDRhM2E5OGFmMjAwYzY4NmMzYWVfMTUxMjQ_99add10c-496c-4dc6-ba96-1dae4598b679">6.2</ix:nonFraction>%</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. For the three months ended March 31, 2021 and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2020</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,&#160;the Company recognized $<ix:nonFraction unitRef="usd" contextRef="id6dde602cd3b497f9beb038644f6e0f6_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN182MS9mcmFnOmQ0ODcwNjAzNDk5MTQ0YTNhOThhZjIwMGM2ODZjM2FlL3RleHRyZWdpb246ZDQ4NzA2MDM0OTkxNDRhM2E5OGFmMjAwYzY4NmMzYWVfMTUxNjM_697380df-086c-4b20-a584-342b091e02bd">59,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i1e80eac2298744338c69ed4a78ebcd6b_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN182MS9mcmFnOmQ0ODcwNjAzNDk5MTQ0YTNhOThhZjIwMGM2ODZjM2FlL3RleHRyZWdpb246ZDQ4NzA2MDM0OTkxNDRhM2E5OGFmMjAwYzY4NmMzYWVfMTUxNzA_8bd5a0af-56d6-4141-8351-c46917700641">62,000</ix:nonFraction>, respectively, of interest expense related to the December 2019 Bonds, of which $<ix:nonFraction unitRef="usd" contextRef="id6dde602cd3b497f9beb038644f6e0f6_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestExpenseDebt" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN182MS9mcmFnOmQ0ODcwNjAzNDk5MTQ0YTNhOThhZjIwMGM2ODZjM2FlL3RleHRyZWdpb246ZDQ4NzA2MDM0OTkxNDRhM2E5OGFmMjAwYzY4NmMzYWVfMTUyNTM_7da41d5f-0001-40f9-af70-56d06af3f785">9,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i1e80eac2298744338c69ed4a78ebcd6b_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestExpenseDebt" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN182MS9mcmFnOmQ0ODcwNjAzNDk5MTQ0YTNhOThhZjIwMGM2ODZjM2FlL3RleHRyZWdpb246ZDQ4NzA2MDM0OTkxNDRhM2E5OGFmMjAwYzY4NmMzYWVfMTUyNjA_ef4c9922-8f15-490d-86de-d7b0b5700485">10,000</ix:nonFraction>, respectively, related to the contractual interest coupon.</span></ix:continuation></div><div style="margin-top:5pt;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="id31fcccf07424442bcda6dd822d3e2b4"> As of March&#160;31, 2021, all outstanding December 2019 Bonds were converted into <ix:nonFraction unitRef="shares" contextRef="id6dde602cd3b497f9beb038644f6e0f6_D20210101-20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DebtConversionConvertedInstrumentSharesIssued1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN182MS9mcmFnOmQ0ODcwNjAzNDk5MTQ0YTNhOThhZjIwMGM2ODZjM2FlL3RleHRyZWdpb246ZDQ4NzA2MDM0OTkxNDRhM2E5OGFmMjAwYzY4NmMzYWVfMjE5OTAyMzI3NTQ5Ng_1902c909-e18c-4338-b3c2-9e635f43b776">1,009,450</ix:nonFraction> shares of the Company's common stock. Upon conversion, the $<ix:nonFraction unitRef="usd" contextRef="id6dde602cd3b497f9beb038644f6e0f6_D20210101-20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueConversionOfUnits" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN182MS9mcmFnOmQ0ODcwNjAzNDk5MTQ0YTNhOThhZjIwMGM2ODZjM2FlL3RleHRyZWdpb246ZDQ4NzA2MDM0OTkxNDRhM2E5OGFmMjAwYzY4NmMzYWVfMTA5OTUxMTY1NjYyNA_d123b05a-cd67-4d5a-871d-d7f58b972fd3">4.4</ix:nonFraction>&#160;million carrying value of the December 2019 Bonds was recorded to stockholders' equity.</ix:continuation>  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:5pt;text-indent:27pt"><span><br/></span></div><div id="i1d23d16a69484b63aa007ec686e80337_67"></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">10. <ix:nonNumeric contextRef="i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN182Ny9mcmFnOjU1OGZmMmM3OWUwYzQ5N2Y4OGJjMGExYjBjN2VhZmViL3RleHRyZWdpb246NTU4ZmYyYzc5ZTBjNDk3Zjg4YmMwYTFiMGM3ZWFmZWJfNTMwMg_e4f0195c-71ce-44af-a215-f740928a4272" continuedAt="i875649c8b95843c2a8059747d733966e" escape="true">Stockholders&#8217; Equity</ix:nonNumeric></span></div><ix:continuation id="i875649c8b95843c2a8059747d733966e" continuedAt="id0d29bd0acb8470aad9f117533b9c294"><ix:nonNumeric contextRef="i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331" name="us-gaap:ScheduleOfStockByClassTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN182Ny9mcmFnOjU1OGZmMmM3OWUwYzQ5N2Y4OGJjMGExYjBjN2VhZmViL3RleHRyZWdpb246NTU4ZmYyYzc5ZTBjNDk3Zjg4YmMwYTFiMGM3ZWFmZWJfNTI5NQ_780219b6-09d0-481f-ae1a-7c6ed37d47ec" escape="true"><div style="margin-bottom:10pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of the Company's authorized and issued common and preferred stock as of March&#160;31, 2021 and December&#160;31, 2020: </span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.830%"><tr><td style="width:1.0%"></td><td style="width:42.095%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.473%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.473%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.136%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.106%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Outstanding as of</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Authorized</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Issued</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common Stock, par value $<ix:nonFraction unitRef="usdPerShare" contextRef="ic36b9cedad7f41a6b9eb223b09b7186c_I20210331" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN182Ny9mcmFnOjU1OGZmMmM3OWUwYzQ5N2Y4OGJjMGExYjBjN2VhZmViL3RhYmxlOmZjODdjMzY0MjY5NzQ4NjA4OGJiYTlkYTA2Yjc0NzNiL3RhYmxlcmFuZ2U6ZmM4N2MzNjQyNjk3NDg2MDg4YmJhOWRhMDZiNzQ3M2JfMi0wLTEtMS0wL3RleHRyZWdpb246MzYyNDgzYWM4YmQ1NDA2MDk5NTY4YjRjMmJjM2U3NTBfMjg_8be60fe0-d632-4779-950e-8e7ee2367c9c"><ix:nonFraction unitRef="usdPerShare" contextRef="i066bb5b0a9e84c0a878b1e800703d92b_I20201231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN182Ny9mcmFnOjU1OGZmMmM3OWUwYzQ5N2Y4OGJjMGExYjBjN2VhZmViL3RhYmxlOmZjODdjMzY0MjY5NzQ4NjA4OGJiYTlkYTA2Yjc0NzNiL3RhYmxlcmFuZ2U6ZmM4N2MzNjQyNjk3NDg2MDg4YmJhOWRhMDZiNzQ3M2JfMi0wLTEtMS0wL3RleHRyZWdpb246MzYyNDgzYWM4YmQ1NDA2MDk5NTY4YjRjMmJjM2U3NTBfMjg_c57d2664-d10f-4f28-b935-ccc73fba18cd">0.001</ix:nonFraction></ix:nonFraction> per share</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic36b9cedad7f41a6b9eb223b09b7186c_I20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN182Ny9mcmFnOjU1OGZmMmM3OWUwYzQ5N2Y4OGJjMGExYjBjN2VhZmViL3RhYmxlOmZjODdjMzY0MjY5NzQ4NjA4OGJiYTlkYTA2Yjc0NzNiL3RhYmxlcmFuZ2U6ZmM4N2MzNjQyNjk3NDg2MDg4YmJhOWRhMDZiNzQ3M2JfMi0xLTEtMS0w_c53ba2ff-d572-4965-9c55-340c25b5d25d">600,000,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic36b9cedad7f41a6b9eb223b09b7186c_I20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN182Ny9mcmFnOjU1OGZmMmM3OWUwYzQ5N2Y4OGJjMGExYjBjN2VhZmViL3RhYmxlOmZjODdjMzY0MjY5NzQ4NjA4OGJiYTlkYTA2Yjc0NzNiL3RhYmxlcmFuZ2U6ZmM4N2MzNjQyNjk3NDg2MDg4YmJhOWRhMDZiNzQ3M2JfMi0zLTEtMS0w_1403fcb2-ea64-4af7-b3b6-03a5f252785a">209,334,036</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic36b9cedad7f41a6b9eb223b09b7186c_I20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN182Ny9mcmFnOjU1OGZmMmM3OWUwYzQ5N2Y4OGJjMGExYjBjN2VhZmViL3RhYmxlOmZjODdjMzY0MjY5NzQ4NjA4OGJiYTlkYTA2Yjc0NzNiL3RhYmxlcmFuZ2U6ZmM4N2MzNjQyNjk3NDg2MDg4YmJhOWRhMDZiNzQ3M2JfMi01LTEtMS0w_c5db721b-8907-42cb-b11c-14d538387220">209,334,036</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i066bb5b0a9e84c0a878b1e800703d92b_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN182Ny9mcmFnOjU1OGZmMmM3OWUwYzQ5N2Y4OGJjMGExYjBjN2VhZmViL3RhYmxlOmZjODdjMzY0MjY5NzQ4NjA4OGJiYTlkYTA2Yjc0NzNiL3RhYmxlcmFuZ2U6ZmM4N2MzNjQyNjk3NDg2MDg4YmJhOWRhMDZiNzQ3M2JfMi03LTEtMS0w_db91d33a-d294-4b0e-a563-15bdcb4f0f74">186,851,493</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Series&#160;C Preferred Stock, par value $<ix:nonFraction unitRef="usdPerShare" contextRef="ic385c05c2d7e4d79bc77a34f466a4d92_I20201231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN182Ny9mcmFnOjU1OGZmMmM3OWUwYzQ5N2Y4OGJjMGExYjBjN2VhZmViL3RhYmxlOmZjODdjMzY0MjY5NzQ4NjA4OGJiYTlkYTA2Yjc0NzNiL3RhYmxlcmFuZ2U6ZmM4N2MzNjQyNjk3NDg2MDg4YmJhOWRhMDZiNzQ3M2JfNS0wLTEtMS0wL3RleHRyZWdpb246MTNkZDQ4Y2NiODcxNDE0MmJiNDc1YWE3NThhMmMyY2VfNDA_177edcda-9370-47c1-9a3c-19cbfd7d05e8"><ix:nonFraction unitRef="usdPerShare" contextRef="i8080707135874457acfda210b14f8caa_I20210331" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN182Ny9mcmFnOjU1OGZmMmM3OWUwYzQ5N2Y4OGJjMGExYjBjN2VhZmViL3RhYmxlOmZjODdjMzY0MjY5NzQ4NjA4OGJiYTlkYTA2Yjc0NzNiL3RhYmxlcmFuZ2U6ZmM4N2MzNjQyNjk3NDg2MDg4YmJhOWRhMDZiNzQ3M2JfNS0wLTEtMS0wL3RleHRyZWdpb246MTNkZDQ4Y2NiODcxNDE0MmJiNDc1YWE3NThhMmMyY2VfNDA_a6dd7763-37ad-4d29-8113-9497184eb88f">0.001</ix:nonFraction></ix:nonFraction> per share</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8080707135874457acfda210b14f8caa_I20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN182Ny9mcmFnOjU1OGZmMmM3OWUwYzQ5N2Y4OGJjMGExYjBjN2VhZmViL3RhYmxlOmZjODdjMzY0MjY5NzQ4NjA4OGJiYTlkYTA2Yjc0NzNiL3RhYmxlcmFuZ2U6ZmM4N2MzNjQyNjk3NDg2MDg4YmJhOWRhMDZiNzQ3M2JfNS0xLTEtMS0w_bd5549bd-965a-4ba1-aac9-b5f3dec9bac3">1,091</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8080707135874457acfda210b14f8caa_I20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN182Ny9mcmFnOjU1OGZmMmM3OWUwYzQ5N2Y4OGJjMGExYjBjN2VhZmViL3RhYmxlOmZjODdjMzY0MjY5NzQ4NjA4OGJiYTlkYTA2Yjc0NzNiL3RhYmxlcmFuZ2U6ZmM4N2MzNjQyNjk3NDg2MDg4YmJhOWRhMDZiNzQ3M2JfNS0zLTEtMS0w_3bd1e55f-68b2-4c59-9be1-483062553696">1,091</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8080707135874457acfda210b14f8caa_I20210331" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN182Ny9mcmFnOjU1OGZmMmM3OWUwYzQ5N2Y4OGJjMGExYjBjN2VhZmViL3RhYmxlOmZjODdjMzY0MjY5NzQ4NjA4OGJiYTlkYTA2Yjc0NzNiL3RhYmxlcmFuZ2U6ZmM4N2MzNjQyNjk3NDg2MDg4YmJhOWRhMDZiNzQ3M2JfNS01LTEtMS0w_33443cee-afba-44fc-9466-68e9c32906d0">9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic385c05c2d7e4d79bc77a34f466a4d92_I20201231" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN182Ny9mcmFnOjU1OGZmMmM3OWUwYzQ5N2Y4OGJjMGExYjBjN2VhZmViL3RhYmxlOmZjODdjMzY0MjY5NzQ4NjA4OGJiYTlkYTA2Yjc0NzNiL3RhYmxlcmFuZ2U6ZmM4N2MzNjQyNjk3NDg2MDg4YmJhOWRhMDZiNzQ3M2JfNS03LTEtMS0w_74e72ed5-9e7b-4716-b931-7ce6a47cb1cf">9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Preferred Stock</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2020, <ix:nonFraction unitRef="shares" contextRef="i25c9bfdd10384a7ea0e5d634721712a4_D20200601-20200630" decimals="INF" name="us-gaap:ConversionOfStockSharesConverted1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN182Ny9mcmFnOjU1OGZmMmM3OWUwYzQ5N2Y4OGJjMGExYjBjN2VhZmViL3RleHRyZWdpb246NTU4ZmYyYzc5ZTBjNDk3Zjg4YmMwYTFiMGM3ZWFmZWJfMTc0_038726a7-1301-467d-80b8-ffc8bec5b93d">14</ix:nonFraction> shares of the Company&#8217;s Series&#160;C preferred stock were converted into an aggregate of <ix:nonFraction unitRef="shares" contextRef="ieee221f2ad874f95afe5bd8f6f749911_D20200601-20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ConversionOfStockSharesIssued1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN182Ny9mcmFnOjU1OGZmMmM3OWUwYzQ5N2Y4OGJjMGExYjBjN2VhZmViL3RleHRyZWdpb246NTU4ZmYyYzc5ZTBjNDk3Zjg4YmMwYTFiMGM3ZWFmZWJfMjYy_de93c379-f18e-4a0a-a534-99f1c8d01025">5,147</ix:nonFraction> shares of the Company&#8217;s common stock.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Common Stock</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 25, 2021, the Company closed an underwritten public offering of <ix:nonFraction unitRef="shares" contextRef="i1105e820c10e4516b0891db1691036b2_D20210125-20210125" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN182Ny9mcmFnOjU1OGZmMmM3OWUwYzQ5N2Y4OGJjMGExYjBjN2VhZmViL3RleHRyZWdpb246NTU4ZmYyYzc5ZTBjNDk3Zjg4YmMwYTFiMGM3ZWFmZWJfMTA5OTUxMTYzNjMwNQ_e0795d1b-8834-4eb6-b71b-72daaa78b121">20,355,000</ix:nonFraction> shares of common stock at a public offering price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i0aaa3652e67040b09e4bec889642601e_I20210125" decimals="2" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN182Ny9mcmFnOjU1OGZmMmM3OWUwYzQ5N2Y4OGJjMGExYjBjN2VhZmViL3RleHRyZWdpb246NTU4ZmYyYzc5ZTBjNDk3Zjg4YmMwYTFiMGM3ZWFmZWJfMjE5OTAyMzI2NDE5Mg_4f6e21be-4246-4f7d-af93-233c7b0828ef">8.50</ix:nonFraction> per share. The net proceeds to the Company, after deducting the underwriters' discounts and commissions and other estimated offering expenses, were $<ix:nonFraction unitRef="usd" contextRef="i0aaa3652e67040b09e4bec889642601e_I20210125" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesForCommissionsExpenseAndTaxes" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN182Ny9mcmFnOjU1OGZmMmM3OWUwYzQ5N2Y4OGJjMGExYjBjN2VhZmViL3RleHRyZWdpb246NTU4ZmYyYzc5ZTBjNDk3Zjg4YmMwYTFiMGM3ZWFmZWJfMTA5OTUxMTYzNjI4OQ_2250e86e-ad2e-4a3c-a618-049ce57b9c17">162.1</ix:nonFraction>&#160;million. </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2018, the Company entered into a Sales Agreement with an outside placement agent (the &#8220;Placement Agent&#8221;) to sell shares of its common stock with aggregate gross proceeds of up to $<ix:nonFraction unitRef="usd" contextRef="if1aa2ac57025445591f02f2a2b4a827d_D20180501-20180531" decimals="INF" format="ixt:numdotdecimal" name="ino:StockSalesAgreementMaximumAuthorizedAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN182Ny9mcmFnOjU1OGZmMmM3OWUwYzQ5N2Y4OGJjMGExYjBjN2VhZmViL3RleHRyZWdpb246NTU4ZmYyYzc5ZTBjNDk3Zjg4YmMwYTFiMGM3ZWFmZWJfNTAy_d9fa0a2d-204e-4d4c-b207-8660ed588c83">100.0</ix:nonFraction> million, from time to time, through an &#8220;at-the-market&#8221; equity offering program under which the Placement Agent acted as sales agent. During the first quarter of 2020, the Company and the Placement Agent entered into a first and second amendment to the Sales Agreement (the "Prior Sales Agreement") to increase the amount of common stock that may be sold under the Sales Agreement from $<ix:nonFraction unitRef="usd" contextRef="if1aa2ac57025445591f02f2a2b4a827d_D20180501-20180531" decimals="INF" format="ixt:numdotdecimal" name="ino:StockSalesAgreementMaximumAuthorizedAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN182Ny9mcmFnOjU1OGZmMmM3OWUwYzQ5N2Y4OGJjMGExYjBjN2VhZmViL3RleHRyZWdpb246NTU4ZmYyYzc5ZTBjNDk3Zjg4YmMwYTFiMGM3ZWFmZWJfODg2_c8583572-5d28-4bf5-90d1-3454abd795d7">100.0</ix:nonFraction> million to $<ix:nonFraction unitRef="usd" contextRef="ie8f61637671d4831a979db68dfe70295_D20200101-20200331" decimals="INF" format="ixt:numdotdecimal" name="ino:StockSalesAgreementMaximumAuthorizedAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN182Ny9mcmFnOjU1OGZmMmM3OWUwYzQ5N2Y4OGJjMGExYjBjN2VhZmViL3RleHRyZWdpb246NTU4ZmYyYzc5ZTBjNDk3Zjg4YmMwYTFiMGM3ZWFmZWJfODky_73e93403-ec9a-4c16-96c3-b565f323f11b">250.0</ix:nonFraction> million. As of March 31, 2020, there was <ix:nonFraction unitRef="usd" contextRef="i33021fc5991544e6bdc6d451e0bf882e_I20200331" decimals="INF" format="ixt-sec:numwordsen" name="ino:StockSalesAgreementRemainingAuthorizedAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN182Ny9mcmFnOjU1OGZmMmM3OWUwYzQ5N2Y4OGJjMGExYjBjN2VhZmViL3RleHRyZWdpb246NTU4ZmYyYzc5ZTBjNDk3Zjg4YmMwYTFiMGM3ZWFmZWJfOTI4_5a71498d-41b9-456e-b295-24efc87b6a5b">no</ix:nonFraction> remaining capacity under the Prior Sales Agreement. On April 3, 2020, the Company and the Placement Agent entered into a new Sales Agreement (the "New Sales Agreement") to sell shares of its common stock</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 3, 2020 and May 12, 2020, the Company filed prospectus supplements pursuant to the New Sales Agreement for the offer and sale of its Common Stock for aggregate gross proceeds of up to an aggregate of $<ix:nonFraction unitRef="usd" contextRef="if1222ca24d5f4b93a286cd93f4df2429_D20200403-20200512" decimals="INF" format="ixt:numdotdecimal" name="ino:StockSalesAgreementMaximumAuthorizedAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN182Ny9mcmFnOjU1OGZmMmM3OWUwYzQ5N2Y4OGJjMGExYjBjN2VhZmViL3RleHRyZWdpb246NTU4ZmYyYzc5ZTBjNDk3Zjg4YmMwYTFiMGM3ZWFmZWJfMTM0Ng_647c275f-1bda-4fa0-98b4-4c965b90ee52">250.0</ix:nonFraction> million. </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March 31, 2020, the Company sold <ix:nonFraction unitRef="shares" contextRef="ie8f61637671d4831a979db68dfe70295_D20200101-20200331" decimals="INF" format="ixt:numdotdecimal" name="ino:StockSaleAgreementAggregateNumberofSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN182Ny9mcmFnOjU1OGZmMmM3OWUwYzQ5N2Y4OGJjMGExYjBjN2VhZmViL3RleHRyZWdpb246NTU4ZmYyYzc5ZTBjNDk3Zjg4YmMwYTFiMGM3ZWFmZWJfMjE0OA_22e8992d-2e53-4a0c-b8de-80162ecd8c30">43,148,952</ix:nonFraction> shares of its common stock under the Prior Sales Agreement. The sales were made at a weighted average price of $<ix:nonFraction unitRef="usdPerShare" contextRef="ie8f61637671d4831a979db68dfe70295_D20200101-20200331" decimals="2" name="ino:StockSaleAgreementWeightedAveragePricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN182Ny9mcmFnOjU1OGZmMmM3OWUwYzQ5N2Y4OGJjMGExYjBjN2VhZmViL3RleHRyZWdpb246NTU4ZmYyYzc5ZTBjNDk3Zjg4YmMwYTFiMGM3ZWFmZWJfMjI2Mg_fbbfd6c7-9048-4a7f-99ee-80779cd9aed2">4.92</ix:nonFraction> per share, resulting in aggregate net proceeds of $<ix:nonFraction unitRef="usd" contextRef="ie8f61637671d4831a979db68dfe70295_D20200101-20200331" decimals="-5" format="ixt:numdotdecimal" name="ino:StockSaleAgreementAggregateProceedsFromIssuanceOfStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN182Ny9mcmFnOjU1OGZmMmM3OWUwYzQ5N2Y4OGJjMGExYjBjN2VhZmViL3RleHRyZWdpb246NTU4ZmYyYzc5ZTBjNDk3Zjg4YmMwYTFiMGM3ZWFmZWJfMjMxNQ_69a58a06-bd8c-4fc8-b748-e46e8168ce55">208.2</ix:nonFraction> million. As of March 31, 2020, there was <ix:nonFraction unitRef="usd" contextRef="i33021fc5991544e6bdc6d451e0bf882e_I20200331" decimals="INF" format="ixt-sec:numwordsen" name="ino:StockSalesAgreementRemainingAuthorizedAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN182Ny9mcmFnOjU1OGZmMmM3OWUwYzQ5N2Y4OGJjMGExYjBjN2VhZmViL3RleHRyZWdpb246NTU4ZmYyYzc5ZTBjNDk3Zjg4YmMwYTFiMGM3ZWFmZWJfMjM1MQ_4aa1411c-8cab-4f78-abf1-14a2f19023fd">no</ix:nonFraction> remaining capacity under the Prior Sales Agreement.</span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">During the year ended December 31, 2020, the Company sold a total of <ix:nonFraction unitRef="shares" contextRef="i5bdeced5a8d5445a82941bb4b6c54b39_D20200101-20201231" decimals="INF" format="ixt:numdotdecimal" name="ino:StockSaleAgreementAggregateNumberofSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN182Ny9mcmFnOjU1OGZmMmM3OWUwYzQ5N2Y4OGJjMGExYjBjN2VhZmViL3RleHRyZWdpb246NTU4ZmYyYzc5ZTBjNDk3Zjg4YmMwYTFiMGM3ZWFmZWJfMjQ2OA_60bfc21c-3bb7-4c02-91e6-96c1851f17f8">22,919,934</ix:nonFraction> shares of its common stock under the New Sales Agreement. The sales were made at a weighted average price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i5bdeced5a8d5445a82941bb4b6c54b39_D20200101-20201231" decimals="2" name="ino:StockSaleAgreementWeightedAveragePricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN182Ny9mcmFnOjU1OGZmMmM3OWUwYzQ5N2Y4OGJjMGExYjBjN2VhZmViL3RleHRyZWdpb246NTU4ZmYyYzc5ZTBjNDk3Zjg4YmMwYTFiMGM3ZWFmZWJfMjU4MA_8ca8f7cc-9e3c-4e49-bf94-a29417f45936">10.91</ix:nonFraction> per share resulting in aggregate net proceeds of $<ix:nonFraction unitRef="usd" contextRef="i5bdeced5a8d5445a82941bb4b6c54b39_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="ino:StockSaleAgreementAggregateProceedsFromIssuanceOfStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN182Ny9mcmFnOjU1OGZmMmM3OWUwYzQ5N2Y4OGJjMGExYjBjN2VhZmViL3RleHRyZWdpb246NTU4ZmYyYzc5ZTBjNDk3Zjg4YmMwYTFiMGM3ZWFmZWJfMjYzMw_c48e6a1d-0e7b-470e-a95e-eb6e656a3ae2">246.2</ix:nonFraction> million. There were no additional sales during the three months ended March 31, 2021, and as of March 31, 2021, there was <ix:nonFraction unitRef="usd" contextRef="ic7ebb6cd60ce4e4c84cfe4f6fd8ca6fa_I20200331" decimals="INF" format="ixt-sec:numwordsen" name="ino:StockSalesAgreementRemainingAuthorizedAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN182Ny9mcmFnOjU1OGZmMmM3OWUwYzQ5N2Y4OGJjMGExYjBjN2VhZmViL3RleHRyZWdpb246NTU4ZmYyYzc5ZTBjNDk3Zjg4YmMwYTFiMGM3ZWFmZWJfMjY0OA_a0af528d-48c6-43c1-a5c7-e1dd8cd933f0">no</ix:nonFraction> remaining capacity under the New Sales Agreement. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock Options and Restricted Stock Units</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has a stock-based incentive plan, the 2016 Omnibus Incentive Plan (as amended to date, the "2016 Incentive Plan"), pursuant to which the Company may grant stock options, restricted stock awards, restricted stock units and other stock-based awards or short-term cash incentive awards to employees, directors and consultants. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2016 Incentive Plan was originally approved by the Company's stockholders on May 13, 2016, and an amendment to the plan to increase the number of shares available for issuance was approved by the stockholders on May 8, 2019. As of March 31, 2021, the maximum number of shares of the Company&#8217;s common stock available for issuance over the term of the 2016 Incentive Plan was <ix:nonFraction unitRef="shares" contextRef="i20753e05a58f4787ad7efb7458e2f0c5_I20160513" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN182Ny9mcmFnOjU1OGZmMmM3OWUwYzQ5N2Y4OGJjMGExYjBjN2VhZmViL3RleHRyZWdpb246NTU4ZmYyYzc5ZTBjNDk3Zjg4YmMwYTFiMGM3ZWFmZWJfMzc1OQ_f7b2dace-6ff3-4033-a630-4a7e867553ad">20,000,000</ix:nonFraction> shares. On the first business day of each calendar year, such maximum number of shares is further increased by&#160;<ix:nonFraction unitRef="shares" contextRef="i20753e05a58f4787ad7efb7458e2f0c5_I20160513" decimals="INF" format="ixt:numdotdecimal" name="ino:NumberOfPotentialSharesAuthorizedForIssuanceUnderShareBasedCompensationPlan" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN182Ny9mcmFnOjU1OGZmMmM3OWUwYzQ5N2Y4OGJjMGExYjBjN2VhZmViL3RleHRyZWdpb246NTU4ZmYyYzc5ZTBjNDk3Zjg4YmMwYTFiMGM3ZWFmZWJfMzkyNA_23a50ef3-543c-4732-9065-acb44a9006e2">2,000,000</ix:nonFraction> shares of common stock unless the Board determines, prior to January 1 for any such calendar year, to increase such maximum amount by a fewer number of shares or not to increase the maximum amount at all for such year. On January 1, 2021, the maximum number of shares increased by <ix:nonFraction unitRef="shares" contextRef="i23432a1ccb974c6d9ef1ec635e8143ed_I20210101" decimals="INF" format="ixt:numdotdecimal" name="ino:SharebasedCompensationArrangementbySharebasedPaymentAwardIncreaseInNumberofSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN182Ny9mcmFnOjU1OGZmMmM3OWUwYzQ5N2Y4OGJjMGExYjBjN2VhZmViL3RleHRyZWdpb246NTU4ZmYyYzc5ZTBjNDk3Zjg4YmMwYTFiMGM3ZWFmZWJfNDI0NA_090ea161-9a2e-4b88-9a5b-7be2dfc0f56f">2,000,000</ix:nonFraction>. At March&#160;31, 2021, the Company had <ix:nonFraction unitRef="shares" contextRef="iddaa5cd4d85f4565b4df009a33385893_I20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN182Ny9mcmFnOjU1OGZmMmM3OWUwYzQ5N2Y4OGJjMGExYjBjN2VhZmViL3RleHRyZWdpb246NTU4ZmYyYzc5ZTBjNDk3Zjg4YmMwYTFiMGM3ZWFmZWJfNDQ0NA_81ffab09-6b2f-4f13-9e68-a754a36e8b73">5,251,776</ix:nonFraction> shares of common stock available for future grant under the 2016 Incentive Plan, <ix:nonFraction unitRef="shares" contextRef="iddaa5cd4d85f4565b4df009a33385893_I20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN182Ny9mcmFnOjU1OGZmMmM3OWUwYzQ5N2Y4OGJjMGExYjBjN2VhZmViL3RleHRyZWdpb246NTU4ZmYyYzc5ZTBjNDk3Zjg4YmMwYTFiMGM3ZWFmZWJfNDUyOA_3f8a1d8f-e8b9-45d2-9e2b-dda2884443d2">2,610,130</ix:nonFraction> shares underlying </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="id0d29bd0acb8470aad9f117533b9c294" continuedAt="ie214d8ba575f4020beaf7b2ebea24a6e">outstanding but unvested restricted stock units and options outstanding to purchase <ix:nonFraction unitRef="shares" contextRef="iddaa5cd4d85f4565b4df009a33385893_I20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockOtherSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN182Ny9mcmFnOjU1OGZmMmM3OWUwYzQ5N2Y4OGJjMGExYjBjN2VhZmViL3RleHRyZWdpb246NTU4ZmYyYzc5ZTBjNDk3Zjg4YmMwYTFiMGM3ZWFmZWJfNDYzMw_414a7934-2c54-4cfa-80bf-3b2bc61b8025">7,994,029</ix:nonFraction> shares of common stock under the 2016 Incentive Plan. The awards granted and available for future grant under the 2016 Incentive Plan generally vest over <ix:nonNumeric contextRef="i52e41bdcfa1f4dd5ae13e4662c088e67_D20210101-20210331" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN182Ny9mcmFnOjU1OGZmMmM3OWUwYzQ5N2Y4OGJjMGExYjBjN2VhZmViL3RleHRyZWdpb246NTU4ZmYyYzc5ZTBjNDk3Zjg4YmMwYTFiMGM3ZWFmZWJfNDc5MA_5776f897-e1be-4176-91bc-7fe52a63becb">three years</ix:nonNumeric> and have a maximum contractual term of <ix:nonNumeric contextRef="i52e41bdcfa1f4dd5ae13e4662c088e67_D20210101-20210331" format="ixt-sec:durwordsen" name="ino:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN182Ny9mcmFnOjU1OGZmMmM3OWUwYzQ5N2Y4OGJjMGExYjBjN2VhZmViL3RleHRyZWdpb246NTU4ZmYyYzc5ZTBjNDk3Zjg4YmMwYTFiMGM3ZWFmZWJfNDgzMg_716b2ba5-2db8-49e4-95c6-21e692761eb7">ten years</ix:nonNumeric>. The 2016 Incentive Plan terminates by its terms on March&#160;9, 2026.</ix:continuation></span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ie214d8ba575f4020beaf7b2ebea24a6e">The Amended and Restated 2007 Omnibus Incentive Plan (the "2007 Incentive Plan") was adopted on March&#160;31, 2007 and terminated by its terms on March&#160;31, 2017. At March&#160;31, 2021, the Company had options outstanding to purchase <ix:nonFraction unitRef="shares" contextRef="i8c0e2d352fcb4b638dd0a198e31e2f72_I20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockOtherSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN182Ny9mcmFnOjU1OGZmMmM3OWUwYzQ5N2Y4OGJjMGExYjBjN2VhZmViL3RleHRyZWdpb246NTU4ZmYyYzc5ZTBjNDk3Zjg4YmMwYTFiMGM3ZWFmZWJfNTExNQ_324cee3b-4050-4310-b47c-ac22ef510285">2,832,443</ix:nonFraction> shares of common stock under the 2007 Incentive Plan. The awards granted under the 2007 Incentive Plan generally vest over <ix:nonNumeric contextRef="i6236143f37a74492a26b2b567dd6525a_D20210101-20210331" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN182Ny9mcmFnOjU1OGZmMmM3OWUwYzQ5N2Y4OGJjMGExYjBjN2VhZmViL3RleHRyZWdpb246NTU4ZmYyYzc5ZTBjNDk3Zjg4YmMwYTFiMGM3ZWFmZWJfNTI0MQ_801aaccd-10e0-484d-8d48-4cfd1e5a91da">three years</ix:nonNumeric> and have a maximum contractual term of <ix:nonNumeric contextRef="i6236143f37a74492a26b2b567dd6525a_D20210101-20210331" format="ixt-sec:durwordsen" name="ino:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN182Ny9mcmFnOjU1OGZmMmM3OWUwYzQ5N2Y4OGJjMGExYjBjN2VhZmViL3RleHRyZWdpb246NTU4ZmYyYzc5ZTBjNDk3Zjg4YmMwYTFiMGM3ZWFmZWJfNTI4Mw_23fbd00f-d92f-4d19-bc42-be9c8f375251">ten years</ix:nonNumeric>.</ix:continuation> </span></div><div><span><br/></span></div><div id="i1d23d16a69484b63aa007ec686e80337_70"></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">11.  <ix:nonNumeric contextRef="i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331" name="us-gaap:EarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN183MC9mcmFnOjFlNmI5Y2VmMzVkOTRhNzY4MzNjMWExNjQ2MjdlYTVhL3RleHRyZWdpb246MWU2YjljZWYzNWQ5NGE3NjgzM2MxYTE2NDYyN2VhNWFfMjEyNw_f81b3a79-c3d1-4289-a45f-c1c22607a887" continuedAt="iadc9ac9f7e6b46f7954d79a2524f56ca" escape="true">Net Loss Per Share </ix:nonNumeric></span></div><ix:continuation id="iadc9ac9f7e6b46f7954d79a2524f56ca"><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net loss per share is computed by dividing the net loss for the period by the weighted average number of shares of common stock outstanding during the period. Diluted net loss per share is calculated in accordance with the treasury stock method for the outstanding stock options and restricted stock units and refle</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">cts the potential dilution that would occur if securities or other con</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">tracts to issue common stock were exercised or converted to common stock. The dilutive impact of the outstanding Notes and Bonds issued by the Company (discussed in Note 9) has been considered using the "if-converted" method. The calculation of diluted net loss per share requires that, to the extent the average market price of the underlying shares for the reporting period exceeds the exercise price of the options or other securities and the presumed exercise of such securities are dilutive to net loss per share for the period, an adjustment to the net loss used in the calculation is required to remove the change in fair value of such securities from the numerator for the period. Likewise, an adjustment to the denominator is required to reflect the related dilutive shares, if any. For the three months ended March 31, 2021 and 2020, basic and diluted net loss per share were the same, as the assumed exercise or settlement of stock options and restricted stock units and the potentially dilutive shares issuable upon conversion of the Notes and Bonds would have been anti-dilutive.</span></div><ix:nonNumeric contextRef="i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN183MC9mcmFnOjFlNmI5Y2VmMzVkOTRhNzY4MzNjMWExNjQ2MjdlYTVhL3RleHRyZWdpb246MWU2YjljZWYzNWQ5NGE3NjgzM2MxYTE2NDYyN2VhNWFfMjEyOA_b0377801-470c-48b9-be48-ba587d000d6c" escape="true"><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes potential shares of common stock that were excluded from the diluted net loss per share calculation because of their anti-dilutive effect for the three months ended March 31, 2021 and 2020: </span></div><div style="margin-bottom:6pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.170%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.549%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.263%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Common Stock Equivalents</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options to purchase common stock</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i87899c635a3d4f67af30c19682c88a69_D20210101-20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN183MC9mcmFnOjFlNmI5Y2VmMzVkOTRhNzY4MzNjMWExNjQ2MjdlYTVhL3RhYmxlOjA2N2RmOTNlMzNkNDQ1MWI5NGY4NDBiZDIwMmQ1OWZlL3RhYmxlcmFuZ2U6MDY3ZGY5M2UzM2Q0NDUxYjk0Zjg0MGJkMjAyZDU5ZmVfMi0xLTEtMS0w_9d6ab1ce-881d-473b-a76c-0fb31c2be1bc">10,826,472</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iaf2883d0b0f44f8aa8540000815316c3_D20200101-20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN183MC9mcmFnOjFlNmI5Y2VmMzVkOTRhNzY4MzNjMWExNjQ2MjdlYTVhL3RhYmxlOjA2N2RmOTNlMzNkNDQ1MWI5NGY4NDBiZDIwMmQ1OWZlL3RhYmxlcmFuZ2U6MDY3ZGY5M2UzM2Q0NDUxYjk0Zjg0MGJkMjAyZDU5ZmVfMi0zLTEtMS0w_8200a753-debe-43cf-81c4-2a9e59024aac">9,615,986</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service-based restricted stock units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6aade12f14664b7bafdd10b536ffc9d1_D20210101-20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN183MC9mcmFnOjFlNmI5Y2VmMzVkOTRhNzY4MzNjMWExNjQ2MjdlYTVhL3RhYmxlOjA2N2RmOTNlMzNkNDQ1MWI5NGY4NDBiZDIwMmQ1OWZlL3RhYmxlcmFuZ2U6MDY3ZGY5M2UzM2Q0NDUxYjk0Zjg0MGJkMjAyZDU5ZmVfMy0xLTEtMS0w_256309fd-1dc3-492e-9b0e-0594a40c2e7d">2,610,130</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iecc10df4b79a45de9ffdafc4389503d2_D20200101-20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN183MC9mcmFnOjFlNmI5Y2VmMzVkOTRhNzY4MzNjMWExNjQ2MjdlYTVhL3RhYmxlOjA2N2RmOTNlMzNkNDQ1MWI5NGY4NDBiZDIwMmQ1OWZlL3RhYmxlcmFuZ2U6MDY3ZGY5M2UzM2Q0NDUxYjk0Zjg0MGJkMjAyZDU5ZmVfMy0zLTEtMS0w_971747a3-a249-4313-866f-50c4bf5c9837">2,667,710</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Performance-based restricted stock units</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i623f1c7b68164c0e86bc10eaa5f5a7e5_D20210101-20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN183MC9mcmFnOjFlNmI5Y2VmMzVkOTRhNzY4MzNjMWExNjQ2MjdlYTVhL3RhYmxlOjA2N2RmOTNlMzNkNDQ1MWI5NGY4NDBiZDIwMmQ1OWZlL3RhYmxlcmFuZ2U6MDY3ZGY5M2UzM2Q0NDUxYjk0Zjg0MGJkMjAyZDU5ZmVfNC0xLTEtMS0w_1e66be7f-a23a-462b-908b-0b2d0bfb1873">663,353</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i75ed8cb3d08c4c16a0b40f1f253b731e_D20200101-20200331" decimals="0" format="ixt:zerodash" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN183MC9mcmFnOjFlNmI5Y2VmMzVkOTRhNzY4MzNjMWExNjQ2MjdlYTVhL3RhYmxlOjA2N2RmOTNlMzNkNDQ1MWI5NGY4NDBiZDIwMmQ1OWZlL3RhYmxlcmFuZ2U6MDY3ZGY5M2UzM2Q0NDUxYjk0Zjg0MGJkMjAyZDU5ZmVfNC0zLTEtMS0w_3f16f9ee-3425-4e13-bfe5-ed3314b88396">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible preferred stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i71ea1499a3b143cb8017808669a7a908_D20210101-20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN183MC9mcmFnOjFlNmI5Y2VmMzVkOTRhNzY4MzNjMWExNjQ2MjdlYTVhL3RhYmxlOjA2N2RmOTNlMzNkNDQ1MWI5NGY4NDBiZDIwMmQ1OWZlL3RhYmxlcmFuZ2U6MDY3ZGY5M2UzM2Q0NDUxYjk0Zjg0MGJkMjAyZDU5ZmVfNS0xLTEtMS0w_d2e7a71d-9a4f-4ccd-b6cc-b5bbf6b2d969">3,309</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ifb05b300647c4bdb9d4dd1b61fa9ee95_D20200101-20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN183MC9mcmFnOjFlNmI5Y2VmMzVkOTRhNzY4MzNjMWExNjQ2MjdlYTVhL3RhYmxlOjA2N2RmOTNlMzNkNDQ1MWI5NGY4NDBiZDIwMmQ1OWZlL3RhYmxlcmFuZ2U6MDY3ZGY5M2UzM2Q0NDUxYjk0Zjg0MGJkMjAyZDU5ZmVfNS0zLTEtMS0w_4c2b97e0-ca5b-4004-a949-aea1b728f286">8,456</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2d25495c4b6c4835a012eb7bc163fc6b_D20210101-20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN183MC9mcmFnOjFlNmI5Y2VmMzVkOTRhNzY4MzNjMWExNjQ2MjdlYTVhL3RhYmxlOjA2N2RmOTNlMzNkNDQ1MWI5NGY4NDBiZDIwMmQ1OWZlL3RhYmxlcmFuZ2U6MDY3ZGY5M2UzM2Q0NDUxYjk0Zjg0MGJkMjAyZDU5ZmVfNi0xLTEtMS0w_c28f486e-4c09-4ac7-acc1-381555027c07">3,049,980</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4a3bb7fa3e594f029a6eba07308e9930_D20200101-20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN183MC9mcmFnOjFlNmI5Y2VmMzVkOTRhNzY4MzNjMWExNjQ2MjdlYTVhL3RhYmxlOjA2N2RmOTNlMzNkNDQ1MWI5NGY4NDBiZDIwMmQ1OWZlL3RhYmxlcmFuZ2U6MDY3ZGY5M2UzM2Q0NDUxYjk0Zjg0MGJkMjAyZDU5ZmVfNi0zLTEtMS0w_01d02827-0a32-4ad8-9cea-2f2363e82cf9">14,585,653</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 2019 Bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i18791cf1783e4dcb8bb78a1be1ac89ad_D20210101-20210331" decimals="0" format="ixt:zerodash" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN183MC9mcmFnOjFlNmI5Y2VmMzVkOTRhNzY4MzNjMWExNjQ2MjdlYTVhL3RhYmxlOjA2N2RmOTNlMzNkNDQ1MWI5NGY4NDBiZDIwMmQ1OWZlL3RhYmxlcmFuZ2U6MDY3ZGY5M2UzM2Q0NDUxYjk0Zjg0MGJkMjAyZDU5ZmVfNy0xLTEtMS0w_cf876153-9d1f-46e9-b1d5-0cc58a7e455d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i40ed0775a40148b78eea3a36a21b29b8_D20200101-20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN183MC9mcmFnOjFlNmI5Y2VmMzVkOTRhNzY4MzNjMWExNjQ2MjdlYTVhL3RhYmxlOjA2N2RmOTNlMzNkNDQ1MWI5NGY4NDBiZDIwMmQ1OWZlL3RhYmxlcmFuZ2U6MDY3ZGY5M2UzM2Q0NDUxYjk0Zjg0MGJkMjAyZDU5ZmVfNy0zLTEtMS0w_3352ea3b-a18c-4d1a-88dc-1ee4fe48119c">4,928,859</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 2019 Bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia21913e3a96f406eaffea5e037b375df_D20210101-20210331" decimals="0" format="ixt:zerodash" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN183MC9mcmFnOjFlNmI5Y2VmMzVkOTRhNzY4MzNjMWExNjQ2MjdlYTVhL3RhYmxlOjA2N2RmOTNlMzNkNDQ1MWI5NGY4NDBiZDIwMmQ1OWZlL3RhYmxlcmFuZ2U6MDY3ZGY5M2UzM2Q0NDUxYjk0Zjg0MGJkMjAyZDU5ZmVfOC0xLTEtMS0w_f7890033-7b67-4fd5-99a1-472b74d3bd0b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib6797a8f65df45e284ff859468b7d490_D20200101-20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN183MC9mcmFnOjFlNmI5Y2VmMzVkOTRhNzY4MzNjMWExNjQ2MjdlYTVhL3RhYmxlOjA2N2RmOTNlMzNkNDQ1MWI5NGY4NDBiZDIwMmQ1OWZlL3RhYmxlcmFuZ2U6MDY3ZGY5M2UzM2Q0NDUxYjk0Zjg0MGJkMjAyZDU5ZmVfOC0zLTEtMS0w_b2e265f3-1ff2-4659-b08b-a37eda15e4ff">1,009,450</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN183MC9mcmFnOjFlNmI5Y2VmMzVkOTRhNzY4MzNjMWExNjQ2MjdlYTVhL3RhYmxlOjA2N2RmOTNlMzNkNDQ1MWI5NGY4NDBiZDIwMmQ1OWZlL3RhYmxlcmFuZ2U6MDY3ZGY5M2UzM2Q0NDUxYjk0Zjg0MGJkMjAyZDU5ZmVfOS0xLTEtMS0w_de3f9e13-6e95-4599-b588-0cfce284f3cb">17,153,244</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i03bccaa0abfb4733b1e2831ecde4e4e8_D20200101-20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN183MC9mcmFnOjFlNmI5Y2VmMzVkOTRhNzY4MzNjMWExNjQ2MjdlYTVhL3RhYmxlOjA2N2RmOTNlMzNkNDQ1MWI5NGY4NDBiZDIwMmQ1OWZlL3RhYmxlcmFuZ2U6MDY3ZGY5M2UzM2Q0NDUxYjk0Zjg0MGJkMjAyZDU5ZmVfOS0zLTEtMS0w_0da3665a-6a39-4f96-8687-53393799d916">32,816,114</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-bottom:6pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.170%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.549%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.263%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.744%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.118%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.120%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div id="i1d23d16a69484b63aa007ec686e80337_76"></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">12.  <ix:nonNumeric contextRef="i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN183Ni9mcmFnOjUwMDdjM2Y2ZmU3ODRhM2NiNjgzYmI5MjA3OWU5M2Y4L3RleHRyZWdpb246NTAwN2MzZjZmZTc4NGEzY2I2ODNiYjkyMDc5ZTkzZjhfNDE2MA_4751a9a2-36fa-4c44-9a7b-86d34810cc87" continuedAt="i51a617abed8246b5a4cfab421ffdb938" escape="true">Stock-Based Compensation</ix:nonNumeric></span></div><ix:continuation id="i51a617abed8246b5a4cfab421ffdb938" continuedAt="ie1dd1ff67b3447fdadf245841899f0a6"><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company incurs stock-based compensation expense related to restricted stock units ("RSUs") and stock options. The fair value of restricted stock is determined by the closing price of the Company's common stock reported on the Nasdaq Global Select Market on the date of grant. The Company estimates the fair value of stock options granted using the Black-Scholes option pricing model. The Black-Scholes option pricing model was developed for use in estimating the fair value of traded options, which have no vesting restrictions and are fully transferable. In addition, option valuation models require the input of subjective assumptions, including the expected stock price volatility and expected option life. The Company amortizes the fair value of the awards on a straight-line basis over the requisite vesting period of the awards. Expected volatility is based on historical volatility. The expected life of options granted is based on historical expected life. The risk-free interest rate is based on the U.S. Treasury yield in effect at the time of grant. The dividend yield is based on the fact that no dividends have been paid historically and none are currently expected to be paid in the foreseeable future. The Company recognizes forfeitures as they occur.</span></div><div style="margin-top:5pt;text-indent:27pt"><ix:nonNumeric contextRef="i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN183Ni9mcmFnOjUwMDdjM2Y2ZmU3ODRhM2NiNjgzYmI5MjA3OWU5M2Y4L3RleHRyZWdpb246NTAwN2MzZjZmZTc4NGEzY2I2ODNiYjkyMDc5ZTkzZjhfNDE0NQ_90ef1589-8608-4f26-bdd1-2ee404e84008" continuedAt="i5f35abeb57b24666ac9f2bbf086cb3e2" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average assumptions used in the Black-Scholes model for option grants to employees and directors are presented below:</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  </span></ix:nonNumeric></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="ie1dd1ff67b3447fdadf245841899f0a6"><div style="margin-bottom:5pt;margin-top:10pt"><ix:continuation id="i5f35abeb57b24666ac9f2bbf086cb3e2"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:73.461%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.914%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i61f2172601e8451ebb73c4ae7a745dab_D20210101-20210331" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN183Ni9mcmFnOjUwMDdjM2Y2ZmU3ODRhM2NiNjgzYmI5MjA3OWU5M2Y4L3RhYmxlOmQ4MTRmMzdlYjYxODQzMzU5ZTIyM2EzNDJkYjNjZTNkL3RhYmxlcmFuZ2U6ZDgxNGYzN2ViNjE4NDMzNTllMjIzYTM0MmRiM2NlM2RfMi0xLTEtMS0w_6b328790-7ac6-4eea-b4f5-72613e76e843">0.88</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i0c1c04ab89af4b82b4d7131a93f0f86f_D20200101-20200331" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN183Ni9mcmFnOjUwMDdjM2Y2ZmU3ODRhM2NiNjgzYmI5MjA3OWU5M2Y4L3RhYmxlOmQ4MTRmMzdlYjYxODQzMzU5ZTIyM2EzNDJkYjNjZTNkL3RhYmxlcmFuZ2U6ZDgxNGYzN2ViNjE4NDMzNTllMjIzYTM0MmRiM2NlM2RfMi0zLTEtMS0w_f18f2e7e-eb25-4108-a1d5-37bac6173959">0.74</ix:nonFraction>%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i61f2172601e8451ebb73c4ae7a745dab_D20210101-20210331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN183Ni9mcmFnOjUwMDdjM2Y2ZmU3ODRhM2NiNjgzYmI5MjA3OWU5M2Y4L3RhYmxlOmQ4MTRmMzdlYjYxODQzMzU5ZTIyM2EzNDJkYjNjZTNkL3RhYmxlcmFuZ2U6ZDgxNGYzN2ViNjE4NDMzNTllMjIzYTM0MmRiM2NlM2RfMy0xLTEtMS0w_bcd63a3d-eb83-49ea-9030-1f59ea5b7ed4">92</ix:nonFraction>%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i0c1c04ab89af4b82b4d7131a93f0f86f_D20200101-20200331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN183Ni9mcmFnOjUwMDdjM2Y2ZmU3ODRhM2NiNjgzYmI5MjA3OWU5M2Y4L3RhYmxlOmQ4MTRmMzdlYjYxODQzMzU5ZTIyM2EzNDJkYjNjZTNkL3RhYmxlcmFuZ2U6ZDgxNGYzN2ViNjE4NDMzNTllMjIzYTM0MmRiM2NlM2RfMy0zLTEtMS0w_fd6c2d21-8d36-493e-ae01-967172698551">76</ix:nonFraction>%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected life in years</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i61f2172601e8451ebb73c4ae7a745dab_D20210101-20210331" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN183Ni9mcmFnOjUwMDdjM2Y2ZmU3ODRhM2NiNjgzYmI5MjA3OWU5M2Y4L3RhYmxlOmQ4MTRmMzdlYjYxODQzMzU5ZTIyM2EzNDJkYjNjZTNkL3RhYmxlcmFuZ2U6ZDgxNGYzN2ViNjE4NDMzNTllMjIzYTM0MmRiM2NlM2RfNC0xLTEtMS0w_3588391a-ac2f-4614-b057-67738ba780da">5.8</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i0c1c04ab89af4b82b4d7131a93f0f86f_D20200101-20200331" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN183Ni9mcmFnOjUwMDdjM2Y2ZmU3ODRhM2NiNjgzYmI5MjA3OWU5M2Y4L3RhYmxlOmQ4MTRmMzdlYjYxODQzMzU5ZTIyM2EzNDJkYjNjZTNkL3RhYmxlcmFuZ2U6ZDgxNGYzN2ViNjE4NDMzNTllMjIzYTM0MmRiM2NlM2RfNC0zLTEtMS0w_73077fdb-cb45-4f90-a0c1-a8dcf30ccc0a">5.9</ix:nonNumeric></span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i61f2172601e8451ebb73c4ae7a745dab_D20210101-20210331" decimals="INF" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN183Ni9mcmFnOjUwMDdjM2Y2ZmU3ODRhM2NiNjgzYmI5MjA3OWU5M2Y4L3RhYmxlOmQ4MTRmMzdlYjYxODQzMzU5ZTIyM2EzNDJkYjNjZTNkL3RhYmxlcmFuZ2U6ZDgxNGYzN2ViNjE4NDMzNTllMjIzYTM0MmRiM2NlM2RfNS0xLTEtMS0w_955b5f7e-bc50-4a72-92a7-259580b32592">&#8212;</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i0c1c04ab89af4b82b4d7131a93f0f86f_D20200101-20200331" decimals="INF" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN183Ni9mcmFnOjUwMDdjM2Y2ZmU3ODRhM2NiNjgzYmI5MjA3OWU5M2Y4L3RhYmxlOmQ4MTRmMzdlYjYxODQzMzU5ZTIyM2EzNDJkYjNjZTNkL3RhYmxlcmFuZ2U6ZDgxNGYzN2ViNjE4NDMzNTllMjIzYTM0MmRiM2NlM2RfNS0zLTEtMS0w_5ac3f2ac-81f7-4f46-be28-9176de2b0d7c">&#8212;</ix:nonFraction></span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></ix:continuation></div><div><span><br/></span></div><div style="margin-bottom:3pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total employee and director stock-based compensation expense recognized in the condensed consolidated statements of operations for the three months ended March 31, 2021 and 2020 was $<ix:nonFraction unitRef="usd" contextRef="ic3dea0b408c94a5c85d39edf3a8a75da_D20210101-20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN183Ni9mcmFnOjUwMDdjM2Y2ZmU3ODRhM2NiNjgzYmI5MjA3OWU5M2Y4L3RleHRyZWdpb246NTAwN2MzZjZmZTc4NGEzY2I2ODNiYjkyMDc5ZTkzZjhfMTUyOA_0f52aedd-10c3-4cd8-b35b-1efff8aa68fe">9.2</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i2be4bda68db445b1873dcb33cd2a7408_D20200101-20200331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN183Ni9mcmFnOjUwMDdjM2Y2ZmU3ODRhM2NiNjgzYmI5MjA3OWU5M2Y4L3RleHRyZWdpb246NTAwN2MzZjZmZTc4NGEzY2I2ODNiYjkyMDc5ZTkzZjhfMjE5OTAyMzI1OTc3Nw_74a5393e-05ad-4587-920b-256aecb9506f">3.6</ix:nonFraction> million, respectively, of which $<ix:nonFraction unitRef="usd" contextRef="ia4defc9758104f38bf6c67e512fbf9c8_D20210101-20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN183Ni9mcmFnOjUwMDdjM2Y2ZmU3ODRhM2NiNjgzYmI5MjA3OWU5M2Y4L3RleHRyZWdpb246NTAwN2MzZjZmZTc4NGEzY2I2ODNiYjkyMDc5ZTkzZjhfMTU2Mw_67d42550-f0b2-41c9-aaed-b75428a09c61">5.2</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ic196d4d46d72427380949ad2f6171b35_D20200101-20200331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN183Ni9mcmFnOjUwMDdjM2Y2ZmU3ODRhM2NiNjgzYmI5MjA3OWU5M2Y4L3RleHRyZWdpb246NTAwN2MzZjZmZTc4NGEzY2I2ODNiYjkyMDc5ZTkzZjhfMjE5OTAyMzI1OTc4MQ_7512f756-0136-4044-b117-4e67f28f91e5">2.3</ix:nonFraction> million, respectively, was included in research and development expenses, and $<ix:nonFraction unitRef="usd" contextRef="i4ac71f8b0252490589829c2ceb42c184_D20210101-20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN183Ni9mcmFnOjUwMDdjM2Y2ZmU3ODRhM2NiNjgzYmI5MjA3OWU5M2Y4L3RleHRyZWdpb246NTAwN2MzZjZmZTc4NGEzY2I2ODNiYjkyMDc5ZTkzZjhfMTY0NA_8338fae3-4673-4cd7-b7f5-962c911aa0d8">4.0</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i16bb9f759a90436abc39b470d3758b82_D20200101-20200331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN183Ni9mcmFnOjUwMDdjM2Y2ZmU3ODRhM2NiNjgzYmI5MjA3OWU5M2Y4L3RleHRyZWdpb246NTAwN2MzZjZmZTc4NGEzY2I2ODNiYjkyMDc5ZTkzZjhfMjE5OTAyMzI1OTc4Nw_04ae6378-6a4b-4c66-86bb-775d7f22db49">1.3</ix:nonFraction> million, respectively, was included in general and administrative expenses.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At March&#160;31, 2021, there was $<ix:nonFraction unitRef="usd" contextRef="ic36b9cedad7f41a6b9eb223b09b7186c_I20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN183Ni9mcmFnOjUwMDdjM2Y2ZmU3ODRhM2NiNjgzYmI5MjA3OWU5M2Y4L3RleHRyZWdpb246NTAwN2MzZjZmZTc4NGEzY2I2ODNiYjkyMDc5ZTkzZjhfMjA3Mw_140e3bba-c665-4f85-8596-6d6642bd0882">22.3</ix:nonFraction> million of total unrecognized compensation expense related to unvested stock options, which is expected to be recognized over a weighted-average period of <ix:nonNumeric contextRef="i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331" format="ixt-sec:duryear" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN183Ni9mcmFnOjUwMDdjM2Y2ZmU3ODRhM2NiNjgzYmI5MjA3OWU5M2Y4L3RleHRyZWdpb246NTAwN2MzZjZmZTc4NGEzY2I2ODNiYjkyMDc5ZTkzZjhfMjIyMw_f9c5708d-43aa-43ab-9f78-b70b489b687f">2.6</ix:nonNumeric> years.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average grant date fair value per share, calculated using the Black-Scholes option pricing model, was $<ix:nonFraction unitRef="usdPerShare" contextRef="i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN183Ni9mcmFnOjUwMDdjM2Y2ZmU3ODRhM2NiNjgzYmI5MjA3OWU5M2Y4L3RleHRyZWdpb246NTAwN2MzZjZmZTc4NGEzY2I2ODNiYjkyMDc5ZTkzZjhfMjM0Mg_5b9ef013-53a1-4483-9109-c817769d97ab">8.34</ix:nonFraction> and $<ix:nonFraction unitRef="usdPerShare" contextRef="i03bccaa0abfb4733b1e2831ecde4e4e8_D20200101-20200331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN183Ni9mcmFnOjUwMDdjM2Y2ZmU3ODRhM2NiNjgzYmI5MjA3OWU5M2Y4L3RleHRyZWdpb246NTAwN2MzZjZmZTc4NGEzY2I2ODNiYjkyMDc5ZTkzZjhfMjE5OTAyMzI2MDEyOQ_33f914f0-88be-49c8-8323-e547e34fd6ad">5.37</ix:nonFraction> for employee and director stock options granted during the three months ended March 31, 2021 and 2020, respectively. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At March&#160;31, 2021, there was $<ix:nonFraction unitRef="usd" contextRef="iced18e00c26943db86d24ef12f5d945b_I20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN183Ni9mcmFnOjUwMDdjM2Y2ZmU3ODRhM2NiNjgzYmI5MjA3OWU5M2Y4L3RleHRyZWdpb246NTAwN2MzZjZmZTc4NGEzY2I2ODNiYjkyMDc5ZTkzZjhfMjUzOA_faa6fa55-b863-4832-8cbf-2e8685c63e79">19.4</ix:nonFraction> million of total unrecognized compensation expense related to unvested service-based RSUs, which is expected to be recognized over a weighted-average period of <ix:nonNumeric contextRef="i2af01b3faa6342e7982d6aae83905e36_D20210101-20210331" format="ixt-sec:duryear" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN183Ni9mcmFnOjUwMDdjM2Y2ZmU3ODRhM2NiNjgzYmI5MjA3OWU5M2Y4L3RleHRyZWdpb246NTAwN2MzZjZmZTc4NGEzY2I2ODNiYjkyMDc5ZTkzZjhfMjcwNg_f0fcfd6f-8cb9-4f95-99f6-98966ed7879a">2.3</ix:nonNumeric> years.  </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average grant date fair value per share was $<ix:nonFraction unitRef="usdPerShare" contextRef="i2af01b3faa6342e7982d6aae83905e36_D20210101-20210331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN183Ni9mcmFnOjUwMDdjM2Y2ZmU3ODRhM2NiNjgzYmI5MjA3OWU5M2Y4L3RleHRyZWdpb246NTAwN2MzZjZmZTc4NGEzY2I2ODNiYjkyMDc5ZTkzZjhfMjE5OTAyMzI2MDQ3MA_209f8a49-8cf4-497b-b1a8-7189d810165b">11.42</ix:nonFraction> and $<ix:nonFraction unitRef="usdPerShare" contextRef="ia74c48fc7c3c456fa308825394481794_D20200101-20200331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN183Ni9mcmFnOjUwMDdjM2Y2ZmU3ODRhM2NiNjgzYmI5MjA3OWU5M2Y4L3RleHRyZWdpb246NTAwN2MzZjZmZTc4NGEzY2I2ODNiYjkyMDc5ZTkzZjhfMjk3OA_aff84960-7c5f-47ae-8775-a0a831f8a056">8.32</ix:nonFraction> for service-based RSUs granted during the three months ended March 31, 2021 and 2020, respectively.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of stock options granted to non-employees was estimated using the Black-Scholes pricing model. Total stock-based compensation expense for stock options and RSUs granted to non-employees for the three months ended March 31, 2021 and 2020 was $<ix:nonFraction unitRef="usd" contextRef="if21238de764544869449deb80f173e01_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN183Ni9mcmFnOjUwMDdjM2Y2ZmU3ODRhM2NiNjgzYmI5MjA3OWU5M2Y4L3RleHRyZWdpb246NTAwN2MzZjZmZTc4NGEzY2I2ODNiYjkyMDc5ZTkzZjhfMzI1MA_339423c9-0a16-4e7b-81db-be9eca13ffba">429,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i337096debaaf43d88b8dd9f4979cb062_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN183Ni9mcmFnOjUwMDdjM2Y2ZmU3ODRhM2NiNjgzYmI5MjA3OWU5M2Y4L3RleHRyZWdpb246NTAwN2MzZjZmZTc4NGEzY2I2ODNiYjkyMDc5ZTkzZjhfMjE5OTAyMzI2MDQ3NQ_fc0ce638-c956-4176-a3ae-b5bb548ad899">383,000</ix:nonFraction>, respectively. </span></div><div style="margin-bottom:5pt;text-indent:27pt"><span style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On August 28, 2020, the Company granted <ix:nonFraction unitRef="shares" contextRef="i76e8a75098d84df7ac61105d88d25844_D20200828-20200828" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN183Ni9mcmFnOjUwMDdjM2Y2ZmU3ODRhM2NiNjgzYmI5MjA3OWU5M2Y4L3RleHRyZWdpb246NTAwN2MzZjZmZTc4NGEzY2I2ODNiYjkyMDc5ZTkzZjhfMzQ0Ng_a122ad86-fd34-4871-8b02-51112019ace0">663,353</ix:nonFraction> performance-based RSUs to executives under the 2016 Incentive Plan. The RSUs will vest in two tranches as follows: <ix:nonFraction unitRef="number" contextRef="ie0eb7f9e131f4570be7731825dd8538f_D20200828-20200828" decimals="2" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN183Ni9mcmFnOjUwMDdjM2Y2ZmU3ODRhM2NiNjgzYmI5MjA3OWU5M2Y4L3RleHRyZWdpb246NTAwN2MzZjZmZTc4NGEzY2I2ODNiYjkyMDc5ZTkzZjhfMzU2Nw_78df6318-6c2a-4a84-b429-8af08d468ccb">50</ix:nonFraction>% of the shares in each tranche will vest upon achievement of the predetermined performance milestones and the remaining <ix:nonFraction unitRef="number" contextRef="i21a58deaf4d24bd381a2d83d3a8d9889_D20200828-20200828" decimals="2" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN183Ni9mcmFnOjUwMDdjM2Y2ZmU3ODRhM2NiNjgzYmI5MjA3OWU5M2Y4L3RleHRyZWdpb246NTAwN2MzZjZmZTc4NGEzY2I2ODNiYjkyMDc5ZTkzZjhfMzY4OQ_a4b8175b-88b1-48e3-8ccb-d8cf05b7b23c">50</ix:nonFraction>% of the shares in each tranche will vest upon subsequent completion of a <ix:nonNumeric contextRef="i21a58deaf4d24bd381a2d83d3a8d9889_D20200828-20200828" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN183Ni9mcmFnOjUwMDdjM2Y2ZmU3ODRhM2NiNjgzYmI5MjA3OWU5M2Y4L3RleHRyZWdpb246NTAwN2MzZjZmZTc4NGEzY2I2ODNiYjkyMDc5ZTkzZjhfNDE0OA_c6105838-103f-4030-84f9-8c17b8040518">one-year</ix:nonNumeric> service period. The total grant date fair value of the performance-based RSUs was $<ix:nonFraction unitRef="usd" contextRef="i76e8a75098d84df7ac61105d88d25844_D20200828-20200828" decimals="-5" format="ixt:numdotdecimal" name="ino:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodGrantDateFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN183Ni9mcmFnOjUwMDdjM2Y2ZmU3ODRhM2NiNjgzYmI5MjA3OWU5M2Y4L3RleHRyZWdpb246NTAwN2MzZjZmZTc4NGEzY2I2ODNiYjkyMDc5ZTkzZjhfMzg0OA_db9f9466-7429-42d0-af11-44c386eead91">8.0</ix:nonFraction>&#160;million based on the grant date closing price per share of $<ix:nonFraction unitRef="usdPerShare" contextRef="i76e8a75098d84df7ac61105d88d25844_D20200828-20200828" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN183Ni9mcmFnOjUwMDdjM2Y2ZmU3ODRhM2NiNjgzYmI5MjA3OWU5M2Y4L3RleHRyZWdpb246NTAwN2MzZjZmZTc4NGEzY2I2ODNiYjkyMDc5ZTkzZjhfMzkwMg_4e9239ba-0e45-4047-8627-ac36fb1a2ecb">12.06</ix:nonFraction>. As of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">March&#160;31, 2021</span><span style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, the underlying performance milestones of the RSUs were not probable of achievement, and no stock-based compensation expense was recognized for the performance-based RSUs for the three months then ended.</span></div></ix:continuation><div style="margin-top:5pt;text-indent:27pt"><span><br/></span></div><div id="i1d23d16a69484b63aa007ec686e80337_79"></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">13.  <ix:nonNumeric contextRef="i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN183OS9mcmFnOjA4NzBhNjMwYjg4OTRlNTk4NzAwM2Q2NWZhMmI0NzVjL3RleHRyZWdpb246MDg3MGE2MzBiODg5NGU1OTg3MDAzZDY1ZmEyYjQ3NWNfODI2MA_8397f2ec-e717-4a19-9b0a-1a2fefd70cb0" continuedAt="i5ada2897535d4b11860d69e6c27de78a" escape="true">Related Party Transactions</ix:nonNumeric></span></div><ix:continuation id="i5ada2897535d4b11860d69e6c27de78a" continuedAt="i85e66cacfc104dae86e590807c189a78"><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Plumbline Life Sciences, Inc.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company owns <ix:nonFraction unitRef="shares" contextRef="i4f1544da548041ab8ee6e7df0bf9ef61_I20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:InvestmentOwnedBalanceShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN183OS9mcmFnOjA4NzBhNjMwYjg4OTRlNTk4NzAwM2Q2NWZhMmI0NzVjL3RleHRyZWdpb246MDg3MGE2MzBiODg5NGU1OTg3MDAzZDY1ZmEyYjQ3NWNfNTIyOQ_d9b80fe7-adff-49a9-89f2-cadeeb021b2a">597,808</ix:nonFraction> shares of common stock in PLS as of March&#160;31, 2021, representing a <ix:nonFraction unitRef="number" contextRef="i4f1544da548041ab8ee6e7df0bf9ef61_I20210331" decimals="3" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN183OS9mcmFnOjA4NzBhNjMwYjg4OTRlNTk4NzAwM2Q2NWZhMmI0NzVjL3RleHRyZWdpb246MDg3MGE2MzBiODg5NGU1OTg3MDAzZDY1ZmEyYjQ3NWNfMTA5OTUxMTY0NjgyMg_f1f9723c-1bf3-41c2-b9c5-52328e8693dc">19.7</ix:nonFraction>% ownership interest, and one of the Company's directors, Dr.&#160;David B. Weiner, acts as a consultant to PLS.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue recognized from PLS consists of milestone, license and patent fees. For the three months ended March 31, 2021 and 2020, the Company recognized revenue from PLS of $<ix:nonFraction unitRef="usd" contextRef="ia2b43dbe48ac4cd98a40e26498a7f881_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN183OS9mcmFnOjA4NzBhNjMwYjg4OTRlNTk4NzAwM2Q2NWZhMmI0NzVjL3RleHRyZWdpb246MDg3MGE2MzBiODg5NGU1OTg3MDAzZDY1ZmEyYjQ3NWNfNTg3MQ_a91ec5f4-d52b-4b79-b092-0076f45552f9">50,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i4c79f6b4729a4ff692ed11a1379cdfcf_D20200101-20200331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN183OS9mcmFnOjA4NzBhNjMwYjg4OTRlNTk4NzAwM2Q2NWZhMmI0NzVjL3RleHRyZWdpb246MDg3MGE2MzBiODg5NGU1OTg3MDAzZDY1ZmEyYjQ3NWNfMjE5OTAyMzI3Mjg3Nw_bbeec715-d6cf-4620-868c-c291d3a39756">1.1</ix:nonFraction> million, respectively. At March&#160;31, 2021 and December&#160;31, 2020, the Company had an accounts receivable balance of $<ix:nonFraction unitRef="usd" contextRef="i5ee95bf76bdd417884688328e2d20f81_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableRelatedParties" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN183OS9mcmFnOjA4NzBhNjMwYjg4OTRlNTk4NzAwM2Q2NWZhMmI0NzVjL3RleHRyZWdpb246MDg3MGE2MzBiODg5NGU1OTg3MDAzZDY1ZmEyYjQ3NWNfNjAwMA_4e45439f-e02a-4b76-b402-9dfcc43b9024">80,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i02eea4d019a94e66ae415d3736f47a49_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableRelatedParties" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN183OS9mcmFnOjA4NzBhNjMwYjg4OTRlNTk4NzAwM2Q2NWZhMmI0NzVjL3RleHRyZWdpb246MDg3MGE2MzBiODg5NGU1OTg3MDAzZDY1ZmEyYjQ3NWNfNjAwNw_c13a9f80-ef70-4019-887c-704a01224f04">67,000</ix:nonFraction>, respectively, related to PLS.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The Wistar Institute</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's director Dr.&#160;David B. Weiner is a director of the Vaccine Center of The Wistar Institute ("Wistar"). Dr. Weiner is also the Executive Vice President of Wistar.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2016, the Company entered into collaborative research agreements with Wistar&#160;for preventive and therapeutic DNA-based immunotherapy applications and products developed by&#160;Dr. Weiner and Wistar for the treatment of cancers and infectious diseases. Under the terms of the agreement, the Company reimbursed Wistar for all direct and indirect costs incurred in the conduct of the collaborative research, not to exceed $<ix:nonFraction unitRef="usd" contextRef="iad065e9a7d2a4690b34e02a44f8e04ee_D20160301-20160331" decimals="-5" format="ixt:numdotdecimal" name="ino:CollaborativeAgreementExpensesToReimburse" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN183OS9mcmFnOjA4NzBhNjMwYjg4OTRlNTk4NzAwM2Q2NWZhMmI0NzVjL3RleHRyZWdpb246MDg3MGE2MzBiODg5NGU1OTg3MDAzZDY1ZmEyYjQ3NWNfNjY2Mw_970dff57-278d-4481-a959-1bfa6d18f0e5">3.1</ix:nonFraction> million during the <ix:nonNumeric contextRef="iad065e9a7d2a4690b34e02a44f8e04ee_D20160301-20160331" format="ixt-sec:durwordsen" name="ino:CollaborativeArrangementTerm" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN183OS9mcmFnOjA4NzBhNjMwYjg4OTRlNTk4NzAwM2Q2NWZhMmI0NzVjL3RleHRyZWdpb246MDg3MGE2MzBiODg5NGU1OTg3MDAzZDY1ZmEyYjQ3NWNfODI1Ng_405b6541-e6c3-49f7-9eca-99f96004752c">five-year</ix:nonNumeric> term of the agreements. In March 2021, upon expiration of the March 2016 agreements, the Company entered into new collaborative research agreements with Wistar&#160;with the same terms. The Company has the exclusive right to in-license new intellectual property developed under the agreements.  </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2016, the Company received a&#160;$<ix:nonFraction unitRef="usd" contextRef="i22530cebfa2d4a3587a9140e7fb29bb7_D20161101-20161130" decimals="-5" format="ixt:numdotdecimal" name="ino:CollaborativeAgreementAwardedAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN183OS9mcmFnOjA4NzBhNjMwYjg4OTRlNTk4NzAwM2Q2NWZhMmI0NzVjL3RleHRyZWdpb246MDg3MGE2MzBiODg5NGU1OTg3MDAzZDY1ZmEyYjQ3NWNfNjg2NQ_309ea6bc-e45d-42c6-8fbe-db9aabe41bd2">6.1</ix:nonFraction> million&#160;sub-grant through Wistar to develop a DMAb against the Zika infection, with funding through June 2021. </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i85e66cacfc104dae86e590807c189a78"><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is also a collaborator with Wistar on an Integrated Preclinical/Clinical AIDS Vaccine Development grant from the NIAID, with funding through February 2022.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2020, the Company received a $<ix:nonFraction unitRef="usd" contextRef="if8801c14501949e385e60e1272378e9f_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="ino:CollaborativeAgreementAwardedAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN183OS9mcmFnOjA4NzBhNjMwYjg4OTRlNTk4NzAwM2Q2NWZhMmI0NzVjL3RleHRyZWdpb246MDg3MGE2MzBiODg5NGU1OTg3MDAzZDY1ZmEyYjQ3NWNfMjE5OTAyMzI3MjgxNA_cbb6d622-2f2b-4330-8457-b25fc380e6ae">10.7</ix:nonFraction>&#160;million sub-grant through Wistar for the preclinical development and translational studies of DMAbs as countermeasures for COVID-19, with funding through September 2022. The sub-grant also includes an option for an additional $<ix:nonFraction unitRef="usd" contextRef="if8801c14501949e385e60e1272378e9f_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="ino:CollaborativeAgreementAwardedOptionAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN183OS9mcmFnOjA4NzBhNjMwYjg4OTRlNTk4NzAwM2Q2NWZhMmI0NzVjL3RleHRyZWdpb246MDg3MGE2MzBiODg5NGU1OTg3MDAzZDY1ZmEyYjQ3NWNfMjE5OTAyMzI3MjgyOQ_7964814a-cd95-4a6d-aa32-cca6ae1dc7ce">6.0</ix:nonFraction>&#160;million in funding through September 2024.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred grant funding recognized from Wistar and recorded as contra-research and development expense is related to work performed by the Company on the research sub-contract agreements. For the three months ended March 31, 2021 and 2020, the Company recorded $<ix:nonFraction unitRef="usd" contextRef="i6e8d2f7132dd4ad696314336b323045a_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="ino:GrantProceedsReceived" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN183OS9mcmFnOjA4NzBhNjMwYjg4OTRlNTk4NzAwM2Q2NWZhMmI0NzVjL3RleHRyZWdpb246MDg3MGE2MzBiODg5NGU1OTg3MDAzZDY1ZmEyYjQ3NWNfNzM4OQ_60de2070-1946-4ffa-a417-0b53daf02bd8">230,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="ib9b1dac9eb2f4b86842d7bbf220a3ec9_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="ino:GrantProceedsReceived" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN183OS9mcmFnOjA4NzBhNjMwYjg4OTRlNTk4NzAwM2Q2NWZhMmI0NzVjL3RleHRyZWdpb246MDg3MGE2MzBiODg5NGU1OTg3MDAzZDY1ZmEyYjQ3NWNfNzQ1MA_662657eb-164f-4886-a907-6e618e990a89">619,000</ix:nonFraction>, respectively, as contra-research and development expense from Wistar. </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses recorded from Wistar relate primarily to the collaborative research agreements and sub-contract agreements related to the Bill &amp; Melinda Gates Foundation and CEPI (see Note 15). Research and development expenses recorded from Wistar for the three months ended March 31, 2021 and 2020 were $<ix:nonFraction unitRef="usd" contextRef="i6e8d2f7132dd4ad696314336b323045a_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN183OS9mcmFnOjA4NzBhNjMwYjg4OTRlNTk4NzAwM2Q2NWZhMmI0NzVjL3RleHRyZWdpb246MDg3MGE2MzBiODg5NGU1OTg3MDAzZDY1ZmEyYjQ3NWNfNzgxNw_a599da5a-5a41-4e03-8656-e404a9302ee4">318,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="ib9b1dac9eb2f4b86842d7bbf220a3ec9_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN183OS9mcmFnOjA4NzBhNjMwYjg4OTRlNTk4NzAwM2Q2NWZhMmI0NzVjL3RleHRyZWdpb246MDg3MGE2MzBiODg5NGU1OTg3MDAzZDY1ZmEyYjQ3NWNfNzkxMw_450b63c9-a4f3-4907-bf81-fa1b33e71a6a">362,000</ix:nonFraction>, respectively. At March&#160;31, 2021 and December&#160;31, 2020, the Company had an accounts receivable balance of $<ix:nonFraction unitRef="usd" contextRef="iab8d55f8b4464cb1af38f6596cf6b33d_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableRelatedParties" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN183OS9mcmFnOjA4NzBhNjMwYjg4OTRlNTk4NzAwM2Q2NWZhMmI0NzVjL3RleHRyZWdpb246MDg3MGE2MzBiODg5NGU1OTg3MDAzZDY1ZmEyYjQ3NWNfODAwMg_2b24c23b-ff22-4d37-a4ca-56b9ea4e5149">256,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="ie31e1b7159e7405fb6b7791df154daf6_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableRelatedParties" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN183OS9mcmFnOjA4NzBhNjMwYjg4OTRlNTk4NzAwM2Q2NWZhMmI0NzVjL3RleHRyZWdpb246MDg3MGE2MzBiODg5NGU1OTg3MDAzZDY1ZmEyYjQ3NWNfODAwOQ_aea272c2-204f-4e62-94a2-8116ca63cd2c">425,000</ix:nonFraction>, respectively, and an accounts payable and accrued liability balance of $<ix:nonFraction unitRef="usd" contextRef="iab8d55f8b4464cb1af38f6596cf6b33d_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DueToRelatedPartiesCurrentAndNoncurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN183OS9mcmFnOjA4NzBhNjMwYjg4OTRlNTk4NzAwM2Q2NWZhMmI0NzVjL3RleHRyZWdpb246MDg3MGE2MzBiODg5NGU1OTg3MDAzZDY1ZmEyYjQ3NWNfODA4NA_074a9a65-e890-43f8-a454-3a2da899a3c1">768,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="ie31e1b7159e7405fb6b7791df154daf6_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DueToRelatedPartiesCurrentAndNoncurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN183OS9mcmFnOjA4NzBhNjMwYjg4OTRlNTk4NzAwM2Q2NWZhMmI0NzVjL3RleHRyZWdpb246MDg3MGE2MzBiODg5NGU1OTg3MDAzZDY1ZmEyYjQ3NWNfODA5MQ_b90e2c09-7901-4610-aea4-4529516fe9d0">643,000</ix:nonFraction>, respectively, related to Wistar. As of March&#160;31, 2021, the Company had $<ix:nonFraction unitRef="usd" contextRef="iab8d55f8b4464cb1af38f6596cf6b33d_I20210331" decimals="-3" format="ixt:numdotdecimal" name="ino:DeferredGrantFundingFromAffiliate" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN183OS9mcmFnOjA4NzBhNjMwYjg4OTRlNTk4NzAwM2Q2NWZhMmI0NzVjL3RleHRyZWdpb246MDg3MGE2MzBiODg5NGU1OTg3MDAzZDY1ZmEyYjQ3NWNfODE1NA_b07b0b3b-5ca8-485b-a083-ea287b865898">76,000</ix:nonFraction> recorded as deferred grant funding on the condensed consolidated balance sheet related to Wistar.</span></div></ix:continuation><div style="margin-top:5pt;text-indent:27pt"><span><br/></span></div><div id="i1d23d16a69484b63aa007ec686e80337_82"></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">14.  <ix:nonNumeric contextRef="i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331" name="us-gaap:LesseeOperatingLeasesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN184Mi9mcmFnOjhhYmI3MjAyY2NjMzQwY2M5NzJhN2FjZmVkZmRjZDQxL3RleHRyZWdpb246OGFiYjcyMDJjY2MzNDBjYzk3MmE3YWNmZWRmZGNkNDFfMjk5NQ_c6c4217e-aa93-485f-9512-9df4a52cf5bf" continuedAt="i0536845a41e749b4a4055fc26b4430c4" escape="true">Leases                                                  </ix:nonNumeric></span></div><ix:continuation id="i0536845a41e749b4a4055fc26b4430c4" continuedAt="i4cdefa0793044551a244fc0987bc3a0b"><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company leases approximately <ix:nonFraction unitRef="sqft" contextRef="ie67e1db182b94da1b67c475206b65805_D20210101-20210331" decimals="0" format="ixt:numdotdecimal" name="ino:LesseeOperatingLeaseAreaofLandUnderLease" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN184Mi9mcmFnOjhhYmI3MjAyY2NjMzQwY2M5NzJhN2FjZmVkZmRjZDQxL3RleHRyZWdpb246OGFiYjcyMDJjY2MzNDBjYzk3MmE3YWNmZWRmZGNkNDFfMTAw_2cbaae33-33d8-42f2-a0c7-edc2243bfbf2">82,200</ix:nonFraction> square feet of office, laboratory, and manufacturing space in San Diego, California and <ix:nonFraction unitRef="sqft" contextRef="ib2743077b3474815ac3d7d4bbcd3dbd9_D20210101-20210331" decimals="0" format="ixt:numdotdecimal" name="ino:LesseeOperatingLeaseAreaofLandUnderLease" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN184Mi9mcmFnOjhhYmI3MjAyY2NjMzQwY2M5NzJhN2FjZmVkZmRjZDQxL3RleHRyZWdpb246OGFiYjcyMDJjY2MzNDBjYzk3MmE3YWNmZWRmZGNkNDFfMTkx_4757d922-3bd7-4b8d-9e28-67f5479cf2aa">57,360</ix:nonFraction> square feet of office space in Plymouth Meeting, Pennsylvania under various non-cancellable operating lease agreements with remaining lease terms as of March&#160;31, 2021</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of <ix:nonNumeric contextRef="ic4e4f4221dec4206a08ffb18e83ff0e2_I20210331" format="ixt-sec:duryear" name="us-gaap:LesseeOperatingLeaseRemainingLeaseTerm" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN184Mi9mcmFnOjhhYmI3MjAyY2NjMzQwY2M5NzJhN2FjZmVkZmRjZDQxL3RleHRyZWdpb246OGFiYjcyMDJjY2MzNDBjYzk3MmE3YWNmZWRmZGNkNDFfMzUy_4ba24181-720b-441d-a3f8-1381983c049a">2.7</ix:nonNumeric> to <ix:nonNumeric contextRef="i02dc7b8bd133444db127be6bff5fedf5_I20210331" format="ixt-sec:duryear" name="us-gaap:LesseeOperatingLeaseRemainingLeaseTerm" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN184Mi9mcmFnOjhhYmI3MjAyY2NjMzQwY2M5NzJhN2FjZmVkZmRjZDQxL3RleHRyZWdpb246OGFiYjcyMDJjY2MzNDBjYzk3MmE3YWNmZWRmZGNkNDFfMzU4_999876d0-ff44-4b52-9eab-dc6c7e83bd92">8.8</ix:nonNumeric> ye</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ars, which represent the non-cancellable periods of the leases. The Company has excluded the extension options from its lease terms in the calculation of future lease payments as they are not reasonably certain to be exercised. The Company's lease payments consist primarily of fixed rental payments for the right to use the underlying leased assets over the lease terms as well as payments for common area maintenance and administrative services. The Company has received customary incentives from its landlords, such as reimbursements for tenant improvements and rent abatement periods, which effectively reduce the total lease payments owed for these leases.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company performed an evaluation of its contracts with customers and suppliers in accordance with ASC Topic 842 and determined that, except for the real estate leases described above and various copier leases, none of its other contracts contain a right-of-use asset. </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease right-of-use assets and liabilities on the condensed consolidated balance sheet represents the present value of the remaining lease payments over the remaining lease terms. Payments for additional monthly fees to cover the Company's share of certain facility expenses are not included in operating lease right-of-use assets and liabilities. The Company uses its incremental borrowing rate to calculate the present value of its lease payments, as the implicit rates in the leases are not readily determinable.</span></div><ix:nonNumeric contextRef="i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN184Mi9mcmFnOjhhYmI3MjAyY2NjMzQwY2M5NzJhN2FjZmVkZmRjZDQxL3RleHRyZWdpb246OGFiYjcyMDJjY2MzNDBjYzk3MmE3YWNmZWRmZGNkNDFfMzAwMg_33a36ea9-b23e-4e4d-8197-0ba1e995db3c" escape="true"><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">As of March&#160;31, 2021, the maturities of the Company's operating lease liabilities were as follows:</span></div><div style="margin-bottom:5pt;margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.449%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.351%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Remainder of 2021</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic36b9cedad7f41a6b9eb223b09b7186c_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN184Mi9mcmFnOjhhYmI3MjAyY2NjMzQwY2M5NzJhN2FjZmVkZmRjZDQxL3RhYmxlOjFhZmZhODk2ZTYyZjRiZGI4NTBlY2EzOTAzN2E2MmU0L3RhYmxlcmFuZ2U6MWFmZmE4OTZlNjJmNGJkYjg1MGVjYTM5MDM3YTYyZTRfMC0xLTEtMS0w_e986657f-d8aa-4e85-9241-89605835569b">2,983,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic36b9cedad7f41a6b9eb223b09b7186c_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN184Mi9mcmFnOjhhYmI3MjAyY2NjMzQwY2M5NzJhN2FjZmVkZmRjZDQxL3RhYmxlOjFhZmZhODk2ZTYyZjRiZGI4NTBlY2EzOTAzN2E2MmU0L3RhYmxlcmFuZ2U6MWFmZmE4OTZlNjJmNGJkYjg1MGVjYTM5MDM3YTYyZTRfMS0xLTEtMS0w_33f04903-f7e1-4b50-ad9b-aca9a3e6feec">4,045,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic36b9cedad7f41a6b9eb223b09b7186c_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN184Mi9mcmFnOjhhYmI3MjAyY2NjMzQwY2M5NzJhN2FjZmVkZmRjZDQxL3RhYmxlOjFhZmZhODk2ZTYyZjRiZGI4NTBlY2EzOTAzN2E2MmU0L3RhYmxlcmFuZ2U6MWFmZmE4OTZlNjJmNGJkYjg1MGVjYTM5MDM3YTYyZTRfMi0xLTEtMS0w_cdc7bb52-5b08-4bd9-84a9-cf57de5976ef">4,023,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic36b9cedad7f41a6b9eb223b09b7186c_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN184Mi9mcmFnOjhhYmI3MjAyY2NjMzQwY2M5NzJhN2FjZmVkZmRjZDQxL3RhYmxlOjFhZmZhODk2ZTYyZjRiZGI4NTBlY2EzOTAzN2E2MmU0L3RhYmxlcmFuZ2U6MWFmZmE4OTZlNjJmNGJkYjg1MGVjYTM5MDM3YTYyZTRfMy0xLTEtMS0w_f913b585-6c81-4fb3-99d5-c0751e51e7fa">3,001,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic36b9cedad7f41a6b9eb223b09b7186c_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN184Mi9mcmFnOjhhYmI3MjAyY2NjMzQwY2M5NzJhN2FjZmVkZmRjZDQxL3RhYmxlOjFhZmZhODk2ZTYyZjRiZGI4NTBlY2EzOTAzN2E2MmU0L3RhYmxlcmFuZ2U6MWFmZmE4OTZlNjJmNGJkYjg1MGVjYTM5MDM3YTYyZTRfNC0xLTEtMS0w_fa66b4ea-ee70-49f4-a5ff-c40ea15317f8">3,063,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic36b9cedad7f41a6b9eb223b09b7186c_I20210331" decimals="-3" format="ixt:numdotdecimal" name="ino:LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN184Mi9mcmFnOjhhYmI3MjAyY2NjMzQwY2M5NzJhN2FjZmVkZmRjZDQxL3RhYmxlOjFhZmZhODk2ZTYyZjRiZGI4NTBlY2EzOTAzN2E2MmU0L3RhYmxlcmFuZ2U6MWFmZmE4OTZlNjJmNGJkYjg1MGVjYTM5MDM3YTYyZTRfNS0xLTEtMS0w_b7f7192c-f546-4854-87c7-e4e605c9aa0a">9,888,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Total remaining lease payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic36b9cedad7f41a6b9eb223b09b7186c_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN184Mi9mcmFnOjhhYmI3MjAyY2NjMzQwY2M5NzJhN2FjZmVkZmRjZDQxL3RhYmxlOjFhZmZhODk2ZTYyZjRiZGI4NTBlY2EzOTAzN2E2MmU0L3RhYmxlcmFuZ2U6MWFmZmE4OTZlNjJmNGJkYjg1MGVjYTM5MDM3YTYyZTRfNi0xLTEtMS0w_e5b9da92-216d-41ab-b62a-f9c5de4d9fca">27,003,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: present value adjustment</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic36b9cedad7f41a6b9eb223b09b7186c_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN184Mi9mcmFnOjhhYmI3MjAyY2NjMzQwY2M5NzJhN2FjZmVkZmRjZDQxL3RhYmxlOjFhZmZhODk2ZTYyZjRiZGI4NTBlY2EzOTAzN2E2MmU0L3RhYmxlcmFuZ2U6MWFmZmE4OTZlNjJmNGJkYjg1MGVjYTM5MDM3YTYyZTRfNy0xLTEtMS0w_459f186b-86ed-4bd5-827d-e2c5c0329294">7,168,000</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Total operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic36b9cedad7f41a6b9eb223b09b7186c_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiability" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN184Mi9mcmFnOjhhYmI3MjAyY2NjMzQwY2M5NzJhN2FjZmVkZmRjZDQxL3RhYmxlOjFhZmZhODk2ZTYyZjRiZGI4NTBlY2EzOTAzN2E2MmU0L3RhYmxlcmFuZ2U6MWFmZmE4OTZlNjJmNGJkYjg1MGVjYTM5MDM3YTYyZTRfOC0xLTEtMS0w_c1470a5e-a427-43a9-afed-11a243d01d74">19,835,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: current portion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic36b9cedad7f41a6b9eb223b09b7186c_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN184Mi9mcmFnOjhhYmI3MjAyY2NjMzQwY2M5NzJhN2FjZmVkZmRjZDQxL3RhYmxlOjFhZmZhODk2ZTYyZjRiZGI4NTBlY2EzOTAzN2E2MmU0L3RhYmxlcmFuZ2U6MWFmZmE4OTZlNjJmNGJkYjg1MGVjYTM5MDM3YTYyZTRfOS0xLTEtMS0w_824bedaf-9103-4d31-ab05-c2357a4c1c1b">2,396,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term operating lease liabilities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic36b9cedad7f41a6b9eb223b09b7186c_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN184Mi9mcmFnOjhhYmI3MjAyY2NjMzQwY2M5NzJhN2FjZmVkZmRjZDQxL3RhYmxlOjFhZmZhODk2ZTYyZjRiZGI4NTBlY2EzOTAzN2E2MmU0L3RhYmxlcmFuZ2U6MWFmZmE4OTZlNjJmNGJkYjg1MGVjYTM5MDM3YTYyZTRfMTAtMS0xLTEtMA_1f861446-4502-45b5-823d-6078872515f0">17,439,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average remaining lease term</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ic36b9cedad7f41a6b9eb223b09b7186c_I20210331" format="ixt-sec:duryear" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN184Mi9mcmFnOjhhYmI3MjAyY2NjMzQwY2M5NzJhN2FjZmVkZmRjZDQxL3RhYmxlOjFhZmZhODk2ZTYyZjRiZGI4NTBlY2EzOTAzN2E2MmU0L3RhYmxlcmFuZ2U6MWFmZmE4OTZlNjJmNGJkYjg1MGVjYTM5MDM3YTYyZTRfMTItMS0xLTEtMA_89c1fe95-aa2d-4920-97d5-26ef0a41d368">7.2</ix:nonNumeric> years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average discount rate</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic36b9cedad7f41a6b9eb223b09b7186c_I20210331" decimals="3" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN184Mi9mcmFnOjhhYmI3MjAyY2NjMzQwY2M5NzJhN2FjZmVkZmRjZDQxL3RhYmxlOjFhZmZhODk2ZTYyZjRiZGI4NTBlY2EzOTAzN2E2MmU0L3RhYmxlcmFuZ2U6MWFmZmE4OTZlNjJmNGJkYjg1MGVjYTM5MDM3YTYyZTRfMTMtMS0xLTEtMA_a621a339-5b3d-4232-b3c1-a2fa6c218745">8.5</ix:nonFraction>%</span></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i4cdefa0793044551a244fc0987bc3a0b"><div style="margin-top:8pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lease costs included in operating expenses in the condensed consolidated statements of operations for the three months ended March 31, 2021 and 2020 were $<ix:nonFraction unitRef="usd" contextRef="i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LeaseCost" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN184Mi9mcmFnOjhhYmI3MjAyY2NjMzQwY2M5NzJhN2FjZmVkZmRjZDQxL3RleHRyZWdpb246OGFiYjcyMDJjY2MzNDBjYzk3MmE3YWNmZWRmZGNkNDFfMjAyNw_5cd0300e-35e7-4b78-a387-545d42cc8a06">850,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i03bccaa0abfb4733b1e2831ecde4e4e8_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LeaseCost" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN184Mi9mcmFnOjhhYmI3MjAyY2NjMzQwY2M5NzJhN2FjZmVkZmRjZDQxL3RleHRyZWdpb246OGFiYjcyMDJjY2MzNDBjYzk3MmE3YWNmZWRmZGNkNDFfMjE3NA_8e5b684a-9b3d-4fa8-9266-bc7fca229c8f">834,000</ix:nonFraction>, respectively. Operating lease costs consisting of the fixed lease payments included in operating lease liabilities are recorded on a straight-line basis over the lease terms. Variable lease costs are recorded as incurred.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the fourth quarter of 2019, the Company entered into two agreements to sublease a total of approximately <ix:nonFraction unitRef="sqft" contextRef="i49a24e6bc43d4cd9a7a914b19403f340_D20191001-20191231" decimals="0" format="ixt:numdotdecimal" name="ino:LesseeOperatingLeaseAreaofLandUnderLease" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN184Mi9mcmFnOjhhYmI3MjAyY2NjMzQwY2M5NzJhN2FjZmVkZmRjZDQxL3RleHRyZWdpb246OGFiYjcyMDJjY2MzNDBjYzk3MmE3YWNmZWRmZGNkNDFfMjE5OTAyMzI1ODk3OA_4c64eb2f-8b2c-43f6-8f4e-cf5d68330e36">13,500</ix:nonFraction> square feet in its Plymouth Meeting headquarters through periods between December 31, 2022 and March 31, 2025.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the normal course of business, the Company is a party to a variety of agreements pursuant to which it may be obligated to indemnify the other party. It is not possible to predict the maximum potential amount of future payments under these types of agreements due to the conditional nature of the Company's obligations and the unique facts and circumstances involved in each particular agreement. Historically, payments made by the Company under these types of agreements have not had a material effect on its business, consolidated results of operations or financial condition.</span></div></ix:continuation><div style="margin-top:5pt;text-indent:27pt"><span><br/></span></div><div id="i1d23d16a69484b63aa007ec686e80337_85"></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">15. <ix:nonNumeric contextRef="i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331" name="us-gaap:CollaborativeArrangementDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN184NS9mcmFnOjE2ZTFhMGJhMzg4NjQzZWI4MzhlNGQ2ZWE5ODVjMzcwL3RleHRyZWdpb246MTZlMWEwYmEzODg2NDNlYjgzOGU0ZDZlYTk4NWMzNzBfMTMwNDM_b206af38-4dc9-495e-8432-d131c85584f9" continuedAt="if0756116032244aead44b249454f3c67" escape="true">Collaborative Agreements</ix:nonNumeric></span></div><ix:continuation id="if0756116032244aead44b249454f3c67" continuedAt="if5dae040eaa645feafcc49b4df772d59"><div style="margin-top:5pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Advaccine Biopharmaceuticals Suzhou Co., Ltd. (Advaccine)</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 31, 2020, the Company entered into a Collaboration and License Agreement (the &#8220;Advaccine Agreement&#8221;) with Advaccine. Under the terms of the Advaccine Agreement, the Company granted to Advaccine the exclusive right to develop, manufacture and commercialize the Company&#8217;s vaccine candidate INO-4800 within the territories of China, Taiwan, Hong Kong and Macau (referred to collectively as &#8220;Greater China&#8221;). Advaccine does not have the right to grant sublicenses, other than to affiliated entities, without the Company&#8217;s express prior written consent. As part of the collaboration, Advaccine has also granted to the Company a non-exclusive license to certain DNA vaccine manufacturing processes.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Advaccine Agreement, Advaccine made an upfront payment to the Company of $<ix:nonFraction unitRef="usd" contextRef="i16a0d0ea59c14de2b4879a3250ddd093_D20210101-20210331" decimals="-5" format="ixt:numdotdecimal" name="ino:CollaborativeAgreementsUpfrontPaymentReceived" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN184NS9mcmFnOjE2ZTFhMGJhMzg4NjQzZWI4MzhlNGQ2ZWE5ODVjMzcwL3RleHRyZWdpb246MTZlMWEwYmEzODg2NDNlYjgzOGU0ZDZlYTk4NWMzNzBfMjE5OTAyMzI3OTcxNA_cda72955-d06c-4147-bab9-5d03ad5ad3f1">3.0</ix:nonFraction>&#160;million. In addition to the upfront payment, the Company is entitled to receive up to an aggregate of $<ix:nonFraction unitRef="usd" contextRef="i16a0d0ea59c14de2b4879a3250ddd093_D20210101-20210331" decimals="-5" format="ixt:numdotdecimal" name="ino:CollaborationAgreementAdditionalRevenueToBeAchieved" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN184NS9mcmFnOjE2ZTFhMGJhMzg4NjQzZWI4MzhlNGQ2ZWE5ODVjMzcwL3RleHRyZWdpb246MTZlMWEwYmEzODg2NDNlYjgzOGU0ZDZlYTk4NWMzNzBfMjE5OTAyMzI3OTc5OA_862885f2-a51e-4730-a21c-cf6d5fbb731d">108.0</ix:nonFraction>&#160;million upon the achievement of specified milestones related to the development, regulatory approval and commercialization of INO-4800, including the achievement of specified net sales thresholds for INO-4800 in Greater China, if approved. As of December 31, 2020 the Company had earned a $<ix:nonFraction unitRef="usd" contextRef="i16a0d0ea59c14de2b4879a3250ddd093_D20210101-20210331" decimals="-5" format="ixt:numdotdecimal" name="ino:CollaborationAgreementPaymentEarned" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN184NS9mcmFnOjE2ZTFhMGJhMzg4NjQzZWI4MzhlNGQ2ZWE5ODVjMzcwL3RleHRyZWdpb246MTZlMWEwYmEzODg2NDNlYjgzOGU0ZDZlYTk4NWMzNzBfMjE5OTAyMzI3OTcyOA_f7c26f9d-88bc-433b-9fff-eefa4aa3eac9">2.0</ix:nonFraction>&#160;million milestone payment based on the enrollment of the first subject in the Phase 2 clinical trial for the product in the Advaccine territory. The Company will also be entitled to receive a royalty equal to a high single-digit percentage of annual net sales in each region within Greater China, subject to reduction in the event of competition from biosimilar products in a particular region and in other specified circumstances. Advaccine&#8217;s obligation to pay royalties will continue, on a licensed product-by-licensed product basis and region-by-region basis, for <ix:nonNumeric contextRef="i16a0d0ea59c14de2b4879a3250ddd093_D20210101-20210331" format="ixt-sec:durwordsen" name="ino:CollaborationAgreementRoyaltyPeriod" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN184NS9mcmFnOjE2ZTFhMGJhMzg4NjQzZWI4MzhlNGQ2ZWE5ODVjMzcwL3RleHRyZWdpb246MTZlMWEwYmEzODg2NDNlYjgzOGU0ZDZlYTk4NWMzNzBfNTQ5NzU1ODE2NTU1MQ_9870efab-3151-4461-8777-8bba10a05e23">ten years</ix:nonNumeric> after the first commercial sale in a particular region within Greater China or, if later, until the expiration of the last-to-expire patent covering a given licensed product in a given region.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Advaccine Agreement, Advaccine is responsible for the development and commercialization of the licensed products at its own cost and expense and is obligated to use commercially reasonable efforts to develop, obtain and maintain regulatory approval of INO-4800, as well as the Company&#8217;s CELLECTRA</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> device and arrays for use in connection with the administration of INO-4800, in each region in Greater China. In the event that the Company has not initiated the planned Phase 3 segment of its ongoing clinical trial of INO-4800 in the United States within <ix:nonNumeric contextRef="i16a0d0ea59c14de2b4879a3250ddd093_D20210101-20210331" format="ixt-sec:durwordsen" name="ino:CollaborativeAgreementPeriodFromEffectiveDateForTermination" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN184NS9mcmFnOjE2ZTFhMGJhMzg4NjQzZWI4MzhlNGQ2ZWE5ODVjMzcwL3RleHRyZWdpb246MTZlMWEwYmEzODg2NDNlYjgzOGU0ZDZlYTk4NWMzNzBfNTQ5NzU1ODE2NTU2OA_382adea3-61e3-4eb3-9d4b-7e97eefed7ed">one year</ix:nonNumeric> after entering into the Advaccine Agreement, Advaccine may elect to conduct a Phase 3 clinical trial outside of Greater China at its own cost and expense for the purposes of obtaining regulatory approval in China, subject to the Company&#8217;s right to review and approve the protocols and design of such a trial.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Advaccine Agreement, the Company will supply Advaccine&#8217;s clinical requirements of INO-4800 and devices, although Advaccine may manufacture INO-4800 for its clinical use and may procure alternate suppliers. Advaccine is responsible for the manufacture and supply of INO-4800 itself or through a contract manufacturer for commercial use. Upon Advaccine&#8217;s reasonable request, the parties may negotiate a separate clinical and/or commercial supply agreement.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Advaccine Agreement will continue in force on a region-by-region basis until Advaccine has no remaining royalty obligations in such region. Either party may terminate the Advaccine Agreement (i) in the event the other party shall have materially breached its obligations thereunder and such default shall have continued for a specified period after written notice thereof or (ii) upon the bankruptcy or insolvency of the other party. In addition, the Company may terminate the agreement, upon prior written notice, if Advaccine (i) ceases all development or commercialization activities for at least nine months, subject to certain exceptions, or (ii) challenges the validity, enforceability or scope of any of the patents licensed by the Company to Advaccine under the Advaccine Agreement, subject to certain conditions. Advaccine may terminate the Advaccine Agreement at any time for convenience upon nine months&#8217; written notice to the Company, if such notice is provided before the first commercial sale of INO-4800 in Greater China, or 18 months&#8217; written notice thereafter; provided that the Company may accelerate the effectiveness of such termination to the extent permitted by law.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="if5dae040eaa645feafcc49b4df772d59" continuedAt="ied9e3233cfb14decbaf6af3103c22a1c"><div style="margin-top:5pt;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluated the terms of the Advaccine Agreement under ASC Topics 606 and 808, and determined that the contract was with a customer and therefore should be accounted for under ASC Topic 606. The license to INO-4800 in the territories was identified as the only distinct performance obligation on a standalone basis as of the inception of the Advaccine Agreement. The Company concluded that the license was distinct from potential future manufacturing and supply obligations. The Company further determined that the transaction price under the Advaccine Agreement consisted of the $<ix:nonFraction unitRef="usd" contextRef="i16a0d0ea59c14de2b4879a3250ddd093_D20210101-20210331" decimals="-5" format="ixt:numdotdecimal" name="ino:CollaborativeAgreementsUpfrontPaymentReceived" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN184NS9mcmFnOjE2ZTFhMGJhMzg4NjQzZWI4MzhlNGQ2ZWE5ODVjMzcwL3RleHRyZWdpb246MTZlMWEwYmEzODg2NDNlYjgzOGU0ZDZlYTk4NWMzNzBfMjE5OTAyMzI3OTc0Mg_66d35f82-7062-4984-93e3-6a6536d659fc">3.0</ix:nonFraction>&#160;million upfront payment plus the initial $<ix:nonFraction unitRef="usd" contextRef="i16a0d0ea59c14de2b4879a3250ddd093_D20210101-20210331" decimals="-5" format="ixt:numdotdecimal" name="ino:CollaborationAgreementPaymentEarned" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN184NS9mcmFnOjE2ZTFhMGJhMzg4NjQzZWI4MzhlNGQ2ZWE5ODVjMzcwL3RleHRyZWdpb246MTZlMWEwYmEzODg2NDNlYjgzOGU0ZDZlYTk4NWMzNzBfMjE5OTAyMzI3OTc1Ng_bfc0d170-8aa9-4330-a396-f8a55bb2d356">2.0</ix:nonFraction>&#160;million milestone payment which was achieved upon contract signing. The future potential milestone amounts were not included in the transaction price, as they were all determined to be fully constrained. As part of the evaluation of the development and regulatory milestones constraint, the Company determined that the achievement of such milestones is contingent upon success in future clinical trials and regulatory approvals, each of which is uncertain. Future potential milestone amounts may be recognized as revenue under the Advaccine Agreement, as well as under other collaborative research and development arrangements, if unconstrained. Reimbursable program costs will be recognized proportionately with the performance of the underlying services or delivery of drug supply and are excluded from the transaction price.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under Topic 606, the entire transaction price of $<ix:nonFraction unitRef="usd" contextRef="i218a10d1c62a4a1d8cff8c3442114b71_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN184NS9mcmFnOjE2ZTFhMGJhMzg4NjQzZWI4MzhlNGQ2ZWE5ODVjMzcwL3RleHRyZWdpb246MTZlMWEwYmEzODg2NDNlYjgzOGU0ZDZlYTk4NWMzNzBfMjE5OTAyMzI3OTc3MA_78bcda29-2036-4ff6-bc92-01ac5e7233a8">5.0</ix:nonFraction>&#160;million was allocated to the license performance obligation. The Company determined that as of December 31, 2020, the transfer of technology has occurred for the use and benefit of the license and accordingly, the performance obligation was fully satisfied. The Company accordingly recognized $<ix:nonFraction unitRef="usd" contextRef="i43ca7eb4e9604967b950979b7b65da58_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN184NS9mcmFnOjE2ZTFhMGJhMzg4NjQzZWI4MzhlNGQ2ZWE5ODVjMzcwL3RleHRyZWdpb246MTZlMWEwYmEzODg2NDNlYjgzOGU0ZDZlYTk4NWMzNzBfMjE5OTAyMzI3OTc4NA_442466ca-275a-4677-896f-acb7d075bbdb">5.0</ix:nonFraction>&#160;million in revenue under collaborative research and development arrangements on the consolidated statement of operations during the year ended December 31, 2020. During the three months ended March 31, 2021, <ix:nonFraction unitRef="usd" contextRef="iff19a2c26f364894a1393fb4bb5ed788_D20210101-20210331" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN184NS9mcmFnOjE2ZTFhMGJhMzg4NjQzZWI4MzhlNGQ2ZWE5ODVjMzcwL3RleHRyZWdpb246MTZlMWEwYmEzODg2NDNlYjgzOGU0ZDZlYTk4NWMzNzBfMTA5OTUxMTY1MjczNA_9ef36836-4373-46d8-b627-e3692f52ef35">no</ix:nonFraction> revenue was recognized from Advaccine.  As of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March&#160;31, 2021 and </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December 31, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2020</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the Company had an accounts receivable balance of $<ix:nonFraction unitRef="usd" contextRef="i9e2527d562564d0da42bfadc4214aabf_I20210331" decimals="-5" name="us-gaap:AccountsReceivableNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN184NS9mcmFnOjE2ZTFhMGJhMzg4NjQzZWI4MzhlNGQ2ZWE5ODVjMzcwL3RleHRyZWdpb246MTZlMWEwYmEzODg2NDNlYjgzOGU0ZDZlYTk4NWMzNzBfMjE5OTAyMzI3OTg2Mg_ca25634d-2a76-440b-9830-3e4caf059118">0</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="ie9a3ac315bd64233b038ae99d2926ee5_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN184NS9mcmFnOjE2ZTFhMGJhMzg4NjQzZWI4MzhlNGQ2ZWE5ODVjMzcwL3RleHRyZWdpb246MTZlMWEwYmEzODg2NDNlYjgzOGU0ZDZlYTk4NWMzNzBfNTQ5NzU1ODE2NTU4NQ_c05f9e52-3761-46c1-8150-ab70877e33f4">7.1</ix:nonFraction>&#160;million, respectively, from Advaccine.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ApolloBio Corporation </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December&#160;29, 2017, the Company entered into an Amended and Restated License and Collaboration Agreement (the "ApolloBio Agreement"),</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">with ApolloBio Corporation ("ApolloBio"), with an effective date of March 20, 2018. Under the terms of the ApolloBio Agreement, the Company has granted to ApolloBio the exclusive right to develop and commercialize&#160;VGX-3100, its DNA immunotherapy product candidate designed to treat&#160;pre-cancers&#160;caused by HPV, within the territories of China, Hong Kong, Macao, Taiwan, and potentially Korea in the event that no patent covering&#160;VGX-3100&#160;is issued in China within the <ix:nonNumeric contextRef="i4ae78b29c7ad4225be2a6e2ef791b855_D20171229-20171229" format="ixt-sec:durwordsen" name="ino:CollaborationAgreementTerritoryExpansionOptionPeriod" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN184NS9mcmFnOjE2ZTFhMGJhMzg4NjQzZWI4MzhlNGQ2ZWE5ODVjMzcwL3RleHRyZWdpb246MTZlMWEwYmEzODg2NDNlYjgzOGU0ZDZlYTk4NWMzNzBfNjU5_6f122f5a-255d-4cef-9ef2-04c2470860be">three years</ix:nonNumeric> following the effective date of the ApolloBio Agreement.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the ApolloBio Agreement, the Company received proceeds of $<ix:nonFraction unitRef="usd" contextRef="ifb1c860482c945d2b8d0a23ea9de9d2b_D20180301-20180331" decimals="-5" format="ixt:numdotdecimal" name="ino:ProceedsFromCollaborativeAgreement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN184NS9mcmFnOjE2ZTFhMGJhMzg4NjQzZWI4MzhlNGQ2ZWE5ODVjMzcwL3RleHRyZWdpb246MTZlMWEwYmEzODg2NDNlYjgzOGU0ZDZlYTk4NWMzNzBfNzgz_b0ac66a0-73a4-486d-9d66-7bcce6c5e323">19.4</ix:nonFraction> million in March 2018 which comprised the upfront payment of $<ix:nonFraction unitRef="usd" contextRef="ifb1c860482c945d2b8d0a23ea9de9d2b_D20180301-20180331" decimals="-5" format="ixt:numdotdecimal" name="ino:CollaborativeAgreementsUpfrontPaymentReceived" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN184NS9mcmFnOjE2ZTFhMGJhMzg4NjQzZWI4MzhlNGQ2ZWE5ODVjMzcwL3RleHRyZWdpb246MTZlMWEwYmEzODg2NDNlYjgzOGU0ZDZlYTk4NWMzNzBfODM5_c31f1af8-f5f8-489a-9851-479208d2b957">23.0</ix:nonFraction> million less $<ix:nonFraction unitRef="usd" contextRef="ic48f2b7387c740dda32316adb9b93c55_D20180301-20180331" decimals="-5" format="ixt:numdotdecimal" name="ino:CollaborativeAgreementCorporateIncomeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN184NS9mcmFnOjE2ZTFhMGJhMzg4NjQzZWI4MzhlNGQ2ZWE5ODVjMzcwL3RleHRyZWdpb246MTZlMWEwYmEzODg2NDNlYjgzOGU0ZDZlYTk4NWMzNzBfODQ3_5c1e77ae-6f2b-47eb-ac3b-efe3b844b286">2.2</ix:nonFraction> million in foreign income taxes and $<ix:nonFraction unitRef="usd" contextRef="ic48f2b7387c740dda32316adb9b93c55_D20180301-20180331" decimals="-5" format="ixt:numdotdecimal" name="ino:CollaborativeAgreementForeignNonIncomeTaxes" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN184NS9mcmFnOjE2ZTFhMGJhMzg4NjQzZWI4MzhlNGQ2ZWE5ODVjMzcwL3RleHRyZWdpb246MTZlMWEwYmEzODg2NDNlYjgzOGU0ZDZlYTk4NWMzNzBfODc4_14b09597-0d27-4ecc-a5a8-54de8d8adcdf">1.4</ix:nonFraction> million in certain foreign non-income taxes. The foreign income taxes were recorded as a provision for income taxes and the foreign non-income taxes were recorded as a general and administrative expense, on the condensed consolidated statement of operations. The Company also incurred advisory fees of $<ix:nonFraction unitRef="usd" contextRef="ifcaf1ba492eb44b08dea1762e6aae5a6_I20180331" decimals="-3" format="ixt:numdotdecimal" name="ino:CollaborativeAgreementAdvisoryFees" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN184NS9mcmFnOjE2ZTFhMGJhMzg4NjQzZWI4MzhlNGQ2ZWE5ODVjMzcwL3RleHRyZWdpb246MTZlMWEwYmEzODg2NDNlYjgzOGU0ZDZlYTk4NWMzNzBfMTE3NQ_994f264f-9963-40ad-ad5a-96ed5b5edf55">960,000</ix:nonFraction> in connection with receiving the upfront payment from ApolloBio. These fees were determined to be incremental costs of obtaining the contract. The Company applied the practical expedient that permits a company to expense incremental costs to obtain a contract when the expected amortization period is one year or less and recorded the fees in general and administrative expense during the quarter ended March 31, 2018. No additional advisory fees are due related to the ApolloBio Agreement. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the upfront payment, the Company is entitled to receive up to an aggregate of $<ix:nonFraction unitRef="usd" contextRef="ibfe7179d0c314ec8b6575735e5576485_D20210101-20210331" decimals="-5" format="ixt:numdotdecimal" name="ino:CollaborationAgreementAdditionalRevenueToBeAchieved" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN184NS9mcmFnOjE2ZTFhMGJhMzg4NjQzZWI4MzhlNGQ2ZWE5ODVjMzcwL3RleHRyZWdpb246MTZlMWEwYmEzODg2NDNlYjgzOGU0ZDZlYTk4NWMzNzBfMTc2Mw_ad02e6d6-6d19-4139-b0a1-07736e73e2a7">20.0</ix:nonFraction> million, less required income, withholding or other taxes, upon the achievement of specified milestones related to the regulatory approval of&#160;VGX-3100&#160;in the United States, China and Korea. In the event that&#160;VGX-3100 is approved for marketing, the Company will be entitled to receive royalty payments based on a tiered percentage of annual net sales, with such percentage being in the&#160;low-&#160;to&#160;mid-teens,&#160;subject to reduction in the event of generic competition in a particular territory. ApolloBio&#8217;s obligation to pay royalties will continue for <ix:nonNumeric contextRef="ibfe7179d0c314ec8b6575735e5576485_D20210101-20210331" format="ixt-sec:duryear" name="ino:CollaborationAgreementRoyaltyPeriod" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN184NS9mcmFnOjE2ZTFhMGJhMzg4NjQzZWI4MzhlNGQ2ZWE5ODVjMzcwL3RleHRyZWdpb246MTZlMWEwYmEzODg2NDNlYjgzOGU0ZDZlYTk4NWMzNzBfMjMwNA_6547788c-fecc-4360-9e06-6a73733978ee">10</ix:nonNumeric> years after the first commercial sale in a particular territory or, if later, until the expiration of the&#160;last-to-expire&#160;patent covering the licensed products in the specified territory. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The ApolloBio Agreement will continue in force until ApolloBio has no remaining royalty obligations. Either party may terminate the ApolloBio Agreement in the event the other party shall materially breach or default in the performance of its material obligations thereunder and such default continues for a specified period after written notice thereof. In addition, ApolloBio may terminate the ApolloBio Agreement at any time beginning <ix:nonNumeric contextRef="ibfe7179d0c314ec8b6575735e5576485_D20210101-20210331" format="ixt-sec:durwordsen" name="ino:CollaborativeAgreementPeriodFromEffectiveDateForTermination" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN184NS9mcmFnOjE2ZTFhMGJhMzg4NjQzZWI4MzhlNGQ2ZWE5ODVjMzcwL3RleHRyZWdpb246MTZlMWEwYmEzODg2NDNlYjgzOGU0ZDZlYTk4NWMzNzBfMTA5OTUxMTY2MTIwMA_4f98766d-6cce-419a-ad2c-1f208a963db3">one year</ix:nonNumeric> after the effective date for any reason upon <ix:nonNumeric contextRef="ibfe7179d0c314ec8b6575735e5576485_D20210101-20210331" format="ixt-sec:durday" name="ino:CollaborativeAgreementNumberofDaysWrittenNoticeBeforeTermination" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN184NS9mcmFnOjE2ZTFhMGJhMzg4NjQzZWI4MzhlNGQ2ZWE5ODVjMzcwL3RleHRyZWdpb246MTZlMWEwYmEzODg2NDNlYjgzOGU0ZDZlYTk4NWMzNzBfMTA5OTUxMTY2MTI0OQ_e9d1ee16-fe4b-4221-a612-30202cbacbe5">90</ix:nonNumeric> days written notice to the Company.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluated the terms of the ApolloBio Agreement under ASC Topic 606, and the license to VGX-3100 in the territories was identified as the only distinct performance obligation on a standalone basis as of the inception of the agreement.  The Company concluded that the license was distinct from potential future manufacturing and supply obligations. The Company further determined that the transaction price under the agreement consisted of the $<ix:nonFraction unitRef="usd" contextRef="ibfe7179d0c314ec8b6575735e5576485_D20210101-20210331" decimals="-5" format="ixt:numdotdecimal" name="ino:CollaborativeAgreementsUpfrontPaymentReceived" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN184NS9mcmFnOjE2ZTFhMGJhMzg4NjQzZWI4MzhlNGQ2ZWE5ODVjMzcwL3RleHRyZWdpb246MTZlMWEwYmEzODg2NDNlYjgzOGU0ZDZlYTk4NWMzNzBfMjk0Mw_06835947-65f2-4c51-8425-242aedc4b973">23.0</ix:nonFraction> million upfront payment.  The future potential milestone amounts were not included in the transaction price, as they were all determined to be fully constrained. As part of the evaluation of the development and regulatory milestones constraint, the Company determined that the achievement of such milestones is contingent upon success in future clinical trials and regulatory approvals, each of which is uncertain at this time. Future potential milestone amounts may be recognized as revenue under the ApolloBio Agreement, as </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="ied9e3233cfb14decbaf6af3103c22a1c" continuedAt="icdb6d7056343425a92b9dcb5a6b76391"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">well as under other collaborative research and development arrangements, if unconstrained. Reimbursable program costs will be recognized proportionately with the performance of the underlying services or delivery of drug supply and are excluded from the transaction price. As of March&#160;31, 2021 there have been no significant reimbursable program costs under the ApolloBio Agreement.</span><span style="color:#ee2724;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under Topic 606, the entire transaction price of $<ix:nonFraction unitRef="usd" contextRef="i166171f55c2146e6a9bfc1cbda21593f_D20180401-20180630" decimals="-5" format="ixt:numdotdecimal" name="ino:CollaborativeAgreementsUpfrontPaymentReceived" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN184NS9mcmFnOjE2ZTFhMGJhMzg4NjQzZWI4MzhlNGQ2ZWE5ODVjMzcwL3RleHRyZWdpb246MTZlMWEwYmEzODg2NDNlYjgzOGU0ZDZlYTk4NWMzNzBfNDMxMA_c91a1dae-390e-4392-8728-45ad02e7ac15">23.0</ix:nonFraction> million was allocated to the license performance obligation. The Company determined that during the quarter ended June 30, 2018, the transfer of technology occurred and accordingly, the performance obligation was fully satisfied. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">AstraZeneca </span></div><div style="margin-bottom:3pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 7, 2015, the Company entered into a license and collaboration agreement with MedImmune, the global biologics research and development arm of AstraZeneca ("AstraZeneca"). Under the agreement, AstraZeneca acquired exclusive rights to the Company's INO-3112 immunotherapy, renamed as MEDI0457, which targets cancers caused by human papillomavirus (HPV) types 16 and 18, with the ability to sublicense those license rights. AstraZeneca made an upfront payment of $<ix:nonFraction unitRef="usd" contextRef="i312dc53a327b4c2584c0408f7ce3c401_D20150901-20150930" decimals="-5" format="ixt:numdotdecimal" name="ino:CollaborativeAgreementsUpfrontPaymentReceived" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN184NS9mcmFnOjE2ZTFhMGJhMzg4NjQzZWI4MzhlNGQ2ZWE5ODVjMzcwL3RleHRyZWdpb246MTZlMWEwYmEzODg2NDNlYjgzOGU0ZDZlYTk4NWMzNzBfNTI2Ng_d2af6377-4aa3-41b4-a9ea-37d8d35f97ed">27.5</ix:nonFraction> million to the Company in September 2015. AstraZeneca may be obligated to make potential future development and regulatory event-based payments to the Company totaling up to $<ix:nonFraction unitRef="usd" contextRef="id271d63e442f4a9f8fb4db1a017f1090_D20210101-20210331" decimals="-6" format="ixt:numdotdecimal" name="ino:CollaborationAgreementAnticipatedDevelopmentandRegulatoryEventBasedPaymentReceivableMilestones" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN184NS9mcmFnOjE2ZTFhMGJhMzg4NjQzZWI4MzhlNGQ2ZWE5ODVjMzcwL3RleHRyZWdpb246MTZlMWEwYmEzODg2NDNlYjgzOGU0ZDZlYTk4NWMzNzBfNTQzNQ_9add39e4-fd24-4fb4-a44e-83e453235ffe">125</ix:nonFraction> million and potential future commercial event-based payments totaling up to $<ix:nonFraction unitRef="usd" contextRef="id271d63e442f4a9f8fb4db1a017f1090_D20210101-20210331" decimals="-6" format="ixt:numdotdecimal" name="ino:CollaborationAgreementAnticipatedCommercialEventBasedPaymentReceivableMilestones" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN184NS9mcmFnOjE2ZTFhMGJhMzg4NjQzZWI4MzhlNGQ2ZWE5ODVjMzcwL3RleHRyZWdpb246MTZlMWEwYmEzODg2NDNlYjgzOGU0ZDZlYTk4NWMzNzBfNTUwNg_25da275e-05a0-4f3a-a060-c7598cc1b0a6">115</ix:nonFraction> million, in each case upon the achievement of specified milestones related to MEDI0457 set forth in the license and collaboration agreement. AstraZeneca will fund all development costs associated with MEDI0457 immunotherapy. The Company is entitled to receive up to mid-single to double-digit tiered royalties on MEDI0457 product sales. Under the agreement, AstraZeneca can also request the Company to provide certain clinical manufacturing at an agreed upon price. The Company determined these options did not represent material rights at the inception of the agreement.   </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2017, the Company had recognized all of the $<ix:nonFraction unitRef="usd" contextRef="iab8cbd4abffa49939bca24df9e09f682_D20171231-20171231" decimals="-5" format="ixt:numdotdecimal" name="ino:CollaborativeAgreementsUpfrontPaymentReceived" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN184NS9mcmFnOjE2ZTFhMGJhMzg4NjQzZWI4MzhlNGQ2ZWE5ODVjMzcwL3RleHRyZWdpb246MTZlMWEwYmEzODg2NDNlYjgzOGU0ZDZlYTk4NWMzNzBfNjUzNw_dc58d413-d46b-4886-876c-abace57ae1dc">27.5</ix:nonFraction> million upfront payment as revenue, as all identified material performance obligations had been met with respect to that payme</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">nt. In both December 2018 and March 2019, the Company recognized as revenue $<ix:nonFraction unitRef="usd" contextRef="i1279cb3397f540cf8c03eff95603717f_D20181201-20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN184NS9mcmFnOjE2ZTFhMGJhMzg4NjQzZWI4MzhlNGQ2ZWE5ODVjMzcwL3RleHRyZWdpb246MTZlMWEwYmEzODg2NDNlYjgzOGU0ZDZlYTk4NWMzNzBfMjE5OTAyMzI3ODEyMA_a99b7a4b-6239-4b70-9704-d70d5b5da2cb"><ix:nonFraction unitRef="usd" contextRef="i0a00fce528054fc1b13da4166be4a7f9_D20190302-20190331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN184NS9mcmFnOjE2ZTFhMGJhMzg4NjQzZWI4MzhlNGQ2ZWE5ODVjMzcwL3RleHRyZWdpb246MTZlMWEwYmEzODg2NDNlYjgzOGU0ZDZlYTk4NWMzNzBfMjE5OTAyMzI3ODEyMA_f78fe4ea-61e3-4d60-8c7f-2534aef0a457">2.0</ix:nonFraction></ix:nonFraction>&#160;million in milestone payments from AstraZeneca triggered by AstraZeneca&#8217;s </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">initiation of the Phase 2 portion of ongoing clinical trials in the second and third major indication, respectively, under the agreement.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Coalition for Epidemic Preparedness Innovations </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2018, the Company entered into agreements with CEPI, pursuant to which the Company intends to develop vaccine candidates against Lassa fever and MERS. The goal of the collaboration between the Company and CEPI is to conduct research and development so that investigational stockpiles will be ready for clinical efficacy trial testing during potential disease outbreaks. The agreements with CEPI contemplate preclinical&#160;studies, as well as Phase 1 and Phase 2 clinical trials, occurring over multiple years. As part of the arrangement between the parties, CEPI has agreed to fund up to an aggregate of $<ix:nonFraction unitRef="usd" contextRef="i26869d6b62d04f7b965bf3b12a74986b_D20180401-20180430" decimals="-6" format="ixt:numdotdecimal" name="ino:CollaborativeAgreementFundingToBeReceived" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN184NS9mcmFnOjE2ZTFhMGJhMzg4NjQzZWI4MzhlNGQ2ZWE5ODVjMzcwL3RleHRyZWdpb246MTZlMWEwYmEzODg2NDNlYjgzOGU0ZDZlYTk4NWMzNzBfNzc1Ng_9e2eb08b-3a55-4d6d-b4dd-4e19d0a3bf00">56</ix:nonFraction> million of costs over a <ix:nonNumeric contextRef="i26869d6b62d04f7b965bf3b12a74986b_D20180401-20180430" format="ixt-sec:durwordsen" name="ino:CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN184NS9mcmFnOjE2ZTFhMGJhMzg4NjQzZWI4MzhlNGQ2ZWE5ODVjMzcwL3RleHRyZWdpb246MTZlMWEwYmEzODg2NDNlYjgzOGU0ZDZlYTk4NWMzNzBfMTMwMzg_ab568341-06cd-4e04-9f5a-2bcaa4edb879">five-year</ix:nonNumeric> period for preclinical studies, as well as planned Phase 1 and Phase 2 clinical trials, to be conducted by the Company and collaborators, with funding from CEPI based on the achievement of identified milestones. During the three months ended March 31, 2021 and 2020, the Company received funding of $<ix:nonFraction unitRef="usd" contextRef="i9e2dfcc4dad04e25a9c9b44b8901a333_D20210101-20210331" decimals="-5" format="ixt:numdotdecimal" name="ino:CollaborativeAgreementFundingReceived" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN184NS9mcmFnOjE2ZTFhMGJhMzg4NjQzZWI4MzhlNGQ2ZWE5ODVjMzcwL3RleHRyZWdpb246MTZlMWEwYmEzODg2NDNlYjgzOGU0ZDZlYTk4NWMzNzBfODA0Mg_83aefe17-1aa8-407c-8633-b5487d5a96e7">2.4</ix:nonFraction> million and  $<ix:nonFraction unitRef="usd" contextRef="id320f2073edd475b8fd5feeb871b3bb2_D20200101-20200331" decimals="-5" format="ixt:numdotdecimal" name="ino:CollaborativeAgreementFundingReceived" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN184NS9mcmFnOjE2ZTFhMGJhMzg4NjQzZWI4MzhlNGQ2ZWE5ODVjMzcwL3RleHRyZWdpb246MTZlMWEwYmEzODg2NDNlYjgzOGU0ZDZlYTk4NWMzNzBfODIzMg_fe9716f3-4518-4ad7-990c-b1e1bc46b1e8">1.1</ix:nonFraction> million, respectively, related to these grants and recorded those payments as contra-research and development expense. As of March&#160;31, 2021, the Company had $<ix:nonFraction unitRef="usd" contextRef="i7705f1893eef43a683c986157751b493_I20210331" decimals="-3" format="ixt:numdotdecimal" name="ino:DeferredGrantFundingCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN184NS9mcmFnOjE2ZTFhMGJhMzg4NjQzZWI4MzhlNGQ2ZWE5ODVjMzcwL3RleHRyZWdpb246MTZlMWEwYmEzODg2NDNlYjgzOGU0ZDZlYTk4NWMzNzBfODM4NQ_567b29c2-1d90-475d-b4f3-683d86af89ce">251,000</ix:nonFraction> recorded as grant funding liability on the condensed consolidated balance sheet related to the CEPI grant. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2020, CEPI awarded the Company a grant of up to $<ix:nonFraction unitRef="usd" contextRef="i4c2c68f34809458b92b1fe442b05fe04_D20200101-20200131" decimals="-5" format="ixt:numdotdecimal" name="ino:CollaborativeAgreementFundingToBeReceived" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN184NS9mcmFnOjE2ZTFhMGJhMzg4NjQzZWI4MzhlNGQ2ZWE5ODVjMzcwL3RleHRyZWdpb246MTZlMWEwYmEzODg2NDNlYjgzOGU0ZDZlYTk4NWMzNzBfODU2NQ_54701191-7702-4dcf-950f-820c17fa41ec">9.0</ix:nonFraction> million to support preclinical and clinical development of INO-4800 through Phase 1 human testing in the United States. In April 2020, CEPI awarded the Company a grant of $<ix:nonFraction unitRef="usd" contextRef="iefa41d3db8c44b3784e3e21a11b9f57b_D20200401-20200430" decimals="-5" format="ixt:numdotdecimal" name="ino:CollaborativeAgreementFundingToBeReceived" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN184NS9mcmFnOjE2ZTFhMGJhMzg4NjQzZWI4MzhlNGQ2ZWE5ODVjMzcwL3RleHRyZWdpb246MTZlMWEwYmEzODg2NDNlYjgzOGU0ZDZlYTk4NWMzNzBfODg2Nw_d13aef93-4ddf-4eb7-8240-996fac4d6fdc">6.9</ix:nonFraction> million to work with the International Vaccine Institute ("IVI") and the Korea National Institute of Health ("KNIH") to conduct clinical trials of INO-4800 in South Korea, a grant of $<ix:nonFraction unitRef="usd" contextRef="ie8d1c12d54e14e8fadc5b66c01656f3f_D20200401-20200430" decimals="-5" format="ixt:numdotdecimal" name="ino:CollaborativeAgreementFundingToBeReceived" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN184NS9mcmFnOjE2ZTFhMGJhMzg4NjQzZWI4MzhlNGQ2ZWE5ODVjMzcwL3RleHRyZWdpb246MTZlMWEwYmEzODg2NDNlYjgzOGU0ZDZlYTk4NWMzNzBfOTA0NQ_3ca9434f-b250-4523-844f-c7edb1b53a29">5.0</ix:nonFraction> million to accelerate development of  the Company's next-generation intradermal electroporation device, known as CELLECTRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 3PSP, for the intradermal delivery of INO-4800, and a grant of $<ix:nonFraction unitRef="usd" contextRef="i4e63edbfeb924628bea29aa126db3731_D20200401-20200430" decimals="-5" format="ixt:numdotdecimal" name="ino:CollaborativeAgreementFundingToBeReceived" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN184NS9mcmFnOjE2ZTFhMGJhMzg4NjQzZWI4MzhlNGQ2ZWE5ODVjMzcwL3RleHRyZWdpb246MTZlMWEwYmEzODg2NDNlYjgzOGU0ZDZlYTk4NWMzNzBfOTIyNw_1dd8135b-7564-4ef2-8b34-3e16f1164b9a">1.3</ix:nonFraction> million to support large-scale manufacturing of INO-4800. During each of the three months ended March 31, 2021 and 2020, the Company received funding of $<ix:nonFraction unitRef="usd" contextRef="i90e840c675604f9ea05a3d3799146d6a_D20210101-20210331" decimals="-5" format="ixt:numdotdecimal" name="ino:CollaborativeAgreementFundingReceived" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN184NS9mcmFnOjE2ZTFhMGJhMzg4NjQzZWI4MzhlNGQ2ZWE5ODVjMzcwL3RleHRyZWdpb246MTZlMWEwYmEzODg2NDNlYjgzOGU0ZDZlYTk4NWMzNzBfOTMyNw_24193cf9-7cda-4278-913d-b41db2a8bf4c"><ix:nonFraction unitRef="usd" contextRef="i9c578a4352674268833b02f441d2630a_D20200101-20200331" decimals="-5" format="ixt:numdotdecimal" name="ino:CollaborativeAgreementFundingReceived" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN184NS9mcmFnOjE2ZTFhMGJhMzg4NjQzZWI4MzhlNGQ2ZWE5ODVjMzcwL3RleHRyZWdpb246MTZlMWEwYmEzODg2NDNlYjgzOGU0ZDZlYTk4NWMzNzBfOTMyNw_7738335e-4cfc-42a6-955f-abfc41cb6d79">2.4</ix:nonFraction></ix:nonFraction> million from CEPI related to these grants for INO-4800 and recorded such amounts as contra-research and development expense. As of March&#160;31, 2021, the Company had $<ix:nonFraction unitRef="usd" contextRef="i462daba8e70241fa90cc3d9158a0e6b1_I20210331" decimals="-5" format="ixt:numdotdecimal" name="ino:DeferredGrantFundingCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN184NS9mcmFnOjE2ZTFhMGJhMzg4NjQzZWI4MzhlNGQ2ZWE5ODVjMzcwL3RleHRyZWdpb246MTZlMWEwYmEzODg2NDNlYjgzOGU0ZDZlYTk4NWMzNzBfOTQ5NQ_ca0875b2-4fad-427e-b691-4457759de3f7">4.0</ix:nonFraction> million recorded as deferred grant funding on the condensed consolidated balance sheet related to the CEPI grants related to INO-4800.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Bill &amp; Melinda Gates Foundation</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2018, the Bill &amp; Melinda Gates Foundation (&#8220;Gates&#8221;) awarded and funded the Company a grant of $<ix:nonFraction unitRef="usd" contextRef="i8914061f84134527886aafd4379342b3_D20181001-20181031" decimals="-5" format="ixt:numdotdecimal" name="ino:CollaborativeAgreementFundingReceived" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN184NS9mcmFnOjE2ZTFhMGJhMzg4NjQzZWI4MzhlNGQ2ZWE5ODVjMzcwL3RleHRyZWdpb246MTZlMWEwYmEzODg2NDNlYjgzOGU0ZDZlYTk4NWMzNzBfOTc2Mg_e692216d-a003-45a6-a317-9659460fd770">2.2</ix:nonFraction> million to advance the development of dMAbs to address issues in infectious disease prevention and therapy. This technology has high relevance for the control of influenza and HIV. This next-generation approach to the delivery of monoclonal antibodies would make the technology accessible to low and middle-income countries. In August 2019, Gates funded an additional $<ix:nonFraction unitRef="usd" contextRef="id9b959950a9d4883a9e0bbc48e5b75b8_D20190801-20190830" decimals="-5" format="ixt:numdotdecimal" name="ino:CollaborativeAgreementFundingReceived" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN184NS9mcmFnOjE2ZTFhMGJhMzg4NjQzZWI4MzhlNGQ2ZWE5ODVjMzcwL3RleHRyZWdpb246MTZlMWEwYmEzODg2NDNlYjgzOGU0ZDZlYTk4NWMzNzBfMTAxNzE_b4342e8a-e814-404d-bfa0-1e144e6f0fc1">1.1</ix:nonFraction> million for the project. During the three months ended March 31, 2021 and 2020, the Company recorded $<ix:nonFraction unitRef="usd" contextRef="ia04b81c5769143f2ad65bc25e43bd9ed_D20210101-20210331" decimals="-3" name="ino:CollaborativeAgreementFundingReceived" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN184NS9mcmFnOjE2ZTFhMGJhMzg4NjQzZWI4MzhlNGQ2ZWE5ODVjMzcwL3RleHRyZWdpb246MTZlMWEwYmEzODg2NDNlYjgzOGU0ZDZlYTk4NWMzNzBfMTAyMjc_6542eeb3-8d55-498c-82c3-74c61dd2ab0e">0</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i091601a25e604419963010db9959837c_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="ino:CollaborativeAgreementFundingReceived" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN184NS9mcmFnOjE2ZTFhMGJhMzg4NjQzZWI4MzhlNGQ2ZWE5ODVjMzcwL3RleHRyZWdpb246MTZlMWEwYmEzODg2NDNlYjgzOGU0ZDZlYTk4NWMzNzBfMTAyMzQ_d262944d-d6c7-42e2-b7b1-51e40c4405f2">134,000</ix:nonFraction>, respectively, as contra-research and development expense related to the Gates dMAb grant. As of March&#160;31, 2021, the Company had $<ix:nonFraction unitRef="usd" contextRef="i870d9127e6314fc4aebaa4f4b2a7931e_I20210331" decimals="-3" format="ixt:numdotdecimal" name="ino:DeferredGrantFundingCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN184NS9mcmFnOjE2ZTFhMGJhMzg4NjQzZWI4MzhlNGQ2ZWE5ODVjMzcwL3RleHRyZWdpb246MTZlMWEwYmEzODg2NDNlYjgzOGU0ZDZlYTk4NWMzNzBfMTA0MTQ_148ed612-528b-4053-a6aa-c0b95eb7ef68">660,000</ix:nonFraction> recorded as deferred grant funding on the condensed consolidated balance sheet related to the grant.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2020, Gates awarded and funded the Company a grant of $<ix:nonFraction unitRef="usd" contextRef="i752ae0ad316946429cc2310340ed7334_D20200301-20200331" decimals="-5" format="ixt:numdotdecimal" name="ino:CollaborativeAgreementFundingReceived" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN184NS9mcmFnOjE2ZTFhMGJhMzg4NjQzZWI4MzhlNGQ2ZWE5ODVjMzcwL3RleHRyZWdpb246MTZlMWEwYmEzODg2NDNlYjgzOGU0ZDZlYTk4NWMzNzBfMTA1ODE_4afe1b67-4128-43c2-93bf-9251055ef559">5.0</ix:nonFraction> million to accelerate the development of the </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="icdb6d7056343425a92b9dcb5a6b76391"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CELLECTRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 3PSP device for the intradermal delivery of INO-4800. During the three months ended March 31, 2021 and 2020, the Company recorded $<ix:nonFraction unitRef="usd" contextRef="i56915aed723e478494673e49cebb3d4e_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="ino:CollaborativeAgreementFundingReceived" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN184NS9mcmFnOjE2ZTFhMGJhMzg4NjQzZWI4MzhlNGQ2ZWE5ODVjMzcwL3RleHRyZWdpb246MTZlMWEwYmEzODg2NDNlYjgzOGU0ZDZlYTk4NWMzNzBfMTA3MjI_82d8303a-8e7c-4967-8879-db7a8f6935b0">893,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i779a998ae097423cbfecbd164c6d6a15_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="ino:CollaborativeAgreementFundingReceived" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN184NS9mcmFnOjE2ZTFhMGJhMzg4NjQzZWI4MzhlNGQ2ZWE5ODVjMzcwL3RleHRyZWdpb246MTZlMWEwYmEzODg2NDNlYjgzOGU0ZDZlYTk4NWMzNzBfMTA3Mjk_fdc15f22-b096-4a3f-aef0-baa53401ef9b">64,000</ix:nonFraction>, respectively, as contra-research and development expense related to this Gates grant. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Department of Defense (DoD) </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2020, the Company entered into an Other Transaction Authority for Prototype Agreement (the &#8220;OTA Agreement&#8221;)&#160;with the DoD to fund the Company&#8217;s efforts in developing the CELLECTRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;3PSP device and associated arrays to be used for delivery of&#160;INO-4800 against&#160;COVID-19. Under the OTA Agreement, the Company intends to develop the CELLECTRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 3PSP device and arrays for use in the U.S. military population and the U.S. population as a whole, subject to approval of the device by the U.S. Food and Drug Administration (the &#8220;FDA&#8221;). The OTA Agreement is also expected to support large-scale manufacturing of the CELLECTRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 3PSP device, as well as large-scale DNA plasmid production for manufacture and supply of a specified number of doses of&#160;INO-4800&#160;in support of FDA approval of the device. The total amount of funding being made available to the Company under the OTA Agreement is approximately $<ix:nonFraction unitRef="usd" contextRef="i264c6f79f8444773b5305906e6e512df_D20200601-20200630" decimals="-5" format="ixt:numdotdecimal" name="ino:CollaborativeAgreementFundingReceived" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN184NS9mcmFnOjE2ZTFhMGJhMzg4NjQzZWI4MzhlNGQ2ZWE5ODVjMzcwL3RleHRyZWdpb246MTZlMWEwYmEzODg2NDNlYjgzOGU0ZDZlYTk4NWMzNzBfMTE4ODM_fb7cdfce-4cbf-4fd4-9d37-5960fef773a7">54.5</ix:nonFraction> million. The Company has determined that the OTA Agreement should be considered under Subtopic 958-605, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Not-for-Profit Entities-</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue Recognition</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which is outside the scope of Topic 606, as the government agency granting the Company funds is not</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">receiving reciprocal value for their contributions. The Company will record contra-research development expense on the condensed consolidated statement of operations in the same period that the underlying expenses are incurred. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Additionally, in June 2020, the Company was awarded a fixed-price contract (the &#8220;Procurement Contract&#8221;) from the DoD for the purchase of the Company&#8217;s intradermal CELLECTRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;2000 device and accessories. The CELLECTRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> 2000 devices will be used to inject&#160;INO-4800&#160;in the Company&#8217;s planned later-stage clinical trials. The total purchase price under the Procurement Contract is approximately $<ix:nonFraction unitRef="usd" contextRef="ic4269fc3e43a44779c7573901206998d_D20200601-20200630" decimals="-5" format="ixt:numdotdecimal" name="ino:CollaborativeArrangementFixedPriceContractAmountAwarded" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN184NS9mcmFnOjE2ZTFhMGJhMzg4NjQzZWI4MzhlNGQ2ZWE5ODVjMzcwL3RleHRyZWdpb246MTZlMWEwYmEzODg2NDNlYjgzOGU0ZDZlYTk4NWMzNzBfMTI1NDQ_f2363a30-f54f-487d-a14d-17784b1daed1">16.6</ix:nonFraction> million. The Company has determined that the Procurement Contract does not currently fall under the scope of ASC 606 as contingencies remain regarding INO-4800 which does not give the Company the ability to satisfy its obligations under the arrangement.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March 31, 2021, the Company recorded $<ix:nonFraction unitRef="usd" contextRef="iccb3ccc026234192a47e7268051e1700_D20210101-20210331" decimals="-5" format="ixt:numdotdecimal" name="ino:GrantProceedsReceived" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN184NS9mcmFnOjE2ZTFhMGJhMzg4NjQzZWI4MzhlNGQ2ZWE5ODVjMzcwL3RleHRyZWdpb246MTZlMWEwYmEzODg2NDNlYjgzOGU0ZDZlYTk4NWMzNzBfMTI4Mjk_19fc5cf4-76cd-4da8-93e1-5b5da27d4911">7.8</ix:nonFraction>&#160;million as contra-research and development expense related to these agreements with the DoD. As of March&#160;31, 2021 and December 31, 2020, the Company had an accounts receivable balance of $<ix:nonFraction unitRef="usd" contextRef="ic1b65e61f4594842852e823b554bc0cb_I20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableRelatedParties" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN184NS9mcmFnOjE2ZTFhMGJhMzg4NjQzZWI4MzhlNGQ2ZWE5ODVjMzcwL3RleHRyZWdpb246MTZlMWEwYmEzODg2NDNlYjgzOGU0ZDZlYTk4NWMzNzBfMTI5Nzg_3aeb3dd7-75fc-47db-91cb-06be5a91b24d">9.6</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="ia71441f3bf2e4190b91ebcea736fec60_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableRelatedParties" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN184NS9mcmFnOjE2ZTFhMGJhMzg4NjQzZWI4MzhlNGQ2ZWE5ODVjMzcwL3RleHRyZWdpb246MTZlMWEwYmEzODg2NDNlYjgzOGU0ZDZlYTk4NWMzNzBfMjE5OTAyMzI4MDEzMg_2fce6064-2b4c-4201-b881-5d4f7d224f11">11.4</ix:nonFraction>&#160;million, respectively, on the condensed consolidated balance sheet from the DoD.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2021, the Company announced that the DoD had notified the Company that it will discontinue funding for the Phase 3 segment of the Company's clinical trial of INO-4800 in the United States, while continuing to fund the completion of the ongoing Phase 2 segment.</span></div></ix:continuation><div style="margin-top:5pt;text-indent:27pt"><span><br/></span></div><div id="i1d23d16a69484b63aa007ec686e80337_88"></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">16. <ix:nonNumeric contextRef="i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331" name="us-gaap:IncomeTaxDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN184OC9mcmFnOjNkY2U2NzNlYWQwMDQ4MGE5YzZhZmIzMTU3YjhkMTZlL3RleHRyZWdpb246M2RjZTY3M2VhZDAwNDgwYTljNmFmYjMxNTdiOGQxNmVfMTg1MQ_e38995e7-4f6b-444a-9714-1095f40ad735" continuedAt="i85a6e776de3f4f7d98280960eb8ab65d" escape="true">Income Taxes </ix:nonNumeric></span></div><div style="margin-bottom:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i85a6e776de3f4f7d98280960eb8ab65d" continuedAt="ib006c9be460a46fa9dffb74001bfe5e9">The Company uses an estimated annual effective tax rate, which is based on expected annual income, statutory tax rates and tax planning opportunities available in the various jurisdictions in which the Company operates, to determine its quarterly provision for income taxes. Certain significant or unusual items are separately recognized in the quarter in which they occur and can be a source of variability in the effective tax rates from quarter to quarter.&#160;Due to the adoption of ASU 2019-12 which removes the exception under ASC 740-20-45-7 to consider all sources of income in order to determine the tax benefit resulting from a loss from continuing operations, ASC 740-20-45-7 no longer applies.</ix:continuation></span></div><div style="margin-bottom:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ib006c9be460a46fa9dffb74001bfe5e9">On March 27, 2020, the United States enacted the Coronavirus Aid, Relief and Economic Security Act (CARES Act).&#160; The CARES Act is an emergency economic stimulus package that includes spending and tax breaks to strengthen the United States economy and fund a nationwide effort to curtail the effect of COVID-19.&#160;The CARES Act provides sweeping tax changes in response to the COVID-19 pandemic; some of the more significant provisions are removal of certain limitations on utilization of net operating losses, increasing the loss carryback period for certain losses to five years, and increasing the ability to deduct interest expense, as well as amending certain provisions of the previously enacted Tax Cuts and Jobs Act.&#160;At March&#160;31, 2021, the Company has not recorded any income tax provision/(benefit) for the impact for the CARES Act due to the Company&#8217;s history of net operating losses generated and the maintenance of a full valuation allowance against its net deferred tax assets.</ix:continuation> </span></div><div style="margin-bottom:5pt;text-indent:27pt"><span><br/></span></div><div id="i1d23d16a69484b63aa007ec686e80337_91"></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">17. <ix:nonNumeric contextRef="i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN185MS9mcmFnOjBmMTk4ODlkNzI3NDQyYzQ4ODM2ZTVlMzcyODg1ZTUzL3RleHRyZWdpb246MGYxOTg4OWQ3Mjc0NDJjNDg4MzZlNWUzNzI4ODVlNTNfNzYxNg_e54b7eac-137b-4dbb-aa96-c79498aadcde" continuedAt="i427e6468c0a4494e8fdfd23ad40095ba" escape="true">Geneos Therapeutics, Inc. </ix:nonNumeric></span></div><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><ix:continuation id="i427e6468c0a4494e8fdfd23ad40095ba" continuedAt="i7164a8bb1a2d4e859da8f55fca518254"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2016, the Company formed Geneos to develop and commercialize neoantigen-based personalized cancer therapies. Geneos was considered a variable interest entity (VIE) for which the Company was the primary beneficiary. In February 2019, Geneos completed the initial closing of a&#160;Series A preferred stock financing. The Company invested&#160;$<ix:nonFraction unitRef="usd" contextRef="i12df974976054802af3d27561d6c09dd_D20190201-20190228" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireAdditionalInterestInSubsidiaries" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN185MS9mcmFnOjBmMTk4ODlkNzI3NDQyYzQ4ODM2ZTVlMzcyODg1ZTUzL3RleHRyZWdpb246MGYxOTg4OWQ3Mjc0NDJjNDg4MzZlNWUzNzI4ODVlNTNfMzcw_6acc7fe0-6594-4459-ab27-3fe21ba4553a">1.2</ix:nonFraction> million&#160;in the Series A preferred stock financing, which was led by an outside investor. Following this transaction, the Company held&#160;<ix:nonFraction unitRef="number" contextRef="i197c02bfa6fb453089c92b4a206b5240_I20190228" decimals="2" name="us-gaap:MinorityInterestOwnershipPercentageByParent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN185MS9mcmFnOjBmMTk4ODlkNzI3NDQyYzQ4ODM2ZTVlMzcyODg1ZTUzL3RleHRyZWdpb246MGYxOTg4OWQ3Mjc0NDJjNDg4MzZlNWUzNzI4ODVlNTNfNDkw_0ed94f19-9391-4479-bf76-034edc64fefb">61</ix:nonFraction>%&#160;of the outstanding equity, on an as-converted to common stock basis, of Geneos and continued to consolidate its investment in Geneos under ASC 810, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Consolidation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span></ix:continuation></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i7164a8bb1a2d4e859da8f55fca518254" continuedAt="id665a72c8fed41f8904ad58cf3eb008d"><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2020, Geneos completed the second closing of the&#160;Series A preferred stock financing, in which the Company invested $<ix:nonFraction unitRef="usd" contextRef="i22e9833894df4c5d90786ba65f0c072a_I20200131" decimals="-3" format="ixt:numdotdecimal" name="ino:StockPurchaseAgreementCommitmentOfAdditionalInvestment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN185MS9mcmFnOjBmMTk4ODlkNzI3NDQyYzQ4ODM2ZTVlMzcyODg1ZTUzL3RleHRyZWdpb246MGYxOTg4OWQ3Mjc0NDJjNDg4MzZlNWUzNzI4ODVlNTNfNzc0_01a0ec75-7477-4f56-bf8b-6559de23c9e7">800,000</ix:nonFraction>. Following this transaction, as of March 31, 2020, the Company held&#160;<ix:nonFraction unitRef="number" contextRef="i9c60a7b844ef4b0685afab98a626ab57_I20200331" decimals="2" name="us-gaap:MinorityInterestOwnershipPercentageByParent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN185MS9mcmFnOjBmMTk4ODlkNzI3NDQyYzQ4ODM2ZTVlMzcyODg1ZTUzL3RleHRyZWdpb246MGYxOTg4OWQ3Mjc0NDJjNDg4MzZlNWUzNzI4ODVlNTNfODQ1_f4af2052-94bd-408d-ac10-022641caa169">52</ix:nonFraction>%&#160;of the outstanding equity, on an as-converted to common stock basis, of Geneos and continued to consolidate its investment in Geneos.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2020, Geneos closed an additional&#160;Series A preferred stock financing round, in which the Company invested $<ix:nonFraction unitRef="usd" contextRef="icf16dce9089247ddb07885bad1158a5b_I20200630" decimals="-3" format="ixt:numdotdecimal" name="ino:StockPurchaseAgreementCommitmentOfAdditionalInvestment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN185MS9mcmFnOjBmMTk4ODlkNzI3NDQyYzQ4ODM2ZTVlMzcyODg1ZTUzL3RleHRyZWdpb246MGYxOTg4OWQ3Mjc0NDJjNDg4MzZlNWUzNzI4ODVlNTNfMTA4Nw_a04ed559-1e51-44b6-a986-98ed6020cc51">800,000</ix:nonFraction>.  Following this transaction, the Company owned <ix:nonFraction unitRef="number" contextRef="i86c6d642fb404b608772c10c34c2a8fc_I20200630" decimals="2" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN185MS9mcmFnOjBmMTk4ODlkNzI3NDQyYzQ4ODM2ZTVlMzcyODg1ZTUzL3RleHRyZWdpb246MGYxOTg4OWQ3Mjc0NDJjNDg4MzZlNWUzNzI4ODVlNTNfMTIwMg_abcfbc61-9365-417b-9c4a-2d19044880e0">47</ix:nonFraction>% of the outstanding equity of Geneos on an as-converted to common stock basis. This transaction triggered a VIE reconsideration, as the Company no longer held a controlling financial interest. Based on the Company&#8217;s assessment, Geneos continued to be a VIE as it did not have sufficient equity at risk to finance its activities without additional subordinated financial support.  However, the Company was not the primary beneficiary of Geneos, as it did not have the power to direct the activities that most significantly impact Geneos&#8217; economic performance.  Accordingly, the Company deconsolidated its investment in Geneos as of June 1, 2020, resulting in a gain of $<ix:nonFraction unitRef="usd" contextRef="i49cf08539f5f4d268c6222c435b55016_D20200601-20200601" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DeconsolidationGainOrLossAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN185MS9mcmFnOjBmMTk4ODlkNzI3NDQyYzQ4ODM2ZTVlMzcyODg1ZTUzL3RleHRyZWdpb246MGYxOTg4OWQ3Mjc0NDJjNDg4MzZlNWUzNzI4ODVlNTNfMTgwOA_5c02a64c-1559-4492-aa12-574f916271e3">4.1</ix:nonFraction> million, of which $<ix:nonFraction unitRef="usd" contextRef="i49cf08539f5f4d268c6222c435b55016_D20200601-20200601" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN185MS9mcmFnOjBmMTk4ODlkNzI3NDQyYzQ4ODM2ZTVlMzcyODg1ZTUzL3RleHRyZWdpb246MGYxOTg4OWQ3Mjc0NDJjNDg4MzZlNWUzNzI4ODVlNTNfMTgyMQ_8a78a32d-08a2-44d6-aa6a-d153970b58f0">2.4</ix:nonFraction> million related to the remeasurement of the retained noncontrolling interest investment to fair value.  The gain has been recorded separately on the Company's condensed consolidated statement of operations.  <ix:nonNumeric contextRef="i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331" name="us-gaap:EquityMethodInvestmentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN185MS9mcmFnOjBmMTk4ODlkNzI3NDQyYzQ4ODM2ZTVlMzcyODg1ZTUzL3RleHRyZWdpb246MGYxOTg4OWQ3Mjc0NDJjNDg4MzZlNWUzNzI4ODVlNTNfNzYxNw_fcd8cbba-b7f9-40ef-a1a6-b01354383a0b" continuedAt="i8989e90941fc4289a19d25729956c54c" escape="true">The following table shows the amounts related to the deconsolidation accounting: </ix:nonNumeric></span></div><ix:continuation id="i8989e90941fc4289a19d25729956c54c" continuedAt="i8f6c64937e4942af9241e18b62529b9d"><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:84.405%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.395%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Working capital (excluding cash) </span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i11b75bcb273c48128928387d5ceda2d2_I20200601" decimals="0" format="ixt:numdotdecimal" name="ino:WorkingCapitalExcludingCash" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN185MS9mcmFnOjBmMTk4ODlkNzI3NDQyYzQ4ODM2ZTVlMzcyODg1ZTUzL3RhYmxlOjNmNjFhODdiNWRiNjRlMDU4MzdiOTkyMDgyYTk4Yzc1L3RhYmxlcmFuZ2U6M2Y2MWE4N2I1ZGI2NGUwNTgzN2I5OTIwODJhOThjNzVfMC0xLTEtMS0w_b2c41928-97e1-41ee-b487-d9a0e4888610">59,992</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Note payable </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11b75bcb273c48128928387d5ceda2d2_I20200601" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NotesPayable" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN185MS9mcmFnOjBmMTk4ODlkNzI3NDQyYzQ4ODM2ZTVlMzcyODg1ZTUzL3RhYmxlOjNmNjFhODdiNWRiNjRlMDU4MzdiOTkyMDgyYTk4Yzc1L3RhYmxlcmFuZ2U6M2Y2MWE4N2I1ZGI2NGUwNTgzN2I5OTIwODJhOThjNzVfMS0xLTEtMS0w_cb664159-115c-4a74-9ce5-affb9670a2e0">171,620</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed assets, net of accumulated depreciation </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i11b75bcb273c48128928387d5ceda2d2_I20200601" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN185MS9mcmFnOjBmMTk4ODlkNzI3NDQyYzQ4ODM2ZTVlMzcyODg1ZTUzL3RhYmxlOjNmNjFhODdiNWRiNjRlMDU4MzdiOTkyMDgyYTk4Yzc1L3RhYmxlcmFuZ2U6M2Y2MWE4N2I1ZGI2NGUwNTgzN2I5OTIwODJhOThjNzVfMi0xLTEtMS0w_640a8800-bdf5-4838-859e-4eb093cdab63">16,340</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Carrying value of noncontrolling interest </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11b75bcb273c48128928387d5ceda2d2_I20200601" decimals="0" format="ixt:numdotdecimal" name="us-gaap:MinorityInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN185MS9mcmFnOjBmMTk4ODlkNzI3NDQyYzQ4ODM2ZTVlMzcyODg1ZTUzL3RhYmxlOjNmNjFhODdiNWRiNjRlMDU4MzdiOTkyMDgyYTk4Yzc1L3RhYmxlcmFuZ2U6M2Y2MWE4N2I1ZGI2NGUwNTgzN2I5OTIwODJhOThjNzVfMy0xLTEtMS0w_20bc6176-845d-423b-8a52-f214c39d2305">3,181,640</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of investment in Geneos retained</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11b75bcb273c48128928387d5ceda2d2_I20200601" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RetainedInterestFairValueDisclosure" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN185MS9mcmFnOjBmMTk4ODlkNzI3NDQyYzQ4ODM2ZTVlMzcyODg1ZTUzL3RhYmxlOjNmNjFhODdiNWRiNjRlMDU4MzdiOTkyMDgyYTk4Yzc1L3RhYmxlcmFuZ2U6M2Y2MWE4N2I1ZGI2NGUwNTgzN2I5OTIwODJhOThjNzVfNC0xLTEtMS0w_cd75162d-3438-4209-8013-ed0f1f908818">3,618,998</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain on deconsolidation of Geneos </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i49cf08539f5f4d268c6222c435b55016_D20200601-20200601" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeconsolidationGainOrLossAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN185MS9mcmFnOjBmMTk4ODlkNzI3NDQyYzQ4ODM2ZTVlMzcyODg1ZTUzL3RhYmxlOjNmNjFhODdiNWRiNjRlMDU4MzdiOTkyMDgyYTk4Yzc1L3RhYmxlcmFuZ2U6M2Y2MWE4N2I1ZGI2NGUwNTgzN2I5OTIwODJhOThjNzVfNS0xLTEtMS0w_55cc83e7-8e95-47ca-a8b6-5f1ab300280b">4,121,075</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Decrease in cash resulting from the deconsolidation of Geneos</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49cf08539f5f4d268c6222c435b55016_D20200601-20200601" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashDivestedFromDeconsolidation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN185MS9mcmFnOjBmMTk4ODlkNzI3NDQyYzQ4ODM2ZTVlMzcyODg1ZTUzL3RhYmxlOjNmNjFhODdiNWRiNjRlMDU4MzdiOTkyMDgyYTk4Yzc1L3RhYmxlcmFuZ2U6M2Y2MWE4N2I1ZGI2NGUwNTgzN2I5OTIwODJhOThjNzVfNi0xLTEtMS0w_5c0aae43-d85a-4de3-9938-43870706bd7e">2,774,851</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">The details of the Company&#8217;s <ix:nonFraction unitRef="number" contextRef="i8ac1a1cef3df4067985d61a1d1aaf9b8_I20210331" decimals="2" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN185MS9mcmFnOjBmMTk4ODlkNzI3NDQyYzQ4ODM2ZTVlMzcyODg1ZTUzL3RleHRyZWdpb246MGYxOTg4OWQ3Mjc0NDJjNDg4MzZlNWUzNzI4ODVlNTNfMjEzOQ_59264192-2ac5-4573-8f15-a6ba0d61f1fa">47</ix:nonFraction>% retained equity investment in Geneos is shown in the table below, with fair values calculated as of June 1, 2020, the date of deconsolidation.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:54.178%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.976%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.973%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.562%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.119%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.392%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Geneos Share Class</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Price per Share</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="idc86dae1ec654c2e8eb6ba13fc81ec0b_I20200601" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:InvestmentOwnedBalanceShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN185MS9mcmFnOjBmMTk4ODlkNzI3NDQyYzQ4ODM2ZTVlMzcyODg1ZTUzL3RhYmxlOjhkNTVjMTllYjM0YzQzODlhNzVjZmIwZTMyYzkyZDgzL3RhYmxlcmFuZ2U6OGQ1NWMxOWViMzRjNDM4OWE3NWNmYjBlMzJjOTJkODNfMS0xLTEtMS0w_b1d0ba03-511e-4711-9234-af59d26b9c38">3,000,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="idc86dae1ec654c2e8eb6ba13fc81ec0b_I20200601" decimals="INF" name="us-gaap:SharePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN185MS9mcmFnOjBmMTk4ODlkNzI3NDQyYzQ4ODM2ZTVlMzcyODg1ZTUzL3RhYmxlOjhkNTVjMTllYjM0YzQzODlhNzVjZmIwZTMyYzkyZDgzL3RhYmxlcmFuZ2U6OGQ1NWMxOWViMzRjNDM4OWE3NWNmYjBlMzJjOTJkODNfMS0zLTEtMS0w_3eb57117-97f7-47d9-8614-f964a7ccd5e0">0.273</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc86dae1ec654c2e8eb6ba13fc81ec0b_I20200601" decimals="0" format="ixt:numdotdecimal" name="us-gaap:EquityMethodInvestments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN185MS9mcmFnOjBmMTk4ODlkNzI3NDQyYzQ4ODM2ZTVlMzcyODg1ZTUzL3RhYmxlOjhkNTVjMTllYjM0YzQzODlhNzVjZmIwZTMyYzkyZDgzL3RhYmxlcmFuZ2U6OGQ1NWMxOWViMzRjNDM4OWE3NWNmYjBlMzJjOTJkODNfMS01LTEtMS0w_906d1395-43bf-4094-b82e-a8e4567ecfdf">819,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Preferred</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib661d85215674c8e93c1385a9ed48322_I20200601" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:InvestmentOwnedBalanceShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN185MS9mcmFnOjBmMTk4ODlkNzI3NDQyYzQ4ODM2ZTVlMzcyODg1ZTUzL3RhYmxlOjhkNTVjMTllYjM0YzQzODlhNzVjZmIwZTMyYzkyZDgzL3RhYmxlcmFuZ2U6OGQ1NWMxOWViMzRjNDM4OWE3NWNmYjBlMzJjOTJkODNfMi0xLTEtMS0w_ca0d0b64-a45e-44b9-a5f9-b25068073e01">2,113,206</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ib661d85215674c8e93c1385a9ed48322_I20200601" decimals="INF" name="us-gaap:SharePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN185MS9mcmFnOjBmMTk4ODlkNzI3NDQyYzQ4ODM2ZTVlMzcyODg1ZTUzL3RhYmxlOjhkNTVjMTllYjM0YzQzODlhNzVjZmIwZTMyYzkyZDgzL3RhYmxlcmFuZ2U6OGQ1NWMxOWViMzRjNDM4OWE3NWNmYjBlMzJjOTJkODNfMi0zLTEtMS0w_c9da8cd6-89b5-46d8-8a4f-7e2f59e8714a">1.325</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib661d85215674c8e93c1385a9ed48322_I20200601" decimals="0" format="ixt:numdotdecimal" name="us-gaap:EquityMethodInvestments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN185MS9mcmFnOjBmMTk4ODlkNzI3NDQyYzQ4ODM2ZTVlMzcyODg1ZTUzL3RhYmxlOjhkNTVjMTllYjM0YzQzODlhNzVjZmIwZTMyYzkyZDgzL3RhYmxlcmFuZ2U6OGQ1NWMxOWViMzRjNDM4OWE3NWNmYjBlMzJjOTJkODNfMi01LTEtMS0w_d3c3ca68-5747-45e9-97c9-381a7fcba35e">2,799,998</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total </span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i11b75bcb273c48128928387d5ceda2d2_I20200601" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:InvestmentOwnedBalanceShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN185MS9mcmFnOjBmMTk4ODlkNzI3NDQyYzQ4ODM2ZTVlMzcyODg1ZTUzL3RhYmxlOjhkNTVjMTllYjM0YzQzODlhNzVjZmIwZTMyYzkyZDgzL3RhYmxlcmFuZ2U6OGQ1NWMxOWViMzRjNDM4OWE3NWNmYjBlMzJjOTJkODNfMy0xLTEtMS0w_24bf746c-6e5c-4afc-beb0-f9cda1bf5f14">5,113,206</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11b75bcb273c48128928387d5ceda2d2_I20200601" decimals="0" format="ixt:numdotdecimal" name="us-gaap:EquityMethodInvestments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN185MS9mcmFnOjBmMTk4ODlkNzI3NDQyYzQ4ODM2ZTVlMzcyODg1ZTUzL3RhYmxlOjhkNTVjMTllYjM0YzQzODlhNzVjZmIwZTMyYzkyZDgzL3RhYmxlcmFuZ2U6OGQ1NWMxOWViMzRjNDM4OWE3NWNmYjBlMzJjOTJkODNfMy01LTEtMS0w_ecb6d353-82f0-44b7-aa8f-8cfb6cefbbdb">3,618,998</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation><div style="margin-top:5pt;text-indent:22.5pt"><span><br/></span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of Geneos Series A preferred stock was based on the per share price paid by third-party investors in connection with the most recent closing of the Series A preferred stock financing for Geneos on June 1, 2020. The fair value of Geneos common stock was determined by a third-party valuation, as there is no public market for such stock. Geneos&#8217; enterprise value, which was estimated using a market approach that derived an implied total equity value from a transaction involving its own securities, was allocated to all classes of equity using the option pricing method. Under the option pricing method, each equity class was modeled as having a call option with a distinct claim on the total value of Geneos. Each option&#8217;s exercise price was based on the total value available for each participating security holder. The characteristics of each class of ownership determined the claim on the total value for that class of ownership.  </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated value allocated to common stock included assumptions related to the fair value of the enterprise, expected volatility, expected term, and risk-free interest rate. Expected volatility was based on historical asset volatilities derived from daily stock price changes of guideline public companies. The estimated expected term was based on a weighted average of the estimated time to Geneo's next financing and successful exit timing assumption.  The risk-free interest rate was based on the yield of U.S. Treasury with a comparable term. Geneos&#8217;s common stock is classified as a Level 3 financial instrument. <ix:nonNumeric contextRef="i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331" name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN185MS9mcmFnOjBmMTk4ODlkNzI3NDQyYzQ4ODM2ZTVlMzcyODg1ZTUzL3RleHRyZWdpb246MGYxOTg4OWQ3Mjc0NDJjNDg4MzZlNWUzNzI4ODVlNTNfNzYxOQ_f3c6cf88-6d76-4ff6-b14e-9867e972e66c" continuedAt="i7459cd7dfa984373ab6bda2f526d82a9" escape="true">The assumptions used in the fair value calculation as of June 1, 2020 are presented below:</ix:nonNumeric></span></div><div style="margin-bottom:5pt;margin-top:8pt;text-align:center"><ix:continuation id="i7459cd7dfa984373ab6bda2f526d82a9"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:78.548%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.252%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term (years)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i496071670fd64b74b11100bd501df568_D20200601-20200601" format="ixt-sec:duryear" name="ino:AlternativeInvestmentMeasurementInputTerm" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN185MS9mcmFnOjBmMTk4ODlkNzI3NDQyYzQ4ODM2ZTVlMzcyODg1ZTUzL3RhYmxlOmE0ZDM5ZDZmZWI1NTQ5MmViMTU0MzFlNjQ2OTE0NDQ5L3RhYmxlcmFuZ2U6YTRkMzlkNmZlYjU1NDkyZWIxNTQzMWU2NDY5MTQ0NDlfMC0xLTEtMS0w_8d16d941-9056-44d2-9595-162ca6b1830f">2.92</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Volatility</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i521f37bfc08d4393a839105bd352f62b_I20200601" decimals="2" name="us-gaap:AlternativeInvestmentMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN185MS9mcmFnOjBmMTk4ODlkNzI3NDQyYzQ4ODM2ZTVlMzcyODg1ZTUzL3RhYmxlOmE0ZDM5ZDZmZWI1NTQ5MmViMTU0MzFlNjQ2OTE0NDQ5L3RhYmxlcmFuZ2U6YTRkMzlkNmZlYjU1NDkyZWIxNTQzMWU2NDY5MTQ0NDlfMS0xLTEtMS0w_5842aa6d-4ba9-4314-94a2-f004cb77ee55">70</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="idf75b7fb59a640709f8bece075b171dd_I20200601" decimals="4" name="us-gaap:AlternativeInvestmentMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN185MS9mcmFnOjBmMTk4ODlkNzI3NDQyYzQ4ODM2ZTVlMzcyODg1ZTUzL3RhYmxlOmE0ZDM5ZDZmZWI1NTQ5MmViMTU0MzFlNjQ2OTE0NDQ5L3RhYmxlcmFuZ2U6YTRkMzlkNmZlYjU1NDkyZWIxNTQzMWU2NDY5MTQ0NDlfMi0xLTEtMS0w_1a88ebea-600d-44f1-815e-72395c9bc158">2.46</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Geneos enterprise value</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="i11b75bcb273c48128928387d5ceda2d2_I20200601" decimals="0" format="ixt:numdotdecimal" name="ino:EquityMethodInvestmentEnterpriseValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN185MS9mcmFnOjBmMTk4ODlkNzI3NDQyYzQ4ODM2ZTVlMzcyODg1ZTUzL3RhYmxlOmE0ZDM5ZDZmZWI1NTQ5MmViMTU0MzFlNjQ2OTE0NDQ5L3RhYmxlcmFuZ2U6YTRkMzlkNmZlYjU1NDkyZWIxNTQzMWU2NDY5MTQ0NDlfMy0xLTEtMS0w_fc781fdf-a8a6-43f3-852c-96536bdcf4a9">4,966,531</ix:nonFraction></span></td></tr></table></ix:continuation></div><div style="margin-top:8pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company applies the equity method to investments in common stock and to other investments in entities that have risk and reward characteristics that are substantially similar to an investment in the investee&#8217;s common stock.  Since the Company&#8217;s Series A preferred stock investment in Geneos has a substantive liquidation preference, it is not substantially similar to the Company&#8217;s common stock investment and will therefore be recorded as an equity security under ASC 321.  </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="id665a72c8fed41f8904ad58cf3eb008d" continuedAt="i5ab40104875748a4922db0166cde4385"><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June 1, 2020, the Company accounts for its common stock investment in Geneos, in which the Company lacks control but does have the ability to exercise significant influence over operating and financial policies, using the equity method. Generally, the ability to exercise significant influence is presumed when the investor possesses more than 20% of the voting interests of the investee. This presumption may be overcome based on specific facts and circumstances that demonstrate that the ability to exercise significant influence is restricted. In applying the equity method, the Company records the investment at cost unless the initial recognition is the result of the deconsolidation of a subsidiary, in which case it is recorded at fair value. The Company's proportionate share of net loss of Geneos is recorded in&#160;equity in net earnings of Geneos in the Company's condensed consolidated statements of operations. The Company's equity method investments are reviewed for indicators of impairment at each reporting period and are written down to fair value if there is evidence of a loss in value that is other-than-temporary.&#160;Any difference between the carrying amount of the Company&#8217;s investment and the amount of underlying equity in Geneos&#8217; net assets is amortized into income or expense accordingly. There were no basis differences identified as of the deconsolidation date that would need to be amortized.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">  </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon deconsolidation, the Company recorded its Series A preferred stock investment at fair value based on the per share price paid by third party investors in connection with the preferred stock financing on June 1, 2020. The Company has determined that its Series A preferred stock investment in Geneos does not have a readily determinable fair value and has therefore elected the measurement alternative in ASC 321 to subsequently record the investment at cost, less any impairments, plus or minus changes resulting from observable price changes in orderly transactions for identical or similar investments of the same issuer.&#160;When fair value becomes determinable, from observable price changes in orderly transactions, the Company&#8217;s investment will be marked to fair value.&#160; There have been no observable price changes or impairments identified since the deconsolidation date.  </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2020, Geneos completed the closing of a Series A-1 preferred stock financing. The Company invested $<ix:nonFraction unitRef="usd" contextRef="i5f2d61cc6bd64875b11002017e8003ca_D20201101-20201130" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireAdditionalInterestInSubsidiaries" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN185MS9mcmFnOjBmMTk4ODlkNzI3NDQyYzQ4ODM2ZTVlMzcyODg1ZTUzL3RleHRyZWdpb246MGYxOTg4OWQ3Mjc0NDJjNDg4MzZlNWUzNzI4ODVlNTNfMjE5OTAyMzI2NTE1Mg_e48f0f59-8126-43d0-b76d-80dd813ac16d">1.4</ix:nonFraction>&#160;million in the Series A-1 preferred stock financing, which was led by outside investors. The closing date of this transaction was determined to be a VIE reconsideration event; based on the Company&#8217;s assessment, Geneos continues to be a VIE as it does not have sufficient equity at risk to finance its activities without additional subordinated financial support. The Company continues to not be the primary beneficiary of Geneos, as it does not have the power to direct the activities that most significantly impact Geneos&#8217;s economic performance and should not consolidate Geneos. Following this transaction, the Company held approximately <ix:nonFraction unitRef="number" contextRef="i26487b836039455e8049dc86128e27ea_I20201130" decimals="2" name="us-gaap:MinorityInterestOwnershipPercentageByParent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN185MS9mcmFnOjBmMTk4ODlkNzI3NDQyYzQ4ODM2ZTVlMzcyODg1ZTUzL3RleHRyZWdpb246MGYxOTg4OWQ3Mjc0NDJjNDg4MzZlNWUzNzI4ODVlNTNfMjE5OTAyMzI2NTE2Ng_14e35b4a-d52b-45f4-813b-6d24c3650d1e">36</ix:nonFraction>% of the outstanding equity, on an as-converted to common stock basis. Accordingly, the Company continues to account for its common stock investment in Geneos as an equity method investment under ASC 323 and its preferred stock investments as equity securities under ASC 321.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of Geneos&#8217;s Series A-1 preferred stock was based on the per share price paid by third-party investors in connection with the closing on November 12, 2020. The Company has concluded that its Series A-1 preferred stock investment is not similar to its prior Series A preferred stock investment due to certain material rights held solely by Series A preferred stockholders. Therefore, the Company will continue to record its Series A preferred stock investment in Geneos at cost, as there have been no observable price changes or impairments identified since the deconsolidation date.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s share of net losses of Geneos for the period from June 1, 2020 through December 31, 2020 was $<ix:nonFraction unitRef="usd" contextRef="ie8cf0b8ea91645f8adbebe6fd2ff82e8_D20200601-20201231" decimals="-5" name="ino:IncomeLossFromEquityMethodInvestmentsRealizedAndAllocatedToInvestment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN185MS9mcmFnOjBmMTk4ODlkNzI3NDQyYzQ4ODM2ZTVlMzcyODg1ZTUzL3RleHRyZWdpb246MGYxOTg4OWQ3Mjc0NDJjNDg4MzZlNWUzNzI4ODVlNTNfNjgyMg_36cff4ae-9158-4af6-9059-6d6373d502c1">4.6</ix:nonFraction> million and for the three months ended March 31, 2021 was $<ix:nonFraction unitRef="usd" contextRef="iecead882e1cc4b15851f3a17bd9de72e_D20210101-20210331" decimals="-5" format="ixt:numdotdecimal" name="ino:IncomeLossFromEquityMethodInvestmentsRealizedAndAllocatedToInvestment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN185MS9mcmFnOjBmMTk4ODlkNzI3NDQyYzQ4ODM2ZTVlMzcyODg1ZTUzL3RleHRyZWdpb246MGYxOTg4OWQ3Mjc0NDJjNDg4MzZlNWUzNzI4ODVlNTNfMTA5OTUxMTY0NzYwOQ_32c6f082-333c-4451-ad9f-830b453819f7">1.5</ix:nonFraction>&#160;million; however, only $<ix:nonFraction unitRef="usd" contextRef="iecead882e1cc4b15851f3a17bd9de72e_D20210101-20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN185MS9mcmFnOjBmMTk4ODlkNzI3NDQyYzQ4ODM2ZTVlMzcyODg1ZTUzL3RleHRyZWdpb246MGYxOTg4OWQ3Mjc0NDJjNDg4MzZlNWUzNzI4ODVlNTNfNTQ5NzU1ODE1OTQ1MA_2e2f2ead-8420-4130-ad4b-d6323d28df8c">434,000</ix:nonFraction> was recorded, reducing the Company's total investment in Geneos to $<ix:nonFraction unitRef="usd" contextRef="i55de06d621d74ea4af67ec695d2aeb62_I20210331" decimals="-3" name="us-gaap:EquityMethodInvestments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN185MS9mcmFnOjBmMTk4ODlkNzI3NDQyYzQ4ODM2ZTVlMzcyODg1ZTUzL3RleHRyZWdpb246MGYxOTg4OWQ3Mjc0NDJjNDg4MzZlNWUzNzI4ODVlNTNfNTQ5NzU1ODE1OTQ2MQ_99dbfb08-e4db-460c-bb6c-fbbe91649a99">0</ix:nonFraction>. Of the total amount, $<ix:nonFraction unitRef="usd" contextRef="ida22e72ec08c488993f6f37b0a40f441_D20200601-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN185MS9mcmFnOjBmMTk4ODlkNzI3NDQyYzQ4ODM2ZTVlMzcyODg1ZTUzL3RleHRyZWdpb246MGYxOTg4OWQ3Mjc0NDJjNDg4MzZlNWUzNzI4ODVlNTNfNjg1MA_948667f2-2309-4538-8345-d9fbfc9f2e7b">819,000</ix:nonFraction> has been allocated to the equity method investment, thereby reducing the balance to $<ix:nonFraction unitRef="usd" contextRef="ic39b978122b34ef0b586d2c3f0a20046_I20200331" decimals="-3" name="us-gaap:EquityMethodInvestments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN185MS9mcmFnOjBmMTk4ODlkNzI3NDQyYzQ4ODM2ZTVlMzcyODg1ZTUzL3RleHRyZWdpb246MGYxOTg4OWQ3Mjc0NDJjNDg4MzZlNWUzNzI4ODVlNTNfNjkzNw_d73e7ab6-f831-4701-ad24-53c73f113618">0</ix:nonFraction> as of March 31, 2021. <ix:continuation id="i8f6c64937e4942af9241e18b62529b9d" continuedAt="i1962ba6698654bfcb62946cbd7e5350d">The remaining $<ix:nonFraction unitRef="usd" contextRef="i819679aabd4442d3be1364eba1821db3_D20200601-20201231" decimals="-5" sign="-" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN185MS9mcmFnOjBmMTk4ODlkNzI3NDQyYzQ4ODM2ZTVlMzcyODg1ZTUzL3RleHRyZWdpb246MGYxOTg4OWQ3Mjc0NDJjNDg4MzZlNWUzNzI4ODVlNTNfNjk4MA_942d016d-a160-4be4-afe1-b06674855193">4.2</ix:nonFraction> million loss has been allocated to the Company&#8217;s Series A and Series A-1 preferred stock investment in Geneos, on a ratable basis, thereby reducing the balance to $<ix:nonFraction unitRef="usd" contextRef="ib3a8dbbd273043a2a304eb2892a14c8c_I20210331" decimals="-3" name="us-gaap:EquityMethodInvestments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN185MS9mcmFnOjBmMTk4ODlkNzI3NDQyYzQ4ODM2ZTVlMzcyODg1ZTUzL3RleHRyZWdpb246MGYxOTg4OWQ3Mjc0NDJjNDg4MzZlNWUzNzI4ODVlNTNfNzEwMg_c1637f68-f387-4804-9930-70efa688d7c0">0</ix:nonFraction> as of March 31, 2021 as shown in the table below:</ix:continuation></span></div><div style="margin-bottom:6pt;margin-top:5pt"><ix:continuation id="i1962ba6698654bfcb62946cbd7e5350d"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:84.133%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.115%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.352%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment in Geneos upon deconsolidation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11b75bcb273c48128928387d5ceda2d2_I20200601" decimals="0" format="ixt:numdotdecimal" name="us-gaap:EquityMethodInvestments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN185MS9mcmFnOjBmMTk4ODlkNzI3NDQyYzQ4ODM2ZTVlMzcyODg1ZTUzL3RhYmxlOjQ0Y2Q1OTY1ODRlMzQwMGFiMTVlYzRlM2MzYmJlM2Y2L3RhYmxlcmFuZ2U6NDRjZDU5NjU4NGUzNDAwYWIxNWVjNGUzYzNiYmUzZjZfMS0yLTEtMS0w_ab0f169f-df38-4a10-8450-9ee081e41b97">3,618,998</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment in Geneos Series A-1 preferred stock</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f89255103014c46a5a9ab71646dba92_I20200601" decimals="0" format="ixt:numdotdecimal" name="us-gaap:EquityMethodInvestments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN185MS9mcmFnOjBmMTk4ODlkNzI3NDQyYzQ4ODM2ZTVlMzcyODg1ZTUzL3RhYmxlOjQ0Y2Q1OTY1ODRlMzQwMGFiMTVlYzRlM2MzYmJlM2Y2L3RhYmxlcmFuZ2U6NDRjZDU5NjU4NGUzNDAwYWIxNWVjNGUzYzNiYmUzZjZfMi0yLTEtMS0yODU1_4b4cf0d6-cf95-4522-8407-64529c4c2fbd">1,399,999</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share in net loss of Geneos from June 1, 2020 - December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie8cf0b8ea91645f8adbebe6fd2ff82e8_D20200601-20201231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN185MS9mcmFnOjBmMTk4ODlkNzI3NDQyYzQ4ODM2ZTVlMzcyODg1ZTUzL3RhYmxlOjQ0Y2Q1OTY1ODRlMzQwMGFiMTVlYzRlM2MzYmJlM2Y2L3RhYmxlcmFuZ2U6NDRjZDU5NjU4NGUzNDAwYWIxNWVjNGUzYzNiYmUzZjZfMi0yLTEtMS0w_ecbecaf6-2649-4ed2-8fce-3acd8edaa3c6">4,584,610</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share in net loss of Geneos for the three months ended March 31, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iecead882e1cc4b15851f3a17bd9de72e_D20210101-20210331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN185MS9mcmFnOjBmMTk4ODlkNzI3NDQyYzQ4ODM2ZTVlMzcyODg1ZTUzL3RhYmxlOjQ0Y2Q1OTY1ODRlMzQwMGFiMTVlYzRlM2MzYmJlM2Y2L3RhYmxlcmFuZ2U6NDRjZDU5NjU4NGUzNDAwYWIxNWVjNGUzYzNiYmUzZjZfNC0yLTEtMS0yODU1_09acded4-f77d-4df5-be72-821348e83bcb">434,387</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment in Geneos as of March 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55de06d621d74ea4af67ec695d2aeb62_I20210331" decimals="0" format="ixt:zerodash" name="us-gaap:EquityMethodInvestments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN185MS9mcmFnOjBmMTk4ODlkNzI3NDQyYzQ4ODM2ZTVlMzcyODg1ZTUzL3RhYmxlOjQ0Y2Q1OTY1ODRlMzQwMGFiMTVlYzRlM2MzYmJlM2Y2L3RhYmxlcmFuZ2U6NDRjZDU5NjU4NGUzNDAwYWIxNWVjNGUzYzNiYmUzZjZfMy0yLTEtMS0w_faaf072e-df11-49ca-982e-5a59659b7d8b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="margin-top:5pt;text-indent:22.5pt"><span><br/></span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company will not reduce its investment below $<ix:nonFraction unitRef="usd" contextRef="i55de06d621d74ea4af67ec695d2aeb62_I20210331" decimals="INF" name="us-gaap:EquityMethodInvestments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN185MS9mcmFnOjBmMTk4ODlkNzI3NDQyYzQ4ODM2ZTVlMzcyODg1ZTUzL3RleHRyZWdpb246MGYxOTg4OWQ3Mjc0NDJjNDg4MzZlNWUzNzI4ODVlNTNfMzI5ODUzNDkwNDkzNg_f4e5b54b-d2e5-4a73-a2dc-ce60f5403839">0</ix:nonFraction> and will not record its share of further net losses of Geneos as the Company has no obligation to fund Geneos.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2021, Geneos completed a second closing of the Series A-1 preferred stock financing, in which the Company did not participate. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following this transaction, the Company held approximately <ix:nonFraction unitRef="number" contextRef="i9ae4c9aeb5d247e7bef7ede5fd594691_I20210228" decimals="2" name="us-gaap:MinorityInterestOwnershipPercentageByParent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN185MS9mcmFnOjBmMTk4ODlkNzI3NDQyYzQ4ODM2ZTVlMzcyODg1ZTUzL3RleHRyZWdpb246MGYxOTg4OWQ3Mjc0NDJjNDg4MzZlNWUzNzI4ODVlNTNfMTA5OTUxMTY0ODMzMw_59aa8057-cf3d-4494-9cca-23023368af29">35</ix:nonFraction>% of the outstanding equity, on an as-converted to common stock basis.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company continues to exclusively license its SynCon</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">immunotherapy and CELLECTRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;technology platform to Geneos to be used in the field of personalized, neoantigen-based therapy for cancer. The license agreement provides for </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i5ab40104875748a4922db0166cde4385">potential royalty payments to the Company in the event that Geneos commercializes any products using the licensed technology. The Company is not obligated to use any of its assets to fund the future operations of Geneos.</ix:continuation>  </span></div><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><div id="i1d23d16a69484b63aa007ec686e80337_103"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 2.&#160;&#160;&#160;&#160;MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</span></div><div style="margin-top:4.5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">This Quarterly Report contains forward-looking statements, as defined in Section&#160;27A of the Securities Act of 1933, as amended, and Section&#160;21E of the Securities Exchange Act of 1934, as amended. These statements relate to future events or our future financial performance. In some cases, you can identify forward-looking statements by terminology such as &#8220;may,&#8221; &#8220;will,&#8221; &#8220;should,&#8221; &#8220;expect,&#8221; &#8220;plan,&#8221; &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;estimate,&#8221; &#8220;predict,&#8221; &#8220;potential&#8221; or &#8220;continue,&#8221; the negative of such terms or other comparable terminology. These statements are only predictions. Actual events or results may differ materially.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Although we believe that the expectations reflected in the forward-looking statements are reasonable based on our current expectations and projections, we cannot guarantee future results, levels of activity, performance or achievements. Moreover, neither we, nor any other person, assume responsibility for the accuracy and completeness of the forward-looking statements. We are under no obligation to update any of the forward-looking statements after the filing of this Quarterly Report to conform such statements to actual results or to changes in our expectations.</span></div><div style="margin-top:9pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The following discussion of our financial condition and results of operations should be read in conjunction with our condensed consolidated financial statements and the related notes and other financial information appearing elsewhere in this Quarterly Report and our audited consolidated financial statements and related notes for the year ended December 31, 2020 included in our Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission, or SEC, on March 1, 2021 (our 2020 Annual Report). Readers are also urged to carefully review and consider the various disclosures made by us that attempt to advise interested parties of the factors that affect our business, including without limitation the disclosures made in Item&#160;1A of Part&#160;II of this Quarterly Report under the captions &#8220;Risk Factors&#8221; and &#8220;Management's Discussion and Analysis of Financial Condition and Results of Operations,&#8221; and the disclosures made in our 2020 Annual Report under the caption &#8220;Risk Factors&#8221; and in our audited consolidated financial statements and related notes. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risk factors that could cause actual results to differ from those contained in the forward-looking statements include but are not limited to: our history of losses; our lack of products that have received regulatory approval; uncertainties inherent in clinical trials and product development programs, including but not limited to the fact that preclinical and clinical results may not be indicative of results achievable in other trials or for other indications, that the studies or trials may not be successful or achieve desired results, that preclinical studies and clinical trials may not commence, have sufficient enrollment or be completed in the time periods anticipated, that results from one study may not necessarily be reflected or supported by the results of other similar studies, that results from an animal study may not be indicative of results achievable in human studies, that clinical testing is expensive and can take many years to complete, that the outcome of any clinical trial is uncertain and failure can occur at any time during the clinical trial process, and that our electroporation technology and product candidates may fail to show the desired safety and efficacy traits in clinical trials; the availability of funding; the ability to manufacture our product candidates; the availability or potential availability of alternative therapies or treatments for the conditions targeted by us or our collaborators, including alternatives that may be more efficacious or cost-effective than any therapy or treatment that we and our collaborators hope to develop; our ability to receive development, regulatory and commercialization event-based payments under our collaborative agreements; whether our proprietary rights are enforceable or defensible or infringe or allegedly infringe on rights of others or can withstand claims of invalidity; the impact of government healthcare laws and proposals; and the impact of COVID-19 on us and our third-party contractors and suppliers.</span></div><div style="margin-top:9pt;text-indent:27pt"><span><br/></span></div><div id="i1d23d16a69484b63aa007ec686e80337_106"></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Overview</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a biotechnology company focused on rapidly bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases, cancer, and diseases associated with human papillomavirus ("HPV"). Our DNA medicines pipeline is comprised of three types of product candidates: DNA vaccines, DNA immunotherapies and DNA encoded monoclonal antibodies ("dMAbs"). In clinical trials, we have demonstrated that DNA medicines can be delivered directly into cells in the body through our proprietary smart device to consistently activate robust and fully functional T cell and antibody responses against targeted pathogens and cancers. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our novel DNA medicine candidates are made using our proprietary SynCon</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> technology that creates optimized plasmids, which are circular strands of DNA that instruct a cell to produce antigens to help the person&#8217;s immune system recognize and destroy cancerous or virally infected cells.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our patented CELLECTRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> smart delivery devices provide optimized uptake of our DNA medicines within the cell, overcoming a key limitation of other DNA-based technology approaches, namely cellular uptake. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Human clinical trial data to date have shown a favorable safety profile of our DNA medicines delivered directly into cells in the body using the CELLECTRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> smart device in more than 7,000 administrations across more than 3,000 patients.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our corporate strategy is to advance, protect and, once approved, commercialize our novel DNA medicines to meet urgent and emerging global health needs. We continue to advance and clinically validate an array of DNA medicine candidates that target HPV-associated diseases, cancer, and infectious diseases, such as COVID-19. We aim to advance these candidates through commercialization and continue to leverage third-party resources through collaborations and partnerships, including product license agreements. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our partners and collaborators include ApolloBio Corp., AstraZeneca, Advaccine, The Bill &amp; Melinda Gates Foundation (Gates), Coalition for Epidemic Preparedness Innovations ("CEPI"), Defense Advanced Research Projects Agency ("DARPA"), The U.S. Department of Defense ("DoD"), GeneOne Life Science, HIV Vaccines Trial Network, the U.S. Defense Threat Reduction Agency&#8217;s Medical CBRN Defense Consortium ("MCDC"), International Vaccine Institute ("IVI"), National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Ology Bioservices, the Parker Institute for Cancer Immunotherapy, Plumbline Life Sciences, Regeneron Pharmaceuticals, Richter-Helm BioLogics, Thermo Fisher Scientific, the University of Pennsylvania, the Walter Reed Army Institute of Research, and The Wistar Institute.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We or our collaborators are currently conducting or planning clinical studies of our DNA medicines for HPV-associated precancers, including cervical, vulvar, and anal dysplasia; HPV-associated cancers, including head &amp; neck, cervical, anal, penile, vulvar, and vaginal; other HPV-associated disorders, such as recurrent respiratory papillomatosis, or RRP; glioblastoma multiforme, or GBM; prostate cancer; HIV; Ebola; Middle East Respiratory Syndrome, or MERS; Lassa fever; Zika virus; and COVID-19.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All of our product candidates are in the research and development phase. We have not generated any revenues from the sale of any products, and we do not expect to generate any such revenues for at least the next several years. We earn revenue from license fees and milestone revenue and collaborative research and development agreements. Our product candidates will require significant additional research and development efforts, including extensive preclinical and clinical testing. All product candidates that we advance to clinical testing will require regulatory approval prior to commercial use, and will require significant costs for commercialization. We may not be successful in our research and development efforts, and we may never generate sufficient product revenue to be profitable.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2021, we had an accumulated deficit of $960.6 million. We expect to continue to incur substantial operating losses in the future due to our commitment to our research and development programs, the funding of preclinical studies, clinical trials and regulatory activities and the costs of general and administrative activities.</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Developments</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2021, we announced preliminary immunogenicity and safety data from the Phase 2 segment of INNOVATE </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(IN</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ovio I</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-4800</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> V</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">accine </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">T</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">rial for </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">E</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">fficacy), our clinical trial evaluating COVID-19 DNA vaccine candidate, INO-4800. Phase 2 data showed the vaccine candidate to be well-tolerated and immunogenic in all tested age groups. The Phase 2 results helped determine our selection of a 2.0 mg dose for the global Phase 3 segment of the trial. The Phase 3 segment of the INNOVATE trial is now planned to be conducted as a predominantly ex-United States global Phase 3 trial.  In the U.S., the trial remains on partial clinical hold until we satisfactorily resolve the FDA's remaining questions related to the CELLECTRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 2000 device that will be used to deliver INO-4800, which is planned for the second quarter 2021.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2021, we were notified by the DoD that it will discontinue funding for the Phase 3 segment of our clinical trial of INO-4800 in the United States, while continuing to fund the completion of the ongoing Phase 2 segment. The Company is currently working with potential funders and partners on plans for the trial.</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impacts of COVID-19 On Our Business</span></div><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operationally, we have not experienced significant disruptions to date as a result of the COVID-19 pandemic.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In response to the outbreak, a number of governmental orders and other public health guidance measures were implemented across much of the United States, including in the locations of our offices, laboratories, clinical trial sites and third parties on whom we rely. We have implemented a work from home policy allowing employees who can work from home to do so, while those needing to work in laboratory facilities work in shifts to reduce the number of people gathered together at one time. Business travel has been suspended, and online and teleconference technology is used to meet virtually rather than in person. We have taken measures to secure our research and development project activities, while work in laboratories has been organized to reduce risk of COVID-19 transmission.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our liquidity has not been negatively impacted to date by the pandemic. During the year ended December 31, 2020, we raised </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$454.5 million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in net proceeds from the sale of shares of our common stock through our "at-the-market" equity offering program and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in January 2021 we closed an underwritten public offering with net proceeds to us of $162.1&#160;million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which further enhanced our liquidity and capital resources. As of March 31, 2021, our cash and cash equivalents and short-term investments were $518.6 million.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are closely monitoring the impact of the COVID-19 pandemic on our employees, collaborators and service providers. The extent to which the pandemic will impact our business and operations will depend on future developments, including travel </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">restrictions and social distancing in the United States and other countries, and the effectiveness of actions taken in the United States and other countries to contain and treat the disease, including mass vaccination efforts, that are highly uncertain. For additional information on the potential effects of the COVID-19 pandemic on our business, financial condition and results of operations, see the &#8220;Risk Factors&#8221; section below in Part II, Item 1A of this Form 10-Q.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span><br/></span></div><div id="i1d23d16a69484b63aa007ec686e80337_109"></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Accounting Policies </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no significant changes to our critical accounting policies since December 31, 2020. For a description of our critical accounting policies that affect our significant judgments and estimates used in the preparation of our condensed consolidated financial statements, refer to Note 3 to our Condensed Consolidated Financial Statements included in this Quarterly Report, as well as Item 7, &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; in our 2020 Annual Report and Note 2 to our audited Consolidated Financial Statements contained in our 2020 Annual Report. </span></div><div style="margin-top:5pt;text-indent:27pt"><span><br/></span></div><div id="i1d23d16a69484b63aa007ec686e80337_112"></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Adoption of Recent Accounting Pronouncements</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information regarding recent accounting pronouncements is contained in Note&#160;4 to the Condensed Consolidated Financial Statements, included in this Quarterly Report.</span></div><div style="margin-top:5pt;text-indent:27pt"><span><br/></span></div><div id="i1d23d16a69484b63aa007ec686e80337_115"></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Results of Operations</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total revenue was $371,000 for the three months ended March 31, 2021, as compared to $1.3 million for the three months ended March 31, 2020. Revenue primarily consisted of revenues under collaborative research and development arrangements, including arrangements with affiliated entities, for the three months ended March 31, 2021 and 2020. The decrease in revenue for the three-month period year over year was primarily due to less milestone revenue earned from our affiliated entity PLS.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and development expenses. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses for the three months ended March 31, 2021 were $39.0 million, as compared to $19.1 million for the three months ended March 31, 2020. The increase for the three-month period year over year was primarily due to higher drug manufacturing expenses and outside services related to our INO-4800 clinical trials of $10.7 million, higher employee and contractor compensation expense of $4.8 million, an increase in engineering services and expensed equipment related to our CELLECTRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 3PSP device array automation project of $4.1 million, higher expensed device materials of $3.1 million, higher employee stock-based compensation expense of $2.9 million and higher immunology related expenses related to our VGX-3100 clinical trials of $2.5 million. These increases were offset by an increase in contra-research and development expense recorded from grant agreements of $8.8 million, among other variances. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contributions received from current grant agreements and recorded as contra-research and development expense were $13.8 million for the three months ended March 31, 2021 as compared to $5.0 million for the three months ended March 31, 2020. The increase for the three-month period year over year was primarily due to increases of $7.8 million and $830,000 earned under grants from the DoD and Gates, respectively, related to INO-4800 and device development activities, as well as a $1.2 million increase from the CEPI grants related to our Lassa fever and MERS vaccine candidates, among other variances.  </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">General and administrative expenses. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses, which include business development expenses, the amortization of intangible assets and patent expenses, were $13.9 million for the three months ended March 31, 2021, as compared to $7.4 million for the three months ended March 31, 2020. The increase for the three-month period year over year was primarily related to higher employee and consultant stock-based compensation expense of $2.7 million, an increase in legal expenses of $1.9 million related to the legal proceedings described in this report, a change in foreign currency exchange rate translation of $945,000 related to our August 2019 and December 2019 Bonds, and higher employee compensation of $838,000, among other variances. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock-based compensation. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation expense is measured at the grant date, based on the fair value of the award, and is recognized as expense over the requisite vesting period. Total employee and director stock-based compensation expense for the three months ended March 31, 2021 and 2020 was $9.2 million and $3.6 million, respectively. Of these amounts, $5.2 million and $2.3 million, respectively, was included in research and development expenses, and $4.0 million and $1.3 million, respectively, was included in general and administrative expenses. The year over year increase was primarily related to a higher weighted average grant date fair value for the awards granted in 2021.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest income. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest income for the three months ended March 31, 2021 was $769,000, as compared to $417,000 for the three months ended March 31, 2020. The increase was related to higher interest earned on our higher balance of short-term investment holdings.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1d23d16a69484b63aa007ec686e80337_7">Table of Contents</a></span></div></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest expense. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense for the three months ended March 31, 2021 was $513,000, as compared to $2.8 million for the three months ended March 31, 2020. The decrease for the three-month period year over year was due to less interest expense recorded for our convertible senior notes, or the Notes, due to the partial conversions of the Notes into shares of our common stock in the third and fourth quarters of 2020, as well as no interest expense recorded on our August 2019 Bonds due to their full conversion into shares of our common stock in August 2020. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Change in fair value of derivative liability.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The change in fair value of derivative liability for the three months ended March 31, 2020 was $13.2 million. We determined that our August 2019 Bonds included an embedded conversion feature that was considered to be a derivative liability requiring bifurcation from the debt instrument and separate recognition in our financial statements. The conversion feature was revalued at the end of each reporting period and immediately prior to the conversion of the August 2019 Bonds in August 2020, with&#160;the resulting changes in fair value reflected in the condensed consolidated&#160;statements of operations. There was no change in fair value for the three months ended March 31, 2021, as the derivative liability was derecognized upon the conversion in full of the August 2019 Bonds in August 2020.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Gain (loss) on investment in affiliated entities. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The gain (loss) results from the change in the fair market value of our investment in PLS for a loss of $830,000 for the three months ended March 31, 2021 as compared to the change in the fair market value of the investments in PLS and GeneOne for a gain of $13.2 million for the three months ended March 31, 2020. During the third quarter of 2020, we sold our full equity interest in GeneOne. We record our investment in PLS at its market value based on the closing price of the shares on the Korea New Exchange Market at each balance sheet date, with changes in fair value reflected in the condensed consolidated statements of operations.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net unrealized loss on available-for-sale equity securities. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The net unrealized loss on available-for-sale equity securities for the three months ended March 31, 2021 and 2020 of $848,000 and $5.1 million, respectively, results from a change in the fair market value of the investments.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Share in net loss of Geneos.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The share in net loss of Geneos represents our share of Geneos' losses during the period after deconsolidation in June 2020. </span></div><div style="margin-top:5pt;text-indent:27pt"><span><br/></span></div><div id="i1d23d16a69484b63aa007ec686e80337_118"></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and Capital Resources</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Historically, our primary uses of cash have been to finance research and development activities including clinical trial activities in the oncology, DNA vaccines and other immunotherapy areas of our business. Since inception, we have satisfied our cash requirements principally from proceeds from the sale of equity securities, indebtedness and grants and government contracts.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Working Capital and Liquidity</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2021, we had cash, cash equivalents and short-term investments of $518.6 million and working capital of $546.9 million, as compared to $411.6 million and $429.5 million, respectively, as of December&#160;31, 2020. The increase in cash and short-term investments during the three months ended March&#160;31, 2021 was primarily due to the net proceeds from the sale of our common stock in an underwritten public offering in January 2021, offset by expenditures related to our research and development activities, clinical trials and various general and administrative expenses related to legal, consultants, accounting and audit, and corporate development.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash Flows</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in operating activities was $52.9 million and $25.5 million for the three months ended March 31, 2021 and 2020, respectively. Net cash used in operating activities for the three months ended March 31, 2021 consisted of net loss of&#160;$54.4 million, less use of net cash in operating assets and liabilities of&#160;$11.1 million partially offset by net non-cash adjustments of&#160;$12.6 million. The net cash used in operating activities included a $19.2 million increase in prepaid expenses and other current assets, primarily made up of prepayments for facilities, equipment and manufacturing related to INO-4800. The primary non-cash adjustments to net loss included stock-based compensation of&#160;$9.6 million, net unrealized loss on available-for-sale equity securities of $848,000, loss on investment in affiliated entity of $830,000 and depreciation and amortization of $797,000, among other items. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in operating activities for the three months ended March 31, 2020 consisted of net loss of&#160;$33.1 million,&#160;less use of net cash in operating assets and liabilities of&#160;$921,000, partially offset by net non-cash adjustments of&#160;$8.6 million. The primary non-cash expenses added back to net loss included the increase in fair value of derivative liability of $13.2 million, net unrealized loss on available-for-sale equity securities of $5.1 million, stock-based compensation of&#160;$4.0 million and depreciation and amortization of&#160;$1.2 million. These non-cash expenses were offset by non-cash gain on investment in affiliated entities of $13.2 million and the acquisition of investment in our affiliated entity PLS of $1.7 million through the settlement of accounts receivable with additional shares of PLS common stock in lieu of cash.</span><span style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:5pt;text-indent:27pt"><span><br/></span></div></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in investing activities was $275.1 million and $51.8 million for the three months ended March 31, 2021 and 2020, respectively. The variance was primarily the result of timing differences in short-term investment purchases, sales and maturities.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by financing activities was $160.9 million and $213.5 million for the three months ended March 31, 2021 and 2020, respectively. The variance was primarily due to the proceeds from the sale of common stock under the ATM sales agreement in 2020, offset by the net proceeds from the January 2021 underwritten public offering.  </span></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:174%">Issuances of Common Stock</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 25, 2021, we closed an underwritten public offering of 20,355,000 shares of our common stock at a public offering price of $8.50 per share. The net proceeds, after deducting the underwriters' discounts and commissions and other estimated offering expenses payable by us, were $162.1&#160;million. </span></div><div style="margin-bottom:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2018, we entered into an At-the-Market Equity Offering Sales Agreement, or the Sales Agreement, with an outside placement agent, or the Placement Agent, to sell shares of our common stock with aggregate gross proceeds of up to $100.0 million, from time to time, through an &#8220;at-the-market&#8221; equity offering program under which the Placement Agent would act as sales agent. In the first quarter of 2020, we entered into amendments to the&#160;Sales Agreement to increase the amount of our common stock that could be sold through the Placement Agent under the Sales Agreement to an aggregate offering price of up to $250.0 million. During the three months ended March 31, 2020, we sold 43,148,952 shares of common stock under the Sales Agreement for aggregate net proceeds of $208.2 million. Following these sales, there was no remaining capacity under this Sales Agreement.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 3, 2020, we entered into a new sales agreement, or the New Sales Agreement, with the same Placement Agent to sell shares of our common stock. On that same day, we filed a prospectus supplement pursuant to the New Sales Agreement for the offer and sale of our common stock for aggregate gross proceeds of up to $150.0 million. On May 12, 2020 we filed an additional prospectus supplement pursuant to the New Sales Agreement for the offer and sale of our common stock for an additional $100.0 million of gross proceeds, bringing the maximum gross proceeds of sales under the New Sales Agreement to $250.0 million. Through December 31, 2020, we sold 22,915,934 shares of common stock under the New Sales Agreement for aggregate net proceeds of $246.2 million. As of December 31, 2020 and March 31, 2021, there was no remaining capacity under the New Sales Agreement.</span></div><div style="text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">three months ended March 31, 2021</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, stock options to purchase 572,857 shares of common stock were exercised for aggregate net proceeds to us of $2.6 million, which proceeds were offset by tax payments made related to net share settlement of RSU awards of $3.8 million. During the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">three months ended March 31, 2020</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, stock options to purchase 904,173 shares of common stock were exercised for aggregate net proceeds of $5.2 million, which proceeds were offset by tax payments made related to net share settlement of RSU awards of $2.1 million.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2021, we had an accumulated deficit of $960.6 million and we expect to continue to operate at a loss for some time. The amount of the accumulated deficit will continue to increase, as it will be expensive to continue research and development efforts. These activities will require additional financing. If these activities are successful and if we receive approval from the FDA to market our product candidates, then we will need to raise additional funding to market and sell the approved products and equipment. We cannot predict the outcome of the above matters at this time. We are evaluating potential collaborations as an additional way to fund operations. We believe that our current cash and short-term investments are sufficient to meet our planned working capital requirements for at least the next twelve months from the date of this report. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:174%">Off-Balance Sheet Arrangements</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We did not have during the periods presented, and we do not currently have, any off-balance sheet arrangements, as defined in the rules and regulations of the SEC.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:174%">Contractual Obligations</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March 31, 2021</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, all outstanding December 2019 Bonds were converted into 1,009,450 shares of the Company's common stock.  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no other significant changes to our contractual obligations and commitments described under Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations in our Annual Report on Form 10-K for the year ended December 31, 2020.</span></div><div style="margin-top:5pt;text-indent:27pt"><span><br/></span></div><div id="i1d23d16a69484b63aa007ec686e80337_121"></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 3.&#160;&#160;&#160;&#160;QUALITATIVE AND QUANTITATIVE DISCLOSURES ABOUT MARKET RISK</span></div><div style="margin-top:5pt;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest Rate Risk</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Market risk represents the risk of loss that may impact our consolidated financial position, results of operations or cash flows due to adverse changes in financial and commodity market prices and rates. We are exposed to market risk primarily in </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:5pt;text-indent:27pt"><span><br/></span></div></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the area of changes in United States interest rates and conditions in the credit markets, and the recent fluctuations in interest rates and availability of funding in the credit markets primarily impact the performance of our investments. We do not have any material foreign currency or other derivative financial instruments. Under our current policies, we do not use interest rate derivative instruments to manage exposure to interest rate changes. We attempt to increase the safety and preservation of our invested principal funds by limiting default risk, market risk and reinvestment risk. We mitigate default risk by investing in investment grade securities.  Due to the short-term maturities of our cash equivalents and the low risk profile of our investments at March&#160;31, 2021, an immediate 100 basis point change in interest rates would not have a material effect on the fair market value of our cash equivalents.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The interest rate on our indebtedness, consisting of the Notes, is fixed and not subject to fluctuations in interest rates.</span></div><div><span><br/></span></div><div style="text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value Measurements</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The investment in affiliated entity at March&#160;31, 2021 represents our ownership interest in the Korean-based company PLS. We report this investment at fair value on the condensed consolidated balance sheet using the closing price of PLS shares of common stock as reported on the date of determination on the Korea New Exchange Market.</span></div><div style="margin-top:14pt;padding-left:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currency Risk</span></div><div style="margin-top:4.5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have operated primarily in the United States and most transactions during the three months ended March 31, 2021 were made in United States dollars. Accordingly, we have not had any material exposure to foreign currency rate fluctuations, with the exception of certain cash and cash equivalents held in South Korea that are denominated in South Korean Won and the valuation of our equity investment in PLS, which is denominated in South Korean Won and then translated into United States dollars. We do not have any foreign currency hedging instruments in place. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain transactions are denominated primarily in foreign currencies, including South Korean Won, Euros, British Pounds and Canadian Dollars. These transactions give rise to monetary assets and liabilities that are denominated in currencies other than the U.S. dollar. The value of these monetary assets and liabilities are subject to changes in currency exchange rates from the time the transactions are originated until settlement in cash. As a result, our financial results could be affected by factors such as changes in foreign currency exchange rates or weak economic conditions in foreign markets where we conduct business.</span></div><div style="margin-top:4.5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not use derivative financial instruments for speculative purposes and do not engage in exchange rate hedging or hold or issue foreign exchange contracts for trading purposes. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div id="i1d23d16a69484b63aa007ec686e80337_124"></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 4.&#160;&#160;&#160;&#160;CONTROLS AND PROCEDURES</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Evaluation of Disclosure Controls and Procedures</span></div><div style="margin-top:4.5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We maintain disclosure controls and procedures, which are designed to ensure that information required to be disclosed in the reports we file or submit under the Securities Exchange Act of 1934, as amended, is recorded, processed, summarized and reported within the time periods specified in the SEC's rules&#160;and forms, and that such information is accumulated and communicated to our management, including our Chief Executive Officer, or CEO, and Chief Financial Officer, or CFO, as appropriate to allow timely decisions regarding required disclosures. </span></div><div style="margin-top:4.5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In designing and evaluating our disclosure controls and procedures, management recognizes that disclosure controls and procedures, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the disclosure controls and procedures are met. Additionally, in designing disclosure controls and procedures, our management necessarily was required to apply its judgment in evaluating the cost-benefit relationship of possible disclosure controls and procedures. The design of any system of controls also is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions; over time, controls may become inadequate because of changes in conditions, or the degree of compliance with policies or procedures may deteriorate. Because of the inherent limitations in a control system, misstatements due to error or fraud may occur and not be detected.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on an evaluation carried out as of the end of the period covered by this Quarterly Report, under the supervision and with the participation of our management, including our CEO and CFO, our CEO and CFO have concluded that, as of the end of such period, our disclosure controls and procedures (as defined in Rule&#160;13a-15(e)&#160;and 15d-15(e)&#160;under the Securities Exchange Act of 1934) were effective as of March&#160;31, 2021 at the reasonable assurance level. </span></div><div style="margin-top:14pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in Internal Control over Financial Reporting</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1d23d16a69484b63aa007ec686e80337_7">Table of Contents</a></span></div></div><div style="margin-top:4.5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have not been any changes in our internal control over financial reporting that occurred during the quarter ended March&#160;31, 2021 that materially affected, or are reasonably likely to materially affect, our internal control over financial reporting. </span></div><div style="text-align:center"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></div></div><div id="i1d23d16a69484b63aa007ec686e80337_127"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Part II. Other Information</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div id="i1d23d16a69484b63aa007ec686e80337_130"></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 1.&#160;&#160;&#160;&#160;LEGAL PROCEEDINGS</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Securities Litigation</span></div><div style="margin-top:5pt;padding-right:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 12, 2020, a purported shareholder class action complaint, McDermid v. Inovio Pharmaceuticals, Inc. and J. Joseph Kim, was filed in the United States District Court for the Eastern District of Pennsylvania, naming us and J. Joseph Kim, our Chief Executive Officer, as defendants. The lawsuit alleges that we made materially false and misleading statements regarding our development of a vaccine for COVID-19 in our public disclosures in violation of certain federal securities laws. The plaintiff seeks unspecified monetary damages on behalf of the putative class and an award of costs and expenses, including reasonable attorneys&#8217; fees. On June 18, 2020, the court appointed Manuel Williams to serve as lead plaintiff. On August 3, 2020, Mr. Williams filed a consolidated complaint, naming us and three of our officers as defendants. On September 21, 2020, Mr. Williams and another purported stockholder, Andrew Zenoff filed a first amended complaint, naming us and three of our officers as defendants. Defendants filed a motion to dismiss plaintiff&#8217;s first amended complaint on November 5, 2020. On February 16, 2021, the court issued an order granting in part, and denying in part, Defendants&#8217; motion to dismiss. The court granted Defendants&#8217; motion to dismiss, and dismissed with prejudice, the claims premised on the April 30 and June 30, 2020 statements. The court denied Defendants&#8217; motion to dismiss as to the remaining statements. On March 9, 2021, Defendants filed their answer to the complaint. The case is now in discovery, and Plaintiffs&#8217; motion for class certification is due on or before July 29, 2021.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 20, 2020, a purported shareholder derivative complaint, Behesti v. Kim, et al., was filed in the United States District Court for the Eastern District of Pennsylvania, naming eight current and former directors as defendants. The lawsuit asserts state and federal claims and is based on the same alleged misstatements as the shareholder class action complaint. The lawsuit accuses our board of directors of failing to exercise reasonable and prudent supervision over our management, policies, practices, and internal controls. The plaintiff seeks unspecified monetary damages on behalf of us as well as governance reforms. On June 5, 2020, the court stayed the Beheshti action pending resolution of a forthcoming motion to dismiss the McDermid securities class action or until any party provides notice that they no longer consent to the stay. On June 12 and June 15, 2020, two additional shareholder derivative complaints were filed in the United States District Court for the Eastern District of Pennsylvania, captioned Isman v. Benito, et al. and Devarakonda et al. v Kim, et. al. The complaints assert substantially similar claims as the Beheshti action and name our current directors as defendants. The Devarakonda complaint also names one of our former directors as a defendant. On July 21, 2020, the court consolidated the three derivative cases under the caption In re Inovio Pharmaceuticals, Inc. Derivative Litigation. The consolidated action is stayed pending resolution of a forthcoming motion to dismiss the McDermid securities class action or until any party provides notice that they no longer consent to the stay.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 7, 2020, a fourth shareholder derivative complaint, Fettig v. Kim et al., was filed in the United States District Court for the Eastern District of Pennsylvania, naming eight current and former directors as defendants. The complaint asserts substantially similar claims as those in the consolidated derivative action. On August 27, 2020, the Fettig action was consolidated with the other derivative cases, which remain stayed as explained above.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We intend to defend these actions vigorously.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">VGXI Litigation</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 3, 2020, we filed a complaint in the Court of Common Pleas of Montgomery County, Pennsylvania against VGXI, Inc. and GeneOne Life Science, Inc., or GeneOne, and together with VGXI, Inc. collectively referred to as VGXI, alleging that VGXI had materially breached our supply agreement with them. The complaint seeks declaratory judgments, specific performance of the agreement, injunctive relief, an accounting, damages, attorneys&#8217; fees, interest, costs and other relief from VGXI. On June 3, 2020, we filed a petition for preliminary injunction, which was denied on June 25, 2020. On June 26, 2020, we filed notice of appeal of the denial of the petition with the Pennsylvania Superior Court.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 7, 2020, VGXI filed an answer, new matter and counterclaims against us, alleging that we had breached the supply agreement, as well as misappropriation of trade secrets and unjust enrichment. The counterclaims seek injunctive relief, damages, attorneys&#8217; fees, interest, costs and other relief from us. Also, on July 7, 2020, VGXI filed a third-party complaint against Ology Bioservices, Inc., a contract manufacturing organization that we had engaged to provide services similar to those that were being provided by VGXI. On July 27, 2020, we filed an answer to VGXI&#8217;s counterclaims, disputing the allegations and the claims raised in VGXI&#8217;s filing. On October 1, 2020, we filed a notice of discontinuance of appeal with the Pennsylvania Superior Court. A trial date for the litigation has not been set.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We intend to aggressively prosecute the claims set forth in our complaint against VGXI and to vigorously defend ourselves against VGXI&#8217;s counterclaims.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 7, 2020, GeneOne filed a complaint in the Court of Common Pleas of Montgomery County, Pennsylvania against us, alleging that we had breached the CELLECTRA Device License Agreement, or the Agreement, between us and </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1d23d16a69484b63aa007ec686e80337_7">Table of Contents</a></span></div></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">GeneOne. We terminated the Agreement on October 9, 2020. The complaint asserts claims for breach of contract, declaratory judgment, unfair competition, and unjust enrichment. The complaint seeks injunctive relief, an accounting, damages, disgorgement of profits, attorneys&#8217; fees, interest, and other relief from us. We intend to vigorously defend ourselves against GeneOne&#8217;s claims. On January 29, 2021, we filed preliminary objections to the complaint.  </span></div><div style="margin-top:5pt"><span><br/></span></div><div id="i1d23d16a69484b63aa007ec686e80337_133"></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 1A.&#160;&#160;&#160;&#160;  RISK FACTORS</span></div><div style="margin-top:4.5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our business is subject to numerous risks. You should carefully consider and evaluate each of the following factors as well as the other information in this Quarterly Report on Form&#160;10-Q, including our financial statements and the related notes, the risk factors discussed in our 2020 Annual Report, which we filed with the SEC on March 1, 2021, in evaluating our business and prospects. The risks and uncertainties described below are not the only ones we face. Additional risks and uncertainties not presently known to us or that we currently consider immaterial may also impair our business operations. If any of the following risks actually occur, our business and financial results could be harmed. In that case, the trading price of our common stock could decline. You should also consider the more detailed description of our business contained in our 2020 Annual Report. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Financial Position and Need for Additional Capital</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have incurred losses since inception, expect to incur significant net losses in the foreseeable future and may never become profitable.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have experienced significant operating losses to date; as of March&#160;31, 2021, our accumulated deficit was approximately $960.6 million. We have generated limited revenues, primarily consisting of license revenue, grant funding and interest income. We expect to continue to incur substantial additional operating losses for at least the next several years as we advance our clinical trials and research and development activities. We may never successfully commercialize our DNA vaccine, DNA immunotherapy and dMAB product candidates or electroporation-based synthetic vaccine delivery technology and thus may never have any significant future revenues or achieve and sustain profitability.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have limited sources of revenue and our success is dependent on our ability to develop our DNA vaccines, DNA immunotherapies, dMAbs and electroporation equipment. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not sell any products and may not have any other products commercially available for several years, if at all. Our ability to generate future revenues depends heavily on our success in: </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">developing and securing United States and/or foreign regulatory approvals for our product candidates, including securing regulatory approval for conducting clinical trials with product candidates; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">developing our electroporation-based DNA delivery technology; and </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">commercializing any products for which we receive approval from the FDA and foreign regulatory authorities. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our electroporation equipment and product candidates will require extensive additional clinical study and evaluation, regulatory approval in multiple jurisdictions, substantial investment and significant marketing efforts before we generate any revenues from product sales. We are not permitted to market or promote our electroporation equipment and product candidates before we receive regulatory approval from the FDA or comparable foreign regulatory authorities. If we do not receive regulatory approval for and successfully commercialize any products, we will not generate any revenues from sales of electroporation equipment and products, and we may not be able to continue our operations. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We will need substantial additional capital to develop our DNA vaccines, DNA immunotherapies and dMAb programs and electroporation delivery technology.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Conducting the costly and time-consuming research, pre-clinical studies and clinical testing necessary to obtain regulatory approvals and bring our product candidates and delivery technology to market will require a commitment of substantial funds in excess of our current capital. Our future capital requirements will depend on many factors, including, among others:</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the progress of our current and new product development programs; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the progress, scope and results of our pre-clinical and clinical testing; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the time and cost involved in obtaining regulatory approvals; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cost of manufacturing our products and product candidates; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cost of prosecuting, enforcing and defending against patent infringement claims and other intellectual property rights; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%;padding-left:14.5pt">debt service obligations</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">competing technological and market developments; and </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability and costs to establish and maintain collaborative and other arrangements with third parties to assist in potentially bringing our products to market. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additional financing may not be available on acceptable terms, or at all. Domestic and international capital markets have from time to time experienced heightened volatility and turmoil, particularly in light of the COVID-19 pandemic, making it more difficult in many cases to raise capital through the issuance of equity securities. Volatility in the capital markets can also negatively impact the cost and availability of credit, creating illiquid credit markets and wider credit spreads. Concern about the stability of the markets generally and the strength of counterparties specifically has led many lenders and institutional investors to reduce, and in some cases cease to provide, funding to borrowers. To the extent we are able to raise additional capital through the sale of equity securities, or we issue securities in connection with another transaction in the future, the ownership position of existing stockholders could be substantially diluted. If additional funds are raised through the issuance of preferred stock or debt securities, these securities are likely to have rights, preferences and privileges senior to our common stock and may involve significant fees, interest expense, restrictive covenants and the granting of security interests in our assets. Fluctuating interest rates could also increase the costs of any debt financing we may obtain. Raising capital through a licensing or other transaction involving our intellectual property could require us to relinquish valuable intellectual property rights and thereby sacrifice long-term value for short-term liquidity.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our failure to successfully address ongoing liquidity requirements would have a substantially negative impact on our business. If we are unable to obtain additional capital on acceptable terms when needed, we may need to take actions that adversely affect our business, our stock price and our ability to achieve cash flow in the future, including possibly surrendering our rights to some technologies or product opportunities, delaying our clinical trials or curtailing or ceasing operations. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Product Development, Manufacturing and Regulatory Approval</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to obtain FDA approval of our products, we will not be able to commercialize them in the United States.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We need FDA approval prior to marketing our electroporation equipment and product candidates in the United States. If we fail to obtain FDA approval to market our electroporation equipment and product candidates, we will be unable to sell our products in the United States, which will significantly impair our ability to generate any revenues.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This regulatory review and approval process, which includes evaluation of preclinical studies and clinical trials of our products as well as the evaluation of our manufacturing processes and our third-party contract manufacturers' facilities, is lengthy, expensive and uncertain. To receive approval, we must, among other things, demonstrate with substantial evidence from well-controlled clinical trials that our electroporation equipment and product candidates are both safe and effective for each indication for which approval is sought. To the extent that our product candidates are manufactured at multiple sites or using different processes, we will also need to demonstrate comparability across the manufacturing batches in order to obtain regulatory approval. Satisfaction of the approval requirements typically takes several years and the time needed to satisfy them may vary substantially, based on the type, complexity and novelty of the product. We do not know if or when we might receive regulatory approvals for our electroporation equipment and any of our product candidates currently under development. Moreover, any approvals that we obtain may not cover all of the clinical indications for which we are seeking approval, or could contain significant limitations in the form of narrow indications, warnings, precautions or contra-indications with respect to conditions of use. In such event, our ability to generate revenues from such products would be greatly reduced and our business would be harmed.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA has substantial discretion in the approval process and may either refuse to consider our application for substantive review or may form the opinion after review of our data that our application is insufficient to allow approval of our electroporation equipment and product candidates. If the FDA does not consider or approve our application, it may require that we conduct additional clinical, preclinical or manufacturing validation studies and submit that data before it will reconsider our application. Depending on the extent of these or any other studies, approval of any applications that we submit may be delayed by several years, or may require us to expend more resources than we have available. It is also possible that additional studies, if performed and completed, may not be successful or considered sufficient by the FDA for approval or even to make our applications approvable. If any of these outcomes occur, we may be forced to abandon one or more of our applications for approval, which might significantly harm our business and prospects.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is possible that none of our products or any product we may seek to develop in the future will ever obtain the appropriate regulatory approvals necessary for us or our collaborators to commence product sales. Any delay in obtaining, or an inability to obtain, applicable regulatory approvals would prevent us from commercializing our products, generating revenues and achieving and sustaining profitability. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Clinical trials involve a lengthy and expensive process with an uncertain outcome, and results of earlier studies and trials may not be predictive of future trial results.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Clinical testing is expensive and can take many years to complete, and its outcome is uncertain. Failure can occur at any time during the clinical trial process. The results of preclinical studies and early clinical trials of our products may not be predictive of the results of later-stage clinical trials. Results from one study may not be reflected or supported by the results of similar studies. Results of an animal study may not be indicative of results achievable in human studies. Human-use equipment and product candidates in later stages of clinical trials may fail to show the desired safety and efficacy traits despite having </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">progressed through preclinical studies and initial clinical testing. The time required to obtain approval by the FDA and similar foreign authorities is unpredictable but typically takes many years following the commencement of clinical trials, depending upon numerous factors. In addition, approval policies, regulations, or the type and amount of clinical data necessary to gain approval may change. We have not obtained regulatory approval for any human-use products.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our products could fail to complete the clinical trial process for many reasons, including the following:</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may be unable to demonstrate to the satisfaction of the FDA or comparable foreign regulatory authorities that our electroporation equipment or product candidate is safe and effective for any indication; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the results of clinical trials may not meet the level of statistical significance required by the FDA or comparable foreign regulatory authorities for approval; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the FDA or comparable foreign regulatory authorities may disagree with the design or implementation of our clinical trials; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may not be successful in enrolling a sufficient number of participants in clinical trials; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may be unable to demonstrate that our electroporation equipment or product candidates' clinical and other benefits outweigh its safety risks; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may be unable to demonstrate that our electroporation equipment or product candidate presents an advantage over existing therapies, or over placebo in any indications for which the FDA requires a placebo-controlled trial; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the FDA or comparable foreign regulatory authorities may disagree with our interpretation of data from preclinical studies or clinical trials; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the data collected from clinical trials of our product candidates may not be sufficient to support the submission of a new drug application or other submission or to obtain regulatory approval in the United States or elsewhere; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the FDA or comparable foreign regulatory authorities may fail to approve the manufacturing processes or facilities of us or third-party manufacturers with which we or our collaborators contract for clinical and commercial supplies; and </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the approval policies or regulations of the FDA or comparable foreign regulatory authorities may significantly change in a manner rendering our clinical data insufficient for approval. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our product candidates are combination products regulated under both the biologic and device regulations of the Public Health Service Act and Federal Food, Drug, and Cosmetic Act. Third-party manufacturers may not be able to comply with cGMP regulations, regulations applicable to biologic/device combination products, including applicable provisions of the FDA&#8217;s drug cGMP regulations, device cGMP requirements embodied in the QSR or similar regulatory requirements outside the United States. Our failure, or the failure of our third-party manufacturers, to comply with applicable regulations could result in sanctions being imposed on us, including clinical holds, fines, injunctions, civil penalties, delays, suspension or withdrawal of approvals, license revocation, seizures or recalls of product candidates, operating restrictions and criminal prosecutions, any of which could significantly affect supplies of our product candidates. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Clinical trials may also be delayed as a result of ambiguous or negative interim results. In addition, a clinical trial may be suspended or terminated by us, the FDA, the IRB overseeing the clinical trial at issue, any of our clinical trial sites with respect to that site, or other regulatory authorities due to a number of factors, including: </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">failure to conduct the clinical trial in accordance with regulatory requirements or our clinical protocols; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">inspection of the clinical trial operations or trial sites by the FDA or other regulatory authorities resulting in the imposition of a clinical hold; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">unforeseen safety issues; and </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">lack of adequate funding to continue the clinical trial. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we experience delays in completion of, or if we terminate, any of our clinical trials, the commercial prospects for our electroporation equipment and our product candidates may be harmed and our ability to generate product revenues will be delayed. In addition, many of the factors that cause, or lead to, a delay in the commencement or completion of clinical trials may also ultimately lead to the denial of regulatory approval of a product candidate. Further, delays in the commencement or completion of clinical trials may adversely affect the trading price of our common stock.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Delays in the commencement or completion of clinical testing could result in increased costs to us and delay or limit our ability to generate revenues.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Delays in the commencement or completion of clinical testing could significantly affect our product development costs. We do not know whether planned clinical trials will begin on time or be completed on schedule, if at all. In addition, ongoing clinical trials may not be completed on schedule, or at all, and could be placed on a hold by the regulators for various reasons. The commencement and completion of clinical trials can be delayed for a number of reasons, including delays related to:</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">obtaining regulatory approval to commence a clinical trial;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">adverse results from third party clinical trials involving gene-based therapies and the regulatory response thereto;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">reaching agreement on acceptable terms with prospective CROs and trial sites, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and trial sites;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">future bans or stricter standards imposed on clinical trials of gene-based therapy;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">manufacturing sufficient quantities of our electroporation equipment and product candidates for use in clinical trials;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">obtaining institutional review board, or IRB, approval to conduct a clinical trial at a prospective site;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">slower than expected recruitment and enrollment of patients to participate in clinical trials for a variety of reasons, including competition from other clinical trial programs for similar indications;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">conducting clinical trials with sites internationally due to regulatory approvals and meeting international standards;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">retaining patients who have initiated a clinical trial but may be prone to withdraw due to side effects from the therapy, lack of efficacy or personal issues, or who are lost to further follow-up;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">collecting, reviewing and analyzing our clinical trial data; and</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">global unrest, global pathogen outbreaks or pandemics, terrorist activities, and economic and other external factors.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Clinical trials may also be delayed as a result of ambiguous or negative interim results. In addition, a clinical trial may be suspended or terminated by us, the FDA, the IRB overseeing the clinical trial at issue, any of our clinical trial sites with respect to that site, or other regulatory authorities due to a number of factors, including:</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">failure to conduct the clinical trial in accordance with regulatory requirements or our clinical protocols;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">inspection of the clinical trial operations or trial sites by the FDA or other regulatory authorities resulting in the imposition of a clinical hold;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">unforeseen safety issues; and</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">lack of adequate funding to continue the clinical trial.</span></div><div style="margin-top:5pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we experience delays in completion of, or if we terminate, any of our clinical trials, the commercial prospects for our electroporation equipment and our product candidates may be harmed and our ability to generate product revenues will be delayed. In addition, many of the factors that cause, or lead to, a delay in the commencement or completion of clinical trials may also ultimately lead to the denial of regulatory approval of a product candidate. Further, delays in the commencement or completion of clinical trials may adversely affect the trading price of our common stock.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">None of our human vaccine candidates, including INO-4800, or our immunotherapy and DNA encoded monoclonal antibody product candidates have been approved for sale, and we may never develop commercially successful vaccine, immunotherapy or DNA encoded monoclonal antibody products.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our human vaccine programs, which includes our COVID-19 vaccine candidate INO-4800, our immunotherapy programs and our DNA encoded monoclonal antibodies program are in various stages of research and development, and currently include product candidates in discovery, preclinical studies and Phase 1, 2 and 3 clinical trials. There are limited data regarding the efficacy of synthetic vaccine candidates and immunotherapy candidates compared with conventional vaccines, and we must conduct a substantial amount of additional research and development before the FDA or any comparable foreign regulatory authority will approve any of our vaccine product candidates, including INO-4800. The success of our efforts to develop and commercialize our product candidates, including INO-4800, could be delayed or fail for a number of reasons. For example, we could experience delays in product development and clinical trials. Our product candidates could be found to be ineffective or unsafe, or otherwise fail to receive necessary regulatory clearances to proceed with further clinical development or to be approved for marketing. Our products, even if they are deemed to be safe and effective by regulatory authorities, could be difficult to manufacture on a large scale or uneconomical to market, or our competitors could develop superior products more quickly and efficiently or more effectively market their competing products. The ability to manufacture sufficient quantities of INO-4800 on a large scale is particularly challenging and will require substantial resources and the engagement of third parties, which we may not be able to obtain on a timely basis, or at all.  </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, adverse events, or the perception of adverse events, relating to vaccine and immunotherapy candidates and delivery technologies may negatively impact our ability to develop commercially successful products. For example, pharmaceutical companies have been subject to claims that the use of some pediatric vaccines has caused personal injuries, including brain damage, central nervous system damage and autism. These and other claims may influence public perception of the use of vaccine and immunotherapy products and could result in greater governmental regulation, stricter labeling requirements and potential regulatory delays in the testing or approval of our potential products.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Our planned clinical development of INO-4800 as a potential COVID-19 vaccine has been placed on partial clinical hold by the FDA, which may cause delays in the commencement of our planned Phase 3 clinical trial or completion of clinical testing, both of which could result in increased costs to us and delay or limit our ability to proceed to commercialization and generate revenues.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our planned clinical development of INO-4800 as a potential COVID-19 vaccine has been placed on partial clinical hold by the FDA. We may not commence our planned Phase 3 clinical trial of INO-4800 until we satisfactorily resolve the FDA&#8217;s remaining questions relating to our CELLECTRA 2000 delivery device to be used in connection with INO-4800 in our Phase 3 clinical trials and commercial product, if authorized or licensed by FDA. We are actively working to address the FDA&#8217;s questions. There can be no assurance regarding the timing of the FDA&#8217;s agreement to lift the partial clinical hold or that we will ultimately be successful in obtaining any such determination from the FDA to do so.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Delays in the commencement of our Phase 3 trial or completion of ongoing clinical testing for INO-4800 could significantly affect our product development costs. We do not know whether our planned Phase 3 clinical trial will begin on time or be completed on schedule, if at all. In addition, our ongoing clinical trials for INO-4800 may not be completed on schedule, or at all, and could be placed on additional holds by regulators for reasons unrelated to our current hold. Our Phase 3 trial for INO-4800 will require interim data results at various points throughout the trial. Our clinical trials may therefore also be delayed as a result of ambiguous or negative interim results. Even if our interim results related to our INO-4800 are positive, there can be no assurance that our topline results will be consistent with the interim results. If we experience delays in completion of, or if we terminate, any of our clinical trials relating to INO-4800, the commercial prospects for our product candidate may be harmed and our ability to generate product revenues will be delayed. In addition, many of the factors that cause, or lead to, a delay in the commencement or completion of clinical trials may also ultimately lead to the denial of regulatory approval of a product candidate. Further, delays in the commencement or completion of clinical trials may adversely affect the trading price of our common stock.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Newly emerging SARS-CoV-2 variants could reduce the immunogenicity and effectiveness of INO-4800 as a potential COVID-19 vaccine.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Multiple variants of the virus that causes COVID-19 have been documented in the United States and globally during this pandemic. The new SARS-CoV-2 variants could be less affected by the immune responses generated by INO-4800 in the vaccine recipients and therefore could reduce the overall efficacy of the vaccine in controlling severe COVID-19 disease.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">There can be no assurance that the product we are developing for COVID-19 would be granted an Emergency Use Authorization by the FDA or similar authorization by regulatory authorities outside of the United States if we were to decide to apply for such an authorization. If we do not apply for such an authorization or, if we do apply and no authorization is granted or, once granted, it is terminated, we will be unable to sell our product in the near future and instead, will be required to pursue the biologic licensure process in order to sell our product, which is lengthy and expensive.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may seek an Emergency Use Authorization, or EUA, from the FDA or similar authorization from regulatory authorities outside of the United States, such as conditional marketing authorization from the EMA. If we apply for an EUA and it is granted, an EUA will authorize us to market and sell our COVID-19 vaccine under certain conditions of authorization as long as the public health emergency exists. The FDA expects that companies which receive an EUA for COVID-19 vaccines will proceed to licensure of their vaccine products under a full Biologics License Application. The FDA may issue an EUA during a Public Health Emergency if the agency determines that the potential benefits of a product outweigh the potential risks and if other regulatory criteria are met. There is no guarantee that we will apply for an EUA or other similar authorization or, if we do apply, that we will be able to obtain such authorization. If an EUA or other authorization is granted, we will rely on the FDA or other applicable regulatory authority policies and guidance governing vaccines authorized in this manner in connection with the marketing and sale of our product. If these policies and guidance change unexpectedly and/or materially or if we misinterpret them, potential sales of our product could be adversely impacted. An EUA authorizing the marketing and sale of our product will terminate upon expiration of the Public Health Emergency, which is a determination made by the Secretary of Health and Human Services. The FDA may also terminate an EUA if safety issues or other concerns about our product arise or if we fail to comply with the conditions of authorization. If we apply for an EUA or similar authorization from regulatory authorities outside of the United States, the failure to obtain such authorization or the termination of such an authorization, if obtained, would adversely impact our ability to market and sell our COVID-19 vaccine, which could adversely impact our business, financial condition and results of operations.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we and the contract manufacturers upon whom we rely fail to produce our electroporation devices and product candidates in the volumes that we require on a timely basis, or at all, or fail to comply with their obligations to us or with stringent regulations, we may face delays in the development and commercialization of our electroporation equipment and product candidates.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We manufacture some components of our electroporation devices and utilize the services of contract manufacturers to manufacture the remaining components of these devices. We also rely on third party contract manufacturers to produce our product candidates for use in our clinical trials and potentially for commercial distribution, if any product candidate is approved by regulatory authorities. The manufacture of these devices and our product candidates requires significant expertise and capital investment, including the development of advanced manufacturing techniques and process controls. Manufacturers often encounter difficulties in production, particularly in scaling up for commercial production. These problems include difficulties with production costs and yields, quality control, including stability of the equipment and product candidates and quality </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">assurance testing, shortages of qualified personnel, as well as compliance with strictly enforced federal, state and foreign regulations. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we or our manufacturers were to encounter any of these difficulties or our manufacturers otherwise fail to comply with their obligations to us, our ability to provide our electroporation equipment to our partners and to supply product candidates for clinical trials or to commercially launch a product would be jeopardized. For example, we previously relied on VGXI to manufacture DNA plasmids for our product candidates, including INO-4800. In 2020, VGXI notified us that they would be unable to produce the necessary plasmids to meet this timeline due to a lack of manufacturing capacity. As a result, we have engaged several additional third-party contract manufacturers to support the planned large-scale manufacturing of INO-4800. However, there can be no assurance that we will be able to secure adequate additional manufacturing capacity on commercially reasonable terms. Our inability to secured sufficient manufacturing capacity, or our inability to transfer necessary manufacturing know-how to third parties, would adversely affect our commercialization plans and could also harm our reputation.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">    </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, any delay or interruption in the supply of clinical trial supplies for INO-4800 or any of our other product candidates could delay the completion of our clinical trials, increase the costs associated with maintaining our clinical trial program and, depending upon the period of delay, require us to commence new trials at significant additional expense or terminate the trials completely. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, all manufacturers of our products must comply with cGMP requirements enforced by the FDA through its facilities inspection program. These requirements include, among other things, quality control, quality assurance and the generation and maintenance of records and documentation. Manufacturers of our products may be unable to comply with these cGMP requirements and with other FDA, state and foreign regulatory requirements. We have little control over our manufacturers' compliance with these regulations and standards. A failure to comply with these requirements may result in fines and civil penalties, suspension of production, suspension or delay in product approval, product seizure or recall, or withdrawal of product approval. If the safety of any product is compromised due to our or our manufacturers' failure to adhere to applicable laws or for other reasons, we may not be able to obtain regulatory approval for or successfully commercialize our products, and we may be held liable for any injuries sustained as a result. Any of these factors could cause a delay of clinical trials, regulatory submissions, approvals or commercialization of our products, entail higher costs or result in our being unable to effectively commercialize our products. Furthermore, if our manufacturers fail to deliver the required commercial quantities on a timely basis, pursuant to provided specifications and at commercially reasonable prices, we may be unable to meet demand for our products and would lose potential revenues.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Even if our products receive regulatory approval, they may still face future development and regulatory difficulties.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if United States regulatory approval is obtained, the FDA may still impose significant restrictions on a product's indicated uses or marketing or impose ongoing requirements for potentially costly post-approval studies. This governmental oversight may be particularly strict with respect to gene-based therapies. Our products will also be subject to ongoing FDA requirements governing the labeling, packaging, storage, advertising, promotion, record keeping and submission of safety and other post-market information. For example, the FDA strictly regulates the promotional claims that may be made about medical products. In particular, a product may not be promoted for uses that are not approved by the FDA as reflected in the product&#8217;s approved labeling. Physicians, on the other hand, may prescribe products for off-label uses. Although the FDA and other regulatory agencies do not regulate a physician&#8217;s choice of drug treatment made in the physician&#8217;s independent medical judgment, they do restrict promotional communications from companies or their sales force with respect to off-label uses of products for which marketing clearance has not been issued. However, companies may in certain circumstances share truthful and not misleading information that is otherwise consistent with the product&#8217;s FDA approved labeling. In addition, manufacturers of drug products and their facilities are subject to continual review and periodic inspections by the FDA and other regulatory authorities for compliance with current good manufacturing practices, or cGMP, regulations. If we or a regulatory agency discover previously unknown problems with a product, such as adverse events of unanticipated severity or frequency, or problems with the facility where the product is manufactured, a regulatory agency may impose restrictions on that product, the manufacturer or us, including requiring withdrawal of the product from the market or suspension of manufacturing. If we, our product candidates or the manufacturing facilities for our product candidates fail to comply with applicable regulatory requirements, a regulatory agency may: </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">issue Warning Letters or untitled letters; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">impose civil or criminal penalties; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">suspend regulatory approval; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">suspend any ongoing clinical trials; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">refuse to approve pending applications or supplements to applications filed by us; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">impose restrictions on operations, including costly new manufacturing requirements; or </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">seize or detain products or require us to initiate a product recall. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Even if our products receive regulatory approval in the United States, we may never receive approval or commercialize our products outside of the United States.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to market any electroporation equipment and product candidates outside of the United States, we must establish and comply with numerous and varying regulatory requirements of other countries regarding safety and efficacy. Approval procedures vary among countries and can involve additional product testing and additional administrative review periods. The time required to obtain approval in other countries might differ from that required to obtain FDA approval. The regulatory approval process in other countries may include all of the risks detailed above regarding FDA approval in the United States as well as other risks. Regulatory approval in one country does not ensure regulatory approval in another, but a failure or delay in obtaining regulatory approval in one country may have a negative effect on the regulatory process in others. Failure to obtain regulatory approval in other countries or any delay or setback in obtaining such approval could have the same adverse effects detailed above regarding FDA approval in the United States. Such effects include the risks that our product candidates may not be approved for all indications requested, which could limit the uses of our product candidates and have an adverse effect on their commercial potential or require costly, post-marketing follow-up studies. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have obtained Orphan Drug Designation for one of our product candidates. As part of our business strategy, we may continue to seek Orphan Drug Designation for additional product candidates, and we may be unsuccessful in obtaining new designations or may be unable to obtain or maintain the benefits associated with Orphan Drug Designation, including the potential for orphan drug exclusivity.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have obtained Orphan Drug Designation from the FDA for INO-3107 for the treatment of for the treatment of recurrent respiratory papillomatosis. We have sought and may continue to seek Orphan Drug Designation for one or more of our other product candidates, including but not limited to VGX-3100 for the treatment of HPV-16-/18-associated anal dysplasia, although we may be unsuccessful in doing so. Regulatory authorities in some jurisdictions, including the United States and Europe, may designate drugs for relatively small patient populations as orphan drugs. Under the Orphan Drug Act, the FDA may designate a drug as an orphan drug if it is a drug intended to treat a rare disease or condition, which is generally defined as a patient population of fewer than 200,000 individuals in the United States, or a patient population greater than 200,000 in the United States where there is no reasonable expectation that the cost of developing the drug will be recovered from sales in the United States. In the United States, Orphan Drug Designation entitles a party to financial incentives such as tax advantages and user fee waivers. Opportunities for grant funding toward clinical trial costs may also be available for clinical trials of drugs for rare diseases, regardless of whether the drugs are designated for the orphan use. In addition, if a product that has Orphan Drug Designation subsequently receives the first FDA approval for the disease for which it has such designation, the product is entitled to orphan drug exclusivity, which means that the FDA may not approve any other applications to market the same product for the same indication for seven years, except in limited circumstances. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we have obtained Orphan Drug Designation for INO-3107 for the treatment of for the treatment of recurrent respiratory papillomatosis, and even if we obtain Orphan Drug Designation for our other product candidates in specific indications, we may not be the first to obtain marketing approval of these product candidates for the orphan-designated indication due to the uncertainties associated with developing pharmaceutical products. If a competitor with a product that is determined by the FDA to be the same as one of our product candidates obtains marketing approval before us for the same indication we are pursuing and obtains orphan drug exclusivity, our product candidate may not be approved until the period of exclusivity ends unless we are able to demonstrate that our product candidate is clinically superior. Even after obtaining approval, we may be limited in our ability to market our product. In addition, exclusive marketing rights in the United States may be limited if we seek approval for an indication broader than the orphan-designated indication or may be lost if the FDA later determines that the request for designation was materially defective or if the manufacturer is unable to assure sufficient quantities of the product to meet the needs of patients with the rare disease or condition. Further, even if we obtain orphan drug exclusivity for a product, that exclusivity may not effectively protect the product from competition because different drugs with different principal molecular structural features can be approved for the same condition. Even after an orphan product is approved, the FDA can subsequently approve the same drug with the same principal molecular structural features for the same condition if the FDA concludes that the later drug is safer, more effective or makes a major contribution to patient care. Orphan Drug Designation neither shortens the development time or regulatory review time of a drug nor gives the drug any advantage in the regulatory review or approval process. In addition, while we may seek Orphan Drug Designation for some of our product candidates, we may never receive such designations. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Tax reform legislation enacted in 2017 reduced the amount of the qualified clinical research costs for a designated orphan product that a sponsor may claim as a credit from 50% to 25%. This reduction could further limit the advantage of, and may impact our future business strategy with respect to, seeking the Orphan Drug Designation.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Reliance on Third Parties</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we lose or are unable to secure collaborators or partners, or if our collaborators or partners do not apply adequate resources to their relationships with us, our product development and potential for profitability will suffer. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have entered into, and may continue to enter into, distribution, co-promotion, partnership, sponsored research and other arrangements for development, manufacturing, sales, marketing and other commercialization activities relating to our products. For example, in the past we have entered into license and collaboration agreements to develop, obtain regulatory approval for and commercialize our product candidates for specified indications, including in jurisdictions outside of the United States. The amount and timing of resources applied by our collaborators are largely outside of our control. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any of our current or future collaborators breaches or terminates our agreements, or fails to conduct our collaborative activities in a timely manner, our commercialization of products could be diminished or blocked completely. We may not receive any event-based payments, milestone payments or royalty payments under our collaborative agreements if our collaborative partners fail to develop products in a timely manner or at all. It is possible that collaborators will change their strategic focus, pursue alternative technologies or develop alternative products, either on their own or in collaboration with others. Further, we may be forced to fund programs that were previously funded by our collaborators, and we may not have, or be able to access, the necessary funding. The effectiveness of our partners, if any, in marketing our products will also affect our revenues and earnings.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We desire to enter into new collaborative agreements. However, we may not be able to successfully negotiate any additional collaborative arrangements and, if established, these relationships may not be scientifically or commercially successful. Our success in the future depends in part on our ability to enter into agreements with other highly-regarded organizations. This can be difficult due to internal and external constraints placed on these organizations. Some organizations may have insufficient administrative and related infrastructure to enable collaborations with many companies at once, which can extend the time it takes to develop, negotiate and implement a collaboration. Once news of discussions regarding possible collaborations are known in the medical community, regardless of whether the news is accurate, failure to announce a collaborative agreement or the entity's announcement of a collaboration with another entity may result in adverse speculation about us, resulting in harm to our reputation and our business. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Disputes could also arise between us and our existing or future collaborators, as to a variety of matters, including financial and intellectual property matters or other obligations under our agreements. These disputes could be both expensive and time-consuming and may result in delays in the development and commercialization of our products or could damage our relationship with a collaborator. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">A small number of licensing partners and government contracts account for a substantial portion of our revenue. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently derive, and in the past we have derived, a significant portion of our revenue from a limited number of licensing partners and government grants and contracts. Revenue can fluctuate significantly depending on the timing of upfront and event-based payments and work performed. If we fail to sign additional future contracts with major licensing partners and the government, if a contract is delayed or deferred, or if an existing contract expires or is canceled and we fail to replace the contract with new business, our revenue would be adversely affected. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have agreements with government agencies, which are subject to termination and uncertain future funding. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have entered into agreements with government agencies, such as the NIAID, DARPA and the DoD, and we intend to continue entering into these types of agreements in the future. Our business is partially dependent on the continued performance by these government agencies of their responsibilities under these agreements, including adequate continued funding of the agencies and their programs. We have no control over the resources and funding that government agencies may devote to these agreements, which may be subject to annual renewal and which generally may be terminated by the government agencies at any time. For example, in April 2021 we were notified by the DoD that they will discontinue funding for the Phase 3 segment of our INNOVATE trial.  </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Government agencies may fail to perform their responsibilities under these agreements, which may cause them to be terminated by the government agencies. In addition, we may fail to perform our responsibilities under these agreements. Many of our government agreements are subject to audits, which may occur several years after the period to which the audit relates. If an audit identifies significant unallowable costs, we could incur a material charge to our earnings or reduction in our cash position. As a result, we may be unsuccessful entering, or ineligible to enter, into future government agreements. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We and our collaborators rely on third parties to conduct our clinical trials. If these third parties do not successfully carry out their contractual duties or meet expected deadlines, we and our collaborators may not be able to obtain regulatory approval for or commercialize our product candidates.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We and our collaborators have entered into agreements with CROs to provide monitors for and to manage data for our on-going clinical programs. We and the CROs conducting clinical trials for our electroporation equipment and product candidates are required to comply with current good clinical practices, or GCPs, regulations and guidelines enforced by the FDA for all of our products in clinical development. The FDA enforces GCPs through periodic inspections of trial sponsors, principal investigators and trial sites. If we or the CROs conducting clinical trials of our product candidates fail to comply with </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">applicable GCPs, the clinical data generated in the clinical trials may be deemed unreliable and the FDA may require additional clinical trials before approving any marketing applications. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any relationships with CROs terminate, we or our collaborators may not be able to enter into arrangements with alternative CROs. In addition, these third-party CROs are not our employees, and we cannot control whether or not they devote sufficient time and resources to our on-going clinical programs or perform trials efficiently. These CROs may also have relationships with other commercial entities, including our competitors, for whom they may also be conducting clinical studies or other drug development activities, which could harm our competitive position. If CROs do not successfully carry out their contractual duties or obligations or meet expected deadlines, if they need to be replaced, or if the quality or accuracy of the clinical data they obtain is compromised due to the failure to adhere to our clinical protocols, regulatory requirements, or for other reasons, our clinical trials may be extended, delayed or terminated, and we may not be able to obtain regulatory approval for or successfully commercialize our product candidates. As a result, our financial results and the commercial prospects for our product candidates would be harmed, our costs could increase and our ability to generate revenues could be delayed. Cost overruns by or disputes with our CROs may significantly increase our expenses.   </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Commercialization of Our Product Candidates</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We currently have no marketing and sales organization. If we are unable to establish marketing and sales capabilities or enter into agreements with third parties to market and sell our products, we may not be able to generate product revenues.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently do not have a sales organization for the marketing, sales and distribution of our electroporation equipment and product candidates. In order to commercialize any products, we must build our marketing, sales, distribution, managerial and other non-technical capabilities or make arrangements with third parties to perform these services. We contemplate establishing our own sales force or seeking third-party partners to sell our products. The establishment and development of our own sales force to market any products we may develop will be expensive and time consuming and could delay any product launch, and we may not be able to successfully develop this capability. We will also have to compete with other pharmaceutical and biotechnology companies to recruit, hire, train and retain marketing and sales personnel. To the extent we rely on third parties to commercialize our approved products, if any, we will receive lower revenues than if we commercialized these products ourselves. In addition, we may have little or no control over the sales efforts of third parties involved in our commercialization efforts. In the event we are unable to develop our own marketing and sales force or collaborate with a third-party marketing and sales organization, we would not be able to commercialize our product candidates which would negatively impact our ability to generate product revenues. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If products for which we receive regulatory approval do not achieve broad market acceptance, the revenues that we generate from their sales will be limited.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The commercial success of our electroporation equipment and product candidates for which we obtain marketing approval from the FDA or other regulatory authorities will depend upon the acceptance of these products by both the medical community and patient population. Coverage and reimbursement of our product candidates by third-party payors, including government payors, generally is also necessary for optimal commercial success. The degree of market acceptance of any of our approved products will depend on a number of factors, including: </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to provide acceptable evidence of safety and efficacy; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the relative convenience and ease of administration; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the prevalence and severity of any actual or perceived adverse side effects; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">limitations or warnings contained in a product's FDA-approved labeling, including, for example, potential &#8220;black box&#8221; warnings </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">availability of alternative treatments; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">pricing and cost effectiveness; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the effectiveness of our or any future collaborators' sales and marketing strategies; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the public perception of new therapies and the reputational challenges that the vaccine industry is facing related to the growing momentum of the anti-vaccine movement, including with respect to COVID-19 vaccines;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to obtain sufficient third-party coverage and adequate reimbursement; and </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the willingness of patients to pay out of pocket in the absence of third-party coverage. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If our electroporation equipment and product candidates are approved but do not achieve an adequate level of acceptance by physicians, healthcare payors and patients, we may not generate sufficient revenue from these products, and we may not become or remain profitable. In addition, our efforts to educate the medical community and third-party payors on the benefits of our product candidates may require significant resources and may never be successful. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are subject to uncertainty relating to coverage and reimbursement policies which, if not favorable to our product candidates, could hinder or prevent our products' commercial success. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patients in the United States and elsewhere generally rely on third-party payors to reimburse part or all of the costs associated with their prescription drugs and medical treatments. Accordingly, our ability to commercialize our electroporation equipment and product candidates successfully will depend in part on the extent to which governmental authorities, including Medicare and Medicaid, private health insurers and other third-party payors establish appropriate coverage and reimbursement levels for our product candidates and related treatments. As a threshold for coverage and reimbursement, third-party payors generally require that drug products have been approved for marketing by the FDA. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant uncertainty exists as to the coverage and reimbursement status of any products for which we may obtain regulatory approval. Coverage decisions may not favor new products when more established or lower cost therapeutic alternatives are already available. Even if we obtain coverage for a given product, the associated reimbursement rate may not be adequate to cover our costs, including research, development, intellectual property, manufacture, sale and distribution expenses, or may require co-payments that patients find unacceptably high. Patients are unlikely to use our products unless reimbursement is adequate to cover all or a significant portion of the cost of our drug products.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, some of our products, if approved, will be provided under the supervision of a physician. When used in connection with medical procedures, our product candidates may not be reimbursed separately but their cost may instead be bundled as part of the payment received by the provider for the procedure only. Separate reimbursement for the product itself or the treatment or procedure in which our product is used may not be available. A decision by a third-party payor not to cover or separately reimburse for our product candidates or procedures using our product candidates, could reduce physician utilization of our products once approved.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Coverage and reimbursement policies for drug products can differ significantly from payor to payor as there is no uniform policy of coverage and reimbursement for drug products among third-party payors in the United States. There may be significant delays in obtaining coverage and reimbursement as the process of determining coverage and reimbursement is often time consuming and costly which will require us to provide scientific and clinical support for the use of our products to each payor separately, with no assurance that coverage or adequate reimbursement will be obtained. It is difficult to predict at this time what government authorities and third-party payors will decide with respect to coverage and reimbursement for our products.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A significant trend in the U.S. healthcare industry and elsewhere is cost containment. Third-party payors have attempted to control costs by limiting coverage and the amount of reimbursement for particular products and services. Third-party payors are increasingly challenging the effectiveness of and prices charged for medical products and services. Moreover, the U.S. government, state legislatures and foreign governmental entities have shown significant interest in implementing cost containment programs to limit the growth of government paid healthcare costs, including price controls, restrictions on reimbursement and coverage and requirements for substitution of generic products for branded prescription drugs. We may not be able to obtain third-party payor coverage or reimbursement for our products in whole or in part.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Managing Our Growth and Employee and Operational Matters</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are currently subject to litigation and may become subject to additional litigation, which could harm our business, financial condition and reputation.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may have actions brought against us by stockholders relating to past transactions, changes in our stock price or other matters. For example, during 2020, numerous purported shareholder class action complaints have been filed against us, naming us and our directors and executive officers as defendants, and alleging that we made materially false and misleading statements regarding the development of our INO-4800 vaccine candidate against COVID-19 in violation of certain federal securities laws. We may also become party to litigation with third parties as a result of our business activities. In 2020, we filed a lawsuit against one of our contract manufacturers, who then filed a counterclaim against us alleging that we had breached our contract with them, among other claims. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These litigation matters, described in this report, are ongoing, and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">even though we intend to vigorously defend ourselves in these actions, there can be no assurance that we will ultimately prevail. These and any potential future actions against us could give rise to substantial damages, which could have a material adverse effect on our financial position, liquidity or results of operations. Even if an action is not resolved against us, the uncertainty and expense associated with litigation could harm our business, financial condition and reputation, as litigation is often costly, time-consuming and disruptive to business operations. The defense of our existing and potential future lawsuits could also result in diversion of our management's time and attention away from business operations, which could harm our business.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our business could be adversely affected by the effects of health epidemics, including the global COVID-19 pandemic.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, a novel strain of coronavirus, since named SARS-CoV-2, causing the disease known as COVID-19, was reported in China. Since then, COVID-19 has spread globally, resulting in the World Health Organization (WHO) declaring the outbreak of COVID-19 as a &#8220;pandemic&#8221; in March 2020 and United States also declaring a national emergency. In response to the COVID-19 pandemic, a number of governmental orders and other public health guidance measures were implemented across much of the United States, including in the locations of our offices, laboratories, clinical trial sites and third parties on whom we rely. As a result, our expected clinical development timelines could be negatively affected by COVID-19, </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">which could then materially and adversely affect our business, financial condition and results of operations. Further, we have implemented a work from home policy allowing employees who can work from home to do so, while those needing to work in laboratory facilities work in shifts to reduce the number of people gathered together at one time. Business travel has been suspended and online and teleconference technology is used to meet virtually rather than in person. We have taken measures to secure our research and development project activities, while work in laboratories has been organized to reduce risk of COVID-19 transmission. Our increased reliance on personnel working from home may negatively impact our productivity, or could disrupt, delay or otherwise adversely impact our business. For example, with our personnel working from home, some of our research activities that require our personnel to be in our laboratories could be delayed.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, as local jurisdictions continue to put restrictions in place, our ability to continue to conduct and enroll patients in our clinical trials, manufacture our product candidates and pursue collaborations may also be limited. Such events may result in business and manufacturing disruption, and in reduced operations, any of which could materially affect our business, financial condition and results of operations.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The spread of COVID-19, which has caused a broad impact globally, could also affect us economically. While the potential economic impact brought by, and the duration of, COVID-19 may be difficult to assess or predict, it has resulted in significant disruption of global financial markets, which could reduce our ability to access capital. Although we have raised significant funds from the sale of our common stock in the public markets during the pandemic, there can be no guarantee that we will be able to continue to so, which could negative affect our future liquidity. In addition, if a global economic recession results following the spread of COVID-19, its impact could materially affect our business and the value of our common stock.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The continued spread of COVID-19 globally has and could continue to adversely affect our clinical trial operations, including our ability to initiate and conduct our planned trials on their expected timelines and to recruit and retain patients and principal investigators and site staff who, as healthcare providers, may have heightened exposure to COVID-19 if an outbreak occurs in their geography. For example, COVID-19 has adversely impacted the timeline for data collection for our VGX-3100 program. An increasing number of trial participants are either not able or do not feel safe going into healthcare facilities, which is necessary for the collection and completion of data samples for this trial. These concerns are magnified by increasing COVID-19 infection rates, surges in cases globally, and lockdowns now occurring in Europe. As a result, it is taking longer than anticipated to complete the data collection process. Further, the COVID-19 outbreak could result in delays in our clinical trials due to prioritization of hospital resources toward the outbreak, restrictions in travel, potential unwillingness of patients to enroll in trials, patients withdrawing from trials following enrollment as a result of contracting COVID-19 or other health conditions, or the inability of patients to comply with clinical trial protocols as quarantines and travel restrictions impede patient movement or interrupt healthcare services. In addition, we rely on independent clinical investigators, contract research organizations and other third-party service providers to assist us in managing, monitoring and otherwise carrying out our preclinical studies and clinical trials, and the outbreak may affect their ability to devote sufficient time and resources to our programs or to travel to sites to perform work for us. These restrictions may delay the conduct of multiple clinical trials including our Phase 1 through 3 clinical trials.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, COVID-19 may also result in delays in receiving approvals from local and foreign regulatory authorities, delays in necessary interactions with local and foreign regulators, ethics committees and other important agencies and contractors due to limitations in employee resources or forced furlough of government employees, and refusals to accept data from clinical trials conducted in these affected geographies.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The global outbreak of COVID-19 continues to rapidly evolve. The extent to which COVID-19 may impact our business, operations and clinical trials will depend on future developments, including travel restrictions and social distancing in the United States and other countries, the effectiveness of actions taken in the United States and other countries to contain and treat the disease, including mass vaccination efforts, and whether the United States and additional countries are required to move to complete lock-down status. The ultimate long-term impact of COVID-19 is highly uncertain.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We face intense and increasing competition and many of our competitors have significantly greater resources and experience. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any of our competitors develop products with efficacy or safety profiles significantly better than our products, we may not be able to commercialize our products, and sales of any of our commercialized products could be harmed. Some of our competitors and potential competitors have substantially greater product development capabilities and financial, scientific, marketing and human resources than we do. Competitors may develop products earlier, obtain FDA approvals for products more rapidly, or develop products that are more effective than those under development by us. We will seek to expand our technological capabilities to remain competitive; however, research and development by others may render our technologies or products obsolete or noncompetitive, or result in treatments or cures superior to ours.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many other companies are pursuing other forms of treatment or prevention for diseases that we target. For example, many of our competitors are working on developing and testing COVID-19 vaccines, cancer vaccines and immunotherapies, and several products such as the CAR-Ts developed by our competitors have been approved for human use. Some of our </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">competitors have already received regulatory approval for their COVID-19 vaccines and have mass vaccination efforts underway in our target markets. The earlier market entry of these other vaccines, and their actual or perceived efficacious or success relative to our own, has led to and may continue to lead to diversion of funding away from us, decreased demand for INO-4800, if approved, and difficulty in finding participants for our clinical trials. All of these factors could substantially impact our ability to complete the development of, commercialize and generate revenues from INO-4800. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, our competitors and potential competitors include large pharmaceutical and more established biotechnology companies. These companies have significantly greater financial and other resources and greater expertise than us in research and development, securing government contracts and grants to support research and development efforts, manufacturing, preclinical and clinical testing, obtaining regulatory approvals and marketing. This may make it easier for them to respond more quickly than us to new or changing opportunities, technologies or market needs. Many of these competitors operate large, well-funded research and development programs and have significant products approved or in development. Small companies may also prove to be significant competitors, particularly through collaborative arrangements with large pharmaceutical companies or through acquisition or development of intellectual property rights. Our potential competitors also include academic institutions, governmental agencies and other public and private research organizations that conduct research, seek patent protection and establish collaborative arrangements for product and clinical development and marketing. Research and development by others may seek to render our technologies or products obsolete or noncompetitive.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our failure to successfully acquire, develop and market additional product candidates or approved products would impair our ability to grow.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may acquire, in-license, develop and/or market additional products and product candidates. The success of these actions depends partly upon our ability to identify, select and acquire promising product candidates and products. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The process of proposing, negotiating and implementing a license or acquisition of a product candidate or approved product is lengthy and complex. Other companies, including some with substantially greater financial, marketing and sales resources, may compete with us for the license or acquisition of product candidates and approved products. We have limited resources to identify and execute the acquisition or in-licensing of third-party products, businesses and technologies and integrate them into our current infrastructure. Moreover, we may devote resources to potential acquisitions or in-licensing opportunities that are never completed, or we may fail to realize the anticipated benefits of such efforts. We may not be able to acquire the rights to additional product candidates on terms that we find acceptable, or at all. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, future acquisitions may entail numerous operational and financial risks, including: </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">exposure to unknown liabilities; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">disruption of our business and diversion of our management's time and attention to develop acquired products or technologies; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">incurrence of substantial debt or dilutive issuances of securities to pay for acquisitions; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">higher than expected acquisition and integration costs; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">increased amortization expenses; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">difficulty and cost in combining the operations and personnel of any acquired businesses with our operations and personnel; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">impairment of relationships with key suppliers or customers of any acquired businesses due to changes in management and ownership; and </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">inability to retain key employees of any acquired businesses. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, any product candidate that we acquire may require additional development efforts prior to commercial sale, including extensive clinical testing and approval by the FDA and applicable foreign regulatory authorities. All product candidates are prone to risks of failure typical of product development, including the possibility that a product candidate will not be shown to be sufficiently safe and effective for approval by regulatory authorities. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We depend upon key personnel who may terminate their employment with us at any time and we may need to hire additional qualified personnel in order to obtain financing, pursue collaborations or develop or market our product candidates. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The success of our business strategy will depend to a significant degree upon the continued services of key management, technical and scientific personnel and our ability to attract and retain additional qualified personnel and managers, including personnel with expertise in clinical trials, government regulation, manufacturing, marketing and other areas. Competition for qualified personnel is intense among companies, academic institutions and other organizations. If we are unable to attract and retain key personnel and advisors, it may negatively affect our ability to successfully develop, test, commercialize and market our products and product candidates. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in funding for the FDA and other government agencies could hinder our ability to hire and retain key leadership and other personnel, or otherwise prevent new products from being developed or commercialized in a timely manner, which could negatively impact our business.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The ability of the FDA to review and approve new products can be affected by a variety of factors, including government budget and funding levels, ability to hire and retain key personnel and accept the payment of user fees, and statutory, regulatory, and policy changes. Average review times at the agency have fluctuated in recent years as a result. In addition, government funding of other government agencies that fund research and development activities is subject to the political process, which is inherently fluid and unpredictable.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Disruptions at the FDA and other agencies may also slow the time necessary for new drugs to be reviewed and/or approved by necessary government agencies, which would adversely affect our business. For example, over the last several years, including for 35 days from December 2018 to January 2019, the U.S. government has shut down several times and certain regulatory agencies, such as the FDA, have had to furlough critical FDA employees and stop critical activities. If a prolonged government shutdown occurs, it could significantly impact the ability of the FDA to timely review and process our regulatory submissions, which could have a material adverse effect on our business.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are dependent on information technology and our systems and infrastructure face certain risks, including from cybersecurity breaches and data leakage.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely to a large extent upon sophisticated information technology systems to operate our businesses, some of which are managed, hosted provided and/or used for third-parties or their vendors. We collect, store and transmit large amounts of confidential information (including personal information and pseudonymized information), and we deploy and operate an array of technical and procedural controls to maintain the confidentiality and integrity of such confidential information. A significant breakdown, invasion, corruption, destruction, interruption, or unavailability of critical information technology systems or infrastructure, by our workforce, others with authorized access to our systems or unauthorized persons could negatively impact operations. Hardware, software, or applications we develop or obtain from third parties may contain defects in design or manufacture or other supply chain problems that could unexpectedly compromise our information and network security. The ever-increasing use and evolution of technology, including cloud-based computing, creates opportunities for the unintentional dissemination or intentional destruction of confidential information stored in our or our third-party providers' systems, portable media or storage devices. We could also experience a business interruption, theft of confidential information or reputational damage from industrial espionage attacks, malware or other cyber-attacks (including ransomware), which may compromise our system infrastructure or lead to data leakage, either internally or at our third-party providers. While we have invested in the protection of data and information technology, there can be no assurance that our efforts will prevent service interruptions or security breaches. Any such interruption or breach of our systems could adversely affect our business operations and/or result in the loss of critical or sensitive confidential information or intellectual property, and could result in financial, legal, business and reputational harm to us. In addition, as the regulatory environment related to information security, data collection and use, and privacy becomes increasingly rigorous, with new and constantly changing requirements applicable to our business, compliance with those requirements could also result in additional costs.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We face potential product liability exposure and, if successful claims are brought against us, we may incur substantial liability.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The use of our electroporation equipment and DNA vaccine, DNA immunotherapy and dMAb candidates in clinical trials and the sale of any products for which we obtain marketing approval expose us to the risk of product liability claims. Product liability claims might be brought against us by consumers, healthcare providers, pharmaceutical companies or others selling or otherwise coming into contact with our products. For example, pharmaceutical companies have been subject to claims that the use of some pediatric vaccines has caused personal injuries, including brain damage, central nervous system damage and autism, and these companies have incurred material costs to defend these claims. If we cannot successfully defend ourselves against product liability claims, we could incur substantial liabilities. In addition, regardless of merit or eventual outcome, product liability claims may result in: </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">decreased demand for our product candidates; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">impairment of our business reputation; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">withdrawal of clinical trial participants; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">costs of related litigation; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">distraction of management's attention from our primary business; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">substantial monetary awards to patients or other claimants; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">loss of revenues; and </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">inability to commercialize our products. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have obtained product liability insurance coverage for our clinical trials, but our insurance coverage may not be sufficient to reimburse us for any expenses or losses we may suffer. Moreover, insurance coverage is becoming increasingly expensive, and, in the future, we may not be able to maintain insurance coverage at a reasonable cost or in sufficient amounts to protect us against losses due to liability. On occasion, large judgments have been awarded in class action lawsuits based on products that had unanticipated side effects. A successful product liability claim or series of claims brought against us could cause our stock price to decline and, if judgments exceed our insurance coverage, could adversely affect our business. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Healthcare reform measures could hinder or prevent our products' commercial success. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In both the United States and certain foreign jurisdictions there have been, and we anticipate there will continue to be, a number of legislative and regulatory changes to the healthcare system that could impact our ability to sell any of our products profitably. In the United States, the federal government enacted healthcare reform legislation, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act, or collectively, the ACA.   Among the ACA&#8217;s provisions of importance to the pharmaceutical industry are that it:</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">imposed an annual excise tax of 2.3% on any entity that manufactures or imports medical devices offered for sale in the United States, with limited exceptions, although the effective rate paid may be lower. However, the 2020 federal spending package permanently eliminated, effective January 1, 2020, this ACA-mandated medical device tax;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">created an annual, nondeductible fee on any entity that manufactures or imports certain specified branded prescription drugs and biologic agents apportioned among these entities according to their market share in some government healthcare programs;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">increased the statutory minimum rebates a manufacturer must pay under the Medicaid Drug Rebate Program, to 23.1% and 13% of the average manufacturer price for most branded and generic drugs, respectively and capped the total rebate amount for innovator drugs at 100% of the Average Manufacturer Price, or AMP;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">created new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for certain drugs and biologics that are inhaled, infused, instilled, implanted or injected;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">expanded eligibility criteria for Medicaid programs by, among other things, allowing states to offer Medicaid coverage to additional individuals and by adding new mandatory eligibility categories for individuals with income at or below 133% of the federal poverty level, thereby potentially increasing manufacturers&#8217; Medicaid rebate liability;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">expanded the entities eligible for discounts under the Public Health program;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">created a new Patient-Centered Outcomes Research Institute to oversee, identify priorities in, and conduct comparative clinical effectiveness research, along with funding for such research; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">established a Center for Medicare &amp; Medicaid Innovation at the Centers for Medicare &amp; Medicaid Services, or CMS, to test innovative payment and service delivery models to lower Medicare and Medicaid spending, potentially including prescription drug spending that began on January 1, 2011; and</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">created a licensure framework for follow on biologic products.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There remain judicial and Congressional challenges to certain aspects of the ACA. While Congress has not passed comprehensive repeal legislation, it has enacted laws that modify certain provisions of the ACA such as removing penalties, starting January 1, 2019, for not complying with the ACA&#8217;s individual mandate to carry qualifying health insurance coverage for all or part of a year. In addition, the 2020 federal spending package permanently eliminated, effective January 1, 2020, the ACA-mandated &#8220;Cadillac&#8221; tax on high-cost employer-sponsored health coverage, and, effective January 1, 2021, also eliminated the health insurer tax. On December 14, 2018, a Texas U.S. District Court Judge ruled that the ACA is unconstitutional in its entirety because the &#8220;individual mandate&#8221; was repealed by Congress as part of the Tax Cuts and Jobs Act of 2017. Additionally, on December 18, 2019, the U.S. Court of Appeals for the 5th Circuit upheld the District Court ruling that the individual mandate was unconstitutional and remanded the case back to the District Court to determine whether the remaining provisions of the ACA are invalid as well. The U.S. Supreme Court is currently reviewing the case, although it is unknown when a decision will be made. Further, although the U.S. Supreme Court has not yet ruled on the constitutionality of the ACA, on January 28, 2021, President Biden issued an executive order to initiate a special enrollment period from February 15, 2021 through May 15, 2021 for purposes of obtaining health insurance coverage through the ACA marketplace. The executive order also instructs certain governmental agencies to review and reconsider their existing policies and rules that limit access to healthcare, including among others, reexamining Medicaid demonstration projects and waiver programs that include work requirements, and policies that create unnecessary barriers to obtaining access to health insurance coverage through Medicaid or the ACA. It is unclear how the Supreme Court ruling, other such litigation, and the healthcare reform measures of the Biden administration will impact the ACA and our business.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, other legislative changes have been proposed and adopted since the ACA was enacted. On August 2, 2011, the Budget Control Act of 2011 was signed into law, which, among other things, included reductions to Medicare payments to providers of 2% per fiscal year, which went into effect on April 1, 2013 and, due to subsequent legislative amendments to the statute will remain in effect through 2030 with the exception of a temporary suspension from May 1, 2020 through March 31, </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2021 unless additional Congressional action is taken. On January 2, 2013, the American Taxpayer Relief Act of 2012 was signed into law, which, among other things, reduced Medicare payments to several providers, including hospitals, and increased the statute of limitations period for the government to recover overpayments to providers from three to five years.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further there has been heightened governmental scrutiny in the United States of pharmaceutical pricing practices in light of the rising cost of prescription drugs and biologics. Such scrutiny has resulted in several recent congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for products. At the federal level, the Trump administration used several means to propose or implement drug pricing reform, including through federal budget proposals, executive orders and policy initiatives. The Department of Health and Human Services, or HHS, has solicited feedback on some of these measures and implemented others under its existing authority. For example, on July 24, 2020 and September 13, 2020, the Trump administration announced several executive orders related to prescription drug pricing that seek to implement several of the administration&#8217;s proposals. As a result, the FDA released a final rule on September 24, 2020, effective November 30, 2020, providing guidance for states to build and submit importation plans for drugs from Canada. Further, on November 20, 2020, HHS finalized a regulation removing safe harbor protection for price reductions from pharmaceutical manufacturers to plan sponsors under Part D, either directly or through pharmacy benefit managers, unless the price reduction is required by law. The implementation of the rule has been delayed by the Biden administration from January 1, 2022 to January 1, 2023 in response to ongoing litigation. The rule also creates a new safe harbor for price reductions reflected at the point-of-sale, as well as a new safe harbor for certain fixed fee arrangements between pharmacy benefit managers and manufacturers, the implementation of which have also been delayed pending review by the Biden administration until March 22, 2021.  On November 20, 2020, CMS issued an interim final rule implementing the Trump administration&#8217;s Most Favored Nation executive order, which would tie Medicare Part B payments for certain physician-administered drugs to the lowest price paid in other economically advanced countries, effective January 1, 2021. On December 28, 2020, the United States District Court in Northern California issued a nationwide preliminary injunction against implementation of the interim final rule. It is unclear whether the Biden administration will work to reverse these measures or pursue similar policy initiatives.  Further, at the state level, legislatures have increasingly passed legislation and implemented regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. It is also possible that additional governmental action is taken in response to the COVID-19 pandemic. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The continuing efforts of the government, insurance companies, managed care organizations and other payors of healthcare services to make and implement healthcare reforms may adversely affect: </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to set a price we believe is fair for our products; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to generate revenues and achieve or maintain profitability; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the availability of capital; and </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to obtain timely approval of our products. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we fail to comply with applicable healthcare regulations, we could face substantial penalties and our business, operations and financial condition could be adversely affected. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain federal, state, local and foreign healthcare laws and regulations pertaining to fraud and abuse, transparency, patients' rights, and privacy are applicable to our business. The laws that may affect our ability to operate include:</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the federal healthcare program Anti-Kickback Statute, which prohibits, among other things, people from soliciting, receiving or providing remuneration, directly or indirectly, to induce or reward either the referral of an individual, or ordering, or leasing of an item, good, facility or service, for which payment may be made by a federal healthcare program such as Medicare or Medicaid. The intent standard under the federal healthcare program Anti-Kickback Statute was amended by the ACA to a stricter standard such that a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation. Further, the ACA codified case law that a claim including items or services resulting from a violation of the federal healthcare program Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the civil False Claims Act; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">federal civil and criminal false claims laws, including the civil False Claims Act, which prohibit, among other things, individuals or entities from knowingly presenting, or causing to be presented, claims for payment from Medicare, Medicaid, or other third-party payors that are false or fraudulent; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, which prohibits, among other things, executing a scheme to defraud any healthcare benefit program or making false statements relating to healthcare matters. Similar to the federal healthcare program Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act, and their implementing regulations, which imposes certain requirements relating to the privacy, security and transmission of individually identifiable health information on certain individuals and entities; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the Physician Payments Sunshine Act, created under the ACA, which requires certain manufacturers of drugs, devices, biologics and medical supplies for which payment is available under Medicare, Medicaid or the Children&#8217;s Health Insurance Program, with certain exceptions, to report annually to the Centers for Medicare &amp; Medicaid Services, or CMS, information related to payments or other transfers of value made to physicians (defined to include doctors, dentists, optometrists, podiatrists, and chiropractors) and teaching hospitals, as well as ownership and investment interests held by physicians and their immediate family members, and which, beginning in 2022, will require applicable manufacturers to report information regarding payments and other transfers of value provided during the previous year to physician assistants, nurse practitioners, clinical nurse specialists, certified nurse anesthetists, anesthesiologist assistants, and certified nurse-midwives;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the Federal Food, Drug, and Cosmetic Act, which among other things, strictly regulates drug product marketing, prohibits manufacturers from marketing drug products for off-label use and regulates the distribution of drug samples; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the U.S. Foreign Corrupt Practices Act, which, among other things, prohibits companies issuing stock in the U.S. from bribing foreign officials for government contracts and other business; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">state law equivalents of each of the above federal laws, such as anti-kickback and false claims laws which may apply to items or services reimbursed by any third-party payor, including commercial insurers, state and local laws requiring the registration of pharmaceutical sales and medical representatives, and state laws governing the privacy and security of health information in certain circumstances, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts; and</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">additional state and local laws such as laws in California and Massachusetts, which mandate implementation of compliance programs, compliance with industry ethics codes, and spending limits, and other state and local laws, such as laws in Vermont, Maine, and Minnesota which require reporting to state governments of gifts, compensation, and other remuneration to physicians. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The shifting regulatory environment, along with the requirement to comply with multiple jurisdictions with different compliance and/or reporting requirements, increases the possibility that a company may run afoul of one or more laws.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will be required to spend substantial time and money to ensure that our business arrangements with third parties comply with applicable healthcare laws and regulations. Because of the breadth of these laws and the narrowness of the statutory exceptions and regulatory safe harbors available, which require strict compliance in order to offer protection, it is possible that governmental authorities may conclude that our business practices do not comply with current or future statutes, regulations, agency guidance or case law involving applicable healthcare laws. If our operations are found to be in violation of any of the laws described above or any other governmental regulations that apply to us, we may be subject to significant penalties, including administrative, civil and criminal penalties, damages, fines, disgorgement, possible exclusion from participation in Medicare, Medicaid and other federal healthcare programs, imprisonment, integrity and/or other oversight obligations, contractual damages, reputational harm, and the curtailment or restructuring of our operations. Any such penalties could adversely affect our ability to operate our business and our financial results. Any action against us for violation of these laws, even if we successfully defend against it, could cause us to incur significant legal expenses and divert our management's attention from the operation of our business. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our business involves the use of hazardous materials and we and our third-party manufacturers must comply with environmental laws and regulations, which can be expensive and restrict how we do business. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our and our third-party manufacturers' activities involve the controlled storage, use and disposal of hazardous materials, including the components of our product candidates and other hazardous compounds. We and our manufacturers are subject to federal, state and local laws and regulations governing the use, manufacture, storage, handling and disposal of these hazardous materials. In the event of an accident, state or federal authorities may curtail the use of these materials and interrupt our business operations. If we are subject to any liability as a result of our or our third-party manufacturers' activities involving hazardous materials, our business and financial condition may be adversely affected. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">We have entered into collaborations with Chinese companies and conduct certain research and development activities in China. Uncertainties regarding the interpretation and enforcement of Chinese laws, rules and regulations, a trade war or political unrest in China could materially adversely affect our business, financial condition and results of operations.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We conduct research and development activities in China through our collaboration with Advaccine, which is conducting and funding the Phase 2 trial of INO-4800 in China. In addition, we are party to a license and collaboration agreement with China-based company ApolloBio, pursuant to which ApolloBio has the exclusive right to develop and commercialize VGX-3100 in China, Hong Kong, Macao and Taiwan. The Chinese legal system is a civil law system based on written statutes. Unlike the common law system, prior court decisions may be cited for reference but have limited precedential value. In </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">addition, the Chinese legal system is based in part on government policies and internal rules, some of which are not published on a timely basis or at all, and which may have a retroactive effect. As a result, we may not be aware of our violation of these policies and rules until after the occurrence of the violation. Any administrative and court proceedings in China may be protracted, resulting in substantial costs and diversion of resources and management attention. Since Chinese administrative and court authorities have significant discretion in interpreting and implementing statutory and contractual terms, it may be more difficult to evaluate the outcome of administrative and court proceedings and the level of legal protection we enjoy than in more developed legal systems. Furthermore, we are exposed to the possibility of disruption of our research and development activities in the event of changes in the policies of the United States or Chinese governments, political unrest or unstable economic conditions in China. For example, a trade war could lead to increased costs for clinical materials that are manufactured in China. These interruptions or failures could also impede commercialization of our product candidates and impair our competitive position. Further, we may be exposed to fluctuations in the value of the local currency in China. These uncertainties may impede our ability to enforce the contracts we have entered into and our ability to continue our research and development activities and could materially and adversely affect our business, financial condition and results of operations.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Intellectual Property</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">It is difficult and costly to generate and protect our intellectual property and our proprietary technologies, and we may not be able to ensure their protection. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our commercial success will depend in part on obtaining and maintaining patent, trademark, trade secret, and other intellectual property protection relating to our electroporation equipment and product candidates, as well as successfully defending these intellectual property rights against third-party challenges. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The patent positions of pharmaceutical and biotechnology companies can be highly uncertain and involve complex legal and factual questions for which important legal principles remain unresolved. The laws and regulations regarding the breadth of claims allowed in biotechnology patents have evolved over recent years and continues to undergo review and revision, both in the United States and abroad. The biotechnology patent situation outside the United States can be even more uncertain depending on the country. Changes in either the patent laws or in interpretations of patent laws in the United States and other countries may diminish the value of our intellectual property. Accordingly, we cannot predict the breadth of claims that may be allowed or enforced in our licensed patents, our patents or in third-party patents, nor can we predict the likelihood of our patents surviving a patent validity challenge. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The degree of future protection for our intellectual property rights is uncertain, because legal decision-making can be unpredictable, thereby often times resulting in limited protection, which may not adequately protect our rights or permit us to gain or keep our competitive advantage, or resulting in an invalid or unenforceable patent. For example: </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we, or the parties from whom we have acquired or licensed patent rights, may not have been the first to file the underlying patent applications or the first to make the inventions covered by such patents; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the named inventors or co-inventors of patents or patent applications that we have licensed or acquired may be incorrect, which may give rise to inventorship and ownership challenges; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">others may develop similar or alternative technologies, or duplicate any of our products or technologies that may not be covered by our patents, including design-arounds; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">pending patent applications may not result in issued patents; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the issued patents covering our products and technologies may not provide us with any competitive advantages or have any commercial value; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the issued patents may be challenged and invalidated, or rendered unenforceable; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the issued patents may be subject to reexamination, which could result in a narrowing of the scope of claims or cancellation of claims found unpatentable; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may not develop or acquire additional proprietary technologies that are patentable; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our trademarks may be invalid or subject to a third party's prior use; or </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to enforce our patent rights will depend on our ability to detect infringement, and litigation to enforce patent rights may not be pursued due to significant financial costs, diversion of resources, and unpredictability of a favorable result or ruling. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We depend, in part, on our licensors and collaborators to protect a portion of our intellectual property rights. In such cases, our licensors and collaborators may be primarily or wholly responsible for the maintenance of patents and prosecution of patent applications relating to important areas of our business. If any of these parties fail to adequately protect these products with issued patents, our business and prospects would be harmed significantly. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also may rely on trade secrets to protect our technology, especially where we do not believe patent protection is appropriate or obtainable. However, trade secrets are difficult to protect. Although we use reasonable efforts to protect our trade </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">54</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">secrets, our employees, consultants, contractors, outside scientific collaborators and other advisors may unintentionally or willfully disclose our trade secrets to competitors. Enforcing a claim that a third-party entity illegally obtained and is using any of our trade secrets is expensive and time consuming, and the outcome is unpredictable. In addition, courts outside the United States are sometimes less willing to protect trade secrets. Moreover, our competitors may independently develop equivalent knowledge, methods and know-how. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we or our licensors fail to obtain or maintain patent protection or trade secret protection for our product candidates or our technologies, third parties could use our proprietary information, which could impair our ability to compete in the market and adversely affect our ability to generate revenues and attain profitability. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, U.S. and other policymakers have proposed reforming the patent laws and regulations of their countries. In September 2011 the America Invents Act (the Act) was signed into law. The Act changed the current &#8220;first-to-invent&#8221; system to a system that awards a patent to the &#8220;first-inventor-to-file&#8221; for an application for a patentable invention. The Act also created a procedure to challenge newly issued patents in the patent office via post-grant proceedings and new inter parties reexamination proceedings. These changes may make it easier for competitors to challenge our patents, which could result in increased competition and have a material adverse effect on our product sales, business and results of operations. The changes may also make it harder to challenge third-party patents and place greater importance on being the first inventor to file a patent application on an invention. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are sued for infringing intellectual property rights of third parties, it will be costly and time-consuming, and an unfavorable outcome in that litigation would have a material adverse effect on our business. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other companies may have or may acquire intellectual property rights that could be enforced against us. If they do so, we may be required to alter our technologies, pay licensing fees or cease activities. If our products or technologies infringe the intellectual property rights of others, they could bring legal action against us or our licensors or collaborators claiming damages and seeking to enjoin any activities that they believe infringe their intellectual property rights. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because patent applications can take many years to issue, and there is a period when the application remains undisclosed to the public, there may be currently pending applications unknown to us or reissue applications that may later result in issued patents upon which our products or technologies may infringe. There could also be existing patents of which we are unaware that our products or technologies may infringe. In addition, if third parties file patent applications or obtain patents claiming products or technologies also claimed by us in pending applications or issued patents, we may have to participate in interference or derivation proceedings in the United States Patent and Trademark Office to determine priority or derivation of the invention. If third parties file oppositions in foreign countries, we may also have to participate in opposition proceedings in foreign tribunals to defend the patentability of our filed foreign patent applications. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If a third party claims that we infringe its intellectual property rights, it could cause our business to suffer in a number of ways, including: </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may become involved in time-consuming and expensive litigation, even if the claim is without merit, the third party's patent is invalid or we have not infringed; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may become liable for substantial damages for past infringement if a court decides that our technologies infringe upon a third party's patent; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may be enjoined by a court to stop making, selling or licensing our products or technologies without a license from a patent holder, which may not be available on commercially acceptable terms, if at all, or which may require us to pay substantial royalties or grant cross-licenses to our patents; and </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may have to redesign our products so that they do not infringe upon others' patent rights, which may not be possible or could require substantial investment or time. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any of these events occur, our business could suffer and the market price of our common stock may decline. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to an Investment in Our Common Stock</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">An active trading market for our common stock may not be sustained.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although our common stock is listed on the Nasdaq Global Select Market, we cannot assure you that an active trading market for our shares will continue to be sustained. If an active market for our common stock is not sustained, it may be difficult for investors in our common stock to sell shares without depressing the market price for the shares or to sell the shares at all.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The price of our common stock has been and may continue to be volatile, and an investment in our common stock could decline substantially in value. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In light of our small size and limited resources, as well as the uncertainties and risks that can affect our business and industry, our stock price has been and may continue to be highly volatile and has been and may in the future be subject to substantial drops, with or even in the absence of news affecting our business. Period to period comparisons are not indicative of </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">55</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">future performance. The following factors, in addition to the other risk factors described in this report, and the potentially low volume of trades in our common stock, may have a significant impact on the market price of our common stock, some of which are beyond our control: </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">developments concerning any research and development, clinical trials, manufacturing, and marketing efforts or collaborations, particularly developments concerning the prospects of INO-4800 as a potential vaccine candidate against COVID-19;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">fluctuating public or scientific interest in the potential for our vaccines or other product candidates to address COVID-19 or other diseases; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our announcement of significant acquisitions, strategic collaborations, joint ventures or capital commitments; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">fluctuations in our operating results; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">announcements of technological innovations; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">new products or services that we or our competitors offer; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in the structure of healthcare payment systems;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the initiation, conduct and/or outcome of intellectual property and/or litigation matters; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in financial or other estimates by securities analysts or other reviewers or evaluators of our business; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">conditions or trends in bio-pharmaceutical or other healthcare industries; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulatory developments in the United States and other countries; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">negative perception of gene-based therapy; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in the economic performance and/or market valuations of other biotechnology and medical device companies; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">additions or departures of key personnel; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">sales or other transactions involving our common stock; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in our capital structure;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">sales or other transactions by executive officers or directors involving our common stock; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in accounting principles; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">global unrest, terrorist activities, and economic and other external factors; and </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">catastrophic weather and/or global disease pandemics, including COVID-19. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The stock market in general has recently experienced relatively large price and volume fluctuations, particularly in response to the COVID-19 outbreak. In particular, the market prices of securities of smaller biotechnology and medical device companies have experienced dramatic fluctuations that often have been unrelated or disproportionate to the operating results of these companies. Continued market fluctuations could result in extreme volatility in the price of our common stock, which could cause a decline in the value of our common stock. In addition, price volatility may increase if the trading volume of our common stock remains limited or declines.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Anti-takeover provisions under our charter documents and Delaware law could delay or prevent a change of control which could limit the market price of our common stock. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our amended and restated certificate of incorporation contains provisions that could delay or prevent a change of control of our company or changes in our board of directors that our stockholders might consider favorable. Some of these provisions include: </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the authority of our board of directors to issue shares of undesignated preferred stock and to determine the rights, preferences and privileges of these shares, without stockholder approval; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">all stockholder actions must be effected at a duly called meeting of stockholders and not by written consent; and </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the elimination of cumulative voting. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we are governed by the provisions of Section 203 of the Delaware General Corporate Law, which may prohibit certain business combinations with stockholders owning 15% or more of our outstanding voting stock. These and other provisions in our amended and restated certificate of incorporation, amended and restated bylaws and Delaware law could make it more difficult for stockholders or potential acquirers to obtain control of our board of directors or initiate actions that are opposed by the then-current board of directors, including to delay or impede a merger, tender offer or proxy contest involving our company. Any delay or prevention of a change of control transaction or changes in our board of directors could cause the market price of our common stock to decline. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have never paid cash dividends on our common stock and we do not anticipate paying dividends in the foreseeable future. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have paid no cash dividends on our common stock to date, and we currently intend to retain our future earnings, if any, to fund the development and growth of our business. In addition, the terms of any future debt or credit facility may preclude or limit our ability to pay any dividends. As a result, capital appreciation, if any, of our common stock will be the sole source of potential gain for the foreseeable future. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">General Risk Factors</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our quarterly operating results may fluctuate significantly.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect our operating results to be subject to quarterly fluctuations. Our net loss and other operating results will be affected by numerous factors, including: </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">variations in the level of expenses related to our electroporation equipment, product candidates or future development programs; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">expenses related to corporate transactions, including ones not fully completed; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">addition or termination of clinical trials or funding support; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any intellectual property infringement lawsuit in which we may become involved; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any legal claims that may be asserted against us or any of our officers; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulatory developments affecting our electroporation equipment and product candidates or those of our competitors; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">debt service obligations on the Notes;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in the fair value of our investments, including investments in affiliated entities;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our execution of any collaborative, licensing or similar arrangements, and the timing of payments we may make or receive under these arrangements; and </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">if any of our products receives regulatory approval, the levels of underlying demand for our products. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If our quarterly operating results fall below the expectations of investors or securities analysts, the price of our common stock could decline substantially. Furthermore, any quarterly fluctuations in our operating results may, in turn, cause the price of our stock to fluctuate substantially. We believe that quarterly comparisons of our financial results are not necessarily meaningful and should not be relied upon as an indication of our future performance. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our results of operations and liquidity needs could be materially affected by market fluctuations and general economic conditions. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our results of operations could be materially affected by economic conditions generally, both in the United States and elsewhere around the world. Concerns over inflation, energy costs, geopolitical issues, global pathogen outbreaks or pandemics, including COVID-19, and the availability and cost of credit have in the past and may continue to contribute to increased volatility and diminished expectations for the economy and the markets going forward. Market upheavals may have an adverse effect on us. In the event of a market downturn, our results of operations could be adversely affected. Our future cost of equity or debt capital and access to the capital markets could be adversely affected, and our stock price could decline. There may be disruption in or delay in the performance of our third-party contractors and suppliers. If our contractors, suppliers and partners are unable to satisfy their contractual commitments, our business could suffer. In addition, we maintain significant amounts of cash and cash equivalents at one or more financial institutions that are in excess of federally insured limits, and we may experience losses on these deposits. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If equity research analysts do not publish research or reports, or publish unfavorable research or reports, about us, our business or our market, our stock price and trading volume could decline.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The trading market for our common stock is influenced by the research and reports that equity research analysts publish about us and our business, and we have limited research coverage by equity research analysts. Equity research analysts may elect not to initiate or continue to provide research coverage of our common stock, and such lack of research coverage may adversely affect the market price of our common stock. Even if we have equity research analyst coverage, we will not have any control over the analysts or the content and opinions included in their reports. The price of our stock could decline if one or more equity research analysts downgrade our stock or issue other unfavorable commentary or research. If one or more equity research analysts ceases coverage of our company or fails to publish reports on us regularly, demand for our stock could decrease, which in turn could cause our stock price or trading volume to decline.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The issuance of additional stock in connection with financings, acquisitions, investments, our stock incentive plans or otherwise will dilute all other stockholders.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our certificate of incorporation authorizes us to issue up to 600,000,000 shares of common stock and up to 10,000,000 shares of preferred stock with such rights and preferences as may be determined by our board of directors. Subject to compliance with applicable rules and regulations, we may issue our shares of common stock or securities convertible into our common stock from time to time in connection with a financing, acquisition, investment, our stock incentive plans or otherwise. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">57</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any such issuance could result in substantial dilution to our existing stockholders and cause the trading price of our common stock to decline.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We incur significant costs and demands upon management as a result of being a public company.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a public company listed in the United States, we incur significant legal, accounting and other costs that could negatively affect our financial results. In addition, changing laws, regulations and standards relating to corporate governance and public disclosure, including regulations implemented by the SEC and stock exchanges, may increase legal and financial compliance costs and make some activities more time-consuming. These laws, regulations and standards are subject to varying interpretations and, as a result, their application in practice may evolve over time as new guidance is provided by regulatory and governing bodies. We intend to invest resources to comply with evolving laws, regulations and standards, and this investment may result in increased general and administrative expenses and a diversion of management's time and attention from revenue-generating activities to compliance activities. If notwithstanding our efforts to comply with new laws, regulations and standards, we fail to comply, regulatory authorities may initiate legal proceedings against us and our business may be harmed.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Failure to comply with these rules might also make it more difficult for us to obtain some types of insurance, including director and officer liability insurance, and we might be forced to accept reduced policy limits and coverage or incur substantially higher costs to obtain the same or similar coverage. The impact of these events could also make it more difficult for us to attract and retain qualified persons to serve on our board of directors, on committees of our board of directors or as members of senior management.</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in tax laws could adversely affect our business and financial condition.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2017, the Tax Cuts and Jobs Act of 2017 was enacted, which significantly revised the Internal Revenue Code of 1986, as amended, or the Code. The new federal income tax law, among other things, contains significant changes to corporate taxation, including reduction of the corporate tax rate from a top marginal rate of 35 percent to a flat rate of 21 percent, limitation of the tax deduction for interest expense to 30 percent of adjusted earnings (except for certain small businesses), limitation of the deduction for net operating losses to 80 percent of current-year taxable income and elimination of net operating loss carrybacks, one time taxation of offshore earnings at reduced rates regardless of whether they are repatriated, immediate deductions for certain new investments instead of deductions for depreciation expense over time, and modifying or repealing many business deductions and credits (including reducing the business tax credit for certain clinical testing expenses incurred in the testing of certain drugs for rare diseases or conditions). Notwithstanding the reduction in the corporate income tax rate, the overall impact of the federal tax law is uncertain and our business and financial condition could be adversely affected. In addition, it is uncertain if and to what extent various states will conform to the federal tax law.</span></div><div style="margin-top:4.5pt;text-indent:24.75pt"><span><br/></span></div><div id="i1d23d16a69484b63aa007ec686e80337_136"></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 2.&#160;&#160;&#160;&#160;UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS</span></div><div style="text-indent:24.75pt"><span><br/></span></div><div style="text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">In March 2021, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">the December 2019 Bonds were fully converted into 1,009,450 shares of our common stock.</span></div><div style="text-indent:24.75pt"><span><br/></span></div><div style="text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">The foregoing issuance of shares of common stock was made in reliance upon the exemption set forth in Section 3(a)(9) of the Securities Act of 1933, as amended, for securities exchanged by the registrant and existing security holders where no commission or other remuneration is paid or given directly or indirectly by the registrant for soliciting such exchange.</span></div><div><span><br/></span></div><div><span><br/></span></div><div id="i1d23d16a69484b63aa007ec686e80337_139"></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 3.&#160;&#160;&#160;&#160;DEFAULTS UPON SENIOR SECURITIES</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div><span><br/></span></div><div id="i1d23d16a69484b63aa007ec686e80337_142"></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 4.&#160;&#160;&#160;&#160;MINE SAFETY DISCLOSURES</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div style="text-indent:24.75pt"><span><br/></span></div><div id="i1d23d16a69484b63aa007ec686e80337_145"></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 5.&#160;&#160;&#160;&#160;OTHER INFORMATION</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div style="padding-left:36pt;text-align:justify"><span><br/></span></div><div id="i1d23d16a69484b63aa007ec686e80337_148"></div><div style="-sec-extract:summary;margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> ITEM 6.&#160;&#160;&#160;&#160;EXHIBITS</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;Exhibits</span></div><div style="margin-top:5pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">58</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="-sec-extract:summary"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1d23d16a69484b63aa007ec686e80337_7">Table of Contents</a></span></div></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:8.284%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:88.783%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Number</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Description of Document</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000119312514277137/d742468dex31.htm">3.1</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000119312514277137/d742468dex31.htm">Certificate of Incorporation with all amendments (incorporated by reference to Exhibit 3.1 of the registrant&#8217;s Form S-3 registration statement, filed on July 23, 2014).</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000095012311076829/w84047exv3w2.htm">3.2</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000095012311076829/w84047exv3w2.htm">Amended and Restated Bylaws of Inovio Pharmaceuticals, Inc. dated August 10, 2011 (incorporated by reference to Exhibit 3.2 to the registrant&#8217;s Form 8-K current report filed on August 12, 2011).</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ino-33121x10qex311.htm">31.1</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ino-33121x10qex311.htm">Certification of Chief Executive Officer Pursuant to Item 601(b)(31) of Regulation S-K, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 (filed herewith)</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ino-33121x10qex312.htm">31.2</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ino-33121x10qex312.htm">Certification of Chief Financial Officer Pursuant to Item 601(b)(31) of Regulation S-K, as adopted pursuant to Section&#160;302 of the Sarbanes-Oxley Act of 2002 (filed herewith).</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ino-33121x10qex321.htm">32.1</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ino-33121x10qex321.htm">Certification of the Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C.&#160;Section&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002 (furnished herewith).*</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.INS</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Instance Document (the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document).</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.SCH</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Schema Document</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.CAL</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Calculation Linkbase Document.</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.DEF</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Definition Linkbase Document.</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.LAB</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Label Linkbase Document.</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.PRE</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Presentation Linkbase Document.</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)</span></td></tr></table></div><div><span><br/></span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:4.894%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:92.906%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">This exhibit shall not be deemed &#8220;filed&#8221; for purposes of Section&#160;18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, whether made before or after the date hereof and irrespective of any general incorporation language in any filings. </span></div><div style="margin-top:7.5pt;padding-left:11.25pt;text-indent:-11.25pt"><span><br/></span></div></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">59</span></div></div></div><div id="i1d23d16a69484b63aa007ec686e80337_151"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        INOVIO PHARMACEUTICALS, INC.</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. </span></div><div style="margin-bottom:5pt;margin-top:14pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:4.325%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.929%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.419%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:49.927%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Inovio Pharmaceuticals, Inc.</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 10, 2021</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">/s/&#160;&#160;&#160;&#160;J. JOSEPH KIM&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">J. Joseph Kim</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">President, Chief Executive Officer and Director                                                                                         (On Behalf of the Registrant)</span></div></td></tr><tr style="height:21pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 10, 2021</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">/s/&#160;&#160;&#160;&#160;PETER KIES&#160;&#160;&#160;&#160;&#160;&#160;</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Peter Kies </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">Chief Financial Officer (Principal Financial and Accounting Officer)</span></div></td></tr></table></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">60</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>ino-33121x10qex311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="icedc79e302d44951a0c56416bf73bb8f_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit&#160;31.1 </font></div><div style="margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Certification of CEO Pursuant to </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Securities Exchange Act Rules&#160;13a-15(e) and 15d-15(e) </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">as Adopted Pursuant to </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section&#160;302 of the Sarbanes-Oxley Act of 2002 </font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, J. Joseph Kim, certify that&#58; </font></div><div style="margin-top:4.5pt;padding-left:24.75pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.&#160;&#160;&#160;&#160;I have reviewed this quarterly report on Form&#160;10-Q of Inovio Pharmaceuticals, Inc.&#59; </font></div><div style="margin-top:4.5pt;padding-left:24.75pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.&#160;&#160;&#160;&#160;Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59; </font></div><div style="margin-top:4.5pt;padding-left:24.75pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.&#160;&#160;&#160;&#160;Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59; </font></div><div style="margin-top:4.5pt;padding-left:24.75pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.&#160;&#160;&#160;&#160;The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules&#160;13a-15(e)&#160;and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules&#160;13a-15(f)&#160;and 15d-15(f)) for the registrant and have&#58; </font></div><div style="margin-top:4.5pt;padding-left:47.25pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a)&#160;&#160;&#160;&#160;Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59; </font></div><div style="margin-top:4.5pt;padding-left:47.25pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b)&#160;&#160;&#160;&#160;Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59; </font></div><div style="margin-top:4.5pt;padding-left:47.25pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c)&#160;&#160;&#160;&#160;Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and </font></div><div style="margin-top:4.5pt;padding-left:47.25pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d)&#160;&#160;&#160;&#160;Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting&#59; and </font></div><div style="margin-top:4.5pt;padding-left:24.75pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.&#160;&#160;&#160;&#160;The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions)&#58; </font></div><div style="margin-top:4.5pt;padding-left:47.25pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a)&#160;&#160;&#160;&#160;all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information&#59; and </font></div><div style="margin-bottom:5pt;margin-top:4.5pt;padding-left:47.25pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b)&#160;&#160;&#160;&#160;any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting. </font></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.269%"><tr><td style="width:1.0%"></td><td style="width:4.349%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.175%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.176%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 10, 2021</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47;&#160;&#160;&#160;&#160;J. J</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">OSEPH</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> K</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">IM&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">J. Joseph Kim</font></div><div style="margin-bottom:0.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">President, Chief Executive Officer and Director                       (Principal Executive Officer)</font></div></td></tr></table></div><div><font><br></font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>ino-33121x10qex312.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i778f1191d3ff469e877b32912f5fe4d5_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit&#160;31.2 </font></div><div style="margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Certification of CFO Pursuant to </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Securities Exchange Act Rules&#160;13a-15(e) and 15d-15(e) </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">as Adopted Pursuant to </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section&#160;302 of the Sarbanes-Oxley Act of 2002 </font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Peter Kies, certify that&#58; </font></div><div style="margin-top:4.5pt;padding-left:24.75pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.&#160;&#160;&#160;&#160;I have reviewed this quarterly report on Form&#160;10-Q of Inovio Pharmaceuticals, Inc.&#59; </font></div><div style="margin-top:4.5pt;padding-left:24.75pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.&#160;&#160;&#160;&#160;Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59; </font></div><div style="margin-top:4.5pt;padding-left:24.75pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.&#160;&#160;&#160;&#160;Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59; </font></div><div style="margin-top:4.5pt;padding-left:24.75pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.&#160;&#160;&#160;&#160;The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules&#160;13a-15(e)&#160;and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules&#160;13a-15(f)&#160;and 15d-15(f)) for the registrant and have&#58; </font></div><div style="margin-top:4.5pt;padding-left:47.25pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a)&#160;&#160;&#160;&#160;Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59; </font></div><div style="margin-top:4.5pt;padding-left:47.25pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b)&#160;&#160;&#160;&#160;Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59; </font></div><div style="margin-top:4.5pt;padding-left:47.25pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c)&#160;&#160;&#160;&#160;Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and </font></div><div style="margin-top:4.5pt;padding-left:47.25pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d)&#160;&#160;&#160;&#160;Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting&#59; and </font></div><div style="margin-top:4.5pt;padding-left:24.75pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.&#160;&#160;&#160;&#160;The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions)&#58; </font></div><div style="margin-top:4.5pt;padding-left:47.25pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a)&#160;&#160;&#160;&#160;all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information&#59; and </font></div><div style="margin-top:4.5pt;padding-left:47.25pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b)&#160;&#160;&#160;&#160;any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting. </font></div><div style="margin-top:9pt;padding-left:72pt"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:4.309%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.198%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:49.193%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 10, 2021</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47;&#160;&#160;&#160;&#160;P</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">ETER</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> K</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">IES&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Peter Kies</font></div><div style="margin-bottom:0.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">Chief Financial Officer                                                                    (Principal Financial and Accounting Officer)</font></div></td></tr></table></div><div><font><br></font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>4
<FILENAME>ino-33121x10qex321.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i498a47a1cf2c4862b0c29f2847660984_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit&#160;32.1 </font></div><div style="margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Certification Pursuant to </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">18 U.S.C. Section&#160;1350, </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">As Adopted Pursuant to </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section&#160;906 of the Sarbanes-Oxley Act of 2002 </font></div><div style="margin-top:9pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the quarterly report of Inovio Pharmaceuticals, Inc. (the &#8220;Company&#8221;) on Form&#160;10-Q for the quarter ending March 31, 2021, as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), each of the undersigned, in the capacities and on the date indicated below, hereby certifies, pursuant to 18 U.S.C. Section&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002, that to his knowledge&#58; </font></div><div style="margin-top:4.5pt;padding-left:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) The Report fully complies with the requirements of Section&#160;13(a)&#160;or 15(d)&#160;of the Securities Exchange Act of 1934&#59; and </font></div><div style="margin-top:4.5pt;padding-left:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.269%"><tr><td style="width:1.0%"></td><td style="width:4.349%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.175%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.176%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 10, 2021</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47;&#160;&#160;&#160;&#160;J. J</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">OSEPH</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> K</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">IM&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">J. Joseph Kim</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">President, Chief Executive Officer and Director</font></div><div style="margin-bottom:0.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">(Principal Executive Officer)</font></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 10, 2021</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47;&#160;&#160;&#160;&#160;P</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">ETER</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> K</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">IES&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Peter Kies</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">Chief Financial Officer</font></div><div style="margin-bottom:0.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">(Principal Financial and Accounting Officer)</font></div></td></tr></table></div><div><font><br></font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The foregoing certification is being furnished solely pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002 and is not filed with the Securities and Exchange Commission as part of the Form&#160;10-Q or as a separate disclosure document and is not incorporated by reference into any filing of Inovio Pharmaceuticals, Inc. under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, irrespective of any general incorporation language contained in such filing. A signed original of this written statement required by Section&#160;906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request. </font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>5
<FILENAME>ino-20210331.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:e9d1bb07-ad73-4929-82ea-6e949ab8c789,g:8e741ee6-3c7b-40cd-9e55-d4abd68b099b-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:ino="http://www.inovio.com/20210331" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.inovio.com/20210331">
  <xs:import namespace="http://fasb.org/srt/2020-01-31" schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2020-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2020-01-31" schemaLocation="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ino-20210331_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ino-20210331_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ino-20210331_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ino-20210331_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="CoverPage" roleURI="http://www.inovio.com/role/CoverPage">
        <link:definition>0001001 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheets" roleURI="http://www.inovio.com/role/CondensedConsolidatedBalanceSheets">
        <link:definition>1001002 - Statement - Condensed Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofOperations" roleURI="http://www.inovio.com/role/CondensedConsolidatedStatementsofOperations">
        <link:definition>1002003 - Statement - Condensed Consolidated Statements of Operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofComprehensiveLoss" roleURI="http://www.inovio.com/role/CondensedConsolidatedStatementsofComprehensiveLoss">
        <link:definition>1003004 - Statement - Condensed Consolidated Statements of Comprehensive Loss</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofStockholdersEquity" roleURI="http://www.inovio.com/role/CondensedConsolidatedStatementsofStockholdersEquity">
        <link:definition>1004005 - Statement - Condensed Consolidated Statements of Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofStockholdersEquityParenthetical" roleURI="http://www.inovio.com/role/CondensedConsolidatedStatementsofStockholdersEquityParenthetical">
        <link:definition>1005006 - Statement - Condensed Consolidated Statements of Stockholders' Equity (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofCashFlows" roleURI="http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows">
        <link:definition>1006007 - Statement - Condensed Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandOperations" roleURI="http://www.inovio.com/role/OrganizationandOperations">
        <link:definition>2101101 - Disclosure - Organization and Operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationLiquidityandRisksandUncertainties" roleURI="http://www.inovio.com/role/BasisofPresentationLiquidityandRisksandUncertainties">
        <link:definition>2102102 - Disclosure - Basis of Presentation, Liquidity and Risks and Uncertainties</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationLiquidityandRisksandUncertaintiesPolicies" roleURI="http://www.inovio.com/role/BasisofPresentationLiquidityandRisksandUncertaintiesPolicies">
        <link:definition>2203201 - Disclosure - Basis of Presentation, Liquidity and Risks and Uncertainties (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationLiquidityandRisksandUncertaintiesDetails" roleURI="http://www.inovio.com/role/BasisofPresentationLiquidityandRisksandUncertaintiesDetails">
        <link:definition>2404401 - Disclosure - Basis of Presentation, Liquidity and Risks and Uncertainties (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CriticalAccountingPolicies" roleURI="http://www.inovio.com/role/CriticalAccountingPolicies">
        <link:definition>2105103 - Disclosure - Critical Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CriticalAccountingPoliciesDetails" roleURI="http://www.inovio.com/role/CriticalAccountingPoliciesDetails">
        <link:definition>2406402 - Disclosure - Critical Accounting Policies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ImpactofRecentlyIssuedAccountingStandards" roleURI="http://www.inovio.com/role/ImpactofRecentlyIssuedAccountingStandards">
        <link:definition>2107104 - Disclosure - Impact of Recently Issued Accounting Standards</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueRecognition" roleURI="http://www.inovio.com/role/RevenueRecognition">
        <link:definition>2108105 - Disclosure - Revenue Recognition</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueRecognitionDetails" roleURI="http://www.inovio.com/role/RevenueRecognitionDetails">
        <link:definition>2409403 - Disclosure - Revenue Recognition (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShorttermInvestments" roleURI="http://www.inovio.com/role/ShorttermInvestments">
        <link:definition>2110106 - Disclosure - Short-term Investments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShorttermInvestmentsTables" roleURI="http://www.inovio.com/role/ShorttermInvestmentsTables">
        <link:definition>2311301 - Disclosure - Short-term Investments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShorttermInvestmentsNarrativeDetails" roleURI="http://www.inovio.com/role/ShorttermInvestmentsNarrativeDetails">
        <link:definition>2412404 - Disclosure - Short-term Investments - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShorttermInvestmentsSummaryofAvailableforsaleSecuritiesDetails" roleURI="http://www.inovio.com/role/ShorttermInvestmentsSummaryofAvailableforsaleSecuritiesDetails">
        <link:definition>2413405 - Disclosure - Short-term Investments - Summary of Available-for-sale Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurements" roleURI="http://www.inovio.com/role/FairValueMeasurements">
        <link:definition>2114107 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsTables" roleURI="http://www.inovio.com/role/FairValueMeasurementsTables">
        <link:definition>2315302 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueDetails" roleURI="http://www.inovio.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueDetails">
        <link:definition>2416406 - Disclosure - Fair Value Measurements - Assets and Liabilities Measured at Fair Value (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsNarrativeDetails" roleURI="http://www.inovio.com/role/FairValueMeasurementsNarrativeDetails">
        <link:definition>2417407 - Disclosure - Fair Value Measurements - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandIntangibleAssets" roleURI="http://www.inovio.com/role/GoodwillandIntangibleAssets">
        <link:definition>2118108 - Disclosure - Goodwill and Intangible Assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandIntangibleAssetsTables" roleURI="http://www.inovio.com/role/GoodwillandIntangibleAssetsTables">
        <link:definition>2319303 - Disclosure - Goodwill and Intangible Assets (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandIntangibleAssetsScheduleGoodwillandIntangibleAssetsDetails" roleURI="http://www.inovio.com/role/GoodwillandIntangibleAssetsScheduleGoodwillandIntangibleAssetsDetails">
        <link:definition>2420408 - Disclosure - Goodwill and Intangible Assets - Schedule Goodwill and Intangible Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandIntangibleAssetsNarrativeDetails" roleURI="http://www.inovio.com/role/GoodwillandIntangibleAssetsNarrativeDetails">
        <link:definition>2421409 - Disclosure - Goodwill and Intangible Assets - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConvertibleDebt" roleURI="http://www.inovio.com/role/ConvertibleDebt">
        <link:definition>2122109 - Disclosure - Convertible Debt</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConvertibleDebtTables" roleURI="http://www.inovio.com/role/ConvertibleDebtTables">
        <link:definition>2323304 - Disclosure - Convertible Debt (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConvertibleDebtNarrativeDetails" roleURI="http://www.inovio.com/role/ConvertibleDebtNarrativeDetails">
        <link:definition>2424410 - Disclosure - Convertible Debt - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConvertibleDebtBalanceofConvertibleBondsandNotesDetails" roleURI="http://www.inovio.com/role/ConvertibleDebtBalanceofConvertibleBondsandNotesDetails">
        <link:definition>2425411 - Disclosure - Convertible Debt - Balance of Convertible Bonds and Notes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConvertibleDebtScheduleofMaturitiesDetails" roleURI="http://www.inovio.com/role/ConvertibleDebtScheduleofMaturitiesDetails">
        <link:definition>2426412 - Disclosure - Convertible Debt - Schedule of Maturities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquity" roleURI="http://www.inovio.com/role/StockholdersEquity">
        <link:definition>2127110 - Disclosure - Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityTables" roleURI="http://www.inovio.com/role/StockholdersEquityTables">
        <link:definition>2328305 - Disclosure - Stockholders' Equity (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquitySummaryofAuthorizedandIssuedCommonandPreferredStockDetails" roleURI="http://www.inovio.com/role/StockholdersEquitySummaryofAuthorizedandIssuedCommonandPreferredStockDetails">
        <link:definition>2429413 - Disclosure - Stockholders' Equity - Summary of Authorized and Issued Common and Preferred Stock (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityNarrativeDetails" roleURI="http://www.inovio.com/role/StockholdersEquityNarrativeDetails">
        <link:definition>2430414 - Disclosure - Stockholders' Equity - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerShare" roleURI="http://www.inovio.com/role/NetLossPerShare">
        <link:definition>2131111 - Disclosure - Net Loss Per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerShareTables" roleURI="http://www.inovio.com/role/NetLossPerShareTables">
        <link:definition>2332306 - Disclosure - Net Loss Per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerShareScheduleofAntiDilutiveSecuritiesDetails" roleURI="http://www.inovio.com/role/NetLossPerShareScheduleofAntiDilutiveSecuritiesDetails">
        <link:definition>2433415 - Disclosure - Net Loss Per Share - Schedule of Anti-Dilutive Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensation" roleURI="http://www.inovio.com/role/StockBasedCompensation">
        <link:definition>2134112 - Disclosure - Stock-Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationTables" roleURI="http://www.inovio.com/role/StockBasedCompensationTables">
        <link:definition>2335307 - Disclosure - Stock-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationDetails" roleURI="http://www.inovio.com/role/StockBasedCompensationDetails">
        <link:definition>2436416 - Disclosure - Stock-Based Compensation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedPartyTransactions" roleURI="http://www.inovio.com/role/RelatedPartyTransactions">
        <link:definition>2137113 - Disclosure - Related Party Transactions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedPartyTransactionsDetails" roleURI="http://www.inovio.com/role/RelatedPartyTransactionsDetails">
        <link:definition>2438417 - Disclosure - Related Party Transactions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Leases" roleURI="http://www.inovio.com/role/Leases">
        <link:definition>2139114 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesTables" roleURI="http://www.inovio.com/role/LeasesTables">
        <link:definition>2340308 - Disclosure - Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesNarrativeDetails" roleURI="http://www.inovio.com/role/LeasesNarrativeDetails">
        <link:definition>2441418 - Disclosure - Leases - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesSummaryofFutureMinimumLeasePaymentsDetails" roleURI="http://www.inovio.com/role/LeasesSummaryofFutureMinimumLeasePaymentsDetails">
        <link:definition>2442419 - Disclosure - Leases - Summary of Future Minimum Lease Payments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborativeAgreements" roleURI="http://www.inovio.com/role/CollaborativeAgreements">
        <link:definition>2143115 - Disclosure - Collaborative Agreements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborativeAgreementsDetails" roleURI="http://www.inovio.com/role/CollaborativeAgreementsDetails">
        <link:definition>2444420 - Disclosure - Collaborative Agreements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://www.inovio.com/role/IncomeTaxes">
        <link:definition>2145116 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GeneosTherapeuticsInc" roleURI="http://www.inovio.com/role/GeneosTherapeuticsInc">
        <link:definition>2146117 - Disclosure - Geneos Therapeutics, Inc.</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GeneosTherapeuticsIncTables" roleURI="http://www.inovio.com/role/GeneosTherapeuticsIncTables">
        <link:definition>2347309 - Disclosure - Geneos Therapeutics, Inc. (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GeneosTherapeuticsIncNarrativeDetails" roleURI="http://www.inovio.com/role/GeneosTherapeuticsIncNarrativeDetails">
        <link:definition>2448421 - Disclosure - Geneos Therapeutics, Inc. - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GeneosTherapeuticsIncDeconsolidationAccountingDetails" roleURI="http://www.inovio.com/role/GeneosTherapeuticsIncDeconsolidationAccountingDetails">
        <link:definition>2449422 - Disclosure - Geneos Therapeutics, Inc. - Deconsolidation Accounting (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GeneosTherapeuticsIncInvestmentInGeneosDetails" roleURI="http://www.inovio.com/role/GeneosTherapeuticsIncInvestmentInGeneosDetails">
        <link:definition>2450423 - Disclosure - Geneos Therapeutics, Inc. - Investment In Geneos (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GeneosTherapeuticsIncFairValueAssumptionsDetails" roleURI="http://www.inovio.com/role/GeneosTherapeuticsIncFairValueAssumptionsDetails">
        <link:definition>2451424 - Disclosure - Geneos Therapeutics, Inc. - Fair Value Assumptions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GeneosTherapeuticsIncPreferredstockInvestmentDetails" roleURI="http://www.inovio.com/role/GeneosTherapeuticsIncPreferredstockInvestmentDetails">
        <link:definition>2452425 - Disclosure - Geneos Therapeutics, Inc. - Preferred stock Investment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="ino_AccruedClinicalTrialExpenseCurrent" abstract="false" name="AccruedClinicalTrialExpenseCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_CoalitionforEpidemicPreparednessInnovationsMember" abstract="true" name="CoalitionforEpidemicPreparednessInnovationsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ino_IncomeLossFromEquityMethodInvestmentsRealizedAndAllocatedToInvestment" abstract="false" name="IncomeLossFromEquityMethodInvestmentsRealizedAndAllocatedToInvestment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_CollaborativeAgreementForeignNonIncomeTaxes" abstract="false" name="CollaborativeAgreementForeignNonIncomeTaxes" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_StockSaleAgreementAggregateProceedsFromIssuanceOfStock" abstract="false" name="StockSaleAgreementAggregateProceedsFromIssuanceOfStock" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_AmortizationOfOperatingLeaseRightOfUseAssets" abstract="false" name="AmortizationOfOperatingLeaseRightOfUseAssets" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_SeriesAOnePreferredStockMember" abstract="true" name="SeriesAOnePreferredStockMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ino_December2019ConvertibleBondsMember" abstract="true" name="December2019ConvertibleBondsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ino_CollaborativeAgreementsUpfrontPaymentReceived" abstract="false" name="CollaborativeAgreementsUpfrontPaymentReceived" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity" abstract="false" name="IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_CollaborativeArrangementTerm" abstract="false" name="CollaborativeArrangementTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="ino_MutualFundsMember" abstract="true" name="MutualFundsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ino_CollaborationAgreementAdditionalRevenueToBeAchieved" abstract="false" name="CollaborationAgreementAdditionalRevenueToBeAchieved" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_LesseeOperatingLeaseAreaofLandUnderLease" abstract="false" name="LesseeOperatingLeaseAreaofLandUnderLease" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:areaItemType"/>
  <xs:element id="ino_INO4800Member" abstract="true" name="INO4800Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ino_CollaborationAgreementAnticipatedDevelopmentandRegulatoryEventBasedPaymentReceivableMilestones" abstract="false" name="CollaborationAgreementAnticipatedDevelopmentandRegulatoryEventBasedPaymentReceivableMilestones" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_A2016IncentivePlanMember" abstract="true" name="A2016IncentivePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ino_OtherCounterpartyMember" abstract="true" name="OtherCounterpartyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ino_NonCashInterestIncomeExpense" abstract="false" name="NonCashInterestIncomeExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_GoodwillAndIntangibleAssetsNet" abstract="false" name="GoodwillAndIntangibleAssetsNet" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_MarketableSecuritiesAndFairValueMeasurementsTextualAbstract" abstract="true" name="MarketableSecuritiesAndFairValueMeasurementsTextualAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="ino_ServiceBasedRestrictedStockUnitsMember" abstract="true" name="ServiceBasedRestrictedStockUnitsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ino_EquityMethodInvestmentEnterpriseValue" abstract="false" name="EquityMethodInvestmentEnterpriseValue" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" abstract="false" name="LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_CollaborativeAgreementAwardedOptionAmount" abstract="false" name="CollaborativeAgreementAwardedOptionAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_StockSalesAgreementMaximumAuthorizedAmount" abstract="false" name="StockSalesAgreementMaximumAuthorizedAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_BiojectMember" abstract="true" name="BiojectMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ino_DebtInstrumentAccruedInterest" abstract="false" name="DebtInstrumentAccruedInterest" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_CollaborativeAgreementFundingReceived" abstract="false" name="CollaborativeAgreementFundingReceived" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_LicensewithAffiliatedEntitiesMember" abstract="true" name="LicensewithAffiliatedEntitiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ino_CollaborativeArrangementFixedPriceContractAmountAwarded" abstract="false" name="CollaborativeArrangementFixedPriceContractAmountAwarded" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_A6.50ConvertibleSeniorNotesDue2024Member" abstract="true" name="A6.50ConvertibleSeniorNotesDue2024Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ino_AlternativeInvestmentMeasurementInputTerm" abstract="false" name="AlternativeInvestmentMeasurementInputTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="ino_SalesAgreementsMember" abstract="true" name="SalesAgreementsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ino_OperatingLeaseNonCashLeaseExpense" abstract="false" name="OperatingLeaseNonCashLeaseExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_CollaborativeAgreementAwardedAmount" abstract="false" name="CollaborativeAgreementAwardedAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="ino_CELLECTRA2000DeviceMember" abstract="true" name="CELLECTRA2000DeviceMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ino_ContractWithCustomerLiabilityAffiliatedEntityCurrent" abstract="false" name="ContractWithCustomerLiabilityAffiliatedEntityCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_CollaborativeAgreementExpensesToReimburse" abstract="false" name="CollaborativeAgreementExpensesToReimburse" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_IncreaseDecreaseinDeferredGrantFundingFromAffiliateCurrent" abstract="false" name="IncreaseDecreaseinDeferredGrantFundingFromAffiliateCurrent" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_August2019ConvertibleBondsMember" abstract="true" name="August2019ConvertibleBondsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ino_BillAndMelindaGatesFoundationMember" abstract="true" name="BillAndMelindaGatesFoundationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ino_NonEmployeeMember" abstract="true" name="NonEmployeeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ino_CollaborativeAgreementCorporateIncomeTax" abstract="false" name="CollaborativeAgreementCorporateIncomeTax" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_DebtSecuritiesAvailableforSaleContractualMaturity" abstract="false" name="DebtSecuritiesAvailableforSaleContractualMaturity" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="ino_AstraZenecaMember" abstract="true" name="AstraZenecaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ino_EmployeesAndDirectorsMember" abstract="true" name="EmployeesAndDirectorsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ino_CollaborationAgreementRoyaltyPeriod" abstract="false" name="CollaborationAgreementRoyaltyPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="ino_GoodwillAndIntangibleAssetsGross" abstract="false" name="GoodwillAndIntangibleAssetsGross" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity" abstract="false" name="PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_DebtInstrumentConvertibleDebtConvertedAmount" abstract="false" name="DebtInstrumentConvertibleDebtConvertedAmount" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_GeneosTherapeuticsInc.Member" abstract="true" name="GeneosTherapeuticsInc.Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ino_CollaborationAgreementPaymentEarned" abstract="false" name="CollaborationAgreementPaymentEarned" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_ChangeInValueOfInvestmentsInAffiliatedCompany" abstract="false" name="ChangeInValueOfInvestmentsInAffiliatedCompany" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_PriorSalesAgreementMember" abstract="true" name="PriorSalesAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ino_AdvaccineMember" abstract="true" name="AdvaccineMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ino_IncreaseDecreaseInDeferredRevenueFromRelatedParties" abstract="false" name="IncreaseDecreaseInDeferredRevenueFromRelatedParties" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_DepartmentOfDefenceMember" abstract="true" name="DepartmentOfDefenceMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ino_SARSCoV2COVID19VaccineMember" abstract="true" name="SARSCoV2COVID19VaccineMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ino_NewSalesAgreementMember" abstract="true" name="NewSalesAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ino_StockPurchaseAgreementCommitmentOfAdditionalInvestment" abstract="false" name="StockPurchaseAgreementCommitmentOfAdditionalInvestment" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_DeferredGrantFundingCurrent" abstract="false" name="DeferredGrantFundingCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_CollaborativeAgreementAdvisoryFees" abstract="false" name="CollaborativeAgreementAdvisoryFees" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodGrantDateFairValue" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodGrantDateFairValue" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_PlumblineLifeSciencesMember" abstract="true" name="PlumblineLifeSciencesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ino_WorkingCapitalExcludingCash" abstract="false" name="WorkingCapitalExcludingCash" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_SanDiegoOfficeMember" abstract="true" name="SanDiegoOfficeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ino_RelatedPartyTransactionsTextualAbstract" abstract="true" name="RelatedPartyTransactionsTextualAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="ino_IncreaseDecreaseinDeferredGrantFundingCurrent" abstract="false" name="IncreaseDecreaseinDeferredGrantFundingCurrent" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_StockSaleAgreementWeightedAveragePricePerShare" abstract="false" name="StockSaleAgreementWeightedAveragePricePerShare" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:perShareItemType"/>
  <xs:element id="ino_CollaborativeAgreementFundingToBeReceived" abstract="false" name="CollaborativeAgreementFundingToBeReceived" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_CollaborationAgreementAnticipatedCommercialEventBasedPaymentReceivableMilestones" abstract="false" name="CollaborationAgreementAnticipatedCommercialEventBasedPaymentReceivableMilestones" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_GrantPolicyPolicyTextBlock" abstract="false" name="GrantPolicyPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="ino_CELLECTRA3PSPProprietarySmartDeviceMember" abstract="true" name="CELLECTRA3PSPProprietarySmartDeviceMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ino_UnderwrittenPublicOfferingMember" abstract="true" name="UnderwrittenPublicOfferingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ino_GrantProceedsReceived" abstract="false" name="GrantProceedsReceived" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet" abstract="false" name="IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_DeferredGrantFundingFromAffiliateNoncurrent" abstract="false" name="DeferredGrantFundingFromAffiliateNoncurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_IncreaseDecreaseInAccruedClinicalTrialExpense" abstract="false" name="IncreaseDecreaseInAccruedClinicalTrialExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_DNAEncodedMonoclonalAntibodyTechnologyMember" abstract="true" name="DNAEncodedMonoclonalAntibodyTechnologyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ino_DeferredGrantFundingFromAffiliate" abstract="false" name="DeferredGrantFundingFromAffiliate" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_ConvertibleBondsMember" abstract="true" name="ConvertibleBondsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ino_DeferredGrantFundingFromAffiliateCurrent" abstract="false" name="DeferredGrantFundingFromAffiliateCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" abstract="false" name="FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment" abstract="false" name="CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="ino_CollaborationAgreementTerritoryExpansionOptionPeriod" abstract="false" name="CollaborationAgreementTerritoryExpansionOptionPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="ino_ApolloBioMember" abstract="true" name="ApolloBioMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ino_SettlementOfReceivableWithSharesOfCommonStockFromEquitySecurity" abstract="false" name="SettlementOfReceivableWithSharesOfCommonStockFromEquitySecurity" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_CollaborativeAgreementPeriodFromEffectiveDateForTermination" abstract="false" name="CollaborativeAgreementPeriodFromEffectiveDateForTermination" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="ino_TheWistarInstituteMember" abstract="true" name="TheWistarInstituteMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ino_StockSalesAgreementRemainingAuthorizedAmount" abstract="false" name="StockSalesAgreementRemainingAuthorizedAmount" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_ProceedsFromCollaborativeAgreement" abstract="false" name="ProceedsFromCollaborativeAgreement" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_PlymouthMeetingPennsylvaniaMember" abstract="true" name="PlymouthMeetingPennsylvaniaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ino_CollaborativeAgreementNumberofDaysWrittenNoticeBeforeTermination" abstract="false" name="CollaborativeAgreementNumberofDaysWrittenNoticeBeforeTermination" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="ino_NumberOfPotentialSharesAuthorizedForIssuanceUnderShareBasedCompensationPlan" abstract="false" name="NumberOfPotentialSharesAuthorizedForIssuanceUnderShareBasedCompensationPlan" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="ino_SharebasedCompensationArrangementbySharebasedPaymentAwardIncreaseInNumberofSharesAuthorized" abstract="false" name="SharebasedCompensationArrangementbySharebasedPaymentAwardIncreaseInNumberofSharesAuthorized" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="ino_A2007IncentivePlanMember" abstract="true" name="A2007IncentivePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ino_InitialConversionPriceMember" abstract="true" name="InitialConversionPriceMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ino_StockSaleAgreementAggregateNumberofSharesIssued" abstract="false" name="StockSaleAgreementAggregateNumberofSharesIssued" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="ino_LassaFeverAndMERSVaccineMember" abstract="true" name="LassaFeverAndMERSVaccineMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>6
<FILENAME>ino-20210331_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:e9d1bb07-ad73-4929-82ea-6e949ab8c789,g:8e741ee6-3c7b-40cd-9e55-d4abd68b099b-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.inovio.com/role/CoverPage" xlink:type="simple" xlink:href="ino-20210331.xsd#CoverPage"/>
  <link:calculationLink xlink:role="http://www.inovio.com/role/CoverPage" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.inovio.com/role/CondensedConsolidatedBalanceSheets" xlink:type="simple" xlink:href="ino-20210331.xsd#CondensedConsolidatedBalanceSheets"/>
  <link:calculationLink xlink:role="http://www.inovio.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_82cbc156-c9fe-4c7e-b5d7-f7a13ddb609a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_69fdb3c5-9ac0-4d9e-807b-746affb87d7c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_82cbc156-c9fe-4c7e-b5d7-f7a13ddb609a" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_69fdb3c5-9ac0-4d9e-807b-746affb87d7c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueToRelatedPartiesCurrent_af46d318-0ff5-429b-9717-c2d13e182164" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DueToRelatedPartiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_82cbc156-c9fe-4c7e-b5d7-f7a13ddb609a" xlink:to="loc_us-gaap_DueToRelatedPartiesCurrent_af46d318-0ff5-429b-9717-c2d13e182164" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_AccruedClinicalTrialExpenseCurrent_42a9debc-8167-4281-9316-7f5ee8eadedd" xlink:href="ino-20210331.xsd#ino_AccruedClinicalTrialExpenseCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_82cbc156-c9fe-4c7e-b5d7-f7a13ddb609a" xlink:to="loc_ino_AccruedClinicalTrialExpenseCurrent_42a9debc-8167-4281-9316-7f5ee8eadedd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_a7c24752-bb14-455a-803a-ee6e726536c8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_82cbc156-c9fe-4c7e-b5d7-f7a13ddb609a" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_a7c24752-bb14-455a-803a-ee6e726536c8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ContractWithCustomerLiabilityAffiliatedEntityCurrent_0f6bd63a-8994-4497-9f2c-a79b29ff734b" xlink:href="ino-20210331.xsd#ino_ContractWithCustomerLiabilityAffiliatedEntityCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_82cbc156-c9fe-4c7e-b5d7-f7a13ddb609a" xlink:to="loc_ino_ContractWithCustomerLiabilityAffiliatedEntityCurrent_0f6bd63a-8994-4497-9f2c-a79b29ff734b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_c85d77d8-3bf1-4042-91fb-6924dc58a63e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_82cbc156-c9fe-4c7e-b5d7-f7a13ddb609a" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_c85d77d8-3bf1-4042-91fb-6924dc58a63e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DeferredGrantFundingCurrent_7dd6d4a8-9348-4223-9154-21f8a12e3eca" xlink:href="ino-20210331.xsd#ino_DeferredGrantFundingCurrent"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_82cbc156-c9fe-4c7e-b5d7-f7a13ddb609a" xlink:to="loc_ino_DeferredGrantFundingCurrent_7dd6d4a8-9348-4223-9154-21f8a12e3eca" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DeferredGrantFundingFromAffiliateCurrent_cc74360b-ec97-423f-87f3-d02f87981f29" xlink:href="ino-20210331.xsd#ino_DeferredGrantFundingFromAffiliateCurrent"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_82cbc156-c9fe-4c7e-b5d7-f7a13ddb609a" xlink:to="loc_ino_DeferredGrantFundingFromAffiliateCurrent_cc74360b-ec97-423f-87f3-d02f87981f29" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_56cb2c22-4936-495b-9746-a71f3b4fe8e0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_e58147db-8c5e-4f0b-a18c-2e844ce41b1e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_56cb2c22-4936-495b-9746-a71f3b4fe8e0" xlink:to="loc_us-gaap_PreferredStockValue_e58147db-8c5e-4f0b-a18c-2e844ce41b1e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_08dd2595-83c7-4514-b084-926bdb2e7a4a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_56cb2c22-4936-495b-9746-a71f3b4fe8e0" xlink:to="loc_us-gaap_CommonStockValue_08dd2595-83c7-4514-b084-926bdb2e7a4a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_8cb04e7a-a6fa-45fa-8eee-9ec374cefc28" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_56cb2c22-4936-495b-9746-a71f3b4fe8e0" xlink:to="loc_us-gaap_AdditionalPaidInCapital_8cb04e7a-a6fa-45fa-8eee-9ec374cefc28" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_c1e65897-c19b-484b-b4ec-cdbec2879644" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_56cb2c22-4936-495b-9746-a71f3b4fe8e0" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_c1e65897-c19b-484b-b4ec-cdbec2879644" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_fc515ad6-1fb3-471e-84e3-aaac619d6644" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_56cb2c22-4936-495b-9746-a71f3b4fe8e0" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_fc515ad6-1fb3-471e-84e3-aaac619d6644" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_c9a068c3-0498-4b80-b066-cdd259e9a21d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_03afdd7f-4365-40a8-8e16-6e62e7741265" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_c9a068c3-0498-4b80-b066-cdd259e9a21d" xlink:to="loc_us-gaap_LiabilitiesCurrent_03afdd7f-4365-40a8-8e16-6e62e7741265" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_97407840-c3ef-444c-a191-9ce25af26705" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_c9a068c3-0498-4b80-b066-cdd259e9a21d" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_97407840-c3ef-444c-a191-9ce25af26705" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebt_f43555c4-6ae3-4b35-9a1b-eccfd7c54a4e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleDebt"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_c9a068c3-0498-4b80-b066-cdd259e9a21d" xlink:to="loc_us-gaap_ConvertibleDebt_f43555c4-6ae3-4b35-9a1b-eccfd7c54a4e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_0b2739b2-ebb9-48cc-95b7-15fa02e0e13b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_c9a068c3-0498-4b80-b066-cdd259e9a21d" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_0b2739b2-ebb9-48cc-95b7-15fa02e0e13b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_2a07d5ee-ae52-4f20-a0ed-03f3e7e22583" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_c9a068c3-0498-4b80-b066-cdd259e9a21d" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_2a07d5ee-ae52-4f20-a0ed-03f3e7e22583" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DeferredGrantFundingFromAffiliateNoncurrent_e0f2511d-f8f7-445e-8f49-8b170df4dc5f" xlink:href="ino-20210331.xsd#ino_DeferredGrantFundingFromAffiliateNoncurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_c9a068c3-0498-4b80-b066-cdd259e9a21d" xlink:to="loc_ino_DeferredGrantFundingFromAffiliateNoncurrent_e0f2511d-f8f7-445e-8f49-8b170df4dc5f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_49974b2b-0767-4d35-a4c7-f127a3f2005a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_c9a068c3-0498-4b80-b066-cdd259e9a21d" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_49974b2b-0767-4d35-a4c7-f127a3f2005a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_60c747f8-5ddd-436f-96bb-23661c7ca711" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_a733bf02-7085-4cf8-8117-a17e17cdbbc6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_60c747f8-5ddd-436f-96bb-23661c7ca711" xlink:to="loc_us-gaap_Liabilities_a733bf02-7085-4cf8-8117-a17e17cdbbc6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_d9703b43-d30e-45ba-8695-d74ff8907283" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_60c747f8-5ddd-436f-96bb-23661c7ca711" xlink:to="loc_us-gaap_StockholdersEquity_d9703b43-d30e-45ba-8695-d74ff8907283" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_4a9f3ebd-1eb8-40ea-be3d-58e4b141567d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_839be366-d90b-4c5e-8779-8aa8f4a37927" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_4a9f3ebd-1eb8-40ea-be3d-58e4b141567d" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_839be366-d90b-4c5e-8779-8aa8f4a37927" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestments_3392e4c8-844f-4522-881f-d89cf1a26e0b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermInvestments"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_4a9f3ebd-1eb8-40ea-be3d-58e4b141567d" xlink:to="loc_us-gaap_ShortTermInvestments_3392e4c8-844f-4522-881f-d89cf1a26e0b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_5ad71e90-922f-471d-87bf-cc42928b2207" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_4a9f3ebd-1eb8-40ea-be3d-58e4b141567d" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_5ad71e90-922f-471d-87bf-cc42928b2207" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableRelatedPartiesCurrent_2b8bbc58-91b4-44bc-b86f-9f66ff549a7d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableRelatedPartiesCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_4a9f3ebd-1eb8-40ea-be3d-58e4b141567d" xlink:to="loc_us-gaap_AccountsReceivableRelatedPartiesCurrent_2b8bbc58-91b4-44bc-b86f-9f66ff549a7d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_e07a748f-26aa-48f1-a2bf-74bf2ecc58dc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_4a9f3ebd-1eb8-40ea-be3d-58e4b141567d" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_e07a748f-26aa-48f1-a2bf-74bf2ecc58dc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity_8717a5c5-f3ce-4882-a744-444c2c4da931" xlink:href="ino-20210331.xsd#ino_PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_4a9f3ebd-1eb8-40ea-be3d-58e4b141567d" xlink:to="loc_ino_PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity_8717a5c5-f3ce-4882-a744-444c2c4da931" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_511eaebb-9383-4311-8f3a-d356b7518233" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_aba37870-8dba-435e-b0d3-f1406bc31f16" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_511eaebb-9383-4311-8f3a-d356b7518233" xlink:to="loc_us-gaap_AssetsCurrent_aba37870-8dba-435e-b0d3-f1406bc31f16" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_08564a9e-d6bd-4c45-aa49-d7e9460ed01e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_511eaebb-9383-4311-8f3a-d356b7518233" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_08564a9e-d6bd-4c45-aa49-d7e9460ed01e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_e54c1f99-ef64-4e5b-a475-365cabd01085" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestments"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_511eaebb-9383-4311-8f3a-d356b7518233" xlink:to="loc_us-gaap_EquityMethodInvestments_e54c1f99-ef64-4e5b-a475-365cabd01085" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_2d1dfacd-7ff5-4f89-85b2-ce56dc87b945" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_511eaebb-9383-4311-8f3a-d356b7518233" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_2d1dfacd-7ff5-4f89-85b2-ce56dc87b945" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_c8fd1d88-e1ae-449b-ad36-a4b4ede6d3d7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_511eaebb-9383-4311-8f3a-d356b7518233" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_c8fd1d88-e1ae-449b-ad36-a4b4ede6d3d7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_17832caa-ec38-463e-aab1-a17ddb6e0ac4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_511eaebb-9383-4311-8f3a-d356b7518233" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_17832caa-ec38-463e-aab1-a17ddb6e0ac4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_a9bc58a4-4e8d-4bd0-8703-283a3f92a11d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_511eaebb-9383-4311-8f3a-d356b7518233" xlink:to="loc_us-gaap_Goodwill_a9bc58a4-4e8d-4bd0-8703-283a3f92a11d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_22399220-6213-4827-aeb3-d459cf14e824" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_511eaebb-9383-4311-8f3a-d356b7518233" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_22399220-6213-4827-aeb3-d459cf14e824" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/CondensedConsolidatedStatementsofOperations" xlink:type="simple" xlink:href="ino-20210331.xsd#CondensedConsolidatedStatementsofOperations"/>
  <link:calculationLink xlink:role="http://www.inovio.com/role/CondensedConsolidatedStatementsofOperations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_2b4dcb02-70fa-4976-9009-6d765e72c7df" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_ac8a1ef8-f81e-4f77-97b0-b621d6f3ce09" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_2b4dcb02-70fa-4976-9009-6d765e72c7df" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_ac8a1ef8-f81e-4f77-97b0-b621d6f3ce09" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_0849e48a-2786-4022-ad50-9a508aee027c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_2b4dcb02-70fa-4976-9009-6d765e72c7df" xlink:to="loc_us-gaap_OperatingExpenses_0849e48a-2786-4022-ad50-9a508aee027c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_988d1497-deca-43c0-954f-6395e06367e0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_e5c97f38-ae50-4cf3-ad9a-7e076cd5c087" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_988d1497-deca-43c0-954f-6395e06367e0" xlink:to="loc_us-gaap_ProfitLoss_e5c97f38-ae50-4cf3-ad9a-7e076cd5c087" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_e5bd505d-e934-4b0e-9552-79fbbeca0876" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_988d1497-deca-43c0-954f-6395e06367e0" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_e5bd505d-e934-4b0e-9552-79fbbeca0876" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_5ec6c416-9be7-45c5-9c04-b595d6ce0d3b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_c745b706-31ec-4d92-874e-4eafa706bd29" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_5ec6c416-9be7-45c5-9c04-b595d6ce0d3b" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_c745b706-31ec-4d92-874e-4eafa706bd29" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_a120bf27-f0e2-4c31-95de-c50c4050d0e4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_5ec6c416-9be7-45c5-9c04-b595d6ce0d3b" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_a120bf27-f0e2-4c31-95de-c50c4050d0e4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_8207b2d4-5bd3-42de-a4d4-4ad9f1488fe1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_d4180d25-5aca-4ad5-8088-a8f7e8bb1fe2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_8207b2d4-5bd3-42de-a4d4-4ad9f1488fe1" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_d4180d25-5aca-4ad5-8088-a8f7e8bb1fe2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_a1f10fd7-e9e7-4f6a-ac91-2dad515e46dd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_8207b2d4-5bd3-42de-a4d4-4ad9f1488fe1" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_a1f10fd7-e9e7-4f6a-ac91-2dad515e46dd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_4ac44e7a-c53c-4a68-97d3-7e1a13f05f03" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_9cd791f4-33dd-47af-bec3-9feb1f853a0f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_4ac44e7a-c53c-4a68-97d3-7e1a13f05f03" xlink:to="loc_us-gaap_OperatingIncomeLoss_9cd791f4-33dd-47af-bec3-9feb1f853a0f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeOperating_89cf2fe8-5630-4e64-bdf2-6cd5de9659bd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestIncomeOperating"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_4ac44e7a-c53c-4a68-97d3-7e1a13f05f03" xlink:to="loc_us-gaap_InterestIncomeOperating_89cf2fe8-5630-4e64-bdf2-6cd5de9659bd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_610bef53-8f47-4fca-8ed5-38359bb70589" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_4ac44e7a-c53c-4a68-97d3-7e1a13f05f03" xlink:to="loc_us-gaap_InterestExpense_610bef53-8f47-4fca-8ed5-38359bb70589" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet_8d862c62-e654-490e-9059-7b4d899472b9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_4ac44e7a-c53c-4a68-97d3-7e1a13f05f03" xlink:to="loc_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet_8d862c62-e654-490e-9059-7b4d899472b9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ChangeInValueOfInvestmentsInAffiliatedCompany_5c870d56-f81d-4da2-ad54-12223a26ed44" xlink:href="ino-20210331.xsd#ino_ChangeInValueOfInvestmentsInAffiliatedCompany"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_4ac44e7a-c53c-4a68-97d3-7e1a13f05f03" xlink:to="loc_ino_ChangeInValueOfInvestmentsInAffiliatedCompany_5c870d56-f81d-4da2-ad54-12223a26ed44" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_449e8e11-3ffa-4bd4-9995-318e615785af" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_4ac44e7a-c53c-4a68-97d3-7e1a13f05f03" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_449e8e11-3ffa-4bd4-9995-318e615785af" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_15fb2419-f75c-4edd-81c7-0166a61cfee6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_4ac44e7a-c53c-4a68-97d3-7e1a13f05f03" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_15fb2419-f75c-4edd-81c7-0166a61cfee6" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/CondensedConsolidatedStatementsofComprehensiveLoss" xlink:type="simple" xlink:href="ino-20210331.xsd#CondensedConsolidatedStatementsofComprehensiveLoss"/>
  <link:calculationLink xlink:role="http://www.inovio.com/role/CondensedConsolidatedStatementsofComprehensiveLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_db02873e-c794-4492-aece-ed54a0d521d5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_4e5a75d3-9246-434f-9b6f-436128ca7a07" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_db02873e-c794-4492-aece-ed54a0d521d5" xlink:to="loc_us-gaap_ProfitLoss_4e5a75d3-9246-434f-9b6f-436128ca7a07" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_945c4f32-73c9-4fae-a0a1-73d62592fbc0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_db02873e-c794-4492-aece-ed54a0d521d5" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_945c4f32-73c9-4fae-a0a1-73d62592fbc0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_64d29f23-641e-4161-b96e-73e9f093ad80" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_db02873e-c794-4492-aece-ed54a0d521d5" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_64d29f23-641e-4161-b96e-73e9f093ad80" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_33b4a4fc-cb43-4512-85d7-65b811a38725" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_80fb6a79-df2e-45f3-a1d9-e5f059870a8c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_33b4a4fc-cb43-4512-85d7-65b811a38725" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_80fb6a79-df2e-45f3-a1d9-e5f059870a8c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_665ac45b-b48c-4ac3-8c35-c18238dd6d05" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_33b4a4fc-cb43-4512-85d7-65b811a38725" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_665ac45b-b48c-4ac3-8c35-c18238dd6d05" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/CondensedConsolidatedStatementsofStockholdersEquity" xlink:type="simple" xlink:href="ino-20210331.xsd#CondensedConsolidatedStatementsofStockholdersEquity"/>
  <link:calculationLink xlink:role="http://www.inovio.com/role/CondensedConsolidatedStatementsofStockholdersEquity" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.inovio.com/role/CondensedConsolidatedStatementsofStockholdersEquityParenthetical" xlink:type="simple" xlink:href="ino-20210331.xsd#CondensedConsolidatedStatementsofStockholdersEquityParenthetical"/>
  <link:calculationLink xlink:role="http://www.inovio.com/role/CondensedConsolidatedStatementsofStockholdersEquityParenthetical" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="ino-20210331.xsd#CondensedConsolidatedStatementsofCashFlows"/>
  <link:calculationLink xlink:role="http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_676d2ce8-d8c9-4d3d-9653-b7a068346071" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3bcb5b0c-ba4a-4089-b9d2-538fda467f49" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_676d2ce8-d8c9-4d3d-9653-b7a068346071" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3bcb5b0c-ba4a-4089-b9d2-538fda467f49" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_17754f84-690f-4399-a0da-e59332874d55" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_676d2ce8-d8c9-4d3d-9653-b7a068346071" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_17754f84-690f-4399-a0da-e59332874d55" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_615978db-2798-4e58-85eb-fe85acce3074" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_676d2ce8-d8c9-4d3d-9653-b7a068346071" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_615978db-2798-4e58-85eb-fe85acce3074" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_73437994-0b18-4ea7-b90b-0091ade75d95" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_676d2ce8-d8c9-4d3d-9653-b7a068346071" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_73437994-0b18-4ea7-b90b-0091ade75d95" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b372fc58-d042-464b-aba1-d3dfad1c7c8d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_ca2a801a-7824-4046-afb9-9baaa0b6e209" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b372fc58-d042-464b-aba1-d3dfad1c7c8d" xlink:to="loc_us-gaap_ProfitLoss_ca2a801a-7824-4046-afb9-9baaa0b6e209" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_b35050cb-3c1a-4ea8-9827-eea81b1a9358" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Depreciation"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b372fc58-d042-464b-aba1-d3dfad1c7c8d" xlink:to="loc_us-gaap_Depreciation_b35050cb-3c1a-4ea8-9827-eea81b1a9358" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_AmortizationOfOperatingLeaseRightOfUseAssets_948f6c4c-ad18-456d-8f37-f5a8e3296692" xlink:href="ino-20210331.xsd#ino_AmortizationOfOperatingLeaseRightOfUseAssets"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b372fc58-d042-464b-aba1-d3dfad1c7c8d" xlink:to="loc_ino_AmortizationOfOperatingLeaseRightOfUseAssets_948f6c4c-ad18-456d-8f37-f5a8e3296692" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_96fb24dc-f806-403f-80cf-160a73ad4169" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b372fc58-d042-464b-aba1-d3dfad1c7c8d" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_96fb24dc-f806-403f-80cf-160a73ad4169" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDerivativeLiabilities_f7d8b882-5dc2-4f47-b9ee-384d4c7800a4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInDerivativeLiabilities"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b372fc58-d042-464b-aba1-d3dfad1c7c8d" xlink:to="loc_us-gaap_IncreaseDecreaseInDerivativeLiabilities_f7d8b882-5dc2-4f47-b9ee-384d4c7800a4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_a666b04e-15d4-4d6c-a443-58d0c807637c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b372fc58-d042-464b-aba1-d3dfad1c7c8d" xlink:to="loc_us-gaap_ShareBasedCompensation_a666b04e-15d4-4d6c-a443-58d0c807637c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_NonCashInterestIncomeExpense_67a25405-4d1d-462d-bb89-4c91a41e0a5a" xlink:href="ino-20210331.xsd#ino_NonCashInterestIncomeExpense"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b372fc58-d042-464b-aba1-d3dfad1c7c8d" xlink:to="loc_ino_NonCashInterestIncomeExpense_67a25405-4d1d-462d-bb89-4c91a41e0a5a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnInvestments_d26d4110-6300-4862-adbf-8704a8668e72" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnInvestments"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b372fc58-d042-464b-aba1-d3dfad1c7c8d" xlink:to="loc_us-gaap_GainLossOnInvestments_d26d4110-6300-4862-adbf-8704a8668e72" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_SettlementOfReceivableWithSharesOfCommonStockFromEquitySecurity_f7bca9fb-8d88-4433-9b06-5e35592f57b8" xlink:href="ino-20210331.xsd#ino_SettlementOfReceivableWithSharesOfCommonStockFromEquitySecurity"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b372fc58-d042-464b-aba1-d3dfad1c7c8d" xlink:to="loc_ino_SettlementOfReceivableWithSharesOfCommonStockFromEquitySecurity_f7bca9fb-8d88-4433-9b06-5e35592f57b8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ChangeInValueOfInvestmentsInAffiliatedCompany_49593ac6-634a-46d7-951f-c46546274c5a" xlink:href="ino-20210331.xsd#ino_ChangeInValueOfInvestmentsInAffiliatedCompany"/>
    <link:calculationArc order="10" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b372fc58-d042-464b-aba1-d3dfad1c7c8d" xlink:to="loc_ino_ChangeInValueOfInvestmentsInAffiliatedCompany_49593ac6-634a-46d7-951f-c46546274c5a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_36b22f04-6108-46a9-916d-6e4e6daaea00" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:calculationArc order="11" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b372fc58-d042-464b-aba1-d3dfad1c7c8d" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_36b22f04-6108-46a9-916d-6e4e6daaea00" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedLoss_0da2b2cc-499d-4065-9e70-423c131dc8c0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedLoss"/>
    <link:calculationArc order="12" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b372fc58-d042-464b-aba1-d3dfad1c7c8d" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedLoss_0da2b2cc-499d-4065-9e70-423c131dc8c0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_OperatingLeaseNonCashLeaseExpense_0b97cd10-d58e-4e15-8bce-ca8768dbe8ed" xlink:href="ino-20210331.xsd#ino_OperatingLeaseNonCashLeaseExpense"/>
    <link:calculationArc order="13" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b372fc58-d042-464b-aba1-d3dfad1c7c8d" xlink:to="loc_ino_OperatingLeaseNonCashLeaseExpense_0b97cd10-d58e-4e15-8bce-ca8768dbe8ed" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_ff4985a6-a2be-47d5-801f-cd84411046f0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <link:calculationArc order="14" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b372fc58-d042-464b-aba1-d3dfad1c7c8d" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_ff4985a6-a2be-47d5-801f-cd84411046f0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_10674680-9fa6-48cb-bfde-308698e58014" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="15" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b372fc58-d042-464b-aba1-d3dfad1c7c8d" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_10674680-9fa6-48cb-bfde-308698e58014" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties_07e0d76c-dc79-4868-a5f9-66a2664701a0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties"/>
    <link:calculationArc order="16" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b372fc58-d042-464b-aba1-d3dfad1c7c8d" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties_07e0d76c-dc79-4868-a5f9-66a2664701a0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_2c48ae85-bbd1-476d-9a13-c28b320ff9c5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="17" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b372fc58-d042-464b-aba1-d3dfad1c7c8d" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_2c48ae85-bbd1-476d-9a13-c28b320ff9c5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity_ed5d7c32-5ce4-430a-bacf-1802c10b3d32" xlink:href="ino-20210331.xsd#ino_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity"/>
    <link:calculationArc order="18" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b372fc58-d042-464b-aba1-d3dfad1c7c8d" xlink:to="loc_ino_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity_ed5d7c32-5ce4-430a-bacf-1802c10b3d32" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_6211e0ca-341e-4f80-9120-d709caf134fa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:calculationArc order="19" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b372fc58-d042-464b-aba1-d3dfad1c7c8d" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_6211e0ca-341e-4f80-9120-d709caf134fa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_a3b47944-fbb4-4d95-ac82-42b1d4f5b1d1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:calculationArc order="20" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b372fc58-d042-464b-aba1-d3dfad1c7c8d" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_a3b47944-fbb4-4d95-ac82-42b1d4f5b1d1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_IncreaseDecreaseInAccruedClinicalTrialExpense_5ef22104-ac07-4a8c-8343-b01cb5611e6d" xlink:href="ino-20210331.xsd#ino_IncreaseDecreaseInAccruedClinicalTrialExpense"/>
    <link:calculationArc order="21" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b372fc58-d042-464b-aba1-d3dfad1c7c8d" xlink:to="loc_ino_IncreaseDecreaseInAccruedClinicalTrialExpense_5ef22104-ac07-4a8c-8343-b01cb5611e6d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties_4a46ebcd-b3b9-4eba-aa40-a5b4df8dffa8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties"/>
    <link:calculationArc order="22" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b372fc58-d042-464b-aba1-d3dfad1c7c8d" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties_4a46ebcd-b3b9-4eba-aa40-a5b4df8dffa8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_773d3cd6-7a32-4500-b744-9f6d0065cb35" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:calculationArc order="23" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b372fc58-d042-464b-aba1-d3dfad1c7c8d" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_773d3cd6-7a32-4500-b744-9f6d0065cb35" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_IncreaseDecreaseInDeferredRevenueFromRelatedParties_40a95d76-4d69-4e09-9657-644d5b40c641" xlink:href="ino-20210331.xsd#ino_IncreaseDecreaseInDeferredRevenueFromRelatedParties"/>
    <link:calculationArc order="24" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b372fc58-d042-464b-aba1-d3dfad1c7c8d" xlink:to="loc_ino_IncreaseDecreaseInDeferredRevenueFromRelatedParties_40a95d76-4d69-4e09-9657-644d5b40c641" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet_70cd57e4-58a0-42b1-8e5c-15db44994456" xlink:href="ino-20210331.xsd#ino_IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet"/>
    <link:calculationArc order="25" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b372fc58-d042-464b-aba1-d3dfad1c7c8d" xlink:to="loc_ino_IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet_70cd57e4-58a0-42b1-8e5c-15db44994456" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_IncreaseDecreaseinDeferredGrantFundingCurrent_8dcaa599-de83-46d5-af93-edf9a14f4219" xlink:href="ino-20210331.xsd#ino_IncreaseDecreaseinDeferredGrantFundingCurrent"/>
    <link:calculationArc order="26" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b372fc58-d042-464b-aba1-d3dfad1c7c8d" xlink:to="loc_ino_IncreaseDecreaseinDeferredGrantFundingCurrent_8dcaa599-de83-46d5-af93-edf9a14f4219" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_IncreaseDecreaseinDeferredGrantFundingFromAffiliateCurrent_45ba1df7-2eb2-4e2d-bd14-daeaedeefecd" xlink:href="ino-20210331.xsd#ino_IncreaseDecreaseinDeferredGrantFundingFromAffiliateCurrent"/>
    <link:calculationArc order="27" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b372fc58-d042-464b-aba1-d3dfad1c7c8d" xlink:to="loc_ino_IncreaseDecreaseinDeferredGrantFundingFromAffiliateCurrent_45ba1df7-2eb2-4e2d-bd14-daeaedeefecd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_f1cd42c9-0742-43f2-85d7-12a4745bd8f4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
    <link:calculationArc order="28" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b372fc58-d042-464b-aba1-d3dfad1c7c8d" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_f1cd42c9-0742-43f2-85d7-12a4745bd8f4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_766f06af-4fa7-4bee-a648-03915d2a126e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireShortTermInvestments_b87b08a5-2736-43bd-872b-d8267307d35a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireShortTermInvestments"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_766f06af-4fa7-4bee-a648-03915d2a126e" xlink:to="loc_us-gaap_PaymentsToAcquireShortTermInvestments_b87b08a5-2736-43bd-872b-d8267307d35a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfShortTermInvestments_9f684ae1-081c-4da0-8462-12555ce7c420" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleOfShortTermInvestments"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_766f06af-4fa7-4bee-a648-03915d2a126e" xlink:to="loc_us-gaap_ProceedsFromSaleOfShortTermInvestments_9f684ae1-081c-4da0-8462-12555ce7c420" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_676109f6-ffce-42a6-aa11-67f7d6384702" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_766f06af-4fa7-4bee-a648-03915d2a126e" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_676109f6-ffce-42a6-aa11-67f7d6384702" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_86907bc0-ed40-4052-b8d9-59162f03b26a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_d6da0588-50d6-4cf6-8a61-45b1c0422170" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_86907bc0-ed40-4052-b8d9-59162f03b26a" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_d6da0588-50d6-4cf6-8a61-45b1c0422170" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_356a7dfb-b4b8-4832-bfd4-313fa3de0455" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_86907bc0-ed40-4052-b8d9-59162f03b26a" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_356a7dfb-b4b8-4832-bfd4-313fa3de0455" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_fbaa62cc-4f46-49a7-bf91-283268e7a958" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_86907bc0-ed40-4052-b8d9-59162f03b26a" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_fbaa62cc-4f46-49a7-bf91-283268e7a958" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMinorityShareholders_a1aa8e14-bc16-43c3-af0a-686bcb742d83" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromMinorityShareholders"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_86907bc0-ed40-4052-b8d9-59162f03b26a" xlink:to="loc_us-gaap_ProceedsFromMinorityShareholders_a1aa8e14-bc16-43c3-af0a-686bcb742d83" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/OrganizationandOperations" xlink:type="simple" xlink:href="ino-20210331.xsd#OrganizationandOperations"/>
  <link:calculationLink xlink:role="http://www.inovio.com/role/OrganizationandOperations" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.inovio.com/role/BasisofPresentationLiquidityandRisksandUncertainties" xlink:type="simple" xlink:href="ino-20210331.xsd#BasisofPresentationLiquidityandRisksandUncertainties"/>
  <link:calculationLink xlink:role="http://www.inovio.com/role/BasisofPresentationLiquidityandRisksandUncertainties" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.inovio.com/role/BasisofPresentationLiquidityandRisksandUncertaintiesPolicies" xlink:type="simple" xlink:href="ino-20210331.xsd#BasisofPresentationLiquidityandRisksandUncertaintiesPolicies"/>
  <link:calculationLink xlink:role="http://www.inovio.com/role/BasisofPresentationLiquidityandRisksandUncertaintiesPolicies" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.inovio.com/role/BasisofPresentationLiquidityandRisksandUncertaintiesDetails" xlink:type="simple" xlink:href="ino-20210331.xsd#BasisofPresentationLiquidityandRisksandUncertaintiesDetails"/>
  <link:calculationLink xlink:role="http://www.inovio.com/role/BasisofPresentationLiquidityandRisksandUncertaintiesDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.inovio.com/role/CriticalAccountingPolicies" xlink:type="simple" xlink:href="ino-20210331.xsd#CriticalAccountingPolicies"/>
  <link:calculationLink xlink:role="http://www.inovio.com/role/CriticalAccountingPolicies" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.inovio.com/role/CriticalAccountingPoliciesDetails" xlink:type="simple" xlink:href="ino-20210331.xsd#CriticalAccountingPoliciesDetails"/>
  <link:calculationLink xlink:role="http://www.inovio.com/role/CriticalAccountingPoliciesDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.inovio.com/role/ImpactofRecentlyIssuedAccountingStandards" xlink:type="simple" xlink:href="ino-20210331.xsd#ImpactofRecentlyIssuedAccountingStandards"/>
  <link:calculationLink xlink:role="http://www.inovio.com/role/ImpactofRecentlyIssuedAccountingStandards" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.inovio.com/role/RevenueRecognition" xlink:type="simple" xlink:href="ino-20210331.xsd#RevenueRecognition"/>
  <link:calculationLink xlink:role="http://www.inovio.com/role/RevenueRecognition" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.inovio.com/role/RevenueRecognitionDetails" xlink:type="simple" xlink:href="ino-20210331.xsd#RevenueRecognitionDetails"/>
  <link:calculationLink xlink:role="http://www.inovio.com/role/RevenueRecognitionDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.inovio.com/role/ShorttermInvestments" xlink:type="simple" xlink:href="ino-20210331.xsd#ShorttermInvestments"/>
  <link:calculationLink xlink:role="http://www.inovio.com/role/ShorttermInvestments" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.inovio.com/role/ShorttermInvestmentsTables" xlink:type="simple" xlink:href="ino-20210331.xsd#ShorttermInvestmentsTables"/>
  <link:calculationLink xlink:role="http://www.inovio.com/role/ShorttermInvestmentsTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.inovio.com/role/ShorttermInvestmentsNarrativeDetails" xlink:type="simple" xlink:href="ino-20210331.xsd#ShorttermInvestmentsNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.inovio.com/role/ShorttermInvestmentsNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.inovio.com/role/ShorttermInvestmentsSummaryofAvailableforsaleSecuritiesDetails" xlink:type="simple" xlink:href="ino-20210331.xsd#ShorttermInvestmentsSummaryofAvailableforsaleSecuritiesDetails"/>
  <link:calculationLink xlink:role="http://www.inovio.com/role/ShorttermInvestmentsSummaryofAvailableforsaleSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_7d108141-d607-4e58-9c52-b31b31487eb3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_9e7ab727-a49d-433b-ba5e-fdace57493ee" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_7d108141-d607-4e58-9c52-b31b31487eb3" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_9e7ab727-a49d-433b-ba5e-fdace57493ee" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_0cf35ffd-b9c9-4ce3-8945-531bf1d75aa9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_7d108141-d607-4e58-9c52-b31b31487eb3" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_0cf35ffd-b9c9-4ce3-8945-531bf1d75aa9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_c663c0a3-423f-4089-96fc-d6d28ae5cd93" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_7d108141-d607-4e58-9c52-b31b31487eb3" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_c663c0a3-423f-4089-96fc-d6d28ae5cd93" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/FairValueMeasurements" xlink:type="simple" xlink:href="ino-20210331.xsd#FairValueMeasurements"/>
  <link:calculationLink xlink:role="http://www.inovio.com/role/FairValueMeasurements" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.inovio.com/role/FairValueMeasurementsTables" xlink:type="simple" xlink:href="ino-20210331.xsd#FairValueMeasurementsTables"/>
  <link:calculationLink xlink:role="http://www.inovio.com/role/FairValueMeasurementsTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.inovio.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueDetails" xlink:type="simple" xlink:href="ino-20210331.xsd#FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueDetails"/>
  <link:calculationLink xlink:role="http://www.inovio.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_4cd9fb4e-e83d-46a9-b1b9-d1013e03a338" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_a07f1a70-55d4-40fa-aa0d-f5e785e7e78e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_4cd9fb4e-e83d-46a9-b1b9-d1013e03a338" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_a07f1a70-55d4-40fa-aa0d-f5e785e7e78e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_c41e1acc-dd68-4041-a62c-67bc56d7108c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_4cd9fb4e-e83d-46a9-b1b9-d1013e03a338" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_c41e1acc-dd68-4041-a62c-67bc56d7108c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_8d551ca8-5dab-432c-93b9-3ad958b48805" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_4cd9fb4e-e83d-46a9-b1b9-d1013e03a338" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_8d551ca8-5dab-432c-93b9-3ad958b48805" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/FairValueMeasurementsNarrativeDetails" xlink:type="simple" xlink:href="ino-20210331.xsd#FairValueMeasurementsNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.inovio.com/role/FairValueMeasurementsNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.inovio.com/role/GoodwillandIntangibleAssets" xlink:type="simple" xlink:href="ino-20210331.xsd#GoodwillandIntangibleAssets"/>
  <link:calculationLink xlink:role="http://www.inovio.com/role/GoodwillandIntangibleAssets" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.inovio.com/role/GoodwillandIntangibleAssetsTables" xlink:type="simple" xlink:href="ino-20210331.xsd#GoodwillandIntangibleAssetsTables"/>
  <link:calculationLink xlink:role="http://www.inovio.com/role/GoodwillandIntangibleAssetsTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.inovio.com/role/GoodwillandIntangibleAssetsScheduleGoodwillandIntangibleAssetsDetails" xlink:type="simple" xlink:href="ino-20210331.xsd#GoodwillandIntangibleAssetsScheduleGoodwillandIntangibleAssetsDetails"/>
  <link:calculationLink xlink:role="http://www.inovio.com/role/GoodwillandIntangibleAssetsScheduleGoodwillandIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ino_GoodwillAndIntangibleAssetsNet_76682d16-c1b2-46d9-afb8-52cefeb9e9d3" xlink:href="ino-20210331.xsd#ino_GoodwillAndIntangibleAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_35fc532a-2e9a-46a8-a3e9-091d09c7919f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ino_GoodwillAndIntangibleAssetsNet_76682d16-c1b2-46d9-afb8-52cefeb9e9d3" xlink:to="loc_us-gaap_Goodwill_35fc532a-2e9a-46a8-a3e9-091d09c7919f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_7189ab06-ce05-488b-a611-20d2206667b3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ino_GoodwillAndIntangibleAssetsNet_76682d16-c1b2-46d9-afb8-52cefeb9e9d3" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_7189ab06-ce05-488b-a611-20d2206667b3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_ac464578-7b00-441e-a8df-1c8a2558d873" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_3281c439-3b7b-45c2-99e6-4a433a7b0171" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_ac464578-7b00-441e-a8df-1c8a2558d873" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_3281c439-3b7b-45c2-99e6-4a433a7b0171" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_1a67fbf7-7219-4350-9b03-a7ed6b3bbb8b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_ac464578-7b00-441e-a8df-1c8a2558d873" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_1a67fbf7-7219-4350-9b03-a7ed6b3bbb8b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_GoodwillAndIntangibleAssetsGross_9477b0f1-83b1-419c-9d55-1ee80636a87f" xlink:href="ino-20210331.xsd#ino_GoodwillAndIntangibleAssetsGross"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillGross_c81637a7-a54d-4791-a391-09202ebd0c2f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ino_GoodwillAndIntangibleAssetsGross_9477b0f1-83b1-419c-9d55-1ee80636a87f" xlink:to="loc_us-gaap_GoodwillGross_c81637a7-a54d-4791-a391-09202ebd0c2f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_3903a82c-b0a7-4682-949f-5481e8fe57a0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ino_GoodwillAndIntangibleAssetsGross_9477b0f1-83b1-419c-9d55-1ee80636a87f" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_3903a82c-b0a7-4682-949f-5481e8fe57a0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_f8c2aebb-dde4-4bdc-8fcb-d0b80c9ac380" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillGross_f1436c7e-9a03-4968-ac1d-5f85f1a92d2d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Goodwill_f8c2aebb-dde4-4bdc-8fcb-d0b80c9ac380" xlink:to="loc_us-gaap_GoodwillGross_f1436c7e-9a03-4968-ac1d-5f85f1a92d2d" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/GoodwillandIntangibleAssetsNarrativeDetails" xlink:type="simple" xlink:href="ino-20210331.xsd#GoodwillandIntangibleAssetsNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.inovio.com/role/GoodwillandIntangibleAssetsNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.inovio.com/role/ConvertibleDebt" xlink:type="simple" xlink:href="ino-20210331.xsd#ConvertibleDebt"/>
  <link:calculationLink xlink:role="http://www.inovio.com/role/ConvertibleDebt" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.inovio.com/role/ConvertibleDebtTables" xlink:type="simple" xlink:href="ino-20210331.xsd#ConvertibleDebtTables"/>
  <link:calculationLink xlink:role="http://www.inovio.com/role/ConvertibleDebtTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.inovio.com/role/ConvertibleDebtNarrativeDetails" xlink:type="simple" xlink:href="ino-20210331.xsd#ConvertibleDebtNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.inovio.com/role/ConvertibleDebtNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.inovio.com/role/ConvertibleDebtBalanceofConvertibleBondsandNotesDetails" xlink:type="simple" xlink:href="ino-20210331.xsd#ConvertibleDebtBalanceofConvertibleBondsandNotesDetails"/>
  <link:calculationLink xlink:role="http://www.inovio.com/role/ConvertibleDebtBalanceofConvertibleBondsandNotesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_c797a487-c118-4555-a58a-18b970bfae8c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_9ac88a9b-57f2-41b9-be9e-9c5efaf3fa45" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_c797a487-c118-4555-a58a-18b970bfae8c" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_9ac88a9b-57f2-41b9-be9e-9c5efaf3fa45" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount_2042f284-b687-4c3b-9f66-05ba92d8f8ba" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_c797a487-c118-4555-a58a-18b970bfae8c" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscount_2042f284-b687-4c3b-9f66-05ba92d8f8ba" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_6187cd71-54f7-4925-bd0c-d8a078dfb62a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_c797a487-c118-4555-a58a-18b970bfae8c" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_6187cd71-54f7-4925-bd0c-d8a078dfb62a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DebtInstrumentAccruedInterest_ea756449-3d97-49f9-9a3d-0f5b0b0e0f08" xlink:href="ino-20210331.xsd#ino_DebtInstrumentAccruedInterest"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_c797a487-c118-4555-a58a-18b970bfae8c" xlink:to="loc_ino_DebtInstrumentAccruedInterest_ea756449-3d97-49f9-9a3d-0f5b0b0e0f08" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DebtInstrumentConvertibleDebtConvertedAmount_2b427185-6c75-45da-96c8-84ec940fa399" xlink:href="ino-20210331.xsd#ino_DebtInstrumentConvertibleDebtConvertedAmount"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_c797a487-c118-4555-a58a-18b970bfae8c" xlink:to="loc_ino_DebtInstrumentConvertibleDebtConvertedAmount_2b427185-6c75-45da-96c8-84ec940fa399" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/ConvertibleDebtScheduleofMaturitiesDetails" xlink:type="simple" xlink:href="ino-20210331.xsd#ConvertibleDebtScheduleofMaturitiesDetails"/>
  <link:calculationLink xlink:role="http://www.inovio.com/role/ConvertibleDebtScheduleofMaturitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_859d3ce8-9e90-4597-9299-4ee1463415e2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_42c9cbbd-2333-4e87-9a36-9f5d1b719562" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_859d3ce8-9e90-4597-9299-4ee1463415e2" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_42c9cbbd-2333-4e87-9a36-9f5d1b719562" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_ca48cb8c-141f-47d1-bced-ac9905ac7441" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_859d3ce8-9e90-4597-9299-4ee1463415e2" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_ca48cb8c-141f-47d1-bced-ac9905ac7441" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_f9e99722-87e3-4c29-8db9-3eabfb5be975" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_859d3ce8-9e90-4597-9299-4ee1463415e2" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_f9e99722-87e3-4c29-8db9-3eabfb5be975" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_43669d7f-0a57-4a9a-9d3c-09604dc1db68" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_859d3ce8-9e90-4597-9299-4ee1463415e2" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_43669d7f-0a57-4a9a-9d3c-09604dc1db68" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/StockholdersEquity" xlink:type="simple" xlink:href="ino-20210331.xsd#StockholdersEquity"/>
  <link:calculationLink xlink:role="http://www.inovio.com/role/StockholdersEquity" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.inovio.com/role/StockholdersEquityTables" xlink:type="simple" xlink:href="ino-20210331.xsd#StockholdersEquityTables"/>
  <link:calculationLink xlink:role="http://www.inovio.com/role/StockholdersEquityTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.inovio.com/role/StockholdersEquitySummaryofAuthorizedandIssuedCommonandPreferredStockDetails" xlink:type="simple" xlink:href="ino-20210331.xsd#StockholdersEquitySummaryofAuthorizedandIssuedCommonandPreferredStockDetails"/>
  <link:calculationLink xlink:role="http://www.inovio.com/role/StockholdersEquitySummaryofAuthorizedandIssuedCommonandPreferredStockDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.inovio.com/role/StockholdersEquityNarrativeDetails" xlink:type="simple" xlink:href="ino-20210331.xsd#StockholdersEquityNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.inovio.com/role/StockholdersEquityNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.inovio.com/role/NetLossPerShare" xlink:type="simple" xlink:href="ino-20210331.xsd#NetLossPerShare"/>
  <link:calculationLink xlink:role="http://www.inovio.com/role/NetLossPerShare" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.inovio.com/role/NetLossPerShareTables" xlink:type="simple" xlink:href="ino-20210331.xsd#NetLossPerShareTables"/>
  <link:calculationLink xlink:role="http://www.inovio.com/role/NetLossPerShareTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.inovio.com/role/NetLossPerShareScheduleofAntiDilutiveSecuritiesDetails" xlink:type="simple" xlink:href="ino-20210331.xsd#NetLossPerShareScheduleofAntiDilutiveSecuritiesDetails"/>
  <link:calculationLink xlink:role="http://www.inovio.com/role/NetLossPerShareScheduleofAntiDilutiveSecuritiesDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.inovio.com/role/StockBasedCompensation" xlink:type="simple" xlink:href="ino-20210331.xsd#StockBasedCompensation"/>
  <link:calculationLink xlink:role="http://www.inovio.com/role/StockBasedCompensation" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.inovio.com/role/StockBasedCompensationTables" xlink:type="simple" xlink:href="ino-20210331.xsd#StockBasedCompensationTables"/>
  <link:calculationLink xlink:role="http://www.inovio.com/role/StockBasedCompensationTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.inovio.com/role/StockBasedCompensationDetails" xlink:type="simple" xlink:href="ino-20210331.xsd#StockBasedCompensationDetails"/>
  <link:calculationLink xlink:role="http://www.inovio.com/role/StockBasedCompensationDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.inovio.com/role/RelatedPartyTransactions" xlink:type="simple" xlink:href="ino-20210331.xsd#RelatedPartyTransactions"/>
  <link:calculationLink xlink:role="http://www.inovio.com/role/RelatedPartyTransactions" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.inovio.com/role/RelatedPartyTransactionsDetails" xlink:type="simple" xlink:href="ino-20210331.xsd#RelatedPartyTransactionsDetails"/>
  <link:calculationLink xlink:role="http://www.inovio.com/role/RelatedPartyTransactionsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.inovio.com/role/Leases" xlink:type="simple" xlink:href="ino-20210331.xsd#Leases"/>
  <link:calculationLink xlink:role="http://www.inovio.com/role/Leases" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.inovio.com/role/LeasesTables" xlink:type="simple" xlink:href="ino-20210331.xsd#LeasesTables"/>
  <link:calculationLink xlink:role="http://www.inovio.com/role/LeasesTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.inovio.com/role/LeasesNarrativeDetails" xlink:type="simple" xlink:href="ino-20210331.xsd#LeasesNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.inovio.com/role/LeasesNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.inovio.com/role/LeasesSummaryofFutureMinimumLeasePaymentsDetails" xlink:type="simple" xlink:href="ino-20210331.xsd#LeasesSummaryofFutureMinimumLeasePaymentsDetails"/>
  <link:calculationLink xlink:role="http://www.inovio.com/role/LeasesSummaryofFutureMinimumLeasePaymentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_ce24f874-fdf9-45dd-bf50-f36b580e5f43" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_9a4d9e9e-a753-4c9a-8af1-67b2780a3a68" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_ce24f874-fdf9-45dd-bf50-f36b580e5f43" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_9a4d9e9e-a753-4c9a-8af1-67b2780a3a68" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_78bb09f5-a500-4fd5-b6c5-b1d92d9dfd2a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_ce24f874-fdf9-45dd-bf50-f36b580e5f43" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_78bb09f5-a500-4fd5-b6c5-b1d92d9dfd2a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_dcc1d528-39e5-4db7-bf04-32c738db2e10" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_ce24f874-fdf9-45dd-bf50-f36b580e5f43" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_dcc1d528-39e5-4db7-bf04-32c738db2e10" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_40b0f982-4380-4f3a-9d08-0e10ac98c319" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_ce24f874-fdf9-45dd-bf50-f36b580e5f43" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_40b0f982-4380-4f3a-9d08-0e10ac98c319" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_88320532-f2a7-4227-b2a4-71a513ac3f56" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_ce24f874-fdf9-45dd-bf50-f36b580e5f43" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_88320532-f2a7-4227-b2a4-71a513ac3f56" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_021b4fe2-b6c2-45a6-8e8c-e5baf6527930" xlink:href="ino-20210331.xsd#ino_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_ce24f874-fdf9-45dd-bf50-f36b580e5f43" xlink:to="loc_ino_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_021b4fe2-b6c2-45a6-8e8c-e5baf6527930" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_20093c5c-7d72-4287-beea-25ed4d1595eb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_acd225a6-46cf-473d-8662-c4c262bdcb75" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_20093c5c-7d72-4287-beea-25ed4d1595eb" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_acd225a6-46cf-473d-8662-c4c262bdcb75" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_af0b10ff-dc9d-4009-96d6-5ae2a64a0fc5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_20093c5c-7d72-4287-beea-25ed4d1595eb" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_af0b10ff-dc9d-4009-96d6-5ae2a64a0fc5" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/CollaborativeAgreements" xlink:type="simple" xlink:href="ino-20210331.xsd#CollaborativeAgreements"/>
  <link:calculationLink xlink:role="http://www.inovio.com/role/CollaborativeAgreements" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.inovio.com/role/CollaborativeAgreementsDetails" xlink:type="simple" xlink:href="ino-20210331.xsd#CollaborativeAgreementsDetails"/>
  <link:calculationLink xlink:role="http://www.inovio.com/role/CollaborativeAgreementsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.inovio.com/role/IncomeTaxes" xlink:type="simple" xlink:href="ino-20210331.xsd#IncomeTaxes"/>
  <link:calculationLink xlink:role="http://www.inovio.com/role/IncomeTaxes" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.inovio.com/role/GeneosTherapeuticsInc" xlink:type="simple" xlink:href="ino-20210331.xsd#GeneosTherapeuticsInc"/>
  <link:calculationLink xlink:role="http://www.inovio.com/role/GeneosTherapeuticsInc" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.inovio.com/role/GeneosTherapeuticsIncTables" xlink:type="simple" xlink:href="ino-20210331.xsd#GeneosTherapeuticsIncTables"/>
  <link:calculationLink xlink:role="http://www.inovio.com/role/GeneosTherapeuticsIncTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.inovio.com/role/GeneosTherapeuticsIncNarrativeDetails" xlink:type="simple" xlink:href="ino-20210331.xsd#GeneosTherapeuticsIncNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.inovio.com/role/GeneosTherapeuticsIncNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.inovio.com/role/GeneosTherapeuticsIncDeconsolidationAccountingDetails" xlink:type="simple" xlink:href="ino-20210331.xsd#GeneosTherapeuticsIncDeconsolidationAccountingDetails"/>
  <link:calculationLink xlink:role="http://www.inovio.com/role/GeneosTherapeuticsIncDeconsolidationAccountingDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.inovio.com/role/GeneosTherapeuticsIncInvestmentInGeneosDetails" xlink:type="simple" xlink:href="ino-20210331.xsd#GeneosTherapeuticsIncInvestmentInGeneosDetails"/>
  <link:calculationLink xlink:role="http://www.inovio.com/role/GeneosTherapeuticsIncInvestmentInGeneosDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.inovio.com/role/GeneosTherapeuticsIncFairValueAssumptionsDetails" xlink:type="simple" xlink:href="ino-20210331.xsd#GeneosTherapeuticsIncFairValueAssumptionsDetails"/>
  <link:calculationLink xlink:role="http://www.inovio.com/role/GeneosTherapeuticsIncFairValueAssumptionsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.inovio.com/role/GeneosTherapeuticsIncPreferredstockInvestmentDetails" xlink:type="simple" xlink:href="ino-20210331.xsd#GeneosTherapeuticsIncPreferredstockInvestmentDetails"/>
  <link:calculationLink xlink:role="http://www.inovio.com/role/GeneosTherapeuticsIncPreferredstockInvestmentDetails" xlink:type="extended"/>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>7
<FILENAME>ino-20210331_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:e9d1bb07-ad73-4929-82ea-6e949ab8c789,g:8e741ee6-3c7b-40cd-9e55-d4abd68b099b-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.inovio.com/role/CoverPage" xlink:type="simple" xlink:href="ino-20210331.xsd#CoverPage"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/CoverPage" xlink:type="extended" id="i34d544180a8842929c873dea14eef6a2_CoverPage"/>
  <link:roleRef roleURI="http://www.inovio.com/role/CondensedConsolidatedBalanceSheets" xlink:type="simple" xlink:href="ino-20210331.xsd#CondensedConsolidatedBalanceSheets"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended" id="icbf274047d574931a7733b7454a4c56e_CondensedConsolidatedBalanceSheets">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_6aa704ff-88d5-4c85-8fbe-67d5431b370b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_b0c4100c-30aa-4e03-89cb-3b24a4bfacf5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_6aa704ff-88d5-4c85-8fbe-67d5431b370b" xlink:to="loc_us-gaap_AssetsAbstract_b0c4100c-30aa-4e03-89cb-3b24a4bfacf5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_af6717de-44fa-4150-a901-0023798ab64f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_b0c4100c-30aa-4e03-89cb-3b24a4bfacf5" xlink:to="loc_us-gaap_AssetsCurrentAbstract_af6717de-44fa-4150-a901-0023798ab64f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_5bca085a-1e11-4ea9-a9fb-d554b068bfd9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_af6717de-44fa-4150-a901-0023798ab64f" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_5bca085a-1e11-4ea9-a9fb-d554b068bfd9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestments_20ed065f-67d7-4c3f-bd63-70db019e811b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_af6717de-44fa-4150-a901-0023798ab64f" xlink:to="loc_us-gaap_ShortTermInvestments_20ed065f-67d7-4c3f-bd63-70db019e811b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_c286ebfd-1967-4ce8-99dc-915003359ca4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_af6717de-44fa-4150-a901-0023798ab64f" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_c286ebfd-1967-4ce8-99dc-915003359ca4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableRelatedPartiesCurrent_376c7158-1fbc-4808-a88f-18a8ec3cb401" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableRelatedPartiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_af6717de-44fa-4150-a901-0023798ab64f" xlink:to="loc_us-gaap_AccountsReceivableRelatedPartiesCurrent_376c7158-1fbc-4808-a88f-18a8ec3cb401" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_40b24c7f-e8f5-4279-afa5-c957dfe57ccf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_af6717de-44fa-4150-a901-0023798ab64f" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_40b24c7f-e8f5-4279-afa5-c957dfe57ccf" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity_6bd5214c-5eb4-44a1-ac73-b285993028a9" xlink:href="ino-20210331.xsd#ino_PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_af6717de-44fa-4150-a901-0023798ab64f" xlink:to="loc_ino_PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity_6bd5214c-5eb4-44a1-ac73-b285993028a9" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_62055bcf-2686-476a-b5a5-2f313f27d4a3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_af6717de-44fa-4150-a901-0023798ab64f" xlink:to="loc_us-gaap_AssetsCurrent_62055bcf-2686-476a-b5a5-2f313f27d4a3" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_35bca910-4ed9-40d1-b4c5-a864d68d22f5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_b0c4100c-30aa-4e03-89cb-3b24a4bfacf5" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_35bca910-4ed9-40d1-b4c5-a864d68d22f5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_8f03fb36-ecf1-47f8-9f14-ec999b3ebfdf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_b0c4100c-30aa-4e03-89cb-3b24a4bfacf5" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_8f03fb36-ecf1-47f8-9f14-ec999b3ebfdf" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_07c0e276-427d-4966-886e-ad1bf1162f4d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_b0c4100c-30aa-4e03-89cb-3b24a4bfacf5" xlink:to="loc_us-gaap_EquityMethodInvestments_07c0e276-427d-4966-886e-ad1bf1162f4d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_befb71bc-e940-4241-80bd-5a1c8ab83eb1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_b0c4100c-30aa-4e03-89cb-3b24a4bfacf5" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_befb71bc-e940-4241-80bd-5a1c8ab83eb1" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_69af975f-c170-4fe0-b404-b10108c92cef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_b0c4100c-30aa-4e03-89cb-3b24a4bfacf5" xlink:to="loc_us-gaap_Goodwill_69af975f-c170-4fe0-b404-b10108c92cef" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_a6891214-098f-4b4a-835e-8ae492170e4e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_b0c4100c-30aa-4e03-89cb-3b24a4bfacf5" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_a6891214-098f-4b4a-835e-8ae492170e4e" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_9fa0b517-b119-4a57-9868-487a1bc30264" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_b0c4100c-30aa-4e03-89cb-3b24a4bfacf5" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_9fa0b517-b119-4a57-9868-487a1bc30264" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_b51f0979-0557-4f8f-a619-1eedb28e162b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_b0c4100c-30aa-4e03-89cb-3b24a4bfacf5" xlink:to="loc_us-gaap_Assets_b51f0979-0557-4f8f-a619-1eedb28e162b" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_49613b3f-9509-450e-9473-b277e5f5b919" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_6aa704ff-88d5-4c85-8fbe-67d5431b370b" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_49613b3f-9509-450e-9473-b277e5f5b919" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_a561915f-bf31-4941-ae15-719ddee745d1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_49613b3f-9509-450e-9473-b277e5f5b919" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_a561915f-bf31-4941-ae15-719ddee745d1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_a37db868-5a7d-40a3-9508-184f43fb331e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_a561915f-bf31-4941-ae15-719ddee745d1" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_a37db868-5a7d-40a3-9508-184f43fb331e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueToRelatedPartiesCurrent_cad9e759-85eb-4220-89c1-fefd8c9b681a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DueToRelatedPartiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_a561915f-bf31-4941-ae15-719ddee745d1" xlink:to="loc_us-gaap_DueToRelatedPartiesCurrent_cad9e759-85eb-4220-89c1-fefd8c9b681a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_AccruedClinicalTrialExpenseCurrent_2c989796-06d6-4bae-ba98-858e4a001afb" xlink:href="ino-20210331.xsd#ino_AccruedClinicalTrialExpenseCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_a561915f-bf31-4941-ae15-719ddee745d1" xlink:to="loc_ino_AccruedClinicalTrialExpenseCurrent_2c989796-06d6-4bae-ba98-858e4a001afb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_f27e0396-233f-43e4-a103-bedd5fe8c22f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_a561915f-bf31-4941-ae15-719ddee745d1" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_f27e0396-233f-43e4-a103-bedd5fe8c22f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ContractWithCustomerLiabilityAffiliatedEntityCurrent_e7f3def1-212d-4fa9-b3b2-1b52ff4e3b43" xlink:href="ino-20210331.xsd#ino_ContractWithCustomerLiabilityAffiliatedEntityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_a561915f-bf31-4941-ae15-719ddee745d1" xlink:to="loc_ino_ContractWithCustomerLiabilityAffiliatedEntityCurrent_e7f3def1-212d-4fa9-b3b2-1b52ff4e3b43" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_3088ada5-e0ef-4c7d-bead-58b0f68fc971" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_a561915f-bf31-4941-ae15-719ddee745d1" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_3088ada5-e0ef-4c7d-bead-58b0f68fc971" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DeferredGrantFundingCurrent_818fd513-cfc8-49c4-8f70-393f431c543e" xlink:href="ino-20210331.xsd#ino_DeferredGrantFundingCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_a561915f-bf31-4941-ae15-719ddee745d1" xlink:to="loc_ino_DeferredGrantFundingCurrent_818fd513-cfc8-49c4-8f70-393f431c543e" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DeferredGrantFundingFromAffiliateCurrent_d99e798e-6112-4d58-afdf-ded4197906e8" xlink:href="ino-20210331.xsd#ino_DeferredGrantFundingFromAffiliateCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_a561915f-bf31-4941-ae15-719ddee745d1" xlink:to="loc_ino_DeferredGrantFundingFromAffiliateCurrent_d99e798e-6112-4d58-afdf-ded4197906e8" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_422c29f4-a44d-4e77-a61b-b479cd3c8f9d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_a561915f-bf31-4941-ae15-719ddee745d1" xlink:to="loc_us-gaap_LiabilitiesCurrent_422c29f4-a44d-4e77-a61b-b479cd3c8f9d" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_17e3ec7b-404f-45d3-86bd-1c330d8c9588" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_49613b3f-9509-450e-9473-b277e5f5b919" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_17e3ec7b-404f-45d3-86bd-1c330d8c9588" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebt_ecae36d9-95b2-4337-9e3c-bbd1189263af" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_49613b3f-9509-450e-9473-b277e5f5b919" xlink:to="loc_us-gaap_ConvertibleDebt_ecae36d9-95b2-4337-9e3c-bbd1189263af" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_54a46552-fe8c-48ad-90ec-f691b114ed1e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_49613b3f-9509-450e-9473-b277e5f5b919" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_54a46552-fe8c-48ad-90ec-f691b114ed1e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_e85108c3-a665-49a2-af79-4c2598d669f4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_49613b3f-9509-450e-9473-b277e5f5b919" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_e85108c3-a665-49a2-af79-4c2598d669f4" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DeferredGrantFundingFromAffiliateNoncurrent_f1ac821a-d86e-480a-a0f7-82dedc5c0efd" xlink:href="ino-20210331.xsd#ino_DeferredGrantFundingFromAffiliateNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_49613b3f-9509-450e-9473-b277e5f5b919" xlink:to="loc_ino_DeferredGrantFundingFromAffiliateNoncurrent_f1ac821a-d86e-480a-a0f7-82dedc5c0efd" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_b0b2c88a-4bc2-4725-a26a-8005fdf5cf5b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_49613b3f-9509-450e-9473-b277e5f5b919" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_b0b2c88a-4bc2-4725-a26a-8005fdf5cf5b" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_f750affd-9815-4551-bcb0-98b795192065" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_49613b3f-9509-450e-9473-b277e5f5b919" xlink:to="loc_us-gaap_Liabilities_f750affd-9815-4551-bcb0-98b795192065" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_7625f762-d50e-41f6-8264-43f2b0a5a18d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_49613b3f-9509-450e-9473-b277e5f5b919" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_7625f762-d50e-41f6-8264-43f2b0a5a18d" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_8eba15eb-ac5f-441e-8983-9a86f6cd12f9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_7625f762-d50e-41f6-8264-43f2b0a5a18d" xlink:to="loc_us-gaap_PreferredStockValue_8eba15eb-ac5f-441e-8983-9a86f6cd12f9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_67e87668-ad61-4464-8508-167b6c98e967" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_7625f762-d50e-41f6-8264-43f2b0a5a18d" xlink:to="loc_us-gaap_CommonStockValue_67e87668-ad61-4464-8508-167b6c98e967" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_9fe44704-03ba-4e45-b43b-649cdff9bd54" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_7625f762-d50e-41f6-8264-43f2b0a5a18d" xlink:to="loc_us-gaap_AdditionalPaidInCapital_9fe44704-03ba-4e45-b43b-649cdff9bd54" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_d7185b76-aaf5-4a66-adbd-0bced407e613" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_7625f762-d50e-41f6-8264-43f2b0a5a18d" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_d7185b76-aaf5-4a66-adbd-0bced407e613" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_9435d737-e45d-4433-ab3d-27062e3a8928" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_7625f762-d50e-41f6-8264-43f2b0a5a18d" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_9435d737-e45d-4433-ab3d-27062e3a8928" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_bb49cd98-62de-4f4f-8ed0-b5c5ad5f9a23" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_7625f762-d50e-41f6-8264-43f2b0a5a18d" xlink:to="loc_us-gaap_StockholdersEquity_bb49cd98-62de-4f4f-8ed0-b5c5ad5f9a23" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_11b1d388-ee53-45a0-bb55-10a42964cc17" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_49613b3f-9509-450e-9473-b277e5f5b919" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_11b1d388-ee53-45a0-bb55-10a42964cc17" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_cba9af00-5a94-4604-a7d7-772ceb0c73a0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_6aa704ff-88d5-4c85-8fbe-67d5431b370b" xlink:to="loc_us-gaap_StatementTable_cba9af00-5a94-4604-a7d7-772ceb0c73a0" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_64fdb318-7fdd-4b48-b89a-31dbdb2a59cf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_cba9af00-5a94-4604-a7d7-772ceb0c73a0" xlink:to="loc_us-gaap_DebtInstrumentAxis_64fdb318-7fdd-4b48-b89a-31dbdb2a59cf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_64fdb318-7fdd-4b48-b89a-31dbdb2a59cf_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_64fdb318-7fdd-4b48-b89a-31dbdb2a59cf" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_64fdb318-7fdd-4b48-b89a-31dbdb2a59cf_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_7d314a98-3b33-477e-aea6-e8ae318f5bac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_64fdb318-7fdd-4b48-b89a-31dbdb2a59cf" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_7d314a98-3b33-477e-aea6-e8ae318f5bac" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_A6.50ConvertibleSeniorNotesDue2024Member_ecec6941-afe9-4228-b7ce-ba5e208fd820" xlink:href="ino-20210331.xsd#ino_A6.50ConvertibleSeniorNotesDue2024Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7d314a98-3b33-477e-aea6-e8ae318f5bac" xlink:to="loc_ino_A6.50ConvertibleSeniorNotesDue2024Member_ecec6941-afe9-4228-b7ce-ba5e208fd820" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ConvertibleBondsMember_00e27134-9255-486c-bd91-ba7bee752ced" xlink:href="ino-20210331.xsd#ino_ConvertibleBondsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7d314a98-3b33-477e-aea6-e8ae318f5bac" xlink:to="loc_ino_ConvertibleBondsMember_00e27134-9255-486c-bd91-ba7bee752ced" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.inovio.com/role/CondensedConsolidatedStatementsofOperations" xlink:type="simple" xlink:href="ino-20210331.xsd#CondensedConsolidatedStatementsofOperations"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/CondensedConsolidatedStatementsofOperations" xlink:type="extended" id="i18e1f3d0499d4d2f88f54945b7dedc39_CondensedConsolidatedStatementsofOperations">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_4ffde4c8-a0cb-4d86-9ae4-75f96315eac5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_075c15c4-d8e4-473c-8921-6472ed7e912d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_4ffde4c8-a0cb-4d86-9ae4-75f96315eac5" xlink:to="loc_us-gaap_RevenuesAbstract_075c15c4-d8e4-473c-8921-6472ed7e912d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_341b9fee-ead3-400f-a70c-71257277e0e3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_075c15c4-d8e4-473c-8921-6472ed7e912d" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_341b9fee-ead3-400f-a70c-71257277e0e3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_c4116a62-e3d7-4e14-8309-e5de9b01a5e8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_4ffde4c8-a0cb-4d86-9ae4-75f96315eac5" xlink:to="loc_us-gaap_OperatingExpensesAbstract_c4116a62-e3d7-4e14-8309-e5de9b01a5e8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_3abe3824-b0c7-454b-b9a5-1194f8047a29" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_c4116a62-e3d7-4e14-8309-e5de9b01a5e8" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_3abe3824-b0c7-454b-b9a5-1194f8047a29" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_96de00ef-f29a-465f-8920-bf32979ea5f2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_c4116a62-e3d7-4e14-8309-e5de9b01a5e8" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_96de00ef-f29a-465f-8920-bf32979ea5f2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_ee671cfc-f974-4daf-87d3-89d39ddfb6f3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_c4116a62-e3d7-4e14-8309-e5de9b01a5e8" xlink:to="loc_us-gaap_OperatingExpenses_ee671cfc-f974-4daf-87d3-89d39ddfb6f3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_7e67df46-7880-4751-8880-497bb2679a27" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_4ffde4c8-a0cb-4d86-9ae4-75f96315eac5" xlink:to="loc_us-gaap_OperatingIncomeLoss_7e67df46-7880-4751-8880-497bb2679a27" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_a3458092-eca4-4be0-b299-15bbc8ffb871" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_4ffde4c8-a0cb-4d86-9ae4-75f96315eac5" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_a3458092-eca4-4be0-b299-15bbc8ffb871" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeOperating_444037fb-19b9-45da-b719-d68f16e9624e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestIncomeOperating"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_a3458092-eca4-4be0-b299-15bbc8ffb871" xlink:to="loc_us-gaap_InterestIncomeOperating_444037fb-19b9-45da-b719-d68f16e9624e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_109f5b78-7233-4b4a-8d4a-4ccde74c9c5e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_a3458092-eca4-4be0-b299-15bbc8ffb871" xlink:to="loc_us-gaap_InterestExpense_109f5b78-7233-4b4a-8d4a-4ccde74c9c5e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet_a99a994b-88b1-4493-89dd-d383c7130e91" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_a3458092-eca4-4be0-b299-15bbc8ffb871" xlink:to="loc_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet_a99a994b-88b1-4493-89dd-d383c7130e91" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ChangeInValueOfInvestmentsInAffiliatedCompany_2e4fc5e6-befa-452b-98ea-66d9cc407859" xlink:href="ino-20210331.xsd#ino_ChangeInValueOfInvestmentsInAffiliatedCompany"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_a3458092-eca4-4be0-b299-15bbc8ffb871" xlink:to="loc_ino_ChangeInValueOfInvestmentsInAffiliatedCompany_2e4fc5e6-befa-452b-98ea-66d9cc407859" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_bbef6f1d-8225-4f23-86ce-e5180d80be97" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_a3458092-eca4-4be0-b299-15bbc8ffb871" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_bbef6f1d-8225-4f23-86ce-e5180d80be97" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_0299131a-6fc4-4e81-ba5f-e1fab2d7105e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_a3458092-eca4-4be0-b299-15bbc8ffb871" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_0299131a-6fc4-4e81-ba5f-e1fab2d7105e" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_c1353d20-5f49-4c63-9d17-ea8fc9f566ec" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_a3458092-eca4-4be0-b299-15bbc8ffb871" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_c1353d20-5f49-4c63-9d17-ea8fc9f566ec" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_fac67cda-2e91-449a-996f-b442ea6677d5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_a3458092-eca4-4be0-b299-15bbc8ffb871" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_fac67cda-2e91-449a-996f-b442ea6677d5" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_81fea252-37b9-4c29-90ca-a6e181968050" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_a3458092-eca4-4be0-b299-15bbc8ffb871" xlink:to="loc_us-gaap_ProfitLoss_81fea252-37b9-4c29-90ca-a6e181968050" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_d0dd1f8e-9b6f-4230-b652-42cf21ba299d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_a3458092-eca4-4be0-b299-15bbc8ffb871" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_d0dd1f8e-9b6f-4230-b652-42cf21ba299d" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_5e83e3d4-ed22-403e-9e37-eeaba232d107" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_a3458092-eca4-4be0-b299-15bbc8ffb871" xlink:to="loc_us-gaap_NetIncomeLoss_5e83e3d4-ed22-403e-9e37-eeaba232d107" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_3a0e9620-ea78-4da6-a8fe-a4c4e539eccb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_4ffde4c8-a0cb-4d86-9ae4-75f96315eac5" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_3a0e9620-ea78-4da6-a8fe-a4c4e539eccb" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_d1fea922-295c-4628-9248-085fd58cf063" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_3a0e9620-ea78-4da6-a8fe-a4c4e539eccb" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDiluted_d1fea922-295c-4628-9248-085fd58cf063" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_35004cb4-dd8e-4ad9-b32f-7cb12d875e72" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_4ffde4c8-a0cb-4d86-9ae4-75f96315eac5" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_35004cb4-dd8e-4ad9-b32f-7cb12d875e72" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_e965c8af-dde3-4218-a3fb-5cc2def16302" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_35004cb4-dd8e-4ad9-b32f-7cb12d875e72" xlink:to="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_e965c8af-dde3-4218-a3fb-5cc2def16302" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_ffabbd6b-b5a8-4930-9d32-b0ddd18d492f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_4ffde4c8-a0cb-4d86-9ae4-75f96315eac5" xlink:to="loc_us-gaap_StatementTable_ffabbd6b-b5a8-4930-9d32-b0ddd18d492f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_d105ce0c-ece0-4be1-9fa4-398354014acb" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_ffabbd6b-b5a8-4930-9d32-b0ddd18d492f" xlink:to="loc_srt_ProductOrServiceAxis_d105ce0c-ece0-4be1-9fa4-398354014acb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_d105ce0c-ece0-4be1-9fa4-398354014acb_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_d105ce0c-ece0-4be1-9fa4-398354014acb" xlink:to="loc_srt_ProductsAndServicesDomain_d105ce0c-ece0-4be1-9fa4-398354014acb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_1c7cc99d-65b9-4dea-9da8-7c1c9fa4ae5b" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_d105ce0c-ece0-4be1-9fa4-398354014acb" xlink:to="loc_srt_ProductsAndServicesDomain_1c7cc99d-65b9-4dea-9da8-7c1c9fa4ae5b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember_3016bf2d-a15f-4dd0-bccd-76a89cd080b8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LicenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_1c7cc99d-65b9-4dea-9da8-7c1c9fa4ae5b" xlink:to="loc_us-gaap_LicenseMember_3016bf2d-a15f-4dd0-bccd-76a89cd080b8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_LicensewithAffiliatedEntitiesMember_81c7f1f3-11b6-4301-bfe2-7d07bbd0b3c6" xlink:href="ino-20210331.xsd#ino_LicensewithAffiliatedEntitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_1c7cc99d-65b9-4dea-9da8-7c1c9fa4ae5b" xlink:to="loc_ino_LicensewithAffiliatedEntitiesMember_81c7f1f3-11b6-4301-bfe2-7d07bbd0b3c6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductAndServiceOtherMember_87157db0-669e-4434-9229-472c04980267" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductAndServiceOtherMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_1c7cc99d-65b9-4dea-9da8-7c1c9fa4ae5b" xlink:to="loc_us-gaap_ProductAndServiceOtherMember_87157db0-669e-4434-9229-472c04980267" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.inovio.com/role/CondensedConsolidatedStatementsofComprehensiveLoss" xlink:type="simple" xlink:href="ino-20210331.xsd#CondensedConsolidatedStatementsofComprehensiveLoss"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/CondensedConsolidatedStatementsofComprehensiveLoss" xlink:type="extended" id="i57aba5dd13ed4a93a673d212a7d37d9e_CondensedConsolidatedStatementsofComprehensiveLoss"/>
  <link:roleRef roleURI="http://www.inovio.com/role/CondensedConsolidatedStatementsofStockholdersEquity" xlink:type="simple" xlink:href="ino-20210331.xsd#CondensedConsolidatedStatementsofStockholdersEquity"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/CondensedConsolidatedStatementsofStockholdersEquity" xlink:type="extended" id="i469eda98afb54a858f2b27c6e72e24c9_CondensedConsolidatedStatementsofStockholdersEquity">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_eb385bad-d993-4b6a-b4ba-62df3a216a14" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_10b3efdb-7677-496b-861a-8f7ad607e069" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_eb385bad-d993-4b6a-b4ba-62df3a216a14" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_10b3efdb-7677-496b-861a-8f7ad607e069" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued_e8b8417b-cf59-4ae7-bb0b-81a1ce966cd4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_10b3efdb-7677-496b-861a-8f7ad607e069" xlink:to="loc_us-gaap_SharesIssued_e8b8417b-cf59-4ae7-bb0b-81a1ce966cd4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_94c3a3e2-257b-464d-a893-a9fa94cc1286" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_10b3efdb-7677-496b-861a-8f7ad607e069" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_94c3a3e2-257b-464d-a893-a9fa94cc1286" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_613d1ec0-8d87-4e44-ac5f-d0764a83b866" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_10b3efdb-7677-496b-861a-8f7ad607e069" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_613d1ec0-8d87-4e44-ac5f-d0764a83b866" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_58b650ca-ed10-4e4c-bb04-4f2733dfd136" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_10b3efdb-7677-496b-861a-8f7ad607e069" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_58b650ca-ed10-4e4c-bb04-4f2733dfd136" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_3586f22f-ed06-4c48-be95-35b494fe6d4e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_10b3efdb-7677-496b-861a-8f7ad607e069" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_3586f22f-ed06-4c48-be95-35b494fe6d4e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_f4928ea0-3bea-415a-9ea3-73490e5b7518" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_10b3efdb-7677-496b-861a-8f7ad607e069" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_f4928ea0-3bea-415a-9ea3-73490e5b7518" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_a84c4ed6-e17f-47ce-bb03-754afd0b76f5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_10b3efdb-7677-496b-861a-8f7ad607e069" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_a84c4ed6-e17f-47ce-bb03-754afd0b76f5" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_208fdea8-b3f9-418d-8ce0-628d0d554dc3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_10b3efdb-7677-496b-861a-8f7ad607e069" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_208fdea8-b3f9-418d-8ce0-628d0d554dc3" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_75ac8a8c-c7a9-4720-8a48-d27292b0f54e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_10b3efdb-7677-496b-861a-8f7ad607e069" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_75ac8a8c-c7a9-4720-8a48-d27292b0f54e" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance_2195c6de-7a31-492a-baa7-6218a9acd5a9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_10b3efdb-7677-496b-861a-8f7ad607e069" xlink:to="loc_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance_2195c6de-7a31-492a-baa7-6218a9acd5a9" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_fac6d413-f19d-42e2-a09c-8b60421c0333" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_10b3efdb-7677-496b-861a-8f7ad607e069" xlink:to="loc_us-gaap_ProfitLoss_fac6d413-f19d-42e2-a09c-8b60421c0333" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_c9761f99-4117-4956-b763-b3cf9cf430d3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_10b3efdb-7677-496b-861a-8f7ad607e069" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_c9761f99-4117-4956-b763-b3cf9cf430d3" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_69402359-a13a-4f05-970c-1a2c3fa43a39" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_10b3efdb-7677-496b-861a-8f7ad607e069" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_69402359-a13a-4f05-970c-1a2c3fa43a39" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued_f5850b7e-eb68-40e3-a2b7-f71831fdddc2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssued"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_3301420a-3754-4242-a271-22bb01320c6c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_1e7f6dc1-d55d-45a8-b1ec-3a26651cac61" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_eb385bad-d993-4b6a-b4ba-62df3a216a14" xlink:to="loc_us-gaap_StatementTable_1e7f6dc1-d55d-45a8-b1ec-3a26651cac61" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_bc2f7daf-8aae-49e3-98d5-4c12609df3e7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1e7f6dc1-d55d-45a8-b1ec-3a26651cac61" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_bc2f7daf-8aae-49e3-98d5-4c12609df3e7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_bc2f7daf-8aae-49e3-98d5-4c12609df3e7_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_bc2f7daf-8aae-49e3-98d5-4c12609df3e7" xlink:to="loc_us-gaap_EquityComponentDomain_bc2f7daf-8aae-49e3-98d5-4c12609df3e7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_01fc7764-b7fa-4c32-ada7-f8a7ce1e01f3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_bc2f7daf-8aae-49e3-98d5-4c12609df3e7" xlink:to="loc_us-gaap_EquityComponentDomain_01fc7764-b7fa-4c32-ada7-f8a7ce1e01f3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember_7d03e72d-9ee6-48b9-99d1-9dc5abb6c5d5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_01fc7764-b7fa-4c32-ada7-f8a7ce1e01f3" xlink:to="loc_us-gaap_PreferredStockMember_7d03e72d-9ee6-48b9-99d1-9dc5abb6c5d5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_e9888f5f-d203-4f24-b059-0ddf0322169e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_01fc7764-b7fa-4c32-ada7-f8a7ce1e01f3" xlink:to="loc_us-gaap_CommonStockMember_e9888f5f-d203-4f24-b059-0ddf0322169e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_ccdd9cb5-b707-48a3-94eb-18c641a0c0d4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_01fc7764-b7fa-4c32-ada7-f8a7ce1e01f3" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_ccdd9cb5-b707-48a3-94eb-18c641a0c0d4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_a33a810c-bc40-4bb8-8da8-c8d1aa324e06" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_01fc7764-b7fa-4c32-ada7-f8a7ce1e01f3" xlink:to="loc_us-gaap_RetainedEarningsMember_a33a810c-bc40-4bb8-8da8-c8d1aa324e06" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_3605804f-6a0c-4a99-b88a-2ecba374db93" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_01fc7764-b7fa-4c32-ada7-f8a7ce1e01f3" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_3605804f-6a0c-4a99-b88a-2ecba374db93" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_2c15a6ec-7e18-4489-9e40-ca68a3ff3a53" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_01fc7764-b7fa-4c32-ada7-f8a7ce1e01f3" xlink:to="loc_us-gaap_NoncontrollingInterestMember_2c15a6ec-7e18-4489-9e40-ca68a3ff3a53" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.inovio.com/role/CondensedConsolidatedStatementsofStockholdersEquityParenthetical" xlink:type="simple" xlink:href="ino-20210331.xsd#CondensedConsolidatedStatementsofStockholdersEquityParenthetical"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/CondensedConsolidatedStatementsofStockholdersEquityParenthetical" xlink:type="extended" id="i36fca754eb6d4d488826730306c3721e_CondensedConsolidatedStatementsofStockholdersEquityParenthetical"/>
  <link:roleRef roleURI="http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="ino-20210331.xsd#CondensedConsolidatedStatementsofCashFlows"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="extended" id="id10c95e7ad804e63abafb2fa30006088_CondensedConsolidatedStatementsofCashFlows"/>
  <link:roleRef roleURI="http://www.inovio.com/role/OrganizationandOperations" xlink:type="simple" xlink:href="ino-20210331.xsd#OrganizationandOperations"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/OrganizationandOperations" xlink:type="extended" id="i1af2bcbb7aaa4f148bfcd3b98857dd79_OrganizationandOperations"/>
  <link:roleRef roleURI="http://www.inovio.com/role/BasisofPresentationLiquidityandRisksandUncertainties" xlink:type="simple" xlink:href="ino-20210331.xsd#BasisofPresentationLiquidityandRisksandUncertainties"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/BasisofPresentationLiquidityandRisksandUncertainties" xlink:type="extended" id="if40cbfb8c2eb454c850cbb708aeeddd2_BasisofPresentationLiquidityandRisksandUncertainties"/>
  <link:roleRef roleURI="http://www.inovio.com/role/BasisofPresentationLiquidityandRisksandUncertaintiesPolicies" xlink:type="simple" xlink:href="ino-20210331.xsd#BasisofPresentationLiquidityandRisksandUncertaintiesPolicies"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/BasisofPresentationLiquidityandRisksandUncertaintiesPolicies" xlink:type="extended" id="ia0204ce564594deeb568df77d0bd2805_BasisofPresentationLiquidityandRisksandUncertaintiesPolicies"/>
  <link:roleRef roleURI="http://www.inovio.com/role/BasisofPresentationLiquidityandRisksandUncertaintiesDetails" xlink:type="simple" xlink:href="ino-20210331.xsd#BasisofPresentationLiquidityandRisksandUncertaintiesDetails"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/BasisofPresentationLiquidityandRisksandUncertaintiesDetails" xlink:type="extended" id="iddc2e1d86b9f49acaa7a4a80357cb35a_BasisofPresentationLiquidityandRisksandUncertaintiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_57959862-003a-4ddf-8a13-fcf0f1387612" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_bdea876f-522f-4885-aea1-2ccae0faf469" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_57959862-003a-4ddf-8a13-fcf0f1387612" xlink:to="loc_us-gaap_NetIncomeLoss_bdea876f-522f-4885-aea1-2ccae0faf469" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Capital_c7d2497e-92a6-4a66-bfa1-a00111a47574" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Capital"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_57959862-003a-4ddf-8a13-fcf0f1387612" xlink:to="loc_us-gaap_Capital_c7d2497e-92a6-4a66-bfa1-a00111a47574" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_9ceae882-e4ff-435b-ad26-b30ef4023c09" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_57959862-003a-4ddf-8a13-fcf0f1387612" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_9ceae882-e4ff-435b-ad26-b30ef4023c09" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_a3a3e280-ca81-4a42-8ce5-9a5ccb0c3b06" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_57959862-003a-4ddf-8a13-fcf0f1387612" xlink:to="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_a3a3e280-ca81-4a42-8ce5-9a5ccb0c3b06" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_9209d04a-6701-4341-87bb-816d21e8c63e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_57959862-003a-4ddf-8a13-fcf0f1387612" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_9209d04a-6701-4341-87bb-816d21e8c63e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_0734f951-bced-4de0-ab3f-5660ac46b994" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_57959862-003a-4ddf-8a13-fcf0f1387612" xlink:to="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_0734f951-bced-4de0-ab3f-5660ac46b994" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_811cb301-a838-490a-b6ab-167b34c11b9e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_0734f951-bced-4de0-ab3f-5660ac46b994" xlink:to="loc_us-gaap_StatementClassOfStockAxis_811cb301-a838-490a-b6ab-167b34c11b9e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_811cb301-a838-490a-b6ab-167b34c11b9e_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_811cb301-a838-490a-b6ab-167b34c11b9e" xlink:to="loc_us-gaap_ClassOfStockDomain_811cb301-a838-490a-b6ab-167b34c11b9e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_4696952d-c176-4d29-8fc3-db30531d651b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_811cb301-a838-490a-b6ab-167b34c11b9e" xlink:to="loc_us-gaap_ClassOfStockDomain_4696952d-c176-4d29-8fc3-db30531d651b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_a3168a85-2e3f-40fd-abe3-3bff99e4760a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_4696952d-c176-4d29-8fc3-db30531d651b" xlink:to="loc_us-gaap_CommonStockMember_a3168a85-2e3f-40fd-abe3-3bff99e4760a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_18c0ed2a-af32-40c6-a086-2ca2dd891f4b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_0734f951-bced-4de0-ab3f-5660ac46b994" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_18c0ed2a-af32-40c6-a086-2ca2dd891f4b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_18c0ed2a-af32-40c6-a086-2ca2dd891f4b_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_18c0ed2a-af32-40c6-a086-2ca2dd891f4b" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_18c0ed2a-af32-40c6-a086-2ca2dd891f4b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1e1cba72-0ab9-44b3-ae99-ad782ac3563f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_18c0ed2a-af32-40c6-a086-2ca2dd891f4b" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1e1cba72-0ab9-44b3-ae99-ad782ac3563f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_UnderwrittenPublicOfferingMember_4ed6dfbc-e146-410a-bdd0-6dbd52dff9c6" xlink:href="ino-20210331.xsd#ino_UnderwrittenPublicOfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1e1cba72-0ab9-44b3-ae99-ad782ac3563f" xlink:to="loc_ino_UnderwrittenPublicOfferingMember_4ed6dfbc-e146-410a-bdd0-6dbd52dff9c6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_SalesAgreementsMember_2d58cebd-e910-4c76-8bff-7004f7dde15a" xlink:href="ino-20210331.xsd#ino_SalesAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1e1cba72-0ab9-44b3-ae99-ad782ac3563f" xlink:to="loc_ino_SalesAgreementsMember_2d58cebd-e910-4c76-8bff-7004f7dde15a" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.inovio.com/role/CriticalAccountingPolicies" xlink:type="simple" xlink:href="ino-20210331.xsd#CriticalAccountingPolicies"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/CriticalAccountingPolicies" xlink:type="extended" id="i78573346797c46bcb7147f9b0ebd2780_CriticalAccountingPolicies"/>
  <link:roleRef roleURI="http://www.inovio.com/role/CriticalAccountingPoliciesDetails" xlink:type="simple" xlink:href="ino-20210331.xsd#CriticalAccountingPoliciesDetails"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/CriticalAccountingPoliciesDetails" xlink:type="extended" id="i209dedfb51e44dafa004af722c437654_CriticalAccountingPoliciesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_ebcfdec5-63bd-494e-a001-bdc755715721" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_52bd21a1-1084-40fb-8310-b0a0f822cfa3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_ebcfdec5-63bd-494e-a001-bdc755715721" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_52bd21a1-1084-40fb-8310-b0a0f822cfa3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_3ec695aa-b47c-47a2-abe9-0805421f4dab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_ebcfdec5-63bd-494e-a001-bdc755715721" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_3ec695aa-b47c-47a2-abe9-0805421f4dab" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_dd7f2767-bebd-4622-8428-b62cc78bcbe3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_ebcfdec5-63bd-494e-a001-bdc755715721" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_dd7f2767-bebd-4622-8428-b62cc78bcbe3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_d6bcc043-0255-4762-88c1-bf1eb1c0cfef" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_dd7f2767-bebd-4622-8428-b62cc78bcbe3" xlink:to="loc_srt_RangeAxis_d6bcc043-0255-4762-88c1-bf1eb1c0cfef" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_d6bcc043-0255-4762-88c1-bf1eb1c0cfef_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_d6bcc043-0255-4762-88c1-bf1eb1c0cfef" xlink:to="loc_srt_RangeMember_d6bcc043-0255-4762-88c1-bf1eb1c0cfef_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_dcee986d-505b-42af-8028-6127c6350c50" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_d6bcc043-0255-4762-88c1-bf1eb1c0cfef" xlink:to="loc_srt_RangeMember_dcee986d-505b-42af-8028-6127c6350c50" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_dbd16149-e148-4cd3-a9bf-9066578b3ee5" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_dcee986d-505b-42af-8028-6127c6350c50" xlink:to="loc_srt_MinimumMember_dbd16149-e148-4cd3-a9bf-9066578b3ee5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_7a0235aa-3787-4cbe-b6f9-a42b24540bc2" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_dcee986d-505b-42af-8028-6127c6350c50" xlink:to="loc_srt_MaximumMember_7a0235aa-3787-4cbe-b6f9-a42b24540bc2" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.inovio.com/role/ImpactofRecentlyIssuedAccountingStandards" xlink:type="simple" xlink:href="ino-20210331.xsd#ImpactofRecentlyIssuedAccountingStandards"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/ImpactofRecentlyIssuedAccountingStandards" xlink:type="extended" id="i99e44fffd2a34c5884e01b09777809e7_ImpactofRecentlyIssuedAccountingStandards"/>
  <link:roleRef roleURI="http://www.inovio.com/role/RevenueRecognition" xlink:type="simple" xlink:href="ino-20210331.xsd#RevenueRecognition"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/RevenueRecognition" xlink:type="extended" id="id598b2bd6f3544a7a4167de2e47b48ab_RevenueRecognition"/>
  <link:roleRef roleURI="http://www.inovio.com/role/RevenueRecognitionDetails" xlink:type="simple" xlink:href="ino-20210331.xsd#RevenueRecognitionDetails"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/RevenueRecognitionDetails" xlink:type="extended" id="i17e8b65b90d7437dac6e9802f59c37d9_RevenueRecognitionDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_f06b8e5d-287a-42ed-a65c-3c0087e8542e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_e3e178be-d69a-4896-86ad-ab92083824fa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_f06b8e5d-287a-42ed-a65c-3c0087e8542e" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_e3e178be-d69a-4896-86ad-ab92083824fa" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_cf2fdf6b-60c5-46cd-bfbd-0c5e31f13df6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_f06b8e5d-287a-42ed-a65c-3c0087e8542e" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_cf2fdf6b-60c5-46cd-bfbd-0c5e31f13df6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_c225079b-a6bd-4a7b-8f10-8e31ad502461" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_f06b8e5d-287a-42ed-a65c-3c0087e8542e" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_c225079b-a6bd-4a7b-8f10-8e31ad502461" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_0a9d09cc-5c96-4d30-80e8-0a83cab3d4fc" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_c225079b-a6bd-4a7b-8f10-8e31ad502461" xlink:to="loc_srt_CounterpartyNameAxis_0a9d09cc-5c96-4d30-80e8-0a83cab3d4fc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_0a9d09cc-5c96-4d30-80e8-0a83cab3d4fc_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_0a9d09cc-5c96-4d30-80e8-0a83cab3d4fc" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_0a9d09cc-5c96-4d30-80e8-0a83cab3d4fc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3806d28c-8c8e-45c9-ae2f-e45ac0e47992" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_0a9d09cc-5c96-4d30-80e8-0a83cab3d4fc" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3806d28c-8c8e-45c9-ae2f-e45ac0e47992" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_PlumblineLifeSciencesMember_42b81eb2-69f2-456b-a2b8-57f1e0d1be09" xlink:href="ino-20210331.xsd#ino_PlumblineLifeSciencesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3806d28c-8c8e-45c9-ae2f-e45ac0e47992" xlink:to="loc_ino_PlumblineLifeSciencesMember_42b81eb2-69f2-456b-a2b8-57f1e0d1be09" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_OtherCounterpartyMember_c8319c8d-84e9-4278-825f-ff0e81e4b263" xlink:href="ino-20210331.xsd#ino_OtherCounterpartyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3806d28c-8c8e-45c9-ae2f-e45ac0e47992" xlink:to="loc_ino_OtherCounterpartyMember_c8319c8d-84e9-4278-825f-ff0e81e4b263" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.inovio.com/role/ShorttermInvestments" xlink:type="simple" xlink:href="ino-20210331.xsd#ShorttermInvestments"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/ShorttermInvestments" xlink:type="extended" id="ie0185e49dd36457fbe289017d0cd3372_ShorttermInvestments"/>
  <link:roleRef roleURI="http://www.inovio.com/role/ShorttermInvestmentsTables" xlink:type="simple" xlink:href="ino-20210331.xsd#ShorttermInvestmentsTables"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/ShorttermInvestmentsTables" xlink:type="extended" id="i2386101e9b1c47ceb8da85b00ede80fd_ShorttermInvestmentsTables"/>
  <link:roleRef roleURI="http://www.inovio.com/role/ShorttermInvestmentsNarrativeDetails" xlink:type="simple" xlink:href="ino-20210331.xsd#ShorttermInvestmentsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/ShorttermInvestmentsNarrativeDetails" xlink:type="extended" id="i07dfb73766a340cd8259cf9623df4d18_ShorttermInvestmentsNarrativeDetails"/>
  <link:roleRef roleURI="http://www.inovio.com/role/ShorttermInvestmentsSummaryofAvailableforsaleSecuritiesDetails" xlink:type="simple" xlink:href="ino-20210331.xsd#ShorttermInvestmentsSummaryofAvailableforsaleSecuritiesDetails"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/ShorttermInvestmentsSummaryofAvailableforsaleSecuritiesDetails" xlink:type="extended" id="i749fe5fc349443d791d3423b0697ad76_ShorttermInvestmentsSummaryofAvailableforsaleSecuritiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_593b97b8-2eb4-4a67-b2a6-0420329499e9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DebtSecuritiesAvailableforSaleContractualMaturity_9af8868c-bbd2-4595-ab97-a3ed749a859f" xlink:href="ino-20210331.xsd#ino_DebtSecuritiesAvailableforSaleContractualMaturity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_593b97b8-2eb4-4a67-b2a6-0420329499e9" xlink:to="loc_ino_DebtSecuritiesAvailableforSaleContractualMaturity_9af8868c-bbd2-4595-ab97-a3ed749a859f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAbstract_257cf299-987b-4b11-890b-4bf7ae2bf8a3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_593b97b8-2eb4-4a67-b2a6-0420329499e9" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAbstract_257cf299-987b-4b11-890b-4bf7ae2bf8a3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_409c39fd-7d5a-4b5e-9b92-1175bf83ca59" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_257cf299-987b-4b11-890b-4bf7ae2bf8a3" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_409c39fd-7d5a-4b5e-9b92-1175bf83ca59" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_204fbc2a-9404-4dc5-bb24-89bb460f71db" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_257cf299-987b-4b11-890b-4bf7ae2bf8a3" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_204fbc2a-9404-4dc5-bb24-89bb460f71db" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_33f40f02-6b74-4353-952f-ac16eafb4e62" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_257cf299-987b-4b11-890b-4bf7ae2bf8a3" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_33f40f02-6b74-4353-952f-ac16eafb4e62" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_f53353a5-a5a8-4ba8-a5d1-76e11be8c4a5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_257cf299-987b-4b11-890b-4bf7ae2bf8a3" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_f53353a5-a5a8-4ba8-a5d1-76e11be8c4a5" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_5c2fee20-0f2e-454c-9b7f-e8ef2bc48dd9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_593b97b8-2eb4-4a67-b2a6-0420329499e9" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_5c2fee20-0f2e-454c-9b7f-e8ef2bc48dd9" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_f314257a-1057-4b2a-961a-76f5c73aa07e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_5c2fee20-0f2e-454c-9b7f-e8ef2bc48dd9" xlink:to="loc_us-gaap_FinancialInstrumentAxis_f314257a-1057-4b2a-961a-76f5c73aa07e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f314257a-1057-4b2a-961a-76f5c73aa07e_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_f314257a-1057-4b2a-961a-76f5c73aa07e" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f314257a-1057-4b2a-961a-76f5c73aa07e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_da8a33af-3a49-4a52-bba6-fdf3abf8dd8f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_f314257a-1057-4b2a-961a-76f5c73aa07e" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_da8a33af-3a49-4a52-bba6-fdf3abf8dd8f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_MutualFundsMember_d5072d9d-cb6d-4892-b5bf-7578c8332cab" xlink:href="ino-20210331.xsd#ino_MutualFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_da8a33af-3a49-4a52-bba6-fdf3abf8dd8f" xlink:to="loc_ino_MutualFundsMember_d5072d9d-cb6d-4892-b5bf-7578c8332cab" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryBillSecuritiesMember_14fc8b6c-c1a4-4fb4-bc15-4d9961e93720" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USTreasuryBillSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_da8a33af-3a49-4a52-bba6-fdf3abf8dd8f" xlink:to="loc_us-gaap_USTreasuryBillSecuritiesMember_14fc8b6c-c1a4-4fb4-bc15-4d9961e93720" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_0ce71db0-7374-4fee-b704-63f6f94f2aa1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_da8a33af-3a49-4a52-bba6-fdf3abf8dd8f" xlink:to="loc_us-gaap_CertificatesOfDepositMember_0ce71db0-7374-4fee-b704-63f6f94f2aa1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember_4ad939a2-cf5f-44a8-9b4f-f87e247ab005" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_da8a33af-3a49-4a52-bba6-fdf3abf8dd8f" xlink:to="loc_us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember_4ad939a2-cf5f-44a8-9b4f-f87e247ab005" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.inovio.com/role/FairValueMeasurements" xlink:type="simple" xlink:href="ino-20210331.xsd#FairValueMeasurements"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/FairValueMeasurements" xlink:type="extended" id="ia12198905db54e60b62c392ffbd05c16_FairValueMeasurements"/>
  <link:roleRef roleURI="http://www.inovio.com/role/FairValueMeasurementsTables" xlink:type="simple" xlink:href="ino-20210331.xsd#FairValueMeasurementsTables"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/FairValueMeasurementsTables" xlink:type="extended" id="ifafe09c2fdbd4570a79c27659ad5b44f_FairValueMeasurementsTables"/>
  <link:roleRef roleURI="http://www.inovio.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueDetails" xlink:type="simple" xlink:href="ino-20210331.xsd#FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueDetails"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueDetails" xlink:type="extended" id="i28007aca8b8a433586044ab262ff751f_FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_767bd444-0f30-40ee-8940-5f154e7e0c11" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_a62b38a7-c020-4b17-830e-1d06a5c0d723" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_767bd444-0f30-40ee-8940-5f154e7e0c11" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_a62b38a7-c020-4b17-830e-1d06a5c0d723" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_904971fc-e61e-4ae4-9ae0-8ece0d2d02f8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_a62b38a7-c020-4b17-830e-1d06a5c0d723" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_904971fc-e61e-4ae4-9ae0-8ece0d2d02f8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_832b59b3-c27c-46c2-bcba-0779e6e7c859" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_a62b38a7-c020-4b17-830e-1d06a5c0d723" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_832b59b3-c27c-46c2-bcba-0779e6e7c859" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_288dcff6-8041-47d4-a7b7-a44664018ad4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_a62b38a7-c020-4b17-830e-1d06a5c0d723" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_288dcff6-8041-47d4-a7b7-a44664018ad4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_d17fc040-d6ba-4de4-a269-34033eddb582" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_a62b38a7-c020-4b17-830e-1d06a5c0d723" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_d17fc040-d6ba-4de4-a269-34033eddb582" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable_364ac3f2-7f59-481e-a675-c1c46f070a81" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_767bd444-0f30-40ee-8940-5f154e7e0c11" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTable_364ac3f2-7f59-481e-a675-c1c46f070a81" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_3e50147d-8ef8-48a9-b9ed-3a6e4bfc64e8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_364ac3f2-7f59-481e-a675-c1c46f070a81" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_3e50147d-8ef8-48a9-b9ed-3a6e4bfc64e8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_3e50147d-8ef8-48a9-b9ed-3a6e4bfc64e8_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_3e50147d-8ef8-48a9-b9ed-3a6e4bfc64e8" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_3e50147d-8ef8-48a9-b9ed-3a6e4bfc64e8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_e65c6c3a-1dd5-4d3c-9581-73cb2b2cea6d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_3e50147d-8ef8-48a9-b9ed-3a6e4bfc64e8" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_e65c6c3a-1dd5-4d3c-9581-73cb2b2cea6d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_3d20ca36-92ff-492d-9192-c9e3136ef7bd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_e65c6c3a-1dd5-4d3c-9581-73cb2b2cea6d" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_3d20ca36-92ff-492d-9192-c9e3136ef7bd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_7a735b3d-a139-40a4-aaf5-834c9aab8a8a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_364ac3f2-7f59-481e-a675-c1c46f070a81" xlink:to="loc_us-gaap_FinancialInstrumentAxis_7a735b3d-a139-40a4-aaf5-834c9aab8a8a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_7a735b3d-a139-40a4-aaf5-834c9aab8a8a_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_7a735b3d-a139-40a4-aaf5-834c9aab8a8a" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_7a735b3d-a139-40a4-aaf5-834c9aab8a8a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_c40cebef-4182-4724-98d8-8030ca731b1d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_7a735b3d-a139-40a4-aaf5-834c9aab8a8a" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_c40cebef-4182-4724-98d8-8030ca731b1d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_MutualFundsMember_a03be2d9-55ed-4419-a977-a8fe3075644e" xlink:href="ino-20210331.xsd#ino_MutualFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_c40cebef-4182-4724-98d8-8030ca731b1d" xlink:to="loc_ino_MutualFundsMember_a03be2d9-55ed-4419-a977-a8fe3075644e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryBillSecuritiesMember_271bee42-5a70-4830-ac27-92a27b36928d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USTreasuryBillSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_c40cebef-4182-4724-98d8-8030ca731b1d" xlink:to="loc_us-gaap_USTreasuryBillSecuritiesMember_271bee42-5a70-4830-ac27-92a27b36928d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_1ec89b39-1d1c-4209-a37f-096543e2101c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_c40cebef-4182-4724-98d8-8030ca731b1d" xlink:to="loc_us-gaap_CertificatesOfDepositMember_1ec89b39-1d1c-4209-a37f-096543e2101c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember_e3c0d414-2ee4-4e6a-b2b3-bf9e02a2baf6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_c40cebef-4182-4724-98d8-8030ca731b1d" xlink:to="loc_us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember_e3c0d414-2ee4-4e6a-b2b3-bf9e02a2baf6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_765db902-5747-4427-83f6-92cd24dc978f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_364ac3f2-7f59-481e-a675-c1c46f070a81" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_765db902-5747-4427-83f6-92cd24dc978f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_765db902-5747-4427-83f6-92cd24dc978f_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_765db902-5747-4427-83f6-92cd24dc978f" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_765db902-5747-4427-83f6-92cd24dc978f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2ccee0fb-1af8-48e3-b63f-970fa20432b2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_765db902-5747-4427-83f6-92cd24dc978f" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2ccee0fb-1af8-48e3-b63f-970fa20432b2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_15e2910b-8e98-4705-922e-1fe1a9442bee" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2ccee0fb-1af8-48e3-b63f-970fa20432b2" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_15e2910b-8e98-4705-922e-1fe1a9442bee" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_f5b28a2d-243e-4676-9471-a4e5ee718853" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2ccee0fb-1af8-48e3-b63f-970fa20432b2" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_f5b28a2d-243e-4676-9471-a4e5ee718853" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_94abae74-ef85-4266-84ff-e36b6c2e31a9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2ccee0fb-1af8-48e3-b63f-970fa20432b2" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_94abae74-ef85-4266-84ff-e36b6c2e31a9" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.inovio.com/role/FairValueMeasurementsNarrativeDetails" xlink:type="simple" xlink:href="ino-20210331.xsd#FairValueMeasurementsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/FairValueMeasurementsNarrativeDetails" xlink:type="extended" id="i4f93d1b888404585a718ddf3392264ab_FairValueMeasurementsNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_b84c50e7-180b-4be9-bc7c-476b1ad07eb1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_MarketableSecuritiesAndFairValueMeasurementsTextualAbstract_733b3053-28b6-436c-af75-fc6989d9a44f" xlink:href="ino-20210331.xsd#ino_MarketableSecuritiesAndFairValueMeasurementsTextualAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_b84c50e7-180b-4be9-bc7c-476b1ad07eb1" xlink:to="loc_ino_MarketableSecuritiesAndFairValueMeasurementsTextualAbstract_733b3053-28b6-436c-af75-fc6989d9a44f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentOwnedBalanceShares_7fc45df3-f896-45ae-b9f0-dd652ad30dd6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentOwnedBalanceShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ino_MarketableSecuritiesAndFairValueMeasurementsTextualAbstract_733b3053-28b6-436c-af75-fc6989d9a44f" xlink:to="loc_us-gaap_InvestmentOwnedBalanceShares_7fc45df3-f896-45ae-b9f0-dd652ad30dd6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable_16e2e649-6896-459f-a63c-5c19b9926082" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_b84c50e7-180b-4be9-bc7c-476b1ad07eb1" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTable_16e2e649-6896-459f-a63c-5c19b9926082" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_f974ca85-0902-4d54-8791-bc9ac190fe46" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_16e2e649-6896-459f-a63c-5c19b9926082" xlink:to="loc_us-gaap_StatementClassOfStockAxis_f974ca85-0902-4d54-8791-bc9ac190fe46" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_f974ca85-0902-4d54-8791-bc9ac190fe46_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_f974ca85-0902-4d54-8791-bc9ac190fe46" xlink:to="loc_us-gaap_ClassOfStockDomain_f974ca85-0902-4d54-8791-bc9ac190fe46_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_066c2cbe-810d-42b8-b4bf-bd85077f7cb2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_f974ca85-0902-4d54-8791-bc9ac190fe46" xlink:to="loc_us-gaap_ClassOfStockDomain_066c2cbe-810d-42b8-b4bf-bd85077f7cb2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_5db0f8dc-d0d9-41dd-984e-668f2d26c4d7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_066c2cbe-810d-42b8-b4bf-bd85077f7cb2" xlink:to="loc_us-gaap_CommonStockMember_5db0f8dc-d0d9-41dd-984e-668f2d26c4d7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_270634f3-c7c1-4323-a898-a1e63b7bfd40" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_16e2e649-6896-459f-a63c-5c19b9926082" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_270634f3-c7c1-4323-a898-a1e63b7bfd40" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_270634f3-c7c1-4323-a898-a1e63b7bfd40_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_270634f3-c7c1-4323-a898-a1e63b7bfd40" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_270634f3-c7c1-4323-a898-a1e63b7bfd40_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_515f638f-161f-48e3-b57e-fed2253eda18" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_270634f3-c7c1-4323-a898-a1e63b7bfd40" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_515f638f-161f-48e3-b57e-fed2253eda18" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_c4189f49-ebfa-4e97-aef0-4653d6ac269d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_515f638f-161f-48e3-b57e-fed2253eda18" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_c4189f49-ebfa-4e97-aef0-4653d6ac269d" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.inovio.com/role/GoodwillandIntangibleAssets" xlink:type="simple" xlink:href="ino-20210331.xsd#GoodwillandIntangibleAssets"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/GoodwillandIntangibleAssets" xlink:type="extended" id="i8a37c0ce8ecd4816b705b8de5caaa583_GoodwillandIntangibleAssets"/>
  <link:roleRef roleURI="http://www.inovio.com/role/GoodwillandIntangibleAssetsTables" xlink:type="simple" xlink:href="ino-20210331.xsd#GoodwillandIntangibleAssetsTables"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/GoodwillandIntangibleAssetsTables" xlink:type="extended" id="ie757657bfa024b20a1a2fead48882077_GoodwillandIntangibleAssetsTables"/>
  <link:roleRef roleURI="http://www.inovio.com/role/GoodwillandIntangibleAssetsScheduleGoodwillandIntangibleAssetsDetails" xlink:type="simple" xlink:href="ino-20210331.xsd#GoodwillandIntangibleAssetsScheduleGoodwillandIntangibleAssetsDetails"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/GoodwillandIntangibleAssetsScheduleGoodwillandIntangibleAssetsDetails" xlink:type="extended" id="ia3e66bd3713b4ef1bc930a82506ead77_GoodwillandIntangibleAssetsScheduleGoodwillandIntangibleAssetsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_3fe5f880-46cf-4133-af6a-60dbc49d7f91" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_a781c649-a03d-4cd9-901d-473c6927725e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_3fe5f880-46cf-4133-af6a-60dbc49d7f91" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_a781c649-a03d-4cd9-901d-473c6927725e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_c349eb09-c987-4260-89d5-8c0fd1bdc4e9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNetAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_a781c649-a03d-4cd9-901d-473c6927725e" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_c349eb09-c987-4260-89d5-8c0fd1bdc4e9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillGross_5c6380dd-a766-4dea-af97-97cbde23f8a5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_c349eb09-c987-4260-89d5-8c0fd1bdc4e9" xlink:to="loc_us-gaap_GoodwillGross_5c6380dd-a766-4dea-af97-97cbde23f8a5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_c78ff7e7-7bfa-4471-a4a4-43c78418a292" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_c349eb09-c987-4260-89d5-8c0fd1bdc4e9" xlink:to="loc_us-gaap_Goodwill_c78ff7e7-7bfa-4471-a4a4-43c78418a292" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_bb1adf7c-e890-4df1-a480-3946b735ac69" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_a781c649-a03d-4cd9-901d-473c6927725e" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_bb1adf7c-e890-4df1-a480-3946b735ac69" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_715603c8-8647-49ca-90a9-b09e80c4a257" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_bb1adf7c-e890-4df1-a480-3946b735ac69" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_715603c8-8647-49ca-90a9-b09e80c4a257" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_fc457d44-9867-4e85-aebe-bbd556811355" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_bb1adf7c-e890-4df1-a480-3946b735ac69" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_fc457d44-9867-4e85-aebe-bbd556811355" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_ec61af95-44c7-4b95-9f5b-5b8e70a0c177" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_bb1adf7c-e890-4df1-a480-3946b735ac69" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_ec61af95-44c7-4b95-9f5b-5b8e70a0c177" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_806e7b56-f0a3-485c-89fe-0a79e0b9ba06" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_bb1adf7c-e890-4df1-a480-3946b735ac69" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_806e7b56-f0a3-485c-89fe-0a79e0b9ba06" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_GoodwillAndIntangibleAssetsGross_8f5f196b-834e-4d9b-a51d-138aa8a4ebf2" xlink:href="ino-20210331.xsd#ino_GoodwillAndIntangibleAssetsGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_a781c649-a03d-4cd9-901d-473c6927725e" xlink:to="loc_ino_GoodwillAndIntangibleAssetsGross_8f5f196b-834e-4d9b-a51d-138aa8a4ebf2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_GoodwillAndIntangibleAssetsNet_394cff18-277c-419b-9548-aa1fddbca597" xlink:href="ino-20210331.xsd#ino_GoodwillAndIntangibleAssetsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_a781c649-a03d-4cd9-901d-473c6927725e" xlink:to="loc_ino_GoodwillAndIntangibleAssetsNet_394cff18-277c-419b-9548-aa1fddbca597" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable_f6625a2f-7f08-4b14-a696-48449d99e20f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_3fe5f880-46cf-4133-af6a-60dbc49d7f91" xlink:to="loc_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable_f6625a2f-7f08-4b14-a696-48449d99e20f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_c6aab640-7821-474b-8777-cc6df13aa2af" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable_f6625a2f-7f08-4b14-a696-48449d99e20f" xlink:to="loc_srt_RangeAxis_c6aab640-7821-474b-8777-cc6df13aa2af" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_c6aab640-7821-474b-8777-cc6df13aa2af_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_c6aab640-7821-474b-8777-cc6df13aa2af" xlink:to="loc_srt_RangeMember_c6aab640-7821-474b-8777-cc6df13aa2af_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_23b1f54a-e7bd-430b-8114-93a02f14f83a" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_c6aab640-7821-474b-8777-cc6df13aa2af" xlink:to="loc_srt_RangeMember_23b1f54a-e7bd-430b-8114-93a02f14f83a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_WeightedAverageMember_ade133d9-2adf-4edf-995a-1a26de6de148" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_WeightedAverageMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_23b1f54a-e7bd-430b-8114-93a02f14f83a" xlink:to="loc_srt_WeightedAverageMember_ade133d9-2adf-4edf-995a-1a26de6de148" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_f635ff1a-5923-4736-9460-4daea0f22eb0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable_f6625a2f-7f08-4b14-a696-48449d99e20f" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_f635ff1a-5923-4736-9460-4daea0f22eb0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_f635ff1a-5923-4736-9460-4daea0f22eb0_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_f635ff1a-5923-4736-9460-4daea0f22eb0" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_f635ff1a-5923-4736-9460-4daea0f22eb0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_d6201918-d19f-4bed-8a45-fb48191c8368" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_f635ff1a-5923-4736-9460-4daea0f22eb0" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_d6201918-d19f-4bed-8a45-fb48191c8368" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicensingAgreementsMember_e3b198d3-b26d-43ea-a184-8a8639371c7f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LicensingAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_d6201918-d19f-4bed-8a45-fb48191c8368" xlink:to="loc_us-gaap_LicensingAgreementsMember_e3b198d3-b26d-43ea-a184-8a8639371c7f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_BiojectMember_7d7fde49-657a-4eaf-b4c1-1cc3144dc89f" xlink:href="ino-20210331.xsd#ino_BiojectMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_d6201918-d19f-4bed-8a45-fb48191c8368" xlink:to="loc_ino_BiojectMember_7d7fde49-657a-4eaf-b4c1-1cc3144dc89f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIntangibleAssetsMember_daa8fba5-e1fb-429b-a097-f6ad23c32633" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherIntangibleAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_d6201918-d19f-4bed-8a45-fb48191c8368" xlink:to="loc_us-gaap_OtherIntangibleAssetsMember_daa8fba5-e1fb-429b-a097-f6ad23c32633" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.inovio.com/role/GoodwillandIntangibleAssetsNarrativeDetails" xlink:type="simple" xlink:href="ino-20210331.xsd#GoodwillandIntangibleAssetsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/GoodwillandIntangibleAssetsNarrativeDetails" xlink:type="extended" id="ia8101c2f09404a55af1cb7b6468384c6_GoodwillandIntangibleAssetsNarrativeDetails"/>
  <link:roleRef roleURI="http://www.inovio.com/role/ConvertibleDebt" xlink:type="simple" xlink:href="ino-20210331.xsd#ConvertibleDebt"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/ConvertibleDebt" xlink:type="extended" id="idb957c38e1c341a1b5be29b388bf228a_ConvertibleDebt"/>
  <link:roleRef roleURI="http://www.inovio.com/role/ConvertibleDebtTables" xlink:type="simple" xlink:href="ino-20210331.xsd#ConvertibleDebtTables"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/ConvertibleDebtTables" xlink:type="extended" id="iaaa9e8c8ee034803bccd36cd94ecabb7_ConvertibleDebtTables"/>
  <link:roleRef roleURI="http://www.inovio.com/role/ConvertibleDebtNarrativeDetails" xlink:type="simple" xlink:href="ino-20210331.xsd#ConvertibleDebtNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/ConvertibleDebtNarrativeDetails" xlink:type="extended" id="i45c5131c9ee247fdbc87bc1e36d65094_ConvertibleDebtNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_82a830bb-736c-4539-83bb-e15ada8cf6a6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_6c8bcd98-ed19-4a89-a649-bde1891fa8d8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_82a830bb-736c-4539-83bb-e15ada8cf6a6" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_6c8bcd98-ed19-4a89-a649-bde1891fa8d8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_e5cad95b-fb58-414d-b464-92bbde101f3e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_82a830bb-736c-4539-83bb-e15ada8cf6a6" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_e5cad95b-fb58-414d-b464-92bbde101f3e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfDebt_11db382a-7ff8-4118-9f04-391180214b6e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_82a830bb-736c-4539-83bb-e15ada8cf6a6" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfDebt_11db382a-7ff8-4118-9f04-391180214b6e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_b51e6d83-9a34-450f-873a-c919d0b6ef3d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionRatio1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_82a830bb-736c-4539-83bb-e15ada8cf6a6" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_b51e6d83-9a34-450f-873a-c919d0b6ef3d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_228a4715-4f95-4493-9f7c-a992ebe5e4ef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_82a830bb-736c-4539-83bb-e15ada8cf6a6" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_228a4715-4f95-4493-9f7c-a992ebe5e4ef" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_bb42de18-7a1f-40db-a0e1-8cf805abc35c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_82a830bb-736c-4539-83bb-e15ada8cf6a6" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_bb42de18-7a1f-40db-a0e1-8cf805abc35c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_b025c248-7fe8-44c8-9286-c7034c80c01a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdTradingDays"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_82a830bb-736c-4539-83bb-e15ada8cf6a6" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_b025c248-7fe8-44c8-9286-c7034c80c01a" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_95431d9c-f505-4d72-8a19-a7dc743b6c9f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_82a830bb-736c-4539-83bb-e15ada8cf6a6" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_95431d9c-f505-4d72-8a19-a7dc743b6c9f" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_c9adaefe-8041-47be-8005-f5350804ffc2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentRedemptionPricePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_82a830bb-736c-4539-83bb-e15ada8cf6a6" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_c9adaefe-8041-47be-8005-f5350804ffc2" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent_b3b56d4d-cdeb-4576-881d-ae395de30609" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_82a830bb-736c-4539-83bb-e15ada8cf6a6" xlink:to="loc_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent_b3b56d4d-cdeb-4576-881d-ae395de30609" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_e50416b3-1952-4749-908d-8f040b06465e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_82a830bb-736c-4539-83bb-e15ada8cf6a6" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_e50416b3-1952-4749-908d-8f040b06465e" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount_071cb127-ade9-4786-9998-4bc2926dd6d0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_82a830bb-736c-4539-83bb-e15ada8cf6a6" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscount_071cb127-ade9-4786-9998-4bc2926dd6d0" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_958173ed-88a2-43b8-b1ad-152f47cb3996" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_82a830bb-736c-4539-83bb-e15ada8cf6a6" xlink:to="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_958173ed-88a2-43b8-b1ad-152f47cb3996" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_d0ba61d1-a55a-4b5c-b343-7213a823c95f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_82a830bb-736c-4539-83bb-e15ada8cf6a6" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_d0ba61d1-a55a-4b5c-b343-7213a823c95f" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_5144d675-2c32-4242-943b-3087bd416d6f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_82a830bb-736c-4539-83bb-e15ada8cf6a6" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_5144d675-2c32-4242-943b-3087bd416d6f" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFairValue_e6c3755d-f492-4f82-b500-6af864b37d5d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_82a830bb-736c-4539-83bb-e15ada8cf6a6" xlink:to="loc_us-gaap_DebtInstrumentFairValue_e6c3755d-f492-4f82-b500-6af864b37d5d" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_f45bed0e-38cd-4144-8049-5e8be7d8ae32" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_82a830bb-736c-4539-83bb-e15ada8cf6a6" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_f45bed0e-38cd-4144-8049-5e8be7d8ae32" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_53b60748-3594-46af-a59e-a57711596a35" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_82a830bb-736c-4539-83bb-e15ada8cf6a6" xlink:to="loc_us-gaap_InterestExpense_53b60748-3594-46af-a59e-a57711596a35" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt_a289b01e-f53d-445f-85d8-b7e4a6c33aac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpenseDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_82a830bb-736c-4539-83bb-e15ada8cf6a6" xlink:to="loc_us-gaap_InterestExpenseDebt_a289b01e-f53d-445f-85d8-b7e4a6c33aac" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability_99c3430f-5754-42f6-b059-55bcbbf9db42" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_82a830bb-736c-4539-83bb-e15ada8cf6a6" xlink:to="loc_us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability_99c3430f-5754-42f6-b059-55bcbbf9db42" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet_ab170245-6b11-4ecc-8b09-59c3ef88aed1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_82a830bb-736c-4539-83bb-e15ada8cf6a6" xlink:to="loc_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet_ab170245-6b11-4ecc-8b09-59c3ef88aed1" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfUnits_c61add6d-4150-4f81-8ebc-0dfddfafab4c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfUnits"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_82a830bb-736c-4539-83bb-e15ada8cf6a6" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfUnits_c61add6d-4150-4f81-8ebc-0dfddfafab4c" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_8348ec4c-5d61-43eb-a9a3-b6cdd3a9f447" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_82a830bb-736c-4539-83bb-e15ada8cf6a6" xlink:to="loc_us-gaap_DebtInstrumentTable_8348ec4c-5d61-43eb-a9a3-b6cdd3a9f447" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_15be3848-a1b2-4849-8fd9-16aa6c6c850e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_8348ec4c-5d61-43eb-a9a3-b6cdd3a9f447" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_15be3848-a1b2-4849-8fd9-16aa6c6c850e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_15be3848-a1b2-4849-8fd9-16aa6c6c850e_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_15be3848-a1b2-4849-8fd9-16aa6c6c850e" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_15be3848-a1b2-4849-8fd9-16aa6c6c850e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_e4902430-7c80-4883-9d13-af8fc3b2eed2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_15be3848-a1b2-4849-8fd9-16aa6c6c850e" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_e4902430-7c80-4883-9d13-af8fc3b2eed2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtMember_758d2f76-534d-4825-85a1-c4dbae99e34a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_e4902430-7c80-4883-9d13-af8fc3b2eed2" xlink:to="loc_us-gaap_ConvertibleDebtMember_758d2f76-534d-4825-85a1-c4dbae99e34a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_e7fb44c2-2655-4f68-8d55-0e0dcc9926cc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_8348ec4c-5d61-43eb-a9a3-b6cdd3a9f447" xlink:to="loc_us-gaap_DebtInstrumentAxis_e7fb44c2-2655-4f68-8d55-0e0dcc9926cc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_e7fb44c2-2655-4f68-8d55-0e0dcc9926cc_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_e7fb44c2-2655-4f68-8d55-0e0dcc9926cc" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_e7fb44c2-2655-4f68-8d55-0e0dcc9926cc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_d114c223-fdaa-4c3c-8774-e4ba1c57253f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_e7fb44c2-2655-4f68-8d55-0e0dcc9926cc" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_d114c223-fdaa-4c3c-8774-e4ba1c57253f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_A6.50ConvertibleSeniorNotesDue2024Member_a6eee139-da1b-4454-af21-7d0968430523" xlink:href="ino-20210331.xsd#ino_A6.50ConvertibleSeniorNotesDue2024Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d114c223-fdaa-4c3c-8774-e4ba1c57253f" xlink:to="loc_ino_A6.50ConvertibleSeniorNotesDue2024Member_a6eee139-da1b-4454-af21-7d0968430523" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_August2019ConvertibleBondsMember_6f937dfd-4b47-40e1-9989-08692aba07ac" xlink:href="ino-20210331.xsd#ino_August2019ConvertibleBondsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d114c223-fdaa-4c3c-8774-e4ba1c57253f" xlink:to="loc_ino_August2019ConvertibleBondsMember_6f937dfd-4b47-40e1-9989-08692aba07ac" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_December2019ConvertibleBondsMember_a895d675-b44e-4214-9bce-e06983099308" xlink:href="ino-20210331.xsd#ino_December2019ConvertibleBondsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d114c223-fdaa-4c3c-8774-e4ba1c57253f" xlink:to="loc_ino_December2019ConvertibleBondsMember_a895d675-b44e-4214-9bce-e06983099308" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionByUniqueDescriptionAxis_7af8955f-a334-468e-b827-489922a382e6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtConversionByUniqueDescriptionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_8348ec4c-5d61-43eb-a9a3-b6cdd3a9f447" xlink:to="loc_us-gaap_DebtConversionByUniqueDescriptionAxis_7af8955f-a334-468e-b827-489922a382e6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionNameDomain_7af8955f-a334-468e-b827-489922a382e6_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtConversionNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtConversionByUniqueDescriptionAxis_7af8955f-a334-468e-b827-489922a382e6" xlink:to="loc_us-gaap_DebtConversionNameDomain_7af8955f-a334-468e-b827-489922a382e6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionNameDomain_fadd11ff-8520-4abb-9a4e-c0baf39139f6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtConversionNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtConversionByUniqueDescriptionAxis_7af8955f-a334-468e-b827-489922a382e6" xlink:to="loc_us-gaap_DebtConversionNameDomain_fadd11ff-8520-4abb-9a4e-c0baf39139f6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_InitialConversionPriceMember_49aae850-8d69-44fb-91c3-2f276752c9dc" xlink:href="ino-20210331.xsd#ino_InitialConversionPriceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtConversionNameDomain_fadd11ff-8520-4abb-9a4e-c0baf39139f6" xlink:to="loc_ino_InitialConversionPriceMember_49aae850-8d69-44fb-91c3-2f276752c9dc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_8099d524-e11d-49ad-a328-96abaaf99875" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_8348ec4c-5d61-43eb-a9a3-b6cdd3a9f447" xlink:to="loc_us-gaap_StatementClassOfStockAxis_8099d524-e11d-49ad-a328-96abaaf99875" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_8099d524-e11d-49ad-a328-96abaaf99875_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_8099d524-e11d-49ad-a328-96abaaf99875" xlink:to="loc_us-gaap_ClassOfStockDomain_8099d524-e11d-49ad-a328-96abaaf99875_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_4e3489e7-2ffe-4a44-b14e-9de6f0d33fc5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_8099d524-e11d-49ad-a328-96abaaf99875" xlink:to="loc_us-gaap_ClassOfStockDomain_4e3489e7-2ffe-4a44-b14e-9de6f0d33fc5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_f282a6c0-da08-43a1-ba11-ec72f722d532" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_4e3489e7-2ffe-4a44-b14e-9de6f0d33fc5" xlink:to="loc_us-gaap_CommonStockMember_f282a6c0-da08-43a1-ba11-ec72f722d532" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.inovio.com/role/ConvertibleDebtBalanceofConvertibleBondsandNotesDetails" xlink:type="simple" xlink:href="ino-20210331.xsd#ConvertibleDebtBalanceofConvertibleBondsandNotesDetails"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/ConvertibleDebtBalanceofConvertibleBondsandNotesDetails" xlink:type="extended" id="i706e746589444186942f4c5327f4e090_ConvertibleDebtBalanceofConvertibleBondsandNotesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_8ff9ce59-b0d6-497f-b6bc-d4bd99c1e608" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_363abe19-19c7-4c6f-9153-693063163164" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_8ff9ce59-b0d6-497f-b6bc-d4bd99c1e608" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_363abe19-19c7-4c6f-9153-693063163164" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DebtInstrumentConvertibleDebtConvertedAmount_18573a80-24e2-4155-8b8f-9191604eeb81" xlink:href="ino-20210331.xsd#ino_DebtInstrumentConvertibleDebtConvertedAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_8ff9ce59-b0d6-497f-b6bc-d4bd99c1e608" xlink:to="loc_ino_DebtInstrumentConvertibleDebtConvertedAmount_18573a80-24e2-4155-8b8f-9191604eeb81" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount_d284bc0b-f329-4218-aa26-a15898f35a1b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_8ff9ce59-b0d6-497f-b6bc-d4bd99c1e608" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscount_d284bc0b-f329-4218-aa26-a15898f35a1b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_bdab947e-4380-427b-93d0-071d15187ccb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_8ff9ce59-b0d6-497f-b6bc-d4bd99c1e608" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_bdab947e-4380-427b-93d0-071d15187ccb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DebtInstrumentAccruedInterest_fdf3d05e-a059-4bce-bed4-499a2f007919" xlink:href="ino-20210331.xsd#ino_DebtInstrumentAccruedInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_8ff9ce59-b0d6-497f-b6bc-d4bd99c1e608" xlink:to="loc_ino_DebtInstrumentAccruedInterest_fdf3d05e-a059-4bce-bed4-499a2f007919" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_aa21dc8e-a841-4121-92e9-6b22a7a43dc8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_8ff9ce59-b0d6-497f-b6bc-d4bd99c1e608" xlink:to="loc_us-gaap_LongTermDebt_aa21dc8e-a841-4121-92e9-6b22a7a43dc8" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_48a57a11-22b5-42be-ad09-e78f68aeb6df" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_8ff9ce59-b0d6-497f-b6bc-d4bd99c1e608" xlink:to="loc_us-gaap_DebtInstrumentTable_48a57a11-22b5-42be-ad09-e78f68aeb6df" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_ac71ec2d-8e57-4943-944c-faa88a04c938" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_48a57a11-22b5-42be-ad09-e78f68aeb6df" xlink:to="loc_us-gaap_DebtInstrumentAxis_ac71ec2d-8e57-4943-944c-faa88a04c938" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_ac71ec2d-8e57-4943-944c-faa88a04c938_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_ac71ec2d-8e57-4943-944c-faa88a04c938" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_ac71ec2d-8e57-4943-944c-faa88a04c938_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_2ac86417-064a-4470-aaf2-28034e730a29" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_ac71ec2d-8e57-4943-944c-faa88a04c938" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_2ac86417-064a-4470-aaf2-28034e730a29" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_A6.50ConvertibleSeniorNotesDue2024Member_5a73abd9-f817-4745-a006-260a2a85c4ea" xlink:href="ino-20210331.xsd#ino_A6.50ConvertibleSeniorNotesDue2024Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2ac86417-064a-4470-aaf2-28034e730a29" xlink:to="loc_ino_A6.50ConvertibleSeniorNotesDue2024Member_5a73abd9-f817-4745-a006-260a2a85c4ea" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.inovio.com/role/ConvertibleDebtScheduleofMaturitiesDetails" xlink:type="simple" xlink:href="ino-20210331.xsd#ConvertibleDebtScheduleofMaturitiesDetails"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/ConvertibleDebtScheduleofMaturitiesDetails" xlink:type="extended" id="i87b28a93dd8a4c009767a481835dfb06_ConvertibleDebtScheduleofMaturitiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_8e3af6e3-2cc2-4127-bb74-b69a3aac8b9b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_2f4da17c-be80-40e2-8016-3cacb96d9045" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_8e3af6e3-2cc2-4127-bb74-b69a3aac8b9b" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_2f4da17c-be80-40e2-8016-3cacb96d9045" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_1677526f-5824-45a2-b1c3-854527fd02f5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_8e3af6e3-2cc2-4127-bb74-b69a3aac8b9b" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_1677526f-5824-45a2-b1c3-854527fd02f5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_8c263bb8-e6c1-45aa-a4ff-46c938527476" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_8e3af6e3-2cc2-4127-bb74-b69a3aac8b9b" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_8c263bb8-e6c1-45aa-a4ff-46c938527476" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_40ccdbf4-df22-40d7-8d38-acc41e5ffbb4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_8e3af6e3-2cc2-4127-bb74-b69a3aac8b9b" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_40ccdbf4-df22-40d7-8d38-acc41e5ffbb4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_6d00176f-46e6-427c-9d44-729be009b079" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_8e3af6e3-2cc2-4127-bb74-b69a3aac8b9b" xlink:to="loc_us-gaap_LongTermDebt_6d00176f-46e6-427c-9d44-729be009b079" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_ad7fcaba-42bc-46c8-a1eb-4a297882ba81" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_8e3af6e3-2cc2-4127-bb74-b69a3aac8b9b" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_ad7fcaba-42bc-46c8-a1eb-4a297882ba81" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_63864ed6-5c60-4e28-806c-824e6af9ceec" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_8e3af6e3-2cc2-4127-bb74-b69a3aac8b9b" xlink:to="loc_us-gaap_DebtInstrumentTable_63864ed6-5c60-4e28-806c-824e6af9ceec" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_d9de6e82-33a8-48bd-8e33-10edf063e455" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_63864ed6-5c60-4e28-806c-824e6af9ceec" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_d9de6e82-33a8-48bd-8e33-10edf063e455" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_d9de6e82-33a8-48bd-8e33-10edf063e455_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_d9de6e82-33a8-48bd-8e33-10edf063e455" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_d9de6e82-33a8-48bd-8e33-10edf063e455_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_77dafbbd-8694-4d45-860d-8d06dab1a79f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_d9de6e82-33a8-48bd-8e33-10edf063e455" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_77dafbbd-8694-4d45-860d-8d06dab1a79f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtMember_2b446277-31fa-4f5c-9abf-f78b07e76a03" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_77dafbbd-8694-4d45-860d-8d06dab1a79f" xlink:to="loc_us-gaap_ConvertibleDebtMember_2b446277-31fa-4f5c-9abf-f78b07e76a03" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_7a27e365-1399-405a-9779-c1255677bae8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_63864ed6-5c60-4e28-806c-824e6af9ceec" xlink:to="loc_us-gaap_DebtInstrumentAxis_7a27e365-1399-405a-9779-c1255677bae8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_7a27e365-1399-405a-9779-c1255677bae8_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_7a27e365-1399-405a-9779-c1255677bae8" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_7a27e365-1399-405a-9779-c1255677bae8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_ec219148-8948-45d0-a885-637ef5cf4bc8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_7a27e365-1399-405a-9779-c1255677bae8" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_ec219148-8948-45d0-a885-637ef5cf4bc8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_A6.50ConvertibleSeniorNotesDue2024Member_eb017766-a8d7-4e8c-97e7-095634cdbca7" xlink:href="ino-20210331.xsd#ino_A6.50ConvertibleSeniorNotesDue2024Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_ec219148-8948-45d0-a885-637ef5cf4bc8" xlink:to="loc_ino_A6.50ConvertibleSeniorNotesDue2024Member_eb017766-a8d7-4e8c-97e7-095634cdbca7" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.inovio.com/role/StockholdersEquity" xlink:type="simple" xlink:href="ino-20210331.xsd#StockholdersEquity"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/StockholdersEquity" xlink:type="extended" id="ib80b96f1ec1b4720bf9cb9ca032697ce_StockholdersEquity"/>
  <link:roleRef roleURI="http://www.inovio.com/role/StockholdersEquityTables" xlink:type="simple" xlink:href="ino-20210331.xsd#StockholdersEquityTables"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/StockholdersEquityTables" xlink:type="extended" id="ifb2b3053868b442cb99928d816f0b77b_StockholdersEquityTables"/>
  <link:roleRef roleURI="http://www.inovio.com/role/StockholdersEquitySummaryofAuthorizedandIssuedCommonandPreferredStockDetails" xlink:type="simple" xlink:href="ino-20210331.xsd#StockholdersEquitySummaryofAuthorizedandIssuedCommonandPreferredStockDetails"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/StockholdersEquitySummaryofAuthorizedandIssuedCommonandPreferredStockDetails" xlink:type="extended" id="iab2c1e4fa13b4589bf19dcb625fd273d_StockholdersEquitySummaryofAuthorizedandIssuedCommonandPreferredStockDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_b9bbba2a-d0df-4f7e-bcf4-03c90b99c29d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_f6ba2912-6441-463b-bdb1-725ae9b7225b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_b9bbba2a-d0df-4f7e-bcf4-03c90b99c29d" xlink:to="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_f6ba2912-6441-463b-bdb1-725ae9b7225b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_b6fd7307-419f-4bcd-8cc9-2ba632bb8cfd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_f6ba2912-6441-463b-bdb1-725ae9b7225b" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_b6fd7307-419f-4bcd-8cc9-2ba632bb8cfd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_504bd1e8-3cf4-4bb2-bfc5-995b53ce2910" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_f6ba2912-6441-463b-bdb1-725ae9b7225b" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_504bd1e8-3cf4-4bb2-bfc5-995b53ce2910" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_52b60045-5c92-4fc2-a9a5-386bdf8449b9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_f6ba2912-6441-463b-bdb1-725ae9b7225b" xlink:to="loc_us-gaap_CommonStockSharesIssued_52b60045-5c92-4fc2-a9a5-386bdf8449b9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_c3258b74-3643-47f7-8380-456150b7be01" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_f6ba2912-6441-463b-bdb1-725ae9b7225b" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_c3258b74-3643-47f7-8380-456150b7be01" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_829480b5-fd5b-48f7-9dff-47ffa00f9be7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_f6ba2912-6441-463b-bdb1-725ae9b7225b" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_829480b5-fd5b-48f7-9dff-47ffa00f9be7" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_18b96160-db62-4d9a-aa8e-502a94faaf21" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_f6ba2912-6441-463b-bdb1-725ae9b7225b" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_18b96160-db62-4d9a-aa8e-502a94faaf21" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_7088e098-d330-4f4e-b164-8eea0117682d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_f6ba2912-6441-463b-bdb1-725ae9b7225b" xlink:to="loc_us-gaap_PreferredStockSharesIssued_7088e098-d330-4f4e-b164-8eea0117682d" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_8068a57b-091a-4b60-a0b7-173ce3409038" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_f6ba2912-6441-463b-bdb1-725ae9b7225b" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_8068a57b-091a-4b60-a0b7-173ce3409038" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_1d8b5bf3-8162-430e-9da7-a8fd863ce253" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_b9bbba2a-d0df-4f7e-bcf4-03c90b99c29d" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_1d8b5bf3-8162-430e-9da7-a8fd863ce253" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_62aa703a-41e2-4635-8dc5-ff8b7255db4a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_1d8b5bf3-8162-430e-9da7-a8fd863ce253" xlink:to="loc_us-gaap_StatementClassOfStockAxis_62aa703a-41e2-4635-8dc5-ff8b7255db4a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_62aa703a-41e2-4635-8dc5-ff8b7255db4a_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_62aa703a-41e2-4635-8dc5-ff8b7255db4a" xlink:to="loc_us-gaap_ClassOfStockDomain_62aa703a-41e2-4635-8dc5-ff8b7255db4a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_2ce7e8f2-f0a7-43e8-a349-510a9eb576ea" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_62aa703a-41e2-4635-8dc5-ff8b7255db4a" xlink:to="loc_us-gaap_ClassOfStockDomain_2ce7e8f2-f0a7-43e8-a349-510a9eb576ea" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesCPreferredStockMember_668e9231-fc36-416d-a938-662c4530e011" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesCPreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_2ce7e8f2-f0a7-43e8-a349-510a9eb576ea" xlink:to="loc_us-gaap_SeriesCPreferredStockMember_668e9231-fc36-416d-a938-662c4530e011" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.inovio.com/role/StockholdersEquityNarrativeDetails" xlink:type="simple" xlink:href="ino-20210331.xsd#StockholdersEquityNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/StockholdersEquityNarrativeDetails" xlink:type="extended" id="ie6da4592685d4571b8d7383a9b5d53bd_StockholdersEquityNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_fc5bcc8d-f98c-4dfd-90e4-90b9cd47700b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockSharesConverted1_906a7f7c-9b36-4777-9c18-f0b048595da2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConversionOfStockSharesConverted1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_fc5bcc8d-f98c-4dfd-90e4-90b9cd47700b" xlink:to="loc_us-gaap_ConversionOfStockSharesConverted1_906a7f7c-9b36-4777-9c18-f0b048595da2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockSharesIssued1_4ddd5175-0eb4-40f8-a303-3d3818d23bd3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConversionOfStockSharesIssued1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_fc5bcc8d-f98c-4dfd-90e4-90b9cd47700b" xlink:to="loc_us-gaap_ConversionOfStockSharesIssued1_4ddd5175-0eb4-40f8-a303-3d3818d23bd3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_180fffef-a964-44f2-bacb-0c24abebcf0e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_fc5bcc8d-f98c-4dfd-90e4-90b9cd47700b" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_180fffef-a964-44f2-bacb-0c24abebcf0e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_afce6fbf-ac0c-4852-8ea3-d9726a17154d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_fc5bcc8d-f98c-4dfd-90e4-90b9cd47700b" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_afce6fbf-ac0c-4852-8ea3-d9726a17154d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesForCommissionsExpenseAndTaxes_9ae35d07-f44c-42d0-9006-ec3b17da6272" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesForCommissionsExpenseAndTaxes"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_fc5bcc8d-f98c-4dfd-90e4-90b9cd47700b" xlink:to="loc_us-gaap_AccruedLiabilitiesForCommissionsExpenseAndTaxes_9ae35d07-f44c-42d0-9006-ec3b17da6272" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_StockSalesAgreementMaximumAuthorizedAmount_f07c9d50-2fbf-41a0-8760-72c8b53953b7" xlink:href="ino-20210331.xsd#ino_StockSalesAgreementMaximumAuthorizedAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_fc5bcc8d-f98c-4dfd-90e4-90b9cd47700b" xlink:to="loc_ino_StockSalesAgreementMaximumAuthorizedAmount_f07c9d50-2fbf-41a0-8760-72c8b53953b7" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_StockSalesAgreementRemainingAuthorizedAmount_3ab554f0-adc3-437f-bea1-d9d5d02d303c" xlink:href="ino-20210331.xsd#ino_StockSalesAgreementRemainingAuthorizedAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_fc5bcc8d-f98c-4dfd-90e4-90b9cd47700b" xlink:to="loc_ino_StockSalesAgreementRemainingAuthorizedAmount_3ab554f0-adc3-437f-bea1-d9d5d02d303c" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_StockSaleAgreementAggregateNumberofSharesIssued_35e9d253-17d2-4d74-9133-0bc8f637b7da" xlink:href="ino-20210331.xsd#ino_StockSaleAgreementAggregateNumberofSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_fc5bcc8d-f98c-4dfd-90e4-90b9cd47700b" xlink:to="loc_ino_StockSaleAgreementAggregateNumberofSharesIssued_35e9d253-17d2-4d74-9133-0bc8f637b7da" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_StockSaleAgreementWeightedAveragePricePerShare_4058b006-7934-49bb-80f9-c8c234aba2c2" xlink:href="ino-20210331.xsd#ino_StockSaleAgreementWeightedAveragePricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_fc5bcc8d-f98c-4dfd-90e4-90b9cd47700b" xlink:to="loc_ino_StockSaleAgreementWeightedAveragePricePerShare_4058b006-7934-49bb-80f9-c8c234aba2c2" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_StockSaleAgreementAggregateProceedsFromIssuanceOfStock_58b53350-b67d-43e8-b233-63e76261b204" xlink:href="ino-20210331.xsd#ino_StockSaleAgreementAggregateProceedsFromIssuanceOfStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_fc5bcc8d-f98c-4dfd-90e4-90b9cd47700b" xlink:to="loc_ino_StockSaleAgreementAggregateProceedsFromIssuanceOfStock_58b53350-b67d-43e8-b233-63e76261b204" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_edf955a6-2e5e-444d-bd6c-738aef4bab6f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_fc5bcc8d-f98c-4dfd-90e4-90b9cd47700b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_edf955a6-2e5e-444d-bd6c-738aef4bab6f" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_NumberOfPotentialSharesAuthorizedForIssuanceUnderShareBasedCompensationPlan_9062ca20-cc2f-4550-81a8-fb2a6bde0da5" xlink:href="ino-20210331.xsd#ino_NumberOfPotentialSharesAuthorizedForIssuanceUnderShareBasedCompensationPlan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_fc5bcc8d-f98c-4dfd-90e4-90b9cd47700b" xlink:to="loc_ino_NumberOfPotentialSharesAuthorizedForIssuanceUnderShareBasedCompensationPlan_9062ca20-cc2f-4550-81a8-fb2a6bde0da5" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_SharebasedCompensationArrangementbySharebasedPaymentAwardIncreaseInNumberofSharesAuthorized_5b9bfd54-4ee2-45ef-b9d4-2163315aea8e" xlink:href="ino-20210331.xsd#ino_SharebasedCompensationArrangementbySharebasedPaymentAwardIncreaseInNumberofSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_fc5bcc8d-f98c-4dfd-90e4-90b9cd47700b" xlink:to="loc_ino_SharebasedCompensationArrangementbySharebasedPaymentAwardIncreaseInNumberofSharesAuthorized_5b9bfd54-4ee2-45ef-b9d4-2163315aea8e" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_10053822-5052-4330-bb1b-95cf7556111a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_fc5bcc8d-f98c-4dfd-90e4-90b9cd47700b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_10053822-5052-4330-bb1b-95cf7556111a" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2998208a-8f08-45e4-8b2a-9665de519858" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_fc5bcc8d-f98c-4dfd-90e4-90b9cd47700b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2998208a-8f08-45e4-8b2a-9665de519858" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockOtherSharesOutstanding_3ddf03eb-ca26-4488-8083-faa24237db34" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockOtherSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_fc5bcc8d-f98c-4dfd-90e4-90b9cd47700b" xlink:to="loc_us-gaap_CommonStockOtherSharesOutstanding_3ddf03eb-ca26-4488-8083-faa24237db34" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_f500abb1-e00c-496f-b37d-9b32db56247f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_fc5bcc8d-f98c-4dfd-90e4-90b9cd47700b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_f500abb1-e00c-496f-b37d-9b32db56247f" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm_37f50a59-206b-439e-a919-7251b4178c5a" xlink:href="ino-20210331.xsd#ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_fc5bcc8d-f98c-4dfd-90e4-90b9cd47700b" xlink:to="loc_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm_37f50a59-206b-439e-a919-7251b4178c5a" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_8b28f09d-13d5-43fc-8d1d-17c1a8f0b198" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_fc5bcc8d-f98c-4dfd-90e4-90b9cd47700b" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_8b28f09d-13d5-43fc-8d1d-17c1a8f0b198" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_795a6582-8e59-4f2c-af4f-c846ca4c90df" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_8b28f09d-13d5-43fc-8d1d-17c1a8f0b198" xlink:to="loc_us-gaap_StatementClassOfStockAxis_795a6582-8e59-4f2c-af4f-c846ca4c90df" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_795a6582-8e59-4f2c-af4f-c846ca4c90df_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_795a6582-8e59-4f2c-af4f-c846ca4c90df" xlink:to="loc_us-gaap_ClassOfStockDomain_795a6582-8e59-4f2c-af4f-c846ca4c90df_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_5ddd05c2-d35d-4038-b008-315f341755a0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_795a6582-8e59-4f2c-af4f-c846ca4c90df" xlink:to="loc_us-gaap_ClassOfStockDomain_5ddd05c2-d35d-4038-b008-315f341755a0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesCPreferredStockMember_be2097be-fce6-4c12-b930-070c940c66b8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesCPreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_5ddd05c2-d35d-4038-b008-315f341755a0" xlink:to="loc_us-gaap_SeriesCPreferredStockMember_be2097be-fce6-4c12-b930-070c940c66b8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_05cdd3ff-4314-45c1-92d1-a190ee2774d9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_5ddd05c2-d35d-4038-b008-315f341755a0" xlink:to="loc_us-gaap_CommonStockMember_05cdd3ff-4314-45c1-92d1-a190ee2774d9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_98b6428d-6a34-4666-9265-55ee15343182" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_8b28f09d-13d5-43fc-8d1d-17c1a8f0b198" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_98b6428d-6a34-4666-9265-55ee15343182" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_98b6428d-6a34-4666-9265-55ee15343182_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_98b6428d-6a34-4666-9265-55ee15343182" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_98b6428d-6a34-4666-9265-55ee15343182_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_8f9b3d95-4844-45f5-a33a-20271e799830" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_98b6428d-6a34-4666-9265-55ee15343182" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_8f9b3d95-4844-45f5-a33a-20271e799830" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_PriorSalesAgreementMember_0ce3c21a-4872-463a-922f-0df033b11ebf" xlink:href="ino-20210331.xsd#ino_PriorSalesAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_8f9b3d95-4844-45f5-a33a-20271e799830" xlink:to="loc_ino_PriorSalesAgreementMember_0ce3c21a-4872-463a-922f-0df033b11ebf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_NewSalesAgreementMember_2e890e65-6b1d-4ec8-86f0-920e83dd750b" xlink:href="ino-20210331.xsd#ino_NewSalesAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_8f9b3d95-4844-45f5-a33a-20271e799830" xlink:to="loc_ino_NewSalesAgreementMember_2e890e65-6b1d-4ec8-86f0-920e83dd750b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_f7ae4b45-08b6-4e0f-b563-ba046ffe35d0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_8b28f09d-13d5-43fc-8d1d-17c1a8f0b198" xlink:to="loc_us-gaap_PlanNameAxis_f7ae4b45-08b6-4e0f-b563-ba046ffe35d0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_f7ae4b45-08b6-4e0f-b563-ba046ffe35d0_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_f7ae4b45-08b6-4e0f-b563-ba046ffe35d0" xlink:to="loc_us-gaap_PlanNameDomain_f7ae4b45-08b6-4e0f-b563-ba046ffe35d0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_482197df-1b09-4beb-9c54-b124b78dd465" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_f7ae4b45-08b6-4e0f-b563-ba046ffe35d0" xlink:to="loc_us-gaap_PlanNameDomain_482197df-1b09-4beb-9c54-b124b78dd465" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_A2016IncentivePlanMember_09129bd4-f562-4602-b869-ccbf57b1c08b" xlink:href="ino-20210331.xsd#ino_A2016IncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_482197df-1b09-4beb-9c54-b124b78dd465" xlink:to="loc_ino_A2016IncentivePlanMember_09129bd4-f562-4602-b869-ccbf57b1c08b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_A2007IncentivePlanMember_d8f93f9d-13b3-4955-accd-bf68fe8682a2" xlink:href="ino-20210331.xsd#ino_A2007IncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_482197df-1b09-4beb-9c54-b124b78dd465" xlink:to="loc_ino_A2007IncentivePlanMember_d8f93f9d-13b3-4955-accd-bf68fe8682a2" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.inovio.com/role/NetLossPerShare" xlink:type="simple" xlink:href="ino-20210331.xsd#NetLossPerShare"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/NetLossPerShare" xlink:type="extended" id="i4add08211b144d32a6d3fcb2332da5ac_NetLossPerShare"/>
  <link:roleRef roleURI="http://www.inovio.com/role/NetLossPerShareTables" xlink:type="simple" xlink:href="ino-20210331.xsd#NetLossPerShareTables"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/NetLossPerShareTables" xlink:type="extended" id="icb69a33d037f47eea0bfd768adbe4ded_NetLossPerShareTables"/>
  <link:roleRef roleURI="http://www.inovio.com/role/NetLossPerShareScheduleofAntiDilutiveSecuritiesDetails" xlink:type="simple" xlink:href="ino-20210331.xsd#NetLossPerShareScheduleofAntiDilutiveSecuritiesDetails"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/NetLossPerShareScheduleofAntiDilutiveSecuritiesDetails" xlink:type="extended" id="i7fa69760c07f4b60a4a722c0105b4c4e_NetLossPerShareScheduleofAntiDilutiveSecuritiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_d6d4f39b-7879-44a5-9961-db46453daaba" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_cbe0e13e-129b-4a73-b7e1-06c1fb60681a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_d6d4f39b-7879-44a5-9961-db46453daaba" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_cbe0e13e-129b-4a73-b7e1-06c1fb60681a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_3ab9857c-d39a-47b6-80fd-36364ecf696f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_d6d4f39b-7879-44a5-9961-db46453daaba" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_3ab9857c-d39a-47b6-80fd-36364ecf696f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_f3da90a5-1a3b-4ee5-b8c7-19c5990833bc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_3ab9857c-d39a-47b6-80fd-36364ecf696f" xlink:to="loc_us-gaap_DebtInstrumentAxis_f3da90a5-1a3b-4ee5-b8c7-19c5990833bc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_f3da90a5-1a3b-4ee5-b8c7-19c5990833bc_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_f3da90a5-1a3b-4ee5-b8c7-19c5990833bc" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_f3da90a5-1a3b-4ee5-b8c7-19c5990833bc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_7f0c7c9e-5871-496a-bb0b-76abbf86aac8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_f3da90a5-1a3b-4ee5-b8c7-19c5990833bc" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_7f0c7c9e-5871-496a-bb0b-76abbf86aac8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_A6.50ConvertibleSeniorNotesDue2024Member_ff9a218e-48dd-42ee-b7ef-c0654a1d13b5" xlink:href="ino-20210331.xsd#ino_A6.50ConvertibleSeniorNotesDue2024Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7f0c7c9e-5871-496a-bb0b-76abbf86aac8" xlink:to="loc_ino_A6.50ConvertibleSeniorNotesDue2024Member_ff9a218e-48dd-42ee-b7ef-c0654a1d13b5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_August2019ConvertibleBondsMember_5e97a91c-8c85-4ee1-bd45-7a0167d859fc" xlink:href="ino-20210331.xsd#ino_August2019ConvertibleBondsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7f0c7c9e-5871-496a-bb0b-76abbf86aac8" xlink:to="loc_ino_August2019ConvertibleBondsMember_5e97a91c-8c85-4ee1-bd45-7a0167d859fc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_December2019ConvertibleBondsMember_01d9c7c6-0c0e-4c1b-a1cd-ae07ee33c7f6" xlink:href="ino-20210331.xsd#ino_December2019ConvertibleBondsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7f0c7c9e-5871-496a-bb0b-76abbf86aac8" xlink:to="loc_ino_December2019ConvertibleBondsMember_01d9c7c6-0c0e-4c1b-a1cd-ae07ee33c7f6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_d66720be-1dbd-4c72-acce-733a42596ad5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_3ab9857c-d39a-47b6-80fd-36364ecf696f" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_d66720be-1dbd-4c72-acce-733a42596ad5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_d66720be-1dbd-4c72-acce-733a42596ad5_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_d66720be-1dbd-4c72-acce-733a42596ad5" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_d66720be-1dbd-4c72-acce-733a42596ad5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_40ebb416-fb6a-490e-a438-d3389361863a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_d66720be-1dbd-4c72-acce-733a42596ad5" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_40ebb416-fb6a-490e-a438-d3389361863a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_60504ac4-1751-4965-8585-7a9984673577" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_40ebb416-fb6a-490e-a438-d3389361863a" xlink:to="loc_us-gaap_EmployeeStockOptionMember_60504ac4-1751-4965-8585-7a9984673577" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ServiceBasedRestrictedStockUnitsMember_14d05ea7-d402-4ae1-b6b0-ee1ee1550ae1" xlink:href="ino-20210331.xsd#ino_ServiceBasedRestrictedStockUnitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_40ebb416-fb6a-490e-a438-d3389361863a" xlink:to="loc_ino_ServiceBasedRestrictedStockUnitsMember_14d05ea7-d402-4ae1-b6b0-ee1ee1550ae1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_d41428a0-10b3-4cbf-8dfc-fa44b0064489" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_40ebb416-fb6a-490e-a438-d3389361863a" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_d41428a0-10b3-4cbf-8dfc-fa44b0064489" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertiblePreferredStockMember_cb62d50e-c655-449b-a941-ae534287fd02" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertiblePreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_40ebb416-fb6a-490e-a438-d3389361863a" xlink:to="loc_us-gaap_ConvertiblePreferredStockMember_cb62d50e-c655-449b-a941-ae534287fd02" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtSecuritiesMember_d5b2812a-b20b-426e-a365-ce44a23aa2b3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_40ebb416-fb6a-490e-a438-d3389361863a" xlink:to="loc_us-gaap_ConvertibleDebtSecuritiesMember_d5b2812a-b20b-426e-a365-ce44a23aa2b3" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.inovio.com/role/StockBasedCompensation" xlink:type="simple" xlink:href="ino-20210331.xsd#StockBasedCompensation"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/StockBasedCompensation" xlink:type="extended" id="ic6ba294d858a41ada6836a1745a06808_StockBasedCompensation"/>
  <link:roleRef roleURI="http://www.inovio.com/role/StockBasedCompensationTables" xlink:type="simple" xlink:href="ino-20210331.xsd#StockBasedCompensationTables"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/StockBasedCompensationTables" xlink:type="extended" id="i65626b6d52bc4d99b39bddf1d7908a9e_StockBasedCompensationTables"/>
  <link:roleRef roleURI="http://www.inovio.com/role/StockBasedCompensationDetails" xlink:type="simple" xlink:href="ino-20210331.xsd#StockBasedCompensationDetails"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/StockBasedCompensationDetails" xlink:type="extended" id="i5f25a99725124595ab49dbc2ef6ac6e0_StockBasedCompensationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_32018434-b098-4974-a346-f82c9c6418fe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_f6768bbf-b7ff-4d2c-ac95-80e670afc3de" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_32018434-b098-4974-a346-f82c9c6418fe" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_f6768bbf-b7ff-4d2c-ac95-80e670afc3de" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_27a990ec-a003-48db-a16a-63804fbfdcad" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_32018434-b098-4974-a346-f82c9c6418fe" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_27a990ec-a003-48db-a16a-63804fbfdcad" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_0bef6cd1-4e91-4540-9178-bf7c6a4aa53c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_32018434-b098-4974-a346-f82c9c6418fe" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_0bef6cd1-4e91-4540-9178-bf7c6a4aa53c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_02221084-b5bc-467f-b37f-e7f0d3f6bd49" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_32018434-b098-4974-a346-f82c9c6418fe" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_02221084-b5bc-467f-b37f-e7f0d3f6bd49" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_66baa88b-0218-4d7d-b9a8-736622b12ab8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_32018434-b098-4974-a346-f82c9c6418fe" xlink:to="loc_us-gaap_ShareBasedCompensation_66baa88b-0218-4d7d-b9a8-736622b12ab8" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_63a3de3a-3c83-4d59-b28e-84dc07b89eed" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_32018434-b098-4974-a346-f82c9c6418fe" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_63a3de3a-3c83-4d59-b28e-84dc07b89eed" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_811e47bc-a282-4b02-9e91-9407e09bc471" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_32018434-b098-4974-a346-f82c9c6418fe" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_811e47bc-a282-4b02-9e91-9407e09bc471" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_4b42d0ef-e323-44bf-b29d-ebad12d18477" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_32018434-b098-4974-a346-f82c9c6418fe" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_4b42d0ef-e323-44bf-b29d-ebad12d18477" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_69d5a859-ddc6-427a-bbc0-891f158ff28b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_32018434-b098-4974-a346-f82c9c6418fe" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_69d5a859-ddc6-427a-bbc0-891f158ff28b" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_7425c791-e17f-45f7-aea0-62a8fb27763f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_32018434-b098-4974-a346-f82c9c6418fe" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_7425c791-e17f-45f7-aea0-62a8fb27763f" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_1726adf1-d4ad-4964-a370-ec8966969204" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_32018434-b098-4974-a346-f82c9c6418fe" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_1726adf1-d4ad-4964-a370-ec8966969204" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_b8e89a59-cfb4-4b23-b576-ac6f461f3781" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_32018434-b098-4974-a346-f82c9c6418fe" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_b8e89a59-cfb4-4b23-b576-ac6f461f3781" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_0efdbc90-99b4-44b5-ad28-717772681a89" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_32018434-b098-4974-a346-f82c9c6418fe" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_0efdbc90-99b4-44b5-ad28-717772681a89" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodGrantDateFairValue_7d56eb4a-49e3-43e3-b155-4ef07bf0ab7d" xlink:href="ino-20210331.xsd#ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_32018434-b098-4974-a346-f82c9c6418fe" xlink:to="loc_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodGrantDateFairValue_7d56eb4a-49e3-43e3-b155-4ef07bf0ab7d" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3bece5c6-434b-4500-b6cb-cd30e63a0077" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_32018434-b098-4974-a346-f82c9c6418fe" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3bece5c6-434b-4500-b6cb-cd30e63a0077" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_4f0eb8c3-160e-4650-ad7b-ebbec5e9fdf0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3bece5c6-434b-4500-b6cb-cd30e63a0077" xlink:to="loc_us-gaap_AwardTypeAxis_4f0eb8c3-160e-4650-ad7b-ebbec5e9fdf0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4f0eb8c3-160e-4650-ad7b-ebbec5e9fdf0_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_4f0eb8c3-160e-4650-ad7b-ebbec5e9fdf0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4f0eb8c3-160e-4650-ad7b-ebbec5e9fdf0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_fd554133-d21b-481f-84b9-9b52530659ad" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_4f0eb8c3-160e-4650-ad7b-ebbec5e9fdf0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_fd554133-d21b-481f-84b9-9b52530659ad" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_b53673d5-de8d-40be-8b67-8caeb3ac01b7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_fd554133-d21b-481f-84b9-9b52530659ad" xlink:to="loc_us-gaap_EmployeeStockOptionMember_b53673d5-de8d-40be-8b67-8caeb3ac01b7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_0900150b-4a0a-412b-b88f-6b2182f5cb09" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_fd554133-d21b-481f-84b9-9b52530659ad" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_0900150b-4a0a-412b-b88f-6b2182f5cb09" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_65a744bf-efef-4c59-92a9-767a35230c4b" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3bece5c6-434b-4500-b6cb-cd30e63a0077" xlink:to="loc_srt_TitleOfIndividualAxis_65a744bf-efef-4c59-92a9-767a35230c4b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_65a744bf-efef-4c59-92a9-767a35230c4b_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_TitleOfIndividualAxis_65a744bf-efef-4c59-92a9-767a35230c4b" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_65a744bf-efef-4c59-92a9-767a35230c4b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_f53cf046-d068-429e-a99e-df15df64bf53" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_TitleOfIndividualAxis_65a744bf-efef-4c59-92a9-767a35230c4b" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_f53cf046-d068-429e-a99e-df15df64bf53" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_EmployeesAndDirectorsMember_fcfc2a7f-bf76-425b-87d0-517a7b719054" xlink:href="ino-20210331.xsd#ino_EmployeesAndDirectorsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_f53cf046-d068-429e-a99e-df15df64bf53" xlink:to="loc_ino_EmployeesAndDirectorsMember_fcfc2a7f-bf76-425b-87d0-517a7b719054" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_NonEmployeeMember_ac99a896-2636-4603-84d1-01be8b209622" xlink:href="ino-20210331.xsd#ino_NonEmployeeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_f53cf046-d068-429e-a99e-df15df64bf53" xlink:to="loc_ino_NonEmployeeMember_ac99a896-2636-4603-84d1-01be8b209622" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_4619c0d8-ad29-42ae-bb2f-396ab33e6489" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3bece5c6-434b-4500-b6cb-cd30e63a0077" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_4619c0d8-ad29-42ae-bb2f-396ab33e6489" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_4619c0d8-ad29-42ae-bb2f-396ab33e6489_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_4619c0d8-ad29-42ae-bb2f-396ab33e6489" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_4619c0d8-ad29-42ae-bb2f-396ab33e6489_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_57df86e2-d178-439b-a92a-6d013b945a54" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_4619c0d8-ad29-42ae-bb2f-396ab33e6489" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_57df86e2-d178-439b-a92a-6d013b945a54" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_7c863417-605b-471e-bc8d-6c6cecd01a5e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_57df86e2-d178-439b-a92a-6d013b945a54" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_7c863417-605b-471e-bc8d-6c6cecd01a5e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_599f74c3-bc70-4514-9b69-1ee545e59520" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_57df86e2-d178-439b-a92a-6d013b945a54" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_599f74c3-bc70-4514-9b69-1ee545e59520" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_6704cc73-91f3-45e5-bc44-cdfac9f6ab4f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3bece5c6-434b-4500-b6cb-cd30e63a0077" xlink:to="loc_us-gaap_PlanNameAxis_6704cc73-91f3-45e5-bc44-cdfac9f6ab4f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_6704cc73-91f3-45e5-bc44-cdfac9f6ab4f_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_6704cc73-91f3-45e5-bc44-cdfac9f6ab4f" xlink:to="loc_us-gaap_PlanNameDomain_6704cc73-91f3-45e5-bc44-cdfac9f6ab4f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_cfa9b2c8-21a6-44c1-97cc-f837c756f88b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_6704cc73-91f3-45e5-bc44-cdfac9f6ab4f" xlink:to="loc_us-gaap_PlanNameDomain_cfa9b2c8-21a6-44c1-97cc-f837c756f88b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_A2016IncentivePlanMember_8a34e12e-ab1e-4d79-bdbf-d63408ddaac1" xlink:href="ino-20210331.xsd#ino_A2016IncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_cfa9b2c8-21a6-44c1-97cc-f837c756f88b" xlink:to="loc_ino_A2016IncentivePlanMember_8a34e12e-ab1e-4d79-bdbf-d63408ddaac1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis_949fb58c-259a-496f-8eb0-227bf37e3239" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VestingAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3bece5c6-434b-4500-b6cb-cd30e63a0077" xlink:to="loc_us-gaap_VestingAxis_949fb58c-259a-496f-8eb0-227bf37e3239" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_949fb58c-259a-496f-8eb0-227bf37e3239_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VestingDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VestingAxis_949fb58c-259a-496f-8eb0-227bf37e3239" xlink:to="loc_us-gaap_VestingDomain_949fb58c-259a-496f-8eb0-227bf37e3239_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_a7867a76-b6f4-4002-aafa-f1781b3c259d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VestingDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VestingAxis_949fb58c-259a-496f-8eb0-227bf37e3239" xlink:to="loc_us-gaap_VestingDomain_a7867a76-b6f4-4002-aafa-f1781b3c259d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_28eefd58-9c63-49a7-a066-00b5a4219121" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_a7867a76-b6f4-4002-aafa-f1781b3c259d" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_28eefd58-9c63-49a7-a066-00b5a4219121" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_44bc8d29-56b4-46b7-92c4-e43c6ed52ec6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_a7867a76-b6f4-4002-aafa-f1781b3c259d" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_44bc8d29-56b4-46b7-92c4-e43c6ed52ec6" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.inovio.com/role/RelatedPartyTransactions" xlink:type="simple" xlink:href="ino-20210331.xsd#RelatedPartyTransactions"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/RelatedPartyTransactions" xlink:type="extended" id="i0852cf8888274c40b097edcbe49da7f4_RelatedPartyTransactions"/>
  <link:roleRef roleURI="http://www.inovio.com/role/RelatedPartyTransactionsDetails" xlink:type="simple" xlink:href="ino-20210331.xsd#RelatedPartyTransactionsDetails"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/RelatedPartyTransactionsDetails" xlink:type="extended" id="i8138fdc0411d4bb3b4b3cc1d9a35ac4f_RelatedPartyTransactionsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_a41dca6a-8f7e-428e-af78-4575133a7548" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_RelatedPartyTransactionsTextualAbstract_52ab8351-b18c-4ddc-ae2e-9ddff2659ef5" xlink:href="ino-20210331.xsd#ino_RelatedPartyTransactionsTextualAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_a41dca6a-8f7e-428e-af78-4575133a7548" xlink:to="loc_ino_RelatedPartyTransactionsTextualAbstract_52ab8351-b18c-4ddc-ae2e-9ddff2659ef5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentOwnedBalanceShares_190703d3-b9c2-4af8-ad69-7e6c81c43211" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentOwnedBalanceShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ino_RelatedPartyTransactionsTextualAbstract_52ab8351-b18c-4ddc-ae2e-9ddff2659ef5" xlink:to="loc_us-gaap_InvestmentOwnedBalanceShares_190703d3-b9c2-4af8-ad69-7e6c81c43211" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_afc2db66-474e-495b-a7f7-321920a03444" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ino_RelatedPartyTransactionsTextualAbstract_52ab8351-b18c-4ddc-ae2e-9ddff2659ef5" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_afc2db66-474e-495b-a7f7-321920a03444" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_7b918fbf-3196-4951-b54b-4c4c83c67608" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ino_RelatedPartyTransactionsTextualAbstract_52ab8351-b18c-4ddc-ae2e-9ddff2659ef5" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_7b918fbf-3196-4951-b54b-4c4c83c67608" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableRelatedParties_a45e3ecd-4570-4163-b8e0-3a3bb6309a3f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableRelatedParties"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ino_RelatedPartyTransactionsTextualAbstract_52ab8351-b18c-4ddc-ae2e-9ddff2659ef5" xlink:to="loc_us-gaap_AccountsReceivableRelatedParties_a45e3ecd-4570-4163-b8e0-3a3bb6309a3f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementExpensesToReimburse_2519d959-207c-482c-b4fa-c74bdb38d40a" xlink:href="ino-20210331.xsd#ino_CollaborativeAgreementExpensesToReimburse"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ino_RelatedPartyTransactionsTextualAbstract_52ab8351-b18c-4ddc-ae2e-9ddff2659ef5" xlink:to="loc_ino_CollaborativeAgreementExpensesToReimburse_2519d959-207c-482c-b4fa-c74bdb38d40a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeArrangementTerm_a5959acb-6e81-451e-a07b-30e6a1c04c4e" xlink:href="ino-20210331.xsd#ino_CollaborativeArrangementTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ino_RelatedPartyTransactionsTextualAbstract_52ab8351-b18c-4ddc-ae2e-9ddff2659ef5" xlink:to="loc_ino_CollaborativeArrangementTerm_a5959acb-6e81-451e-a07b-30e6a1c04c4e" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementAwardedAmount_1ff830d7-b350-4d2a-b111-c2c14d1bd598" xlink:href="ino-20210331.xsd#ino_CollaborativeAgreementAwardedAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ino_RelatedPartyTransactionsTextualAbstract_52ab8351-b18c-4ddc-ae2e-9ddff2659ef5" xlink:to="loc_ino_CollaborativeAgreementAwardedAmount_1ff830d7-b350-4d2a-b111-c2c14d1bd598" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementAwardedOptionAmount_78692d59-8afa-4b0d-83b5-13f8729d972c" xlink:href="ino-20210331.xsd#ino_CollaborativeAgreementAwardedOptionAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ino_RelatedPartyTransactionsTextualAbstract_52ab8351-b18c-4ddc-ae2e-9ddff2659ef5" xlink:to="loc_ino_CollaborativeAgreementAwardedOptionAmount_78692d59-8afa-4b0d-83b5-13f8729d972c" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_GrantProceedsReceived_61620a7b-2408-4f31-856d-c0af540d090c" xlink:href="ino-20210331.xsd#ino_GrantProceedsReceived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ino_RelatedPartyTransactionsTextualAbstract_52ab8351-b18c-4ddc-ae2e-9ddff2659ef5" xlink:to="loc_ino_GrantProceedsReceived_61620a7b-2408-4f31-856d-c0af540d090c" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_0192377e-fff8-44b2-8867-c2c61b178487" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ino_RelatedPartyTransactionsTextualAbstract_52ab8351-b18c-4ddc-ae2e-9ddff2659ef5" xlink:to="loc_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_0192377e-fff8-44b2-8867-c2c61b178487" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_a5bfc30e-9987-41bc-bffc-c5d3d4b9072a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DueToRelatedPartiesCurrentAndNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ino_RelatedPartyTransactionsTextualAbstract_52ab8351-b18c-4ddc-ae2e-9ddff2659ef5" xlink:to="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_a5bfc30e-9987-41bc-bffc-c5d3d4b9072a" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DeferredGrantFundingFromAffiliate_7e08f0ac-fabe-4b19-9306-182eaa4aaa6e" xlink:href="ino-20210331.xsd#ino_DeferredGrantFundingFromAffiliate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ino_RelatedPartyTransactionsTextualAbstract_52ab8351-b18c-4ddc-ae2e-9ddff2659ef5" xlink:to="loc_ino_DeferredGrantFundingFromAffiliate_7e08f0ac-fabe-4b19-9306-182eaa4aaa6e" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_8e1c2864-7dc0-4c54-87a1-22799d337509" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_a41dca6a-8f7e-428e-af78-4575133a7548" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_8e1c2864-7dc0-4c54-87a1-22799d337509" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_c3244419-9336-410c-9c94-aee6db98d1f9" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_8e1c2864-7dc0-4c54-87a1-22799d337509" xlink:to="loc_srt_CounterpartyNameAxis_c3244419-9336-410c-9c94-aee6db98d1f9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c3244419-9336-410c-9c94-aee6db98d1f9_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_c3244419-9336-410c-9c94-aee6db98d1f9" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c3244419-9336-410c-9c94-aee6db98d1f9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f4b7d7db-9b8b-4902-b2c9-cd799a0895cc" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_c3244419-9336-410c-9c94-aee6db98d1f9" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f4b7d7db-9b8b-4902-b2c9-cd799a0895cc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_PlumblineLifeSciencesMember_12ac2afc-7f92-4c55-bccb-23cd0f7dc401" xlink:href="ino-20210331.xsd#ino_PlumblineLifeSciencesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f4b7d7db-9b8b-4902-b2c9-cd799a0895cc" xlink:to="loc_ino_PlumblineLifeSciencesMember_12ac2afc-7f92-4c55-bccb-23cd0f7dc401" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InformationByCategoryOfDebtSecurityAxis_60250258-4999-4443-989c-bd31eab9eac8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InformationByCategoryOfDebtSecurityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_8e1c2864-7dc0-4c54-87a1-22799d337509" xlink:to="loc_us-gaap_InformationByCategoryOfDebtSecurityAxis_60250258-4999-4443-989c-bd31eab9eac8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain_60250258-4999-4443-989c-bd31eab9eac8_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_InformationByCategoryOfDebtSecurityAxis_60250258-4999-4443-989c-bd31eab9eac8" xlink:to="loc_us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain_60250258-4999-4443-989c-bd31eab9eac8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain_a76f7962-e030-42ab-9e78-ef793c7eb8be" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_InformationByCategoryOfDebtSecurityAxis_60250258-4999-4443-989c-bd31eab9eac8" xlink:to="loc_us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain_a76f7962-e030-42ab-9e78-ef793c7eb8be" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableforsaleSecuritiesMember_0a8f8e67-e198-492e-9a7b-505bc7939516" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableforsaleSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain_a76f7962-e030-42ab-9e78-ef793c7eb8be" xlink:to="loc_us-gaap_AvailableforsaleSecuritiesMember_0a8f8e67-e198-492e-9a7b-505bc7939516" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_ebc8a8d8-9929-4092-b6b3-5233a534a91b" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_8e1c2864-7dc0-4c54-87a1-22799d337509" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_ebc8a8d8-9929-4092-b6b3-5233a534a91b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_ebc8a8d8-9929-4092-b6b3-5233a534a91b_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_ebc8a8d8-9929-4092-b6b3-5233a534a91b" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_ebc8a8d8-9929-4092-b6b3-5233a534a91b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_eebf8c9c-7853-41ae-accb-c5c52e54d072" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_ebc8a8d8-9929-4092-b6b3-5233a534a91b" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_eebf8c9c-7853-41ae-accb-c5c52e54d072" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_PlumblineLifeSciencesMember_b9f68bd1-5d18-4898-aef6-3e9fe1158db6" xlink:href="ino-20210331.xsd#ino_PlumblineLifeSciencesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_eebf8c9c-7853-41ae-accb-c5c52e54d072" xlink:to="loc_ino_PlumblineLifeSciencesMember_b9f68bd1-5d18-4898-aef6-3e9fe1158db6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_5467cfb7-bf11-4055-a7bf-52e8e75cb9e1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_8e1c2864-7dc0-4c54-87a1-22799d337509" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_5467cfb7-bf11-4055-a7bf-52e8e75cb9e1" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_5467cfb7-bf11-4055-a7bf-52e8e75cb9e1_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_5467cfb7-bf11-4055-a7bf-52e8e75cb9e1" xlink:to="loc_us-gaap_RelatedPartyDomain_5467cfb7-bf11-4055-a7bf-52e8e75cb9e1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_7fd5a492-1121-450e-b1d0-9c5c5d3392b4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_5467cfb7-bf11-4055-a7bf-52e8e75cb9e1" xlink:to="loc_us-gaap_RelatedPartyDomain_7fd5a492-1121-450e-b1d0-9c5c5d3392b4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_DirectorMember_d20b320d-dcd3-4ab4-9f32-334eac1e783c" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_DirectorMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_7fd5a492-1121-450e-b1d0-9c5c5d3392b4" xlink:to="loc_srt_DirectorMember_d20b320d-dcd3-4ab4-9f32-334eac1e783c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_TheWistarInstituteMember_89231b73-14cd-4be1-b403-e1ee4cd50e23" xlink:href="ino-20210331.xsd#ino_TheWistarInstituteMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_7fd5a492-1121-450e-b1d0-9c5c5d3392b4" xlink:to="loc_ino_TheWistarInstituteMember_89231b73-14cd-4be1-b403-e1ee4cd50e23" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.inovio.com/role/Leases" xlink:type="simple" xlink:href="ino-20210331.xsd#Leases"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/Leases" xlink:type="extended" id="i2f5cdef1d11449d4b6ed7b41e7203d5d_Leases"/>
  <link:roleRef roleURI="http://www.inovio.com/role/LeasesTables" xlink:type="simple" xlink:href="ino-20210331.xsd#LeasesTables"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/LeasesTables" xlink:type="extended" id="ia26bd9d8f15d49edaabe7e38a23914c0_LeasesTables"/>
  <link:roleRef roleURI="http://www.inovio.com/role/LeasesNarrativeDetails" xlink:type="simple" xlink:href="ino-20210331.xsd#LeasesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/LeasesNarrativeDetails" xlink:type="extended" id="i1619b66f94e4401a9a082a3db44a38ee_LeasesNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_8928927a-7416-4df5-a898-791ae2f63d86" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_LesseeOperatingLeaseAreaofLandUnderLease_fa16885a-48ca-4b71-a554-e25b344157d1" xlink:href="ino-20210331.xsd#ino_LesseeOperatingLeaseAreaofLandUnderLease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_8928927a-7416-4df5-a898-791ae2f63d86" xlink:to="loc_ino_LesseeOperatingLeaseAreaofLandUnderLease_fa16885a-48ca-4b71-a554-e25b344157d1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_4b15cb38-ea30-4817-9692-b52dbd488419" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_8928927a-7416-4df5-a898-791ae2f63d86" xlink:to="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_4b15cb38-ea30-4817-9692-b52dbd488419" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_6adc5938-967f-4af8-9733-e2a02fc65e40" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_8928927a-7416-4df5-a898-791ae2f63d86" xlink:to="loc_us-gaap_LeaseCost_6adc5938-967f-4af8-9733-e2a02fc65e40" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_4625e22e-3f5c-4c77-87c2-1117ef7a0df6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_8928927a-7416-4df5-a898-791ae2f63d86" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_4625e22e-3f5c-4c77-87c2-1117ef7a0df6" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_db6d3faa-f9cf-492a-826a-f7ebc84ac35a" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_4625e22e-3f5c-4c77-87c2-1117ef7a0df6" xlink:to="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_db6d3faa-f9cf-492a-826a-f7ebc84ac35a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_db6d3faa-f9cf-492a-826a-f7ebc84ac35a_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_db6d3faa-f9cf-492a-826a-f7ebc84ac35a" xlink:to="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_db6d3faa-f9cf-492a-826a-f7ebc84ac35a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_110bf7f0-6d00-41d7-be17-29c6e35aee20" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_db6d3faa-f9cf-492a-826a-f7ebc84ac35a" xlink:to="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_110bf7f0-6d00-41d7-be17-29c6e35aee20" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_SanDiegoOfficeMember_aedad3c2-5ff8-4538-8044-faa7dc79d0bb" xlink:href="ino-20210331.xsd#ino_SanDiegoOfficeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_110bf7f0-6d00-41d7-be17-29c6e35aee20" xlink:to="loc_ino_SanDiegoOfficeMember_aedad3c2-5ff8-4538-8044-faa7dc79d0bb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_PlymouthMeetingPennsylvaniaMember_f21214ae-af69-4289-a384-f15211da803b" xlink:href="ino-20210331.xsd#ino_PlymouthMeetingPennsylvaniaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_110bf7f0-6d00-41d7-be17-29c6e35aee20" xlink:to="loc_ino_PlymouthMeetingPennsylvaniaMember_f21214ae-af69-4289-a384-f15211da803b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_18941c51-44a2-4838-b764-d6189f8697a8" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_4625e22e-3f5c-4c77-87c2-1117ef7a0df6" xlink:to="loc_srt_RangeAxis_18941c51-44a2-4838-b764-d6189f8697a8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_18941c51-44a2-4838-b764-d6189f8697a8_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_18941c51-44a2-4838-b764-d6189f8697a8" xlink:to="loc_srt_RangeMember_18941c51-44a2-4838-b764-d6189f8697a8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_3ad3e412-0bce-4d11-b195-3568508c53e0" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_18941c51-44a2-4838-b764-d6189f8697a8" xlink:to="loc_srt_RangeMember_3ad3e412-0bce-4d11-b195-3568508c53e0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_092b9108-dbcd-4f88-a9cc-1fe550d1fb48" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_3ad3e412-0bce-4d11-b195-3568508c53e0" xlink:to="loc_srt_MinimumMember_092b9108-dbcd-4f88-a9cc-1fe550d1fb48" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_5dbb6122-178b-458f-97b1-d5d692b6ad67" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_3ad3e412-0bce-4d11-b195-3568508c53e0" xlink:to="loc_srt_MaximumMember_5dbb6122-178b-458f-97b1-d5d692b6ad67" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.inovio.com/role/LeasesSummaryofFutureMinimumLeasePaymentsDetails" xlink:type="simple" xlink:href="ino-20210331.xsd#LeasesSummaryofFutureMinimumLeasePaymentsDetails"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/LeasesSummaryofFutureMinimumLeasePaymentsDetails" xlink:type="extended" id="ib47122e48e4941f785c8ff9ebfb64386_LeasesSummaryofFutureMinimumLeasePaymentsDetails"/>
  <link:roleRef roleURI="http://www.inovio.com/role/CollaborativeAgreements" xlink:type="simple" xlink:href="ino-20210331.xsd#CollaborativeAgreements"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/CollaborativeAgreements" xlink:type="extended" id="ie701444a76cf4f9fb301d460909a4a0a_CollaborativeAgreements"/>
  <link:roleRef roleURI="http://www.inovio.com/role/CollaborativeAgreementsDetails" xlink:type="simple" xlink:href="ino-20210331.xsd#CollaborativeAgreementsDetails"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/CollaborativeAgreementsDetails" xlink:type="extended" id="i7340316a5c0741f09125f7f47fddec82_CollaborativeAgreementsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4418f15a-5143-4dd3-bf19-d5e1576e2246" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementsUpfrontPaymentReceived_243030d4-4e31-42d2-990e-779842f794c0" xlink:href="ino-20210331.xsd#ino_CollaborativeAgreementsUpfrontPaymentReceived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4418f15a-5143-4dd3-bf19-d5e1576e2246" xlink:to="loc_ino_CollaborativeAgreementsUpfrontPaymentReceived_243030d4-4e31-42d2-990e-779842f794c0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborationAgreementAdditionalRevenueToBeAchieved_bc69d82d-8804-477f-b6db-a6fe6915b55b" xlink:href="ino-20210331.xsd#ino_CollaborationAgreementAdditionalRevenueToBeAchieved"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4418f15a-5143-4dd3-bf19-d5e1576e2246" xlink:to="loc_ino_CollaborationAgreementAdditionalRevenueToBeAchieved_bc69d82d-8804-477f-b6db-a6fe6915b55b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborationAgreementPaymentEarned_786089c0-3d2e-4e12-956a-e5e4dde0b7ff" xlink:href="ino-20210331.xsd#ino_CollaborationAgreementPaymentEarned"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4418f15a-5143-4dd3-bf19-d5e1576e2246" xlink:to="loc_ino_CollaborationAgreementPaymentEarned_786089c0-3d2e-4e12-956a-e5e4dde0b7ff" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborationAgreementRoyaltyPeriod_80215243-4210-4685-b99d-d19b568bc569" xlink:href="ino-20210331.xsd#ino_CollaborationAgreementRoyaltyPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4418f15a-5143-4dd3-bf19-d5e1576e2246" xlink:to="loc_ino_CollaborationAgreementRoyaltyPeriod_80215243-4210-4685-b99d-d19b568bc569" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementPeriodFromEffectiveDateForTermination_390663ca-7288-43c6-a1d1-ed5d7258b933" xlink:href="ino-20210331.xsd#ino_CollaborativeAgreementPeriodFromEffectiveDateForTermination"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4418f15a-5143-4dd3-bf19-d5e1576e2246" xlink:to="loc_ino_CollaborativeAgreementPeriodFromEffectiveDateForTermination_390663ca-7288-43c6-a1d1-ed5d7258b933" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_6b2c1029-b2ba-47f0-9f12-a5e0112ad7d8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4418f15a-5143-4dd3-bf19-d5e1576e2246" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_6b2c1029-b2ba-47f0-9f12-a5e0112ad7d8" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNet_969679c0-681b-4e42-9c24-bd1b84fe7afa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4418f15a-5143-4dd3-bf19-d5e1576e2246" xlink:to="loc_us-gaap_AccountsReceivableNet_969679c0-681b-4e42-9c24-bd1b84fe7afa" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborationAgreementTerritoryExpansionOptionPeriod_b2fb3e24-9701-422e-a87a-04bc892f3264" xlink:href="ino-20210331.xsd#ino_CollaborationAgreementTerritoryExpansionOptionPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4418f15a-5143-4dd3-bf19-d5e1576e2246" xlink:to="loc_ino_CollaborationAgreementTerritoryExpansionOptionPeriod_b2fb3e24-9701-422e-a87a-04bc892f3264" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ProceedsFromCollaborativeAgreement_f0e112f9-bb28-42a0-ad47-6c14bffd327a" xlink:href="ino-20210331.xsd#ino_ProceedsFromCollaborativeAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4418f15a-5143-4dd3-bf19-d5e1576e2246" xlink:to="loc_ino_ProceedsFromCollaborativeAgreement_f0e112f9-bb28-42a0-ad47-6c14bffd327a" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementCorporateIncomeTax_ee698f55-0abf-483f-bfbc-16a0aaee4ef0" xlink:href="ino-20210331.xsd#ino_CollaborativeAgreementCorporateIncomeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4418f15a-5143-4dd3-bf19-d5e1576e2246" xlink:to="loc_ino_CollaborativeAgreementCorporateIncomeTax_ee698f55-0abf-483f-bfbc-16a0aaee4ef0" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementForeignNonIncomeTaxes_ee26e9db-b322-40d9-a688-750c39733e81" xlink:href="ino-20210331.xsd#ino_CollaborativeAgreementForeignNonIncomeTaxes"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4418f15a-5143-4dd3-bf19-d5e1576e2246" xlink:to="loc_ino_CollaborativeAgreementForeignNonIncomeTaxes_ee26e9db-b322-40d9-a688-750c39733e81" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementAdvisoryFees_de67e8c6-dea5-4801-838f-cc7d4f17ac38" xlink:href="ino-20210331.xsd#ino_CollaborativeAgreementAdvisoryFees"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4418f15a-5143-4dd3-bf19-d5e1576e2246" xlink:to="loc_ino_CollaborativeAgreementAdvisoryFees_de67e8c6-dea5-4801-838f-cc7d4f17ac38" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementNumberofDaysWrittenNoticeBeforeTermination_c656509d-703e-41c2-a4a4-3fc4de4fef4b" xlink:href="ino-20210331.xsd#ino_CollaborativeAgreementNumberofDaysWrittenNoticeBeforeTermination"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4418f15a-5143-4dd3-bf19-d5e1576e2246" xlink:to="loc_ino_CollaborativeAgreementNumberofDaysWrittenNoticeBeforeTermination_c656509d-703e-41c2-a4a4-3fc4de4fef4b" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborationAgreementAnticipatedDevelopmentandRegulatoryEventBasedPaymentReceivableMilestones_67cf0e92-c7c1-4210-a256-59fddf62b313" xlink:href="ino-20210331.xsd#ino_CollaborationAgreementAnticipatedDevelopmentandRegulatoryEventBasedPaymentReceivableMilestones"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4418f15a-5143-4dd3-bf19-d5e1576e2246" xlink:to="loc_ino_CollaborationAgreementAnticipatedDevelopmentandRegulatoryEventBasedPaymentReceivableMilestones_67cf0e92-c7c1-4210-a256-59fddf62b313" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborationAgreementAnticipatedCommercialEventBasedPaymentReceivableMilestones_549c1c97-3e8f-41d5-be57-a3b6678e10f5" xlink:href="ino-20210331.xsd#ino_CollaborationAgreementAnticipatedCommercialEventBasedPaymentReceivableMilestones"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4418f15a-5143-4dd3-bf19-d5e1576e2246" xlink:to="loc_ino_CollaborationAgreementAnticipatedCommercialEventBasedPaymentReceivableMilestones_549c1c97-3e8f-41d5-be57-a3b6678e10f5" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementFundingToBeReceived_d873e984-4587-48be-91c7-04be159ed370" xlink:href="ino-20210331.xsd#ino_CollaborativeAgreementFundingToBeReceived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4418f15a-5143-4dd3-bf19-d5e1576e2246" xlink:to="loc_ino_CollaborativeAgreementFundingToBeReceived_d873e984-4587-48be-91c7-04be159ed370" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment_3cc22677-fd16-48d5-a68e-f6219d206733" xlink:href="ino-20210331.xsd#ino_CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4418f15a-5143-4dd3-bf19-d5e1576e2246" xlink:to="loc_ino_CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment_3cc22677-fd16-48d5-a68e-f6219d206733" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementFundingReceived_91a724bf-c17b-418f-a227-d481b2d3f0b9" xlink:href="ino-20210331.xsd#ino_CollaborativeAgreementFundingReceived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4418f15a-5143-4dd3-bf19-d5e1576e2246" xlink:to="loc_ino_CollaborativeAgreementFundingReceived_91a724bf-c17b-418f-a227-d481b2d3f0b9" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DeferredGrantFundingCurrent_43789eac-e31d-4ee5-bf0f-017e365c154f" xlink:href="ino-20210331.xsd#ino_DeferredGrantFundingCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4418f15a-5143-4dd3-bf19-d5e1576e2246" xlink:to="loc_ino_DeferredGrantFundingCurrent_43789eac-e31d-4ee5-bf0f-017e365c154f" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeArrangementFixedPriceContractAmountAwarded_f04d91ab-e0c6-41b9-8605-753f6ee876f0" xlink:href="ino-20210331.xsd#ino_CollaborativeArrangementFixedPriceContractAmountAwarded"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4418f15a-5143-4dd3-bf19-d5e1576e2246" xlink:to="loc_ino_CollaborativeArrangementFixedPriceContractAmountAwarded_f04d91ab-e0c6-41b9-8605-753f6ee876f0" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_GrantProceedsReceived_a7c86077-0662-48c5-8785-c0ffe42b4ca5" xlink:href="ino-20210331.xsd#ino_GrantProceedsReceived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4418f15a-5143-4dd3-bf19-d5e1576e2246" xlink:to="loc_ino_GrantProceedsReceived_a7c86077-0662-48c5-8785-c0ffe42b4ca5" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableRelatedParties_9305833e-353d-4986-bfb1-3e8282c957e3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableRelatedParties"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4418f15a-5143-4dd3-bf19-d5e1576e2246" xlink:to="loc_us-gaap_AccountsReceivableRelatedParties_9305833e-353d-4986-bfb1-3e8282c957e3" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_c81b169b-34ad-4818-8342-57d5a70f302e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4418f15a-5143-4dd3-bf19-d5e1576e2246" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_c81b169b-34ad-4818-8342-57d5a70f302e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_787a765b-204a-4092-add0-a2433515110f" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_c81b169b-34ad-4818-8342-57d5a70f302e" xlink:to="loc_srt_CounterpartyNameAxis_787a765b-204a-4092-add0-a2433515110f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_787a765b-204a-4092-add0-a2433515110f_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_787a765b-204a-4092-add0-a2433515110f" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_787a765b-204a-4092-add0-a2433515110f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1ea5e028-05a7-4ad9-ad6a-bd63fb63a867" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_787a765b-204a-4092-add0-a2433515110f" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1ea5e028-05a7-4ad9-ad6a-bd63fb63a867" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_AdvaccineMember_b9540c8c-baf6-496c-8d12-9d6f8c70298b" xlink:href="ino-20210331.xsd#ino_AdvaccineMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1ea5e028-05a7-4ad9-ad6a-bd63fb63a867" xlink:to="loc_ino_AdvaccineMember_b9540c8c-baf6-496c-8d12-9d6f8c70298b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ApolloBioMember_0e448688-d2a1-4c92-be9a-7b31b4513594" xlink:href="ino-20210331.xsd#ino_ApolloBioMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1ea5e028-05a7-4ad9-ad6a-bd63fb63a867" xlink:to="loc_ino_ApolloBioMember_0e448688-d2a1-4c92-be9a-7b31b4513594" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_AstraZenecaMember_15345785-657c-4792-a1e2-b430f5672bf2" xlink:href="ino-20210331.xsd#ino_AstraZenecaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1ea5e028-05a7-4ad9-ad6a-bd63fb63a867" xlink:to="loc_ino_AstraZenecaMember_15345785-657c-4792-a1e2-b430f5672bf2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CoalitionforEpidemicPreparednessInnovationsMember_aa07d986-df43-4e2e-be5c-d7b488f3c8fc" xlink:href="ino-20210331.xsd#ino_CoalitionforEpidemicPreparednessInnovationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1ea5e028-05a7-4ad9-ad6a-bd63fb63a867" xlink:to="loc_ino_CoalitionforEpidemicPreparednessInnovationsMember_aa07d986-df43-4e2e-be5c-d7b488f3c8fc" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_BillAndMelindaGatesFoundationMember_1e3e4283-d403-4346-b8e5-753207776a9c" xlink:href="ino-20210331.xsd#ino_BillAndMelindaGatesFoundationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1ea5e028-05a7-4ad9-ad6a-bd63fb63a867" xlink:to="loc_ino_BillAndMelindaGatesFoundationMember_1e3e4283-d403-4346-b8e5-753207776a9c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DepartmentOfDefenceMember_9a6b46c4-fed5-4624-8c55-db8de96978e5" xlink:href="ino-20210331.xsd#ino_DepartmentOfDefenceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1ea5e028-05a7-4ad9-ad6a-bd63fb63a867" xlink:to="loc_ino_DepartmentOfDefenceMember_9a6b46c4-fed5-4624-8c55-db8de96978e5" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_905cc205-5061-4d4d-b1a9-0a0445798ad1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_c81b169b-34ad-4818-8342-57d5a70f302e" xlink:to="loc_us-gaap_TypeOfArrangementAxis_905cc205-5061-4d4d-b1a9-0a0445798ad1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_905cc205-5061-4d4d-b1a9-0a0445798ad1_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_905cc205-5061-4d4d-b1a9-0a0445798ad1" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_905cc205-5061-4d4d-b1a9-0a0445798ad1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_596ffc4f-abfb-4982-9713-df364782ab66" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_905cc205-5061-4d4d-b1a9-0a0445798ad1" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_596ffc4f-abfb-4982-9713-df364782ab66" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementMember_c9ab7d29-6b1f-4ae2-a2be-d1319a4c3f8b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_596ffc4f-abfb-4982-9713-df364782ab66" xlink:to="loc_us-gaap_CollaborativeArrangementMember_c9ab7d29-6b1f-4ae2-a2be-d1319a4c3f8b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_8568e3ae-99b7-46da-b47e-b5da9a0205eb" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_c81b169b-34ad-4818-8342-57d5a70f302e" xlink:to="loc_srt_ProductOrServiceAxis_8568e3ae-99b7-46da-b47e-b5da9a0205eb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_8568e3ae-99b7-46da-b47e-b5da9a0205eb_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_8568e3ae-99b7-46da-b47e-b5da9a0205eb" xlink:to="loc_srt_ProductsAndServicesDomain_8568e3ae-99b7-46da-b47e-b5da9a0205eb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_0619ca4f-6ee8-45bf-906b-f0915c73f13f" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_8568e3ae-99b7-46da-b47e-b5da9a0205eb" xlink:to="loc_srt_ProductsAndServicesDomain_0619ca4f-6ee8-45bf-906b-f0915c73f13f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember_eb35184b-a7bc-497d-a804-2be7c2c96810" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LicenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_0619ca4f-6ee8-45bf-906b-f0915c73f13f" xlink:to="loc_us-gaap_LicenseMember_eb35184b-a7bc-497d-a804-2be7c2c96810" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_LassaFeverAndMERSVaccineMember_581ef705-5697-4d76-bb83-336b688f82bf" xlink:href="ino-20210331.xsd#ino_LassaFeverAndMERSVaccineMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_0619ca4f-6ee8-45bf-906b-f0915c73f13f" xlink:to="loc_ino_LassaFeverAndMERSVaccineMember_581ef705-5697-4d76-bb83-336b688f82bf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_SARSCoV2COVID19VaccineMember_9aa66596-925e-450b-98be-35f4992ec025" xlink:href="ino-20210331.xsd#ino_SARSCoV2COVID19VaccineMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_0619ca4f-6ee8-45bf-906b-f0915c73f13f" xlink:to="loc_ino_SARSCoV2COVID19VaccineMember_9aa66596-925e-450b-98be-35f4992ec025" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CELLECTRA3PSPProprietarySmartDeviceMember_3c9b9d28-6cdc-4458-8d27-33dd9a90c329" xlink:href="ino-20210331.xsd#ino_CELLECTRA3PSPProprietarySmartDeviceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_0619ca4f-6ee8-45bf-906b-f0915c73f13f" xlink:to="loc_ino_CELLECTRA3PSPProprietarySmartDeviceMember_3c9b9d28-6cdc-4458-8d27-33dd9a90c329" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_INO4800Member_b08355cf-2798-4f85-96d8-91cb46616abd" xlink:href="ino-20210331.xsd#ino_INO4800Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_0619ca4f-6ee8-45bf-906b-f0915c73f13f" xlink:to="loc_ino_INO4800Member_b08355cf-2798-4f85-96d8-91cb46616abd" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DNAEncodedMonoclonalAntibodyTechnologyMember_6cc43eb9-7cb9-42bd-8983-fa202210aa66" xlink:href="ino-20210331.xsd#ino_DNAEncodedMonoclonalAntibodyTechnologyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_0619ca4f-6ee8-45bf-906b-f0915c73f13f" xlink:to="loc_ino_DNAEncodedMonoclonalAntibodyTechnologyMember_6cc43eb9-7cb9-42bd-8983-fa202210aa66" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CELLECTRA2000DeviceMember_5fd00735-d50f-4255-91ce-e08019c5c401" xlink:href="ino-20210331.xsd#ino_CELLECTRA2000DeviceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_0619ca4f-6ee8-45bf-906b-f0915c73f13f" xlink:to="loc_ino_CELLECTRA2000DeviceMember_5fd00735-d50f-4255-91ce-e08019c5c401" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_4698c896-3086-4da1-abce-f84dd3f431e3" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_c81b169b-34ad-4818-8342-57d5a70f302e" xlink:to="loc_srt_MajorCustomersAxis_4698c896-3086-4da1-abce-f84dd3f431e3" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_4698c896-3086-4da1-abce-f84dd3f431e3_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_4698c896-3086-4da1-abce-f84dd3f431e3" xlink:to="loc_srt_NameOfMajorCustomerDomain_4698c896-3086-4da1-abce-f84dd3f431e3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_1b3c589a-668e-43bf-9f25-b92b4e8a109d" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_4698c896-3086-4da1-abce-f84dd3f431e3" xlink:to="loc_srt_NameOfMajorCustomerDomain_1b3c589a-668e-43bf-9f25-b92b4e8a109d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_AdvaccineMember_ce37ce94-af6b-4bac-a9fe-c31616fc258c" xlink:href="ino-20210331.xsd#ino_AdvaccineMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_1b3c589a-668e-43bf-9f25-b92b4e8a109d" xlink:to="loc_ino_AdvaccineMember_ce37ce94-af6b-4bac-a9fe-c31616fc258c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_4d7038d0-9ab5-4bfe-bf19-1a42f7c7d8d1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_c81b169b-34ad-4818-8342-57d5a70f302e" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_4d7038d0-9ab5-4bfe-bf19-1a42f7c7d8d1" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_4d7038d0-9ab5-4bfe-bf19-1a42f7c7d8d1_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_4d7038d0-9ab5-4bfe-bf19-1a42f7c7d8d1" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_4d7038d0-9ab5-4bfe-bf19-1a42f7c7d8d1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_3c874599-60d7-40f8-8bd9-f9347da8979b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_4d7038d0-9ab5-4bfe-bf19-1a42f7c7d8d1" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_3c874599-60d7-40f8-8bd9-f9347da8979b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_4e9a9680-d115-4506-9c50-41db9a916c44" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_3c874599-60d7-40f8-8bd9-f9347da8979b" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_4e9a9680-d115-4506-9c50-41db9a916c44" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_89cfbce3-9e5f-497c-b8d9-16aeba7ab875" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_c81b169b-34ad-4818-8342-57d5a70f302e" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_89cfbce3-9e5f-497c-b8d9-16aeba7ab875" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_89cfbce3-9e5f-497c-b8d9-16aeba7ab875_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_89cfbce3-9e5f-497c-b8d9-16aeba7ab875" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_89cfbce3-9e5f-497c-b8d9-16aeba7ab875_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_61fccaf6-b141-4468-af9f-2d2b92cc7362" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_89cfbce3-9e5f-497c-b8d9-16aeba7ab875" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_61fccaf6-b141-4468-af9f-2d2b92cc7362" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCountryMember_3807aec2-3b5a-4b44-b1af-a055d9ebdb39" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCountryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_61fccaf6-b141-4468-af9f-2d2b92cc7362" xlink:to="loc_us-gaap_ForeignCountryMember_3807aec2-3b5a-4b44-b1af-a055d9ebdb39" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.inovio.com/role/IncomeTaxes" xlink:type="simple" xlink:href="ino-20210331.xsd#IncomeTaxes"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/IncomeTaxes" xlink:type="extended" id="id139bae905294c89824a95ad04d96326_IncomeTaxes"/>
  <link:roleRef roleURI="http://www.inovio.com/role/GeneosTherapeuticsInc" xlink:type="simple" xlink:href="ino-20210331.xsd#GeneosTherapeuticsInc"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/GeneosTherapeuticsInc" xlink:type="extended" id="i90afe27a4840408b840f3375f4bc192e_GeneosTherapeuticsInc"/>
  <link:roleRef roleURI="http://www.inovio.com/role/GeneosTherapeuticsIncTables" xlink:type="simple" xlink:href="ino-20210331.xsd#GeneosTherapeuticsIncTables"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/GeneosTherapeuticsIncTables" xlink:type="extended" id="i7612cfe6af2448d5b90d25efcc204324_GeneosTherapeuticsIncTables"/>
  <link:roleRef roleURI="http://www.inovio.com/role/GeneosTherapeuticsIncNarrativeDetails" xlink:type="simple" xlink:href="ino-20210331.xsd#GeneosTherapeuticsIncNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/GeneosTherapeuticsIncNarrativeDetails" xlink:type="extended" id="i1bd27ab139614ad5a3eb9ac6c3224b69_GeneosTherapeuticsIncNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestLineItems_3d591310-faac-4180-aca0-0df1b3804438" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterestLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries_2f88655b-c318-4e10-866c-2e4b359e92da" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MinorityInterestLineItems_3d591310-faac-4180-aca0-0df1b3804438" xlink:to="loc_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries_2f88655b-c318-4e10-866c-2e4b359e92da" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_667d01c2-68aa-467c-8a38-69a000e28973" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MinorityInterestLineItems_3d591310-faac-4180-aca0-0df1b3804438" xlink:to="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_667d01c2-68aa-467c-8a38-69a000e28973" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_StockPurchaseAgreementCommitmentOfAdditionalInvestment_0bd6a842-c5fc-4093-9ee7-6c5d77136c7c" xlink:href="ino-20210331.xsd#ino_StockPurchaseAgreementCommitmentOfAdditionalInvestment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MinorityInterestLineItems_3d591310-faac-4180-aca0-0df1b3804438" xlink:to="loc_ino_StockPurchaseAgreementCommitmentOfAdditionalInvestment_0bd6a842-c5fc-4093-9ee7-6c5d77136c7c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_2abd38ed-ddb6-451b-8b9f-d97dde9125d7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MinorityInterestLineItems_3d591310-faac-4180-aca0-0df1b3804438" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_2abd38ed-ddb6-451b-8b9f-d97dde9125d7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeconsolidationGainOrLossAmount_eb136bcc-41b6-46ff-b77d-bfbb291dbd9c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeconsolidationGainOrLossAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MinorityInterestLineItems_3d591310-faac-4180-aca0-0df1b3804438" xlink:to="loc_us-gaap_DeconsolidationGainOrLossAmount_eb136bcc-41b6-46ff-b77d-bfbb291dbd9c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount_c66927e4-76fb-4d9e-8747-d4b9a114caea" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MinorityInterestLineItems_3d591310-faac-4180-aca0-0df1b3804438" xlink:to="loc_us-gaap_DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount_c66927e4-76fb-4d9e-8747-d4b9a114caea" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_IncomeLossFromEquityMethodInvestmentsRealizedAndAllocatedToInvestment_ba5624a0-a114-4934-a8e4-39725334325e" xlink:href="ino-20210331.xsd#ino_IncomeLossFromEquityMethodInvestmentsRealizedAndAllocatedToInvestment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MinorityInterestLineItems_3d591310-faac-4180-aca0-0df1b3804438" xlink:to="loc_ino_IncomeLossFromEquityMethodInvestmentsRealizedAndAllocatedToInvestment_ba5624a0-a114-4934-a8e4-39725334325e" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_9a147c2c-80ef-4dd4-811e-6300b6eaa781" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MinorityInterestLineItems_3d591310-faac-4180-aca0-0df1b3804438" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_9a147c2c-80ef-4dd4-811e-6300b6eaa781" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_fd3943b7-4da9-4001-a6dc-ce17f6b2e773" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MinorityInterestLineItems_3d591310-faac-4180-aca0-0df1b3804438" xlink:to="loc_us-gaap_EquityMethodInvestments_fd3943b7-4da9-4001-a6dc-ce17f6b2e773" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestTable_1ff3eba0-3f86-412e-85af-8dc27b93f3dd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterestTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_MinorityInterestLineItems_3d591310-faac-4180-aca0-0df1b3804438" xlink:to="loc_us-gaap_MinorityInterestTable_1ff3eba0-3f86-412e-85af-8dc27b93f3dd" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_e125744e-7efe-4882-bd43-18553eab6f12" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_MinorityInterestTable_1ff3eba0-3f86-412e-85af-8dc27b93f3dd" xlink:to="loc_srt_CounterpartyNameAxis_e125744e-7efe-4882-bd43-18553eab6f12" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e125744e-7efe-4882-bd43-18553eab6f12_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_e125744e-7efe-4882-bd43-18553eab6f12" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e125744e-7efe-4882-bd43-18553eab6f12_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_013bd6ee-e6b8-4094-adbf-8f55d3f82126" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_e125744e-7efe-4882-bd43-18553eab6f12" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_013bd6ee-e6b8-4094-adbf-8f55d3f82126" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_GeneosTherapeuticsInc.Member_4cdd9011-cbf6-4db9-85df-3f62bb005dbe" xlink:href="ino-20210331.xsd#ino_GeneosTherapeuticsInc.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_013bd6ee-e6b8-4094-adbf-8f55d3f82126" xlink:to="loc_ino_GeneosTherapeuticsInc.Member_4cdd9011-cbf6-4db9-85df-3f62bb005dbe" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_a59348d1-91bc-448b-b3e7-5a301f7a32e3" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_OwnershipAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_MinorityInterestTable_1ff3eba0-3f86-412e-85af-8dc27b93f3dd" xlink:to="loc_srt_OwnershipAxis_a59348d1-91bc-448b-b3e7-5a301f7a32e3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_a59348d1-91bc-448b-b3e7-5a301f7a32e3_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_OwnershipAxis_a59348d1-91bc-448b-b3e7-5a301f7a32e3" xlink:to="loc_srt_OwnershipDomain_a59348d1-91bc-448b-b3e7-5a301f7a32e3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_bc45239b-05e3-4844-8a32-83a844761ddd" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_OwnershipAxis_a59348d1-91bc-448b-b3e7-5a301f7a32e3" xlink:to="loc_srt_OwnershipDomain_bc45239b-05e3-4844-8a32-83a844761ddd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_GeneosTherapeuticsInc.Member_5f13b036-3fbd-44de-9f57-4c5639d60b81" xlink:href="ino-20210331.xsd#ino_GeneosTherapeuticsInc.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_OwnershipDomain_bc45239b-05e3-4844-8a32-83a844761ddd" xlink:to="loc_ino_GeneosTherapeuticsInc.Member_5f13b036-3fbd-44de-9f57-4c5639d60b81" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_fc000191-e497-4264-a2a4-6fd2a733e850" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_MinorityInterestTable_1ff3eba0-3f86-412e-85af-8dc27b93f3dd" xlink:to="loc_us-gaap_StatementClassOfStockAxis_fc000191-e497-4264-a2a4-6fd2a733e850" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_fc000191-e497-4264-a2a4-6fd2a733e850_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_fc000191-e497-4264-a2a4-6fd2a733e850" xlink:to="loc_us-gaap_ClassOfStockDomain_fc000191-e497-4264-a2a4-6fd2a733e850_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_6732092d-a446-4b53-b340-3ca747fa1fa2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_fc000191-e497-4264-a2a4-6fd2a733e850" xlink:to="loc_us-gaap_ClassOfStockDomain_6732092d-a446-4b53-b340-3ca747fa1fa2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_21db8b1e-c417-47ea-8e10-a9dafcceac7e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_6732092d-a446-4b53-b340-3ca747fa1fa2" xlink:to="loc_us-gaap_CommonStockMember_21db8b1e-c417-47ea-8e10-a9dafcceac7e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember_499cb4ea-9dcd-4cf9-aa89-128c7d0f5103" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_6732092d-a446-4b53-b340-3ca747fa1fa2" xlink:to="loc_us-gaap_PreferredStockMember_499cb4ea-9dcd-4cf9-aa89-128c7d0f5103" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_SeriesAOnePreferredStockMember_8dc18211-2956-4167-a530-74e3393910f7" xlink:href="ino-20210331.xsd#ino_SeriesAOnePreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_6732092d-a446-4b53-b340-3ca747fa1fa2" xlink:to="loc_ino_SeriesAOnePreferredStockMember_8dc18211-2956-4167-a530-74e3393910f7" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.inovio.com/role/GeneosTherapeuticsIncDeconsolidationAccountingDetails" xlink:type="simple" xlink:href="ino-20210331.xsd#GeneosTherapeuticsIncDeconsolidationAccountingDetails"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/GeneosTherapeuticsIncDeconsolidationAccountingDetails" xlink:type="extended" id="i254e98fcfb3f4679b9638aac2017db1f_GeneosTherapeuticsIncDeconsolidationAccountingDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestLineItems_d683c748-156c-4d9c-abb8-c2f770c80082" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterestLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_WorkingCapitalExcludingCash_f7db0f7b-fa85-453a-8f74-1d213827562d" xlink:href="ino-20210331.xsd#ino_WorkingCapitalExcludingCash"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MinorityInterestLineItems_d683c748-156c-4d9c-abb8-c2f770c80082" xlink:to="loc_ino_WorkingCapitalExcludingCash_f7db0f7b-fa85-453a-8f74-1d213827562d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayable_43f3e30c-dbf1-4415-99c5-4f021d52ca54" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NotesPayable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MinorityInterestLineItems_d683c748-156c-4d9c-abb8-c2f770c80082" xlink:to="loc_us-gaap_NotesPayable_43f3e30c-dbf1-4415-99c5-4f021d52ca54" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_8e57d6d4-b680-43ac-a39f-6ded2116e045" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MinorityInterestLineItems_d683c748-156c-4d9c-abb8-c2f770c80082" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_8e57d6d4-b680-43ac-a39f-6ded2116e045" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_ef83f0cc-6222-4be5-8f7a-1ba8ee06a2ea" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MinorityInterestLineItems_d683c748-156c-4d9c-abb8-c2f770c80082" xlink:to="loc_us-gaap_MinorityInterest_ef83f0cc-6222-4be5-8f7a-1ba8ee06a2ea" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedInterestFairValueDisclosure_228e7d21-b526-4803-99d4-5e465e29ad57" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedInterestFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MinorityInterestLineItems_d683c748-156c-4d9c-abb8-c2f770c80082" xlink:to="loc_us-gaap_RetainedInterestFairValueDisclosure_228e7d21-b526-4803-99d4-5e465e29ad57" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeconsolidationGainOrLossAmount_c0046c67-5d5a-4205-a142-34906ae80035" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeconsolidationGainOrLossAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MinorityInterestLineItems_d683c748-156c-4d9c-abb8-c2f770c80082" xlink:to="loc_us-gaap_DeconsolidationGainOrLossAmount_c0046c67-5d5a-4205-a142-34906ae80035" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashDivestedFromDeconsolidation_2148ea6a-11c5-44c4-846e-4c91d9a1f7ef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashDivestedFromDeconsolidation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MinorityInterestLineItems_d683c748-156c-4d9c-abb8-c2f770c80082" xlink:to="loc_us-gaap_CashDivestedFromDeconsolidation_2148ea6a-11c5-44c4-846e-4c91d9a1f7ef" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestTable_8f3074c2-1ad3-4b66-8d4a-6db31c8a3b8b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterestTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_MinorityInterestLineItems_d683c748-156c-4d9c-abb8-c2f770c80082" xlink:to="loc_us-gaap_MinorityInterestTable_8f3074c2-1ad3-4b66-8d4a-6db31c8a3b8b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_236d3847-fc27-43a9-87f2-da40a42c08c4" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_MinorityInterestTable_8f3074c2-1ad3-4b66-8d4a-6db31c8a3b8b" xlink:to="loc_srt_CounterpartyNameAxis_236d3847-fc27-43a9-87f2-da40a42c08c4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_236d3847-fc27-43a9-87f2-da40a42c08c4_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_236d3847-fc27-43a9-87f2-da40a42c08c4" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_236d3847-fc27-43a9-87f2-da40a42c08c4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_9e167b90-4d2a-4021-8b0b-c5bd64f37a84" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_236d3847-fc27-43a9-87f2-da40a42c08c4" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_9e167b90-4d2a-4021-8b0b-c5bd64f37a84" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_GeneosTherapeuticsInc.Member_b53ef947-f3c1-4a04-8d76-dea1a8f8d25e" xlink:href="ino-20210331.xsd#ino_GeneosTherapeuticsInc.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_9e167b90-4d2a-4021-8b0b-c5bd64f37a84" xlink:to="loc_ino_GeneosTherapeuticsInc.Member_b53ef947-f3c1-4a04-8d76-dea1a8f8d25e" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.inovio.com/role/GeneosTherapeuticsIncInvestmentInGeneosDetails" xlink:type="simple" xlink:href="ino-20210331.xsd#GeneosTherapeuticsIncInvestmentInGeneosDetails"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/GeneosTherapeuticsIncInvestmentInGeneosDetails" xlink:type="extended" id="ib7c349f8dd03424a87f731a5652986d5_GeneosTherapeuticsIncInvestmentInGeneosDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestLineItems_944036ce-4afe-4333-8439-e5fbe5032dd5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterestLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentOwnedBalanceShares_ffcc5cb1-915a-472d-a7a2-120f393e5cd9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentOwnedBalanceShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MinorityInterestLineItems_944036ce-4afe-4333-8439-e5fbe5032dd5" xlink:to="loc_us-gaap_InvestmentOwnedBalanceShares_ffcc5cb1-915a-472d-a7a2-120f393e5cd9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice_ba284036-d21d-492e-8b22-309599a09b0d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MinorityInterestLineItems_944036ce-4afe-4333-8439-e5fbe5032dd5" xlink:to="loc_us-gaap_SharePrice_ba284036-d21d-492e-8b22-309599a09b0d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_0c344587-df16-444a-8a77-c9089faa0bd5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MinorityInterestLineItems_944036ce-4afe-4333-8439-e5fbe5032dd5" xlink:to="loc_us-gaap_EquityMethodInvestments_0c344587-df16-444a-8a77-c9089faa0bd5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestTable_e7476180-2234-4a70-9908-05941a09418d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterestTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_MinorityInterestLineItems_944036ce-4afe-4333-8439-e5fbe5032dd5" xlink:to="loc_us-gaap_MinorityInterestTable_e7476180-2234-4a70-9908-05941a09418d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_a8e980d8-7ed5-4bed-b97c-5b4edba3cc3f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_MinorityInterestTable_e7476180-2234-4a70-9908-05941a09418d" xlink:to="loc_us-gaap_StatementClassOfStockAxis_a8e980d8-7ed5-4bed-b97c-5b4edba3cc3f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_a8e980d8-7ed5-4bed-b97c-5b4edba3cc3f_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_a8e980d8-7ed5-4bed-b97c-5b4edba3cc3f" xlink:to="loc_us-gaap_ClassOfStockDomain_a8e980d8-7ed5-4bed-b97c-5b4edba3cc3f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_b4a6faf4-28db-49d9-89da-461cb548f878" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_a8e980d8-7ed5-4bed-b97c-5b4edba3cc3f" xlink:to="loc_us-gaap_ClassOfStockDomain_b4a6faf4-28db-49d9-89da-461cb548f878" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_f03766de-ed72-4aee-958c-8b751c2b249c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_b4a6faf4-28db-49d9-89da-461cb548f878" xlink:to="loc_us-gaap_CommonStockMember_f03766de-ed72-4aee-958c-8b751c2b249c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember_6fcaa87c-2ee9-4fc1-b8c7-803bea753e0f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_b4a6faf4-28db-49d9-89da-461cb548f878" xlink:to="loc_us-gaap_PreferredStockMember_6fcaa87c-2ee9-4fc1-b8c7-803bea753e0f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_65df8831-e634-4730-85b9-044094a065c4" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_MinorityInterestTable_e7476180-2234-4a70-9908-05941a09418d" xlink:to="loc_srt_CounterpartyNameAxis_65df8831-e634-4730-85b9-044094a065c4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_65df8831-e634-4730-85b9-044094a065c4_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_65df8831-e634-4730-85b9-044094a065c4" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_65df8831-e634-4730-85b9-044094a065c4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_06d3cb36-5a85-44f0-be83-a404a86cdd18" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_65df8831-e634-4730-85b9-044094a065c4" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_06d3cb36-5a85-44f0-be83-a404a86cdd18" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_GeneosTherapeuticsInc.Member_14c7090c-06f4-4b57-9225-83e44dcfc5a7" xlink:href="ino-20210331.xsd#ino_GeneosTherapeuticsInc.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_06d3cb36-5a85-44f0-be83-a404a86cdd18" xlink:to="loc_ino_GeneosTherapeuticsInc.Member_14c7090c-06f4-4b57-9225-83e44dcfc5a7" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.inovio.com/role/GeneosTherapeuticsIncFairValueAssumptionsDetails" xlink:type="simple" xlink:href="ino-20210331.xsd#GeneosTherapeuticsIncFairValueAssumptionsDetails"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/GeneosTherapeuticsIncFairValueAssumptionsDetails" xlink:type="extended" id="i9422aa677d4d4f12b2fe72937529966f_GeneosTherapeuticsIncFairValueAssumptionsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestLineItems_254a7911-f3c1-4f94-8bae-a4fbfe6784ef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterestLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_AlternativeInvestmentMeasurementInputTerm_e29884df-14a7-418e-86b5-ba414bdfc10e" xlink:href="ino-20210331.xsd#ino_AlternativeInvestmentMeasurementInputTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MinorityInterestLineItems_254a7911-f3c1-4f94-8bae-a4fbfe6784ef" xlink:to="loc_ino_AlternativeInvestmentMeasurementInputTerm_e29884df-14a7-418e-86b5-ba414bdfc10e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AlternativeInvestmentMeasurementInput_edd20864-3bc2-4d1e-8999-6d84a6bfdc1c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AlternativeInvestmentMeasurementInput"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MinorityInterestLineItems_254a7911-f3c1-4f94-8bae-a4fbfe6784ef" xlink:to="loc_us-gaap_AlternativeInvestmentMeasurementInput_edd20864-3bc2-4d1e-8999-6d84a6bfdc1c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_EquityMethodInvestmentEnterpriseValue_4eecc52a-b3df-4345-b1ce-686ac38a68cc" xlink:href="ino-20210331.xsd#ino_EquityMethodInvestmentEnterpriseValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MinorityInterestLineItems_254a7911-f3c1-4f94-8bae-a4fbfe6784ef" xlink:to="loc_ino_EquityMethodInvestmentEnterpriseValue_4eecc52a-b3df-4345-b1ce-686ac38a68cc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestTable_daeae690-7ea4-4a67-a108-6bcacf99a907" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterestTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_MinorityInterestLineItems_254a7911-f3c1-4f94-8bae-a4fbfe6784ef" xlink:to="loc_us-gaap_MinorityInterestTable_daeae690-7ea4-4a67-a108-6bcacf99a907" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_ea368f48-6999-4e58-b98f-da13390be698" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_MinorityInterestTable_daeae690-7ea4-4a67-a108-6bcacf99a907" xlink:to="loc_srt_CounterpartyNameAxis_ea368f48-6999-4e58-b98f-da13390be698" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_ea368f48-6999-4e58-b98f-da13390be698_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_ea368f48-6999-4e58-b98f-da13390be698" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_ea368f48-6999-4e58-b98f-da13390be698_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a7db71b5-7856-48ca-a76d-e330b07710d5" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_ea368f48-6999-4e58-b98f-da13390be698" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a7db71b5-7856-48ca-a76d-e330b07710d5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_GeneosTherapeuticsInc.Member_a1eb3d5a-6d2c-4a96-9726-f4ce95e84175" xlink:href="ino-20210331.xsd#ino_GeneosTherapeuticsInc.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a7db71b5-7856-48ca-a76d-e330b07710d5" xlink:to="loc_ino_GeneosTherapeuticsInc.Member_a1eb3d5a-6d2c-4a96-9726-f4ce95e84175" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_c72c070a-8042-4cd6-9cda-396a294eae25" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_MinorityInterestTable_daeae690-7ea4-4a67-a108-6bcacf99a907" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_c72c070a-8042-4cd6-9cda-396a294eae25" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_c72c070a-8042-4cd6-9cda-396a294eae25_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_c72c070a-8042-4cd6-9cda-396a294eae25" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_c72c070a-8042-4cd6-9cda-396a294eae25_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_541d0036-a086-472c-8e0d-c8fb176fe990" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_c72c070a-8042-4cd6-9cda-396a294eae25" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_541d0036-a086-472c-8e0d-c8fb176fe990" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputExpectedTermMember_d3637677-43dd-486c-9957-b4079d7cf826" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputExpectedTermMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_541d0036-a086-472c-8e0d-c8fb176fe990" xlink:to="loc_us-gaap_MeasurementInputExpectedTermMember_d3637677-43dd-486c-9957-b4079d7cf826" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputPriceVolatilityMember_7d67618b-b237-4bfb-b32e-6f579466b346" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputPriceVolatilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_541d0036-a086-472c-8e0d-c8fb176fe990" xlink:to="loc_us-gaap_MeasurementInputPriceVolatilityMember_7d67618b-b237-4bfb-b32e-6f579466b346" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_c80bb4a0-686d-4396-bc3d-a97de20d66ae" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_541d0036-a086-472c-8e0d-c8fb176fe990" xlink:to="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_c80bb4a0-686d-4396-bc3d-a97de20d66ae" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.inovio.com/role/GeneosTherapeuticsIncPreferredstockInvestmentDetails" xlink:type="simple" xlink:href="ino-20210331.xsd#GeneosTherapeuticsIncPreferredstockInvestmentDetails"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/GeneosTherapeuticsIncPreferredstockInvestmentDetails" xlink:type="extended" id="i9328c439ecf04bb9b5b4c62dba38845c_GeneosTherapeuticsIncPreferredstockInvestmentDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestLineItems_5a2e9106-d89a-42bf-b6c4-eb4542fc6f0b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterestLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MovementInMinorityInterestRollForward_0e44e2d1-2bec-4702-86b2-8dd9a2133c36" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MovementInMinorityInterestRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MinorityInterestLineItems_5a2e9106-d89a-42bf-b6c4-eb4542fc6f0b" xlink:to="loc_us-gaap_MovementInMinorityInterestRollForward_0e44e2d1-2bec-4702-86b2-8dd9a2133c36" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_b9c71a80-b365-4c8a-8169-4fef15e23d51" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MovementInMinorityInterestRollForward_0e44e2d1-2bec-4702-86b2-8dd9a2133c36" xlink:to="loc_us-gaap_EquityMethodInvestments_b9c71a80-b365-4c8a-8169-4fef15e23d51" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_0d92eb93-3cdb-478b-bb27-2efe33128a51" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MovementInMinorityInterestRollForward_0e44e2d1-2bec-4702-86b2-8dd9a2133c36" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_0d92eb93-3cdb-478b-bb27-2efe33128a51" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_ce73e867-66b1-461e-89bc-80a6a442e9f4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestments"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestTable_65676789-1876-4263-bac1-f38ed53e19ca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterestTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_MinorityInterestLineItems_5a2e9106-d89a-42bf-b6c4-eb4542fc6f0b" xlink:to="loc_us-gaap_MinorityInterestTable_65676789-1876-4263-bac1-f38ed53e19ca" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_a074e4a1-fab5-47bb-94cf-8385bb2be814" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_MinorityInterestTable_65676789-1876-4263-bac1-f38ed53e19ca" xlink:to="loc_srt_CounterpartyNameAxis_a074e4a1-fab5-47bb-94cf-8385bb2be814" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a074e4a1-fab5-47bb-94cf-8385bb2be814_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_a074e4a1-fab5-47bb-94cf-8385bb2be814" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a074e4a1-fab5-47bb-94cf-8385bb2be814_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4f301293-cc4e-4606-97a7-885e8b747888" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_a074e4a1-fab5-47bb-94cf-8385bb2be814" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4f301293-cc4e-4606-97a7-885e8b747888" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_GeneosTherapeuticsInc.Member_97e426d3-8585-497c-9528-31a06d917019" xlink:href="ino-20210331.xsd#ino_GeneosTherapeuticsInc.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4f301293-cc4e-4606-97a7-885e8b747888" xlink:to="loc_ino_GeneosTherapeuticsInc.Member_97e426d3-8585-497c-9528-31a06d917019" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_5d41b88c-089c-4af1-a47c-bc635c9db724" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_MinorityInterestTable_65676789-1876-4263-bac1-f38ed53e19ca" xlink:to="loc_us-gaap_StatementClassOfStockAxis_5d41b88c-089c-4af1-a47c-bc635c9db724" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_5d41b88c-089c-4af1-a47c-bc635c9db724_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_5d41b88c-089c-4af1-a47c-bc635c9db724" xlink:to="loc_us-gaap_ClassOfStockDomain_5d41b88c-089c-4af1-a47c-bc635c9db724_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_7f0f0300-0659-43f8-a4e1-edcb8d9fbc1a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_5d41b88c-089c-4af1-a47c-bc635c9db724" xlink:to="loc_us-gaap_ClassOfStockDomain_7f0f0300-0659-43f8-a4e1-edcb8d9fbc1a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_SeriesAOnePreferredStockMember_e6e4a27f-8048-4287-acca-e76de6c989bb" xlink:href="ino-20210331.xsd#ino_SeriesAOnePreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_7f0f0300-0659-43f8-a4e1-edcb8d9fbc1a" xlink:to="loc_ino_SeriesAOnePreferredStockMember_e6e4a27f-8048-4287-acca-e76de6c989bb" xlink:type="arc" order="0"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>8
<FILENAME>ino-20210331_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:e9d1bb07-ad73-4929-82ea-6e949ab8c789,g:8e741ee6-3c7b-40cd-9e55-d4abd68b099b-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_8b0c1db7-968d-4337-9323-71d868d3c05d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_95965497-ed3c-41bd-a13b-53fab4defba8_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_a9ad7178-392b-4d8a-834d-72f28ef79e13_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income (expense), net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_6e97c618-fe99-4ae8-ba93-c1f50d09d83f_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of common and preferred stock authorized, issued and outstanding</link:label>
    <link:label id="lab_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Number of Shares, Par Value and Other Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="lab_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity_b318fb61-db51-4cbc-b5c9-1b85aeab36db_negatedLabel_en-US" xlink:label="lab_ino_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets from affiliated entities</link:label>
    <link:label id="lab_ino_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity_label_en-US" xlink:label="lab_ino_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase Decrease in Prepaid Expenses and Other Current Assets from Affiliated Entity</link:label>
    <link:label id="lab_ino_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity_documentation_en-US" xlink:label="lab_ino_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The net change during the reporting period in the value of prepaid expenses and other current assets from related parties.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity" xlink:href="ino-20210331.xsd#ino_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity" xlink:to="lab_ino_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_4c849952-710f-47e9-b36a-5886a26ec93b_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_NonCashInterestIncomeExpense_0651db9a-3a3d-4806-a306-f587b00bfa1d_negatedTerseLabel_en-US" xlink:label="lab_ino_NonCashInterestIncomeExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash interest expense</link:label>
    <link:label id="lab_ino_NonCashInterestIncomeExpense_label_en-US" xlink:label="lab_ino_NonCashInterestIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Cash Interest Income (Expense)</link:label>
    <link:label id="lab_ino_NonCashInterestIncomeExpense_documentation_en-US" xlink:label="lab_ino_NonCashInterestIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Cash Interest Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_NonCashInterestIncomeExpense" xlink:href="ino-20210331.xsd#ino_NonCashInterestIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_NonCashInterestIncomeExpense" xlink:to="lab_ino_NonCashInterestIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_6c398a37-17bd-4f4f-9bc7-9c5a886caf31_verboseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable and accrued expenses</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable and Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_45142de8-945d-4772-b302-61703d3fcded_verboseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term Investments</link:label>
    <link:label id="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterestTable_71914cb2-093e-48ce-96da-d1fbb17f03d6_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterestTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest [Table]</link:label>
    <link:label id="lab_us-gaap_MinorityInterestTable_label_en-US" xlink:label="lab_us-gaap_MinorityInterestTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterestTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterestTable" xlink:to="lab_us-gaap_MinorityInterestTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_UnderwrittenPublicOfferingMember_c542f510-9eb7-4d7f-80b9-daa8747fb032_terseLabel_en-US" xlink:label="lab_ino_UnderwrittenPublicOfferingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Underwritten Public Offering</link:label>
    <link:label id="lab_ino_UnderwrittenPublicOfferingMember_label_en-US" xlink:label="lab_ino_UnderwrittenPublicOfferingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Underwritten Public Offering [Member]</link:label>
    <link:label id="lab_ino_UnderwrittenPublicOfferingMember_documentation_en-US" xlink:label="lab_ino_UnderwrittenPublicOfferingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Underwritten Public Offering [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_UnderwrittenPublicOfferingMember" xlink:href="ino-20210331.xsd#ino_UnderwrittenPublicOfferingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_UnderwrittenPublicOfferingMember" xlink:to="lab_ino_UnderwrittenPublicOfferingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValuePolicyTextBlock_e934ef0e-29c6-4132-a9e4-d599eccc262f_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValuePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Investments</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValuePolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValuePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities without Readily Determinable Fair Value [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValuePolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValuePolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValuePolicyTextBlock" xlink:to="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValuePolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_3022c622-2df4-45ab-b92f-3e70e9dcfc50_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Unobservable Inputs (Level&#160;3)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability_0f34420d-07a4-4bff-8bd3-0e46bb1e804c_terseLabel_en-US" xlink:label="lab_us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of derivative liability</link:label>
    <link:label id="lab_us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability_label_en-US" xlink:label="lab_us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Embedded Derivative, Fair Value of Embedded Derivative Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability" xlink:to="lab_us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_32a40842-5697-4d08-8fd0-cad2d2ed59c5_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Leases [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_DeferredGrantFundingFromAffiliateNoncurrent_10d93498-665a-472c-87a4-9cc8c729f47f_terseLabel_en-US" xlink:label="lab_ino_DeferredGrantFundingFromAffiliateNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grant funding liability from affiliated entity, net of current portion</link:label>
    <link:label id="lab_ino_DeferredGrantFundingFromAffiliateNoncurrent_label_en-US" xlink:label="lab_ino_DeferredGrantFundingFromAffiliateNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Grant Funding, From Affiliate, Noncurrent</link:label>
    <link:label id="lab_ino_DeferredGrantFundingFromAffiliateNoncurrent_documentation_en-US" xlink:label="lab_ino_DeferredGrantFundingFromAffiliateNoncurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Grant Funding, From Affiliate, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DeferredGrantFundingFromAffiliateNoncurrent" xlink:href="ino-20210331.xsd#ino_DeferredGrantFundingFromAffiliateNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_DeferredGrantFundingFromAffiliateNoncurrent" xlink:to="lab_ino_DeferredGrantFundingFromAffiliateNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_1ab27784-3c2a-4c55-851a-e4788987c10a_verboseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating expenses related to affiliated entity</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction, Expenses from Transactions with Related Party</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:to="lab_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_c6cd351b-08c0-434f-b05e-3c229e100770_verboseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Definite lived:</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets (Excluding Goodwill) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LicensingAgreementsMember_c020cdfa-4394-40ad-bdbe-d456f66ae740_verboseLabel_en-US" xlink:label="lab_us-gaap_LicensingAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Licenses</link:label>
    <link:label id="lab_us-gaap_LicensingAgreementsMember_label_en-US" xlink:label="lab_us-gaap_LicensingAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Licensing Agreements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicensingAgreementsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LicensingAgreementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LicensingAgreementsMember" xlink:to="lab_us-gaap_LicensingAgreementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_4bed65ac-7339-4b73-9b74-23f3d29f2617_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_f66b04d2-c89a-43fd-a817-07571781b168_verboseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3cd0b979-811f-4273-8668-c6c3629df474_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_30452937-58da-43c9-9b10-326443aadf79_verboseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Liabilities, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfDebt_d20a5a6f-e28c-45cf-b396-27f32bb29e17_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of debt</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfDebt" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockMember_30ab9f2e-0c6f-4604-9bd1-4b2a5b58c016_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock</link:label>
    <link:label id="lab_us-gaap_PreferredStockMember_label_en-US" xlink:label="lab_us-gaap_PreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockMember" xlink:to="lab_us-gaap_PreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_420807ba-3403-451c-aa84-d7e16e0080e6_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_ace8b3ef-8813-4a26-8ffe-b7ac42bc0ae6_verboseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets, net</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_53c5b14c-2069-4cb8-a73c-8c0328b428b4_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets, net</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_NumberOfPotentialSharesAuthorizedForIssuanceUnderShareBasedCompensationPlan_58e51ebe-067d-4656-bf87-d1af8e2fbb4b_terseLabel_en-US" xlink:label="lab_ino_NumberOfPotentialSharesAuthorizedForIssuanceUnderShareBasedCompensationPlan" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of potential shares authorized for issuance under share based compensation plan (in shares)</link:label>
    <link:label id="lab_ino_NumberOfPotentialSharesAuthorizedForIssuanceUnderShareBasedCompensationPlan_label_en-US" xlink:label="lab_ino_NumberOfPotentialSharesAuthorizedForIssuanceUnderShareBasedCompensationPlan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Potential Shares Authorized For Issuance Under Share Based Compensation Plan</link:label>
    <link:label id="lab_ino_NumberOfPotentialSharesAuthorizedForIssuanceUnderShareBasedCompensationPlan_documentation_en-US" xlink:label="lab_ino_NumberOfPotentialSharesAuthorizedForIssuanceUnderShareBasedCompensationPlan" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of potential shares authorized for issuance under a share-based compensation plan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_NumberOfPotentialSharesAuthorizedForIssuanceUnderShareBasedCompensationPlan" xlink:href="ino-20210331.xsd#ino_NumberOfPotentialSharesAuthorizedForIssuanceUnderShareBasedCompensationPlan"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_NumberOfPotentialSharesAuthorizedForIssuanceUnderShareBasedCompensationPlan" xlink:to="lab_ino_NumberOfPotentialSharesAuthorizedForIssuanceUnderShareBasedCompensationPlan" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_A2007IncentivePlanMember_6ed28bc9-9e69-49ba-896c-973eeb05693e_terseLabel_en-US" xlink:label="lab_ino_A2007IncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2007 Incentive Plan</link:label>
    <link:label id="lab_ino_A2007IncentivePlanMember_label_en-US" xlink:label="lab_ino_A2007IncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2007 Incentive Plan [Member]</link:label>
    <link:label id="lab_ino_A2007IncentivePlanMember_documentation_en-US" xlink:label="lab_ino_A2007IncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2007 Incentive Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_A2007IncentivePlanMember" xlink:href="ino-20210331.xsd#ino_A2007IncentivePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_A2007IncentivePlanMember" xlink:to="lab_ino_A2007IncentivePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_b6501d5d-d1e1-484c-8d1a-bf355533bfff_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_CollaborationAgreementPaymentEarned_f35fe67b-bcd8-4ecd-a0e6-34678277606a_terseLabel_en-US" xlink:label="lab_ino_CollaborationAgreementPaymentEarned" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement, Payment Earned</link:label>
    <link:label id="lab_ino_CollaborationAgreementPaymentEarned_label_en-US" xlink:label="lab_ino_CollaborationAgreementPaymentEarned" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement, Payment Earned</link:label>
    <link:label id="lab_ino_CollaborationAgreementPaymentEarned_documentation_en-US" xlink:label="lab_ino_CollaborationAgreementPaymentEarned" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement, Payment Earned</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborationAgreementPaymentEarned" xlink:href="ino-20210331.xsd#ino_CollaborationAgreementPaymentEarned"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_CollaborationAgreementPaymentEarned" xlink:to="lab_ino_CollaborationAgreementPaymentEarned" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_CollaborativeAgreementCorporateIncomeTax_6ea07209-927f-4c98-bd28-bace1b419374_terseLabel_en-US" xlink:label="lab_ino_CollaborativeAgreementCorporateIncomeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign corporate income taxes reducing upfront payment</link:label>
    <link:label id="lab_ino_CollaborativeAgreementCorporateIncomeTax_label_en-US" xlink:label="lab_ino_CollaborativeAgreementCorporateIncomeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreement, Corporate Income Tax</link:label>
    <link:label id="lab_ino_CollaborativeAgreementCorporateIncomeTax_documentation_en-US" xlink:label="lab_ino_CollaborativeAgreementCorporateIncomeTax" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreement, Corporate Income Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementCorporateIncomeTax" xlink:href="ino-20210331.xsd#ino_CollaborativeAgreementCorporateIncomeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_CollaborativeAgreementCorporateIncomeTax" xlink:to="lab_ino_CollaborativeAgreementCorporateIncomeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfUnits_9e03a28d-abcf-405b-8e06-3bb04e0d92ba_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion of carrying value</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfUnits_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Conversion of Units</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfUnits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_58997fca-ea2e-44aa-87eb-3def7b44b273_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_AmortizationOfOperatingLeaseRightOfUseAssets_59f62bf4-9901-4c05-8a5b-4a2b246d7f90_terseLabel_en-US" xlink:label="lab_ino_AmortizationOfOperatingLeaseRightOfUseAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization Of Operating Lease Right-Of-Use Assets</link:label>
    <link:label id="lab_ino_AmortizationOfOperatingLeaseRightOfUseAssets_label_en-US" xlink:label="lab_ino_AmortizationOfOperatingLeaseRightOfUseAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization Of Operating Lease Right-Of-Use Assets</link:label>
    <link:label id="lab_ino_AmortizationOfOperatingLeaseRightOfUseAssets_documentation_en-US" xlink:label="lab_ino_AmortizationOfOperatingLeaseRightOfUseAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization Of Operating Lease Right-Of-Use Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_AmortizationOfOperatingLeaseRightOfUseAssets" xlink:href="ino-20210331.xsd#ino_AmortizationOfOperatingLeaseRightOfUseAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_AmortizationOfOperatingLeaseRightOfUseAssets" xlink:to="lab_ino_AmortizationOfOperatingLeaseRightOfUseAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_GrantProceedsReceived_a140f0da-b376-4e2d-be96-9f883a7a6a65_terseLabel_en-US" xlink:label="lab_ino_GrantProceedsReceived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contra-research and development expense</link:label>
    <link:label id="lab_ino_GrantProceedsReceived_label_en-US" xlink:label="lab_ino_GrantProceedsReceived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grant Proceeds Received</link:label>
    <link:label id="lab_ino_GrantProceedsReceived_documentation_en-US" xlink:label="lab_ino_GrantProceedsReceived" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grant Proceeds Received</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_GrantProceedsReceived" xlink:href="ino-20210331.xsd#ino_GrantProceedsReceived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_GrantProceedsReceived" xlink:to="lab_ino_GrantProceedsReceived" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_179523e4-b985-4955-bf3a-915eef017bce_verboseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss_80fe0b27-633f-47b3-a2b0-8a85c52a0dc9_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Realized loss on investments</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Realized Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_3052ae34-3ea2-4664-abdd-ecb3ee4b33c4_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tranche Two</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Tranche Two [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:to="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_GoodwillAndIntangibleAssetsNet_9d669d0b-8908-4b25-b98e-abb22c4cf50b_totalLabel_en-US" xlink:label="lab_ino_GoodwillAndIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total goodwill and intangible assets, net book value</link:label>
    <link:label id="lab_ino_GoodwillAndIntangibleAssetsNet_label_en-US" xlink:label="lab_ino_GoodwillAndIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Net</link:label>
    <link:label id="lab_ino_GoodwillAndIntangibleAssetsNet_documentation_en-US" xlink:label="lab_ino_GoodwillAndIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and intangible assets net.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_GoodwillAndIntangibleAssetsNet" xlink:href="ino-20210331.xsd#ino_GoodwillAndIntangibleAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_GoodwillAndIntangibleAssetsNet" xlink:to="lab_ino_GoodwillAndIntangibleAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_6a717e46-3691-4720-b115-fb12814c0356_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ASSETS</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_4e462d92-4175-47c3-a751-2a9a5abda582_terseLabel_en-US" xlink:label="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Axis]</link:label>
    <link:label id="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_label_en-US" xlink:label="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_6063b2e6-aa29-4860-80bb-7f25a520f53e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award vesting period (in years)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_45eb9592-a5fc-43fe-89ad-e63d397533da_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_047eb0bb-6673-47e8-b48e-011eb3f9ee6f_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise of stock options for cash and vesting of RSUs, net of tax payments</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_eca3b267-20a1-40a7-9869-19444110844b_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DueToRelatedPartiesCurrent_71b9257f-db03-4a05-b855-6a3f4bae2e6d_verboseLabel_en-US" xlink:label="lab_us-gaap_DueToRelatedPartiesCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable and accrued expenses due to affiliated entities</link:label>
    <link:label id="lab_us-gaap_DueToRelatedPartiesCurrent_label_en-US" xlink:label="lab_us-gaap_DueToRelatedPartiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due to Related Parties, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueToRelatedPartiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DueToRelatedPartiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DueToRelatedPartiesCurrent" xlink:to="lab_us-gaap_DueToRelatedPartiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour_59e32235-c00e-487f-9e32-bef08b383de1_terseLabel_en-US" xlink:label="lab_ino_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated aggregate amortization expense for 2026</link:label>
    <link:label id="lab_ino_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour_label_en-US" xlink:label="lab_ino_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, After Year Four</link:label>
    <link:label id="lab_ino_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour_documentation_en-US" xlink:label="lab_ino_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, After Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" xlink:href="ino-20210331.xsd#ino_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" xlink:to="lab_ino_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_e0d5f8ec-724d-4b55-bc34-c21841ac3abe_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_abbb79bb-8dc0-4f5b-abbc-34281b7fe57a_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_4ff441cb-6dc7-4a14-92d4-a18bca551d8d_netLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_957f3436-dbd6-45be-8b04-d9f5a509e382_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained earnings (accumulated deficit)</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_b965b87f-e554-4624-9dea-c98a95f38e27_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease right-of-use assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_AlternativeInvestmentMeasurementInputTerm_3f191f61-7f65-41c8-8dee-f00bfd098b50_terseLabel_en-US" xlink:label="lab_ino_AlternativeInvestmentMeasurementInputTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity method investment, measurement input, expected term</link:label>
    <link:label id="lab_ino_AlternativeInvestmentMeasurementInputTerm_label_en-US" xlink:label="lab_ino_AlternativeInvestmentMeasurementInputTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Alternative Investment, Measurement Input, Term</link:label>
    <link:label id="lab_ino_AlternativeInvestmentMeasurementInputTerm_documentation_en-US" xlink:label="lab_ino_AlternativeInvestmentMeasurementInputTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Alternative Investment, Measurement Input, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_AlternativeInvestmentMeasurementInputTerm" xlink:href="ino-20210331.xsd#ino_AlternativeInvestmentMeasurementInputTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_AlternativeInvestmentMeasurementInputTerm" xlink:to="lab_ino_AlternativeInvestmentMeasurementInputTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_CollaborationAgreementTerritoryExpansionOptionPeriod_d2adb8f2-9083-4d1e-8a6b-a9ea2fbafd0e_terseLabel_en-US" xlink:label="lab_ino_CollaborationAgreementTerritoryExpansionOptionPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Territory expansion option period</link:label>
    <link:label id="lab_ino_CollaborationAgreementTerritoryExpansionOptionPeriod_label_en-US" xlink:label="lab_ino_CollaborationAgreementTerritoryExpansionOptionPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement, Territory Expansion Option Period</link:label>
    <link:label id="lab_ino_CollaborationAgreementTerritoryExpansionOptionPeriod_documentation_en-US" xlink:label="lab_ino_CollaborationAgreementTerritoryExpansionOptionPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement, Territory Expansion Option Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborationAgreementTerritoryExpansionOptionPeriod" xlink:href="ino-20210331.xsd#ino_CollaborationAgreementTerritoryExpansionOptionPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_CollaborationAgreementTerritoryExpansionOptionPeriod" xlink:to="lab_ino_CollaborationAgreementTerritoryExpansionOptionPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_8bbff606-8306-4819-9ee9-b35998aefe21_terseLabel_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain on extinguishment of debt</link:label>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_label_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Extinguishment of Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscount_f7b056e9-357a-48eb-beaa-e4fd46cff470_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument, unamortized discount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscount_b8bfd26b-7f3c-462b-a662-be138711fd31_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unamortized debt discount on the liability component</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Unamortized Discount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:to="lab_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_5c91a121-38dd-4ac7-96cb-1024aa7dfa47_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertibleDebtTableTextBlock_8ea6c455-62fd-43d7-982e-e039dce301fa_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Convertible Debt</link:label>
    <link:label id="lab_us-gaap_ConvertibleDebtTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ConvertibleDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Debt [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleDebtTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebtTableTextBlock" xlink:to="lab_us-gaap_ConvertibleDebtTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_DepartmentOfDefenceMember_33d2bbd4-0517-4784-b559-0e3beba18c38_terseLabel_en-US" xlink:label="lab_ino_DepartmentOfDefenceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Department of Defence</link:label>
    <link:label id="lab_ino_DepartmentOfDefenceMember_label_en-US" xlink:label="lab_ino_DepartmentOfDefenceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Department Of Defence [Member]</link:label>
    <link:label id="lab_ino_DepartmentOfDefenceMember_documentation_en-US" xlink:label="lab_ino_DepartmentOfDefenceMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Department Of Defence [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DepartmentOfDefenceMember" xlink:href="ino-20210331.xsd#ino_DepartmentOfDefenceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_DepartmentOfDefenceMember" xlink:to="lab_ino_DepartmentOfDefenceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_8bb0ca76-01c5-4923-8c78-bc09c49c2bdb_verboseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders&#8217; equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_c3e8cbbf-fabe-4c45-ae76-e4a93dac6907_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_December2019ConvertibleBondsMember_525bf3f0-c66f-43c2-b056-08da3cfea605_terseLabel_en-US" xlink:label="lab_ino_December2019ConvertibleBondsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">December 2019 Bonds</link:label>
    <link:label id="lab_ino_December2019ConvertibleBondsMember_label_en-US" xlink:label="lab_ino_December2019ConvertibleBondsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">December 2019 Convertible Bonds [Member]</link:label>
    <link:label id="lab_ino_December2019ConvertibleBondsMember_documentation_en-US" xlink:label="lab_ino_December2019ConvertibleBondsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">December 2019 Convertible Bonds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_December2019ConvertibleBondsMember" xlink:href="ino-20210331.xsd#ino_December2019ConvertibleBondsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_December2019ConvertibleBondsMember" xlink:to="lab_ino_December2019ConvertibleBondsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_7792c603-7061-44fe-a5f6-a14dd997fa61_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_ec363f9a-7b30-4be6-80c3-438d2b33a388_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total unrecognized compensation cost related to unvested stock options</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_f074ff51-e0e8-497b-80fa-813b7c2b9aa5_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements or Change in Accounting Principle [Line Items]</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements or Change in Accounting Principle [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MajorCustomersAxis_f8df796e-1263-458e-aab5-20ab2fa22b40_terseLabel_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:label id="lab_srt_MajorCustomersAxis_label_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MajorCustomersAxis" xlink:to="lab_srt_MajorCustomersAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockValue_faf60f0a-7451-4af2-8c25-ed19df3173ff_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCost_b8d60859-10e7-4ada-a435-4da2581cd8c0_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease cost</link:label>
    <link:label id="lab_us-gaap_LeaseCost_label_en-US" xlink:label="lab_us-gaap_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCost" xlink:to="lab_us-gaap_LeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpenses_b025d14d-dcaf-4382-9d9a-6e86f8966266_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_label_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="lab_us-gaap_OperatingExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_78825f08-fe34-4bfc-92b4-f2ae379f10d7_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss):</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_ec094c47-b7d4-4645-a2bc-fcbff8c1874b_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_MutualFundsMember_dc3ceddc-56e8-4103-870b-b5d4ca9a90fb_verboseLabel_en-US" xlink:label="lab_ino_MutualFundsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mutual funds</link:label>
    <link:label id="lab_ino_MutualFundsMember_9d36de4d-7ecc-40a5-a0b3-fb9172146e0a_terseLabel_en-US" xlink:label="lab_ino_MutualFundsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mutual funds</link:label>
    <link:label id="lab_ino_MutualFundsMember_label_en-US" xlink:label="lab_ino_MutualFundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mutual Funds [Member]</link:label>
    <link:label id="lab_ino_MutualFundsMember_documentation_en-US" xlink:label="lab_ino_MutualFundsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mutual funds.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_MutualFundsMember" xlink:href="ino-20210331.xsd#ino_MutualFundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_MutualFundsMember" xlink:to="lab_ino_MutualFundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_ac189908-e632-4d9b-9e5a-ea246cb65d11_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_INO4800Member_80234c24-5cae-4adc-bdba-1b9874090708_terseLabel_en-US" xlink:label="lab_ino_INO4800Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">INO-4800</link:label>
    <link:label id="lab_ino_INO4800Member_label_en-US" xlink:label="lab_ino_INO4800Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">INO-4800 [Member]</link:label>
    <link:label id="lab_ino_INO4800Member_documentation_en-US" xlink:label="lab_ino_INO4800Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">INO-4800 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_INO4800Member" xlink:href="ino-20210331.xsd#ino_INO4800Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_INO4800Member" xlink:to="lab_ino_INO4800Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_14319725-8058-4da2-b771-d7f9f41d740b_terseLabel_en-US" xlink:label="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_label_en-US" xlink:label="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems" xlink:to="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_f7894f33-9973-4905-9f65-ddcd5fc327ea_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_5ed706b3-a19e-484a-887e-1e616af44e58_terseLabel_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of exchange rate changes on cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable_027a0be8-b55b-42cb-a2d7-f7871a46a31e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Acquired Finite-Lived Intangible Asset by Major Class [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Acquired Finite-Lived Intangible Asset by Major Class [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable" xlink:to="lab_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_06bb7cb2-1d8e-44d3-853d-51467fb47aa8_verboseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total revenues</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_ce8d5b59-2670-4264-8c80-666b2643edda_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from related parties</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_f318ee83-61e0-43e6-8331-8c41ba905841_netLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_4bcd4738-1eac-4a27-a8e9-fb5528beb6be_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_ea733c1b-f4fd-4071-a703-24923d95a113_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average number of common shares outstanding</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharePrice_2c5b2e37-5987-431b-8972-3251d290946c_terseLabel_en-US" xlink:label="lab_us-gaap_SharePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Price per Share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_SharePrice_label_en-US" xlink:label="lab_us-gaap_SharePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharePrice" xlink:to="lab_us-gaap_SharePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_BiojectMember_6efacf8d-ff73-4369-bd44-24840d9490da_terseLabel_en-US" xlink:label="lab_ino_BiojectMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bioject</link:label>
    <link:label id="lab_ino_BiojectMember_label_en-US" xlink:label="lab_ino_BiojectMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bioject [Member]</link:label>
    <link:label id="lab_ino_BiojectMember_documentation_en-US" xlink:label="lab_ino_BiojectMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bioject [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_BiojectMember" xlink:href="ino-20210331.xsd#ino_BiojectMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_BiojectMember" xlink:to="lab_ino_BiojectMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1_77708ecb-d135-45ae-b418-9662e97c7edd_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument, convertible, conversion ratio</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Conversion Ratio</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionRatio1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:to="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_CollaborativeAgreementsUpfrontPaymentReceived_e751ca18-2906-4ef2-b464-7ccb5732fee1_terseLabel_en-US" xlink:label="lab_ino_CollaborativeAgreementsUpfrontPaymentReceived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront payment received</link:label>
    <link:label id="lab_ino_CollaborativeAgreementsUpfrontPaymentReceived_label_en-US" xlink:label="lab_ino_CollaborativeAgreementsUpfrontPaymentReceived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreements, Upfront Payment Received</link:label>
    <link:label id="lab_ino_CollaborativeAgreementsUpfrontPaymentReceived_documentation_en-US" xlink:label="lab_ino_CollaborativeAgreementsUpfrontPaymentReceived" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreements, Upfront Payment Received</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementsUpfrontPaymentReceived" xlink:href="ino-20210331.xsd#ino_CollaborativeAgreementsUpfrontPaymentReceived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_CollaborativeAgreementsUpfrontPaymentReceived" xlink:to="lab_ino_CollaborativeAgreementsUpfrontPaymentReceived" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_489612d7-7d92-4fcb-8106-18251f2ab4f0_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_f91934fd-384f-4b48-9b19-dbf8c23177c0_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockDomain_b2a443b6-0962-4a8e-8033-719e4a1c3cac_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="lab_us-gaap_ClassOfStockDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDilutedAbstract_43d90a27-3665-487d-b60f-8ac6ddaa811f_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss per share attributable to Inovio Pharmaceuticals, Inc. stockholders</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDilutedAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic and Diluted [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:to="lab_us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_ProceedsFromCollaborativeAgreement_4fd8b814-7979-405f-90ae-b32a865cfb7f_terseLabel_en-US" xlink:label="lab_ino_ProceedsFromCollaborativeAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds received in upfront payment</link:label>
    <link:label id="lab_ino_ProceedsFromCollaborativeAgreement_label_en-US" xlink:label="lab_ino_ProceedsFromCollaborativeAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Collaborative Agreement</link:label>
    <link:label id="lab_ino_ProceedsFromCollaborativeAgreement_documentation_en-US" xlink:label="lab_ino_ProceedsFromCollaborativeAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Collaborative Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ProceedsFromCollaborativeAgreement" xlink:href="ino-20210331.xsd#ino_ProceedsFromCollaborativeAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_ProceedsFromCollaborativeAgreement" xlink:to="lab_ino_ProceedsFromCollaborativeAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_6fddad05-8cce-4f07-98ca-a6c1cbc52aec_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_ad94d841-f84d-4413-b5f0-7e74675333b8_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeDomain" xlink:to="lab_us-gaap_MeasurementInputTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_3c65841f-fd9b-474d-92d0-92bc74e6ff53_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_91d278b0-2b32-42f0-bd2d-3c8b1ef88820_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_StockPurchaseAgreementCommitmentOfAdditionalInvestment_83f750be-6369-47c5-8726-274d59cbad1d_terseLabel_en-US" xlink:label="lab_ino_StockPurchaseAgreementCommitmentOfAdditionalInvestment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock purchase agreement, commitment of additional investment</link:label>
    <link:label id="lab_ino_StockPurchaseAgreementCommitmentOfAdditionalInvestment_label_en-US" xlink:label="lab_ino_StockPurchaseAgreementCommitmentOfAdditionalInvestment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Purchase Agreement, Commitment Of Additional Investment</link:label>
    <link:label id="lab_ino_StockPurchaseAgreementCommitmentOfAdditionalInvestment_documentation_en-US" xlink:label="lab_ino_StockPurchaseAgreementCommitmentOfAdditionalInvestment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Purchase Agreement, Commitment Of Additional Investment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_StockPurchaseAgreementCommitmentOfAdditionalInvestment" xlink:href="ino-20210331.xsd#ino_StockPurchaseAgreementCommitmentOfAdditionalInvestment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_StockPurchaseAgreementCommitmentOfAdditionalInvestment" xlink:to="lab_ino_StockPurchaseAgreementCommitmentOfAdditionalInvestment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertibleDebtSecuritiesMember_0f9f5ba2-a2c3-4465-b25f-af58e486f249_verboseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible notes</link:label>
    <link:label id="lab_us-gaap_ConvertibleDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_ConvertibleDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtSecuritiesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebtSecuritiesMember" xlink:to="lab_us-gaap_ConvertibleDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedInterestFairValueDisclosure_99c78dde-b16e-46bf-afe0-88153fcb2fcf_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedInterestFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of investment in Geneos retained</link:label>
    <link:label id="lab_us-gaap_RetainedInterestFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_RetainedInterestFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Interest, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedInterestFairValueDisclosure" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedInterestFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedInterestFairValueDisclosure" xlink:to="lab_us-gaap_RetainedInterestFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_StockSalesAgreementRemainingAuthorizedAmount_c2689853-5398-4018-862b-68db55fc3b59_terseLabel_en-US" xlink:label="lab_ino_StockSalesAgreementRemainingAuthorizedAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remaining authorized amount</link:label>
    <link:label id="lab_ino_StockSalesAgreementRemainingAuthorizedAmount_label_en-US" xlink:label="lab_ino_StockSalesAgreementRemainingAuthorizedAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Sales Agreement, Remaining Authorized Amount</link:label>
    <link:label id="lab_ino_StockSalesAgreementRemainingAuthorizedAmount_documentation_en-US" xlink:label="lab_ino_StockSalesAgreementRemainingAuthorizedAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Sales Agreement, Remaining Authorized Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_StockSalesAgreementRemainingAuthorizedAmount" xlink:href="ino-20210331.xsd#ino_StockSalesAgreementRemainingAuthorizedAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_StockSalesAgreementRemainingAuthorizedAmount" xlink:to="lab_ino_StockSalesAgreementRemainingAuthorizedAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFairValue_05933bfe-69b8-4d59-9441-1c2405933911_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of date conversion</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFairValue_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFairValue" xlink:to="lab_us-gaap_DebtInstrumentFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_ServiceBasedRestrictedStockUnitsMember_de207856-91c9-45b2-a03d-1ea74d60bcdd_verboseLabel_en-US" xlink:label="lab_ino_ServiceBasedRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Service-based restricted stock units</link:label>
    <link:label id="lab_ino_ServiceBasedRestrictedStockUnitsMember_label_en-US" xlink:label="lab_ino_ServiceBasedRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Service-Based Restricted Stock Units [Member]</link:label>
    <link:label id="lab_ino_ServiceBasedRestrictedStockUnitsMember_documentation_en-US" xlink:label="lab_ino_ServiceBasedRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Service-Based Restricted Stock Units</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ServiceBasedRestrictedStockUnitsMember" xlink:href="ino-20210331.xsd#ino_ServiceBasedRestrictedStockUnitsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_ServiceBasedRestrictedStockUnitsMember" xlink:to="lab_ino_ServiceBasedRestrictedStockUnitsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_ac0b4400-baca-465f-9e86-79600e3c2993_verboseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_WorkingCapitalExcludingCash_5a952ba8-d7d0-4cce-b39f-19572c568c79_negatedTerseLabel_en-US" xlink:label="lab_ino_WorkingCapitalExcludingCash" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Working capital (excluding cash)</link:label>
    <link:label id="lab_ino_WorkingCapitalExcludingCash_label_en-US" xlink:label="lab_ino_WorkingCapitalExcludingCash" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Working Capital, Excluding Cash</link:label>
    <link:label id="lab_ino_WorkingCapitalExcludingCash_documentation_en-US" xlink:label="lab_ino_WorkingCapitalExcludingCash" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Working Capital, Excluding Cash</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_WorkingCapitalExcludingCash" xlink:href="ino-20210331.xsd#ino_WorkingCapitalExcludingCash"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_WorkingCapitalExcludingCash" xlink:to="lab_ino_WorkingCapitalExcludingCash" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries_09906bb5-f4bb-4cdd-b1a4-fe557b7202bc_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to acquire additional interest in subsidiaries</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Additional Interest in Subsidiaries</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries" xlink:to="lab_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCountryMember_f0627d2e-8017-474a-b8d8-045d84cd93ca_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCountryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Tax Authority</link:label>
    <link:label id="lab_us-gaap_ForeignCountryMember_label_en-US" xlink:label="lab_us-gaap_ForeignCountryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Tax Authority [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCountryMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCountryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCountryMember" xlink:to="lab_us-gaap_ForeignCountryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_WeightedAverageMember_6c9d5450-8107-4ccb-a01f-9506d9a1a12d_terseLabel_en-US" xlink:label="lab_srt_WeightedAverageMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average</link:label>
    <link:label id="lab_srt_WeightedAverageMember_label_en-US" xlink:label="lab_srt_WeightedAverageMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_WeightedAverageMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_WeightedAverageMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_WeightedAverageMember" xlink:to="lab_srt_WeightedAverageMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDiluted_f32750ab-a2e3-4ccf-8044-d800f2c097c2_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic and diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic and Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="lab_us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_BillAndMelindaGatesFoundationMember_3374c1bc-17f7-4b14-a355-f8ab139612d0_terseLabel_en-US" xlink:label="lab_ino_BillAndMelindaGatesFoundationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bill and Melinda Gates Foundation</link:label>
    <link:label id="lab_ino_BillAndMelindaGatesFoundationMember_label_en-US" xlink:label="lab_ino_BillAndMelindaGatesFoundationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bill And Melinda Gates Foundation [Member]</link:label>
    <link:label id="lab_ino_BillAndMelindaGatesFoundationMember_documentation_en-US" xlink:label="lab_ino_BillAndMelindaGatesFoundationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bill And Melinda Gates Foundation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_BillAndMelindaGatesFoundationMember" xlink:href="ino-20210331.xsd#ino_BillAndMelindaGatesFoundationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_BillAndMelindaGatesFoundationMember" xlink:to="lab_ino_BillAndMelindaGatesFoundationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_92033609-3ec8-4e3d-a702-5a0f6c94286f_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_662f27b5-f65b-42c4-a829-3899388a7e67_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_268de56a-fe33-428c-af07-605bccaac6b7_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Debt</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock" xlink:to="lab_us-gaap_DebtDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_78047c8b-6051-439a-ab0b-0c6acf87d29b_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurements, Fair Value Hierarchy [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_CollaborativeAgreementAdvisoryFees_03596a11-5d56-4fa6-ae71-193efd5f201c_terseLabel_en-US" xlink:label="lab_ino_CollaborativeAgreementAdvisoryFees" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advisory fees</link:label>
    <link:label id="lab_ino_CollaborativeAgreementAdvisoryFees_label_en-US" xlink:label="lab_ino_CollaborativeAgreementAdvisoryFees" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreement, Advisory Fees</link:label>
    <link:label id="lab_ino_CollaborativeAgreementAdvisoryFees_documentation_en-US" xlink:label="lab_ino_CollaborativeAgreementAdvisoryFees" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreement, Advisory Fees</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementAdvisoryFees" xlink:href="ino-20210331.xsd#ino_CollaborativeAgreementAdvisoryFees"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_CollaborativeAgreementAdvisoryFees" xlink:to="lab_ino_CollaborativeAgreementAdvisoryFees" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_StockSalesAgreementMaximumAuthorizedAmount_0e154875-3bf7-41be-b87e-0a6ef8b91a99_terseLabel_en-US" xlink:label="lab_ino_StockSalesAgreementMaximumAuthorizedAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum authorized amount</link:label>
    <link:label id="lab_ino_StockSalesAgreementMaximumAuthorizedAmount_label_en-US" xlink:label="lab_ino_StockSalesAgreementMaximumAuthorizedAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Sales Agreement, Maximum Authorized Amount</link:label>
    <link:label id="lab_ino_StockSalesAgreementMaximumAuthorizedAmount_documentation_en-US" xlink:label="lab_ino_StockSalesAgreementMaximumAuthorizedAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Sales Agreement, Maximum Authorized Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_StockSalesAgreementMaximumAuthorizedAmount" xlink:href="ino-20210331.xsd#ino_StockSalesAgreementMaximumAuthorizedAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_StockSalesAgreementMaximumAuthorizedAmount" xlink:to="lab_ino_StockSalesAgreementMaximumAuthorizedAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementMember_7b7743a9-6bed-4c77-8d36-c33920527a1f_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Product</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementMember_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementMember" xlink:to="lab_us-gaap_CollaborativeArrangementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_73e631fd-3883-456d-9f51-838bed2276b1_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of common stock, net of issuance costs</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_2c4aa6b0-1e00-4be0-bd32-d029ed12b40c_verboseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of stock</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_453a8963-69fd-4b33-99b9-221d7107e74d_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_7e49a9de-78b1-4b5f-88ef-811027fa8e9c_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_1b107ce1-a0ff-429d-ad2e-de344fd96263_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_71232684-335c-445c-8e6b-0f2f78c970f4_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_b7d19ab1-638a-40af-97ee-325c0dd5e0a3_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares available for grant (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_SettlementOfReceivableWithSharesOfCommonStockFromEquitySecurity_43b41843-1d38-4970-ab0a-ca8dcc63567e_negatedLabel_en-US" xlink:label="lab_ino_SettlementOfReceivableWithSharesOfCommonStockFromEquitySecurity" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Settlement of receivable with shares of common stock from affiliated entity (PLS)</link:label>
    <link:label id="lab_ino_SettlementOfReceivableWithSharesOfCommonStockFromEquitySecurity_label_en-US" xlink:label="lab_ino_SettlementOfReceivableWithSharesOfCommonStockFromEquitySecurity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Settlement Of Receivable With Shares Of Common Stock From Equity Security</link:label>
    <link:label id="lab_ino_SettlementOfReceivableWithSharesOfCommonStockFromEquitySecurity_documentation_en-US" xlink:label="lab_ino_SettlementOfReceivableWithSharesOfCommonStockFromEquitySecurity" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Settlement Of Receivable With Shares Of Common Stock From Equity Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_SettlementOfReceivableWithSharesOfCommonStockFromEquitySecurity" xlink:href="ino-20210331.xsd#ino_SettlementOfReceivableWithSharesOfCommonStockFromEquitySecurity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_SettlementOfReceivableWithSharesOfCommonStockFromEquitySecurity" xlink:to="lab_ino_SettlementOfReceivableWithSharesOfCommonStockFromEquitySecurity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsTextBlock_38271d85-c35c-4961-8141-f3705f42909e_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Equity Method Investments</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsTextBlock_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentsTextBlock" xlink:to="lab_us-gaap_EquityMethodInvestmentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_31fb306e-bbc4-41f2-8260-6e60fcaeb431_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesForCommissionsExpenseAndTaxes_1d8e367a-d286-4619-9a88-e60fd512c29a_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesForCommissionsExpenseAndTaxes" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commissions and other estimated offering expenses</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesForCommissionsExpenseAndTaxes_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesForCommissionsExpenseAndTaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities for Commissions, Expense and Taxes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesForCommissionsExpenseAndTaxes" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesForCommissionsExpenseAndTaxes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesForCommissionsExpenseAndTaxes" xlink:to="lab_us-gaap_AccruedLiabilitiesForCommissionsExpenseAndTaxes" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_31263608-9665-4f9d-926b-9451154fd1c6_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyDomain_620baf16-3b26-4d94-b098-78454c5ef76d_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyDomain_label_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyDomain" xlink:to="lab_us-gaap_RelatedPartyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_ae6c8819-7d5e-4cf5-aed6-e51712be85c5_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_646061b4-7e07-4d68-8e0b-bec3595c017e_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems" xlink:to="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d12bcf8a-35e1-4008-9e3b-777fa4bf0952_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Domain]</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_32c58a69-81c9-4cad-9a76-09aef8f033de_verboseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Domain]</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_bf2812ec-7418-4fb6-944a-9001197bfc8a_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_SalesAgreementsMember_6374d632-5819-4f31-a49f-25c8e9d77b7b_terseLabel_en-US" xlink:label="lab_ino_SalesAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales Agreements</link:label>
    <link:label id="lab_ino_SalesAgreementsMember_label_en-US" xlink:label="lab_ino_SalesAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales Agreements [Member]</link:label>
    <link:label id="lab_ino_SalesAgreementsMember_documentation_en-US" xlink:label="lab_ino_SalesAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales Agreements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_SalesAgreementsMember" xlink:href="ino-20210331.xsd#ino_SalesAgreementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_SalesAgreementsMember" xlink:to="lab_ino_SalesAgreementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_GoodwillAndIntangibleAssetsGross_2491aa1d-e282-4ce4-996e-1f3bfac87563_totalLabel_en-US" xlink:label="lab_ino_GoodwillAndIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total goodwill and intangible assets, gross</link:label>
    <link:label id="lab_ino_GoodwillAndIntangibleAssetsGross_label_en-US" xlink:label="lab_ino_GoodwillAndIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Gross</link:label>
    <link:label id="lab_ino_GoodwillAndIntangibleAssetsGross_documentation_en-US" xlink:label="lab_ino_GoodwillAndIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and intangible assets gross.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_GoodwillAndIntangibleAssetsGross" xlink:href="ino-20210331.xsd#ino_GoodwillAndIntangibleAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_GoodwillAndIntangibleAssetsGross" xlink:to="lab_ino_GoodwillAndIntangibleAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_ed6a4dbb-7f1e-43f1-b920-8354aaa9a269_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_4b145f08-b060-4b02-9b2e-4d293d6a2292_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross&#160;Unrealized Gains</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_ca9e0cf7-3e4a-45b6-97e0-4710df320e0b_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_EmployeesAndDirectorsMember_229ee5dd-da8d-49ce-b384-66b77b739609_terseLabel_en-US" xlink:label="lab_ino_EmployeesAndDirectorsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employees and Directors</link:label>
    <link:label id="lab_ino_EmployeesAndDirectorsMember_label_en-US" xlink:label="lab_ino_EmployeesAndDirectorsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employees and Directors [Member]</link:label>
    <link:label id="lab_ino_EmployeesAndDirectorsMember_documentation_en-US" xlink:label="lab_ino_EmployeesAndDirectorsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employees and Directors [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_EmployeesAndDirectorsMember" xlink:href="ino-20210331.xsd#ino_EmployeesAndDirectorsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_EmployeesAndDirectorsMember" xlink:to="lab_ino_EmployeesAndDirectorsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount_423727a2-fa2c-4fb1-9167-9097fb6b8ffc_terseLabel_en-US" xlink:label="lab_us-gaap_DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deconsolidation gain, remeasurement of retained noncontrolling investment to fair value</link:label>
    <link:label id="lab_us-gaap_DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount_label_en-US" xlink:label="lab_us-gaap_DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deconsolidation, Revaluation of Retained Investment, Gain (Loss), Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount" xlink:to="lab_us-gaap_DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_04a4bf4b-e2ac-4a46-b1c3-eac95558e4b7_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs, by Report Line [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_0a0ec7f9-b919-43f1-af01-358af2d1ae62_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_a0dffa74-e9b5-4feb-a839-b46a450a4ead_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Service Share-based Compensation, Allocation of Recognized Period Costs, Report Line [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_2ed71ac7-1c50-4e07-b547-35922e342326_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_42c6fb74-acff-4321-9d84-18b353562adc_verboseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from financing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_49d33b2f-f152-41c9-a69f-16906ae93047_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Summary of Investments</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Available-for-sale Securities Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteAbstract_5db80fae-93e8-4bf4-8ed9-27566cc0be54_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note [Abstract]</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract" xlink:to="lab_us-gaap_StockholdersEquityNoteAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_7b6d9c9f-499c-4dfd-b497-a965fef02022_verboseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of intangible assets</link:label>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_7cb02e2a-61f4-4985-9afd-9b79bf144cf4_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate amortization expense on intangible assets</link:label>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:to="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_f9f46589-81d0-45cc-91cf-c12367c112db_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_ff7af79c-171a-4b76-a7c2-5037ce0cf0de_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_EquityMethodInvestmentEnterpriseValue_0a1126f4-6402-4da0-b706-9e1fc2a5daa9_verboseLabel_en-US" xlink:label="lab_ino_EquityMethodInvestmentEnterpriseValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geneos enterprise value</link:label>
    <link:label id="lab_ino_EquityMethodInvestmentEnterpriseValue_label_en-US" xlink:label="lab_ino_EquityMethodInvestmentEnterpriseValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Enterprise Value</link:label>
    <link:label id="lab_ino_EquityMethodInvestmentEnterpriseValue_documentation_en-US" xlink:label="lab_ino_EquityMethodInvestmentEnterpriseValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Enterprise Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_EquityMethodInvestmentEnterpriseValue" xlink:href="ino-20210331.xsd#ino_EquityMethodInvestmentEnterpriseValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_EquityMethodInvestmentEnterpriseValue" xlink:to="lab_ino_EquityMethodInvestmentEnterpriseValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_4f788542-f18b-4703-a9fa-51e54ab2c218_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_a42c4869-9bf8-4c5d-b98e-e7294e3fb19a_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument, convertible, threshold percentage of stock price trigger</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:to="lab_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_48339925-a17e-4b4c-a62a-b89b616055da_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock for cash, net of financing costs</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtConversionConvertedInstrumentAmount1_41571339-202b-4b66-8256-644ba0aba69d_terseLabel_en-US" xlink:label="lab_us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt conversion, converted instrument principal amount</link:label>
    <link:label id="lab_us-gaap_DebtConversionConvertedInstrumentAmount1_label_en-US" xlink:label="lab_us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Conversion, Converted Instrument, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:to="lab_us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_a999c801-c4ae-4357-ad72-27298b0268c6_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents, fair value</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_ChangeInValueOfInvestmentsInAffiliatedCompany_ec0202df-61ba-451f-9b75-06c1c850f7cb_verboseLabel_en-US" xlink:label="lab_ino_ChangeInValueOfInvestmentsInAffiliatedCompany" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (loss) on investment in affiliated entities</link:label>
    <link:label id="lab_ino_ChangeInValueOfInvestmentsInAffiliatedCompany_237bccb5-6c9c-4ca5-a434-9dde92cf4222_negatedLabel_en-US" xlink:label="lab_ino_ChangeInValueOfInvestmentsInAffiliatedCompany" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">(Gain) loss on equity investment in affiliated entities</link:label>
    <link:label id="lab_ino_ChangeInValueOfInvestmentsInAffiliatedCompany_label_en-US" xlink:label="lab_ino_ChangeInValueOfInvestmentsInAffiliatedCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in Value of Investments in Affiliated Company</link:label>
    <link:label id="lab_ino_ChangeInValueOfInvestmentsInAffiliatedCompany_documentation_en-US" xlink:label="lab_ino_ChangeInValueOfInvestmentsInAffiliatedCompany" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The net result for the period of the change in fair value of the investment in affiliated entity. This investment is measured at fair value on a recurring basis.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ChangeInValueOfInvestmentsInAffiliatedCompany" xlink:href="ino-20210331.xsd#ino_ChangeInValueOfInvestmentsInAffiliatedCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_ChangeInValueOfInvestmentsInAffiliatedCompany" xlink:to="lab_ino_ChangeInValueOfInvestmentsInAffiliatedCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_edc5b8fc-0be4-4713-bad8-61035ac9a50c_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_ecd8492e-a397-4e98-a8cd-88d6e9c83ecf_verboseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpenseDebt_a23efb30-551c-4244-af3c-2162ff1348ad_terseLabel_en-US" xlink:label="lab_us-gaap_InterestExpenseDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense, contractual interest</link:label>
    <link:label id="lab_us-gaap_InterestExpenseDebt_label_en-US" xlink:label="lab_us-gaap_InterestExpenseDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense, Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpenseDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpenseDebt" xlink:to="lab_us-gaap_InterestExpenseDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_7314552d-f543-4244-ba3f-376f308b2cff_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares of unvested restricted stock units and options outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_StockSaleAgreementAggregateNumberofSharesIssued_5ea05554-9429-40f7-bf76-5aa342d305c8_terseLabel_en-US" xlink:label="lab_ino_StockSaleAgreementAggregateNumberofSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate number of shares issued (in shares)</link:label>
    <link:label id="lab_ino_StockSaleAgreementAggregateNumberofSharesIssued_label_en-US" xlink:label="lab_ino_StockSaleAgreementAggregateNumberofSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Sale Agreement, Aggregate Number of Shares Issued</link:label>
    <link:label id="lab_ino_StockSaleAgreementAggregateNumberofSharesIssued_documentation_en-US" xlink:label="lab_ino_StockSaleAgreementAggregateNumberofSharesIssued" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Sale Agreement, Aggregate Number of Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_StockSaleAgreementAggregateNumberofSharesIssued" xlink:href="ino-20210331.xsd#ino_StockSaleAgreementAggregateNumberofSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_StockSaleAgreementAggregateNumberofSharesIssued" xlink:to="lab_ino_StockSaleAgreementAggregateNumberofSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_0618f2ee-d43d-48e2-a7ca-a52b6519f9a1_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_cfc551b5-c0f0-4cac-af70-210c08ce71e4_terseLabel_en-US" xlink:label="lab_us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt conversion, converted instrument, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_label_en-US" xlink:label="lab_us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Conversion, Converted Instrument, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:to="lab_us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_b39d50e5-4af8-45b1-83c5-1b672ee3620f_totalLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets, net book value</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_1b6f187e-1eee-46af-a1cf-103b528eed08_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average grant date fair value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConversionOfStockSharesIssued1_1b9b39fc-fd34-40da-87c7-8e4c6c01e61e_terseLabel_en-US" xlink:label="lab_us-gaap_ConversionOfStockSharesIssued1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion of stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_ConversionOfStockSharesIssued1_label_en-US" xlink:label="lab_us-gaap_ConversionOfStockSharesIssued1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion of Stock, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockSharesIssued1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConversionOfStockSharesIssued1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConversionOfStockSharesIssued1" xlink:to="lab_us-gaap_ConversionOfStockSharesIssued1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_338bec0b-90ad-4223-b762-107b1948370f_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized gain (loss) on short-term investments, net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_b12a701b-70fd-4861-a40a-044ab2e53d5a_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_AdvaccineMember_7c84e18c-f37a-46b6-97eb-d3f5e24e7050_terseLabel_en-US" xlink:label="lab_ino_AdvaccineMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advaccine</link:label>
    <link:label id="lab_ino_AdvaccineMember_label_en-US" xlink:label="lab_ino_AdvaccineMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advaccine [Member]</link:label>
    <link:label id="lab_ino_AdvaccineMember_documentation_en-US" xlink:label="lab_ino_AdvaccineMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advaccine</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_AdvaccineMember" xlink:href="ino-20210331.xsd#ino_AdvaccineMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_AdvaccineMember" xlink:to="lab_ino_AdvaccineMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_CollaborativeAgreementAwardedOptionAmount_d7b33794-9d0a-4338-beb8-ea5da4525836_terseLabel_en-US" xlink:label="lab_ino_CollaborativeAgreementAwardedOptionAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Awarded option amount</link:label>
    <link:label id="lab_ino_CollaborativeAgreementAwardedOptionAmount_label_en-US" xlink:label="lab_ino_CollaborativeAgreementAwardedOptionAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreement, Awarded Option Amount</link:label>
    <link:label id="lab_ino_CollaborativeAgreementAwardedOptionAmount_documentation_en-US" xlink:label="lab_ino_CollaborativeAgreementAwardedOptionAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreement, Awarded Option Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementAwardedOptionAmount" xlink:href="ino-20210331.xsd#ino_CollaborativeAgreementAwardedOptionAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_CollaborativeAgreementAwardedOptionAmount" xlink:to="lab_ino_CollaborativeAgreementAwardedOptionAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_d96a8d59-d135-43f5-b342-4f672d4422ec_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, Debt and Equity Securities [Abstract]</link:label>
    <link:label id="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_label_en-US" xlink:label="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, Debt and Equity Securities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_1da7ca72-e5b3-4617-998a-5ac987f6498f_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation, Liquidity and Risks and Uncertainties</link:label>
    <link:label id="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_label_en-US" xlink:label="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Description and Basis of Presentation [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:to="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VestingDomain_24e27230-da12-45a5-9b31-070187899f3d_terseLabel_en-US" xlink:label="lab_us-gaap_VestingDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting [Domain]</link:label>
    <link:label id="lab_us-gaap_VestingDomain_label_en-US" xlink:label="lab_us-gaap_VestingDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VestingDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VestingDomain" xlink:to="lab_us-gaap_VestingDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpense_34d65bc6-91ee-4609-95a9-c6649f0cc998_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_8f2767d1-98bb-4746-8f73-8377103481bf_terseLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_label_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense" xlink:to="lab_us-gaap_InterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_DeferredGrantFundingFromAffiliate_53eae0e3-fdd1-40ff-ba53-3acc5af52882_terseLabel_en-US" xlink:label="lab_ino_DeferredGrantFundingFromAffiliate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred grant funding, from affiliate</link:label>
    <link:label id="lab_ino_DeferredGrantFundingFromAffiliate_label_en-US" xlink:label="lab_ino_DeferredGrantFundingFromAffiliate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Grant Funding, From Affiliate</link:label>
    <link:label id="lab_ino_DeferredGrantFundingFromAffiliate_documentation_en-US" xlink:label="lab_ino_DeferredGrantFundingFromAffiliate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Grant Funding, From Affiliate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DeferredGrantFundingFromAffiliate" xlink:href="ino-20210331.xsd#ino_DeferredGrantFundingFromAffiliate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_DeferredGrantFundingFromAffiliate" xlink:to="lab_ino_DeferredGrantFundingFromAffiliate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherIntangibleAssetsMember_bbf7b602-3ae1-4b47-9444-601900048932_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherIntangibleAssetsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherIntangibleAssetsMember_label_en-US" xlink:label="lab_us-gaap_OtherIntangibleAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Intangible Assets [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIntangibleAssetsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherIntangibleAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherIntangibleAssetsMember" xlink:to="lab_us-gaap_OtherIntangibleAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_803dfa9b-a0cc-4248-a2ec-31d53cf0ca58_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net unrealized loss on available-for-sale equity securities</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_9afb892b-2613-4d23-b42d-00c2f57b755f_verboseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized gain (loss) on available-for-sale equity securities</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Unrealized Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:to="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_3cddac96-c18b-4879-b720-d34b1d70badd_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_9f91dac9-7a05-4f9a-810a-7abbe4ba7598_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_TheWistarInstituteMember_c021a817-955c-463d-9edb-bb0e643aaeb0_terseLabel_en-US" xlink:label="lab_ino_TheWistarInstituteMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The Wistar Institute</link:label>
    <link:label id="lab_ino_TheWistarInstituteMember_label_en-US" xlink:label="lab_ino_TheWistarInstituteMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The Wistar Institute [Member]</link:label>
    <link:label id="lab_ino_TheWistarInstituteMember_documentation_en-US" xlink:label="lab_ino_TheWistarInstituteMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The Wistar Institute [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_TheWistarInstituteMember" xlink:href="ino-20210331.xsd#ino_TheWistarInstituteMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_TheWistarInstituteMember" xlink:to="lab_ino_TheWistarInstituteMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_bde19dbc-15c3-47aa-aba2-c23a7b18c6db_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Period over which total unrecognized compensation cost related to unvested stock options will be recognized (in years)</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_0de340be-39cf-4b9a-9b04-4a7371930bec_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected volatility</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_79c9d4f7-b838-4a6e-b2fb-894a07467485_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: present value adjustment</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_422906ef-0761-462a-9805-109c31041d7e_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_72f2ce1e-60f3-4e29-b282-2dbf4c0087e3_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTextBlock_80d76f53-d743-4b43-b43a-2644623030d3_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Summary of Common and Preferred Stock Authorized, Issued and Outstanding</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockByClassTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTextBlock" xlink:to="lab_us-gaap_ScheduleOfStockByClassTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_7d9cc967-507a-465c-9994-2443c6b182f7_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue recognized from deferred revenue</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Revenue Recognized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_257f3cbc-f340-4ad3-8647-2e314ea9285a_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Quoted Prices in Active Markets (Level&#160;1)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_cba972c0-d554-494e-8abd-6033397a20d1_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_A6.50ConvertibleSeniorNotesDue2024Member_9429cdce-b83b-4d96-8743-c41d8cffee73_terseLabel_en-US" xlink:label="lab_ino_A6.50ConvertibleSeniorNotesDue2024Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">6.50% Convertible Senior Notes Due 2024</link:label>
    <link:label id="lab_ino_A6.50ConvertibleSeniorNotesDue2024Member_label_en-US" xlink:label="lab_ino_A6.50ConvertibleSeniorNotesDue2024Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">6.50% Convertible Senior Notes Due 2024 [Member]</link:label>
    <link:label id="lab_ino_A6.50ConvertibleSeniorNotesDue2024Member_documentation_en-US" xlink:label="lab_ino_A6.50ConvertibleSeniorNotesDue2024Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">6.50% Convertible Senior Notes Due 2024 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_A6.50ConvertibleSeniorNotesDue2024Member" xlink:href="ino-20210331.xsd#ino_A6.50ConvertibleSeniorNotesDue2024Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_A6.50ConvertibleSeniorNotesDue2024Member" xlink:to="lab_ino_A6.50ConvertibleSeniorNotesDue2024Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockOtherSharesOutstanding_d3855b77-81fa-4252-b1eb-3e76b40fc8a2_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockOtherSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, other shares, outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockOtherSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockOtherSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Other Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockOtherSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockOtherSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockOtherSharesOutstanding" xlink:to="lab_us-gaap_CommonStockOtherSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_8006b870-913d-4b82-a9ed-af9b888dece4_terseLabel_en-US" xlink:label="lab_ino_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_ino_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_label_en-US" xlink:label="lab_ino_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, To Be Paid, After Year Four</link:label>
    <link:label id="lab_ino_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_documentation_en-US" xlink:label="lab_ino_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, To Be Paid, After Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:href="ino-20210331.xsd#ino_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:to="lab_ino_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain_1e52bf0c-9457-4c96-ac3d-e5bf43da30ec_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Realized gain on investments</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Realized Gain</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedGain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_181a6671-c4c4-41da-a4e0-063591ede79d_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_d202e35e-2909-4506-b1c7-0702da00f72b_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputExpectedTermMember_f5f75035-9581-4b6f-8d96-a075d0cb884d_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputExpectedTermMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected term (years)</link:label>
    <link:label id="lab_us-gaap_MeasurementInputExpectedTermMember_label_en-US" xlink:label="lab_us-gaap_MeasurementInputExpectedTermMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Expected Term [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputExpectedTermMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputExpectedTermMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputExpectedTermMember" xlink:to="lab_us-gaap_MeasurementInputExpectedTermMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_62b0d994-c464-429b-8168-99cf7e274b9b_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_ConvertibleBondsMember_416583f6-afaa-4567-b91c-1018e7b30ee2_terseLabel_en-US" xlink:label="lab_ino_ConvertibleBondsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible bonds</link:label>
    <link:label id="lab_ino_ConvertibleBondsMember_label_en-US" xlink:label="lab_ino_ConvertibleBondsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Bonds [Member]</link:label>
    <link:label id="lab_ino_ConvertibleBondsMember_documentation_en-US" xlink:label="lab_ino_ConvertibleBondsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Bonds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ConvertibleBondsMember" xlink:href="ino-20210331.xsd#ino_ConvertibleBondsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_ConvertibleBondsMember" xlink:to="lab_ino_ConvertibleBondsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_14fe4b87-9cf8-493d-94f6-8c68b42bba96_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:to="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_52467e3e-eafd-4105-abf9-116e219bf032_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_e86ad007-b881-4758-8403-fc7a81de8baa_verboseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_label_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockLineItems" xlink:to="lab_us-gaap_ClassOfStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_b465e9d6-554b-4e6a-b0f6-ea7e82c2a42b_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesIssued_3b5ba118-9e34-46c5-aa69-697fbd87857a_periodStartLabel_en-US" xlink:label="lab_us-gaap_SharesIssued" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesIssued_e34e5520-8efc-4d3e-a3a1-ac14ef943169_periodEndLabel_en-US" xlink:label="lab_us-gaap_SharesIssued" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesIssued_label_en-US" xlink:label="lab_us-gaap_SharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesIssued" xlink:to="lab_us-gaap_SharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_CoalitionforEpidemicPreparednessInnovationsMember_6040db1e-2193-48fa-9716-d980553799d4_terseLabel_en-US" xlink:label="lab_ino_CoalitionforEpidemicPreparednessInnovationsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Coalition for Epidemic Preparedness Innovations</link:label>
    <link:label id="lab_ino_CoalitionforEpidemicPreparednessInnovationsMember_label_en-US" xlink:label="lab_ino_CoalitionforEpidemicPreparednessInnovationsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Coalition for Epidemic Preparedness Innovations [Member]</link:label>
    <link:label id="lab_ino_CoalitionforEpidemicPreparednessInnovationsMember_documentation_en-US" xlink:label="lab_ino_CoalitionforEpidemicPreparednessInnovationsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Coalition for Epidemic Preparedness Innovations [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CoalitionforEpidemicPreparednessInnovationsMember" xlink:href="ino-20210331.xsd#ino_CoalitionforEpidemicPreparednessInnovationsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_CoalitionforEpidemicPreparednessInnovationsMember" xlink:to="lab_ino_CoalitionforEpidemicPreparednessInnovationsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_13cc11f4-e7a8-45f6-9008-bd4a214c5001_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_fe23824c-023f-43e9-953c-c4c1610d1a8b_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares, outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestments_59602c96-422a-4fef-b569-2a1fb2b76375_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment in Geneos</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestments_eaeaa292-274e-4fd6-8128-9bd7889d9653_verboseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment in equity method investments</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestments_e3cadfae-086c-4292-9642-f8af9e2256bc_netLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestments" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestments_6247f70b-c6e4-4267-b6a0-ae929db4d245_periodStartLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment in Geneos upon deconsolidation</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestments_e5c59134-e294-4002-80c4-38469461432f_periodEndLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment in Geneos as of March 31, 2021</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestments_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestments" xlink:to="lab_us-gaap_EquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_1c90c52a-6505-4bdb-b65a-4d82c5d8ffb4_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_DeferredGrantFundingFromAffiliateCurrent_a9e72f84-487d-4978-b9ef-9546c77797e3_terseLabel_en-US" xlink:label="lab_ino_DeferredGrantFundingFromAffiliateCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grant funding liability from affiliated entities</link:label>
    <link:label id="lab_ino_DeferredGrantFundingFromAffiliateCurrent_label_en-US" xlink:label="lab_ino_DeferredGrantFundingFromAffiliateCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Grant Funding, From Affiliate, Current</link:label>
    <link:label id="lab_ino_DeferredGrantFundingFromAffiliateCurrent_documentation_en-US" xlink:label="lab_ino_DeferredGrantFundingFromAffiliateCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Grant Funding, From Affiliate, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DeferredGrantFundingFromAffiliateCurrent" xlink:href="ino-20210331.xsd#ino_DeferredGrantFundingFromAffiliateCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_DeferredGrantFundingFromAffiliateCurrent" xlink:to="lab_ino_DeferredGrantFundingFromAffiliateCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_SARSCoV2COVID19VaccineMember_45f0737f-01ef-4db5-8fbd-157cb8b965b2_terseLabel_en-US" xlink:label="lab_ino_SARSCoV2COVID19VaccineMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SARS-CoV-2/COVID-19 Vaccine</link:label>
    <link:label id="lab_ino_SARSCoV2COVID19VaccineMember_label_en-US" xlink:label="lab_ino_SARSCoV2COVID19VaccineMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SARS-CoV-2/COVID-19 Vaccine [Member]</link:label>
    <link:label id="lab_ino_SARSCoV2COVID19VaccineMember_documentation_en-US" xlink:label="lab_ino_SARSCoV2COVID19VaccineMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SARS-CoV-2/COVID-19 Vaccine [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_SARSCoV2COVID19VaccineMember" xlink:href="ino-20210331.xsd#ino_SARSCoV2COVID19VaccineMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_SARSCoV2COVID19VaccineMember" xlink:to="lab_ino_SARSCoV2COVID19VaccineMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_ae83aa9c-dd75-4279-adbf-41789585f3a1_verboseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_DebtInstrumentAccruedInterest_2ca4ded4-8cf1-4bf7-9539-f5a5e684441d_terseLabel_en-US" xlink:label="lab_ino_DebtInstrumentAccruedInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued interest</link:label>
    <link:label id="lab_ino_DebtInstrumentAccruedInterest_label_en-US" xlink:label="lab_ino_DebtInstrumentAccruedInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Accrued Interest</link:label>
    <link:label id="lab_ino_DebtInstrumentAccruedInterest_documentation_en-US" xlink:label="lab_ino_DebtInstrumentAccruedInterest" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Accrued Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DebtInstrumentAccruedInterest" xlink:href="ino-20210331.xsd#ino_DebtInstrumentAccruedInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_DebtInstrumentAccruedInterest" xlink:to="lab_ino_DebtInstrumentAccruedInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_9977b845-a20b-4dd0-895c-17f9c3337d7f_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares, authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_bed126ab-5cff-455c-9f49-f3927a9a473e_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:to="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_1c2cebc2-a949-40e8-8fa5-61da187246ba_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from stock option exercises</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:to="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_CollaborativeAgreementAwardedAmount_808df62d-4235-452d-9869-15f81ab6e9b4_terseLabel_en-US" xlink:label="lab_ino_CollaborativeAgreementAwardedAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Awarded amount</link:label>
    <link:label id="lab_ino_CollaborativeAgreementAwardedAmount_label_en-US" xlink:label="lab_ino_CollaborativeAgreementAwardedAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreement, Awarded Amount</link:label>
    <link:label id="lab_ino_CollaborativeAgreementAwardedAmount_documentation_en-US" xlink:label="lab_ino_CollaborativeAgreementAwardedAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreement, Awarded Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementAwardedAmount" xlink:href="ino-20210331.xsd#ino_CollaborativeAgreementAwardedAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_CollaborativeAgreementAwardedAmount" xlink:to="lab_ino_CollaborativeAgreementAwardedAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_NonEmployeeMember_9b1d9a67-c702-49d4-853b-e0d56eae3388_terseLabel_en-US" xlink:label="lab_ino_NonEmployeeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non Employee</link:label>
    <link:label id="lab_ino_NonEmployeeMember_label_en-US" xlink:label="lab_ino_NonEmployeeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non Employee [Member]</link:label>
    <link:label id="lab_ino_NonEmployeeMember_documentation_en-US" xlink:label="lab_ino_NonEmployeeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non employee.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_NonEmployeeMember" xlink:href="ino-20210331.xsd#ino_NonEmployeeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_NonEmployeeMember" xlink:to="lab_ino_NonEmployeeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiUnrealizedLoss_44c18dba-ca2a-4428-80e8-5d7ac807dfb6_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiUnrealizedLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net unrealized loss on available-for-sale equity securities</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiUnrealizedLoss_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiUnrealizedLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Unrealized Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNiUnrealizedLoss" xlink:to="lab_us-gaap_EquitySecuritiesFvNiUnrealizedLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestIncomeOperating_63521029-a34f-488f-bcba-ef1d4a4c6745_terseLabel_en-US" xlink:label="lab_us-gaap_InterestIncomeOperating" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest income</link:label>
    <link:label id="lab_us-gaap_InterestIncomeOperating_label_en-US" xlink:label="lab_us-gaap_InterestIncomeOperating" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Income, Operating</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeOperating" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestIncomeOperating"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestIncomeOperating" xlink:to="lab_us-gaap_InterestIncomeOperating" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b30a5fb9-19d7-4dff-b474-f6cb789840a7_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_DebtSecuritiesAvailableforSaleContractualMaturity_900ddc6e-116f-44ed-8880-ec8386075c86_terseLabel_en-US" xlink:label="lab_ino_DebtSecuritiesAvailableforSaleContractualMaturity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual maturity (less than)</link:label>
    <link:label id="lab_ino_DebtSecuritiesAvailableforSaleContractualMaturity_label_en-US" xlink:label="lab_ino_DebtSecuritiesAvailableforSaleContractualMaturity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale Contractual Maturity</link:label>
    <link:label id="lab_ino_DebtSecuritiesAvailableforSaleContractualMaturity_documentation_en-US" xlink:label="lab_ino_DebtSecuritiesAvailableforSaleContractualMaturity" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale contractual maturity.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DebtSecuritiesAvailableforSaleContractualMaturity" xlink:href="ino-20210331.xsd#ino_DebtSecuritiesAvailableforSaleContractualMaturity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_DebtSecuritiesAvailableforSaleContractualMaturity" xlink:to="lab_ino_DebtSecuritiesAvailableforSaleContractualMaturity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_80da5f14-3f12-41c2-a9e5-7d3a87375361_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_e8975d0d-51f5-402f-a394-11ceea23c08f_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_eee55ca6-868f-4549-9634-3f87f5dee294_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liability, net of current portion</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_d296c055-0989-428f-8fda-d48ad1ecdb73_netLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_7f576b6f-9ca6-4903-b77f-536aa1e8e50a_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated aggregate amortization expense for 2025</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_4ab474ec-6b66-48c4-afae-cf9f5ff2d84f_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_b85a6b9e-d39b-40da-a85b-40ebdb55f36f_terseLabel_en-US" xlink:label="lab_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Name of Property [Domain]</link:label>
    <link:label id="lab_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_label_en-US" xlink:label="lab_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Name of Property [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:to="lab_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_5b2745e1-8978-4def-a713-c5b996d1fab8_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtConversionNameDomain_2e078e9a-cccf-4912-a758-ce4635e0cd07_terseLabel_en-US" xlink:label="lab_us-gaap_DebtConversionNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Conversion, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtConversionNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtConversionNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Conversion, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtConversionNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtConversionNameDomain" xlink:to="lab_us-gaap_DebtConversionNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_68e35a33-f7e0-41da-b0f0-ca44ab7abfe1_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:to="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InformationByCategoryOfDebtSecurityAxis_e3499eee-b0c5-4e32-bef6-95b0d76c430e_terseLabel_en-US" xlink:label="lab_us-gaap_InformationByCategoryOfDebtSecurityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Security Category [Axis]</link:label>
    <link:label id="lab_us-gaap_InformationByCategoryOfDebtSecurityAxis_label_en-US" xlink:label="lab_us-gaap_InformationByCategoryOfDebtSecurityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Security Category [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InformationByCategoryOfDebtSecurityAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InformationByCategoryOfDebtSecurityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InformationByCategoryOfDebtSecurityAxis" xlink:to="lab_us-gaap_InformationByCategoryOfDebtSecurityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillGross_6c548325-e60a-4044-b0e2-71469f757b52_verboseLabel_en-US" xlink:label="lab_us-gaap_GoodwillGross" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, gross</link:label>
    <link:label id="lab_us-gaap_GoodwillGross_label_en-US" xlink:label="lab_us-gaap_GoodwillGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillGross" xlink:to="lab_us-gaap_GoodwillGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_9311646a-a423-45b5-bc91-fa0428bd070c_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive loss attributable to Inovio Pharmaceuticals, Inc.</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_711dac8a-8015-4c89-aab5-e55c022be512_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividend yield</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_f9fea9d5-5138-4da7-9128-551075635866_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_341c87b7-bc43-412d-8632-9adfe38b6e6d_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LicenseMember_82f9acd0-805e-429e-98b4-61270cc15e29_terseLabel_en-US" xlink:label="lab_us-gaap_LicenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue under collaborative research and development arrangements</link:label>
    <link:label id="lab_us-gaap_LicenseMember_label_en-US" xlink:label="lab_us-gaap_LicenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LicenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LicenseMember" xlink:to="lab_us-gaap_LicenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_0bbf1abe-0319-4849-a91a-c1493046ccdc_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_d087f1e6-0482-4883-9a6e-9d2c0aa8d559_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of capital assets</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_603062ff-2fd9-4d0f-9ff4-bc271923bfab_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet_de9b6122-118d-420a-b288-25725e23d772_terseLabel_en-US" xlink:label="lab_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in fair value of derivative liability</link:label>
    <link:label id="lab_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet_label_en-US" xlink:label="lab_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Embedded Derivative, Gain (Loss) on Embedded Derivative, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet" xlink:to="lab_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_01be4ab1-11bb-4c54-b937-afe5715650e2_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:to="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_a0818888-171d-4d9c-afc3-6cc6acea44eb_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_58801f4c-32a1-4b45-a7bb-45b76b7b9c3a_verboseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_CollaborativeAgreementExpensesToReimburse_64258929-63a1-4e53-ae40-35f344c7f04d_terseLabel_en-US" xlink:label="lab_ino_CollaborativeAgreementExpensesToReimburse" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expenses to reimburse</link:label>
    <link:label id="lab_ino_CollaborativeAgreementExpensesToReimburse_label_en-US" xlink:label="lab_ino_CollaborativeAgreementExpensesToReimburse" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreement, Expenses To Reimburse</link:label>
    <link:label id="lab_ino_CollaborativeAgreementExpensesToReimburse_documentation_en-US" xlink:label="lab_ino_CollaborativeAgreementExpensesToReimburse" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreement, Expenses To Reimburse</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementExpensesToReimburse" xlink:href="ino-20210331.xsd#ino_CollaborativeAgreementExpensesToReimburse"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_CollaborativeAgreementExpensesToReimburse" xlink:to="lab_ino_CollaborativeAgreementExpensesToReimburse" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_DirectorMember_9b0c65c2-db78-4770-bc09-163b580c2d23_terseLabel_en-US" xlink:label="lab_srt_DirectorMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Director</link:label>
    <link:label id="lab_srt_DirectorMember_label_en-US" xlink:label="lab_srt_DirectorMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Director [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_DirectorMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_DirectorMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_DirectorMember" xlink:to="lab_srt_DirectorMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_740e781c-7b39-4b72-b39e-0852eb4d5fe5_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share in net loss of Geneos</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_780ef2da-4d13-4ef2-adbf-202ceb71eb18_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share of net loss in Geneos</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Equity Method Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:to="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProfitLoss_e76e6a86-428b-4a46-bad5-4a80155ad2c6_totalLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_a1dc0786-7fa5-4a6e-8071-fcdb4a3c59dc_terseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_8b2745f1-a14d-4302-90ff-877e35115050_netLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss attributable to common stockholders</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_51e67d21-6bb9-4f80-93df-ce756d2cd5ae_verboseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_label_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss" xlink:to="lab_us-gaap_ProfitLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableRelatedPartiesCurrent_4c0dae55-1b0a-4b81-aec8-7b699de4b60f_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableRelatedPartiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable from affiliated entities</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableRelatedPartiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableRelatedPartiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Related Parties, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableRelatedPartiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableRelatedPartiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableRelatedPartiesCurrent" xlink:to="lab_us-gaap_AccountsReceivableRelatedPartiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_GeneosTherapeuticsInc.Member_152ba40b-9b91-408d-bd68-b8338d35b53e_terseLabel_en-US" xlink:label="lab_ino_GeneosTherapeuticsInc.Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geneos Therapeutics, Inc.</link:label>
    <link:label id="lab_ino_GeneosTherapeuticsInc.Member_label_en-US" xlink:label="lab_ino_GeneosTherapeuticsInc.Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geneos Therapeutics, Inc. [Member]</link:label>
    <link:label id="lab_ino_GeneosTherapeuticsInc.Member_documentation_en-US" xlink:label="lab_ino_GeneosTherapeuticsInc.Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geneos Therapeutics, Inc. [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_GeneosTherapeuticsInc.Member" xlink:href="ino-20210331.xsd#ino_GeneosTherapeuticsInc.Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_GeneosTherapeuticsInc.Member" xlink:to="lab_ino_GeneosTherapeuticsInc.Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_e2d11498-593b-4075-95d8-3bb56fab332d_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss before share in net loss of Geneos</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_09fdaa11-8e40-4699-9844-3f5dc5335429_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable" xlink:to="lab_us-gaap_DisaggregationOfRevenueTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_0df088e1-9e1c-43c1-b1ec-1515334752e3_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain" xlink:to="lab_us-gaap_LongtermDebtTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_315f31d9-a170-4ae3-bf1f-6373495b4374_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNi_50af8f05-e891-4986-8a86-fb4c98f79089_verboseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNi" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment in affiliated entities</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNi_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNi" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNi" xlink:to="lab_us-gaap_EquitySecuritiesFvNi" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_SeriesAOnePreferredStockMember_54c09728-2987-4993-8771-a0211a31aaa5_terseLabel_en-US" xlink:label="lab_ino_SeriesAOnePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series A One Preferred Stock</link:label>
    <link:label id="lab_ino_SeriesAOnePreferredStockMember_label_en-US" xlink:label="lab_ino_SeriesAOnePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series A One Preferred Stock [Member]</link:label>
    <link:label id="lab_ino_SeriesAOnePreferredStockMember_documentation_en-US" xlink:label="lab_ino_SeriesAOnePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series A One Preferred Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_SeriesAOnePreferredStockMember" xlink:href="ino-20210331.xsd#ino_SeriesAOnePreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_SeriesAOnePreferredStockMember" xlink:to="lab_ino_SeriesAOnePreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_CollaborativeAgreementFundingToBeReceived_5172b29d-c935-458c-a893-bf1482d94f2b_terseLabel_en-US" xlink:label="lab_ino_CollaborativeAgreementFundingToBeReceived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative agreement, funding to be received</link:label>
    <link:label id="lab_ino_CollaborativeAgreementFundingToBeReceived_label_en-US" xlink:label="lab_ino_CollaborativeAgreementFundingToBeReceived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreement, Funding To Be Received</link:label>
    <link:label id="lab_ino_CollaborativeAgreementFundingToBeReceived_documentation_en-US" xlink:label="lab_ino_CollaborativeAgreementFundingToBeReceived" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreement, Funding Received for Research and Development</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementFundingToBeReceived" xlink:href="ino-20210331.xsd#ino_CollaborativeAgreementFundingToBeReceived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_CollaborativeAgreementFundingToBeReceived" xlink:to="lab_ino_CollaborativeAgreementFundingToBeReceived" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_eff007fc-8dd9-40b6-8f8f-ff07f734e4c9_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remainder of 2021</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_080ea75c-6e4a-4c79-9b56-c33cbaf228b1_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Taxes paid related to net share settlement of equity awards</link:label>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment, Tax Withholding, Share-based Payment Arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_9a3f9430-86ca-4743-8aa1-cf13746da509_verboseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of intangible assets by major asset class</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_42b7bf1f-c237-4535-90a4-b4ab9e5bc6f8_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_a9c654e0-67b2-4abb-b5be-a6a47198e8d7_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeAxis" xlink:to="lab_us-gaap_MeasurementInputTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_AccruedClinicalTrialExpenseCurrent_6fa60b9a-a49b-49fa-8c37-1801ca4030b5_verboseLabel_en-US" xlink:label="lab_ino_AccruedClinicalTrialExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued clinical trial expenses</link:label>
    <link:label id="lab_ino_AccruedClinicalTrialExpenseCurrent_label_en-US" xlink:label="lab_ino_AccruedClinicalTrialExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Clinical Trial Expense, Current</link:label>
    <link:label id="lab_ino_AccruedClinicalTrialExpenseCurrent_documentation_en-US" xlink:label="lab_ino_AccruedClinicalTrialExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Clinical Trial Expense, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_AccruedClinicalTrialExpenseCurrent" xlink:href="ino-20210331.xsd#ino_AccruedClinicalTrialExpenseCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_AccruedClinicalTrialExpenseCurrent" xlink:to="lab_ino_AccruedClinicalTrialExpenseCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebt_e9348c3c-2c29-427b-9401-288f3725e43f_totalLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net carrying amount</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_label_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebt" xlink:to="lab_us-gaap_LongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_11999454-279c-4861-ac46-508625c4a414_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_1a26178d-4b20-4b41-aaed-59c785bd36fc_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:to="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_6190904a-0d4c-4b59-ada2-1345b77e2f73_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Leases [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_373fef49-cf50-4712-9d84-269bc8695036_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_01f8fa12-229f-4428-b59e-b44458839195_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair&#160;Market&#160;Value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_1c05e100-2840-425a-8e4b-65aa087eaded_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt securities, available for sale</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtConversionByUniqueDescriptionAxis_f42e4f04-4596-4786-a6bc-06b97a68bdac_terseLabel_en-US" xlink:label="lab_us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Conversion Description [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtConversionByUniqueDescriptionAxis_label_en-US" xlink:label="lab_us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Conversion Description [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtConversionByUniqueDescriptionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:to="lab_us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_c4ef58d6-1fce-46e2-82f5-15f4a172a056_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_4c20bffc-ee50-49e8-8427-316e983aad06_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_4dbee157-21b1-48f7-9d5d-ea9f31f170e0_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_42bd1524-6ea3-4af6-a789-0c7327574cd9_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_IncreaseDecreaseinDeferredGrantFundingCurrent_b39c3ec2-fc58-4cde-b35d-319972766d01_terseLabel_en-US" xlink:label="lab_ino_IncreaseDecreaseinDeferredGrantFundingCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grant funding liability</link:label>
    <link:label id="lab_ino_IncreaseDecreaseinDeferredGrantFundingCurrent_label_en-US" xlink:label="lab_ino_IncreaseDecreaseinDeferredGrantFundingCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Deferred Grant Funding, Current</link:label>
    <link:label id="lab_ino_IncreaseDecreaseinDeferredGrantFundingCurrent_documentation_en-US" xlink:label="lab_ino_IncreaseDecreaseinDeferredGrantFundingCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Deferred Grant Funding, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_IncreaseDecreaseinDeferredGrantFundingCurrent" xlink:href="ino-20210331.xsd#ino_IncreaseDecreaseinDeferredGrantFundingCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_IncreaseDecreaseinDeferredGrantFundingCurrent" xlink:to="lab_ino_IncreaseDecreaseinDeferredGrantFundingCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember_78b3825d-fe84-4476-9932-f8a0a6beb5ae_terseLabel_en-US" xlink:label="lab_us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. agency mortgage-backed securities</link:label>
    <link:label id="lab_us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember_label_en-US" xlink:label="lab_us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mortgage-backed Securities, Issued by US Government Sponsored Enterprises [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember" xlink:to="lab_us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_c66d4955-30fa-40db-9262-b1648f6b375e_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liability</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_f5911d67-6e02-4af8-8efe-588c8ce8d314_negatedLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: current portion</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_CollaborationAgreementAnticipatedDevelopmentandRegulatoryEventBasedPaymentReceivableMilestones_7e9448b6-7ba0-4b75-9fdd-1c148d264bdc_terseLabel_en-US" xlink:label="lab_ino_CollaborationAgreementAnticipatedDevelopmentandRegulatoryEventBasedPaymentReceivableMilestones" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Anticipated development and regulatory event based payment receivable milestones</link:label>
    <link:label id="lab_ino_CollaborationAgreementAnticipatedDevelopmentandRegulatoryEventBasedPaymentReceivableMilestones_label_en-US" xlink:label="lab_ino_CollaborationAgreementAnticipatedDevelopmentandRegulatoryEventBasedPaymentReceivableMilestones" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement, Anticipated Development and Regulatory Event Based Payment Receivable Milestones</link:label>
    <link:label id="lab_ino_CollaborationAgreementAnticipatedDevelopmentandRegulatoryEventBasedPaymentReceivableMilestones_documentation_en-US" xlink:label="lab_ino_CollaborationAgreementAnticipatedDevelopmentandRegulatoryEventBasedPaymentReceivableMilestones" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement, Anticipated Development and Regulatory Event Based Payment Receivable Milestones</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborationAgreementAnticipatedDevelopmentandRegulatoryEventBasedPaymentReceivableMilestones" xlink:href="ino-20210331.xsd#ino_CollaborationAgreementAnticipatedDevelopmentandRegulatoryEventBasedPaymentReceivableMilestones"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_CollaborationAgreementAnticipatedDevelopmentandRegulatoryEventBasedPaymentReceivableMilestones" xlink:to="lab_ino_CollaborationAgreementAnticipatedDevelopmentandRegulatoryEventBasedPaymentReceivableMilestones" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_c0c84cf8-6d05-472f-a4b4-87f42aa98149_negatedLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss attributable to non-controlling interest</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_0a2e35a7-b496-4970-a063-cbfc650c3ab8_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Weighted Average Assumptions</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_9cf0d325-3456-4ac1-9fa0-0fad5143da32_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenuesAbstract_abb5bbbb-62b8-4d92-898d-67fe07ea9d43_verboseLabel_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues:</link:label>
    <link:label id="lab_us-gaap_RevenuesAbstract_label_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesAbstract" xlink:to="lab_us-gaap_RevenuesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_1b825203-d2e7-46ca-b2bc-ba14f184af65_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_b4524871-dc5b-4128-807d-1fa66f3c2571_verboseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from operating activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_64b27db5-ec4a-474f-ab31-a35bb1e09625_verboseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_SanDiegoOfficeMember_5eb24b55-b323-43a1-a2a6-8afdec127d57_terseLabel_en-US" xlink:label="lab_ino_SanDiegoOfficeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">San Diego, California</link:label>
    <link:label id="lab_ino_SanDiegoOfficeMember_label_en-US" xlink:label="lab_ino_SanDiegoOfficeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">San Diego Office [Member]</link:label>
    <link:label id="lab_ino_SanDiegoOfficeMember_documentation_en-US" xlink:label="lab_ino_SanDiegoOfficeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">San Diego Office [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_SanDiegoOfficeMember" xlink:href="ino-20210331.xsd#ino_SanDiegoOfficeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_SanDiegoOfficeMember" xlink:to="lab_ino_SanDiegoOfficeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_c602ea11-60a8-4bd2-92b9-7f302d67261e_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated aggregate amortization expense for remainder of 2021</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_93693b78-00c3-4554-9389-6d98a2c6cedf_terseLabel_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_label_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_NameOfMajorCustomerDomain" xlink:to="lab_srt_NameOfMajorCustomerDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_LesseeOperatingLeaseAreaofLandUnderLease_2084ed68-4bba-431b-b2a5-e5ec6a488ae3_terseLabel_en-US" xlink:label="lab_ino_LesseeOperatingLeaseAreaofLandUnderLease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Area leased (in square feet)</link:label>
    <link:label id="lab_ino_LesseeOperatingLeaseAreaofLandUnderLease_label_en-US" xlink:label="lab_ino_LesseeOperatingLeaseAreaofLandUnderLease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Area of Land Under Lease</link:label>
    <link:label id="lab_ino_LesseeOperatingLeaseAreaofLandUnderLease_documentation_en-US" xlink:label="lab_ino_LesseeOperatingLeaseAreaofLandUnderLease" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Area of Land Under Lease</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_LesseeOperatingLeaseAreaofLandUnderLease" xlink:href="ino-20210331.xsd#ino_LesseeOperatingLeaseAreaofLandUnderLease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_LesseeOperatingLeaseAreaofLandUnderLease" xlink:to="lab_ino_LesseeOperatingLeaseAreaofLandUnderLease" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_PriorSalesAgreementMember_d2524ba4-6e5e-4b74-b967-34f0ca036adc_verboseLabel_en-US" xlink:label="lab_ino_PriorSalesAgreementMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prior Sales Agreement</link:label>
    <link:label id="lab_ino_PriorSalesAgreementMember_label_en-US" xlink:label="lab_ino_PriorSalesAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prior Sales Agreement [Member]</link:label>
    <link:label id="lab_ino_PriorSalesAgreementMember_documentation_en-US" xlink:label="lab_ino_PriorSalesAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prior Sales Agreement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_PriorSalesAgreementMember" xlink:href="ino-20210331.xsd#ino_PriorSalesAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_PriorSalesAgreementMember" xlink:to="lab_ino_PriorSalesAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_RelatedPartyTransactionsTextualAbstract_15beaf53-b37d-4603-8335-7e47f797d448_verboseLabel_en-US" xlink:label="lab_ino_RelatedPartyTransactionsTextualAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related-Party Transactions (Textual) [Abstract]</link:label>
    <link:label id="lab_ino_RelatedPartyTransactionsTextualAbstract_label_en-US" xlink:label="lab_ino_RelatedPartyTransactionsTextualAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions (Textual) [Abstract]</link:label>
    <link:label id="lab_ino_RelatedPartyTransactionsTextualAbstract_documentation_en-US" xlink:label="lab_ino_RelatedPartyTransactionsTextualAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related party transactions.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_RelatedPartyTransactionsTextualAbstract" xlink:href="ino-20210331.xsd#ino_RelatedPartyTransactionsTextualAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_RelatedPartyTransactionsTextualAbstract" xlink:to="lab_ino_RelatedPartyTransactionsTextualAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_baa6938d-7bc1-4a3a-b87f-ce8216dfc893_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_ae82f7fe-5222-4cb3-ab14-6b44f71254ad_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_1d9e1497-d333-4406-bb30-67f99a9332a4_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average discount rate</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_502f7ab6-0886-4ac3-ae0e-f5e84bf49212_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets:</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_59dd133e-4b49-4896-8078-b1be399193f3_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Operating Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_AstraZenecaMember_f31ed4b4-2228-44be-a537-2cfc602ec2eb_terseLabel_en-US" xlink:label="lab_ino_AstraZenecaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AstraZeneca</link:label>
    <link:label id="lab_ino_AstraZenecaMember_label_en-US" xlink:label="lab_ino_AstraZenecaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AstraZeneca [Member]</link:label>
    <link:label id="lab_ino_AstraZenecaMember_documentation_en-US" xlink:label="lab_ino_AstraZenecaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AstraZeneca [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_AstraZenecaMember" xlink:href="ino-20210331.xsd#ino_AstraZenecaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_AstraZenecaMember" xlink:to="lab_ino_AstraZenecaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredFinanceCostsNet_bf8e2601-2bcb-44bb-9149-7b08c864c698_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unamortized debt issuance cost</link:label>
    <link:label id="lab_us-gaap_DeferredFinanceCostsNet_e4909ed1-725e-46fb-9f57-242c0f6cbddf_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsNet" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unamortized debt issuance cost</link:label>
    <link:label id="lab_us-gaap_DeferredFinanceCostsNet_label_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Issuance Costs, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFinanceCostsNet" xlink:to="lab_us-gaap_DeferredFinanceCostsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodGrantDateFairValue_3dee57a0-ba9f-4e62-bb7a-2d221c0f99b3_terseLabel_en-US" xlink:label="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grant date fair value</link:label>
    <link:label id="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodGrantDateFairValue_label_en-US" xlink:label="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Grant Date Fair Value</link:label>
    <link:label id="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodGrantDateFairValue_documentation_en-US" xlink:label="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodGrantDateFairValue" xlink:href="ino-20210331.xsd#ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodGrantDateFairValue" xlink:to="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInDerivativeLiabilities_fd140e4a-eefa-4dc3-aa84-232a7ecea1b1_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDerivativeLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in fair value of derivative liability</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInDerivativeLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDerivativeLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Derivative Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDerivativeLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInDerivativeLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInDerivativeLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInDerivativeLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage_2224c83d-d677-4239-a16f-bfd23b1a8c4e_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument, effective interest rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Effective Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_ffd3adac-52a1-44d9-87a0-3b34a8545edb_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_OtherCounterpartyMember_05a6de4a-fa87-48a2-8233-495bd2882b82_terseLabel_en-US" xlink:label="lab_ino_OtherCounterpartyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Counterparty</link:label>
    <link:label id="lab_ino_OtherCounterpartyMember_label_en-US" xlink:label="lab_ino_OtherCounterpartyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Counterparty [Member]</link:label>
    <link:label id="lab_ino_OtherCounterpartyMember_documentation_en-US" xlink:label="lab_ino_OtherCounterpartyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Counterparty [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_OtherCounterpartyMember" xlink:href="ino-20210331.xsd#ino_OtherCounterpartyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_OtherCounterpartyMember" xlink:to="lab_ino_OtherCounterpartyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_309bb566-825e-4f71-9718-b6e5a371feab_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion of preferred stock to common stock</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Conversion of Convertible Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_df51065c-c16c-4f5f-82c2-fe60a08c965e_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_August2019ConvertibleBondsMember_36b140bc-170e-4e63-8999-eb99f1e7e50f_terseLabel_en-US" xlink:label="lab_ino_August2019ConvertibleBondsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">August 2019 Bonds</link:label>
    <link:label id="lab_ino_August2019ConvertibleBondsMember_label_en-US" xlink:label="lab_ino_August2019ConvertibleBondsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">August 2019 Convertible Bonds [Member]</link:label>
    <link:label id="lab_ino_August2019ConvertibleBondsMember_documentation_en-US" xlink:label="lab_ino_August2019ConvertibleBondsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">August 2019 Convertible Bonds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_August2019ConvertibleBondsMember" xlink:href="ino-20210331.xsd#ino_August2019ConvertibleBondsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_August2019ConvertibleBondsMember" xlink:to="lab_ino_August2019ConvertibleBondsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_c2453245-8a74-4d7e-b468-e3bad609a18c_verboseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterestOwnershipPercentageByParent_76fa2d1d-7cd6-4bea-a0e9-48ab1b585c2f_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling interest, ownership percentage by parent</link:label>
    <link:label id="lab_us-gaap_MinorityInterestOwnershipPercentageByParent_label_en-US" xlink:label="lab_us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest, Ownership Percentage by Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:to="lab_us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_85068d1e-3852-4dfb-8deb-2b8eb3d4e0b9_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total remaining lease payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_IncreaseDecreaseInAccruedClinicalTrialExpense_fde6d16a-8ff5-42f5-8ed7-331e3efd1eb4_terseLabel_en-US" xlink:label="lab_ino_IncreaseDecreaseInAccruedClinicalTrialExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued clinical trial expenses</link:label>
    <link:label id="lab_ino_IncreaseDecreaseInAccruedClinicalTrialExpense_label_en-US" xlink:label="lab_ino_IncreaseDecreaseInAccruedClinicalTrialExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Accrued Clinical Trial Expense</link:label>
    <link:label id="lab_ino_IncreaseDecreaseInAccruedClinicalTrialExpense_documentation_en-US" xlink:label="lab_ino_IncreaseDecreaseInAccruedClinicalTrialExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Accrued Clinical Trial Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_IncreaseDecreaseInAccruedClinicalTrialExpense" xlink:href="ino-20210331.xsd#ino_IncreaseDecreaseInAccruedClinicalTrialExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_IncreaseDecreaseInAccruedClinicalTrialExpense" xlink:to="lab_ino_IncreaseDecreaseInAccruedClinicalTrialExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncontrollingInterestAbstract_f7c2269d-3736-40a2-a54a-5ff0e3c0c8f7_terseLabel_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest [Abstract]</link:label>
    <link:label id="lab_us-gaap_NoncontrollingInterestAbstract_label_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncontrollingInterestAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncontrollingInterestAbstract" xlink:to="lab_us-gaap_NoncontrollingInterestAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_CollaborativeArrangementFixedPriceContractAmountAwarded_8e072659-4d0f-4aff-b2cf-a81ee8912222_terseLabel_en-US" xlink:label="lab_ino_CollaborativeArrangementFixedPriceContractAmountAwarded" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase price, procurement contract</link:label>
    <link:label id="lab_ino_CollaborativeArrangementFixedPriceContractAmountAwarded_label_en-US" xlink:label="lab_ino_CollaborativeArrangementFixedPriceContractAmountAwarded" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Fixed-Price Contract, Amount Awarded</link:label>
    <link:label id="lab_ino_CollaborativeArrangementFixedPriceContractAmountAwarded_documentation_en-US" xlink:label="lab_ino_CollaborativeArrangementFixedPriceContractAmountAwarded" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Fixed-Price Contract, Amount Awarded</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeArrangementFixedPriceContractAmountAwarded" xlink:href="ino-20210331.xsd#ino_CollaborativeArrangementFixedPriceContractAmountAwarded"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_CollaborativeArrangementFixedPriceContractAmountAwarded" xlink:to="lab_ino_CollaborativeArrangementFixedPriceContractAmountAwarded" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain_f8f16f57-b93c-4501-a039-9853a36efaca_terseLabel_en-US" xlink:label="lab_us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other than Temporary Impairment, Credit Losses Recognized in Earnings, Categories of Investments [Domain]</link:label>
    <link:label id="lab_us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain_label_en-US" xlink:label="lab_us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other than Temporary Impairment, Credit Losses Recognized in Earnings, Categories of Investments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain" xlink:to="lab_us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_f3845c0c-c739-4e8a-a960-a77497f52e6c_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdTradingDays" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument, convertible, threshold trading days</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdTradingDays" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Threshold Trading Days</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdTradingDays"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays" xlink:to="lab_us-gaap_DebtInstrumentConvertibleThresholdTradingDays" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_aac3cfe6-e2a6-4808-9613-e47a5754587b_negatedLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross&#160;Unrealized Losses</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_b31a4c6e-8621-4aa4-a9a6-c9208a2e3a96_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease, remaining lease term</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:to="lab_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_055a079c-69bb-49fc-9b0f-1c9e6d17e625_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Translation</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Transactions and Translations Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_82de069b-bd8d-4d85-bb19-927ca07e9a94_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_021e2d25-3315-4234-932d-c04ad822e000_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_CollaborativeAgreementPeriodFromEffectiveDateForTermination_1387ab3f-f2f2-41e4-9de1-3cad72342e98_terseLabel_en-US" xlink:label="lab_ino_CollaborativeAgreementPeriodFromEffectiveDateForTermination" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Period from effective date for termination</link:label>
    <link:label id="lab_ino_CollaborativeAgreementPeriodFromEffectiveDateForTermination_label_en-US" xlink:label="lab_ino_CollaborativeAgreementPeriodFromEffectiveDateForTermination" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreement, Period From Effective Date For Termination</link:label>
    <link:label id="lab_ino_CollaborativeAgreementPeriodFromEffectiveDateForTermination_documentation_en-US" xlink:label="lab_ino_CollaborativeAgreementPeriodFromEffectiveDateForTermination" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreement, Period From Effective Date For Termination</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementPeriodFromEffectiveDateForTermination" xlink:href="ino-20210331.xsd#ino_CollaborativeAgreementPeriodFromEffectiveDateForTermination"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_CollaborativeAgreementPeriodFromEffectiveDateForTermination" xlink:to="lab_ino_CollaborativeAgreementPeriodFromEffectiveDateForTermination" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_30920e04-81a6-45ce-8af7-65ed126e612a_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic and diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic and Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Goodwill_195edf0e-923f-46d4-abb1-fdacdd4430be_verboseLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_ca6c772a-d09b-416d-9cbc-528d4e8a7b4d_totalLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, net book value</link:label>
    <link:label id="lab_us-gaap_Goodwill_label_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill" xlink:to="lab_us-gaap_Goodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_0f8604eb-41cb-40b1-9e6f-ac736d62fc20_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_a7eb8cd7-a0a7-4d16-941a-e35eca7dfd32_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value Measurement Inputs and Valuation Techniques</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_ec4d3ad8-514f-4098-bc5b-26b866f67161_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_TitleOfIndividualAxis_63734ef2-4230-40f2-9a93-c2653b2ae960_terseLabel_en-US" xlink:label="lab_srt_TitleOfIndividualAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:label id="lab_srt_TitleOfIndividualAxis_label_en-US" xlink:label="lab_srt_TitleOfIndividualAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualAxis" xlink:to="lab_srt_TitleOfIndividualAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_a085bb6c-4eec-4481-a44e-d8a54f27f623_terseLabel_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_label_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_ContractWithCustomerLiabilityAffiliatedEntityCurrent_05c0377f-b333-46d0-836c-deb572115015_verboseLabel_en-US" xlink:label="lab_ino_ContractWithCustomerLiabilityAffiliatedEntityCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue from affiliated entities</link:label>
    <link:label id="lab_ino_ContractWithCustomerLiabilityAffiliatedEntityCurrent_label_en-US" xlink:label="lab_ino_ContractWithCustomerLiabilityAffiliatedEntityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer, Liability, Affiliated Entity, Current</link:label>
    <link:label id="lab_ino_ContractWithCustomerLiabilityAffiliatedEntityCurrent_documentation_en-US" xlink:label="lab_ino_ContractWithCustomerLiabilityAffiliatedEntityCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The carrying amount of consideration received or receivable from related parties as of the balance sheet date on potential earnings that were not recognized as revenue in conformity with GAAP, and which are expected to be recognized as such within one year or the normal operating cycle, if longer, including sales, license fees, and royalties, but excluding interest income.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ContractWithCustomerLiabilityAffiliatedEntityCurrent" xlink:href="ino-20210331.xsd#ino_ContractWithCustomerLiabilityAffiliatedEntityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_ContractWithCustomerLiabilityAffiliatedEntityCurrent" xlink:to="lab_ino_ContractWithCustomerLiabilityAffiliatedEntityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_StockSaleAgreementAggregateProceedsFromIssuanceOfStock_47757b5a-1dba-4288-a8de-e815d6d7ee27_terseLabel_en-US" xlink:label="lab_ino_StockSaleAgreementAggregateProceedsFromIssuanceOfStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate proceeds</link:label>
    <link:label id="lab_ino_StockSaleAgreementAggregateProceedsFromIssuanceOfStock_label_en-US" xlink:label="lab_ino_StockSaleAgreementAggregateProceedsFromIssuanceOfStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Sale Agreement, Aggregate Proceeds From Issuance Of Stock</link:label>
    <link:label id="lab_ino_StockSaleAgreementAggregateProceedsFromIssuanceOfStock_documentation_en-US" xlink:label="lab_ino_StockSaleAgreementAggregateProceedsFromIssuanceOfStock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Sale Agreement, Aggregate Proceeds From Issuance Of Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_StockSaleAgreementAggregateProceedsFromIssuanceOfStock" xlink:href="ino-20210331.xsd#ino_StockSaleAgreementAggregateProceedsFromIssuanceOfStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_StockSaleAgreementAggregateProceedsFromIssuanceOfStock" xlink:to="lab_ino_StockSaleAgreementAggregateProceedsFromIssuanceOfStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_66cfedcd-63b7-429b-8ade-db98d5b6a8f9_verboseLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income (expense):</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_02597689-f790-4714-add1-1620976e2746_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Original principal amount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Face Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFaceAmount" xlink:to="lab_us-gaap_DebtInstrumentFaceAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_bd8eba97-d078-4bb5-aa57-2b545adcd7ce_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Other Unobservable Inputs (Level&#160;2)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_CELLECTRA3PSPProprietarySmartDeviceMember_c7b06f68-df47-4db4-8250-8a6a68061e46_terseLabel_en-US" xlink:label="lab_ino_CELLECTRA3PSPProprietarySmartDeviceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CELLECTRA 3PSP Proprietary Smart Device</link:label>
    <link:label id="lab_ino_CELLECTRA3PSPProprietarySmartDeviceMember_label_en-US" xlink:label="lab_ino_CELLECTRA3PSPProprietarySmartDeviceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CELLECTRA 3PSP Proprietary Smart Device [Member]</link:label>
    <link:label id="lab_ino_CELLECTRA3PSPProprietarySmartDeviceMember_documentation_en-US" xlink:label="lab_ino_CELLECTRA3PSPProprietarySmartDeviceMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CELLECTRA 3PSP Proprietary Smart Device [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CELLECTRA3PSPProprietarySmartDeviceMember" xlink:href="ino-20210331.xsd#ino_CELLECTRA3PSPProprietarySmartDeviceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_CELLECTRA3PSPProprietarySmartDeviceMember" xlink:to="lab_ino_CELLECTRA3PSPProprietarySmartDeviceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_200785dd-0c6d-4a9c-b7c7-531eae99ef3f_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VestingAxis_436b0328-712a-424b-8017-e25bc6e8732f_terseLabel_en-US" xlink:label="lab_us-gaap_VestingAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting [Axis]</link:label>
    <link:label id="lab_us-gaap_VestingAxis_label_en-US" xlink:label="lab_us-gaap_VestingAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VestingAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VestingAxis" xlink:to="lab_us-gaap_VestingAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionDueFromToRelatedPartyAbstract_5cd9ceee-5032-4714-9b9c-7eb88ba50ee8_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionDueFromToRelatedPartyAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction, Due from (to) Related Party [Abstract]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionDueFromToRelatedPartyAbstract_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionDueFromToRelatedPartyAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction, Due from (to) Related Party [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDueFromToRelatedPartyAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionDueFromToRelatedPartyAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionDueFromToRelatedPartyAbstract" xlink:to="lab_us-gaap_RelatedPartyTransactionDueFromToRelatedPartyAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableRelatedParties_ef805dc8-4005-4da8-9142-14e21f34b8bb_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableRelatedParties" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableRelatedParties_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableRelatedParties" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Related Parties</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableRelatedParties" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableRelatedParties"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableRelatedParties" xlink:to="lab_us-gaap_AccountsReceivableRelatedParties" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_7b9d1c5b-8cd4-4655-a115-448c4106d2b4_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConversionOfStockSharesConverted1_d5b5553b-d81b-4296-8fa3-bdaa4e2b3991_terseLabel_en-US" xlink:label="lab_us-gaap_ConversionOfStockSharesConverted1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion of stock, shares converted (in shares)</link:label>
    <link:label id="lab_us-gaap_ConversionOfStockSharesConverted1_label_en-US" xlink:label="lab_us-gaap_ConversionOfStockSharesConverted1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion of Stock, Shares Converted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockSharesConverted1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConversionOfStockSharesConverted1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConversionOfStockSharesConverted1" xlink:to="lab_us-gaap_ConversionOfStockSharesConverted1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_8d0ce06c-becf-487d-aeb3-2fe529e87c2b_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets measured at fair value</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosure" xlink:to="lab_us-gaap_AssetsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_c840a3c2-db01-4397-9b8e-6272ef72cc3f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_f8e56f43-e156-4159-ac26-1926adbdb220_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Summary of Intangible Assets by Major Asset Class</link:label>
    <link:label id="lab_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Intangible Assets and Goodwill [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_26fc5ef5-b411-4efa-a2e9-9077a7ae9f87_verboseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_da452d75-5331-42ef-add4-a03adc86720b_terseLabel_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Concentration Risk</link:label>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_label_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Concentration Risk [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CustomerConcentrationRiskMember" xlink:to="lab_us-gaap_CustomerConcentrationRiskMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_8139c1b1-0e58-4e7f-b5e9-0082c46f5440_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impact of Recently Issued Accounting Standards</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update and Change in Accounting Principle [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1_bf08d81a-11f1-45f5-983b-7a4727bf7c00_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument, convertible conversion price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Conversion Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:to="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_d2f929ff-2fbb-4bc4-a718-0368ae9396c6_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected life in years</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_7cb16074-f4d9-4807-970f-07436019ea1f_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_b89051c9-970f-4611-bd96-1979a5283550_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract" xlink:to="lab_us-gaap_DebtDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_16f760c2-f74d-4732-aa41-9311360a1917_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average remaining lease term</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_IncreaseDecreaseInDeferredRevenueFromRelatedParties_2f2854c0-dc9e-455e-b8df-ead17c6c0059_verboseLabel_en-US" xlink:label="lab_ino_IncreaseDecreaseInDeferredRevenueFromRelatedParties" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue from affiliated entities</link:label>
    <link:label id="lab_ino_IncreaseDecreaseInDeferredRevenueFromRelatedParties_label_en-US" xlink:label="lab_ino_IncreaseDecreaseInDeferredRevenueFromRelatedParties" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase Decrease in Deferred Revenue From Related Parties</link:label>
    <link:label id="lab_ino_IncreaseDecreaseInDeferredRevenueFromRelatedParties_documentation_en-US" xlink:label="lab_ino_IncreaseDecreaseInDeferredRevenueFromRelatedParties" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The net change during the reporting period, excluding the portion taken into income, in the liability reflecting services yet to be performed by the reporting entity for which cash or other forms of consideration was received or recorded as a receivable from a related party.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_IncreaseDecreaseInDeferredRevenueFromRelatedParties" xlink:href="ino-20210331.xsd#ino_IncreaseDecreaseInDeferredRevenueFromRelatedParties"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_IncreaseDecreaseInDeferredRevenueFromRelatedParties" xlink:to="lab_ino_IncreaseDecreaseInDeferredRevenueFromRelatedParties" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_SharebasedCompensationArrangementbySharebasedPaymentAwardIncreaseInNumberofSharesAuthorized_365d4294-08af-4697-bd78-acb4fc2b29aa_terseLabel_en-US" xlink:label="lab_ino_SharebasedCompensationArrangementbySharebasedPaymentAwardIncreaseInNumberofSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase in number of shares authorized (in shares)</link:label>
    <link:label id="lab_ino_SharebasedCompensationArrangementbySharebasedPaymentAwardIncreaseInNumberofSharesAuthorized_label_en-US" xlink:label="lab_ino_SharebasedCompensationArrangementbySharebasedPaymentAwardIncreaseInNumberofSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Increase In Number of Shares Authorized</link:label>
    <link:label id="lab_ino_SharebasedCompensationArrangementbySharebasedPaymentAwardIncreaseInNumberofSharesAuthorized_documentation_en-US" xlink:label="lab_ino_SharebasedCompensationArrangementbySharebasedPaymentAwardIncreaseInNumberofSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Increase In Number of Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_SharebasedCompensationArrangementbySharebasedPaymentAwardIncreaseInNumberofSharesAuthorized" xlink:href="ino-20210331.xsd#ino_SharebasedCompensationArrangementbySharebasedPaymentAwardIncreaseInNumberofSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_SharebasedCompensationArrangementbySharebasedPaymentAwardIncreaseInNumberofSharesAuthorized" xlink:to="lab_ino_SharebasedCompensationArrangementbySharebasedPaymentAwardIncreaseInNumberofSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_9f51747f-3212-4c81-8a28-931a0c19c1c9_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromMinorityShareholders_b60727b4-5633-447c-a9b2-b66f95e01736_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromMinorityShareholders" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition of non-controlling interest</link:label>
    <link:label id="lab_us-gaap_ProceedsFromMinorityShareholders_label_en-US" xlink:label="lab_us-gaap_ProceedsFromMinorityShareholders" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Noncontrolling Interests</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMinorityShareholders" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromMinorityShareholders"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromMinorityShareholders" xlink:to="lab_us-gaap_ProceedsFromMinorityShareholders" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_a05efb2d-165e-4b66-b7d6-34941f8a0642_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allocated share-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CounterpartyNameAxis_7b953105-b441-47ec-82c3-fb5fcbc71525_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_cd4ea8e2-f40c-4661-93c8-d58c5966be9b_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_2b6e36c0-a2e0-4740-864a-55fa57d8b368_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_fa57ebeb-b2cc-45de-a6c5-5d76fc83d5e1_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_5c182d1c-771b-4927-9cdd-8875c8a4deec_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_a4195418-38b5-4e7d-806a-e7e1a549aac6_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated aggregate amortization expense for 2023</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_cbe27790-e37b-46f0-9dd5-345678ddb187_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_130d49f6-f87a-4c1c-a845-efe7ebbf85a3_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of stock, price per share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_label_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockPricePerShare" xlink:to="lab_us-gaap_SaleOfStockPricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableforsaleSecuritiesMember_df85ea14-a78f-40bb-ae30-a964eae04ba7_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableforsaleSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale Securities</link:label>
    <link:label id="lab_us-gaap_AvailableforsaleSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_AvailableforsaleSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableforsaleSecuritiesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableforsaleSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableforsaleSecuritiesMember" xlink:to="lab_us-gaap_AvailableforsaleSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputPriceVolatilityMember_31e18b7a-bf4c-4662-8e1d-7b16289a9444_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputPriceVolatilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Volatility</link:label>
    <link:label id="lab_us-gaap_MeasurementInputPriceVolatilityMember_label_en-US" xlink:label="lab_us-gaap_MeasurementInputPriceVolatilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Price Volatility [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputPriceVolatilityMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputPriceVolatilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputPriceVolatilityMember" xlink:to="lab_us-gaap_MeasurementInputPriceVolatilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet_80979bba-f7ee-48cd-b790-e2e4a5c414e3_terseLabel_en-US" xlink:label="lab_ino_IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease right-of-use assets and liabilities, net</link:label>
    <link:label id="lab_ino_IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet_label_en-US" xlink:label="lab_ino_IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Operating Lease, Right-Of-Use Asset (Lease Liability), Net</link:label>
    <link:label id="lab_ino_IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet_documentation_en-US" xlink:label="lab_ino_IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Operating Lease, Right-Of-Use Asset (Lease Liability), Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet" xlink:href="ino-20210331.xsd#ino_IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet" xlink:to="lab_ino_IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_8617984f-9124-43a1-a96b-bcb3dad27513_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise of stock options for cash and vesting of RSUs, net of tax payments (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_0ebc2c17-2aed-4b6d-a066-c9ab1b0a07ea_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTable_a142a733-a16a-4117-b143-2f1c2fb7be26_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable" xlink:to="lab_us-gaap_DebtInstrumentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterest_1708c87d-6879-4454-95d8-207d45103b55_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying value of noncontrolling interest</link:label>
    <link:label id="lab_us-gaap_MinorityInterest_label_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterest" xlink:to="lab_us-gaap_MinorityInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_bfd038f3-5249-421c-9090-dff53726bff0_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average grant date fair value, restricted stock units (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USTreasuryBillSecuritiesMember_271b568f-41c6-4596-8454-cfbf0d927e0d_terseLabel_en-US" xlink:label="lab_us-gaap_USTreasuryBillSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. treasury securities</link:label>
    <link:label id="lab_us-gaap_USTreasuryBillSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USTreasuryBillSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Treasury Bill Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryBillSecuritiesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USTreasuryBillSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USTreasuryBillSecuritiesMember" xlink:to="lab_us-gaap_USTreasuryBillSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_2dd6006e-13b1-4512-a624-7c2960550b5e_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting percentage</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_d2cb95d6-0f52-4c59-9766-ad93dc4d9ea5_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreements</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_b119c9bb-427d-47e0-bb5e-7ff2095a237f_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares, issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_1e8a00ed-ca64-4253-8ab7-358bc5752ca4_verboseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from investing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_fd767a3e-5e12-43ad-a9d4-99532550b964_verboseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_DNAEncodedMonoclonalAntibodyTechnologyMember_6ca3c14c-52bc-4eea-abcc-a302cbe8048d_terseLabel_en-US" xlink:label="lab_ino_DNAEncodedMonoclonalAntibodyTechnologyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">DNA-Encoded Monoclonal Antibody Technology</link:label>
    <link:label id="lab_ino_DNAEncodedMonoclonalAntibodyTechnologyMember_label_en-US" xlink:label="lab_ino_DNAEncodedMonoclonalAntibodyTechnologyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">DNA-Encoded Monoclonal Antibody Technology [Member]</link:label>
    <link:label id="lab_ino_DNAEncodedMonoclonalAntibodyTechnologyMember_documentation_en-US" xlink:label="lab_ino_DNAEncodedMonoclonalAntibodyTechnologyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">DNA-Encoded Monoclonal Antibody Technology [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DNAEncodedMonoclonalAntibodyTechnologyMember" xlink:href="ino-20210331.xsd#ino_DNAEncodedMonoclonalAntibodyTechnologyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_DNAEncodedMonoclonalAntibodyTechnologyMember" xlink:to="lab_ino_DNAEncodedMonoclonalAntibodyTechnologyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeconsolidationGainOrLossAmount_90eb8a79-9b3a-43c2-a16d-85d0835b67c8_verboseLabel_en-US" xlink:label="lab_us-gaap_DeconsolidationGainOrLossAmount" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain on deconsolidation of investment</link:label>
    <link:label id="lab_us-gaap_DeconsolidationGainOrLossAmount_86cb114d-a222-47d4-9581-00c4ea537251_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeconsolidationGainOrLossAmount" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain on deconsolidation of Geneos</link:label>
    <link:label id="lab_us-gaap_DeconsolidationGainOrLossAmount_label_en-US" xlink:label="lab_us-gaap_DeconsolidationGainOrLossAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deconsolidation, Gain (Loss), Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeconsolidationGainOrLossAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeconsolidationGainOrLossAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeconsolidationGainOrLossAmount" xlink:to="lab_us-gaap_DeconsolidationGainOrLossAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember_4b0e7640-6e48-4319-b9fd-2be99f15c467_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-free interest rate</link:label>
    <link:label id="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember_label_en-US" xlink:label="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Risk Free Interest Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:to="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentOwnedBalanceShares_57779165-fa99-4949-a657-9f3b356efdc5_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentOwnedBalanceShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment owned (in shares)</link:label>
    <link:label id="lab_us-gaap_InvestmentOwnedBalanceShares_bb79dc0c-73c9-4ae0-b0b8-22858cae4c43_verboseLabel_en-US" xlink:label="lab_us-gaap_InvestmentOwnedBalanceShares" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares (in shares)</link:label>
    <link:label id="lab_us-gaap_InvestmentOwnedBalanceShares_label_en-US" xlink:label="lab_us-gaap_InvestmentOwnedBalanceShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Owned, Balance, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentOwnedBalanceShares" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentOwnedBalanceShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentOwnedBalanceShares" xlink:to="lab_us-gaap_InvestmentOwnedBalanceShares" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_NewSalesAgreementMember_66bb25b8-a0f4-47b4-9b9a-ccdf8cefece2_terseLabel_en-US" xlink:label="lab_ino_NewSalesAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Sales Agreement</link:label>
    <link:label id="lab_ino_NewSalesAgreementMember_label_en-US" xlink:label="lab_ino_NewSalesAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Sales Agreement [Member]</link:label>
    <link:label id="lab_ino_NewSalesAgreementMember_documentation_en-US" xlink:label="lab_ino_NewSalesAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Sales Agreement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_NewSalesAgreementMember" xlink:href="ino-20210331.xsd#ino_NewSalesAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_NewSalesAgreementMember" xlink:to="lab_ino_NewSalesAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_20a180ae-1d80-4ad8-8df2-7c07d3a78abc_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNet_6ddce61e-7327-4651-bbd2-4f2ebf41297b_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNet_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNet" xlink:to="lab_us-gaap_AccountsReceivableNet" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_GrantPolicyPolicyTextBlock_fb3243e3-206e-4b19-939d-fc50a82061cb_terseLabel_en-US" xlink:label="lab_ino_GrantPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grants</link:label>
    <link:label id="lab_ino_GrantPolicyPolicyTextBlock_label_en-US" xlink:label="lab_ino_GrantPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grant Policy [Policy Text Block]</link:label>
    <link:label id="lab_ino_GrantPolicyPolicyTextBlock_documentation_en-US" xlink:label="lab_ino_GrantPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grant Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_GrantPolicyPolicyTextBlock" xlink:href="ino-20210331.xsd#ino_GrantPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_GrantPolicyPolicyTextBlock" xlink:to="lab_ino_GrantPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_OperatingLeaseNonCashLeaseExpense_451dbd69-f6d3-4e2a-8b42-9e45451009d8_terseLabel_en-US" xlink:label="lab_ino_OperatingLeaseNonCashLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash lease expense</link:label>
    <link:label id="lab_ino_OperatingLeaseNonCashLeaseExpense_label_en-US" xlink:label="lab_ino_OperatingLeaseNonCashLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Non-Cash Lease Expense</link:label>
    <link:label id="lab_ino_OperatingLeaseNonCashLeaseExpense_documentation_en-US" xlink:label="lab_ino_OperatingLeaseNonCashLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Non-Cash Lease Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_OperatingLeaseNonCashLeaseExpense" xlink:href="ino-20210331.xsd#ino_OperatingLeaseNonCashLeaseExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_OperatingLeaseNonCashLeaseExpense" xlink:to="lab_ino_OperatingLeaseNonCashLeaseExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_c6b65fbe-5e6b-4430-92e7-904bced64e1c_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_53fc3253-7c5e-4256-80b4-50d3b2a87d08_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems" xlink:to="lab_us-gaap_DebtInstrumentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_c43488bc-3237-4d28-bc26-c43e0c7c696a_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_8c99b590-7fb8-4dc3-a38f-339bb92c9bb9_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Inovio Pharmaceuticals, Inc. stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NatureOfOperations_93c66550-ba9f-4baa-82f4-02631c2a1068_terseLabel_en-US" xlink:label="lab_us-gaap_NatureOfOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization and Operations</link:label>
    <link:label id="lab_us-gaap_NatureOfOperations_label_en-US" xlink:label="lab_us-gaap_NatureOfOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nature of Operations [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NatureOfOperations" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NatureOfOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NatureOfOperations" xlink:to="lab_us-gaap_NatureOfOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfStockIssuanceCosts_c0fe91fc-3941-41a4-aeb1-feef5573ec66_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock issuance costs</link:label>
    <link:label id="lab_us-gaap_PaymentsOfStockIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of Stock Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_b4e41e7f-60b2-469c-9d3f-7bd49bab8d76_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:to="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AlternativeInvestmentMeasurementInput_6b70ec71-4aed-46d7-8a86-790c26e1542c_terseLabel_en-US" xlink:label="lab_us-gaap_AlternativeInvestmentMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity method investment, measurement input</link:label>
    <link:label id="lab_us-gaap_AlternativeInvestmentMeasurementInput_label_en-US" xlink:label="lab_us-gaap_AlternativeInvestmentMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Alternative Investment, Measurement Input</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AlternativeInvestmentMeasurementInput" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AlternativeInvestmentMeasurementInput"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AlternativeInvestmentMeasurementInput" xlink:to="lab_us-gaap_AlternativeInvestmentMeasurementInput" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_2d4a8a7e-ce82-470a-af0d-c6b13a0d52ca_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_08446bc8-ad7a-44fc-a5f3-3ae01fd3dd65_verboseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_39af5a0d-4664-4af5-80fe-a79952d93d96_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_772b3f99-5257-48bc-83e1-07e2c680f305_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NotesPayable_96e5f6fb-26b4-4c08-b835-2332330d76e5_terseLabel_en-US" xlink:label="lab_us-gaap_NotesPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Note payable</link:label>
    <link:label id="lab_us-gaap_NotesPayable_label_en-US" xlink:label="lab_us-gaap_NotesPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NotesPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotesPayable" xlink:to="lab_us-gaap_NotesPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_CollaborativeAgreementForeignNonIncomeTaxes_eea3650a-1dd4-455d-a5d4-db087a9c5f5f_terseLabel_en-US" xlink:label="lab_ino_CollaborativeAgreementForeignNonIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign non-corporate income taxes reducing upfront payment</link:label>
    <link:label id="lab_ino_CollaborativeAgreementForeignNonIncomeTaxes_label_en-US" xlink:label="lab_ino_CollaborativeAgreementForeignNonIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreement, Foreign Non-Income Taxes</link:label>
    <link:label id="lab_ino_CollaborativeAgreementForeignNonIncomeTaxes_documentation_en-US" xlink:label="lab_ino_CollaborativeAgreementForeignNonIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreement, Non-Income Taxes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementForeignNonIncomeTaxes" xlink:href="ino-20210331.xsd#ino_CollaborativeAgreementForeignNonIncomeTaxes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_CollaborativeAgreementForeignNonIncomeTaxes" xlink:to="lab_ino_CollaborativeAgreementForeignNonIncomeTaxes" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_7fd6c284-d697-424c-9fc1-82792606969d_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_b306b141-5860-493b-bcd5-6cecf1e52d7a_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance-based restricted stock units</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_8108b95d-7d2a-4972-abf1-4e92c5269d93_verboseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable and accrued expenses</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable and Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_7cb98d6d-8aaf-4266-b25e-7b00c430c0af_verboseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_f9e1b545-1dcc-4fe3-b54a-63f58795ca6b_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_4918bbcc-3b13-42b7-8689-17f28b8689f0_verboseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis" xlink:to="lab_us-gaap_FinancialInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SeriesCPreferredStockMember_b3be75e9-2612-437e-8bc3-eb2632918f2c_verboseLabel_en-US" xlink:label="lab_us-gaap_SeriesCPreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series C Preferred Stock</link:label>
    <link:label id="lab_us-gaap_SeriesCPreferredStockMember_label_en-US" xlink:label="lab_us-gaap_SeriesCPreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series C Preferred Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesCPreferredStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesCPreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeriesCPreferredStockMember" xlink:to="lab_us-gaap_SeriesCPreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_9d0106e4-c6b3-4439-854f-4e9c456fa9ee_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive securities excluded (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_fbd1a6f9-c3c0-467e-9cd5-099ff87f100a_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Useful life (in years)</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_f0982733-3354-4a4b-b243-486a5d7705e2_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments_203601f1-da9b-4fbe-b2b2-00fbd886489c_terseLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents, and short-term investments</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, and Short-term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:to="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MovementInMinorityInterestRollForward_6c7b0ffb-aa75-4f68-af20-c6ced58a4683_terseLabel_en-US" xlink:label="lab_us-gaap_MovementInMinorityInterestRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Noncontrolling Interest [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_MovementInMinorityInterestRollForward_label_en-US" xlink:label="lab_us-gaap_MovementInMinorityInterestRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Noncontrolling Interest [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MovementInMinorityInterestRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MovementInMinorityInterestRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MovementInMinorityInterestRollForward" xlink:to="lab_us-gaap_MovementInMinorityInterestRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_49021ef0-e1c1-489c-8823-9c1654e46bcd_verboseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fixed assets, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_450d9ed6-1e1d-4787-9295-efde482ef30c_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fixed assets, net of accumulated depreciation</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_743e5d07-b736-4645-9022-8cc7c404b1f3_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated aggregate amortization expense for 2024</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_755428cc-9431-4ebc-805a-635f69008bfc_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_d908f392-6295-4bd2-8601-e31773a0d11b_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_06541c23-f99e-4eec-a49e-54e80ea94daa_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:to="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_95aab65e-cde3-48d3-8722-cbe5bfdca988_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-Based Compensation</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_3703c446-4496-4aa5-910f-8ebfd731e669_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss attributable to Inovio Pharmaceuticals, Inc.</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_c00c1142-2426-4044-980b-090b2ee496db_negatedLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_CollaborationAgreementAnticipatedCommercialEventBasedPaymentReceivableMilestones_56d94b3e-2135-45d8-8dd4-6bb0caf410e4_terseLabel_en-US" xlink:label="lab_ino_CollaborationAgreementAnticipatedCommercialEventBasedPaymentReceivableMilestones" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Anticipated commercial event based payment receivable milestones</link:label>
    <link:label id="lab_ino_CollaborationAgreementAnticipatedCommercialEventBasedPaymentReceivableMilestones_label_en-US" xlink:label="lab_ino_CollaborationAgreementAnticipatedCommercialEventBasedPaymentReceivableMilestones" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement, Anticipated Commercial Event Based Payment Receivable Milestones</link:label>
    <link:label id="lab_ino_CollaborationAgreementAnticipatedCommercialEventBasedPaymentReceivableMilestones_documentation_en-US" xlink:label="lab_ino_CollaborationAgreementAnticipatedCommercialEventBasedPaymentReceivableMilestones" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement, Anticipated Commercial Event Based Payment Receivable Milestones</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborationAgreementAnticipatedCommercialEventBasedPaymentReceivableMilestones" xlink:href="ino-20210331.xsd#ino_CollaborationAgreementAnticipatedCommercialEventBasedPaymentReceivableMilestones"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_CollaborationAgreementAnticipatedCommercialEventBasedPaymentReceivableMilestones" xlink:to="lab_ino_CollaborationAgreementAnticipatedCommercialEventBasedPaymentReceivableMilestones" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_33d965b1-518c-4bde-a45d-bd399c74c23a_verboseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity_b2a98383-e171-49a9-99a0-bc4b847d0e55_verboseLabel_en-US" xlink:label="lab_ino_PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets from affiliated entities</link:label>
    <link:label id="lab_ino_PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity_label_en-US" xlink:label="lab_ino_PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expenses and Other Current Assets from Affiliated Entity</link:label>
    <link:label id="lab_ino_PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity_documentation_en-US" xlink:label="lab_ino_PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The total amounts paid to related parties in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity" xlink:href="ino-20210331.xsd#ino_PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity" xlink:to="lab_ino_PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_222be4b5-348f-4adf-9f69-0cbd0235980d_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remainder of 2021</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent_fde2fa19-b248-46ef-b82a-2a360995e213_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying value</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Carrying Amount of Equity Component</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent" xlink:to="lab_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_EquityMethodInvesteeNameDomain_0ae6b4dd-684f-4332-a2f1-cc2bb3cc7c0a_terseLabel_en-US" xlink:label="lab_srt_EquityMethodInvesteeNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Domain]</link:label>
    <link:label id="lab_srt_EquityMethodInvesteeNameDomain_label_en-US" xlink:label="lab_srt_EquityMethodInvesteeNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_EquityMethodInvesteeNameDomain" xlink:to="lab_srt_EquityMethodInvesteeNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeasesAbstract_0ee57390-df08-4f4f-ac8d-798a7107f9d3_terseLabel_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:label id="lab_us-gaap_LeasesAbstract_label_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesAbstract" xlink:to="lab_us-gaap_LeasesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_DeferredGrantFundingCurrent_7ffdbe61-cca6-4e43-8f09-3547996c6332_terseLabel_en-US" xlink:label="lab_ino_DeferredGrantFundingCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grant funding liability</link:label>
    <link:label id="lab_ino_DeferredGrantFundingCurrent_label_en-US" xlink:label="lab_ino_DeferredGrantFundingCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Grant Funding, Current</link:label>
    <link:label id="lab_ino_DeferredGrantFundingCurrent_documentation_en-US" xlink:label="lab_ino_DeferredGrantFundingCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Grant Funding, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DeferredGrantFundingCurrent" xlink:href="ino-20210331.xsd#ino_DeferredGrantFundingCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_DeferredGrantFundingCurrent" xlink:to="lab_ino_DeferredGrantFundingCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_CollaborativeAgreementFundingReceived_e17956d4-fca9-468c-a2cf-e350bec47b11_verboseLabel_en-US" xlink:label="lab_ino_CollaborativeAgreementFundingReceived" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Funding received for research and development</link:label>
    <link:label id="lab_ino_CollaborativeAgreementFundingReceived_label_en-US" xlink:label="lab_ino_CollaborativeAgreementFundingReceived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreement, Funding Received</link:label>
    <link:label id="lab_ino_CollaborativeAgreementFundingReceived_documentation_en-US" xlink:label="lab_ino_CollaborativeAgreementFundingReceived" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreement, Funding Received</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementFundingReceived" xlink:href="ino-20210331.xsd#ino_CollaborativeAgreementFundingReceived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_CollaborativeAgreementFundingReceived" xlink:to="lab_ino_CollaborativeAgreementFundingReceived" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_93681ab2-845d-43a8-8c59-5169ed7b1a41_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis" xlink:to="lab_us-gaap_LongtermDebtTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_4600143d-685f-4f47-b6a7-5046dd3719d6_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_f6b1c691-c8ce-4650-bfc2-4d96e831b852_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_8f5b9444-e3d4-40a9-8803-50bb407ed778_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating expenses:</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_91fa83a4-767b-44c1-aac3-9c8b570a77db_negatedLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive loss attributable to non-controlling interest</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_124bf616-5f7f-4544-8606-53928aebba2a_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_DebtInstrumentConvertibleDebtConvertedAmount_7dce70e7-a497-4e91-adcf-82bfe3f63952_negatedTerseLabel_en-US" xlink:label="lab_ino_DebtInstrumentConvertibleDebtConvertedAmount" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principal amount converted into common shares</link:label>
    <link:label id="lab_ino_DebtInstrumentConvertibleDebtConvertedAmount_label_en-US" xlink:label="lab_ino_DebtInstrumentConvertibleDebtConvertedAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible Debt, Converted Amount</link:label>
    <link:label id="lab_ino_DebtInstrumentConvertibleDebtConvertedAmount_documentation_en-US" xlink:label="lab_ino_DebtInstrumentConvertibleDebtConvertedAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible Debt, Converted Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DebtInstrumentConvertibleDebtConvertedAmount" xlink:href="ino-20210331.xsd#ino_DebtInstrumentConvertibleDebtConvertedAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_DebtInstrumentConvertibleDebtConvertedAmount" xlink:to="lab_ino_DebtInstrumentConvertibleDebtConvertedAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_10fe0b7d-7edb-45a6-a634-cd185ee70a71_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance_d5a9e005-1ce5-46b6-a902-a421a1ae0631_terseLabel_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition of non-controlling interest in Geneos</link:label>
    <link:label id="lab_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance_label_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest, Increase from Subsidiary Equity Issuance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance" xlink:to="lab_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_CollaborativeArrangementTerm_d8f2fd8d-890b-4b30-af64-8ead3b0400bc_terseLabel_en-US" xlink:label="lab_ino_CollaborativeArrangementTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term</link:label>
    <link:label id="lab_ino_CollaborativeArrangementTerm_label_en-US" xlink:label="lab_ino_CollaborativeArrangementTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Term</link:label>
    <link:label id="lab_ino_CollaborativeArrangementTerm_documentation_en-US" xlink:label="lab_ino_CollaborativeArrangementTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeArrangementTerm" xlink:href="ino-20210331.xsd#ino_CollaborativeArrangementTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_CollaborativeArrangementTerm" xlink:to="lab_ino_CollaborativeArrangementTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfShortTermInvestments_12f62c64-ee73-43bb-82c1-7878634b77a9_verboseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sale or maturity of investments</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfShortTermInvestments_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale of Short-term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfShortTermInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleOfShortTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfShortTermInvestments" xlink:to="lab_us-gaap_ProceedsFromSaleOfShortTermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_565f414e-4e30-4170-bf49-cd0fe691cdef_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertibleDebt_67479d35-a5df-4e43-a56e-66465926c6ed_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible debt</link:label>
    <link:label id="lab_us-gaap_ConvertibleDebt_label_en-US" xlink:label="lab_us-gaap_ConvertibleDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebt" xlink:to="lab_us-gaap_ConvertibleDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CertificatesOfDepositMember_260319fe-de6e-4469-968e-db8ae2cf1895_terseLabel_en-US" xlink:label="lab_us-gaap_CertificatesOfDepositMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Certificates of deposit</link:label>
    <link:label id="lab_us-gaap_CertificatesOfDepositMember_label_en-US" xlink:label="lab_us-gaap_CertificatesOfDepositMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Certificates of Deposit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CertificatesOfDepositMember" xlink:to="lab_us-gaap_CertificatesOfDepositMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_773d080a-2cb6-4f4e-8e15-5f32ed9f5a95_verboseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue, net of current portion</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_6dd221c6-dbdb-47e4-9dbc-b88c2604aa31_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental disclosures:</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPricePercentage_bbc0f9bd-b4aa-46b0-a9ef-1b14c67c3224_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument, redemption price percentage</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPricePercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption Price, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentRedemptionPricePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_IncomeLossFromEquityMethodInvestmentsRealizedAndAllocatedToInvestment_a40e32f2-39fd-48bf-99d9-10f55f49b3de_negatedLabel_en-US" xlink:label="lab_ino_IncomeLossFromEquityMethodInvestmentsRealizedAndAllocatedToInvestment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss from equity method investment, recorded and allocated to investment</link:label>
    <link:label id="lab_ino_IncomeLossFromEquityMethodInvestmentsRealizedAndAllocatedToInvestment_label_en-US" xlink:label="lab_ino_IncomeLossFromEquityMethodInvestmentsRealizedAndAllocatedToInvestment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) From Equity Method Investments, Realized And Allocated to Investment</link:label>
    <link:label id="lab_ino_IncomeLossFromEquityMethodInvestmentsRealizedAndAllocatedToInvestment_documentation_en-US" xlink:label="lab_ino_IncomeLossFromEquityMethodInvestmentsRealizedAndAllocatedToInvestment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) From Equity Method Investments, Realized And Allocated to Investment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_IncomeLossFromEquityMethodInvestmentsRealizedAndAllocatedToInvestment" xlink:href="ino-20210331.xsd#ino_IncomeLossFromEquityMethodInvestmentsRealizedAndAllocatedToInvestment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_IncomeLossFromEquityMethodInvestmentsRealizedAndAllocatedToInvestment" xlink:to="lab_ino_IncomeLossFromEquityMethodInvestmentsRealizedAndAllocatedToInvestment" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_65a2dab0-21d1-4516-909a-9dbcc7832692_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_cb9fdab6-8b86-499d-90ea-ce83e1105c7f_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_805a1009-b707-441b-9953-eba0c5a4f74a_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_CELLECTRA2000DeviceMember_0ecf0ddc-56c0-4e56-8c9a-e202801a27e2_terseLabel_en-US" xlink:label="lab_ino_CELLECTRA2000DeviceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CELLECTRA 2000 Device</link:label>
    <link:label id="lab_ino_CELLECTRA2000DeviceMember_label_en-US" xlink:label="lab_ino_CELLECTRA2000DeviceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CELLECTRA 2000 Device [Member]</link:label>
    <link:label id="lab_ino_CELLECTRA2000DeviceMember_documentation_en-US" xlink:label="lab_ino_CELLECTRA2000DeviceMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CELLECTRA 2000 Device [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CELLECTRA2000DeviceMember" xlink:href="ino-20210331.xsd#ino_CELLECTRA2000DeviceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_CELLECTRA2000DeviceMember" xlink:to="lab_ino_CELLECTRA2000DeviceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_3810c54b-5840-40de-830b-e3b6127b19a8_terseLabel_en-US" xlink:label="lab_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable/accrued liabilities</link:label>
    <link:label id="lab_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_label_en-US" xlink:label="lab_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due to Related Parties</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DueToRelatedPartiesCurrentAndNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:to="lab_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertibleDebtMember_6c75860f-7db0-43ff-8098-b67f75d05a98_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleDebtMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Debt</link:label>
    <link:label id="lab_us-gaap_ConvertibleDebtMember_label_en-US" xlink:label="lab_us-gaap_ConvertibleDebtMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Debt [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleDebtMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebtMember" xlink:to="lab_us-gaap_ConvertibleDebtMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm_ce4f72ef-592f-4687-9e36-562d2646abbe_terseLabel_en-US" xlink:label="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum contractual term (in years)</link:label>
    <link:label id="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm_label_en-US" xlink:label="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share based Compensation Arrangement By Share based Payment Award Maximum Contractual Term</link:label>
    <link:label id="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm_documentation_en-US" xlink:label="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share based compensation arrangement by share based payment award maximum contractual term.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm" xlink:href="ino-20210331.xsd#ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm" xlink:to="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_9612699f-a2b1-4904-aa29-0baacb2074fa_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock for cash, net of financing costs (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_8445e612-8ba1-4dc2-a612-678ae466b462_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Underwritten public offering, common stock (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementAccountingPolicy_3e6ea023-dd93-4296-9639-cf55e9c0d3af_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementAccountingPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreements</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementAccountingPolicy_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementAccountingPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Accounting Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementAccountingPolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementAccountingPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementAccountingPolicy" xlink:to="lab_us-gaap_CollaborativeArrangementAccountingPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_5c87d805-ad07-4adf-8d42-f7842c4330db_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets, gross</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment_5529675e-ad24-4e9f-8a65-069f7d5b2d72_terseLabel_en-US" xlink:label="lab_ino_CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative agreement, period to receive funding for research and development</link:label>
    <link:label id="lab_ino_CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment_label_en-US" xlink:label="lab_ino_CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreement, Period to Receive Funding for Research and Development</link:label>
    <link:label id="lab_ino_CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment_documentation_en-US" xlink:label="lab_ino_CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreement, Period to Receive Funding for Research and Development</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment" xlink:href="ino-20210331.xsd#ino_CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment" xlink:to="lab_ino_CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_2f412989-db2a-479f-88b4-686223b410a5_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stated interest rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_5d0f9db2-8d0f-4834-86a8-79bcb8360019_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite lived:</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Net [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNetAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_1e0fb6fd-7891-45f0-a881-c9205799ef33_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion of preferred stock to common stock (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Conversion of Convertible Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_b02e0a40-d946-4212-84e0-b1c287d2d114_terseLabel_en-US" xlink:label="lab_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Name of Property [Axis]</link:label>
    <link:label id="lab_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_label_en-US" xlink:label="lab_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Name of Property [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:to="lab_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_PlymouthMeetingPennsylvaniaMember_a4b7b464-6ddb-4864-9c8e-b0dd7d63d1da_terseLabel_en-US" xlink:label="lab_ino_PlymouthMeetingPennsylvaniaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plymouth Meeting, Pennsylvania</link:label>
    <link:label id="lab_ino_PlymouthMeetingPennsylvaniaMember_label_en-US" xlink:label="lab_ino_PlymouthMeetingPennsylvaniaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plymouth Meeting, Pennsylvania [Member]</link:label>
    <link:label id="lab_ino_PlymouthMeetingPennsylvaniaMember_documentation_en-US" xlink:label="lab_ino_PlymouthMeetingPennsylvaniaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plymouth Meeting, Pennsylvania [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_PlymouthMeetingPennsylvaniaMember" xlink:href="ino-20210331.xsd#ino_PlymouthMeetingPennsylvaniaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_PlymouthMeetingPennsylvaniaMember" xlink:to="lab_ino_PlymouthMeetingPennsylvaniaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProductAndServiceOtherMember_25e99099-606e-421f-b9bb-e067880cf0e5_terseLabel_en-US" xlink:label="lab_us-gaap_ProductAndServiceOtherMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other revenue</link:label>
    <link:label id="lab_us-gaap_ProductAndServiceOtherMember_label_en-US" xlink:label="lab_us-gaap_ProductAndServiceOtherMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service, Other [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductAndServiceOtherMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductAndServiceOtherMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductAndServiceOtherMember" xlink:to="lab_us-gaap_ProductAndServiceOtherMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_47a3527c-88ff-4d6e-b064-b3106a1315a3_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_232942e2-c51c-479e-8ff8-4fbed595a644_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Future Minimum Rental Payments for Operating Leases</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_00f09493-9176-47bf-97ab-81bca0a13778_verboseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options to purchase common stock</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_28562c19-9f74-49cd-93d5-195f48991e61_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_73b25982-7661-438a-9460-69f5a6fa6c53_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities_31c7d43f-3b4d-4660-bc04-43696ba78982_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amounts accrued for purchases of property and equipment</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_LicensewithAffiliatedEntitiesMember_c5298a1d-65b0-44fe-98de-43e7e0d0ea93_terseLabel_en-US" xlink:label="lab_ino_LicensewithAffiliatedEntitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue under collaborative research and development arrangements with affiliated entities</link:label>
    <link:label id="lab_ino_LicensewithAffiliatedEntitiesMember_label_en-US" xlink:label="lab_ino_LicensewithAffiliatedEntitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License with Affiliated Entities [Member]</link:label>
    <link:label id="lab_ino_LicensewithAffiliatedEntitiesMember_documentation_en-US" xlink:label="lab_ino_LicensewithAffiliatedEntitiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License with Affiliated Entities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_LicensewithAffiliatedEntitiesMember" xlink:href="ino-20210331.xsd#ino_LicensewithAffiliatedEntitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_LicensewithAffiliatedEntitiesMember" xlink:to="lab_ino_LicensewithAffiliatedEntitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesAbstract_ec43bf20-2501-4ca6-a1bd-1f34ceca94f7_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Abstract]</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesAbstract_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_6f792bc2-05fb-4fa6-b367-f7eacf7e922e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-free interest rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_OwnershipAxis_0f29efee-bb0a-4e57-9d92-69eb28a7d410_terseLabel_en-US" xlink:label="lab_srt_OwnershipAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership [Axis]</link:label>
    <link:label id="lab_srt_OwnershipAxis_label_en-US" xlink:label="lab_srt_OwnershipAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_OwnershipAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_OwnershipAxis" xlink:to="lab_srt_OwnershipAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_2e545a21-602e-4611-ac0c-3eb6ddbd7f76_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency translation</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConsolidationVariableInterestEntityPolicy_5b7adede-d110-4064-a844-7b8528d6b447_terseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationVariableInterestEntityPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Interest Entities (VIE)</link:label>
    <link:label id="lab_us-gaap_ConsolidationVariableInterestEntityPolicy_label_en-US" xlink:label="lab_us-gaap_ConsolidationVariableInterestEntityPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation, Variable Interest Entity, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationVariableInterestEntityPolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConsolidationVariableInterestEntityPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationVariableInterestEntityPolicy" xlink:to="lab_us-gaap_ConsolidationVariableInterestEntityPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_b485d215-aa60-4038-a58f-20ab8df39770_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_OwnershipDomain_8ee56a8e-cd80-48f6-ac1c-a25a249fbeb3_terseLabel_en-US" xlink:label="lab_srt_OwnershipDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership [Domain]</link:label>
    <link:label id="lab_srt_OwnershipDomain_label_en-US" xlink:label="lab_srt_OwnershipDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_OwnershipDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_OwnershipDomain" xlink:to="lab_srt_OwnershipDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_ff33eadb-1db7-4101-b630-e15619641c42_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage_49b145d7-1028-4686-85bc-b5fee522909c_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership percentage</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Ownership Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:to="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_02e881ad-5fba-42f1-af75-df4aac7dbb6e_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestPaidNet_ca88bd57-4eaa-43b5-9c7a-ab0995c3e113_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest paid</link:label>
    <link:label id="lab_us-gaap_InterestPaidNet_label_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaidNet" xlink:to="lab_us-gaap_InterestPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_CollaborationAgreementAdditionalRevenueToBeAchieved_a5b963b5-0c0a-41f3-804a-b63b13c3b1f7_terseLabel_en-US" xlink:label="lab_ino_CollaborationAgreementAdditionalRevenueToBeAchieved" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional revenue to be achieved</link:label>
    <link:label id="lab_ino_CollaborationAgreementAdditionalRevenueToBeAchieved_label_en-US" xlink:label="lab_ino_CollaborationAgreementAdditionalRevenueToBeAchieved" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement, Additional Revenue To Be Achieved</link:label>
    <link:label id="lab_ino_CollaborationAgreementAdditionalRevenueToBeAchieved_documentation_en-US" xlink:label="lab_ino_CollaborationAgreementAdditionalRevenueToBeAchieved" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement, Additional Revenue To Be Achieved</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborationAgreementAdditionalRevenueToBeAchieved" xlink:href="ino-20210331.xsd#ino_CollaborationAgreementAdditionalRevenueToBeAchieved"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_CollaborationAgreementAdditionalRevenueToBeAchieved" xlink:to="lab_ino_CollaborationAgreementAdditionalRevenueToBeAchieved" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_50318857-1c4f-4d2d-a88d-4f4cd2951712_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_d29f713c-056f-4848-ac0d-cf0451cb868a_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_dc77f1ec-a609-4786-9c10-8d75687eede9_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geneos Therapeutics, Inc.</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_CollaborativeAgreementNumberofDaysWrittenNoticeBeforeTermination_9fc1f447-2f50-452d-ad3a-ff9cd32042d0_terseLabel_en-US" xlink:label="lab_ino_CollaborativeAgreementNumberofDaysWrittenNoticeBeforeTermination" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of days written notice before termination</link:label>
    <link:label id="lab_ino_CollaborativeAgreementNumberofDaysWrittenNoticeBeforeTermination_label_en-US" xlink:label="lab_ino_CollaborativeAgreementNumberofDaysWrittenNoticeBeforeTermination" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreement, Number of Days Written Notice Before Termination</link:label>
    <link:label id="lab_ino_CollaborativeAgreementNumberofDaysWrittenNoticeBeforeTermination_documentation_en-US" xlink:label="lab_ino_CollaborativeAgreementNumberofDaysWrittenNoticeBeforeTermination" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreement, Number of Days Written Notice Before Termination</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementNumberofDaysWrittenNoticeBeforeTermination" xlink:href="ino-20210331.xsd#ino_CollaborativeAgreementNumberofDaysWrittenNoticeBeforeTermination"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_CollaborativeAgreementNumberofDaysWrittenNoticeBeforeTermination" xlink:to="lab_ino_CollaborativeAgreementNumberofDaysWrittenNoticeBeforeTermination" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_e879cf16-5dcd-4af6-b485-c15f1ea1b643_verboseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital" xlink:to="lab_us-gaap_AdditionalPaidInCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_2c4ff4cd-7ea6-474b-b7a0-f10a7dc3396a_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated aggregate amortization expense for 2022</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_704b53b7-d5d7-4060-9826-26bf253d96b4_terseLabel_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_label_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis" xlink:to="lab_us-gaap_StatementClassOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_61001ce3-bf0e-410d-bbe7-97893d43be66_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized transaction loss on foreign-currency denominated debt</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Transaction Gain (Loss), before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:to="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_20b5e2ff-a525-4794-97f1-65774b8fe371_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents, beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_786d7758-52c0-4fad-9c8f-9ff3fc2b362e_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents, end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_354da07d-0c64-42b7-9f1f-c0b31a867230_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Maturities of Long-term Debt</link:label>
    <link:label id="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Maturities of Long-term Debt [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_fed673a9-262b-479c-9807-421094a1e262_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Table]</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_748db258-63bf-48fb-abbc-69ccff51caca_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update and Change in Accounting Principle [Table]</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update and Change in Accounting Principle [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:to="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_bae96e55-41f3-40fe-8fa6-ad0b4d4acba8_terseLabel_en-US" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual with Relationship to Entity [Domain]</link:label>
    <link:label id="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_label_en-US" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_c6449e5d-640a-4e0f-b983-b7e8d8ed0333_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties_54a38189-29c2-4f7e-928e-2a4c591b922d_verboseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable and accrued expenses due to affiliated entities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable, Related Parties</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_a2bba660-c353-40db-8c7b-49fdefab307a_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_label_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis" xlink:to="lab_us-gaap_TypeOfArrangementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember_f8053c1c-c262-46ee-bfe8-671f7f20e86a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tranche One</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Tranche One [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:to="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_66c232c4-b529-4bee-82e7-ec08608ec3fa_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable" xlink:to="lab_us-gaap_ScheduleOfStockByClassTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterestLineItems_bb89964f-48f2-4f20-82bf-44ee7f1f6f8c_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterestLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest [Line Items]</link:label>
    <link:label id="lab_us-gaap_MinorityInterestLineItems_label_en-US" xlink:label="lab_us-gaap_MinorityInterestLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterestLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterestLineItems" xlink:to="lab_us-gaap_MinorityInterestLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_A2016IncentivePlanMember_d40c8e98-00ce-4eb2-8679-fd88b10709d1_terseLabel_en-US" xlink:label="lab_ino_A2016IncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2016 Incentive Plan</link:label>
    <link:label id="lab_ino_A2016IncentivePlanMember_label_en-US" xlink:label="lab_ino_A2016IncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2016 Incentive Plan [Member]</link:label>
    <link:label id="lab_ino_A2016IncentivePlanMember_documentation_en-US" xlink:label="lab_ino_A2016IncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2016 Incentive Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_A2016IncentivePlanMember" xlink:href="ino-20210331.xsd#ino_A2016IncentivePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_A2016IncentivePlanMember" xlink:to="lab_ino_A2016IncentivePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_f2f231ee-0f85-48b0-82f5-ca1f3ee215b1_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation of Intangible Assets and Goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_CollaborationAgreementRoyaltyPeriod_96385ccb-7026-4a6a-a881-a0e31a48c80f_terseLabel_en-US" xlink:label="lab_ino_CollaborationAgreementRoyaltyPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty period</link:label>
    <link:label id="lab_ino_CollaborationAgreementRoyaltyPeriod_label_en-US" xlink:label="lab_ino_CollaborationAgreementRoyaltyPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement, Royalty Period</link:label>
    <link:label id="lab_ino_CollaborationAgreementRoyaltyPeriod_documentation_en-US" xlink:label="lab_ino_CollaborationAgreementRoyaltyPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement, Royalty Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborationAgreementRoyaltyPeriod" xlink:href="ino-20210331.xsd#ino_CollaborationAgreementRoyaltyPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_CollaborationAgreementRoyaltyPeriod" xlink:to="lab_ino_CollaborationAgreementRoyaltyPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Depreciation_ff7164a5-4871-4e2b-921b-6052d4294fa3_verboseLabel_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation</link:label>
    <link:label id="lab_us-gaap_Depreciation_label_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Depreciation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation" xlink:to="lab_us-gaap_Depreciation" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_7aa57cd9-50e4-40f3-96a6-553bbd51260b_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_PlumblineLifeSciencesMember_3dcd7aeb-3a1b-41cc-9329-1f6db1afed64_terseLabel_en-US" xlink:label="lab_ino_PlumblineLifeSciencesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plumbline Life Sciences</link:label>
    <link:label id="lab_ino_PlumblineLifeSciencesMember_label_en-US" xlink:label="lab_ino_PlumblineLifeSciencesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plumbline Life Sciences [Member]</link:label>
    <link:label id="lab_ino_PlumblineLifeSciencesMember_documentation_en-US" xlink:label="lab_ino_PlumblineLifeSciencesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plumbline Life Sciences [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_PlumblineLifeSciencesMember" xlink:href="ino-20210331.xsd#ino_PlumblineLifeSciencesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_PlumblineLifeSciencesMember" xlink:to="lab_ino_PlumblineLifeSciencesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_e29e05c8-b165-4c57-b2f1-9012717b8e43_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Operating Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_fcc448f6-de56-42c4-8536-8371a270da0e_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertiblePreferredStockMember_cb4534dc-a012-403f-b4be-b0bdfc6cc2b1_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible preferred stock</link:label>
    <link:label id="lab_us-gaap_ConvertiblePreferredStockMember_label_en-US" xlink:label="lab_us-gaap_ConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Preferred Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertiblePreferredStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertiblePreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertiblePreferredStockMember" xlink:to="lab_us-gaap_ConvertiblePreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_9e1e4328-4ebe-463b-b677-0bf6f16879e1_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument, convertible, threshold consecutive trading days</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Threshold Consecutive Trading Days</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" xlink:to="lab_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_963cb375-328c-43ed-a751-debf5452bd95_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Capital_418b6968-69cd-4108-9f9d-9adef9d233a3_terseLabel_en-US" xlink:label="lab_us-gaap_Capital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Working capital</link:label>
    <link:label id="lab_us-gaap_Capital_label_en-US" xlink:label="lab_us-gaap_Capital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Banking Regulation, Total Capital, Actual</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Capital" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Capital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Capital" xlink:to="lab_us-gaap_Capital" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_StockSaleAgreementWeightedAveragePricePerShare_0540361a-c71f-4f8a-bb91-6892e7e25a25_terseLabel_en-US" xlink:label="lab_ino_StockSaleAgreementWeightedAveragePricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock sale agreement weighted average price per share</link:label>
    <link:label id="lab_ino_StockSaleAgreementWeightedAveragePricePerShare_label_en-US" xlink:label="lab_ino_StockSaleAgreementWeightedAveragePricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Sale Agreement, Weighted Average Price Per Share</link:label>
    <link:label id="lab_ino_StockSaleAgreementWeightedAveragePricePerShare_documentation_en-US" xlink:label="lab_ino_StockSaleAgreementWeightedAveragePricePerShare" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Sale Agreement Weighted Average Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_StockSaleAgreementWeightedAveragePricePerShare" xlink:href="ino-20210331.xsd#ino_StockSaleAgreementWeightedAveragePricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_StockSaleAgreementWeightedAveragePricePerShare" xlink:to="lab_ino_StockSaleAgreementWeightedAveragePricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_ApolloBioMember_f74f4496-99a7-491d-a238-16a2edc615db_terseLabel_en-US" xlink:label="lab_ino_ApolloBioMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ApolloBio</link:label>
    <link:label id="lab_ino_ApolloBioMember_label_en-US" xlink:label="lab_ino_ApolloBioMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ApolloBio [Member]</link:label>
    <link:label id="lab_ino_ApolloBioMember_documentation_en-US" xlink:label="lab_ino_ApolloBioMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ApolloBio [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ApolloBioMember" xlink:href="ino-20210331.xsd#ino_ApolloBioMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_ApolloBioMember" xlink:to="lab_ino_ApolloBioMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_d95d337e-2578-4d32-9f51-f3d93404c13b_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_InitialConversionPriceMember_b46c6ca0-1e14-4a67-ac3e-e8f123372f87_terseLabel_en-US" xlink:label="lab_ino_InitialConversionPriceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Initial Conversion Price</link:label>
    <link:label id="lab_ino_InitialConversionPriceMember_label_en-US" xlink:label="lab_ino_InitialConversionPriceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Initial Conversion Price [Member]</link:label>
    <link:label id="lab_ino_InitialConversionPriceMember_documentation_en-US" xlink:label="lab_ino_InitialConversionPriceMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Initial Conversion Price [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_InitialConversionPriceMember" xlink:href="ino-20210331.xsd#ino_InitialConversionPriceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_InitialConversionPriceMember" xlink:to="lab_ino_InitialConversionPriceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_3d57efe8-6276-41ca-aadc-de913cb13d05_negatedLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets, accumulated amortization</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Accumulated Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_44b07f88-204f-4d61-97ab-e87bb06e4708_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_bd3e886a-05b7-4ab7-8d9e-200886275047_verboseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_288dc4f2-9c59-47ed-85c2-be726f391cbf_terseLabel_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non- controlling interest</link:label>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_label_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncontrollingInterestMember" xlink:to="lab_us-gaap_NoncontrollingInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnInvestments_b0b700fc-3832-419f-a4d5-64eadc40ffb0_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss on short-term investments</link:label>
    <link:label id="lab_us-gaap_GainLossOnInvestments_label_en-US" xlink:label="lab_us-gaap_GainLossOnInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnInvestments" xlink:to="lab_us-gaap_GainLossOnInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireShortTermInvestments_9ae8b689-7f9d-40e4-b9db-07ad693adc30_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireShortTermInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of investments</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireShortTermInvestments_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Short-term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireShortTermInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireShortTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireShortTermInvestments" xlink:to="lab_us-gaap_PaymentsToAcquireShortTermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_00434720-d59e-433f-a3fe-620aae7dd07e_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_5888a8e4-f4f2-49df-8d18-14e2a7e6b10c_verboseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_MarketableSecuritiesAndFairValueMeasurementsTextualAbstract_05812aae-5c18-441a-8d9e-e8474ae5d456_verboseLabel_en-US" xlink:label="lab_ino_MarketableSecuritiesAndFairValueMeasurementsTextualAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities and Fair Value Measurements (Textual) [Abstract]</link:label>
    <link:label id="lab_ino_MarketableSecuritiesAndFairValueMeasurementsTextualAbstract_label_en-US" xlink:label="lab_ino_MarketableSecuritiesAndFairValueMeasurementsTextualAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities and Fair Value Measurements (Textual) [Abstract]</link:label>
    <link:label id="lab_ino_MarketableSecuritiesAndFairValueMeasurementsTextualAbstract_documentation_en-US" xlink:label="lab_ino_MarketableSecuritiesAndFairValueMeasurementsTextualAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable securities and fair value measurements.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_MarketableSecuritiesAndFairValueMeasurementsTextualAbstract" xlink:href="ino-20210331.xsd#ino_MarketableSecuritiesAndFairValueMeasurementsTextualAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_MarketableSecuritiesAndFairValueMeasurementsTextualAbstract" xlink:to="lab_ino_MarketableSecuritiesAndFairValueMeasurementsTextualAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_60d1a95d-d6fa-46df-b7e4-deaac01d7764_verboseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Critical Accounting Policies</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_4ff26574-e6a7-46df-84b6-54b8ab3aa3b6_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0e73d9ff-a312-43be-9d1d-51d76dbd164f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d19ce805-6e39-4dbf-aa1b-a094237ec5e0_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties_d52fdcc7-f97a-4e15-886e-b092c71a7d3d_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable from affiliated entities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Receivable, Related Parties</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_69c3e35b-4c54-42eb-b40a-bb9b8f376cb4_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashDivestedFromDeconsolidation_c95bb07f-d3bd-4ff0-9de1-666733c765da_terseLabel_en-US" xlink:label="lab_us-gaap_CashDivestedFromDeconsolidation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Decrease in cash resulting from the deconsolidation of Geneos</link:label>
    <link:label id="lab_us-gaap_CashDivestedFromDeconsolidation_label_en-US" xlink:label="lab_us-gaap_CashDivestedFromDeconsolidation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Divested from Deconsolidation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashDivestedFromDeconsolidation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashDivestedFromDeconsolidation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashDivestedFromDeconsolidation" xlink:to="lab_us-gaap_CashDivestedFromDeconsolidation" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_IncreaseDecreaseinDeferredGrantFundingFromAffiliateCurrent_11e31da2-c498-4dab-8638-88c3d04ceca9_terseLabel_en-US" xlink:label="lab_ino_IncreaseDecreaseinDeferredGrantFundingFromAffiliateCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grant funding liability from affiliated entities</link:label>
    <link:label id="lab_ino_IncreaseDecreaseinDeferredGrantFundingFromAffiliateCurrent_label_en-US" xlink:label="lab_ino_IncreaseDecreaseinDeferredGrantFundingFromAffiliateCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Deferred Grant Funding, From Affiliate, Current</link:label>
    <link:label id="lab_ino_IncreaseDecreaseinDeferredGrantFundingFromAffiliateCurrent_documentation_en-US" xlink:label="lab_ino_IncreaseDecreaseinDeferredGrantFundingFromAffiliateCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Deferred Grant Funding, From Affiliate, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_IncreaseDecreaseinDeferredGrantFundingFromAffiliateCurrent" xlink:href="ino-20210331.xsd#ino_IncreaseDecreaseinDeferredGrantFundingFromAffiliateCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_IncreaseDecreaseinDeferredGrantFundingFromAffiliateCurrent" xlink:to="lab_ino_IncreaseDecreaseinDeferredGrantFundingFromAffiliateCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByBalanceSheetGroupingTable_a4438302-5fb7-4631-8766-c44fc1d48b83_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, by Balance Sheet Grouping [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueByBalanceSheetGroupingTable_label_en-US" xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, by Balance Sheet Grouping [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="lab_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_f1a55347-1401-4d8b-9737-a1a2d9a09e38_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Loss Per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_4efb08d3-ecd8-46a2-b41c-ba0785384473_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_a4a1b3eb-e4e7-457c-8fa0-2b327eacd620_verboseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_d23e2666-6d52-4913-a7f0-31521778f277_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_LassaFeverAndMERSVaccineMember_2a8566f2-6726-40cd-b90f-cc522fd2a254_terseLabel_en-US" xlink:label="lab_ino_LassaFeverAndMERSVaccineMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lassa Fever and MERS Vaccine</link:label>
    <link:label id="lab_ino_LassaFeverAndMERSVaccineMember_label_en-US" xlink:label="lab_ino_LassaFeverAndMERSVaccineMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lassa Fever And MERS Vaccine [Member]</link:label>
    <link:label id="lab_ino_LassaFeverAndMERSVaccineMember_documentation_en-US" xlink:label="lab_ino_LassaFeverAndMERSVaccineMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lassa Fever And MERS Vaccine [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_LassaFeverAndMERSVaccineMember" xlink:href="ino-20210331.xsd#ino_LassaFeverAndMERSVaccineMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_LassaFeverAndMERSVaccineMember" xlink:to="lab_ino_LassaFeverAndMERSVaccineMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_f10c3d9b-e5c8-47ed-acf4-9ee87302bfa5_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurements, Recurring</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_a47308d8-0502-4d12-9556-37c8535ded9d_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recently Issued Accounting Standards</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_9c83964c-2e06-44f6-91f1-ddb9c6bfff09_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermInvestments_a3526df4-7a72-47c9-ae9a-a0228ab07329_verboseLabel_en-US" xlink:label="lab_us-gaap_ShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term investments</link:label>
    <link:label id="lab_us-gaap_ShortTermInvestments_label_en-US" xlink:label="lab_us-gaap_ShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermInvestments" xlink:to="lab_us-gaap_ShortTermInvestments" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>9
<FILENAME>ino-20210331_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:e9d1bb07-ad73-4929-82ea-6e949ab8c789,g:8e741ee6-3c7b-40cd-9e55-d4abd68b099b-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.inovio.com/role/CoverPage" xlink:type="simple" xlink:href="ino-20210331.xsd#CoverPage"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_2f98cd07-9a4b-4bc3-85a4-f70387a167b3" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_60d65396-7ae2-4a9c-b2a3-a85acebd701c" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2f98cd07-9a4b-4bc3-85a4-f70387a167b3" xlink:to="loc_dei_DocumentType_60d65396-7ae2-4a9c-b2a3-a85acebd701c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_251613cd-04d1-4275-87d9-67da3cd73a1b" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2f98cd07-9a4b-4bc3-85a4-f70387a167b3" xlink:to="loc_dei_DocumentQuarterlyReport_251613cd-04d1-4275-87d9-67da3cd73a1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_8bb7c84c-200f-49ac-bd81-95b8ddb4f796" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2f98cd07-9a4b-4bc3-85a4-f70387a167b3" xlink:to="loc_dei_DocumentPeriodEndDate_8bb7c84c-200f-49ac-bd81-95b8ddb4f796" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_b3ba4810-07fd-40a2-badb-4bc349fbe55e" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2f98cd07-9a4b-4bc3-85a4-f70387a167b3" xlink:to="loc_dei_DocumentTransitionReport_b3ba4810-07fd-40a2-badb-4bc349fbe55e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_1e5c2e7e-1021-403d-8067-1318c97013e8" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2f98cd07-9a4b-4bc3-85a4-f70387a167b3" xlink:to="loc_dei_EntityFileNumber_1e5c2e7e-1021-403d-8067-1318c97013e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_e9a31b2c-34df-4c9c-8994-40351541d563" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2f98cd07-9a4b-4bc3-85a4-f70387a167b3" xlink:to="loc_dei_EntityRegistrantName_e9a31b2c-34df-4c9c-8994-40351541d563" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_0e5bdd6d-6361-440a-8efe-4d3a0c7db5c0" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2f98cd07-9a4b-4bc3-85a4-f70387a167b3" xlink:to="loc_dei_EntityIncorporationStateCountryCode_0e5bdd6d-6361-440a-8efe-4d3a0c7db5c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_81d109ef-6880-47d8-8213-8120e311a94f" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2f98cd07-9a4b-4bc3-85a4-f70387a167b3" xlink:to="loc_dei_EntityTaxIdentificationNumber_81d109ef-6880-47d8-8213-8120e311a94f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_8501c1e2-3196-4787-b7c6-4c3d00cd020a" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2f98cd07-9a4b-4bc3-85a4-f70387a167b3" xlink:to="loc_dei_EntityAddressAddressLine1_8501c1e2-3196-4787-b7c6-4c3d00cd020a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_9ee4979c-ae2d-4fe3-a71d-b0e1c26d6ad7" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2f98cd07-9a4b-4bc3-85a4-f70387a167b3" xlink:to="loc_dei_EntityAddressCityOrTown_9ee4979c-ae2d-4fe3-a71d-b0e1c26d6ad7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_875c7084-65be-4ba4-945b-3955f4e305f6" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2f98cd07-9a4b-4bc3-85a4-f70387a167b3" xlink:to="loc_dei_EntityAddressStateOrProvince_875c7084-65be-4ba4-945b-3955f4e305f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_c627e58a-8fcc-41f4-8eca-6fcbc870a725" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2f98cd07-9a4b-4bc3-85a4-f70387a167b3" xlink:to="loc_dei_EntityAddressPostalZipCode_c627e58a-8fcc-41f4-8eca-6fcbc870a725" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_3d3b36bb-6274-4c65-9492-8f7c4fff9b87" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2f98cd07-9a4b-4bc3-85a4-f70387a167b3" xlink:to="loc_dei_CityAreaCode_3d3b36bb-6274-4c65-9492-8f7c4fff9b87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_5ef2c1de-9385-466d-bc63-c74854257ab3" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2f98cd07-9a4b-4bc3-85a4-f70387a167b3" xlink:to="loc_dei_LocalPhoneNumber_5ef2c1de-9385-466d-bc63-c74854257ab3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_488d7ba0-f339-4693-a53d-df5ee9291186" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2f98cd07-9a4b-4bc3-85a4-f70387a167b3" xlink:to="loc_dei_Security12bTitle_488d7ba0-f339-4693-a53d-df5ee9291186" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_12093210-fcb8-449d-b2ee-09aa65bb9f7b" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2f98cd07-9a4b-4bc3-85a4-f70387a167b3" xlink:to="loc_dei_TradingSymbol_12093210-fcb8-449d-b2ee-09aa65bb9f7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_6cdeb682-2d9d-410e-8e38-3d5957ced1f8" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2f98cd07-9a4b-4bc3-85a4-f70387a167b3" xlink:to="loc_dei_SecurityExchangeName_6cdeb682-2d9d-410e-8e38-3d5957ced1f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_fdc3b66a-586d-4f9f-a6fb-c79784615ee0" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2f98cd07-9a4b-4bc3-85a4-f70387a167b3" xlink:to="loc_dei_EntityCurrentReportingStatus_fdc3b66a-586d-4f9f-a6fb-c79784615ee0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_23920eff-41b4-4f4c-840c-e2660bc39336" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2f98cd07-9a4b-4bc3-85a4-f70387a167b3" xlink:to="loc_dei_EntityInteractiveDataCurrent_23920eff-41b4-4f4c-840c-e2660bc39336" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_437a1437-fb45-40f8-af93-67a78224613f" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2f98cd07-9a4b-4bc3-85a4-f70387a167b3" xlink:to="loc_dei_EntityFilerCategory_437a1437-fb45-40f8-af93-67a78224613f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_c1e93f98-1547-4601-8aa9-a0091cf5b160" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2f98cd07-9a4b-4bc3-85a4-f70387a167b3" xlink:to="loc_dei_EntitySmallBusiness_c1e93f98-1547-4601-8aa9-a0091cf5b160" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_df022122-eb49-4299-8a61-330b63432c6f" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2f98cd07-9a4b-4bc3-85a4-f70387a167b3" xlink:to="loc_dei_EntityEmergingGrowthCompany_df022122-eb49-4299-8a61-330b63432c6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_302ca64c-cd03-4d4b-b038-56ef78d5f7da" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2f98cd07-9a4b-4bc3-85a4-f70387a167b3" xlink:to="loc_dei_EntityShellCompany_302ca64c-cd03-4d4b-b038-56ef78d5f7da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_6fa1a36c-ce6e-4f5f-9689-b9c2fc3918ad" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2f98cd07-9a4b-4bc3-85a4-f70387a167b3" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_6fa1a36c-ce6e-4f5f-9689-b9c2fc3918ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_846fe39d-5700-49ab-b321-84b2ab92bf45" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2f98cd07-9a4b-4bc3-85a4-f70387a167b3" xlink:to="loc_dei_AmendmentFlag_846fe39d-5700-49ab-b321-84b2ab92bf45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_565d48f3-2585-466b-8453-7a6cec252cd8" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2f98cd07-9a4b-4bc3-85a4-f70387a167b3" xlink:to="loc_dei_DocumentFiscalYearFocus_565d48f3-2585-466b-8453-7a6cec252cd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_0d89835f-9f68-4d00-916d-5b14664c0474" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2f98cd07-9a4b-4bc3-85a4-f70387a167b3" xlink:to="loc_dei_DocumentFiscalPeriodFocus_0d89835f-9f68-4d00-916d-5b14664c0474" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_badf69fa-c798-4166-8f48-70aa8edfa477" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2f98cd07-9a4b-4bc3-85a4-f70387a167b3" xlink:to="loc_dei_EntityCentralIndexKey_badf69fa-c798-4166-8f48-70aa8edfa477" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_32655495-047d-4832-8903-a2fc6a2a9e87" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2f98cd07-9a4b-4bc3-85a4-f70387a167b3" xlink:to="loc_dei_CurrentFiscalYearEndDate_32655495-047d-4832-8903-a2fc6a2a9e87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/CondensedConsolidatedBalanceSheets" xlink:type="simple" xlink:href="ino-20210331.xsd#CondensedConsolidatedBalanceSheets"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_11f2186b-107a-4ebd-b870-f76523ab4ea3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_cba9af00-5a94-4604-a7d7-772ceb0c73a0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_11f2186b-107a-4ebd-b870-f76523ab4ea3" xlink:to="loc_us-gaap_StatementTable_cba9af00-5a94-4604-a7d7-772ceb0c73a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_64fdb318-7fdd-4b48-b89a-31dbdb2a59cf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_cba9af00-5a94-4604-a7d7-772ceb0c73a0" xlink:to="loc_us-gaap_DebtInstrumentAxis_64fdb318-7fdd-4b48-b89a-31dbdb2a59cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_7d314a98-3b33-477e-aea6-e8ae318f5bac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_64fdb318-7fdd-4b48-b89a-31dbdb2a59cf" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_7d314a98-3b33-477e-aea6-e8ae318f5bac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_A6.50ConvertibleSeniorNotesDue2024Member_ecec6941-afe9-4228-b7ce-ba5e208fd820" xlink:href="ino-20210331.xsd#ino_A6.50ConvertibleSeniorNotesDue2024Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7d314a98-3b33-477e-aea6-e8ae318f5bac" xlink:to="loc_ino_A6.50ConvertibleSeniorNotesDue2024Member_ecec6941-afe9-4228-b7ce-ba5e208fd820" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ConvertibleBondsMember_00e27134-9255-486c-bd91-ba7bee752ced" xlink:href="ino-20210331.xsd#ino_ConvertibleBondsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7d314a98-3b33-477e-aea6-e8ae318f5bac" xlink:to="loc_ino_ConvertibleBondsMember_00e27134-9255-486c-bd91-ba7bee752ced" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_6aa704ff-88d5-4c85-8fbe-67d5431b370b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_cba9af00-5a94-4604-a7d7-772ceb0c73a0" xlink:to="loc_us-gaap_StatementLineItems_6aa704ff-88d5-4c85-8fbe-67d5431b370b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_b0c4100c-30aa-4e03-89cb-3b24a4bfacf5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6aa704ff-88d5-4c85-8fbe-67d5431b370b" xlink:to="loc_us-gaap_AssetsAbstract_b0c4100c-30aa-4e03-89cb-3b24a4bfacf5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_af6717de-44fa-4150-a901-0023798ab64f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_b0c4100c-30aa-4e03-89cb-3b24a4bfacf5" xlink:to="loc_us-gaap_AssetsCurrentAbstract_af6717de-44fa-4150-a901-0023798ab64f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_5bca085a-1e11-4ea9-a9fb-d554b068bfd9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_af6717de-44fa-4150-a901-0023798ab64f" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_5bca085a-1e11-4ea9-a9fb-d554b068bfd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestments_20ed065f-67d7-4c3f-bd63-70db019e811b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_af6717de-44fa-4150-a901-0023798ab64f" xlink:to="loc_us-gaap_ShortTermInvestments_20ed065f-67d7-4c3f-bd63-70db019e811b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_c286ebfd-1967-4ce8-99dc-915003359ca4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_af6717de-44fa-4150-a901-0023798ab64f" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_c286ebfd-1967-4ce8-99dc-915003359ca4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableRelatedPartiesCurrent_376c7158-1fbc-4808-a88f-18a8ec3cb401" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableRelatedPartiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_af6717de-44fa-4150-a901-0023798ab64f" xlink:to="loc_us-gaap_AccountsReceivableRelatedPartiesCurrent_376c7158-1fbc-4808-a88f-18a8ec3cb401" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_40b24c7f-e8f5-4279-afa5-c957dfe57ccf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_af6717de-44fa-4150-a901-0023798ab64f" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_40b24c7f-e8f5-4279-afa5-c957dfe57ccf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity_6bd5214c-5eb4-44a1-ac73-b285993028a9" xlink:href="ino-20210331.xsd#ino_PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_af6717de-44fa-4150-a901-0023798ab64f" xlink:to="loc_ino_PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity_6bd5214c-5eb4-44a1-ac73-b285993028a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_62055bcf-2686-476a-b5a5-2f313f27d4a3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_af6717de-44fa-4150-a901-0023798ab64f" xlink:to="loc_us-gaap_AssetsCurrent_62055bcf-2686-476a-b5a5-2f313f27d4a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_35bca910-4ed9-40d1-b4c5-a864d68d22f5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_b0c4100c-30aa-4e03-89cb-3b24a4bfacf5" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_35bca910-4ed9-40d1-b4c5-a864d68d22f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_8f03fb36-ecf1-47f8-9f14-ec999b3ebfdf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_b0c4100c-30aa-4e03-89cb-3b24a4bfacf5" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_8f03fb36-ecf1-47f8-9f14-ec999b3ebfdf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_07c0e276-427d-4966-886e-ad1bf1162f4d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_b0c4100c-30aa-4e03-89cb-3b24a4bfacf5" xlink:to="loc_us-gaap_EquityMethodInvestments_07c0e276-427d-4966-886e-ad1bf1162f4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_befb71bc-e940-4241-80bd-5a1c8ab83eb1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_b0c4100c-30aa-4e03-89cb-3b24a4bfacf5" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_befb71bc-e940-4241-80bd-5a1c8ab83eb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_69af975f-c170-4fe0-b404-b10108c92cef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_b0c4100c-30aa-4e03-89cb-3b24a4bfacf5" xlink:to="loc_us-gaap_Goodwill_69af975f-c170-4fe0-b404-b10108c92cef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_a6891214-098f-4b4a-835e-8ae492170e4e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_b0c4100c-30aa-4e03-89cb-3b24a4bfacf5" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_a6891214-098f-4b4a-835e-8ae492170e4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_9fa0b517-b119-4a57-9868-487a1bc30264" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_b0c4100c-30aa-4e03-89cb-3b24a4bfacf5" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_9fa0b517-b119-4a57-9868-487a1bc30264" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_b51f0979-0557-4f8f-a619-1eedb28e162b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_b0c4100c-30aa-4e03-89cb-3b24a4bfacf5" xlink:to="loc_us-gaap_Assets_b51f0979-0557-4f8f-a619-1eedb28e162b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_49613b3f-9509-450e-9473-b277e5f5b919" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6aa704ff-88d5-4c85-8fbe-67d5431b370b" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_49613b3f-9509-450e-9473-b277e5f5b919" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_a561915f-bf31-4941-ae15-719ddee745d1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_49613b3f-9509-450e-9473-b277e5f5b919" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_a561915f-bf31-4941-ae15-719ddee745d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_a37db868-5a7d-40a3-9508-184f43fb331e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_a561915f-bf31-4941-ae15-719ddee745d1" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_a37db868-5a7d-40a3-9508-184f43fb331e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueToRelatedPartiesCurrent_cad9e759-85eb-4220-89c1-fefd8c9b681a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DueToRelatedPartiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_a561915f-bf31-4941-ae15-719ddee745d1" xlink:to="loc_us-gaap_DueToRelatedPartiesCurrent_cad9e759-85eb-4220-89c1-fefd8c9b681a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_AccruedClinicalTrialExpenseCurrent_2c989796-06d6-4bae-ba98-858e4a001afb" xlink:href="ino-20210331.xsd#ino_AccruedClinicalTrialExpenseCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_a561915f-bf31-4941-ae15-719ddee745d1" xlink:to="loc_ino_AccruedClinicalTrialExpenseCurrent_2c989796-06d6-4bae-ba98-858e4a001afb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_f27e0396-233f-43e4-a103-bedd5fe8c22f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_a561915f-bf31-4941-ae15-719ddee745d1" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_f27e0396-233f-43e4-a103-bedd5fe8c22f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ContractWithCustomerLiabilityAffiliatedEntityCurrent_e7f3def1-212d-4fa9-b3b2-1b52ff4e3b43" xlink:href="ino-20210331.xsd#ino_ContractWithCustomerLiabilityAffiliatedEntityCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_a561915f-bf31-4941-ae15-719ddee745d1" xlink:to="loc_ino_ContractWithCustomerLiabilityAffiliatedEntityCurrent_e7f3def1-212d-4fa9-b3b2-1b52ff4e3b43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_3088ada5-e0ef-4c7d-bead-58b0f68fc971" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_a561915f-bf31-4941-ae15-719ddee745d1" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_3088ada5-e0ef-4c7d-bead-58b0f68fc971" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DeferredGrantFundingCurrent_818fd513-cfc8-49c4-8f70-393f431c543e" xlink:href="ino-20210331.xsd#ino_DeferredGrantFundingCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_a561915f-bf31-4941-ae15-719ddee745d1" xlink:to="loc_ino_DeferredGrantFundingCurrent_818fd513-cfc8-49c4-8f70-393f431c543e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DeferredGrantFundingFromAffiliateCurrent_d99e798e-6112-4d58-afdf-ded4197906e8" xlink:href="ino-20210331.xsd#ino_DeferredGrantFundingFromAffiliateCurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_a561915f-bf31-4941-ae15-719ddee745d1" xlink:to="loc_ino_DeferredGrantFundingFromAffiliateCurrent_d99e798e-6112-4d58-afdf-ded4197906e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_422c29f4-a44d-4e77-a61b-b479cd3c8f9d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_a561915f-bf31-4941-ae15-719ddee745d1" xlink:to="loc_us-gaap_LiabilitiesCurrent_422c29f4-a44d-4e77-a61b-b479cd3c8f9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_17e3ec7b-404f-45d3-86bd-1c330d8c9588" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_49613b3f-9509-450e-9473-b277e5f5b919" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_17e3ec7b-404f-45d3-86bd-1c330d8c9588" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebt_ecae36d9-95b2-4337-9e3c-bbd1189263af" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleDebt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_49613b3f-9509-450e-9473-b277e5f5b919" xlink:to="loc_us-gaap_ConvertibleDebt_ecae36d9-95b2-4337-9e3c-bbd1189263af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_54a46552-fe8c-48ad-90ec-f691b114ed1e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_49613b3f-9509-450e-9473-b277e5f5b919" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_54a46552-fe8c-48ad-90ec-f691b114ed1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_e85108c3-a665-49a2-af79-4c2598d669f4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_49613b3f-9509-450e-9473-b277e5f5b919" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_e85108c3-a665-49a2-af79-4c2598d669f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DeferredGrantFundingFromAffiliateNoncurrent_f1ac821a-d86e-480a-a0f7-82dedc5c0efd" xlink:href="ino-20210331.xsd#ino_DeferredGrantFundingFromAffiliateNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_49613b3f-9509-450e-9473-b277e5f5b919" xlink:to="loc_ino_DeferredGrantFundingFromAffiliateNoncurrent_f1ac821a-d86e-480a-a0f7-82dedc5c0efd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_b0b2c88a-4bc2-4725-a26a-8005fdf5cf5b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_49613b3f-9509-450e-9473-b277e5f5b919" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_b0b2c88a-4bc2-4725-a26a-8005fdf5cf5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_f750affd-9815-4551-bcb0-98b795192065" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_49613b3f-9509-450e-9473-b277e5f5b919" xlink:to="loc_us-gaap_Liabilities_f750affd-9815-4551-bcb0-98b795192065" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_7625f762-d50e-41f6-8264-43f2b0a5a18d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_49613b3f-9509-450e-9473-b277e5f5b919" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_7625f762-d50e-41f6-8264-43f2b0a5a18d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_8eba15eb-ac5f-441e-8983-9a86f6cd12f9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_7625f762-d50e-41f6-8264-43f2b0a5a18d" xlink:to="loc_us-gaap_PreferredStockValue_8eba15eb-ac5f-441e-8983-9a86f6cd12f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_67e87668-ad61-4464-8508-167b6c98e967" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_7625f762-d50e-41f6-8264-43f2b0a5a18d" xlink:to="loc_us-gaap_CommonStockValue_67e87668-ad61-4464-8508-167b6c98e967" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_9fe44704-03ba-4e45-b43b-649cdff9bd54" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_7625f762-d50e-41f6-8264-43f2b0a5a18d" xlink:to="loc_us-gaap_AdditionalPaidInCapital_9fe44704-03ba-4e45-b43b-649cdff9bd54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_d7185b76-aaf5-4a66-adbd-0bced407e613" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_7625f762-d50e-41f6-8264-43f2b0a5a18d" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_d7185b76-aaf5-4a66-adbd-0bced407e613" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_9435d737-e45d-4433-ab3d-27062e3a8928" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_7625f762-d50e-41f6-8264-43f2b0a5a18d" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_9435d737-e45d-4433-ab3d-27062e3a8928" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_bb49cd98-62de-4f4f-8ed0-b5c5ad5f9a23" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_7625f762-d50e-41f6-8264-43f2b0a5a18d" xlink:to="loc_us-gaap_StockholdersEquity_bb49cd98-62de-4f4f-8ed0-b5c5ad5f9a23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_11b1d388-ee53-45a0-bb55-10a42964cc17" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_49613b3f-9509-450e-9473-b277e5f5b919" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_11b1d388-ee53-45a0-bb55-10a42964cc17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/CondensedConsolidatedStatementsofOperations" xlink:type="simple" xlink:href="ino-20210331.xsd#CondensedConsolidatedStatementsofOperations"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/CondensedConsolidatedStatementsofOperations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_84baa74d-07a1-410c-87d7-b0b04d87db4d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_ffabbd6b-b5a8-4930-9d32-b0ddd18d492f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_84baa74d-07a1-410c-87d7-b0b04d87db4d" xlink:to="loc_us-gaap_StatementTable_ffabbd6b-b5a8-4930-9d32-b0ddd18d492f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_d105ce0c-ece0-4be1-9fa4-398354014acb" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_ffabbd6b-b5a8-4930-9d32-b0ddd18d492f" xlink:to="loc_srt_ProductOrServiceAxis_d105ce0c-ece0-4be1-9fa4-398354014acb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_1c7cc99d-65b9-4dea-9da8-7c1c9fa4ae5b" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_d105ce0c-ece0-4be1-9fa4-398354014acb" xlink:to="loc_srt_ProductsAndServicesDomain_1c7cc99d-65b9-4dea-9da8-7c1c9fa4ae5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember_3016bf2d-a15f-4dd0-bccd-76a89cd080b8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LicenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_1c7cc99d-65b9-4dea-9da8-7c1c9fa4ae5b" xlink:to="loc_us-gaap_LicenseMember_3016bf2d-a15f-4dd0-bccd-76a89cd080b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_LicensewithAffiliatedEntitiesMember_81c7f1f3-11b6-4301-bfe2-7d07bbd0b3c6" xlink:href="ino-20210331.xsd#ino_LicensewithAffiliatedEntitiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_1c7cc99d-65b9-4dea-9da8-7c1c9fa4ae5b" xlink:to="loc_ino_LicensewithAffiliatedEntitiesMember_81c7f1f3-11b6-4301-bfe2-7d07bbd0b3c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductAndServiceOtherMember_87157db0-669e-4434-9229-472c04980267" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductAndServiceOtherMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_1c7cc99d-65b9-4dea-9da8-7c1c9fa4ae5b" xlink:to="loc_us-gaap_ProductAndServiceOtherMember_87157db0-669e-4434-9229-472c04980267" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_4ffde4c8-a0cb-4d86-9ae4-75f96315eac5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_ffabbd6b-b5a8-4930-9d32-b0ddd18d492f" xlink:to="loc_us-gaap_StatementLineItems_4ffde4c8-a0cb-4d86-9ae4-75f96315eac5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_075c15c4-d8e4-473c-8921-6472ed7e912d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4ffde4c8-a0cb-4d86-9ae4-75f96315eac5" xlink:to="loc_us-gaap_RevenuesAbstract_075c15c4-d8e4-473c-8921-6472ed7e912d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_341b9fee-ead3-400f-a70c-71257277e0e3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_075c15c4-d8e4-473c-8921-6472ed7e912d" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_341b9fee-ead3-400f-a70c-71257277e0e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_c4116a62-e3d7-4e14-8309-e5de9b01a5e8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4ffde4c8-a0cb-4d86-9ae4-75f96315eac5" xlink:to="loc_us-gaap_OperatingExpensesAbstract_c4116a62-e3d7-4e14-8309-e5de9b01a5e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_3abe3824-b0c7-454b-b9a5-1194f8047a29" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_c4116a62-e3d7-4e14-8309-e5de9b01a5e8" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_3abe3824-b0c7-454b-b9a5-1194f8047a29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_96de00ef-f29a-465f-8920-bf32979ea5f2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_c4116a62-e3d7-4e14-8309-e5de9b01a5e8" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_96de00ef-f29a-465f-8920-bf32979ea5f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_ee671cfc-f974-4daf-87d3-89d39ddfb6f3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_c4116a62-e3d7-4e14-8309-e5de9b01a5e8" xlink:to="loc_us-gaap_OperatingExpenses_ee671cfc-f974-4daf-87d3-89d39ddfb6f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_7e67df46-7880-4751-8880-497bb2679a27" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4ffde4c8-a0cb-4d86-9ae4-75f96315eac5" xlink:to="loc_us-gaap_OperatingIncomeLoss_7e67df46-7880-4751-8880-497bb2679a27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_a3458092-eca4-4be0-b299-15bbc8ffb871" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4ffde4c8-a0cb-4d86-9ae4-75f96315eac5" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_a3458092-eca4-4be0-b299-15bbc8ffb871" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeOperating_444037fb-19b9-45da-b719-d68f16e9624e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestIncomeOperating"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_a3458092-eca4-4be0-b299-15bbc8ffb871" xlink:to="loc_us-gaap_InterestIncomeOperating_444037fb-19b9-45da-b719-d68f16e9624e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_109f5b78-7233-4b4a-8d4a-4ccde74c9c5e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_a3458092-eca4-4be0-b299-15bbc8ffb871" xlink:to="loc_us-gaap_InterestExpense_109f5b78-7233-4b4a-8d4a-4ccde74c9c5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet_a99a994b-88b1-4493-89dd-d383c7130e91" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_a3458092-eca4-4be0-b299-15bbc8ffb871" xlink:to="loc_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet_a99a994b-88b1-4493-89dd-d383c7130e91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ChangeInValueOfInvestmentsInAffiliatedCompany_2e4fc5e6-befa-452b-98ea-66d9cc407859" xlink:href="ino-20210331.xsd#ino_ChangeInValueOfInvestmentsInAffiliatedCompany"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_a3458092-eca4-4be0-b299-15bbc8ffb871" xlink:to="loc_ino_ChangeInValueOfInvestmentsInAffiliatedCompany_2e4fc5e6-befa-452b-98ea-66d9cc407859" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_bbef6f1d-8225-4f23-86ce-e5180d80be97" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_a3458092-eca4-4be0-b299-15bbc8ffb871" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_bbef6f1d-8225-4f23-86ce-e5180d80be97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_0299131a-6fc4-4e81-ba5f-e1fab2d7105e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_a3458092-eca4-4be0-b299-15bbc8ffb871" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_0299131a-6fc4-4e81-ba5f-e1fab2d7105e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_c1353d20-5f49-4c63-9d17-ea8fc9f566ec" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_a3458092-eca4-4be0-b299-15bbc8ffb871" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_c1353d20-5f49-4c63-9d17-ea8fc9f566ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_fac67cda-2e91-449a-996f-b442ea6677d5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_a3458092-eca4-4be0-b299-15bbc8ffb871" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_fac67cda-2e91-449a-996f-b442ea6677d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_81fea252-37b9-4c29-90ca-a6e181968050" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_a3458092-eca4-4be0-b299-15bbc8ffb871" xlink:to="loc_us-gaap_ProfitLoss_81fea252-37b9-4c29-90ca-a6e181968050" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_d0dd1f8e-9b6f-4230-b652-42cf21ba299d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_a3458092-eca4-4be0-b299-15bbc8ffb871" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_d0dd1f8e-9b6f-4230-b652-42cf21ba299d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_5e83e3d4-ed22-403e-9e37-eeaba232d107" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_a3458092-eca4-4be0-b299-15bbc8ffb871" xlink:to="loc_us-gaap_NetIncomeLoss_5e83e3d4-ed22-403e-9e37-eeaba232d107" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_3a0e9620-ea78-4da6-a8fe-a4c4e539eccb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4ffde4c8-a0cb-4d86-9ae4-75f96315eac5" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_3a0e9620-ea78-4da6-a8fe-a4c4e539eccb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_d1fea922-295c-4628-9248-085fd58cf063" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_3a0e9620-ea78-4da6-a8fe-a4c4e539eccb" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDiluted_d1fea922-295c-4628-9248-085fd58cf063" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_35004cb4-dd8e-4ad9-b32f-7cb12d875e72" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4ffde4c8-a0cb-4d86-9ae4-75f96315eac5" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_35004cb4-dd8e-4ad9-b32f-7cb12d875e72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_e965c8af-dde3-4218-a3fb-5cc2def16302" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_35004cb4-dd8e-4ad9-b32f-7cb12d875e72" xlink:to="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_e965c8af-dde3-4218-a3fb-5cc2def16302" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/CondensedConsolidatedStatementsofComprehensiveLoss" xlink:type="simple" xlink:href="ino-20210331.xsd#CondensedConsolidatedStatementsofComprehensiveLoss"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/CondensedConsolidatedStatementsofComprehensiveLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_8124c2c9-8bd8-4484-bfeb-c860e3ab04c1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_76c1ab04-264c-4e64-96ec-b0068c5656e2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_8124c2c9-8bd8-4484-bfeb-c860e3ab04c1" xlink:to="loc_us-gaap_ProfitLoss_76c1ab04-264c-4e64-96ec-b0068c5656e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_ec18caff-1948-4b3f-a9c8-a41b63065c34" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_8124c2c9-8bd8-4484-bfeb-c860e3ab04c1" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_ec18caff-1948-4b3f-a9c8-a41b63065c34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_efafbb10-aea3-4c05-881b-e5c6faa4826d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_ec18caff-1948-4b3f-a9c8-a41b63065c34" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_efafbb10-aea3-4c05-881b-e5c6faa4826d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_95afe7f3-a38c-42cf-8f3a-3cdb2e05e1e6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_ec18caff-1948-4b3f-a9c8-a41b63065c34" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_95afe7f3-a38c-42cf-8f3a-3cdb2e05e1e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_21efffd5-16b6-4885-9c8e-19d918a50a89" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_8124c2c9-8bd8-4484-bfeb-c860e3ab04c1" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_21efffd5-16b6-4885-9c8e-19d918a50a89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_e75bd021-bc01-4f76-abd5-898ec231a72e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_8124c2c9-8bd8-4484-bfeb-c860e3ab04c1" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_e75bd021-bc01-4f76-abd5-898ec231a72e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_6768bdfa-28f0-45a1-b189-48e0e827ad1d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_8124c2c9-8bd8-4484-bfeb-c860e3ab04c1" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_6768bdfa-28f0-45a1-b189-48e0e827ad1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/CondensedConsolidatedStatementsofStockholdersEquity" xlink:type="simple" xlink:href="ino-20210331.xsd#CondensedConsolidatedStatementsofStockholdersEquity"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/CondensedConsolidatedStatementsofStockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_023698dc-94cf-41d1-a4ac-ceb308740bc8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_1e7f6dc1-d55d-45a8-b1ec-3a26651cac61" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_023698dc-94cf-41d1-a4ac-ceb308740bc8" xlink:to="loc_us-gaap_StatementTable_1e7f6dc1-d55d-45a8-b1ec-3a26651cac61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_bc2f7daf-8aae-49e3-98d5-4c12609df3e7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1e7f6dc1-d55d-45a8-b1ec-3a26651cac61" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_bc2f7daf-8aae-49e3-98d5-4c12609df3e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_01fc7764-b7fa-4c32-ada7-f8a7ce1e01f3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_bc2f7daf-8aae-49e3-98d5-4c12609df3e7" xlink:to="loc_us-gaap_EquityComponentDomain_01fc7764-b7fa-4c32-ada7-f8a7ce1e01f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember_7d03e72d-9ee6-48b9-99d1-9dc5abb6c5d5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_01fc7764-b7fa-4c32-ada7-f8a7ce1e01f3" xlink:to="loc_us-gaap_PreferredStockMember_7d03e72d-9ee6-48b9-99d1-9dc5abb6c5d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_e9888f5f-d203-4f24-b059-0ddf0322169e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_01fc7764-b7fa-4c32-ada7-f8a7ce1e01f3" xlink:to="loc_us-gaap_CommonStockMember_e9888f5f-d203-4f24-b059-0ddf0322169e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_ccdd9cb5-b707-48a3-94eb-18c641a0c0d4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_01fc7764-b7fa-4c32-ada7-f8a7ce1e01f3" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_ccdd9cb5-b707-48a3-94eb-18c641a0c0d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_a33a810c-bc40-4bb8-8da8-c8d1aa324e06" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_01fc7764-b7fa-4c32-ada7-f8a7ce1e01f3" xlink:to="loc_us-gaap_RetainedEarningsMember_a33a810c-bc40-4bb8-8da8-c8d1aa324e06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_3605804f-6a0c-4a99-b88a-2ecba374db93" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_01fc7764-b7fa-4c32-ada7-f8a7ce1e01f3" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_3605804f-6a0c-4a99-b88a-2ecba374db93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_2c15a6ec-7e18-4489-9e40-ca68a3ff3a53" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_01fc7764-b7fa-4c32-ada7-f8a7ce1e01f3" xlink:to="loc_us-gaap_NoncontrollingInterestMember_2c15a6ec-7e18-4489-9e40-ca68a3ff3a53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_eb385bad-d993-4b6a-b4ba-62df3a216a14" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1e7f6dc1-d55d-45a8-b1ec-3a26651cac61" xlink:to="loc_us-gaap_StatementLineItems_eb385bad-d993-4b6a-b4ba-62df3a216a14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_10b3efdb-7677-496b-861a-8f7ad607e069" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_eb385bad-d993-4b6a-b4ba-62df3a216a14" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_10b3efdb-7677-496b-861a-8f7ad607e069" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued_e8b8417b-cf59-4ae7-bb0b-81a1ce966cd4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssued"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_10b3efdb-7677-496b-861a-8f7ad607e069" xlink:to="loc_us-gaap_SharesIssued_e8b8417b-cf59-4ae7-bb0b-81a1ce966cd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_94c3a3e2-257b-464d-a893-a9fa94cc1286" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_10b3efdb-7677-496b-861a-8f7ad607e069" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_94c3a3e2-257b-464d-a893-a9fa94cc1286" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_613d1ec0-8d87-4e44-ac5f-d0764a83b866" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_10b3efdb-7677-496b-861a-8f7ad607e069" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_613d1ec0-8d87-4e44-ac5f-d0764a83b866" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_58b650ca-ed10-4e4c-bb04-4f2733dfd136" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_10b3efdb-7677-496b-861a-8f7ad607e069" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_58b650ca-ed10-4e4c-bb04-4f2733dfd136" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_3586f22f-ed06-4c48-be95-35b494fe6d4e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_10b3efdb-7677-496b-861a-8f7ad607e069" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_3586f22f-ed06-4c48-be95-35b494fe6d4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_f4928ea0-3bea-415a-9ea3-73490e5b7518" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_10b3efdb-7677-496b-861a-8f7ad607e069" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_f4928ea0-3bea-415a-9ea3-73490e5b7518" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_a84c4ed6-e17f-47ce-bb03-754afd0b76f5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_10b3efdb-7677-496b-861a-8f7ad607e069" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_a84c4ed6-e17f-47ce-bb03-754afd0b76f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_208fdea8-b3f9-418d-8ce0-628d0d554dc3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_10b3efdb-7677-496b-861a-8f7ad607e069" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_208fdea8-b3f9-418d-8ce0-628d0d554dc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_75ac8a8c-c7a9-4720-8a48-d27292b0f54e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_10b3efdb-7677-496b-861a-8f7ad607e069" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_75ac8a8c-c7a9-4720-8a48-d27292b0f54e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance_2195c6de-7a31-492a-baa7-6218a9acd5a9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_10b3efdb-7677-496b-861a-8f7ad607e069" xlink:to="loc_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance_2195c6de-7a31-492a-baa7-6218a9acd5a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_fac6d413-f19d-42e2-a09c-8b60421c0333" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_10b3efdb-7677-496b-861a-8f7ad607e069" xlink:to="loc_us-gaap_ProfitLoss_fac6d413-f19d-42e2-a09c-8b60421c0333" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_c9761f99-4117-4956-b763-b3cf9cf430d3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_10b3efdb-7677-496b-861a-8f7ad607e069" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_c9761f99-4117-4956-b763-b3cf9cf430d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_69402359-a13a-4f05-970c-1a2c3fa43a39" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_10b3efdb-7677-496b-861a-8f7ad607e069" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_69402359-a13a-4f05-970c-1a2c3fa43a39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued_f5850b7e-eb68-40e3-a2b7-f71831fdddc2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssued"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_10b3efdb-7677-496b-861a-8f7ad607e069" xlink:to="loc_us-gaap_SharesIssued_f5850b7e-eb68-40e3-a2b7-f71831fdddc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_3301420a-3754-4242-a271-22bb01320c6c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_10b3efdb-7677-496b-861a-8f7ad607e069" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_3301420a-3754-4242-a271-22bb01320c6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/CondensedConsolidatedStatementsofStockholdersEquityParenthetical" xlink:type="simple" xlink:href="ino-20210331.xsd#CondensedConsolidatedStatementsofStockholdersEquityParenthetical"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/CondensedConsolidatedStatementsofStockholdersEquityParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_3ac34ca6-6f07-4053-94cb-a35f316b584a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_958d7f0a-6f79-4880-9787-31243182c7b4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_3ac34ca6-6f07-4053-94cb-a35f316b584a" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_958d7f0a-6f79-4880-9787-31243182c7b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="ino-20210331.xsd#CondensedConsolidatedStatementsofCashFlows"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_6a88a61a-7ca2-4210-a369-434c4c8a7136" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1efed283-8eca-46f9-9489-f70fea647924" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_6a88a61a-7ca2-4210-a369-434c4c8a7136" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1efed283-8eca-46f9-9489-f70fea647924" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_0b3e0d2e-ebfd-4d4e-a414-316fd4a9b804" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1efed283-8eca-46f9-9489-f70fea647924" xlink:to="loc_us-gaap_ProfitLoss_0b3e0d2e-ebfd-4d4e-a414-316fd4a9b804" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_cb265ceb-9316-41a5-9d01-96a03600aef8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1efed283-8eca-46f9-9489-f70fea647924" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_cb265ceb-9316-41a5-9d01-96a03600aef8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_9fc5d903-da51-4823-91ad-4ee6d8fe8f52" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Depreciation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_cb265ceb-9316-41a5-9d01-96a03600aef8" xlink:to="loc_us-gaap_Depreciation_9fc5d903-da51-4823-91ad-4ee6d8fe8f52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_003f5957-a94f-4138-9b39-d69ae1598cd4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_cb265ceb-9316-41a5-9d01-96a03600aef8" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_003f5957-a94f-4138-9b39-d69ae1598cd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDerivativeLiabilities_488f2330-f9fd-4f1b-81f7-af1b3b4e0875" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInDerivativeLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_cb265ceb-9316-41a5-9d01-96a03600aef8" xlink:to="loc_us-gaap_IncreaseDecreaseInDerivativeLiabilities_488f2330-f9fd-4f1b-81f7-af1b3b4e0875" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_ce7f34bc-2e9b-4f02-b059-09a1d5bf0554" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_cb265ceb-9316-41a5-9d01-96a03600aef8" xlink:to="loc_us-gaap_ShareBasedCompensation_ce7f34bc-2e9b-4f02-b059-09a1d5bf0554" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_NonCashInterestIncomeExpense_d8e4d8bc-dc5e-4f66-8605-71bd720ba4a7" xlink:href="ino-20210331.xsd#ino_NonCashInterestIncomeExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_cb265ceb-9316-41a5-9d01-96a03600aef8" xlink:to="loc_ino_NonCashInterestIncomeExpense_d8e4d8bc-dc5e-4f66-8605-71bd720ba4a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnInvestments_a8bd131c-fd4c-4734-85eb-8f448362d7ca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnInvestments"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_cb265ceb-9316-41a5-9d01-96a03600aef8" xlink:to="loc_us-gaap_GainLossOnInvestments_a8bd131c-fd4c-4734-85eb-8f448362d7ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_SettlementOfReceivableWithSharesOfCommonStockFromEquitySecurity_5a849b99-2c88-4d22-b8bf-eefa001e885d" xlink:href="ino-20210331.xsd#ino_SettlementOfReceivableWithSharesOfCommonStockFromEquitySecurity"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_cb265ceb-9316-41a5-9d01-96a03600aef8" xlink:to="loc_ino_SettlementOfReceivableWithSharesOfCommonStockFromEquitySecurity_5a849b99-2c88-4d22-b8bf-eefa001e885d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ChangeInValueOfInvestmentsInAffiliatedCompany_953bc39d-1d63-4e4d-b48b-5ed63ae1dbfc" xlink:href="ino-20210331.xsd#ino_ChangeInValueOfInvestmentsInAffiliatedCompany"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_cb265ceb-9316-41a5-9d01-96a03600aef8" xlink:to="loc_ino_ChangeInValueOfInvestmentsInAffiliatedCompany_953bc39d-1d63-4e4d-b48b-5ed63ae1dbfc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_9839d643-ea20-4fa7-8f0a-0e6a8fdd8715" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_cb265ceb-9316-41a5-9d01-96a03600aef8" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_9839d643-ea20-4fa7-8f0a-0e6a8fdd8715" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedLoss_f0293ccf-a939-4ab2-903e-9c4ca2d7a97f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedLoss"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_cb265ceb-9316-41a5-9d01-96a03600aef8" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedLoss_f0293ccf-a939-4ab2-903e-9c4ca2d7a97f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_OperatingLeaseNonCashLeaseExpense_d22e5851-9d20-43c6-9ee0-1f2436ad8837" xlink:href="ino-20210331.xsd#ino_OperatingLeaseNonCashLeaseExpense"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_cb265ceb-9316-41a5-9d01-96a03600aef8" xlink:to="loc_ino_OperatingLeaseNonCashLeaseExpense_d22e5851-9d20-43c6-9ee0-1f2436ad8837" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_ae6b4d9f-8412-4bf3-9123-20d21e878af6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_cb265ceb-9316-41a5-9d01-96a03600aef8" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_ae6b4d9f-8412-4bf3-9123-20d21e878af6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_3e5987e7-f458-4bc6-b1dc-b4f4abe451db" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_cb265ceb-9316-41a5-9d01-96a03600aef8" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_3e5987e7-f458-4bc6-b1dc-b4f4abe451db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_eebf8f83-84dc-4630-833c-76035a575600" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_3e5987e7-f458-4bc6-b1dc-b4f4abe451db" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_eebf8f83-84dc-4630-833c-76035a575600" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties_9e0a3a69-8feb-4317-ae38-bad2e73b6d72" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_3e5987e7-f458-4bc6-b1dc-b4f4abe451db" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties_9e0a3a69-8feb-4317-ae38-bad2e73b6d72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_576df692-1007-4020-bd8e-12bdb30baa7d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_3e5987e7-f458-4bc6-b1dc-b4f4abe451db" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_576df692-1007-4020-bd8e-12bdb30baa7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity_f6d17d3f-fb7a-4767-b03b-093c86b4802c" xlink:href="ino-20210331.xsd#ino_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_3e5987e7-f458-4bc6-b1dc-b4f4abe451db" xlink:to="loc_ino_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity_f6d17d3f-fb7a-4767-b03b-093c86b4802c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_9a710283-5c8f-455a-bb86-13e7db81780d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_3e5987e7-f458-4bc6-b1dc-b4f4abe451db" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_9a710283-5c8f-455a-bb86-13e7db81780d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_9bc17708-c2b8-4ebf-9cbe-8ec2fc0524e3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_3e5987e7-f458-4bc6-b1dc-b4f4abe451db" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_9bc17708-c2b8-4ebf-9cbe-8ec2fc0524e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_IncreaseDecreaseInAccruedClinicalTrialExpense_26b5e250-a6f5-4d5f-8d94-a8907ae6d12a" xlink:href="ino-20210331.xsd#ino_IncreaseDecreaseInAccruedClinicalTrialExpense"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_3e5987e7-f458-4bc6-b1dc-b4f4abe451db" xlink:to="loc_ino_IncreaseDecreaseInAccruedClinicalTrialExpense_26b5e250-a6f5-4d5f-8d94-a8907ae6d12a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties_45d83a37-570d-4465-942f-c97085873ee6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_3e5987e7-f458-4bc6-b1dc-b4f4abe451db" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties_45d83a37-570d-4465-942f-c97085873ee6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_1312fa43-19c8-4618-8581-6ef182494587" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_3e5987e7-f458-4bc6-b1dc-b4f4abe451db" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_1312fa43-19c8-4618-8581-6ef182494587" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_IncreaseDecreaseInDeferredRevenueFromRelatedParties_4d3cffc5-045a-435a-8ebf-daad6a257c60" xlink:href="ino-20210331.xsd#ino_IncreaseDecreaseInDeferredRevenueFromRelatedParties"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_3e5987e7-f458-4bc6-b1dc-b4f4abe451db" xlink:to="loc_ino_IncreaseDecreaseInDeferredRevenueFromRelatedParties_4d3cffc5-045a-435a-8ebf-daad6a257c60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet_879863d3-3f5e-418a-9535-a5e873f74b13" xlink:href="ino-20210331.xsd#ino_IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_3e5987e7-f458-4bc6-b1dc-b4f4abe451db" xlink:to="loc_ino_IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet_879863d3-3f5e-418a-9535-a5e873f74b13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_IncreaseDecreaseinDeferredGrantFundingCurrent_8fcaa4e5-6362-43b3-8f5c-b4d1fb6cf22f" xlink:href="ino-20210331.xsd#ino_IncreaseDecreaseinDeferredGrantFundingCurrent"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_3e5987e7-f458-4bc6-b1dc-b4f4abe451db" xlink:to="loc_ino_IncreaseDecreaseinDeferredGrantFundingCurrent_8fcaa4e5-6362-43b3-8f5c-b4d1fb6cf22f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_IncreaseDecreaseinDeferredGrantFundingFromAffiliateCurrent_13d9bc10-daa3-419c-8a4e-e25f49a8fed5" xlink:href="ino-20210331.xsd#ino_IncreaseDecreaseinDeferredGrantFundingFromAffiliateCurrent"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_3e5987e7-f458-4bc6-b1dc-b4f4abe451db" xlink:to="loc_ino_IncreaseDecreaseinDeferredGrantFundingFromAffiliateCurrent_13d9bc10-daa3-419c-8a4e-e25f49a8fed5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_1b5a39e3-a0bb-41ec-b2e5-e4016627f25a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_3e5987e7-f458-4bc6-b1dc-b4f4abe451db" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_1b5a39e3-a0bb-41ec-b2e5-e4016627f25a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_91811b3f-f660-4777-ab58-206509dad49d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1efed283-8eca-46f9-9489-f70fea647924" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_91811b3f-f660-4777-ab58-206509dad49d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_7ac5ba33-a498-4e08-bac2-26c1f3fe9d18" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_6a88a61a-7ca2-4210-a369-434c4c8a7136" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_7ac5ba33-a498-4e08-bac2-26c1f3fe9d18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireShortTermInvestments_920f976b-96fc-4346-b60d-1794947bb17d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireShortTermInvestments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_7ac5ba33-a498-4e08-bac2-26c1f3fe9d18" xlink:to="loc_us-gaap_PaymentsToAcquireShortTermInvestments_920f976b-96fc-4346-b60d-1794947bb17d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfShortTermInvestments_373bedbd-ddc0-4db1-b43e-8d251cef9c95" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleOfShortTermInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_7ac5ba33-a498-4e08-bac2-26c1f3fe9d18" xlink:to="loc_us-gaap_ProceedsFromSaleOfShortTermInvestments_373bedbd-ddc0-4db1-b43e-8d251cef9c95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_da8a877c-d651-4ee0-9a4c-11077bdd89f7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_7ac5ba33-a498-4e08-bac2-26c1f3fe9d18" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_da8a877c-d651-4ee0-9a4c-11077bdd89f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_7d4836dd-f176-4f75-b816-01aa507cd2a1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_7ac5ba33-a498-4e08-bac2-26c1f3fe9d18" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_7d4836dd-f176-4f75-b816-01aa507cd2a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_3ac29ecf-8ded-47fb-9c12-62623d85cf0b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_6a88a61a-7ca2-4210-a369-434c4c8a7136" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_3ac29ecf-8ded-47fb-9c12-62623d85cf0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_2706792a-2b55-4455-99fc-2c8879217e5b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_3ac29ecf-8ded-47fb-9c12-62623d85cf0b" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_2706792a-2b55-4455-99fc-2c8879217e5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_9d36ca1b-e7d5-4057-9607-b1c9601cfd30" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_3ac29ecf-8ded-47fb-9c12-62623d85cf0b" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_9d36ca1b-e7d5-4057-9607-b1c9601cfd30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_b14c2558-5d87-4148-b59e-d377aea12e17" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_3ac29ecf-8ded-47fb-9c12-62623d85cf0b" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_b14c2558-5d87-4148-b59e-d377aea12e17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMinorityShareholders_86f46c98-3cb8-4c31-a076-0d34ecb3b0d8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromMinorityShareholders"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_3ac29ecf-8ded-47fb-9c12-62623d85cf0b" xlink:to="loc_us-gaap_ProceedsFromMinorityShareholders_86f46c98-3cb8-4c31-a076-0d34ecb3b0d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_3cb2f13f-6fbc-4fde-8b08-b984e130a57c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_3ac29ecf-8ded-47fb-9c12-62623d85cf0b" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_3cb2f13f-6fbc-4fde-8b08-b984e130a57c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_c8f605fd-5a0e-49d5-b187-5fb2239f6173" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_6a88a61a-7ca2-4210-a369-434c4c8a7136" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_c8f605fd-5a0e-49d5-b187-5fb2239f6173" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_c474adfa-d9e5-4434-bc17-0d31c5fa75b0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_6a88a61a-7ca2-4210-a369-434c4c8a7136" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_c474adfa-d9e5-4434-bc17-0d31c5fa75b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_265496d9-4e45-4e11-b0e0-8d3c6bd37bac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_6a88a61a-7ca2-4210-a369-434c4c8a7136" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_265496d9-4e45-4e11-b0e0-8d3c6bd37bac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_62e6388a-b72a-4465-a01b-195d71e74332" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_6a88a61a-7ca2-4210-a369-434c4c8a7136" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_62e6388a-b72a-4465-a01b-195d71e74332" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_053d3c7c-1bab-40a3-b1ee-cf89d5f9518b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_6a88a61a-7ca2-4210-a369-434c4c8a7136" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_053d3c7c-1bab-40a3-b1ee-cf89d5f9518b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities_a6b09dfd-c0b4-485c-ba81-a290540827b8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherAccruedLiabilities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_053d3c7c-1bab-40a3-b1ee-cf89d5f9518b" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities_a6b09dfd-c0b4-485c-ba81-a290540827b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet_51aaafdf-9873-421b-8e10-b6120e81f1c4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestPaidNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_053d3c7c-1bab-40a3-b1ee-cf89d5f9518b" xlink:to="loc_us-gaap_InterestPaidNet_51aaafdf-9873-421b-8e10-b6120e81f1c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_AmortizationOfOperatingLeaseRightOfUseAssets_a2926656-44ad-4dcf-88a9-e8354b742ebb" xlink:href="ino-20210331.xsd#ino_AmortizationOfOperatingLeaseRightOfUseAssets"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_6a88a61a-7ca2-4210-a369-434c4c8a7136" xlink:to="loc_ino_AmortizationOfOperatingLeaseRightOfUseAssets_a2926656-44ad-4dcf-88a9-e8354b742ebb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/OrganizationandOperations" xlink:type="simple" xlink:href="ino-20210331.xsd#OrganizationandOperations"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/OrganizationandOperations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_b6e43fd6-4253-491c-9989-3ecb3cd2ac06" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NatureOfOperations_0ba2fdee-6727-4df0-9e82-2691658b0751" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NatureOfOperations"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_b6e43fd6-4253-491c-9989-3ecb3cd2ac06" xlink:to="loc_us-gaap_NatureOfOperations_0ba2fdee-6727-4df0-9e82-2691658b0751" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/BasisofPresentationLiquidityandRisksandUncertainties" xlink:type="simple" xlink:href="ino-20210331.xsd#BasisofPresentationLiquidityandRisksandUncertainties"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/BasisofPresentationLiquidityandRisksandUncertainties" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_8ac8eedb-17f7-4654-a5d2-5fe9d88b8c3e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_af934c70-6409-4371-a7c7-b144480e9c13" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8ac8eedb-17f7-4654-a5d2-5fe9d88b8c3e" xlink:to="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_af934c70-6409-4371-a7c7-b144480e9c13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/BasisofPresentationLiquidityandRisksandUncertaintiesPolicies" xlink:type="simple" xlink:href="ino-20210331.xsd#BasisofPresentationLiquidityandRisksandUncertaintiesPolicies"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/BasisofPresentationLiquidityandRisksandUncertaintiesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_0106ffe4-4e67-44a8-b398-493d040feec2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_801fea55-2c90-474a-8b0f-00273b1b60db" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0106ffe4-4e67-44a8-b398-493d040feec2" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_801fea55-2c90-474a-8b0f-00273b1b60db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementAccountingPolicy_06a13fdc-3cfd-4c9e-b9a2-e44aba9f9250" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementAccountingPolicy"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0106ffe4-4e67-44a8-b398-493d040feec2" xlink:to="loc_us-gaap_CollaborativeArrangementAccountingPolicy_06a13fdc-3cfd-4c9e-b9a2-e44aba9f9250" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_8ee46a18-a9ec-4c70-bf5f-a6b9355e2787" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0106ffe4-4e67-44a8-b398-493d040feec2" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_8ee46a18-a9ec-4c70-bf5f-a6b9355e2787" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_GrantPolicyPolicyTextBlock_5b00605c-6bea-4469-ab5e-56392c041c19" xlink:href="ino-20210331.xsd#ino_GrantPolicyPolicyTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0106ffe4-4e67-44a8-b398-493d040feec2" xlink:to="loc_ino_GrantPolicyPolicyTextBlock_5b00605c-6bea-4469-ab5e-56392c041c19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock_18a4f539-aa60-43f3-b30b-5e38db35ba97" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0106ffe4-4e67-44a8-b398-493d040feec2" xlink:to="loc_us-gaap_LesseeLeasesPolicyTextBlock_18a4f539-aa60-43f3-b30b-5e38db35ba97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_cbea0a31-f432-4f6d-9a0e-df82f9805174" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0106ffe4-4e67-44a8-b398-493d040feec2" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_cbea0a31-f432-4f6d-9a0e-df82f9805174" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_7ad9add9-1dce-4cc4-8415-2c61ae77c052" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0106ffe4-4e67-44a8-b398-493d040feec2" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_7ad9add9-1dce-4cc4-8415-2c61ae77c052" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_5ffcd0d3-6f40-476f-b09a-673eeb276465" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0106ffe4-4e67-44a8-b398-493d040feec2" xlink:to="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_5ffcd0d3-6f40-476f-b09a-673eeb276465" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationVariableInterestEntityPolicy_ec722740-477d-42c2-828e-4f6dd0b41acd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConsolidationVariableInterestEntityPolicy"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0106ffe4-4e67-44a8-b398-493d040feec2" xlink:to="loc_us-gaap_ConsolidationVariableInterestEntityPolicy_ec722740-477d-42c2-828e-4f6dd0b41acd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValuePolicyTextBlock_44f90fd6-0741-4911-9319-4bfae96902cd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValuePolicyTextBlock"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0106ffe4-4e67-44a8-b398-493d040feec2" xlink:to="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValuePolicyTextBlock_44f90fd6-0741-4911-9319-4bfae96902cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_66d1c6df-9a09-4a46-ab5d-71bcf5382fe6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0106ffe4-4e67-44a8-b398-493d040feec2" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_66d1c6df-9a09-4a46-ab5d-71bcf5382fe6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/BasisofPresentationLiquidityandRisksandUncertaintiesDetails" xlink:type="simple" xlink:href="ino-20210331.xsd#BasisofPresentationLiquidityandRisksandUncertaintiesDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/BasisofPresentationLiquidityandRisksandUncertaintiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_8e83769c-a46f-4fc3-ae99-27e89c579c8f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_0734f951-bced-4de0-ab3f-5660ac46b994" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8e83769c-a46f-4fc3-ae99-27e89c579c8f" xlink:to="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_0734f951-bced-4de0-ab3f-5660ac46b994" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_811cb301-a838-490a-b6ab-167b34c11b9e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_0734f951-bced-4de0-ab3f-5660ac46b994" xlink:to="loc_us-gaap_StatementClassOfStockAxis_811cb301-a838-490a-b6ab-167b34c11b9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_4696952d-c176-4d29-8fc3-db30531d651b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_811cb301-a838-490a-b6ab-167b34c11b9e" xlink:to="loc_us-gaap_ClassOfStockDomain_4696952d-c176-4d29-8fc3-db30531d651b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_a3168a85-2e3f-40fd-abe3-3bff99e4760a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_4696952d-c176-4d29-8fc3-db30531d651b" xlink:to="loc_us-gaap_CommonStockMember_a3168a85-2e3f-40fd-abe3-3bff99e4760a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_18c0ed2a-af32-40c6-a086-2ca2dd891f4b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_0734f951-bced-4de0-ab3f-5660ac46b994" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_18c0ed2a-af32-40c6-a086-2ca2dd891f4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1e1cba72-0ab9-44b3-ae99-ad782ac3563f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_18c0ed2a-af32-40c6-a086-2ca2dd891f4b" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1e1cba72-0ab9-44b3-ae99-ad782ac3563f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_UnderwrittenPublicOfferingMember_4ed6dfbc-e146-410a-bdd0-6dbd52dff9c6" xlink:href="ino-20210331.xsd#ino_UnderwrittenPublicOfferingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1e1cba72-0ab9-44b3-ae99-ad782ac3563f" xlink:to="loc_ino_UnderwrittenPublicOfferingMember_4ed6dfbc-e146-410a-bdd0-6dbd52dff9c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_SalesAgreementsMember_2d58cebd-e910-4c76-8bff-7004f7dde15a" xlink:href="ino-20210331.xsd#ino_SalesAgreementsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1e1cba72-0ab9-44b3-ae99-ad782ac3563f" xlink:to="loc_ino_SalesAgreementsMember_2d58cebd-e910-4c76-8bff-7004f7dde15a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_57959862-003a-4ddf-8a13-fcf0f1387612" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_0734f951-bced-4de0-ab3f-5660ac46b994" xlink:to="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_57959862-003a-4ddf-8a13-fcf0f1387612" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_bdea876f-522f-4885-aea1-2ccae0faf469" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_57959862-003a-4ddf-8a13-fcf0f1387612" xlink:to="loc_us-gaap_NetIncomeLoss_bdea876f-522f-4885-aea1-2ccae0faf469" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Capital_c7d2497e-92a6-4a66-bfa1-a00111a47574" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Capital"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_57959862-003a-4ddf-8a13-fcf0f1387612" xlink:to="loc_us-gaap_Capital_c7d2497e-92a6-4a66-bfa1-a00111a47574" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_9ceae882-e4ff-435b-ad26-b30ef4023c09" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_57959862-003a-4ddf-8a13-fcf0f1387612" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_9ceae882-e4ff-435b-ad26-b30ef4023c09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_a3a3e280-ca81-4a42-8ce5-9a5ccb0c3b06" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_57959862-003a-4ddf-8a13-fcf0f1387612" xlink:to="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_a3a3e280-ca81-4a42-8ce5-9a5ccb0c3b06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_9209d04a-6701-4341-87bb-816d21e8c63e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_57959862-003a-4ddf-8a13-fcf0f1387612" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_9209d04a-6701-4341-87bb-816d21e8c63e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/CriticalAccountingPolicies" xlink:type="simple" xlink:href="ino-20210331.xsd#CriticalAccountingPolicies"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/CriticalAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_ca82c183-457f-41f9-ae54-a8cfebd3fe93" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_d817a261-1618-441b-8286-f89eddd48008" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_ca82c183-457f-41f9-ae54-a8cfebd3fe93" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_d817a261-1618-441b-8286-f89eddd48008" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/CriticalAccountingPoliciesDetails" xlink:type="simple" xlink:href="ino-20210331.xsd#CriticalAccountingPoliciesDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/CriticalAccountingPoliciesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_16f55fa2-721e-4e74-bae0-4a9a4892d9ff" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_dd7f2767-bebd-4622-8428-b62cc78bcbe3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_16f55fa2-721e-4e74-bae0-4a9a4892d9ff" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_dd7f2767-bebd-4622-8428-b62cc78bcbe3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_d6bcc043-0255-4762-88c1-bf1eb1c0cfef" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_dd7f2767-bebd-4622-8428-b62cc78bcbe3" xlink:to="loc_srt_RangeAxis_d6bcc043-0255-4762-88c1-bf1eb1c0cfef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_dcee986d-505b-42af-8028-6127c6350c50" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_d6bcc043-0255-4762-88c1-bf1eb1c0cfef" xlink:to="loc_srt_RangeMember_dcee986d-505b-42af-8028-6127c6350c50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_dbd16149-e148-4cd3-a9bf-9066578b3ee5" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_dcee986d-505b-42af-8028-6127c6350c50" xlink:to="loc_srt_MinimumMember_dbd16149-e148-4cd3-a9bf-9066578b3ee5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_7a0235aa-3787-4cbe-b6f9-a42b24540bc2" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_dcee986d-505b-42af-8028-6127c6350c50" xlink:to="loc_srt_MaximumMember_7a0235aa-3787-4cbe-b6f9-a42b24540bc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_ebcfdec5-63bd-494e-a001-bdc755715721" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_dd7f2767-bebd-4622-8428-b62cc78bcbe3" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_ebcfdec5-63bd-494e-a001-bdc755715721" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_52bd21a1-1084-40fb-8310-b0a0f822cfa3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_ebcfdec5-63bd-494e-a001-bdc755715721" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_52bd21a1-1084-40fb-8310-b0a0f822cfa3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_3ec695aa-b47c-47a2-abe9-0805421f4dab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_ebcfdec5-63bd-494e-a001-bdc755715721" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_3ec695aa-b47c-47a2-abe9-0805421f4dab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/ImpactofRecentlyIssuedAccountingStandards" xlink:type="simple" xlink:href="ino-20210331.xsd#ImpactofRecentlyIssuedAccountingStandards"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/ImpactofRecentlyIssuedAccountingStandards" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_71dab2dc-1446-4d1a-9c3d-cbf61174000f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_89896ffd-42bf-40c4-be36-8c4657bbb2ff" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_71dab2dc-1446-4d1a-9c3d-cbf61174000f" xlink:to="loc_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_89896ffd-42bf-40c4-be36-8c4657bbb2ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/RevenueRecognition" xlink:type="simple" xlink:href="ino-20210331.xsd#RevenueRecognition"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/RevenueRecognition" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_e85b7694-521c-4cbf-bd87-b2ee9365bb72" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_328c0700-0979-48f2-b457-8099f537dc3d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_e85b7694-521c-4cbf-bd87-b2ee9365bb72" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_328c0700-0979-48f2-b457-8099f537dc3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/RevenueRecognitionDetails" xlink:type="simple" xlink:href="ino-20210331.xsd#RevenueRecognitionDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/RevenueRecognitionDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_c2dc2faa-aff7-40c9-aea3-4a8168de76a9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_c225079b-a6bd-4a7b-8f10-8e31ad502461" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_c2dc2faa-aff7-40c9-aea3-4a8168de76a9" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_c225079b-a6bd-4a7b-8f10-8e31ad502461" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_0a9d09cc-5c96-4d30-80e8-0a83cab3d4fc" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_c225079b-a6bd-4a7b-8f10-8e31ad502461" xlink:to="loc_srt_CounterpartyNameAxis_0a9d09cc-5c96-4d30-80e8-0a83cab3d4fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3806d28c-8c8e-45c9-ae2f-e45ac0e47992" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_0a9d09cc-5c96-4d30-80e8-0a83cab3d4fc" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3806d28c-8c8e-45c9-ae2f-e45ac0e47992" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_PlumblineLifeSciencesMember_42b81eb2-69f2-456b-a2b8-57f1e0d1be09" xlink:href="ino-20210331.xsd#ino_PlumblineLifeSciencesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3806d28c-8c8e-45c9-ae2f-e45ac0e47992" xlink:to="loc_ino_PlumblineLifeSciencesMember_42b81eb2-69f2-456b-a2b8-57f1e0d1be09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_OtherCounterpartyMember_c8319c8d-84e9-4278-825f-ff0e81e4b263" xlink:href="ino-20210331.xsd#ino_OtherCounterpartyMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3806d28c-8c8e-45c9-ae2f-e45ac0e47992" xlink:to="loc_ino_OtherCounterpartyMember_c8319c8d-84e9-4278-825f-ff0e81e4b263" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_f06b8e5d-287a-42ed-a65c-3c0087e8542e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_c225079b-a6bd-4a7b-8f10-8e31ad502461" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_f06b8e5d-287a-42ed-a65c-3c0087e8542e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_e3e178be-d69a-4896-86ad-ab92083824fa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_f06b8e5d-287a-42ed-a65c-3c0087e8542e" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_e3e178be-d69a-4896-86ad-ab92083824fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_cf2fdf6b-60c5-46cd-bfbd-0c5e31f13df6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_f06b8e5d-287a-42ed-a65c-3c0087e8542e" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_cf2fdf6b-60c5-46cd-bfbd-0c5e31f13df6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/ShorttermInvestments" xlink:type="simple" xlink:href="ino-20210331.xsd#ShorttermInvestments"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/ShorttermInvestments" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_946bc532-6207-4d76-b7d5-3a46213d7348" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_79d94486-e6c6-4a48-b93d-556034b09cd8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_946bc532-6207-4d76-b7d5-3a46213d7348" xlink:to="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_79d94486-e6c6-4a48-b93d-556034b09cd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/ShorttermInvestmentsTables" xlink:type="simple" xlink:href="ino-20210331.xsd#ShorttermInvestmentsTables"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/ShorttermInvestmentsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_eef26b15-cb15-45ad-82e1-4049c7da9b67" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_199263cb-f675-445a-9e5d-da89beaf62d0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_eef26b15-cb15-45ad-82e1-4049c7da9b67" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_199263cb-f675-445a-9e5d-da89beaf62d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/ShorttermInvestmentsNarrativeDetails" xlink:type="simple" xlink:href="ino-20210331.xsd#ShorttermInvestmentsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/ShorttermInvestmentsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_596ae92f-4297-4200-b072-10794ac3271a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain_bac73f81-771f-47d6-86ec-8f24456ae4f2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedGain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_596ae92f-4297-4200-b072-10794ac3271a" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain_bac73f81-771f-47d6-86ec-8f24456ae4f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss_f7ca1639-babc-490a-92a3-5e6092ce00b2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_596ae92f-4297-4200-b072-10794ac3271a" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss_f7ca1639-babc-490a-92a3-5e6092ce00b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_37bed02d-6374-401f-922d-727944dda617" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_596ae92f-4297-4200-b072-10794ac3271a" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_37bed02d-6374-401f-922d-727944dda617" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/ShorttermInvestmentsSummaryofAvailableforsaleSecuritiesDetails" xlink:type="simple" xlink:href="ino-20210331.xsd#ShorttermInvestmentsSummaryofAvailableforsaleSecuritiesDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/ShorttermInvestmentsSummaryofAvailableforsaleSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_d24fbdad-6f79-499a-a57f-c25a3b9fc2e3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_5c2fee20-0f2e-454c-9b7f-e8ef2bc48dd9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_d24fbdad-6f79-499a-a57f-c25a3b9fc2e3" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_5c2fee20-0f2e-454c-9b7f-e8ef2bc48dd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_f314257a-1057-4b2a-961a-76f5c73aa07e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_5c2fee20-0f2e-454c-9b7f-e8ef2bc48dd9" xlink:to="loc_us-gaap_FinancialInstrumentAxis_f314257a-1057-4b2a-961a-76f5c73aa07e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_da8a33af-3a49-4a52-bba6-fdf3abf8dd8f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_f314257a-1057-4b2a-961a-76f5c73aa07e" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_da8a33af-3a49-4a52-bba6-fdf3abf8dd8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_MutualFundsMember_d5072d9d-cb6d-4892-b5bf-7578c8332cab" xlink:href="ino-20210331.xsd#ino_MutualFundsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_da8a33af-3a49-4a52-bba6-fdf3abf8dd8f" xlink:to="loc_ino_MutualFundsMember_d5072d9d-cb6d-4892-b5bf-7578c8332cab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryBillSecuritiesMember_14fc8b6c-c1a4-4fb4-bc15-4d9961e93720" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USTreasuryBillSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_da8a33af-3a49-4a52-bba6-fdf3abf8dd8f" xlink:to="loc_us-gaap_USTreasuryBillSecuritiesMember_14fc8b6c-c1a4-4fb4-bc15-4d9961e93720" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_0ce71db0-7374-4fee-b704-63f6f94f2aa1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_da8a33af-3a49-4a52-bba6-fdf3abf8dd8f" xlink:to="loc_us-gaap_CertificatesOfDepositMember_0ce71db0-7374-4fee-b704-63f6f94f2aa1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember_4ad939a2-cf5f-44a8-9b4f-f87e247ab005" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_da8a33af-3a49-4a52-bba6-fdf3abf8dd8f" xlink:to="loc_us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember_4ad939a2-cf5f-44a8-9b4f-f87e247ab005" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_593b97b8-2eb4-4a67-b2a6-0420329499e9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_5c2fee20-0f2e-454c-9b7f-e8ef2bc48dd9" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_593b97b8-2eb4-4a67-b2a6-0420329499e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DebtSecuritiesAvailableforSaleContractualMaturity_9af8868c-bbd2-4595-ab97-a3ed749a859f" xlink:href="ino-20210331.xsd#ino_DebtSecuritiesAvailableforSaleContractualMaturity"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_593b97b8-2eb4-4a67-b2a6-0420329499e9" xlink:to="loc_ino_DebtSecuritiesAvailableforSaleContractualMaturity_9af8868c-bbd2-4595-ab97-a3ed749a859f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAbstract_257cf299-987b-4b11-890b-4bf7ae2bf8a3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_593b97b8-2eb4-4a67-b2a6-0420329499e9" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAbstract_257cf299-987b-4b11-890b-4bf7ae2bf8a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_409c39fd-7d5a-4b5e-9b92-1175bf83ca59" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_257cf299-987b-4b11-890b-4bf7ae2bf8a3" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_409c39fd-7d5a-4b5e-9b92-1175bf83ca59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_204fbc2a-9404-4dc5-bb24-89bb460f71db" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_257cf299-987b-4b11-890b-4bf7ae2bf8a3" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_204fbc2a-9404-4dc5-bb24-89bb460f71db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_33f40f02-6b74-4353-952f-ac16eafb4e62" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_257cf299-987b-4b11-890b-4bf7ae2bf8a3" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_33f40f02-6b74-4353-952f-ac16eafb4e62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_f53353a5-a5a8-4ba8-a5d1-76e11be8c4a5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_257cf299-987b-4b11-890b-4bf7ae2bf8a3" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_f53353a5-a5a8-4ba8-a5d1-76e11be8c4a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/FairValueMeasurements" xlink:type="simple" xlink:href="ino-20210331.xsd#FairValueMeasurements"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/FairValueMeasurements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_5f18de4f-367c-4947-bf05-f3677c27f00f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_11a7ed86-8caf-49d2-ac18-5d4b2fbdd896" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_5f18de4f-367c-4947-bf05-f3677c27f00f" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_11a7ed86-8caf-49d2-ac18-5d4b2fbdd896" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/FairValueMeasurementsTables" xlink:type="simple" xlink:href="ino-20210331.xsd#FairValueMeasurementsTables"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/FairValueMeasurementsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_520d9275-2687-4361-b5b0-480acb018031" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_4cddfe37-e709-46b1-a567-f337c091f271" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_520d9275-2687-4361-b5b0-480acb018031" xlink:to="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_4cddfe37-e709-46b1-a567-f337c091f271" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueDetails" xlink:type="simple" xlink:href="ino-20210331.xsd#FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_c4ddb5b4-76f4-4947-8899-f699e3015a64" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable_364ac3f2-7f59-481e-a675-c1c46f070a81" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_c4ddb5b4-76f4-4947-8899-f699e3015a64" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTable_364ac3f2-7f59-481e-a675-c1c46f070a81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_3e50147d-8ef8-48a9-b9ed-3a6e4bfc64e8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_364ac3f2-7f59-481e-a675-c1c46f070a81" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_3e50147d-8ef8-48a9-b9ed-3a6e4bfc64e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_e65c6c3a-1dd5-4d3c-9581-73cb2b2cea6d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_3e50147d-8ef8-48a9-b9ed-3a6e4bfc64e8" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_e65c6c3a-1dd5-4d3c-9581-73cb2b2cea6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_3d20ca36-92ff-492d-9192-c9e3136ef7bd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_e65c6c3a-1dd5-4d3c-9581-73cb2b2cea6d" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_3d20ca36-92ff-492d-9192-c9e3136ef7bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_7a735b3d-a139-40a4-aaf5-834c9aab8a8a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_364ac3f2-7f59-481e-a675-c1c46f070a81" xlink:to="loc_us-gaap_FinancialInstrumentAxis_7a735b3d-a139-40a4-aaf5-834c9aab8a8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_c40cebef-4182-4724-98d8-8030ca731b1d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_7a735b3d-a139-40a4-aaf5-834c9aab8a8a" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_c40cebef-4182-4724-98d8-8030ca731b1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_MutualFundsMember_a03be2d9-55ed-4419-a977-a8fe3075644e" xlink:href="ino-20210331.xsd#ino_MutualFundsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_c40cebef-4182-4724-98d8-8030ca731b1d" xlink:to="loc_ino_MutualFundsMember_a03be2d9-55ed-4419-a977-a8fe3075644e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryBillSecuritiesMember_271bee42-5a70-4830-ac27-92a27b36928d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USTreasuryBillSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_c40cebef-4182-4724-98d8-8030ca731b1d" xlink:to="loc_us-gaap_USTreasuryBillSecuritiesMember_271bee42-5a70-4830-ac27-92a27b36928d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_1ec89b39-1d1c-4209-a37f-096543e2101c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_c40cebef-4182-4724-98d8-8030ca731b1d" xlink:to="loc_us-gaap_CertificatesOfDepositMember_1ec89b39-1d1c-4209-a37f-096543e2101c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember_e3c0d414-2ee4-4e6a-b2b3-bf9e02a2baf6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_c40cebef-4182-4724-98d8-8030ca731b1d" xlink:to="loc_us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember_e3c0d414-2ee4-4e6a-b2b3-bf9e02a2baf6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_765db902-5747-4427-83f6-92cd24dc978f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_364ac3f2-7f59-481e-a675-c1c46f070a81" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_765db902-5747-4427-83f6-92cd24dc978f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2ccee0fb-1af8-48e3-b63f-970fa20432b2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_765db902-5747-4427-83f6-92cd24dc978f" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2ccee0fb-1af8-48e3-b63f-970fa20432b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_15e2910b-8e98-4705-922e-1fe1a9442bee" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2ccee0fb-1af8-48e3-b63f-970fa20432b2" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_15e2910b-8e98-4705-922e-1fe1a9442bee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_f5b28a2d-243e-4676-9471-a4e5ee718853" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2ccee0fb-1af8-48e3-b63f-970fa20432b2" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_f5b28a2d-243e-4676-9471-a4e5ee718853" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_94abae74-ef85-4266-84ff-e36b6c2e31a9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2ccee0fb-1af8-48e3-b63f-970fa20432b2" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_94abae74-ef85-4266-84ff-e36b6c2e31a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_767bd444-0f30-40ee-8940-5f154e7e0c11" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_364ac3f2-7f59-481e-a675-c1c46f070a81" xlink:to="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_767bd444-0f30-40ee-8940-5f154e7e0c11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_a62b38a7-c020-4b17-830e-1d06a5c0d723" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_767bd444-0f30-40ee-8940-5f154e7e0c11" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_a62b38a7-c020-4b17-830e-1d06a5c0d723" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_904971fc-e61e-4ae4-9ae0-8ece0d2d02f8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_a62b38a7-c020-4b17-830e-1d06a5c0d723" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_904971fc-e61e-4ae4-9ae0-8ece0d2d02f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_832b59b3-c27c-46c2-bcba-0779e6e7c859" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_a62b38a7-c020-4b17-830e-1d06a5c0d723" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_832b59b3-c27c-46c2-bcba-0779e6e7c859" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_288dcff6-8041-47d4-a7b7-a44664018ad4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_a62b38a7-c020-4b17-830e-1d06a5c0d723" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_288dcff6-8041-47d4-a7b7-a44664018ad4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_d17fc040-d6ba-4de4-a269-34033eddb582" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_a62b38a7-c020-4b17-830e-1d06a5c0d723" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_d17fc040-d6ba-4de4-a269-34033eddb582" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/FairValueMeasurementsNarrativeDetails" xlink:type="simple" xlink:href="ino-20210331.xsd#FairValueMeasurementsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/FairValueMeasurementsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_09e5460d-0be4-408e-b292-2af784eee815" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable_16e2e649-6896-459f-a63c-5c19b9926082" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_09e5460d-0be4-408e-b292-2af784eee815" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTable_16e2e649-6896-459f-a63c-5c19b9926082" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_f974ca85-0902-4d54-8791-bc9ac190fe46" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_16e2e649-6896-459f-a63c-5c19b9926082" xlink:to="loc_us-gaap_StatementClassOfStockAxis_f974ca85-0902-4d54-8791-bc9ac190fe46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_066c2cbe-810d-42b8-b4bf-bd85077f7cb2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_f974ca85-0902-4d54-8791-bc9ac190fe46" xlink:to="loc_us-gaap_ClassOfStockDomain_066c2cbe-810d-42b8-b4bf-bd85077f7cb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_5db0f8dc-d0d9-41dd-984e-668f2d26c4d7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_066c2cbe-810d-42b8-b4bf-bd85077f7cb2" xlink:to="loc_us-gaap_CommonStockMember_5db0f8dc-d0d9-41dd-984e-668f2d26c4d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_270634f3-c7c1-4323-a898-a1e63b7bfd40" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_16e2e649-6896-459f-a63c-5c19b9926082" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_270634f3-c7c1-4323-a898-a1e63b7bfd40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_515f638f-161f-48e3-b57e-fed2253eda18" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_270634f3-c7c1-4323-a898-a1e63b7bfd40" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_515f638f-161f-48e3-b57e-fed2253eda18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_c4189f49-ebfa-4e97-aef0-4653d6ac269d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_515f638f-161f-48e3-b57e-fed2253eda18" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_c4189f49-ebfa-4e97-aef0-4653d6ac269d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_b84c50e7-180b-4be9-bc7c-476b1ad07eb1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_16e2e649-6896-459f-a63c-5c19b9926082" xlink:to="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_b84c50e7-180b-4be9-bc7c-476b1ad07eb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_MarketableSecuritiesAndFairValueMeasurementsTextualAbstract_733b3053-28b6-436c-af75-fc6989d9a44f" xlink:href="ino-20210331.xsd#ino_MarketableSecuritiesAndFairValueMeasurementsTextualAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_b84c50e7-180b-4be9-bc7c-476b1ad07eb1" xlink:to="loc_ino_MarketableSecuritiesAndFairValueMeasurementsTextualAbstract_733b3053-28b6-436c-af75-fc6989d9a44f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentOwnedBalanceShares_7fc45df3-f896-45ae-b9f0-dd652ad30dd6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentOwnedBalanceShares"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ino_MarketableSecuritiesAndFairValueMeasurementsTextualAbstract_733b3053-28b6-436c-af75-fc6989d9a44f" xlink:to="loc_us-gaap_InvestmentOwnedBalanceShares_7fc45df3-f896-45ae-b9f0-dd652ad30dd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/GoodwillandIntangibleAssets" xlink:type="simple" xlink:href="ino-20210331.xsd#GoodwillandIntangibleAssets"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/GoodwillandIntangibleAssets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_418e1dfe-894f-476e-833b-4b37b82d559a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_be54f268-3a04-4c47-ba7b-e9ce7c77d92e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_418e1dfe-894f-476e-833b-4b37b82d559a" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_be54f268-3a04-4c47-ba7b-e9ce7c77d92e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/GoodwillandIntangibleAssetsTables" xlink:type="simple" xlink:href="ino-20210331.xsd#GoodwillandIntangibleAssetsTables"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/GoodwillandIntangibleAssetsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_384285ba-4365-404c-ba8f-7cdf982d5feb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_1cdbf14c-b5fa-418a-8c8f-c38b9f62057d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_384285ba-4365-404c-ba8f-7cdf982d5feb" xlink:to="loc_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_1cdbf14c-b5fa-418a-8c8f-c38b9f62057d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/GoodwillandIntangibleAssetsScheduleGoodwillandIntangibleAssetsDetails" xlink:type="simple" xlink:href="ino-20210331.xsd#GoodwillandIntangibleAssetsScheduleGoodwillandIntangibleAssetsDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/GoodwillandIntangibleAssetsScheduleGoodwillandIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_e5c61df2-addc-4238-9647-7c84fecf788d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable_f6625a2f-7f08-4b14-a696-48449d99e20f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_e5c61df2-addc-4238-9647-7c84fecf788d" xlink:to="loc_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable_f6625a2f-7f08-4b14-a696-48449d99e20f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_c6aab640-7821-474b-8777-cc6df13aa2af" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable_f6625a2f-7f08-4b14-a696-48449d99e20f" xlink:to="loc_srt_RangeAxis_c6aab640-7821-474b-8777-cc6df13aa2af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_23b1f54a-e7bd-430b-8114-93a02f14f83a" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_c6aab640-7821-474b-8777-cc6df13aa2af" xlink:to="loc_srt_RangeMember_23b1f54a-e7bd-430b-8114-93a02f14f83a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_WeightedAverageMember_ade133d9-2adf-4edf-995a-1a26de6de148" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_WeightedAverageMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_23b1f54a-e7bd-430b-8114-93a02f14f83a" xlink:to="loc_srt_WeightedAverageMember_ade133d9-2adf-4edf-995a-1a26de6de148" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_f635ff1a-5923-4736-9460-4daea0f22eb0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable_f6625a2f-7f08-4b14-a696-48449d99e20f" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_f635ff1a-5923-4736-9460-4daea0f22eb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_d6201918-d19f-4bed-8a45-fb48191c8368" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_f635ff1a-5923-4736-9460-4daea0f22eb0" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_d6201918-d19f-4bed-8a45-fb48191c8368" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicensingAgreementsMember_e3b198d3-b26d-43ea-a184-8a8639371c7f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LicensingAgreementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_d6201918-d19f-4bed-8a45-fb48191c8368" xlink:to="loc_us-gaap_LicensingAgreementsMember_e3b198d3-b26d-43ea-a184-8a8639371c7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_BiojectMember_7d7fde49-657a-4eaf-b4c1-1cc3144dc89f" xlink:href="ino-20210331.xsd#ino_BiojectMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_d6201918-d19f-4bed-8a45-fb48191c8368" xlink:to="loc_ino_BiojectMember_7d7fde49-657a-4eaf-b4c1-1cc3144dc89f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIntangibleAssetsMember_daa8fba5-e1fb-429b-a097-f6ad23c32633" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherIntangibleAssetsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_d6201918-d19f-4bed-8a45-fb48191c8368" xlink:to="loc_us-gaap_OtherIntangibleAssetsMember_daa8fba5-e1fb-429b-a097-f6ad23c32633" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_3fe5f880-46cf-4133-af6a-60dbc49d7f91" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable_f6625a2f-7f08-4b14-a696-48449d99e20f" xlink:to="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_3fe5f880-46cf-4133-af6a-60dbc49d7f91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_a781c649-a03d-4cd9-901d-473c6927725e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_3fe5f880-46cf-4133-af6a-60dbc49d7f91" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_a781c649-a03d-4cd9-901d-473c6927725e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_c349eb09-c987-4260-89d5-8c0fd1bdc4e9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNetAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_a781c649-a03d-4cd9-901d-473c6927725e" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_c349eb09-c987-4260-89d5-8c0fd1bdc4e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillGross_5c6380dd-a766-4dea-af97-97cbde23f8a5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_c349eb09-c987-4260-89d5-8c0fd1bdc4e9" xlink:to="loc_us-gaap_GoodwillGross_5c6380dd-a766-4dea-af97-97cbde23f8a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_c78ff7e7-7bfa-4471-a4a4-43c78418a292" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_c349eb09-c987-4260-89d5-8c0fd1bdc4e9" xlink:to="loc_us-gaap_Goodwill_c78ff7e7-7bfa-4471-a4a4-43c78418a292" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_bb1adf7c-e890-4df1-a480-3946b735ac69" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_a781c649-a03d-4cd9-901d-473c6927725e" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_bb1adf7c-e890-4df1-a480-3946b735ac69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_715603c8-8647-49ca-90a9-b09e80c4a257" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_bb1adf7c-e890-4df1-a480-3946b735ac69" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_715603c8-8647-49ca-90a9-b09e80c4a257" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_fc457d44-9867-4e85-aebe-bbd556811355" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_bb1adf7c-e890-4df1-a480-3946b735ac69" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_fc457d44-9867-4e85-aebe-bbd556811355" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_ec61af95-44c7-4b95-9f5b-5b8e70a0c177" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_bb1adf7c-e890-4df1-a480-3946b735ac69" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_ec61af95-44c7-4b95-9f5b-5b8e70a0c177" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_806e7b56-f0a3-485c-89fe-0a79e0b9ba06" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_bb1adf7c-e890-4df1-a480-3946b735ac69" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_806e7b56-f0a3-485c-89fe-0a79e0b9ba06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_GoodwillAndIntangibleAssetsGross_8f5f196b-834e-4d9b-a51d-138aa8a4ebf2" xlink:href="ino-20210331.xsd#ino_GoodwillAndIntangibleAssetsGross"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_a781c649-a03d-4cd9-901d-473c6927725e" xlink:to="loc_ino_GoodwillAndIntangibleAssetsGross_8f5f196b-834e-4d9b-a51d-138aa8a4ebf2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_GoodwillAndIntangibleAssetsNet_394cff18-277c-419b-9548-aa1fddbca597" xlink:href="ino-20210331.xsd#ino_GoodwillAndIntangibleAssetsNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_a781c649-a03d-4cd9-901d-473c6927725e" xlink:to="loc_ino_GoodwillAndIntangibleAssetsNet_394cff18-277c-419b-9548-aa1fddbca597" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/GoodwillandIntangibleAssetsNarrativeDetails" xlink:type="simple" xlink:href="ino-20210331.xsd#GoodwillandIntangibleAssetsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/GoodwillandIntangibleAssetsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_fe1040a0-c31b-45eb-959d-493c42c19125" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_dc8971e5-deb9-402b-b277-c739207a08b6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_fe1040a0-c31b-45eb-959d-493c42c19125" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_dc8971e5-deb9-402b-b277-c739207a08b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_50d08057-ec3d-4acf-822c-56aa977939f5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_fe1040a0-c31b-45eb-959d-493c42c19125" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_50d08057-ec3d-4acf-822c-56aa977939f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_242ff30e-7475-4cfa-8f10-d1a47152e193" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_fe1040a0-c31b-45eb-959d-493c42c19125" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_242ff30e-7475-4cfa-8f10-d1a47152e193" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_b11552fd-5510-48bb-a030-39414967f57b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_fe1040a0-c31b-45eb-959d-493c42c19125" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_b11552fd-5510-48bb-a030-39414967f57b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_1796f5af-9a46-4372-b508-4d28f57fc898" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_fe1040a0-c31b-45eb-959d-493c42c19125" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_1796f5af-9a46-4372-b508-4d28f57fc898" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_a8ce6c08-6180-4528-b0fd-191f634b7c25" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_fe1040a0-c31b-45eb-959d-493c42c19125" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_a8ce6c08-6180-4528-b0fd-191f634b7c25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour_793b6866-69c3-4f71-b8a9-4091e43ce3a2" xlink:href="ino-20210331.xsd#ino_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_fe1040a0-c31b-45eb-959d-493c42c19125" xlink:to="loc_ino_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour_793b6866-69c3-4f71-b8a9-4091e43ce3a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/ConvertibleDebt" xlink:type="simple" xlink:href="ino-20210331.xsd#ConvertibleDebt"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/ConvertibleDebt" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_ad9af05c-741c-4b88-abc9-4c44c8f748b2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_ae193f7e-aabd-4cf0-9f13-4c717dc9ed58" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_ad9af05c-741c-4b88-abc9-4c44c8f748b2" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_ae193f7e-aabd-4cf0-9f13-4c717dc9ed58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/ConvertibleDebtTables" xlink:type="simple" xlink:href="ino-20210331.xsd#ConvertibleDebtTables"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/ConvertibleDebtTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_786013fa-d163-4e30-8b12-cff9517cd02f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtTableTextBlock_5b3be942-7aac-4ef4-9e61-aba0f498688f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleDebtTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_786013fa-d163-4e30-8b12-cff9517cd02f" xlink:to="loc_us-gaap_ConvertibleDebtTableTextBlock_5b3be942-7aac-4ef4-9e61-aba0f498688f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_71e13160-f1aa-463d-bf47-3aa188471720" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_786013fa-d163-4e30-8b12-cff9517cd02f" xlink:to="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_71e13160-f1aa-463d-bf47-3aa188471720" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/ConvertibleDebtNarrativeDetails" xlink:type="simple" xlink:href="ino-20210331.xsd#ConvertibleDebtNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/ConvertibleDebtNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_56d78541-e2d7-4aa3-834b-33d9a4eae4d3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_8348ec4c-5d61-43eb-a9a3-b6cdd3a9f447" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_56d78541-e2d7-4aa3-834b-33d9a4eae4d3" xlink:to="loc_us-gaap_DebtInstrumentTable_8348ec4c-5d61-43eb-a9a3-b6cdd3a9f447" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_15be3848-a1b2-4849-8fd9-16aa6c6c850e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_8348ec4c-5d61-43eb-a9a3-b6cdd3a9f447" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_15be3848-a1b2-4849-8fd9-16aa6c6c850e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_e4902430-7c80-4883-9d13-af8fc3b2eed2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_15be3848-a1b2-4849-8fd9-16aa6c6c850e" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_e4902430-7c80-4883-9d13-af8fc3b2eed2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtMember_758d2f76-534d-4825-85a1-c4dbae99e34a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_e4902430-7c80-4883-9d13-af8fc3b2eed2" xlink:to="loc_us-gaap_ConvertibleDebtMember_758d2f76-534d-4825-85a1-c4dbae99e34a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_e7fb44c2-2655-4f68-8d55-0e0dcc9926cc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_8348ec4c-5d61-43eb-a9a3-b6cdd3a9f447" xlink:to="loc_us-gaap_DebtInstrumentAxis_e7fb44c2-2655-4f68-8d55-0e0dcc9926cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_d114c223-fdaa-4c3c-8774-e4ba1c57253f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_e7fb44c2-2655-4f68-8d55-0e0dcc9926cc" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_d114c223-fdaa-4c3c-8774-e4ba1c57253f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_A6.50ConvertibleSeniorNotesDue2024Member_a6eee139-da1b-4454-af21-7d0968430523" xlink:href="ino-20210331.xsd#ino_A6.50ConvertibleSeniorNotesDue2024Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d114c223-fdaa-4c3c-8774-e4ba1c57253f" xlink:to="loc_ino_A6.50ConvertibleSeniorNotesDue2024Member_a6eee139-da1b-4454-af21-7d0968430523" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_August2019ConvertibleBondsMember_6f937dfd-4b47-40e1-9989-08692aba07ac" xlink:href="ino-20210331.xsd#ino_August2019ConvertibleBondsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d114c223-fdaa-4c3c-8774-e4ba1c57253f" xlink:to="loc_ino_August2019ConvertibleBondsMember_6f937dfd-4b47-40e1-9989-08692aba07ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_December2019ConvertibleBondsMember_a895d675-b44e-4214-9bce-e06983099308" xlink:href="ino-20210331.xsd#ino_December2019ConvertibleBondsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d114c223-fdaa-4c3c-8774-e4ba1c57253f" xlink:to="loc_ino_December2019ConvertibleBondsMember_a895d675-b44e-4214-9bce-e06983099308" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionByUniqueDescriptionAxis_7af8955f-a334-468e-b827-489922a382e6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtConversionByUniqueDescriptionAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_8348ec4c-5d61-43eb-a9a3-b6cdd3a9f447" xlink:to="loc_us-gaap_DebtConversionByUniqueDescriptionAxis_7af8955f-a334-468e-b827-489922a382e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionNameDomain_fadd11ff-8520-4abb-9a4e-c0baf39139f6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtConversionNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtConversionByUniqueDescriptionAxis_7af8955f-a334-468e-b827-489922a382e6" xlink:to="loc_us-gaap_DebtConversionNameDomain_fadd11ff-8520-4abb-9a4e-c0baf39139f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_InitialConversionPriceMember_49aae850-8d69-44fb-91c3-2f276752c9dc" xlink:href="ino-20210331.xsd#ino_InitialConversionPriceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtConversionNameDomain_fadd11ff-8520-4abb-9a4e-c0baf39139f6" xlink:to="loc_ino_InitialConversionPriceMember_49aae850-8d69-44fb-91c3-2f276752c9dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_8099d524-e11d-49ad-a328-96abaaf99875" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_8348ec4c-5d61-43eb-a9a3-b6cdd3a9f447" xlink:to="loc_us-gaap_StatementClassOfStockAxis_8099d524-e11d-49ad-a328-96abaaf99875" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_4e3489e7-2ffe-4a44-b14e-9de6f0d33fc5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_8099d524-e11d-49ad-a328-96abaaf99875" xlink:to="loc_us-gaap_ClassOfStockDomain_4e3489e7-2ffe-4a44-b14e-9de6f0d33fc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_f282a6c0-da08-43a1-ba11-ec72f722d532" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_4e3489e7-2ffe-4a44-b14e-9de6f0d33fc5" xlink:to="loc_us-gaap_CommonStockMember_f282a6c0-da08-43a1-ba11-ec72f722d532" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_82a830bb-736c-4539-83bb-e15ada8cf6a6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_8348ec4c-5d61-43eb-a9a3-b6cdd3a9f447" xlink:to="loc_us-gaap_DebtInstrumentLineItems_82a830bb-736c-4539-83bb-e15ada8cf6a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_6c8bcd98-ed19-4a89-a649-bde1891fa8d8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_82a830bb-736c-4539-83bb-e15ada8cf6a6" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_6c8bcd98-ed19-4a89-a649-bde1891fa8d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_e5cad95b-fb58-414d-b464-92bbde101f3e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_82a830bb-736c-4539-83bb-e15ada8cf6a6" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_e5cad95b-fb58-414d-b464-92bbde101f3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfDebt_11db382a-7ff8-4118-9f04-391180214b6e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfDebt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_82a830bb-736c-4539-83bb-e15ada8cf6a6" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfDebt_11db382a-7ff8-4118-9f04-391180214b6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_b51e6d83-9a34-450f-873a-c919d0b6ef3d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionRatio1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_82a830bb-736c-4539-83bb-e15ada8cf6a6" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_b51e6d83-9a34-450f-873a-c919d0b6ef3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_228a4715-4f95-4493-9f7c-a992ebe5e4ef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_82a830bb-736c-4539-83bb-e15ada8cf6a6" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_228a4715-4f95-4493-9f7c-a992ebe5e4ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_bb42de18-7a1f-40db-a0e1-8cf805abc35c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_82a830bb-736c-4539-83bb-e15ada8cf6a6" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_bb42de18-7a1f-40db-a0e1-8cf805abc35c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_b025c248-7fe8-44c8-9286-c7034c80c01a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdTradingDays"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_82a830bb-736c-4539-83bb-e15ada8cf6a6" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_b025c248-7fe8-44c8-9286-c7034c80c01a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_95431d9c-f505-4d72-8a19-a7dc743b6c9f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_82a830bb-736c-4539-83bb-e15ada8cf6a6" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_95431d9c-f505-4d72-8a19-a7dc743b6c9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_c9adaefe-8041-47be-8005-f5350804ffc2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentRedemptionPricePercentage"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_82a830bb-736c-4539-83bb-e15ada8cf6a6" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_c9adaefe-8041-47be-8005-f5350804ffc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent_b3b56d4d-cdeb-4576-881d-ae395de30609" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_82a830bb-736c-4539-83bb-e15ada8cf6a6" xlink:to="loc_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent_b3b56d4d-cdeb-4576-881d-ae395de30609" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_e50416b3-1952-4749-908d-8f040b06465e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_82a830bb-736c-4539-83bb-e15ada8cf6a6" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_e50416b3-1952-4749-908d-8f040b06465e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount_071cb127-ade9-4786-9998-4bc2926dd6d0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_82a830bb-736c-4539-83bb-e15ada8cf6a6" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscount_071cb127-ade9-4786-9998-4bc2926dd6d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_958173ed-88a2-43b8-b1ad-152f47cb3996" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_82a830bb-736c-4539-83bb-e15ada8cf6a6" xlink:to="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_958173ed-88a2-43b8-b1ad-152f47cb3996" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_d0ba61d1-a55a-4b5c-b343-7213a823c95f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_82a830bb-736c-4539-83bb-e15ada8cf6a6" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_d0ba61d1-a55a-4b5c-b343-7213a823c95f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_5144d675-2c32-4242-943b-3087bd416d6f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_82a830bb-736c-4539-83bb-e15ada8cf6a6" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_5144d675-2c32-4242-943b-3087bd416d6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFairValue_e6c3755d-f492-4f82-b500-6af864b37d5d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFairValue"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_82a830bb-736c-4539-83bb-e15ada8cf6a6" xlink:to="loc_us-gaap_DebtInstrumentFairValue_e6c3755d-f492-4f82-b500-6af864b37d5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_f45bed0e-38cd-4144-8049-5e8be7d8ae32" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_82a830bb-736c-4539-83bb-e15ada8cf6a6" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_f45bed0e-38cd-4144-8049-5e8be7d8ae32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_53b60748-3594-46af-a59e-a57711596a35" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_82a830bb-736c-4539-83bb-e15ada8cf6a6" xlink:to="loc_us-gaap_InterestExpense_53b60748-3594-46af-a59e-a57711596a35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt_a289b01e-f53d-445f-85d8-b7e4a6c33aac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpenseDebt"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_82a830bb-736c-4539-83bb-e15ada8cf6a6" xlink:to="loc_us-gaap_InterestExpenseDebt_a289b01e-f53d-445f-85d8-b7e4a6c33aac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability_99c3430f-5754-42f6-b059-55bcbbf9db42" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_82a830bb-736c-4539-83bb-e15ada8cf6a6" xlink:to="loc_us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability_99c3430f-5754-42f6-b059-55bcbbf9db42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet_ab170245-6b11-4ecc-8b09-59c3ef88aed1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_82a830bb-736c-4539-83bb-e15ada8cf6a6" xlink:to="loc_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet_ab170245-6b11-4ecc-8b09-59c3ef88aed1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfUnits_c61add6d-4150-4f81-8ebc-0dfddfafab4c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfUnits"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_82a830bb-736c-4539-83bb-e15ada8cf6a6" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfUnits_c61add6d-4150-4f81-8ebc-0dfddfafab4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/ConvertibleDebtBalanceofConvertibleBondsandNotesDetails" xlink:type="simple" xlink:href="ino-20210331.xsd#ConvertibleDebtBalanceofConvertibleBondsandNotesDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/ConvertibleDebtBalanceofConvertibleBondsandNotesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_d0db68b9-f351-4a9f-b52b-b55b9175cea5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_48a57a11-22b5-42be-ad09-e78f68aeb6df" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_d0db68b9-f351-4a9f-b52b-b55b9175cea5" xlink:to="loc_us-gaap_DebtInstrumentTable_48a57a11-22b5-42be-ad09-e78f68aeb6df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_ac71ec2d-8e57-4943-944c-faa88a04c938" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_48a57a11-22b5-42be-ad09-e78f68aeb6df" xlink:to="loc_us-gaap_DebtInstrumentAxis_ac71ec2d-8e57-4943-944c-faa88a04c938" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_2ac86417-064a-4470-aaf2-28034e730a29" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_ac71ec2d-8e57-4943-944c-faa88a04c938" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_2ac86417-064a-4470-aaf2-28034e730a29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_A6.50ConvertibleSeniorNotesDue2024Member_5a73abd9-f817-4745-a006-260a2a85c4ea" xlink:href="ino-20210331.xsd#ino_A6.50ConvertibleSeniorNotesDue2024Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2ac86417-064a-4470-aaf2-28034e730a29" xlink:to="loc_ino_A6.50ConvertibleSeniorNotesDue2024Member_5a73abd9-f817-4745-a006-260a2a85c4ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_8ff9ce59-b0d6-497f-b6bc-d4bd99c1e608" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_48a57a11-22b5-42be-ad09-e78f68aeb6df" xlink:to="loc_us-gaap_DebtInstrumentLineItems_8ff9ce59-b0d6-497f-b6bc-d4bd99c1e608" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_363abe19-19c7-4c6f-9153-693063163164" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_8ff9ce59-b0d6-497f-b6bc-d4bd99c1e608" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_363abe19-19c7-4c6f-9153-693063163164" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DebtInstrumentConvertibleDebtConvertedAmount_18573a80-24e2-4155-8b8f-9191604eeb81" xlink:href="ino-20210331.xsd#ino_DebtInstrumentConvertibleDebtConvertedAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_8ff9ce59-b0d6-497f-b6bc-d4bd99c1e608" xlink:to="loc_ino_DebtInstrumentConvertibleDebtConvertedAmount_18573a80-24e2-4155-8b8f-9191604eeb81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount_d284bc0b-f329-4218-aa26-a15898f35a1b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_8ff9ce59-b0d6-497f-b6bc-d4bd99c1e608" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscount_d284bc0b-f329-4218-aa26-a15898f35a1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_bdab947e-4380-427b-93d0-071d15187ccb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_8ff9ce59-b0d6-497f-b6bc-d4bd99c1e608" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_bdab947e-4380-427b-93d0-071d15187ccb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DebtInstrumentAccruedInterest_fdf3d05e-a059-4bce-bed4-499a2f007919" xlink:href="ino-20210331.xsd#ino_DebtInstrumentAccruedInterest"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_8ff9ce59-b0d6-497f-b6bc-d4bd99c1e608" xlink:to="loc_ino_DebtInstrumentAccruedInterest_fdf3d05e-a059-4bce-bed4-499a2f007919" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_aa21dc8e-a841-4121-92e9-6b22a7a43dc8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_8ff9ce59-b0d6-497f-b6bc-d4bd99c1e608" xlink:to="loc_us-gaap_LongTermDebt_aa21dc8e-a841-4121-92e9-6b22a7a43dc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/ConvertibleDebtScheduleofMaturitiesDetails" xlink:type="simple" xlink:href="ino-20210331.xsd#ConvertibleDebtScheduleofMaturitiesDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/ConvertibleDebtScheduleofMaturitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_9abb9b76-3569-41a0-b4b6-569a146bf076" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_63864ed6-5c60-4e28-806c-824e6af9ceec" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_9abb9b76-3569-41a0-b4b6-569a146bf076" xlink:to="loc_us-gaap_DebtInstrumentTable_63864ed6-5c60-4e28-806c-824e6af9ceec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_d9de6e82-33a8-48bd-8e33-10edf063e455" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_63864ed6-5c60-4e28-806c-824e6af9ceec" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_d9de6e82-33a8-48bd-8e33-10edf063e455" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_77dafbbd-8694-4d45-860d-8d06dab1a79f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_d9de6e82-33a8-48bd-8e33-10edf063e455" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_77dafbbd-8694-4d45-860d-8d06dab1a79f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtMember_2b446277-31fa-4f5c-9abf-f78b07e76a03" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_77dafbbd-8694-4d45-860d-8d06dab1a79f" xlink:to="loc_us-gaap_ConvertibleDebtMember_2b446277-31fa-4f5c-9abf-f78b07e76a03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_7a27e365-1399-405a-9779-c1255677bae8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_63864ed6-5c60-4e28-806c-824e6af9ceec" xlink:to="loc_us-gaap_DebtInstrumentAxis_7a27e365-1399-405a-9779-c1255677bae8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_ec219148-8948-45d0-a885-637ef5cf4bc8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_7a27e365-1399-405a-9779-c1255677bae8" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_ec219148-8948-45d0-a885-637ef5cf4bc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_A6.50ConvertibleSeniorNotesDue2024Member_eb017766-a8d7-4e8c-97e7-095634cdbca7" xlink:href="ino-20210331.xsd#ino_A6.50ConvertibleSeniorNotesDue2024Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_ec219148-8948-45d0-a885-637ef5cf4bc8" xlink:to="loc_ino_A6.50ConvertibleSeniorNotesDue2024Member_eb017766-a8d7-4e8c-97e7-095634cdbca7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_8e3af6e3-2cc2-4127-bb74-b69a3aac8b9b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_63864ed6-5c60-4e28-806c-824e6af9ceec" xlink:to="loc_us-gaap_DebtInstrumentLineItems_8e3af6e3-2cc2-4127-bb74-b69a3aac8b9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_2f4da17c-be80-40e2-8016-3cacb96d9045" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_8e3af6e3-2cc2-4127-bb74-b69a3aac8b9b" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_2f4da17c-be80-40e2-8016-3cacb96d9045" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_1677526f-5824-45a2-b1c3-854527fd02f5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_8e3af6e3-2cc2-4127-bb74-b69a3aac8b9b" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_1677526f-5824-45a2-b1c3-854527fd02f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_8c263bb8-e6c1-45aa-a4ff-46c938527476" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_8e3af6e3-2cc2-4127-bb74-b69a3aac8b9b" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_8c263bb8-e6c1-45aa-a4ff-46c938527476" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_40ccdbf4-df22-40d7-8d38-acc41e5ffbb4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_8e3af6e3-2cc2-4127-bb74-b69a3aac8b9b" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_40ccdbf4-df22-40d7-8d38-acc41e5ffbb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_6d00176f-46e6-427c-9d44-729be009b079" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_8e3af6e3-2cc2-4127-bb74-b69a3aac8b9b" xlink:to="loc_us-gaap_LongTermDebt_6d00176f-46e6-427c-9d44-729be009b079" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_ad7fcaba-42bc-46c8-a1eb-4a297882ba81" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_8e3af6e3-2cc2-4127-bb74-b69a3aac8b9b" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_ad7fcaba-42bc-46c8-a1eb-4a297882ba81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/StockholdersEquity" xlink:type="simple" xlink:href="ino-20210331.xsd#StockholdersEquity"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/StockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_fba1d810-458d-4016-a883-7fac729e937c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_2c48ec40-8030-4d33-ba55-bd0eb844e49e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_fba1d810-458d-4016-a883-7fac729e937c" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_2c48ec40-8030-4d33-ba55-bd0eb844e49e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/StockholdersEquityTables" xlink:type="simple" xlink:href="ino-20210331.xsd#StockholdersEquityTables"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/StockholdersEquityTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_eda0be1a-4ce5-428b-bafb-3bb98af61b8b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTextBlock_9457cb91-ed99-49b4-8641-9813bd217541" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockByClassTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_eda0be1a-4ce5-428b-bafb-3bb98af61b8b" xlink:to="loc_us-gaap_ScheduleOfStockByClassTextBlock_9457cb91-ed99-49b4-8641-9813bd217541" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/StockholdersEquitySummaryofAuthorizedandIssuedCommonandPreferredStockDetails" xlink:type="simple" xlink:href="ino-20210331.xsd#StockholdersEquitySummaryofAuthorizedandIssuedCommonandPreferredStockDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/StockholdersEquitySummaryofAuthorizedandIssuedCommonandPreferredStockDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_0783abec-fafe-4505-b2c0-4c3b2713f9b1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_1d8b5bf3-8162-430e-9da7-a8fd863ce253" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_0783abec-fafe-4505-b2c0-4c3b2713f9b1" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_1d8b5bf3-8162-430e-9da7-a8fd863ce253" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_62aa703a-41e2-4635-8dc5-ff8b7255db4a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_1d8b5bf3-8162-430e-9da7-a8fd863ce253" xlink:to="loc_us-gaap_StatementClassOfStockAxis_62aa703a-41e2-4635-8dc5-ff8b7255db4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_2ce7e8f2-f0a7-43e8-a349-510a9eb576ea" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_62aa703a-41e2-4635-8dc5-ff8b7255db4a" xlink:to="loc_us-gaap_ClassOfStockDomain_2ce7e8f2-f0a7-43e8-a349-510a9eb576ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesCPreferredStockMember_668e9231-fc36-416d-a938-662c4530e011" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesCPreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_2ce7e8f2-f0a7-43e8-a349-510a9eb576ea" xlink:to="loc_us-gaap_SeriesCPreferredStockMember_668e9231-fc36-416d-a938-662c4530e011" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_b9bbba2a-d0df-4f7e-bcf4-03c90b99c29d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_1d8b5bf3-8162-430e-9da7-a8fd863ce253" xlink:to="loc_us-gaap_ClassOfStockLineItems_b9bbba2a-d0df-4f7e-bcf4-03c90b99c29d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_f6ba2912-6441-463b-bdb1-725ae9b7225b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_b9bbba2a-d0df-4f7e-bcf4-03c90b99c29d" xlink:to="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_f6ba2912-6441-463b-bdb1-725ae9b7225b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_b6fd7307-419f-4bcd-8cc9-2ba632bb8cfd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_f6ba2912-6441-463b-bdb1-725ae9b7225b" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_b6fd7307-419f-4bcd-8cc9-2ba632bb8cfd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_504bd1e8-3cf4-4bb2-bfc5-995b53ce2910" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_f6ba2912-6441-463b-bdb1-725ae9b7225b" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_504bd1e8-3cf4-4bb2-bfc5-995b53ce2910" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_52b60045-5c92-4fc2-a9a5-386bdf8449b9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_f6ba2912-6441-463b-bdb1-725ae9b7225b" xlink:to="loc_us-gaap_CommonStockSharesIssued_52b60045-5c92-4fc2-a9a5-386bdf8449b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_c3258b74-3643-47f7-8380-456150b7be01" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_f6ba2912-6441-463b-bdb1-725ae9b7225b" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_c3258b74-3643-47f7-8380-456150b7be01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_829480b5-fd5b-48f7-9dff-47ffa00f9be7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_f6ba2912-6441-463b-bdb1-725ae9b7225b" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_829480b5-fd5b-48f7-9dff-47ffa00f9be7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_18b96160-db62-4d9a-aa8e-502a94faaf21" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_f6ba2912-6441-463b-bdb1-725ae9b7225b" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_18b96160-db62-4d9a-aa8e-502a94faaf21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_7088e098-d330-4f4e-b164-8eea0117682d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_f6ba2912-6441-463b-bdb1-725ae9b7225b" xlink:to="loc_us-gaap_PreferredStockSharesIssued_7088e098-d330-4f4e-b164-8eea0117682d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_8068a57b-091a-4b60-a0b7-173ce3409038" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_f6ba2912-6441-463b-bdb1-725ae9b7225b" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_8068a57b-091a-4b60-a0b7-173ce3409038" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/StockholdersEquityNarrativeDetails" xlink:type="simple" xlink:href="ino-20210331.xsd#StockholdersEquityNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/StockholdersEquityNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_d89d9fce-ef9c-498b-b9c9-36dba8deec5e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_8b28f09d-13d5-43fc-8d1d-17c1a8f0b198" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_d89d9fce-ef9c-498b-b9c9-36dba8deec5e" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_8b28f09d-13d5-43fc-8d1d-17c1a8f0b198" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_795a6582-8e59-4f2c-af4f-c846ca4c90df" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_8b28f09d-13d5-43fc-8d1d-17c1a8f0b198" xlink:to="loc_us-gaap_StatementClassOfStockAxis_795a6582-8e59-4f2c-af4f-c846ca4c90df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_5ddd05c2-d35d-4038-b008-315f341755a0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_795a6582-8e59-4f2c-af4f-c846ca4c90df" xlink:to="loc_us-gaap_ClassOfStockDomain_5ddd05c2-d35d-4038-b008-315f341755a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesCPreferredStockMember_be2097be-fce6-4c12-b930-070c940c66b8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesCPreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_5ddd05c2-d35d-4038-b008-315f341755a0" xlink:to="loc_us-gaap_SeriesCPreferredStockMember_be2097be-fce6-4c12-b930-070c940c66b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_05cdd3ff-4314-45c1-92d1-a190ee2774d9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_5ddd05c2-d35d-4038-b008-315f341755a0" xlink:to="loc_us-gaap_CommonStockMember_05cdd3ff-4314-45c1-92d1-a190ee2774d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_98b6428d-6a34-4666-9265-55ee15343182" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_8b28f09d-13d5-43fc-8d1d-17c1a8f0b198" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_98b6428d-6a34-4666-9265-55ee15343182" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_8f9b3d95-4844-45f5-a33a-20271e799830" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_98b6428d-6a34-4666-9265-55ee15343182" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_8f9b3d95-4844-45f5-a33a-20271e799830" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_PriorSalesAgreementMember_0ce3c21a-4872-463a-922f-0df033b11ebf" xlink:href="ino-20210331.xsd#ino_PriorSalesAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_8f9b3d95-4844-45f5-a33a-20271e799830" xlink:to="loc_ino_PriorSalesAgreementMember_0ce3c21a-4872-463a-922f-0df033b11ebf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_NewSalesAgreementMember_2e890e65-6b1d-4ec8-86f0-920e83dd750b" xlink:href="ino-20210331.xsd#ino_NewSalesAgreementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_8f9b3d95-4844-45f5-a33a-20271e799830" xlink:to="loc_ino_NewSalesAgreementMember_2e890e65-6b1d-4ec8-86f0-920e83dd750b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_f7ae4b45-08b6-4e0f-b563-ba046ffe35d0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_8b28f09d-13d5-43fc-8d1d-17c1a8f0b198" xlink:to="loc_us-gaap_PlanNameAxis_f7ae4b45-08b6-4e0f-b563-ba046ffe35d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_482197df-1b09-4beb-9c54-b124b78dd465" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_f7ae4b45-08b6-4e0f-b563-ba046ffe35d0" xlink:to="loc_us-gaap_PlanNameDomain_482197df-1b09-4beb-9c54-b124b78dd465" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_A2016IncentivePlanMember_09129bd4-f562-4602-b869-ccbf57b1c08b" xlink:href="ino-20210331.xsd#ino_A2016IncentivePlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_482197df-1b09-4beb-9c54-b124b78dd465" xlink:to="loc_ino_A2016IncentivePlanMember_09129bd4-f562-4602-b869-ccbf57b1c08b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_A2007IncentivePlanMember_d8f93f9d-13b3-4955-accd-bf68fe8682a2" xlink:href="ino-20210331.xsd#ino_A2007IncentivePlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_482197df-1b09-4beb-9c54-b124b78dd465" xlink:to="loc_ino_A2007IncentivePlanMember_d8f93f9d-13b3-4955-accd-bf68fe8682a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_fc5bcc8d-f98c-4dfd-90e4-90b9cd47700b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_8b28f09d-13d5-43fc-8d1d-17c1a8f0b198" xlink:to="loc_us-gaap_ClassOfStockLineItems_fc5bcc8d-f98c-4dfd-90e4-90b9cd47700b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockSharesConverted1_906a7f7c-9b36-4777-9c18-f0b048595da2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConversionOfStockSharesConverted1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_fc5bcc8d-f98c-4dfd-90e4-90b9cd47700b" xlink:to="loc_us-gaap_ConversionOfStockSharesConverted1_906a7f7c-9b36-4777-9c18-f0b048595da2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockSharesIssued1_4ddd5175-0eb4-40f8-a303-3d3818d23bd3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConversionOfStockSharesIssued1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_fc5bcc8d-f98c-4dfd-90e4-90b9cd47700b" xlink:to="loc_us-gaap_ConversionOfStockSharesIssued1_4ddd5175-0eb4-40f8-a303-3d3818d23bd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_180fffef-a964-44f2-bacb-0c24abebcf0e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_fc5bcc8d-f98c-4dfd-90e4-90b9cd47700b" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_180fffef-a964-44f2-bacb-0c24abebcf0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_afce6fbf-ac0c-4852-8ea3-d9726a17154d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_fc5bcc8d-f98c-4dfd-90e4-90b9cd47700b" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_afce6fbf-ac0c-4852-8ea3-d9726a17154d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesForCommissionsExpenseAndTaxes_9ae35d07-f44c-42d0-9006-ec3b17da6272" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesForCommissionsExpenseAndTaxes"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_fc5bcc8d-f98c-4dfd-90e4-90b9cd47700b" xlink:to="loc_us-gaap_AccruedLiabilitiesForCommissionsExpenseAndTaxes_9ae35d07-f44c-42d0-9006-ec3b17da6272" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_StockSalesAgreementMaximumAuthorizedAmount_f07c9d50-2fbf-41a0-8760-72c8b53953b7" xlink:href="ino-20210331.xsd#ino_StockSalesAgreementMaximumAuthorizedAmount"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_fc5bcc8d-f98c-4dfd-90e4-90b9cd47700b" xlink:to="loc_ino_StockSalesAgreementMaximumAuthorizedAmount_f07c9d50-2fbf-41a0-8760-72c8b53953b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_StockSalesAgreementRemainingAuthorizedAmount_3ab554f0-adc3-437f-bea1-d9d5d02d303c" xlink:href="ino-20210331.xsd#ino_StockSalesAgreementRemainingAuthorizedAmount"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_fc5bcc8d-f98c-4dfd-90e4-90b9cd47700b" xlink:to="loc_ino_StockSalesAgreementRemainingAuthorizedAmount_3ab554f0-adc3-437f-bea1-d9d5d02d303c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_StockSaleAgreementAggregateNumberofSharesIssued_35e9d253-17d2-4d74-9133-0bc8f637b7da" xlink:href="ino-20210331.xsd#ino_StockSaleAgreementAggregateNumberofSharesIssued"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_fc5bcc8d-f98c-4dfd-90e4-90b9cd47700b" xlink:to="loc_ino_StockSaleAgreementAggregateNumberofSharesIssued_35e9d253-17d2-4d74-9133-0bc8f637b7da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_StockSaleAgreementWeightedAveragePricePerShare_4058b006-7934-49bb-80f9-c8c234aba2c2" xlink:href="ino-20210331.xsd#ino_StockSaleAgreementWeightedAveragePricePerShare"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_fc5bcc8d-f98c-4dfd-90e4-90b9cd47700b" xlink:to="loc_ino_StockSaleAgreementWeightedAveragePricePerShare_4058b006-7934-49bb-80f9-c8c234aba2c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_StockSaleAgreementAggregateProceedsFromIssuanceOfStock_58b53350-b67d-43e8-b233-63e76261b204" xlink:href="ino-20210331.xsd#ino_StockSaleAgreementAggregateProceedsFromIssuanceOfStock"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_fc5bcc8d-f98c-4dfd-90e4-90b9cd47700b" xlink:to="loc_ino_StockSaleAgreementAggregateProceedsFromIssuanceOfStock_58b53350-b67d-43e8-b233-63e76261b204" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_edf955a6-2e5e-444d-bd6c-738aef4bab6f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_fc5bcc8d-f98c-4dfd-90e4-90b9cd47700b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_edf955a6-2e5e-444d-bd6c-738aef4bab6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_NumberOfPotentialSharesAuthorizedForIssuanceUnderShareBasedCompensationPlan_9062ca20-cc2f-4550-81a8-fb2a6bde0da5" xlink:href="ino-20210331.xsd#ino_NumberOfPotentialSharesAuthorizedForIssuanceUnderShareBasedCompensationPlan"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_fc5bcc8d-f98c-4dfd-90e4-90b9cd47700b" xlink:to="loc_ino_NumberOfPotentialSharesAuthorizedForIssuanceUnderShareBasedCompensationPlan_9062ca20-cc2f-4550-81a8-fb2a6bde0da5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_SharebasedCompensationArrangementbySharebasedPaymentAwardIncreaseInNumberofSharesAuthorized_5b9bfd54-4ee2-45ef-b9d4-2163315aea8e" xlink:href="ino-20210331.xsd#ino_SharebasedCompensationArrangementbySharebasedPaymentAwardIncreaseInNumberofSharesAuthorized"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_fc5bcc8d-f98c-4dfd-90e4-90b9cd47700b" xlink:to="loc_ino_SharebasedCompensationArrangementbySharebasedPaymentAwardIncreaseInNumberofSharesAuthorized_5b9bfd54-4ee2-45ef-b9d4-2163315aea8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_10053822-5052-4330-bb1b-95cf7556111a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_fc5bcc8d-f98c-4dfd-90e4-90b9cd47700b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_10053822-5052-4330-bb1b-95cf7556111a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2998208a-8f08-45e4-8b2a-9665de519858" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_fc5bcc8d-f98c-4dfd-90e4-90b9cd47700b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2998208a-8f08-45e4-8b2a-9665de519858" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockOtherSharesOutstanding_3ddf03eb-ca26-4488-8083-faa24237db34" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockOtherSharesOutstanding"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_fc5bcc8d-f98c-4dfd-90e4-90b9cd47700b" xlink:to="loc_us-gaap_CommonStockOtherSharesOutstanding_3ddf03eb-ca26-4488-8083-faa24237db34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_f500abb1-e00c-496f-b37d-9b32db56247f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_fc5bcc8d-f98c-4dfd-90e4-90b9cd47700b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_f500abb1-e00c-496f-b37d-9b32db56247f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm_37f50a59-206b-439e-a919-7251b4178c5a" xlink:href="ino-20210331.xsd#ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_fc5bcc8d-f98c-4dfd-90e4-90b9cd47700b" xlink:to="loc_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm_37f50a59-206b-439e-a919-7251b4178c5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/NetLossPerShare" xlink:type="simple" xlink:href="ino-20210331.xsd#NetLossPerShare"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/NetLossPerShare" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_299975be-5416-4963-8355-3c9570d5acc6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_d5ec60a7-ec0a-449c-b501-3122d1087144" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_299975be-5416-4963-8355-3c9570d5acc6" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_d5ec60a7-ec0a-449c-b501-3122d1087144" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/NetLossPerShareTables" xlink:type="simple" xlink:href="ino-20210331.xsd#NetLossPerShareTables"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/NetLossPerShareTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_47a14802-610e-4ead-b5be-ddb52e78cb9e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_833b1d22-7aac-407d-ae7a-ce0d95e4d545" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_47a14802-610e-4ead-b5be-ddb52e78cb9e" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_833b1d22-7aac-407d-ae7a-ce0d95e4d545" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/NetLossPerShareScheduleofAntiDilutiveSecuritiesDetails" xlink:type="simple" xlink:href="ino-20210331.xsd#NetLossPerShareScheduleofAntiDilutiveSecuritiesDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/NetLossPerShareScheduleofAntiDilutiveSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_1bef3b79-0dad-4928-99f5-7de3b28c1c87" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_3ab9857c-d39a-47b6-80fd-36364ecf696f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_1bef3b79-0dad-4928-99f5-7de3b28c1c87" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_3ab9857c-d39a-47b6-80fd-36364ecf696f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_f3da90a5-1a3b-4ee5-b8c7-19c5990833bc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_3ab9857c-d39a-47b6-80fd-36364ecf696f" xlink:to="loc_us-gaap_DebtInstrumentAxis_f3da90a5-1a3b-4ee5-b8c7-19c5990833bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_7f0c7c9e-5871-496a-bb0b-76abbf86aac8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_f3da90a5-1a3b-4ee5-b8c7-19c5990833bc" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_7f0c7c9e-5871-496a-bb0b-76abbf86aac8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_A6.50ConvertibleSeniorNotesDue2024Member_ff9a218e-48dd-42ee-b7ef-c0654a1d13b5" xlink:href="ino-20210331.xsd#ino_A6.50ConvertibleSeniorNotesDue2024Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7f0c7c9e-5871-496a-bb0b-76abbf86aac8" xlink:to="loc_ino_A6.50ConvertibleSeniorNotesDue2024Member_ff9a218e-48dd-42ee-b7ef-c0654a1d13b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_August2019ConvertibleBondsMember_5e97a91c-8c85-4ee1-bd45-7a0167d859fc" xlink:href="ino-20210331.xsd#ino_August2019ConvertibleBondsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7f0c7c9e-5871-496a-bb0b-76abbf86aac8" xlink:to="loc_ino_August2019ConvertibleBondsMember_5e97a91c-8c85-4ee1-bd45-7a0167d859fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_December2019ConvertibleBondsMember_01d9c7c6-0c0e-4c1b-a1cd-ae07ee33c7f6" xlink:href="ino-20210331.xsd#ino_December2019ConvertibleBondsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7f0c7c9e-5871-496a-bb0b-76abbf86aac8" xlink:to="loc_ino_December2019ConvertibleBondsMember_01d9c7c6-0c0e-4c1b-a1cd-ae07ee33c7f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_d66720be-1dbd-4c72-acce-733a42596ad5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_3ab9857c-d39a-47b6-80fd-36364ecf696f" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_d66720be-1dbd-4c72-acce-733a42596ad5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_40ebb416-fb6a-490e-a438-d3389361863a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_d66720be-1dbd-4c72-acce-733a42596ad5" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_40ebb416-fb6a-490e-a438-d3389361863a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_60504ac4-1751-4965-8585-7a9984673577" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_40ebb416-fb6a-490e-a438-d3389361863a" xlink:to="loc_us-gaap_EmployeeStockOptionMember_60504ac4-1751-4965-8585-7a9984673577" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ServiceBasedRestrictedStockUnitsMember_14d05ea7-d402-4ae1-b6b0-ee1ee1550ae1" xlink:href="ino-20210331.xsd#ino_ServiceBasedRestrictedStockUnitsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_40ebb416-fb6a-490e-a438-d3389361863a" xlink:to="loc_ino_ServiceBasedRestrictedStockUnitsMember_14d05ea7-d402-4ae1-b6b0-ee1ee1550ae1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_d41428a0-10b3-4cbf-8dfc-fa44b0064489" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_40ebb416-fb6a-490e-a438-d3389361863a" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_d41428a0-10b3-4cbf-8dfc-fa44b0064489" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertiblePreferredStockMember_cb62d50e-c655-449b-a941-ae534287fd02" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertiblePreferredStockMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_40ebb416-fb6a-490e-a438-d3389361863a" xlink:to="loc_us-gaap_ConvertiblePreferredStockMember_cb62d50e-c655-449b-a941-ae534287fd02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtSecuritiesMember_d5b2812a-b20b-426e-a365-ce44a23aa2b3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleDebtSecuritiesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_40ebb416-fb6a-490e-a438-d3389361863a" xlink:to="loc_us-gaap_ConvertibleDebtSecuritiesMember_d5b2812a-b20b-426e-a365-ce44a23aa2b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_d6d4f39b-7879-44a5-9961-db46453daaba" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_3ab9857c-d39a-47b6-80fd-36364ecf696f" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_d6d4f39b-7879-44a5-9961-db46453daaba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_cbe0e13e-129b-4a73-b7e1-06c1fb60681a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_d6d4f39b-7879-44a5-9961-db46453daaba" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_cbe0e13e-129b-4a73-b7e1-06c1fb60681a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/StockBasedCompensation" xlink:type="simple" xlink:href="ino-20210331.xsd#StockBasedCompensation"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/StockBasedCompensation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_87f83d18-f25d-4924-99b6-f4f7a44c5635" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_4bd34904-d5de-41a0-a828-88d3980039d7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_87f83d18-f25d-4924-99b6-f4f7a44c5635" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_4bd34904-d5de-41a0-a828-88d3980039d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/StockBasedCompensationTables" xlink:type="simple" xlink:href="ino-20210331.xsd#StockBasedCompensationTables"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/StockBasedCompensationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_4914f6c1-0329-446c-9f7a-fc3326ac56b4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_0380f4f7-9104-4c91-93b7-895b30f88de2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_4914f6c1-0329-446c-9f7a-fc3326ac56b4" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_0380f4f7-9104-4c91-93b7-895b30f88de2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/StockBasedCompensationDetails" xlink:type="simple" xlink:href="ino-20210331.xsd#StockBasedCompensationDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/StockBasedCompensationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1053488d-37e6-40a3-bc76-cad11cf8a260" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3bece5c6-434b-4500-b6cb-cd30e63a0077" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1053488d-37e6-40a3-bc76-cad11cf8a260" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3bece5c6-434b-4500-b6cb-cd30e63a0077" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_4f0eb8c3-160e-4650-ad7b-ebbec5e9fdf0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3bece5c6-434b-4500-b6cb-cd30e63a0077" xlink:to="loc_us-gaap_AwardTypeAxis_4f0eb8c3-160e-4650-ad7b-ebbec5e9fdf0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_fd554133-d21b-481f-84b9-9b52530659ad" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_4f0eb8c3-160e-4650-ad7b-ebbec5e9fdf0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_fd554133-d21b-481f-84b9-9b52530659ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_b53673d5-de8d-40be-8b67-8caeb3ac01b7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_fd554133-d21b-481f-84b9-9b52530659ad" xlink:to="loc_us-gaap_EmployeeStockOptionMember_b53673d5-de8d-40be-8b67-8caeb3ac01b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_0900150b-4a0a-412b-b88f-6b2182f5cb09" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_fd554133-d21b-481f-84b9-9b52530659ad" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_0900150b-4a0a-412b-b88f-6b2182f5cb09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_65a744bf-efef-4c59-92a9-767a35230c4b" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3bece5c6-434b-4500-b6cb-cd30e63a0077" xlink:to="loc_srt_TitleOfIndividualAxis_65a744bf-efef-4c59-92a9-767a35230c4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_f53cf046-d068-429e-a99e-df15df64bf53" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualAxis_65a744bf-efef-4c59-92a9-767a35230c4b" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_f53cf046-d068-429e-a99e-df15df64bf53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_EmployeesAndDirectorsMember_fcfc2a7f-bf76-425b-87d0-517a7b719054" xlink:href="ino-20210331.xsd#ino_EmployeesAndDirectorsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_f53cf046-d068-429e-a99e-df15df64bf53" xlink:to="loc_ino_EmployeesAndDirectorsMember_fcfc2a7f-bf76-425b-87d0-517a7b719054" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_NonEmployeeMember_ac99a896-2636-4603-84d1-01be8b209622" xlink:href="ino-20210331.xsd#ino_NonEmployeeMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_f53cf046-d068-429e-a99e-df15df64bf53" xlink:to="loc_ino_NonEmployeeMember_ac99a896-2636-4603-84d1-01be8b209622" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_4619c0d8-ad29-42ae-bb2f-396ab33e6489" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3bece5c6-434b-4500-b6cb-cd30e63a0077" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_4619c0d8-ad29-42ae-bb2f-396ab33e6489" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_57df86e2-d178-439b-a92a-6d013b945a54" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_4619c0d8-ad29-42ae-bb2f-396ab33e6489" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_57df86e2-d178-439b-a92a-6d013b945a54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_7c863417-605b-471e-bc8d-6c6cecd01a5e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_57df86e2-d178-439b-a92a-6d013b945a54" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_7c863417-605b-471e-bc8d-6c6cecd01a5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_599f74c3-bc70-4514-9b69-1ee545e59520" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_57df86e2-d178-439b-a92a-6d013b945a54" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_599f74c3-bc70-4514-9b69-1ee545e59520" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_6704cc73-91f3-45e5-bc44-cdfac9f6ab4f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3bece5c6-434b-4500-b6cb-cd30e63a0077" xlink:to="loc_us-gaap_PlanNameAxis_6704cc73-91f3-45e5-bc44-cdfac9f6ab4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_cfa9b2c8-21a6-44c1-97cc-f837c756f88b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_6704cc73-91f3-45e5-bc44-cdfac9f6ab4f" xlink:to="loc_us-gaap_PlanNameDomain_cfa9b2c8-21a6-44c1-97cc-f837c756f88b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_A2016IncentivePlanMember_8a34e12e-ab1e-4d79-bdbf-d63408ddaac1" xlink:href="ino-20210331.xsd#ino_A2016IncentivePlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_cfa9b2c8-21a6-44c1-97cc-f837c756f88b" xlink:to="loc_ino_A2016IncentivePlanMember_8a34e12e-ab1e-4d79-bdbf-d63408ddaac1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis_949fb58c-259a-496f-8eb0-227bf37e3239" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VestingAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3bece5c6-434b-4500-b6cb-cd30e63a0077" xlink:to="loc_us-gaap_VestingAxis_949fb58c-259a-496f-8eb0-227bf37e3239" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_a7867a76-b6f4-4002-aafa-f1781b3c259d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VestingDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingAxis_949fb58c-259a-496f-8eb0-227bf37e3239" xlink:to="loc_us-gaap_VestingDomain_a7867a76-b6f4-4002-aafa-f1781b3c259d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_28eefd58-9c63-49a7-a066-00b5a4219121" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_a7867a76-b6f4-4002-aafa-f1781b3c259d" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_28eefd58-9c63-49a7-a066-00b5a4219121" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_44bc8d29-56b4-46b7-92c4-e43c6ed52ec6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_a7867a76-b6f4-4002-aafa-f1781b3c259d" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_44bc8d29-56b4-46b7-92c4-e43c6ed52ec6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_32018434-b098-4974-a346-f82c9c6418fe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3bece5c6-434b-4500-b6cb-cd30e63a0077" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_32018434-b098-4974-a346-f82c9c6418fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_f6768bbf-b7ff-4d2c-ac95-80e670afc3de" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_32018434-b098-4974-a346-f82c9c6418fe" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_f6768bbf-b7ff-4d2c-ac95-80e670afc3de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_27a990ec-a003-48db-a16a-63804fbfdcad" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_32018434-b098-4974-a346-f82c9c6418fe" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_27a990ec-a003-48db-a16a-63804fbfdcad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_0bef6cd1-4e91-4540-9178-bf7c6a4aa53c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_32018434-b098-4974-a346-f82c9c6418fe" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_0bef6cd1-4e91-4540-9178-bf7c6a4aa53c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_02221084-b5bc-467f-b37f-e7f0d3f6bd49" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_32018434-b098-4974-a346-f82c9c6418fe" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_02221084-b5bc-467f-b37f-e7f0d3f6bd49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_66baa88b-0218-4d7d-b9a8-736622b12ab8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_32018434-b098-4974-a346-f82c9c6418fe" xlink:to="loc_us-gaap_ShareBasedCompensation_66baa88b-0218-4d7d-b9a8-736622b12ab8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_63a3de3a-3c83-4d59-b28e-84dc07b89eed" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_32018434-b098-4974-a346-f82c9c6418fe" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_63a3de3a-3c83-4d59-b28e-84dc07b89eed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_811e47bc-a282-4b02-9e91-9407e09bc471" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_32018434-b098-4974-a346-f82c9c6418fe" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_811e47bc-a282-4b02-9e91-9407e09bc471" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_4b42d0ef-e323-44bf-b29d-ebad12d18477" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_32018434-b098-4974-a346-f82c9c6418fe" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_4b42d0ef-e323-44bf-b29d-ebad12d18477" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_69d5a859-ddc6-427a-bbc0-891f158ff28b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_32018434-b098-4974-a346-f82c9c6418fe" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_69d5a859-ddc6-427a-bbc0-891f158ff28b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_7425c791-e17f-45f7-aea0-62a8fb27763f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_32018434-b098-4974-a346-f82c9c6418fe" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_7425c791-e17f-45f7-aea0-62a8fb27763f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_1726adf1-d4ad-4964-a370-ec8966969204" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_32018434-b098-4974-a346-f82c9c6418fe" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_1726adf1-d4ad-4964-a370-ec8966969204" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_b8e89a59-cfb4-4b23-b576-ac6f461f3781" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_32018434-b098-4974-a346-f82c9c6418fe" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_b8e89a59-cfb4-4b23-b576-ac6f461f3781" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_0efdbc90-99b4-44b5-ad28-717772681a89" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_32018434-b098-4974-a346-f82c9c6418fe" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_0efdbc90-99b4-44b5-ad28-717772681a89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodGrantDateFairValue_7d56eb4a-49e3-43e3-b155-4ef07bf0ab7d" xlink:href="ino-20210331.xsd#ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodGrantDateFairValue"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_32018434-b098-4974-a346-f82c9c6418fe" xlink:to="loc_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodGrantDateFairValue_7d56eb4a-49e3-43e3-b155-4ef07bf0ab7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/RelatedPartyTransactions" xlink:type="simple" xlink:href="ino-20210331.xsd#RelatedPartyTransactions"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/RelatedPartyTransactions" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDueFromToRelatedPartyAbstract_74ac4f50-e156-44f3-933b-717a0328f12e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionDueFromToRelatedPartyAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_ede840b6-b996-4b04-9563-6a74b61e181e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDueFromToRelatedPartyAbstract_74ac4f50-e156-44f3-933b-717a0328f12e" xlink:to="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_ede840b6-b996-4b04-9563-6a74b61e181e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/RelatedPartyTransactionsDetails" xlink:type="simple" xlink:href="ino-20210331.xsd#RelatedPartyTransactionsDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/RelatedPartyTransactionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDueFromToRelatedPartyAbstract_d592c66e-c218-4881-bfce-b968be2b408e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionDueFromToRelatedPartyAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_8e1c2864-7dc0-4c54-87a1-22799d337509" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDueFromToRelatedPartyAbstract_d592c66e-c218-4881-bfce-b968be2b408e" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_8e1c2864-7dc0-4c54-87a1-22799d337509" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_c3244419-9336-410c-9c94-aee6db98d1f9" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_8e1c2864-7dc0-4c54-87a1-22799d337509" xlink:to="loc_srt_CounterpartyNameAxis_c3244419-9336-410c-9c94-aee6db98d1f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f4b7d7db-9b8b-4902-b2c9-cd799a0895cc" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_c3244419-9336-410c-9c94-aee6db98d1f9" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f4b7d7db-9b8b-4902-b2c9-cd799a0895cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_PlumblineLifeSciencesMember_12ac2afc-7f92-4c55-bccb-23cd0f7dc401" xlink:href="ino-20210331.xsd#ino_PlumblineLifeSciencesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f4b7d7db-9b8b-4902-b2c9-cd799a0895cc" xlink:to="loc_ino_PlumblineLifeSciencesMember_12ac2afc-7f92-4c55-bccb-23cd0f7dc401" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InformationByCategoryOfDebtSecurityAxis_60250258-4999-4443-989c-bd31eab9eac8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InformationByCategoryOfDebtSecurityAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_8e1c2864-7dc0-4c54-87a1-22799d337509" xlink:to="loc_us-gaap_InformationByCategoryOfDebtSecurityAxis_60250258-4999-4443-989c-bd31eab9eac8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain_a76f7962-e030-42ab-9e78-ef793c7eb8be" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InformationByCategoryOfDebtSecurityAxis_60250258-4999-4443-989c-bd31eab9eac8" xlink:to="loc_us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain_a76f7962-e030-42ab-9e78-ef793c7eb8be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableforsaleSecuritiesMember_0a8f8e67-e198-492e-9a7b-505bc7939516" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableforsaleSecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain_a76f7962-e030-42ab-9e78-ef793c7eb8be" xlink:to="loc_us-gaap_AvailableforsaleSecuritiesMember_0a8f8e67-e198-492e-9a7b-505bc7939516" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_ebc8a8d8-9929-4092-b6b3-5233a534a91b" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_8e1c2864-7dc0-4c54-87a1-22799d337509" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_ebc8a8d8-9929-4092-b6b3-5233a534a91b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_eebf8c9c-7853-41ae-accb-c5c52e54d072" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_ebc8a8d8-9929-4092-b6b3-5233a534a91b" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_eebf8c9c-7853-41ae-accb-c5c52e54d072" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_PlumblineLifeSciencesMember_b9f68bd1-5d18-4898-aef6-3e9fe1158db6" xlink:href="ino-20210331.xsd#ino_PlumblineLifeSciencesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_eebf8c9c-7853-41ae-accb-c5c52e54d072" xlink:to="loc_ino_PlumblineLifeSciencesMember_b9f68bd1-5d18-4898-aef6-3e9fe1158db6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_5467cfb7-bf11-4055-a7bf-52e8e75cb9e1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_8e1c2864-7dc0-4c54-87a1-22799d337509" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_5467cfb7-bf11-4055-a7bf-52e8e75cb9e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_7fd5a492-1121-450e-b1d0-9c5c5d3392b4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_5467cfb7-bf11-4055-a7bf-52e8e75cb9e1" xlink:to="loc_us-gaap_RelatedPartyDomain_7fd5a492-1121-450e-b1d0-9c5c5d3392b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_DirectorMember_d20b320d-dcd3-4ab4-9f32-334eac1e783c" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_DirectorMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_7fd5a492-1121-450e-b1d0-9c5c5d3392b4" xlink:to="loc_srt_DirectorMember_d20b320d-dcd3-4ab4-9f32-334eac1e783c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_TheWistarInstituteMember_89231b73-14cd-4be1-b403-e1ee4cd50e23" xlink:href="ino-20210331.xsd#ino_TheWistarInstituteMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_7fd5a492-1121-450e-b1d0-9c5c5d3392b4" xlink:to="loc_ino_TheWistarInstituteMember_89231b73-14cd-4be1-b403-e1ee4cd50e23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_a41dca6a-8f7e-428e-af78-4575133a7548" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_8e1c2864-7dc0-4c54-87a1-22799d337509" xlink:to="loc_us-gaap_RelatedPartyTransactionLineItems_a41dca6a-8f7e-428e-af78-4575133a7548" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_RelatedPartyTransactionsTextualAbstract_52ab8351-b18c-4ddc-ae2e-9ddff2659ef5" xlink:href="ino-20210331.xsd#ino_RelatedPartyTransactionsTextualAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_a41dca6a-8f7e-428e-af78-4575133a7548" xlink:to="loc_ino_RelatedPartyTransactionsTextualAbstract_52ab8351-b18c-4ddc-ae2e-9ddff2659ef5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentOwnedBalanceShares_190703d3-b9c2-4af8-ad69-7e6c81c43211" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentOwnedBalanceShares"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ino_RelatedPartyTransactionsTextualAbstract_52ab8351-b18c-4ddc-ae2e-9ddff2659ef5" xlink:to="loc_us-gaap_InvestmentOwnedBalanceShares_190703d3-b9c2-4af8-ad69-7e6c81c43211" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_afc2db66-474e-495b-a7f7-321920a03444" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ino_RelatedPartyTransactionsTextualAbstract_52ab8351-b18c-4ddc-ae2e-9ddff2659ef5" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_afc2db66-474e-495b-a7f7-321920a03444" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_7b918fbf-3196-4951-b54b-4c4c83c67608" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ino_RelatedPartyTransactionsTextualAbstract_52ab8351-b18c-4ddc-ae2e-9ddff2659ef5" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_7b918fbf-3196-4951-b54b-4c4c83c67608" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableRelatedParties_a45e3ecd-4570-4163-b8e0-3a3bb6309a3f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableRelatedParties"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ino_RelatedPartyTransactionsTextualAbstract_52ab8351-b18c-4ddc-ae2e-9ddff2659ef5" xlink:to="loc_us-gaap_AccountsReceivableRelatedParties_a45e3ecd-4570-4163-b8e0-3a3bb6309a3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementExpensesToReimburse_2519d959-207c-482c-b4fa-c74bdb38d40a" xlink:href="ino-20210331.xsd#ino_CollaborativeAgreementExpensesToReimburse"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ino_RelatedPartyTransactionsTextualAbstract_52ab8351-b18c-4ddc-ae2e-9ddff2659ef5" xlink:to="loc_ino_CollaborativeAgreementExpensesToReimburse_2519d959-207c-482c-b4fa-c74bdb38d40a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeArrangementTerm_a5959acb-6e81-451e-a07b-30e6a1c04c4e" xlink:href="ino-20210331.xsd#ino_CollaborativeArrangementTerm"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ino_RelatedPartyTransactionsTextualAbstract_52ab8351-b18c-4ddc-ae2e-9ddff2659ef5" xlink:to="loc_ino_CollaborativeArrangementTerm_a5959acb-6e81-451e-a07b-30e6a1c04c4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementAwardedAmount_1ff830d7-b350-4d2a-b111-c2c14d1bd598" xlink:href="ino-20210331.xsd#ino_CollaborativeAgreementAwardedAmount"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ino_RelatedPartyTransactionsTextualAbstract_52ab8351-b18c-4ddc-ae2e-9ddff2659ef5" xlink:to="loc_ino_CollaborativeAgreementAwardedAmount_1ff830d7-b350-4d2a-b111-c2c14d1bd598" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementAwardedOptionAmount_78692d59-8afa-4b0d-83b5-13f8729d972c" xlink:href="ino-20210331.xsd#ino_CollaborativeAgreementAwardedOptionAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ino_RelatedPartyTransactionsTextualAbstract_52ab8351-b18c-4ddc-ae2e-9ddff2659ef5" xlink:to="loc_ino_CollaborativeAgreementAwardedOptionAmount_78692d59-8afa-4b0d-83b5-13f8729d972c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_GrantProceedsReceived_61620a7b-2408-4f31-856d-c0af540d090c" xlink:href="ino-20210331.xsd#ino_GrantProceedsReceived"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ino_RelatedPartyTransactionsTextualAbstract_52ab8351-b18c-4ddc-ae2e-9ddff2659ef5" xlink:to="loc_ino_GrantProceedsReceived_61620a7b-2408-4f31-856d-c0af540d090c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_0192377e-fff8-44b2-8867-c2c61b178487" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ino_RelatedPartyTransactionsTextualAbstract_52ab8351-b18c-4ddc-ae2e-9ddff2659ef5" xlink:to="loc_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_0192377e-fff8-44b2-8867-c2c61b178487" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_a5bfc30e-9987-41bc-bffc-c5d3d4b9072a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DueToRelatedPartiesCurrentAndNoncurrent"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ino_RelatedPartyTransactionsTextualAbstract_52ab8351-b18c-4ddc-ae2e-9ddff2659ef5" xlink:to="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_a5bfc30e-9987-41bc-bffc-c5d3d4b9072a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DeferredGrantFundingFromAffiliate_7e08f0ac-fabe-4b19-9306-182eaa4aaa6e" xlink:href="ino-20210331.xsd#ino_DeferredGrantFundingFromAffiliate"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ino_RelatedPartyTransactionsTextualAbstract_52ab8351-b18c-4ddc-ae2e-9ddff2659ef5" xlink:to="loc_ino_DeferredGrantFundingFromAffiliate_7e08f0ac-fabe-4b19-9306-182eaa4aaa6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/Leases" xlink:type="simple" xlink:href="ino-20210331.xsd#Leases"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/Leases" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_bc31e402-8228-4b93-841f-68108b7dcb45" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock_a55e3a75-0291-43f9-b259-a38516043cae" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_bc31e402-8228-4b93-841f-68108b7dcb45" xlink:to="loc_us-gaap_LesseeOperatingLeasesTextBlock_a55e3a75-0291-43f9-b259-a38516043cae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/LeasesTables" xlink:type="simple" xlink:href="ino-20210331.xsd#LeasesTables"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/LeasesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_e940de96-ad39-4d8d-a7bd-4d211f9093b5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_f70313fa-76cf-4818-8478-e328e22811bc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_e940de96-ad39-4d8d-a7bd-4d211f9093b5" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_f70313fa-76cf-4818-8478-e328e22811bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/LeasesNarrativeDetails" xlink:type="simple" xlink:href="ino-20210331.xsd#LeasesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/LeasesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_f759a3f4-4f92-4832-8ceb-1907f606af90" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_4625e22e-3f5c-4c77-87c2-1117ef7a0df6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_f759a3f4-4f92-4832-8ceb-1907f606af90" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_4625e22e-3f5c-4c77-87c2-1117ef7a0df6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_db6d3faa-f9cf-492a-826a-f7ebc84ac35a" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_4625e22e-3f5c-4c77-87c2-1117ef7a0df6" xlink:to="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_db6d3faa-f9cf-492a-826a-f7ebc84ac35a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_110bf7f0-6d00-41d7-be17-29c6e35aee20" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_db6d3faa-f9cf-492a-826a-f7ebc84ac35a" xlink:to="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_110bf7f0-6d00-41d7-be17-29c6e35aee20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_SanDiegoOfficeMember_aedad3c2-5ff8-4538-8044-faa7dc79d0bb" xlink:href="ino-20210331.xsd#ino_SanDiegoOfficeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_110bf7f0-6d00-41d7-be17-29c6e35aee20" xlink:to="loc_ino_SanDiegoOfficeMember_aedad3c2-5ff8-4538-8044-faa7dc79d0bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_PlymouthMeetingPennsylvaniaMember_f21214ae-af69-4289-a384-f15211da803b" xlink:href="ino-20210331.xsd#ino_PlymouthMeetingPennsylvaniaMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_110bf7f0-6d00-41d7-be17-29c6e35aee20" xlink:to="loc_ino_PlymouthMeetingPennsylvaniaMember_f21214ae-af69-4289-a384-f15211da803b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_18941c51-44a2-4838-b764-d6189f8697a8" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_4625e22e-3f5c-4c77-87c2-1117ef7a0df6" xlink:to="loc_srt_RangeAxis_18941c51-44a2-4838-b764-d6189f8697a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_3ad3e412-0bce-4d11-b195-3568508c53e0" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_18941c51-44a2-4838-b764-d6189f8697a8" xlink:to="loc_srt_RangeMember_3ad3e412-0bce-4d11-b195-3568508c53e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_092b9108-dbcd-4f88-a9cc-1fe550d1fb48" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_3ad3e412-0bce-4d11-b195-3568508c53e0" xlink:to="loc_srt_MinimumMember_092b9108-dbcd-4f88-a9cc-1fe550d1fb48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_5dbb6122-178b-458f-97b1-d5d692b6ad67" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_3ad3e412-0bce-4d11-b195-3568508c53e0" xlink:to="loc_srt_MaximumMember_5dbb6122-178b-458f-97b1-d5d692b6ad67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_8928927a-7416-4df5-a898-791ae2f63d86" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_4625e22e-3f5c-4c77-87c2-1117ef7a0df6" xlink:to="loc_us-gaap_LesseeLeaseDescriptionLineItems_8928927a-7416-4df5-a898-791ae2f63d86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_LesseeOperatingLeaseAreaofLandUnderLease_fa16885a-48ca-4b71-a554-e25b344157d1" xlink:href="ino-20210331.xsd#ino_LesseeOperatingLeaseAreaofLandUnderLease"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_8928927a-7416-4df5-a898-791ae2f63d86" xlink:to="loc_ino_LesseeOperatingLeaseAreaofLandUnderLease_fa16885a-48ca-4b71-a554-e25b344157d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_4b15cb38-ea30-4817-9692-b52dbd488419" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_8928927a-7416-4df5-a898-791ae2f63d86" xlink:to="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_4b15cb38-ea30-4817-9692-b52dbd488419" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_6adc5938-967f-4af8-9733-e2a02fc65e40" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseCost"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_8928927a-7416-4df5-a898-791ae2f63d86" xlink:to="loc_us-gaap_LeaseCost_6adc5938-967f-4af8-9733-e2a02fc65e40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/LeasesSummaryofFutureMinimumLeasePaymentsDetails" xlink:type="simple" xlink:href="ino-20210331.xsd#LeasesSummaryofFutureMinimumLeasePaymentsDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/LeasesSummaryofFutureMinimumLeasePaymentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_bd14add7-7f53-40cc-9128-597490993c30" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_11c70b27-1e3e-41f6-b877-711dbc822746" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_bd14add7-7f53-40cc-9128-597490993c30" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_11c70b27-1e3e-41f6-b877-711dbc822746" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_d4063b99-4538-4915-90ff-59f996971268" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_bd14add7-7f53-40cc-9128-597490993c30" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_d4063b99-4538-4915-90ff-59f996971268" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_085d5d3f-7973-4a9e-86aa-e07276944c23" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_bd14add7-7f53-40cc-9128-597490993c30" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_085d5d3f-7973-4a9e-86aa-e07276944c23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_1b724e45-f272-4c0e-9706-67659309f70f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_bd14add7-7f53-40cc-9128-597490993c30" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_1b724e45-f272-4c0e-9706-67659309f70f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_142ef5d2-45aa-458f-af87-b3d4041841c9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_bd14add7-7f53-40cc-9128-597490993c30" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_142ef5d2-45aa-458f-af87-b3d4041841c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_8a0ee0d3-89e4-4abe-b41e-26de41262bd6" xlink:href="ino-20210331.xsd#ino_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_bd14add7-7f53-40cc-9128-597490993c30" xlink:to="loc_ino_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_8a0ee0d3-89e4-4abe-b41e-26de41262bd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_113790eb-4565-4ed8-8ad4-ee1e15da6117" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_bd14add7-7f53-40cc-9128-597490993c30" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_113790eb-4565-4ed8-8ad4-ee1e15da6117" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_e499ce89-1e8b-45e0-9300-b9d9b76a3575" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_bd14add7-7f53-40cc-9128-597490993c30" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_e499ce89-1e8b-45e0-9300-b9d9b76a3575" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_3827db71-a3ea-476e-8597-268ab0b5ee62" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_bd14add7-7f53-40cc-9128-597490993c30" xlink:to="loc_us-gaap_OperatingLeaseLiability_3827db71-a3ea-476e-8597-268ab0b5ee62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_d0fef066-851a-4217-ada1-a773dee70a5a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_bd14add7-7f53-40cc-9128-597490993c30" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_d0fef066-851a-4217-ada1-a773dee70a5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_b17dd801-463d-4871-bce8-02cb825eecb6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_bd14add7-7f53-40cc-9128-597490993c30" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_b17dd801-463d-4871-bce8-02cb825eecb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_55b1e15c-d4a3-4aa5-99d0-dabeabe913e5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_bd14add7-7f53-40cc-9128-597490993c30" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_55b1e15c-d4a3-4aa5-99d0-dabeabe913e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_3ffb9873-9e32-4967-a657-301879bbc8ae" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_bd14add7-7f53-40cc-9128-597490993c30" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_3ffb9873-9e32-4967-a657-301879bbc8ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/CollaborativeAgreements" xlink:type="simple" xlink:href="ino-20210331.xsd#CollaborativeAgreements"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/CollaborativeAgreements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_9650bae6-26ac-4078-96f7-8a925980016c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_5da9a015-ac88-48a7-8c27-beb97cfcce4f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_9650bae6-26ac-4078-96f7-8a925980016c" xlink:to="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_5da9a015-ac88-48a7-8c27-beb97cfcce4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/CollaborativeAgreementsDetails" xlink:type="simple" xlink:href="ino-20210331.xsd#CollaborativeAgreementsDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/CollaborativeAgreementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_3872be11-001e-4cb5-a0a4-0181ecb22592" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_c81b169b-34ad-4818-8342-57d5a70f302e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_3872be11-001e-4cb5-a0a4-0181ecb22592" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_c81b169b-34ad-4818-8342-57d5a70f302e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_787a765b-204a-4092-add0-a2433515110f" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_c81b169b-34ad-4818-8342-57d5a70f302e" xlink:to="loc_srt_CounterpartyNameAxis_787a765b-204a-4092-add0-a2433515110f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1ea5e028-05a7-4ad9-ad6a-bd63fb63a867" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_787a765b-204a-4092-add0-a2433515110f" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1ea5e028-05a7-4ad9-ad6a-bd63fb63a867" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_AdvaccineMember_b9540c8c-baf6-496c-8d12-9d6f8c70298b" xlink:href="ino-20210331.xsd#ino_AdvaccineMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1ea5e028-05a7-4ad9-ad6a-bd63fb63a867" xlink:to="loc_ino_AdvaccineMember_b9540c8c-baf6-496c-8d12-9d6f8c70298b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ApolloBioMember_0e448688-d2a1-4c92-be9a-7b31b4513594" xlink:href="ino-20210331.xsd#ino_ApolloBioMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1ea5e028-05a7-4ad9-ad6a-bd63fb63a867" xlink:to="loc_ino_ApolloBioMember_0e448688-d2a1-4c92-be9a-7b31b4513594" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_AstraZenecaMember_15345785-657c-4792-a1e2-b430f5672bf2" xlink:href="ino-20210331.xsd#ino_AstraZenecaMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1ea5e028-05a7-4ad9-ad6a-bd63fb63a867" xlink:to="loc_ino_AstraZenecaMember_15345785-657c-4792-a1e2-b430f5672bf2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CoalitionforEpidemicPreparednessInnovationsMember_aa07d986-df43-4e2e-be5c-d7b488f3c8fc" xlink:href="ino-20210331.xsd#ino_CoalitionforEpidemicPreparednessInnovationsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1ea5e028-05a7-4ad9-ad6a-bd63fb63a867" xlink:to="loc_ino_CoalitionforEpidemicPreparednessInnovationsMember_aa07d986-df43-4e2e-be5c-d7b488f3c8fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_BillAndMelindaGatesFoundationMember_1e3e4283-d403-4346-b8e5-753207776a9c" xlink:href="ino-20210331.xsd#ino_BillAndMelindaGatesFoundationMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1ea5e028-05a7-4ad9-ad6a-bd63fb63a867" xlink:to="loc_ino_BillAndMelindaGatesFoundationMember_1e3e4283-d403-4346-b8e5-753207776a9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DepartmentOfDefenceMember_9a6b46c4-fed5-4624-8c55-db8de96978e5" xlink:href="ino-20210331.xsd#ino_DepartmentOfDefenceMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1ea5e028-05a7-4ad9-ad6a-bd63fb63a867" xlink:to="loc_ino_DepartmentOfDefenceMember_9a6b46c4-fed5-4624-8c55-db8de96978e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_905cc205-5061-4d4d-b1a9-0a0445798ad1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_c81b169b-34ad-4818-8342-57d5a70f302e" xlink:to="loc_us-gaap_TypeOfArrangementAxis_905cc205-5061-4d4d-b1a9-0a0445798ad1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_596ffc4f-abfb-4982-9713-df364782ab66" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_905cc205-5061-4d4d-b1a9-0a0445798ad1" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_596ffc4f-abfb-4982-9713-df364782ab66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementMember_c9ab7d29-6b1f-4ae2-a2be-d1319a4c3f8b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_596ffc4f-abfb-4982-9713-df364782ab66" xlink:to="loc_us-gaap_CollaborativeArrangementMember_c9ab7d29-6b1f-4ae2-a2be-d1319a4c3f8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_8568e3ae-99b7-46da-b47e-b5da9a0205eb" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_c81b169b-34ad-4818-8342-57d5a70f302e" xlink:to="loc_srt_ProductOrServiceAxis_8568e3ae-99b7-46da-b47e-b5da9a0205eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_0619ca4f-6ee8-45bf-906b-f0915c73f13f" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_8568e3ae-99b7-46da-b47e-b5da9a0205eb" xlink:to="loc_srt_ProductsAndServicesDomain_0619ca4f-6ee8-45bf-906b-f0915c73f13f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember_eb35184b-a7bc-497d-a804-2be7c2c96810" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LicenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_0619ca4f-6ee8-45bf-906b-f0915c73f13f" xlink:to="loc_us-gaap_LicenseMember_eb35184b-a7bc-497d-a804-2be7c2c96810" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_LassaFeverAndMERSVaccineMember_581ef705-5697-4d76-bb83-336b688f82bf" xlink:href="ino-20210331.xsd#ino_LassaFeverAndMERSVaccineMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_0619ca4f-6ee8-45bf-906b-f0915c73f13f" xlink:to="loc_ino_LassaFeverAndMERSVaccineMember_581ef705-5697-4d76-bb83-336b688f82bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_SARSCoV2COVID19VaccineMember_9aa66596-925e-450b-98be-35f4992ec025" xlink:href="ino-20210331.xsd#ino_SARSCoV2COVID19VaccineMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_0619ca4f-6ee8-45bf-906b-f0915c73f13f" xlink:to="loc_ino_SARSCoV2COVID19VaccineMember_9aa66596-925e-450b-98be-35f4992ec025" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CELLECTRA3PSPProprietarySmartDeviceMember_3c9b9d28-6cdc-4458-8d27-33dd9a90c329" xlink:href="ino-20210331.xsd#ino_CELLECTRA3PSPProprietarySmartDeviceMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_0619ca4f-6ee8-45bf-906b-f0915c73f13f" xlink:to="loc_ino_CELLECTRA3PSPProprietarySmartDeviceMember_3c9b9d28-6cdc-4458-8d27-33dd9a90c329" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_INO4800Member_b08355cf-2798-4f85-96d8-91cb46616abd" xlink:href="ino-20210331.xsd#ino_INO4800Member"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_0619ca4f-6ee8-45bf-906b-f0915c73f13f" xlink:to="loc_ino_INO4800Member_b08355cf-2798-4f85-96d8-91cb46616abd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DNAEncodedMonoclonalAntibodyTechnologyMember_6cc43eb9-7cb9-42bd-8983-fa202210aa66" xlink:href="ino-20210331.xsd#ino_DNAEncodedMonoclonalAntibodyTechnologyMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_0619ca4f-6ee8-45bf-906b-f0915c73f13f" xlink:to="loc_ino_DNAEncodedMonoclonalAntibodyTechnologyMember_6cc43eb9-7cb9-42bd-8983-fa202210aa66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CELLECTRA2000DeviceMember_5fd00735-d50f-4255-91ce-e08019c5c401" xlink:href="ino-20210331.xsd#ino_CELLECTRA2000DeviceMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_0619ca4f-6ee8-45bf-906b-f0915c73f13f" xlink:to="loc_ino_CELLECTRA2000DeviceMember_5fd00735-d50f-4255-91ce-e08019c5c401" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_4698c896-3086-4da1-abce-f84dd3f431e3" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_c81b169b-34ad-4818-8342-57d5a70f302e" xlink:to="loc_srt_MajorCustomersAxis_4698c896-3086-4da1-abce-f84dd3f431e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_1b3c589a-668e-43bf-9f25-b92b4e8a109d" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_4698c896-3086-4da1-abce-f84dd3f431e3" xlink:to="loc_srt_NameOfMajorCustomerDomain_1b3c589a-668e-43bf-9f25-b92b4e8a109d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_AdvaccineMember_ce37ce94-af6b-4bac-a9fe-c31616fc258c" xlink:href="ino-20210331.xsd#ino_AdvaccineMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_1b3c589a-668e-43bf-9f25-b92b4e8a109d" xlink:to="loc_ino_AdvaccineMember_ce37ce94-af6b-4bac-a9fe-c31616fc258c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_4d7038d0-9ab5-4bfe-bf19-1a42f7c7d8d1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_c81b169b-34ad-4818-8342-57d5a70f302e" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_4d7038d0-9ab5-4bfe-bf19-1a42f7c7d8d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_3c874599-60d7-40f8-8bd9-f9347da8979b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_4d7038d0-9ab5-4bfe-bf19-1a42f7c7d8d1" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_3c874599-60d7-40f8-8bd9-f9347da8979b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_4e9a9680-d115-4506-9c50-41db9a916c44" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_3c874599-60d7-40f8-8bd9-f9347da8979b" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_4e9a9680-d115-4506-9c50-41db9a916c44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_89cfbce3-9e5f-497c-b8d9-16aeba7ab875" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_c81b169b-34ad-4818-8342-57d5a70f302e" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_89cfbce3-9e5f-497c-b8d9-16aeba7ab875" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_61fccaf6-b141-4468-af9f-2d2b92cc7362" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_89cfbce3-9e5f-497c-b8d9-16aeba7ab875" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_61fccaf6-b141-4468-af9f-2d2b92cc7362" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCountryMember_3807aec2-3b5a-4b44-b1af-a055d9ebdb39" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCountryMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_61fccaf6-b141-4468-af9f-2d2b92cc7362" xlink:to="loc_us-gaap_ForeignCountryMember_3807aec2-3b5a-4b44-b1af-a055d9ebdb39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4418f15a-5143-4dd3-bf19-d5e1576e2246" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_c81b169b-34ad-4818-8342-57d5a70f302e" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4418f15a-5143-4dd3-bf19-d5e1576e2246" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementsUpfrontPaymentReceived_243030d4-4e31-42d2-990e-779842f794c0" xlink:href="ino-20210331.xsd#ino_CollaborativeAgreementsUpfrontPaymentReceived"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4418f15a-5143-4dd3-bf19-d5e1576e2246" xlink:to="loc_ino_CollaborativeAgreementsUpfrontPaymentReceived_243030d4-4e31-42d2-990e-779842f794c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborationAgreementAdditionalRevenueToBeAchieved_bc69d82d-8804-477f-b6db-a6fe6915b55b" xlink:href="ino-20210331.xsd#ino_CollaborationAgreementAdditionalRevenueToBeAchieved"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4418f15a-5143-4dd3-bf19-d5e1576e2246" xlink:to="loc_ino_CollaborationAgreementAdditionalRevenueToBeAchieved_bc69d82d-8804-477f-b6db-a6fe6915b55b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborationAgreementPaymentEarned_786089c0-3d2e-4e12-956a-e5e4dde0b7ff" xlink:href="ino-20210331.xsd#ino_CollaborationAgreementPaymentEarned"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4418f15a-5143-4dd3-bf19-d5e1576e2246" xlink:to="loc_ino_CollaborationAgreementPaymentEarned_786089c0-3d2e-4e12-956a-e5e4dde0b7ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborationAgreementRoyaltyPeriod_80215243-4210-4685-b99d-d19b568bc569" xlink:href="ino-20210331.xsd#ino_CollaborationAgreementRoyaltyPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4418f15a-5143-4dd3-bf19-d5e1576e2246" xlink:to="loc_ino_CollaborationAgreementRoyaltyPeriod_80215243-4210-4685-b99d-d19b568bc569" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementPeriodFromEffectiveDateForTermination_390663ca-7288-43c6-a1d1-ed5d7258b933" xlink:href="ino-20210331.xsd#ino_CollaborativeAgreementPeriodFromEffectiveDateForTermination"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4418f15a-5143-4dd3-bf19-d5e1576e2246" xlink:to="loc_ino_CollaborativeAgreementPeriodFromEffectiveDateForTermination_390663ca-7288-43c6-a1d1-ed5d7258b933" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_6b2c1029-b2ba-47f0-9f12-a5e0112ad7d8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4418f15a-5143-4dd3-bf19-d5e1576e2246" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_6b2c1029-b2ba-47f0-9f12-a5e0112ad7d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNet_969679c0-681b-4e42-9c24-bd1b84fe7afa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNet"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4418f15a-5143-4dd3-bf19-d5e1576e2246" xlink:to="loc_us-gaap_AccountsReceivableNet_969679c0-681b-4e42-9c24-bd1b84fe7afa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborationAgreementTerritoryExpansionOptionPeriod_b2fb3e24-9701-422e-a87a-04bc892f3264" xlink:href="ino-20210331.xsd#ino_CollaborationAgreementTerritoryExpansionOptionPeriod"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4418f15a-5143-4dd3-bf19-d5e1576e2246" xlink:to="loc_ino_CollaborationAgreementTerritoryExpansionOptionPeriod_b2fb3e24-9701-422e-a87a-04bc892f3264" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ProceedsFromCollaborativeAgreement_f0e112f9-bb28-42a0-ad47-6c14bffd327a" xlink:href="ino-20210331.xsd#ino_ProceedsFromCollaborativeAgreement"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4418f15a-5143-4dd3-bf19-d5e1576e2246" xlink:to="loc_ino_ProceedsFromCollaborativeAgreement_f0e112f9-bb28-42a0-ad47-6c14bffd327a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementCorporateIncomeTax_ee698f55-0abf-483f-bfbc-16a0aaee4ef0" xlink:href="ino-20210331.xsd#ino_CollaborativeAgreementCorporateIncomeTax"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4418f15a-5143-4dd3-bf19-d5e1576e2246" xlink:to="loc_ino_CollaborativeAgreementCorporateIncomeTax_ee698f55-0abf-483f-bfbc-16a0aaee4ef0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementForeignNonIncomeTaxes_ee26e9db-b322-40d9-a688-750c39733e81" xlink:href="ino-20210331.xsd#ino_CollaborativeAgreementForeignNonIncomeTaxes"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4418f15a-5143-4dd3-bf19-d5e1576e2246" xlink:to="loc_ino_CollaborativeAgreementForeignNonIncomeTaxes_ee26e9db-b322-40d9-a688-750c39733e81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementAdvisoryFees_de67e8c6-dea5-4801-838f-cc7d4f17ac38" xlink:href="ino-20210331.xsd#ino_CollaborativeAgreementAdvisoryFees"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4418f15a-5143-4dd3-bf19-d5e1576e2246" xlink:to="loc_ino_CollaborativeAgreementAdvisoryFees_de67e8c6-dea5-4801-838f-cc7d4f17ac38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementNumberofDaysWrittenNoticeBeforeTermination_c656509d-703e-41c2-a4a4-3fc4de4fef4b" xlink:href="ino-20210331.xsd#ino_CollaborativeAgreementNumberofDaysWrittenNoticeBeforeTermination"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4418f15a-5143-4dd3-bf19-d5e1576e2246" xlink:to="loc_ino_CollaborativeAgreementNumberofDaysWrittenNoticeBeforeTermination_c656509d-703e-41c2-a4a4-3fc4de4fef4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborationAgreementAnticipatedDevelopmentandRegulatoryEventBasedPaymentReceivableMilestones_67cf0e92-c7c1-4210-a256-59fddf62b313" xlink:href="ino-20210331.xsd#ino_CollaborationAgreementAnticipatedDevelopmentandRegulatoryEventBasedPaymentReceivableMilestones"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4418f15a-5143-4dd3-bf19-d5e1576e2246" xlink:to="loc_ino_CollaborationAgreementAnticipatedDevelopmentandRegulatoryEventBasedPaymentReceivableMilestones_67cf0e92-c7c1-4210-a256-59fddf62b313" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborationAgreementAnticipatedCommercialEventBasedPaymentReceivableMilestones_549c1c97-3e8f-41d5-be57-a3b6678e10f5" xlink:href="ino-20210331.xsd#ino_CollaborationAgreementAnticipatedCommercialEventBasedPaymentReceivableMilestones"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4418f15a-5143-4dd3-bf19-d5e1576e2246" xlink:to="loc_ino_CollaborationAgreementAnticipatedCommercialEventBasedPaymentReceivableMilestones_549c1c97-3e8f-41d5-be57-a3b6678e10f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementFundingToBeReceived_d873e984-4587-48be-91c7-04be159ed370" xlink:href="ino-20210331.xsd#ino_CollaborativeAgreementFundingToBeReceived"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4418f15a-5143-4dd3-bf19-d5e1576e2246" xlink:to="loc_ino_CollaborativeAgreementFundingToBeReceived_d873e984-4587-48be-91c7-04be159ed370" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment_3cc22677-fd16-48d5-a68e-f6219d206733" xlink:href="ino-20210331.xsd#ino_CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4418f15a-5143-4dd3-bf19-d5e1576e2246" xlink:to="loc_ino_CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment_3cc22677-fd16-48d5-a68e-f6219d206733" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementFundingReceived_91a724bf-c17b-418f-a227-d481b2d3f0b9" xlink:href="ino-20210331.xsd#ino_CollaborativeAgreementFundingReceived"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4418f15a-5143-4dd3-bf19-d5e1576e2246" xlink:to="loc_ino_CollaborativeAgreementFundingReceived_91a724bf-c17b-418f-a227-d481b2d3f0b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DeferredGrantFundingCurrent_43789eac-e31d-4ee5-bf0f-017e365c154f" xlink:href="ino-20210331.xsd#ino_DeferredGrantFundingCurrent"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4418f15a-5143-4dd3-bf19-d5e1576e2246" xlink:to="loc_ino_DeferredGrantFundingCurrent_43789eac-e31d-4ee5-bf0f-017e365c154f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeArrangementFixedPriceContractAmountAwarded_f04d91ab-e0c6-41b9-8605-753f6ee876f0" xlink:href="ino-20210331.xsd#ino_CollaborativeArrangementFixedPriceContractAmountAwarded"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4418f15a-5143-4dd3-bf19-d5e1576e2246" xlink:to="loc_ino_CollaborativeArrangementFixedPriceContractAmountAwarded_f04d91ab-e0c6-41b9-8605-753f6ee876f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_GrantProceedsReceived_a7c86077-0662-48c5-8785-c0ffe42b4ca5" xlink:href="ino-20210331.xsd#ino_GrantProceedsReceived"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4418f15a-5143-4dd3-bf19-d5e1576e2246" xlink:to="loc_ino_GrantProceedsReceived_a7c86077-0662-48c5-8785-c0ffe42b4ca5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableRelatedParties_9305833e-353d-4986-bfb1-3e8282c957e3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableRelatedParties"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4418f15a-5143-4dd3-bf19-d5e1576e2246" xlink:to="loc_us-gaap_AccountsReceivableRelatedParties_9305833e-353d-4986-bfb1-3e8282c957e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/IncomeTaxes" xlink:type="simple" xlink:href="ino-20210331.xsd#IncomeTaxes"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_c6a417c2-4af4-41d4-ac38-1afe38e17edf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_8ff1dece-4eb1-4391-b3e4-0c9bda58a8e9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_c6a417c2-4af4-41d4-ac38-1afe38e17edf" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_8ff1dece-4eb1-4391-b3e4-0c9bda58a8e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/GeneosTherapeuticsInc" xlink:type="simple" xlink:href="ino-20210331.xsd#GeneosTherapeuticsInc"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/GeneosTherapeuticsInc" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestAbstract_877077f6-5773-4757-85d4-81180a1fdbe3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncontrollingInterestAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_343db708-8a0f-41fc-9fec-27407b8cf57f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncontrollingInterestAbstract_877077f6-5773-4757-85d4-81180a1fdbe3" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_343db708-8a0f-41fc-9fec-27407b8cf57f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/GeneosTherapeuticsIncTables" xlink:type="simple" xlink:href="ino-20210331.xsd#GeneosTherapeuticsIncTables"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/GeneosTherapeuticsIncTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestAbstract_c25ef62e-93a6-4bf5-b0d1-21e4b604ef2b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncontrollingInterestAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsTextBlock_3f96dd86-d8a6-4f00-a0b8-c8cf78815f0f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncontrollingInterestAbstract_c25ef62e-93a6-4bf5-b0d1-21e4b604ef2b" xlink:to="loc_us-gaap_EquityMethodInvestmentsTextBlock_3f96dd86-d8a6-4f00-a0b8-c8cf78815f0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_d54c8ae2-183e-40b0-94a8-4e457cfc0727" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncontrollingInterestAbstract_c25ef62e-93a6-4bf5-b0d1-21e4b604ef2b" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_d54c8ae2-183e-40b0-94a8-4e457cfc0727" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/GeneosTherapeuticsIncNarrativeDetails" xlink:type="simple" xlink:href="ino-20210331.xsd#GeneosTherapeuticsIncNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/GeneosTherapeuticsIncNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestAbstract_61b5b019-12fa-4a5f-9cec-7bec9de4a16b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncontrollingInterestAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestTable_1ff3eba0-3f86-412e-85af-8dc27b93f3dd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterestTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncontrollingInterestAbstract_61b5b019-12fa-4a5f-9cec-7bec9de4a16b" xlink:to="loc_us-gaap_MinorityInterestTable_1ff3eba0-3f86-412e-85af-8dc27b93f3dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_e125744e-7efe-4882-bd43-18553eab6f12" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestTable_1ff3eba0-3f86-412e-85af-8dc27b93f3dd" xlink:to="loc_srt_CounterpartyNameAxis_e125744e-7efe-4882-bd43-18553eab6f12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_013bd6ee-e6b8-4094-adbf-8f55d3f82126" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_e125744e-7efe-4882-bd43-18553eab6f12" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_013bd6ee-e6b8-4094-adbf-8f55d3f82126" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_GeneosTherapeuticsInc.Member_4cdd9011-cbf6-4db9-85df-3f62bb005dbe" xlink:href="ino-20210331.xsd#ino_GeneosTherapeuticsInc.Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_013bd6ee-e6b8-4094-adbf-8f55d3f82126" xlink:to="loc_ino_GeneosTherapeuticsInc.Member_4cdd9011-cbf6-4db9-85df-3f62bb005dbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_a59348d1-91bc-448b-b3e7-5a301f7a32e3" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_OwnershipAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestTable_1ff3eba0-3f86-412e-85af-8dc27b93f3dd" xlink:to="loc_srt_OwnershipAxis_a59348d1-91bc-448b-b3e7-5a301f7a32e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_bc45239b-05e3-4844-8a32-83a844761ddd" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_OwnershipDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipAxis_a59348d1-91bc-448b-b3e7-5a301f7a32e3" xlink:to="loc_srt_OwnershipDomain_bc45239b-05e3-4844-8a32-83a844761ddd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_GeneosTherapeuticsInc.Member_5f13b036-3fbd-44de-9f57-4c5639d60b81" xlink:href="ino-20210331.xsd#ino_GeneosTherapeuticsInc.Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipDomain_bc45239b-05e3-4844-8a32-83a844761ddd" xlink:to="loc_ino_GeneosTherapeuticsInc.Member_5f13b036-3fbd-44de-9f57-4c5639d60b81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_fc000191-e497-4264-a2a4-6fd2a733e850" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestTable_1ff3eba0-3f86-412e-85af-8dc27b93f3dd" xlink:to="loc_us-gaap_StatementClassOfStockAxis_fc000191-e497-4264-a2a4-6fd2a733e850" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_6732092d-a446-4b53-b340-3ca747fa1fa2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_fc000191-e497-4264-a2a4-6fd2a733e850" xlink:to="loc_us-gaap_ClassOfStockDomain_6732092d-a446-4b53-b340-3ca747fa1fa2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_21db8b1e-c417-47ea-8e10-a9dafcceac7e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_6732092d-a446-4b53-b340-3ca747fa1fa2" xlink:to="loc_us-gaap_CommonStockMember_21db8b1e-c417-47ea-8e10-a9dafcceac7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember_499cb4ea-9dcd-4cf9-aa89-128c7d0f5103" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_6732092d-a446-4b53-b340-3ca747fa1fa2" xlink:to="loc_us-gaap_PreferredStockMember_499cb4ea-9dcd-4cf9-aa89-128c7d0f5103" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_SeriesAOnePreferredStockMember_8dc18211-2956-4167-a530-74e3393910f7" xlink:href="ino-20210331.xsd#ino_SeriesAOnePreferredStockMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_6732092d-a446-4b53-b340-3ca747fa1fa2" xlink:to="loc_ino_SeriesAOnePreferredStockMember_8dc18211-2956-4167-a530-74e3393910f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestLineItems_3d591310-faac-4180-aca0-0df1b3804438" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterestLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestTable_1ff3eba0-3f86-412e-85af-8dc27b93f3dd" xlink:to="loc_us-gaap_MinorityInterestLineItems_3d591310-faac-4180-aca0-0df1b3804438" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries_2f88655b-c318-4e10-866c-2e4b359e92da" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestLineItems_3d591310-faac-4180-aca0-0df1b3804438" xlink:to="loc_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries_2f88655b-c318-4e10-866c-2e4b359e92da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_667d01c2-68aa-467c-8a38-69a000e28973" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestLineItems_3d591310-faac-4180-aca0-0df1b3804438" xlink:to="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_667d01c2-68aa-467c-8a38-69a000e28973" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_StockPurchaseAgreementCommitmentOfAdditionalInvestment_0bd6a842-c5fc-4093-9ee7-6c5d77136c7c" xlink:href="ino-20210331.xsd#ino_StockPurchaseAgreementCommitmentOfAdditionalInvestment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestLineItems_3d591310-faac-4180-aca0-0df1b3804438" xlink:to="loc_ino_StockPurchaseAgreementCommitmentOfAdditionalInvestment_0bd6a842-c5fc-4093-9ee7-6c5d77136c7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_2abd38ed-ddb6-451b-8b9f-d97dde9125d7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestLineItems_3d591310-faac-4180-aca0-0df1b3804438" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_2abd38ed-ddb6-451b-8b9f-d97dde9125d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeconsolidationGainOrLossAmount_eb136bcc-41b6-46ff-b77d-bfbb291dbd9c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeconsolidationGainOrLossAmount"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestLineItems_3d591310-faac-4180-aca0-0df1b3804438" xlink:to="loc_us-gaap_DeconsolidationGainOrLossAmount_eb136bcc-41b6-46ff-b77d-bfbb291dbd9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount_c66927e4-76fb-4d9e-8747-d4b9a114caea" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestLineItems_3d591310-faac-4180-aca0-0df1b3804438" xlink:to="loc_us-gaap_DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount_c66927e4-76fb-4d9e-8747-d4b9a114caea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_IncomeLossFromEquityMethodInvestmentsRealizedAndAllocatedToInvestment_ba5624a0-a114-4934-a8e4-39725334325e" xlink:href="ino-20210331.xsd#ino_IncomeLossFromEquityMethodInvestmentsRealizedAndAllocatedToInvestment"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestLineItems_3d591310-faac-4180-aca0-0df1b3804438" xlink:to="loc_ino_IncomeLossFromEquityMethodInvestmentsRealizedAndAllocatedToInvestment_ba5624a0-a114-4934-a8e4-39725334325e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_9a147c2c-80ef-4dd4-811e-6300b6eaa781" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestLineItems_3d591310-faac-4180-aca0-0df1b3804438" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_9a147c2c-80ef-4dd4-811e-6300b6eaa781" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_fd3943b7-4da9-4001-a6dc-ce17f6b2e773" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestments"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestLineItems_3d591310-faac-4180-aca0-0df1b3804438" xlink:to="loc_us-gaap_EquityMethodInvestments_fd3943b7-4da9-4001-a6dc-ce17f6b2e773" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/GeneosTherapeuticsIncDeconsolidationAccountingDetails" xlink:type="simple" xlink:href="ino-20210331.xsd#GeneosTherapeuticsIncDeconsolidationAccountingDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/GeneosTherapeuticsIncDeconsolidationAccountingDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestAbstract_2b231216-8f02-4e18-afa2-39eb669b9db2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncontrollingInterestAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestTable_8f3074c2-1ad3-4b66-8d4a-6db31c8a3b8b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterestTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncontrollingInterestAbstract_2b231216-8f02-4e18-afa2-39eb669b9db2" xlink:to="loc_us-gaap_MinorityInterestTable_8f3074c2-1ad3-4b66-8d4a-6db31c8a3b8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_236d3847-fc27-43a9-87f2-da40a42c08c4" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestTable_8f3074c2-1ad3-4b66-8d4a-6db31c8a3b8b" xlink:to="loc_srt_CounterpartyNameAxis_236d3847-fc27-43a9-87f2-da40a42c08c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_9e167b90-4d2a-4021-8b0b-c5bd64f37a84" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_236d3847-fc27-43a9-87f2-da40a42c08c4" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_9e167b90-4d2a-4021-8b0b-c5bd64f37a84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_GeneosTherapeuticsInc.Member_b53ef947-f3c1-4a04-8d76-dea1a8f8d25e" xlink:href="ino-20210331.xsd#ino_GeneosTherapeuticsInc.Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_9e167b90-4d2a-4021-8b0b-c5bd64f37a84" xlink:to="loc_ino_GeneosTherapeuticsInc.Member_b53ef947-f3c1-4a04-8d76-dea1a8f8d25e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestLineItems_d683c748-156c-4d9c-abb8-c2f770c80082" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterestLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestTable_8f3074c2-1ad3-4b66-8d4a-6db31c8a3b8b" xlink:to="loc_us-gaap_MinorityInterestLineItems_d683c748-156c-4d9c-abb8-c2f770c80082" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_WorkingCapitalExcludingCash_f7db0f7b-fa85-453a-8f74-1d213827562d" xlink:href="ino-20210331.xsd#ino_WorkingCapitalExcludingCash"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestLineItems_d683c748-156c-4d9c-abb8-c2f770c80082" xlink:to="loc_ino_WorkingCapitalExcludingCash_f7db0f7b-fa85-453a-8f74-1d213827562d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayable_43f3e30c-dbf1-4415-99c5-4f021d52ca54" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NotesPayable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestLineItems_d683c748-156c-4d9c-abb8-c2f770c80082" xlink:to="loc_us-gaap_NotesPayable_43f3e30c-dbf1-4415-99c5-4f021d52ca54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_8e57d6d4-b680-43ac-a39f-6ded2116e045" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestLineItems_d683c748-156c-4d9c-abb8-c2f770c80082" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_8e57d6d4-b680-43ac-a39f-6ded2116e045" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_ef83f0cc-6222-4be5-8f7a-1ba8ee06a2ea" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterest"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestLineItems_d683c748-156c-4d9c-abb8-c2f770c80082" xlink:to="loc_us-gaap_MinorityInterest_ef83f0cc-6222-4be5-8f7a-1ba8ee06a2ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedInterestFairValueDisclosure_228e7d21-b526-4803-99d4-5e465e29ad57" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedInterestFairValueDisclosure"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestLineItems_d683c748-156c-4d9c-abb8-c2f770c80082" xlink:to="loc_us-gaap_RetainedInterestFairValueDisclosure_228e7d21-b526-4803-99d4-5e465e29ad57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeconsolidationGainOrLossAmount_c0046c67-5d5a-4205-a142-34906ae80035" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeconsolidationGainOrLossAmount"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestLineItems_d683c748-156c-4d9c-abb8-c2f770c80082" xlink:to="loc_us-gaap_DeconsolidationGainOrLossAmount_c0046c67-5d5a-4205-a142-34906ae80035" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashDivestedFromDeconsolidation_2148ea6a-11c5-44c4-846e-4c91d9a1f7ef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashDivestedFromDeconsolidation"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestLineItems_d683c748-156c-4d9c-abb8-c2f770c80082" xlink:to="loc_us-gaap_CashDivestedFromDeconsolidation_2148ea6a-11c5-44c4-846e-4c91d9a1f7ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/GeneosTherapeuticsIncInvestmentInGeneosDetails" xlink:type="simple" xlink:href="ino-20210331.xsd#GeneosTherapeuticsIncInvestmentInGeneosDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/GeneosTherapeuticsIncInvestmentInGeneosDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestAbstract_06f22bca-baf2-4eb8-a0c6-679851ad6962" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncontrollingInterestAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestTable_e7476180-2234-4a70-9908-05941a09418d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterestTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncontrollingInterestAbstract_06f22bca-baf2-4eb8-a0c6-679851ad6962" xlink:to="loc_us-gaap_MinorityInterestTable_e7476180-2234-4a70-9908-05941a09418d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_a8e980d8-7ed5-4bed-b97c-5b4edba3cc3f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestTable_e7476180-2234-4a70-9908-05941a09418d" xlink:to="loc_us-gaap_StatementClassOfStockAxis_a8e980d8-7ed5-4bed-b97c-5b4edba3cc3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_b4a6faf4-28db-49d9-89da-461cb548f878" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_a8e980d8-7ed5-4bed-b97c-5b4edba3cc3f" xlink:to="loc_us-gaap_ClassOfStockDomain_b4a6faf4-28db-49d9-89da-461cb548f878" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_f03766de-ed72-4aee-958c-8b751c2b249c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_b4a6faf4-28db-49d9-89da-461cb548f878" xlink:to="loc_us-gaap_CommonStockMember_f03766de-ed72-4aee-958c-8b751c2b249c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember_6fcaa87c-2ee9-4fc1-b8c7-803bea753e0f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_b4a6faf4-28db-49d9-89da-461cb548f878" xlink:to="loc_us-gaap_PreferredStockMember_6fcaa87c-2ee9-4fc1-b8c7-803bea753e0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_65df8831-e634-4730-85b9-044094a065c4" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestTable_e7476180-2234-4a70-9908-05941a09418d" xlink:to="loc_srt_CounterpartyNameAxis_65df8831-e634-4730-85b9-044094a065c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_06d3cb36-5a85-44f0-be83-a404a86cdd18" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_65df8831-e634-4730-85b9-044094a065c4" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_06d3cb36-5a85-44f0-be83-a404a86cdd18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_GeneosTherapeuticsInc.Member_14c7090c-06f4-4b57-9225-83e44dcfc5a7" xlink:href="ino-20210331.xsd#ino_GeneosTherapeuticsInc.Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_06d3cb36-5a85-44f0-be83-a404a86cdd18" xlink:to="loc_ino_GeneosTherapeuticsInc.Member_14c7090c-06f4-4b57-9225-83e44dcfc5a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestLineItems_944036ce-4afe-4333-8439-e5fbe5032dd5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterestLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestTable_e7476180-2234-4a70-9908-05941a09418d" xlink:to="loc_us-gaap_MinorityInterestLineItems_944036ce-4afe-4333-8439-e5fbe5032dd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentOwnedBalanceShares_ffcc5cb1-915a-472d-a7a2-120f393e5cd9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentOwnedBalanceShares"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestLineItems_944036ce-4afe-4333-8439-e5fbe5032dd5" xlink:to="loc_us-gaap_InvestmentOwnedBalanceShares_ffcc5cb1-915a-472d-a7a2-120f393e5cd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice_ba284036-d21d-492e-8b22-309599a09b0d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestLineItems_944036ce-4afe-4333-8439-e5fbe5032dd5" xlink:to="loc_us-gaap_SharePrice_ba284036-d21d-492e-8b22-309599a09b0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_0c344587-df16-444a-8a77-c9089faa0bd5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestLineItems_944036ce-4afe-4333-8439-e5fbe5032dd5" xlink:to="loc_us-gaap_EquityMethodInvestments_0c344587-df16-444a-8a77-c9089faa0bd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/GeneosTherapeuticsIncFairValueAssumptionsDetails" xlink:type="simple" xlink:href="ino-20210331.xsd#GeneosTherapeuticsIncFairValueAssumptionsDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/GeneosTherapeuticsIncFairValueAssumptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestAbstract_146ffef7-1338-4ce3-b595-6e8cd45a6c7e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncontrollingInterestAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestTable_daeae690-7ea4-4a67-a108-6bcacf99a907" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterestTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncontrollingInterestAbstract_146ffef7-1338-4ce3-b595-6e8cd45a6c7e" xlink:to="loc_us-gaap_MinorityInterestTable_daeae690-7ea4-4a67-a108-6bcacf99a907" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_ea368f48-6999-4e58-b98f-da13390be698" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestTable_daeae690-7ea4-4a67-a108-6bcacf99a907" xlink:to="loc_srt_CounterpartyNameAxis_ea368f48-6999-4e58-b98f-da13390be698" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a7db71b5-7856-48ca-a76d-e330b07710d5" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_ea368f48-6999-4e58-b98f-da13390be698" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a7db71b5-7856-48ca-a76d-e330b07710d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_GeneosTherapeuticsInc.Member_a1eb3d5a-6d2c-4a96-9726-f4ce95e84175" xlink:href="ino-20210331.xsd#ino_GeneosTherapeuticsInc.Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a7db71b5-7856-48ca-a76d-e330b07710d5" xlink:to="loc_ino_GeneosTherapeuticsInc.Member_a1eb3d5a-6d2c-4a96-9726-f4ce95e84175" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_c72c070a-8042-4cd6-9cda-396a294eae25" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestTable_daeae690-7ea4-4a67-a108-6bcacf99a907" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_c72c070a-8042-4cd6-9cda-396a294eae25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_541d0036-a086-472c-8e0d-c8fb176fe990" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_c72c070a-8042-4cd6-9cda-396a294eae25" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_541d0036-a086-472c-8e0d-c8fb176fe990" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputExpectedTermMember_d3637677-43dd-486c-9957-b4079d7cf826" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputExpectedTermMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_541d0036-a086-472c-8e0d-c8fb176fe990" xlink:to="loc_us-gaap_MeasurementInputExpectedTermMember_d3637677-43dd-486c-9957-b4079d7cf826" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputPriceVolatilityMember_7d67618b-b237-4bfb-b32e-6f579466b346" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputPriceVolatilityMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_541d0036-a086-472c-8e0d-c8fb176fe990" xlink:to="loc_us-gaap_MeasurementInputPriceVolatilityMember_7d67618b-b237-4bfb-b32e-6f579466b346" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_c80bb4a0-686d-4396-bc3d-a97de20d66ae" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_541d0036-a086-472c-8e0d-c8fb176fe990" xlink:to="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_c80bb4a0-686d-4396-bc3d-a97de20d66ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestLineItems_254a7911-f3c1-4f94-8bae-a4fbfe6784ef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterestLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestTable_daeae690-7ea4-4a67-a108-6bcacf99a907" xlink:to="loc_us-gaap_MinorityInterestLineItems_254a7911-f3c1-4f94-8bae-a4fbfe6784ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_AlternativeInvestmentMeasurementInputTerm_e29884df-14a7-418e-86b5-ba414bdfc10e" xlink:href="ino-20210331.xsd#ino_AlternativeInvestmentMeasurementInputTerm"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestLineItems_254a7911-f3c1-4f94-8bae-a4fbfe6784ef" xlink:to="loc_ino_AlternativeInvestmentMeasurementInputTerm_e29884df-14a7-418e-86b5-ba414bdfc10e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AlternativeInvestmentMeasurementInput_edd20864-3bc2-4d1e-8999-6d84a6bfdc1c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AlternativeInvestmentMeasurementInput"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestLineItems_254a7911-f3c1-4f94-8bae-a4fbfe6784ef" xlink:to="loc_us-gaap_AlternativeInvestmentMeasurementInput_edd20864-3bc2-4d1e-8999-6d84a6bfdc1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_EquityMethodInvestmentEnterpriseValue_4eecc52a-b3df-4345-b1ce-686ac38a68cc" xlink:href="ino-20210331.xsd#ino_EquityMethodInvestmentEnterpriseValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestLineItems_254a7911-f3c1-4f94-8bae-a4fbfe6784ef" xlink:to="loc_ino_EquityMethodInvestmentEnterpriseValue_4eecc52a-b3df-4345-b1ce-686ac38a68cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/GeneosTherapeuticsIncPreferredstockInvestmentDetails" xlink:type="simple" xlink:href="ino-20210331.xsd#GeneosTherapeuticsIncPreferredstockInvestmentDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/GeneosTherapeuticsIncPreferredstockInvestmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestAbstract_427ad232-f909-44ff-8a93-906244506394" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncontrollingInterestAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestTable_65676789-1876-4263-bac1-f38ed53e19ca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterestTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncontrollingInterestAbstract_427ad232-f909-44ff-8a93-906244506394" xlink:to="loc_us-gaap_MinorityInterestTable_65676789-1876-4263-bac1-f38ed53e19ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_a074e4a1-fab5-47bb-94cf-8385bb2be814" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestTable_65676789-1876-4263-bac1-f38ed53e19ca" xlink:to="loc_srt_CounterpartyNameAxis_a074e4a1-fab5-47bb-94cf-8385bb2be814" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4f301293-cc4e-4606-97a7-885e8b747888" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_a074e4a1-fab5-47bb-94cf-8385bb2be814" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4f301293-cc4e-4606-97a7-885e8b747888" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_GeneosTherapeuticsInc.Member_97e426d3-8585-497c-9528-31a06d917019" xlink:href="ino-20210331.xsd#ino_GeneosTherapeuticsInc.Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4f301293-cc4e-4606-97a7-885e8b747888" xlink:to="loc_ino_GeneosTherapeuticsInc.Member_97e426d3-8585-497c-9528-31a06d917019" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_5d41b88c-089c-4af1-a47c-bc635c9db724" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestTable_65676789-1876-4263-bac1-f38ed53e19ca" xlink:to="loc_us-gaap_StatementClassOfStockAxis_5d41b88c-089c-4af1-a47c-bc635c9db724" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_7f0f0300-0659-43f8-a4e1-edcb8d9fbc1a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_5d41b88c-089c-4af1-a47c-bc635c9db724" xlink:to="loc_us-gaap_ClassOfStockDomain_7f0f0300-0659-43f8-a4e1-edcb8d9fbc1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_SeriesAOnePreferredStockMember_e6e4a27f-8048-4287-acca-e76de6c989bb" xlink:href="ino-20210331.xsd#ino_SeriesAOnePreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_7f0f0300-0659-43f8-a4e1-edcb8d9fbc1a" xlink:to="loc_ino_SeriesAOnePreferredStockMember_e6e4a27f-8048-4287-acca-e76de6c989bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestLineItems_5a2e9106-d89a-42bf-b6c4-eb4542fc6f0b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterestLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestTable_65676789-1876-4263-bac1-f38ed53e19ca" xlink:to="loc_us-gaap_MinorityInterestLineItems_5a2e9106-d89a-42bf-b6c4-eb4542fc6f0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MovementInMinorityInterestRollForward_0e44e2d1-2bec-4702-86b2-8dd9a2133c36" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MovementInMinorityInterestRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestLineItems_5a2e9106-d89a-42bf-b6c4-eb4542fc6f0b" xlink:to="loc_us-gaap_MovementInMinorityInterestRollForward_0e44e2d1-2bec-4702-86b2-8dd9a2133c36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_b9c71a80-b365-4c8a-8169-4fef15e23d51" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInMinorityInterestRollForward_0e44e2d1-2bec-4702-86b2-8dd9a2133c36" xlink:to="loc_us-gaap_EquityMethodInvestments_b9c71a80-b365-4c8a-8169-4fef15e23d51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_0d92eb93-3cdb-478b-bb27-2efe33128a51" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInMinorityInterestRollForward_0e44e2d1-2bec-4702-86b2-8dd9a2133c36" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_0d92eb93-3cdb-478b-bb27-2efe33128a51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_ce73e867-66b1-461e-89bc-80a6a442e9f4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInMinorityInterestRollForward_0e44e2d1-2bec-4702-86b2-8dd9a2133c36" xlink:to="loc_us-gaap_EquityMethodInvestments_ce73e867-66b1-461e-89bc-80a6a442e9f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>ino-20210331_g1.jpg
<TEXT>
begin 644 ino-20210331_g1.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_X@Q824-#7U!23T9)3$4  0$   Q(3&EN
M;P(0  !M;G1R4D="(%A96B 'S@ "  D !@ Q  !A8W-P35-&5     !)14,@
M<U)'0@                  ]M8  0    #3+4A0("
M                                             !%C<')T   !4
M #-D97-C   !A    &QW='!T   !\    !1B:W!T   "!    !1R6%E:   "
M&    !1G6%E:   "+    !1B6%E:   "0    !1D;6YD   "5    '!D;61D
M   "Q    (AV=65D   #3    (9V:65W   #U    "1L=6UI   #^    !1M
M96%S   $#    "1T96-H   $,     QR5%)#   $/   " QG5%)#   $/
M" QB5%)#   $/   " QT97AT     $-O<'ER:6=H=" H8RD@,3DY."!(97=L
M971T+5!A8VMA<F0@0V]M<&%N>0  9&5S8P         2<U)'0B!)14,V,3DV
M-BTR+C$              !)S4D="($E%0S8Q.38V+3(N,0
M                                                    6%E:(
M     /-1  $    !%LQ865H@                     %A96B        !O
MH@  ./4   .06%E:(        &*9  "WA0  &-I865H@        )*    ^$
M  "VSV1E<V,         %DE%0R!H='1P.B\O=W=W+FEE8RYC:
M    %DE%0R!H='1P.B\O=W=W+FEE8RYC:
M                                  !D97-C         "Y)14,@-C$Y
M-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92 M('-21T(
M     "Y)14,@-C$Y-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92 M
M('-21T(                             9&5S8P         L4F5F97)E
M;F-E(%9I97=I;F<@0V]N9&ET:6]N(&EN($E%0S8Q.38V+3(N,0
M    +%)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,V,3DV-BTR
M+C$                                  '9I97<      !.D_@ 47RX
M$,\4  /MS  $$PL  UR>     5A96B       $P)5@!0    5Q_G;65A<P
M       !                         H\    "<VEG(     !#4E0@8W5R
M=@        0     !0 *  \ %  9 !X (P H "T ,@ W #L 0 !% $H 3P!4
M %D 7@!C &@ ;0!R '< ? "! (8 BP"0 )4 F@"? *0 J0"N +( MP"\ ,$
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M])5?E<F6-):?EPJ7=9?@F$R8N)DDF9"9_)IHFM6;0INOG!R<B9SWG62=TIY
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MX5.2T_$F1&."E:+"18,H1F2EQ"='9H2C_\0 '@$!  (# 0 # 0
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M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M(B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B
M(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
MB(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(
MB (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
M B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"
M(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B
M( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@
M"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (
MB( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(
M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M(B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B
M(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
MB(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(
MB (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
M B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (G*\,Z \
MHB\<H#RB\<KR@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
MB(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(
MB (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
M B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"
M(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B
M( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@
M"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (
MB( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(
M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M(B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B
M(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
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M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M(B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B
M(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
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M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M(B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B
M(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
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M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
MB(@"(B (B( B(@"(O'* \HB( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(
M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
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M20"N8;*1@+W,5>$/)IZTA<#(S-'9@**U!S#-&ZR#0!$1 $1$ 1$0!$1 $1$
M1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$
M1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0$<7>K[M
MZET1LYE]0:3S%K!9J#,:=KPY&F,!3QPV\M7@LQBUF&>+IFA,HRYC=^'Y%V?A
MVJW_ ));OU_9/U!_@L/_ +K5DSOJOB$SGV>TI^'*JIH(#./\DMWZ_LGZ@_P6
M'_W6GY);OU_9/U!_@L/_ +K6#B(#./\ )+=^O[)^H/\ !8?_ '6GY);OU_9/
MU!_@L/\ [K6#B(#./\DMWZ_LGZ@_P6'_ -UJVOW=6XN<U9LOH74.I,E/E\WD
MJ62DOY&TT33VCASN4K1%(T$<,3.$$$43=$8MT@W+<\N]$57ANZG^E^VX^Q^7
M_&3,H"0I$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1
M$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 %66[\[O9I-$5;>S6VN38-
M996G)#K//T9C&?26+NP!X>+Q]F Q*#4>3KS/(<P$TN'HN,HO'=MUI:TEG>N=
MX'4V VTM9:D5>SKC4+R8?1.,F<2%\@8-ZSFK<+\N>.P-<_79@<>FW:]2QSE'
MZX\T5!+;#;O-;A9W(YO-7;=M[F1GR>H,W<,YK>2R%Z<[=M_'/SFO6Y3DEGE=
MW:!I/%-O:BC.N/C[XN4Z%A6XM=ZINE5SY5R?O8]$^D:Z]GO](O>RC%>\H--+
M>R$EJW%/$-.!CV666*N,8[SGZQ3Z*,5W<YMI12Z]5MU:/A[0;-W-13=0L5;'
M1%TV+KBS^?O>&!BY\2<O>[NSA'SU2>;B!R2Z7T72Q-6.G0@&&$/-^/,Y3=F9
MY99/HI)"X;DR^1F%N!9F7-,'I>K0K0U*<$=:M #!%#$+" M^U[R=W=S(N2(G
M<G<G?E<CAQWUEQZXS\0[]4M?5U8T9?54)_\ 7M:^W8U_LP3<8_>E*EO%O%N1
MJMKWWKQ82^JH3_)3MVZ2L:_V8=5#NY2XO#CO=Y+H3%0O#G,C"[<.UV9G;EO>
M3]?R?5ZO_/S4EG9O[-V:W*U-5TYAA:(2;UC)Y*2,I*V)QH&(SW9V%QZW;J:.
MM7ZXWLV"CA&2-G.0,>NVMM%0T#O;K'2F+&9L?C9<,51[!E+/)'<P6,NO-*91
MQ]4DQSG(3@#1MU<1<@PKKA_<:=(U):]Q3J<Z90TK*T:K$JOF^59&;CZA19)4
MQ:WLC17;*-MFZC&=L81<I<ZAB9Z!D?HK+SG7MBN4<:-C^_<U*;4%MUC",7SR
MZ)2E&*;>_+D7W16::CVBM.QN3#\)X75&-9G=FZ^<=Z_T^;/U?\W]7 \/[///
M#/S<Z94<.[QS/P=VBMK;#DXA+G<A0-F(A8VR>GLSCHQ+I9^IFGLQ&PNW2Y@#
MNXLW4-X]ETH]I/'Y-<QI[=+=-J;?[4<G*BU^*CR_O+0^ &3SZ%L_N95B7X.F
MB7];?[CRB(J]$X$=/>S_ $O.Y?V*H?AO&*EOBO\ FL_^Z'^AU=/[UZK)+V>]
MS1C%R<<-6E)FX;B.'+XZ64O/CR&,")V][LW#,[NJ6&+_ .:S_P"Z'^AU=CV9
MW_ZGS?\ \1G_ /IL8J-[1_\ RS3O]%#_ ']I;-[BWXC7^W74W^FBID5#=W%O
MQ&O]NFIO]-%3(JL/B;_[0ZS_ /B&3_O&60X(_P #Z9_J6-_NHA>'7E%HIM)2
M0[T+*>N=I#71"0\U"P--G!RY$J^#H/YN[^1MU^?2[,S\<>:^%V>]:9C4NI*>
MBX*4V4R=Z.T^**#I]9F>C4FN303,1"TAO7KR/ ;.TDD@C#TRR&#KC_;RR'KG
M:'W4F?KZ0U.-<6-V=Q:IBL=6=FXY;I<XC(6YY9B;GSY9=Q]TUC?7.T7I7WOZ
MKCM2W7X)F9O"Q4L?+\^]N9F9V;S=W;RX96A\>?9ZX5X]\-8:7Q-IU>3]"T*&
M5IN?7RU:CI.:M/A*.1@97*Y5-RC!7TR4\?*A%5Y%-L%%*@7$W#>/KG%N1@Y/
M,J\C,LJ=E;2LK4\B47.MM27,HK=*491?:46NA[FZ>S^.U10FQ&8KR0S0R&,,
M_AM'>QMH'<2*-I!Z@(2%PGKR-T2,SA(/RM#CNAM)D]*9.3'9*+D7<CIVP9_
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M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
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MG*OX#Q* P41$0!$1 %(KW2OTQ>V?]OU=_![JY1U*17NE?IB]L_[?J[^#W5R
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M#K/_ .(9/^\98W@C_ ^F?ZEC?[J(1%X6BFTE [M%9-KV\VZMEG%V_FA:O@Y
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MO$W#&>.MWL+9=N?,^9@R]<B9O-@&")BXX<AY<FVW1O;AX'R6ED6:IIN_=Y>
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M!+)XNU1LV:-ZO+4NTK$U2Y5F'IFJVZTA0V*\H_H9(9@.,Q^0A=O/WN!Z*(B
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MBO=*_3%[9_V_5W\'NKE'4I%>Z5^F+VS_ +?J[^#W5R N]HB( B(@"(B (B(
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MFFLSJ;(NXB5;#T9K?@N3.XO:F 6KTXW82+Q;<T$3"+DYLS.[3;=G;T>+<S4
M0W=PL[B=!5).DCQ=5X=2:@$']XRO2LCA*Q_*+1Y*^WR&,9,[*O'"W >KZNTM
M/P+[X;[.Y1\O'BUW4LBSEIBU^KS\S](LD;3M(R<E[44SFM_M*.T%L_6R6T$_
MDY;_ "*\\=9Y#8!'DB+@?+RY_P#+ZOUEE;M=HJ* 6D<&9V9BD/CI)^.7=W?W
M_K-SPW/#>2SF[?G90VIVEU3B]NM!S9S4.H\;7#):SU/GLC#.]:S>B_,.G*%#
M'T\=C*[Q5V^%+LKUK5J,+M&IZ_)(-R*+&2],&-I,'Z,@9RX\W;R\F;CSY?ZC
M<NZ[7^PY[,$>&=-OU_7L;%NUG4]HX490C>L#3%%-.N5D$H7YUCE.V4-U]'KQ
ME&?UEL7%7B;J=E-BTNJ:=SER6^7+F49?>3:75PWVEMNE/INS],7M9KG6V6+#
M[98K.Y?4458[Q8_!2L/-&"6&"Q9MC8GAI1P1R6(0>><XV>66.+J,I!!\PM"=
MWAVNRZ7L:!KSQMYN&9RFG:,W2)<=+2T[PMU%[V<PD)V\W=6+^Z)[&Y[9[?CG
M\Y5:'6>NA@RN5 V%Y<7B68SPF&<F9W:2.M+Z[?!B<1O6Y8&<AK!(<LZKO[2G
M@+P1Q7Q3EZA7I>/BU0KCB7?HZC$QJL[(IG8[<^3ACN2NL<U3YM4X^;717;+>
M<G(F'A+P7Q9Z;C/497.^=:G*"\M.N,NL(.4ZYV<ZCMSK=*+?+M[N[J#8+N\=
M^2A,LKMT5*6,'-_4]18#(Q2.+>8QB%Z*PTA?H(WA(?Z:5EU3)#K3;G.O$?P_
MH[/U^#Z6*UB[11\D(R 0$ 6ZQ$QL$@//6D=C82?@E=/7!-PML=/ZLQYXK4>(
MHYB@?GX%V )?#/\ ^+!(_$M>9N&XE@..1O<Q<>2IGQC[!FDRBLGAC5]0T?4:
M6YT_2+'D8[FDW%*VI4Y>-)RV^NA9?R+M1)GTUCV?\5Q5FF9N1BY,'S0\]JRM
MR7;:=4:K:GO]^+LY?2ML@G[/?>T9[%O!C]P:7S0TF<(WS>-BK5,Q"'DSR6*8
MM7H9#I;Z)XO4)79G)_&E?VIR-JMX--ZUQ<>8TSE:V4I'PQO"73/6D=N? N5C
M89ZDX^?,4\8$_#D/(\.\+/:;[I^U0CL9C;6Q/D8 \6:33&1GC*]&'/7X>(OR
M-$-L8VY:.K?+ULQ9A:Y:G=A.+;;W<75FW>?*]A[=[ 9NC(=6Y!)&4;FT4GSV
MCDZ,XL$\32#[=>S&_2;,0]$C,;1IHWC]Q[X;9U.D\?8.1J^DS:A1J2DKLAUK
MO9B:DU&O4'&.\IXV=*&6MX\]M"V4M7P_$3B#AC(AA\046YF(WRPR')3M<5WG
M1E=(Y.RZRJR&KEO%2G5T3N=(H]NR'V_M/[BA!B,N]; :QX$/@TI"&EER:/J.
M?"S3$3N74Q]6-GF.[$+<QG;C8YFD(9UT;X+XWTOB'3Z-4T?,JS<*]>[96_>A
M-)<U-U;VLIOKW2LIMC&<>FZV:;LMH6OXFI8T,K"NA?3/[T>\9+O"R#VE79'?
MWH32DNCVV:;\HB+:S,!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0'AU3N[YWL
MVOHS=!]44(&CP>OJ[Y07 .F.OJ"KTP9JL_'+,]AGJ90"9VZSN6@$&:NY%<24
M>G>>]FK^:9M+G:5.#Q<_IYFU-IYQ8.L[F, RMT6<FYZ<CC"N5!$2%O63JREU
M>"P$!1Z1.?Y/Y/\ MM\G'RLB (B( B(@)/\ ND.TE_,_W;QU*[8>+!:X"'2^
M28BZ8 OSV!+ 79&Y9F.#($]$9'9VCAREGR9C<@NHK6X,3MPXDXDSLXD+NQ"3
M>;$+MP[$+\.+L_+.W*OB]@7M)!NIM=IW4\DPR9>.$L-J,&\BAS^+&.&ZYCR_
M2]R(JV3B;R8J]Z$V$&+I8#,I$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
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M2JXIJQ31'[<-N>U&7F+NI,$ 1$0!$1 $1$ 6!7>@?$'N9]@X?PKCUGJL"N]
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MB(B (B( I%>Z5^F+VS_M^KOX/=7*.I2*]TK],7MG_;]7?P>ZN0%WM$1 $1$
M1$0!$1 $1$ 1$0!$1 $1$!%1WT7Q ZD^S.DOQDQRIC*YSWT7Q ZD^S.DOQDQ
MRIC( B(@"(B (B( B(@"(B +GFV.YN<T=G\7J;3E^;&YG$6H[=.U"1-[0/\
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M-F$;T?/W?R_S+^'I+F94_P"7\F7Y%2^L_P#+^\JUK*^9RDAJ_IN^WR,-MS<
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M0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
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M'4R2 (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
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M4TDAU9"DZ:&0=H6C]7NE)4M1H#RB(@"(B (B( B(@"(B (B( B(@"(B (B(
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M0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
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M[3W1WQ":*_NQ^&;R CD[X?N[G/U[=_1-%RE_H^N\16%N"C"-A?5%.$1Y>0&
M1S<4?]$#C*,#F%^22MBSK9%SP!*!QR ,D<@D$D9BQ 8&SB0&),XD)"[B0NSL
M[.[.SLJ>?>I=WH6UN;+5^E*9?S/L[99GKPQ_.]*Y>P9<XLNGD8\5;+@\1([
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M"(B (B( B(@(GN^J^(3.?9[2GX<JJF@KE_?5?$)G/L]I3\.55300!$1 $1$
M5X;NI_I?MN/L?E_QDS*H\J\-W4_TOVW'V/R_XR9E 2%(B( B(@"(B (B( B(
M@"(B (B( B(@"(B (B( B(@"(B (B\.@(/>_;[9TFVNU;:3PEOU?56Y$EC"P
MG&7$U#344;/J+(!P[$,L\4L&'K$W#B>1EL@7748#I-[>:6/*WH:PL[0#Q)9,
M?T$(^3LS_P!,;\ #?5?GAV%UFYWNG:BDW3WVU;?@M>-I_2TWS&Z<C&1S@"E@
MCDBR-J/R$'/(YLLC:*1AZG@*K7(Y JQFNO=J-.1XG&0-89X[>3%YI'?V3 &
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MTK$5FK,<-B NN.4/HA+W.W'T+B[<B0DSB0NXDSB_#Y[[-[Q4]11M4L=%7+Q
MY20?0Q61'R>>HY._/U9('=SB^3KCX-1F%-]=>:V1FKRQSP2R031&TD4T,A1R
MQF/F)QR [&!L_FQ"[.WNY7%75^&ZLROE?N6I/R[$NJ?PDOO0;[K=;=TUZPKX
MX^SII/&VG>3?MAZICPE^CM5K@I6T2>\O)OC[OGX<Y/WZ7).+;LIE">[E-J(,
MR\]3+A79=J:OU[H[/:GBPLUREI.W5H9C(4V\1R]:@*P-IZ48O*(5XA$K\D8G
M# ,@3EX<3R-%RYB;W\^7U6\_[RAG6]#R]/G"&7193YT';1.4)*O(J4Y5>;1-
MI*VM60G6Y1WY9PE7+EG&45Q,X[\']:X6U.>F:WB3Q[UO.FU)RQLW'4Y5QRL.
M_90OHG*$H\RVG"<9TW0KNA97'^W)<1UMHRAGJ$N/R$77%*W(2"[#-!*+/X<\
M!NS]$D;OY>3B3.X2"<9&!<H(_J+\G?ZJ_'0>(L[2L[$U/3<N_ U# R*LK#S,
M6R561C9%,E.JVFR+4HSC)?@UNI)Q;1Z.&,;*P<G'S<*VW&RL6V%^/D4RE7;3
M;6U*$ZYQ:<91:_L?1M')^P]WC6J>S]E:^A];O<U%ME*?1CY(Q*;(Z>@>0?S5
MA.H^9:$0GQ>P!._@FPR8R2%G>*]:1U[J_!ZZVLU%EM.92IF,+F](YN6AD:4O
M7!8B+&VF\B<>N*0#%XYH9HPF@E$XIHXY0(1J+:UT;1SU$Z-Z)B!_;BE9A\:M
M,S.P3P$[/T&/+L[>8F+N!L0$0OUOV<>UCKWL_9?(XJ(CS&D,[#8ARFG[$TL6
M,R4-F ZIY+%R/XXXO-0B0^)+$!^-X<<%T)X/ D#OS[-WC_I7C%I=N!D2Q=+\
M1\+#F\[!7)CX7%-%=;5FJ:='W:Z<UKWL_%CM&NR3NC'Z+-V8_>WV5_:NCQ'I
MRTC6W&O5J<=UV+;ECE5J'(\K%CV:VV>3B1]ZAMV4)T?5U]JZ%/KQI?+S #_+
M_2L_N_E_YSA]S1D_^1]?TN?.+/8RVP^UY#8QSPOQ^@9G*J_N?GGGEN.'4#NT
M.I*F3H2R4Y6,6!QDC=V\6$G;EHY1;S$N/<_'2;>T+NSLZFC[FG(].:W)HN_O
MIZ9MQCR7M<3YN&8N/H&Z?S.SOY$74WO$?*K?A)IV5I?&UNGYN/=BY54\JB_'
MOKE5;59'%MDXSA-)Q?N)KIM)---IHFWPZFX:MIR:V;636T^G7Z-=+K^<>A/2
MB(KUEI3$_MU_$YN3]J.7_>Q*J?I__FL_^[_X.K6';J^)S<G[4<O^]B54_3W_
M #6?_=_\'5-/:B_Y5IG^B7^_D5^\6/\ "6+_ *C+_>VD_/<]SF^WF=C<G<(]
M6W>@?+@>NCCR+C_O/YJ6=1)]SQ\7^H/MMM?@['J6Q62\-/\  &E?ZG7_ &DI
M\!O_ -3X'^@7_>D%$]WQN2>':W#PLY<7M=86L[,S.SM'BL_>X)W\V'FFSLX^
M?6PM]"[NTL*AJ[Y^^S:-T53]GF;6+V>'=V+BK@\I$[LWN<6]=9B=_-G<./>Z
M^?$F[DT+5)?_ '64?Z<HP_\ $?7C^SET;/?QIY/Z<X0V_/FV(.<A[.*#_P"^
M_P!5E:7[O_'>K;-;?!QQXF"&UQT]'+7;=JZS\?*SM8YZ_P#K&?K?Z)59,^73
MC8V_[!/_ "_O*SCM=O5I3;+93;C(:KRU;&Q#H32[15O$::]D+98*E--!C:8O
MZQ=E>0S+B('"('ZY2BC9R:KGLWYN/B6ZQG9=]6-C48TG=D7V0JIJ@\B#<IV3
M<8Q7N=VTO3N1+X:95&-E9N5DVUT448"\VZZ<:ZZXRMK;<YS:C%>YW;Z^AG5+
M((B1D0B(LY$1.PB(BW)$1/PS,S,[N[NS,WO4&G;S[T[%8^KE=$[=209C*6X;
M.*RVI79Y,5BXYP>M:BQ3^0Y/(B!R -ENJA5E;JYN&)0C@1VR.\AU5N2UG#8C
MUC2VCR?H+'5K+MD\M&+OYYF[ X,\$OD18NN[U&9F">6YQUO&$(,\L8LW#=3-
M]1O\RUGQ/]JZ6?DUZ/POS5X]^15CY&K60<+KH661KE#!JFE*B$E+;Z3;%7--
M^554U&UZ'Q[[0WTRW]': W&B<U5=J,XN-EL92Y91Q*Y)2J@T]O/L2M>[\N%3
M4;)9,:(B:/'F[-PS1,+,W[3-_>X6*N[,W5=C'^EC-_\ YBX__(\OVUEK@!Z,
M4;^[EA;_ #%[EAIN1,QY$^'YZ(P!^'Y\^9"?]O@FY5?^+;O[UU![_P KDT5K
M_9FK=O\ LS3.(7RXM4?BXK;\]_[#J.W\O[7^E<8M_+^NZY/;^7Z_#<+E^WVT
M&9U1E:.)Q6/N9#(Y&<:]'&4H7ENW)2_0B/+-#&PLYRS2N,<43'+*<<8/(WE\
M+?"?7^+]06FZ!I]N9<MIY%W2K#P:-_>R<[,LY:,6B"3;E;-2GLX4PLM<8/&Z
M31.R<8PBYM[)))O=M]%T3ZOLEW;Z(RPV>M-=TWBY?>\<#U2?Y>JJ90<?6\HV
M;ZG''"['>E];C^7\OD636Z78ER&S&"TE4R=V&Y=S]?(7+\56-O4\9?KG3\3'
M03N[G;:.&S"4EJ1A\>SZR4(-"(\=%/$+_)_>4%^+W!=O#'$NKZ#=D4Y=FG9*
M@\G&5JQKXWTU94+*/.C79*IUWQY)RA%S7O<JWV.%7M)<*Y/#G'?$^DWU.F5.
MIVY,*WM[E&HPAJ6-'IT26/EU;)=NW38XJ]'ZW^;S_P!"X)J:R.*R.!RQM[ W
MWQ-@N/9"OF0&"(G_ +IPXUG=_9$',G\F7<;PCS[EU/OAACL:4S;0L[SUJ1WX
M&%GZO&Q[M<CZ>GSZ^J'@6'DN7;I]KA93P'U&F'&'#U65/R\3/U&O1\NU_P")
MP]=A9HN9?W[T8N?=:GZ.">TMMGY_9ZXUEI/&_#&:VX06K8V-=+?;EQ\^3T_(
M;VVZ*C*LW]-M]U+LY;>ZT[/YZFU=<U_DX7+$:5(JN(8Q^=V]16(FZIFZOH@Q
M5*1S\F_/5RL3$/JY@=BAEB#V!<?I^'9W;Z?37MXS)Z;H9@IRZ/'M9#*Q-=RD
M]MP\FM/?FL!+$[\UGC:HPQA7&,,OUVZX%X(_]'M/KTV<5')JE+Z;MU_OO[-L
M4]EO&IQ54'LMXP4FDVS^KS@K0XX&GTU])66I7WS3W4K;8IO9^L81Y:XOUC%2
M[MGAU7@[\SMB/0Q539C 6^,EJ*&OD]9' []=73K3.='$G(W]#DS5FOXMJ-G\
M1\96>*86KY$6EG(WOW@Q6@]*YG568+BGB:9SC#U"$MVT_L4Z%?J\GL7;)1UX
MFX?ASZR;H G:G#GL:.MM2YK6VIX MYC.79<C>E*29P9SX""K$Q2-TUJ=<(JE
M6-F9@@AC%F;AUL=7C/PWP;J.+G<04Y^8JHRR,;#TZG'NMG?"2C3.U9.3BUQA
M&7-.OWVY6UQW7*I;ZKXI\2RQ\5X&-)++S*Y)MMI58_6,I2:3:=KWA'H]XJSL
MTC!KF/&T?D$R#E^>/(6;ZO\ +_.ZM3]RWV.2T9HZ7<;/5"AU5KVK&5..<7:Q
MB](M*,^.KN!,SP2YHXX<Q:!O:*#X+CG8)ZQ110S]BWL8R[J;P08JW ;Z)TV=
M?4>HY.'*&>@TY/CL!UOPW5EKD!U91Y>3X-KWI0]L&)KHM:M'" 11 $448#'%
M%&(A''& L(  "S"( +,(B+,PBS,S,S<*UGB_XPXFK:1IE&CW^9BZMAXNIW6+
MI)8N17&[&QK$FU"V3:LR*V^:MPA%])21'/@3P).N5VKYD4[7.RO'WZISW<;+
M8M]=HK>N#[-N;[Q1^Z(BK"6<"Z?W[WOP.W&D<YK/4MGU?$X.F=F41=GL6YWX
M"ICJ<;NSS7LA9**I4A;Z.:4.IQ!B(>WW?R\_+Z_U/K_M*FQWK?;?/=S6@Z0T
MS<>70&CKDL,<U:;KJZFU!$1P6\PY1\!8Q]%NJEAWZI8I6]9R,9D-NOX,A>&O
M ENOZC#&7-'%JY;<VY?XNG?[$7V\VYIPJ77;WK-G&N1I_''%M.C8%F58X^8T
MXT0;^W9MW:W3<(?:GMZ;1W3DC!;>7>7/;KZWS>O=3'Q:RDWYEIB3E6P^)KNX
M8[$U!=WX@IU^&(OHK-D[%J5RFL2._,.S?V>LUO#KO$Z'P;20UYB]9SF5 .J+
M!X*N0^NY"1R9X_&)G:O0B-G]8OSP1=+Q^(0='VAF'U;%XZO-;O6YH:E6I4B*
M>U;MV#&&O5KP1"4DT\TT@10Q1B1R2D("SD0JYSW:_8CK[-:(CBR 0S:UU$\6
M1U7>%@-X)G#FK@JLHN?-+$1D\;D!D%J\=RXW 311Q7'\3.-,?AC2(4XD:X9-
ME?T;3J(I<M<:X*+N<>OU>/%Q:3W4['7![J4VJF^'7"U_$^KV9^9SRQ:I^;;*
M6^\^:3:@GZ3N:?;;DK4FMGLGFOM3M?A=%:<PVE=.U!HX7!4(,?0KL_4310 S
M/+-(_M3V;!]4]JP?,D]B26:1W,W==@HBY]773LG.RR4IV62E.<Y-RE.<FY2E
M)OJVVVVWU;ZLN_77&$8PA%1C"*C&,4E&,8K91271))))+HD$1>'=?F?<@V[W
MW:@0ETSK:"/@I6/3F1,6?@G!I[^,(W]S$POD 9_HB;I%WZ8Q952NVSI/YYA<
MU&+>V$^-LOPWFX/ZS4=^/^R]L7=_D:-O)F5@3O/N\2IZJU=2VITA)5O:>P>5
M:356=B>.Q%>SD$-FO%B<9*S$+5\1-*[W[<1<SY ?5(W\&M.\\//:@P;7='WS
MZ>3HS5;8OQR[,,X0R<?6Z)GZO^R+_(WERB]K[PXR^#_$_1=4MH^C8_%VG8VH
MPC]GW[K+M*R(V0Z<MDG1CYTUMU^DPG+ZQS2Y[^.\,5ZUGV8DE.,X5VVN'V5D
MUQY;E%KONZDY2[.<Y]UU>$W8J[5N7V1W+T_N!BFEFAH2O2U!C8W9OAG35TXF
MR^-X(A!Y2CBBMT7,A"/(U*<IDP@2V5^A=:XO4F%Q6H,+;BOXC-8^IE,;<A?F
M.S2NP!8KRC\HN<1BY 3,<9=0&S$+LVJ[MU??_+^^KBGHY?:X/.Z-S^T>8NO+
MDM%SEF=---*SS'I3*2"UBC$QOUR1X;,E,X.SDT%7*5*K###7@8K*^SKQNZLF
MS1[I/RLKFNQ=WTAD0CO9!?!6UK?^?6MEO.3-M]FKCWRLNS1KI[TYN]V+N^E>
M57#>R"W]+Z8;_!3IBDN:R3++:(BN07;"(B (B( B(@"(B (B( B(@"(B (B(
M NN]VMLL9K/3&=TIF <\;G\9;QEOIXZXPM1$ SQ<^RTU>1PL0N3.+2Q@Y,[<
ML_8B(#74;F[<Y72&H<UI;-QM%EL!DK6+O,'5X1S59'C\>!R9B>M:#HLUB)A(
MJ\T9$(N[LW!E/YWZ_9I?%ZDP>Y^-@<:.HJ\>!U T<3M'%F\>$LF.O2F/+=>2
MQKO3/J8!8L3"0O))9DZ8 T 1$0!$1 %;*[CKM)-J'0=[;V_8Z\IH:<I<<)E\
M]ETWE;$L]<6Y\Y QV0.U49_-H*LE"!F$!CYJ:K,;L$=H]]J]T=.ZHFF>'$22
MEA=1^VX1O@,J<(7)9N/(HZ$T57*])<MUT )FY9G8"^4B_.*43$3 A,#%B A=
MB$A)N1(2;EB%V=G9V=V=G9V\E^B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
MB(@"(B (B( B(@"(B (B( B(@"(B (B( B+^3-A9R)V869W=W?AF9O-W=W\F
M9F\W=_)F0$,/?9=I-])[;P:,QTXQYC7UHJ5EA?B6OIJBS3Y:4>'Y$KL[TL8/
M4'25>U>(3&6$.:AZSL[Q_M'EN;NUJ3+U[+S8+$RMIS38B?5".,Q3E%-:CZ>
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M-F5PDK9+5KA(_P ]O,1#)5PIL('6Q11Q3S,[RY3ERCI5(=T1 $1$ 1$0!$1
M%_)&PL[D[,S-R[N_#,S>]W=_)F7;6S&QVJ]PLY6T[I#"W,SD[!!UC7C=JU*
MBX*YDKA<5L?3C\W.Q9DC%W;PXFDF*.([5/8?[H326W?JFH=:^IZRUD'1-$$]
M=CT[@IV=C#X.I6&+U^["3,XY.\'(&S'3JU#%I" AG[%_=(:YW+]6S>I1GT5H
MV3ID&W<A9L]EHG\_^2<7,/,$),[<9')#%"[.SU:UUF/HM-]G/LHZ%VJQ0XO1
MF#@H=<<87LG-^:LSE3#AWFR61D;QIB,^9/!#P:<)/TU:L$0A&.1;,O* (B(
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MV[CK836A-+9O8=GAK874\SLYF3\L$>+S,Q>37>L*-HR_-\<9D5T*I>KM(Y7
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M%4>?6(8A9O$S6,AZBC\VDOT0>HWBV(*415/?Y?K?K_7^1V^1 $1$ 1$0!$1
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MC=@?R<H9QXZ@+CD)8RZ989&\XY0 V\Q95$MR=L,GMUK#-:+S/)OC[)-3M.W
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MK@W)S6)GBKPQB4LTL<8$33H]GKN/[DG@7MS=0QUH_(SP&F)'FFZ?)_"MYJS
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M;S$XS$3 F\Q)F=O-E?'[!G:-#=':[3&IY) ++-3'%:AC N7BSN,8:M\^GEW
M+I .1@!W=QKVXA(B(2=4,U.7W&_:2?3^N,KM[D+#MB]:UVN8H"=NB#4F*AD-
MQC]SC\)XII@E]_5+CJ;,P\F1 6Q41$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
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MFL:!U!.9X&V[G*6*M.Q2S:>OR%R7BUQ8I<?.9%ZY2;S)[->RS1G( B(@"(B
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MMVY AP)LF4 P4*$,UJY9DCKP5JL1SV;5F8ACAK5H(1*6::60PCBAB$CDD(0
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M?4'[TPZF24-O<8_$I8^W?4'[TPZF20!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$
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M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
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MTM!.3%)A")V<;!GC!<VFH11V9UK=:]B2&2.:&22&:(PEBEB,HY8I8R8XY8I
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M?\9,RJ/*O#=U/]+]MQ]C\O\ C)F4!(4B(@"(B (B( B(@"(B (B( B(@"(B
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MEM"S@]!I#YDL::R9R25' 2?J=L9>&U2D86Z(8),<W5U3=(@3?(B( B(@"(B
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M&B(@"(B +MG8W>G.[>:JP^L--V/5\IA[(S )]3U[E<O9MXZZ D+RT[T#G7L
MQ"3";21&$T<<@]3(@-@UV;.T'@=T-'8C66GI'>GDHB&Q5D?\TXS(UW\*_C+8
M\"[6*=AB#JZ6">)XK4/5!/$9=[*EUW6';?+:?6@XG-V^C0VK9H:F8>>4A@PN
M1?B*AJ .7\...-^FGE'?I%Z$C63/JH1@=T*.02%B$F(29B$A=B$A)N6)G;R=
MG;S9V\G;W(#^T1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$
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MPG%[QE%]FG_6NZ?1[-%?3O(^Q86F[=K<W1U3IPUF5IM5XFJ#\8RU*;L6<J1
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M;V2R-R4I9I781=R,S)V".(1CAB$8HHXX8P 9U-8T:&3C. @\2*>,HYP(&Z"
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MC",4DDDDD6WQ<6JBN%--<*JJHJ%==<5"$(16RC&*22279)!$1>X] 1$0!$1
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M.[.6G=S=.3:>U!"0^93XW)P,#7\1>Z'".Y3D)G;Y>FQ7/YS:AYBE;Z @J/\
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M"VEQ5:_9]8U!HTFTSEW(W*:>"H'.%O2=7).5G%/7BFD<B\6Y5M2\BQL R=H
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M0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
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M%FM/&[C)#/!*(2Q2 [.Q 8B3?473FJMO&-RLXX>#=^J2KRS"3^;N4+_H2_\
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MI8^W?4'[TPZF24-O<8_$I8^W?4'[TPZF20!$1 $1$ 1$0!$1 $1$ 1$0!$1
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M0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
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MNP+.5I8X':)A<F;Z)V;RX^5F_P#-OD6(>Z/:BITRDKT'^$+;.X\1DWJL1?\
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M&9+=_2<2,8QG)^M^/TJM6_64HJNZ3;WM[(V[#U>VK9-\\.GNRZ[+Y/NOXI?
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M $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$
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M.<A=I(-,8UWBJ>;LSL^1R'KMTNEW ZHX]_(QD9 3<PPA& QQB(1@(@ "S"(
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M1R%'&4</B&T;.@.^41$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
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MM(=HPB(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
MB(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"^%J;4%?$XZ_E
M+9=-7'4[-ZP3<<M#5A.>3CJ=F<G$'86=VY?AOE7W5@OWC.X/S/[59T0D:.SG
M9J6GJO//)O?D*2V(NWFQCC:UZ47_ /N?'RNM2X]XHAHFB:MJ]FW+INGY>8DV
MDISHHG.NOKZV6*-<5ZRDDNK-:XSX@CI6D:GJ4MG]!P<K*C%_?G33.==?S=EB
MC!+NW))=65JM2:IM9K)Y',WBZKN6O6\G:=G?I\>].=F00YYXCC*5PC#R8(Q$
M!9F%F;YT9?YU\V,F7M@2_G-GE3MG.VV<K+;9RLLLD]Y3LFW*<Y-]Y2DW*3]6
MWN?S8\::+999;;8Y3LLE.=EDNLISFW*<Y/UE*3<I/XML^B!?R==-;LQY?,S8
MO1NF\==S.>U%8Z(,9C83L7)X(.#(1C#S%I"'DI#<88Z\-F24XXXB)=M^(PLY
M$[,(L[N[OPS,S<N[N_N9FYY^19[]R/MP6I]::_W4M0%ZEB(H-':;E,?8>6PP
MW<H43\\M)'2#&R2\CQ_RMT"3]!LW0#^YX^&,-5XPNXIS<>-^E\"X].KRKL7U
M61KF1:\?A_%D^Z<,N-NJ;QW?+I<HO;GW4A>QAX$_^DW'6+D9$/[PT+;/NER\
MR>7[_P! AUZ*==D+,R&Z:Y\2,)+WSU>R5W&EFXU?-[T7RBA)FDCT3I^](,O1
MRW3'G,]5<#C(A;B2IA)NH!)NC+,?4 6*]O-ML!I+%5L'IG#X[!8BH/%?'XRK
M%4K1^0BY]$0CURDPCXDTG5+(XLYF3KFR+L?Q;QYJ>MV^9GY$IPB]Z\>&\,:G
MT^KI3:WVZ>9-SMDME*;/Z#>'.$L#2J_+PZ(UMI*=KVE=9M^O8UNUOUY5M!/M
M%!$7P]1:FQN'ISY'+9"EB\?5 I+-[(6H*5.O&+<D<]FR<<,0LS.[D9BS,S^:
MU&,7)J,4W)O9)+=MOHDDNK;^"-C<DDVVDEU;?1)?,^XO7M6HH(I)YI(X888S
MEEFE,8XHHHQ<Y)))#=@",!9R,R=A$6=R=F9U!KVH._/T!IMK.-VWI2;AYIF.
M./(B4V.TG6F9V#Q"R$D/K>6C!^3%L77>K:81&+)1!(TXU_.T-VP-V=XI9!UA
MJ2Q'A2E>4-,8=Y,5IR)G=G$9:,4I%D?"X'PY,M/>D A>0"$R(GFGA#P)UG4^
M6S(A^C<:77S,F+\^2_S>+O&S\'<Z8M=8N78C#BGQ;TG3(R7FK*N7W*9+D3^$
MK>L?Z"L>_1I%E;M1=\]M5H([.*T[-/N%J2+KC]4T_)'\"5)A\F;(:ADYINS%
MSU18H,G8%Q<98X&(3>O;VC>\;WEW;.S4OYPM,:9L>( Z8TL\F/K%7D\GBR63
M9_A7+$\;,$K3V8:)^T\6/@:21BPQK8C'X\&ZW B%O(!X9F^MRWR?)PS+M#:?
M:O7&XN0;$: TME-06&,(II*$#!CZ763 TF1RM@H<;0B'GDI+EN)N&X;J)Q%[
M/<-^%'#^@5_2;8UVVU)2GG:A*MJMK[T%/EHH2?V9*/F)=':^K=<]<\5]=URS
MZ-I]5E==CY8UX\9IR3]'R[VV].ZWY'WY5V75-#2]"@#>)T,XM] #-Y?K\,S-
M[ER_16&SNJLI%@-'8/(YW+3^4=#$U);<["[\>+,\;.%:!G;@K%DX8!?R<V=V
M9Y\^S5W#P&]?*;NZDDLDS-(^E-*S/!5\3J;YUD\_-%ZU8BZ6?KAQE>A(YN)#
MD' 3CDGNVCV/TCH+%AAM':>Q6GL</2YPXVI% =DQ;AIKMAA>Q=L<>7CVI9IN
MG@>OI9F;5>+_ &A],P^:G2ZWJ-ZW7F[NK$C+^?*/F7;/KM7&,)+[-R,[PQX!
M9N7*-^L7NF+VDZND[6OAR)^77^,Y3DGWK*WO9J[C#5.<\#*;L9V/3E _#E;3
M6G9H[V=.-_,XLAE)83QF-EX]GPJ09=_-B*Q%()1/,K-W6FP4^B[&@;>VF!OX
M"YX<EH[P6+6;FMQ@0Q9'YHY)WSD&1A<B*O;JY" ZI.S5?!C$ &0%EY58N)/%
M+7-4M5E^=;3&$U.JG$G/&IJE%[PE%5R4I3@^L;+9V61?:2+(\.\#:7I<%'%Q
M:U/;9W615ETEZ^^U[J?K&M0B_P!4HE]XQZ-WJ[1(7=5[(V+>N-+0C/8N:0O&
M+ZTQ$(EU#\%2A''7U/5"-W$XOS'F8VB$HX<J4TCUX).R%VL]9;$[A8W7>D9#
MJYC#SRX_,8>X,D$&9Q?K,;9?369@(?&A"<ZS 77'ZSCLA7@LB'CU>A]L<Z@F
M[UGN1-';]5;FK-*-2T;NO"!SCF(8 BQ.KBCA<(\?JV"&)S.8^F(*V>KM\(U'
M  L->IL]5I=X$\=5;#]&<2QCDXM\'0\UPW?)-<KCF5Q6UD'%\OG5I60^U.-C
M;LCZ\W1MGYF.W&47OR;_  _4;[/Y/H_3;;9RB]D?M4Z4WHT#@=P]'6GGQ.;@
M?Q*TA ]W$Y*N_AY'#9*.,B:&_CK+%#,#\=8^'/'U031$62JU]7<^]K[5O94W
MRO;1[J4;>FM-:LRT&&U9B\JX@VF=3F U\!JJM+&<E6SCKKM7QEVY5DDJW<99
MIY.&R88L8I]@F),[,[/RS^;.WFSM\CL_RL_R/]11%XE<$/1-0\NJ7G8&5!9.
MGY"DIQLQY]H^9'W9SJW4923]^+KM24;8HRFGYGG5[M;3B^6R/;:2^7=)]_EU
M7H?TB(H]/>$1$ 1$0!$1 $1$ 1$0!=;;P;78S6VE\]I/,!UX[/XRUC;/#<E$
MUB)QCL1^8_/JTOAV(?:9O$B'E^/)=DH@-=+N5MYD](Z@S6E\U%X.6P&2MXJ^
M#<N#SU)2B>6%W87.O8%AL5I'9O%KRQ2<,Q+A*GT[]3LU/B=3X3<S'0,-#4L
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M16)A;\]Y&P9V\I==^D'=[F0GLV.7%G9I&'AN&9N^$ 1$0!$1 $1$ 1$0!$1
M$1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1
M$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
M $1$ 1$0!$1 0M]]5V66U=M_'KK&5?$SV@6DL67B%WFM:7LF'PI&_2S^(V,-
MH\J+%_0J\5]XW8I2"2HFMC_E\36OU+-&Y#'8J7*\U6U7E;JCGKV(RBFBD'Y0
MDC,@)OE9W94'>V1V>;.UVX^IM'R@;4J=X[6#G-GXMX"^[V<5,Q.S,9Q5S:E9
M<?(;E6R NXBQ.!C$B(@"(B *='N,^TA\!:XRNWF0GZ,;K&H=[$]1"P1:CQ(=
M90MU.W#9+%>LLY,[N]C'58A GG<A@N7+]OM>9+2V=P^I,/+X.4P62J96@?40
MB]BE,$P1R=#B;PS=+P3B),YP22!RW4@-C"BZ[VDW+Q^LM,8'56*/KQ^H,52R
ME9NIB*,;< 2'7D<?9\:M(YUYF;R:6(Q^1=B( B(@"(B (B( B(@"(B (B( B
M(@"(B (B( B(@"(B *BUWFWQ][F_9RK^ \2KTJHM=YM\?>YOV<J_@/$H#!1$
M1 $1$ 4BO=*_3%[9_P!OU=_![JY1U*17NE?IB]L_[?J[^#W5R N]HB( B(@"
M(B (B( B(@"(B (B( B(@(J.^B^('4GV9TE^,F.5,97.>^B^('4GV9TE^,F.
M5,9 $1$ 1$0!7:>Z.^(317]V/PS>5)97:>Z.^(317]V/PS>0$DZ(B (B( B(
M@"(B (B( B(@"(B (B(#$OMF]D? [QZ-M::RPQULA YW=.YMH^JQA<L,9!'.
M+CP<E2P+O7R%1R\.S 7/2UB&M+%1JW;VFSVAM1Y72NIJ)X_,X>R5>U"7+Q2#
M]%!;J2N(M8I6XG&Q4L W3+"8OP),0CL25%EWG78 K;O:;?-8*O%%N#IVI(^'
MFZFB'-T0(IY=/W3?@?GI/))B[$C\5+LA"1!6M670%+Q%[V4QEFE9LTKE>:K<
MIV)ZENK8C**Q6M5I"AL5YXC9BCF@E XI )F(3$F=F=EZ* (B( B(@"D([N[M
MRY'9?5HR62L6]%9V:"#5.*C=S*,&^=19RC$3L/PCCP+D@'H>]48ZIFQ-7.&/
M=$!L<-*:JQV<QE#,XBY!D,7E*D%_'WJLC2U[52U&,L$\1CY$$D9"3?*W/#LS
ML[-R!5*.Z4[Q#Y@LE#MSK*ZP:*S%IVPF0L$_1IG,W)^IXI)')PBPF4FD(IW=
MF&C?/ULB&&Q;(+:W* \HB( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"
M(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B B>[ZKXA,Y]GM*
M?ARJJ:"N7]]5\0F<^SVE/PY55-! $1$ 1$0!7ANZG^E^VX^Q^7_&3,JCRKPW
M=3_2_;<?8_+_ (R9E 2%(B( B(@"(B (B( B(@"\.Z\K'GM7;[U-L]N]5ZWM
M,QO@\7))1KO[[N8N21X_"8\6X=NJ_E[=.HSOP ^+UR$$8F8^G#Q+,BZJBF+G
M;?9"FJ"[RLLDH0BOFY-(_*^^-4)V3:C"N,ISD^T8Q3E)OY))LK!=^%VE)=PM
MQ\?M;A;A/I[;QRL:A*"3JK6=57XH^L)6'V9)L'0?U* 7_H-R_DXSYDC(88X-
M!:$N9*YCM/:?QT]Z_>GBI8['U(BEL6;,Q<"(LW+N1/R<LINP +'+(0QB1-QR
MKZS)+=R&0E>UELQ?N9C,W'ZB.YE<E9DN7IW=^3)Y+4\I-R[D_4Y.[D1.]L/N
MKNPI'H/!PZZU-28=:Z@IN]2O.S$>GL)9X.*L ^;1Y'(1,$^0-OGD,11T.1Z+
M#27AUC6<3A#0L;'BHV3IAY./5ORO+RY)SNNGM[RK\R4K)R_Q<'"J+YI03K=C
MXF1Q#J=DDW"IRY[)]U32GRPBO1S<4HPC]YIS:V4VNTNP-W=V%VGH1YG,A6S&
MO;L ^MY)P&6MA(Y!9Y,9A',>1'GV;>0X&>X3=(^%6$8GDOX7E%2O6]<RM1R;
M,O+ME;=8^K?:,5]F$(]H5Q72,([)?BVW8?3=-HQ*848]:KK@NB7=OUE)]Y2E
MW<GU?X!>.%Y18D]YZMRC#8B."Q%'/!*+A)#, 2Q2"_O$XS8@,7^429V^LHDN
MTMW,NU&MO6;^FJY[=9^;JD:UIR&/X$EG?DNNWILCBHLQ%YR/C#QDANY2&92D
MYJ7=%F]"XDS],M\[ R[L6SIOY4VHSV[*RM[UVQ_9LC*/R,9JFC8F;6ZLO'JR
M(=>ED4W'?NX2^U!_.#B_F4D>T1W;6\NU;6+EG#/J_3E?K,L]I..SD0BK W7X
M^1Q'A?"F/$8^2L'X%FG6Z#(KIPBTQ8'5LKCL@/M=(D_ERSL[?K.W][_R6Q>X
M4?W:>[LW:;=/Q[F6P/P)J&1B<=3:9*/%97Q'ZG8[8!%)C\H/43N8Y&G9-^2>
M.2(W\1K*<(^TG)<M.M8O.NB>7B))_C9C2:3^,I561V7V:6^A7[BOV>\>URNT
MJ]X]G=56-\N_PC;'KM\(V0EU[S2*6>G#S6G,A%F]*YG)8/*0.Q0Y'"WK&/M@
M[/R+/-5DC,@Y=^8SZHRY=B%V=V4P79P[\O7VEVKX[<W#!KG'1=,1YO%A4Q&I
MQC8FYEEKB%?"9.40=V8&##O)P'788_$D/@W:,[F_=G0A3Y'1QP[BZ?B8Y'"@
MT=#4]6$7?CQL+8E\+(<!T^>)MV;)FY<8^.('-187<AX-NQC,Q2L8_(U#\&W2
MNUY:=VM+PS]%BM.$<L1N),3-)&+D),3<B0N\V68O#7%F/S;8F>E'[<7R9='P
M3DO+RJ.K^Q+EC+IO&2V(HAG<4<+6\MD;U5O\.>FQ?)/FHL?SBW)?)[EYCLV]
MNK;#=>(&T?J>I8R3@YRZ?R#MC-0P,(=<CEB;1#/,$3?T2Q3]9K-[VG<7$GR[
MY6N>DTH!RPVZ$YPV:\@SUK%>4X+-6:%_$">":)QFAEA<>N.6$AE F9P?GA26
M=G;O=]X=NBK4,Y8BW#T[ PPE4U 91YN" & !>AJ" 7M$8 '##EX<F,C>SS6-
MRG>!N+O9NR*N:W1\E9$.K6+E.-=RV]*\B*55F_IYD:$O6;W)FX3\?L+*VKU"
MOZ-;T3LK3E#?UYJG]9#;]EV;_!%S9%&7V9.]FV@W)*#'_#):0U'+P/P!JM@Q
MYS2>3=./RW46'R#N[\##%<"\XB4A4@C;J4F0&Q,Q,[$Q,SL3.SL3.W+.SMY.
MSMYL[>7"KEK&A9FGVNC-QKL6U?<NKE#F7ZT&URSC\)P<HOT;)WT_4\?+K5N-
M=7?6_O5S4DG\'MUB_C&237JC"+O%]JVU;L[K.D$?7:QN.+4%+R9R&Q@W]?+H
M=V=Q>2M%8A+I]HHY#C]QNRHY9C"UI3>:/FO*7M.<7 L3OY\F''03OS[1.W6_
M]-\JV,-^E%9@FK3QC+!8BD@FB-F()(I0>.2,Q?R<3 G$F?R=G=EKVMY-%2Z5
MU/J/3,SD4F S>3Q/6;=)RQT;<L$,Q,S,WS^$(YFX9OH_=]2D'M&\0Z]PKKFB
M<4<-ZIG:1F78]VGY%^%=*N-JQ;%D8U655NZ,NJ:R<A^1DU74OR4Y0;2.:OMV
MZ3FZ9K/#O$NF7W8MN5BY.E95M,N6,WAVQRL6%\/L71LCEY/N60G!JGJND3JZ
M><A 1*3K<&Z>I_+GSYYX^3W\<-Y,S,WGY\]T]F_5GP3J?3>8<W%L3JS!9 G9
M_=%4R-&S*W_=,!D$O/S9W;GZF.U^Y[__ *_Y?^7]]<CT5.Y5\@S.[./),XN[
M.SO%PW#^]G9QY9_>WE]1?A[$O$F=K'B[B:CJV59F9^MU:]+/R;%%3R+<C3,N
MVR4HUQA5%<T$XUPA"J"A&,(QC&,56[P'S,B7%6/FW3<[[OIEEMC23G8Z+;-V
MHJ,8^]%;**48I)12226Q]7E?*P61:Y2IVV<2:U5KV6<&=@=IX0E9P8N287ZN
M18G=V;CE^5]572E%IM/HTVG^*.Y">Z379]4$1%\'R$1$ 1$0!$1 $1$ 1$0!
M$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1
M$ 1$0!$1 $1$ 1$0!$1 %"IWPFL>FKHK3XD3>):R6:E#GV2>O!'0K&[>_J!K
M=MF^M(_U'4U:K:]Z[JGUS<Z"@Q]4>'TYC8"#CZ"S=FMWI..6;Z*O+4+R=V;S
M^7EFJ=[:_$#P?#_4ZXRY9ZCE:?@1>Z6ZGDPR;8]>_-1BVII==FWU29"?M"7-
M<+9U$>^79C8_Y>=&^:_.%,E^#(X(R7N 7^=?*C)>Y&:XA53..'&?#.W-[OQ]
M#JG?C6?P1I^QX9]-F^[4H7YX<!-G*S+_ /HZXFPNWND.-W\N5;%[LK8QMO\
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M=.34E&#PL)N%'/FXF'^AQ9ZN\,>H(1\FX>Q--6RA-R7SW(R]+B+" @1&(B(
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MR$W/46-JO6QSNQ$#G5,XWZ39 9UHB( B(@"(B (B( B(@"(B (B( B(@"(B
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M>;Z:]:P7OZ6I95L?;,^ER]7BL1CQXKJ\N@"(B (B( B(@"(B (B( B(@"(B
M(B( B(@"(B (B( J+7>;?'WN;]G*OX#Q*O2JBUWFWQ][F_9RK^ \2@,%$1$
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M $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$
M1$0'AU4_[P;,O:WGUR7+N,5O$519_+I:IIW#UR9N>>&*2*0_J.1.3,S$S*V
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M>@*,B(B (B( B(@+?W<8_$I8^W?4'[TPZF24-O<8_$I8^W?4'[TPZF20!$1
M$1$ 1$0!$1 $1$ 1$0!?)SV;JXRC=R5Z:.M2Q]2Q>N6)2Z(H*M2$Y[$TA/Y#
M'%%&9F3^3"+NOK*,+O>=ZOF/V4S]>";PK^KYH-(U&9W8SBR82RY5AX^1\/5O
M@?+.SB?1Y.0NP%0;?K=FSKO6FI]8V^MI=19FYD@C/Z*"I+)TT*S_ %/5J(5X
M.&9A;P^!81X9NI41 $1$ 1$0&<O=Q; %N-N_I/#S0O+B,;:^:3/.XN\;8S".
M-H:\CMY<9#(-1QW'+$P6CD'EHBXO5,W#<,W#-Y,S>YF^10#=PSL3\'Z3U/N%
M;A8;&I,G\!X@R;VO@?"</;G'^E&UEY[%=Q?VO^2V-O8D%3]( B(@"(B (B(
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M3;RU*[GB[%75.(C)Q\Z>0?U#+A&+>UTUKL-"8R?EG+)"S.W#L@+$J(B (B(
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M>,V?GV"8?[W#^3J^GOAV/]L]QXW'66B\%F;'0X1Y0Z85<W7;EWXK9JGZOE(
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M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
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MC'XE+'V[Z@_>F'4R2AM[C'XE+'V[Z@_>F'4R2 (B( B(@"(B (B( B(@"(B
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M^MT..!PM*C/)&W SW0B8[]EO)GXL73GF;JY)A-F=W=N7[J1$ 1$0!$1 $1$
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MMU/YL+.7[3-S^UY?*L"]O,]5JZOPV4O^=&MJG&9*][/B.].OF8+5OV'X8^8
ME]E_HOH7?S69H6?G4OG_ -5)_J%Q_G4=E6/Q&,?>Y]0\?5<O+_.[_P"=?;^X
MU:+#D\1<F7VK/_1O$36W-&&VN62Y7MTYG*._7JX1W70JSP!+;Z3/]7R=M_\
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MY<!HXCJTF?WE#/G;U4+U@'XZ3*KC\;)TD0Q2QD(RJQQ#"$8#'& A& L(  L
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M'6+,0B[M\\("9Q(1)K_^E]24LSC,=E\;.%K'96C4R5"S&_,=BE>KQVJLX/\
M*$T$H2"_RB3+7&*W%W(W:5;5.WEO0U^?JR^@9HH:HF7)SZ;R93RXTX^KAR&A
M9BN8^00<FKPQT6/H:Q"+@37(B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
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MXG;G_E7-''A<5RWO<6R&0KN?'F,;&?+,+NU"-FX9FY=_KN_+O]=W^5W][O\
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M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
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MP.0 >2LUA'(,W+6_#FH6N3T=K#)Z?RN/SF%NSX[+8JW#>Q]ZL?1/5M0$QQR
M_FS_ "B8$Q1RQD<<@D!D+W<>[Z[<.+WITB%LRKT]886.O5U7AHNH!BM&'$>4
MH1R$9EB<FX225OGDSU91FHS3'+7\24#/M$1 $1$ 1$0!$1 $1$ 1$0!$1 $1
M$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0$3W?5?$)G/L
M]I3\.55305R_OJOB$SGV>TI^'*JIH( B(@"(B *\-W4_TOVW'V/R_P",F95'
ME7ANZG^E^VX^Q^7_ !DS* D*1$0!$1 $1$ 1$0!$1 5F._TQ3CG]N+_#])XC
M/4V)W?CJCN4)G'CCCEFD9W\^>']WRJN;'I=[N0N6HG(9ZQ42CD G&2(Q#K"2
M,A=B Q*-B QX<2#D79V5I_O]M*E)H_;[/,/LT=4W\,9-QY/F,-->CZO+JX;X
M!DZ7YX9R=N.3;BJ+E=12XS)-*'/AV*L8FS?TT4DW#_4=V8F;]9_[]]O!#)C9
MP_I^^VU?TJJ2^#65<UO^4HOKZ,JUXJXV0L[-6-)1NFL>RMOINE"KF73;NHR2
M^9*-M3WJ_:#T;X4!ZLCU9CX6$6HZNQE7)2, ^_C,5@HYLY";R:2YD;@CQSX?
MO9Y*=K/2#*3/%#KW;C)U.7Z9<AI#(5<D#<\-U?!>9/%2"#>9&X9.:3CR"(R9
MF*M_C-S F<0)F,B=A$7%W(B)^EA9N.IW=^&%FY=_D^1<BKY_%W&\V'WNSN#L
M[,[>3L[/SYL_D[>]G\G;GR6S:SX3<.:AO*S3L>N;[V8N^++=_>:QW"$I/OO9
M"6[WWW(\T_Q1XET[:-KMM@O2S:];?+S4YI?*,EMV+KNT7>E[%:R\*.AKW&8N
MW,["-#4S2Z<M"?'+@[Y4*]8NE_9ZH[,D9%PT9FSB[Y\XW)5KD$5JI8@M59P&
M6"S6ECG@FC)N1DBFB(HY )O,3 G%V]SK743Z8H66?H,'ZOT),S<\_K^7UERC
M;W4FL=$3%:T7J?/::D(_$-L)E+-*O-(/FQV*D$C4[+L_N>S!+Q^V_,1:W[,E
M$MY:=J5M3^[5EU1NB_D[J?*E%?/R;"2-&]HZIN,<[$4'ZRKE*MKYJNU23_Z2
M)L.^5Y5-':[OFM^]+O%%EK&GM;40]F2+4&)>ID7C;WM7RN$L8[HF<N.9KU')
M-T=0M$S]!!);M1W_ -HBXT4.M]&:CTS.["TUK$G!J/' ;OPY,PMC\CX0MYNX
MT9)7;R"(GY9H@UOP+XBP]W'%AF07W\.V-C_Z&:JO;_FU27S):TCQ6T3,VY<M
M4R?W<A<G_73E6OSFBP"BP\V=[?\ LUKUHVTSN%I^U8D;EL??GEP66;Y/:Q.>
MAQN1'VO98GK=)/\ 0$7+<Y?QRB0L8NQ"3,0D+LXD+MRQ"3>3L[<.SMY.S^2B
MS/TW)Q9NK*Q[\:Q=Z[ZITS7XQLC&2_<;]C9E5T5.FVNV#[3JG&<7^$HMK^)^
MB+PSKRO$>@(B(#X6HM,8W,5):&6Q]+)T9Q<9J>0JP7*LHNW2XR5[ 21&SL[M
MP0.W#J*7?;N5]G-5^/:T_2NZ RLO6;3::G?X)\4N7%SP%QY\?#$Q=+/!C1QT
M;@Q,/29>(TNZ+.:)Q-J&FS\S S,C%DVG)562C">W965]:[%\K(R7R,7JFB8>
M;#DR\:G(CZ>9",G'^;+;F@_G%IE/+>SN:]Z=&O/9TW)B]PL5%R498B1\7GGC
M;CGQL+DC>'K9W=A&CEK[FP];C$Y>&T8>HBNX:_+A]38;(8/*P/Q-C\Q0LXR_
M'[1 Q/6MQ0RO&1"31RL#QR,W5&9CPZV)*ZVW-V=TKK2@6+U9I[#ZBH$Q,U?+
M4*]P8^KCJ*$I@*2 RZ1Y. XS=F9NKA3WPU[2>?3RUZGBU9L%LG=0UCW_ #E*
M&TJ+'^S"-"_:V(5XD]GW3,INS"LGAV]TGO97OZ)2WC;'\7*S\#7U2X3'W&YC
M(6=V^A+CS\O=Y?5_:7S\1H6M6M1V9  SKB[5O)B:'JZN2CYY8>&,V%FX9G,B
MXY4Y?>>=W]LOMCCJN9TSE<_I_4>8M].,T9!;#+8FU7B=GOW.+XED\33AY8?&
M^$K%=YY8:E.@(]95X']TMR(--8P[#]$EV5GBH5G\_%FX_HAMSY00\]<A?+[,
M;/U&RL?I'$V%Q!@U9&/CV2JLM3C#,H46K*)J49PC+S*Y.NQ)QNKE)0G!\LU.
M+Y8:CP#FZ9G/$R,B&0H\KA7"2L7,WO"4VTG'D2YDIQ4EO&;:BMY8Z=K3<U@A
MCTU3D]J3HLY4A?Z&-G$ZU1^//F0N9Y6?C@1A'A^M^FU)Z+SL\^*V?UAK.6,&
MDUCK6>K5E<7:0\?IFG#C^EBXX* <E-D6'I=^)AG9_-E2*SMNU?M33R/);NW)
MR-V;VI;%F<^& 6Y^CDD)@C!N&;D0'AN.-H1W<W9S':?8_;;03QL%O"Z;KSY?
MI;I8]09N:?/ZBE9G9B%I<YE,A((%R48$($1N/4\9^T-JL<30Z,&,OK<[+ANO
MUJ<>+MME\>ESQDEVV?RV++<!Z6J=DNOEP<IR_6LGLM_Z/,E\$D9KHB*DI)H1
M$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
M $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!<1U]HJCJ/"9; 9*-I:
M&9QUS&6P=A=_ N0' 9"Q,[=8,?7&[M[)B)?(N7(OROHA;"=5D5.NR$JYPDMX
MSA-.,HR7JI1;37JF?2RN,XRA-*49Q<91?52C);-->J:>S* VX&ALCI;.YS2^
M6!PR>$R%[$W!82$3EJR'#XT3%P7@V08;%<G^C@EC-N>IG4<V,9H[0L7T,=D6
M+ZS!*S$WG];ZO]Y6HN^L[.1XC4^)W*QT'&.U'#%B,YX8/TP9V@!/3MR.+<,V
M2QPC [DS,T^-<G(SLL(U<<]2>ME+\+_H+DSCY</T2&\L1?MQF!-^NM*_N9NB
M2X7XQ\2^$[>;=TZ-J>!S;?78&/D9]2O2[2WAJ6'"<ETC9S5R>ZV*78&A2TO4
M]6TR>^U;A*EOO/';FZK-^SWKLAS;??YH]TT9/V<Y0I"[1B'(\^T7']_CW,WE
M\O\ H69.Q78"WJW/:"Q@]*V,-AI^EPSVJGEP.,>(G%O'KQS029*["PDQC)1Q
M]B.0/:B(_-FB)BU'D(;4-J&W/6MT[$5FK8KF\4U:S6E:6O8A,?,)H98PECD]
MXF(DWN9;!?NX>V-4WJVRQ&HSFA^:3'!'A=8TXQ:/U;4%2"-Y[ 0_H*F5B*+)
M4V#JC".P59C*2M*P]/?%WCO4M$PJLC QJ;(V6.JZ^WGDL:4EO4_*ARIJSWES
MRGR1FHQ<).<3)>'WA-IV5D2CGWVV6QCSPA'9>;L_?^LGS-<O1N,8)M-M22BS
M ;8#N'M&XQH+FY6H<AK.ZS"<N)Q96-/X #ZF)XGEKSOF;@"W,3S-<H/*S-(U
M>N[^&TT.U^S&D]$X\,5I'3F&TYCP;CU;$4*](9'?CJ.8X0&2>4G9BDFG.260
MO;,R)W=^S45)>(N-M5U:3>?FWWQWYE4Y<F/%_&&/7RTQ?S4.9^K9:31>&,#3
MHJ.'BTT=-G.,=[&OA*V6]DE\G+;X((B+5C/!$7SLEEJU*"2U<L05*T+=4MBU
M-'7@C'W=4DLI!&#<_*1,R^4FVDENWT27=OX(-GT449N]_>Z[%Z(.:J>K&U1E
MH7<7Q6CZDV<-C;WC-E(FCP-8@+AI(I\J%D>7Z8#<29HBMZ>_OUME/%J[<Z)Q
M.GX"Z@'+:HDES>2Z'\FDKXVC/C\?5G#CK K5C*POSTG5]E^J1>'_  FU_4N5
MTZ?;55+JKLM?1J^5_>CYNUED?G578:=K/'VD8"?GYM3DNGEU25L]UZ-0W47_
M #Y1+4I$S,[N_#-R[N_DS,WO=W^1F6!V^/>8[)Z \6+,ZYQE[(0]7.(TX[ZA
MR3R"[CX)18OUB&O+UMX9-;GKC&3_ #XHQ9R:GON_VA=UMR_$'6^ML[EJ,Q$1
MXGUIL=A'8O>!8C'C5H2 WFXC-!+T\OTNS.ZZ4IZ5QU(68R!NG] #"S<,W'EP
MW'][Y/<IQX?]F:*Y9ZIJ$I/[U&%!12__ .B]-OX/;'CMMTD_2&->]HK'@Y0T
M_%=LNRG:W+K_ **OHOSM:?P)^=Y/2 ;]KQ:VVVWQ5P?Q ARVM+<;S>;,T4K8
M3#3S1#TOR3@>;DZQ=F?PW9^8I-W>VKO?N,4HZEU[F8\?-Y? ^"(-.8>.-_?&
M5;$!5EMBS\NTF2LWIVZG'QNC@6QF+45.$XX:T7B32F,4,8B\LTTINS!'%&#.
M4DAN["( )&3NS"SOY+,?:/L![Z[@>">%T-?QN.FZ?^5]3R1:<QT8$_3XOAWR
M#*60;CVO@_&79!X\XV4O8?!?"W#]:NG1@8S759.=9"=K:[^7;E2DXR?ZM/*W
MV42,LCC7BO79.O&CD\C[PIA*,4G^M"A)-?.QO;NV87U='TJSD<I Y$_6;M[1
MD;OR1$3^\G=WZB)W=_?SRO8L9_&TQ=@$&X^4W;_SXY5B'9WN!H3\*QN-KZY8
M?D#EQ6CZT5.-_+EXBR^6@N2F'5[)%%C8#,'=P.$^DFEWV0[OS9_;WPI--Z'Q
M 7H>''+90),YEW-GY\3X1RYW+$9,7M#X)1#'R[1" \"VJZ_[0VAXF\<2-^H6
M+HO*AY-'X.ZY1E^#A39'Y]M\[I'@'J^8U/4LI8\'U<'/GGU^%=3Y7_M6Q?\
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M1$1 $1$ 4BO=*_3%[9_V_5W\'NKE'4I%>Z5^F+VS_M^KOX/=7("[VB(@"(B
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M(=FJ&<Q(R/QSX>0Q7-IX1;E_%M8NF[\.S1^;<UA-:T\QIBVV.U?I[*Z>ND1
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MNY.7#F%Y.-%M;3M]^7QV?V%_1Z[>CDT$1%#9G@B(@"(B (B( B(@"(B (B(
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M:G ?<-C,VQGR<H=7)^$5IX1,B((Q<G62J(H@S<^_)L=N1=;?;+[5EUD[9O\
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MFM-9G'UP?GA[5BA.%1WX9W]FUX1>3/[O<ZUYM:5CC V]Q@)-^L0L[(#]D1$
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MQ1P0011PP0Q ,<4,,0,$<48"S"$<8"(  LPB+,S,S,O91%S_ &R80B(@"(B
M(B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B
M(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( O3OT8;4$U:S#%8K6(
MI(+$$T8RPS0S \<L4L9L021R 1!(!,XF!.),[.Z]Q>'9 T4!>\7['LFSNYF8
MTU!!,VF,J/PUI&S(W(2X:X9,5)I&\GGPMQIL;(!\3^#%5M2#T6X3DQ#V[P=6
MRT\,YA'8K2.Y"3LSG$3^S(#>\FYY$N/,>1YXZF5Y?O.NQ3'O-M[/4QT<(:QT
MX<F8TI9-F9YIPCXNX64_)QK9BN+PL7N@NQTK+L00R1R41<_B[5*8S>.>G<IR
MR5;D,@'#8KS0R/#-%/$3"<<L,HE#/$;,0DS@;-TNRO\ ^$?'<=7TRMVR4LW#
M4,?+BW[T]H[59'X7QBW)_P"5A:DE'E*P^)7"EE,[*J9RHKO?FX]D5NH;/>=3
M7PCOR[=U&4);M]#OU@QE-OD-V_69N?\ /_X+V,#DKN8R5'":?Q\V1RV3L!3Q
MV.HQ/-;N6I7XC@KQC[1RGQY-[N.7?AFY6,,F7L2_1RO]?CR^I]1?K3LRQ21S
M122131&$L4T1E'+%+&3''+%(#B<<D9LQ@8$) 3,0NSLSJ3\K4VHR5<4I;/E<
MEO%2^ZW&+3DD]MTI1;71-=U#6-P14I*67;9?[R<ES;;KN]MTXI[=GR/;X,GO
MV:[EG>?5/A6=53X;0%"40/PK]N/-9I@/VO/'XB:2E"?0[.T<^4"8"=PGAB,7
M%I9MDNX[VBTV\-K4TN<U_D0X>1LU9CH83K]SO!AL4,!/&0^3Q9+(93A^2$A\
MF'%[NO.^#AS88[;O=O)!!G!\"EI[6MZ:,(,XY%X4&-S\A#''5RS?.HZV4DD>
M'+$3C;>"\+29"QRSJE7B/X@\64Y5F'F9#PH/?RUI\713=7V4ZLC>61*+7249
M7;Q;<)QC+H6GX&X*X<>/"_#QH7R6RF\K:RVN>W6-E72J,EWBXU[27O0DUU."
M;?;7:;TG1'&:8P6)T_CQX?U3$4*U"$R$>EI)1K1Q^-+QY/++UR%[R)W\USM>
M44%6W3LE*<Y2G.3WE.<G*4G\92;;;^;9+,(1BE&,5&*6RC%))+X)+HE^ 1%T
MGNWVD= Z#B\;6.L=.Z<9P*6.'*92I7N3QC]$5:@\CW;7'N=JU>5V^LOOC8MM
MTU7379;9+[-=<)3G+\(Q3D_R1\6W0KBY62C"*[RG)1BOQ;:2.[$4'>\??R[5
M81Y:^D<1J37=T'<0EK5X\#A'(??XF3RG-UQ?R<)*>&N@7+\D/'G%]NUWW&]6
MI6D@TM1P&A*LC.(S5:C9W+ SER)#;R\94!DZ?9)_@@A?WBP/YJ4="\$^(L[E
M?T+Z)7+;ZS-FJ-M_C3M/)_[$T/6/$_1<)/S,R%LH_<H7F?NGTJ_[0M[9'*5J
M<)V+=B"K7C;DY[,T<$(-YOR<LA" MPW/+DS*/O>7O6=B=$G+7N:YHYO(PNXE
MC-)QS:DLL;?11RV,:,N,JRCY=45V_6D;Y!?A^*=&X>O->:WE.QK766I-1D;D
M[QYC,6[%,>I^2"#'O*./K1<^Z"M5BA'EV",66/FN,G0PL/JU1XY<@8LS,(L\
M=4'_ .L/W>V[?T*/Z[&7L\,<RZ)[,]$-IZEJ-EG;>K#A&J._P\ZY62DOPIK>
MWJB+,OQ^^D7+&TK"\RR3V4[I.<8KUG-5\L81BNK;LE\$FVDYJN\&[]^UK'2^
M7T-MM@<KIF'-P24,KJC)7XH<P.,F;HM5,52Q_BM1EOP$4,E\\AZS6KG(,%<)
MY0L05A;HL(\,S,S#PS,W#,S-Y,S-Y,S?(S+FMZ1RZB)W(B=R(G?EW=WY=W=_
M-W=_-UPR_P"Y_P!93[PMPCI^C8[Q]/H5-<Y>99)RE.RV>R7-99-N3V2VC%;0
MCUY8K=[^F[5<G+G&S)L\R:7+TBH02[[0BNB6_P =Y/IS-G"+WR_KO_XK(OL+
M=ER[O+N[HC;^K$9TLKFJMK4<X,SM2TIC)H[NHK3N[.+2%C8IJ=/J$@+(6Z82
M#X9&XXZ7OE_7?_Q5T;T;[L0EI?1F7WDSM7IS&X 18_2P31\24='X^>4I+L+O
MYB6I,CQ.1>;'C\9C#B<1GF\3#^)G%T=%T?*RU)+(G'Z/AQ?>63<FH22]?)BI
MWR3Z-5./=I/:>'L)WWQAM[J?--_L1VW7YO:/Y[]DRR[B\;!2K5Z=6(8*M2"*
MM6@!N AKUXQBAB!O/@(XP$1;E_)F7OHBYO-[]7U;[LF$(B+X 1$0!$1 $1$
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MVMR\CK/5&H-69:0I,CJ++WLM9Y)R:%[<Y20U(N7=QKTJ[Q4ZL?+M%6KQ1,_
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M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
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MG49Q1<E\&W)I9</=L&+?T*KDI)*/47NDRE<6\G\@*R*(B (B( B(@+,_</\
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M$5JO7Y NJHOG8G+5;]6O>I6(+E.Y!%9J6JTH35[-><!DAG@FC(HY8I8R$XY
M)P,28A=V?E?10!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
M $1$ 1$0!$1 $1$!$]WU7Q"9S[/:4_#E54T%<O[ZKXA,Y]GM*?ARJJ:" (B(
M B(@"O#=U/\ 2_;<?8_+_C)F51Y5X;NI_I?MN/L?E_QDS* D*1$0!$1 $1$
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M0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
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M $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$
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MLJPW)^5"QIV./H[''IWZJ"<N5;)RG)<QZ9_+^VO2/WKW3^7]M>D?O60K]/\
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MVL=>NUVEP&B(QU+DW,>8IKT4GAX*CY\LYRY#B\8NSB];'3@3B4D;O=.0!$1
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M $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$
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MC&^/79617O1_\2^3_@^GP;[,1$46&3"(B (B( B(@"(B (B( B(@"(B (B(
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M8Z[?@>+4&M9&U-E&,>F6O5L1C'A,>_N=AKXT8[,@ORXW+UMF)P:/IE%7XUX
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MU1$0!$1 %9R]'W_YBW.^S.F_WADE6-5G+T?C_F+<W[,Z;_>&20%AY$1 $1$
M1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$
M1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$
M 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 %&9WQ'TNFX']OT3_"%I
M129J,7OC; AV=]= _/,UO1<8<-Y=0Z[TS._5YMPW1"?FW/M<-QP_+ 4J41$
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M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
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M $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$
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M<>>\+O'7(GE/#UZ]60R;%Y&;*%52HMELE5<JH5UJB;^S9RKR9/WVZFW5O$^
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M_20]RS]\HMKY,(B+3#.!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$
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M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
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M B(@"D5[I7Z8O;/^WZN_@]U<HZE(KW2OTQ>V?]OU=_![JY 7>T1$ 1$0!$1
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M9RED(M)Y.T8C'I_)VI'9\59GD(>C#Y&<Q>J9OTX^\9"Y#5M?F8"U:B(@"(B
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M=*_3%[9_V_5W\'NKE'4I%>Z5^F+VS_M^KOX/=7("[VB(@"(B (B( B(@"(B
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M$[DZ_P =I73^9U+EYF@QF"QMS*792=AX@IPG,8L[^76?0T<;?HC(6^5 5O\
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M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
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M $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$
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M0G<=+Y:?I <M$Q/P&.LD(1Y>,'%HQZ<B E)!-'8B+3A ;(JO8CFC"6(PEBE
M9(Y(R$XY(S9B P,7<3 Q=B$A=Q)G9V=V\U^RK7=SOWB'AO0V?UM=]EWAIZ!R
ML[OY>3B&EK4K\LS>0M@C)V;WXOGJ]1 K** (B( B(@"(B (B( B(@"(B (B(
M B(@"(B (B(")[OJOB$SGV>TI^'*JIH*Y?WU7Q"9S[/:4_#E54T$ 1$0!$1
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MYV<W,>&KB-50XC-R]+%IW4\?P%E6D)OZ'7>T7P?DG9_)RQ5^\(NXB;@9,"D
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M=G;EG;S9V?W.WUG7E $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1%X=
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M0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
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M B(@"O#=U/\ 2_;<?8_+_C)F51Y5X;NI_I?MN/L?E_QDS* D*1$0!$1 $1$
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M:PQV=>X>QT/@9#=G4TF<L=3')IS2\UJAAQ;_ .#8S<L=;+W6=_,SJ08AV9W
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M4I3KR8^I8?.2D[ACZU_DW?(]]_B=F:V0VXVVL5\UNQ;JS0W<A&T%O$[?#,#
M%C(L?7#=U(XF\V/PGAS15?#:UFVBA*I3R-!;4VI<IG<I?S&8O6\MF,M<GOY+
M)WYBLW<A>LF\EBU:GDY.6:61W(B)^&;@19@81:R_@UX/3RITZOJE3CAP:LP\
M:::EE376%UL7LUC1?O0C+_E#V;3H_E==U?55%.JM^\^DY>D5ZI?-]G^K_.[?
M!BB?R ?D]WGSPWU7=_?^V_/^=7Y/1HNQW\Q6T^6W.R=;HS6Z=NK)CBDC9C@T
M=@"N0XCPG+J,1RU^YE,G(8/&%JJ6*8XS]3AE.G+V$>R5D=Z]U=([:8[QHPSE
MP[&=R%=GYQ&F,:'K6=R9'P[0^%68:E24_8+*WL=6;F6Q&!;4'1&C<9IS#8C3
MV%IPX_#X+&4,/B:%<&"O2QN,JQ4J-2 &9F&*O6ABBC%O(1!F6Y^T;Q@J,.G1
MJI_6YDHY&4EZ8M4]ZH2_TN1#G79I8_7I-;^+A_%YINY_9AO&'SFUU?Y1>W^U
M\CE*(BIJ;>$1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$
M0&*';<[/,6Z&V6J-)=,?PC8HG=P,T@]35\]CF>WBRY;S$)IXVIV"%G)JMF?I
M$BX9Z$]VC/5FFK689*]FM+)7L02BXRP3PF4<T,@OYC)%() 8O[B%V6R'5,_O
MA^S5\PNZUK.48&BP.O8SSU1@'B.OF \.'/U1X;AFDMD&4%N6Z?A$HA$0B#D"
M)]$1 $1$ 7\F+$SL[<L[<.S^[A_>OZ1 7?\ NO>TK_-*VEP=JY9>SG]-"&E]
M0%)(\EF:WC*\(U;]@BY,I<GCCJW)97=_%L'8?EB8A&1%4YNYF[2;:*W2#35Z
M=XL-N'%6PAL3LT4>?K'-)IZ5^2;I.Q+8MXH..IY)LC #@7 G'<90!$1 $1$
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MT>"I>YV>2?)]-SI+@2K8VWY]72)76$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
M$1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 %@5WH'Q![F?8.'\*X]9ZK KO0/B
M#W,^P</X5QZ HR(B( B(@"(B M_=QC\2EC[=]0?O3#J9)0V]QC\2EC[=]0?O
M3#J9) $1$ 1$0!$1 $1$ 1$0!$1 %2<[VW9KYD-[M32PQ/'0U8-?5M3@.D'G
MRC$&787_ $9%EZ]VU(3>Y[3#YNW*NQJOYW]NRSW]+:/U[5B9Y=/92Q@<J8M[
M3XS.C'+2ED?A^0J9.B,$;-T^UE9"=B9O9 JY(B( B(@"[P[-6\4NW^OM)ZQC
M<FCP.:IV[@AU.4F,(_ RD3"'F9'CYK+ '#L1]+.S^Y='KP[<^3^Y_) ;(FI:
MBGBCGAD":&:,)898S:2.6*06..2,Q=Q,#!V(2%W8A=G9W;AU["CA[J;?7YN]
ME]-RSSO/D],/)I#*N3L\C3X:*#U$CX9N?&PUG&3,_G_1'8B>034CR (B( B(
M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
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MMG0.]&#^%]'949+=80',Z?NMZKG<'9(6ZH+U(^".'JY&#(57GQ]KA_ LF0R
M&6ZUI&CM<:BTEEZFI](YG):?SN/-C@R&)M25;+"W#$!/&_38KR#R%FG8&:K;
MA(HK$$L9$!3V[4^D&ZU@TJ]+4&@<9J#5<0!%3S\&4DQ&+MM[0G9RF'BHV9&G
MC=A=X\?;KP6^HF;U#H9Y?RXP]G[-INYM&:S,>R72BVRNO(QTWZSL<*[:X_KI
MQL2Z.N6SF_STGQ,Q?*_]8-8\X1ZVQC*55FWPC%2G";V^SLXOTDND2V-+*("1
MF0@ "Y&1$PB(BW)$1.[,(LS.[N[\,S.[J,CM*][?LYMQ)9QWPX6K]15V,2P6
MDA')/#,/EX-_+B0X:A)U>102W3N@W!O4<'8E5KW^[;6\6[4L@:GU7>JX:3R'
M3.GRFPN 8.KJ$;-6I*TV4<>!=CRMBZT9#U0C#U$SXT4M*4J8MXKQCT_H69N6
MX^3CW-_+R6V<)^S7!<MNL9;D^C^BX;Y8?':S)LCS27I*-=4/V;=MFXZXJ]H.
MBERJTZGS)]E9:N9OYQJA+I\4YR:^,"3?M"]\GO)KT[%+3/JFW> D=QBCPK';
MU'+$XN!>N9ZTW0'7RY .+QV..!WZ7LV7 )GC";2LMFS8R65M6+=ZY*\]R_?L
M2V[MR8N'.>U:L')9LRD[>U++(9EY<EY<OS71^)R^H<A'A=(Z?RNH<K-PT='"
MX^UD[?3R(O(<=6*5X(0<A\6Q-X<$(^U+* <DTP79][C_ %_J4J^0W(SU?16-
M)VDEPN,\'-:CG#AG\$[0S-A\4?+^<S%F';I(/5?;&<)EMS.&>%*.1O$T].*V
MK@N?*O2[;QBK,J_K]^?-%-^].*(HA'BGBBW>$;W5O]NQ\M5>[Z[;N-%?3[L?
M>V72+[$+7K]&J4<, ///(8Q0QB#R22RF["$<40,YR2&3LP +$1$_##SPRD&[
M/W=B;T[E%!:+"?,3IV7@FS6JF*G+)&_F[T,"!/F;!<.)#)9K4*9B_P [MR$)
M K0_9S[O_:G:X8IM,Z5HGF CZ#U)EP'+:@/GS/P\C<&0Z02/P\D&.&G ;B#G
M&3@+MF8H+XK]I2V?-5HV(JH]4LK,2E9_.KQX2\N+7H[9VIKO4B6N%_9YQ:G&
M[5,B65:MFZJFU7OWVE9)*37Q5<:VMNDV1#]F[N8]J=$G!D=11V]PL[&\<OK&
MHAA'"U9@=B_,&GZPC5<.IA+G*S969B%WCEBC)XE+7C<=7J5X:M2"&K5KQA#7
MK5XHX(((8Q88XH88A".*,!9A",!$0%F9F9F7O(JY:[Q+GZG;YV?EW94_3S)[
MPAOZ5UK:NM?LUQBOD3]I.B8F#7Y6)CU8\/55Q2<OG.7VIOYR;81>.5'[VJ.\
MRVGVG&S4S&>#-:DKL8MI331P93-M,(\C#>$)@J8AR]G_ )ULU"Z28Q V7ETK
M1\K.NCCX>/;DW2[5TPE.6W;F>RVC%>LI-1CW;2/3FY]&-6[<BVNFN/>=DE%?
M@M^[^"6[?HC)+M)[RUMOM#:EU?:<'^!L9--5CDY<;&1F<:V,JNS.+EZS?FKP
M]+.//7]$/T3:]'=S5UG+Y6U-9G*Q-):LV[DYNY'9R5R8[%VQ(3_12'-(74[^
M?6\COYDZE"[:?>EZQW@Q-C'38FEI72,%^&SCL+6GDO9*[=@"<*T^6RA!7"<8
M!G*<:5:G!5CF".0WL2UX9FAWE9W=W=W=R=W=W?EW)_-W=_E=W?E^?>ZN1X4<
M"WZ)BW?3(PAFY5D960C*-GE4UQ^JJE.+<7/FG;*?)*4>L5NW$KCQ[Q95J614
ML:3GC40DH2:<599-^_-)[/EVC",>9)^[)^J/BRA^TO0D!?9E!>A*'\O\ZF.J
M9IU4_P#CY'/-D-I;FN]::4T7CP,K>I]08O"BX,[O#!=M1QW+A=+.XPX^CZS>
MLFS/X=>M+)P_1PME1I33-3"XO&XBA'X5'%4:F.IQ,PMX=:E!'6@'@1$>6BC%
MGX%FYY=F95&_1]>SE\.:^U'N-=KN]'1./CQ6)EDCYCDU!GXIQL% ;LXO-C</
M#(T_#L<89FMY.,S\7!%4'V@N(UD:E1@0>\,"KFL_UC)4+)+X>[3&G\)2FNA8
M'PST[R\2>3)>]DSVC_HZFXI_G-S^6RBT$1% !)(1$0!$1 $1$ 1$0!$1 $1$
M 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!
M$1 $1$ 1$0!$1 $1$ 1$0!1X=ZAMF^I]D=71QQ]=K"#1U)4X;DQ/#VHYK+@W
M#\D>..["_N]F4N'9U(>N/ZKTU5S.+R.(O!XE+*T;>.MQ^7)UKM>2M.+<L[,[
MQR%P_#\/PZRV@ZF\+-Q,N.^^-DTW[+U5=D9./^TDTUZI['AU/#61C7T/M=39
M7U]'.#BG^3:?Y&L_R%7PK-B/Y FD9F_[/6_3_FX=?W5J'*;11MR9,3LWEY,+
M<O\ Z%V=OAM_<TKJK.8#(CTWL1D+>.M>RXB<]"Q+2EDC8N7\*62N4L3\EU1F
M),[L[._6> SHTK\%@V9P8G&1G;EO#D9Q?GR=O9Y8OJ\,NC5$H6.#4N:N;C)2
MB^DH2V::^3333^!3'.\V,;5&&]M<9[5OHW.">T'\'S+8^-EL;8C8F.-W;AV?
MY>6?R]WO]W/^=7Y.ZIWQ;7NQ.@\E)-XU_#XP=*91W?F0;VFN,6SS<NY^+/3A
MJ6B*3@I?':;S&07>EFXXZ^/N",B;ZSL__C^M[UVQLKO=N+M;=+(;?ZKR>%CD
MF&Q<QD4WK6"R1@+!SDL+9\7'V9'B;P6LO -V*-W&O:A?@FU?Q1\,GKF#"G&M
MKJR*+O-IE;S.MIPE"=4I14IP4]X/F49[."W6W5>GP^\6*-.RI?3*;:XVU^79
M%;=U).,X\S49<NTEMS+I)O==GL!$5;OLZ=_=#UP8S=G2<M N!C+5.E6.W3<_
M)G._@+#^N50X8G*7'W,B1&[ -*(&*1IW]F>T+HC<+'_">B]3XC4-5NGQFQ]R
M.2U4(QZQCOT2<;M"4@X,8K=>$RC<9 $HR$GI1Q/P#JVCR:SL*VNO?97P2MQY
M;]MKJ^:";_4FXV+U@F6QT+BS3]2@I8>57:]MW7ORVK\:Y;2V7ZR3C\&SN5?G
M+&)B0$+$),XD)-U"0NW!"3.SL[.WDXOY.W++^^5Y6G&Q$9_:,[IC9O<3QK18
M$](9N3J(<WHTJV(F>5W<NJUCBK6,/=$B_HOCX]YW!R:*Q!([2#!YO]W)^[&D
M?'O:'NT=PL7$Y&-2$X,+J2.$6=^7I7K XZZ0BSN05,B-F1^D*U.:0NAK>:*3
M>%_%[7=*Y8U9;R*(_P#NV9OD5<OZL9.2NKC\(U6PC\C1>(O#C2-34O/Q80LE
MWNH2JLW^+23KF_BYPDW^1KN=3AE]/WSP^J<+D<)DX^>NAF:%G'VV$7Z7(8K4
M<1F#$SMX@,<?4SLQ.[.R^+8Q.-OB_#B+DWF)<.S\_)SQ[OUVX6P-W6V0T?KK
M'EBM8Z9PFI:!?0P9C'5KO@&WF,M66:,IJE@']J.Q5DAGB+VHY!+S4*?:"[A?
M2F2\>_MGJ:]I"Z_688;,C+G,!*3N[C#'8\:++XP?/I:=Y<J$8,S-2,N35C>%
M_:-TS)Y:]3ILT^Q]';%/(QF_CO"*OKW?HZK(Q];-NI '$/L^9=#E;I.3YB75
M5-JJSUZ<LGY,_P >:#?I'T((-B^U/NSM1X46A]79"KBH6XCT_><<MIUA=^7&
M+%7'D@IB3]3O\'E4-R(CZNM^IIK.S[W^>.E:&CNOI&;"V.KIES^D1L9#$NW'
M]&EPEN:;+TQ8GX>*M;S)] ];$1$T+1!;\=AK>;:TI9=0Z1OY##1%P^H=.1S9
MW#,'F[26Y*<)6L9&[,S/+DZE2%C(8AE*0Q%\ M=[Y:<Q%<WO-ZQ=Z7>.A5Z7
ML&7R>+S[%<'=O,Y>GR^A _H7WG5.">&N)*GDJO%O=G7Z;A60A=S/UG;2VIS7
MZN1"S9]X[KIKFB\4<6Z+D0PW3D7]5&./97*46ETWY+-N2'9N=<X12Z\VV[-A
M#MGVN-LM88.SJ/3FN-.Y'#4*LEW)6WR$-,\55B!Y)I<O4O\ JMW$M#&SG,.1
MK53B;SD$551[U;TBT[P7] =G>\\=0_&IYS=%X9HY90Y**2MH:*;PCB$B9^K4
MUJ$PDA?JPD!>)!E8ZLFYF[N4SLTS=3T*,C%%\'TY9 BD@=V?PKACT/=9^D7<
M9A\'J;J"$'Y765+%22MU/S''_3E\O_=;Y?U_=]=:GPQ[/^E:?F2RK[;-0A!I
MXV/D5P5=;_6O4?=R9)[<B<*ZUWE5-[<MF:.(\NW%K>177C72C]:JK'-)_JQ?
MW7^LHRGUZ1FUU?I-XD\LAD1S3SRRV)YI#*266>>0IIY[$LA$<LLTLAS332$<
MDLIG)(1F;N_TN@*X.3NW+,[D;\,S,S<O^L+>]_J_Z/IF(0CT@S-]5_+EW^J[
M_P#A[F^HI\.XB[KD]Y]9AN)K7%M+M;HF\$@5KU?Q*>L]453CEKX9HI1\*YA<
M8_YJSSNTM>>4:V'DCE"S>&O+O$O$6-I6%?GY<^6FB.^RVY[)OI736GWLLEM&
M*[+K*348R:\F-3*^<807?^I=W+X)?\=2P!Z/AW=D^T^W4VX6JZ+U]>;E0UK@
M5IP<;& T< C/AL7(Q"QQWLD9EF<FWDP--0HN#'0DEGL,KPS>[CRX^1O=^TO*
MYL\3\19&JYV1GY+^MR)\W*M^6N"2C75#?KR55J,([]6EO+>3;<CXV/&J$:X]
MHK;\7ZM_-OJ$1%@3]PB(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B
M( B(@"(B *-CO5NS3_-(VFRS4X'ES^DC?5.#\-F>64J%>8,E0;RZC"[C)++#
M$+MU6X:<G!%" O).O#MS[_-G^1 :V\29V9V\V=F=G^L_FR\K-_O$>S:.UNZN
MH-/U(/ PE]PU#IP1C\.$,-EI9W"K![A>/'7(+F-$0X8 J W''#OA @"(B (B
M(#W<9DK%*S6NU)2@MT[$%NK.#\'#9K2A/7F!_D**6,#%VX=G%N'97YNQQV@Z
MVZ&V^E]90N#6<C1\#+P#PSU,WCY#HY:N0?1 +7()):_4PO+3EKV!;PY@=Z!B
MG[[BGM+/B]29O;')3]-'44$F>P#R2\!%F\>$<>0HQ@7+=>2QO%L.EP9BQ,HN
MTASAT@6E41$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$!T%VHM]:6VN@M3:T
MN^$387'224X)7=AN92=QJXNEPQ"1>MWYJ\+L)"709.SMQRU '.YRYE+U[)Y"
M<[60R=RUD+]J1^9+-V]/):MV)'^4YK$LDA/_ $Q.K!G?O]I4;>2T_M7CK'5'
MB_"U/J08I/)KUF":'"49V']%#2FL9$HC=FZ;E&=P=_!,:[R (B( B(@"\._'
MF_DS>;_6;Y77E9>]A/LY2;I;H:9TN<9EBAMAEM12"Q<!@,7)'9OQ.8\>&60X
MCQD4G+.$MP9!8G#I<"T)W0W9K+0&T]#(Y"N4.?UO*VI,B,@LTE:C*'AX*D_D
MSMT8UH[LH%[<=J_8B?D8QXE/7XUJT<,<<,,8111 $<448B$<<8"PA& "S"
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M?K M-:4EMXZM9KR<MX&5R'C/D<J)1^Q/%+-#0L<F[X\!<8PPTP^F*F.=I)7
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M?VOR5CJLX.<]0:=:0W<WP]\XX\G1C9W\XZ&3=K8<<NS960'Z8X8V5A! $1$
M1$0!$1 $1$ 1$0!$1 $1$ 1$0!<+W&U]CM+8#-:ER\S5\7@<5?R]^7WN-7'U
MI+,W0+>9RD$;A%$/)RRD$8"YDS/S10*]^EVEGPND\+MKCI^+^KY2R><8"=BK
MZ?Q,\+UH)69V_P"=LKT^'SUB\.*N"8BY1$X%:C>O=?(ZZU;J+6&5=_7]0Y2S
MD90=^KP(Y'8*E07;R\.E3CKTXF;@6C@%@9A9F;K!$0!$1 $1$ 5KWN->S6VG
M]$Y3<3(0<9/6TPU,61M[4&G,3/-&)1\^8MD\F\\\SMY2PT\>_'$;$5:#8'9Z
M_N!K736B\:Q^M:ARL%%Y(VY*M49CLY*Z_D3,%#&P6[AN[.S! [NS^Y]@1H71
MF/TYA<1I_%0#6QF$QM'$X^N#<##2Q]:.K6C;_NPQ SN_+N_+N[N[N@.5(B(
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MKAR27:U%I?=_ODMK\"4E73<&6UM>!W%CQL0X[#,3.[.QY7(],IL[<.!T<=>
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M$OSW?4(B+0S(!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
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MW=+F;(72;@7ZKEZ6Q9?J;J;Q."=W9W?NQ $1$ 1$0!$1 $1$ 1$0!$1 $1$
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MR[.SNQ,0DSNQ"0N)"[/PXD+\.),_DXOYL_+/[EX0!$1 %X=N?)>40%S'N?\
MM/OK_:ZMALE9\;4>A9 P-WK)GFM8E@Z\%D';ER+FFSXZ4W\RLX^60N&F#F5]
M48>[@[4;[4;HXC+V[/@:<S7_ -C^J1)W\$<9=D#P+YMSTB6)OC7N>*[.XU1N
MQ,X#8,FO-12B8B8$)@8L0&+L0D)-R)"[<LXDSL[.SNSL_+(#]$1$ 1$0!$1
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M!$1 $1$ 1$0!$1 $1$!$]WU7Q"9S[/:4_#E54T%<O[ZKXA,Y]GM*?ARJJ:"
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MR(>T-&I;F=Q"(C'*14Z>^#[7_P#-!U^6D\18\32N@YYZ,1QD)09/49"T>6R
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M;7] ;B[$+D)"[$)"3B0D+\B0D+L0D+LSB0NSB[,[.SL@-D<BAG[J/O#FW*Q
M:(U=<9]>8*HWJURQ*WBZKQ%<!'U_DN"DR](68,J')G8#HR?412VAKS,( B(@
M"(B (B( B(@"(B B>[ZKXA,Y]GM*?ARJJ:"N7]]5\0F<^SVE/PY55-! $1$
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MV?VM<%LSH?(:MS#C8M<^HZ?PS2,%C.9N>,RJT(/>0Q"P'8NV&%QJTX9IB\V
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MDW][]1_>^R]Y;;V8T1%5DWD(B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
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M0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
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M$$D4L9$$D9BXF!.),[.[+VT0%+OO.>[^GV@U$V9T_7EEV]U!8+X+EZCF+ Y
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M,DTTIG-/*1S32'(9$_".S[L%IO;/2N,T?I6FU3%XT'<C+H>WD+LO!6\GD9@
M'LW[DC,<\Q,S,S1PQ#'7AAC#NI5"\4/$F_B#,W7-7I^/*2Q,=]-UV=]RW:=U
MB].JJA]7'=\\YV>\.^ <?0L.-45&659&+R+DN[[^7!OKY<7OWZSEO.7W8Q(B
M*+R0CC&M-8XO3V)R6=S5V#&XC#TK.2R5^R;1P5*=.(IK$\A/^A","?AN2)^!
M%B)V9Z,W;@[7N6WWU_-G"]8K:2Q+R4-&X:47C>ICN0\;(VXN?/*9>0/6;1$W
M57@]5QX^55SDSY[Y/M[OK7-2;1:,O]>FL!=,=97ZDG5%F\]4E$1PH2AY'C\%
M8CE:\(D<=K*LT1=+8U_&AK=X<53<R<1DZ'?SX;I'CS=_Y>[S5U? CPR^@T+6
M,VO;,R:_[UKG'WL;&G]_9K>-V1'K\84-1Z.RR*JEXV>([G+]$X,N9<W+;*#Z
M66K[NZ?6NI]_25BW6_+%ODN!TME,[E<3I+3=.3(9W.78<=CZ</T5BU/Y,SEQ
MQ'#"#'/8F+V(*\4LYNT<9.UV7L*=CS$[,:&IZ>JO';SEWP\AJK,B'2>5S)AQ
M)X;O[8T*+.]/&PE]!7#Q#9YYIC+!/N@>P-)H?#_S2M84NC6FIJC?!%&S#TS:
M9T]8$3",A-NN'+9=G&:_Y =:HU>CTA(USQ)O&;A1?XY^)OZ2R'I>%9O@8EGU
MUD'[N5DPW71KO30_=A]V=BE9[T55);[X->'*TK%6;E1WS\J/-[WVJ:I==OE9
M9T<O6$-H='SI\&W-V]QVK-/9G366B&;'9O'6L;;!Q8N(K,11M(#>7$D)N,T3
M\MTR1@3<.S.J&^[FV%O3N;U)H_,Q<6L1D,G@KP$W#2M!)+6\</)NJ"W!T6:\
MC,S20312C[),ZV 2JW]];LPV&U[A-85H>FIK#%RP7# 68?AC /7@D>5V\F.S
MCK=%XG/@I?5K'3RT)<>?P"XC=&H7:=.7U>;6[:DWVR,>+D^7X<]'F.7Q=4/@
MMLWXJ:3YF+5F17OXTU&;2_Q5K44W_,MY.7X<\GW*DV9P)5+-BJ;/U5YI(2Y]
M[O&;CS^WQ_[+\].YC(X3)8_,XBY8QN6Q-VMD<9D*A^':HWZ<P6*MJO)P[#)#
M, R [LXNX\$)"[L_>^\N#:'-S2L+,-R.*PW'NZV!H9&^N[E%XC\_+(NGI:/U
ME=V#C9#JE)2CM*+2:::VDFGT:[IIK9HCO%SFXPGOLVHOH^S_ +-G^!L+NZT[
M>-3?G;6EF+4E>+6NGQK8?7..KAX(199H7>'*U8'.0H\9GHHCNTQZY&@E&W0\
M20Z4AO)2M=)W9';#L[';K8?44LDGS+YHH-/ZTK"Y.)X*W9C_ .4O"'RDLX&<
MFR4#=+F4(7*L;@]PG?8HT;T-F&*Q7ECGKV(HYX)X3&2&:&46.*6*0'<)(Y(R
M$P,'<2$F(7=G7/\ \8> UHFIMT1VP,WFOQ/A6]UYV-_S,I+D_P U.M-N2DR<
M^%M;69C^\_KJMH6?/]2S_;2>_P"TI>FQ[2(BB4V8(B( B(@"(B (B( B(@"(
MB (B( B(@"(B (B( B(@"(B +T<GDJ]*O8N6YXJU2I!-9M69Y!B@KUX(WEGG
MFE-V&.**,2DD,G80 2(G9F7NNZK9=^AVZRH5@V8TO=8;F0BANZ[M5I7:6KCI
M0:;'Z<)P?V#R@D%_(@3];4 J0N+Q9 ^-HX-X5OUG4*,&CW?,?-=;MO&BB&WF
M6R_FII16ZY[)0@FG)&*UK5Z\+&LR+.O*MH0WV=ECWY8+\=MV]GM%2EMT(ON\
MZ[P6YO3JLJ&%L2P[=Z=L''IZITE%\,6QZXIM27HR]IY+(N\>,@D$7IX_ARC"
MU:M**O+9KP&\.)V>5V\W][1M]7ZY/\C>YO>[/Y<_E<N^"'2/#R%Y#_V?-_:=
MOK?)]?ZS.OJZ.T,64:>Q*9#%%[F9O;GD?S+AW]PAY.9>]W=F'W.[=$=!T/'T
M_&HP<.M0IIARQ73>3[RLLDDN:R<MY3ELN:3;Z=$5;X@X@6]N9F6=927,^^SD
MU&$(1Z[);J,5Z16[>R;.M'!R=R)W=W\W=_-W=_-W?GWO_?68_8;['&<WLU[C
MM(XMI:N-C<;^I\VPL\6#P41?/['M<B=VV3#1Q=?I+QKLT92L%2&U/#CE8TC;
M/(08^C4L7+=VQ#5HTZL1SVK=JQ(,5>K7A!BDFGGE,(H8P9R,S$6;DF5]ONV>
MQ'2V0V\JX>6.&75F;>'+ZPR(.$A2Y0X1&/&0S#RQ8_"Q.]2H(D\1R^M76YEN
M3&6A>*W'OZ"P'Y;3S\KGJQ(/9J#27F9$DULXTJ4>5--2LE"+3CS[;+P3HRU6
M^,MW]%K4;+9+IS)[\E2?H[&GOMVA&6S3Y=\NMH=G=/:%TQB-'Z:Q\6/P.$HQ
MT*=06ZW.,!XEFM2$SE:M6S<Y[EF9RELV)9992(C=U4,[TCL02;-:V'46G:GA
M;>:OM22XT8N7CT_G#:2Q=P!-TLT=600DNX9^I_S*UBEP/J G-="72W:%V(P&
MY>D,UHO4E=I\9FJKQ.8B+STK<1#-2R5,W\XKE"T$5FO(+M[4?07,9F+U,\.?
M$/(T35/IED[+:,F7+J$')RE;"4W)W=7[U]4I2L@V]Y;S@Y)629+_ !MP91JV
MGRQ'"$)UQWQ9;)*N2CLH=%TKFDHR26R]V6S<$B@I<>4O5<ICYY:M^C/7N5K5
M<_#L5;=609ZUJ"0?..6"< EB,?,) 8OD97+N[,[<5?>71 -DYH8]=:9"#'ZL
MI S1^L&[&%//58N>?4\M'$\D@BSC5OA;J<N$<4DE0[>#9O4&U6M<SH34\?%S
M&3NU>VP$-7+XJ4B?'Y>GU>^M>@9CZ>7>O8&>J;O+7-<E[/\ O]G=G]<XK7NG
M&>QZMU5LMB_%*&#.8.R497\58(>1%Y/"CGJ2F$C5;]>K:\,O!Z2N#XE<$X_$
M^DPMQ95SR:Z_I.GY$6N6Q3@I.IR?^*R(\JW;7)8H3?2,E*J?AUQ5?PSJT\#-
M4XXMDW5;&2>\'&6RDE^O2V^G7F@Y175IJ_BSKRNM-GMV\#KO36(U;IJZ%_"Y
MNI'<ISCPQBQ<C+6L1LY/!<J3#)6MUR?JAL121EYBNRUSZOHG5.==D)0LKE*$
MX33C*$XMQE&47U4HM--/JFMF7>KMC.,9PDI0DE*,HM.,HR6Z::Z--=4UW1ZU
MRI%8BE@GBCG@FC.&:&8!DBFBD%PDBEC-B"2.0"<3 V<2%W$F=G=E3-[SCL!V
M-EM2CJ?3%:0MM=1W":HP$4GS+Y>8CE+!6.>2#'S,Q282<B-O#"6A*0R5X"M7
M.UU_NGMA@]9Z>RVE]24(<GA,W3DHY"G,S=,D1\$$D9<=4-FO*,=BI8CXEK68
MHIX2&2,";?/#CC[(T#/CD0YK,6WEAF8Z?2VI/I.*?175;N54GMWE!M0G(U'C
M?@['UK"GCVI*V*DZ+6MW7-KL_7RY[)37R4DN:*-?+D*K7HH[=8RBLPD$X2PF
M4<T4T1-)#/#(#B<<L4@#(!B3&!B)B[$S.UM#NI^\3'=+#?,;J^W&&X^GJO,L
MDG3$^JL/!T1AF:X^R)Y&OR,>:K1,W$CA?C 8+)1UZXG;$[)N?V*UQ-I[(>-=
MT[D"FMZ2SY 3197&,0\UK#LW0&6QOB!7R-<7X)_"MQMX%F/IZ)P.I<OIO,8K
M5VE;TN,SF%M1WL?=KEP<$X,XD!LW#25[$125[,$G,=FM+-!*)!(3/='C'A;
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M7*4;3 [^V 9/)C9EZ>!:6M4I6!<PDC=@)T:U>.&..*(!CBB 8XXP%A (P%A
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M'!93(X7+U):.4Q-VQC\A3F%QDK7*DI0SQ$SLW/28OTDWLF#B8\B3.@./HB(
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MR>\-UM=>?R'G[K_WW:1O]#+VQ]F_.VZZEA)^OU=[7[^7^Q'DGXJXR[8F0_\
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M8RUB_A&2S&%$(G*P4S]/@.#?/(Y1?S:0?-F9N>M^/"ZF,>J*77NHFR^8RN3
M2$;UVQ/$!-[;1&;M ),WEUM$P,3,_#%RS>2NH^O5>OH0[X2U:A1=G863&?D8
MZARRFFDK92:Y.OWN2,G+;TY&^Z+M'HX\Q0OEJG#L,NW.CIS8N6(9(2;V7'R;
MWW)&]INH.&%G\R5J=5<^X!Q_JFHM35/ZET)@ZWUOG%R"+ZK_ -)]5U:,7/CQ
MOV_](\Q[=Z\5_P#P]:_J2+#^'UG-IL)>CORFOP>18_[0B(HD-V"(B (B( B(
M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
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MF\@))T1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
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M7!?/E@HK=]V]MVVVV13J6M])WY-SZ)N=ELI2>WXO=OX)+\$CX99TF^AB%O\
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MW'V/R_XR9E4>5>&[J?Z7[;C['Y?\9,R@)"D1$ 1$0!$1 $1$ 1$0!$1 $1$
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M#5RH^'#GZ3.WL\G=XR@"SCTAD_! &C@9W BF1$0!$1 %X)N6=OJ_R\G;W/\
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MSE!CZY=#/U3W3ACM7;/.;: (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
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MZ%E\7(PC]1C+];RZ>?\ \;]I9VT/G>*-V?WB+?\ XK_RX6PZ?6DI/U_LV_\
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MRW1$5'B>@B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
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M2Q]N^H/WIAU,DH;>XQ^)2Q]N^H/WIAU,D@"(B (B( B(@"(B (B( B(@"(B
M(B( B(@"(B (B( L->V_V.,)O/HZ? WW"GFJ+3W-,9OHZI,5E#B86:1F]N7'
M77CBAR5879YH0"0.+%> PS*1 :[+=?:K.Z(U%E=*ZEH28[-8>R5:Y6/@@?R8
MX;-:4?8LT[4)!/5LQ.\<T)B0OSRS=>*Z]WCO=\XW>; ->Q;5L=K["P&6%R9
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MCD=R#-VH96:K5DCBDP\764S/?GZ:$_C,@/*(B (B( B(@"(B (B( B(@"(B
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M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
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M5[>Q^YE[3@^(>F,N\V9T=;D<B\7"RV'$L=+*3,TMW"2F-"T_M$<7J=N3I]=
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M0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
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M+%7LZ=+R;AWKYJ<1+@2=G=F>0/1G;6V?U#$,V%W/T%D8RXZ7KZKPK]74XLW
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M;OWIHZU2K$ ,Y$<L\H1LW'DY=3\,W+7>^PAV2Z.SFWN+TO'X-C-6.K*:HR@
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M1'KXE\S,UC2[I;SCD^2HR?7=U0KIY7^W%*'-\=TWUW+^>.I!6KP5H_H*\,4
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MQCX9G/3SV2=@<.7MY"[9Y=G\W?B5O:_1<=3>3LL^53_C:[S-9U:?ZVI9K_\
MB;-BU/#5?)IV!']7#QE_V, H3._IY_F+XUF^77>!Y=WXX_,F5=OU^7X;]OS\
ME-FH3._J^)?&_;U@/WKE%E?"[_VAT?\ UVK^MGAXW_P1J/\ JMO_ '2JJ;/\
M$NWN?E_?\G ^?/U./KJ[[W:_Q#[6_:I1_P!>7S_;]ZI!RF[XCA_JNWUW\O+G
MZO''E_\ 5Q=\[M?XA]K?M3H_ZTJLI[3/^"]/_P!?_P#EKBN7LX_\MU3^8_\
M?0,X$1%2XML0S=^QAO6-BSM=/46.U?IFPWT7(M/9EI$7L^7##:\W-NGCGW%P
MJG0OUXIV]_'_ ).KC??(X3UWL^:U-AZO4)<!D/<;]+09['@Y>Q[N&E\W/D&;
MWM[E3BQ#]>,D;W\,S\?W_P#S_E\MY/9OOYM!OAW=>H9"_!2IQI)+\VW^93WV
MBJN74<*S;O51^]76QW_=LBZMW5&8]<[/^VQ>_P!6P\]%_+CSI9&[7^J_/'0S
M<MPS\>3-[E(4HGNY2RCV.S_IR,F=CI9K5E,VZ>EN!U!>GBZ?-^IO L1<EY<G
MU-QPW+RPJH_'E'E:WJ]?I'4\Y+\/I-FW\"TG"UWF:9I\_P!;"Q7^^F!\C4&'
MBR-"[CY_Z#>J6:<WES\ZM0G!)Y<MS[)OY<MS[N6]ZUV.GL7)C<CD\3./1-CK
M]_&3 [_02TK4U24'][>P<1#^U\JV,CJA+VPM(?,WOMNKBF#PXWUSFLK$/GTM
M#J&Q\T,;!S^@$,JP"S>R+#T#Y!PT[^S%G\N7JN+O_*48]Z7^ALG5)_\ Q$/X
M$,>T3I_F:9CW)?R=EL-_G.$9Q_W4B3?N$]8O3W(W#TVY/QF-)4,W&/+]#'IW
M,A1D=AYX8S'4T?4[-R81#R_3&*[(])L[20:>VET]MO7L,-_<34$5N[7&1AD/
M3^D)JF6F(X_)S@?.'@A?Y.L!Y\N5@[W3.JVPO:)TV)&X19S%:AP9LW_6//0]
M?@!_K/:QL!/]3I43'?I=K*+=/M$ZJEQ]I[."T-!#M[AN@V*N3X"W?FS=J)@9
MA([&H+V2B*<F>66"G5B<RAKP<;IJ7!GTKQ AE2B_)HPL?4[);='=3S8F-'?L
MI*VFNQ+UC3+\3W>%NK>;PO3!-<RMMQU\HRVNE^35C7^TB//2N\5R@T=:VY7*
M0.PBTC\V*\?/T,,CO[48>;C!([BWT,91LZR6Q&?JWX!L5)@FB+Y1XY$OE"0?
M>!M\HDS.W/+>3L[QUG8+]9?:TYJN]BI_'IS/&[\,<9-U12CS]#)&_D7U&)N#
M'WB3.I]MQ$^L>C_@S\]4X6KNWG7M7;W?3:$W^TDNC?ZR7QW3[J0DI5^3RKB&
MV&=M:J@NR8_&7YI<76>WDQJUIK4=6J '));,X0-PK11QR2S2RB(UX@DEE<8A
M*1ON>*SLSL_+/\OR.WU>?E7B4-FUTYEMNM^JW[;_  W]#0[<&=4Y0LCRRB]F
MGL_3?OV?1I[K=--'O/+_ "_ERO3G 3;S;ZS/_+W_ *WU/J+\7E_DR_(I?Y<^
M:_6$'W6Z?R/M"O;KV/OX35%[&2,=>9^EGYZ";JC?]<'?V?UQ=OUW7=6FM^;.
M/RN+SV/.7#Y["WJN2QN0JDYC#>IRC-!,S-T2 W6##)'R8G&Y@1=)N*QP>5?D
M\GRM_F7K:4HRA9%2A*+C*+2<91:V:::V::;33Z-/9GER-%QKK89$J_+R*VG"
M^INNU-/=-N+2EL]MN=2V]-F;&WL3]LS3&\>BL+J#%Y+%CG9<?!\T>G(<A7FR
M.#RT?SB[#/48AM#4DL@<F-M2UXAMTI()A$"(HQS*Y6K;PV?M8ZU#>H6[./O5
MRZJ]VE8FJ6X"_IH+58XYX2\F]J.07;C]921[-=[QO_HQH8:>O)\Y1BZ>,=JR
ME4U!7,0^A K<XQ9F.-OE&KEJ[E\KN[#Q4[B;V;KO-MMTK-I\J<Y3AC94;*W5
M%MM51O@KO,Y5[L7.%;Z+FDWO)S?IGB)!0A#*IL<HQC&5U?++G:23G*#Y.5ON
MU%M;]DET-@$JJG?:]C+YF,_#O'INHX8C4ER"CK.O6BXAH9\X^BGG#"-F&"#-
M!"U:],[,!9AH992*UE2*3UMJ_2.\K&,46M=MZ-MV86EN:7R\U-Y"_1&&.RL=
ML8F9^':-\E+U>;/(S^:S O=]7V;]R-.Y72FN*NK<%BL]CYL;DX,MIZ7(5BBL
MBX$]>SIJ?-6@D@)QF@LE3@."8 E!F(&=:QPEPEQ1PSJE.:M,R,BA/RLJO#E7
MD^?C3:YU&%,YSYH[*RO>":LA'FZ<R/VXER=)UK MQ+,FJ$I+FJE<G7Y5J3Y)
M-S2CL]W&6SZQD]NNS*R^1A'(U&EC=QFC9G8P)QD$A=B"0#!V(3$F9V(79Q=F
M(79V97#.ZA[:G\U?0(8K-VVEUUHJ*GBM1>*8^LY6KX918O4?2S#U/DHZ\D=\
M@%@')U[+\1QS0"].7)7</@L]E,3C-05-18:K=FBQ>=A">M%E<:[\U+9U[4-:
M>K8. @:U7EA!X+0S1CU (&7??9C[35S:'<+"ZZPM@+-.*4:FH<;#-&_PMIVW
M+%\)4NGEV]9CC$;= WX:._6KN3^$\HG9+Q2X*KXATEJJ/]^4Q^DX,I1<)\SB
MG*B:FE*"R()0E&2CR6JN4]O+:*U>&NO9'#FK2Q<B,_H5\G78TG*M+F>TXR6\
M7Y4O>BXM\U;E&._,MK]Z+JO1V]VDL]B<;F\7J'#V,=E:5;(4IOA&F+G7M1#+
M&Y \W5&;"3#)&7!QR,49LQ"[+[MG<O3D(]<V?PD0<LW7)E:$8<O[FZCL,W+_
M "-RN>\\.Z,G"55BE%N+BX234D]FFMMTT^C1=J-\&DU.+32::DMFGU33WZIK
ML<W6'7;B[(.'WGT)?TM?>*IE87?(:9S91,<V&S< OX$S.W!O2MCS3R=<"9IZ
M<INS-/'!)'V1J/M5[9X@'/):_P!'5!'GGQ=1XGEN.KGD0M$3<=)?)\CLL4]?
M][MV?L !]6OJV9F%N0KZ<QV5SA2OS]"%FC3/'@[-R[E8N0Q^7'7U.(OL/#^E
M:Q#)HR=.P\Z6119&RJRC&NGRSB^C]V#CR^DE+W7'=2WBVC&:IE8,J;*<N['5
M5D'"R%EL(J49+9KK)/?X;=4]FNNQ3BR6GLKIK,YC2>I:4N/S.$OV,7DZ5@2$
MX;58W!S#K$?%KS#T6*=D.8;=2:&S <D$T9EEUV"NV'>V+U\&1LG:L:(S[14-
M6XR'KE$(.L7JY^I6;GKR.(?K=F#@[5">W5=CE*J4/T^\U[7^VN\&I,1J71&G
M=0X?-TX),?F,ME@Q]6'/8Z-F*@\N/J6KT@VZ$GB!7MG8CDDI6'@LQ.4%0:\;
M-S/V+(B$I\QC]"(LS-^V_'47[;NS/SPS+H#1MK.C1IU;"G1/+H\O*Q)[;US3
MV<H23ER[3BKJ)?;A[G,E.+13A<.9&DZX\K2LJN6/"SF5F\MIQVWVY%'WGLW7
M8FXPFN;:336_;W>2=NW7G:KU+7KC5OZ'VDT_;F^ M/W)">_E[ 2''\T6;JAX
M<<^3E@X"C4=SHX6(YA@LW;$DUB3'C0VA,7I^KZMCJXQ]3,\]DN"LVB']'/+Q
MR_'GT@W$<;<L(MR_/:^V&VVH-9YRCIO2^*MYK.9 G:KCZ0,<K@) ,EB8R<8:
MM.!Y \>[9DBJP=8-+,#F'-F#L5]R)C,,534.[TU7.Y(/"LU](8^:0\'3E;ID
M <S<88BS,L;\--2A8,4YL44AY.L_5)K6K\3Z+PM@U8N\**ZH?WO@T^_D7;M[
MS<6^9N<MW.^Z48.6ZYM]HDLJ&IZY:^6+56_O2>\*(;?K2V?/)=-H1YFNC4(]
M61@]@+NTM2[P7*^:RK6M/;?03<VLS+"06\YX1<24-/1RL+2=3L\5C+.Q4Z;M
M(,;6K43UAN([8[88+1N"QVF]-8VOBL-BX!KU*=8.D1%OHY93\SGLSGS+9LS$
M<]B8SEF,C)W?F-#'5ZD$-6K!%6K5XPA@KP1A#!!#&+!'%#%&PA'& LP@ "PB
MS,S,S+W53GCSQ$S=>N4K?J<6MMX^)"3<*_3GLELG;<UT<VDDMU",$VG+_#7"
MV/IM;4/?NFOK;Y+:4OV8KKR5I]HIO?O)R>VQ$11^;.$1$ 1$0!$1 $1$ 1$0
M!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $
M1$ 1$0!$1 $1$ 1$0!$1 %7)[^'LV/+5TYNGC:[.=0FTSJ<HX^2>M.138*_*
M8^Z."SZUCY2/GDKM$1<6 NJQLNI=]MHL=KW1VH]'Y1OS'J#%6\>4G')59Y8W
M>I=B;R^?4K30VXN>1>2$6-B!R%P->2BY9KS1&2TSF\MIW,0^KY7"9"WB\A#Y
M\#:IS%#*X._OB-Q\2$O+KB(#X]I<30!$1 $1$!DSV.^T!8VPW(TMK*(S:IC[
MXU\U"!$PV\#D&>IEH)!;R/HK2/<KL3$(7:M6?H(HA97Z<7DX+M:O<JRA/5MP
M16:T\;L4<U>>,9890)O(@DC,3%V]XNSK6^JXGW,?:3^;/:V/3%ZP\V:V\D@P
MDG6[/+)@9QFDT[,_M<O'!6@GQ0%TB_3C!ZNH^J0P)=K5J."*2:8PBAAC.666
M0F"...,7,Y#(N!$ %G(B=V9A9W?R94+>W-VBYMT=SM3ZI8S?%O</%Z>B,G=H
ML!C))*V.-A]T9WA8\E. \]$UPX^N3H8WM!=[_P!I0M![47<5C['@Y_7$KZ=H
M$)<2U\<8M)GK@LSL3=..8Z,1L[/'9OPRMSX3L],9F9O)O)F]S?60!$1 $1$
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M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
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M*..IQ5&C.'PVE>>/I<9S/VI)G(>6?J=WXX?@181;R9F;[>^>YM?!8R:;J%R
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M--B\"B6\7<]GESB^G1K>%&Z_5=DT]G&V.Q*NG\)2>T\^Y7/O]'I3KQE\IO\
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M $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$
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M:G,[,[^!:CBF9F?D&X797* (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
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M=C\,WD!).B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M(B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B
M(@"(B (B( B(@"J?=[CW=CZ+OV=S=%T6'2&4LB6H\;6 1#3>6MS= W((8Q%H
M\+DYY #I$>FAD)/#Y:O:@""V"OB:ETUC\SC[N)RM.MD<9DJL]*_1N1!/5MU+
M,913UYXI&()(I8R(#$F=G9T!KBD4B_>-]A&_LQJISI#8MZ'U!8LS::R1 1>I
M$S^-+I_(3-U"UVB!OZI+(X%DJ,;V8P>6"Z$$=" (B( B(@"(B (B( B(@"O#
M=U/]+]MQ]C\O^,F95'E7ANZG^E^VX^Q^7_&3,H"0I$1 $1$ 1$0!$1 $1$ 1
M$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 %XX7E$!Q/6&@\)J&J]'/8
MC&YFF_5^9LG1K7H6<FZ2(0L1R"!N/DQ@PDWR/Y,L"]P^Z=V0U YR#I>; 63Y
MXL:<R=W&L#EYNXT3DLXMWY\VZZ!\>YO)W9Y($67TSB#.PGOB9F3C>K5-UE<7
M_.C&2C+YJ2:9C\W2<7)6V1CTW?.RN$VOP;3:_)H@NU'W%.BY2+X(UQJFD+_0
MAD*N'RCM_P!XJ];$\_K]#?K?5ZMM]Q ?)^K[CMT\>QXVGO:YX_1]&2XXZOZ7
MSX^NK$:+<J/%WB*M;+49R7[=&--_OE2W^]FOV< Z1+OAQ6_ZMET?X*Q)?DBN
MI3[B*SP'C[C0\\MXG@Z?)VZ6+SZ.O)<N_3[NKRZOK+LG!=Q-ID'%\GK_ #]D
M?T04<7C:+\<OY#).>0X\N/-XWX?E^'\E/#PO*^UWB_Q%-;?I&4?YF/BQ?[U1
MO^YGUK\/](CVQ$_YUM\OX.S8BLT/W..R^)(3NT]1:DD!^IGS>=ECCYX;R>#!
MP8:"0&X?@)HY6?GVNK@>G.#;?LR[?:0\,M-:.T]B)8G9X[-7&5O7!)F^C:Y(
M$EKK?WD?B]1/YD[OYKO-%JNI\6:GF;K*S\NZ+^Y.^QU_E6I*M?E$SF%H.%C[
M.C%HK:^]&J'/^<]N=_FSQPO*(M>,L$1$ 7CA>40$'7>Y=DX[U%MTL!6<K>)K
MC7U;6B%G>QBHW9JV98&9G>7&<E#>)NIRH%%,[ %&0CKP-8AEX9V\W]W\O_+A
M7V;]""U!-6LPQV*]B*2"Q!, R1303 \<L4L9LXG'(!$!@3.)"[B[.SNJ?'>,
M=CBWM%JHKN,ADDT-J.S-+@; @7AXJR[/-/IZU)YB,E=FDDQI$XO:QP/TL<M.
MV36_\ _$2-]4=#S9KSJ8R>GSF_Y6E;REC-OO.E;RJ7K3O!)>4N:GWCWX7<MT
MM<PH;5W-+/A!;>7<_=CD[+[ESVC;\+MIO=VR<<(Y\2!M[+M_XLNN];:";(4Y
M(F9AGCYDKG\@RLWDSOQY ?F!/\C.Q-R[<+D-;-_7_P ZY!!F&+R?AV_O_P"G
M]966EB1?5=&5HQKLK$LA;7)\U<E*+^:_@T^S7JMT>UW<W;FRNP^N?6K36K&D
M<N84-8X0&>23P8SZ8LO1AZF;X5Q1.1 (OQ=J%8I%R4E>6&^#HW66+U#BL?G,
M)>KY/$9:I!?QV0J'XE>W4L TD,T1>3\$)-R),)@3.$@B8D+:\G=O1(61?+T@
M^?@S-=B!O.6,6X:P+-[SB%F&1N.2CX+SZ/:DD[I?O,I-K,G%H76ER67;S-77
M*M?L3F8Z,R%CABM@)L?3@;DK,61KPO''2L2290 )Y+S2U]\:O"UZC7+4\"O?
M/IA]?3!=<RF"Z.*^]D517NKK*VM>6MYQJB[H>%7B-5=3"NU\M4Y<LDWN\7(?
MVHM_Y&Q^]&79;J;VWGRY=^D*93KSNTM#G^@T=6W.GK=^/6;&!AY\/]#SZIQU
MMYEQT_H&4!NMXI#Q30PMU2RPF$8\B/5)(SA&W).(MR3LW)$PMSR[LWFTU7?V
M:@KW]PMM6J6(;-9]%V[T$\!#-!-%?R_,$T-B-RCFAFAA$XSC(@('8Q=V-1"U
ML>US*Z;H.PNUS-86HXD'B"36LG6A=BC]YL[2>8>\VY'WOPM]\&UY'"VG2:VY
M:LBQI[^N5D3>_J1/XO-W<41K3WWMICT_U>J/\-S81Z9H!4QV/JQ]7AUJ-2N'
M6[$;A#!'&/43,S.72+<NS,SOY\-[E]Q?C7#I !]W2 CQQQ[A9O=\G\OJ+]ES
MQG+=MOU;?[V7?BMDE\%L%"9W]7Q+XW[>L!^]LHILU"9W]7Q+XW[>L!^]LHM[
M\+O_ &AT?_7:OZV:OQO_ ((U'_5;?^Z54S_YH_;?_0ZN_P#=K_$/M;]J='_6
ME5( _P#FC]M_]#J[_P!VO\0^UOVIT?\ 6E5E/:9_P7IW^O?_ "]Q7/V<O^6Z
MI_,?^^@9P(B*EQ;4ZSWIP+Y71NK<6P];Y+3.>H,# ,CD]S%6J_2T9<#)U>)Q
MT$["7/2_DZUZ>VD_B40?W]=9G_O@SM^O^WY_Z%L9\Q#XE2U'_3UIP]SO]%$0
M^YO-_?[F\UKI](8YJ5FY0XX:E9MT^GI<>EJL\D'3TE[0\='#"3N0\</Y\JV_
MLOW^[K-7PE@S2_&.7&7]42LGM)T;XF#9\/I"?Y>1*/\ XBQ!Z/OE6$]V<>[^
M93Z2N@'4_DPQYV"0F#CCVN8F(^6?V1'A^&Z;)*JX=P;E?#UUN51<N&GTYA;0
M@\C-UE7R=J)W&/Z(W ;#<F+^PQ,SM[;*T>HD\<Z.3B?4/VXXD_WX="_\)*?A
M'=S\/:>_U8W1_=?:%7R](3?%MH?;LY[E>#,#K2S\&5#D9K=RD^$MCEGKQ,[D
M4-8WQLMF7IZ8B>L#DQ3@)SL[C;AX326!R^I]29*IA\#@<?:RF6REZ8(*E*C3
MB*:>>:4W$680%V$>>J0W&,&(R$7UL?;4[Q#,]H'?0=7V@FH:7H27].Z%PDLQ
MG\&:;>64H;ED'&,(LQJ"2"KDLP  7@2O6Q;6+<.+KVI,IX#\*9.;K-6?#>O%
MTUNRZW;[=EE<X5X\/C*:DY3?:%2>_O3K4LOQVXRTO,H:WE;19RQ_F+GYG^#B
MMOB]OF=Y6V:;%B_OXY_:Y9^%#%NACO5=09:+CR]=ED;Y.6FXFYX^NYO_ "]\
MS>#+Q<;(/U!9_P#2WZ_R^]12;TX:7(:UL4,;"=JW8*I $$ N9G9>$6(69F\N
M@68I7]P,)D3L(N[7RGZ/TV[_  *J>#.1Y>9J-#Z1496/=](I3@]V^R6TGU9P
M#;3;Z]J;+U<51'AY28[,[MS'4J 0^/9D^KT"7$8?]9*4<?+=?+7T.XU[$%33
MN)#<6W1>& :MC#:+AF%F(JQ2/'F=0NWES->G"6E7G(6(HOA"0.8;41E"AW5O
M=TSZNU!5P ,0U8VJ9/7F>AB=VK8\)"<,34F=N FN.TU+&]9<D?K63> PKRP-
M>^TYIRCB*%+%XRK#2Q^.JPTZ52N#1PUJU>,8H88P;R80 6%OE?CEW=_-5>\?
M/$)54?H?%G];D14LIQ?6O'?50?PED?#_ ""ES1VNBRQ'#&(]0REF27]YXDFL
M5/M?DKI*_;UC2MU7NOMM--2C**^VB(J?$J!$1 >.%T_NWV?-#:]J^I:TTCI[
M5%;P_"$,WBJ=\XX^KKZ(9IXCG@'J=R=H9 Y=W=_>Z[A1?M1D653C95.=<XO>
M,ZY.$XOXQE%II_-,^LX*2:DDT^Z:33_%/H06[S^CR=GG5!S6,-3U1H.W)UGS
MI?.E+CWD+Z'JQ>H:V<JPP _'SC'?!S./DQB[]2C8W)]%TO=1EI'=Z$@XY"'4
MNF2\0G9G]A[&*R0"W+\-XOJQ<-R[Q.ZM\HI#TOQ>XCQ$HUZI?9&/1+)5>5T^
M'-D0LGLNR][HNQB+N'\.>^]$%O\ J;U_P@XK^!0JUEZ-?VB:)&6+R6VN=A%G
M<&BU'E\=<D=A)^/5[VFVJ#SPPBY9'CK)NKI!GD;H?(>C]]JJ*4XX]#86R(]/
M$]?6^E6ADY%B?H:UDJT[=+NX%XD$?M"71U!TF6Q,X7E;A1[1?$$%M*&G6O\
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M0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
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M4D?1-%BGAZ-/TGY]KPXZ4AWQ9_=-D[#\-U*5Y $1$ 1$0!$1 $1$ 1$0!$1
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M0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
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M 1$0!$1 %@5WH'Q![F?8.'\*X]9ZK KO0/B#W,^P</X5QZ HR(B( B(@"(B
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M/4FDX9JV;&U@;///#MX>7KU.>'\G<2(?<[$XNSO1>7AV9_?YH#8YZ>U5B\O
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M_"N/0%&1$1 $1$ 1$0%O[N,?B4L?;OJ#]Z8=3)*&WN,?B4L?;OJ#]Z8=3)(
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M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
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M0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
M$1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1
M$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
M $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$
M1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$
M1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$
M 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!
M$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1
M$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0
M!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $
M1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$
M0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
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M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M(B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B
M(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
MB(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(
MB (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
M B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"
M(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B
M( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@
M"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (
MB( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(
M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M(B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B
M(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
MB(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(
MB (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
M B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"
M(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B
M( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@
M"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (
MB( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(
M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M(B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B
M(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
MB(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(
MB (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
M B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"
M(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B
M( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@
M"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (
MB( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(
M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M(B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B
M(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
MB(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(
MB (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
M B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"
M(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B
M( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@
M"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (
MB( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(
M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M(B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B
M(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
MB(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(
MB (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
M B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"
M(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B
M( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@
M"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (
MB( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(
M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M(B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B
M(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
MB(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(
MB (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
M B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"
M(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B
M( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@
M"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (
MB( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(
M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M(B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B
M(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
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MB (B( B(@"(B (B( B(@"(B (B( B(@"(O#(#RB(@"(B (B( B(@"(B (B(
MB(@"+PO* (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (O'*\H
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M0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
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MOT^]ERG">EP=D.V3#/;W,QC.Y,YWMOKT@BS-RSNV-N9 ^"?V1Z1)^?HF$?-
M6=44'^W'I'_8LU//'5J[X8G$V9./8U7IS6ND*X.3DS,62U+IO%XEWX'J)X[Y
MB#./6XN3,I/MH>UEM?N!7AM:'W$T5JV"P[#7DT[J;#Y9IW+Z%HFI7)BDZOT/
M0S]7R<H#()$1 $1$ 1$0!$1 $1$ 1%XY0'E$1 $1$ 1$0!$1 $1$ 1$0!$1
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MM*[0XZ7Q BN1?_9OJB.(G;H,<CF:%#"0V8V;EB;3LT/).)1R,S$]4B.,0%A
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M6TM<8MN=UN@ +1.>N5Y*N?D&+KFLZ+S(D$6:@$F-CQ]F&AG*[MR>.DK/#;F
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M 3"K1M3W].R122028N&3U2[1 VSZ+!_L!]X5MGVD]"5]>[9Y<[=-I IYS"9
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MP<6+P0V]0:2M/I+5$,+$ 36VQ-J/(8#+V A9Y&I^M:>"Q.1/Z]6CZ0:G+RB
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M!]SS;[][91 85_D\W;'_ %0FM_\ %M+?Q=3\GF[8_P"J$UO_ (MI;^+JB21
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M(R>=RDT4NAIY8L=B*4^0NR10AIWKFD"M7E((@]J0F8!\W96;UB]VW_B6W?\
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M$0!$1 $1$ 1$0!$1 %I%^V!\;^[GW5=R/QTSBW="TB_; ^-_=S[JNY'XZ9Q
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M,?G2U^QY_P!R)?17SLQ^=+7['G_<B0&][K_T./\ [@_ZK+]E^-?^AQ_]P?\
M59?L@"(B U\7IIGQA;!?:;K[\-Z85*Q74_33/C"V"^TW7WX;TPJ5B (LM>PQ
MV1LKOONEIK:C!Y:GA,UJN+.AB<AD*TEJBV0Q&G\IG*U2V$,\$L4&1DQHX\[@
M%(]#UEKCUK;0/6EZ#W.VQU%HG4><TAJ_#W=/:HTUDK.'SN%R$3Q6\=D:A],T
M)L[,TD1CTSU+43E7NU)8+E626M/%(0'W]AM\-4;9:UTQN%HK)GAM6:/RT&9P
M>1!G(8K,0G%-6M0L8-:QV1J2V,=E*1F,=W'6K-61V&7J;;G]TAWH6E>U1M70
MUIB&@Q>JL9X.*U_I)IO%GTWJ,(W>1HG)ADL8;*"!7\'>(1>Q2D:.88[=>S#%
MIV%GWW:O>):T[,6Z.+W(TAUWJS V,U=I62V56AK#3,LP2VL3:/IECAN0&+6\
M-D3KSECKX,8B\$]F.4#<ZHL=>RAVJ-%;U:!T[N3M_EHLQIC4E-K-687!K-.Q
M&3PWL5DZX&;TLMB[82TLC2,G.O:A,>3#H,LBD 1$0!$1 $1$ 1$0!$1 8[=K
M[XI=T?N=ZV_%K)K2#X?\Z5?V/!^Y"MWQVOOBEW1^YWK;\6LFM(/A_P Z5?V/
M!^Y"@/HK;!^C$_2/[+?LC=/^&;<-:GQ;8/T8GZ1_9;]D;I_PS;AH">U$1 $1
M$ 7YRRB D9D(  N1F3L(B(L[D1$_#,(LSN[N_#,W+^2_14._2:>_6LC9S/9I
MV;S<M;PF]3W;UIAKI0V!D<G\;;W#7*IM- ?0(MJ^Y#+&;P3?,_&1-+EQ #YG
M?P^DNVY[.=V6[-F;]6K5SR&$UQNSC9)0M2S@[U+F%VZO121/7:O(-B&]K"'Q
M7DD$1TW,(A\*E1F\^2)W(R,BDD,R(Y))#)SDDDD-R.220W<Y)#(C,R(C)R=W
M?^0 1%A%F$19F$6;AF9FX9F9O)F9O)F9?T@"[9V2V$UON5GZ^E=O=(Z@UIJ*
MUTO'B=.XRQD;$<9/TM8MG$/JV/J,3.SW,A/5J"XOU3-PZG+[FST>W7W:9EI:
MUU7+<T#LP$X2/GI*[MJ#6L44GSZIHVI.+1QT9.DH9M3W&*G%R[XRKDY6<H-D
MKV.NPIM3L'IB+26U6C<3I;&MTG?M5H6FS6<M](B>0U!FY_$R>9OR=(MX]ZS*
MT,8A7K!!5BA@C I#=B7T.[7.H(*>7WZUY#H*O*T<LVC]#MCM0:FBC(0)Z][4
MEL+>FZ-MNHPE]0I:BK12Q.\5FU'(QA:.[+OH^O9.VICJ'BMJL3JC+U? )]0[
M@D^LLO/-"S\SDV4$L56>9WZY:V.QE*@Y<>'4C%NE31(@..Z6TCB<%2BQN$Q>
M.P^.@Y\"ABZ5;'TH>KW^%5J10P1\_+T1MS\JY$B( O"\H@/"Q$[0'8"V2W4&
M9MQ-JM":MEL$)S7,OIO&39*0P9Q BR@UPR+N#?0_FK@7829NH1=LO$0%0?M>
M>A\;*:G"UD=H-6ZIVMS!QOX.&R$[:RT6<[/*3&];)O'J>B\I2",GJ^I)J444
M,85<9"3RG)3F[P'N4NT'V;Y+5W6VCY,QHN$S>'<31[R9O2I0"_LR99XHQR>F
M9NCVY(<[2JU1Z9?5<A>AA.=;A%>CDL96N5YJERO!;JV8SAL5K,4<]>>&07&2
M*:&42CEC,7<3C,2$A=V=G9T!HG&?EN6]S^Y_D=OJM]9>5L.>^']%BTQJZKDM
MP>S/C\9HW5\3';R.V4;ACM&ZE 0(I6TT(\5M)YER9B@IPQQZ?NF9Q'%C3<++
M:^+5&ELK@LGD<)G<9D,)F\/<GQV7PV6J3T,IB\A5-X[-'(4K(1SU;4$C.,D4
MH,_N)N1<2<#.+NY^\IW.[,.N!UGMUDF.I=]7@U7H[)362TQK#&PRB?J^4J12
M,U?)01^(&*S]8/A'%%-*T;STYK=&UM;N[=[R;;KM/;?5]=Z!MG#-7E#'ZITK
MD"C'/Z1SGA!-)C,K"'LR121FTV.RE7Q,?DZS^+5E>2.S!7TR:S^[M?O%M<=F
M/<_$[AZ/GGM4&..EK'2)6S@Q>LM-F3^LXRZ#L<,=ZMU/<P>3>)YL;D8HR8WI
MSW:]@#<Y(L?.RMVG=([R;?:6W*T-D0R6F]5XNODJ4GLC9J22 WK>+R,#$[U,
MIB[+2T<C4-^JO;@D#VA82+(- $1$ 1$0!$1 $1$ 1$0!$1 8W=LGXH-U?N;Z
MY_%C*+2'X?\ .E7]CP?N0K=X=LGXH-U?N;ZY_%C*+2'X?\Z5?V/!^Y"@/HJ\
M5W0/HU^PF_O9VV[W9UGJ'=2CJ75D6HSR573FH].4<-$^(U=G\#6]2JW]'92U
M$Q4\77.9I;T_58*4Q< (8PHZK;,>C2?23;)_L?7'\)&L$!@Y^4[.RY^FS>_[
M[M(?\/D_*=G9<_39O?\ ?=I#_A\K7:("J)^4[.RY^FS>_P"^[2'_  ^3\IV=
MES]-F]_WW:0_X?*UVB JB?E.SLN?ILWO^^[2'_#Y/RG9V7/TV;W_ 'W:0_X?
M*UVB JB?E.SLN?ILWO\ ONTA_P /D_*=?9<_39OA]]VD/^'RM=H@*A.I_0S^
MSW/$?P/N?O=C9R(W![V3V_RU6-BYZ :"/;[&62&-W9N9+Q2&+<%)UNYK"3=G
MT+.Y'$1Z#WZ"S-R1#7UCHL8P86%^B-K>"RX\D1,S/*5,6%G?YV_RWT40&I=[
M5/HXO:UVJ">]+MV&O\% )R'F]M,G!J3PH@ZB<K6 F'':IB<(A>68Z^$N4X68
MA>Z?#.4'^4Q=JA;LT+]6UC[]*8J]VA?K3TKU*P'D=>Y3LQQ6:LX?HX9XHY!^
M466]B47_ &_^Y[V%[2%"9MP-%T8M3M7D@QVOM/10X76F.(N2B?X9JQ#)E:L$
MKO*&,S89'&]1S.-4"GE,@-.>OSEA"07$Q8Q?CEB9G;R=G9_/Y6=F=G^1V9V\
MV;B:WO;.X\W0[*61^%,@3ZSVLR%UJF$W$QM,Z\5>>=S>IBM78\2F' Y:8!<(
M)FGFQ63E _5+$4Y#1&%9 72>XC]):R&D[.%V<[2&=]<T<4<&,TENOE[,TF1T
MU+UQUZ6'US<E\3UW $!-%7U5:DCL85HA;.RVZ,AY+'["&"P$L82Q&$L<@#)'
M)&0F$D9LQ 8&+N) 0NQ"0NXDSL[/PZT29@Q,XDS$),XD+LSL[.W#L[/Y.SMY
M.S^3LK[/HN??76<J6/[,6ZN8EM9*..7^9%J?*VREFNTZM8IIMO[]J<G*6WCZ
M]>6UI>>:4IK=)IL*W5+1H#.!>91$0!$1 %JY/2ROIPLE]S+0'[IJ!;1M:N3T
MLKZ<+)?<RT!^Z:@0%:I$6<O80[ NL.T/E];Z8T%+!)JO2>WV5U[C,'/"Y%JO
MX&RF&HV=.TK7CQ!0R=JOE9+.-GGCLU[%NI'CI1KM=]=J@8-+,+L%]N#6G9UW
M0P.ZNA)(BRN)&:CE,3:,X\=JC3=V2 \MIK*%'R8U;WJT$]>P(R'C\G5HY&..
M4JO@R8CWJ,]6>>K;KV*ENK/-5MU+<,E:W4MUI3@LU+5:80FK6JT\<D%BO, 2
MPS1G%((F)"WJH#==]A_MHZ)W_P!MM/;G:!O>M87.5^FQ4F<6R.#R\ @.3P&7
MA%W]7R>+L$\%@/,9!\.Q"1UYXI"RU6HU[D7O<\WV5-RPM73NY/:G6%FE1W$T
MY#(9O7C O JZPP]8G>+X;P4<CE/$ QR9G%@>-.8)(Z,D&V4VVW'P6L-/X;56
MF,K2SFG=18RGF,)F,;.%FCDL9D( LT[E6>-W&2*:&03%V?EN7$F$F<6 YLB(
M@"(B (B( B(@"(B *&+TAOZ2[M ?:?6_&+"*9U0Q>D-_27=H#[3ZWXQ81 :B
MQ>']SKRO#^YT!N<NZ=^E8[-/W -F_P"#K3BS_6 '=._2L=FG[@&S?\'6G%G^
M@"(B (B( B(@"(B ^3G\[4Q=&[D\A/'5H8ZI9OW;4I=,5:I4A.Q9GE)_(8X8
M8SD,OD$7=:9OO/NVI<[0>^^X>Z<TTLF*S.8*AI&O(Y]./T5A&^#=-58@D87B
M\>E$^6M#X4+GD<G>G.&.68Q5_?TK#MY-M?V?2VVQ%OP=5[X37-+"$1LT]?1-
M(:TVM[1BSL35[U&U5TV1>?4^=Z6%V8SCUB+-Q[D!Y62MGLDZYBV@K;YGB)6V
M\MZ^L;<Q93ID8WSM?$QY7UCH>-A?$2&4V(#(B;PMFZTN,+BSTB_2N@M"9C5.
M=PNF-/4SR.>U'EL?@\+1CYZK63RMJ*E2A=V9^B-YY@>:5_9AA:28^  G;;-Z
ML[GS35GL5GV5:STBL5=N@QU#/250$'W+J5OA:OK*6(&*5GFUF/PG. R%9:C*
M=..RQ,$K :CE9?=@/M;9+8G>;;S=G&/*1:/U!#9R=:+EWR&F\A#-B=3XT@%G
M>5KF"O7@CC9N?61KR X2QQR!BYJ?3&2P>3R6$S5*7&YC"Y&]B,MCYW%Y:.3Q
MEF6E?IR$+N!'6M0RQ.8.0'T=<9$!"[_$0&] V^UYB=4X'":FP-R+(X346)QV
M<P]^N;'!>Q>6IPWZ%N$Q=Q**Q5GBE F?AQ)N%S!5+/1)NWRVO]F,ILOFK;GJ
M;9F>"/$#-)U2WMO\]/;GPIP\@)$.!R,60P4T?7.]6H&'<CCCN5X([:: (B(
MB(@"(B (B( B(@"(B (B( B(@"K^>E#_ $DF[/V3VO\ X6-$JP&J_GI0_P!)
M)NS]D]K_ .%C1* U22(O3R,Y15YY!XZHXI#'EO+D <FY^MRWGYH#W%_)@)"X
MDS$),XD+MRSL[<.SL_D[.S\.WU%++WP_=]%V?]Q]/U\54GBT+N-H33&NM%3R
M%-,$7K6)H0:GP969BD*6WA\XY6#8YCD^#LQBI7$&E8 B<0&TA]&#[Q+^;-L#
M2T5J#*M>W V=]7TIE_6)WDR.2TL[3?,7G;'B&4\Y'BX"PERZ75ZSD,-9GDD>
M>>01LGK3S]RUW@;]FSM Z3U[>GEBT?E1/1FX,<?60/I+.VJCRY*2(&=Y?F=R
M5:AG6Z6*5J]*Y'"!G.\4FX-H7X+4$-FK-%9K68HYZ]B"0)H)X)@&2*:&6-RC
MEBEC(3CD B P)B%W%V= >VB(@"(B (B( B(@"(B (B( B(@"P,[S/MNXGL\;
M):[W4R7@3V\%B98-,XN>5H6SFKLBST]-8<2Z9"8+>4E@>W($<IUZ$=NUX9M
MXOGFM;1Z6=WB/\T'=C$[(:;R0S:4VE:2YJ8:DXR5\CN)E8 &2"PX.[&>D\.3
M48XO^HOYC+!*SS01- !5.UQK;+:FS>9U)GKLF1SFH<MD<YF;\KD\ES*9:W->
MO6"ZB)V:2S/(0!U.T8=,;/P++BZ+/SNO>Q!D^T3OIH/:RD-B/&Y7(OE=79&"
M,S;$:*P3#?U#=D,'%JYVH1BP>/F.2-FR^7QT8D\A@! 8!HN?[LZ?JXC5NK<1
M1$@HXC5>IL31"0WDD"EC,Y>HU DD?SD,:\$0F;^9DSD_FZX @-DKZ&K]+1N-
M]W_4G\&>TRMMJI)Z&K]+1N-]W_4G\&>TRMMH B(@,7^V]\2V[WW+]?\ XJ99
M:1[#_G2K^QX/W(5NX>V]\2V[WW+]?_BIEEI'L/\ G2K^QX/W(4!]%7D.Z']&
MKV#W[[.NV^[6L]0[JT=2ZNKZCER=73FH].4<-$6(UAJ' 5FI5+VCLI:B$J6*
MK',TU^PYV"FD%P @BCHWK;0^C5_22['?L/6_\)FLT!@G^4[.RY^FS>_[[M(?
M\/D_*=G9<_39O?\ ?=I#_A\K7:("J)^4[.RY^FS>_P"^[2'_  ^3\IV=ES]-
MF]_WW:0_X?*UVB JB?E.SLN?ILWO^^[2'_#Y/RG9V7/TV;W_ 'W:0_X?*UVB
M JB?E.SLN?ILWO\ ONTA_P /D_*=G9<_39O?]]VD/^'RM=H@*HGY3L[+GZ;-
M[_ONTA_P^3\IV=ES]-F]_P!]VD/^'RM=H@*HGY3L[+GZ;-[_ +[M(?\ #Y/R
MG9V7/TV;W_?=I#_A\K7:("J)^4[.RY^FS>_[[M(?\/D_*=G9<_39O?\ ?=I#
M_A\K7:("OEV)/1K]A=A-R\!NIHS4.ZE[4>G R 4*VH]1:<O8>1LE2EHV/6JM
M#1^+M2.,,Q%$\5V'HD87?J#J K!J(@"(B T/F%_.=7^T1?Z@KZ:^9A?SG5_M
M$7^H*^F@+C'<0^C\[*=IS8R3<O<'.[DX[/AKC4^FVKZ3SV QN*]0PS8YZDGJ
MV2TKFK/K1^MR^/)ZYX9\#T0QLS]4SOY3L[+GZ;-[_ONTA_P^7+O1"_I2IONL
M:]_U<(K1J JB?E.SLN?ILWO^^[2'_#Y/RG9V7/TV;W_?=I#_ (?*UVB JB?E
M.SLN?ILWO^^[2'_#Y/RG9V7/TV;W_?=I#_A\K7:("J)^4[.RY^FS>_[[M(?\
M/D_*=G9<_39O?]]VD/\ A\K7:("J)^4[.RY^FS>_[[M(?\/EQ#47H:?9SFCD
M^"]R=\L=.3\Q^L9K;_)5(O9=N/!?;JI:D;JX+VK_ #QU"SMR+C;J1 42MTO0
ML(6A,]#[^V_6'D;HKZPT55F@"+S=V*W@LM3DDD?R%G:G&(^9</Y H2.U)Z,C
MVM=M8YKU#1F.W0PT+.17]N<M!D,E&'4XB\^E\K\%YXY"9NMX\/6S81@[/+.+
M]3-M;$0&BNU7I3*X')6\+G<7D<)F*$GA7L3EZ-K&9*G)Y\#9HW8H;,+EP[@\
MD0L8\$#D+L[_  %N>.V]W8^R/:'Q+XW=+0F(S5V&&:/&:HK0!C=7X1Y@Z"/$
MZEI#%E*\;NP224CGFQUB2& [5.=X8NC7,=\)Z/;N-V86MZRP%JUN+LYZP _-
M3#3\//Z3&P73!7UKC:D;UHJ@S.-6+4M'HQEB22NURKBIYP@<"O88,0N),Q"3
M.Q"[,[.SMP[.S^3L[>3L_DK6O<5>D99S8^;#;4;TY"[J#9KYWC\+J2P]S)9_
M;,7DX@!S%[-O,:*K@11'BQBEOX" 8'Q!%C:WP6U4SGZB.@-ZKIO4F/S./I9;
M$7JF3Q>2JP7L=D:%B*W1O4K40S5K=2U <D-BM8A,)89HC*.0"$P)Q=G7VUKM
M?1@.^IL:'S^+[-NYV6DDT3J6Z4.V6?R=QRBT?J"P/(:/FEL%^9].9^<";""T
MC0XS/S^IQQA5RS%4V)2 (B( B(@*BGIDOTO.WGW8<7^*.KEK>ELA?3)?I>=O
M/NPXO\4=7+6](#OSLG_&OM5]T_;S\<<*MWHM(7V3_C7VJ^Z?MY^..%6[T0!$
M1 $1$ 7!-SMS=/:,T]F-5ZLS%#3^F]/T+&4S6:REB.I0QU"J#R3V;$\CL(B
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MV5LN4VK]/T:S&VD[]J<G.SJ?3]:&8\?++*4^:P40CTR7L5:GN70T 1$0!$1
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M=K7.TVI/$EOZ/S4E2K?.)X1S6"M1A>T]GH!X87ARV(L5+).#,$=I[-;@3KF
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M)W:4KV/!ADLX#,2@ !%J/ D?@V1<6')4/5<M [O/:@J7R/16OI-=$?;/K_\
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M_MP#\#T5/$L#^P-V)6V.T]FL"VIGU1\+YALMZV^&;"^K\4X*GJ_@-E<KXO\
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M-6"'X1TKJ6M&#WL7;!B+Q*\G4-S%7HR."_CIX)A,9FL002$H B(@"(B (B(
MH8O2&_I+NT!]I];\8L(IG5#%Z0W])=V@/M/K?C%A$!J+%X?W.O*\/[G0&YR[
MIWZ5CLT_< V;_@ZTXL_U@!W3OTK'9I^X!LW_  =:<6?Z (B( B(@"(B \.M6
MCZ4#V]I=WNT9?T7BK92Z+V7A/2>-".0"K9#5EH(;>L,PS1\B;P6'JZ=K$9&4
M0XB[)'X8WY0?8!=[SVYH.SOV?MPMR(YJX:BK8B;"Z'@L@4L5O6^=C/'::"2
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M]5JPW;,T76;POFJ4U#4$0NXB4&5B., C(1:7% $1$ 1$0!$1 $1$ 1$0!$1
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M4,OBK<-_&92G6R&/NUS:2O;I7(0L5;,)M]%%-#($@/Y<B3<LSH#[B(B (B(
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M- ;./T0OZ4J;[K&O?]7"*T:JN7HA?TI4WW6->_ZN$5HU $1$ 1$0!$1 $1$
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M;6Z8C%L5H_!U,9ZPT;1R9*^PO-E<O9'DG>UE<E):OSN9R%XEAQ>0^GE90(B
M(B( B(@"(B (B( B(@"(B (B("M[Z4KV/Z^Y?9<S^JZ],9M1;.W(=?XRP(.5
MF/#0]-'5]:-Q'EX)<%-+>LQF8P<XR"R;%-4KN.K16\FWFVXHZQT?JO2.4KC;
MQFJM-9W3>1JFPN%FCG,7:QENN;&Q!TS5[4D9,8D/!/U,[<LM2Q>]'][8U*>>
MG'L/J^_'4FEJQWX;NE1BNQUY"BCN1C+J1I1"R -.(R-UBQLQ<NSN@(>K$(R
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M\O>WD_N?S;Y?-?J@-JKZ+KOU3UKV0-#XZ*;Q,CMWEM1[?YB'@!>M-C,@^5Q
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MD+&[>\G#@0+FB(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
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MDJ]RO7N5)XK52U#%9JV:\@306*\\8RPSP2QN02PRQD,D<@$X&!,0NXNSKW4
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M,MD];S\OYNS-+J A$'\X@$8O+HX8"85$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$
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MI *3PP .KI$68#>3(M(1_/6;K?V5=SO\H6L/]\I_/6;K?V5=SO\ *%K#_?*
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M*G]55_\ #Q?[2 \? U3^I:_^!C_V4^!JG]2U_P# Q_[*\_#%3^JJ_P#AXO\
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M?*Z?U-B,=GL)DZDL<U:_BLK4BO4;<$L1'')'/6GCD$@,A=G\G= <X1$0!$1
M$1$ 4/O?C=XM!V;-@M2ZKI6XHM<:CYT?MW4<N9Y=49>M8Z<D,0DQ^JZ=Q\5O
M.6YWZ8@]3@K]3V+=6">8):J[TEKO%2WR[061TS@KS6-OMG3MZ0T^\$_B5<MJ
M,FKOK+/N -X74&5A+3M$F*9_4L,=H90^$Y*M<"N[&+L+,1'(7Z*20NJ20W\S
MDD)_,I)"=SD)^7(W<G?EUYD-A%R)V$19R(G?AA%FY=W?ZC-YO]1E_2EW[C_N
M[Y>TEV@-,:4NQ$6BM+R5];;A2L)N$NG,-?K%'@7,';PY-47_  <.YN0O'1DR
M,\;O+  D!>?]%_[N0MF-AH-=:BQ\E/<#>7U35&4AM0-%<P^DXQF;1F"E8XQL
M12OCISSU^M,3/6R&:FJ%%')5D*2RTO7J5(J\44$$4<$$$80PPP@,<4,48L$<
M448,(1QQ@+   S"(LPBS,S,O80!$1 :.??[XP-P/M]UK^,^574Z[8W^^,#<#
M[?=:_C/E5U.@-DKZ&K]+1N-]W_4G\&>TRMMJI)Z&K]+1N-]W_4G\&>TRMMH
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MP-4_J6O_ (&/_97GX8J?U57_ ,/%_M)\,5/ZJK_X>+_:0'CX&J?U+7_P,?\
MLI\#5/ZEK_X&/_97GX8J?U57_P /%_M)\,5/ZJK_ .'B_P!I >/@:I_4M?\
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M=G;F/+$WEY^8EDW$F^JSL[/[G9V7:6CNY=[)>"D&6AV<]GRD NH"R>AL%G'
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M/&X'_P F"_WTMPLB T]/Y!=VP_U/&X'_ ,F"_P!])^07=L/]3QN!_P#)@O\
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MPNIL!?K97 ZBQ&-SN$RE*:.Q3R6(R].'(8V_4L0D<,]:Y3L0V()HC..6*0#
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MM3^=,VK_ +&>W_WF:<_W:L@40&/W\Z9M7_8SV_\ O,TY_NU/YTS:O^QGM_\
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MQQ&XXNO6D:1JD<A 0.+YV8_.EK]CS_N1+Z*^=F/SI:_8\_[D2 WP*(B (B(
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MV@/MRJ?BQ@$!$2KP?H4W_2/M(?87:7]_;DJCXKP?H4W_ $C[2'V%VE_?VY*
MOVHB( N&[B_]'L[]ALI^\9US)<-W%_Z/9W[#93]XSH#188?\Z5?V/!^Y"OHK
MYV'_ #I5_8\'[D*^B@-J%Z*U])KHC[9]?_C7D58N5='T5KZ371'VSZ__ !KR
M*L7( B(@"(B (B(#^#!B9Q)F(29Q(79G9V=N'9V?EG9V\G9V\V6M8])7[DO^
M8OG[V^VVF/$-J-6Y:%M586J!,&@=6Y>R\;68(Q'HBTKJ2])&-?S%L5G;3T>'
MJ9"D%?95+A^X6W^$U9@LOIG4F,IYK 9_'7,1F<3D(1L4LCC;\!UK=2S"?D<4
MT,A@7N)N>H7$F9V T7Z_DP$A<29B$F<29VY9Q=N'9V?RX=G=G;Y?E4TO?;=T
M1G.RCN3ZE1#(93:?5TMJWMWJ:U\_DB&(BEM:/S=L!$'S^$A*,HIY(X/AK&$%
M^ "FKY(*T+B V%_HQ??>2:XQ]#LY[N9UY];XB"2/;#4>3-AFU;IVC4:5]+7[
MAE^:]3Z?KPV)*,TC#8S& A#K>SD<9>LV[H*T56F=39+"Y+'9G#7[6*R^(O5,
MGBLG1E*"[C\C1G"S3NU9A\XYZ\\82@_#B[CTF) Y"^U2[@WOF<9VH= /@M36
M*E'>C0F/H0ZSQ@"]>/45 ^NI2UOAHB9HY*V3DKD.;I5#E^ \L;1S1UJ62P[V
M + :(B UZ/II'QF[#_:+K7\/X-4O5="]-(^,W8?[1=:_A_!JEZ@)L?1R?IV=
MA?LKKC^"K7BVWZU('HY/T[.POV5UQ_!5KQ;;] $1$ 6K0]*Z^G'U!]SS;[][
M91;2]:M#TKKZ<?4'W/-OOWME$!6^5KST._Z9S6/W&,_^-^BE5#5KST._Z9S6
M/W&,_P#C?HI ;+1$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1?C8ZN@^CR+H+I?Z
MA</T_P"=:E7<#OZ.VC@]0ZBP=C?3403X/4.=PLP_ ND&Z9,1EKF.-N/@ ^."
MK.W'6?'NZS^B<#;8(M1'^6#^V7_9VU%_^!M(_P 7E>6]&-[=^X.^^RNK<IN;
MJFUJ_5>FMP\AAY<M=KX^K8;'6<5BLGCZKPXVG2KM'!%:)@/PG,W<W(W+EF L
MC(B( B(@"(B (B( B(@"(B X7N'MU@=78/*::U1A\;J#3V:IS4,MALO3@OX[
M(4YQZ9:UNI8 X9HB;SX,7<283%V(1=M6YW_O<KGV6]9TM2:(AN6]EM;6#AT]
M)9LV<A<T=GHXY)[.D<I=M'-;M5):X/=T]E;<\]BU -O'W9/6J$5C(;5=1U][
M%V/<?OMV>]S]N+@ US):=L933MLFY/&ZKTZXYW3=^-Q$I&"/+4*T5R*-P*YC
MI[N/.0(;<CH#31HO#!(/LS1E#,#N$T)?10S _3+$7DWM1R,0%Y-YBZ\H#:$^
MBE=KBSN-V8H=*96T]C-;0:ENZ&?Q"8II--RU*><TK.7#,_AQ4LC8PL;R.\IG
MA)C)W$@(K,ZH >A9:ZLQZLW\TPS\4[. T-J$A\O:MU<AG\8)/Y<MTPV79O:X
M?J?R\N5?_0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 6D7[8'QO[
MN?=5W(_'3.+=T+2+]L#XW]W/NJ[D?CIG$!CNMCWZ&O\ $!N1]UV]^*6EEKA%
ML>_0U_B W(^Z[>_%+2R MZHB( B(@"(B (B( B(@"(B (B( B(@"(B CH[V+
ML30=H38'</;#HB^%\KB6R6E;,@B[T=78*8,MIVS&3G%T=>0JQT['$L0S4K5J
MM,?J\\PEIJ[%2Q7DEK7*TU.Y6EEK7*=B,HK%.Y7D*"U4L12"$D<]:>.2":,P
M$PDC(3$29V;>UK6/^E,=VC+M)O)_-<TUC&AV_P!X[-B_>.L+-!A]R6>:UJ&K
M-%& A6BU) \>H*4C^5O(_#[&XRQ@4X%6]6W?1/.\MAVWW-R.P^J;;5]);MW"
MR.EK<\[A7Q6XU*A%"%,P/YU%#JS"T!I!.)QDV7Q6)J$$[Y$#J5(E[F.R5JE9
MK7:-JQ1O4;->[1O4Y3KVZ-VI,%BI<J3QNTD%JI8CCL5Y@=CBFC"078A9 ;V1
M% /W!7?#8WM/;:AB-1W(8-X] T<?0US0,8J[Z@@\+P*>M\5 #M&=+,'#(V4@
MKB(XK,-/7*&"I8QSSS\( B(@"(B (B( B(@"(B (B( B+ #O+.\,T;V9]J\W
MN1JR1K,\ M0TOIR&6,<EJK4MIG#'8B@!D+M&QOZUD[G]"QV+@M7).7C".0"N
M)Z7!WEH:7T7B>SCI:Z#Z@W B#-[@R03MXN)T/3G!\?AYXP+J"?5V4C=_GK='
MP1A\@'0Y7:\L6O)7=W:2[1&J]VM>:JW(UOD"R6J-7Y>SELG/R_@5VE=@IXRA
M'P(P8S$T@KXW&UP !BIUHF<>MS)^D4 =^&=W\F^J_P G\O\ ZUM!_16NP\>U
MW9QJZYR]+U74^]-V/64WB1N%F+24(2U-$US(F8O!M8HI-00Q\] MGB+AC,V:
MB-W-W=UY#M,[Z:8T,5>5]&XF:#4^Y&0#AHZFD,;9C*?'-([$PW=2V6CP5(>D
MG$;5JYTE'1E9;@_"X>KCJ=3'T8(ZM*C6@ITZT(],->K6B"&O!$+>0QQ1 $8#
M\@BS(#Z:(B (B( B(@*+GIFG9/*6AM'O=CJW_-UG*[<ZLF "?\RY1H\WI*W*
M0^S''5O4\]CS.7DI9LQ0B P\/HDH9+<@]\+V2'WN[-F[.@*U<+.<MZ5O9C2@
M'Q_TMTV'P[IT!(G88WM9.A!1*8F-H8K1RL)$#+3=QFY").) [LSN!MTF#_*$
M@OYB8/R)B_T),[?(@.Y.SUO=D]M->Z+W$P[RMD]#ZGPNIZH0%T2S_!-Z&S9J
M ?Z%[U,;%)RX?@;!?K+=I;5[CXK6.E]-ZNP=J&]A-58'#ZCP]ZL;2U[F+SF.
MKY/'VH)&\I(;%2U#+$;<,8&)-Y.M&8MIAZ+-VK0W%[*NG].6)RES.TF5O[>W
M@D<RD'&UNC*Z9-R,GZX_@+(U*L11LT,;4RJA[=>01 L):^UOCM,X+,:CS$[5
M<5@<7>S&2L$X,T-''5I;=H^9" .1AA/I8C%G+ANIN>5I+^T[V@LKNQN/KK<W
M-R')DM=ZIS&I96,S/U6MD;9GB\;$Y^TU;$XD:.*J [-T5:<(NW+.[[+CTISM
M<EMKV6LSIO'VO S^[N9H: I]!=,P825I,OJVP/E_0SP>.FPYN+M)'+F8) ^@
M(AU:K( MBWZ'3V2RT_M!KG>'(U&BO;DZJDP6 F(?;ETEHH7HG.!\^<=G5<^H
M:_AN/(_!8RL;M-TAKO-.Z6R>=R..P>$JR7LUG,C0PN&I1,Q2W,OEK<..QE2)
MG\GDL7;,$(,[LW4;=7#<K=C=COLY8W:':S0.V6)8'I:)TKA]/C)&Y$-B>C3C
MCN6V*01E/UNYX]GKE;Q2\7F1W/J= 9)(B( B(@"(B (B("E%Z9-V/I,MHK;/
M?+&0.4VBLM;T-JH@ >?@#5QP6,%>F-W8FCQNHZ#8T #K(CU-UD/APE)'K[%N
MI^\*[*]7>W9+<W:VR\4<VL=(9G&8JU,+F&/S_JDD^G\D3")&XT,S#1M2C'Q)
M)#')$)#XG*TLV4P]W'6[>-R=66CD\;;M8[)TIVZ9J61H6)*=^G,WN:6K;AF@
MDXY;JC?I=VX= >SI[4=_#9''9G$S^K97#9"CE\59\_S-D\7:AO8^QY>_P;=>
M&1V\^6'AV=GX6ZG["7:<H;S[-[:[I8YQ:'6ND</F;$+&,A4LK)6&#-XR4P$0
M*?%9F&_C;/0+ UBK(P^3,M*"MB5Z'1VN6S^UFOMF<A:<\AMSJ"/4F#@D)NLM
M+:U.U/,,'43D84=1TLFTX@+1U@R-'JX*RSD!<CD,1%R)V$19R(B=A81;S<B=
MW9F9F\W=_)F;S6FI[VWM73;U=I#=W7OCE/BK&K\GI_2_)F8!I+2=B33V .)C
M9GB'(U:#YN:!N0AN96T G(S>(>T'[Z_M=-LEV8MU];UYABS1X!]+Z7%_#(I-
M3:PL0Z<Q)C'(<;2QX^3(GE[@"32MC\=<DB8I $7T[D,?0 CR1=(L/43\D7#<
M=1/\I%[R?Y7=W0'ZJ]3Z&;V2QDDW9WROTV=XI:6V&F;4D3.[.$-+4FJSJROP
M0"7K6G*UA@8HYC@8')I*I"U$^U.T44DKL[M'&9NS>]V 7)V;GY?);D/N=.R*
MVQ_9NVKT!/7]7S%;3D&;U,+B0R%J?4I%G<[XPFS&,L-Z])5*-W)H6@&",GBC
MC0$FB(B (B( B(@"TK?>/?3&=H3[N^\?\(^I5NI%I6^\>^F,[0GW=]X_X1]2
MH##-;";T+7XL-\?NDX/\4J2U[*V$WH6OQ8;X_=)P?XI4D!=*1$0!$1 $1$ 1
M$0!$1 $1$ 1$0!$1 $1$!3L],Z^(W:/[L8?B'K):Z);%WTSKXC=H_NQA^(>L
MEKHD!E'V&_CMV;^ZKMY^-N(6[-6DR[#?QV[-_=5V\_&W$+=FH B(@"(B (B(
M B(@"(B (B(#PM0)W]NV4>D>V-O]B(8PBAFU=CM00QQLPQB&K=(Z;U231L(B
M+"TN8D%V%N!D8P=W(2=]OXM65Z5KIF*AVR-26H^GJS>W^WN5G81<7\:*CD,(
MSF[N[&;P8:#VV8?G;1AQR'4X%<17+?0OM=RUMV][=,LY-!F=N=-9TQ8G8"ET
MUJ:UCXW(&9Q(@#5DK";DSBQFPL3&71325I#T1#4S4^U3E*'6(EF-J=4PL#@9
M%(U++Z<N.PF/L1N+@).\GD3>R/M(#9P(B( JR_I:_P!*!D_NC;>_A:56:%67
M]+7^E R?W1MO?PM*@-7NOG9C\Z6OV//^Y$OHKYV8_.EK]CS_ +D2 WO=?^AQ
M_P#<'_59?LOQK_T./_N#_JLOV0!$1 :^+TTSXPM@OM-U]^&],*E8KJ?IIGQA
M;!?:;K[\-Z85*Q 38>CH?3G[(?9/5'XCZE6W 6H_]'0^G/V0^R>J/Q'U*MN
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M<=D:L]'(XVY;QV1H60\.S1R%"Q+4O4[ /]!/5M0RP2CYLQQOP[MYK>P+6/\
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M5</N!IWUK*;=:ME$V^"LP<+C)B\H<,<LUC3>;88ZV7JC',<3A7R5./UZC6=
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MJ%OA^B0L3B;6=RM=G^A<X6SV(D)F\P:87=^#9FO&H B(@"(B (B( B(@"(B
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M6PF]"U^+#?'[I.#_ !2I+7LK83>A:_%AOC]TG!_BE20%TI$1 $1$ 1$0!$1
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M!2<*,>GLZ^4RDT0OE-4:BRF+EAR>H<P8ES/?OR-& 1^+X5.E#4QM1XZE.N
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MG5@$YK-NU.<<%:M"!S3S&$48$9,+@=X]ESLU:KWBW#TEMCHBGZ]J?6.5CQM
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M (B( B(@"(B JX>D;]R0&_NEY=V-M<7%_-GT;BQ";'UAAKEN'IFD12R82P?
MC+J#%P'//INU.3%.X_ <L\5:Q!)5UD<\$D4DD,T4L$T,DD$\$\9PSP3PF44T
M$\,HA+#/#*!Q30R ,D4H'&8B8NS;VM4&_2>^X]#%'F.TWM'A8X\?,=O)[SZ9
MQT9 U:>0@EEW%Q=.,'B:*4GL2:VCC*)VE>+4 12R2YF9@*.:LB>CS=]19[-V
MM0V_UW?<MD=<Y4"RDUF24PV^U%9!J\6JZ0,QM'B+YC6K:KKBP@$$<.;#Y[3M
MA<K=L_\ >7AVY\G]R N:^F:Y.O=W$V N4YX;52WM]J^S5M5Y FKV:\^;P4L$
M\$T;E'+#-$0212 1 8$)"[B[.J9:[[W5[36LM;Z6VYTAJ?)_"N)VJP^6T]HH
MYP(LAC\!EKU>^6'GME*3VJ6.EK108B,HP*A1$:8F<,<3#T(@)L?1R?IV=A?L
MKKC^"K7BVWZU('HY/T[.POV5UQ_!5KQ;;] $1$ 6K0]*Z^G'U!]SS;[][91;
M2]:M#TKKZ<?4'W/-OOWME$!6^5KST._Z9S6/W&,_^-^BE5#5KST._P"F<UC]
MQC/_ (WZ*0&RT1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 %7$]*#[#=G=[LUY+4.
M"IR7-6;0Y$-?8RM!&<EF_A(8):&KL=!'&SG+-\!V)LK7A$2*>UB8*X,QSL36
M.UZ>0Q\%NO/5M0Q6:MF&6O9KSQC+!/!,!1S0S1&Q!)%+&1!)&8N)@3B3.SNR
M T3(&Q"Q"[$),SB0OR+L[<L[.WD[.WFS_*WN0Q8F<29B$F=B%VY9V?R=G9_>
MSMY.WU'=3-]^AW8=KLP;UY#"XZO(VV^N),GJC;2X[D<<&+*X)932AS.S=5O2
M5FY7J").\AX>UB+$A'++*;PS(#9">BU][C5W)T)7[/\ KO+!_-%V]HO'H^Q=
MG?UG6&@:<4?JP!),9'<S>E&ZZ%^,'*63#!C,@XD37I MU\K1C[:;F:AT9J'#
M:LTEFLAIW4VG<A!E,'G,5.];(8V_7=_#GKR,Q"3$!'#8KS!+6MU99ZEN&>K/
M-">RR[F3TD70F^M/$[?[KVL?H'>.*O2HQS7)J]'2>X5QV>#UK3-N69AQ^:M2
M1C-;TQ>\(QFM1QX.SE86E&J!:'1$0!$1 $1$ 1$0!$1 %3V]+:[QS':2VNK]
MGG 9$#UAN<6-R6K(:E@PLX/;_%Y2.^PVWA<2B^:S+8L,2%:20?7</!FXI89J
MDAL4D'?!]_3MKV7L58P6/DJ:[W@NQE%BM"8R]7<,$4M>26#,ZXM1R$6$Q,;M
M%X=( FS>3.: :=$:96<E2U;7: W_ -7[IZSU!N!KW-6,_JS4]TKV6R4[, N7
M#1P4Z5</G5'&T*XQU<?1@9H:M:,(QZCZY# Z=7\22" D9/P("Y$_U!%N7?\
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MWXI:66N$6Q[]#7^(#<C[KM[\4M+("WJB(@"(B (B( B(@"(B (B( B(@"(B
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M,3F)*[-7''Y.]&T]X"HLLS>QMWA>\W9_R,M_:37F7TI%:L!;R.$#P<AIC+V
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M,[,(LP&\X7P\SJ;&XX>O(9"C0#AGZKEN"J/#]7#]4\@-P_0?#\^?07]*_&D
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ML,3-&#%6*$V !%@8NCI#IZ6P@S'YTM?L>?\ <B0&^!1$0!$1 $1$ 1$0!$1
M$1$!C=VR?B@W5^YOKG\6,HM(?A_SI5_8\'[D*W>';)^*#=7[F^N?Q8RBTA^'
M_.E7]CP?N0H#Z*M;]VWZ4%=[/&RVB]GH=F*^JX]'QYN,<^>N3PY7_AG4>7U
M[OCFTQD6KO7?+/5X:Y+XC0-+['B= U2$0%YO\NJY']3M5_RER?Q+3\NJY']3
MM5_RER?Q+5&1$!>;_+JN1_4[5?\ *7)_$M/RZKD?U.U7_*7)_$M49$0%YO\
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MD\K%TSX31E2UTR6-/Z1:6&.8C?@(,OJ"9AM98HNBM#0Q_%4K&2(@"(B (B(
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MM49$0%YO\NJY']3M5_RER?Q+3\NJY']3M5_RER?Q+5&1$!>;_+JN1_4[5?\
M*7)_$M/RZKD?U.U7_*7)_$M49$0%YO\ +JN1_4[5?\I<G\2T_+JN1_4[5?\
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MJ[4<1='E[/,>3%^GR;V?=Y-Y>2]RUOMKR<'BGU[KJ:,N'>.76>II =Q=G%W
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M_P"N>R_W[ZF_B GY4,[6?]<]E_OWU-_$!;.9$!K&?RH9VL_ZY[+_ '[ZF_B
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M4TUJ;6M[.31Y'3>8Q$'J%7*;<86A,8VK\!2C8RE01KM-(!G( 0RWID1 $1$
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M  \C3HO=S]KPV-@DR&I<M)?U#DYV8S9[&0R=F<F)V*1V6:2( B(@"(B (B(
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MDN8;3V%Q-N2J<DE8[..QM:G.=>26*"4X"EA-XCD@AD*-Q<XHR=P;L)$0!$1
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MGLO]^^IOX@+9S(@-8S^5#.UG_7/9?[]]3?Q 3\J&=K/^N>R_W[ZF_B MG,B
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MS'Z'J8<-#9C4F6.L>F;&K)KQ9+X?TAI<81F'/U6J>JO<<WBL>,T##&\MGM$
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M 681%F869F9E["( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
MB(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(
MB (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
M B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"
M(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B
M( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@
M"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (
MB( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(
M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M(B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B
M(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
MB(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(
MB (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
M B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"
M(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B
M( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@
M"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (
MB( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(
M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M(B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B
M(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
MB(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(
MB (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
M B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"
M(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B
M( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@
M"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (
MB( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(
M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M(B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B
M(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
MB(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(
MB (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
M B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"
M(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B
M( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@
M"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (
MB( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(
M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M(B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B
M(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
J (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@/__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>ino-20210331_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31"
  xmlns:ino="http://www.inovio.com/20210331"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2020-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="ino-20210331.xsd" xlink:type="simple"/>
    <context id="i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i884c8c9ea12c402d9c05f28dee28eb3a_I20210506">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
        </entity>
        <period>
            <instant>2021-05-06</instant>
        </period>
    </context>
    <context id="ic36b9cedad7f41a6b9eb223b09b7186c_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i066bb5b0a9e84c0a878b1e800703d92b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ibf1dda891fd044098c213cc6a530fa62_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:A6.50ConvertibleSeniorNotesDue2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i09cc78b6ef5244c28a45a7069619a8b5_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:A6.50ConvertibleSeniorNotesDue2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="icda7d72fec364e2ea292b925ab363121_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:ConvertibleBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ifc2893c2a85c477f8396936402f496e2_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:ConvertibleBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i09001f493159423f9996d4b99e003558_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i2b0dec7a04644e5da0ed8efcc8dcc6e4_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i2e683dd292fa4879b525cd0f84179804_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:LicensewithAffiliatedEntitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i800a1e3bd482439e9d1e93a9ff22ac27_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:LicensewithAffiliatedEntitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="ica16a3607c6a4031a1fa37be362346d3_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i72f1fa77c5894104884af93e5e365e2a_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i03bccaa0abfb4733b1e2831ecde4e4e8_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="ib30ce8820d124ee6af51f2c43013f18e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia94bfbadb09f4968b33b4adabfa4233d_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ieaec7233643d498d97b1141ea9dad4c5_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i96283fe249ee4626aab2bf451b2e5efe_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ic6306740b10d4a7593195541124d73d5_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i5c4f0048d9644ed3b4e12718fd6404f9_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ida491abe9af7462cbd6838e5420a3bdb_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i4ede063da1fe4025a2e0bc527b82ca1e_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i0f5bad0d4b8641e4b0f54e165e445044_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i3f929f0365a3465f8cc7dc1c57314519_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ibab5fbbfe0ef465e8c296f3289e726c2_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i33c2b6d1adae4987a8b43311a9b56620_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i1541412d9b3c4836ae64bd33efc16e22_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i65691acaad974fca8ed0492dec85d517_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i1e99d4dac75643f384514d28d4cd004b_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i1b91f37fad654b1d9c8a1e92d45461a0_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="id632c5e641ae4912873249f66ba9b746_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i40ec371b74df4b3db7e8d29aaa614a0d_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i3d58693671394234b39dd81063245378_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="iba11ad45e728416593567d5d5ccc86c8_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ib7d8df8a887e444f9147b293456ba26e_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="if11b90ef299e496ebeb77cd256ffe8e4_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="id25261a874ce40da9cfbcc6297ee52ac_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ic68df58c3630416794b34bec56896e49_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="iba0cb12c2be843b2bd24ae59f143d7a9_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="ieac446e98d7241d8a6a13f0e4a3044da_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i344d70813010473f9e5c16b3e01640b5_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="ie9701f9c982742d69bfc64ed972293c3_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="ia55b1d91150f431281e2f695e0515501_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i90229a4122af48d0aef6e89c51605f73_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i7516614b1b654183b04111cbc3406079_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i94124ab8558d4ae989f26b588119e983_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i54cb3f5e003c480faccd9444adf9d1fe_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i63a61b36187545e5820f6cdb1e65f011_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i98369f585c4549d585af1f9094a77fd9_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="ic50cd4505b98463e9b947cd4aaebd07b_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ino:UnderwrittenPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ia9f4c44746fd42179d0515c760ec6715_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ino:SalesAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i9c175399baa843e28de7ed23419b160e_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i2f37abb9631043cc818c2a98efb857df_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ia2b43dbe48ac4cd98a40e26498a7f881_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:PlumblineLifeSciencesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i54393acc697d46e9aadd822f4955d2fa_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:OtherCounterpartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ibc97cab144454f34933b056f760ee615_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ino:MutualFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i4af67d24a9704503878ba27b39ec0b38_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ibd7b23cb5c014502a4a19618e0a1c8c8_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i4a59d94b00fb4beead53f1520382f2ac_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i07337481fc814fa2a711b1ff37845f55_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i333c95a51d3f4b7595b348f7c6eb52c5_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i9038be9382ec4b1694bd9bfd7bcda170_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ino:MutualFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i47be9d2882e243b7ace441a9b9205c92_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i7ed17972d6064f0bad14d06c6c595208_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i6f07020b0bd84e2b85baecf8191dddd4_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id49e93fcdfff47499add351e50b2b851_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ino:MutualFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ibb9d7da2bb9f4083a0f78f4d762e46e4_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ino:MutualFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i08f3093795f1462c897c6cadd1da8aed_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ino:MutualFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ib5e1a14b053e47c79b64277a69e380a9_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ino:MutualFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i8963e309e7dd4867bea8e9ee34e0a52b_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ie4a6d945ad73450191ce911b7e550ccc_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i22850f7499b2483f9428ba6cd51e1702_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ie7c31848f0e94bee88a97957caa0dac9_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i8576b8faf8064d92a55a1d7a9230294b_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i081a1114c57c4457a6e656fb47caa2fc_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i23aedffa2f0c42b9b43cb0b83beea039_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ia2a22ff53c7d437b9e4758ed1dd0655b_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i79f50420241043d0abd5aedb34d9926b_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i700d1959d79f4c7891a22d010cdfd228_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ic7b40fbbf0484fb98e57b0b99619b678_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ib8736cce87614b07956326c0d9cc3035_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="idc037a18dec8422896679a520fe0751f_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i950b0135e402482fae846256144517d6_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i536f602826fe46979bdba143abf2858a_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="iaef1617b1a33479ebd53313a3c7a7812_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i679e853e6cb64bb9bee2cde9c5fa48ab_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i95f3040264524bd7aafa7c66012a9ed0_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i77ffd233d1de4e33aa7330413610496e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie0d4dc3c347a44199532a6ee4469f31e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i765820c859204f75a1eaeb4f280fd337_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ino:MutualFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i42280087f6b44742aa1b7f2971c27575_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ino:MutualFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ifcda11a978e44c92b373b4913520b88b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ino:MutualFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i691500b3ba21482aa5fe5467025f71c3_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ino:MutualFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i3b31046c5de349d1937a204cdc2973ae_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iaaf44a738a1345828679d9a1b25f8327_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie2357d9b866e4be7afcd9fe0ac4e6a56_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i8501b73ca4034d94b92aab9e80a10e2f_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i2921a4efcf7f4fc1bbbf11dcd4e24dc8_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i165dd8f0bd4343b5b394ee5a10eee714_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ibc90ce5aa5c04e718823e5f0bfad97e7_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i2a4a04a42ab7478daf3585b30a5dc600_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i8b1d59d5ed834f6b91384f272748379f_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iea068b74107644b3a5e86a21d960799f_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i9eeb5e9d4f914f2591ba8b7f2f2631da_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i57bed7dd45b14e9f953dd397ed3bdce9_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i0cce4e82b88342c787d49f1a7ed20009_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="id00cf7a7665d4381ba225961343d2ea4_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="iff289276fdba4033befe45d8c121487e_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i545fa05cd5804fa9a426a541fbe08f6d_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i677b4aa23e734ea1ae840c65c0f2ac0c_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ino:BiojectMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i87af82b668704e509e894f5e917c76ee_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ino:BiojectMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="icc09668324be44f4a3c6526161d237ec_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ino:BiojectMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i1bf527072286443a829aab2684009143_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i04d8063070ed47dca91d948e0b527543_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i9898566a542a49b4bf69010ae439ab9a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i16a35fdf0e8348e0a1ede684610bae3e_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="iff75d456dbf843feb55dc8e27df1e4c3_I20190301">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:A6.50ConvertibleSeniorNotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-01</instant>
        </period>
    </context>
    <context id="i50447e531b3c434fb8e3ede17ab45a89_D20190219-20190301">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:A6.50ConvertibleSeniorNotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-02-19</startDate>
            <endDate>2019-03-01</endDate>
        </period>
    </context>
    <context id="i334e05b1c2d349408f504085686e16e6_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:A6.50ConvertibleSeniorNotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ibaba303f793542bd8caae6689d64fb35_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:A6.50ConvertibleSeniorNotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ida7e6795aad44fb38ae767d0d07173d2_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:A6.50ConvertibleSeniorNotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="icdb93151b4be464b9f1281340d4933cc_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:A6.50ConvertibleSeniorNotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i105fc1ec677d41beb16a21a24c107e45_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:A6.50ConvertibleSeniorNotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i700b790825e646eaa141e79f67d14908_I20190801">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:August2019ConvertibleBondsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-08-01</instant>
        </period>
    </context>
    <context id="ibbf41c9c4e33452d8cf96974a53ed0d2_D20190801-20190801">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:August2019ConvertibleBondsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-08-01</startDate>
            <endDate>2019-08-01</endDate>
        </period>
    </context>
    <context id="i6b6ee21ba47743bcbf1e8f17210f4948_D20200803-20200803">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:August2019ConvertibleBondsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-03</startDate>
            <endDate>2020-08-03</endDate>
        </period>
    </context>
    <context id="ie81a2e682215493ab64bdb0c300f4bf3_I20200803">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtConversionByUniqueDescriptionAxis">ino:InitialConversionPriceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:August2019ConvertibleBondsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-08-03</instant>
        </period>
    </context>
    <context id="i7871b982a7494885bca85b1422f54c5a_I20200803">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:August2019ConvertibleBondsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-08-03</instant>
        </period>
    </context>
    <context id="i1db0e391023844c58ee91836f1ff6032_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:August2019ConvertibleBondsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i4856d99dc58e4812bb359ff1035109a0_I20200831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:August2019ConvertibleBondsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-08-31</instant>
        </period>
    </context>
    <context id="id61aefb0cd4c41cba239205ade4953a0_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:August2019ConvertibleBondsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ic05ddd45fe7a4ed3a38c628d55f5113b_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ia9abd9a211df4a149587dd748625eb64_I20191226">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:December2019ConvertibleBondsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-26</instant>
        </period>
    </context>
    <context id="i244e899ef7a94a67bec0648d010019b1_D20191226-20191226">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:December2019ConvertibleBondsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-26</startDate>
            <endDate>2019-12-26</endDate>
        </period>
    </context>
    <context id="if2025599c3af4215ad074b05ca0a1e96_I20191226">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtConversionByUniqueDescriptionAxis">ino:InitialConversionPriceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:December2019ConvertibleBondsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-26</instant>
        </period>
    </context>
    <context id="ibfeaa89fdfd14b48b6469e81e8224d6e_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:December2019ConvertibleBondsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="id6dde602cd3b497f9beb038644f6e0f6_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:December2019ConvertibleBondsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i1e80eac2298744338c69ed4a78ebcd6b_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:December2019ConvertibleBondsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="ia5769dc297d64d63934b48c24c6fac0a_D20200803-20200803">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtConversionByUniqueDescriptionAxis">ino:InitialConversionPriceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:August2019ConvertibleBondsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-03</startDate>
            <endDate>2020-08-03</endDate>
        </period>
    </context>
    <context id="i2159423bb63f4a1fbf69220efa1f3870_D20191226-20191226">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtConversionByUniqueDescriptionAxis">ino:InitialConversionPriceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:December2019ConvertibleBondsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-26</startDate>
            <endDate>2019-12-26</endDate>
        </period>
    </context>
    <context id="ic385c05c2d7e4d79bc77a34f466a4d92_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i8080707135874457acfda210b14f8caa_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i25c9bfdd10384a7ea0e5d634721712a4_D20200601-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ieee221f2ad874f95afe5bd8f6f749911_D20200601-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i1105e820c10e4516b0891db1691036b2_D20210125-20210125">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
        </entity>
        <period>
            <startDate>2021-01-25</startDate>
            <endDate>2021-01-25</endDate>
        </period>
    </context>
    <context id="i0aaa3652e67040b09e4bec889642601e_I20210125">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
        </entity>
        <period>
            <instant>2021-01-25</instant>
        </period>
    </context>
    <context id="if1aa2ac57025445591f02f2a2b4a827d_D20180501-20180531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ino:PriorSalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-05-01</startDate>
            <endDate>2018-05-31</endDate>
        </period>
    </context>
    <context id="ie8f61637671d4831a979db68dfe70295_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ino:PriorSalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i33021fc5991544e6bdc6d451e0bf882e_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ino:PriorSalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="if1222ca24d5f4b93a286cd93f4df2429_D20200403-20200512">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ino:NewSalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-03</startDate>
            <endDate>2020-05-12</endDate>
        </period>
    </context>
    <context id="i5bdeced5a8d5445a82941bb4b6c54b39_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ino:NewSalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ic7ebb6cd60ce4e4c84cfe4f6fd8ca6fa_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ino:NewSalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i20753e05a58f4787ad7efb7458e2f0c5_I20160513">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ino:A2016IncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-05-13</instant>
        </period>
    </context>
    <context id="i23432a1ccb974c6d9ef1ec635e8143ed_I20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ino:A2016IncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-01</instant>
        </period>
    </context>
    <context id="iddaa5cd4d85f4565b4df009a33385893_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ino:A2016IncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i52e41bdcfa1f4dd5ae13e4662c088e67_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ino:A2016IncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i8c0e2d352fcb4b638dd0a198e31e2f72_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ino:A2007IncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i6236143f37a74492a26b2b567dd6525a_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ino:A2007IncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i87899c635a3d4f67af30c19682c88a69_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="iaf2883d0b0f44f8aa8540000815316c3_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i6aade12f14664b7bafdd10b536ffc9d1_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">ino:ServiceBasedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="iecc10df4b79a45de9ffdafc4389503d2_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">ino:ServiceBasedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i623f1c7b68164c0e86bc10eaa5f5a7e5_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i75ed8cb3d08c4c16a0b40f1f253b731e_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i71ea1499a3b143cb8017808669a7a908_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ifb05b300647c4bdb9d4dd1b61fa9ee95_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i2d25495c4b6c4835a012eb7bc163fc6b_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:A6.50ConvertibleSeniorNotesDue2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i4a3bb7fa3e594f029a6eba07308e9930_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:A6.50ConvertibleSeniorNotesDue2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i18791cf1783e4dcb8bb78a1be1ac89ad_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:August2019ConvertibleBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i40ed0775a40148b78eea3a36a21b29b8_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:August2019ConvertibleBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="ia21913e3a96f406eaffea5e037b375df_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:December2019ConvertibleBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ib6797a8f65df45e284ff859468b7d490_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:December2019ConvertibleBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i61f2172601e8451ebb73c4ae7a745dab_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ino:EmployeesAndDirectorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i0c1c04ab89af4b82b4d7131a93f0f86f_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ino:EmployeesAndDirectorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="ic3dea0b408c94a5c85d39edf3a8a75da_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ino:EmployeesAndDirectorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i2be4bda68db445b1873dcb33cd2a7408_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ino:EmployeesAndDirectorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="ia4defc9758104f38bf6c67e512fbf9c8_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ic196d4d46d72427380949ad2f6171b35_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i4ac71f8b0252490589829c2ceb42c184_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i16bb9f759a90436abc39b470d3758b82_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="iced18e00c26943db86d24ef12f5d945b_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i2af01b3faa6342e7982d6aae83905e36_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ia74c48fc7c3c456fa308825394481794_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="if21238de764544869449deb80f173e01_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ino:NonEmployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i337096debaaf43d88b8dd9f4979cb062_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ino:NonEmployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i76e8a75098d84df7ac61105d88d25844_D20200828-20200828">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ino:A2016IncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-28</startDate>
            <endDate>2020-08-28</endDate>
        </period>
    </context>
    <context id="ie0eb7f9e131f4570be7731825dd8538f_D20200828-20200828">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ino:A2016IncentivePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-28</startDate>
            <endDate>2020-08-28</endDate>
        </period>
    </context>
    <context id="i21a58deaf4d24bd381a2d83d3a8d9889_D20200828-20200828">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ino:A2016IncentivePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-28</startDate>
            <endDate>2020-08-28</endDate>
        </period>
    </context>
    <context id="i4f1544da548041ab8ee6e7df0bf9ef61_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:PlumblineLifeSciencesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:AvailableforsaleSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i4c79f6b4729a4ff692ed11a1379cdfcf_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:PlumblineLifeSciencesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i5ee95bf76bdd417884688328e2d20f81_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:PlumblineLifeSciencesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i02eea4d019a94e66ae415d3736f47a49_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:PlumblineLifeSciencesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iad065e9a7d2a4690b34e02a44f8e04ee_D20160301-20160331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:DirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-03-01</startDate>
            <endDate>2016-03-31</endDate>
        </period>
    </context>
    <context id="i22530cebfa2d4a3587a9140e7fb29bb7_D20161101-20161130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:DirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-11-01</startDate>
            <endDate>2016-11-30</endDate>
        </period>
    </context>
    <context id="if8801c14501949e385e60e1272378e9f_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ino:TheWistarInstituteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i6e8d2f7132dd4ad696314336b323045a_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:DirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ib9b1dac9eb2f4b86842d7bbf220a3ec9_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:DirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="iab8d55f8b4464cb1af38f6596cf6b33d_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:DirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ie31e1b7159e7405fb6b7791df154daf6_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:DirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie67e1db182b94da1b67c475206b65805_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">ino:SanDiegoOfficeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ib2743077b3474815ac3d7d4bbcd3dbd9_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">ino:PlymouthMeetingPennsylvaniaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ic4e4f4221dec4206a08ffb18e83ff0e2_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i02dc7b8bd133444db127be6bff5fedf5_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i49a24e6bc43d4cd9a7a914b19403f340_D20191001-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">ino:PlymouthMeetingPennsylvaniaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i16a0d0ea59c14de2b4879a3250ddd093_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:AdvaccineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i218a10d1c62a4a1d8cff8c3442114b71_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:AdvaccineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i43ca7eb4e9604967b950979b7b65da58_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:AdvaccineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="iff19a2c26f364894a1393fb4bb5ed788_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:AdvaccineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i9e2527d562564d0da42bfadc4214aabf_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ino:AdvaccineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ie9a3ac315bd64233b038ae99d2926ee5_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ino:AdvaccineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i4ae78b29c7ad4225be2a6e2ef791b855_D20171229-20171229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:ApolloBioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-12-29</startDate>
            <endDate>2017-12-29</endDate>
        </period>
    </context>
    <context id="ifb1c860482c945d2b8d0a23ea9de9d2b_D20180301-20180331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:ApolloBioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-03-01</startDate>
            <endDate>2018-03-31</endDate>
        </period>
    </context>
    <context id="ic48f2b7387c740dda32316adb9b93c55_D20180301-20180331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:ApolloBioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-03-01</startDate>
            <endDate>2018-03-31</endDate>
        </period>
    </context>
    <context id="ifcaf1ba492eb44b08dea1762e6aae5a6_I20180331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:ApolloBioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-03-31</instant>
        </period>
    </context>
    <context id="ibfe7179d0c314ec8b6575735e5576485_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:ApolloBioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i166171f55c2146e6a9bfc1cbda21593f_D20180401-20180630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:ApolloBioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="i312dc53a327b4c2584c0408f7ce3c401_D20150901-20150930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:AstraZenecaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-09-01</startDate>
            <endDate>2015-09-30</endDate>
        </period>
    </context>
    <context id="id271d63e442f4a9f8fb4db1a017f1090_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:AstraZenecaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="iab8cbd4abffa49939bca24df9e09f682_D20171231-20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:AstraZenecaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-12-31</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="i1279cb3397f540cf8c03eff95603717f_D20181201-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:AstraZenecaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i0a00fce528054fc1b13da4166be4a7f9_D20190302-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:AstraZenecaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-03-02</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="i26869d6b62d04f7b965bf3b12a74986b_D20180401-20180430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:CoalitionforEpidemicPreparednessInnovationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:LassaFeverAndMERSVaccineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-04-30</endDate>
        </period>
    </context>
    <context id="i9e2dfcc4dad04e25a9c9b44b8901a333_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:CoalitionforEpidemicPreparednessInnovationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:LassaFeverAndMERSVaccineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="id320f2073edd475b8fd5feeb871b3bb2_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:CoalitionforEpidemicPreparednessInnovationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:LassaFeverAndMERSVaccineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i7705f1893eef43a683c986157751b493_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:CoalitionforEpidemicPreparednessInnovationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:LassaFeverAndMERSVaccineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i4c2c68f34809458b92b1fe442b05fe04_D20200101-20200131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:CoalitionforEpidemicPreparednessInnovationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:SARSCoV2COVID19VaccineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-01-31</endDate>
        </period>
    </context>
    <context id="iefa41d3db8c44b3784e3e21a11b9f57b_D20200401-20200430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:CoalitionforEpidemicPreparednessInnovationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-04-30</endDate>
        </period>
    </context>
    <context id="ie8d1c12d54e14e8fadc5b66c01656f3f_D20200401-20200430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:CoalitionforEpidemicPreparednessInnovationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:CELLECTRA3PSPProprietarySmartDeviceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-04-30</endDate>
        </period>
    </context>
    <context id="i4e63edbfeb924628bea29aa126db3731_D20200401-20200430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:CoalitionforEpidemicPreparednessInnovationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:INO4800Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-04-30</endDate>
        </period>
    </context>
    <context id="i90e840c675604f9ea05a3d3799146d6a_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:CoalitionforEpidemicPreparednessInnovationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:SARSCoV2COVID19VaccineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i9c578a4352674268833b02f441d2630a_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:CoalitionforEpidemicPreparednessInnovationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:SARSCoV2COVID19VaccineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i462daba8e70241fa90cc3d9158a0e6b1_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:CoalitionforEpidemicPreparednessInnovationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:SARSCoV2COVID19VaccineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i8914061f84134527886aafd4379342b3_D20181001-20181031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:BillAndMelindaGatesFoundationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:DNAEncodedMonoclonalAntibodyTechnologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-10-01</startDate>
            <endDate>2018-10-31</endDate>
        </period>
    </context>
    <context id="id9b959950a9d4883a9e0bbc48e5b75b8_D20190801-20190830">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:BillAndMelindaGatesFoundationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:DNAEncodedMonoclonalAntibodyTechnologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-08-01</startDate>
            <endDate>2019-08-30</endDate>
        </period>
    </context>
    <context id="ia04b81c5769143f2ad65bc25e43bd9ed_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:BillAndMelindaGatesFoundationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:DNAEncodedMonoclonalAntibodyTechnologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i091601a25e604419963010db9959837c_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:BillAndMelindaGatesFoundationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:DNAEncodedMonoclonalAntibodyTechnologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i870d9127e6314fc4aebaa4f4b2a7931e_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:BillAndMelindaGatesFoundationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:DNAEncodedMonoclonalAntibodyTechnologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i752ae0ad316946429cc2310340ed7334_D20200301-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:BillAndMelindaGatesFoundationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:CELLECTRA3PSPProprietarySmartDeviceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i56915aed723e478494673e49cebb3d4e_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:BillAndMelindaGatesFoundationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:CELLECTRA3PSPProprietarySmartDeviceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i779a998ae097423cbfecbd164c6d6a15_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:BillAndMelindaGatesFoundationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:CELLECTRA3PSPProprietarySmartDeviceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i264c6f79f8444773b5305906e6e512df_D20200601-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:DepartmentOfDefenceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:CELLECTRA3PSPProprietarySmartDeviceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ic4269fc3e43a44779c7573901206998d_D20200601-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:DepartmentOfDefenceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:CELLECTRA2000DeviceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="iccb3ccc026234192a47e7268051e1700_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:DepartmentOfDefenceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ic1b65e61f4594842852e823b554bc0cb_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:DepartmentOfDefenceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ia71441f3bf2e4190b91ebcea736fec60_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:DepartmentOfDefenceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i12df974976054802af3d27561d6c09dd_D20190201-20190228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-02-01</startDate>
            <endDate>2019-02-28</endDate>
        </period>
    </context>
    <context id="i197c02bfa6fb453089c92b4a206b5240_I20190228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-02-28</instant>
        </period>
    </context>
    <context id="i22e9833894df4c5d90786ba65f0c072a_I20200131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-31</instant>
        </period>
    </context>
    <context id="i9c60a7b844ef4b0685afab98a626ab57_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="icf16dce9089247ddb07885bad1158a5b_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i86c6d642fb404b608772c10c34c2a8fc_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i49cf08539f5f4d268c6222c435b55016_D20200601-20200601">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-01</startDate>
            <endDate>2020-06-01</endDate>
        </period>
    </context>
    <context id="i11b75bcb273c48128928387d5ceda2d2_I20200601">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-01</instant>
        </period>
    </context>
    <context id="i8ac1a1cef3df4067985d61a1d1aaf9b8_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="idc86dae1ec654c2e8eb6ba13fc81ec0b_I20200601">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-01</instant>
        </period>
    </context>
    <context id="ib661d85215674c8e93c1385a9ed48322_I20200601">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-01</instant>
        </period>
    </context>
    <context id="i496071670fd64b74b11100bd501df568_D20200601-20200601">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-01</startDate>
            <endDate>2020-06-01</endDate>
        </period>
    </context>
    <context id="i521f37bfc08d4393a839105bd352f62b_I20200601">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-01</instant>
        </period>
    </context>
    <context id="idf75b7fb59a640709f8bece075b171dd_I20200601">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-01</instant>
        </period>
    </context>
    <context id="i5f2d61cc6bd64875b11002017e8003ca_D20201101-20201130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-11-01</startDate>
            <endDate>2020-11-30</endDate>
        </period>
    </context>
    <context id="i26487b836039455e8049dc86128e27ea_I20201130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-11-30</instant>
        </period>
    </context>
    <context id="ie8cf0b8ea91645f8adbebe6fd2ff82e8_D20200601-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="iecead882e1cc4b15851f3a17bd9de72e_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i55de06d621d74ea4af67ec695d2aeb62_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ida22e72ec08c488993f6f37b0a40f441_D20200601-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ino:SeriesAOnePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ic39b978122b34ef0b586d2c3f0a20046_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i819679aabd4442d3be1364eba1821db3_D20200601-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ib3a8dbbd273043a2a304eb2892a14c8c_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i5f89255103014c46a5a9ab71646dba92_I20200601">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ino:SeriesAOnePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-01</instant>
        </period>
    </context>
    <context id="i9ae4c9aeb5d247e7bef7ede5fd594691_I20210228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-02-28</instant>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="day">
        <measure>ino:day</measure>
    </unit>
    <unit id="krw">
        <measure>iso4217:KRW</measure>
    </unit>
    <unit id="sqft">
        <measure>utr:sqft</measure>
    </unit>
    <dei:AmendmentFlag
      contextRef="i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN180L2ZyYWc6NzRmMDA0NjcwZjM0NDcyNGE2YzY4MTZhYjExMjAyMzQvdGFibGU6MGE1Y2M4MWIwMzIzNDRkNzlkNTA3MjA4MDczNjBlN2MvdGFibGVyYW5nZTowYTVjYzgxYjAzMjM0NGQ3OWQ1MDcyMDgwNzM2MGU3Y180LTEtMS0xLTA_fed92ebf-e68f-4a7f-990a-57133a41bf9d">false</dei:AmendmentFlag>
    <dei:DocumentFiscalYearFocus
      contextRef="i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN180L2ZyYWc6NzRmMDA0NjcwZjM0NDcyNGE2YzY4MTZhYjExMjAyMzQvdGFibGU6MGE1Y2M4MWIwMzIzNDRkNzlkNTA3MjA4MDczNjBlN2MvdGFibGVyYW5nZTowYTVjYzgxYjAzMjM0NGQ3OWQ1MDcyMDgwNzM2MGU3Y182LTEtMS0xLTA_6196f318-c00a-445c-9fc5-8a756986437c">2021</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN180L2ZyYWc6NzRmMDA0NjcwZjM0NDcyNGE2YzY4MTZhYjExMjAyMzQvdGFibGU6MGE1Y2M4MWIwMzIzNDRkNzlkNTA3MjA4MDczNjBlN2MvdGFibGVyYW5nZTowYTVjYzgxYjAzMjM0NGQ3OWQ1MDcyMDgwNzM2MGU3Y183LTEtMS0xLTA_926b7462-ecb7-403d-9e62-c13145629fcf">Q1</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey
      contextRef="i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN180L2ZyYWc6NzRmMDA0NjcwZjM0NDcyNGE2YzY4MTZhYjExMjAyMzQvdGFibGU6MGE1Y2M4MWIwMzIzNDRkNzlkNTA3MjA4MDczNjBlN2MvdGFibGVyYW5nZTowYTVjYzgxYjAzMjM0NGQ3OWQ1MDcyMDgwNzM2MGU3Y185LTEtMS0xLTA_25a6b41d-575c-46f3-a33a-e9ab9b432b70">0001055726</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate
      contextRef="i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN180L2ZyYWc6NzRmMDA0NjcwZjM0NDcyNGE2YzY4MTZhYjExMjAyMzQvdGFibGU6MGE1Y2M4MWIwMzIzNDRkNzlkNTA3MjA4MDczNjBlN2MvdGFibGVyYW5nZTowYTVjYzgxYjAzMjM0NGQ3OWQ1MDcyMDgwNzM2MGU3Y18xMC0xLTEtMS0w_6f9ccae2-c86e-4b4c-a2d7-7fe6dfe60352">--12-31</dei:CurrentFiscalYearEndDate>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i9c175399baa843e28de7ed23419b160e_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18zNy9mcmFnOmE0NTZiM2ZhOTA0ZjQ0ZjNiYTUyYzg0OWE5YTIxNGRiL3RleHRyZWdpb246YTQ1NmIzZmE5MDRmNDRmM2JhNTJjODQ5YTlhMjE0ZGJfOTk1Nw_def5a8b0-cb2d-4478-a5a4-79b9dd366f59">P2Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:DebtInstrumentConvertibleConversionRatio1
      contextRef="i50447e531b3c434fb8e3ede17ab45a89_D20190219-20190301"
      decimals="7"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN182NC9mcmFnOjkxYjcwZjc3MGM3ZDRiNzdhZTliZDE0ZTdkMzc2NTRlL3RhYmxlOjM3NGI2NmZmOGM4NzRlZWFhNjBhM2ZkNzI4NDRjODIzL3RhYmxlcmFuZ2U6Mzc0YjY2ZmY4Yzg3NGVlYWE2MGEzZmQ3Mjg0NGM4MjNfMi0xLTEtMS0w_4d2fc008-1fa8-4e13-b781-1c928b2384bd"
      unitRef="number">0.1858045</us-gaap:DebtInstrumentConvertibleConversionRatio1>
    <us-gaap:DebtInstrumentConvertibleConversionRatio1
      contextRef="ia5769dc297d64d63934b48c24c6fac0a_D20200803-20200803"
      decimals="10"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN182NC9mcmFnOjkxYjcwZjc3MGM3ZDRiNzdhZTliZDE0ZTdkMzc2NTRlL3RhYmxlOjM3NGI2NmZmOGM4NzRlZWFhNjBhM2ZkNzI4NDRjODIzL3RhYmxlcmFuZ2U6Mzc0YjY2ZmY4Yzg3NGVlYWE2MGEzZmQ3Mjg0NGM4MjNfNS0yLTEtMS0w_281e617d-beb2-4389-8b3c-44bfb51cccd6"
      unitRef="number">0.0002110595</us-gaap:DebtInstrumentConvertibleConversionRatio1>
    <us-gaap:DebtInstrumentConvertibleConversionRatio1
      contextRef="i6b6ee21ba47743bcbf1e8f17210f4948_D20200803-20200803"
      decimals="10"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN182NC9mcmFnOjkxYjcwZjc3MGM3ZDRiNzdhZTliZDE0ZTdkMzc2NTRlL3RhYmxlOjM3NGI2NmZmOGM4NzRlZWFhNjBhM2ZkNzI4NDRjODIzL3RhYmxlcmFuZ2U6Mzc0YjY2ZmY4Yzg3NGVlYWE2MGEzZmQ3Mjg0NGM4MjNfNi0yLTEtMS0w_ca3947cc-5a44-4480-9219-98c7bc1aca8b"
      unitRef="number">0.0002756873</us-gaap:DebtInstrumentConvertibleConversionRatio1>
    <us-gaap:DebtInstrumentConvertibleConversionRatio1
      contextRef="i2159423bb63f4a1fbf69220efa1f3870_D20191226-20191226"
      decimals="10"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN182NC9mcmFnOjkxYjcwZjc3MGM3ZDRiNzdhZTliZDE0ZTdkMzc2NTRlL3RhYmxlOjM3NGI2NmZmOGM4NzRlZWFhNjBhM2ZkNzI4NDRjODIzL3RhYmxlcmFuZ2U6Mzc0YjY2ZmY4Yzg3NGVlYWE2MGEzZmQ3Mjg0NGM4MjNfNy0yLTEtMS0w_afc02c1c-2d80-4fa0-81c4-a9e42cbfa409"
      unitRef="number">0.0002147766</us-gaap:DebtInstrumentConvertibleConversionRatio1>
    <dei:DocumentType
      contextRef="i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18xL2ZyYWc6NTM4MmMyNzY1Y2NiNGZiYWExMzNkMGYwZDkwMjNmYzAvdGV4dHJlZ2lvbjo1MzgyYzI3NjVjY2I0ZmJhYTEzM2QwZjBkOTAyM2ZjMF8yMTA2_30e51c43-9d22-4d88-8279-f47d43efb02f">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18xL2ZyYWc6NTM4MmMyNzY1Y2NiNGZiYWExMzNkMGYwZDkwMjNmYzAvdGFibGU6NDQ0NGRhYjE5OTZjNDZlMGIwZGYzZTc2Zjc1MjM2ZTAvdGFibGVyYW5nZTo0NDQ0ZGFiMTk5NmM0NmUwYjBkZjNlNzZmNzUyMzZlMF8wLTAtMS0xLTA_1cef70ae-cfc0-48f2-9aca-be4d17cca9a6">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18xL2ZyYWc6NTM4MmMyNzY1Y2NiNGZiYWExMzNkMGYwZDkwMjNmYzAvdGV4dHJlZ2lvbjo1MzgyYzI3NjVjY2I0ZmJhYTEzM2QwZjBkOTAyM2ZjMF8xMzI_4df55fc3-6861-4ca7-b4e4-bce077331f19">2021-03-31</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18xL2ZyYWc6NTM4MmMyNzY1Y2NiNGZiYWExMzNkMGYwZDkwMjNmYzAvdGFibGU6Yjc2OTY5ZDM5ODM2NGM1MGJmMTcxOTQyMzczYTg3ZmQvdGFibGVyYW5nZTpiNzY5NjlkMzk4MzY0YzUwYmYxNzE5NDIzNzNhODdmZF8wLTAtMS0xLTA_f0a2e97b-e6cb-45c0-8ef5-b121aabf6c2c">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18xL2ZyYWc6NTM4MmMyNzY1Y2NiNGZiYWExMzNkMGYwZDkwMjNmYzAvdGV4dHJlZ2lvbjo1MzgyYzI3NjVjY2I0ZmJhYTEzM2QwZjBkOTAyM2ZjMF8yMTEw_babe0f0b-1425-4d9c-add5-c018e66647e2">001-14888</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18xL2ZyYWc6NTM4MmMyNzY1Y2NiNGZiYWExMzNkMGYwZDkwMjNmYzAvdGV4dHJlZ2lvbjo1MzgyYzI3NjVjY2I0ZmJhYTEzM2QwZjBkOTAyM2ZjMF8yMTEx_eb58a84f-7f10-4a9d-ae8a-9b02b6339daf">INOVIO PHARMACEUTICALS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18xL2ZyYWc6NTM4MmMyNzY1Y2NiNGZiYWExMzNkMGYwZDkwMjNmYzAvdGFibGU6YTM4NmIwNDllMDJlNGIyOGFkYzg0NjM3ZmQ3M2JkYWYvdGFibGVyYW5nZTphMzg2YjA0OWUwMmU0YjI4YWRjODQ2MzdmZDczYmRhZl8wLTAtMS0xLTA_f94abe28-7258-447a-918a-3207f8e35d9e">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18xL2ZyYWc6NTM4MmMyNzY1Y2NiNGZiYWExMzNkMGYwZDkwMjNmYzAvdGFibGU6YTM4NmIwNDllMDJlNGIyOGFkYzg0NjM3ZmQ3M2JkYWYvdGFibGVyYW5nZTphMzg2YjA0OWUwMmU0YjI4YWRjODQ2MzdmZDczYmRhZl8wLTItMS0xLTA_d6bf0eb2-71ac-4f01-9e77-49baa40f0cda">33-0969592</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18xL2ZyYWc6NTM4MmMyNzY1Y2NiNGZiYWExMzNkMGYwZDkwMjNmYzAvdGV4dHJlZ2lvbjo1MzgyYzI3NjVjY2I0ZmJhYTEzM2QwZjBkOTAyM2ZjMF8yMTEy_45c30210-848b-4071-8741-b2db12f3bd30">660 W. GERMANTOWN PIKE, SUITE 110</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18xL2ZyYWc6NTM4MmMyNzY1Y2NiNGZiYWExMzNkMGYwZDkwMjNmYzAvdGV4dHJlZ2lvbjo1MzgyYzI3NjVjY2I0ZmJhYTEzM2QwZjBkOTAyM2ZjMF8yMTA3_57277e60-a12f-4dce-b1db-09fcf2eb54ad">PLYMOUTH MEETING</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18xL2ZyYWc6NTM4MmMyNzY1Y2NiNGZiYWExMzNkMGYwZDkwMjNmYzAvdGV4dHJlZ2lvbjo1MzgyYzI3NjVjY2I0ZmJhYTEzM2QwZjBkOTAyM2ZjMF8yMTEz_c132ea97-5d31-4fe0-9c7f-875ca8276678">PA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18xL2ZyYWc6NTM4MmMyNzY1Y2NiNGZiYWExMzNkMGYwZDkwMjNmYzAvdGV4dHJlZ2lvbjo1MzgyYzI3NjVjY2I0ZmJhYTEzM2QwZjBkOTAyM2ZjMF8yMTE0_76595a9a-87de-4f12-8765-99831b11644c">19462</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18xL2ZyYWc6NTM4MmMyNzY1Y2NiNGZiYWExMzNkMGYwZDkwMjNmYzAvdGV4dHJlZ2lvbjo1MzgyYzI3NjVjY2I0ZmJhYTEzM2QwZjBkOTAyM2ZjMF8yMTE1_2aa72edc-de18-45d0-8bb9-a202774797a8">267</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18xL2ZyYWc6NTM4MmMyNzY1Y2NiNGZiYWExMzNkMGYwZDkwMjNmYzAvdGV4dHJlZ2lvbjo1MzgyYzI3NjVjY2I0ZmJhYTEzM2QwZjBkOTAyM2ZjMF8yMTE2_595fdd6f-8618-422d-8b16-31be294f541c">440-4200</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18xL2ZyYWc6NTM4MmMyNzY1Y2NiNGZiYWExMzNkMGYwZDkwMjNmYzAvdGFibGU6YWY0Mzk3YjZjZWQ0NDdhMmJiZjc3NTU4MjIyNWYzMzQvdGFibGVyYW5nZTphZjQzOTdiNmNlZDQ0N2EyYmJmNzc1NTgyMjI1ZjMzNF8xLTAtMS0xLTA_765ad9eb-a50a-4bc7-8ede-94832111caf6">COMMON STOCK, $0.001 PAR VALUE</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18xL2ZyYWc6NTM4MmMyNzY1Y2NiNGZiYWExMzNkMGYwZDkwMjNmYzAvdGFibGU6YWY0Mzk3YjZjZWQ0NDdhMmJiZjc3NTU4MjIyNWYzMzQvdGFibGVyYW5nZTphZjQzOTdiNmNlZDQ0N2EyYmJmNzc1NTgyMjI1ZjMzNF8xLTEtMS0xLTA_daa7d5eb-1093-4097-baf8-dc66c419e54f">INO</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18xL2ZyYWc6NTM4MmMyNzY1Y2NiNGZiYWExMzNkMGYwZDkwMjNmYzAvdGFibGU6YWY0Mzk3YjZjZWQ0NDdhMmJiZjc3NTU4MjIyNWYzMzQvdGFibGVyYW5nZTphZjQzOTdiNmNlZDQ0N2EyYmJmNzc1NTgyMjI1ZjMzNF8xLTItMS0xLTA_ad49e61d-80ff-485c-898d-ea9cab024d55">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus
      contextRef="i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18xL2ZyYWc6NTM4MmMyNzY1Y2NiNGZiYWExMzNkMGYwZDkwMjNmYzAvdGV4dHJlZ2lvbjo1MzgyYzI3NjVjY2I0ZmJhYTEzM2QwZjBkOTAyM2ZjMF8yMTE3_1e5e6303-2915-467b-8bbf-01acfdccd22b">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18xL2ZyYWc6NTM4MmMyNzY1Y2NiNGZiYWExMzNkMGYwZDkwMjNmYzAvdGV4dHJlZ2lvbjo1MzgyYzI3NjVjY2I0ZmJhYTEzM2QwZjBkOTAyM2ZjMF8yMTA4_c51b5314-e681-47db-bf61-047e25beb8a4">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18xL2ZyYWc6NTM4MmMyNzY1Y2NiNGZiYWExMzNkMGYwZDkwMjNmYzAvdGFibGU6NzBmYjM5Y2JkMmE3NGFmYjg3NjM4ODZlOWViMDcxZTAvdGFibGVyYW5nZTo3MGZiMzljYmQyYTc0YWZiODc2Mzg4NmU5ZWIwNzFlMF8wLTAtMS0xLTI4NjU_b3d72721-e976-4788-8607-675398411088">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18xL2ZyYWc6NTM4MmMyNzY1Y2NiNGZiYWExMzNkMGYwZDkwMjNmYzAvdGFibGU6NzBmYjM5Y2JkMmE3NGFmYjg3NjM4ODZlOWViMDcxZTAvdGFibGVyYW5nZTo3MGZiMzljYmQyYTc0YWZiODc2Mzg4NmU5ZWIwNzFlMF8yLTQtMS0xLTA_6aad417a-5e7a-40d3-b153-de5dce677e20">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18xL2ZyYWc6NTM4MmMyNzY1Y2NiNGZiYWExMzNkMGYwZDkwMjNmYzAvdGFibGU6NzBmYjM5Y2JkMmE3NGFmYjg3NjM4ODZlOWViMDcxZTAvdGFibGVyYW5nZTo3MGZiMzljYmQyYTc0YWZiODc2Mzg4NmU5ZWIwNzFlMF80LTQtMS0xLTA_a23721ba-9f35-4c32-a641-178903cd79cb">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany
      contextRef="i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18xL2ZyYWc6NTM4MmMyNzY1Y2NiNGZiYWExMzNkMGYwZDkwMjNmYzAvdGV4dHJlZ2lvbjo1MzgyYzI3NjVjY2I0ZmJhYTEzM2QwZjBkOTAyM2ZjMF8yMTA5_babc02b7-9b34-4120-a668-3059b1628077">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="i884c8c9ea12c402d9c05f28dee28eb3a_I20210506"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18xL2ZyYWc6NTM4MmMyNzY1Y2NiNGZiYWExMzNkMGYwZDkwMjNmYzAvdGV4dHJlZ2lvbjo1MzgyYzI3NjVjY2I0ZmJhYTEzM2QwZjBkOTAyM2ZjMF8yMDky_129e0feb-4152-40ff-b290-1fcaba577ae9"
      unitRef="shares">209399260</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ic36b9cedad7f41a6b9eb223b09b7186c_I20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18xMy9mcmFnOjVkY2JmNGI1ZTM3MzQyM2ZhMWY1NTcyM2Q3MTJlZWE1L3RhYmxlOjg4MmZmMDUyMmQ0NjRkYjdhZTY0MTg5MWY2NGEzODY3L3RhYmxlcmFuZ2U6ODgyZmYwNTIyZDQ2NGRiN2FlNjQxODkxZjY0YTM4NjdfNC0xLTEtMS0w_7d5bcaaa-5d74-4917-a2a2-29f53e5b6fcb"
      unitRef="usd">83634176</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i066bb5b0a9e84c0a878b1e800703d92b_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18xMy9mcmFnOjVkY2JmNGI1ZTM3MzQyM2ZhMWY1NTcyM2Q3MTJlZWE1L3RhYmxlOjg4MmZmMDUyMmQ0NjRkYjdhZTY0MTg5MWY2NGEzODY3L3RhYmxlcmFuZ2U6ODgyZmYwNTIyZDQ2NGRiN2FlNjQxODkxZjY0YTM4NjdfNC0zLTEtMS0w_fb736d15-4e81-4ce0-a730-5286e18aca52"
      unitRef="usd">250728118</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:ShortTermInvestments
      contextRef="ic36b9cedad7f41a6b9eb223b09b7186c_I20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18xMy9mcmFnOjVkY2JmNGI1ZTM3MzQyM2ZhMWY1NTcyM2Q3MTJlZWE1L3RhYmxlOjg4MmZmMDUyMmQ0NjRkYjdhZTY0MTg5MWY2NGEzODY3L3RhYmxlcmFuZ2U6ODgyZmYwNTIyZDQ2NGRiN2FlNjQxODkxZjY0YTM4NjdfNS0xLTEtMS0w_c49f4d00-b715-44d2-b0b9-705f09b89a22"
      unitRef="usd">434969528</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments
      contextRef="i066bb5b0a9e84c0a878b1e800703d92b_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18xMy9mcmFnOjVkY2JmNGI1ZTM3MzQyM2ZhMWY1NTcyM2Q3MTJlZWE1L3RhYmxlOjg4MmZmMDUyMmQ0NjRkYjdhZTY0MTg5MWY2NGEzODY3L3RhYmxlcmFuZ2U6ODgyZmYwNTIyZDQ2NGRiN2FlNjQxODkxZjY0YTM4NjdfNS0zLTEtMS0w_d63f213a-a549-4415-b258-58e6e1d368ff"
      unitRef="usd">160914935</us-gaap:ShortTermInvestments>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="ic36b9cedad7f41a6b9eb223b09b7186c_I20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18xMy9mcmFnOjVkY2JmNGI1ZTM3MzQyM2ZhMWY1NTcyM2Q3MTJlZWE1L3RhYmxlOjg4MmZmMDUyMmQ0NjRkYjdhZTY0MTg5MWY2NGEzODY3L3RhYmxlcmFuZ2U6ODgyZmYwNTIyZDQ2NGRiN2FlNjQxODkxZjY0YTM4NjdfNi0xLTEtMS0w_089361b9-a846-43d0-9131-3f4b08885ae8"
      unitRef="usd">9911922</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i066bb5b0a9e84c0a878b1e800703d92b_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18xMy9mcmFnOjVkY2JmNGI1ZTM3MzQyM2ZhMWY1NTcyM2Q3MTJlZWE1L3RhYmxlOjg4MmZmMDUyMmQ0NjRkYjdhZTY0MTg5MWY2NGEzODY3L3RhYmxlcmFuZ2U6ODgyZmYwNTIyZDQ2NGRiN2FlNjQxODkxZjY0YTM4NjdfNi0zLTEtMS0w_9dfae3a7-4962-4724-bae6-f09fcb16538c"
      unitRef="usd">18559967</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableRelatedPartiesCurrent
      contextRef="ic36b9cedad7f41a6b9eb223b09b7186c_I20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18xMy9mcmFnOjVkY2JmNGI1ZTM3MzQyM2ZhMWY1NTcyM2Q3MTJlZWE1L3RhYmxlOjg4MmZmMDUyMmQ0NjRkYjdhZTY0MTg5MWY2NGEzODY3L3RhYmxlcmFuZ2U6ODgyZmYwNTIyZDQ2NGRiN2FlNjQxODkxZjY0YTM4NjdfNy0xLTEtMS0w_6e2a5021-b7e4-45a6-974f-ba5841d2474d"
      unitRef="usd">346974</us-gaap:AccountsReceivableRelatedPartiesCurrent>
    <us-gaap:AccountsReceivableRelatedPartiesCurrent
      contextRef="i066bb5b0a9e84c0a878b1e800703d92b_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18xMy9mcmFnOjVkY2JmNGI1ZTM3MzQyM2ZhMWY1NTcyM2Q3MTJlZWE1L3RhYmxlOjg4MmZmMDUyMmQ0NjRkYjdhZTY0MTg5MWY2NGEzODY3L3RhYmxlcmFuZ2U6ODgyZmYwNTIyZDQ2NGRiN2FlNjQxODkxZjY0YTM4NjdfNy0zLTEtMS0w_76c8dffb-a0a8-4a66-b130-0978fcf55d84"
      unitRef="usd">503782</us-gaap:AccountsReceivableRelatedPartiesCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="ic36b9cedad7f41a6b9eb223b09b7186c_I20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18xMy9mcmFnOjVkY2JmNGI1ZTM3MzQyM2ZhMWY1NTcyM2Q3MTJlZWE1L3RhYmxlOjg4MmZmMDUyMmQ0NjRkYjdhZTY0MTg5MWY2NGEzODY3L3RhYmxlcmFuZ2U6ODgyZmYwNTIyZDQ2NGRiN2FlNjQxODkxZjY0YTM4NjdfOC0xLTEtMS0w_91284f6d-a536-4d13-a6d9-135c1a0d28f2"
      unitRef="usd">59572236</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i066bb5b0a9e84c0a878b1e800703d92b_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18xMy9mcmFnOjVkY2JmNGI1ZTM3MzQyM2ZhMWY1NTcyM2Q3MTJlZWE1L3RhYmxlOjg4MmZmMDUyMmQ0NjRkYjdhZTY0MTg5MWY2NGEzODY3L3RhYmxlcmFuZ2U6ODgyZmYwNTIyZDQ2NGRiN2FlNjQxODkxZjY0YTM4NjdfOC0zLTEtMS0w_b5a2dd86-c0c9-4c93-b68b-e23cb9645cf5"
      unitRef="usd">40357456</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <ino:PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity
      contextRef="ic36b9cedad7f41a6b9eb223b09b7186c_I20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18xMy9mcmFnOjVkY2JmNGI1ZTM3MzQyM2ZhMWY1NTcyM2Q3MTJlZWE1L3RhYmxlOjg4MmZmMDUyMmQ0NjRkYjdhZTY0MTg5MWY2NGEzODY3L3RhYmxlcmFuZ2U6ODgyZmYwNTIyZDQ2NGRiN2FlNjQxODkxZjY0YTM4NjdfOS0xLTEtMS0w_5afb9e1d-4a45-4e9c-84cc-74f5afab7071"
      unitRef="usd">0</ino:PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity>
    <ino:PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity
      contextRef="i066bb5b0a9e84c0a878b1e800703d92b_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18xMy9mcmFnOjVkY2JmNGI1ZTM3MzQyM2ZhMWY1NTcyM2Q3MTJlZWE1L3RhYmxlOjg4MmZmMDUyMmQ0NjRkYjdhZTY0MTg5MWY2NGEzODY3L3RhYmxlcmFuZ2U6ODgyZmYwNTIyZDQ2NGRiN2FlNjQxODkxZjY0YTM4NjdfOS0zLTEtMS0w_a3b1125b-92ae-48bd-9447-5a74dc5ddc6e"
      unitRef="usd">106432</ino:PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity>
    <us-gaap:AssetsCurrent
      contextRef="ic36b9cedad7f41a6b9eb223b09b7186c_I20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18xMy9mcmFnOjVkY2JmNGI1ZTM3MzQyM2ZhMWY1NTcyM2Q3MTJlZWE1L3RhYmxlOjg4MmZmMDUyMmQ0NjRkYjdhZTY0MTg5MWY2NGEzODY3L3RhYmxlcmFuZ2U6ODgyZmYwNTIyZDQ2NGRiN2FlNjQxODkxZjY0YTM4NjdfMTEtMS0xLTEtMA_11aac481-36b7-46c6-b431-7eccd9cc52c0"
      unitRef="usd">588434836</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i066bb5b0a9e84c0a878b1e800703d92b_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18xMy9mcmFnOjVkY2JmNGI1ZTM3MzQyM2ZhMWY1NTcyM2Q3MTJlZWE1L3RhYmxlOjg4MmZmMDUyMmQ0NjRkYjdhZTY0MTg5MWY2NGEzODY3L3RhYmxlcmFuZ2U6ODgyZmYwNTIyZDQ2NGRiN2FlNjQxODkxZjY0YTM4NjdfMTEtMy0xLTEtMA_01c4394c-1be1-4439-aa3f-8cc37f863fe8"
      unitRef="usd">471170690</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="ic36b9cedad7f41a6b9eb223b09b7186c_I20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18xMy9mcmFnOjVkY2JmNGI1ZTM3MzQyM2ZhMWY1NTcyM2Q3MTJlZWE1L3RhYmxlOjg4MmZmMDUyMmQ0NjRkYjdhZTY0MTg5MWY2NGEzODY3L3RhYmxlcmFuZ2U6ODgyZmYwNTIyZDQ2NGRiN2FlNjQxODkxZjY0YTM4NjdfMTItMS0xLTEtMA_508aad03-c705-4570-b103-9a8a571b21b2"
      unitRef="usd">10930312</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i066bb5b0a9e84c0a878b1e800703d92b_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18xMy9mcmFnOjVkY2JmNGI1ZTM3MzQyM2ZhMWY1NTcyM2Q3MTJlZWE1L3RhYmxlOjg4MmZmMDUyMmQ0NjRkYjdhZTY0MTg5MWY2NGEzODY3L3RhYmxlcmFuZ2U6ODgyZmYwNTIyZDQ2NGRiN2FlNjQxODkxZjY0YTM4NjdfMTItMy0xLTEtMA_8ef2e237-be81-4d62-9cc8-40091527473b"
      unitRef="usd">11348144</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="ic36b9cedad7f41a6b9eb223b09b7186c_I20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18xMy9mcmFnOjVkY2JmNGI1ZTM3MzQyM2ZhMWY1NTcyM2Q3MTJlZWE1L3RhYmxlOjg4MmZmMDUyMmQ0NjRkYjdhZTY0MTg5MWY2NGEzODY3L3RhYmxlcmFuZ2U6ODgyZmYwNTIyZDQ2NGRiN2FlNjQxODkxZjY0YTM4NjdfMTMtMS0xLTEtMA_210bc4d8-8313-401f-b7d9-838573e6d94e"
      unitRef="usd">3629891</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i066bb5b0a9e84c0a878b1e800703d92b_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18xMy9mcmFnOjVkY2JmNGI1ZTM3MzQyM2ZhMWY1NTcyM2Q3MTJlZWE1L3RhYmxlOjg4MmZmMDUyMmQ0NjRkYjdhZTY0MTg5MWY2NGEzODY3L3RhYmxlcmFuZ2U6ODgyZmYwNTIyZDQ2NGRiN2FlNjQxODkxZjY0YTM4NjdfMTMtMy0xLTEtMA_cee38bc1-4c1d-45c8-b0e4-9358d1070ba1"
      unitRef="usd">4460366</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquityMethodInvestments
      contextRef="ic36b9cedad7f41a6b9eb223b09b7186c_I20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18xMy9mcmFnOjVkY2JmNGI1ZTM3MzQyM2ZhMWY1NTcyM2Q3MTJlZWE1L3RhYmxlOjg4MmZmMDUyMmQ0NjRkYjdhZTY0MTg5MWY2NGEzODY3L3RhYmxlcmFuZ2U6ODgyZmYwNTIyZDQ2NGRiN2FlNjQxODkxZjY0YTM4NjdfMTQtMS0xLTEtMA_08a40d4e-1c8d-4a8c-9ac5-3ba3fda3793b"
      unitRef="usd">0</us-gaap:EquityMethodInvestments>
    <us-gaap:EquityMethodInvestments
      contextRef="i066bb5b0a9e84c0a878b1e800703d92b_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18xMy9mcmFnOjVkY2JmNGI1ZTM3MzQyM2ZhMWY1NTcyM2Q3MTJlZWE1L3RhYmxlOjg4MmZmMDUyMmQ0NjRkYjdhZTY0MTg5MWY2NGEzODY3L3RhYmxlcmFuZ2U6ODgyZmYwNTIyZDQ2NGRiN2FlNjQxODkxZjY0YTM4NjdfMTQtMy0xLTEtMA_a2c232ed-00bb-4453-be6c-de18266d1ed7"
      unitRef="usd">434387</us-gaap:EquityMethodInvestments>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="ic36b9cedad7f41a6b9eb223b09b7186c_I20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18xMy9mcmFnOjVkY2JmNGI1ZTM3MzQyM2ZhMWY1NTcyM2Q3MTJlZWE1L3RhYmxlOjg4MmZmMDUyMmQ0NjRkYjdhZTY0MTg5MWY2NGEzODY3L3RhYmxlcmFuZ2U6ODgyZmYwNTIyZDQ2NGRiN2FlNjQxODkxZjY0YTM4NjdfMTUtMS0xLTEtMA_5bf36924-a30d-46ff-b1c5-1e504143acf5"
      unitRef="usd">3010000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i066bb5b0a9e84c0a878b1e800703d92b_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18xMy9mcmFnOjVkY2JmNGI1ZTM3MzQyM2ZhMWY1NTcyM2Q3MTJlZWE1L3RhYmxlOjg4MmZmMDUyMmQ0NjRkYjdhZTY0MTg5MWY2NGEzODY3L3RhYmxlcmFuZ2U6ODgyZmYwNTIyZDQ2NGRiN2FlNjQxODkxZjY0YTM4NjdfMTUtMy0xLTEtMA_6a73ba62-cb7b-4010-b906-ecf5665252b6"
      unitRef="usd">3146770</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:Goodwill
      contextRef="ic36b9cedad7f41a6b9eb223b09b7186c_I20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18xMy9mcmFnOjVkY2JmNGI1ZTM3MzQyM2ZhMWY1NTcyM2Q3MTJlZWE1L3RhYmxlOjg4MmZmMDUyMmQ0NjRkYjdhZTY0MTg5MWY2NGEzODY3L3RhYmxlcmFuZ2U6ODgyZmYwNTIyZDQ2NGRiN2FlNjQxODkxZjY0YTM4NjdfMTYtMS0xLTEtMA_634a5bf1-bc61-4e4d-996f-29a620509dc2"
      unitRef="usd">10513371</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i066bb5b0a9e84c0a878b1e800703d92b_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18xMy9mcmFnOjVkY2JmNGI1ZTM3MzQyM2ZhMWY1NTcyM2Q3MTJlZWE1L3RhYmxlOjg4MmZmMDUyMmQ0NjRkYjdhZTY0MTg5MWY2NGEzODY3L3RhYmxlcmFuZ2U6ODgyZmYwNTIyZDQ2NGRiN2FlNjQxODkxZjY0YTM4NjdfMTYtMy0xLTEtMA_5a8784ff-e583-4350-8f4f-a831df00481f"
      unitRef="usd">10513371</us-gaap:Goodwill>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="ic36b9cedad7f41a6b9eb223b09b7186c_I20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18xMy9mcmFnOjVkY2JmNGI1ZTM3MzQyM2ZhMWY1NTcyM2Q3MTJlZWE1L3RhYmxlOjg4MmZmMDUyMmQ0NjRkYjdhZTY0MTg5MWY2NGEzODY3L3RhYmxlcmFuZ2U6ODgyZmYwNTIyZDQ2NGRiN2FlNjQxODkxZjY0YTM4NjdfMTctMS0xLTEtMA_8fabc858-2ce1-4a81-ad3d-aaaea9b08ebf"
      unitRef="usd">12463006</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i066bb5b0a9e84c0a878b1e800703d92b_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18xMy9mcmFnOjVkY2JmNGI1ZTM3MzQyM2ZhMWY1NTcyM2Q3MTJlZWE1L3RhYmxlOjg4MmZmMDUyMmQ0NjRkYjdhZTY0MTg5MWY2NGEzODY3L3RhYmxlcmFuZ2U6ODgyZmYwNTIyZDQ2NGRiN2FlNjQxODkxZjY0YTM4NjdfMTctMy0xLTEtMA_5ddf24ce-7e17-478a-a727-897e6fb84de9"
      unitRef="usd">12741296</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="ic36b9cedad7f41a6b9eb223b09b7186c_I20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18xMy9mcmFnOjVkY2JmNGI1ZTM3MzQyM2ZhMWY1NTcyM2Q3MTJlZWE1L3RhYmxlOjg4MmZmMDUyMmQ0NjRkYjdhZTY0MTg5MWY2NGEzODY3L3RhYmxlcmFuZ2U6ODgyZmYwNTIyZDQ2NGRiN2FlNjQxODkxZjY0YTM4NjdfMTgtMS0xLTEtMA_e34b386a-4967-4db4-ab93-e7be649d6f3d"
      unitRef="usd">25881934</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i066bb5b0a9e84c0a878b1e800703d92b_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18xMy9mcmFnOjVkY2JmNGI1ZTM3MzQyM2ZhMWY1NTcyM2Q3MTJlZWE1L3RhYmxlOjg4MmZmMDUyMmQ0NjRkYjdhZTY0MTg5MWY2NGEzODY3L3RhYmxlcmFuZ2U6ODgyZmYwNTIyZDQ2NGRiN2FlNjQxODkxZjY0YTM4NjdfMTgtMy0xLTEtMA_47677822-3fb2-4d54-9d3f-256de0ad216b"
      unitRef="usd">25957448</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="ic36b9cedad7f41a6b9eb223b09b7186c_I20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18xMy9mcmFnOjVkY2JmNGI1ZTM3MzQyM2ZhMWY1NTcyM2Q3MTJlZWE1L3RhYmxlOjg4MmZmMDUyMmQ0NjRkYjdhZTY0MTg5MWY2NGEzODY3L3RhYmxlcmFuZ2U6ODgyZmYwNTIyZDQ2NGRiN2FlNjQxODkxZjY0YTM4NjdfMTktMS0xLTEtMA_6ef473fc-794d-41f1-8a75-148e0c009369"
      unitRef="usd">654863350</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i066bb5b0a9e84c0a878b1e800703d92b_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18xMy9mcmFnOjVkY2JmNGI1ZTM3MzQyM2ZhMWY1NTcyM2Q3MTJlZWE1L3RhYmxlOjg4MmZmMDUyMmQ0NjRkYjdhZTY0MTg5MWY2NGEzODY3L3RhYmxlcmFuZ2U6ODgyZmYwNTIyZDQ2NGRiN2FlNjQxODkxZjY0YTM4NjdfMTktMy0xLTEtMA_9906ab90-2485-4f5f-8c46-a9f357b0ac06"
      unitRef="usd">539772472</us-gaap:Assets>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="ic36b9cedad7f41a6b9eb223b09b7186c_I20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18xMy9mcmFnOjVkY2JmNGI1ZTM3MzQyM2ZhMWY1NTcyM2Q3MTJlZWE1L3RhYmxlOjg4MmZmMDUyMmQ0NjRkYjdhZTY0MTg5MWY2NGEzODY3L3RhYmxlcmFuZ2U6ODgyZmYwNTIyZDQ2NGRiN2FlNjQxODkxZjY0YTM4NjdfMjItMS0xLTEtMA_debee0eb-6698-40a0-8159-c9a79bacc428"
      unitRef="usd">25974530</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="i066bb5b0a9e84c0a878b1e800703d92b_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18xMy9mcmFnOjVkY2JmNGI1ZTM3MzQyM2ZhMWY1NTcyM2Q3MTJlZWE1L3RhYmxlOjg4MmZmMDUyMmQ0NjRkYjdhZTY0MTg5MWY2NGEzODY3L3RhYmxlcmFuZ2U6ODgyZmYwNTIyZDQ2NGRiN2FlNjQxODkxZjY0YTM4NjdfMjItMy0xLTEtMA_c25b21c2-3013-4b22-865c-c19dac7aef90"
      unitRef="usd">21203808</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:DueToRelatedPartiesCurrent
      contextRef="ic36b9cedad7f41a6b9eb223b09b7186c_I20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18xMy9mcmFnOjVkY2JmNGI1ZTM3MzQyM2ZhMWY1NTcyM2Q3MTJlZWE1L3RhYmxlOjg4MmZmMDUyMmQ0NjRkYjdhZTY0MTg5MWY2NGEzODY3L3RhYmxlcmFuZ2U6ODgyZmYwNTIyZDQ2NGRiN2FlNjQxODkxZjY0YTM4NjdfMjMtMS0xLTEtMA_806ce4f8-a5e3-41db-976e-a905db0d1ff3"
      unitRef="usd">768261</us-gaap:DueToRelatedPartiesCurrent>
    <us-gaap:DueToRelatedPartiesCurrent
      contextRef="i066bb5b0a9e84c0a878b1e800703d92b_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18xMy9mcmFnOjVkY2JmNGI1ZTM3MzQyM2ZhMWY1NTcyM2Q3MTJlZWE1L3RhYmxlOjg4MmZmMDUyMmQ0NjRkYjdhZTY0MTg5MWY2NGEzODY3L3RhYmxlcmFuZ2U6ODgyZmYwNTIyZDQ2NGRiN2FlNjQxODkxZjY0YTM4NjdfMjMtMy0xLTEtMA_777f8632-02bc-45ab-8875-2448fdaf93f2"
      unitRef="usd">642969</us-gaap:DueToRelatedPartiesCurrent>
    <ino:AccruedClinicalTrialExpenseCurrent
      contextRef="ic36b9cedad7f41a6b9eb223b09b7186c_I20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18xMy9mcmFnOjVkY2JmNGI1ZTM3MzQyM2ZhMWY1NTcyM2Q3MTJlZWE1L3RhYmxlOjg4MmZmMDUyMmQ0NjRkYjdhZTY0MTg5MWY2NGEzODY3L3RhYmxlcmFuZ2U6ODgyZmYwNTIyZDQ2NGRiN2FlNjQxODkxZjY0YTM4NjdfMjQtMS0xLTEtMA_b97c2d79-8c29-451b-8503-979c273a7b51"
      unitRef="usd">7370869</ino:AccruedClinicalTrialExpenseCurrent>
    <ino:AccruedClinicalTrialExpenseCurrent
      contextRef="i066bb5b0a9e84c0a878b1e800703d92b_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18xMy9mcmFnOjVkY2JmNGI1ZTM3MzQyM2ZhMWY1NTcyM2Q3MTJlZWE1L3RhYmxlOjg4MmZmMDUyMmQ0NjRkYjdhZTY0MTg5MWY2NGEzODY3L3RhYmxlcmFuZ2U6ODgyZmYwNTIyZDQ2NGRiN2FlNjQxODkxZjY0YTM4NjdfMjQtMy0xLTEtMA_58ccd8ba-6e1d-4eb8-8fc9-c24154c5efd7"
      unitRef="usd">9950345</ino:AccruedClinicalTrialExpenseCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="ic36b9cedad7f41a6b9eb223b09b7186c_I20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18xMy9mcmFnOjVkY2JmNGI1ZTM3MzQyM2ZhMWY1NTcyM2Q3MTJlZWE1L3RhYmxlOjg4MmZmMDUyMmQ0NjRkYjdhZTY0MTg5MWY2NGEzODY3L3RhYmxlcmFuZ2U6ODgyZmYwNTIyZDQ2NGRiN2FlNjQxODkxZjY0YTM4NjdfMjYtMS0xLTEtMA_6b6a0afd-b8bc-479b-8861-be4a4064bfe5"
      unitRef="usd">15378</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i066bb5b0a9e84c0a878b1e800703d92b_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18xMy9mcmFnOjVkY2JmNGI1ZTM3MzQyM2ZhMWY1NTcyM2Q3MTJlZWE1L3RhYmxlOjg4MmZmMDUyMmQ0NjRkYjdhZTY0MTg5MWY2NGEzODY3L3RhYmxlcmFuZ2U6ODgyZmYwNTIyZDQ2NGRiN2FlNjQxODkxZjY0YTM4NjdfMjYtMy0xLTEtMA_ca6aef6f-fa92-48d9-bd09-52e40599248b"
      unitRef="usd">46628</us-gaap:ContractWithCustomerLiabilityCurrent>
    <ino:ContractWithCustomerLiabilityAffiliatedEntityCurrent
      contextRef="ic36b9cedad7f41a6b9eb223b09b7186c_I20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18xMy9mcmFnOjVkY2JmNGI1ZTM3MzQyM2ZhMWY1NTcyM2Q3MTJlZWE1L3RhYmxlOjg4MmZmMDUyMmQ0NjRkYjdhZTY0MTg5MWY2NGEzODY3L3RhYmxlcmFuZ2U6ODgyZmYwNTIyZDQ2NGRiN2FlNjQxODkxZjY0YTM4NjdfMjctMS0xLTEtMA_3fd00f3b-0dad-415c-8a39-af9f3491a333"
      unitRef="usd">39000</ino:ContractWithCustomerLiabilityAffiliatedEntityCurrent>
    <ino:ContractWithCustomerLiabilityAffiliatedEntityCurrent
      contextRef="i066bb5b0a9e84c0a878b1e800703d92b_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18xMy9mcmFnOjVkY2JmNGI1ZTM3MzQyM2ZhMWY1NTcyM2Q3MTJlZWE1L3RhYmxlOjg4MmZmMDUyMmQ0NjRkYjdhZTY0MTg5MWY2NGEzODY3L3RhYmxlcmFuZ2U6ODgyZmYwNTIyZDQ2NGRiN2FlNjQxODkxZjY0YTM4NjdfMjctMy0xLTEtMA_629f78ae-634b-4911-932e-4e65e88a0af4"
      unitRef="usd">0</ino:ContractWithCustomerLiabilityAffiliatedEntityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="ic36b9cedad7f41a6b9eb223b09b7186c_I20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18xMy9mcmFnOjVkY2JmNGI1ZTM3MzQyM2ZhMWY1NTcyM2Q3MTJlZWE1L3RhYmxlOjg4MmZmMDUyMmQ0NjRkYjdhZTY0MTg5MWY2NGEzODY3L3RhYmxlcmFuZ2U6ODgyZmYwNTIyZDQ2NGRiN2FlNjQxODkxZjY0YTM4NjdfMjktMS0xLTEtMA_192a066b-066a-48c2-8637-79938916d9fa"
      unitRef="usd">2395928</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i066bb5b0a9e84c0a878b1e800703d92b_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18xMy9mcmFnOjVkY2JmNGI1ZTM3MzQyM2ZhMWY1NTcyM2Q3MTJlZWE1L3RhYmxlOjg4MmZmMDUyMmQ0NjRkYjdhZTY0MTg5MWY2NGEzODY3L3RhYmxlcmFuZ2U6ODgyZmYwNTIyZDQ2NGRiN2FlNjQxODkxZjY0YTM4NjdfMjktMy0xLTEtMA_08f133e0-86d8-4576-a5dc-24da4265e0b5"
      unitRef="usd">2329394</us-gaap:OperatingLeaseLiabilityCurrent>
    <ino:DeferredGrantFundingCurrent
      contextRef="ic36b9cedad7f41a6b9eb223b09b7186c_I20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18xMy9mcmFnOjVkY2JmNGI1ZTM3MzQyM2ZhMWY1NTcyM2Q3MTJlZWE1L3RhYmxlOjg4MmZmMDUyMmQ0NjRkYjdhZTY0MTg5MWY2NGEzODY3L3RhYmxlcmFuZ2U6ODgyZmYwNTIyZDQ2NGRiN2FlNjQxODkxZjY0YTM4NjdfMzAtMS0xLTEtMA_5be0976e-19ea-43ef-8df5-1b50c8e790b4"
      unitRef="usd">4975484</ino:DeferredGrantFundingCurrent>
    <ino:DeferredGrantFundingCurrent
      contextRef="i066bb5b0a9e84c0a878b1e800703d92b_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18xMy9mcmFnOjVkY2JmNGI1ZTM3MzQyM2ZhMWY1NTcyM2Q3MTJlZWE1L3RhYmxlOjg4MmZmMDUyMmQ0NjRkYjdhZTY0MTg5MWY2NGEzODY3L3RhYmxlcmFuZ2U6ODgyZmYwNTIyZDQ2NGRiN2FlNjQxODkxZjY0YTM4NjdfMzAtMy0xLTEtMA_fb990ce3-3afc-48e9-bdf9-02bb5cb1fc60"
      unitRef="usd">7474310</ino:DeferredGrantFundingCurrent>
    <ino:DeferredGrantFundingFromAffiliateCurrent
      contextRef="ic36b9cedad7f41a6b9eb223b09b7186c_I20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18xMy9mcmFnOjVkY2JmNGI1ZTM3MzQyM2ZhMWY1NTcyM2Q3MTJlZWE1L3RhYmxlOjg4MmZmMDUyMmQ0NjRkYjdhZTY0MTg5MWY2NGEzODY3L3RhYmxlcmFuZ2U6ODgyZmYwNTIyZDQ2NGRiN2FlNjQxODkxZjY0YTM4NjdfMzEtMS0xLTEtMA_58c706f7-0f44-4921-a548-084810473676"
      unitRef="usd">0</ino:DeferredGrantFundingFromAffiliateCurrent>
    <ino:DeferredGrantFundingFromAffiliateCurrent
      contextRef="i066bb5b0a9e84c0a878b1e800703d92b_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18xMy9mcmFnOjVkY2JmNGI1ZTM3MzQyM2ZhMWY1NTcyM2Q3MTJlZWE1L3RhYmxlOjg4MmZmMDUyMmQ0NjRkYjdhZTY0MTg5MWY2NGEzODY3L3RhYmxlcmFuZ2U6ODgyZmYwNTIyZDQ2NGRiN2FlNjQxODkxZjY0YTM4NjdfMzEtMy0xLTEtMA_f44c6b7d-1b62-49c4-ab6b-d1cddc95bfe2"
      unitRef="usd">58500</ino:DeferredGrantFundingFromAffiliateCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="ic36b9cedad7f41a6b9eb223b09b7186c_I20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18xMy9mcmFnOjVkY2JmNGI1ZTM3MzQyM2ZhMWY1NTcyM2Q3MTJlZWE1L3RhYmxlOjg4MmZmMDUyMmQ0NjRkYjdhZTY0MTg5MWY2NGEzODY3L3RhYmxlcmFuZ2U6ODgyZmYwNTIyZDQ2NGRiN2FlNjQxODkxZjY0YTM4NjdfMzMtMS0xLTEtMA_6850d9d9-a753-40c8-a8b0-22bdf85c3825"
      unitRef="usd">41539450</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i066bb5b0a9e84c0a878b1e800703d92b_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18xMy9mcmFnOjVkY2JmNGI1ZTM3MzQyM2ZhMWY1NTcyM2Q3MTJlZWE1L3RhYmxlOjg4MmZmMDUyMmQ0NjRkYjdhZTY0MTg5MWY2NGEzODY3L3RhYmxlcmFuZ2U6ODgyZmYwNTIyZDQ2NGRiN2FlNjQxODkxZjY0YTM4NjdfMzMtMy0xLTEtMA_5f2396ff-cc35-4ce5-a975-3d0197364207"
      unitRef="usd">41705954</us-gaap:LiabilitiesCurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="ic36b9cedad7f41a6b9eb223b09b7186c_I20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18xMy9mcmFnOjVkY2JmNGI1ZTM3MzQyM2ZhMWY1NTcyM2Q3MTJlZWE1L3RhYmxlOjg4MmZmMDUyMmQ0NjRkYjdhZTY0MTg5MWY2NGEzODY3L3RhYmxlcmFuZ2U6ODgyZmYwNTIyZDQ2NGRiN2FlNjQxODkxZjY0YTM4NjdfMzQtMS0xLTEtMA_ea0f1ed8-0f2d-4c30-a2eb-80501524698c"
      unitRef="usd">75501</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="i066bb5b0a9e84c0a878b1e800703d92b_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18xMy9mcmFnOjVkY2JmNGI1ZTM3MzQyM2ZhMWY1NTcyM2Q3MTJlZWE1L3RhYmxlOjg4MmZmMDUyMmQ0NjRkYjdhZTY0MTg5MWY2NGEzODY3L3RhYmxlcmFuZ2U6ODgyZmYwNTIyZDQ2NGRiN2FlNjQxODkxZjY0YTM4NjdfMzQtMy0xLTEtMA_db93c4ca-1f23-49b9-8cba-9cb2f0bfbc03"
      unitRef="usd">79214</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ConvertibleDebt
      contextRef="ibf1dda891fd044098c213cc6a530fa62_I20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18xMy9mcmFnOjVkY2JmNGI1ZTM3MzQyM2ZhMWY1NTcyM2Q3MTJlZWE1L3RhYmxlOjg4MmZmMDUyMmQ0NjRkYjdhZTY0MTg5MWY2NGEzODY3L3RhYmxlcmFuZ2U6ODgyZmYwNTIyZDQ2NGRiN2FlNjQxODkxZjY0YTM4NjdfMzYtMS0xLTEtMA_34968e8f-142a-475b-b17b-7c2785d4d234"
      unitRef="usd">14069722</us-gaap:ConvertibleDebt>
    <us-gaap:ConvertibleDebt
      contextRef="i09cc78b6ef5244c28a45a7069619a8b5_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18xMy9mcmFnOjVkY2JmNGI1ZTM3MzQyM2ZhMWY1NTcyM2Q3MTJlZWE1L3RhYmxlOjg4MmZmMDUyMmQ0NjRkYjdhZTY0MTg5MWY2NGEzODY3L3RhYmxlcmFuZ2U6ODgyZmYwNTIyZDQ2NGRiN2FlNjQxODkxZjY0YTM4NjdfMzYtMy0xLTEtMA_d5f57b14-d7c9-4460-8157-7d105e8bac1f"
      unitRef="usd">14139988</us-gaap:ConvertibleDebt>
    <us-gaap:ConvertibleDebt
      contextRef="icda7d72fec364e2ea292b925ab363121_I20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18xMy9mcmFnOjVkY2JmNGI1ZTM3MzQyM2ZhMWY1NTcyM2Q3MTJlZWE1L3RhYmxlOjg4MmZmMDUyMmQ0NjRkYjdhZTY0MTg5MWY2NGEzODY3L3RhYmxlcmFuZ2U6ODgyZmYwNTIyZDQ2NGRiN2FlNjQxODkxZjY0YTM4NjdfMzctMS0xLTEtMA_be0ee862-b697-44cb-b754-fb641bf396fb"
      unitRef="usd">0</us-gaap:ConvertibleDebt>
    <us-gaap:ConvertibleDebt
      contextRef="ifc2893c2a85c477f8396936402f496e2_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18xMy9mcmFnOjVkY2JmNGI1ZTM3MzQyM2ZhMWY1NTcyM2Q3MTJlZWE1L3RhYmxlOjg4MmZmMDUyMmQ0NjRkYjdhZTY0MTg5MWY2NGEzODY3L3RhYmxlcmFuZ2U6ODgyZmYwNTIyZDQ2NGRiN2FlNjQxODkxZjY0YTM4NjdfMzctMy0xLTEtMA_de76163a-5a3b-4e0e-b70e-1c7b7471b852"
      unitRef="usd">4515834</us-gaap:ConvertibleDebt>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="ic36b9cedad7f41a6b9eb223b09b7186c_I20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18xMy9mcmFnOjVkY2JmNGI1ZTM3MzQyM2ZhMWY1NTcyM2Q3MTJlZWE1L3RhYmxlOjg4MmZmMDUyMmQ0NjRkYjdhZTY0MTg5MWY2NGEzODY3L3RhYmxlcmFuZ2U6ODgyZmYwNTIyZDQ2NGRiN2FlNjQxODkxZjY0YTM4NjdfNDAtMS0xLTEtMA_1355fd6c-f5c6-432d-8310-54a67a3fc222"
      unitRef="usd">17438841</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i066bb5b0a9e84c0a878b1e800703d92b_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18xMy9mcmFnOjVkY2JmNGI1ZTM3MzQyM2ZhMWY1NTcyM2Q3MTJlZWE1L3RhYmxlOjg4MmZmMDUyMmQ0NjRkYjdhZTY0MTg5MWY2NGEzODY3L3RhYmxlcmFuZ2U6ODgyZmYwNTIyZDQ2NGRiN2FlNjQxODkxZjY0YTM4NjdfNDAtMy0xLTEtMA_d6173114-58a2-44b4-8607-7b85f962b485"
      unitRef="usd">18063515</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="ic36b9cedad7f41a6b9eb223b09b7186c_I20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18xMy9mcmFnOjVkY2JmNGI1ZTM3MzQyM2ZhMWY1NTcyM2Q3MTJlZWE1L3RhYmxlOjg4MmZmMDUyMmQ0NjRkYjdhZTY0MTg5MWY2NGEzODY3L3RhYmxlcmFuZ2U6ODgyZmYwNTIyZDQ2NGRiN2FlNjQxODkxZjY0YTM4NjdfNDEtMS0xLTEtMA_4ff4e430-12bb-4257-97ea-388c96965bd5"
      unitRef="usd">32046</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="i066bb5b0a9e84c0a878b1e800703d92b_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18xMy9mcmFnOjVkY2JmNGI1ZTM3MzQyM2ZhMWY1NTcyM2Q3MTJlZWE1L3RhYmxlOjg4MmZmMDUyMmQ0NjRkYjdhZTY0MTg5MWY2NGEzODY3L3RhYmxlcmFuZ2U6ODgyZmYwNTIyZDQ2NGRiN2FlNjQxODkxZjY0YTM4NjdfNDEtMy0xLTEtMA_03942e07-5127-4c35-bfa9-924e8d4dc0ae"
      unitRef="usd">32046</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <ino:DeferredGrantFundingFromAffiliateNoncurrent
      contextRef="ic36b9cedad7f41a6b9eb223b09b7186c_I20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18xMy9mcmFnOjVkY2JmNGI1ZTM3MzQyM2ZhMWY1NTcyM2Q3MTJlZWE1L3RhYmxlOjg4MmZmMDUyMmQ0NjRkYjdhZTY0MTg5MWY2NGEzODY3L3RhYmxlcmFuZ2U6ODgyZmYwNTIyZDQ2NGRiN2FlNjQxODkxZjY0YTM4NjdfNDItMS0xLTEtMA_784f650c-cffd-416f-84ab-54c94d6b7717"
      unitRef="usd">37500</ino:DeferredGrantFundingFromAffiliateNoncurrent>
    <ino:DeferredGrantFundingFromAffiliateNoncurrent
      contextRef="i066bb5b0a9e84c0a878b1e800703d92b_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18xMy9mcmFnOjVkY2JmNGI1ZTM3MzQyM2ZhMWY1NTcyM2Q3MTJlZWE1L3RhYmxlOjg4MmZmMDUyMmQ0NjRkYjdhZTY0MTg5MWY2NGEzODY3L3RhYmxlcmFuZ2U6ODgyZmYwNTIyZDQ2NGRiN2FlNjQxODkxZjY0YTM4NjdfNDItMy0xLTEtMA_82b26004-e67f-41e7-876d-9f43269df0bb"
      unitRef="usd">37500</ino:DeferredGrantFundingFromAffiliateNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="ic36b9cedad7f41a6b9eb223b09b7186c_I20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18xMy9mcmFnOjVkY2JmNGI1ZTM3MzQyM2ZhMWY1NTcyM2Q3MTJlZWE1L3RhYmxlOjg4MmZmMDUyMmQ0NjRkYjdhZTY0MTg5MWY2NGEzODY3L3RhYmxlcmFuZ2U6ODgyZmYwNTIyZDQ2NGRiN2FlNjQxODkxZjY0YTM4NjdfNDMtMS0xLTEtMA_251907ce-a3b5-406e-9800-8a5d8541931e"
      unitRef="usd">64141</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i066bb5b0a9e84c0a878b1e800703d92b_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18xMy9mcmFnOjVkY2JmNGI1ZTM3MzQyM2ZhMWY1NTcyM2Q3MTJlZWE1L3RhYmxlOjg4MmZmMDUyMmQ0NjRkYjdhZTY0MTg5MWY2NGEzODY3L3RhYmxlcmFuZ2U6ODgyZmYwNTIyZDQ2NGRiN2FlNjQxODkxZjY0YTM4NjdfNDMtMy0xLTEtMA_1b9f7923-628d-4d22-b2e2-1b0fa18e8ffc"
      unitRef="usd">57663</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="ic36b9cedad7f41a6b9eb223b09b7186c_I20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18xMy9mcmFnOjVkY2JmNGI1ZTM3MzQyM2ZhMWY1NTcyM2Q3MTJlZWE1L3RhYmxlOjg4MmZmMDUyMmQ0NjRkYjdhZTY0MTg5MWY2NGEzODY3L3RhYmxlcmFuZ2U6ODgyZmYwNTIyZDQ2NGRiN2FlNjQxODkxZjY0YTM4NjdfNDQtMS0xLTEtMA_bfac19d5-cca0-4b3e-bd5f-da668b19718d"
      unitRef="usd">73257201</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="i066bb5b0a9e84c0a878b1e800703d92b_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18xMy9mcmFnOjVkY2JmNGI1ZTM3MzQyM2ZhMWY1NTcyM2Q3MTJlZWE1L3RhYmxlOjg4MmZmMDUyMmQ0NjRkYjdhZTY0MTg5MWY2NGEzODY3L3RhYmxlcmFuZ2U6ODgyZmYwNTIyZDQ2NGRiN2FlNjQxODkxZjY0YTM4NjdfNDQtMy0xLTEtMA_22532fc3-1ef5-4f95-ab2f-0f503f771de6"
      unitRef="usd">78631714</us-gaap:Liabilities>
    <us-gaap:PreferredStockValue
      contextRef="ic36b9cedad7f41a6b9eb223b09b7186c_I20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18xMy9mcmFnOjVkY2JmNGI1ZTM3MzQyM2ZhMWY1NTcyM2Q3MTJlZWE1L3RhYmxlOjg4MmZmMDUyMmQ0NjRkYjdhZTY0MTg5MWY2NGEzODY3L3RhYmxlcmFuZ2U6ODgyZmYwNTIyZDQ2NGRiN2FlNjQxODkxZjY0YTM4NjdfNDYtMS0xLTEtMA_8fec68e8-ab69-47f0-bcab-302244ff6d35"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="i066bb5b0a9e84c0a878b1e800703d92b_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18xMy9mcmFnOjVkY2JmNGI1ZTM3MzQyM2ZhMWY1NTcyM2Q3MTJlZWE1L3RhYmxlOjg4MmZmMDUyMmQ0NjRkYjdhZTY0MTg5MWY2NGEzODY3L3RhYmxlcmFuZ2U6ODgyZmYwNTIyZDQ2NGRiN2FlNjQxODkxZjY0YTM4NjdfNDYtMy0xLTEtMA_4fbff785-5bca-4ea5-8c99-ac51fb986e03"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockValue
      contextRef="ic36b9cedad7f41a6b9eb223b09b7186c_I20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18xMy9mcmFnOjVkY2JmNGI1ZTM3MzQyM2ZhMWY1NTcyM2Q3MTJlZWE1L3RhYmxlOjg4MmZmMDUyMmQ0NjRkYjdhZTY0MTg5MWY2NGEzODY3L3RhYmxlcmFuZ2U6ODgyZmYwNTIyZDQ2NGRiN2FlNjQxODkxZjY0YTM4NjdfNDctMS0xLTEtMA_9ecd81a0-ad83-475d-bc2f-dbd85ee26659"
      unitRef="usd">209333</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="i066bb5b0a9e84c0a878b1e800703d92b_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18xMy9mcmFnOjVkY2JmNGI1ZTM3MzQyM2ZhMWY1NTcyM2Q3MTJlZWE1L3RhYmxlOjg4MmZmMDUyMmQ0NjRkYjdhZTY0MTg5MWY2NGEzODY3L3RhYmxlcmFuZ2U6ODgyZmYwNTIyZDQ2NGRiN2FlNjQxODkxZjY0YTM4NjdfNDctMy0xLTEtMA_04aaa9ef-c050-4ea2-974c-fbfab7271b8b"
      unitRef="usd">186851</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="ic36b9cedad7f41a6b9eb223b09b7186c_I20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18xMy9mcmFnOjVkY2JmNGI1ZTM3MzQyM2ZhMWY1NTcyM2Q3MTJlZWE1L3RhYmxlOjg4MmZmMDUyMmQ0NjRkYjdhZTY0MTg5MWY2NGEzODY3L3RhYmxlcmFuZ2U6ODgyZmYwNTIyZDQ2NGRiN2FlNjQxODkxZjY0YTM4NjdfNDgtMS0xLTEtMA_201efff1-e066-4b9f-95f6-e2c7e7611166"
      unitRef="usd">1542261467</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i066bb5b0a9e84c0a878b1e800703d92b_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18xMy9mcmFnOjVkY2JmNGI1ZTM3MzQyM2ZhMWY1NTcyM2Q3MTJlZWE1L3RhYmxlOjg4MmZmMDUyMmQ0NjRkYjdhZTY0MTg5MWY2NGEzODY3L3RhYmxlcmFuZ2U6ODgyZmYwNTIyZDQ2NGRiN2FlNjQxODkxZjY0YTM4NjdfNDgtMy0xLTEtMA_d6236880-41ae-4875-a816-5e4c2d427c98"
      unitRef="usd">1367406869</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="ic36b9cedad7f41a6b9eb223b09b7186c_I20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18xMy9mcmFnOjVkY2JmNGI1ZTM3MzQyM2ZhMWY1NTcyM2Q3MTJlZWE1L3RhYmxlOjg4MmZmMDUyMmQ0NjRkYjdhZTY0MTg5MWY2NGEzODY3L3RhYmxlcmFuZ2U6ODgyZmYwNTIyZDQ2NGRiN2FlNjQxODkxZjY0YTM4NjdfNDktMS0xLTEtMA_57528c28-4604-4dd2-bd72-1ca521695f1c"
      unitRef="usd">-960598943</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i066bb5b0a9e84c0a878b1e800703d92b_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18xMy9mcmFnOjVkY2JmNGI1ZTM3MzQyM2ZhMWY1NTcyM2Q3MTJlZWE1L3RhYmxlOjg4MmZmMDUyMmQ0NjRkYjdhZTY0MTg5MWY2NGEzODY3L3RhYmxlcmFuZ2U6ODgyZmYwNTIyZDQ2NGRiN2FlNjQxODkxZjY0YTM4NjdfNDktMy0xLTEtMA_285d94f8-7501-4948-92ab-288856160940"
      unitRef="usd">-906196812</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="ic36b9cedad7f41a6b9eb223b09b7186c_I20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18xMy9mcmFnOjVkY2JmNGI1ZTM3MzQyM2ZhMWY1NTcyM2Q3MTJlZWE1L3RhYmxlOjg4MmZmMDUyMmQ0NjRkYjdhZTY0MTg5MWY2NGEzODY3L3RhYmxlcmFuZ2U6ODgyZmYwNTIyZDQ2NGRiN2FlNjQxODkxZjY0YTM4NjdfNTAtMS0xLTEtMA_981653ba-bd72-4f3a-97ea-faed00b625d3"
      unitRef="usd">-265708</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i066bb5b0a9e84c0a878b1e800703d92b_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18xMy9mcmFnOjVkY2JmNGI1ZTM3MzQyM2ZhMWY1NTcyM2Q3MTJlZWE1L3RhYmxlOjg4MmZmMDUyMmQ0NjRkYjdhZTY0MTg5MWY2NGEzODY3L3RhYmxlcmFuZ2U6ODgyZmYwNTIyZDQ2NGRiN2FlNjQxODkxZjY0YTM4NjdfNTAtMy0xLTEtMA_1dca97f5-f913-4e4d-bf38-9586bec96fbe"
      unitRef="usd">-256150</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquity
      contextRef="ic36b9cedad7f41a6b9eb223b09b7186c_I20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18xMy9mcmFnOjVkY2JmNGI1ZTM3MzQyM2ZhMWY1NTcyM2Q3MTJlZWE1L3RhYmxlOjg4MmZmMDUyMmQ0NjRkYjdhZTY0MTg5MWY2NGEzODY3L3RhYmxlcmFuZ2U6ODgyZmYwNTIyZDQ2NGRiN2FlNjQxODkxZjY0YTM4NjdfNTEtMS0xLTEtMA_879fbbd5-6af7-4368-a267-9ef16c566846"
      unitRef="usd">581606149</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i066bb5b0a9e84c0a878b1e800703d92b_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18xMy9mcmFnOjVkY2JmNGI1ZTM3MzQyM2ZhMWY1NTcyM2Q3MTJlZWE1L3RhYmxlOjg4MmZmMDUyMmQ0NjRkYjdhZTY0MTg5MWY2NGEzODY3L3RhYmxlcmFuZ2U6ODgyZmYwNTIyZDQ2NGRiN2FlNjQxODkxZjY0YTM4NjdfNTEtMy0xLTEtMA_88562dfe-16a7-49e3-9b76-754e2ae2eea7"
      unitRef="usd">461140758</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="ic36b9cedad7f41a6b9eb223b09b7186c_I20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18xMy9mcmFnOjVkY2JmNGI1ZTM3MzQyM2ZhMWY1NTcyM2Q3MTJlZWE1L3RhYmxlOjg4MmZmMDUyMmQ0NjRkYjdhZTY0MTg5MWY2NGEzODY3L3RhYmxlcmFuZ2U6ODgyZmYwNTIyZDQ2NGRiN2FlNjQxODkxZjY0YTM4NjdfNTQtMS0xLTEtMA_55a7dcea-5957-4797-b8da-418bfa4b745c"
      unitRef="usd">654863350</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i066bb5b0a9e84c0a878b1e800703d92b_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18xMy9mcmFnOjVkY2JmNGI1ZTM3MzQyM2ZhMWY1NTcyM2Q3MTJlZWE1L3RhYmxlOjg4MmZmMDUyMmQ0NjRkYjdhZTY0MTg5MWY2NGEzODY3L3RhYmxlcmFuZ2U6ODgyZmYwNTIyZDQ2NGRiN2FlNjQxODkxZjY0YTM4NjdfNTQtMy0xLTEtMA_e9a8b0ef-ac0c-45d9-87a2-1b10c6e6db9a"
      unitRef="usd">539772472</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i09001f493159423f9996d4b99e003558_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18xNi9mcmFnOjAwM2U2NzdhMmJmMDRhYTM4NWVmMjFlNzAzNTYxZmUzL3RhYmxlOmYxNTM5MTVmMTRmMTQ3NzRhY2Y1ZGIzNTcxZmYxM2NhL3RhYmxlcmFuZ2U6ZjE1MzkxNWYxNGYxNDc3NGFjZjVkYjM1NzFmZjEzY2FfMy0xLTEtMS0w_128e5863-2b7e-4bfa-a7f9-bd9ce8b0dd55"
      unitRef="usd">39615</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2b0dec7a04644e5da0ed8efcc8dcc6e4_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18xNi9mcmFnOjAwM2U2NzdhMmJmMDRhYTM4NWVmMjFlNzAzNTYxZmUzL3RhYmxlOmYxNTM5MTVmMTRmMTQ3NzRhY2Y1ZGIzNTcxZmYxM2NhL3RhYmxlcmFuZ2U6ZjE1MzkxNWYxNGYxNDc3NGFjZjVkYjM1NzFmZjEzY2FfMy0zLTEtMS0w_1cef2734-cca8-4965-9016-6ef9b8d07ecd"
      unitRef="usd">71500</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2e683dd292fa4879b525cd0f84179804_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18xNi9mcmFnOjAwM2U2NzdhMmJmMDRhYTM4NWVmMjFlNzAzNTYxZmUzL3RhYmxlOmYxNTM5MTVmMTRmMTQ3NzRhY2Y1ZGIzNTcxZmYxM2NhL3RhYmxlcmFuZ2U6ZjE1MzkxNWYxNGYxNDc3NGFjZjVkYjM1NzFmZjEzY2FfNC0xLTEtMS0w_f26a804c-eb93-47ae-8fe2-f0594a243364"
      unitRef="usd">49949</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i800a1e3bd482439e9d1e93a9ff22ac27_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18xNi9mcmFnOjAwM2U2NzdhMmJmMDRhYTM4NWVmMjFlNzAzNTYxZmUzL3RhYmxlOmYxNTM5MTVmMTRmMTQ3NzRhY2Y1ZGIzNTcxZmYxM2NhL3RhYmxlcmFuZ2U6ZjE1MzkxNWYxNGYxNDc3NGFjZjVkYjM1NzFmZjEzY2FfNC0zLTEtMS0w_c9984c10-ec9f-4233-905f-6f00bfaf3cbe"
      unitRef="usd">1172126</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ica16a3607c6a4031a1fa37be362346d3_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18xNi9mcmFnOjAwM2U2NzdhMmJmMDRhYTM4NWVmMjFlNzAzNTYxZmUzL3RhYmxlOmYxNTM5MTVmMTRmMTQ3NzRhY2Y1ZGIzNTcxZmYxM2NhL3RhYmxlcmFuZ2U6ZjE1MzkxNWYxNGYxNDc3NGFjZjVkYjM1NzFmZjEzY2FfNS0xLTEtMS0w_f971d145-7c10-4304-a3c3-976196c8a424"
      unitRef="usd">281556</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i72f1fa77c5894104884af93e5e365e2a_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18xNi9mcmFnOjAwM2U2NzdhMmJmMDRhYTM4NWVmMjFlNzAzNTYxZmUzL3RhYmxlOmYxNTM5MTVmMTRmMTQ3NzRhY2Y1ZGIzNTcxZmYxM2NhL3RhYmxlcmFuZ2U6ZjE1MzkxNWYxNGYxNDc3NGFjZjVkYjM1NzFmZjEzY2FfNS0zLTEtMS0w_8cd3d54d-3dd7-4939-a69c-9fd411328dbc"
      unitRef="usd">83648</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18xNi9mcmFnOjAwM2U2NzdhMmJmMDRhYTM4NWVmMjFlNzAzNTYxZmUzL3RhYmxlOmYxNTM5MTVmMTRmMTQ3NzRhY2Y1ZGIzNTcxZmYxM2NhL3RhYmxlcmFuZ2U6ZjE1MzkxNWYxNGYxNDc3NGFjZjVkYjM1NzFmZjEzY2FfOC0xLTEtMS0w_725d10bf-d296-4b17-886a-edafb698421e"
      unitRef="usd">371120</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i03bccaa0abfb4733b1e2831ecde4e4e8_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18xNi9mcmFnOjAwM2U2NzdhMmJmMDRhYTM4NWVmMjFlNzAzNTYxZmUzL3RhYmxlOmYxNTM5MTVmMTRmMTQ3NzRhY2Y1ZGIzNTcxZmYxM2NhL3RhYmxlcmFuZ2U6ZjE1MzkxNWYxNGYxNDc3NGFjZjVkYjM1NzFmZjEzY2FfOC0zLTEtMS0w_84cb229a-a2f9-4f80-a808-2b05b95f1656"
      unitRef="usd">1327274</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18xNi9mcmFnOjAwM2U2NzdhMmJmMDRhYTM4NWVmMjFlNzAzNTYxZmUzL3RhYmxlOmYxNTM5MTVmMTRmMTQ3NzRhY2Y1ZGIzNTcxZmYxM2NhL3RhYmxlcmFuZ2U6ZjE1MzkxNWYxNGYxNDc3NGFjZjVkYjM1NzFmZjEzY2FfMTAtMS0xLTEtMA_2795fb7c-01ee-41c6-8e2b-3add1b8f04ff"
      unitRef="usd">39044418</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i03bccaa0abfb4733b1e2831ecde4e4e8_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18xNi9mcmFnOjAwM2U2NzdhMmJmMDRhYTM4NWVmMjFlNzAzNTYxZmUzL3RhYmxlOmYxNTM5MTVmMTRmMTQ3NzRhY2Y1ZGIzNTcxZmYxM2NhL3RhYmxlcmFuZ2U6ZjE1MzkxNWYxNGYxNDc3NGFjZjVkYjM1NzFmZjEzY2FfMTAtMy0xLTEtMA_41b522e9-7305-436d-8c82-ac954c249edd"
      unitRef="usd">19111188</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18xNi9mcmFnOjAwM2U2NzdhMmJmMDRhYTM4NWVmMjFlNzAzNTYxZmUzL3RhYmxlOmYxNTM5MTVmMTRmMTQ3NzRhY2Y1ZGIzNTcxZmYxM2NhL3RhYmxlcmFuZ2U6ZjE1MzkxNWYxNGYxNDc3NGFjZjVkYjM1NzFmZjEzY2FfMTEtMS0xLTEtMA_663fa66a-a32e-4634-b0e2-d9d74b6746ad"
      unitRef="usd">13881194</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i03bccaa0abfb4733b1e2831ecde4e4e8_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18xNi9mcmFnOjAwM2U2NzdhMmJmMDRhYTM4NWVmMjFlNzAzNTYxZmUzL3RhYmxlOmYxNTM5MTVmMTRmMTQ3NzRhY2Y1ZGIzNTcxZmYxM2NhL3RhYmxlcmFuZ2U6ZjE1MzkxNWYxNGYxNDc3NGFjZjVkYjM1NzFmZjEzY2FfMTEtMy0xLTEtMA_7cdfb58a-160d-4f36-b61c-a9e6752eb6bd"
      unitRef="usd">7448354</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18xNi9mcmFnOjAwM2U2NzdhMmJmMDRhYTM4NWVmMjFlNzAzNTYxZmUzL3RhYmxlOmYxNTM5MTVmMTRmMTQ3NzRhY2Y1ZGIzNTcxZmYxM2NhL3RhYmxlcmFuZ2U6ZjE1MzkxNWYxNGYxNDc3NGFjZjVkYjM1NzFmZjEzY2FfMTMtMS0xLTEtMA_68cb96e1-40e9-43bf-85f5-3f5df05cc201"
      unitRef="usd">52925612</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="i03bccaa0abfb4733b1e2831ecde4e4e8_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18xNi9mcmFnOjAwM2U2NzdhMmJmMDRhYTM4NWVmMjFlNzAzNTYxZmUzL3RhYmxlOmYxNTM5MTVmMTRmMTQ3NzRhY2Y1ZGIzNTcxZmYxM2NhL3RhYmxlcmFuZ2U6ZjE1MzkxNWYxNGYxNDc3NGFjZjVkYjM1NzFmZjEzY2FfMTMtMy0xLTEtMA_96342e63-ed0e-4f0b-9734-f8ceb226a0ab"
      unitRef="usd">26559542</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18xNi9mcmFnOjAwM2U2NzdhMmJmMDRhYTM4NWVmMjFlNzAzNTYxZmUzL3RhYmxlOmYxNTM5MTVmMTRmMTQ3NzRhY2Y1ZGIzNTcxZmYxM2NhL3RhYmxlcmFuZ2U6ZjE1MzkxNWYxNGYxNDc3NGFjZjVkYjM1NzFmZjEzY2FfMTQtMS0xLTEtMA_0e9f9b99-402f-4de5-8c65-73c6bd264e99"
      unitRef="usd">-52554492</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i03bccaa0abfb4733b1e2831ecde4e4e8_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18xNi9mcmFnOjAwM2U2NzdhMmJmMDRhYTM4NWVmMjFlNzAzNTYxZmUzL3RhYmxlOmYxNTM5MTVmMTRmMTQ3NzRhY2Y1ZGIzNTcxZmYxM2NhL3RhYmxlcmFuZ2U6ZjE1MzkxNWYxNGYxNDc3NGFjZjVkYjM1NzFmZjEzY2FfMTQtMy0xLTEtMA_ac896295-a1d1-4b7d-8134-92bdd454d146"
      unitRef="usd">-25232268</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestIncomeOperating
      contextRef="i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18xNi9mcmFnOjAwM2U2NzdhMmJmMDRhYTM4NWVmMjFlNzAzNTYxZmUzL3RhYmxlOmYxNTM5MTVmMTRmMTQ3NzRhY2Y1ZGIzNTcxZmYxM2NhL3RhYmxlcmFuZ2U6ZjE1MzkxNWYxNGYxNDc3NGFjZjVkYjM1NzFmZjEzY2FfMTYtMS0xLTEtMA_490f0e8b-92c9-4967-ae6a-ce510152f66b"
      unitRef="usd">769237</us-gaap:InterestIncomeOperating>
    <us-gaap:InterestIncomeOperating
      contextRef="i03bccaa0abfb4733b1e2831ecde4e4e8_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18xNi9mcmFnOjAwM2U2NzdhMmJmMDRhYTM4NWVmMjFlNzAzNTYxZmUzL3RhYmxlOmYxNTM5MTVmMTRmMTQ3NzRhY2Y1ZGIzNTcxZmYxM2NhL3RhYmxlcmFuZ2U6ZjE1MzkxNWYxNGYxNDc3NGFjZjVkYjM1NzFmZjEzY2FfMTYtMy0xLTEtMA_ff93a11e-50e6-4a72-b581-66d6a0f4bfbe"
      unitRef="usd">416569</us-gaap:InterestIncomeOperating>
    <us-gaap:InterestExpense
      contextRef="i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18xNi9mcmFnOjAwM2U2NzdhMmJmMDRhYTM4NWVmMjFlNzAzNTYxZmUzL3RhYmxlOmYxNTM5MTVmMTRmMTQ3NzRhY2Y1ZGIzNTcxZmYxM2NhL3RhYmxlcmFuZ2U6ZjE1MzkxNWYxNGYxNDc3NGFjZjVkYjM1NzFmZjEzY2FfMTctMS0xLTEtMA_5370f412-e08b-4721-b031-7a386832d046"
      unitRef="usd">513034</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i03bccaa0abfb4733b1e2831ecde4e4e8_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18xNi9mcmFnOjAwM2U2NzdhMmJmMDRhYTM4NWVmMjFlNzAzNTYxZmUzL3RhYmxlOmYxNTM5MTVmMTRmMTQ3NzRhY2Y1ZGIzNTcxZmYxM2NhL3RhYmxlcmFuZ2U6ZjE1MzkxNWYxNGYxNDc3NGFjZjVkYjM1NzFmZjEzY2FfMTctMy0xLTEtMA_e0fb695e-2378-4783-b634-1929bcf31867"
      unitRef="usd">2803755</us-gaap:InterestExpense>
    <us-gaap:EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet
      contextRef="i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18xNi9mcmFnOjAwM2U2NzdhMmJmMDRhYTM4NWVmMjFlNzAzNTYxZmUzL3RhYmxlOmYxNTM5MTVmMTRmMTQ3NzRhY2Y1ZGIzNTcxZmYxM2NhL3RhYmxlcmFuZ2U6ZjE1MzkxNWYxNGYxNDc3NGFjZjVkYjM1NzFmZjEzY2FfMTktMS0xLTEtMA_ea674d29-d909-4fa6-890f-ab9e165dac47"
      unitRef="usd">0</us-gaap:EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet>
    <us-gaap:EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet
      contextRef="i03bccaa0abfb4733b1e2831ecde4e4e8_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18xNi9mcmFnOjAwM2U2NzdhMmJmMDRhYTM4NWVmMjFlNzAzNTYxZmUzL3RhYmxlOmYxNTM5MTVmMTRmMTQ3NzRhY2Y1ZGIzNTcxZmYxM2NhL3RhYmxlcmFuZ2U6ZjE1MzkxNWYxNGYxNDc3NGFjZjVkYjM1NzFmZjEzY2FfMTktMy0xLTEtMA_2f494188-82c3-4d26-a34b-0e54b19bacda"
      unitRef="usd">-13221977</us-gaap:EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet>
    <ino:ChangeInValueOfInvestmentsInAffiliatedCompany
      contextRef="i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18xNi9mcmFnOjAwM2U2NzdhMmJmMDRhYTM4NWVmMjFlNzAzNTYxZmUzL3RhYmxlOmYxNTM5MTVmMTRmMTQ3NzRhY2Y1ZGIzNTcxZmYxM2NhL3RhYmxlcmFuZ2U6ZjE1MzkxNWYxNGYxNDc3NGFjZjVkYjM1NzFmZjEzY2FfMjAtMS0xLTEtMA_636071a6-3d45-4182-95e0-4224adaa1b8f"
      unitRef="usd">-830475</ino:ChangeInValueOfInvestmentsInAffiliatedCompany>
    <ino:ChangeInValueOfInvestmentsInAffiliatedCompany
      contextRef="i03bccaa0abfb4733b1e2831ecde4e4e8_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18xNi9mcmFnOjAwM2U2NzdhMmJmMDRhYTM4NWVmMjFlNzAzNTYxZmUzL3RhYmxlOmYxNTM5MTVmMTRmMTQ3NzRhY2Y1ZGIzNTcxZmYxM2NhL3RhYmxlcmFuZ2U6ZjE1MzkxNWYxNGYxNDc3NGFjZjVkYjM1NzFmZjEzY2FfMjAtMy0xLTEtMA_98d42e4b-c21a-468a-8da8-cacf6a4cdc34"
      unitRef="usd">13181619</ino:ChangeInValueOfInvestmentsInAffiliatedCompany>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18xNi9mcmFnOjAwM2U2NzdhMmJmMDRhYTM4NWVmMjFlNzAzNTYxZmUzL3RhYmxlOmYxNTM5MTVmMTRmMTQ3NzRhY2Y1ZGIzNTcxZmYxM2NhL3RhYmxlcmFuZ2U6ZjE1MzkxNWYxNGYxNDc3NGFjZjVkYjM1NzFmZjEzY2FfMjEtMS0xLTEtMA_66d4a8d1-1268-4e39-a200-a1cdfa431b1b"
      unitRef="usd">-847958</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="i03bccaa0abfb4733b1e2831ecde4e4e8_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18xNi9mcmFnOjAwM2U2NzdhMmJmMDRhYTM4NWVmMjFlNzAzNTYxZmUzL3RhYmxlOmYxNTM5MTVmMTRmMTQ3NzRhY2Y1ZGIzNTcxZmYxM2NhL3RhYmxlcmFuZ2U6ZjE1MzkxNWYxNGYxNDc3NGFjZjVkYjM1NzFmZjEzY2FfMjEtMy0xLTEtMA_ff5043de-f84a-4ade-b7e4-266a073f51f9"
      unitRef="usd">-5050092</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18xNi9mcmFnOjAwM2U2NzdhMmJmMDRhYTM4NWVmMjFlNzAzNTYxZmUzL3RhYmxlOmYxNTM5MTVmMTRmMTQ3NzRhY2Y1ZGIzNTcxZmYxM2NhL3RhYmxlcmFuZ2U6ZjE1MzkxNWYxNGYxNDc3NGFjZjVkYjM1NzFmZjEzY2FfMjItMS0xLTEtMA_7434d35c-c911-40e8-be4b-ebad8347384b"
      unitRef="usd">8978</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i03bccaa0abfb4733b1e2831ecde4e4e8_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18xNi9mcmFnOjAwM2U2NzdhMmJmMDRhYTM4NWVmMjFlNzAzNTYxZmUzL3RhYmxlOmYxNTM5MTVmMTRmMTQ3NzRhY2Y1ZGIzNTcxZmYxM2NhL3RhYmxlcmFuZ2U6ZjE1MzkxNWYxNGYxNDc3NGFjZjVkYjM1NzFmZjEzY2FfMjItMy0xLTEtMA_a7e20eed-fc7a-4c66-8b1a-a788b3c08d21"
      unitRef="usd">-425500</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18xNi9mcmFnOjAwM2U2NzdhMmJmMDRhYTM4NWVmMjFlNzAzNTYxZmUzL3RhYmxlOmYxNTM5MTVmMTRmMTQ3NzRhY2Y1ZGIzNTcxZmYxM2NhL3RhYmxlcmFuZ2U6ZjE1MzkxNWYxNGYxNDc3NGFjZjVkYjM1NzFmZjEzY2FfMjctMS0xLTEtMA_c7d8d3a4-25d3-46c2-89c7-3458b1d1c46f"
      unitRef="usd">-53967744</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="i03bccaa0abfb4733b1e2831ecde4e4e8_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18xNi9mcmFnOjAwM2U2NzdhMmJmMDRhYTM4NWVmMjFlNzAzNTYxZmUzL3RhYmxlOmYxNTM5MTVmMTRmMTQ3NzRhY2Y1ZGIzNTcxZmYxM2NhL3RhYmxlcmFuZ2U6ZjE1MzkxNWYxNGYxNDc3NGFjZjVkYjM1NzFmZjEzY2FfMjctMy0xLTEtMA_be547f15-4ae2-4220-b947-3624f0fa67c2"
      unitRef="usd">-33135404</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18xNi9mcmFnOjAwM2U2NzdhMmJmMDRhYTM4NWVmMjFlNzAzNTYxZmUzL3RhYmxlOmYxNTM5MTVmMTRmMTQ3NzRhY2Y1ZGIzNTcxZmYxM2NhL3RhYmxlcmFuZ2U6ZjE1MzkxNWYxNGYxNDc3NGFjZjVkYjM1NzFmZjEzY2FfMjktMS0xLTEtMA_bdb4a9ed-61e5-4d7a-aeda-b3b08b2b6aa0"
      unitRef="usd">-434387</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i03bccaa0abfb4733b1e2831ecde4e4e8_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18xNi9mcmFnOjAwM2U2NzdhMmJmMDRhYTM4NWVmMjFlNzAzNTYxZmUzL3RhYmxlOmYxNTM5MTVmMTRmMTQ3NzRhY2Y1ZGIzNTcxZmYxM2NhL3RhYmxlcmFuZ2U6ZjE1MzkxNWYxNGYxNDc3NGFjZjVkYjM1NzFmZjEzY2FfMjktMy0xLTEtMA_f97650a2-2557-433a-8f84-f0182ba11055"
      unitRef="usd">0</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:ProfitLoss
      contextRef="i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18xNi9mcmFnOjAwM2U2NzdhMmJmMDRhYTM4NWVmMjFlNzAzNTYxZmUzL3RhYmxlOmYxNTM5MTVmMTRmMTQ3NzRhY2Y1ZGIzNTcxZmYxM2NhL3RhYmxlcmFuZ2U6ZjE1MzkxNWYxNGYxNDc3NGFjZjVkYjM1NzFmZjEzY2FfMzAtMS0xLTEtMA_ef26fe6c-4fe6-4acb-adc4-f5625422c78f"
      unitRef="usd">-54402131</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i03bccaa0abfb4733b1e2831ecde4e4e8_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18xNi9mcmFnOjAwM2U2NzdhMmJmMDRhYTM4NWVmMjFlNzAzNTYxZmUzL3RhYmxlOmYxNTM5MTVmMTRmMTQ3NzRhY2Y1ZGIzNTcxZmYxM2NhL3RhYmxlcmFuZ2U6ZjE1MzkxNWYxNGYxNDc3NGFjZjVkYjM1NzFmZjEzY2FfMzAtMy0xLTEtMA_57ceb320-113d-4a44-b4af-e43c56a14692"
      unitRef="usd">-33135404</us-gaap:ProfitLoss>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18xNi9mcmFnOjAwM2U2NzdhMmJmMDRhYTM4NWVmMjFlNzAzNTYxZmUzL3RhYmxlOmYxNTM5MTVmMTRmMTQ3NzRhY2Y1ZGIzNTcxZmYxM2NhL3RhYmxlcmFuZ2U6ZjE1MzkxNWYxNGYxNDc3NGFjZjVkYjM1NzFmZjEzY2FfMzEtMS0xLTEtMA_9596f5bc-84d1-426a-8905-0ca0a60984e4"
      unitRef="usd">0</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i03bccaa0abfb4733b1e2831ecde4e4e8_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18xNi9mcmFnOjAwM2U2NzdhMmJmMDRhYTM4NWVmMjFlNzAzNTYxZmUzL3RhYmxlOmYxNTM5MTVmMTRmMTQ3NzRhY2Y1ZGIzNTcxZmYxM2NhL3RhYmxlcmFuZ2U6ZjE1MzkxNWYxNGYxNDc3NGFjZjVkYjM1NzFmZjEzY2FfMzEtMy0xLTEtMA_8cdc640b-4db3-4954-b729-b4071dccc0cd"
      unitRef="usd">-594350</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18xNi9mcmFnOjAwM2U2NzdhMmJmMDRhYTM4NWVmMjFlNzAzNTYxZmUzL3RhYmxlOmYxNTM5MTVmMTRmMTQ3NzRhY2Y1ZGIzNTcxZmYxM2NhL3RhYmxlcmFuZ2U6ZjE1MzkxNWYxNGYxNDc3NGFjZjVkYjM1NzFmZjEzY2FfMzItMS0xLTEtMA_05d2ee85-5c22-43c6-9e13-45138d9bf877"
      unitRef="usd">-54402131</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i03bccaa0abfb4733b1e2831ecde4e4e8_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18xNi9mcmFnOjAwM2U2NzdhMmJmMDRhYTM4NWVmMjFlNzAzNTYxZmUzL3RhYmxlOmYxNTM5MTVmMTRmMTQ3NzRhY2Y1ZGIzNTcxZmYxM2NhL3RhYmxlcmFuZ2U6ZjE1MzkxNWYxNGYxNDc3NGFjZjVkYjM1NzFmZjEzY2FfMzItMy0xLTEtMA_c5e6bdb4-d794-4960-8191-8abc10f1074d"
      unitRef="usd">-32541054</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18xNi9mcmFnOjAwM2U2NzdhMmJmMDRhYTM4NWVmMjFlNzAzNTYxZmUzL3RhYmxlOmYxNTM5MTVmMTRmMTQ3NzRhY2Y1ZGIzNTcxZmYxM2NhL3RhYmxlcmFuZ2U6ZjE1MzkxNWYxNGYxNDc3NGFjZjVkYjM1NzFmZjEzY2FfMzQtMS0xLTEtMA_6e5d26ec-1af9-40b0-8f75-e1d0d2ba453a"
      unitRef="usdPerShare">-0.27</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="i03bccaa0abfb4733b1e2831ecde4e4e8_D20200101-20200331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18xNi9mcmFnOjAwM2U2NzdhMmJmMDRhYTM4NWVmMjFlNzAzNTYxZmUzL3RhYmxlOmYxNTM5MTVmMTRmMTQ3NzRhY2Y1ZGIzNTcxZmYxM2NhL3RhYmxlcmFuZ2U6ZjE1MzkxNWYxNGYxNDc3NGFjZjVkYjM1NzFmZjEzY2FfMzQtMy0xLTEtMA_2afbc78a-5e44-4c23-8b69-c841e6691f3a"
      unitRef="usdPerShare">-0.26</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18xNi9mcmFnOjAwM2U2NzdhMmJmMDRhYTM4NWVmMjFlNzAzNTYxZmUzL3RhYmxlOmYxNTM5MTVmMTRmMTQ3NzRhY2Y1ZGIzNTcxZmYxM2NhL3RhYmxlcmFuZ2U6ZjE1MzkxNWYxNGYxNDc3NGFjZjVkYjM1NzFmZjEzY2FfMzctMS0xLTEtMA_31f947c6-8dae-41bc-84ea-c90a9d59f2b9"
      unitRef="shares">202414445</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="i03bccaa0abfb4733b1e2831ecde4e4e8_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18xNi9mcmFnOjAwM2U2NzdhMmJmMDRhYTM4NWVmMjFlNzAzNTYxZmUzL3RhYmxlOmYxNTM5MTVmMTRmMTQ3NzRhY2Y1ZGIzNTcxZmYxM2NhL3RhYmxlcmFuZ2U6ZjE1MzkxNWYxNGYxNDc3NGFjZjVkYjM1NzFmZjEzY2FfMzctMy0xLTEtMA_7ee9e29c-47ee-41c7-8905-b8c865538ee2"
      unitRef="shares">124623263</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:ProfitLoss
      contextRef="i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18xOS9mcmFnOjRkZDg5N2JmYWY5NDQ4NzlhZjljNGQwYTI5MDk1ZGYzL3RhYmxlOjUwNWE2M2JmODQ3ZTQxMDE5N2ZmNWZiMjg5YWI4ZGU5L3RhYmxlcmFuZ2U6NTA1YTYzYmY4NDdlNDEwMTk3ZmY1ZmIyODlhYjhkZTlfMi0xLTEtMS0w_5063ccd2-23c7-49b9-8683-ac116b7d030f"
      unitRef="usd">-54402131</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i03bccaa0abfb4733b1e2831ecde4e4e8_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18xOS9mcmFnOjRkZDg5N2JmYWY5NDQ4NzlhZjljNGQwYTI5MDk1ZGYzL3RhYmxlOjUwNWE2M2JmODQ3ZTQxMDE5N2ZmNWZiMjg5YWI4ZGU5L3RhYmxlcmFuZ2U6NTA1YTYzYmY4NDdlNDEwMTk3ZmY1ZmIyODlhYjhkZTlfMi0zLTEtMS0w_37940248-8ba8-4ed5-a0eb-f447f2212543"
      unitRef="usd">-33135404</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18xOS9mcmFnOjRkZDg5N2JmYWY5NDQ4NzlhZjljNGQwYTI5MDk1ZGYzL3RhYmxlOjUwNWE2M2JmODQ3ZTQxMDE5N2ZmNWZiMjg5YWI4ZGU5L3RhYmxlcmFuZ2U6NTA1YTYzYmY4NDdlNDEwMTk3ZmY1ZmIyODlhYjhkZTlfNS0xLTEtMS0w_4e290744-4b8d-4306-8cbe-a8033b8e3743"
      unitRef="usd">-14419</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="i03bccaa0abfb4733b1e2831ecde4e4e8_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18xOS9mcmFnOjRkZDg5N2JmYWY5NDQ4NzlhZjljNGQwYTI5MDk1ZGYzL3RhYmxlOjUwNWE2M2JmODQ3ZTQxMDE5N2ZmNWZiMjg5YWI4ZGU5L3RhYmxlcmFuZ2U6NTA1YTYzYmY4NDdlNDEwMTk3ZmY1ZmIyODlhYjhkZTlfNS0zLTEtMS0w_636ddcb8-6dc1-47a7-bb1b-07f4b874d53e"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18xOS9mcmFnOjRkZDg5N2JmYWY5NDQ4NzlhZjljNGQwYTI5MDk1ZGYzL3RhYmxlOjUwNWE2M2JmODQ3ZTQxMDE5N2ZmNWZiMjg5YWI4ZGU5L3RhYmxlcmFuZ2U6NTA1YTYzYmY4NDdlNDEwMTk3ZmY1ZmIyODlhYjhkZTlfNi0xLTEtMS0w_af5e2f15-60e3-4bb9-a396-e432f6a6c902"
      unitRef="usd">4861</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i03bccaa0abfb4733b1e2831ecde4e4e8_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18xOS9mcmFnOjRkZDg5N2JmYWY5NDQ4NzlhZjljNGQwYTI5MDk1ZGYzL3RhYmxlOjUwNWE2M2JmODQ3ZTQxMDE5N2ZmNWZiMjg5YWI4ZGU5L3RhYmxlcmFuZ2U6NTA1YTYzYmY4NDdlNDEwMTk3ZmY1ZmIyODlhYjhkZTlfNi0zLTEtMS0w_851f6f5a-ed0a-4154-949a-32abb06b0f1d"
      unitRef="usd">-1929538</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18xOS9mcmFnOjRkZDg5N2JmYWY5NDQ4NzlhZjljNGQwYTI5MDk1ZGYzL3RhYmxlOjUwNWE2M2JmODQ3ZTQxMDE5N2ZmNWZiMjg5YWI4ZGU5L3RhYmxlcmFuZ2U6NTA1YTYzYmY4NDdlNDEwMTk3ZmY1ZmIyODlhYjhkZTlfOS0xLTEtMS0w_0eaf0268-8c74-47f8-a4c9-50524a021fdd"
      unitRef="usd">-54411689</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i03bccaa0abfb4733b1e2831ecde4e4e8_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18xOS9mcmFnOjRkZDg5N2JmYWY5NDQ4NzlhZjljNGQwYTI5MDk1ZGYzL3RhYmxlOjUwNWE2M2JmODQ3ZTQxMDE5N2ZmNWZiMjg5YWI4ZGU5L3RhYmxlcmFuZ2U6NTA1YTYzYmY4NDdlNDEwMTk3ZmY1ZmIyODlhYjhkZTlfOS0zLTEtMS0w_290997da-c7c2-4f73-9eef-9a496d158e6a"
      unitRef="usd">-35064942</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
      contextRef="i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18xOS9mcmFnOjRkZDg5N2JmYWY5NDQ4NzlhZjljNGQwYTI5MDk1ZGYzL3RhYmxlOjUwNWE2M2JmODQ3ZTQxMDE5N2ZmNWZiMjg5YWI4ZGU5L3RhYmxlcmFuZ2U6NTA1YTYzYmY4NDdlNDEwMTk3ZmY1ZmIyODlhYjhkZTlfMTAtMS0xLTEtMA_408968fa-1a97-4123-b657-34a4677558a5"
      unitRef="usd">0</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
      contextRef="i03bccaa0abfb4733b1e2831ecde4e4e8_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18xOS9mcmFnOjRkZDg5N2JmYWY5NDQ4NzlhZjljNGQwYTI5MDk1ZGYzL3RhYmxlOjUwNWE2M2JmODQ3ZTQxMDE5N2ZmNWZiMjg5YWI4ZGU5L3RhYmxlcmFuZ2U6NTA1YTYzYmY4NDdlNDEwMTk3ZmY1ZmIyODlhYjhkZTlfMTAtMy0xLTEtMA_39dee4b4-09e2-4998-b0d4-023916141c9d"
      unitRef="usd">-594350</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18xOS9mcmFnOjRkZDg5N2JmYWY5NDQ4NzlhZjljNGQwYTI5MDk1ZGYzL3RhYmxlOjUwNWE2M2JmODQ3ZTQxMDE5N2ZmNWZiMjg5YWI4ZGU5L3RhYmxlcmFuZ2U6NTA1YTYzYmY4NDdlNDEwMTk3ZmY1ZmIyODlhYjhkZTlfMTEtMS0xLTEtMA_88882b8f-1f1b-46f3-8c9e-081dbc1173aa"
      unitRef="usd">-54411689</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i03bccaa0abfb4733b1e2831ecde4e4e8_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18xOS9mcmFnOjRkZDg5N2JmYWY5NDQ4NzlhZjljNGQwYTI5MDk1ZGYzL3RhYmxlOjUwNWE2M2JmODQ3ZTQxMDE5N2ZmNWZiMjg5YWI4ZGU5L3RhYmxlcmFuZ2U6NTA1YTYzYmY4NDdlNDEwMTk3ZmY1ZmIyODlhYjhkZTlfMTEtMy0xLTEtMA_fb0c5e0f-2122-4304-97f4-c9754f662211"
      unitRef="usd">-34470592</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:SharesIssued
      contextRef="ib30ce8820d124ee6af51f2c43013f18e_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18yMi9mcmFnOjg2MjFjNDJiNjI3NDRkMmNhMzQ1NDQwN2UzZjI0N2QzL3RhYmxlOmQwOWRlNWFiMWM0MjQ1ODk5YzUwNzc4YjIzZWI0ZWNjL3RhYmxlcmFuZ2U6ZDA5ZGU1YWIxYzQyNDU4OTljNTA3NzhiMjNlYjRlY2NfMy0xLTEtMS0yNzM_8e554740-6e78-4a11-b836-d38523533841"
      unitRef="shares">9</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ib30ce8820d124ee6af51f2c43013f18e_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18yMi9mcmFnOjg2MjFjNDJiNjI3NDRkMmNhMzQ1NDQwN2UzZjI0N2QzL3RhYmxlOmQwOWRlNWFiMWM0MjQ1ODk5YzUwNzc4YjIzZWI0ZWNjL3RhYmxlcmFuZ2U6ZDA5ZGU1YWIxYzQyNDU4OTljNTA3NzhiMjNlYjRlY2NfMy0zLTEtMS0yNzM_298256a5-0982-4ea9-a258-403098870e9c"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesIssued
      contextRef="ia94bfbadb09f4968b33b4adabfa4233d_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18yMi9mcmFnOjg2MjFjNDJiNjI3NDRkMmNhMzQ1NDQwN2UzZjI0N2QzL3RhYmxlOmQwOWRlNWFiMWM0MjQ1ODk5YzUwNzc4YjIzZWI0ZWNjL3RhYmxlcmFuZ2U6ZDA5ZGU1YWIxYzQyNDU4OTljNTA3NzhiMjNlYjRlY2NfMy01LTEtMS0yNzM_bef19972-8d0c-49f0-a1e8-97486619ec55"
      unitRef="shares">186851493</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ia94bfbadb09f4968b33b4adabfa4233d_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18yMi9mcmFnOjg2MjFjNDJiNjI3NDRkMmNhMzQ1NDQwN2UzZjI0N2QzL3RhYmxlOmQwOWRlNWFiMWM0MjQ1ODk5YzUwNzc4YjIzZWI0ZWNjL3RhYmxlcmFuZ2U6ZDA5ZGU1YWIxYzQyNDU4OTljNTA3NzhiMjNlYjRlY2NfMy03LTEtMS0yNzM_2b5f850f-2498-4073-b587-d1799dfcdf9e"
      unitRef="usd">186851</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ieaec7233643d498d97b1141ea9dad4c5_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18yMi9mcmFnOjg2MjFjNDJiNjI3NDRkMmNhMzQ1NDQwN2UzZjI0N2QzL3RhYmxlOmQwOWRlNWFiMWM0MjQ1ODk5YzUwNzc4YjIzZWI0ZWNjL3RhYmxlcmFuZ2U6ZDA5ZGU1YWIxYzQyNDU4OTljNTA3NzhiMjNlYjRlY2NfMy05LTEtMS0yNzM_c4065e49-f0ee-4907-ad0c-28f112e8a81f"
      unitRef="usd">1367406869</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i96283fe249ee4626aab2bf451b2e5efe_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18yMi9mcmFnOjg2MjFjNDJiNjI3NDRkMmNhMzQ1NDQwN2UzZjI0N2QzL3RhYmxlOmQwOWRlNWFiMWM0MjQ1ODk5YzUwNzc4YjIzZWI0ZWNjL3RhYmxlcmFuZ2U6ZDA5ZGU1YWIxYzQyNDU4OTljNTA3NzhiMjNlYjRlY2NfMy0xMS0xLTEtMjcz_4605668a-1ee9-4de2-8341-e908e8daeaa2"
      unitRef="usd">-906196812</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ic6306740b10d4a7593195541124d73d5_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18yMi9mcmFnOjg2MjFjNDJiNjI3NDRkMmNhMzQ1NDQwN2UzZjI0N2QzL3RhYmxlOmQwOWRlNWFiMWM0MjQ1ODk5YzUwNzc4YjIzZWI0ZWNjL3RhYmxlcmFuZ2U6ZDA5ZGU1YWIxYzQyNDU4OTljNTA3NzhiMjNlYjRlY2NfMy0xMy0xLTEtMjcz_bf0082fd-e8a5-46d7-95f4-ba73706c09a2"
      unitRef="usd">-256150</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i5c4f0048d9644ed3b4e12718fd6404f9_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18yMi9mcmFnOjg2MjFjNDJiNjI3NDRkMmNhMzQ1NDQwN2UzZjI0N2QzL3RhYmxlOmQwOWRlNWFiMWM0MjQ1ODk5YzUwNzc4YjIzZWI0ZWNjL3RhYmxlcmFuZ2U6ZDA5ZGU1YWIxYzQyNDU4OTljNTA3NzhiMjNlYjRlY2NfMy0xNS0xLTEtMjcz_77b147d7-51e1-4bb2-b732-29cffefede0d"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i066bb5b0a9e84c0a878b1e800703d92b_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18yMi9mcmFnOjg2MjFjNDJiNjI3NDRkMmNhMzQ1NDQwN2UzZjI0N2QzL3RhYmxlOmQwOWRlNWFiMWM0MjQ1ODk5YzUwNzc4YjIzZWI0ZWNjL3RhYmxlcmFuZ2U6ZDA5ZGU1YWIxYzQyNDU4OTljNTA3NzhiMjNlYjRlY2NfMy0xNy0xLTEtMjcz_0ab6deed-5208-4658-8734-0e88359b36c5"
      unitRef="usd">461140758</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18yMi9mcmFnOjg2MjFjNDJiNjI3NDRkMmNhMzQ1NDQwN2UzZjI0N2QzL3RhYmxlOmQwOWRlNWFiMWM0MjQ1ODk5YzUwNzc4YjIzZWI0ZWNjL3RhYmxlcmFuZ2U6ZDA5ZGU1YWIxYzQyNDU4OTljNTA3NzhiMjNlYjRlY2NfNC0wLTEtMS0zNjc0L3RleHRyZWdpb246YmFiM2YxNzg0NjMyNDAzZjgxZGU4ZGM0NWVlODUwYjdfMzI5ODUzNDg4MzQwOQ_6663ed19-bd26-4210-be6d-1e4b3ea29048"
      unitRef="usd">531000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="ida491abe9af7462cbd6838e5420a3bdb_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18yMi9mcmFnOjg2MjFjNDJiNjI3NDRkMmNhMzQ1NDQwN2UzZjI0N2QzL3RhYmxlOmQwOWRlNWFiMWM0MjQ1ODk5YzUwNzc4YjIzZWI0ZWNjL3RhYmxlcmFuZ2U6ZDA5ZGU1YWIxYzQyNDU4OTljNTA3NzhiMjNlYjRlY2NfNC01LTEtMS0yNTM5_984e6e8b-67ee-4467-87ac-30c45e0d07d6"
      unitRef="shares">20355000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="ida491abe9af7462cbd6838e5420a3bdb_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18yMi9mcmFnOjg2MjFjNDJiNjI3NDRkMmNhMzQ1NDQwN2UzZjI0N2QzL3RhYmxlOmQwOWRlNWFiMWM0MjQ1ODk5YzUwNzc4YjIzZWI0ZWNjL3RhYmxlcmFuZ2U6ZDA5ZGU1YWIxYzQyNDU4OTljNTA3NzhiMjNlYjRlY2NfNC03LTEtMS0yNTM5_82a90eac-8019-4e89-ac34-6af447e949c2"
      unitRef="usd">20355</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i4ede063da1fe4025a2e0bc527b82ca1e_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18yMi9mcmFnOjg2MjFjNDJiNjI3NDRkMmNhMzQ1NDQwN2UzZjI0N2QzL3RhYmxlOmQwOWRlNWFiMWM0MjQ1ODk5YzUwNzc4YjIzZWI0ZWNjL3RhYmxlcmFuZ2U6ZDA5ZGU1YWIxYzQyNDU4OTljNTA3NzhiMjNlYjRlY2NfNC05LTEtMS0yNTM5_8c156153-7223-438b-bdb7-2045415c1adf"
      unitRef="usd">162084675</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18yMi9mcmFnOjg2MjFjNDJiNjI3NDRkMmNhMzQ1NDQwN2UzZjI0N2QzL3RhYmxlOmQwOWRlNWFiMWM0MjQ1ODk5YzUwNzc4YjIzZWI0ZWNjL3RhYmxlcmFuZ2U6ZDA5ZGU1YWIxYzQyNDU4OTljNTA3NzhiMjNlYjRlY2NfNC0xNy0xLTEtMjUzOQ_d926f72e-ec50-4ece-9887-55b73d119894"
      unitRef="usd">162105030</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="ida491abe9af7462cbd6838e5420a3bdb_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18yMi9mcmFnOjg2MjFjNDJiNjI3NDRkMmNhMzQ1NDQwN2UzZjI0N2QzL3RhYmxlOmQwOWRlNWFiMWM0MjQ1ODk5YzUwNzc4YjIzZWI0ZWNjL3RhYmxlcmFuZ2U6ZDA5ZGU1YWIxYzQyNDU4OTljNTA3NzhiMjNlYjRlY2NfNC01LTEtMS0yNzM_ee93ae6c-e3fe-45ea-87eb-051571eb043f"
      unitRef="shares">1009450</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="ida491abe9af7462cbd6838e5420a3bdb_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18yMi9mcmFnOjg2MjFjNDJiNjI3NDRkMmNhMzQ1NDQwN2UzZjI0N2QzL3RhYmxlOmQwOWRlNWFiMWM0MjQ1ODk5YzUwNzc4YjIzZWI0ZWNjL3RhYmxlcmFuZ2U6ZDA5ZGU1YWIxYzQyNDU4OTljNTA3NzhiMjNlYjRlY2NfNC03LTEtMS0yNzM_1bacef74-7cbf-4ec6-8467-50d1b232b4c7"
      unitRef="usd">1009</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="i4ede063da1fe4025a2e0bc527b82ca1e_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18yMi9mcmFnOjg2MjFjNDJiNjI3NDRkMmNhMzQ1NDQwN2UzZjI0N2QzL3RhYmxlOmQwOWRlNWFiMWM0MjQ1ODk5YzUwNzc4YjIzZWI0ZWNjL3RhYmxlcmFuZ2U6ZDA5ZGU1YWIxYzQyNDU4OTljNTA3NzhiMjNlYjRlY2NfNC05LTEtMS0yNzM_f669c872-3d40-452a-82e2-74c716c79421"
      unitRef="usd">4376883</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18yMi9mcmFnOjg2MjFjNDJiNjI3NDRkMmNhMzQ1NDQwN2UzZjI0N2QzL3RhYmxlOmQwOWRlNWFiMWM0MjQ1ODk5YzUwNzc4YjIzZWI0ZWNjL3RhYmxlcmFuZ2U6ZDA5ZGU1YWIxYzQyNDU4OTljNTA3NzhiMjNlYjRlY2NfNC0xNy0xLTEtMjcz_b2d6d8b8-2aa6-41e4-bee2-d7c29395c712"
      unitRef="usd">4377892</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="ida491abe9af7462cbd6838e5420a3bdb_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18yMi9mcmFnOjg2MjFjNDJiNjI3NDRkMmNhMzQ1NDQwN2UzZjI0N2QzL3RhYmxlOmQwOWRlNWFiMWM0MjQ1ODk5YzUwNzc4YjIzZWI0ZWNjL3RhYmxlcmFuZ2U6ZDA5ZGU1YWIxYzQyNDU4OTljNTA3NzhiMjNlYjRlY2NfNS01LTEtMS0yNzM_ffa0ddb7-489a-4fa6-b00f-487c960df0b1"
      unitRef="shares">1118093</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="ida491abe9af7462cbd6838e5420a3bdb_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18yMi9mcmFnOjg2MjFjNDJiNjI3NDRkMmNhMzQ1NDQwN2UzZjI0N2QzL3RhYmxlOmQwOWRlNWFiMWM0MjQ1ODk5YzUwNzc4YjIzZWI0ZWNjL3RhYmxlcmFuZ2U6ZDA5ZGU1YWIxYzQyNDU4OTljNTA3NzhiMjNlYjRlY2NfNS03LTEtMS0yNzM_58723cd7-9bce-4952-89ec-f5145693345b"
      unitRef="usd">1118</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i4ede063da1fe4025a2e0bc527b82ca1e_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18yMi9mcmFnOjg2MjFjNDJiNjI3NDRkMmNhMzQ1NDQwN2UzZjI0N2QzL3RhYmxlOmQwOWRlNWFiMWM0MjQ1ODk5YzUwNzc4YjIzZWI0ZWNjL3RhYmxlcmFuZ2U6ZDA5ZGU1YWIxYzQyNDU4OTljNTA3NzhiMjNlYjRlY2NfNS05LTEtMS0yNzM_44a28e5a-84c9-48f3-955d-373ddf5d8e8a"
      unitRef="usd">-1202907</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18yMi9mcmFnOjg2MjFjNDJiNjI3NDRkMmNhMzQ1NDQwN2UzZjI0N2QzL3RhYmxlOmQwOWRlNWFiMWM0MjQ1ODk5YzUwNzc4YjIzZWI0ZWNjL3RhYmxlcmFuZ2U6ZDA5ZGU1YWIxYzQyNDU4OTljNTA3NzhiMjNlYjRlY2NfNS0xNy0xLTEtMjcz_a0b06db3-d986-4699-8e50-5d00adb3603c"
      unitRef="usd">-1201789</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i4ede063da1fe4025a2e0bc527b82ca1e_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18yMi9mcmFnOjg2MjFjNDJiNjI3NDRkMmNhMzQ1NDQwN2UzZjI0N2QzL3RhYmxlOmQwOWRlNWFiMWM0MjQ1ODk5YzUwNzc4YjIzZWI0ZWNjL3RhYmxlcmFuZ2U6ZDA5ZGU1YWIxYzQyNDU4OTljNTA3NzhiMjNlYjRlY2NfNi05LTEtMS0yNzM_54f64bad-335b-483c-8ff3-bd8f15db358a"
      unitRef="usd">9595947</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18yMi9mcmFnOjg2MjFjNDJiNjI3NDRkMmNhMzQ1NDQwN2UzZjI0N2QzL3RhYmxlOmQwOWRlNWFiMWM0MjQ1ODk5YzUwNzc4YjIzZWI0ZWNjL3RhYmxlcmFuZ2U6ZDA5ZGU1YWIxYzQyNDU4OTljNTA3NzhiMjNlYjRlY2NfNi0xNy0xLTEtMjcz_0a7ace5a-c481-4fac-99e4-f3347c07f5fa"
      unitRef="usd">9595947</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:ProfitLoss
      contextRef="i0f5bad0d4b8641e4b0f54e165e445044_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18yMi9mcmFnOjg2MjFjNDJiNjI3NDRkMmNhMzQ1NDQwN2UzZjI0N2QzL3RhYmxlOmQwOWRlNWFiMWM0MjQ1ODk5YzUwNzc4YjIzZWI0ZWNjL3RhYmxlcmFuZ2U6ZDA5ZGU1YWIxYzQyNDU4OTljNTA3NzhiMjNlYjRlY2NfNy0xMS0xLTEtMjcz_065c2120-6030-40c6-b64a-c4c1f4ad3c01"
      unitRef="usd">-54402131</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18yMi9mcmFnOjg2MjFjNDJiNjI3NDRkMmNhMzQ1NDQwN2UzZjI0N2QzL3RhYmxlOmQwOWRlNWFiMWM0MjQ1ODk5YzUwNzc4YjIzZWI0ZWNjL3RhYmxlcmFuZ2U6ZDA5ZGU1YWIxYzQyNDU4OTljNTA3NzhiMjNlYjRlY2NfNy0xNy0xLTEtMjcz_eeb619f0-8f9a-445e-abe9-c6b4d3b26d33"
      unitRef="usd">-54402131</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i3f929f0365a3465f8cc7dc1c57314519_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18yMi9mcmFnOjg2MjFjNDJiNjI3NDRkMmNhMzQ1NDQwN2UzZjI0N2QzL3RhYmxlOmQwOWRlNWFiMWM0MjQ1ODk5YzUwNzc4YjIzZWI0ZWNjL3RhYmxlcmFuZ2U6ZDA5ZGU1YWIxYzQyNDU4OTljNTA3NzhiMjNlYjRlY2NfOC0xMy0xLTEtMjcz_27f6818a-8087-40f9-a3be-35ad673555db"
      unitRef="usd">4861</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18yMi9mcmFnOjg2MjFjNDJiNjI3NDRkMmNhMzQ1NDQwN2UzZjI0N2QzL3RhYmxlOmQwOWRlNWFiMWM0MjQ1ODk5YzUwNzc4YjIzZWI0ZWNjL3RhYmxlcmFuZ2U6ZDA5ZGU1YWIxYzQyNDU4OTljNTA3NzhiMjNlYjRlY2NfOC0xNy0xLTEtMjcz_2af0f985-c0e3-4d72-b1ef-2da942261cb9"
      unitRef="usd">4861</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="i3f929f0365a3465f8cc7dc1c57314519_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18yMi9mcmFnOjg2MjFjNDJiNjI3NDRkMmNhMzQ1NDQwN2UzZjI0N2QzL3RhYmxlOmQwOWRlNWFiMWM0MjQ1ODk5YzUwNzc4YjIzZWI0ZWNjL3RhYmxlcmFuZ2U6ZDA5ZGU1YWIxYzQyNDU4OTljNTA3NzhiMjNlYjRlY2NfOS0xMy0xLTEtMjcz_2a1d7139-7b7b-488e-97dd-79f20f1c75e1"
      unitRef="usd">-14419</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18yMi9mcmFnOjg2MjFjNDJiNjI3NDRkMmNhMzQ1NDQwN2UzZjI0N2QzL3RhYmxlOmQwOWRlNWFiMWM0MjQ1ODk5YzUwNzc4YjIzZWI0ZWNjL3RhYmxlcmFuZ2U6ZDA5ZGU1YWIxYzQyNDU4OTljNTA3NzhiMjNlYjRlY2NfOS0xNy0xLTEtMjcz_9370e38f-5ea0-4b7d-9642-81b8d4e07332"
      unitRef="usd">-14419</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:SharesIssued
      contextRef="ibab5fbbfe0ef465e8c296f3289e726c2_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18yMi9mcmFnOjg2MjFjNDJiNjI3NDRkMmNhMzQ1NDQwN2UzZjI0N2QzL3RhYmxlOmQwOWRlNWFiMWM0MjQ1ODk5YzUwNzc4YjIzZWI0ZWNjL3RhYmxlcmFuZ2U6ZDA5ZGU1YWIxYzQyNDU4OTljNTA3NzhiMjNlYjRlY2NfMTAtMS0xLTEtMjcz_d2df84dc-edc4-450b-9ae4-90e9b356c1e8"
      unitRef="shares">9</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ibab5fbbfe0ef465e8c296f3289e726c2_I20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18yMi9mcmFnOjg2MjFjNDJiNjI3NDRkMmNhMzQ1NDQwN2UzZjI0N2QzL3RhYmxlOmQwOWRlNWFiMWM0MjQ1ODk5YzUwNzc4YjIzZWI0ZWNjL3RhYmxlcmFuZ2U6ZDA5ZGU1YWIxYzQyNDU4OTljNTA3NzhiMjNlYjRlY2NfMTAtMy0xLTEtMjcz_9c04b931-df82-4c7c-9cb2-41b0c6e43c4e"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesIssued
      contextRef="i33c2b6d1adae4987a8b43311a9b56620_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18yMi9mcmFnOjg2MjFjNDJiNjI3NDRkMmNhMzQ1NDQwN2UzZjI0N2QzL3RhYmxlOmQwOWRlNWFiMWM0MjQ1ODk5YzUwNzc4YjIzZWI0ZWNjL3RhYmxlcmFuZ2U6ZDA5ZGU1YWIxYzQyNDU4OTljNTA3NzhiMjNlYjRlY2NfMTAtNS0xLTEtMjcz_69dbfa89-a470-4ac9-9672-287afccedafb"
      unitRef="shares">209334036</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i33c2b6d1adae4987a8b43311a9b56620_I20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18yMi9mcmFnOjg2MjFjNDJiNjI3NDRkMmNhMzQ1NDQwN2UzZjI0N2QzL3RhYmxlOmQwOWRlNWFiMWM0MjQ1ODk5YzUwNzc4YjIzZWI0ZWNjL3RhYmxlcmFuZ2U6ZDA5ZGU1YWIxYzQyNDU4OTljNTA3NzhiMjNlYjRlY2NfMTAtNy0xLTEtMjcz_7ef5cd7a-391d-4061-aacb-5a552ca692b3"
      unitRef="usd">209333</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i1541412d9b3c4836ae64bd33efc16e22_I20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18yMi9mcmFnOjg2MjFjNDJiNjI3NDRkMmNhMzQ1NDQwN2UzZjI0N2QzL3RhYmxlOmQwOWRlNWFiMWM0MjQ1ODk5YzUwNzc4YjIzZWI0ZWNjL3RhYmxlcmFuZ2U6ZDA5ZGU1YWIxYzQyNDU4OTljNTA3NzhiMjNlYjRlY2NfMTAtOS0xLTEtMjcz_2bd36c9b-7a4d-4ed1-8fe8-29e110e60f2f"
      unitRef="usd">1542261467</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i65691acaad974fca8ed0492dec85d517_I20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18yMi9mcmFnOjg2MjFjNDJiNjI3NDRkMmNhMzQ1NDQwN2UzZjI0N2QzL3RhYmxlOmQwOWRlNWFiMWM0MjQ1ODk5YzUwNzc4YjIzZWI0ZWNjL3RhYmxlcmFuZ2U6ZDA5ZGU1YWIxYzQyNDU4OTljNTA3NzhiMjNlYjRlY2NfMTAtMTEtMS0xLTI3Mw_f3267ada-7964-4cca-9f9a-b27ef1caa0f1"
      unitRef="usd">-960598943</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i1e99d4dac75643f384514d28d4cd004b_I20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18yMi9mcmFnOjg2MjFjNDJiNjI3NDRkMmNhMzQ1NDQwN2UzZjI0N2QzL3RhYmxlOmQwOWRlNWFiMWM0MjQ1ODk5YzUwNzc4YjIzZWI0ZWNjL3RhYmxlcmFuZ2U6ZDA5ZGU1YWIxYzQyNDU4OTljNTA3NzhiMjNlYjRlY2NfMTAtMTMtMS0xLTI3Mw_2b4819ac-47a5-4903-9dce-602d400d1505"
      unitRef="usd">-265708</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i1b91f37fad654b1d9c8a1e92d45461a0_I20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18yMi9mcmFnOjg2MjFjNDJiNjI3NDRkMmNhMzQ1NDQwN2UzZjI0N2QzL3RhYmxlOmQwOWRlNWFiMWM0MjQ1ODk5YzUwNzc4YjIzZWI0ZWNjL3RhYmxlcmFuZ2U6ZDA5ZGU1YWIxYzQyNDU4OTljNTA3NzhiMjNlYjRlY2NfMTAtMTUtMS0xLTI3Mw_3b19e452-f7aa-47b8-ae06-54366dcc078d"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ic36b9cedad7f41a6b9eb223b09b7186c_I20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18yMi9mcmFnOjg2MjFjNDJiNjI3NDRkMmNhMzQ1NDQwN2UzZjI0N2QzL3RhYmxlOmQwOWRlNWFiMWM0MjQ1ODk5YzUwNzc4YjIzZWI0ZWNjL3RhYmxlcmFuZ2U6ZDA5ZGU1YWIxYzQyNDU4OTljNTA3NzhiMjNlYjRlY2NfMTAtMTctMS0xLTI3Mw_6a6b5a6d-120c-4e03-8a3f-c12379b8d1c1"
      unitRef="usd">581606149</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesIssued
      contextRef="id632c5e641ae4912873249f66ba9b746_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18yMi9mcmFnOjg2MjFjNDJiNjI3NDRkMmNhMzQ1NDQwN2UzZjI0N2QzL3RhYmxlOjM0YjQ5NWMwODljMzRkMmI4OWRhYTVlMmI3NTRmNmM5L3RhYmxlcmFuZ2U6MzRiNDk1YzA4OWMzNGQyYjg5ZGFhNWUyYjc1NGY2YzlfMzMtMS0xLTEtMA_edd60230-d7e6-42fd-8f3a-dbe03521d40a"
      unitRef="shares">23</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="id632c5e641ae4912873249f66ba9b746_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18yMi9mcmFnOjg2MjFjNDJiNjI3NDRkMmNhMzQ1NDQwN2UzZjI0N2QzL3RhYmxlOjM0YjQ5NWMwODljMzRkMmI4OWRhYTVlMmI3NTRmNmM5L3RhYmxlcmFuZ2U6MzRiNDk1YzA4OWMzNGQyYjg5ZGFhNWUyYjc1NGY2YzlfMzMtMy0xLTEtMA_c2512b68-20f2-44ce-8cfa-e7a47025f31e"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesIssued
      contextRef="i40ec371b74df4b3db7e8d29aaa614a0d_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18yMi9mcmFnOjg2MjFjNDJiNjI3NDRkMmNhMzQ1NDQwN2UzZjI0N2QzL3RhYmxlOjM0YjQ5NWMwODljMzRkMmI4OWRhYTVlMmI3NTRmNmM5L3RhYmxlcmFuZ2U6MzRiNDk1YzA4OWMzNGQyYjg5ZGFhNWUyYjc1NGY2YzlfMzMtNS0xLTEtMA_a7ef673a-138c-475b-b832-1d870ff02059"
      unitRef="shares">101361034</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i40ec371b74df4b3db7e8d29aaa614a0d_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18yMi9mcmFnOjg2MjFjNDJiNjI3NDRkMmNhMzQ1NDQwN2UzZjI0N2QzL3RhYmxlOjM0YjQ5NWMwODljMzRkMmI4OWRhYTVlMmI3NTRmNmM5L3RhYmxlcmFuZ2U6MzRiNDk1YzA4OWMzNGQyYjg5ZGFhNWUyYjc1NGY2YzlfMzMtNy0xLTEtMA_7754fe4a-b7ab-4a36-8936-91418d085fec"
      unitRef="usd">101361</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i3d58693671394234b39dd81063245378_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18yMi9mcmFnOjg2MjFjNDJiNjI3NDRkMmNhMzQ1NDQwN2UzZjI0N2QzL3RhYmxlOjM0YjQ5NWMwODljMzRkMmI4OWRhYTVlMmI3NTRmNmM5L3RhYmxlcmFuZ2U6MzRiNDk1YzA4OWMzNGQyYjg5ZGFhNWUyYjc1NGY2YzlfMzMtOS0xLTEtMA_091259c8-7915-463f-812c-234e90b9358a"
      unitRef="usd">742646785</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iba11ad45e728416593567d5d5ccc86c8_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18yMi9mcmFnOjg2MjFjNDJiNjI3NDRkMmNhMzQ1NDQwN2UzZjI0N2QzL3RhYmxlOjM0YjQ5NWMwODljMzRkMmI4OWRhYTVlMmI3NTRmNmM5L3RhYmxlcmFuZ2U6MzRiNDk1YzA4OWMzNGQyYjg5ZGFhNWUyYjc1NGY2YzlfMzMtMTEtMS0xLTA_91f4e64b-038b-45c9-bdd6-7ad7d357606c"
      unitRef="usd">-739785655</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ib7d8df8a887e444f9147b293456ba26e_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18yMi9mcmFnOjg2MjFjNDJiNjI3NDRkMmNhMzQ1NDQwN2UzZjI0N2QzL3RhYmxlOjM0YjQ5NWMwODljMzRkMmI4OWRhYTVlMmI3NTRmNmM5L3RhYmxlcmFuZ2U6MzRiNDk1YzA4OWMzNGQyYjg5ZGFhNWUyYjc1NGY2YzlfMzMtMTMtMS0xLTA_3961b1c3-0877-4094-ba96-a3f8820d326e"
      unitRef="usd">472608</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="if11b90ef299e496ebeb77cd256ffe8e4_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18yMi9mcmFnOjg2MjFjNDJiNjI3NDRkMmNhMzQ1NDQwN2UzZjI0N2QzL3RhYmxlOjM0YjQ5NWMwODljMzRkMmI4OWRhYTVlMmI3NTRmNmM5L3RhYmxlcmFuZ2U6MzRiNDk1YzA4OWMzNGQyYjg5ZGFhNWUyYjc1NGY2YzlfMzMtMTUtMS0xLTA_f28dea85-4fde-4a32-9eaa-ad04e0fe631a"
      unitRef="usd">1969759</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="id25261a874ce40da9cfbcc6297ee52ac_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18yMi9mcmFnOjg2MjFjNDJiNjI3NDRkMmNhMzQ1NDQwN2UzZjI0N2QzL3RhYmxlOjM0YjQ5NWMwODljMzRkMmI4OWRhYTVlMmI3NTRmNmM5L3RhYmxlcmFuZ2U6MzRiNDk1YzA4OWMzNGQyYjg5ZGFhNWUyYjc1NGY2YzlfMzMtMTctMS0xLTA_fb93c5d4-d7fc-4f3f-b11b-df4fb2c80680"
      unitRef="usd">5404858</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="ic68df58c3630416794b34bec56896e49_D20200101-20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18yMi9mcmFnOjg2MjFjNDJiNjI3NDRkMmNhMzQ1NDQwN2UzZjI0N2QzL3RhYmxlOjM0YjQ5NWMwODljMzRkMmI4OWRhYTVlMmI3NTRmNmM5L3RhYmxlcmFuZ2U6MzRiNDk1YzA4OWMzNGQyYjg5ZGFhNWUyYjc1NGY2YzlfMzQtNS0xLTEtMA_b0505937-2fc8-42e3-b7f5-4b99f2ee7a11"
      unitRef="shares">43148952</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="ic68df58c3630416794b34bec56896e49_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18yMi9mcmFnOjg2MjFjNDJiNjI3NDRkMmNhMzQ1NDQwN2UzZjI0N2QzL3RhYmxlOjM0YjQ5NWMwODljMzRkMmI4OWRhYTVlMmI3NTRmNmM5L3RhYmxlcmFuZ2U6MzRiNDk1YzA4OWMzNGQyYjg5ZGFhNWUyYjc1NGY2YzlfMzQtNy0xLTEtMA_94fbd435-e786-4576-ba92-162862a297ce"
      unitRef="usd">43149</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="iba0cb12c2be843b2bd24ae59f143d7a9_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18yMi9mcmFnOjg2MjFjNDJiNjI3NDRkMmNhMzQ1NDQwN2UzZjI0N2QzL3RhYmxlOjM0YjQ5NWMwODljMzRkMmI4OWRhYTVlMmI3NTRmNmM5L3RhYmxlcmFuZ2U6MzRiNDk1YzA4OWMzNGQyYjg5ZGFhNWUyYjc1NGY2YzlfMzQtOS0xLTEtMA_0b865750-1315-4a86-8a90-7af69345d1c0"
      unitRef="usd">208198784</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i03bccaa0abfb4733b1e2831ecde4e4e8_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18yMi9mcmFnOjg2MjFjNDJiNjI3NDRkMmNhMzQ1NDQwN2UzZjI0N2QzL3RhYmxlOjM0YjQ5NWMwODljMzRkMmI4OWRhYTVlMmI3NTRmNmM5L3RhYmxlcmFuZ2U6MzRiNDk1YzA4OWMzNGQyYjg5ZGFhNWUyYjc1NGY2YzlfMzQtMTctMS0xLTA_49536127-c202-4549-8eda-dedcd1f8d552"
      unitRef="usd">208241933</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="ic68df58c3630416794b34bec56896e49_D20200101-20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18yMi9mcmFnOjg2MjFjNDJiNjI3NDRkMmNhMzQ1NDQwN2UzZjI0N2QzL3RhYmxlOjM0YjQ5NWMwODljMzRkMmI4OWRhYTVlMmI3NTRmNmM5L3RhYmxlcmFuZ2U6MzRiNDk1YzA4OWMzNGQyYjg5ZGFhNWUyYjc1NGY2YzlfMzUtNS0xLTEtMA_f63d858c-577f-4053-a6d2-03e8f00d8968"
      unitRef="shares">1405114</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="ic68df58c3630416794b34bec56896e49_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18yMi9mcmFnOjg2MjFjNDJiNjI3NDRkMmNhMzQ1NDQwN2UzZjI0N2QzL3RhYmxlOjM0YjQ5NWMwODljMzRkMmI4OWRhYTVlMmI3NTRmNmM5L3RhYmxlcmFuZ2U6MzRiNDk1YzA4OWMzNGQyYjg5ZGFhNWUyYjc1NGY2YzlfMzUtNy0xLTEtMA_388566b7-7843-4cef-9deb-e940f35ee027"
      unitRef="usd">1405</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="iba0cb12c2be843b2bd24ae59f143d7a9_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18yMi9mcmFnOjg2MjFjNDJiNjI3NDRkMmNhMzQ1NDQwN2UzZjI0N2QzL3RhYmxlOjM0YjQ5NWMwODljMzRkMmI4OWRhYTVlMmI3NTRmNmM5L3RhYmxlcmFuZ2U6MzRiNDk1YzA4OWMzNGQyYjg5ZGFhNWUyYjc1NGY2YzlfMzUtOS0xLTEtMA_22512618-e891-46a2-9cb9-6eea272df22a"
      unitRef="usd">3099298</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i03bccaa0abfb4733b1e2831ecde4e4e8_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18yMi9mcmFnOjg2MjFjNDJiNjI3NDRkMmNhMzQ1NDQwN2UzZjI0N2QzL3RhYmxlOjM0YjQ5NWMwODljMzRkMmI4OWRhYTVlMmI3NTRmNmM5L3RhYmxlcmFuZ2U6MzRiNDk1YzA4OWMzNGQyYjg5ZGFhNWUyYjc1NGY2YzlfMzUtMTctMS0xLTA_4de04d29-9f42-4000-8c53-5ab5764ce1df"
      unitRef="usd">3100703</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="iba0cb12c2be843b2bd24ae59f143d7a9_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18yMi9mcmFnOjg2MjFjNDJiNjI3NDRkMmNhMzQ1NDQwN2UzZjI0N2QzL3RhYmxlOjM0YjQ5NWMwODljMzRkMmI4OWRhYTVlMmI3NTRmNmM5L3RhYmxlcmFuZ2U6MzRiNDk1YzA4OWMzNGQyYjg5ZGFhNWUyYjc1NGY2YzlfMzYtOS0xLTEtMA_507da46e-72f3-4c56-9308-b6d1c0c82229"
      unitRef="usd">4017761</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ieac446e98d7241d8a6a13f0e4a3044da_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18yMi9mcmFnOjg2MjFjNDJiNjI3NDRkMmNhMzQ1NDQwN2UzZjI0N2QzL3RhYmxlOjM0YjQ5NWMwODljMzRkMmI4OWRhYTVlMmI3NTRmNmM5L3RhYmxlcmFuZ2U6MzRiNDk1YzA4OWMzNGQyYjg5ZGFhNWUyYjc1NGY2YzlfMzYtMTUtMS0xLTA_995c682f-5e6a-4649-8150-17f92ee12c48"
      unitRef="usd">-16208</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i03bccaa0abfb4733b1e2831ecde4e4e8_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18yMi9mcmFnOjg2MjFjNDJiNjI3NDRkMmNhMzQ1NDQwN2UzZjI0N2QzL3RhYmxlOjM0YjQ5NWMwODljMzRkMmI4OWRhYTVlMmI3NTRmNmM5L3RhYmxlcmFuZ2U6MzRiNDk1YzA4OWMzNGQyYjg5ZGFhNWUyYjc1NGY2YzlfMzYtMTctMS0xLTA_893f4c79-8506-4dc4-ad82-bd1f54870eb2"
      unitRef="usd">4001553</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance
      contextRef="ieac446e98d7241d8a6a13f0e4a3044da_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18yMi9mcmFnOjg2MjFjNDJiNjI3NDRkMmNhMzQ1NDQwN2UzZjI0N2QzL3RhYmxlOjM0YjQ5NWMwODljMzRkMmI4OWRhYTVlMmI3NTRmNmM5L3RhYmxlcmFuZ2U6MzRiNDk1YzA4OWMzNGQyYjg5ZGFhNWUyYjc1NGY2YzlfMzctMTUtMS0xLTA_cfd55fdf-a6fb-4fc9-a007-5c32cd949cc2"
      unitRef="usd">2169998</us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance>
    <us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance
      contextRef="i03bccaa0abfb4733b1e2831ecde4e4e8_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18yMi9mcmFnOjg2MjFjNDJiNjI3NDRkMmNhMzQ1NDQwN2UzZjI0N2QzL3RhYmxlOjM0YjQ5NWMwODljMzRkMmI4OWRhYTVlMmI3NTRmNmM5L3RhYmxlcmFuZ2U6MzRiNDk1YzA4OWMzNGQyYjg5ZGFhNWUyYjc1NGY2YzlfMzctMTctMS0xLTA_288afeb8-49b0-4337-bb65-67ec040f327f"
      unitRef="usd">2169998</us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance>
    <us-gaap:ProfitLoss
      contextRef="i344d70813010473f9e5c16b3e01640b5_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18yMi9mcmFnOjg2MjFjNDJiNjI3NDRkMmNhMzQ1NDQwN2UzZjI0N2QzL3RhYmxlOjM0YjQ5NWMwODljMzRkMmI4OWRhYTVlMmI3NTRmNmM5L3RhYmxlcmFuZ2U6MzRiNDk1YzA4OWMzNGQyYjg5ZGFhNWUyYjc1NGY2YzlfMzgtMTEtMS0xLTA_60e05fc3-018b-4b2c-af95-941c7002dc2d"
      unitRef="usd">-32541054</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="ieac446e98d7241d8a6a13f0e4a3044da_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18yMi9mcmFnOjg2MjFjNDJiNjI3NDRkMmNhMzQ1NDQwN2UzZjI0N2QzL3RhYmxlOjM0YjQ5NWMwODljMzRkMmI4OWRhYTVlMmI3NTRmNmM5L3RhYmxlcmFuZ2U6MzRiNDk1YzA4OWMzNGQyYjg5ZGFhNWUyYjc1NGY2YzlfMzgtMTUtMS0xLTA_5dac852a-e06d-4a2e-97f4-9c6aad66d145"
      unitRef="usd">-594350</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i03bccaa0abfb4733b1e2831ecde4e4e8_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18yMi9mcmFnOjg2MjFjNDJiNjI3NDRkMmNhMzQ1NDQwN2UzZjI0N2QzL3RhYmxlOjM0YjQ5NWMwODljMzRkMmI4OWRhYTVlMmI3NTRmNmM5L3RhYmxlcmFuZ2U6MzRiNDk1YzA4OWMzNGQyYjg5ZGFhNWUyYjc1NGY2YzlfMzgtMTctMS0xLTA_786db85d-0e59-4fcc-8b92-218f37e99622"
      unitRef="usd">-33135404</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="ie9701f9c982742d69bfc64ed972293c3_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18yMi9mcmFnOjg2MjFjNDJiNjI3NDRkMmNhMzQ1NDQwN2UzZjI0N2QzL3RhYmxlOjM0YjQ5NWMwODljMzRkMmI4OWRhYTVlMmI3NTRmNmM5L3RhYmxlcmFuZ2U6MzRiNDk1YzA4OWMzNGQyYjg5ZGFhNWUyYjc1NGY2YzlfMzktMTMtMS0xLTA_7fe5fe14-83c3-42db-8091-c34b4e647ccf"
      unitRef="usd">-1929538</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i03bccaa0abfb4733b1e2831ecde4e4e8_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18yMi9mcmFnOjg2MjFjNDJiNjI3NDRkMmNhMzQ1NDQwN2UzZjI0N2QzL3RhYmxlOjM0YjQ5NWMwODljMzRkMmI4OWRhYTVlMmI3NTRmNmM5L3RhYmxlcmFuZ2U6MzRiNDk1YzA4OWMzNGQyYjg5ZGFhNWUyYjc1NGY2YzlfMzktMTctMS0xLTA_753f8953-8a12-40d5-8fd7-0ba8397cc826"
      unitRef="usd">-1929538</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:SharesIssued
      contextRef="ia55b1d91150f431281e2f695e0515501_I20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18yMi9mcmFnOjg2MjFjNDJiNjI3NDRkMmNhMzQ1NDQwN2UzZjI0N2QzL3RhYmxlOjM0YjQ5NWMwODljMzRkMmI4OWRhYTVlMmI3NTRmNmM5L3RhYmxlcmFuZ2U6MzRiNDk1YzA4OWMzNGQyYjg5ZGFhNWUyYjc1NGY2YzlfNDAtMS0xLTEtMA_981cfb9f-f794-46e9-b076-25fac3142cc8"
      unitRef="shares">23</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ia55b1d91150f431281e2f695e0515501_I20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18yMi9mcmFnOjg2MjFjNDJiNjI3NDRkMmNhMzQ1NDQwN2UzZjI0N2QzL3RhYmxlOjM0YjQ5NWMwODljMzRkMmI4OWRhYTVlMmI3NTRmNmM5L3RhYmxlcmFuZ2U6MzRiNDk1YzA4OWMzNGQyYjg5ZGFhNWUyYjc1NGY2YzlfNDAtMy0xLTEtMA_8da14004-7f43-438e-8a14-fd85653a5ba4"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesIssued
      contextRef="i90229a4122af48d0aef6e89c51605f73_I20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18yMi9mcmFnOjg2MjFjNDJiNjI3NDRkMmNhMzQ1NDQwN2UzZjI0N2QzL3RhYmxlOjM0YjQ5NWMwODljMzRkMmI4OWRhYTVlMmI3NTRmNmM5L3RhYmxlcmFuZ2U6MzRiNDk1YzA4OWMzNGQyYjg5ZGFhNWUyYjc1NGY2YzlfNDAtNS0xLTEtMA_2f7bfcff-db59-461f-967f-43ec566ea54e"
      unitRef="shares">145915100</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i90229a4122af48d0aef6e89c51605f73_I20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18yMi9mcmFnOjg2MjFjNDJiNjI3NDRkMmNhMzQ1NDQwN2UzZjI0N2QzL3RhYmxlOjM0YjQ5NWMwODljMzRkMmI4OWRhYTVlMmI3NTRmNmM5L3RhYmxlcmFuZ2U6MzRiNDk1YzA4OWMzNGQyYjg5ZGFhNWUyYjc1NGY2YzlfNDAtNy0xLTEtMA_f304817d-3944-47d9-b37a-0ac49c3e8d6c"
      unitRef="usd">145915</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i7516614b1b654183b04111cbc3406079_I20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18yMi9mcmFnOjg2MjFjNDJiNjI3NDRkMmNhMzQ1NDQwN2UzZjI0N2QzL3RhYmxlOjM0YjQ5NWMwODljMzRkMmI4OWRhYTVlMmI3NTRmNmM5L3RhYmxlcmFuZ2U6MzRiNDk1YzA4OWMzNGQyYjg5ZGFhNWUyYjc1NGY2YzlfNDAtOS0xLTEtMA_675236e0-5376-49a1-9673-a05bf9a7080b"
      unitRef="usd">957962628</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i94124ab8558d4ae989f26b588119e983_I20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18yMi9mcmFnOjg2MjFjNDJiNjI3NDRkMmNhMzQ1NDQwN2UzZjI0N2QzL3RhYmxlOjM0YjQ5NWMwODljMzRkMmI4OWRhYTVlMmI3NTRmNmM5L3RhYmxlcmFuZ2U6MzRiNDk1YzA4OWMzNGQyYjg5ZGFhNWUyYjc1NGY2YzlfNDAtMTEtMS0xLTA_2536a6e5-a940-4e2a-ac04-b8cad08016e4"
      unitRef="usd">-772326709</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i54cb3f5e003c480faccd9444adf9d1fe_I20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18yMi9mcmFnOjg2MjFjNDJiNjI3NDRkMmNhMzQ1NDQwN2UzZjI0N2QzL3RhYmxlOjM0YjQ5NWMwODljMzRkMmI4OWRhYTVlMmI3NTRmNmM5L3RhYmxlcmFuZ2U6MzRiNDk1YzA4OWMzNGQyYjg5ZGFhNWUyYjc1NGY2YzlfNDAtMTMtMS0xLTA_5b18c428-39ae-410f-af8e-71220a381c4c"
      unitRef="usd">-1456930</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i63a61b36187545e5820f6cdb1e65f011_I20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18yMi9mcmFnOjg2MjFjNDJiNjI3NDRkMmNhMzQ1NDQwN2UzZjI0N2QzL3RhYmxlOjM0YjQ5NWMwODljMzRkMmI4OWRhYTVlMmI3NTRmNmM5L3RhYmxlcmFuZ2U6MzRiNDk1YzA4OWMzNGQyYjg5ZGFhNWUyYjc1NGY2YzlfNDAtMTUtMS0xLTA_5bd909d5-0da6-459c-b0f7-aff41dfd6cf6"
      unitRef="usd">3529199</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i98369f585c4549d585af1f9094a77fd9_I20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18yMi9mcmFnOjg2MjFjNDJiNjI3NDRkMmNhMzQ1NDQwN2UzZjI0N2QzL3RhYmxlOjM0YjQ5NWMwODljMzRkMmI4OWRhYTVlMmI3NTRmNmM5L3RhYmxlcmFuZ2U6MzRiNDk1YzA4OWMzNGQyYjg5ZGFhNWUyYjc1NGY2YzlfNDAtMTctMS0xLTA_2d1b5251-53c2-466e-98d7-8261227bf881"
      unitRef="usd">187854103</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss
      contextRef="i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18yNS9mcmFnOjdiNjAzZGI3ZTMwMDRhOGNiOWVkMDQ4YTYzYjhhMjQxL3RhYmxlOmMxOTk4MmY4NGY5NzRmYjQ5ZGE5YjIzMjFmZmQzNWRiL3RhYmxlcmFuZ2U6YzE5OTgyZjg0Zjk3NGZiNDlkYTliMjMyMWZmZDM1ZGJfMy0xLTEtMS0w_c65d7472-c0bb-43c3-9f49-05b12ee2cb0f"
      unitRef="usd">-54402131</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i03bccaa0abfb4733b1e2831ecde4e4e8_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18yNS9mcmFnOjdiNjAzZGI3ZTMwMDRhOGNiOWVkMDQ4YTYzYjhhMjQxL3RhYmxlOmMxOTk4MmY4NGY5NzRmYjQ5ZGE5YjIzMjFmZmQzNWRiL3RhYmxlcmFuZ2U6YzE5OTgyZjg0Zjk3NGZiNDlkYTliMjMyMWZmZDM1ZGJfMy0zLTEtMS0w_049102d1-fb87-4249-9612-08715200312f"
      unitRef="usd">-33135404</us-gaap:ProfitLoss>
    <us-gaap:Depreciation
      contextRef="i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18yNS9mcmFnOjdiNjAzZGI3ZTMwMDRhOGNiOWVkMDQ4YTYzYjhhMjQxL3RhYmxlOmMxOTk4MmY4NGY5NzRmYjQ5ZGE5YjIzMjFmZmQzNWRiL3RhYmxlcmFuZ2U6YzE5OTgyZjg0Zjk3NGZiNDlkYTliMjMyMWZmZDM1ZGJfNS0xLTEtMS0w_c3e95a0d-778e-45c8-ac11-94a31e6ced1d"
      unitRef="usd">660697</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="i03bccaa0abfb4733b1e2831ecde4e4e8_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18yNS9mcmFnOjdiNjAzZGI3ZTMwMDRhOGNiOWVkMDQ4YTYzYjhhMjQxL3RhYmxlOmMxOTk4MmY4NGY5NzRmYjQ5ZGE5YjIzMjFmZmQzNWRiL3RhYmxlcmFuZ2U6YzE5OTgyZjg0Zjk3NGZiNDlkYTliMjMyMWZmZDM1ZGJfNS0zLTEtMS0w_c9070867-e5c1-4adc-ae58-e929f72df9f8"
      unitRef="usd">809559</us-gaap:Depreciation>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18yNS9mcmFnOjdiNjAzZGI3ZTMwMDRhOGNiOWVkMDQ4YTYzYjhhMjQxL3RhYmxlOmMxOTk4MmY4NGY5NzRmYjQ5ZGE5YjIzMjFmZmQzNWRiL3RhYmxlcmFuZ2U6YzE5OTgyZjg0Zjk3NGZiNDlkYTliMjMyMWZmZDM1ZGJfNi0xLTEtMS0w_be0b0e12-6417-4433-8095-ab6df28b0da3"
      unitRef="usd">136770</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i03bccaa0abfb4733b1e2831ecde4e4e8_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18yNS9mcmFnOjdiNjAzZGI3ZTMwMDRhOGNiOWVkMDQ4YTYzYjhhMjQxL3RhYmxlOmMxOTk4MmY4NGY5NzRmYjQ5ZGE5YjIzMjFmZmQzNWRiL3RhYmxlcmFuZ2U6YzE5OTgyZjg0Zjk3NGZiNDlkYTliMjMyMWZmZDM1ZGJfNi0zLTEtMS0w_1f090676-ddba-444c-af8c-9a2f28b62843"
      unitRef="usd">136770</us-gaap:AmortizationOfIntangibleAssets>
    <ino:AmortizationOfOperatingLeaseRightOfUseAssets
      contextRef="i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18yNS9mcmFnOjdiNjAzZGI3ZTMwMDRhOGNiOWVkMDQ4YTYzYjhhMjQxL3RhYmxlOmMxOTk4MmY4NGY5NzRmYjQ5ZGE5YjIzMjFmZmQzNWRiL3RhYmxlcmFuZ2U6YzE5OTgyZjg0Zjk3NGZiNDlkYTliMjMyMWZmZDM1ZGJfNy0xLTEtMS0w_627a02b9-7051-4889-8f8f-8e9175fde8ba"
      unitRef="usd">0</ino:AmortizationOfOperatingLeaseRightOfUseAssets>
    <ino:AmortizationOfOperatingLeaseRightOfUseAssets
      contextRef="i03bccaa0abfb4733b1e2831ecde4e4e8_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18yNS9mcmFnOjdiNjAzZGI3ZTMwMDRhOGNiOWVkMDQ4YTYzYjhhMjQxL3RhYmxlOmMxOTk4MmY4NGY5NzRmYjQ5ZGE5YjIzMjFmZmQzNWRiL3RhYmxlcmFuZ2U6YzE5OTgyZjg0Zjk3NGZiNDlkYTliMjMyMWZmZDM1ZGJfNy0zLTEtMS0w_b2413ab5-943e-447c-8cd6-51a681861879"
      unitRef="usd">271628</ino:AmortizationOfOperatingLeaseRightOfUseAssets>
    <us-gaap:IncreaseDecreaseInDerivativeLiabilities
      contextRef="i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18yNS9mcmFnOjdiNjAzZGI3ZTMwMDRhOGNiOWVkMDQ4YTYzYjhhMjQxL3RhYmxlOmMxOTk4MmY4NGY5NzRmYjQ5ZGE5YjIzMjFmZmQzNWRiL3RhYmxlcmFuZ2U6YzE5OTgyZjg0Zjk3NGZiNDlkYTliMjMyMWZmZDM1ZGJfOC0xLTEtMS0w_0a7326ca-5758-4301-923d-c6dfc46fbaf2"
      unitRef="usd">0</us-gaap:IncreaseDecreaseInDerivativeLiabilities>
    <us-gaap:IncreaseDecreaseInDerivativeLiabilities
      contextRef="i03bccaa0abfb4733b1e2831ecde4e4e8_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18yNS9mcmFnOjdiNjAzZGI3ZTMwMDRhOGNiOWVkMDQ4YTYzYjhhMjQxL3RhYmxlOmMxOTk4MmY4NGY5NzRmYjQ5ZGE5YjIzMjFmZmQzNWRiL3RhYmxlcmFuZ2U6YzE5OTgyZjg0Zjk3NGZiNDlkYTliMjMyMWZmZDM1ZGJfOC0zLTEtMS0w_03237f4d-c1c2-44a6-8084-cfaf5a9f8353"
      unitRef="usd">13221977</us-gaap:IncreaseDecreaseInDerivativeLiabilities>
    <us-gaap:ShareBasedCompensation
      contextRef="i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18yNS9mcmFnOjdiNjAzZGI3ZTMwMDRhOGNiOWVkMDQ4YTYzYjhhMjQxL3RhYmxlOmMxOTk4MmY4NGY5NzRmYjQ5ZGE5YjIzMjFmZmQzNWRiL3RhYmxlcmFuZ2U6YzE5OTgyZjg0Zjk3NGZiNDlkYTliMjMyMWZmZDM1ZGJfOS0xLTEtMS0w_1248d920-e6bd-4a8a-8975-1c4e280d94a2"
      unitRef="usd">9595947</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i03bccaa0abfb4733b1e2831ecde4e4e8_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18yNS9mcmFnOjdiNjAzZGI3ZTMwMDRhOGNiOWVkMDQ4YTYzYjhhMjQxL3RhYmxlOmMxOTk4MmY4NGY5NzRmYjQ5ZGE5YjIzMjFmZmQzNWRiL3RhYmxlcmFuZ2U6YzE5OTgyZjg0Zjk3NGZiNDlkYTliMjMyMWZmZDM1ZGJfOS0zLTEtMS0w_8316d8b3-53c2-44e9-8c1b-f91e7e739d0d"
      unitRef="usd">4001553</us-gaap:ShareBasedCompensation>
    <ino:NonCashInterestIncomeExpense
      contextRef="i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18yNS9mcmFnOjdiNjAzZGI3ZTMwMDRhOGNiOWVkMDQ4YTYzYjhhMjQxL3RhYmxlOmMxOTk4MmY4NGY5NzRmYjQ5ZGE5YjIzMjFmZmQzNWRiL3RhYmxlcmFuZ2U6YzE5OTgyZjg0Zjk3NGZiNDlkYTliMjMyMWZmZDM1ZGJfMTItMS0xLTEtMA_211ea232-73b2-45d5-9126-9659abdc1725"
      unitRef="usd">31281</ino:NonCashInterestIncomeExpense>
    <ino:NonCashInterestIncomeExpense
      contextRef="i03bccaa0abfb4733b1e2831ecde4e4e8_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18yNS9mcmFnOjdiNjAzZGI3ZTMwMDRhOGNiOWVkMDQ4YTYzYjhhMjQxL3RhYmxlOmMxOTk4MmY4NGY5NzRmYjQ5ZGE5YjIzMjFmZmQzNWRiL3RhYmxlcmFuZ2U6YzE5OTgyZjg0Zjk3NGZiNDlkYTliMjMyMWZmZDM1ZGJfMTItMy0xLTEtMA_1a54bb72-d289-4e6e-a583-cf763d3b9f31"
      unitRef="usd">-213559</ino:NonCashInterestIncomeExpense>
    <us-gaap:GainLossOnInvestments
      contextRef="i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18yNS9mcmFnOjdiNjAzZGI3ZTMwMDRhOGNiOWVkMDQ4YTYzYjhhMjQxL3RhYmxlOmMxOTk4MmY4NGY5NzRmYjQ5ZGE5YjIzMjFmZmQzNWRiL3RhYmxlcmFuZ2U6YzE5OTgyZjg0Zjk3NGZiNDlkYTliMjMyMWZmZDM1ZGJfMTQtMS0xLTEtMA_6fa1c4a8-0dd7-45de-bc9a-37ce79f9d577"
      unitRef="usd">-10151</us-gaap:GainLossOnInvestments>
    <us-gaap:GainLossOnInvestments
      contextRef="i03bccaa0abfb4733b1e2831ecde4e4e8_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18yNS9mcmFnOjdiNjAzZGI3ZTMwMDRhOGNiOWVkMDQ4YTYzYjhhMjQxL3RhYmxlOmMxOTk4MmY4NGY5NzRmYjQ5ZGE5YjIzMjFmZmQzNWRiL3RhYmxlcmFuZ2U6YzE5OTgyZjg0Zjk3NGZiNDlkYTliMjMyMWZmZDM1ZGJfMTQtMy0xLTEtMA_84c991b6-3518-46ae-b530-b08b7fa1f26b"
      unitRef="usd">-475490</us-gaap:GainLossOnInvestments>
    <ino:SettlementOfReceivableWithSharesOfCommonStockFromEquitySecurity
      contextRef="i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18yNS9mcmFnOjdiNjAzZGI3ZTMwMDRhOGNiOWVkMDQ4YTYzYjhhMjQxL3RhYmxlOmMxOTk4MmY4NGY5NzRmYjQ5ZGE5YjIzMjFmZmQzNWRiL3RhYmxlcmFuZ2U6YzE5OTgyZjg0Zjk3NGZiNDlkYTliMjMyMWZmZDM1ZGJfMTYtMS0xLTEtMA_eccbc1a1-7eb2-4d77-a6b0-b94c5aa2e17d"
      unitRef="usd">0</ino:SettlementOfReceivableWithSharesOfCommonStockFromEquitySecurity>
    <ino:SettlementOfReceivableWithSharesOfCommonStockFromEquitySecurity
      contextRef="i03bccaa0abfb4733b1e2831ecde4e4e8_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18yNS9mcmFnOjdiNjAzZGI3ZTMwMDRhOGNiOWVkMDQ4YTYzYjhhMjQxL3RhYmxlOmMxOTk4MmY4NGY5NzRmYjQ5ZGE5YjIzMjFmZmQzNWRiL3RhYmxlcmFuZ2U6YzE5OTgyZjg0Zjk3NGZiNDlkYTliMjMyMWZmZDM1ZGJfMTYtMy0xLTEtMA_7668159b-00f9-4616-ae2b-81c1ce975fbe"
      unitRef="usd">1713770</ino:SettlementOfReceivableWithSharesOfCommonStockFromEquitySecurity>
    <ino:ChangeInValueOfInvestmentsInAffiliatedCompany
      contextRef="i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18yNS9mcmFnOjdiNjAzZGI3ZTMwMDRhOGNiOWVkMDQ4YTYzYjhhMjQxL3RhYmxlOmMxOTk4MmY4NGY5NzRmYjQ5ZGE5YjIzMjFmZmQzNWRiL3RhYmxlcmFuZ2U6YzE5OTgyZjg0Zjk3NGZiNDlkYTliMjMyMWZmZDM1ZGJfMTgtMS0xLTEtMA_742d9f1d-ddca-4134-a931-4e7c90c53790"
      unitRef="usd">-830475</ino:ChangeInValueOfInvestmentsInAffiliatedCompany>
    <ino:ChangeInValueOfInvestmentsInAffiliatedCompany
      contextRef="i03bccaa0abfb4733b1e2831ecde4e4e8_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18yNS9mcmFnOjdiNjAzZGI3ZTMwMDRhOGNiOWVkMDQ4YTYzYjhhMjQxL3RhYmxlOmMxOTk4MmY4NGY5NzRmYjQ5ZGE5YjIzMjFmZmQzNWRiL3RhYmxlcmFuZ2U6YzE5OTgyZjg0Zjk3NGZiNDlkYTliMjMyMWZmZDM1ZGJfMTgtMy0xLTEtMA_804fad50-34a8-4746-993e-568482fe11de"
      unitRef="usd">13181619</ino:ChangeInValueOfInvestmentsInAffiliatedCompany>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18yNS9mcmFnOjdiNjAzZGI3ZTMwMDRhOGNiOWVkMDQ4YTYzYjhhMjQxL3RhYmxlOmMxOTk4MmY4NGY5NzRmYjQ5ZGE5YjIzMjFmZmQzNWRiL3RhYmxlcmFuZ2U6YzE5OTgyZjg0Zjk3NGZiNDlkYTliMjMyMWZmZDM1ZGJfMTktMS0xLTEtMA_86bb4980-b538-4be1-9507-ceda461dab1a"
      unitRef="usd">-434387</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i03bccaa0abfb4733b1e2831ecde4e4e8_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18yNS9mcmFnOjdiNjAzZGI3ZTMwMDRhOGNiOWVkMDQ4YTYzYjhhMjQxL3RhYmxlOmMxOTk4MmY4NGY5NzRmYjQ5ZGE5YjIzMjFmZmQzNWRiL3RhYmxlcmFuZ2U6YzE5OTgyZjg0Zjk3NGZiNDlkYTliMjMyMWZmZDM1ZGJfMTktMy0xLTEtMA_cb5dbf65-2295-40e8-8e70-3d794cf9743e"
      unitRef="usd">0</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:EquitySecuritiesFvNiUnrealizedLoss
      contextRef="i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18yNS9mcmFnOjdiNjAzZGI3ZTMwMDRhOGNiOWVkMDQ4YTYzYjhhMjQxL3RhYmxlOmMxOTk4MmY4NGY5NzRmYjQ5ZGE5YjIzMjFmZmQzNWRiL3RhYmxlcmFuZ2U6YzE5OTgyZjg0Zjk3NGZiNDlkYTliMjMyMWZmZDM1ZGJfMjItMS0xLTEtMA_e4cd1084-2fd4-4ac3-8773-67b665d22108"
      unitRef="usd">847958</us-gaap:EquitySecuritiesFvNiUnrealizedLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedLoss
      contextRef="i03bccaa0abfb4733b1e2831ecde4e4e8_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18yNS9mcmFnOjdiNjAzZGI3ZTMwMDRhOGNiOWVkMDQ4YTYzYjhhMjQxL3RhYmxlOmMxOTk4MmY4NGY5NzRmYjQ5ZGE5YjIzMjFmZmQzNWRiL3RhYmxlcmFuZ2U6YzE5OTgyZjg0Zjk3NGZiNDlkYTliMjMyMWZmZDM1ZGJfMjItMy0xLTEtMA_91c54c69-7c46-40e4-9936-7cccf323d582"
      unitRef="usd">5050092</us-gaap:EquitySecuritiesFvNiUnrealizedLoss>
    <ino:OperatingLeaseNonCashLeaseExpense
      contextRef="i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18yNS9mcmFnOjdiNjAzZGI3ZTMwMDRhOGNiOWVkMDQ4YTYzYjhhMjQxL3RhYmxlOmMxOTk4MmY4NGY5NzRmYjQ5ZGE5YjIzMjFmZmQzNWRiL3RhYmxlcmFuZ2U6YzE5OTgyZjg0Zjk3NGZiNDlkYTliMjMyMWZmZDM1ZGJfMjMtMS0xLTEtMA_f6061e4a-cf36-4447-b16c-051dfba6ec54"
      unitRef="usd">278290</ino:OperatingLeaseNonCashLeaseExpense>
    <ino:OperatingLeaseNonCashLeaseExpense
      contextRef="i03bccaa0abfb4733b1e2831ecde4e4e8_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18yNS9mcmFnOjdiNjAzZGI3ZTMwMDRhOGNiOWVkMDQ4YTYzYjhhMjQxL3RhYmxlOmMxOTk4MmY4NGY5NzRmYjQ5ZGE5YjIzMjFmZmQzNWRiL3RhYmxlcmFuZ2U6YzE5OTgyZjg0Zjk3NGZiNDlkYTliMjMyMWZmZDM1ZGJfMjMtMy0xLTEtMA_180f63c4-0ba7-4780-90a3-3202429dd9fc"
      unitRef="usd">0</ino:OperatingLeaseNonCashLeaseExpense>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18yNS9mcmFnOjdiNjAzZGI3ZTMwMDRhOGNiOWVkMDQ4YTYzYjhhMjQxL3RhYmxlOmMxOTk4MmY4NGY5NzRmYjQ5ZGE5YjIzMjFmZmQzNWRiL3RhYmxlcmFuZ2U6YzE5OTgyZjg0Zjk3NGZiNDlkYTliMjMyMWZmZDM1ZGJfMjUtMS0xLTEtMA_cd0456a1-b8b2-4a2f-9450-459b6f979d08"
      unitRef="usd">176927</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="i03bccaa0abfb4733b1e2831ecde4e4e8_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18yNS9mcmFnOjdiNjAzZGI3ZTMwMDRhOGNiOWVkMDQ4YTYzYjhhMjQxL3RhYmxlOmMxOTk4MmY4NGY5NzRmYjQ5ZGE5YjIzMjFmZmQzNWRiL3RhYmxlcmFuZ2U6YzE5OTgyZjg0Zjk3NGZiNDlkYTliMjMyMWZmZDM1ZGJfMjUtMy0xLTEtMA_53853ba1-63ed-4cd5-8fe9-2767b2567981"
      unitRef="usd">681151</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18yNS9mcmFnOjdiNjAzZGI3ZTMwMDRhOGNiOWVkMDQ4YTYzYjhhMjQxL3RhYmxlOmMxOTk4MmY4NGY5NzRmYjQ5ZGE5YjIzMjFmZmQzNWRiL3RhYmxlcmFuZ2U6YzE5OTgyZjg0Zjk3NGZiNDlkYTliMjMyMWZmZDM1ZGJfMjctMS0xLTEtMA_afaa8645-3f41-4529-ba5a-0f5ff4cc22ef"
      unitRef="usd">-8648045</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i03bccaa0abfb4733b1e2831ecde4e4e8_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18yNS9mcmFnOjdiNjAzZGI3ZTMwMDRhOGNiOWVkMDQ4YTYzYjhhMjQxL3RhYmxlOmMxOTk4MmY4NGY5NzRmYjQ5ZGE5YjIzMjFmZmQzNWRiL3RhYmxlcmFuZ2U6YzE5OTgyZjg0Zjk3NGZiNDlkYTliMjMyMWZmZDM1ZGJfMjctMy0xLTEtMA_330c63ed-9bcd-4a9a-9704-14fe9523f658"
      unitRef="usd">-58430</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivableRelatedParties
      contextRef="i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18yNS9mcmFnOjdiNjAzZGI3ZTMwMDRhOGNiOWVkMDQ4YTYzYjhhMjQxL3RhYmxlOmMxOTk4MmY4NGY5NzRmYjQ5ZGE5YjIzMjFmZmQzNWRiL3RhYmxlcmFuZ2U6YzE5OTgyZjg0Zjk3NGZiNDlkYTliMjMyMWZmZDM1ZGJfMjgtMS0xLTEtMA_83a7a8f7-cd48-4a04-8a48-37a44c0bf2ac"
      unitRef="usd">-156808</us-gaap:IncreaseDecreaseInAccountsReceivableRelatedParties>
    <us-gaap:IncreaseDecreaseInAccountsReceivableRelatedParties
      contextRef="i03bccaa0abfb4733b1e2831ecde4e4e8_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18yNS9mcmFnOjdiNjAzZGI3ZTMwMDRhOGNiOWVkMDQ4YTYzYjhhMjQxL3RhYmxlOmMxOTk4MmY4NGY5NzRmYjQ5ZGE5YjIzMjFmZmQzNWRiL3RhYmxlcmFuZ2U6YzE5OTgyZjg0Zjk3NGZiNDlkYTliMjMyMWZmZDM1ZGJfMjgtMy0xLTEtMA_3a77829e-e950-47f4-8acc-8413c6eb9e5d"
      unitRef="usd">-697846</us-gaap:IncreaseDecreaseInAccountsReceivableRelatedParties>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18yNS9mcmFnOjdiNjAzZGI3ZTMwMDRhOGNiOWVkMDQ4YTYzYjhhMjQxL3RhYmxlOmMxOTk4MmY4NGY5NzRmYjQ5ZGE5YjIzMjFmZmQzNWRiL3RhYmxlcmFuZ2U6YzE5OTgyZjg0Zjk3NGZiNDlkYTliMjMyMWZmZDM1ZGJfMjktMS0xLTEtMA_4c8928e9-440e-4468-9ec2-d5ac24d43691"
      unitRef="usd">19214780</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="i03bccaa0abfb4733b1e2831ecde4e4e8_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18yNS9mcmFnOjdiNjAzZGI3ZTMwMDRhOGNiOWVkMDQ4YTYzYjhhMjQxL3RhYmxlOmMxOTk4MmY4NGY5NzRmYjQ5ZGE5YjIzMjFmZmQzNWRiL3RhYmxlcmFuZ2U6YzE5OTgyZjg0Zjk3NGZiNDlkYTliMjMyMWZmZDM1ZGJfMjktMy0xLTEtMA_0d85c6d6-c64f-4279-84f4-73fa64ba3d1d"
      unitRef="usd">894606</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <ino:IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity
      contextRef="i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18yNS9mcmFnOjdiNjAzZGI3ZTMwMDRhOGNiOWVkMDQ4YTYzYjhhMjQxL3RhYmxlOmMxOTk4MmY4NGY5NzRmYjQ5ZGE5YjIzMjFmZmQzNWRiL3RhYmxlcmFuZ2U6YzE5OTgyZjg0Zjk3NGZiNDlkYTliMjMyMWZmZDM1ZGJfMzAtMS0xLTEtMA_e3505883-668e-417e-824c-474dc88d435e"
      unitRef="usd">-106432</ino:IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity>
    <ino:IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity
      contextRef="i03bccaa0abfb4733b1e2831ecde4e4e8_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18yNS9mcmFnOjdiNjAzZGI3ZTMwMDRhOGNiOWVkMDQ4YTYzYjhhMjQxL3RhYmxlOmMxOTk4MmY4NGY5NzRmYjQ5ZGE5YjIzMjFmZmQzNWRiL3RhYmxlcmFuZ2U6YzE5OTgyZjg0Zjk3NGZiNDlkYTliMjMyMWZmZDM1ZGJfMzAtMy0xLTEtMA_cff363ba-72e2-4c77-a7df-a002546ca618"
      unitRef="usd">740469</ino:IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18yNS9mcmFnOjdiNjAzZGI3ZTMwMDRhOGNiOWVkMDQ4YTYzYjhhMjQxL3RhYmxlOmMxOTk4MmY4NGY5NzRmYjQ5ZGE5YjIzMjFmZmQzNWRiL3RhYmxlcmFuZ2U6YzE5OTgyZjg0Zjk3NGZiNDlkYTliMjMyMWZmZDM1ZGJfMzItMS0xLTEtMA_5e192ee9-7d1e-49ae-bc8c-ea47f9df0fab"
      unitRef="usd">-75514</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="i03bccaa0abfb4733b1e2831ecde4e4e8_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18yNS9mcmFnOjdiNjAzZGI3ZTMwMDRhOGNiOWVkMDQ4YTYzYjhhMjQxL3RhYmxlOmMxOTk4MmY4NGY5NzRmYjQ5ZGE5YjIzMjFmZmQzNWRiL3RhYmxlcmFuZ2U6YzE5OTgyZjg0Zjk3NGZiNDlkYTliMjMyMWZmZDM1ZGJfMzItMy0xLTEtMA_8c519b27-7103-423f-91bf-fe901c84ccca"
      unitRef="usd">-191937</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18yNS9mcmFnOjdiNjAzZGI3ZTMwMDRhOGNiOWVkMDQ4YTYzYjhhMjQxL3RhYmxlOmMxOTk4MmY4NGY5NzRmYjQ5ZGE5YjIzMjFmZmQzNWRiL3RhYmxlcmFuZ2U6YzE5OTgyZjg0Zjk3NGZiNDlkYTliMjMyMWZmZDM1ZGJfMzMtMS0xLTEtMA_587d4808-2357-4d76-9dc8-f6e9cf2cd7e9"
      unitRef="usd">4735352</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="i03bccaa0abfb4733b1e2831ecde4e4e8_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18yNS9mcmFnOjdiNjAzZGI3ZTMwMDRhOGNiOWVkMDQ4YTYzYjhhMjQxL3RhYmxlOmMxOTk4MmY4NGY5NzRmYjQ5ZGE5YjIzMjFmZmQzNWRiL3RhYmxlcmFuZ2U6YzE5OTgyZjg0Zjk3NGZiNDlkYTliMjMyMWZmZDM1ZGJfMzMtMy0xLTEtMA_52d267aa-e42a-4c13-b746-daed2986a427"
      unitRef="usd">-7217676</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <ino:IncreaseDecreaseInAccruedClinicalTrialExpense
      contextRef="i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18yNS9mcmFnOjdiNjAzZGI3ZTMwMDRhOGNiOWVkMDQ4YTYzYjhhMjQxL3RhYmxlOmMxOTk4MmY4NGY5NzRmYjQ5ZGE5YjIzMjFmZmQzNWRiL3RhYmxlcmFuZ2U6YzE5OTgyZjg0Zjk3NGZiNDlkYTliMjMyMWZmZDM1ZGJfMzQtMS0xLTEtMA_1d9b12f8-e513-4d11-9f49-400c383c0398"
      unitRef="usd">-2579476</ino:IncreaseDecreaseInAccruedClinicalTrialExpense>
    <ino:IncreaseDecreaseInAccruedClinicalTrialExpense
      contextRef="i03bccaa0abfb4733b1e2831ecde4e4e8_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18yNS9mcmFnOjdiNjAzZGI3ZTMwMDRhOGNiOWVkMDQ4YTYzYjhhMjQxL3RhYmxlOmMxOTk4MmY4NGY5NzRmYjQ5ZGE5YjIzMjFmZmQzNWRiL3RhYmxlcmFuZ2U6YzE5OTgyZjg0Zjk3NGZiNDlkYTliMjMyMWZmZDM1ZGJfMzQtMy0xLTEtMA_20d89914-ed4d-466e-9d6c-aaaebd52013c"
      unitRef="usd">1011439</ino:IncreaseDecreaseInAccruedClinicalTrialExpense>
    <us-gaap:IncreaseDecreaseInAccountsPayableRelatedParties
      contextRef="i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18yNS9mcmFnOjdiNjAzZGI3ZTMwMDRhOGNiOWVkMDQ4YTYzYjhhMjQxL3RhYmxlOmMxOTk4MmY4NGY5NzRmYjQ5ZGE5YjIzMjFmZmQzNWRiL3RhYmxlcmFuZ2U6YzE5OTgyZjg0Zjk3NGZiNDlkYTliMjMyMWZmZDM1ZGJfMzUtMS0xLTEtMA_8ef9d71c-7081-4f38-80b1-22eec39d4525"
      unitRef="usd">125292</us-gaap:IncreaseDecreaseInAccountsPayableRelatedParties>
    <us-gaap:IncreaseDecreaseInAccountsPayableRelatedParties
      contextRef="i03bccaa0abfb4733b1e2831ecde4e4e8_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18yNS9mcmFnOjdiNjAzZGI3ZTMwMDRhOGNiOWVkMDQ4YTYzYjhhMjQxL3RhYmxlOmMxOTk4MmY4NGY5NzRmYjQ5ZGE5YjIzMjFmZmQzNWRiL3RhYmxlcmFuZ2U6YzE5OTgyZjg0Zjk3NGZiNDlkYTliMjMyMWZmZDM1ZGJfMzUtMy0xLTEtMA_c68fdf8e-e63a-4a95-83d0-0b67c494ba43"
      unitRef="usd">-466273</us-gaap:IncreaseDecreaseInAccountsPayableRelatedParties>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18yNS9mcmFnOjdiNjAzZGI3ZTMwMDRhOGNiOWVkMDQ4YTYzYjhhMjQxL3RhYmxlOmMxOTk4MmY4NGY5NzRmYjQ5ZGE5YjIzMjFmZmQzNWRiL3RhYmxlcmFuZ2U6YzE5OTgyZjg0Zjk3NGZiNDlkYTliMjMyMWZmZDM1ZGJfMzYtMS0xLTEtMA_be5e4f30-0bd1-4501-b1d4-a302dfb455db"
      unitRef="usd">-34963</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="i03bccaa0abfb4733b1e2831ecde4e4e8_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18yNS9mcmFnOjdiNjAzZGI3ZTMwMDRhOGNiOWVkMDQ4YTYzYjhhMjQxL3RhYmxlOmMxOTk4MmY4NGY5NzRmYjQ5ZGE5YjIzMjFmZmQzNWRiL3RhYmxlcmFuZ2U6YzE5OTgyZjg0Zjk3NGZiNDlkYTliMjMyMWZmZDM1ZGJfMzYtMy0xLTEtMA_3bb4aa12-3fc6-472a-ba5d-4d2ba7848d86"
      unitRef="usd">-26297</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <ino:IncreaseDecreaseInDeferredRevenueFromRelatedParties
      contextRef="i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18yNS9mcmFnOjdiNjAzZGI3ZTMwMDRhOGNiOWVkMDQ4YTYzYjhhMjQxL3RhYmxlOmMxOTk4MmY4NGY5NzRmYjQ5ZGE5YjIzMjFmZmQzNWRiL3RhYmxlcmFuZ2U6YzE5OTgyZjg0Zjk3NGZiNDlkYTliMjMyMWZmZDM1ZGJfMzctMS0xLTEtMA_87e59cd4-2436-4f5a-bf38-6cd7e9e2626f"
      unitRef="usd">-37500</ino:IncreaseDecreaseInDeferredRevenueFromRelatedParties>
    <ino:IncreaseDecreaseInDeferredRevenueFromRelatedParties
      contextRef="i03bccaa0abfb4733b1e2831ecde4e4e8_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18yNS9mcmFnOjdiNjAzZGI3ZTMwMDRhOGNiOWVkMDQ4YTYzYjhhMjQxL3RhYmxlOmMxOTk4MmY4NGY5NzRmYjQ5ZGE5YjIzMjFmZmQzNWRiL3RhYmxlcmFuZ2U6YzE5OTgyZjg0Zjk3NGZiNDlkYTliMjMyMWZmZDM1ZGJfMzctMy0xLTEtMA_c84a5793-b204-4aa6-8e9c-c85284e8d7ca"
      unitRef="usd">-31250</ino:IncreaseDecreaseInDeferredRevenueFromRelatedParties>
    <ino:IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet
      contextRef="i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18yNS9mcmFnOjdiNjAzZGI3ZTMwMDRhOGNiOWVkMDQ4YTYzYjhhMjQxL3RhYmxlOmMxOTk4MmY4NGY5NzRmYjQ5ZGE5YjIzMjFmZmQzNWRiL3RhYmxlcmFuZ2U6YzE5OTgyZjg0Zjk3NGZiNDlkYTliMjMyMWZmZDM1ZGJfMzktMS0xLTEtMA_ee5f18fc-c460-4941-a77a-df7b5ab08fca"
      unitRef="usd">-558140</ino:IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet>
    <ino:IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet
      contextRef="i03bccaa0abfb4733b1e2831ecde4e4e8_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18yNS9mcmFnOjdiNjAzZGI3ZTMwMDRhOGNiOWVkMDQ4YTYzYjhhMjQxL3RhYmxlOmMxOTk4MmY4NGY5NzRmYjQ5ZGE5YjIzMjFmZmQzNWRiL3RhYmxlcmFuZ2U6YzE5OTgyZjg0Zjk3NGZiNDlkYTliMjMyMWZmZDM1ZGJfMzktMy0xLTEtMA_3d36aab6-0b6e-42ad-9039-35fc8adc7200"
      unitRef="usd">-517949</ino:IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet>
    <ino:IncreaseDecreaseinDeferredGrantFundingCurrent
      contextRef="i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18yNS9mcmFnOjdiNjAzZGI3ZTMwMDRhOGNiOWVkMDQ4YTYzYjhhMjQxL3RhYmxlOmMxOTk4MmY4NGY5NzRmYjQ5ZGE5YjIzMjFmZmQzNWRiL3RhYmxlcmFuZ2U6YzE5OTgyZjg0Zjk3NGZiNDlkYTliMjMyMWZmZDM1ZGJfNDAtMS0xLTEtMA_1e438d09-7828-450a-9779-5a937421db0d"
      unitRef="usd">-2461326</ino:IncreaseDecreaseinDeferredGrantFundingCurrent>
    <ino:IncreaseDecreaseinDeferredGrantFundingCurrent
      contextRef="i03bccaa0abfb4733b1e2831ecde4e4e8_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18yNS9mcmFnOjdiNjAzZGI3ZTMwMDRhOGNiOWVkMDQ4YTYzYjhhMjQxL3RhYmxlOmMxOTk4MmY4NGY5NzRmYjQ5ZGE5YjIzMjFmZmQzNWRiL3RhYmxlcmFuZ2U6YzE5OTgyZjg0Zjk3NGZiNDlkYTliMjMyMWZmZDM1ZGJfNDAtMy0xLTEtMA_be378474-e5b7-40d2-ac51-4419a8797d63"
      unitRef="usd">7026212</ino:IncreaseDecreaseinDeferredGrantFundingCurrent>
    <ino:IncreaseDecreaseinDeferredGrantFundingFromAffiliateCurrent
      contextRef="i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18yNS9mcmFnOjdiNjAzZGI3ZTMwMDRhOGNiOWVkMDQ4YTYzYjhhMjQxL3RhYmxlOmMxOTk4MmY4NGY5NzRmYjQ5ZGE5YjIzMjFmZmQzNWRiL3RhYmxlcmFuZ2U6YzE5OTgyZjg0Zjk3NGZiNDlkYTliMjMyMWZmZDM1ZGJfNDEtMS0xLTEtMA_52ca6ac5-035a-4143-b7d1-a47452f13f99"
      unitRef="usd">-19500</ino:IncreaseDecreaseinDeferredGrantFundingFromAffiliateCurrent>
    <ino:IncreaseDecreaseinDeferredGrantFundingFromAffiliateCurrent
      contextRef="i03bccaa0abfb4733b1e2831ecde4e4e8_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18yNS9mcmFnOjdiNjAzZGI3ZTMwMDRhOGNiOWVkMDQ4YTYzYjhhMjQxL3RhYmxlOmMxOTk4MmY4NGY5NzRmYjQ5ZGE5YjIzMjFmZmQzNWRiL3RhYmxlcmFuZ2U6YzE5OTgyZjg0Zjk3NGZiNDlkYTliMjMyMWZmZDM1ZGJfNDEtMy0xLTEtMA_fe0d4a59-1d71-4720-81f0-eb5978b159cf"
      unitRef="usd">-49250</ino:IncreaseDecreaseinDeferredGrantFundingFromAffiliateCurrent>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities
      contextRef="i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18yNS9mcmFnOjdiNjAzZGI3ZTMwMDRhOGNiOWVkMDQ4YTYzYjhhMjQxL3RhYmxlOmMxOTk4MmY4NGY5NzRmYjQ5ZGE5YjIzMjFmZmQzNWRiL3RhYmxlcmFuZ2U6YzE5OTgyZjg0Zjk3NGZiNDlkYTliMjMyMWZmZDM1ZGJfNDMtMS0xLTEtMA_31379712-37fe-40b8-9a71-f12421c5433b"
      unitRef="usd">6478</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities
      contextRef="i03bccaa0abfb4733b1e2831ecde4e4e8_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18yNS9mcmFnOjdiNjAzZGI3ZTMwMDRhOGNiOWVkMDQ4YTYzYjhhMjQxL3RhYmxlOmMxOTk4MmY4NGY5NzRmYjQ5ZGE5YjIzMjFmZmQzNWRiL3RhYmxlcmFuZ2U6YzE5OTgyZjg0Zjk3NGZiNDlkYTliMjMyMWZmZDM1ZGJfNDMtMy0xLTEtMA_db095ed3-18ed-4f76-9413-7654791720dc"
      unitRef="usd">36501</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18yNS9mcmFnOjdiNjAzZGI3ZTMwMDRhOGNiOWVkMDQ4YTYzYjhhMjQxL3RhYmxlOmMxOTk4MmY4NGY5NzRmYjQ5ZGE5YjIzMjFmZmQzNWRiL3RhYmxlcmFuZ2U6YzE5OTgyZjg0Zjk3NGZiNDlkYTliMjMyMWZmZDM1ZGJfNDQtMS0xLTEtMA_8b58543c-8e0f-4b8c-9837-544989a518d9"
      unitRef="usd">-52867428</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i03bccaa0abfb4733b1e2831ecde4e4e8_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18yNS9mcmFnOjdiNjAzZGI3ZTMwMDRhOGNiOWVkMDQ4YTYzYjhhMjQxL3RhYmxlOmMxOTk4MmY4NGY5NzRmYjQ5ZGE5YjIzMjFmZmQzNWRiL3RhYmxlcmFuZ2U6YzE5OTgyZjg0Zjk3NGZiNDlkYTliMjMyMWZmZDM1ZGJfNDQtMy0xLTEtMA_46ef2b75-5a49-4f5c-a36d-a7cf184c96da"
      unitRef="usd">-25452721</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireShortTermInvestments
      contextRef="i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18yNS9mcmFnOjdiNjAzZGI3ZTMwMDRhOGNiOWVkMDQ4YTYzYjhhMjQxL3RhYmxlOmMxOTk4MmY4NGY5NzRmYjQ5ZGE5YjIzMjFmZmQzNWRiL3RhYmxlcmFuZ2U6YzE5OTgyZjg0Zjk3NGZiNDlkYTliMjMyMWZmZDM1ZGJfNDYtMS0xLTEtMA_82f3d105-ac39-44ad-8a7b-de7b44ee401e"
      unitRef="usd">275408976</us-gaap:PaymentsToAcquireShortTermInvestments>
    <us-gaap:PaymentsToAcquireShortTermInvestments
      contextRef="i03bccaa0abfb4733b1e2831ecde4e4e8_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18yNS9mcmFnOjdiNjAzZGI3ZTMwMDRhOGNiOWVkMDQ4YTYzYjhhMjQxL3RhYmxlOmMxOTk4MmY4NGY5NzRmYjQ5ZGE5YjIzMjFmZmQzNWRiL3RhYmxlcmFuZ2U6YzE5OTgyZjg0Zjk3NGZiNDlkYTliMjMyMWZmZDM1ZGJfNDYtMy0xLTEtMA_3ea0e8a9-25ec-4511-b6fe-47ac790be514"
      unitRef="usd">56698250</us-gaap:PaymentsToAcquireShortTermInvestments>
    <us-gaap:ProceedsFromSaleOfShortTermInvestments
      contextRef="i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18yNS9mcmFnOjdiNjAzZGI3ZTMwMDRhOGNiOWVkMDQ4YTYzYjhhMjQxL3RhYmxlOmMxOTk4MmY4NGY5NzRmYjQ5ZGE5YjIzMjFmZmQzNWRiL3RhYmxlcmFuZ2U6YzE5OTgyZjg0Zjk3NGZiNDlkYTliMjMyMWZmZDM1ZGJfNDctMS0xLTEtMA_fa616ff2-c67a-4468-bc0a-5e2449fa9ffa"
      unitRef="usd">504464</us-gaap:ProceedsFromSaleOfShortTermInvestments>
    <us-gaap:ProceedsFromSaleOfShortTermInvestments
      contextRef="i03bccaa0abfb4733b1e2831ecde4e4e8_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18yNS9mcmFnOjdiNjAzZGI3ZTMwMDRhOGNiOWVkMDQ4YTYzYjhhMjQxL3RhYmxlOmMxOTk4MmY4NGY5NzRmYjQ5ZGE5YjIzMjFmZmQzNWRiL3RhYmxlcmFuZ2U6YzE5OTgyZjg0Zjk3NGZiNDlkYTliMjMyMWZmZDM1ZGJfNDctMy0xLTEtMA_fc9e4a4c-33a8-47c9-b07a-2f8ab6358e04"
      unitRef="usd">5030257</us-gaap:ProceedsFromSaleOfShortTermInvestments>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18yNS9mcmFnOjdiNjAzZGI3ZTMwMDRhOGNiOWVkMDQ4YTYzYjhhMjQxL3RhYmxlOmMxOTk4MmY4NGY5NzRmYjQ5ZGE5YjIzMjFmZmQzNWRiL3RhYmxlcmFuZ2U6YzE5OTgyZjg0Zjk3NGZiNDlkYTliMjMyMWZmZDM1ZGJfNDgtMS0xLTEtMA_e6e50700-6d00-497c-be29-7c483617b18b"
      unitRef="usd">210824</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i03bccaa0abfb4733b1e2831ecde4e4e8_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18yNS9mcmFnOjdiNjAzZGI3ZTMwMDRhOGNiOWVkMDQ4YTYzYjhhMjQxL3RhYmxlOmMxOTk4MmY4NGY5NzRmYjQ5ZGE5YjIzMjFmZmQzNWRiL3RhYmxlcmFuZ2U6YzE5OTgyZjg0Zjk3NGZiNDlkYTliMjMyMWZmZDM1ZGJfNDgtMy0xLTEtMA_3fdbbd28-65b7-4dd2-80ab-989229b4fcaf"
      unitRef="usd">140952</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18yNS9mcmFnOjdiNjAzZGI3ZTMwMDRhOGNiOWVkMDQ4YTYzYjhhMjQxL3RhYmxlOmMxOTk4MmY4NGY5NzRmYjQ5ZGE5YjIzMjFmZmQzNWRiL3RhYmxlcmFuZ2U6YzE5OTgyZjg0Zjk3NGZiNDlkYTliMjMyMWZmZDM1ZGJfNTQtMS0xLTEtMA_81800181-c84b-45d2-af60-6bb165e6f327"
      unitRef="usd">-275115336</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i03bccaa0abfb4733b1e2831ecde4e4e8_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18yNS9mcmFnOjdiNjAzZGI3ZTMwMDRhOGNiOWVkMDQ4YTYzYjhhMjQxL3RhYmxlOmMxOTk4MmY4NGY5NzRmYjQ5ZGE5YjIzMjFmZmQzNWRiL3RhYmxlcmFuZ2U6YzE5OTgyZjg0Zjk3NGZiNDlkYTliMjMyMWZmZDM1ZGJfNTQtMy0xLTEtMA_3eaa27e5-2c5e-4cbf-9ce3-4b8b0255da02"
      unitRef="usd">-51808945</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18yNS9mcmFnOjdiNjAzZGI3ZTMwMDRhOGNiOWVkMDQ4YTYzYjhhMjQxL3RhYmxlOmMxOTk4MmY4NGY5NzRmYjQ5ZGE5YjIzMjFmZmQzNWRiL3RhYmxlcmFuZ2U6YzE5OTgyZjg0Zjk3NGZiNDlkYTliMjMyMWZmZDM1ZGJfNTgtMS0xLTEtMA_21ff07d5-c8a9-4e8b-a20e-a91538eeed0b"
      unitRef="usd">162105030</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="i03bccaa0abfb4733b1e2831ecde4e4e8_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18yNS9mcmFnOjdiNjAzZGI3ZTMwMDRhOGNiOWVkMDQ4YTYzYjhhMjQxL3RhYmxlOmMxOTk4MmY4NGY5NzRmYjQ5ZGE5YjIzMjFmZmQzNWRiL3RhYmxlcmFuZ2U6YzE5OTgyZjg0Zjk3NGZiNDlkYTliMjMyMWZmZDM1ZGJfNTgtMy0xLTEtMA_83d760ff-8027-4561-b1c9-be0f2ca56c54"
      unitRef="usd">208241933</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18yNS9mcmFnOjdiNjAzZGI3ZTMwMDRhOGNiOWVkMDQ4YTYzYjhhMjQxL3RhYmxlOmMxOTk4MmY4NGY5NzRmYjQ5ZGE5YjIzMjFmZmQzNWRiL3RhYmxlcmFuZ2U6YzE5OTgyZjg0Zjk3NGZiNDlkYTliMjMyMWZmZDM1ZGJfNTktMS0xLTEtMA_70a545df-247f-4caa-bdde-43860902e6b0"
      unitRef="usd">2632996</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="i03bccaa0abfb4733b1e2831ecde4e4e8_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18yNS9mcmFnOjdiNjAzZGI3ZTMwMDRhOGNiOWVkMDQ4YTYzYjhhMjQxL3RhYmxlOmMxOTk4MmY4NGY5NzRmYjQ5ZGE5YjIzMjFmZmQzNWRiL3RhYmxlcmFuZ2U6YzE5OTgyZjg0Zjk3NGZiNDlkYTliMjMyMWZmZDM1ZGJfNTktMy0xLTEtMA_b1587735-6897-4c84-90b8-e4193f9d2f43"
      unitRef="usd">5173534</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18yNS9mcmFnOjdiNjAzZGI3ZTMwMDRhOGNiOWVkMDQ4YTYzYjhhMjQxL3RhYmxlOmMxOTk4MmY4NGY5NzRmYjQ5ZGE5YjIzMjFmZmQzNWRiL3RhYmxlcmFuZ2U6YzE5OTgyZjg0Zjk3NGZiNDlkYTliMjMyMWZmZDM1ZGJfNjAtMS0xLTEtMA_7f110d59-17c2-4c08-be93-b7cfd070605d"
      unitRef="usd">3834785</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i03bccaa0abfb4733b1e2831ecde4e4e8_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18yNS9mcmFnOjdiNjAzZGI3ZTMwMDRhOGNiOWVkMDQ4YTYzYjhhMjQxL3RhYmxlOmMxOTk4MmY4NGY5NzRmYjQ5ZGE5YjIzMjFmZmQzNWRiL3RhYmxlcmFuZ2U6YzE5OTgyZjg0Zjk3NGZiNDlkYTliMjMyMWZmZDM1ZGJfNjAtMy0xLTEtMA_b00b81c7-9ffd-478c-a30f-f8ea741a50ed"
      unitRef="usd">2072831</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:ProceedsFromMinorityShareholders
      contextRef="i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18yNS9mcmFnOjdiNjAzZGI3ZTMwMDRhOGNiOWVkMDQ4YTYzYjhhMjQxL3RhYmxlOmMxOTk4MmY4NGY5NzRmYjQ5ZGE5YjIzMjFmZmQzNWRiL3RhYmxlcmFuZ2U6YzE5OTgyZjg0Zjk3NGZiNDlkYTliMjMyMWZmZDM1ZGJfNjEtMS0xLTEtMA_5cc86311-934f-417a-bb04-7b05a8d0433f"
      unitRef="usd">0</us-gaap:ProceedsFromMinorityShareholders>
    <us-gaap:ProceedsFromMinorityShareholders
      contextRef="i03bccaa0abfb4733b1e2831ecde4e4e8_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18yNS9mcmFnOjdiNjAzZGI3ZTMwMDRhOGNiOWVkMDQ4YTYzYjhhMjQxL3RhYmxlOmMxOTk4MmY4NGY5NzRmYjQ5ZGE5YjIzMjFmZmQzNWRiL3RhYmxlcmFuZ2U6YzE5OTgyZjg0Zjk3NGZiNDlkYTliMjMyMWZmZDM1ZGJfNjEtMy0xLTEtMA_b543f67e-753c-4f88-ba5f-cd6a4b82f9a9"
      unitRef="usd">2169998</us-gaap:ProceedsFromMinorityShareholders>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18yNS9mcmFnOjdiNjAzZGI3ZTMwMDRhOGNiOWVkMDQ4YTYzYjhhMjQxL3RhYmxlOmMxOTk4MmY4NGY5NzRmYjQ5ZGE5YjIzMjFmZmQzNWRiL3RhYmxlcmFuZ2U6YzE5OTgyZjg0Zjk3NGZiNDlkYTliMjMyMWZmZDM1ZGJfNjMtMS0xLTEtMA_2f8509d7-f7ed-49d6-b18d-b6205d6fc963"
      unitRef="usd">160903241</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i03bccaa0abfb4733b1e2831ecde4e4e8_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18yNS9mcmFnOjdiNjAzZGI3ZTMwMDRhOGNiOWVkMDQ4YTYzYjhhMjQxL3RhYmxlOmMxOTk4MmY4NGY5NzRmYjQ5ZGE5YjIzMjFmZmQzNWRiL3RhYmxlcmFuZ2U6YzE5OTgyZjg0Zjk3NGZiNDlkYTliMjMyMWZmZDM1ZGJfNjMtMy0xLTEtMA_97544c99-9106-457b-90a7-787ff8ca7928"
      unitRef="usd">213512634</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18yNS9mcmFnOjdiNjAzZGI3ZTMwMDRhOGNiOWVkMDQ4YTYzYjhhMjQxL3RhYmxlOmMxOTk4MmY4NGY5NzRmYjQ5ZGE5YjIzMjFmZmQzNWRiL3RhYmxlcmFuZ2U6YzE5OTgyZjg0Zjk3NGZiNDlkYTliMjMyMWZmZDM1ZGJfNjQtMS0xLTEtMA_2ae28c6f-a476-498e-b130-d7dce2a5ce48"
      unitRef="usd">-14419</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i03bccaa0abfb4733b1e2831ecde4e4e8_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18yNS9mcmFnOjdiNjAzZGI3ZTMwMDRhOGNiOWVkMDQ4YTYzYjhhMjQxL3RhYmxlOmMxOTk4MmY4NGY5NzRmYjQ5ZGE5YjIzMjFmZmQzNWRiL3RhYmxlcmFuZ2U6YzE5OTgyZjg0Zjk3NGZiNDlkYTliMjMyMWZmZDM1ZGJfNjQtMy0xLTEtMA_b6c29df9-23e9-46cc-a988-2f5d9b45007f"
      unitRef="usd">0</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18yNS9mcmFnOjdiNjAzZGI3ZTMwMDRhOGNiOWVkMDQ4YTYzYjhhMjQxL3RhYmxlOmMxOTk4MmY4NGY5NzRmYjQ5ZGE5YjIzMjFmZmQzNWRiL3RhYmxlcmFuZ2U6YzE5OTgyZjg0Zjk3NGZiNDlkYTliMjMyMWZmZDM1ZGJfNjUtMS0xLTEtMA_670b2960-6de0-43f3-b66c-9ec1ab58062e"
      unitRef="usd">-167093942</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i03bccaa0abfb4733b1e2831ecde4e4e8_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18yNS9mcmFnOjdiNjAzZGI3ZTMwMDRhOGNiOWVkMDQ4YTYzYjhhMjQxL3RhYmxlOmMxOTk4MmY4NGY5NzRmYjQ5ZGE5YjIzMjFmZmQzNWRiL3RhYmxlcmFuZ2U6YzE5OTgyZjg0Zjk3NGZiNDlkYTliMjMyMWZmZDM1ZGJfNjUtMy0xLTEtMA_c29464af-b260-4ae9-b56d-c421f9fe7a21"
      unitRef="usd">136250968</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i066bb5b0a9e84c0a878b1e800703d92b_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18yNS9mcmFnOjdiNjAzZGI3ZTMwMDRhOGNiOWVkMDQ4YTYzYjhhMjQxL3RhYmxlOmMxOTk4MmY4NGY5NzRmYjQ5ZGE5YjIzMjFmZmQzNWRiL3RhYmxlcmFuZ2U6YzE5OTgyZjg0Zjk3NGZiNDlkYTliMjMyMWZmZDM1ZGJfNjYtMS0xLTEtMA_9c89181b-befe-468b-a178-89c583a7a54e"
      unitRef="usd">250728118</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="id25261a874ce40da9cfbcc6297ee52ac_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18yNS9mcmFnOjdiNjAzZGI3ZTMwMDRhOGNiOWVkMDQ4YTYzYjhhMjQxL3RhYmxlOmMxOTk4MmY4NGY5NzRmYjQ5ZGE5YjIzMjFmZmQzNWRiL3RhYmxlcmFuZ2U6YzE5OTgyZjg0Zjk3NGZiNDlkYTliMjMyMWZmZDM1ZGJfNjYtMy0xLTEtMA_337321b9-d94e-4edc-893f-cf8ae5d37771"
      unitRef="usd">22196097</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ic36b9cedad7f41a6b9eb223b09b7186c_I20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18yNS9mcmFnOjdiNjAzZGI3ZTMwMDRhOGNiOWVkMDQ4YTYzYjhhMjQxL3RhYmxlOmMxOTk4MmY4NGY5NzRmYjQ5ZGE5YjIzMjFmZmQzNWRiL3RhYmxlcmFuZ2U6YzE5OTgyZjg0Zjk3NGZiNDlkYTliMjMyMWZmZDM1ZGJfNjctMS0xLTEtMA_ef961c90-3401-4c5b-a50f-28de262911b4"
      unitRef="usd">83634176</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i98369f585c4549d585af1f9094a77fd9_I20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18yNS9mcmFnOjdiNjAzZGI3ZTMwMDRhOGNiOWVkMDQ4YTYzYjhhMjQxL3RhYmxlOmMxOTk4MmY4NGY5NzRmYjQ5ZGE5YjIzMjFmZmQzNWRiL3RhYmxlcmFuZ2U6YzE5OTgyZjg0Zjk3NGZiNDlkYTliMjMyMWZmZDM1ZGJfNjctMy0xLTEtMA_86ef5b2b-3a57-4d75-9606-af670384721e"
      unitRef="usd">158447065</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:IncreaseDecreaseInOtherAccruedLiabilities
      contextRef="i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18yNS9mcmFnOjdiNjAzZGI3ZTMwMDRhOGNiOWVkMDQ4YTYzYjhhMjQxL3RhYmxlOmMxOTk4MmY4NGY5NzRmYjQ5ZGE5YjIzMjFmZmQzNWRiL3RhYmxlcmFuZ2U6YzE5OTgyZjg0Zjk3NGZiNDlkYTliMjMyMWZmZDM1ZGJfNzAtMS0xLTEtMA_29f57291-ad7e-498c-812d-bdcdcebea8ce"
      unitRef="usd">35370</us-gaap:IncreaseDecreaseInOtherAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInOtherAccruedLiabilities
      contextRef="i03bccaa0abfb4733b1e2831ecde4e4e8_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18yNS9mcmFnOjdiNjAzZGI3ZTMwMDRhOGNiOWVkMDQ4YTYzYjhhMjQxL3RhYmxlOmMxOTk4MmY4NGY5NzRmYjQ5ZGE5YjIzMjFmZmQzNWRiL3RhYmxlcmFuZ2U6YzE5OTgyZjg0Zjk3NGZiNDlkYTliMjMyMWZmZDM1ZGJfNzAtMy0xLTEtMA_4f5b4806-3f83-4408-94f1-0cc64e1bd6b7"
      unitRef="usd">0</us-gaap:IncreaseDecreaseInOtherAccruedLiabilities>
    <us-gaap:InterestPaidNet
      contextRef="i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18yNS9mcmFnOjdiNjAzZGI3ZTMwMDRhOGNiOWVkMDQ4YTYzYjhhMjQxL3RhYmxlOmMxOTk4MmY4NGY5NzRmYjQ5ZGE5YjIzMjFmZmQzNWRiL3RhYmxlcmFuZ2U6YzE5OTgyZjg0Zjk3NGZiNDlkYTliMjMyMWZmZDM1ZGJfNzEtMS0xLTEtMA_ee6c699b-ff46-4fde-a3c3-27c60de4d8cb"
      unitRef="usd">544315</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="i03bccaa0abfb4733b1e2831ecde4e4e8_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18yNS9mcmFnOjdiNjAzZGI3ZTMwMDRhOGNiOWVkMDQ4YTYzYjhhMjQxL3RhYmxlOmMxOTk4MmY4NGY5NzRmYjQ5ZGE5YjIzMjFmZmQzNWRiL3RhYmxlcmFuZ2U6YzE5OTgyZjg0Zjk3NGZiNDlkYTliMjMyMWZmZDM1ZGJfNzEtMy0xLTEtMA_562c01f8-5888-4eb0-839e-8366eb84be1e"
      unitRef="usd">2590196</us-gaap:InterestPaidNet>
    <us-gaap:NatureOfOperations
      contextRef="i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18zMS9mcmFnOjBjMjUzMjIzY2VmYzQzYjg5OWYxNGQ1ZmM0MzI4YzU5L3RleHRyZWdpb246MGMyNTMyMjNjZWZjNDNiODk5ZjE0ZDVmYzQzMjhjNTlfMzQ3Nw_c74723c0-3775-4c18-927c-8ff9548d9fc8">Organization and Operations&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inovio Pharmaceuticals, Inc. (the &#x201c;Company&#x201d; or &#x201c;INOVIO&#x201d;), is a biotechnology company focused on rapidly bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases, cancer, and diseases associated with human papillomavirus ("HPV"). INOVIO's DNA medicines pipeline is comprised of three types of product candidates: DNA vaccines, DNA immunotherapies and DNA encoded monoclonal antibodies ("dMAbs"). In clinical trials, INOVIO has demonstrated that DNA medicines can be delivered directly into cells in the body through its proprietary smart device to consistently activate robust and fully functional T cell and antibody responses against targeted pathogens and cancers. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's novel DNA medicine candidates are made using its proprietary SynCon&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; technology that creates optimized plasmids, which are circular strands of DNA that instruct a cell to produce antigens to help the person&#x2019;s immune system recognize and destroy cancerous or virally infected cells.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;INOVIO's patented CELLECTRA&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; smart delivery devices provide optimized uptake of its DNA medicines within the cell, overcoming a key limitation of other DNA-based technology approaches. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Human clinical trial data to date have shown a favorable safety profile of INOVIO's DNA medicines delivered directly into cells in the body using the CELLECTRA&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; smart device in more than 7,000 administrations across more than 3,000 patients.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; INOVIO's corporate strategy is to advance, protect and, once approved, commercialize its novel DNA medicines to meet urgent and emerging global health needs. The Company continues to advance and clinically validate an array of DNA medicine candidates that target HPV-associated diseases, cancer, and infectious diseases, such as COVID-19. The Company aims to advance these candidates through commercialization and continue to leverage third-party resources through collaborations and partnerships, including product license agreements. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company's partners and collaborators include ApolloBio Corporation.,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; AstraZeneca, Beijing Advaccine, The Bill &amp;amp; Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations ("CEPI"), The U.S. Department of Defense ("DoD"), Defense Advanced Research Projects Agency ("DARPA"), GeneOne Life Science, HIV Vaccines Trial Network, the U.S. Defense Threat Reduction Agency&#x2019;s Medical CBRN Defense Consortium ("MCDC"), International Vaccine Institute ("IVI"), National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Ology Bioservices, the Parker Institute for Cancer Immunotherapy, Plumbline Life Sciences, Regeneron Pharmaceuticals, Inc., Richter-Helm BioLogics, Thermo Fisher Scientific, the University of Pennsylvania, the Walter Reed Army Institute of Research, and The Wistar Institute.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company and its collaborators are currently conducting or planning clinical studies of its DNA medicines for HPV-associated precancers, including cervical, vulvar, and anal dysplasia; HPV-associated cancers, including head &amp;amp; neck, cervical, anal, penile, vulvar, and vaginal; other HPV-associated disorders, such as recurrent respiratory papillomatosis ("RRP"); glioblastoma multiforme ("GBM"); prostate cancer; HIV; Ebola; Middle East Respiratory Syndrome ("MERS"); Lassa fever; Zika virus; and COVID-19.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;INOVIO was incorporated in Delaware in June 2001 and has its principal executive offices in Plymouth Meeting, Pennsylvania.&lt;/span&gt;&lt;/div&gt;</us-gaap:NatureOfOperations>
    <us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock
      contextRef="i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18zNC9mcmFnOjZhYmNjYjdmMmEyYzRiYWE5NWQ0OTMzN2M2MzBhYzdmL3RleHRyZWdpb246NmFiY2NiN2YyYTJjNGJhYTk1ZDQ5MzM3YzYzMGFjN2ZfODEzMw_05abfb94-b003-47bb-bb99-c47df79c18ee">Basis of Presentation, Liquidity and Risks and Uncertainties&lt;div style="margin-bottom:3pt;margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying unaudited condensed consolidated financial statements of Inovio have been prepared in accordance with U.S. generally accepted accounting principles (&#x201c;U.S. GAAP&#x201d;) as contained in the Financial Accounting Standards Board ("FASB") Accounting Standards Codification ("ASC") for interim financial information and with instructions to Form&#160;10-Q and Article&#160;10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. The condensed consolidated balance sheet as of March&#160;31, 2021, the condensed consolidated statements of operations, the condensed consolidated statements of comprehensive loss, the condensed consolidated statements of stockholders' equity and the condensed consolidated statements of cash flows for the three months ended March 31, 2021 and 2020 are unaudited, but include all adjustments (consisting of normal recurring adjustments) that the Company considers necessary for a fair presentation of the financial position, results of operations, cash flows and changes in stockholders' equity for the periods presented. The results of operations for the three months ended March 31, 2021 shown herein are not necessarily indicative of the results that may be expected for the year ending December&#160;31, 2021, or for any other period. These unaudited financial statements, and notes thereto, should be read in conjunction with the audited consolidated financial statements for the &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;year ended December&#160;31, 2020, included in the Company's Annual Report on Form&#160;10-K filed with the U.S. Securities and Exchange Commission (&#x201c;SEC&#x201d;) on March&#160;1, 2021. The balance sheet at December&#160;31, 2020 has been derived from the audited financial statements at that date, but does not include all of the information and footnotes required by U.S. GAAP for complete financial statements. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2020, the Company formed a wholly-owned subsidiary, Inovio Asia LLC, under the laws of South Korea, through which the Company intends to advance its corporate development projects and other functions in South Korea and other Asian countries.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;These unaudited condensed consolidated financial statements include the accounts of Inovio Pharmaceuticals, Inc. and its subsidiarie&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;s. As of March 31, 2021, the Company consolidated its wholly-owned subsidiary Inovio Asia LLC. On December 31, 2020, former wholly-owned subsidiaries Genetronics, Inc. and VGX Pharmaceuticals Inc. and former majority -owned subsidiary VGX Animal Health, Inc. were merged into Inovio Pharmaceuticals, Inc. All intercompany accounts and transactions were eliminated upon consolidation. As of June 1, 2020, the Company deconsolidated its former subsidiary Geneos Therapeutics, Inc. ("Geneos"), as the Company no longer held a controlling financial interest.  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Refer to Footnote 17 for further discussion.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Liquidity &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company incurred a net loss attributable to common stockholders of $54.4 million for the three months ended March 31, 2021. The Company had working capital of $546.9 million and an accumulated deficit of $960.6 million as of March&#160;31, 2021. The Company has incurred losses in each year since its inception and expects to continue to incur significant expenses and operating losses for the foreseeable future in connection with the research and preclinical and clinical development of its product candidates. The Company&#x2019;s cash, cash equivalents and short-term investments of $518.6 million as of March&#160;31, 2021 are sufficient to support the Company's operations for a period of at least 12 months from the date of issuance of these financial statements. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In order to continue to fund future research and development activit&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ies, the Company will need to seek additional capital. This may occur through strategic alliance and licensing arrangements, grant agreements and/or future public or private debt or equity financings including use of potential future At-the-Market Equity Offering Sales Agreements (&#x201c;Sales Agreements&#x201d;). The Company&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; has a history of conducting debt and equity financings, including the receipt of net proceeds of $162.1&#160;million from a January 2021 underwritten public offering and net proceeds of $454.5 million under past Sales Agreements &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;for the year ended December 31, 2020. However, sufficient funding may not be available in the future, or if available, may be on terms that significantly dilute or otherwise adversely affect the rights of existing stockholders. If adequate funds are not available, the Company may need to delay, reduce the scope of or put on hold one or more of its clinical and/or preclinical programs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s ability to continue its operations is dependent upon its ability to obtain additional capital in the future and achieve profitable operations. The Company expects to continue to rely on outside sources of financing to meet its capital needs and the Company may never achieve positive cash flow. These condensed consolidated financial statements do not include any adjustments to the specific amounts and classifications of assets and liabilities, which might be necessary should Inovio be unable to continue as a going concern. The Company's condensed consolidated financial statements as of and for the three months ended March 31, 2021 have been prepared on a going concern basis, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business for the foreseeable future. The Company has evaluated subsequent events after the balance sheet date through the date it issued these condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is and, from time to time,&#160;may in the future be subject to various legal proceedings and claims arising in the ordinary course of business. The Company assesses contingencies to determine the degree of probability and range of possible loss for potential accrual in its consolidated financial statements. An estimated loss contingency is accrued in the consolidated financial statements if it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated. Legal proceedings, including litigation, government investigations and enforcement actions, could result in material costs, occupy significant management resources and entail civil and criminal penalties, even if the Company ultimately prevails.&#160;Any of the foregoing consequences could result in serious harm to the Company&#x2019;s business, results of operations and financial condition. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Risks and Uncertainties&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The global pandemic resulting from COVID-19, caused by a novel strain of coronavirus, SARS-CoV-2, has caused national and global economic and financial market disruptions. The impact of this pandemic has been and will likely continue to be extensive in many aspects of society, which has resulted in and will continue to cause significant disruptions to the global economy, as well as businesses and capital markets around the world. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company is closely monitoring the impact of the COVID-19 pandemic on its employees, collaborators and service providers. The extent to which the pandemic will continue to impact the Company's business and operations will depend on future developments, including travel restrictions and social distancing in the United States and other countries, and the &lt;/span&gt;&lt;/div&gt;effectiveness of actions taken in the United States and other countries to contain and treat the disease, including mass vaccination efforts, that are highly uncertain as of the date the Company is issuing these financial statements.</us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18zNC9mcmFnOjZhYmNjYjdmMmEyYzRiYWE5NWQ0OTMzN2M2MzBhYzdmL3RleHRyZWdpb246NmFiY2NiN2YyYTJjNGJhYTk1ZDQ5MzM3YzYzMGFjN2ZfODE0MA_87581140-801b-4c16-b507-1c36f9a1f1b1">&lt;div style="margin-bottom:3pt;margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying unaudited condensed consolidated financial statements of Inovio have been prepared in accordance with U.S. generally accepted accounting principles (&#x201c;U.S. GAAP&#x201d;) as contained in the Financial Accounting Standards Board ("FASB") Accounting Standards Codification ("ASC") for interim financial information and with instructions to Form&#160;10-Q and Article&#160;10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. The condensed consolidated balance sheet as of March&#160;31, 2021, the condensed consolidated statements of operations, the condensed consolidated statements of comprehensive loss, the condensed consolidated statements of stockholders' equity and the condensed consolidated statements of cash flows for the three months ended March 31, 2021 and 2020 are unaudited, but include all adjustments (consisting of normal recurring adjustments) that the Company considers necessary for a fair presentation of the financial position, results of operations, cash flows and changes in stockholders' equity for the periods presented. The results of operations for the three months ended March 31, 2021 shown herein are not necessarily indicative of the results that may be expected for the year ending December&#160;31, 2021, or for any other period. These unaudited financial statements, and notes thereto, should be read in conjunction with the audited consolidated financial statements for the &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;year ended December&#160;31, 2020, included in the Company's Annual Report on Form&#160;10-K filed with the U.S. Securities and Exchange Commission (&#x201c;SEC&#x201d;) on March&#160;1, 2021. The balance sheet at December&#160;31, 2020 has been derived from the audited financial statements at that date, but does not include all of the information and footnotes required by U.S. GAAP for complete financial statements. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2020, the Company formed a wholly-owned subsidiary, Inovio Asia LLC, under the laws of South Korea, through which the Company intends to advance its corporate development projects and other functions in South Korea and other Asian countries.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;These unaudited condensed consolidated financial statements include the accounts of Inovio Pharmaceuticals, Inc. and its subsidiarie&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;s. As of March 31, 2021, the Company consolidated its wholly-owned subsidiary Inovio Asia LLC. On December 31, 2020, former wholly-owned subsidiaries Genetronics, Inc. and VGX Pharmaceuticals Inc. and former majority -owned subsidiary VGX Animal Health, Inc. were merged into Inovio Pharmaceuticals, Inc. All intercompany accounts and transactions were eliminated upon consolidation. As of June 1, 2020, the Company deconsolidated its former subsidiary Geneos Therapeutics, Inc. ("Geneos"), as the Company no longer held a controlling financial interest.  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Refer to Footnote 17 for further discussion.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Liquidity &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company incurred a net loss attributable to common stockholders of $54.4 million for the three months ended March 31, 2021. The Company had working capital of $546.9 million and an accumulated deficit of $960.6 million as of March&#160;31, 2021. The Company has incurred losses in each year since its inception and expects to continue to incur significant expenses and operating losses for the foreseeable future in connection with the research and preclinical and clinical development of its product candidates. The Company&#x2019;s cash, cash equivalents and short-term investments of $518.6 million as of March&#160;31, 2021 are sufficient to support the Company's operations for a period of at least 12 months from the date of issuance of these financial statements. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In order to continue to fund future research and development activit&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ies, the Company will need to seek additional capital. This may occur through strategic alliance and licensing arrangements, grant agreements and/or future public or private debt or equity financings including use of potential future At-the-Market Equity Offering Sales Agreements (&#x201c;Sales Agreements&#x201d;). The Company&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; has a history of conducting debt and equity financings, including the receipt of net proceeds of $162.1&#160;million from a January 2021 underwritten public offering and net proceeds of $454.5 million under past Sales Agreements &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;for the year ended December 31, 2020. However, sufficient funding may not be available in the future, or if available, may be on terms that significantly dilute or otherwise adversely affect the rights of existing stockholders. If adequate funds are not available, the Company may need to delay, reduce the scope of or put on hold one or more of its clinical and/or preclinical programs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s ability to continue its operations is dependent upon its ability to obtain additional capital in the future and achieve profitable operations. The Company expects to continue to rely on outside sources of financing to meet its capital needs and the Company may never achieve positive cash flow. These condensed consolidated financial statements do not include any adjustments to the specific amounts and classifications of assets and liabilities, which might be necessary should Inovio be unable to continue as a going concern. The Company's condensed consolidated financial statements as of and for the three months ended March 31, 2021 have been prepared on a going concern basis, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business for the foreseeable future. The Company has evaluated subsequent events after the balance sheet date through the date it issued these condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is and, from time to time,&#160;may in the future be subject to various legal proceedings and claims arising in the ordinary course of business. The Company assesses contingencies to determine the degree of probability and range of possible loss for potential accrual in its consolidated financial statements. An estimated loss contingency is accrued in the consolidated financial statements if it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated. Legal proceedings, including litigation, government investigations and enforcement actions, could result in material costs, occupy significant management resources and entail civil and criminal penalties, even if the Company ultimately prevails.&#160;Any of the foregoing consequences could result in serious harm to the Company&#x2019;s business, results of operations and financial condition. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Risks and Uncertainties&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The global pandemic resulting from COVID-19, caused by a novel strain of coronavirus, SARS-CoV-2, has caused national and global economic and financial market disruptions. The impact of this pandemic has been and will likely continue to be extensive in many aspects of society, which has resulted in and will continue to cause significant disruptions to the global economy, as well as businesses and capital markets around the world. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company is closely monitoring the impact of the COVID-19 pandemic on its employees, collaborators and service providers. The extent to which the pandemic will continue to impact the Company's business and operations will depend on future developments, including travel restrictions and social distancing in the United States and other countries, and the &lt;/span&gt;&lt;/div&gt;effectiveness of actions taken in the United States and other countries to contain and treat the disease, including mass vaccination efforts, that are highly uncertain as of the date the Company is issuing these financial statements.</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18zNC9mcmFnOjZhYmNjYjdmMmEyYzRiYWE5NWQ0OTMzN2M2MzBhYzdmL3RleHRyZWdpb246NmFiY2NiN2YyYTJjNGJhYTk1ZDQ5MzM3YzYzMGFjN2ZfMjk5Ng_67ea475c-0b05-4f12-a037-9e74d86f978b"
      unitRef="usd">-54400000</us-gaap:NetIncomeLoss>
    <us-gaap:Capital
      contextRef="ic36b9cedad7f41a6b9eb223b09b7186c_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18zNC9mcmFnOjZhYmNjYjdmMmEyYzRiYWE5NWQ0OTMzN2M2MzBhYzdmL3RleHRyZWdpb246NmFiY2NiN2YyYTJjNGJhYTk1ZDQ5MzM3YzYzMGFjN2ZfMzA2Mg_4da33738-ce24-4564-9282-d1fbaec2a4f3"
      unitRef="usd">546900000</us-gaap:Capital>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="ic36b9cedad7f41a6b9eb223b09b7186c_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18zNC9mcmFnOjZhYmNjYjdmMmEyYzRiYWE5NWQ0OTMzN2M2MzBhYzdmL3RleHRyZWdpb246NmFiY2NiN2YyYTJjNGJhYTk1ZDQ5MzM3YzYzMGFjN2ZfMzA5Ng_7d88d62d-b255-4ae0-b476-26e49d47b9ac"
      unitRef="usd">-960600000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:CashCashEquivalentsAndShortTermInvestments
      contextRef="ic36b9cedad7f41a6b9eb223b09b7186c_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18zNC9mcmFnOjZhYmNjYjdmMmEyYzRiYWE5NWQ0OTMzN2M2MzBhYzdmL3RleHRyZWdpb246NmFiY2NiN2YyYTJjNGJhYTk1ZDQ5MzM3YzYzMGFjN2ZfMzQ0Mw_b90a4a35-28dc-40a8-a69e-7fdaa790ee2a"
      unitRef="usd">518600000</us-gaap:CashCashEquivalentsAndShortTermInvestments>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="ic50cd4505b98463e9b947cd4aaebd07b_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18zNC9mcmFnOjZhYmNjYjdmMmEyYzRiYWE5NWQ0OTMzN2M2MzBhYzdmL3RleHRyZWdpb246NmFiY2NiN2YyYTJjNGJhYTk1ZDQ5MzM3YzYzMGFjN2ZfMTA5OTUxMTYzOTQ4Ng_e1906a4e-93c0-491e-9bd4-1f35fc320362"
      unitRef="usd">162100000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="ia9f4c44746fd42179d0515c760ec6715_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18zNC9mcmFnOjZhYmNjYjdmMmEyYzRiYWE5NWQ0OTMzN2M2MzBhYzdmL3RleHRyZWdpb246NmFiY2NiN2YyYTJjNGJhYTk1ZDQ5MzM3YzYzMGFjN2ZfNDE2OQ_c2094c0d-a3a0-4388-8006-27cb395c3ce9"
      unitRef="usd">454500000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18zNy9mcmFnOmE0NTZiM2ZhOTA0ZjQ0ZjNiYTUyYzg0OWE5YTIxNGRiL3RleHRyZWdpb246YTQ1NmIzZmE5MDRmNDRmM2JhNTJjODQ5YTlhMjE0ZGJfMTgxNDA_943113d0-2941-48c8-a34e-6f1fb58a0fb2">Critical Accounting Policies&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Collaboration Agreements &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company assesses whether its collaboration agreements are subject to ASC Topic 808:&#160;Collaborative Arrangements&#160;(&#x201c;Topic 808&#x201d;) based on whether they involve joint operating activities and whether both parties have active participation in the arrangement and are exposed to significant risks and rewards. To the extent that the arrangement falls within the scope of Topic 808 and the Company concludes that its collaboration partner is not a customer, the Company presents such payments as a reduction of research and development expense. If payments from the collaboration partner to the Company represent consideration from a customer, then the Company accounts for those payments within the scope of Accounting Standards Update (&#x201c;ASU&#x201d;) 2014-09, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue from Contracts with Customers&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (&#x201c;Topic 606&#x201d;). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue Recognition &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which it expects to be entitled in exchange for those goods or services. To determine revenue recognition for contracts with customers, the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the Company satisfies its performance obligations. At contract inception, the Company assesses the goods or services agreed upon within each contract and assess whether each good or service is distinct and determine those that are&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;performance obligations. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Collaborative Arrangements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company enters into collaborative arrangements with partners that typically include payment of one or more of the following: (i) license fees; (ii) product supply services; (iii) milestone payments related to the achievement of developmental, regulatory, or commercial goals; and (iv) royalties on net sales of licensed products. Where a portion of non-refundable, upfront fees or other payments received are allocated to continuing performance obligations under the terms of a collaborative arrangement, they are recorded as deferred revenue and recognized as revenue when (or as) the underlying performance obligation is satisfied.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As part of the accounting for these arrangements, the Company must develop estimates and assumptions that require judgment of management to determine the underlying stand-alone selling price for each performance obligation which determines how the transaction price is allocated among the performance obligation. The standalone selling price may include items such as forecasted revenues, development timelines, discount rates and probabilities of technical and regulatory success. The Company evaluates each performance obligation to determine if it can be satisfied at a point in time or over time. In addition, variable consideration must be evaluated to determine if it is constrained and, therefore, excluded from the transaction price.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;License Fees&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;If a license to intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company will recognize revenues from non-refundable, upfront fees allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license. For licenses that are bundled with other promises, the Company will utilize judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Product Supply Services&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Arrangements that include a promise for future supply of drug product for either clinical development or commercial supply at the licensee&#x2019;s discretion are generally considered as options. The Company will assess if these options provide a material right to the licensee and if so, they will be accounted for as separate performance obligations. The Company evaluates whether it is the principal or agent in the arrangement. The Company had determined that it is the principal in the current arrangements as the Company controls the product supply before it is transferred to the customer. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Milestone Payments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At the inception of each arrangement that includes milestone payments (variable consideration), the Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the Company's or its collaboration partner&#x2019;s control, such as regulatory approvals, are generally not considered probable of being achieved until those approvals are received. The transaction price is then allocated to each performance obligation on a relative stand-alone selling price basis, for which the Company recognizes revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, the Company re-evaluates the probability of achieving such milestones and any related constraint, and if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect license, collaboration or other revenues and earnings in the period of adjustment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Royalties&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and for which the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). To date, the Company has not recognized any royalty revenue resulting from any of its collaborative arrangements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Grants&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for various grant agreements under the contributions guidance under Subtopic 958-605, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Not-for-Profit Entities-Revenue Recognition&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, which is outside the scope of Topic 606, as the government agencies granting the Company funds are not receiving reciprocal value for their contributions. All contributions received from current grant agreements are recorded as a contra-expense as opposed to revenue on the condensed consolidated statement of operations. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For its long-term operating leases, the Company recognizes an operating lease right-of-use asset and an operating lease liability on its condensed consolidated balance sheets. The lease liability is determined as the present value of future lease payments using an estimated rate of interest that the Company would pay to borrow equivalent funds on a collateralized basis at the lease commencement date. The right-of-use asset is based on the liability adjusted for any prepaid or deferred rent. The Company determines the lease term at the commencement date by considering whether renewal options and termination options are reasonably assured of exercise. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fixed rent expense for the Company's operating leases is recognized on a straight-line basis over the term of the lease and is included in operating expenses on the condensed consolidated statements of operations. Variable lease payments including lease operating expenses are recorded as incurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Research and Development Expenses&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s activities have largely consisted of research and development efforts related to developing electroporation delivery technologies, DNA vaccines, DNA immunotherapies and dMABs. Research and development expenses consist of expenses incurred in performing research and development activities including salaries and benefits, facilities and other overhead expenses, clinical trials, contract services and other outside expenses. Research and development expenses are charged to operations as they are incurred. These expenses result from the Company's independent research and development efforts as well as efforts associated with collaborations and licensing arrangements. The Company reviews and accrues clinical trial expense based on work performed, which relies on estimates of total costs incurred based on patient enrollment, completion of studies and other events. Accrued clinical trial costs are subject to revisions as trials progress. Revisions are charged to expense in the period in which the facts that give rise to the revision become known. Historically, revisions have not resulted in material changes to research and development expense; however, a modification in the protocol of a clinical trial or cancellation of a trial could result in a charge to the Company's results of operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Valuation of Intangible Assets and Goodwill&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intangible assets are amortized over their estimated useful lives ranging from &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18zNy9mcmFnOmE0NTZiM2ZhOTA0ZjQ0ZjNiYTUyYzg0OWE5YTIxNGRiL3RleHRyZWdpb246YTQ1NmIzZmE5MDRmNDRmM2JhNTJjODQ5YTlhMjE0ZGJfOTk1Nw_def5a8b0-cb2d-4478-a5a4-79b9dd366f59"&gt;two&lt;/span&gt; to 18&#160;years. Acquired intangible assets are continuously being developed for the future economic viability contemplated at the time of acquisition. The Company is concurrently conducting preclinical studies and clinical trials using the acquired intangibles and has entered into licensing agreements for the use of these acquired intangibles.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;License costs are recorded based on the fair value of consideration paid and are amortized using the straight-line method over the shorter of the expected useful life of the underlying patents or the term of the related license agreement to the extent the license has an alternative future use. As of March&#160;31, 2021 and December&#160;31, 2020, the Company&#x2019;s intangible assets &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;resulting from the acquisition of Inovio AS and Bioject Medical Technologies, Inc. ("Bioject"), and additional intangibles including license costs, net of accumulated amortization, totaled $3.0 million and $3.1 million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The determination of the value of intangible assets requires management to make estimates and assumptions that affect the Company&#x2019;s condensed consolidated financial statements. The Company assesses potential impairments to intangible assets when there is evidence that events or changes in circumstances indicate that the carrying amount of an asset may not be recovered. The Company&#x2019;s judgments regarding the existence of impairment indicators and future cash flows related to intangible assets are based on operational performance of its acquired businesses, market conditions and other factors. If impairment is indicated, the Company will reduce the carrying value of the intangible asset to fair value. While current and historical operating and cash flow losses are potential indicators of impairment, the Company believes the future cash flows to be received from its intangible assets will exceed the intangible assets&#x2019; carrying value, and accordingly, the Company has not recognized any impairment losses through March&#160;31, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Goodwill represents the excess of acquisition cost over the fair value of the net assets of acquired businesses. Goodwill is reviewed for impairment at least annually at November 30, or more frequently if an event occurs indicating the potential for impairment. During its goodwill impairment review, the Company may assess qualitative factors to determine whether it is more likely than not that the fair value of its reporting unit is less than its carrying amount, including goodwill. The qualitative factors include, but are not limited to, macroeconomic conditions, industry and market considerations, and the overall financial performance of the Company. If, after assessing the totality of these qualitative factors, the Company determines that it is not likely that the fair value of its reporting unit is less than its carrying amount, then no additional assessment is deemed necessary. Otherwise, the Company will proceed to perform the impairment test in which the fair value of the reporting unit is compared with its carrying amount, and an impairment charge will be recorded for the amount by which the carrying amount exceeds the reporting unit's fair value, if any. The Company performed its annual assessment for goodwill impairment as of November 30, 2020, identifying no impairment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Although there are inherent uncertainties in this assessment process, the estimates and assumptions the Company is using are consistent with its internal planning. If these estimates or their related assumptions change in the future, the Company may be required to record an impairment charge on all or a portion of its goodwill and intangible assets. Furthermore, the Company cannot predict the occurrence of future impairment triggering events nor the impact such events might have on its reported asset values. Future events could cause the Company to conclude that impairment indicators exist and that goodwill or other intangible assets associated with its acquired businesses are impaired. Any resulting impairment loss could have an adverse impact on the Company&#x2019;s results of operations. See Note&#160;8 for further discussion of the Company&#x2019;s goodwill and intangible assets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Foreign Currency Translation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The functional and presentation currency of the Company is the U.S. dollar. Transactions denominated in a currency other than the functional currency are recorded on the initial recognition at the exchange rate at the date of the transaction. After initial recognition monetary assets and liabilities denominated in foreign currency are translated at the end of each reporting period into the functional currency at the exchange rate at that date. The cumulative translation adjustment is included in the accumulated other comprehensive income (loss) within the statement of stockholders' equity. Exchange differences are included in general and administrative expenses in the condensed consolidated statement of operations. Non- monetary assets and liabilities measured at cost are translated at the exchange rate at the date of the transaction.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Variable Interest Entities (VIE)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company evaluates its ownership, contractual and other interests in entities that are not wholly-owned to determine if these entities are VIEs, and, if so, whether the Company is the primary beneficiary of the VIE. In determining whether the Company is the primary beneficiary of a VIE and therefore required to consolidate the VIE, the Company applies a qualitative approach that determines whether it has both (1) the power to direct the activities of the VIE that most significantly impact the VIE&#x2019;s economic performance and (2) the obligation to absorb losses of, or the rights to receive benefits from, the VIE that could potentially be significant to that VIE. The Company will continuously perform this assessment, as changes to existing relationships or future transactions may result in the consolidation or deconsolidation of a VIE.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Equity Investments&lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under ASC Topic 321, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Investments - Equity Securities,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; the Company must measure equity investments (except those accounted for under the equity method, those that result in consolidation of the investee and certain other investments) at fair value and recognize any changes in fair value in the condensed consolidated statement of operations. The Company can elect a measurement alternative for equity investments that do not have readily determinable fair values and do not qualify for the practical expedient in ASC 820, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Fair Value Measurement,&lt;/span&gt; to estimate fair value using the net asset value per share (or its equivalent).&#160;The Company's equity investments that do not have readily determinable fair values and do not qualify for the net asset value practical expedient for estimating fair value are measured at cost, less any impairments, plus or minus changes resulting from observable price changes in orderly transactions for identifiable or similar investments of the same issuer.</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:CollaborativeArrangementAccountingPolicy
      contextRef="i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18zNy9mcmFnOmE0NTZiM2ZhOTA0ZjQ0ZjNiYTUyYzg0OWE5YTIxNGRiL3RleHRyZWdpb246YTQ1NmIzZmE5MDRmNDRmM2JhNTJjODQ5YTlhMjE0ZGJfMTgxNTY_48e13594-6f19-4841-abe4-2d336663dbbd">Collaboration Agreements &lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company assesses whether its collaboration agreements are subject to ASC Topic 808:&#160;Collaborative Arrangements&#160;(&#x201c;Topic 808&#x201d;) based on whether they involve joint operating activities and whether both parties have active participation in the arrangement and are exposed to significant risks and rewards. To the extent that the arrangement falls within the scope of Topic 808 and the Company concludes that its collaboration partner is not a customer, the Company presents such payments as a reduction of research and development expense. If payments from the collaboration partner to the Company represent consideration from a customer, then the Company accounts for those payments within the scope of Accounting Standards Update (&#x201c;ASU&#x201d;) 2014-09, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue from Contracts with Customers&lt;/span&gt; (&#x201c;Topic 606&#x201d;).</us-gaap:CollaborativeArrangementAccountingPolicy>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock
      contextRef="i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18zNy9mcmFnOmE0NTZiM2ZhOTA0ZjQ0ZjNiYTUyYzg0OWE5YTIxNGRiL3RleHRyZWdpb246YTQ1NmIzZmE5MDRmNDRmM2JhNTJjODQ5YTlhMjE0ZGJfMTgxMzQ_80aefc09-d61e-4f0d-a387-56eb7a76d4cf">&lt;div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue Recognition &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which it expects to be entitled in exchange for those goods or services. To determine revenue recognition for contracts with customers, the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the Company satisfies its performance obligations. At contract inception, the Company assesses the goods or services agreed upon within each contract and assess whether each good or service is distinct and determine those that are&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;performance obligations. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Collaborative Arrangements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company enters into collaborative arrangements with partners that typically include payment of one or more of the following: (i) license fees; (ii) product supply services; (iii) milestone payments related to the achievement of developmental, regulatory, or commercial goals; and (iv) royalties on net sales of licensed products. Where a portion of non-refundable, upfront fees or other payments received are allocated to continuing performance obligations under the terms of a collaborative arrangement, they are recorded as deferred revenue and recognized as revenue when (or as) the underlying performance obligation is satisfied.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As part of the accounting for these arrangements, the Company must develop estimates and assumptions that require judgment of management to determine the underlying stand-alone selling price for each performance obligation which determines how the transaction price is allocated among the performance obligation. The standalone selling price may include items such as forecasted revenues, development timelines, discount rates and probabilities of technical and regulatory success. The Company evaluates each performance obligation to determine if it can be satisfied at a point in time or over time. In addition, variable consideration must be evaluated to determine if it is constrained and, therefore, excluded from the transaction price.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;License Fees&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;If a license to intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company will recognize revenues from non-refundable, upfront fees allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license. For licenses that are bundled with other promises, the Company will utilize judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Product Supply Services&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Arrangements that include a promise for future supply of drug product for either clinical development or commercial supply at the licensee&#x2019;s discretion are generally considered as options. The Company will assess if these options provide a material right to the licensee and if so, they will be accounted for as separate performance obligations. The Company evaluates whether it is the principal or agent in the arrangement. The Company had determined that it is the principal in the current arrangements as the Company controls the product supply before it is transferred to the customer. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Milestone Payments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At the inception of each arrangement that includes milestone payments (variable consideration), the Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the Company's or its collaboration partner&#x2019;s control, such as regulatory approvals, are generally not considered probable of being achieved until those approvals are received. The transaction price is then allocated to each performance obligation on a relative stand-alone selling price basis, for which the Company recognizes revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, the Company re-evaluates the probability of achieving such milestones and any related constraint, and if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect license, collaboration or other revenues and earnings in the period of adjustment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Royalties&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and for which the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). To date, the Company has not recognized any royalty revenue resulting from any of its collaborative arrangements.&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <ino:GrantPolicyPolicyTextBlock
      contextRef="i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18zNy9mcmFnOmE0NTZiM2ZhOTA0ZjQ0ZjNiYTUyYzg0OWE5YTIxNGRiL3RleHRyZWdpb246YTQ1NmIzZmE5MDRmNDRmM2JhNTJjODQ5YTlhMjE0ZGJfMTgxNDI_5e828c14-01f2-44bf-bc9a-bc310359b630">Grants&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for various grant agreements under the contributions guidance under Subtopic 958-605, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Not-for-Profit Entities-Revenue Recognition&lt;/span&gt;, which is outside the scope of Topic 606, as the government agencies granting the Company funds are not receiving reciprocal value for their contributions. All contributions received from current grant agreements are recorded as a contra-expense as opposed to revenue on the condensed consolidated statement of operations.</ino:GrantPolicyPolicyTextBlock>
    <us-gaap:LesseeLeasesPolicyTextBlock
      contextRef="i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18zNy9mcmFnOmE0NTZiM2ZhOTA0ZjQ0ZjNiYTUyYzg0OWE5YTIxNGRiL3RleHRyZWdpb246YTQ1NmIzZmE5MDRmNDRmM2JhNTJjODQ5YTlhMjE0ZGJfMTgxMjg_d6a73699-8462-4341-b402-467c9a232eea">&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For its long-term operating leases, the Company recognizes an operating lease right-of-use asset and an operating lease liability on its condensed consolidated balance sheets. The lease liability is determined as the present value of future lease payments using an estimated rate of interest that the Company would pay to borrow equivalent funds on a collateralized basis at the lease commencement date. The right-of-use asset is based on the liability adjusted for any prepaid or deferred rent. The Company determines the lease term at the commencement date by considering whether renewal options and termination options are reasonably assured of exercise. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fixed rent expense for the Company's operating leases is recognized on a straight-line basis over the term of the lease and is included in operating expenses on the condensed consolidated statements of operations. Variable lease payments including lease operating expenses are recorded as incurred.&lt;/span&gt;&lt;/div&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18zNy9mcmFnOmE0NTZiM2ZhOTA0ZjQ0ZjNiYTUyYzg0OWE5YTIxNGRiL3RleHRyZWdpb246YTQ1NmIzZmE5MDRmNDRmM2JhNTJjODQ5YTlhMjE0ZGJfMTgxMzg_48c1f157-4f63-4b58-bdc8-c2cc6004dc88">&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Research and Development Expenses&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s activities have largely consisted of research and development efforts related to developing electroporation delivery technologies, DNA vaccines, DNA immunotherapies and dMABs. Research and development expenses consist of expenses incurred in performing research and development activities including salaries and benefits, facilities and other overhead expenses, clinical trials, contract services and other outside expenses. Research and development expenses are charged to operations as they are incurred. These expenses result from the Company's independent research and development efforts as well as efforts associated with collaborations and licensing arrangements. The Company reviews and accrues clinical trial expense based on work performed, which relies on estimates of total costs incurred based on patient enrollment, completion of studies and other events. Accrued clinical trial costs are subject to revisions as trials progress. Revisions are charged to expense in the period in which the facts that give rise to the revision become known. Historically, revisions have not resulted in material changes to research and development expense; however, a modification in the protocol of a clinical trial or cancellation of a trial could result in a charge to the Company's results of operations.&lt;/span&gt;&lt;/div&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock
      contextRef="i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18zNy9mcmFnOmE0NTZiM2ZhOTA0ZjQ0ZjNiYTUyYzg0OWE5YTIxNGRiL3RleHRyZWdpb246YTQ1NmIzZmE5MDRmNDRmM2JhNTJjODQ5YTlhMjE0ZGJfMTgxNDU_6ac83c48-21af-4983-9c6a-ac76d6472d53">&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Valuation of Intangible Assets and Goodwill&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intangible assets are amortized over their estimated useful lives ranging from &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18zNy9mcmFnOmE0NTZiM2ZhOTA0ZjQ0ZjNiYTUyYzg0OWE5YTIxNGRiL3RleHRyZWdpb246YTQ1NmIzZmE5MDRmNDRmM2JhNTJjODQ5YTlhMjE0ZGJfOTk1Nw_def5a8b0-cb2d-4478-a5a4-79b9dd366f59"&gt;two&lt;/span&gt; to 18&#160;years. Acquired intangible assets are continuously being developed for the future economic viability contemplated at the time of acquisition. The Company is concurrently conducting preclinical studies and clinical trials using the acquired intangibles and has entered into licensing agreements for the use of these acquired intangibles.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;License costs are recorded based on the fair value of consideration paid and are amortized using the straight-line method over the shorter of the expected useful life of the underlying patents or the term of the related license agreement to the extent the license has an alternative future use. As of March&#160;31, 2021 and December&#160;31, 2020, the Company&#x2019;s intangible assets &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;resulting from the acquisition of Inovio AS and Bioject Medical Technologies, Inc. ("Bioject"), and additional intangibles including license costs, net of accumulated amortization, totaled $3.0 million and $3.1 million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The determination of the value of intangible assets requires management to make estimates and assumptions that affect the Company&#x2019;s condensed consolidated financial statements. The Company assesses potential impairments to intangible assets when there is evidence that events or changes in circumstances indicate that the carrying amount of an asset may not be recovered. The Company&#x2019;s judgments regarding the existence of impairment indicators and future cash flows related to intangible assets are based on operational performance of its acquired businesses, market conditions and other factors. If impairment is indicated, the Company will reduce the carrying value of the intangible asset to fair value. While current and historical operating and cash flow losses are potential indicators of impairment, the Company believes the future cash flows to be received from its intangible assets will exceed the intangible assets&#x2019; carrying value, and accordingly, the Company has not recognized any impairment losses through March&#160;31, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Goodwill represents the excess of acquisition cost over the fair value of the net assets of acquired businesses. Goodwill is reviewed for impairment at least annually at November 30, or more frequently if an event occurs indicating the potential for impairment. During its goodwill impairment review, the Company may assess qualitative factors to determine whether it is more likely than not that the fair value of its reporting unit is less than its carrying amount, including goodwill. The qualitative factors include, but are not limited to, macroeconomic conditions, industry and market considerations, and the overall financial performance of the Company. If, after assessing the totality of these qualitative factors, the Company determines that it is not likely that the fair value of its reporting unit is less than its carrying amount, then no additional assessment is deemed necessary. Otherwise, the Company will proceed to perform the impairment test in which the fair value of the reporting unit is compared with its carrying amount, and an impairment charge will be recorded for the amount by which the carrying amount exceeds the reporting unit's fair value, if any. The Company performed its annual assessment for goodwill impairment as of November 30, 2020, identifying no impairment.&lt;/span&gt;&lt;/div&gt;Although there are inherent uncertainties in this assessment process, the estimates and assumptions the Company is using are consistent with its internal planning. If these estimates or their related assumptions change in the future, the Company may be required to record an impairment charge on all or a portion of its goodwill and intangible assets. Furthermore, the Company cannot predict the occurrence of future impairment triggering events nor the impact such events might have on its reported asset values. Future events could cause the Company to conclude that impairment indicators exist and that goodwill or other intangible assets associated with its acquired businesses are impaired. Any resulting impairment loss could have an adverse impact on the Company&#x2019;s results of operations.</us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i2f37abb9631043cc818c2a98efb857df_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18zNy9mcmFnOmE0NTZiM2ZhOTA0ZjQ0ZjNiYTUyYzg0OWE5YTIxNGRiL3RleHRyZWdpb246YTQ1NmIzZmE5MDRmNDRmM2JhNTJjODQ5YTlhMjE0ZGJfOTk2Mw_f14e3e3d-2647-408f-b931-b0e0cc74946d">P18Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="ic36b9cedad7f41a6b9eb223b09b7186c_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18zNy9mcmFnOmE0NTZiM2ZhOTA0ZjQ0ZjNiYTUyYzg0OWE5YTIxNGRiL3RleHRyZWdpb246YTQ1NmIzZmE5MDRmNDRmM2JhNTJjODQ5YTlhMjE0ZGJfMTA4Mzc_56c6b5c0-0110-4314-89e2-db24f83fa681"
      unitRef="usd">3000000.0</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i066bb5b0a9e84c0a878b1e800703d92b_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18zNy9mcmFnOmE0NTZiM2ZhOTA0ZjQ0ZjNiYTUyYzg0OWE5YTIxNGRiL3RleHRyZWdpb246YTQ1NmIzZmE5MDRmNDRmM2JhNTJjODQ5YTlhMjE0ZGJfMTA4NDU_bc0c2b55-8d4d-4263-92c4-2193b2f4d249"
      unitRef="usd">3100000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock
      contextRef="i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18zNy9mcmFnOmE0NTZiM2ZhOTA0ZjQ0ZjNiYTUyYzg0OWE5YTIxNGRiL3RleHRyZWdpb246YTQ1NmIzZmE5MDRmNDRmM2JhNTJjODQ5YTlhMjE0ZGJfMTgxMzk_63ab33ce-9c5d-420e-a875-c4aee6e9b6ce">&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Foreign Currency Translation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The functional and presentation currency of the Company is the U.S. dollar. Transactions denominated in a currency other than the functional currency are recorded on the initial recognition at the exchange rate at the date of the transaction. After initial recognition monetary assets and liabilities denominated in foreign currency are translated at the end of each reporting period into the functional currency at the exchange rate at that date. The cumulative translation adjustment is included in the accumulated other comprehensive income (loss) within the statement of stockholders' equity. Exchange differences are included in general and administrative expenses in the condensed consolidated statement of operations. Non- monetary assets and liabilities measured at cost are translated at the exchange rate at the date of the transaction.&lt;/span&gt;&lt;/div&gt;</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
    <us-gaap:ConsolidationVariableInterestEntityPolicy
      contextRef="i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18zNy9mcmFnOmE0NTZiM2ZhOTA0ZjQ0ZjNiYTUyYzg0OWE5YTIxNGRiL3RleHRyZWdpb246YTQ1NmIzZmE5MDRmNDRmM2JhNTJjODQ5YTlhMjE0ZGJfMTgxNTg_45d6da93-23cf-49dd-b3f3-9e7cc0b25bb8">&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Variable Interest Entities (VIE)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company evaluates its ownership, contractual and other interests in entities that are not wholly-owned to determine if these entities are VIEs, and, if so, whether the Company is the primary beneficiary of the VIE. In determining whether the Company is the primary beneficiary of a VIE and therefore required to consolidate the VIE, the Company applies a qualitative approach that determines whether it has both (1) the power to direct the activities of the VIE that most significantly impact the VIE&#x2019;s economic performance and (2) the obligation to absorb losses of, or the rights to receive benefits from, the VIE that could potentially be significant to that VIE. The Company will continuously perform this assessment, as changes to existing relationships or future transactions may result in the consolidation or deconsolidation of a VIE.&lt;/span&gt;&lt;/div&gt;</us-gaap:ConsolidationVariableInterestEntityPolicy>
    <us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValuePolicyTextBlock
      contextRef="i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18zNy9mcmFnOmE0NTZiM2ZhOTA0ZjQ0ZjNiYTUyYzg0OWE5YTIxNGRiL3RleHRyZWdpb246YTQ1NmIzZmE5MDRmNDRmM2JhNTJjODQ5YTlhMjE0ZGJfMTgxMzE_d7a5d973-10ec-46b0-85e4-8c6037e72a96">Equity Investments&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under ASC Topic 321, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Investments - Equity Securities,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; the Company must measure equity investments (except those accounted for under the equity method, those that result in consolidation of the investee and certain other investments) at fair value and recognize any changes in fair value in the condensed consolidated statement of operations. The Company can elect a measurement alternative for equity investments that do not have readily determinable fair values and do not qualify for the practical expedient in ASC 820, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Fair Value Measurement,&lt;/span&gt; to estimate fair value using the net asset value per share (or its equivalent).&#160;The Company's equity investments that do not have readily determinable fair values and do not qualify for the net asset value practical expedient for estimating fair value are measured at cost, less any impairments, plus or minus changes resulting from observable price changes in orderly transactions for identifiable or similar investments of the same issuer.</us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValuePolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock
      contextRef="i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN180My9mcmFnOjE2YjBmNmZlNjlhZTQwNjdhYmQ0N2RlNGM4M2ZhYTg3L3RleHRyZWdpb246MTZiMGY2ZmU2OWFlNDA2N2FiZDQ3ZGU0YzgzZmFhODdfNTE5MA_2f95db5e-3729-45b5-9d39-aa3f7be4be49">Impact of Recently Issued Accounting Standards &lt;div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The recent accounting pronouncements below may have a significant effect on the Company's financial statements. Recent accounting pronouncements that are not anticipated to have an impact on or are unrelated to the Company's financial condition, results of operations, or related disclosures are not discussed. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Accounting Standards Pending Adoption&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;ASU No. 2020-06.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; In August 2020, the FASB issued ASU No. 2020-06, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Debt&#x2014;Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging&#x2014;Contracts in Entity&#x2019;s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity&#x2019;s Own Equity&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (&#x201c;ASU 2020-06&#x201d;), which simplifies the guidance on an issuer&#x2019;s accounting for convertible instruments and contracts in its own equity. The standard is effective for the Company beginning in the first quarter of 2022, with early adoption permitted in the first quarter of 2021. The Company did not elect to early adopt the standard and does not expect ASU 2020-06 to have a material impact to its condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN180My9mcmFnOjE2YjBmNmZlNjlhZTQwNjdhYmQ0N2RlNGM4M2ZhYTg3L3RleHRyZWdpb246MTZiMGY2ZmU2OWFlNDA2N2FiZDQ3ZGU0YzgzZmFhODdfNTE5Mw_ac7d4575-738b-4177-9217-db5de1d75f44">&lt;div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The recent accounting pronouncements below may have a significant effect on the Company's financial statements. Recent accounting pronouncements that are not anticipated to have an impact on or are unrelated to the Company's financial condition, results of operations, or related disclosures are not discussed. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Accounting Standards Pending Adoption&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;ASU No. 2020-06.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; In August 2020, the FASB issued ASU No. 2020-06, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Debt&#x2014;Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging&#x2014;Contracts in Entity&#x2019;s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity&#x2019;s Own Equity&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (&#x201c;ASU 2020-06&#x201d;), which simplifies the guidance on an issuer&#x2019;s accounting for convertible instruments and contracts in its own equity. The standard is effective for the Company beginning in the first quarter of 2022, with early adoption permitted in the first quarter of 2021. The Company did not elect to early adopt the standard and does not expect ASU 2020-06 to have a material impact to its condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:RevenueFromContractWithCustomerTextBlock
      contextRef="i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN180Ni9mcmFnOjZkOWI0OTc4YjgwMDQ3ZjhiOTg3ZGRlODJmM2MyNzk2L3RleHRyZWdpb246NmQ5YjQ5NzhiODAwNDdmOGI5ODdkZGU4MmYzYzI3OTZfNTU3_ebad08c6-6373-45e0-bbf8-02b7cf279f70">Revenue Recognition  During the three months ended March 31, 2021, the Company recognized total revenue under collaborative research and development and other agreements of $50,000 from its affiliated entity Plumbline Life Sciences, Inc. ("PLS") and $321,000 from various other contracts as a result of performance obligations being satisfied. Of the total revenue recognized during the three months ended March 31, 2021, $4,000 was in deferred revenue as of December 31, 2020.</us-gaap:RevenueFromContractWithCustomerTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia2b43dbe48ac4cd98a40e26498a7f881_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN180Ni9mcmFnOjZkOWI0OTc4YjgwMDQ3ZjhiOTg3ZGRlODJmM2MyNzk2L3RleHRyZWdpb246NmQ5YjQ5NzhiODAwNDdmOGI5ODdkZGU4MmYzYzI3OTZfMTUx_a91ec5f4-d52b-4b79-b092-0076f45552f9"
      unitRef="usd">50000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i54393acc697d46e9aadd822f4955d2fa_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN180Ni9mcmFnOjZkOWI0OTc4YjgwMDQ3ZjhiOTg3ZGRlODJmM2MyNzk2L3RleHRyZWdpb246NmQ5YjQ5NzhiODAwNDdmOGI5ODdkZGU4MmYzYzI3OTZfMjg4_69f38cf3-ec0c-4051-a01a-71147105f0c8"
      unitRef="usd">321000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN180Ni9mcmFnOjZkOWI0OTc4YjgwMDQ3ZjhiOTg3ZGRlODJmM2MyNzk2L3RleHRyZWdpb246NmQ5YjQ5NzhiODAwNDdmOGI5ODdkZGU4MmYzYzI3OTZfMzkw_75f2d893-48bc-4c01-b2e6-6a44ef7d31d7"
      unitRef="usd">4000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock
      contextRef="i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN180OS9mcmFnOjBmMTE0ZmJjNDQ1ZDRiYTBiODFjMjhjYWE3YzZjNmE2L3RleHRyZWdpb246MGYxMTRmYmM0NDVkNGJhMGI4MWMyOGNhYTdjNmM2YTZfMzQyNg_3b2b1ee2-19e7-4a7d-ab44-ca25330d80fc">Short-term Investments&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Short-term investments at March&#160;31, 2021 consisted of mutual funds, U.S. treasury securities, certificates of deposit and U.S. agency mortgage-backed securities. Short-term investments at December&#160;31, 2020 consisted of mutual funds, certificates of deposit and U.S. agency mortgage-backed securities. Short-term investments are recorded at fair value, based on current market valuations. Unrealized gains and losses on the Company's short-term debt investments are excluded from earnings and reported as a separate component of other comprehensive loss until realized. Realized gains and losses and unrealized gains and losses on available-for-sale equity securities are included in non-operating other income (expense) on the condensed consolidated statements of operations and are derived using the specific identification method for determining the cost of the securities sold. During the three months ended March 31, 2021 and 2020, the Company recorded gross realized gain on investments of $0 and $50,000, respectively, and gross realized loss on investments of $10,000 and $525,000, respectively. During the three months ended March 31, 2021 and 2020, the Company recorded net unrealized loss on available-for-sale equity securities of $(848,000) and $(5.1) million, respectively. No&#160;material balances were&#160;reclassified out of accumulated&#160;other comprehensive income (loss) for the three months ended March 31, 2021 and 2020. Interest and dividends on investments classified as available-for-sale are included in interest income in the condensed consolidated statements of operations. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following is a summary of available-for-sale securities as of March&#160;31, 2021 and December&#160;31, 2020:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:25.839%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.394%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.809%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.809%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.809%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.812%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:21pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Contractual&lt;br/&gt;Maturity&#160;(in&#160;years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&#160;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&#160;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&#160;Market&#160;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Mutual funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;---&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;228,101,615&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,562,498&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(714,957)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;228,949,156&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less than 1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;200,408,976&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,404&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,380)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;200,414,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less than 1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,977,623&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,123)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,992,200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. agency mortgage-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,646,077&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(33,005)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,614,172&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;434,134,291&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,597,702&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(762,465)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;434,969,528&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:25.839%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.394%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.809%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.809%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.809%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.812%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:21pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Contractual&lt;br/&gt;Maturity&#160;(in&#160;years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&#160;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&#160;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&#160;Market&#160;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Mutual funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;---&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;153,177,675&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,339,639&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(644,140)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;154,873,174&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less&#160;than&#160;1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,000,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,260&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,016,260&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. agency mortgage-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,062,256&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(36,755)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,025,501&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;159,239,931&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,365,899&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(690,895)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;160,914,935&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;*No single maturity date.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company periodically reviews its portfolio of available-for-sale debt securities to determine if any investment is impaired due to credit loss or other potential valuation concerns. For the debt securities where the fair value of the investment is less than the amortized cost basis, the Company has assessed at the individual security level for various quantitative factors including, but not limited to, the nature of the investments, changes in credit ratings, interest rate fluctuations, industry analyst reports, and the severity of impairment. Unrealized losses on available-for-sale debt securities as of&#160;March&#160;31, 2021&#160;were primarily due to changes in interest rates, including credit spreads from perceived increased credit risks as a result of the COVID-19 global pandemic, and not due to increased credit risks associated with specific securities. The Company does not intend to sell these investments and it is not more likely than not that the Company will be required to sell the investments before recovery of their amortized cost basis, which may be at maturity. Based on the credit quality of the available-for-sale debt securities that are in an unrealized loss position, and the Company&#x2019;s estimates of future cash flows to be collected from those securities, the Company believes the unrealized losses are not credit losses. Accordingly, at March&#160;31, 2021, the Company has not recorded an allowance for credit losses related to its available-for-sale debt securities.&lt;/span&gt;&lt;/div&gt;</us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedGain
      contextRef="i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN180OS9mcmFnOjBmMTE0ZmJjNDQ1ZDRiYTBiODFjMjhjYWE3YzZjNmE2L3RleHRyZWdpb246MGYxMTRmYmM0NDVkNGJhMGI4MWMyOGNhYTdjNmM2YTZfOTE4_8ba9db78-59d4-4d00-a553-f98ac68eeb1c"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleRealizedGain>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedGain
      contextRef="i03bccaa0abfb4733b1e2831ecde4e4e8_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN180OS9mcmFnOjBmMTE0ZmJjNDQ1ZDRiYTBiODFjMjhjYWE3YzZjNmE2L3RleHRyZWdpb246MGYxMTRmYmM0NDVkNGJhMGI4MWMyOGNhYTdjNmM2YTZfOTI1_32a3772d-fda7-4e6f-b442-d3942a8d5870"
      unitRef="usd">50000</us-gaap:DebtSecuritiesAvailableForSaleRealizedGain>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss
      contextRef="i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN180OS9mcmFnOjBmMTE0ZmJjNDQ1ZDRiYTBiODFjMjhjYWE3YzZjNmE2L3RleHRyZWdpb246MGYxMTRmYmM0NDVkNGJhMGI4MWMyOGNhYTdjNmM2YTZfOTg1_83f96af7-5a8e-4174-a658-f7d161a450d7"
      unitRef="usd">10000</us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss
      contextRef="i03bccaa0abfb4733b1e2831ecde4e4e8_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN180OS9mcmFnOjBmMTE0ZmJjNDQ1ZDRiYTBiODFjMjhjYWE3YzZjNmE2L3RleHRyZWdpb246MGYxMTRmYmM0NDVkNGJhMGI4MWMyOGNhYTdjNmM2YTZfOTky_9c16a836-63d0-480e-9d86-4ed28ec0ef5c"
      unitRef="usd">525000</us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN180OS9mcmFnOjBmMTE0ZmJjNDQ1ZDRiYTBiODFjMjhjYWE3YzZjNmE2L3RleHRyZWdpb246MGYxMTRmYmM0NDVkNGJhMGI4MWMyOGNhYTdjNmM2YTZfMTI4Mw_9878f61d-85ba-4892-92a4-331882da994a"
      unitRef="usd">-848000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="i03bccaa0abfb4733b1e2831ecde4e4e8_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN180OS9mcmFnOjBmMTE0ZmJjNDQ1ZDRiYTBiODFjMjhjYWE3YzZjNmE2L3RleHRyZWdpb246MGYxMTRmYmM0NDVkNGJhMGI4MWMyOGNhYTdjNmM2YTZfMTI5MA_abb51152-d72f-4948-9213-ed318b1faca9"
      unitRef="usd">-5100000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock
      contextRef="i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN180OS9mcmFnOjBmMTE0ZmJjNDQ1ZDRiYTBiODFjMjhjYWE3YzZjNmE2L3RleHRyZWdpb246MGYxMTRmYmM0NDVkNGJhMGI4MWMyOGNhYTdjNmM2YTZfMzQzNw_b45b3444-e6b7-43f0-b385-b0f37edcd6fb">&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following is a summary of available-for-sale securities as of March&#160;31, 2021 and December&#160;31, 2020:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:25.839%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.394%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.809%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.809%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.809%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.812%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:21pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Contractual&lt;br/&gt;Maturity&#160;(in&#160;years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&#160;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&#160;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&#160;Market&#160;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Mutual funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;---&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;228,101,615&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,562,498&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(714,957)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;228,949,156&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less than 1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;200,408,976&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,404&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,380)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;200,414,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less than 1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,977,623&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,123)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,992,200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. agency mortgage-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,646,077&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(33,005)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,614,172&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;434,134,291&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,597,702&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(762,465)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;434,969,528&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:25.839%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.394%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.809%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.809%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.809%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.812%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:21pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Contractual&lt;br/&gt;Maturity&#160;(in&#160;years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&#160;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&#160;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&#160;Market&#160;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Mutual funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;---&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;153,177,675&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,339,639&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(644,140)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;154,873,174&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less&#160;than&#160;1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,000,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,260&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,016,260&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. agency mortgage-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,062,256&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(36,755)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,025,501&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;159,239,931&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,365,899&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(690,895)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;160,914,935&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;*No single maturity date.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ibc97cab144454f34933b056f760ee615_I20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN180OS9mcmFnOjBmMTE0ZmJjNDQ1ZDRiYTBiODFjMjhjYWE3YzZjNmE2L3RhYmxlOmU2NGMxMTM5YTU3YTRhOTE4NTliNDUzM2EzNGJkNWQxL3RhYmxlcmFuZ2U6ZTY0YzExMzlhNTdhNGE5MTg1OWI0NTMzYTM0YmQ1ZDFfMi0zLTEtMS0w_11e3aa3c-5205-4c10-844c-f085b919b947"
      unitRef="usd">228101615</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ibc97cab144454f34933b056f760ee615_I20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN180OS9mcmFnOjBmMTE0ZmJjNDQ1ZDRiYTBiODFjMjhjYWE3YzZjNmE2L3RhYmxlOmU2NGMxMTM5YTU3YTRhOTE4NTliNDUzM2EzNGJkNWQxL3RhYmxlcmFuZ2U6ZTY0YzExMzlhNTdhNGE5MTg1OWI0NTMzYTM0YmQ1ZDFfMi01LTEtMS0w_158701ef-6c45-4fd3-921c-decb100a170b"
      unitRef="usd">1562498</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ibc97cab144454f34933b056f760ee615_I20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN180OS9mcmFnOjBmMTE0ZmJjNDQ1ZDRiYTBiODFjMjhjYWE3YzZjNmE2L3RhYmxlOmU2NGMxMTM5YTU3YTRhOTE4NTliNDUzM2EzNGJkNWQxL3RhYmxlcmFuZ2U6ZTY0YzExMzlhNTdhNGE5MTg1OWI0NTMzYTM0YmQ1ZDFfMi03LTEtMS0w_601c2a28-389b-4ab4-9e32-9cc8db53a793"
      unitRef="usd">714957</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ibc97cab144454f34933b056f760ee615_I20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN180OS9mcmFnOjBmMTE0ZmJjNDQ1ZDRiYTBiODFjMjhjYWE3YzZjNmE2L3RhYmxlOmU2NGMxMTM5YTU3YTRhOTE4NTliNDUzM2EzNGJkNWQxL3RhYmxlcmFuZ2U6ZTY0YzExMzlhNTdhNGE5MTg1OWI0NTMzYTM0YmQ1ZDFfMi05LTEtMS0w_3eb8d915-8ab7-4eaa-87f1-60ca70c2cc05"
      unitRef="usd">228949156</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <ino:DebtSecuritiesAvailableforSaleContractualMaturity
      contextRef="i4af67d24a9704503878ba27b39ec0b38_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN180OS9mcmFnOjBmMTE0ZmJjNDQ1ZDRiYTBiODFjMjhjYWE3YzZjNmE2L3RhYmxlOmU2NGMxMTM5YTU3YTRhOTE4NTliNDUzM2EzNGJkNWQxL3RhYmxlcmFuZ2U6ZTY0YzExMzlhNTdhNGE5MTg1OWI0NTMzYTM0YmQ1ZDFfMy0xLTEtMS00NDE3L3RleHRyZWdpb246OWJmYmExMGI3YzAyNGI2ZGE4ZWJiNGVhNmZkN2E5ZWZfMzI5ODUzNDg4MzM0NA_5ce133e6-797b-41ff-82ce-b9c3c30a53cc">P1Y</ino:DebtSecuritiesAvailableforSaleContractualMaturity>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ibd7b23cb5c014502a4a19618e0a1c8c8_I20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN180OS9mcmFnOjBmMTE0ZmJjNDQ1ZDRiYTBiODFjMjhjYWE3YzZjNmE2L3RhYmxlOmU2NGMxMTM5YTU3YTRhOTE4NTliNDUzM2EzNGJkNWQxL3RhYmxlcmFuZ2U6ZTY0YzExMzlhNTdhNGE5MTg1OWI0NTMzYTM0YmQ1ZDFfMy0zLTEtMS0w_fb861b6c-2d28-49e0-917f-76b5d7a3a6b4"
      unitRef="usd">200408976</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ibd7b23cb5c014502a4a19618e0a1c8c8_I20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN180OS9mcmFnOjBmMTE0ZmJjNDQ1ZDRiYTBiODFjMjhjYWE3YzZjNmE2L3RhYmxlOmU2NGMxMTM5YTU3YTRhOTE4NTliNDUzM2EzNGJkNWQxL3RhYmxlcmFuZ2U6ZTY0YzExMzlhNTdhNGE5MTg1OWI0NTMzYTM0YmQ1ZDFfMy01LTEtMS0w_7c609be1-17c8-4bca-9b35-9784a76af0b7"
      unitRef="usd">14404</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ibd7b23cb5c014502a4a19618e0a1c8c8_I20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN180OS9mcmFnOjBmMTE0ZmJjNDQ1ZDRiYTBiODFjMjhjYWE3YzZjNmE2L3RhYmxlOmU2NGMxMTM5YTU3YTRhOTE4NTliNDUzM2EzNGJkNWQxL3RhYmxlcmFuZ2U6ZTY0YzExMzlhNTdhNGE5MTg1OWI0NTMzYTM0YmQ1ZDFfMy03LTEtMS0w_7a1aa932-5a75-4d90-8f80-20c3cf275718"
      unitRef="usd">9380</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ibd7b23cb5c014502a4a19618e0a1c8c8_I20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN180OS9mcmFnOjBmMTE0ZmJjNDQ1ZDRiYTBiODFjMjhjYWE3YzZjNmE2L3RhYmxlOmU2NGMxMTM5YTU3YTRhOTE4NTliNDUzM2EzNGJkNWQxL3RhYmxlcmFuZ2U6ZTY0YzExMzlhNTdhNGE5MTg1OWI0NTMzYTM0YmQ1ZDFfMy05LTEtMS0w_54ff1078-4504-4bd6-a0a3-bf4abe712f7e"
      unitRef="usd">200414000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <ino:DebtSecuritiesAvailableforSaleContractualMaturity
      contextRef="i4a59d94b00fb4beead53f1520382f2ac_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN180OS9mcmFnOjBmMTE0ZmJjNDQ1ZDRiYTBiODFjMjhjYWE3YzZjNmE2L3RhYmxlOmU2NGMxMTM5YTU3YTRhOTE4NTliNDUzM2EzNGJkNWQxL3RhYmxlcmFuZ2U6ZTY0YzExMzlhNTdhNGE5MTg1OWI0NTMzYTM0YmQ1ZDFfNS0xLTEtMS00NDEzL3RleHRyZWdpb246NTNlNGY4YzIzYWRhNDgwOWFlMmJhM2ZkNTAzNWYzY2VfMzI5ODUzNDg4MzM0NA_3294376a-e729-44bb-bbea-9c0b4d772ce7">P1Y</ino:DebtSecuritiesAvailableforSaleContractualMaturity>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i07337481fc814fa2a711b1ff37845f55_I20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN180OS9mcmFnOjBmMTE0ZmJjNDQ1ZDRiYTBiODFjMjhjYWE3YzZjNmE2L3RhYmxlOmU2NGMxMTM5YTU3YTRhOTE4NTliNDUzM2EzNGJkNWQxL3RhYmxlcmFuZ2U6ZTY0YzExMzlhNTdhNGE5MTg1OWI0NTMzYTM0YmQ1ZDFfNS0zLTEtMS0w_dcbd43ba-6924-424d-ba09-beddf4f672dd"
      unitRef="usd">2977623</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i07337481fc814fa2a711b1ff37845f55_I20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN180OS9mcmFnOjBmMTE0ZmJjNDQ1ZDRiYTBiODFjMjhjYWE3YzZjNmE2L3RhYmxlOmU2NGMxMTM5YTU3YTRhOTE4NTliNDUzM2EzNGJkNWQxL3RhYmxlcmFuZ2U6ZTY0YzExMzlhNTdhNGE5MTg1OWI0NTMzYTM0YmQ1ZDFfNS01LTEtMS0w_299b1057-e3b6-4c23-9563-1346c88a76ca"
      unitRef="usd">19700</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i07337481fc814fa2a711b1ff37845f55_I20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN180OS9mcmFnOjBmMTE0ZmJjNDQ1ZDRiYTBiODFjMjhjYWE3YzZjNmE2L3RhYmxlOmU2NGMxMTM5YTU3YTRhOTE4NTliNDUzM2EzNGJkNWQxL3RhYmxlcmFuZ2U6ZTY0YzExMzlhNTdhNGE5MTg1OWI0NTMzYTM0YmQ1ZDFfNS03LTEtMS0w_c4e3c037-b905-4e33-81f5-d8fbacf8d33d"
      unitRef="usd">5123</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i07337481fc814fa2a711b1ff37845f55_I20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN180OS9mcmFnOjBmMTE0ZmJjNDQ1ZDRiYTBiODFjMjhjYWE3YzZjNmE2L3RhYmxlOmU2NGMxMTM5YTU3YTRhOTE4NTliNDUzM2EzNGJkNWQxL3RhYmxlcmFuZ2U6ZTY0YzExMzlhNTdhNGE5MTg1OWI0NTMzYTM0YmQ1ZDFfNS05LTEtMS0w_4a9b0030-9614-4af6-80b7-592de93d7005"
      unitRef="usd">2992200</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i333c95a51d3f4b7595b348f7c6eb52c5_I20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN180OS9mcmFnOjBmMTE0ZmJjNDQ1ZDRiYTBiODFjMjhjYWE3YzZjNmE2L3RhYmxlOmU2NGMxMTM5YTU3YTRhOTE4NTliNDUzM2EzNGJkNWQxL3RhYmxlcmFuZ2U6ZTY0YzExMzlhNTdhNGE5MTg1OWI0NTMzYTM0YmQ1ZDFfNi0zLTEtMS0w_f58c7f34-1043-409f-9575-f9971b0fd103"
      unitRef="usd">2646077</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i333c95a51d3f4b7595b348f7c6eb52c5_I20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN180OS9mcmFnOjBmMTE0ZmJjNDQ1ZDRiYTBiODFjMjhjYWE3YzZjNmE2L3RhYmxlOmU2NGMxMTM5YTU3YTRhOTE4NTliNDUzM2EzNGJkNWQxL3RhYmxlcmFuZ2U6ZTY0YzExMzlhNTdhNGE5MTg1OWI0NTMzYTM0YmQ1ZDFfNi01LTEtMS0w_1b17bb36-07cb-4cbe-aa13-37d240474b59"
      unitRef="usd">1100</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i333c95a51d3f4b7595b348f7c6eb52c5_I20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN180OS9mcmFnOjBmMTE0ZmJjNDQ1ZDRiYTBiODFjMjhjYWE3YzZjNmE2L3RhYmxlOmU2NGMxMTM5YTU3YTRhOTE4NTliNDUzM2EzNGJkNWQxL3RhYmxlcmFuZ2U6ZTY0YzExMzlhNTdhNGE5MTg1OWI0NTMzYTM0YmQ1ZDFfNi03LTEtMS0w_6a152d11-e360-49ab-bf52-c6d8605148bd"
      unitRef="usd">33005</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i333c95a51d3f4b7595b348f7c6eb52c5_I20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN180OS9mcmFnOjBmMTE0ZmJjNDQ1ZDRiYTBiODFjMjhjYWE3YzZjNmE2L3RhYmxlOmU2NGMxMTM5YTU3YTRhOTE4NTliNDUzM2EzNGJkNWQxL3RhYmxlcmFuZ2U6ZTY0YzExMzlhNTdhNGE5MTg1OWI0NTMzYTM0YmQ1ZDFfNi05LTEtMS0w_d48c06f1-c56d-4780-9497-4ed31154d03a"
      unitRef="usd">2614172</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ic36b9cedad7f41a6b9eb223b09b7186c_I20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN180OS9mcmFnOjBmMTE0ZmJjNDQ1ZDRiYTBiODFjMjhjYWE3YzZjNmE2L3RhYmxlOmU2NGMxMTM5YTU3YTRhOTE4NTliNDUzM2EzNGJkNWQxL3RhYmxlcmFuZ2U6ZTY0YzExMzlhNTdhNGE5MTg1OWI0NTMzYTM0YmQ1ZDFfOC0zLTEtMS0w_d5914599-2a3b-4da3-b423-bbcc2ac9a5df"
      unitRef="usd">434134291</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ic36b9cedad7f41a6b9eb223b09b7186c_I20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN180OS9mcmFnOjBmMTE0ZmJjNDQ1ZDRiYTBiODFjMjhjYWE3YzZjNmE2L3RhYmxlOmU2NGMxMTM5YTU3YTRhOTE4NTliNDUzM2EzNGJkNWQxL3RhYmxlcmFuZ2U6ZTY0YzExMzlhNTdhNGE5MTg1OWI0NTMzYTM0YmQ1ZDFfOC01LTEtMS0w_7ca681dc-4f88-42a5-a16a-a8f739f5e495"
      unitRef="usd">1597702</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ic36b9cedad7f41a6b9eb223b09b7186c_I20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN180OS9mcmFnOjBmMTE0ZmJjNDQ1ZDRiYTBiODFjMjhjYWE3YzZjNmE2L3RhYmxlOmU2NGMxMTM5YTU3YTRhOTE4NTliNDUzM2EzNGJkNWQxL3RhYmxlcmFuZ2U6ZTY0YzExMzlhNTdhNGE5MTg1OWI0NTMzYTM0YmQ1ZDFfOC03LTEtMS0w_741d30be-9edb-4ed8-b270-063f1077f4be"
      unitRef="usd">762465</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ic36b9cedad7f41a6b9eb223b09b7186c_I20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN180OS9mcmFnOjBmMTE0ZmJjNDQ1ZDRiYTBiODFjMjhjYWE3YzZjNmE2L3RhYmxlOmU2NGMxMTM5YTU3YTRhOTE4NTliNDUzM2EzNGJkNWQxL3RhYmxlcmFuZ2U6ZTY0YzExMzlhNTdhNGE5MTg1OWI0NTMzYTM0YmQ1ZDFfOC05LTEtMS0w_cfe05cf7-5181-4511-9aee-c90ce0cc5bcd"
      unitRef="usd">434969528</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i9038be9382ec4b1694bd9bfd7bcda170_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN180OS9mcmFnOjBmMTE0ZmJjNDQ1ZDRiYTBiODFjMjhjYWE3YzZjNmE2L3RhYmxlOjk2YjEwY2MxZTI2ZDQyMGFiNTE3NGRkYjU4Zjk0YTY4L3RhYmxlcmFuZ2U6OTZiMTBjYzFlMjZkNDIwYWI1MTc0ZGRiNThmOTRhNjhfMi0zLTEtMS0w_5a50ad23-acfb-481b-934a-741b25ce7f78"
      unitRef="usd">153177675</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i9038be9382ec4b1694bd9bfd7bcda170_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN180OS9mcmFnOjBmMTE0ZmJjNDQ1ZDRiYTBiODFjMjhjYWE3YzZjNmE2L3RhYmxlOjk2YjEwY2MxZTI2ZDQyMGFiNTE3NGRkYjU4Zjk0YTY4L3RhYmxlcmFuZ2U6OTZiMTBjYzFlMjZkNDIwYWI1MTc0ZGRiNThmOTRhNjhfMi01LTEtMS0w_937f9021-4650-4365-8179-0756d749ce91"
      unitRef="usd">2339639</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i9038be9382ec4b1694bd9bfd7bcda170_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN180OS9mcmFnOjBmMTE0ZmJjNDQ1ZDRiYTBiODFjMjhjYWE3YzZjNmE2L3RhYmxlOjk2YjEwY2MxZTI2ZDQyMGFiNTE3NGRkYjU4Zjk0YTY4L3RhYmxlcmFuZ2U6OTZiMTBjYzFlMjZkNDIwYWI1MTc0ZGRiNThmOTRhNjhfMi03LTEtMS0w_e1907c58-a1bc-40e3-9d45-bdb5bd9c754a"
      unitRef="usd">644140</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i9038be9382ec4b1694bd9bfd7bcda170_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN180OS9mcmFnOjBmMTE0ZmJjNDQ1ZDRiYTBiODFjMjhjYWE3YzZjNmE2L3RhYmxlOjk2YjEwY2MxZTI2ZDQyMGFiNTE3NGRkYjU4Zjk0YTY4L3RhYmxlcmFuZ2U6OTZiMTBjYzFlMjZkNDIwYWI1MTc0ZGRiNThmOTRhNjhfMi05LTEtMS0w_4664b182-2cdd-474a-b065-67245baefd8b"
      unitRef="usd">154873174</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <ino:DebtSecuritiesAvailableforSaleContractualMaturity
      contextRef="i47be9d2882e243b7ace441a9b9205c92_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN180OS9mcmFnOjBmMTE0ZmJjNDQ1ZDRiYTBiODFjMjhjYWE3YzZjNmE2L3RhYmxlOjk2YjEwY2MxZTI2ZDQyMGFiNTE3NGRkYjU4Zjk0YTY4L3RhYmxlcmFuZ2U6OTZiMTBjYzFlMjZkNDIwYWI1MTc0ZGRiNThmOTRhNjhfMy0xLTEtMS00NDIxL3RleHRyZWdpb246ODg1OWRjMzFmNzJiNDU2Mzg0MzI0YzExYTdjZjkzZmJfMzI5ODUzNDg4MzM0OA_e5010b9c-39c8-4b0a-80c7-a425adf41367">P1Y</ino:DebtSecuritiesAvailableforSaleContractualMaturity>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i7ed17972d6064f0bad14d06c6c595208_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN180OS9mcmFnOjBmMTE0ZmJjNDQ1ZDRiYTBiODFjMjhjYWE3YzZjNmE2L3RhYmxlOjk2YjEwY2MxZTI2ZDQyMGFiNTE3NGRkYjU4Zjk0YTY4L3RhYmxlcmFuZ2U6OTZiMTBjYzFlMjZkNDIwYWI1MTc0ZGRiNThmOTRhNjhfMy0zLTEtMS0w_2f147ad7-a0dc-4c6d-88e2-25ba1f7aa826"
      unitRef="usd">3000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i7ed17972d6064f0bad14d06c6c595208_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN180OS9mcmFnOjBmMTE0ZmJjNDQ1ZDRiYTBiODFjMjhjYWE3YzZjNmE2L3RhYmxlOjk2YjEwY2MxZTI2ZDQyMGFiNTE3NGRkYjU4Zjk0YTY4L3RhYmxlcmFuZ2U6OTZiMTBjYzFlMjZkNDIwYWI1MTc0ZGRiNThmOTRhNjhfMy01LTEtMS0w_42e19b17-31c5-42ac-8553-ffd96ec23acd"
      unitRef="usd">26260</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i7ed17972d6064f0bad14d06c6c595208_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN180OS9mcmFnOjBmMTE0ZmJjNDQ1ZDRiYTBiODFjMjhjYWE3YzZjNmE2L3RhYmxlOjk2YjEwY2MxZTI2ZDQyMGFiNTE3NGRkYjU4Zjk0YTY4L3RhYmxlcmFuZ2U6OTZiMTBjYzFlMjZkNDIwYWI1MTc0ZGRiNThmOTRhNjhfMy03LTEtMS0w_93fc5601-5f9d-45b8-9acc-32b0c34480c8"
      unitRef="usd">10000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i7ed17972d6064f0bad14d06c6c595208_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN180OS9mcmFnOjBmMTE0ZmJjNDQ1ZDRiYTBiODFjMjhjYWE3YzZjNmE2L3RhYmxlOjk2YjEwY2MxZTI2ZDQyMGFiNTE3NGRkYjU4Zjk0YTY4L3RhYmxlcmFuZ2U6OTZiMTBjYzFlMjZkNDIwYWI1MTc0ZGRiNThmOTRhNjhfMy05LTEtMS0w_93dd794d-442b-43b8-9d68-098732e8bd62"
      unitRef="usd">3016260</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i6f07020b0bd84e2b85baecf8191dddd4_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN180OS9mcmFnOjBmMTE0ZmJjNDQ1ZDRiYTBiODFjMjhjYWE3YzZjNmE2L3RhYmxlOjk2YjEwY2MxZTI2ZDQyMGFiNTE3NGRkYjU4Zjk0YTY4L3RhYmxlcmFuZ2U6OTZiMTBjYzFlMjZkNDIwYWI1MTc0ZGRiNThmOTRhNjhfNC0zLTEtMS0w_b08b7270-592b-458e-8186-8a0fa2bb7252"
      unitRef="usd">3062256</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i6f07020b0bd84e2b85baecf8191dddd4_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN180OS9mcmFnOjBmMTE0ZmJjNDQ1ZDRiYTBiODFjMjhjYWE3YzZjNmE2L3RhYmxlOjk2YjEwY2MxZTI2ZDQyMGFiNTE3NGRkYjU4Zjk0YTY4L3RhYmxlcmFuZ2U6OTZiMTBjYzFlMjZkNDIwYWI1MTc0ZGRiNThmOTRhNjhfNC01LTEtMS0w_591286c4-3a20-4ead-8a6b-8594de7776fa"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i6f07020b0bd84e2b85baecf8191dddd4_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN180OS9mcmFnOjBmMTE0ZmJjNDQ1ZDRiYTBiODFjMjhjYWE3YzZjNmE2L3RhYmxlOjk2YjEwY2MxZTI2ZDQyMGFiNTE3NGRkYjU4Zjk0YTY4L3RhYmxlcmFuZ2U6OTZiMTBjYzFlMjZkNDIwYWI1MTc0ZGRiNThmOTRhNjhfNC03LTEtMS0w_fc93d80b-4ff4-4cf3-b4c9-dc57ff49f1d2"
      unitRef="usd">36755</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i6f07020b0bd84e2b85baecf8191dddd4_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN180OS9mcmFnOjBmMTE0ZmJjNDQ1ZDRiYTBiODFjMjhjYWE3YzZjNmE2L3RhYmxlOjk2YjEwY2MxZTI2ZDQyMGFiNTE3NGRkYjU4Zjk0YTY4L3RhYmxlcmFuZ2U6OTZiMTBjYzFlMjZkNDIwYWI1MTc0ZGRiNThmOTRhNjhfNC05LTEtMS0w_2c6d6095-3c23-4110-bcfe-60467d752c84"
      unitRef="usd">3025501</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i066bb5b0a9e84c0a878b1e800703d92b_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN180OS9mcmFnOjBmMTE0ZmJjNDQ1ZDRiYTBiODFjMjhjYWE3YzZjNmE2L3RhYmxlOjk2YjEwY2MxZTI2ZDQyMGFiNTE3NGRkYjU4Zjk0YTY4L3RhYmxlcmFuZ2U6OTZiMTBjYzFlMjZkNDIwYWI1MTc0ZGRiNThmOTRhNjhfNy0zLTEtMS0yODk1_74cc3ac2-070d-4483-88fc-99cc13501f3f"
      unitRef="usd">159239931</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i066bb5b0a9e84c0a878b1e800703d92b_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN180OS9mcmFnOjBmMTE0ZmJjNDQ1ZDRiYTBiODFjMjhjYWE3YzZjNmE2L3RhYmxlOjk2YjEwY2MxZTI2ZDQyMGFiNTE3NGRkYjU4Zjk0YTY4L3RhYmxlcmFuZ2U6OTZiMTBjYzFlMjZkNDIwYWI1MTc0ZGRiNThmOTRhNjhfNy01LTEtMS0yODk1_e248bc47-c5dc-4136-8c82-489d8846641e"
      unitRef="usd">2365899</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i066bb5b0a9e84c0a878b1e800703d92b_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN180OS9mcmFnOjBmMTE0ZmJjNDQ1ZDRiYTBiODFjMjhjYWE3YzZjNmE2L3RhYmxlOjk2YjEwY2MxZTI2ZDQyMGFiNTE3NGRkYjU4Zjk0YTY4L3RhYmxlcmFuZ2U6OTZiMTBjYzFlMjZkNDIwYWI1MTc0ZGRiNThmOTRhNjhfNy03LTEtMS0yODk1_73d7c811-c013-4540-b283-65487b4d8614"
      unitRef="usd">690895</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i066bb5b0a9e84c0a878b1e800703d92b_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN180OS9mcmFnOjBmMTE0ZmJjNDQ1ZDRiYTBiODFjMjhjYWE3YzZjNmE2L3RhYmxlOjk2YjEwY2MxZTI2ZDQyMGFiNTE3NGRkYjU4Zjk0YTY4L3RhYmxlcmFuZ2U6OTZiMTBjYzFlMjZkNDIwYWI1MTc0ZGRiNThmOTRhNjhfNy05LTEtMS0yODk1_a1c6352b-e793-4fa9-879f-c3a0e22f8a69"
      unitRef="usd">160914935</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN181NS9mcmFnOjRiYWIyMmQ4MWJlYjQzNGQ4YzRkYjQwOTE5NTc4MGE4L3RleHRyZWdpb246NGJhYjIyZDgxYmViNDM0ZDhjNGRiNDA5MTk1NzgwYThfNTgzNA_5ae9547b-64a2-45ae-b0d4-7f783abf3a96">Fair Value Measurements&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The guidance regarding fair value measurements establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value. These tiers include: Level&#160;1, defined as observable inputs such as quoted prices in active markets that are accessible at the measurement date; Level&#160;2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable; and Level&#160;3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Assets are classified based on the lowest level of input that is significant to the fair value measurements. The Company reviews the fair value hierarchy classification on a quarterly basis. Changes in the ability to observe valuation inputs may result in a reclassification of levels for certain securities within the fair value hierarchy. The Company does not have any liabilities measured at fair value on a recurring basis and did not have any transfer of assets or liabilities between Level 1, Level 2 and Level 3 of the fair value hierarchy during the three months ended March 31, 2021 or 2020. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the Company&#x2019;s assets that were measured at fair value on a recurring basis, determined using the following inputs as of March&#160;31, 2021:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:35.796%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.541%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.541%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.737%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.689%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements at&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Quoted Prices&lt;br/&gt;in Active Markets&lt;br/&gt;(Level&#160;1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Other Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level&#160;2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level&#160;3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Mutual funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;228,949,156&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;228,949,156&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;200,414,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;200,414,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,992,200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,992,200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S. agency mortgage-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,614,172&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,614,172&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;434,969,528&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;429,363,156&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,606,372&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investment in affiliated entity&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,629,891&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,629,891&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets measured at fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;438,599,419&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;432,993,047&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,606,372&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the Company&#x2019;s assets that were measured at fair value on a recurring basis, determined using the following inputs as of December&#160;31, 2020:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:35.796%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.541%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.541%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.737%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.689%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements at&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Quoted Prices&lt;br/&gt;in Active Markets&lt;br/&gt;(Level&#160;1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Other Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level&#160;2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level&#160;3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59,996,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59,996,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Mutual funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;154,873,174&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;154,873,174&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,016,260&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,016,260&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S. agency mortgage-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,025,501&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,025,501&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;160,914,935&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;154,873,174&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,041,761&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investment in affiliated entities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,460,366&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,460,366&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets measured at fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;225,372,101&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;219,330,340&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,041,761&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Level 1 assets at March&#160;31, 2021 consisted of mutual funds and U.S. treasury securities held by the Company that are valued at quoted market prices, as well as the Company&#x2019;s investment in its affiliated entity, PLS. The Company accounts for its investment in 597,808 common shares of PLS based on the closing price of the shares on the Korea New Exchange Market on the applicable balance sheet date. Unrealized gains and losses on the Company's equity securities are reported in the condensed consolidated statement of ope&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;rations as unrealized gain (loss) on available-for-sale equity securities &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;or as a gain (loss) on investment in affiliated entities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 2 assets at March&#160;31, 2021 consisted of certificates of deposit and U.S. agency mortgage-backed securities held by the Company that are initially valued at the transaction price and subsequently valued, at the end of each reporting period, typically utilizing market observable data. The Company obtains the fair value of its Level 2 assets from a professional pricing service, which may use quoted market prices for identical or comparable instruments, or inputs other than quoted prices that are observable either directly or indirectly. The professional pricing service gathers quoted market prices and observable inputs from a variety of industry data providers. The valuation techniques used to measure the fair value of the Company's Level 2 financial instruments were derived from non-binding market consensus prices that are corroborated by observable market data, quoted market prices for similar instruments, or pricing models such as discounted cash flow techniques. The Company validates the quoted market prices provided by the primary pricing service by comparing the service's assessment of the fair values of the Company's investment portfolio balance against the fair values of the Company's investment portfolio balance obtained from an independent source.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There were no Level 3 assets held as of March&#160;31, 2021.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock
      contextRef="i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN181NS9mcmFnOjRiYWIyMmQ4MWJlYjQzNGQ4YzRkYjQwOTE5NTc4MGE4L3RleHRyZWdpb246NGJhYjIyZDgxYmViNDM0ZDhjNGRiNDA5MTk1NzgwYThfNTgxNg_9cd6b261-7545-4212-aa1b-1d7fc154eeb5">&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the Company&#x2019;s assets that were measured at fair value on a recurring basis, determined using the following inputs as of March&#160;31, 2021:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:35.796%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.541%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.541%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.737%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.689%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements at&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Quoted Prices&lt;br/&gt;in Active Markets&lt;br/&gt;(Level&#160;1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Other Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level&#160;2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level&#160;3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Mutual funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;228,949,156&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;228,949,156&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;200,414,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;200,414,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,992,200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,992,200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S. agency mortgage-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,614,172&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,614,172&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;434,969,528&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;429,363,156&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,606,372&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investment in affiliated entity&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,629,891&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,629,891&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets measured at fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;438,599,419&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;432,993,047&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,606,372&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the Company&#x2019;s assets that were measured at fair value on a recurring basis, determined using the following inputs as of December&#160;31, 2020:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:35.796%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.541%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.541%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.737%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.689%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements at&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Quoted Prices&lt;br/&gt;in Active Markets&lt;br/&gt;(Level&#160;1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Other Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level&#160;2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level&#160;3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59,996,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59,996,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Mutual funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;154,873,174&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;154,873,174&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,016,260&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,016,260&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S. agency mortgage-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,025,501&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,025,501&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;160,914,935&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;154,873,174&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,041,761&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investment in affiliated entities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,460,366&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,460,366&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets measured at fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;225,372,101&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;219,330,340&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,041,761&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="id49e93fcdfff47499add351e50b2b851_I20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN181NS9mcmFnOjRiYWIyMmQ4MWJlYjQzNGQ4YzRkYjQwOTE5NTc4MGE4L3RhYmxlOmJjYzNkM2MwZTdmMjRiMjhhZTgxNTljYzc4MzViNDU3L3RhYmxlcmFuZ2U6YmNjM2QzYzBlN2YyNGIyOGFlODE1OWNjNzgzNWI0NTdfOS0xLTEtMS0w_19273a7c-18fa-49c8-a628-8669c99cc33a"
      unitRef="usd">228949156</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ibb9d7da2bb9f4083a0f78f4d762e46e4_I20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN181NS9mcmFnOjRiYWIyMmQ4MWJlYjQzNGQ4YzRkYjQwOTE5NTc4MGE4L3RhYmxlOmJjYzNkM2MwZTdmMjRiMjhhZTgxNTljYzc4MzViNDU3L3RhYmxlcmFuZ2U6YmNjM2QzYzBlN2YyNGIyOGFlODE1OWNjNzgzNWI0NTdfOS0zLTEtMS0w_1cdfdba6-258b-456f-9622-c014ef201e56"
      unitRef="usd">228949156</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i08f3093795f1462c897c6cadd1da8aed_I20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN181NS9mcmFnOjRiYWIyMmQ4MWJlYjQzNGQ4YzRkYjQwOTE5NTc4MGE4L3RhYmxlOmJjYzNkM2MwZTdmMjRiMjhhZTgxNTljYzc4MzViNDU3L3RhYmxlcmFuZ2U6YmNjM2QzYzBlN2YyNGIyOGFlODE1OWNjNzgzNWI0NTdfOS01LTEtMS0w_3698d466-fcab-44f4-85ec-3fef9e6193b5"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ib5e1a14b053e47c79b64277a69e380a9_I20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN181NS9mcmFnOjRiYWIyMmQ4MWJlYjQzNGQ4YzRkYjQwOTE5NTc4MGE4L3RhYmxlOmJjYzNkM2MwZTdmMjRiMjhhZTgxNTljYzc4MzViNDU3L3RhYmxlcmFuZ2U6YmNjM2QzYzBlN2YyNGIyOGFlODE1OWNjNzgzNWI0NTdfOS03LTEtMS0w_3c9b3c4a-c9fd-4994-9ef7-dba5022ec50d"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i8963e309e7dd4867bea8e9ee34e0a52b_I20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN181NS9mcmFnOjRiYWIyMmQ4MWJlYjQzNGQ4YzRkYjQwOTE5NTc4MGE4L3RhYmxlOmJjYzNkM2MwZTdmMjRiMjhhZTgxNTljYzc4MzViNDU3L3RhYmxlcmFuZ2U6YmNjM2QzYzBlN2YyNGIyOGFlODE1OWNjNzgzNWI0NTdfMTAtMS0xLTEtMjU2Mg_5a5dc029-fe7c-48fd-aad5-8597a2692c77"
      unitRef="usd">200414000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ie4a6d945ad73450191ce911b7e550ccc_I20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN181NS9mcmFnOjRiYWIyMmQ4MWJlYjQzNGQ4YzRkYjQwOTE5NTc4MGE4L3RhYmxlOmJjYzNkM2MwZTdmMjRiMjhhZTgxNTljYzc4MzViNDU3L3RhYmxlcmFuZ2U6YmNjM2QzYzBlN2YyNGIyOGFlODE1OWNjNzgzNWI0NTdfMTAtMy0xLTEtMjU2Mg_e20c17e7-a74e-4d6a-bab0-68765af52bd7"
      unitRef="usd">200414000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i22850f7499b2483f9428ba6cd51e1702_I20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN181NS9mcmFnOjRiYWIyMmQ4MWJlYjQzNGQ4YzRkYjQwOTE5NTc4MGE4L3RhYmxlOmJjYzNkM2MwZTdmMjRiMjhhZTgxNTljYzc4MzViNDU3L3RhYmxlcmFuZ2U6YmNjM2QzYzBlN2YyNGIyOGFlODE1OWNjNzgzNWI0NTdfMTAtNS0xLTEtMjU2Mg_bf5220a6-f11a-4020-ab1b-649c1b742100"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ie7c31848f0e94bee88a97957caa0dac9_I20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN181NS9mcmFnOjRiYWIyMmQ4MWJlYjQzNGQ4YzRkYjQwOTE5NTc4MGE4L3RhYmxlOmJjYzNkM2MwZTdmMjRiMjhhZTgxNTljYzc4MzViNDU3L3RhYmxlcmFuZ2U6YmNjM2QzYzBlN2YyNGIyOGFlODE1OWNjNzgzNWI0NTdfMTAtNy0xLTEtMjU2Mg_c325764d-e597-4db4-8525-057dd38dfaac"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i8576b8faf8064d92a55a1d7a9230294b_I20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN181NS9mcmFnOjRiYWIyMmQ4MWJlYjQzNGQ4YzRkYjQwOTE5NTc4MGE4L3RhYmxlOmJjYzNkM2MwZTdmMjRiMjhhZTgxNTljYzc4MzViNDU3L3RhYmxlcmFuZ2U6YmNjM2QzYzBlN2YyNGIyOGFlODE1OWNjNzgzNWI0NTdfMTEtMS0xLTEtMA_121d0d85-3895-4d10-8a82-bc15e6e23ec0"
      unitRef="usd">2992200</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i081a1114c57c4457a6e656fb47caa2fc_I20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN181NS9mcmFnOjRiYWIyMmQ4MWJlYjQzNGQ4YzRkYjQwOTE5NTc4MGE4L3RhYmxlOmJjYzNkM2MwZTdmMjRiMjhhZTgxNTljYzc4MzViNDU3L3RhYmxlcmFuZ2U6YmNjM2QzYzBlN2YyNGIyOGFlODE1OWNjNzgzNWI0NTdfMTEtMy0xLTEtMA_6281a613-0329-4e5e-a5cb-9cc9cc8b484e"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i23aedffa2f0c42b9b43cb0b83beea039_I20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN181NS9mcmFnOjRiYWIyMmQ4MWJlYjQzNGQ4YzRkYjQwOTE5NTc4MGE4L3RhYmxlOmJjYzNkM2MwZTdmMjRiMjhhZTgxNTljYzc4MzViNDU3L3RhYmxlcmFuZ2U6YmNjM2QzYzBlN2YyNGIyOGFlODE1OWNjNzgzNWI0NTdfMTEtNS0xLTEtMA_8ed13903-9615-491e-8305-e2cc53232576"
      unitRef="usd">2992200</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ia2a22ff53c7d437b9e4758ed1dd0655b_I20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN181NS9mcmFnOjRiYWIyMmQ4MWJlYjQzNGQ4YzRkYjQwOTE5NTc4MGE4L3RhYmxlOmJjYzNkM2MwZTdmMjRiMjhhZTgxNTljYzc4MzViNDU3L3RhYmxlcmFuZ2U6YmNjM2QzYzBlN2YyNGIyOGFlODE1OWNjNzgzNWI0NTdfMTEtNy0xLTEtMA_260b1ab5-b817-439e-accc-c4abe472bfe9"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i79f50420241043d0abd5aedb34d9926b_I20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN181NS9mcmFnOjRiYWIyMmQ4MWJlYjQzNGQ4YzRkYjQwOTE5NTc4MGE4L3RhYmxlOmJjYzNkM2MwZTdmMjRiMjhhZTgxNTljYzc4MzViNDU3L3RhYmxlcmFuZ2U6YmNjM2QzYzBlN2YyNGIyOGFlODE1OWNjNzgzNWI0NTdfMTItMS0xLTEtMA_96999ca8-9a5e-40a8-a434-167a5d29f838"
      unitRef="usd">2614172</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i700d1959d79f4c7891a22d010cdfd228_I20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN181NS9mcmFnOjRiYWIyMmQ4MWJlYjQzNGQ4YzRkYjQwOTE5NTc4MGE4L3RhYmxlOmJjYzNkM2MwZTdmMjRiMjhhZTgxNTljYzc4MzViNDU3L3RhYmxlcmFuZ2U6YmNjM2QzYzBlN2YyNGIyOGFlODE1OWNjNzgzNWI0NTdfMTItMy0xLTEtMA_7040c3fa-75ea-46bc-a13b-9adf12a87ab9"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ic7b40fbbf0484fb98e57b0b99619b678_I20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN181NS9mcmFnOjRiYWIyMmQ4MWJlYjQzNGQ4YzRkYjQwOTE5NTc4MGE4L3RhYmxlOmJjYzNkM2MwZTdmMjRiMjhhZTgxNTljYzc4MzViNDU3L3RhYmxlcmFuZ2U6YmNjM2QzYzBlN2YyNGIyOGFlODE1OWNjNzgzNWI0NTdfMTItNS0xLTEtMA_51695ef9-3514-4875-ab8b-92afbf1aa8ca"
      unitRef="usd">2614172</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ib8736cce87614b07956326c0d9cc3035_I20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN181NS9mcmFnOjRiYWIyMmQ4MWJlYjQzNGQ4YzRkYjQwOTE5NTc4MGE4L3RhYmxlOmJjYzNkM2MwZTdmMjRiMjhhZTgxNTljYzc4MzViNDU3L3RhYmxlcmFuZ2U6YmNjM2QzYzBlN2YyNGIyOGFlODE1OWNjNzgzNWI0NTdfMTItNy0xLTEtMA_07ed362a-2e63-40a2-8ef5-9487bc66e410"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="idc037a18dec8422896679a520fe0751f_I20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN181NS9mcmFnOjRiYWIyMmQ4MWJlYjQzNGQ4YzRkYjQwOTE5NTc4MGE4L3RhYmxlOmJjYzNkM2MwZTdmMjRiMjhhZTgxNTljYzc4MzViNDU3L3RhYmxlcmFuZ2U6YmNjM2QzYzBlN2YyNGIyOGFlODE1OWNjNzgzNWI0NTdfMTMtMS0xLTEtMA_6fc6dc15-6a29-4326-892b-271bd0d7a9b4"
      unitRef="usd">434969528</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i950b0135e402482fae846256144517d6_I20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN181NS9mcmFnOjRiYWIyMmQ4MWJlYjQzNGQ4YzRkYjQwOTE5NTc4MGE4L3RhYmxlOmJjYzNkM2MwZTdmMjRiMjhhZTgxNTljYzc4MzViNDU3L3RhYmxlcmFuZ2U6YmNjM2QzYzBlN2YyNGIyOGFlODE1OWNjNzgzNWI0NTdfMTMtMy0xLTEtMA_ca5a4aa3-75f2-47c1-a1da-453bd9bafd58"
      unitRef="usd">429363156</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i536f602826fe46979bdba143abf2858a_I20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN181NS9mcmFnOjRiYWIyMmQ4MWJlYjQzNGQ4YzRkYjQwOTE5NTc4MGE4L3RhYmxlOmJjYzNkM2MwZTdmMjRiMjhhZTgxNTljYzc4MzViNDU3L3RhYmxlcmFuZ2U6YmNjM2QzYzBlN2YyNGIyOGFlODE1OWNjNzgzNWI0NTdfMTMtNS0xLTEtMA_ca083690-b187-4c39-be5c-a51063a6b2ae"
      unitRef="usd">5606372</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="iaef1617b1a33479ebd53313a3c7a7812_I20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN181NS9mcmFnOjRiYWIyMmQ4MWJlYjQzNGQ4YzRkYjQwOTE5NTc4MGE4L3RhYmxlOmJjYzNkM2MwZTdmMjRiMjhhZTgxNTljYzc4MzViNDU3L3RhYmxlcmFuZ2U6YmNjM2QzYzBlN2YyNGIyOGFlODE1OWNjNzgzNWI0NTdfMTMtNy0xLTEtMA_5453be7d-c550-462c-9207-737a92755678"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="idc037a18dec8422896679a520fe0751f_I20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN181NS9mcmFnOjRiYWIyMmQ4MWJlYjQzNGQ4YzRkYjQwOTE5NTc4MGE4L3RhYmxlOmJjYzNkM2MwZTdmMjRiMjhhZTgxNTljYzc4MzViNDU3L3RhYmxlcmFuZ2U6YmNjM2QzYzBlN2YyNGIyOGFlODE1OWNjNzgzNWI0NTdfMTUtMS0xLTEtMA_f63c1fec-9ace-497e-bb6a-240b20f643df"
      unitRef="usd">3629891</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i950b0135e402482fae846256144517d6_I20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN181NS9mcmFnOjRiYWIyMmQ4MWJlYjQzNGQ4YzRkYjQwOTE5NTc4MGE4L3RhYmxlOmJjYzNkM2MwZTdmMjRiMjhhZTgxNTljYzc4MzViNDU3L3RhYmxlcmFuZ2U6YmNjM2QzYzBlN2YyNGIyOGFlODE1OWNjNzgzNWI0NTdfMTUtMy0xLTEtMA_0cb4c52e-7a26-4442-9a06-8a08c571aee1"
      unitRef="usd">3629891</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i536f602826fe46979bdba143abf2858a_I20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN181NS9mcmFnOjRiYWIyMmQ4MWJlYjQzNGQ4YzRkYjQwOTE5NTc4MGE4L3RhYmxlOmJjYzNkM2MwZTdmMjRiMjhhZTgxNTljYzc4MzViNDU3L3RhYmxlcmFuZ2U6YmNjM2QzYzBlN2YyNGIyOGFlODE1OWNjNzgzNWI0NTdfMTUtNS0xLTEtMA_07c7036e-8740-4f34-b5d1-5f260b31ee5e"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="iaef1617b1a33479ebd53313a3c7a7812_I20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN181NS9mcmFnOjRiYWIyMmQ4MWJlYjQzNGQ4YzRkYjQwOTE5NTc4MGE4L3RhYmxlOmJjYzNkM2MwZTdmMjRiMjhhZTgxNTljYzc4MzViNDU3L3RhYmxlcmFuZ2U6YmNjM2QzYzBlN2YyNGIyOGFlODE1OWNjNzgzNWI0NTdfMTUtNy0xLTEtMA_ce037b0f-5e2c-4fe0-8154-bc6205eaace4"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="idc037a18dec8422896679a520fe0751f_I20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN181NS9mcmFnOjRiYWIyMmQ4MWJlYjQzNGQ4YzRkYjQwOTE5NTc4MGE4L3RhYmxlOmJjYzNkM2MwZTdmMjRiMjhhZTgxNTljYzc4MzViNDU3L3RhYmxlcmFuZ2U6YmNjM2QzYzBlN2YyNGIyOGFlODE1OWNjNzgzNWI0NTdfMTctMS0xLTEtMA_a5255c8a-b299-4728-b6c4-d200be455487"
      unitRef="usd">438599419</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i950b0135e402482fae846256144517d6_I20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN181NS9mcmFnOjRiYWIyMmQ4MWJlYjQzNGQ4YzRkYjQwOTE5NTc4MGE4L3RhYmxlOmJjYzNkM2MwZTdmMjRiMjhhZTgxNTljYzc4MzViNDU3L3RhYmxlcmFuZ2U6YmNjM2QzYzBlN2YyNGIyOGFlODE1OWNjNzgzNWI0NTdfMTctMy0xLTEtMA_fcc0fe07-e5e1-4603-80a8-7960e8656113"
      unitRef="usd">432993047</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i536f602826fe46979bdba143abf2858a_I20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN181NS9mcmFnOjRiYWIyMmQ4MWJlYjQzNGQ4YzRkYjQwOTE5NTc4MGE4L3RhYmxlOmJjYzNkM2MwZTdmMjRiMjhhZTgxNTljYzc4MzViNDU3L3RhYmxlcmFuZ2U6YmNjM2QzYzBlN2YyNGIyOGFlODE1OWNjNzgzNWI0NTdfMTctNS0xLTEtMA_6ed4ee92-1fd3-477d-b134-d44988ad55b4"
      unitRef="usd">5606372</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="iaef1617b1a33479ebd53313a3c7a7812_I20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN181NS9mcmFnOjRiYWIyMmQ4MWJlYjQzNGQ4YzRkYjQwOTE5NTc4MGE4L3RhYmxlOmJjYzNkM2MwZTdmMjRiMjhhZTgxNTljYzc4MzViNDU3L3RhYmxlcmFuZ2U6YmNjM2QzYzBlN2YyNGIyOGFlODE1OWNjNzgzNWI0NTdfMTctNy0xLTEtMA_f77f1cd4-98f3-4e22-99b1-82db1537d935"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i679e853e6cb64bb9bee2cde9c5fa48ab_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN181NS9mcmFnOjRiYWIyMmQ4MWJlYjQzNGQ4YzRkYjQwOTE5NTc4MGE4L3RhYmxlOjM3OThiYWExNDZkZTQ4OWVhOGUwOTU3OTUyNzRhOGE4L3RhYmxlcmFuZ2U6Mzc5OGJhYTE0NmRlNDg5ZWE4ZTA5NTc5NTI3NGE4YThfNS0xLTEtMS0w_63c34413-322e-428f-8e5d-fdf28ab944da"
      unitRef="usd">59996800</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i95f3040264524bd7aafa7c66012a9ed0_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN181NS9mcmFnOjRiYWIyMmQ4MWJlYjQzNGQ4YzRkYjQwOTE5NTc4MGE4L3RhYmxlOjM3OThiYWExNDZkZTQ4OWVhOGUwOTU3OTUyNzRhOGE4L3RhYmxlcmFuZ2U6Mzc5OGJhYTE0NmRlNDg5ZWE4ZTA5NTc5NTI3NGE4YThfNS0zLTEtMS0w_e0bc58ab-2ef5-4db2-bcb2-0f96adca727a"
      unitRef="usd">59996800</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i77ffd233d1de4e33aa7330413610496e_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN181NS9mcmFnOjRiYWIyMmQ4MWJlYjQzNGQ4YzRkYjQwOTE5NTc4MGE4L3RhYmxlOjM3OThiYWExNDZkZTQ4OWVhOGUwOTU3OTUyNzRhOGE4L3RhYmxlcmFuZ2U6Mzc5OGJhYTE0NmRlNDg5ZWE4ZTA5NTc5NTI3NGE4YThfNS01LTEtMS0w_83a88f8a-8495-4eca-8c34-01126a033c38"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ie0d4dc3c347a44199532a6ee4469f31e_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN181NS9mcmFnOjRiYWIyMmQ4MWJlYjQzNGQ4YzRkYjQwOTE5NTc4MGE4L3RhYmxlOjM3OThiYWExNDZkZTQ4OWVhOGUwOTU3OTUyNzRhOGE4L3RhYmxlcmFuZ2U6Mzc5OGJhYTE0NmRlNDg5ZWE4ZTA5NTc5NTI3NGE4YThfNS03LTEtMS0w_ee548533-54db-4538-8814-346fd3c77fa4"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i765820c859204f75a1eaeb4f280fd337_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN181NS9mcmFnOjRiYWIyMmQ4MWJlYjQzNGQ4YzRkYjQwOTE5NTc4MGE4L3RhYmxlOjM3OThiYWExNDZkZTQ4OWVhOGUwOTU3OTUyNzRhOGE4L3RhYmxlcmFuZ2U6Mzc5OGJhYTE0NmRlNDg5ZWE4ZTA5NTc5NTI3NGE4YThfOC0xLTEtMS0w_166dc0b0-2f8c-4f02-9122-01c383d905d8"
      unitRef="usd">154873174</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i42280087f6b44742aa1b7f2971c27575_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN181NS9mcmFnOjRiYWIyMmQ4MWJlYjQzNGQ4YzRkYjQwOTE5NTc4MGE4L3RhYmxlOjM3OThiYWExNDZkZTQ4OWVhOGUwOTU3OTUyNzRhOGE4L3RhYmxlcmFuZ2U6Mzc5OGJhYTE0NmRlNDg5ZWE4ZTA5NTc5NTI3NGE4YThfOC0zLTEtMS0w_9c7a773a-87c7-439b-b7b1-d6da3c611410"
      unitRef="usd">154873174</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ifcda11a978e44c92b373b4913520b88b_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN181NS9mcmFnOjRiYWIyMmQ4MWJlYjQzNGQ4YzRkYjQwOTE5NTc4MGE4L3RhYmxlOjM3OThiYWExNDZkZTQ4OWVhOGUwOTU3OTUyNzRhOGE4L3RhYmxlcmFuZ2U6Mzc5OGJhYTE0NmRlNDg5ZWE4ZTA5NTc5NTI3NGE4YThfOC01LTEtMS0w_97a47f84-f7bb-498e-ac01-5895375cc158"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i691500b3ba21482aa5fe5467025f71c3_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN181NS9mcmFnOjRiYWIyMmQ4MWJlYjQzNGQ4YzRkYjQwOTE5NTc4MGE4L3RhYmxlOjM3OThiYWExNDZkZTQ4OWVhOGUwOTU3OTUyNzRhOGE4L3RhYmxlcmFuZ2U6Mzc5OGJhYTE0NmRlNDg5ZWE4ZTA5NTc5NTI3NGE4YThfOC03LTEtMS0w_1abc2501-6e0b-4735-8c14-d4cce2bea89c"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i3b31046c5de349d1937a204cdc2973ae_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN181NS9mcmFnOjRiYWIyMmQ4MWJlYjQzNGQ4YzRkYjQwOTE5NTc4MGE4L3RhYmxlOjM3OThiYWExNDZkZTQ4OWVhOGUwOTU3OTUyNzRhOGE4L3RhYmxlcmFuZ2U6Mzc5OGJhYTE0NmRlNDg5ZWE4ZTA5NTc5NTI3NGE4YThfOS0xLTEtMS0w_dc45ee87-dda7-409b-8021-fdbae94f34d2"
      unitRef="usd">3016260</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="iaaf44a738a1345828679d9a1b25f8327_I20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN181NS9mcmFnOjRiYWIyMmQ4MWJlYjQzNGQ4YzRkYjQwOTE5NTc4MGE4L3RhYmxlOjM3OThiYWExNDZkZTQ4OWVhOGUwOTU3OTUyNzRhOGE4L3RhYmxlcmFuZ2U6Mzc5OGJhYTE0NmRlNDg5ZWE4ZTA5NTc5NTI3NGE4YThfOS0zLTEtMS0w_729c3015-8899-42ab-bd58-248f719b49ce"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ie2357d9b866e4be7afcd9fe0ac4e6a56_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN181NS9mcmFnOjRiYWIyMmQ4MWJlYjQzNGQ4YzRkYjQwOTE5NTc4MGE4L3RhYmxlOjM3OThiYWExNDZkZTQ4OWVhOGUwOTU3OTUyNzRhOGE4L3RhYmxlcmFuZ2U6Mzc5OGJhYTE0NmRlNDg5ZWE4ZTA5NTc5NTI3NGE4YThfOS01LTEtMS0w_e093fd3c-8ed1-45e6-981d-3622a647543b"
      unitRef="usd">3016260</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i8501b73ca4034d94b92aab9e80a10e2f_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN181NS9mcmFnOjRiYWIyMmQ4MWJlYjQzNGQ4YzRkYjQwOTE5NTc4MGE4L3RhYmxlOjM3OThiYWExNDZkZTQ4OWVhOGUwOTU3OTUyNzRhOGE4L3RhYmxlcmFuZ2U6Mzc5OGJhYTE0NmRlNDg5ZWE4ZTA5NTc5NTI3NGE4YThfOS03LTEtMS0w_11361dbb-6010-4498-9779-139f342df847"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i2921a4efcf7f4fc1bbbf11dcd4e24dc8_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN181NS9mcmFnOjRiYWIyMmQ4MWJlYjQzNGQ4YzRkYjQwOTE5NTc4MGE4L3RhYmxlOjM3OThiYWExNDZkZTQ4OWVhOGUwOTU3OTUyNzRhOGE4L3RhYmxlcmFuZ2U6Mzc5OGJhYTE0NmRlNDg5ZWE4ZTA5NTc5NTI3NGE4YThfMTAtMS0xLTEtMA_c9725b3c-732e-4a7a-908d-a323fed96a7c"
      unitRef="usd">3025501</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i165dd8f0bd4343b5b394ee5a10eee714_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN181NS9mcmFnOjRiYWIyMmQ4MWJlYjQzNGQ4YzRkYjQwOTE5NTc4MGE4L3RhYmxlOjM3OThiYWExNDZkZTQ4OWVhOGUwOTU3OTUyNzRhOGE4L3RhYmxlcmFuZ2U6Mzc5OGJhYTE0NmRlNDg5ZWE4ZTA5NTc5NTI3NGE4YThfMTAtMy0xLTEtMA_49096d96-3e0d-4c2f-b84b-d3f019356447"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ibc90ce5aa5c04e718823e5f0bfad97e7_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN181NS9mcmFnOjRiYWIyMmQ4MWJlYjQzNGQ4YzRkYjQwOTE5NTc4MGE4L3RhYmxlOjM3OThiYWExNDZkZTQ4OWVhOGUwOTU3OTUyNzRhOGE4L3RhYmxlcmFuZ2U6Mzc5OGJhYTE0NmRlNDg5ZWE4ZTA5NTc5NTI3NGE4YThfMTAtNS0xLTEtMA_5cc43ef4-7821-4682-967c-2fafce8e8b7c"
      unitRef="usd">3025501</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i2a4a04a42ab7478daf3585b30a5dc600_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN181NS9mcmFnOjRiYWIyMmQ4MWJlYjQzNGQ4YzRkYjQwOTE5NTc4MGE4L3RhYmxlOjM3OThiYWExNDZkZTQ4OWVhOGUwOTU3OTUyNzRhOGE4L3RhYmxlcmFuZ2U6Mzc5OGJhYTE0NmRlNDg5ZWE4ZTA5NTc5NTI3NGE4YThfMTAtNy0xLTEtMA_ca832da8-e6b7-438b-9f0a-58412e9f77bc"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i8b1d59d5ed834f6b91384f272748379f_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN181NS9mcmFnOjRiYWIyMmQ4MWJlYjQzNGQ4YzRkYjQwOTE5NTc4MGE4L3RhYmxlOjM3OThiYWExNDZkZTQ4OWVhOGUwOTU3OTUyNzRhOGE4L3RhYmxlcmFuZ2U6Mzc5OGJhYTE0NmRlNDg5ZWE4ZTA5NTc5NTI3NGE4YThfMTItMS0xLTEtMjg5OA_99ca1117-6176-4d59-bc8a-41af82f705de"
      unitRef="usd">160914935</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="iea068b74107644b3a5e86a21d960799f_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN181NS9mcmFnOjRiYWIyMmQ4MWJlYjQzNGQ4YzRkYjQwOTE5NTc4MGE4L3RhYmxlOjM3OThiYWExNDZkZTQ4OWVhOGUwOTU3OTUyNzRhOGE4L3RhYmxlcmFuZ2U6Mzc5OGJhYTE0NmRlNDg5ZWE4ZTA5NTc5NTI3NGE4YThfMTItMy0xLTEtMjg5OA_8e210a4b-429d-477b-8559-23c3aba92350"
      unitRef="usd">154873174</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i9eeb5e9d4f914f2591ba8b7f2f2631da_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN181NS9mcmFnOjRiYWIyMmQ4MWJlYjQzNGQ4YzRkYjQwOTE5NTc4MGE4L3RhYmxlOjM3OThiYWExNDZkZTQ4OWVhOGUwOTU3OTUyNzRhOGE4L3RhYmxlcmFuZ2U6Mzc5OGJhYTE0NmRlNDg5ZWE4ZTA5NTc5NTI3NGE4YThfMTItNS0xLTEtMjg5OA_e24bdda8-3ff3-4f7e-8629-0dd7aa78d8ac"
      unitRef="usd">6041761</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i57bed7dd45b14e9f953dd397ed3bdce9_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN181NS9mcmFnOjRiYWIyMmQ4MWJlYjQzNGQ4YzRkYjQwOTE5NTc4MGE4L3RhYmxlOjM3OThiYWExNDZkZTQ4OWVhOGUwOTU3OTUyNzRhOGE4L3RhYmxlcmFuZ2U6Mzc5OGJhYTE0NmRlNDg5ZWE4ZTA5NTc5NTI3NGE4YThfMTItNy0xLTEtMjg5OA_6b8c92d5-1f9f-42e3-863d-e8139c668810"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i8b1d59d5ed834f6b91384f272748379f_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN181NS9mcmFnOjRiYWIyMmQ4MWJlYjQzNGQ4YzRkYjQwOTE5NTc4MGE4L3RhYmxlOjM3OThiYWExNDZkZTQ4OWVhOGUwOTU3OTUyNzRhOGE4L3RhYmxlcmFuZ2U6Mzc5OGJhYTE0NmRlNDg5ZWE4ZTA5NTc5NTI3NGE4YThfMTMtMS0xLTEtMA_45ba6e3e-08f1-482f-84d2-00017a640560"
      unitRef="usd">4460366</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="iea068b74107644b3a5e86a21d960799f_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN181NS9mcmFnOjRiYWIyMmQ4MWJlYjQzNGQ4YzRkYjQwOTE5NTc4MGE4L3RhYmxlOjM3OThiYWExNDZkZTQ4OWVhOGUwOTU3OTUyNzRhOGE4L3RhYmxlcmFuZ2U6Mzc5OGJhYTE0NmRlNDg5ZWE4ZTA5NTc5NTI3NGE4YThfMTMtMy0xLTEtMA_46cddb5c-6524-44e0-9c88-c46d9bb83d99"
      unitRef="usd">4460366</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i9eeb5e9d4f914f2591ba8b7f2f2631da_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN181NS9mcmFnOjRiYWIyMmQ4MWJlYjQzNGQ4YzRkYjQwOTE5NTc4MGE4L3RhYmxlOjM3OThiYWExNDZkZTQ4OWVhOGUwOTU3OTUyNzRhOGE4L3RhYmxlcmFuZ2U6Mzc5OGJhYTE0NmRlNDg5ZWE4ZTA5NTc5NTI3NGE4YThfMTMtNS0xLTEtMA_a43ad605-1376-4055-986b-817f02095481"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i57bed7dd45b14e9f953dd397ed3bdce9_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN181NS9mcmFnOjRiYWIyMmQ4MWJlYjQzNGQ4YzRkYjQwOTE5NTc4MGE4L3RhYmxlOjM3OThiYWExNDZkZTQ4OWVhOGUwOTU3OTUyNzRhOGE4L3RhYmxlcmFuZ2U6Mzc5OGJhYTE0NmRlNDg5ZWE4ZTA5NTc5NTI3NGE4YThfMTMtNy0xLTEtMA_278de89e-41bf-4ecc-b7a8-48b654f12163"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i8b1d59d5ed834f6b91384f272748379f_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN181NS9mcmFnOjRiYWIyMmQ4MWJlYjQzNGQ4YzRkYjQwOTE5NTc4MGE4L3RhYmxlOjM3OThiYWExNDZkZTQ4OWVhOGUwOTU3OTUyNzRhOGE4L3RhYmxlcmFuZ2U6Mzc5OGJhYTE0NmRlNDg5ZWE4ZTA5NTc5NTI3NGE4YThfMTUtMS0xLTEtMA_af842d24-848c-49f5-885e-f829456cf057"
      unitRef="usd">225372101</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="iea068b74107644b3a5e86a21d960799f_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN181NS9mcmFnOjRiYWIyMmQ4MWJlYjQzNGQ4YzRkYjQwOTE5NTc4MGE4L3RhYmxlOjM3OThiYWExNDZkZTQ4OWVhOGUwOTU3OTUyNzRhOGE4L3RhYmxlcmFuZ2U6Mzc5OGJhYTE0NmRlNDg5ZWE4ZTA5NTc5NTI3NGE4YThfMTUtMy0xLTEtMA_5f3c7968-a506-4cf6-9b8d-eacb35480be9"
      unitRef="usd">219330340</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i9eeb5e9d4f914f2591ba8b7f2f2631da_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN181NS9mcmFnOjRiYWIyMmQ4MWJlYjQzNGQ4YzRkYjQwOTE5NTc4MGE4L3RhYmxlOjM3OThiYWExNDZkZTQ4OWVhOGUwOTU3OTUyNzRhOGE4L3RhYmxlcmFuZ2U6Mzc5OGJhYTE0NmRlNDg5ZWE4ZTA5NTc5NTI3NGE4YThfMTUtNS0xLTEtMA_f6f55f44-d167-48f8-9fc1-f9fd007ff4d5"
      unitRef="usd">6041761</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i57bed7dd45b14e9f953dd397ed3bdce9_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN181NS9mcmFnOjRiYWIyMmQ4MWJlYjQzNGQ4YzRkYjQwOTE5NTc4MGE4L3RhYmxlOjM3OThiYWExNDZkZTQ4OWVhOGUwOTU3OTUyNzRhOGE4L3RhYmxlcmFuZ2U6Mzc5OGJhYTE0NmRlNDg5ZWE4ZTA5NTc5NTI3NGE4YThfMTUtNy0xLTEtMA_18738026-131c-40c4-8645-d6ae37f95e5e"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:InvestmentOwnedBalanceShares
      contextRef="i0cce4e82b88342c787d49f1a7ed20009_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN181NS9mcmFnOjRiYWIyMmQ4MWJlYjQzNGQ4YzRkYjQwOTE5NTc4MGE4L3RleHRyZWdpb246NGJhYjIyZDgxYmViNDM0ZDhjNGRiNDA5MTk1NzgwYThfMTg2Nw_56f50889-8ff4-43eb-9b4e-25ba72fa7570"
      unitRef="shares">597808</us-gaap:InvestmentOwnedBalanceShares>
    <us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock
      contextRef="i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN181OC9mcmFnOjI1NjFhMjhkNjFlNTRlMDBhYzE0ZDI2YWM3ODA3OTY2L3RleHRyZWdpb246MjU2MWEyOGQ2MWU1NGUwMGFjMTRkMjZhYzc4MDc5NjZfOTg2_d3d089f0-c854-457b-a8a0-2dbcbd87bfff">Goodwill and Intangible Assets&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following sets forth the goodwill and intangible assets by major asset class:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.206%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.647%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.060%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.060%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.500%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.918%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:45pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted Average Useful&lt;br/&gt;Life&lt;br/&gt;(Yrs)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net Book&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net Book&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Indefinite lived:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill(a)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,513,371&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,513,371&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,513,371&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,513,371&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Definite lived:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Licenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,323,761&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,284,039)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,722&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,323,761&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,276,852)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46,909&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Bioject(b)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,100,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,542,222)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,557,778&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,100,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,468,889)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,631,111&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other(c)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,050,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,637,500)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;412,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,050,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,581,250)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;468,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,473,761&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,463,761)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,010,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,473,761&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,326,991)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,146,770&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total goodwill and intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,987,132&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,463,761)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,523,371&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,987,132&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,326,991)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,660,141&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;padding-left:36pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt"&gt;Goodwill was recorded from the acquisition of other companies. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;padding-left:36pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(b)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt"&gt;Bioject intangible assets represent the estimated fair value of developed technology and intellectual property which were recorded from an asset acquisition.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;padding-left:36pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(c)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt"&gt;Other intangible assets represent the estimated fair value of acquired intellectual property. &lt;/span&gt;&lt;/div&gt;Aggregate amortization expense on intangible assets for each of the three months ended March 31, 2021 and 2020 was $137,000. Estimated aggregate amortization expense is $384,000 for the remainder of fiscal year 2021, $493,000 for 2022, $276,000 for 2023, $253,000 for 2024, $253,000 for 2025 and $1.4 million for 2026 and subsequent years combined.</us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock>
    <us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock
      contextRef="i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN181OC9mcmFnOjI1NjFhMjhkNjFlNTRlMDBhYzE0ZDI2YWM3ODA3OTY2L3RleHRyZWdpb246MjU2MWEyOGQ2MWU1NGUwMGFjMTRkMjZhYzc4MDc5NjZfOTY4_b01319bd-0823-4539-bfa6-827bfc4266e4">&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following sets forth the goodwill and intangible assets by major asset class:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.206%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.647%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.060%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.060%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.500%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.918%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:45pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted Average Useful&lt;br/&gt;Life&lt;br/&gt;(Yrs)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net Book&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net Book&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Indefinite lived:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill(a)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,513,371&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,513,371&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,513,371&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,513,371&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Definite lived:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Licenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,323,761&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,284,039)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,722&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,323,761&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,276,852)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46,909&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Bioject(b)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,100,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,542,222)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,557,778&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,100,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,468,889)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,631,111&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other(c)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,050,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,637,500)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;412,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,050,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,581,250)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;468,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,473,761&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,463,761)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,010,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,473,761&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,326,991)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,146,770&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total goodwill and intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,987,132&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,463,761)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,523,371&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,987,132&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,326,991)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,660,141&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;padding-left:36pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt"&gt;Goodwill was recorded from the acquisition of other companies. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;padding-left:36pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(b)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt"&gt;Bioject intangible assets represent the estimated fair value of developed technology and intellectual property which were recorded from an asset acquisition.&lt;/span&gt;&lt;/div&gt;(c)Other intangible assets represent the estimated fair value of acquired intellectual property.</us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock>
    <us-gaap:GoodwillGross
      contextRef="ic36b9cedad7f41a6b9eb223b09b7186c_I20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN181OC9mcmFnOjI1NjFhMjhkNjFlNTRlMDBhYzE0ZDI2YWM3ODA3OTY2L3RhYmxlOjZhN2QxMDQ5OTk3YjQyNTNiMmJhOGVlYmI4M2VlOTVkL3RhYmxlcmFuZ2U6NmE3ZDEwNDk5OTdiNDI1M2IyYmE4ZWViYjgzZWU5NWRfMy0zLTEtMS0w_71569106-35fb-4ebf-9f16-7abf2dbf610c"
      unitRef="usd">10513371</us-gaap:GoodwillGross>
    <us-gaap:Goodwill
      contextRef="ic36b9cedad7f41a6b9eb223b09b7186c_I20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN181OC9mcmFnOjI1NjFhMjhkNjFlNTRlMDBhYzE0ZDI2YWM3ODA3OTY2L3RhYmxlOjZhN2QxMDQ5OTk3YjQyNTNiMmJhOGVlYmI4M2VlOTVkL3RhYmxlcmFuZ2U6NmE3ZDEwNDk5OTdiNDI1M2IyYmE4ZWViYjgzZWU5NWRfMy03LTEtMS0w_7691b035-c856-47c6-8ad9-7d7d0cce9fd5"
      unitRef="usd">10513371</us-gaap:Goodwill>
    <us-gaap:GoodwillGross
      contextRef="i066bb5b0a9e84c0a878b1e800703d92b_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN181OC9mcmFnOjI1NjFhMjhkNjFlNTRlMDBhYzE0ZDI2YWM3ODA3OTY2L3RhYmxlOjZhN2QxMDQ5OTk3YjQyNTNiMmJhOGVlYmI4M2VlOTVkL3RhYmxlcmFuZ2U6NmE3ZDEwNDk5OTdiNDI1M2IyYmE4ZWViYjgzZWU5NWRfMy05LTEtMS0w_86e91bab-0d48-4f64-a3f9-63243e5e55fc"
      unitRef="usd">10513371</us-gaap:GoodwillGross>
    <us-gaap:Goodwill
      contextRef="i066bb5b0a9e84c0a878b1e800703d92b_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN181OC9mcmFnOjI1NjFhMjhkNjFlNTRlMDBhYzE0ZDI2YWM3ODA3OTY2L3RhYmxlOjZhN2QxMDQ5OTk3YjQyNTNiMmJhOGVlYmI4M2VlOTVkL3RhYmxlcmFuZ2U6NmE3ZDEwNDk5OTdiNDI1M2IyYmE4ZWViYjgzZWU5NWRfMy0xMy0xLTEtMA_2d478d11-59ab-4ecb-9168-4cf06f4adb66"
      unitRef="usd">10513371</us-gaap:Goodwill>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="id00cf7a7665d4381ba225961343d2ea4_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN181OC9mcmFnOjI1NjFhMjhkNjFlNTRlMDBhYzE0ZDI2YWM3ODA3OTY2L3RhYmxlOjZhN2QxMDQ5OTk3YjQyNTNiMmJhOGVlYmI4M2VlOTVkL3RhYmxlcmFuZ2U6NmE3ZDEwNDk5OTdiNDI1M2IyYmE4ZWViYjgzZWU5NWRfNi0xLTEtMS0w_51f727d4-c337-4839-b94e-ce84d7fc3361">P10Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="iff289276fdba4033befe45d8c121487e_I20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN181OC9mcmFnOjI1NjFhMjhkNjFlNTRlMDBhYzE0ZDI2YWM3ODA3OTY2L3RhYmxlOjZhN2QxMDQ5OTk3YjQyNTNiMmJhOGVlYmI4M2VlOTVkL3RhYmxlcmFuZ2U6NmE3ZDEwNDk5OTdiNDI1M2IyYmE4ZWViYjgzZWU5NWRfNi0zLTEtMS0w_6c1a4ebc-08dc-466d-a462-5d57d6af6e9a"
      unitRef="usd">1323761</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="iff289276fdba4033befe45d8c121487e_I20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN181OC9mcmFnOjI1NjFhMjhkNjFlNTRlMDBhYzE0ZDI2YWM3ODA3OTY2L3RhYmxlOjZhN2QxMDQ5OTk3YjQyNTNiMmJhOGVlYmI4M2VlOTVkL3RhYmxlcmFuZ2U6NmE3ZDEwNDk5OTdiNDI1M2IyYmE4ZWViYjgzZWU5NWRfNi01LTEtMS0w_3ddd97a2-bce1-499a-8e47-b618d49f2e43"
      unitRef="usd">1284039</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="iff289276fdba4033befe45d8c121487e_I20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN181OC9mcmFnOjI1NjFhMjhkNjFlNTRlMDBhYzE0ZDI2YWM3ODA3OTY2L3RhYmxlOjZhN2QxMDQ5OTk3YjQyNTNiMmJhOGVlYmI4M2VlOTVkL3RhYmxlcmFuZ2U6NmE3ZDEwNDk5OTdiNDI1M2IyYmE4ZWViYjgzZWU5NWRfNi03LTEtMS0w_826771ed-27ef-4e85-85c0-f1bbd220c741"
      unitRef="usd">39722</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i545fa05cd5804fa9a426a541fbe08f6d_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN181OC9mcmFnOjI1NjFhMjhkNjFlNTRlMDBhYzE0ZDI2YWM3ODA3OTY2L3RhYmxlOjZhN2QxMDQ5OTk3YjQyNTNiMmJhOGVlYmI4M2VlOTVkL3RhYmxlcmFuZ2U6NmE3ZDEwNDk5OTdiNDI1M2IyYmE4ZWViYjgzZWU5NWRfNi05LTEtMS0w_7a0326ab-7542-4f66-bc9f-87e441fd1cd2"
      unitRef="usd">1323761</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i545fa05cd5804fa9a426a541fbe08f6d_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN181OC9mcmFnOjI1NjFhMjhkNjFlNTRlMDBhYzE0ZDI2YWM3ODA3OTY2L3RhYmxlOjZhN2QxMDQ5OTk3YjQyNTNiMmJhOGVlYmI4M2VlOTVkL3RhYmxlcmFuZ2U6NmE3ZDEwNDk5OTdiNDI1M2IyYmE4ZWViYjgzZWU5NWRfNi0xMS0xLTEtMA_d1484422-1cb1-49b7-8dfd-4567196cded7"
      unitRef="usd">1276852</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i545fa05cd5804fa9a426a541fbe08f6d_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN181OC9mcmFnOjI1NjFhMjhkNjFlNTRlMDBhYzE0ZDI2YWM3ODA3OTY2L3RhYmxlOjZhN2QxMDQ5OTk3YjQyNTNiMmJhOGVlYmI4M2VlOTVkL3RhYmxlcmFuZ2U6NmE3ZDEwNDk5OTdiNDI1M2IyYmE4ZWViYjgzZWU5NWRfNi0xMy0xLTEtMA_dace161a-8723-444a-82b8-0fc7beef0aee"
      unitRef="usd">46909</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i677b4aa23e734ea1ae840c65c0f2ac0c_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN181OC9mcmFnOjI1NjFhMjhkNjFlNTRlMDBhYzE0ZDI2YWM3ODA3OTY2L3RhYmxlOjZhN2QxMDQ5OTk3YjQyNTNiMmJhOGVlYmI4M2VlOTVkL3RhYmxlcmFuZ2U6NmE3ZDEwNDk5OTdiNDI1M2IyYmE4ZWViYjgzZWU5NWRfOS0xLTEtMS0w_95419027-e188-4635-895e-e95d46110996">P12Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i87af82b668704e509e894f5e917c76ee_I20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN181OC9mcmFnOjI1NjFhMjhkNjFlNTRlMDBhYzE0ZDI2YWM3ODA3OTY2L3RhYmxlOjZhN2QxMDQ5OTk3YjQyNTNiMmJhOGVlYmI4M2VlOTVkL3RhYmxlcmFuZ2U6NmE3ZDEwNDk5OTdiNDI1M2IyYmE4ZWViYjgzZWU5NWRfOS0zLTEtMS0w_a6fe5c66-b585-4242-9450-45b5f3adb86d"
      unitRef="usd">5100000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i87af82b668704e509e894f5e917c76ee_I20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN181OC9mcmFnOjI1NjFhMjhkNjFlNTRlMDBhYzE0ZDI2YWM3ODA3OTY2L3RhYmxlOjZhN2QxMDQ5OTk3YjQyNTNiMmJhOGVlYmI4M2VlOTVkL3RhYmxlcmFuZ2U6NmE3ZDEwNDk5OTdiNDI1M2IyYmE4ZWViYjgzZWU5NWRfOS01LTEtMS0w_d77e5094-260f-4041-bf13-784c359f5d5d"
      unitRef="usd">2542222</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i87af82b668704e509e894f5e917c76ee_I20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN181OC9mcmFnOjI1NjFhMjhkNjFlNTRlMDBhYzE0ZDI2YWM3ODA3OTY2L3RhYmxlOjZhN2QxMDQ5OTk3YjQyNTNiMmJhOGVlYmI4M2VlOTVkL3RhYmxlcmFuZ2U6NmE3ZDEwNDk5OTdiNDI1M2IyYmE4ZWViYjgzZWU5NWRfOS03LTEtMS0w_389c8307-cedc-46cf-9202-edc941c22d68"
      unitRef="usd">2557778</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="icc09668324be44f4a3c6526161d237ec_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN181OC9mcmFnOjI1NjFhMjhkNjFlNTRlMDBhYzE0ZDI2YWM3ODA3OTY2L3RhYmxlOjZhN2QxMDQ5OTk3YjQyNTNiMmJhOGVlYmI4M2VlOTVkL3RhYmxlcmFuZ2U6NmE3ZDEwNDk5OTdiNDI1M2IyYmE4ZWViYjgzZWU5NWRfOS05LTEtMS0w_22867cd1-5ccb-4234-95ad-ae4025777d4a"
      unitRef="usd">5100000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="icc09668324be44f4a3c6526161d237ec_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN181OC9mcmFnOjI1NjFhMjhkNjFlNTRlMDBhYzE0ZDI2YWM3ODA3OTY2L3RhYmxlOjZhN2QxMDQ5OTk3YjQyNTNiMmJhOGVlYmI4M2VlOTVkL3RhYmxlcmFuZ2U6NmE3ZDEwNDk5OTdiNDI1M2IyYmE4ZWViYjgzZWU5NWRfOS0xMS0xLTEtMA_5f37f3ab-dfa5-44c3-b337-092063faa5a5"
      unitRef="usd">2468889</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="icc09668324be44f4a3c6526161d237ec_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN181OC9mcmFnOjI1NjFhMjhkNjFlNTRlMDBhYzE0ZDI2YWM3ODA3OTY2L3RhYmxlOjZhN2QxMDQ5OTk3YjQyNTNiMmJhOGVlYmI4M2VlOTVkL3RhYmxlcmFuZ2U6NmE3ZDEwNDk5OTdiNDI1M2IyYmE4ZWViYjgzZWU5NWRfOS0xMy0xLTEtMA_c8601ae0-3a59-4273-98ea-05481cc3deed"
      unitRef="usd">2631111</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i1bf527072286443a829aab2684009143_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN181OC9mcmFnOjI1NjFhMjhkNjFlNTRlMDBhYzE0ZDI2YWM3ODA3OTY2L3RhYmxlOjZhN2QxMDQ5OTk3YjQyNTNiMmJhOGVlYmI4M2VlOTVkL3RhYmxlcmFuZ2U6NmE3ZDEwNDk5OTdiNDI1M2IyYmE4ZWViYjgzZWU5NWRfMTAtMS0xLTEtMA_fa1f74fa-bb3d-4e9a-9993-50d4759f7853">P18Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i04d8063070ed47dca91d948e0b527543_I20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN181OC9mcmFnOjI1NjFhMjhkNjFlNTRlMDBhYzE0ZDI2YWM3ODA3OTY2L3RhYmxlOjZhN2QxMDQ5OTk3YjQyNTNiMmJhOGVlYmI4M2VlOTVkL3RhYmxlcmFuZ2U6NmE3ZDEwNDk5OTdiNDI1M2IyYmE4ZWViYjgzZWU5NWRfMTAtMy0xLTEtMA_af581e90-0a6c-4cef-84f3-c95313c75573"
      unitRef="usd">4050000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i04d8063070ed47dca91d948e0b527543_I20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN181OC9mcmFnOjI1NjFhMjhkNjFlNTRlMDBhYzE0ZDI2YWM3ODA3OTY2L3RhYmxlOjZhN2QxMDQ5OTk3YjQyNTNiMmJhOGVlYmI4M2VlOTVkL3RhYmxlcmFuZ2U6NmE3ZDEwNDk5OTdiNDI1M2IyYmE4ZWViYjgzZWU5NWRfMTAtNS0xLTEtMA_ab30542e-2260-4ed7-b911-44b7407ed703"
      unitRef="usd">3637500</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i04d8063070ed47dca91d948e0b527543_I20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN181OC9mcmFnOjI1NjFhMjhkNjFlNTRlMDBhYzE0ZDI2YWM3ODA3OTY2L3RhYmxlOjZhN2QxMDQ5OTk3YjQyNTNiMmJhOGVlYmI4M2VlOTVkL3RhYmxlcmFuZ2U6NmE3ZDEwNDk5OTdiNDI1M2IyYmE4ZWViYjgzZWU5NWRfMTAtNy0xLTEtMA_07fb123b-2668-467a-b646-1642ccb24da3"
      unitRef="usd">412500</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i9898566a542a49b4bf69010ae439ab9a_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN181OC9mcmFnOjI1NjFhMjhkNjFlNTRlMDBhYzE0ZDI2YWM3ODA3OTY2L3RhYmxlOjZhN2QxMDQ5OTk3YjQyNTNiMmJhOGVlYmI4M2VlOTVkL3RhYmxlcmFuZ2U6NmE3ZDEwNDk5OTdiNDI1M2IyYmE4ZWViYjgzZWU5NWRfMTAtOS0xLTEtMA_9e46a0bc-0e61-4669-b41c-1087df2f50bf"
      unitRef="usd">4050000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i9898566a542a49b4bf69010ae439ab9a_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN181OC9mcmFnOjI1NjFhMjhkNjFlNTRlMDBhYzE0ZDI2YWM3ODA3OTY2L3RhYmxlOjZhN2QxMDQ5OTk3YjQyNTNiMmJhOGVlYmI4M2VlOTVkL3RhYmxlcmFuZ2U6NmE3ZDEwNDk5OTdiNDI1M2IyYmE4ZWViYjgzZWU5NWRfMTAtMTEtMS0xLTA_de1c81df-380e-4dc1-97c6-700bc6f65dc3"
      unitRef="usd">3581250</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i9898566a542a49b4bf69010ae439ab9a_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN181OC9mcmFnOjI1NjFhMjhkNjFlNTRlMDBhYzE0ZDI2YWM3ODA3OTY2L3RhYmxlOjZhN2QxMDQ5OTk3YjQyNTNiMmJhOGVlYmI4M2VlOTVkL3RhYmxlcmFuZ2U6NmE3ZDEwNDk5OTdiNDI1M2IyYmE4ZWViYjgzZWU5NWRfMTAtMTMtMS0xLTA_81e5212f-fb78-4201-aaea-7046f3ea6003"
      unitRef="usd">468750</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i16a35fdf0e8348e0a1ede684610bae3e_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN181OC9mcmFnOjI1NjFhMjhkNjFlNTRlMDBhYzE0ZDI2YWM3ODA3OTY2L3RhYmxlOjZhN2QxMDQ5OTk3YjQyNTNiMmJhOGVlYmI4M2VlOTVkL3RhYmxlcmFuZ2U6NmE3ZDEwNDk5OTdiNDI1M2IyYmE4ZWViYjgzZWU5NWRfMTEtMS0xLTEtMA_6c42b062-8ad9-4ae1-a733-e191a44dbde2">P11Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="ic36b9cedad7f41a6b9eb223b09b7186c_I20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN181OC9mcmFnOjI1NjFhMjhkNjFlNTRlMDBhYzE0ZDI2YWM3ODA3OTY2L3RhYmxlOjZhN2QxMDQ5OTk3YjQyNTNiMmJhOGVlYmI4M2VlOTVkL3RhYmxlcmFuZ2U6NmE3ZDEwNDk5OTdiNDI1M2IyYmE4ZWViYjgzZWU5NWRfMTEtMy0xLTEtMA_a4ec42d0-edfc-4212-a33f-e9fd90ae74a5"
      unitRef="usd">10473761</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="ic36b9cedad7f41a6b9eb223b09b7186c_I20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN181OC9mcmFnOjI1NjFhMjhkNjFlNTRlMDBhYzE0ZDI2YWM3ODA3OTY2L3RhYmxlOjZhN2QxMDQ5OTk3YjQyNTNiMmJhOGVlYmI4M2VlOTVkL3RhYmxlcmFuZ2U6NmE3ZDEwNDk5OTdiNDI1M2IyYmE4ZWViYjgzZWU5NWRfMTEtNS0xLTEtMA_d2790499-f032-48ed-9bce-23bad1b5e5d0"
      unitRef="usd">7463761</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="ic36b9cedad7f41a6b9eb223b09b7186c_I20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN181OC9mcmFnOjI1NjFhMjhkNjFlNTRlMDBhYzE0ZDI2YWM3ODA3OTY2L3RhYmxlOjZhN2QxMDQ5OTk3YjQyNTNiMmJhOGVlYmI4M2VlOTVkL3RhYmxlcmFuZ2U6NmE3ZDEwNDk5OTdiNDI1M2IyYmE4ZWViYjgzZWU5NWRfMTEtNy0xLTEtMA_96d8a06c-7b1d-411a-87fb-11ae758b1309"
      unitRef="usd">3010000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i066bb5b0a9e84c0a878b1e800703d92b_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN181OC9mcmFnOjI1NjFhMjhkNjFlNTRlMDBhYzE0ZDI2YWM3ODA3OTY2L3RhYmxlOjZhN2QxMDQ5OTk3YjQyNTNiMmJhOGVlYmI4M2VlOTVkL3RhYmxlcmFuZ2U6NmE3ZDEwNDk5OTdiNDI1M2IyYmE4ZWViYjgzZWU5NWRfMTEtOS0xLTEtMA_88693b7b-9eb0-4249-babb-43bc3bad9723"
      unitRef="usd">10473761</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i066bb5b0a9e84c0a878b1e800703d92b_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN181OC9mcmFnOjI1NjFhMjhkNjFlNTRlMDBhYzE0ZDI2YWM3ODA3OTY2L3RhYmxlOjZhN2QxMDQ5OTk3YjQyNTNiMmJhOGVlYmI4M2VlOTVkL3RhYmxlcmFuZ2U6NmE3ZDEwNDk5OTdiNDI1M2IyYmE4ZWViYjgzZWU5NWRfMTEtMTEtMS0xLTA_d275a010-5ee2-45be-b658-bf5165d19a6b"
      unitRef="usd">7326991</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i066bb5b0a9e84c0a878b1e800703d92b_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN181OC9mcmFnOjI1NjFhMjhkNjFlNTRlMDBhYzE0ZDI2YWM3ODA3OTY2L3RhYmxlOjZhN2QxMDQ5OTk3YjQyNTNiMmJhOGVlYmI4M2VlOTVkL3RhYmxlcmFuZ2U6NmE3ZDEwNDk5OTdiNDI1M2IyYmE4ZWViYjgzZWU5NWRfMTEtMTMtMS0xLTA_bab3d57f-c94d-4f3c-8a6e-94cd79e8892a"
      unitRef="usd">3146770</us-gaap:FiniteLivedIntangibleAssetsNet>
    <ino:GoodwillAndIntangibleAssetsGross
      contextRef="ic36b9cedad7f41a6b9eb223b09b7186c_I20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN181OC9mcmFnOjI1NjFhMjhkNjFlNTRlMDBhYzE0ZDI2YWM3ODA3OTY2L3RhYmxlOjZhN2QxMDQ5OTk3YjQyNTNiMmJhOGVlYmI4M2VlOTVkL3RhYmxlcmFuZ2U6NmE3ZDEwNDk5OTdiNDI1M2IyYmE4ZWViYjgzZWU5NWRfMTItMy0xLTEtMA_027ce404-c292-474c-8598-ae91eb4a98fd"
      unitRef="usd">20987132</ino:GoodwillAndIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="ic36b9cedad7f41a6b9eb223b09b7186c_I20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN181OC9mcmFnOjI1NjFhMjhkNjFlNTRlMDBhYzE0ZDI2YWM3ODA3OTY2L3RhYmxlOjZhN2QxMDQ5OTk3YjQyNTNiMmJhOGVlYmI4M2VlOTVkL3RhYmxlcmFuZ2U6NmE3ZDEwNDk5OTdiNDI1M2IyYmE4ZWViYjgzZWU5NWRfMTItNS0xLTEtMA_dd0ede93-22f0-4330-8020-ff2d0521a691"
      unitRef="usd">7463761</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <ino:GoodwillAndIntangibleAssetsNet
      contextRef="ic36b9cedad7f41a6b9eb223b09b7186c_I20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN181OC9mcmFnOjI1NjFhMjhkNjFlNTRlMDBhYzE0ZDI2YWM3ODA3OTY2L3RhYmxlOjZhN2QxMDQ5OTk3YjQyNTNiMmJhOGVlYmI4M2VlOTVkL3RhYmxlcmFuZ2U6NmE3ZDEwNDk5OTdiNDI1M2IyYmE4ZWViYjgzZWU5NWRfMTItNy0xLTEtMA_7cd9285a-7ceb-4160-a451-95b369b93e07"
      unitRef="usd">13523371</ino:GoodwillAndIntangibleAssetsNet>
    <ino:GoodwillAndIntangibleAssetsGross
      contextRef="i066bb5b0a9e84c0a878b1e800703d92b_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN181OC9mcmFnOjI1NjFhMjhkNjFlNTRlMDBhYzE0ZDI2YWM3ODA3OTY2L3RhYmxlOjZhN2QxMDQ5OTk3YjQyNTNiMmJhOGVlYmI4M2VlOTVkL3RhYmxlcmFuZ2U6NmE3ZDEwNDk5OTdiNDI1M2IyYmE4ZWViYjgzZWU5NWRfMTItOS0xLTEtMA_1124b1eb-18fb-4e8f-8007-eb0c41ac3b2f"
      unitRef="usd">20987132</ino:GoodwillAndIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i066bb5b0a9e84c0a878b1e800703d92b_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN181OC9mcmFnOjI1NjFhMjhkNjFlNTRlMDBhYzE0ZDI2YWM3ODA3OTY2L3RhYmxlOjZhN2QxMDQ5OTk3YjQyNTNiMmJhOGVlYmI4M2VlOTVkL3RhYmxlcmFuZ2U6NmE3ZDEwNDk5OTdiNDI1M2IyYmE4ZWViYjgzZWU5NWRfMTItMTEtMS0xLTA_8aff7276-3f1d-4c7d-a5df-56d080cd0865"
      unitRef="usd">7326991</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <ino:GoodwillAndIntangibleAssetsNet
      contextRef="i066bb5b0a9e84c0a878b1e800703d92b_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN181OC9mcmFnOjI1NjFhMjhkNjFlNTRlMDBhYzE0ZDI2YWM3ODA3OTY2L3RhYmxlOjZhN2QxMDQ5OTk3YjQyNTNiMmJhOGVlYmI4M2VlOTVkL3RhYmxlcmFuZ2U6NmE3ZDEwNDk5OTdiNDI1M2IyYmE4ZWViYjgzZWU5NWRfMTItMTMtMS0xLTA_f8a1124b-93e5-4196-aa8f-574ecbd8580e"
      unitRef="usd">13660141</ino:GoodwillAndIntangibleAssetsNet>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN181OC9mcmFnOjI1NjFhMjhkNjFlNTRlMDBhYzE0ZDI2YWM3ODA3OTY2L3RleHRyZWdpb246MjU2MWEyOGQ2MWU1NGUwMGFjMTRkMjZhYzc4MDc5NjZfNjcx_0dbfb1dd-42b4-47b1-84fa-5e9c7f3208a3"
      unitRef="usd">137000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i03bccaa0abfb4733b1e2831ecde4e4e8_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN181OC9mcmFnOjI1NjFhMjhkNjFlNTRlMDBhYzE0ZDI2YWM3ODA3OTY2L3RleHRyZWdpb246MjU2MWEyOGQ2MWU1NGUwMGFjMTRkMjZhYzc4MDc5NjZfNjcx_ad109319-9a0d-40a4-8b96-1d0e48870c3f"
      unitRef="usd">137000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear
      contextRef="ic36b9cedad7f41a6b9eb223b09b7186c_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN181OC9mcmFnOjI1NjFhMjhkNjFlNTRlMDBhYzE0ZDI2YWM3ODA3OTY2L3RleHRyZWdpb246MjU2MWEyOGQ2MWU1NGUwMGFjMTRkMjZhYzc4MDc5NjZfODMz_8b4897c3-e15f-4b7f-8921-a0a6f59c032f"
      unitRef="usd">384000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
      contextRef="ic36b9cedad7f41a6b9eb223b09b7186c_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN181OC9mcmFnOjI1NjFhMjhkNjFlNTRlMDBhYzE0ZDI2YWM3ODA3OTY2L3RleHRyZWdpb246MjU2MWEyOGQ2MWU1NGUwMGFjMTRkMjZhYzc4MDc5NjZfODcz_155ca0b9-e1ad-4a5f-8dcd-3e1524864a41"
      unitRef="usd">493000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
      contextRef="ic36b9cedad7f41a6b9eb223b09b7186c_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN181OC9mcmFnOjI1NjFhMjhkNjFlNTRlMDBhYzE0ZDI2YWM3ODA3OTY2L3RleHRyZWdpb246MjU2MWEyOGQ2MWU1NGUwMGFjMTRkMjZhYzc4MDc5NjZfODg1_c7d6664a-7e02-49c5-ba50-bd3e9897f873"
      unitRef="usd">276000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
      contextRef="ic36b9cedad7f41a6b9eb223b09b7186c_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN181OC9mcmFnOjI1NjFhMjhkNjFlNTRlMDBhYzE0ZDI2YWM3ODA3OTY2L3RleHRyZWdpb246MjU2MWEyOGQ2MWU1NGUwMGFjMTRkMjZhYzc4MDc5NjZfODk3_037a3970-4123-442f-83a2-cbb5ff175112"
      unitRef="usd">253000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
      contextRef="ic36b9cedad7f41a6b9eb223b09b7186c_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN181OC9mcmFnOjI1NjFhMjhkNjFlNTRlMDBhYzE0ZDI2YWM3ODA3OTY2L3RleHRyZWdpb246MjU2MWEyOGQ2MWU1NGUwMGFjMTRkMjZhYzc4MDc5NjZfOTA5_32037b38-f268-4864-be4e-11afa7f78435"
      unitRef="usd">253000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
    <ino:FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour
      contextRef="ic36b9cedad7f41a6b9eb223b09b7186c_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN181OC9mcmFnOjI1NjFhMjhkNjFlNTRlMDBhYzE0ZDI2YWM3ODA3OTY2L3RleHRyZWdpb246MjU2MWEyOGQ2MWU1NGUwMGFjMTRkMjZhYzc4MDc5NjZfOTI0_9d79a5ff-defa-4bc5-98b1-20f1113bf36e"
      unitRef="usd">1400000</ino:FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour>
    <us-gaap:DebtDisclosureTextBlock
      contextRef="i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN182MS9mcmFnOmQ0ODcwNjAzNDk5MTQ0YTNhOThhZjIwMGM2ODZjM2FlL3RleHRyZWdpb246ZDQ4NzA2MDM0OTkxNDRhM2E5OGFmMjAwYzY4NmMzYWVfMTU4ODE_cfbb5a74-c531-4477-a87e-fecd9a957683">Convertible Debt&lt;div style="margin-bottom:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Convertible Senior Notes &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On February 19, 2019 and March 1, 2019, the Company completed a private placement of $78.5 million aggregate principal amount of its 6.50% convertible senior notes due 2024 (the &#x201c;Notes&#x201d;). The Notes were sold in a private offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended. Net proceeds from the offering were approximately $75.7 million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Notes are senior unsecured obligations of the Company and accrue interest payable in cash semi-annually in arrears on March 1 and September 1 of each year, beginning on September 1, 2019, at a rate of 6.50% per annum. The Notes will mature on March 1, 2024, unless earlier converted, redeemed or repurchased.&#160;Prior to the close of business on the business day immediately preceding November 1, 2023, the Notes will be convertible at the option of the holders only upon the satisfaction of certain circumstances. Thereafter, the Notes will be convertible at the option of the holders at any time until the close of business on the scheduled trading day immediately before the maturity date. Upon conversion, the Company will pay or deliver, as the case may be, cash, shares of its common stock or a combination of cash and shares of its common stock, at its election. The initial conversion rate will be 185.8045 shares per $1,000 principal amount of Notes (equivalent to an initial conversion price of approximately $5.38 per share), subject to adjustment upon the occurrence of specified events.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company may not redeem the Notes prior to March 1, 2022. On or after March 1, 2022, the Company may redeem all, or any portion, of the Notes for cash if the last reported sale price per share of the Company's common stock exceeds 130% of the conversion price on (i) each of at least 20 trading days (whether or not consecutive) during the 30 consecutive trading days ending on, and including, the trading day immediately before the Company sends the related redemption notice; and (ii) the trading day immediately before the date the Company sends such redemption notice.&#160;The redemption price will be equal to 100% of the principal amount of the Notes to be redeemed, plus accrued and unpaid interest to, but excluding, the redemption date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company evaluated the accounting for the issuance of the Notes and concluded that the embedded conversion features meet the requirements for a derivative scope exception for instruments that are both indexed to an entity&#x2019;s own stock and classified in stockholders&#x2019; equity in its condensed consolidated balance sheet, and that the cash conversion guidance applies. Therefore, the Notes issuance proceeds of $78.5 million are allocated first to the liability component based on the fair &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;value of non-convertible debt with otherwise identical residual terms with the residual proceeds allocated to equity for the conversion featu&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;res. The Company determined that the fair value of the non-convertible debt upon issuance of the Notes was $62.2 million and recorded this amount as a liability and the offsetting amount as a debt discount as a reduction to the carrying value of the Notes on the closing date. The debt issuance costs associated with the Notes of $2.8 million are allocated to the liability and equity component in the same proportion as the issuance proceeds. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company determined that all other features of the Notes were clearly and closely associated with a debt host and did not require bifurcation as a derivative liability, or the fair value of the feature was immaterial to the Company's condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company determined that the expected life of the Notes was equal to the period through November 1, 2023 as this represents the point at which the Notes are initially subject to repurchase by the Company at the option of the holders. Accordingly, the total debt discount of $18.6 million, inclusive of the fair value of the embedded conversion feature derivative at issuance, is being amortized using the effective interest method through November 1, 2023.&#160;The effective interest rate of the liability component is 13.1%. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;During the year ended December 31, 2020, the Company received notices for the conversion of $62.1&#160;million of principal amount of the Notes, which were settled for&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; an aggregate of 11,535,660 shares of the Company's common stock&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;. The fair value of the Notes at the date of conversion was $43.7&#160;million compared to the carrying value of $52.5&#160;million, resulting in a $8.8 million gain on extinguishment of debt. This gain was recorded in the condensed consolidated statement of operations. To measure the fair value of the converted Notes as of the conversion dates, the Company engaged a third-party valuation expert and utilized a binomial lattice model.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The balance of the Notes at March&#160;31, 2021 is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:10pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:69.617%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:28.183%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Original principal amount&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78,500,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Principal amount converted into common shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(62,085,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unamortized debt discount on the liability component&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,139,698)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unamortized debt issuance cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(294,495)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;88,915&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Net carrying amount &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,069,722&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the three months ended March 31, 2021 and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2020&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;,&#160;the Company recognized $463,000 and $2.1 million, respectively, of interest expense related to the Notes, of which $267,000 and $1.3 million, respectively, related to the contractual interest coupon.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March&#160;31, 2021, future minimum payments due under the Notes, representing contractual amounts due, including interest based on the fixed rate of 6.5% per annum, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:10pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:85.742%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.328%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Remainder of 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;534,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,067,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,067,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,948,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,616,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;padding-left:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;August 2019 Convertible Bonds&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On August 1, 2019, the Company closed a private placem&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ent of the August 2019 Bonds with an aggregate principal amount of 18 billion Korean Won (KRW) (approximately USD $15.0 million based on the exchange rate on the date of issuance) issued to institutional investors led by Korea Investment Partners (KIP), a global venture capital and private equity firm based in Seoul, Korea. Net proceeds from the offering were approximately $14.5 million. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The August 2019 Bonds, which were unsecured obligations of the Company, were issued on August 1, 2019 and accrued interest at a coupon rate of 1.00% per annum, payable quarterly. The August 2019 Bonds were scheduled to mature on July 31, 2024, unless earlier converted or repurchased. On August 3, 2020 the August 2019 Bonds were converted in full into an aggregate of 4,962,364 shares of the Company's common stock, leaving no further August 2019 Bonds outstanding. The initial conversion rate was 211.0595 shares per KRW1,000,000 in principal amount (equivalent to an initial conversion price of approximately USD $4.00 per share based on the exchange rate as of July 30, 2019), subject to adjustment upon the occurrence of specified events. The conversion rate was reset on January 2, 2020 and was subject to reset quarterly thereafter if the current &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;market price was lower than the conversion price then in effect. The conversion rate as of the date of conversion on August 1, 2020 was 275.6873 shares per KRW 1,000,000 in principal amount (equivalent to a conversion price of approximately USD $3.14 per share).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company evaluated the accounting for the issuance of the August 2019 Bonds and concluded that the embedded conversion feature was considered a derivative requiring bifurcation from the August 2019 Bonds as it did not meet the equity scope exception due to the fact that it was denominated in a currency other than the Company's functional currency. The fair value of the conversion feature at August 1, 2019 was $7.1 million, which was recorded as a reduction to the carrying value of the debt. This debt discount was being amortized to&#160;interest expense over the term of the debt using the effective interest method. The conversion option was accounted for as a derivative liability, which was revalued each reporting period with&#160;the resulting change in fair value reflected in other income (expense), net, in the condensed consolidated&#160;statements of operations.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company determined that all other features of the August 2019 Bonds were clearly and closely associated with a debt host and did not require bifurcation as a derivative liability, or the fair value of the feature was immaterial to the Company's condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At their issuance, the Company determined that the expected life of the August 2019 Bonds was equal to the period through August 1, 2022 as this represented the point at which the August 2019 Bonds were initially subject to repurchase by the Company at the option of the holders. Accordingly, the total debt discount of $7.3 million, inclusive of the fair value of the embedded conversion feature derivative at issuance, was being amortized using the effective interest method through August 1, 2022&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. For the three months ended March 31, 2020, the Company recognized $641,000 of interest expense related to the August 2019 Bonds, of which $38,000 related to the contractual interest coupon.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Immediately prior to the August 2020 conversion, the derivative liability associated with the August 2019 Bonds was revalued at $84.5 million. The change in fair value of the derivative liability was an increase of $75.7 million, which was recorded on the consolidated statement of operations for the year ended December 31, 2020. To measure the fair value of the derivative liability as of the conversion date, the Company engaged a third-party valuation expert.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Upon conversion, a loss on extinguishment of $8.2&#160;million was recorded on the consolidated statement of operations for the year ended December 31, 2020. This loss represents the difference between (a) the calculated fair value of the derivative liability immediately prior to its derecognition plus the carrying amount of the debt component including any unamortized debt discount and issuance costs and (b) the fair value of the 4,692,364 shares of the Company's common stock issued upon conversion.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;December 2019 Convertible Bonds &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On December&#160;26, 2019, the Company closed a private placement of convertible promissory notes (the &#x201c;December 2019 Bonds&#x201d;) with an aggregate principal amount of 4.7 billion KRW (approximately USD $4.1 million based on the exchange rate on the date of issuance) issued to a Korea-based institutional investor. Net proceeds from the offering were approximately $4.0 million.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The December 2019 Bonds, which were unsecured obligations of the Company, were issued on December&#160;31, 2019 and accrued interest at a coupon rate of 1.00% per annum, payable quarterly. The December 2019 Bonds were scheduled to mature on December&#160;31, 2024, unless earlier converted or repurchased. On March 17, 2021, the December 2019 Bonds were converted in full into an aggregate of 1,009,450 shares of the Company's common stock, leaving no further December 2019 Bonds outstanding. The initial conversion rate was 214.7766 shares per KRW1,000,000 principal amount of Bonds (equivalent to an initial conversion price of approximately USD $4.00 per share based on the exchange rate as of December&#160;19, 2019), subject to adjustment upon the occurrence of certain events. As of the conversion date of March 17, 2021, the conversion rate had not been reset from the initial conversion rate.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company evaluated the accounting for the issuance of the December 2019 Bonds and concluded that the embedded conversion feature does not require bifurcation from the December 2019 Bonds. Although the embedded conversion feature meets the definition of a derivative, it qualifies for the equity scope exception for instruments that are both indexed to an entity&#x2019;s own stock and classified in stockholders&#x2019; equity in its consolidated balance sheet. The December 2019 Bonds were denominated in a foreign currency other than the Company&#x2019;s functional currency, which would typically violate the settlement provision criteria when analyzing whether the conversion option is indexed to an entity&#x2019;s own stock. However, per the terms of the agreement, the functional currency rate required to be used in a conversion scenario was fixed as of the date preceding the date of issuance of the Bonds. Therefore, the fluctuation in functional currency did not impact the settlement of the conversion option. Further, as there was no cash conversion feature or beneficial conversion feature on the date of issuance, and the Bonds were not issued at a substantial premium, all of the proceeds were recorded as a liability. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company determined that all other features of the December 2019 Bonds were clearly and closely associated with a debt host and did not require bifurcation as a derivative liability, or the fair value of the feature was immaterial to the Company's condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At their issuance, the Company determined that the expected life of the December 2019 Bonds was equal to the period through December 31, 2022 as this represented the point at which the December 2019 Bonds were initially subject to repurchase by the Company at the option of the holders. The effective interest rate of the December 2019 Bonds was 6.2%&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. For the three months ended March 31, 2021 and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2020&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;,&#160;the Company recognized $59,000 and $62,000, respectively, of interest expense related to the December 2019 Bonds, of which $9,000 and $10,000, respectively, related to the contractual interest coupon.&lt;/span&gt; As of March&#160;31, 2021, all outstanding December 2019 Bonds were converted into 1,009,450 shares of the Company's common stock. Upon conversion, the $4.4&#160;million carrying value of the December 2019 Bonds was recorded to stockholders' equity.</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="iff75d456dbf843feb55dc8e27df1e4c3_I20190301"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN182MS9mcmFnOmQ0ODcwNjAzNDk5MTQ0YTNhOThhZjIwMGM2ODZjM2FlL3RleHRyZWdpb246ZDQ4NzA2MDM0OTkxNDRhM2E5OGFmMjAwYzY4NmMzYWVfMTM2_51dbddae-93c7-49a1-a168-8e8d519a7341"
      unitRef="usd">78500000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="iff75d456dbf843feb55dc8e27df1e4c3_I20190301"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN182MS9mcmFnOmQ0ODcwNjAzNDk5MTQ0YTNhOThhZjIwMGM2ODZjM2FlL3RleHRyZWdpb246ZDQ4NzA2MDM0OTkxNDRhM2E5OGFmMjAwYzY4NmMzYWVfMjE5OTAyMzI3NDY4Mg_b30c308f-2649-42a1-90de-857adde10cde"
      unitRef="number">0.0650</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="i50447e531b3c434fb8e3ede17ab45a89_D20190219-20190301"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN182MS9mcmFnOmQ0ODcwNjAzNDk5MTQ0YTNhOThhZjIwMGM2ODZjM2FlL3RleHRyZWdpb246ZDQ4NzA2MDM0OTkxNDRhM2E5OGFmMjAwYzY4NmMzYWVfMzMx_d76f8976-c93a-493a-aca4-8b6ff2daa3f9"
      unitRef="usd">75700000</us-gaap:ProceedsFromIssuanceOfDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="iff75d456dbf843feb55dc8e27df1e4c3_I20190301"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN182MS9mcmFnOmQ0ODcwNjAzNDk5MTQ0YTNhOThhZjIwMGM2ODZjM2FlL3RleHRyZWdpb246ZDQ4NzA2MDM0OTkxNDRhM2E5OGFmMjAwYzY4NmMzYWVfNTQw_657a9090-b39e-4fd5-ac29-84cfabcdcff0"
      unitRef="number">0.0650</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="iff75d456dbf843feb55dc8e27df1e4c3_I20190301"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN182MS9mcmFnOmQ0ODcwNjAzNDk5MTQ0YTNhOThhZjIwMGM2ODZjM2FlL3RleHRyZWdpb246ZDQ4NzA2MDM0OTkxNDRhM2E5OGFmMjAwYzY4NmMzYWVfMTM1Mg_4509fe42-e04d-42f7-8ef1-0bca1d1b1d7a"
      unitRef="usdPerShare">5.38</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger
      contextRef="i50447e531b3c434fb8e3ede17ab45a89_D20190219-20190301"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN182MS9mcmFnOmQ0ODcwNjAzNDk5MTQ0YTNhOThhZjIwMGM2ODZjM2FlL3RleHRyZWdpb246ZDQ4NzA2MDM0OTkxNDRhM2E5OGFmMjAwYzY4NmMzYWVfMTY2Ng_0b69674a-1c2a-4d0f-b1a5-2407981b9c24"
      unitRef="number">1.30</us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger>
    <us-gaap:DebtInstrumentConvertibleThresholdTradingDays
      contextRef="i50447e531b3c434fb8e3ede17ab45a89_D20190219-20190301"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN182MS9mcmFnOmQ0ODcwNjAzNDk5MTQ0YTNhOThhZjIwMGM2ODZjM2FlL3RleHRyZWdpb246ZDQ4NzA2MDM0OTkxNDRhM2E5OGFmMjAwYzY4NmMzYWVfMTcxNw_367541ee-7c21-445f-a308-bca35781e09b"
      unitRef="day">20</us-gaap:DebtInstrumentConvertibleThresholdTradingDays>
    <us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1
      contextRef="i50447e531b3c434fb8e3ede17ab45a89_D20190219-20190301"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN182MS9mcmFnOmQ0ODcwNjAzNDk5MTQ0YTNhOThhZjIwMGM2ODZjM2FlL3RleHRyZWdpb246ZDQ4NzA2MDM0OTkxNDRhM2E5OGFmMjAwYzY4NmMzYWVfMTc3Mw_749106ac-248e-45a4-a90a-850d6f1609c2"
      unitRef="day">30</us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1>
    <us-gaap:DebtInstrumentRedemptionPricePercentage
      contextRef="i50447e531b3c434fb8e3ede17ab45a89_D20190219-20190301"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN182MS9mcmFnOmQ0ODcwNjAzNDk5MTQ0YTNhOThhZjIwMGM2ODZjM2FlL3RleHRyZWdpb246ZDQ4NzA2MDM0OTkxNDRhM2E5OGFmMjAwYzY4NmMzYWVfMjA0NA_4fe4910b-0b3c-4230-9440-d646985d1e4a"
      unitRef="number">1</us-gaap:DebtInstrumentRedemptionPricePercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="iff75d456dbf843feb55dc8e27df1e4c3_I20190301"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN182MS9mcmFnOmQ0ODcwNjAzNDk5MTQ0YTNhOThhZjIwMGM2ODZjM2FlL3RleHRyZWdpb246ZDQ4NzA2MDM0OTkxNDRhM2E5OGFmMjAwYzY4NmMzYWVfMjU4Mw_8b183c79-2758-4106-b403-fcba67f44434"
      unitRef="usd">78500000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent
      contextRef="iff75d456dbf843feb55dc8e27df1e4c3_I20190301"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN182MS9mcmFnOmQ0ODcwNjAzNDk5MTQ0YTNhOThhZjIwMGM2ODZjM2FlL3RleHRyZWdpb246ZDQ4NzA2MDM0OTkxNDRhM2E5OGFmMjAwYzY4NmMzYWVfMjg5OQ_8df0a64d-241e-4242-93ba-efcb0a4e344b"
      unitRef="usd">62200000</us-gaap:DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent>
    <us-gaap:DeferredFinanceCostsNet
      contextRef="iff75d456dbf843feb55dc8e27df1e4c3_I20190301"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN182MS9mcmFnOmQ0ODcwNjAzNDk5MTQ0YTNhOThhZjIwMGM2ODZjM2FlL3RleHRyZWdpb246ZDQ4NzA2MDM0OTkxNDRhM2E5OGFmMjAwYzY4NmMzYWVfMzExMQ_ff88efd4-ddb5-4a34-aba0-0c66d4905a06"
      unitRef="usd">2800000</us-gaap:DeferredFinanceCostsNet>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="iff75d456dbf843feb55dc8e27df1e4c3_I20190301"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN182MS9mcmFnOmQ0ODcwNjAzNDk5MTQ0YTNhOThhZjIwMGM2ODZjM2FlL3RleHRyZWdpb246ZDQ4NzA2MDM0OTkxNDRhM2E5OGFmMjAwYzY4NmMzYWVfMzc3NQ_c048deb3-abef-491a-b6a5-1104241645b8"
      unitRef="usd">18600000</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="i334e05b1c2d349408f504085686e16e6_I20210331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN182MS9mcmFnOmQ0ODcwNjAzNDk5MTQ0YTNhOThhZjIwMGM2ODZjM2FlL3RleHRyZWdpb246ZDQ4NzA2MDM0OTkxNDRhM2E5OGFmMjAwYzY4NmMzYWVfNDAwNQ_18886e67-d486-4d71-9ec1-263ce2049976"
      unitRef="number">0.131</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtConversionConvertedInstrumentAmount1
      contextRef="ibaba303f793542bd8caae6689d64fb35_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN182MS9mcmFnOmQ0ODcwNjAzNDk5MTQ0YTNhOThhZjIwMGM2ODZjM2FlL3RleHRyZWdpb246ZDQ4NzA2MDM0OTkxNDRhM2E5OGFmMjAwYzY4NmMzYWVfNDA3NQ_88d9733a-6f57-4680-9482-2b0546e77c2b"
      unitRef="usd">62100000</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <us-gaap:DebtConversionConvertedInstrumentSharesIssued1
      contextRef="ibaba303f793542bd8caae6689d64fb35_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN182MS9mcmFnOmQ0ODcwNjAzNDk5MTQ0YTNhOThhZjIwMGM2ODZjM2FlL3RleHRyZWdpb246ZDQ4NzA2MDM0OTkxNDRhM2E5OGFmMjAwYzY4NmMzYWVfNDE2NQ_ec248693-80cb-42af-8a62-f27c74535b3e"
      unitRef="shares">11535660</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
    <us-gaap:DebtInstrumentFairValue
      contextRef="ida7e6795aad44fb38ae767d0d07173d2_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN182MS9mcmFnOmQ0ODcwNjAzNDk5MTQ0YTNhOThhZjIwMGM2ODZjM2FlL3RleHRyZWdpb246ZDQ4NzA2MDM0OTkxNDRhM2E5OGFmMjAwYzY4NmMzYWVfNDI2NA_f96d2e9c-62ba-42d1-8025-83600b2a0b8f"
      unitRef="usd">43700000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent
      contextRef="ida7e6795aad44fb38ae767d0d07173d2_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN182MS9mcmFnOmQ0ODcwNjAzNDk5MTQ0YTNhOThhZjIwMGM2ODZjM2FlL3RleHRyZWdpb246ZDQ4NzA2MDM0OTkxNDRhM2E5OGFmMjAwYzY4NmMzYWVfNDMwMQ_0867e707-ad70-454f-a86a-bff839a32829"
      unitRef="usd">52500000</us-gaap:DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="ibaba303f793542bd8caae6689d64fb35_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN182MS9mcmFnOmQ0ODcwNjAzNDk5MTQ0YTNhOThhZjIwMGM2ODZjM2FlL3RleHRyZWdpb246ZDQ4NzA2MDM0OTkxNDRhM2E5OGFmMjAwYzY4NmMzYWVfNDMyMA_5374bd15-a2e2-4874-b7aa-526afc769ecc"
      unitRef="usd">8800000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:ConvertibleDebtTableTextBlock
      contextRef="i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN182MS9mcmFnOmQ0ODcwNjAzNDk5MTQ0YTNhOThhZjIwMGM2ODZjM2FlL3RleHRyZWdpb246ZDQ4NzA2MDM0OTkxNDRhM2E5OGFmMjAwYzY4NmMzYWVfMTU4ODk_5f1dfe80-322a-4111-8e62-44a38da3ba2a">&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The balance of the Notes at March&#160;31, 2021 is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:10pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:69.617%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:28.183%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Original principal amount&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78,500,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Principal amount converted into common shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(62,085,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unamortized debt discount on the liability component&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,139,698)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unamortized debt issuance cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(294,495)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;88,915&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Net carrying amount &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,069,722&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ConvertibleDebtTableTextBlock>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="ibf1dda891fd044098c213cc6a530fa62_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN182MS9mcmFnOmQ0ODcwNjAzNDk5MTQ0YTNhOThhZjIwMGM2ODZjM2FlL3RhYmxlOjAzNTA3YjU4ZGU5ODQ5YmE5NzhiMDg1ZmQwZWE0NzU1L3RhYmxlcmFuZ2U6MDM1MDdiNThkZTk4NDliYTk3OGIwODVmZDBlYTQ3NTVfMC0xLTEtMS0w_ca5f838b-8e50-4504-a2d1-1764fb0f00e6"
      unitRef="usd">78500000</us-gaap:DebtInstrumentFaceAmount>
    <ino:DebtInstrumentConvertibleDebtConvertedAmount
      contextRef="ibf1dda891fd044098c213cc6a530fa62_I20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN182MS9mcmFnOmQ0ODcwNjAzNDk5MTQ0YTNhOThhZjIwMGM2ODZjM2FlL3RhYmxlOjAzNTA3YjU4ZGU5ODQ5YmE5NzhiMDg1ZmQwZWE0NzU1L3RhYmxlcmFuZ2U6MDM1MDdiNThkZTk4NDliYTk3OGIwODVmZDBlYTQ3NTVfMS0xLTEtMS0w_a7550380-ea68-4c70-a4fe-c16ad455efaf"
      unitRef="usd">62085000</ino:DebtInstrumentConvertibleDebtConvertedAmount>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="ibf1dda891fd044098c213cc6a530fa62_I20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN182MS9mcmFnOmQ0ODcwNjAzNDk5MTQ0YTNhOThhZjIwMGM2ODZjM2FlL3RhYmxlOjAzNTA3YjU4ZGU5ODQ5YmE5NzhiMDg1ZmQwZWE0NzU1L3RhYmxlcmFuZ2U6MDM1MDdiNThkZTk4NDliYTk3OGIwODVmZDBlYTQ3NTVfMi0xLTEtMS0w_f5b67f53-244e-4fc1-b8a5-5d6f734be01d"
      unitRef="usd">2139698</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:DeferredFinanceCostsNet
      contextRef="ibf1dda891fd044098c213cc6a530fa62_I20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN182MS9mcmFnOmQ0ODcwNjAzNDk5MTQ0YTNhOThhZjIwMGM2ODZjM2FlL3RhYmxlOjAzNTA3YjU4ZGU5ODQ5YmE5NzhiMDg1ZmQwZWE0NzU1L3RhYmxlcmFuZ2U6MDM1MDdiNThkZTk4NDliYTk3OGIwODVmZDBlYTQ3NTVfMy0xLTEtMS0w_bf4ccfe9-fb08-4879-afb0-93a98959203f"
      unitRef="usd">294495</us-gaap:DeferredFinanceCostsNet>
    <ino:DebtInstrumentAccruedInterest
      contextRef="ibf1dda891fd044098c213cc6a530fa62_I20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN182MS9mcmFnOmQ0ODcwNjAzNDk5MTQ0YTNhOThhZjIwMGM2ODZjM2FlL3RhYmxlOjAzNTA3YjU4ZGU5ODQ5YmE5NzhiMDg1ZmQwZWE0NzU1L3RhYmxlcmFuZ2U6MDM1MDdiNThkZTk4NDliYTk3OGIwODVmZDBlYTQ3NTVfNC0xLTEtMS0w_1b0ec873-2801-4d12-ad61-0060b02783dc"
      unitRef="usd">88915</ino:DebtInstrumentAccruedInterest>
    <us-gaap:LongTermDebt
      contextRef="ibf1dda891fd044098c213cc6a530fa62_I20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN182MS9mcmFnOmQ0ODcwNjAzNDk5MTQ0YTNhOThhZjIwMGM2ODZjM2FlL3RhYmxlOjAzNTA3YjU4ZGU5ODQ5YmE5NzhiMDg1ZmQwZWE0NzU1L3RhYmxlcmFuZ2U6MDM1MDdiNThkZTk4NDliYTk3OGIwODVmZDBlYTQ3NTVfNS0xLTEtMS0w_b6f67642-e36a-40b5-97c9-0a885df2a7ae"
      unitRef="usd">14069722</us-gaap:LongTermDebt>
    <us-gaap:InterestExpense
      contextRef="icdb93151b4be464b9f1281340d4933cc_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN182MS9mcmFnOmQ0ODcwNjAzNDk5MTQ0YTNhOThhZjIwMGM2ODZjM2FlL3RleHRyZWdpb246ZDQ4NzA2MDM0OTkxNDRhM2E5OGFmMjAwYzY4NmMzYWVfNDY4NQ_790f59d8-b645-4d8e-8e06-883fd6f5019a"
      unitRef="usd">463000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i105fc1ec677d41beb16a21a24c107e45_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN182MS9mcmFnOmQ0ODcwNjAzNDk5MTQ0YTNhOThhZjIwMGM2ODZjM2FlL3RleHRyZWdpb246ZDQ4NzA2MDM0OTkxNDRhM2E5OGFmMjAwYzY4NmMzYWVfNDY5Mg_5ac2d6b3-9f77-4ca1-95ab-66c6e5159cc4"
      unitRef="usd">2100000</us-gaap:InterestExpense>
    <us-gaap:InterestExpenseDebt
      contextRef="icdb93151b4be464b9f1281340d4933cc_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN182MS9mcmFnOmQ0ODcwNjAzNDk5MTQ0YTNhOThhZjIwMGM2ODZjM2FlL3RleHRyZWdpb246ZDQ4NzA2MDM0OTkxNDRhM2E5OGFmMjAwYzY4NmMzYWVfNDc2MQ_6be75159-cfa3-491a-857c-3201ea09360e"
      unitRef="usd">267000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="i105fc1ec677d41beb16a21a24c107e45_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN182MS9mcmFnOmQ0ODcwNjAzNDk5MTQ0YTNhOThhZjIwMGM2ODZjM2FlL3RleHRyZWdpb246ZDQ4NzA2MDM0OTkxNDRhM2E5OGFmMjAwYzY4NmMzYWVfNDc2OA_f9f60eef-6c15-4c3b-bf87-aa27957f8ad3"
      unitRef="usd">1300000</us-gaap:InterestExpenseDebt>
    <us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock
      contextRef="i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN182MS9mcmFnOmQ0ODcwNjAzNDk5MTQ0YTNhOThhZjIwMGM2ODZjM2FlL3RleHRyZWdpb246ZDQ4NzA2MDM0OTkxNDRhM2E5OGFmMjAwYzY4NmMzYWVfMzI5ODUzNDkxMjI2MA_878e1f86-97ac-4fd0-b7c0-bbf19dee6e49">&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March&#160;31, 2021, future minimum payments due under the Notes, representing contractual amounts due, including interest based on the fixed rate of 6.5% per annum, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:10pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:85.742%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.328%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Remainder of 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;534,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,067,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,067,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,948,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,616,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i334e05b1c2d349408f504085686e16e6_I20210331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN182MS9mcmFnOmQ0ODcwNjAzNDk5MTQ0YTNhOThhZjIwMGM2ODZjM2FlL3RleHRyZWdpb246ZDQ4NzA2MDM0OTkxNDRhM2E5OGFmMjAwYzY4NmMzYWVfMzI5ODUzNDkxMjI1NQ_99dc7d24-af10-4c3d-a9d4-3101a391676e"
      unitRef="number">0.065</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear
      contextRef="i334e05b1c2d349408f504085686e16e6_I20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN182MS9mcmFnOmQ0ODcwNjAzNDk5MTQ0YTNhOThhZjIwMGM2ODZjM2FlL3RhYmxlOjVhYzU2YTc5ZDk2NzRhY2Y5ZTdkZWRiZWVmZWQxNDcxL3RhYmxlcmFuZ2U6NWFjNTZhNzlkOTY3NGFjZjllN2RlZGJlZWZlZDE0NzFfMi0yLTEtMS0zODk3_701c6978-520d-476f-83da-5236ce589ba9"
      unitRef="usd">534000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
      contextRef="i334e05b1c2d349408f504085686e16e6_I20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN182MS9mcmFnOmQ0ODcwNjAzNDk5MTQ0YTNhOThhZjIwMGM2ODZjM2FlL3RhYmxlOjVhYzU2YTc5ZDk2NzRhY2Y5ZTdkZWRiZWVmZWQxNDcxL3RhYmxlcmFuZ2U6NWFjNTZhNzlkOTY3NGFjZjllN2RlZGJlZWZlZDE0NzFfMy0yLTEtMS0zODk3_d187a090-87dc-4124-8188-cec169000829"
      unitRef="usd">1067000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
      contextRef="i334e05b1c2d349408f504085686e16e6_I20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN182MS9mcmFnOmQ0ODcwNjAzNDk5MTQ0YTNhOThhZjIwMGM2ODZjM2FlL3RhYmxlOjVhYzU2YTc5ZDk2NzRhY2Y5ZTdkZWRiZWVmZWQxNDcxL3RhYmxlcmFuZ2U6NWFjNTZhNzlkOTY3NGFjZjllN2RlZGJlZWZlZDE0NzFfNC0yLTEtMS0zODk3_23f2eeb6-e623-4521-8703-40fccb149aab"
      unitRef="usd">1067000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
      contextRef="i334e05b1c2d349408f504085686e16e6_I20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN182MS9mcmFnOmQ0ODcwNjAzNDk5MTQ0YTNhOThhZjIwMGM2ODZjM2FlL3RhYmxlOjVhYzU2YTc5ZDk2NzRhY2Y5ZTdkZWRiZWVmZWQxNDcxL3RhYmxlcmFuZ2U6NWFjNTZhNzlkOTY3NGFjZjllN2RlZGJlZWZlZDE0NzFfNS0yLTEtMS0zODk3_4e98c208-8b88-4a26-951e-4847497bfae2"
      unitRef="usd">16948000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree>
    <us-gaap:LongTermDebt
      contextRef="i334e05b1c2d349408f504085686e16e6_I20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN182MS9mcmFnOmQ0ODcwNjAzNDk5MTQ0YTNhOThhZjIwMGM2ODZjM2FlL3RhYmxlOjVhYzU2YTc5ZDk2NzRhY2Y5ZTdkZWRiZWVmZWQxNDcxL3RhYmxlcmFuZ2U6NWFjNTZhNzlkOTY3NGFjZjllN2RlZGJlZWZlZDE0NzFfNi0yLTEtMS00Mzgz_70b9d0e3-980e-4ef4-996d-9160f3ce93b5"
      unitRef="usd">19616000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i700b790825e646eaa141e79f67d14908_I20190801"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN182MS9mcmFnOmQ0ODcwNjAzNDk5MTQ0YTNhOThhZjIwMGM2ODZjM2FlL3RleHRyZWdpb246ZDQ4NzA2MDM0OTkxNDRhM2E5OGFmMjAwYzY4NmMzYWVfNTMzMw_0cd35b1c-d2cc-4331-956b-558aaf48e54e"
      unitRef="krw">18000000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i700b790825e646eaa141e79f67d14908_I20190801"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN182MS9mcmFnOmQ0ODcwNjAzNDk5MTQ0YTNhOThhZjIwMGM2ODZjM2FlL3RleHRyZWdpb246ZDQ4NzA2MDM0OTkxNDRhM2E5OGFmMjAwYzY4NmMzYWVfNTM1OQ_70dd5d16-3a12-4a51-86a1-91aa0703857c"
      unitRef="usd">15000000.0</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="ibbf41c9c4e33452d8cf96974a53ed0d2_D20190801-20190801"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN182MS9mcmFnOmQ0ODcwNjAzNDk5MTQ0YTNhOThhZjIwMGM2ODZjM2FlL3RleHRyZWdpb246ZDQ4NzA2MDM0OTkxNDRhM2E5OGFmMjAwYzY4NmMzYWVfNTYxMA_fd3fc873-c9d1-4b72-8e54-528028856d55"
      unitRef="usd">14500000</us-gaap:ProceedsFromIssuanceOfDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i700b790825e646eaa141e79f67d14908_I20190801"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN182MS9mcmFnOmQ0ODcwNjAzNDk5MTQ0YTNhOThhZjIwMGM2ODZjM2FlL3RleHRyZWdpb246ZDQ4NzA2MDM0OTkxNDRhM2E5OGFmMjAwYzY4NmMzYWVfNTkzNA_8d556462-b0f3-4d0f-a834-03603a38c78c"
      unitRef="number">0.0100</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtConversionConvertedInstrumentSharesIssued1
      contextRef="i6b6ee21ba47743bcbf1e8f17210f4948_D20200803-20200803"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN182MS9mcmFnOmQ0ODcwNjAzNDk5MTQ0YTNhOThhZjIwMGM2ODZjM2FlL3RleHRyZWdpb246ZDQ4NzA2MDM0OTkxNDRhM2E5OGFmMjAwYzY4NmMzYWVfNjE1Nw_4ef7f676-00c4-45da-8dd7-085dea105616"
      unitRef="shares">4962364</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="ie81a2e682215493ab64bdb0c300f4bf3_I20200803"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN182MS9mcmFnOmQ0ODcwNjAzNDk5MTQ0YTNhOThhZjIwMGM2ODZjM2FlL3RleHRyZWdpb246ZDQ4NzA2MDM0OTkxNDRhM2E5OGFmMjAwYzY4NmMzYWVfNjM4NA_4065c985-0303-4be3-b1ee-bdfa5b022afe"
      unitRef="usdPerShare">4.00</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="i7871b982a7494885bca85b1422f54c5a_I20200803"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN182MS9mcmFnOmQ0ODcwNjAzNDk5MTQ0YTNhOThhZjIwMGM2ODZjM2FlL3RleHRyZWdpb246ZDQ4NzA2MDM0OTkxNDRhM2E5OGFmMjAwYzY4NmMzYWVfNjg2NA_78997f8e-0aab-4631-a64b-ad3d030399a1"
      unitRef="usdPerShare">3.14</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent
      contextRef="i700b790825e646eaa141e79f67d14908_I20190801"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN182MS9mcmFnOmQ0ODcwNjAzNDk5MTQ0YTNhOThhZjIwMGM2ODZjM2FlL3RleHRyZWdpb246ZDQ4NzA2MDM0OTkxNDRhM2E5OGFmMjAwYzY4NmMzYWVfNzM0Mw_951eb676-d0e6-44e0-ae05-509f3732b317"
      unitRef="usd">7100000</us-gaap:DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="i700b790825e646eaa141e79f67d14908_I20190801"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN182MS9mcmFnOmQ0ODcwNjAzNDk5MTQ0YTNhOThhZjIwMGM2ODZjM2FlL3RleHRyZWdpb246ZDQ4NzA2MDM0OTkxNDRhM2E5OGFmMjAwYzY4NmMzYWVfODQwMA_7535496a-9767-4b0b-b102-0c0d96380b09"
      unitRef="usd">7300000</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:InterestExpense
      contextRef="i1db0e391023844c58ee91836f1ff6032_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN182MS9mcmFnOmQ0ODcwNjAzNDk5MTQ0YTNhOThhZjIwMGM2ODZjM2FlL3RleHRyZWdpb246ZDQ4NzA2MDM0OTkxNDRhM2E5OGFmMjAwYzY4NmMzYWVfODkwOQ_25e4ac10-76b9-4271-9db7-471cee56e7da"
      unitRef="usd">641000</us-gaap:InterestExpense>
    <us-gaap:InterestExpenseDebt
      contextRef="i1db0e391023844c58ee91836f1ff6032_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN182MS9mcmFnOmQ0ODcwNjAzNDk5MTQ0YTNhOThhZjIwMGM2ODZjM2FlL3RleHRyZWdpb246ZDQ4NzA2MDM0OTkxNDRhM2E5OGFmMjAwYzY4NmMzYWVfODk3NQ_f5fe9660-bb47-45ad-a45f-4bacb43c0326"
      unitRef="usd">38000</us-gaap:InterestExpenseDebt>
    <us-gaap:EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability
      contextRef="i4856d99dc58e4812bb359ff1035109a0_I20200831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN182MS9mcmFnOmQ0ODcwNjAzNDk5MTQ0YTNhOThhZjIwMGM2ODZjM2FlL3RleHRyZWdpb246ZDQ4NzA2MDM0OTkxNDRhM2E5OGFmMjAwYzY4NmMzYWVfOTE4NA_6cab8325-f8bb-4960-91c4-a64ebbaea430"
      unitRef="usd">84500000</us-gaap:EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability>
    <us-gaap:EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet
      contextRef="id61aefb0cd4c41cba239205ade4953a0_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN182MS9mcmFnOmQ0ODcwNjAzNDk5MTQ0YTNhOThhZjIwMGM2ODZjM2FlL3RleHRyZWdpb246ZDQ4NzA2MDM0OTkxNDRhM2E5OGFmMjAwYzY4NmMzYWVfOTI4Mw_53716e10-3dce-47cf-8d50-179fb92c3967"
      unitRef="usd">75700000</us-gaap:EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="id61aefb0cd4c41cba239205ade4953a0_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN182MS9mcmFnOmQ0ODcwNjAzNDk5MTQ0YTNhOThhZjIwMGM2ODZjM2FlL3RleHRyZWdpb246ZDQ4NzA2MDM0OTkxNDRhM2E5OGFmMjAwYzY4NmMzYWVfOTU2NQ_b9d1d8df-91a4-44be-9243-1981706b1f7f"
      unitRef="usd">8200000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:DebtConversionConvertedInstrumentSharesIssued1
      contextRef="ic05ddd45fe7a4ed3a38c628d55f5113b_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN182MS9mcmFnOmQ0ODcwNjAzNDk5MTQ0YTNhOThhZjIwMGM2ODZjM2FlL3RleHRyZWdpb246ZDQ4NzA2MDM0OTkxNDRhM2E5OGFmMjAwYzY4NmMzYWVfOTk1OQ_a4edced3-0677-4370-a4b8-c8bec60859e5"
      unitRef="shares">4692364</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="ia9abd9a211df4a149587dd748625eb64_I20191226"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN182MS9mcmFnOmQ0ODcwNjAzNDk5MTQ0YTNhOThhZjIwMGM2ODZjM2FlL3RleHRyZWdpb246ZDQ4NzA2MDM0OTkxNDRhM2E5OGFmMjAwYzY4NmMzYWVfMTAyMTU_f7ebd97f-000d-4918-a3d2-98de7fd9ab41"
      unitRef="krw">4700000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="ia9abd9a211df4a149587dd748625eb64_I20191226"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN182MS9mcmFnOmQ0ODcwNjAzNDk5MTQ0YTNhOThhZjIwMGM2ODZjM2FlL3RleHRyZWdpb246ZDQ4NzA2MDM0OTkxNDRhM2E5OGFmMjAwYzY4NmMzYWVfMTAyNDE_901e7ef1-2b05-4d40-826a-82f2225013a7"
      unitRef="usd">4100000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="i244e899ef7a94a67bec0648d010019b1_D20191226-20191226"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN182MS9mcmFnOmQ0ODcwNjAzNDk5MTQ0YTNhOThhZjIwMGM2ODZjM2FlL3RleHRyZWdpb246ZDQ4NzA2MDM0OTkxNDRhM2E5OGFmMjAwYzY4NmMzYWVfMTAzOTQ_f6c7ff00-26ce-4d59-9325-f73af2b161c3"
      unitRef="usd">4000000.0</us-gaap:ProceedsFromIssuanceOfDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ia9abd9a211df4a149587dd748625eb64_I20191226"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN182MS9mcmFnOmQ0ODcwNjAzNDk5MTQ0YTNhOThhZjIwMGM2ODZjM2FlL3RleHRyZWdpb246ZDQ4NzA2MDM0OTkxNDRhM2E5OGFmMjAwYzY4NmMzYWVfMTA1NTE_6ea3c298-82b9-4f23-aa6e-0d2ffd425e2b"
      unitRef="number">0.0100</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtConversionConvertedInstrumentSharesIssued1
      contextRef="i244e899ef7a94a67bec0648d010019b1_D20191226-20191226"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN182MS9mcmFnOmQ0ODcwNjAzNDk5MTQ0YTNhOThhZjIwMGM2ODZjM2FlL3RleHRyZWdpb246ZDQ4NzA2MDM0OTkxNDRhM2E5OGFmMjAwYzY4NmMzYWVfNTQ5NzU1ODE2NjYzMA_e8f73c78-a6f2-46e3-8cef-07cdcc7ffa7b"
      unitRef="shares">1009450</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="if2025599c3af4215ad074b05ca0a1e96_I20191226"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN182MS9mcmFnOmQ0ODcwNjAzNDk5MTQ0YTNhOThhZjIwMGM2ODZjM2FlL3RleHRyZWdpb246ZDQ4NzA2MDM0OTkxNDRhM2E5OGFmMjAwYzY4NmMzYWVfMTEzNjg_165e4005-5121-4cd5-88d3-fdb073d467ed"
      unitRef="usdPerShare">4.00</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="ibfeaa89fdfd14b48b6469e81e8224d6e_I20210331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN182MS9mcmFnOmQ0ODcwNjAzNDk5MTQ0YTNhOThhZjIwMGM2ODZjM2FlL3RleHRyZWdpb246ZDQ4NzA2MDM0OTkxNDRhM2E5OGFmMjAwYzY4NmMzYWVfMTUxMjQ_99add10c-496c-4dc6-ba96-1dae4598b679"
      unitRef="number">0.062</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:InterestExpense
      contextRef="id6dde602cd3b497f9beb038644f6e0f6_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN182MS9mcmFnOmQ0ODcwNjAzNDk5MTQ0YTNhOThhZjIwMGM2ODZjM2FlL3RleHRyZWdpb246ZDQ4NzA2MDM0OTkxNDRhM2E5OGFmMjAwYzY4NmMzYWVfMTUxNjM_697380df-086c-4b20-a584-342b091e02bd"
      unitRef="usd">59000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i1e80eac2298744338c69ed4a78ebcd6b_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN182MS9mcmFnOmQ0ODcwNjAzNDk5MTQ0YTNhOThhZjIwMGM2ODZjM2FlL3RleHRyZWdpb246ZDQ4NzA2MDM0OTkxNDRhM2E5OGFmMjAwYzY4NmMzYWVfMTUxNzA_8bd5a0af-56d6-4141-8351-c46917700641"
      unitRef="usd">62000</us-gaap:InterestExpense>
    <us-gaap:InterestExpenseDebt
      contextRef="id6dde602cd3b497f9beb038644f6e0f6_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN182MS9mcmFnOmQ0ODcwNjAzNDk5MTQ0YTNhOThhZjIwMGM2ODZjM2FlL3RleHRyZWdpb246ZDQ4NzA2MDM0OTkxNDRhM2E5OGFmMjAwYzY4NmMzYWVfMTUyNTM_7da41d5f-0001-40f9-af70-56d06af3f785"
      unitRef="usd">9000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="i1e80eac2298744338c69ed4a78ebcd6b_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN182MS9mcmFnOmQ0ODcwNjAzNDk5MTQ0YTNhOThhZjIwMGM2ODZjM2FlL3RleHRyZWdpb246ZDQ4NzA2MDM0OTkxNDRhM2E5OGFmMjAwYzY4NmMzYWVfMTUyNjA_ef4c9922-8f15-490d-86de-d7b0b5700485"
      unitRef="usd">10000</us-gaap:InterestExpenseDebt>
    <us-gaap:DebtConversionConvertedInstrumentSharesIssued1
      contextRef="id6dde602cd3b497f9beb038644f6e0f6_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN182MS9mcmFnOmQ0ODcwNjAzNDk5MTQ0YTNhOThhZjIwMGM2ODZjM2FlL3RleHRyZWdpb246ZDQ4NzA2MDM0OTkxNDRhM2E5OGFmMjAwYzY4NmMzYWVfMjE5OTAyMzI3NTQ5Ng_1902c909-e18c-4338-b3c2-9e635f43b776"
      unitRef="shares">1009450</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfUnits
      contextRef="id6dde602cd3b497f9beb038644f6e0f6_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN182MS9mcmFnOmQ0ODcwNjAzNDk5MTQ0YTNhOThhZjIwMGM2ODZjM2FlL3RleHRyZWdpb246ZDQ4NzA2MDM0OTkxNDRhM2E5OGFmMjAwYzY4NmMzYWVfMTA5OTUxMTY1NjYyNA_d123b05a-cd67-4d5a-871d-d7f58b972fd3"
      unitRef="usd">4400000</us-gaap:StockIssuedDuringPeriodValueConversionOfUnits>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN182Ny9mcmFnOjU1OGZmMmM3OWUwYzQ5N2Y4OGJjMGExYjBjN2VhZmViL3RleHRyZWdpb246NTU4ZmYyYzc5ZTBjNDk3Zjg4YmMwYTFiMGM3ZWFmZWJfNTMwMg_e4f0195c-71ce-44af-a215-f740928a4272">Stockholders&#x2019; Equity&lt;div style="margin-bottom:10pt;margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following is a summary of the Company's authorized and issued common and preferred stock as of March&#160;31, 2021 and December&#160;31, 2020: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.830%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.095%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.473%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.539%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.473%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.539%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.136%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.539%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.106%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Outstanding as of&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Authorized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Issued&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Common Stock, par value $0.001 per share&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;600,000,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;209,334,036&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;209,334,036&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;186,851,493&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Series&#160;C Preferred Stock, par value $0.001 per share&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,091&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,091&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Preferred Stock&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2020, 14 shares of the Company&#x2019;s Series&#160;C preferred stock were converted into an aggregate of 5,147 shares of the Company&#x2019;s common stock.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Common Stock&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On January 25, 2021, the Company closed an underwritten public offering of 20,355,000 shares of common stock at a public offering price of $8.50 per share. The net proceeds to the Company, after deducting the underwriters' discounts and commissions and other estimated offering expenses, were $162.1&#160;million. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2018, the Company entered into a Sales Agreement with an outside placement agent (the &#x201c;Placement Agent&#x201d;) to sell shares of its common stock with aggregate gross proceeds of up to $100.0 million, from time to time, through an &#x201c;at-the-market&#x201d; equity offering program under which the Placement Agent acted as sales agent. During the first quarter of 2020, the Company and the Placement Agent entered into a first and second amendment to the Sales Agreement (the "Prior Sales Agreement") to increase the amount of common stock that may be sold under the Sales Agreement from $100.0 million to $250.0 million. As of March 31, 2020, there was no remaining capacity under the Prior Sales Agreement. On April 3, 2020, the Company and the Placement Agent entered into a new Sales Agreement (the "New Sales Agreement") to sell shares of its common stock&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On April 3, 2020 and May 12, 2020, the Company filed prospectus supplements pursuant to the New Sales Agreement for the offer and sale of its Common Stock for aggregate gross proceeds of up to an aggregate of $250.0 million. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three months ended March 31, 2020, the Company sold 43,148,952 shares of its common stock under the Prior Sales Agreement. The sales were made at a weighted average price of $4.92 per share, resulting in aggregate net proceeds of $208.2 million. As of March 31, 2020, there was no remaining capacity under the Prior Sales Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;During the year ended December 31, 2020, the Company sold a total of 22,919,934 shares of its common stock under the New Sales Agreement. The sales were made at a weighted average price of $10.91 per share resulting in aggregate net proceeds of $246.2 million. There were no additional sales during the three months ended March 31, 2021, and as of March 31, 2021, there was no remaining capacity under the New Sales Agreement. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Stock Options and Restricted Stock Units&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has a stock-based incentive plan, the 2016 Omnibus Incentive Plan (as amended to date, the "2016 Incentive Plan"), pursuant to which the Company may grant stock options, restricted stock awards, restricted stock units and other stock-based awards or short-term cash incentive awards to employees, directors and consultants. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The 2016 Incentive Plan was originally approved by the Company's stockholders on May 13, 2016, and an amendment to the plan to increase the number of shares available for issuance was approved by the stockholders on May 8, 2019. As of March 31, 2021, the maximum number of shares of the Company&#x2019;s common stock available for issuance over the term of the 2016 Incentive Plan was 20,000,000 shares. On the first business day of each calendar year, such maximum number of shares is further increased by&#160;2,000,000 shares of common stock unless the Board determines, prior to January 1 for any such calendar year, to increase such maximum amount by a fewer number of shares or not to increase the maximum amount at all for such year. On January 1, 2021, the maximum number of shares increased by 2,000,000. At March&#160;31, 2021, the Company had 5,251,776 shares of common stock available for future grant under the 2016 Incentive Plan, 2,610,130 shares underlying &lt;/span&gt;&lt;/div&gt;outstanding but unvested restricted stock units and options outstanding to purchase 7,994,029 shares of common stock under the 2016 Incentive Plan. The awards granted and available for future grant under the 2016 Incentive Plan generally vest over three years and have a maximum contractual term of ten years. The 2016 Incentive Plan terminates by its terms on March&#160;9, 2026.The Amended and Restated 2007 Omnibus Incentive Plan (the "2007 Incentive Plan") was adopted on March&#160;31, 2007 and terminated by its terms on March&#160;31, 2017. At March&#160;31, 2021, the Company had options outstanding to purchase 2,832,443 shares of common stock under the 2007 Incentive Plan. The awards granted under the 2007 Incentive Plan generally vest over three years and have a maximum contractual term of ten years.</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:ScheduleOfStockByClassTextBlock
      contextRef="i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN182Ny9mcmFnOjU1OGZmMmM3OWUwYzQ5N2Y4OGJjMGExYjBjN2VhZmViL3RleHRyZWdpb246NTU4ZmYyYzc5ZTBjNDk3Zjg4YmMwYTFiMGM3ZWFmZWJfNTI5NQ_780219b6-09d0-481f-ae1a-7c6ed37d47ec">&lt;div style="margin-bottom:10pt;margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following is a summary of the Company's authorized and issued common and preferred stock as of March&#160;31, 2021 and December&#160;31, 2020: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.830%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.095%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.473%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.539%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.473%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.539%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.136%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.539%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.106%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Outstanding as of&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Authorized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Issued&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Common Stock, par value $0.001 per share&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;600,000,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;209,334,036&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;209,334,036&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;186,851,493&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Series&#160;C Preferred Stock, par value $0.001 per share&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,091&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,091&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfStockByClassTextBlock>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="ic36b9cedad7f41a6b9eb223b09b7186c_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN182Ny9mcmFnOjU1OGZmMmM3OWUwYzQ5N2Y4OGJjMGExYjBjN2VhZmViL3RhYmxlOmZjODdjMzY0MjY5NzQ4NjA4OGJiYTlkYTA2Yjc0NzNiL3RhYmxlcmFuZ2U6ZmM4N2MzNjQyNjk3NDg2MDg4YmJhOWRhMDZiNzQ3M2JfMi0wLTEtMS0wL3RleHRyZWdpb246MzYyNDgzYWM4YmQ1NDA2MDk5NTY4YjRjMmJjM2U3NTBfMjg_8be60fe0-d632-4779-950e-8e7ee2367c9c"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i066bb5b0a9e84c0a878b1e800703d92b_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN182Ny9mcmFnOjU1OGZmMmM3OWUwYzQ5N2Y4OGJjMGExYjBjN2VhZmViL3RhYmxlOmZjODdjMzY0MjY5NzQ4NjA4OGJiYTlkYTA2Yjc0NzNiL3RhYmxlcmFuZ2U6ZmM4N2MzNjQyNjk3NDg2MDg4YmJhOWRhMDZiNzQ3M2JfMi0wLTEtMS0wL3RleHRyZWdpb246MzYyNDgzYWM4YmQ1NDA2MDk5NTY4YjRjMmJjM2U3NTBfMjg_c57d2664-d10f-4f28-b935-ccc73fba18cd"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="ic36b9cedad7f41a6b9eb223b09b7186c_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN182Ny9mcmFnOjU1OGZmMmM3OWUwYzQ5N2Y4OGJjMGExYjBjN2VhZmViL3RhYmxlOmZjODdjMzY0MjY5NzQ4NjA4OGJiYTlkYTA2Yjc0NzNiL3RhYmxlcmFuZ2U6ZmM4N2MzNjQyNjk3NDg2MDg4YmJhOWRhMDZiNzQ3M2JfMi0xLTEtMS0w_c53ba2ff-d572-4965-9c55-340c25b5d25d"
      unitRef="shares">600000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="ic36b9cedad7f41a6b9eb223b09b7186c_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN182Ny9mcmFnOjU1OGZmMmM3OWUwYzQ5N2Y4OGJjMGExYjBjN2VhZmViL3RhYmxlOmZjODdjMzY0MjY5NzQ4NjA4OGJiYTlkYTA2Yjc0NzNiL3RhYmxlcmFuZ2U6ZmM4N2MzNjQyNjk3NDg2MDg4YmJhOWRhMDZiNzQ3M2JfMi0zLTEtMS0w_1403fcb2-ea64-4af7-b3b6-03a5f252785a"
      unitRef="shares">209334036</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ic36b9cedad7f41a6b9eb223b09b7186c_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN182Ny9mcmFnOjU1OGZmMmM3OWUwYzQ5N2Y4OGJjMGExYjBjN2VhZmViL3RhYmxlOmZjODdjMzY0MjY5NzQ4NjA4OGJiYTlkYTA2Yjc0NzNiL3RhYmxlcmFuZ2U6ZmM4N2MzNjQyNjk3NDg2MDg4YmJhOWRhMDZiNzQ3M2JfMi01LTEtMS0w_c5db721b-8907-42cb-b11c-14d538387220"
      unitRef="shares">209334036</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i066bb5b0a9e84c0a878b1e800703d92b_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN182Ny9mcmFnOjU1OGZmMmM3OWUwYzQ5N2Y4OGJjMGExYjBjN2VhZmViL3RhYmxlOmZjODdjMzY0MjY5NzQ4NjA4OGJiYTlkYTA2Yjc0NzNiL3RhYmxlcmFuZ2U6ZmM4N2MzNjQyNjk3NDg2MDg4YmJhOWRhMDZiNzQ3M2JfMi03LTEtMS0w_db91d33a-d294-4b0e-a563-15bdcb4f0f74"
      unitRef="shares">186851493</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="ic385c05c2d7e4d79bc77a34f466a4d92_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN182Ny9mcmFnOjU1OGZmMmM3OWUwYzQ5N2Y4OGJjMGExYjBjN2VhZmViL3RhYmxlOmZjODdjMzY0MjY5NzQ4NjA4OGJiYTlkYTA2Yjc0NzNiL3RhYmxlcmFuZ2U6ZmM4N2MzNjQyNjk3NDg2MDg4YmJhOWRhMDZiNzQ3M2JfNS0wLTEtMS0wL3RleHRyZWdpb246MTNkZDQ4Y2NiODcxNDE0MmJiNDc1YWE3NThhMmMyY2VfNDA_177edcda-9370-47c1-9a3c-19cbfd7d05e8"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i8080707135874457acfda210b14f8caa_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN182Ny9mcmFnOjU1OGZmMmM3OWUwYzQ5N2Y4OGJjMGExYjBjN2VhZmViL3RhYmxlOmZjODdjMzY0MjY5NzQ4NjA4OGJiYTlkYTA2Yjc0NzNiL3RhYmxlcmFuZ2U6ZmM4N2MzNjQyNjk3NDg2MDg4YmJhOWRhMDZiNzQ3M2JfNS0wLTEtMS0wL3RleHRyZWdpb246MTNkZDQ4Y2NiODcxNDE0MmJiNDc1YWE3NThhMmMyY2VfNDA_a6dd7763-37ad-4d29-8113-9497184eb88f"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i8080707135874457acfda210b14f8caa_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN182Ny9mcmFnOjU1OGZmMmM3OWUwYzQ5N2Y4OGJjMGExYjBjN2VhZmViL3RhYmxlOmZjODdjMzY0MjY5NzQ4NjA4OGJiYTlkYTA2Yjc0NzNiL3RhYmxlcmFuZ2U6ZmM4N2MzNjQyNjk3NDg2MDg4YmJhOWRhMDZiNzQ3M2JfNS0xLTEtMS0w_bd5549bd-965a-4ba1-aac9-b5f3dec9bac3"
      unitRef="shares">1091</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i8080707135874457acfda210b14f8caa_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN182Ny9mcmFnOjU1OGZmMmM3OWUwYzQ5N2Y4OGJjMGExYjBjN2VhZmViL3RhYmxlOmZjODdjMzY0MjY5NzQ4NjA4OGJiYTlkYTA2Yjc0NzNiL3RhYmxlcmFuZ2U6ZmM4N2MzNjQyNjk3NDg2MDg4YmJhOWRhMDZiNzQ3M2JfNS0zLTEtMS0w_3bd1e55f-68b2-4c59-9be1-483062553696"
      unitRef="shares">1091</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i8080707135874457acfda210b14f8caa_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN182Ny9mcmFnOjU1OGZmMmM3OWUwYzQ5N2Y4OGJjMGExYjBjN2VhZmViL3RhYmxlOmZjODdjMzY0MjY5NzQ4NjA4OGJiYTlkYTA2Yjc0NzNiL3RhYmxlcmFuZ2U6ZmM4N2MzNjQyNjk3NDg2MDg4YmJhOWRhMDZiNzQ3M2JfNS01LTEtMS0w_33443cee-afba-44fc-9466-68e9c32906d0"
      unitRef="shares">9</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="ic385c05c2d7e4d79bc77a34f466a4d92_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN182Ny9mcmFnOjU1OGZmMmM3OWUwYzQ5N2Y4OGJjMGExYjBjN2VhZmViL3RhYmxlOmZjODdjMzY0MjY5NzQ4NjA4OGJiYTlkYTA2Yjc0NzNiL3RhYmxlcmFuZ2U6ZmM4N2MzNjQyNjk3NDg2MDg4YmJhOWRhMDZiNzQ3M2JfNS03LTEtMS0w_74e72ed5-9e7b-4716-b931-7ce6a47cb1cf"
      unitRef="shares">9</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:ConversionOfStockSharesConverted1
      contextRef="i25c9bfdd10384a7ea0e5d634721712a4_D20200601-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN182Ny9mcmFnOjU1OGZmMmM3OWUwYzQ5N2Y4OGJjMGExYjBjN2VhZmViL3RleHRyZWdpb246NTU4ZmYyYzc5ZTBjNDk3Zjg4YmMwYTFiMGM3ZWFmZWJfMTc0_038726a7-1301-467d-80b8-ffc8bec5b93d"
      unitRef="shares">14</us-gaap:ConversionOfStockSharesConverted1>
    <us-gaap:ConversionOfStockSharesIssued1
      contextRef="ieee221f2ad874f95afe5bd8f6f749911_D20200601-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN182Ny9mcmFnOjU1OGZmMmM3OWUwYzQ5N2Y4OGJjMGExYjBjN2VhZmViL3RleHRyZWdpb246NTU4ZmYyYzc5ZTBjNDk3Zjg4YmMwYTFiMGM3ZWFmZWJfMjYy_de93c379-f18e-4a0a-a534-99f1c8d01025"
      unitRef="shares">5147</us-gaap:ConversionOfStockSharesIssued1>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i1105e820c10e4516b0891db1691036b2_D20210125-20210125"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN182Ny9mcmFnOjU1OGZmMmM3OWUwYzQ5N2Y4OGJjMGExYjBjN2VhZmViL3RleHRyZWdpb246NTU4ZmYyYzc5ZTBjNDk3Zjg4YmMwYTFiMGM3ZWFmZWJfMTA5OTUxMTYzNjMwNQ_e0795d1b-8834-4eb6-b71b-72daaa78b121"
      unitRef="shares">20355000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="i0aaa3652e67040b09e4bec889642601e_I20210125"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN182Ny9mcmFnOjU1OGZmMmM3OWUwYzQ5N2Y4OGJjMGExYjBjN2VhZmViL3RleHRyZWdpb246NTU4ZmYyYzc5ZTBjNDk3Zjg4YmMwYTFiMGM3ZWFmZWJfMjE5OTAyMzI2NDE5Mg_4f6e21be-4246-4f7d-af93-233c7b0828ef"
      unitRef="usdPerShare">8.50</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:AccruedLiabilitiesForCommissionsExpenseAndTaxes
      contextRef="i0aaa3652e67040b09e4bec889642601e_I20210125"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN182Ny9mcmFnOjU1OGZmMmM3OWUwYzQ5N2Y4OGJjMGExYjBjN2VhZmViL3RleHRyZWdpb246NTU4ZmYyYzc5ZTBjNDk3Zjg4YmMwYTFiMGM3ZWFmZWJfMTA5OTUxMTYzNjI4OQ_2250e86e-ad2e-4a3c-a618-049ce57b9c17"
      unitRef="usd">162100000</us-gaap:AccruedLiabilitiesForCommissionsExpenseAndTaxes>
    <ino:StockSalesAgreementMaximumAuthorizedAmount
      contextRef="if1aa2ac57025445591f02f2a2b4a827d_D20180501-20180531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN182Ny9mcmFnOjU1OGZmMmM3OWUwYzQ5N2Y4OGJjMGExYjBjN2VhZmViL3RleHRyZWdpb246NTU4ZmYyYzc5ZTBjNDk3Zjg4YmMwYTFiMGM3ZWFmZWJfNTAy_d9fa0a2d-204e-4d4c-b207-8660ed588c83"
      unitRef="usd">100000000.0</ino:StockSalesAgreementMaximumAuthorizedAmount>
    <ino:StockSalesAgreementMaximumAuthorizedAmount
      contextRef="if1aa2ac57025445591f02f2a2b4a827d_D20180501-20180531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN182Ny9mcmFnOjU1OGZmMmM3OWUwYzQ5N2Y4OGJjMGExYjBjN2VhZmViL3RleHRyZWdpb246NTU4ZmYyYzc5ZTBjNDk3Zjg4YmMwYTFiMGM3ZWFmZWJfODg2_c8583572-5d28-4bf5-90d1-3454abd795d7"
      unitRef="usd">100000000.0</ino:StockSalesAgreementMaximumAuthorizedAmount>
    <ino:StockSalesAgreementMaximumAuthorizedAmount
      contextRef="ie8f61637671d4831a979db68dfe70295_D20200101-20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN182Ny9mcmFnOjU1OGZmMmM3OWUwYzQ5N2Y4OGJjMGExYjBjN2VhZmViL3RleHRyZWdpb246NTU4ZmYyYzc5ZTBjNDk3Zjg4YmMwYTFiMGM3ZWFmZWJfODky_73e93403-ec9a-4c16-96c3-b565f323f11b"
      unitRef="usd">250000000.0</ino:StockSalesAgreementMaximumAuthorizedAmount>
    <ino:StockSalesAgreementRemainingAuthorizedAmount
      contextRef="i33021fc5991544e6bdc6d451e0bf882e_I20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN182Ny9mcmFnOjU1OGZmMmM3OWUwYzQ5N2Y4OGJjMGExYjBjN2VhZmViL3RleHRyZWdpb246NTU4ZmYyYzc5ZTBjNDk3Zjg4YmMwYTFiMGM3ZWFmZWJfOTI4_5a71498d-41b9-456e-b295-24efc87b6a5b"
      unitRef="usd">0</ino:StockSalesAgreementRemainingAuthorizedAmount>
    <ino:StockSalesAgreementMaximumAuthorizedAmount
      contextRef="if1222ca24d5f4b93a286cd93f4df2429_D20200403-20200512"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN182Ny9mcmFnOjU1OGZmMmM3OWUwYzQ5N2Y4OGJjMGExYjBjN2VhZmViL3RleHRyZWdpb246NTU4ZmYyYzc5ZTBjNDk3Zjg4YmMwYTFiMGM3ZWFmZWJfMTM0Ng_647c275f-1bda-4fa0-98b4-4c965b90ee52"
      unitRef="usd">250000000.0</ino:StockSalesAgreementMaximumAuthorizedAmount>
    <ino:StockSaleAgreementAggregateNumberofSharesIssued
      contextRef="ie8f61637671d4831a979db68dfe70295_D20200101-20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN182Ny9mcmFnOjU1OGZmMmM3OWUwYzQ5N2Y4OGJjMGExYjBjN2VhZmViL3RleHRyZWdpb246NTU4ZmYyYzc5ZTBjNDk3Zjg4YmMwYTFiMGM3ZWFmZWJfMjE0OA_22e8992d-2e53-4a0c-b8de-80162ecd8c30"
      unitRef="shares">43148952</ino:StockSaleAgreementAggregateNumberofSharesIssued>
    <ino:StockSaleAgreementWeightedAveragePricePerShare
      contextRef="ie8f61637671d4831a979db68dfe70295_D20200101-20200331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN182Ny9mcmFnOjU1OGZmMmM3OWUwYzQ5N2Y4OGJjMGExYjBjN2VhZmViL3RleHRyZWdpb246NTU4ZmYyYzc5ZTBjNDk3Zjg4YmMwYTFiMGM3ZWFmZWJfMjI2Mg_fbbfd6c7-9048-4a7f-99ee-80779cd9aed2"
      unitRef="usdPerShare">4.92</ino:StockSaleAgreementWeightedAveragePricePerShare>
    <ino:StockSaleAgreementAggregateProceedsFromIssuanceOfStock
      contextRef="ie8f61637671d4831a979db68dfe70295_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN182Ny9mcmFnOjU1OGZmMmM3OWUwYzQ5N2Y4OGJjMGExYjBjN2VhZmViL3RleHRyZWdpb246NTU4ZmYyYzc5ZTBjNDk3Zjg4YmMwYTFiMGM3ZWFmZWJfMjMxNQ_69a58a06-bd8c-4fc8-b748-e46e8168ce55"
      unitRef="usd">208200000</ino:StockSaleAgreementAggregateProceedsFromIssuanceOfStock>
    <ino:StockSalesAgreementRemainingAuthorizedAmount
      contextRef="i33021fc5991544e6bdc6d451e0bf882e_I20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN182Ny9mcmFnOjU1OGZmMmM3OWUwYzQ5N2Y4OGJjMGExYjBjN2VhZmViL3RleHRyZWdpb246NTU4ZmYyYzc5ZTBjNDk3Zjg4YmMwYTFiMGM3ZWFmZWJfMjM1MQ_4aa1411c-8cab-4f78-abf1-14a2f19023fd"
      unitRef="usd">0</ino:StockSalesAgreementRemainingAuthorizedAmount>
    <ino:StockSaleAgreementAggregateNumberofSharesIssued
      contextRef="i5bdeced5a8d5445a82941bb4b6c54b39_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN182Ny9mcmFnOjU1OGZmMmM3OWUwYzQ5N2Y4OGJjMGExYjBjN2VhZmViL3RleHRyZWdpb246NTU4ZmYyYzc5ZTBjNDk3Zjg4YmMwYTFiMGM3ZWFmZWJfMjQ2OA_60bfc21c-3bb7-4c02-91e6-96c1851f17f8"
      unitRef="shares">22919934</ino:StockSaleAgreementAggregateNumberofSharesIssued>
    <ino:StockSaleAgreementWeightedAveragePricePerShare
      contextRef="i5bdeced5a8d5445a82941bb4b6c54b39_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN182Ny9mcmFnOjU1OGZmMmM3OWUwYzQ5N2Y4OGJjMGExYjBjN2VhZmViL3RleHRyZWdpb246NTU4ZmYyYzc5ZTBjNDk3Zjg4YmMwYTFiMGM3ZWFmZWJfMjU4MA_8ca8f7cc-9e3c-4e49-bf94-a29417f45936"
      unitRef="usdPerShare">10.91</ino:StockSaleAgreementWeightedAveragePricePerShare>
    <ino:StockSaleAgreementAggregateProceedsFromIssuanceOfStock
      contextRef="i5bdeced5a8d5445a82941bb4b6c54b39_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN182Ny9mcmFnOjU1OGZmMmM3OWUwYzQ5N2Y4OGJjMGExYjBjN2VhZmViL3RleHRyZWdpb246NTU4ZmYyYzc5ZTBjNDk3Zjg4YmMwYTFiMGM3ZWFmZWJfMjYzMw_c48e6a1d-0e7b-470e-a95e-eb6e656a3ae2"
      unitRef="usd">246200000</ino:StockSaleAgreementAggregateProceedsFromIssuanceOfStock>
    <ino:StockSalesAgreementRemainingAuthorizedAmount
      contextRef="ic7ebb6cd60ce4e4c84cfe4f6fd8ca6fa_I20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN182Ny9mcmFnOjU1OGZmMmM3OWUwYzQ5N2Y4OGJjMGExYjBjN2VhZmViL3RleHRyZWdpb246NTU4ZmYyYzc5ZTBjNDk3Zjg4YmMwYTFiMGM3ZWFmZWJfMjY0OA_a0af528d-48c6-43c1-a5c7-e1dd8cd933f0"
      unitRef="usd">0</ino:StockSalesAgreementRemainingAuthorizedAmount>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="i20753e05a58f4787ad7efb7458e2f0c5_I20160513"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN182Ny9mcmFnOjU1OGZmMmM3OWUwYzQ5N2Y4OGJjMGExYjBjN2VhZmViL3RleHRyZWdpb246NTU4ZmYyYzc5ZTBjNDk3Zjg4YmMwYTFiMGM3ZWFmZWJfMzc1OQ_f7b2dace-6ff3-4033-a630-4a7e867553ad"
      unitRef="shares">20000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <ino:NumberOfPotentialSharesAuthorizedForIssuanceUnderShareBasedCompensationPlan
      contextRef="i20753e05a58f4787ad7efb7458e2f0c5_I20160513"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN182Ny9mcmFnOjU1OGZmMmM3OWUwYzQ5N2Y4OGJjMGExYjBjN2VhZmViL3RleHRyZWdpb246NTU4ZmYyYzc5ZTBjNDk3Zjg4YmMwYTFiMGM3ZWFmZWJfMzkyNA_23a50ef3-543c-4732-9065-acb44a9006e2"
      unitRef="shares">2000000</ino:NumberOfPotentialSharesAuthorizedForIssuanceUnderShareBasedCompensationPlan>
    <ino:SharebasedCompensationArrangementbySharebasedPaymentAwardIncreaseInNumberofSharesAuthorized
      contextRef="i23432a1ccb974c6d9ef1ec635e8143ed_I20210101"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN182Ny9mcmFnOjU1OGZmMmM3OWUwYzQ5N2Y4OGJjMGExYjBjN2VhZmViL3RleHRyZWdpb246NTU4ZmYyYzc5ZTBjNDk3Zjg4YmMwYTFiMGM3ZWFmZWJfNDI0NA_090ea161-9a2e-4b88-9a5b-7be2dfc0f56f"
      unitRef="shares">2000000</ino:SharebasedCompensationArrangementbySharebasedPaymentAwardIncreaseInNumberofSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="iddaa5cd4d85f4565b4df009a33385893_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN182Ny9mcmFnOjU1OGZmMmM3OWUwYzQ5N2Y4OGJjMGExYjBjN2VhZmViL3RleHRyZWdpb246NTU4ZmYyYzc5ZTBjNDk3Zjg4YmMwYTFiMGM3ZWFmZWJfNDQ0NA_81ffab09-6b2f-4f13-9e68-a754a36e8b73"
      unitRef="shares">5251776</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="iddaa5cd4d85f4565b4df009a33385893_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN182Ny9mcmFnOjU1OGZmMmM3OWUwYzQ5N2Y4OGJjMGExYjBjN2VhZmViL3RleHRyZWdpb246NTU4ZmYyYzc5ZTBjNDk3Zjg4YmMwYTFiMGM3ZWFmZWJfNDUyOA_3f8a1d8f-e8b9-45d2-9e2b-dda2884443d2"
      unitRef="shares">2610130</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:CommonStockOtherSharesOutstanding
      contextRef="iddaa5cd4d85f4565b4df009a33385893_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN182Ny9mcmFnOjU1OGZmMmM3OWUwYzQ5N2Y4OGJjMGExYjBjN2VhZmViL3RleHRyZWdpb246NTU4ZmYyYzc5ZTBjNDk3Zjg4YmMwYTFiMGM3ZWFmZWJfNDYzMw_414a7934-2c54-4cfa-80bf-3b2bc61b8025"
      unitRef="shares">7994029</us-gaap:CommonStockOtherSharesOutstanding>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i52e41bdcfa1f4dd5ae13e4662c088e67_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN182Ny9mcmFnOjU1OGZmMmM3OWUwYzQ5N2Y4OGJjMGExYjBjN2VhZmViL3RleHRyZWdpb246NTU4ZmYyYzc5ZTBjNDk3Zjg4YmMwYTFiMGM3ZWFmZWJfNDc5MA_5776f897-e1be-4176-91bc-7fe52a63becb">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <ino:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm
      contextRef="i52e41bdcfa1f4dd5ae13e4662c088e67_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN182Ny9mcmFnOjU1OGZmMmM3OWUwYzQ5N2Y4OGJjMGExYjBjN2VhZmViL3RleHRyZWdpb246NTU4ZmYyYzc5ZTBjNDk3Zjg4YmMwYTFiMGM3ZWFmZWJfNDgzMg_716b2ba5-2db8-49e4-95c6-21e692761eb7">P10Y</ino:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm>
    <us-gaap:CommonStockOtherSharesOutstanding
      contextRef="i8c0e2d352fcb4b638dd0a198e31e2f72_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN182Ny9mcmFnOjU1OGZmMmM3OWUwYzQ5N2Y4OGJjMGExYjBjN2VhZmViL3RleHRyZWdpb246NTU4ZmYyYzc5ZTBjNDk3Zjg4YmMwYTFiMGM3ZWFmZWJfNTExNQ_324cee3b-4050-4310-b47c-ac22ef510285"
      unitRef="shares">2832443</us-gaap:CommonStockOtherSharesOutstanding>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i6236143f37a74492a26b2b567dd6525a_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN182Ny9mcmFnOjU1OGZmMmM3OWUwYzQ5N2Y4OGJjMGExYjBjN2VhZmViL3RleHRyZWdpb246NTU4ZmYyYzc5ZTBjNDk3Zjg4YmMwYTFiMGM3ZWFmZWJfNTI0MQ_801aaccd-10e0-484d-8d48-4cfd1e5a91da">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <ino:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm
      contextRef="i6236143f37a74492a26b2b567dd6525a_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN182Ny9mcmFnOjU1OGZmMmM3OWUwYzQ5N2Y4OGJjMGExYjBjN2VhZmViL3RleHRyZWdpb246NTU4ZmYyYzc5ZTBjNDk3Zjg4YmMwYTFiMGM3ZWFmZWJfNTI4Mw_23fbd00f-d92f-4d19-bc42-be9c8f375251">P10Y</ino:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN183MC9mcmFnOjFlNmI5Y2VmMzVkOTRhNzY4MzNjMWExNjQ2MjdlYTVhL3RleHRyZWdpb246MWU2YjljZWYzNWQ5NGE3NjgzM2MxYTE2NDYyN2VhNWFfMjEyNw_f81b3a79-c3d1-4289-a45f-c1c22607a887">Net Loss Per Share &lt;div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic net loss per share is computed by dividing the net loss for the period by the weighted average number of shares of common stock outstanding during the period. Diluted net loss per share is calculated in accordance with the treasury stock method for the outstanding stock options and restricted stock units and refle&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;cts the potential dilution that would occur if securities or other con&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;tracts to issue common stock were exercised or converted to common stock. The dilutive impact of the outstanding Notes and Bonds issued by the Company (discussed in Note 9) has been considered using the "if-converted" method. The calculation of diluted net loss per share requires that, to the extent the average market price of the underlying shares for the reporting period exceeds the exercise price of the options or other securities and the presumed exercise of such securities are dilutive to net loss per share for the period, an adjustment to the net loss used in the calculation is required to remove the change in fair value of such securities from the numerator for the period. Likewise, an adjustment to the denominator is required to reflect the related dilutive shares, if any. For the three months ended March 31, 2021 and 2020, basic and diluted net loss per share were the same, as the assumed exercise or settlement of stock options and restricted stock units and the potentially dilutive shares issuable upon conversion of the Notes and Bonds would have been anti-dilutive.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes potential shares of common stock that were excluded from the diluted net loss per share calculation because of their anti-dilutive effect for the three months ended March 31, 2021 and 2020: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.170%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.549%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.263%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;Common Stock Equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options to purchase common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,826,472&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,615,986&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Service-based restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,610,130&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,667,710&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Performance-based restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;663,353&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Convertible preferred stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,309&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,456&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Convertible notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,049,980&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,585,653&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;August 2019 Bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,928,859&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 2019 Bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,009,450&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,153,244&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,816,114&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN183MC9mcmFnOjFlNmI5Y2VmMzVkOTRhNzY4MzNjMWExNjQ2MjdlYTVhL3RleHRyZWdpb246MWU2YjljZWYzNWQ5NGE3NjgzM2MxYTE2NDYyN2VhNWFfMjEyOA_b0377801-470c-48b9-be48-ba587d000d6c">&lt;div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes potential shares of common stock that were excluded from the diluted net loss per share calculation because of their anti-dilutive effect for the three months ended March 31, 2021 and 2020: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.170%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.549%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.263%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;Common Stock Equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options to purchase common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,826,472&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,615,986&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Service-based restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,610,130&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,667,710&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Performance-based restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;663,353&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Convertible preferred stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,309&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,456&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Convertible notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,049,980&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,585,653&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;August 2019 Bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,928,859&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 2019 Bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,009,450&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,153,244&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,816,114&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i87899c635a3d4f67af30c19682c88a69_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN183MC9mcmFnOjFlNmI5Y2VmMzVkOTRhNzY4MzNjMWExNjQ2MjdlYTVhL3RhYmxlOjA2N2RmOTNlMzNkNDQ1MWI5NGY4NDBiZDIwMmQ1OWZlL3RhYmxlcmFuZ2U6MDY3ZGY5M2UzM2Q0NDUxYjk0Zjg0MGJkMjAyZDU5ZmVfMi0xLTEtMS0w_9d6ab1ce-881d-473b-a76c-0fb31c2be1bc"
      unitRef="shares">10826472</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="iaf2883d0b0f44f8aa8540000815316c3_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN183MC9mcmFnOjFlNmI5Y2VmMzVkOTRhNzY4MzNjMWExNjQ2MjdlYTVhL3RhYmxlOjA2N2RmOTNlMzNkNDQ1MWI5NGY4NDBiZDIwMmQ1OWZlL3RhYmxlcmFuZ2U6MDY3ZGY5M2UzM2Q0NDUxYjk0Zjg0MGJkMjAyZDU5ZmVfMi0zLTEtMS0w_8200a753-debe-43cf-81c4-2a9e59024aac"
      unitRef="shares">9615986</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i6aade12f14664b7bafdd10b536ffc9d1_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN183MC9mcmFnOjFlNmI5Y2VmMzVkOTRhNzY4MzNjMWExNjQ2MjdlYTVhL3RhYmxlOjA2N2RmOTNlMzNkNDQ1MWI5NGY4NDBiZDIwMmQ1OWZlL3RhYmxlcmFuZ2U6MDY3ZGY5M2UzM2Q0NDUxYjk0Zjg0MGJkMjAyZDU5ZmVfMy0xLTEtMS0w_256309fd-1dc3-492e-9b0e-0594a40c2e7d"
      unitRef="shares">2610130</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="iecc10df4b79a45de9ffdafc4389503d2_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN183MC9mcmFnOjFlNmI5Y2VmMzVkOTRhNzY4MzNjMWExNjQ2MjdlYTVhL3RhYmxlOjA2N2RmOTNlMzNkNDQ1MWI5NGY4NDBiZDIwMmQ1OWZlL3RhYmxlcmFuZ2U6MDY3ZGY5M2UzM2Q0NDUxYjk0Zjg0MGJkMjAyZDU5ZmVfMy0zLTEtMS0w_971747a3-a249-4313-866f-50c4bf5c9837"
      unitRef="shares">2667710</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i623f1c7b68164c0e86bc10eaa5f5a7e5_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN183MC9mcmFnOjFlNmI5Y2VmMzVkOTRhNzY4MzNjMWExNjQ2MjdlYTVhL3RhYmxlOjA2N2RmOTNlMzNkNDQ1MWI5NGY4NDBiZDIwMmQ1OWZlL3RhYmxlcmFuZ2U6MDY3ZGY5M2UzM2Q0NDUxYjk0Zjg0MGJkMjAyZDU5ZmVfNC0xLTEtMS0w_1e66be7f-a23a-462b-908b-0b2d0bfb1873"
      unitRef="shares">663353</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i75ed8cb3d08c4c16a0b40f1f253b731e_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN183MC9mcmFnOjFlNmI5Y2VmMzVkOTRhNzY4MzNjMWExNjQ2MjdlYTVhL3RhYmxlOjA2N2RmOTNlMzNkNDQ1MWI5NGY4NDBiZDIwMmQ1OWZlL3RhYmxlcmFuZ2U6MDY3ZGY5M2UzM2Q0NDUxYjk0Zjg0MGJkMjAyZDU5ZmVfNC0zLTEtMS0w_3f16f9ee-3425-4e13-bfe5-ed3314b88396"
      unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i71ea1499a3b143cb8017808669a7a908_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN183MC9mcmFnOjFlNmI5Y2VmMzVkOTRhNzY4MzNjMWExNjQ2MjdlYTVhL3RhYmxlOjA2N2RmOTNlMzNkNDQ1MWI5NGY4NDBiZDIwMmQ1OWZlL3RhYmxlcmFuZ2U6MDY3ZGY5M2UzM2Q0NDUxYjk0Zjg0MGJkMjAyZDU5ZmVfNS0xLTEtMS0w_d2e7a71d-9a4f-4ccd-b6cc-b5bbf6b2d969"
      unitRef="shares">3309</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ifb05b300647c4bdb9d4dd1b61fa9ee95_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN183MC9mcmFnOjFlNmI5Y2VmMzVkOTRhNzY4MzNjMWExNjQ2MjdlYTVhL3RhYmxlOjA2N2RmOTNlMzNkNDQ1MWI5NGY4NDBiZDIwMmQ1OWZlL3RhYmxlcmFuZ2U6MDY3ZGY5M2UzM2Q0NDUxYjk0Zjg0MGJkMjAyZDU5ZmVfNS0zLTEtMS0w_4c2b97e0-ca5b-4004-a949-aea1b728f286"
      unitRef="shares">8456</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i2d25495c4b6c4835a012eb7bc163fc6b_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN183MC9mcmFnOjFlNmI5Y2VmMzVkOTRhNzY4MzNjMWExNjQ2MjdlYTVhL3RhYmxlOjA2N2RmOTNlMzNkNDQ1MWI5NGY4NDBiZDIwMmQ1OWZlL3RhYmxlcmFuZ2U6MDY3ZGY5M2UzM2Q0NDUxYjk0Zjg0MGJkMjAyZDU5ZmVfNi0xLTEtMS0w_c28f486e-4c09-4ac7-acc1-381555027c07"
      unitRef="shares">3049980</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i4a3bb7fa3e594f029a6eba07308e9930_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN183MC9mcmFnOjFlNmI5Y2VmMzVkOTRhNzY4MzNjMWExNjQ2MjdlYTVhL3RhYmxlOjA2N2RmOTNlMzNkNDQ1MWI5NGY4NDBiZDIwMmQ1OWZlL3RhYmxlcmFuZ2U6MDY3ZGY5M2UzM2Q0NDUxYjk0Zjg0MGJkMjAyZDU5ZmVfNi0zLTEtMS0w_01d02827-0a32-4ad8-9cea-2f2363e82cf9"
      unitRef="shares">14585653</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i18791cf1783e4dcb8bb78a1be1ac89ad_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN183MC9mcmFnOjFlNmI5Y2VmMzVkOTRhNzY4MzNjMWExNjQ2MjdlYTVhL3RhYmxlOjA2N2RmOTNlMzNkNDQ1MWI5NGY4NDBiZDIwMmQ1OWZlL3RhYmxlcmFuZ2U6MDY3ZGY5M2UzM2Q0NDUxYjk0Zjg0MGJkMjAyZDU5ZmVfNy0xLTEtMS0w_cf876153-9d1f-46e9-b1d5-0cc58a7e455d"
      unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i40ed0775a40148b78eea3a36a21b29b8_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN183MC9mcmFnOjFlNmI5Y2VmMzVkOTRhNzY4MzNjMWExNjQ2MjdlYTVhL3RhYmxlOjA2N2RmOTNlMzNkNDQ1MWI5NGY4NDBiZDIwMmQ1OWZlL3RhYmxlcmFuZ2U6MDY3ZGY5M2UzM2Q0NDUxYjk0Zjg0MGJkMjAyZDU5ZmVfNy0zLTEtMS0w_3352ea3b-a18c-4d1a-88dc-1ee4fe48119c"
      unitRef="shares">4928859</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ia21913e3a96f406eaffea5e037b375df_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN183MC9mcmFnOjFlNmI5Y2VmMzVkOTRhNzY4MzNjMWExNjQ2MjdlYTVhL3RhYmxlOjA2N2RmOTNlMzNkNDQ1MWI5NGY4NDBiZDIwMmQ1OWZlL3RhYmxlcmFuZ2U6MDY3ZGY5M2UzM2Q0NDUxYjk0Zjg0MGJkMjAyZDU5ZmVfOC0xLTEtMS0w_f7890033-7b67-4fd5-99a1-472b74d3bd0b"
      unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ib6797a8f65df45e284ff859468b7d490_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN183MC9mcmFnOjFlNmI5Y2VmMzVkOTRhNzY4MzNjMWExNjQ2MjdlYTVhL3RhYmxlOjA2N2RmOTNlMzNkNDQ1MWI5NGY4NDBiZDIwMmQ1OWZlL3RhYmxlcmFuZ2U6MDY3ZGY5M2UzM2Q0NDUxYjk0Zjg0MGJkMjAyZDU5ZmVfOC0zLTEtMS0w_b2e265f3-1ff2-4659-b08b-a37eda15e4ff"
      unitRef="shares">1009450</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN183MC9mcmFnOjFlNmI5Y2VmMzVkOTRhNzY4MzNjMWExNjQ2MjdlYTVhL3RhYmxlOjA2N2RmOTNlMzNkNDQ1MWI5NGY4NDBiZDIwMmQ1OWZlL3RhYmxlcmFuZ2U6MDY3ZGY5M2UzM2Q0NDUxYjk0Zjg0MGJkMjAyZDU5ZmVfOS0xLTEtMS0w_de3f9e13-6e95-4599-b588-0cfce284f3cb"
      unitRef="shares">17153244</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i03bccaa0abfb4733b1e2831ecde4e4e8_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN183MC9mcmFnOjFlNmI5Y2VmMzVkOTRhNzY4MzNjMWExNjQ2MjdlYTVhL3RhYmxlOjA2N2RmOTNlMzNkNDQ1MWI5NGY4NDBiZDIwMmQ1OWZlL3RhYmxlcmFuZ2U6MDY3ZGY5M2UzM2Q0NDUxYjk0Zjg0MGJkMjAyZDU5ZmVfOS0zLTEtMS0w_0da3665a-6a39-4f96-8687-53393799d916"
      unitRef="shares">32816114</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN183Ni9mcmFnOjUwMDdjM2Y2ZmU3ODRhM2NiNjgzYmI5MjA3OWU5M2Y4L3RleHRyZWdpb246NTAwN2MzZjZmZTc4NGEzY2I2ODNiYjkyMDc5ZTkzZjhfNDE2MA_4751a9a2-36fa-4c44-9a7b-86d34810cc87">Stock-Based Compensation&lt;div style="text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company incurs stock-based compensation expense related to restricted stock units ("RSUs") and stock options. The fair value of restricted stock is determined by the closing price of the Company's common stock reported on the Nasdaq Global Select Market on the date of grant. The Company estimates the fair value of stock options granted using the Black-Scholes option pricing model. The Black-Scholes option pricing model was developed for use in estimating the fair value of traded options, which have no vesting restrictions and are fully transferable. In addition, option valuation models require the input of subjective assumptions, including the expected stock price volatility and expected option life. The Company amortizes the fair value of the awards on a straight-line basis over the requisite vesting period of the awards. Expected volatility is based on historical volatility. The expected life of options granted is based on historical expected life. The risk-free interest rate is based on the U.S. Treasury yield in effect at the time of grant. The dividend yield is based on the fact that no dividends have been paid historically and none are currently expected to be paid in the foreseeable future. The Company recognizes forfeitures as they occur.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The weighted average assumptions used in the Black-Scholes model for option grants to employees and directors are presented below:&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:73.461%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.914%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.88%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.74%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;92%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;76%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected life in years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.8&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.9&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total employee and director stock-based compensation expense recognized in the condensed consolidated statements of operations for the three months ended March 31, 2021 and 2020 was $9.2 million and $3.6 million, respectively, of which $5.2 million and $2.3 million, respectively, was included in research and development expenses, and $4.0 million and $1.3 million, respectively, was included in general and administrative expenses.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At March&#160;31, 2021, there was $22.3 million of total unrecognized compensation expense related to unvested stock options, which is expected to be recognized over a weighted-average period of 2.6 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The weighted average grant date fair value per share, calculated using the Black-Scholes option pricing model, was $8.34 and $5.37 for employee and director stock options granted during the three months ended March 31, 2021 and 2020, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At March&#160;31, 2021, there was $19.4 million of total unrecognized compensation expense related to unvested service-based RSUs, which is expected to be recognized over a weighted-average period of 2.3 years.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The weighted average grant date fair value per share was $11.42 and $8.32 for service-based RSUs granted during the three months ended March 31, 2021 and 2020, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of stock options granted to non-employees was estimated using the Black-Scholes pricing model. Total stock-based compensation expense for stock options and RSUs granted to non-employees for the three months ended March 31, 2021 and 2020 was $429,000 and $383,000, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-indent:27pt"&gt;&lt;span style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;On August 28, 2020, the Company granted 663,353 performance-based RSUs to executives under the 2016 Incentive Plan. The RSUs will vest in two tranches as follows: 50% of the shares in each tranche will vest upon achievement of the predetermined performance milestones and the remaining 50% of the shares in each tranche will vest upon subsequent completion of a one-year service period. The total grant date fair value of the performance-based RSUs was $8.0&#160;million based on the grant date closing price per share of $12.06. As of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;March&#160;31, 2021&lt;/span&gt;&lt;span style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;, the underlying performance milestones of the RSUs were not probable of achievement, and no stock-based compensation expense was recognized for the performance-based RSUs for the three months then ended.&lt;/span&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN183Ni9mcmFnOjUwMDdjM2Y2ZmU3ODRhM2NiNjgzYmI5MjA3OWU5M2Y4L3RleHRyZWdpb246NTAwN2MzZjZmZTc4NGEzY2I2ODNiYjkyMDc5ZTkzZjhfNDE0NQ_90ef1589-8608-4f26-bdd1-2ee404e84008">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The weighted average assumptions used in the Black-Scholes model for option grants to employees and directors are presented below:&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;  &lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:73.461%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.914%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.88%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.74%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;92%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;76%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected life in years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.8&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.9&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i61f2172601e8451ebb73c4ae7a745dab_D20210101-20210331"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN183Ni9mcmFnOjUwMDdjM2Y2ZmU3ODRhM2NiNjgzYmI5MjA3OWU5M2Y4L3RhYmxlOmQ4MTRmMzdlYjYxODQzMzU5ZTIyM2EzNDJkYjNjZTNkL3RhYmxlcmFuZ2U6ZDgxNGYzN2ViNjE4NDMzNTllMjIzYTM0MmRiM2NlM2RfMi0xLTEtMS0w_6b328790-7ac6-4eea-b4f5-72613e76e843"
      unitRef="number">0.0088</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i0c1c04ab89af4b82b4d7131a93f0f86f_D20200101-20200331"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN183Ni9mcmFnOjUwMDdjM2Y2ZmU3ODRhM2NiNjgzYmI5MjA3OWU5M2Y4L3RhYmxlOmQ4MTRmMzdlYjYxODQzMzU5ZTIyM2EzNDJkYjNjZTNkL3RhYmxlcmFuZ2U6ZDgxNGYzN2ViNjE4NDMzNTllMjIzYTM0MmRiM2NlM2RfMi0zLTEtMS0w_f18f2e7e-eb25-4108-a1d5-37bac6173959"
      unitRef="number">0.0074</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i61f2172601e8451ebb73c4ae7a745dab_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN183Ni9mcmFnOjUwMDdjM2Y2ZmU3ODRhM2NiNjgzYmI5MjA3OWU5M2Y4L3RhYmxlOmQ4MTRmMzdlYjYxODQzMzU5ZTIyM2EzNDJkYjNjZTNkL3RhYmxlcmFuZ2U6ZDgxNGYzN2ViNjE4NDMzNTllMjIzYTM0MmRiM2NlM2RfMy0xLTEtMS0w_bcd63a3d-eb83-49ea-9030-1f59ea5b7ed4"
      unitRef="number">0.92</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i0c1c04ab89af4b82b4d7131a93f0f86f_D20200101-20200331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN183Ni9mcmFnOjUwMDdjM2Y2ZmU3ODRhM2NiNjgzYmI5MjA3OWU5M2Y4L3RhYmxlOmQ4MTRmMzdlYjYxODQzMzU5ZTIyM2EzNDJkYjNjZTNkL3RhYmxlcmFuZ2U6ZDgxNGYzN2ViNjE4NDMzNTllMjIzYTM0MmRiM2NlM2RfMy0zLTEtMS0w_fd6c2d21-8d36-493e-ae01-967172698551"
      unitRef="number">0.76</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i61f2172601e8451ebb73c4ae7a745dab_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN183Ni9mcmFnOjUwMDdjM2Y2ZmU3ODRhM2NiNjgzYmI5MjA3OWU5M2Y4L3RhYmxlOmQ4MTRmMzdlYjYxODQzMzU5ZTIyM2EzNDJkYjNjZTNkL3RhYmxlcmFuZ2U6ZDgxNGYzN2ViNjE4NDMzNTllMjIzYTM0MmRiM2NlM2RfNC0xLTEtMS0w_3588391a-ac2f-4614-b057-67738ba780da">P5Y9M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i0c1c04ab89af4b82b4d7131a93f0f86f_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN183Ni9mcmFnOjUwMDdjM2Y2ZmU3ODRhM2NiNjgzYmI5MjA3OWU5M2Y4L3RhYmxlOmQ4MTRmMzdlYjYxODQzMzU5ZTIyM2EzNDJkYjNjZTNkL3RhYmxlcmFuZ2U6ZDgxNGYzN2ViNjE4NDMzNTllMjIzYTM0MmRiM2NlM2RfNC0zLTEtMS0w_73077fdb-cb45-4f90-a0c1-a8dcf30ccc0a">P5Y10M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i61f2172601e8451ebb73c4ae7a745dab_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN183Ni9mcmFnOjUwMDdjM2Y2ZmU3ODRhM2NiNjgzYmI5MjA3OWU5M2Y4L3RhYmxlOmQ4MTRmMzdlYjYxODQzMzU5ZTIyM2EzNDJkYjNjZTNkL3RhYmxlcmFuZ2U6ZDgxNGYzN2ViNjE4NDMzNTllMjIzYTM0MmRiM2NlM2RfNS0xLTEtMS0w_955b5f7e-bc50-4a72-92a7-259580b32592"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i0c1c04ab89af4b82b4d7131a93f0f86f_D20200101-20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN183Ni9mcmFnOjUwMDdjM2Y2ZmU3ODRhM2NiNjgzYmI5MjA3OWU5M2Y4L3RhYmxlOmQ4MTRmMzdlYjYxODQzMzU5ZTIyM2EzNDJkYjNjZTNkL3RhYmxlcmFuZ2U6ZDgxNGYzN2ViNjE4NDMzNTllMjIzYTM0MmRiM2NlM2RfNS0zLTEtMS0w_5ac3f2ac-81f7-4f46-be28-9176de2b0d7c"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensation
      contextRef="ic3dea0b408c94a5c85d39edf3a8a75da_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN183Ni9mcmFnOjUwMDdjM2Y2ZmU3ODRhM2NiNjgzYmI5MjA3OWU5M2Y4L3RleHRyZWdpb246NTAwN2MzZjZmZTc4NGEzY2I2ODNiYjkyMDc5ZTkzZjhfMTUyOA_0f52aedd-10c3-4cd8-b35b-1efff8aa68fe"
      unitRef="usd">9200000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i2be4bda68db445b1873dcb33cd2a7408_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN183Ni9mcmFnOjUwMDdjM2Y2ZmU3ODRhM2NiNjgzYmI5MjA3OWU5M2Y4L3RleHRyZWdpb246NTAwN2MzZjZmZTc4NGEzY2I2ODNiYjkyMDc5ZTkzZjhfMjE5OTAyMzI1OTc3Nw_74a5393e-05ad-4587-920b-256aecb9506f"
      unitRef="usd">3600000</us-gaap:ShareBasedCompensation>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ia4defc9758104f38bf6c67e512fbf9c8_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN183Ni9mcmFnOjUwMDdjM2Y2ZmU3ODRhM2NiNjgzYmI5MjA3OWU5M2Y4L3RleHRyZWdpb246NTAwN2MzZjZmZTc4NGEzY2I2ODNiYjkyMDc5ZTkzZjhfMTU2Mw_67d42550-f0b2-41c9-aaed-b75428a09c61"
      unitRef="usd">5200000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ic196d4d46d72427380949ad2f6171b35_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN183Ni9mcmFnOjUwMDdjM2Y2ZmU3ODRhM2NiNjgzYmI5MjA3OWU5M2Y4L3RleHRyZWdpb246NTAwN2MzZjZmZTc4NGEzY2I2ODNiYjkyMDc5ZTkzZjhfMjE5OTAyMzI1OTc4MQ_7512f756-0136-4044-b117-4e67f28f91e5"
      unitRef="usd">2300000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i4ac71f8b0252490589829c2ceb42c184_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN183Ni9mcmFnOjUwMDdjM2Y2ZmU3ODRhM2NiNjgzYmI5MjA3OWU5M2Y4L3RleHRyZWdpb246NTAwN2MzZjZmZTc4NGEzY2I2ODNiYjkyMDc5ZTkzZjhfMTY0NA_8338fae3-4673-4cd7-b7f5-962c911aa0d8"
      unitRef="usd">4000000.0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i16bb9f759a90436abc39b470d3758b82_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN183Ni9mcmFnOjUwMDdjM2Y2ZmU3ODRhM2NiNjgzYmI5MjA3OWU5M2Y4L3RleHRyZWdpb246NTAwN2MzZjZmZTc4NGEzY2I2ODNiYjkyMDc5ZTkzZjhfMjE5OTAyMzI1OTc4Nw_04ae6378-6a4b-4c66-86bb-775d7f22db49"
      unitRef="usd">1300000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="ic36b9cedad7f41a6b9eb223b09b7186c_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN183Ni9mcmFnOjUwMDdjM2Y2ZmU3ODRhM2NiNjgzYmI5MjA3OWU5M2Y4L3RleHRyZWdpb246NTAwN2MzZjZmZTc4NGEzY2I2ODNiYjkyMDc5ZTkzZjhfMjA3Mw_140e3bba-c665-4f85-8596-6d6642bd0882"
      unitRef="usd">22300000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN183Ni9mcmFnOjUwMDdjM2Y2ZmU3ODRhM2NiNjgzYmI5MjA3OWU5M2Y4L3RleHRyZWdpb246NTAwN2MzZjZmZTc4NGEzY2I2ODNiYjkyMDc5ZTkzZjhfMjIyMw_f9c5708d-43aa-43ab-9f78-b70b489b687f">P2Y7M6D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN183Ni9mcmFnOjUwMDdjM2Y2ZmU3ODRhM2NiNjgzYmI5MjA3OWU5M2Y4L3RleHRyZWdpb246NTAwN2MzZjZmZTc4NGEzY2I2ODNiYjkyMDc5ZTkzZjhfMjM0Mg_5b9ef013-53a1-4483-9109-c817769d97ab"
      unitRef="usdPerShare">8.34</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i03bccaa0abfb4733b1e2831ecde4e4e8_D20200101-20200331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN183Ni9mcmFnOjUwMDdjM2Y2ZmU3ODRhM2NiNjgzYmI5MjA3OWU5M2Y4L3RleHRyZWdpb246NTAwN2MzZjZmZTc4NGEzY2I2ODNiYjkyMDc5ZTkzZjhfMjE5OTAyMzI2MDEyOQ_33f914f0-88be-49c8-8323-e547e34fd6ad"
      unitRef="usdPerShare">5.37</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="iced18e00c26943db86d24ef12f5d945b_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN183Ni9mcmFnOjUwMDdjM2Y2ZmU3ODRhM2NiNjgzYmI5MjA3OWU5M2Y4L3RleHRyZWdpb246NTAwN2MzZjZmZTc4NGEzY2I2ODNiYjkyMDc5ZTkzZjhfMjUzOA_faa6fa55-b863-4832-8cbf-2e8685c63e79"
      unitRef="usd">19400000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i2af01b3faa6342e7982d6aae83905e36_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN183Ni9mcmFnOjUwMDdjM2Y2ZmU3ODRhM2NiNjgzYmI5MjA3OWU5M2Y4L3RleHRyZWdpb246NTAwN2MzZjZmZTc4NGEzY2I2ODNiYjkyMDc5ZTkzZjhfMjcwNg_f0fcfd6f-8cb9-4f95-99f6-98966ed7879a">P2Y3M18D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i2af01b3faa6342e7982d6aae83905e36_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN183Ni9mcmFnOjUwMDdjM2Y2ZmU3ODRhM2NiNjgzYmI5MjA3OWU5M2Y4L3RleHRyZWdpb246NTAwN2MzZjZmZTc4NGEzY2I2ODNiYjkyMDc5ZTkzZjhfMjE5OTAyMzI2MDQ3MA_209f8a49-8cf4-497b-b1a8-7189d810165b"
      unitRef="usdPerShare">11.42</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="ia74c48fc7c3c456fa308825394481794_D20200101-20200331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN183Ni9mcmFnOjUwMDdjM2Y2ZmU3ODRhM2NiNjgzYmI5MjA3OWU5M2Y4L3RleHRyZWdpb246NTAwN2MzZjZmZTc4NGEzY2I2ODNiYjkyMDc5ZTkzZjhfMjk3OA_aff84960-7c5f-47ae-8775-a0a831f8a056"
      unitRef="usdPerShare">8.32</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensation
      contextRef="if21238de764544869449deb80f173e01_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN183Ni9mcmFnOjUwMDdjM2Y2ZmU3ODRhM2NiNjgzYmI5MjA3OWU5M2Y4L3RleHRyZWdpb246NTAwN2MzZjZmZTc4NGEzY2I2ODNiYjkyMDc5ZTkzZjhfMzI1MA_339423c9-0a16-4e7b-81db-be9eca13ffba"
      unitRef="usd">429000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i337096debaaf43d88b8dd9f4979cb062_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN183Ni9mcmFnOjUwMDdjM2Y2ZmU3ODRhM2NiNjgzYmI5MjA3OWU5M2Y4L3RleHRyZWdpb246NTAwN2MzZjZmZTc4NGEzY2I2ODNiYjkyMDc5ZTkzZjhfMjE5OTAyMzI2MDQ3NQ_fc0ce638-c956-4176-a3ae-b5bb548ad899"
      unitRef="usd">383000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i76e8a75098d84df7ac61105d88d25844_D20200828-20200828"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN183Ni9mcmFnOjUwMDdjM2Y2ZmU3ODRhM2NiNjgzYmI5MjA3OWU5M2Y4L3RleHRyZWdpb246NTAwN2MzZjZmZTc4NGEzY2I2ODNiYjkyMDc5ZTkzZjhfMzQ0Ng_a122ad86-fd34-4871-8b02-51112019ace0"
      unitRef="shares">663353</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="ie0eb7f9e131f4570be7731825dd8538f_D20200828-20200828"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN183Ni9mcmFnOjUwMDdjM2Y2ZmU3ODRhM2NiNjgzYmI5MjA3OWU5M2Y4L3RleHRyZWdpb246NTAwN2MzZjZmZTc4NGEzY2I2ODNiYjkyMDc5ZTkzZjhfMzU2Nw_78df6318-6c2a-4a84-b429-8af08d468ccb"
      unitRef="number">0.50</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="i21a58deaf4d24bd381a2d83d3a8d9889_D20200828-20200828"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN183Ni9mcmFnOjUwMDdjM2Y2ZmU3ODRhM2NiNjgzYmI5MjA3OWU5M2Y4L3RleHRyZWdpb246NTAwN2MzZjZmZTc4NGEzY2I2ODNiYjkyMDc5ZTkzZjhfMzY4OQ_a4b8175b-88b1-48e3-8ccb-d8cf05b7b23c"
      unitRef="number">0.50</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i21a58deaf4d24bd381a2d83d3a8d9889_D20200828-20200828"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN183Ni9mcmFnOjUwMDdjM2Y2ZmU3ODRhM2NiNjgzYmI5MjA3OWU5M2Y4L3RleHRyZWdpb246NTAwN2MzZjZmZTc4NGEzY2I2ODNiYjkyMDc5ZTkzZjhfNDE0OA_c6105838-103f-4030-84f9-8c17b8040518">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <ino:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodGrantDateFairValue
      contextRef="i76e8a75098d84df7ac61105d88d25844_D20200828-20200828"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN183Ni9mcmFnOjUwMDdjM2Y2ZmU3ODRhM2NiNjgzYmI5MjA3OWU5M2Y4L3RleHRyZWdpb246NTAwN2MzZjZmZTc4NGEzY2I2ODNiYjkyMDc5ZTkzZjhfMzg0OA_db9f9466-7429-42d0-af11-44c386eead91"
      unitRef="usd">8000000.0</ino:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i76e8a75098d84df7ac61105d88d25844_D20200828-20200828"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN183Ni9mcmFnOjUwMDdjM2Y2ZmU3ODRhM2NiNjgzYmI5MjA3OWU5M2Y4L3RleHRyZWdpb246NTAwN2MzZjZmZTc4NGEzY2I2ODNiYjkyMDc5ZTkzZjhfMzkwMg_4e9239ba-0e45-4047-8627-ac36fb1a2ecb"
      unitRef="usdPerShare">12.06</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock
      contextRef="i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN183OS9mcmFnOjA4NzBhNjMwYjg4OTRlNTk4NzAwM2Q2NWZhMmI0NzVjL3RleHRyZWdpb246MDg3MGE2MzBiODg5NGU1OTg3MDAzZDY1ZmEyYjQ3NWNfODI2MA_8397f2ec-e717-4a19-9b0a-1a2fefd70cb0">Related Party Transactions&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Plumbline Life Sciences, Inc.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company owns 597,808 shares of common stock in PLS as of March&#160;31, 2021, representing a 19.7% ownership interest, and one of the Company's directors, Dr.&#160;David B. Weiner, acts as a consultant to PLS.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenue recognized from PLS consists of milestone, license and patent fees. For the three months ended March 31, 2021 and 2020, the Company recognized revenue from PLS of $50,000 and $1.1 million, respectively. At March&#160;31, 2021 and December&#160;31, 2020, the Company had an accounts receivable balance of $80,000 and $67,000, respectively, related to PLS.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;The Wistar Institute&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's director Dr.&#160;David B. Weiner is a director of the Vaccine Center of The Wistar Institute ("Wistar"). Dr. Weiner is also the Executive Vice President of Wistar.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2016, the Company entered into collaborative research agreements with Wistar&#160;for preventive and therapeutic DNA-based immunotherapy applications and products developed by&#160;Dr. Weiner and Wistar for the treatment of cancers and infectious diseases. Under the terms of the agreement, the Company reimbursed Wistar for all direct and indirect costs incurred in the conduct of the collaborative research, not to exceed $3.1 million during the five-year term of the agreements. In March 2021, upon expiration of the March 2016 agreements, the Company entered into new collaborative research agreements with Wistar&#160;with the same terms. The Company has the exclusive right to in-license new intellectual property developed under the agreements.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2016, the Company received a&#160;$6.1 million&#160;sub-grant through Wistar to develop a DMAb against the Zika infection, with funding through June 2021. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is also a collaborator with Wistar on an Integrated Preclinical/Clinical AIDS Vaccine Development grant from the NIAID, with funding through February 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2020, the Company received a $10.7&#160;million sub-grant through Wistar for the preclinical development and translational studies of DMAbs as countermeasures for COVID-19, with funding through September 2022. The sub-grant also includes an option for an additional $6.0&#160;million in funding through September 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred grant funding recognized from Wistar and recorded as contra-research and development expense is related to work performed by the Company on the research sub-contract agreements. For the three months ended March 31, 2021 and 2020, the Company recorded $230,000 and $619,000, respectively, as contra-research and development expense from Wistar. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development expenses recorded from Wistar relate primarily to the collaborative research agreements and sub-contract agreements related to the Bill &amp;amp; Melinda Gates Foundation and CEPI (see Note 15). Research and development expenses recorded from Wistar for the three months ended March 31, 2021 and 2020 were $318,000 and $362,000, respectively. At March&#160;31, 2021 and December&#160;31, 2020, the Company had an accounts receivable balance of $256,000 and $425,000, respectively, and an accounts payable and accrued liability balance of $768,000 and $643,000, respectively, related to Wistar. As of March&#160;31, 2021, the Company had $76,000 recorded as deferred grant funding on the condensed consolidated balance sheet related to Wistar.&lt;/span&gt;&lt;/div&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:InvestmentOwnedBalanceShares
      contextRef="i4f1544da548041ab8ee6e7df0bf9ef61_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN183OS9mcmFnOjA4NzBhNjMwYjg4OTRlNTk4NzAwM2Q2NWZhMmI0NzVjL3RleHRyZWdpb246MDg3MGE2MzBiODg5NGU1OTg3MDAzZDY1ZmEyYjQ3NWNfNTIyOQ_d9b80fe7-adff-49a9-89f2-cadeeb021b2a"
      unitRef="shares">597808</us-gaap:InvestmentOwnedBalanceShares>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="i4f1544da548041ab8ee6e7df0bf9ef61_I20210331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN183OS9mcmFnOjA4NzBhNjMwYjg4OTRlNTk4NzAwM2Q2NWZhMmI0NzVjL3RleHRyZWdpb246MDg3MGE2MzBiODg5NGU1OTg3MDAzZDY1ZmEyYjQ3NWNfMTA5OTUxMTY0NjgyMg_f1f9723c-1bf3-41c2-b9c5-52328e8693dc"
      unitRef="number">0.197</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia2b43dbe48ac4cd98a40e26498a7f881_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN183OS9mcmFnOjA4NzBhNjMwYjg4OTRlNTk4NzAwM2Q2NWZhMmI0NzVjL3RleHRyZWdpb246MDg3MGE2MzBiODg5NGU1OTg3MDAzZDY1ZmEyYjQ3NWNfNTg3MQ_a91ec5f4-d52b-4b79-b092-0076f45552f9"
      unitRef="usd">50000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4c79f6b4729a4ff692ed11a1379cdfcf_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN183OS9mcmFnOjA4NzBhNjMwYjg4OTRlNTk4NzAwM2Q2NWZhMmI0NzVjL3RleHRyZWdpb246MDg3MGE2MzBiODg5NGU1OTg3MDAzZDY1ZmEyYjQ3NWNfMjE5OTAyMzI3Mjg3Nw_bbeec715-d6cf-4620-868c-c291d3a39756"
      unitRef="usd">1100000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:AccountsReceivableRelatedParties
      contextRef="i5ee95bf76bdd417884688328e2d20f81_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN183OS9mcmFnOjA4NzBhNjMwYjg4OTRlNTk4NzAwM2Q2NWZhMmI0NzVjL3RleHRyZWdpb246MDg3MGE2MzBiODg5NGU1OTg3MDAzZDY1ZmEyYjQ3NWNfNjAwMA_4e45439f-e02a-4b76-b402-9dfcc43b9024"
      unitRef="usd">80000</us-gaap:AccountsReceivableRelatedParties>
    <us-gaap:AccountsReceivableRelatedParties
      contextRef="i02eea4d019a94e66ae415d3736f47a49_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN183OS9mcmFnOjA4NzBhNjMwYjg4OTRlNTk4NzAwM2Q2NWZhMmI0NzVjL3RleHRyZWdpb246MDg3MGE2MzBiODg5NGU1OTg3MDAzZDY1ZmEyYjQ3NWNfNjAwNw_c13a9f80-ef70-4019-887c-704a01224f04"
      unitRef="usd">67000</us-gaap:AccountsReceivableRelatedParties>
    <ino:CollaborativeAgreementExpensesToReimburse
      contextRef="iad065e9a7d2a4690b34e02a44f8e04ee_D20160301-20160331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN183OS9mcmFnOjA4NzBhNjMwYjg4OTRlNTk4NzAwM2Q2NWZhMmI0NzVjL3RleHRyZWdpb246MDg3MGE2MzBiODg5NGU1OTg3MDAzZDY1ZmEyYjQ3NWNfNjY2Mw_970dff57-278d-4481-a959-1bfa6d18f0e5"
      unitRef="usd">3100000</ino:CollaborativeAgreementExpensesToReimburse>
    <ino:CollaborativeArrangementTerm
      contextRef="iad065e9a7d2a4690b34e02a44f8e04ee_D20160301-20160331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN183OS9mcmFnOjA4NzBhNjMwYjg4OTRlNTk4NzAwM2Q2NWZhMmI0NzVjL3RleHRyZWdpb246MDg3MGE2MzBiODg5NGU1OTg3MDAzZDY1ZmEyYjQ3NWNfODI1Ng_405b6541-e6c3-49f7-9eca-99f96004752c">P5Y</ino:CollaborativeArrangementTerm>
    <ino:CollaborativeAgreementAwardedAmount
      contextRef="i22530cebfa2d4a3587a9140e7fb29bb7_D20161101-20161130"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN183OS9mcmFnOjA4NzBhNjMwYjg4OTRlNTk4NzAwM2Q2NWZhMmI0NzVjL3RleHRyZWdpb246MDg3MGE2MzBiODg5NGU1OTg3MDAzZDY1ZmEyYjQ3NWNfNjg2NQ_309ea6bc-e45d-42c6-8fbe-db9aabe41bd2"
      unitRef="usd">6100000</ino:CollaborativeAgreementAwardedAmount>
    <ino:CollaborativeAgreementAwardedAmount
      contextRef="if8801c14501949e385e60e1272378e9f_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN183OS9mcmFnOjA4NzBhNjMwYjg4OTRlNTk4NzAwM2Q2NWZhMmI0NzVjL3RleHRyZWdpb246MDg3MGE2MzBiODg5NGU1OTg3MDAzZDY1ZmEyYjQ3NWNfMjE5OTAyMzI3MjgxNA_cbb6d622-2f2b-4330-8457-b25fc380e6ae"
      unitRef="usd">10700000</ino:CollaborativeAgreementAwardedAmount>
    <ino:CollaborativeAgreementAwardedOptionAmount
      contextRef="if8801c14501949e385e60e1272378e9f_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN183OS9mcmFnOjA4NzBhNjMwYjg4OTRlNTk4NzAwM2Q2NWZhMmI0NzVjL3RleHRyZWdpb246MDg3MGE2MzBiODg5NGU1OTg3MDAzZDY1ZmEyYjQ3NWNfMjE5OTAyMzI3MjgyOQ_7964814a-cd95-4a6d-aa32-cca6ae1dc7ce"
      unitRef="usd">6000000.0</ino:CollaborativeAgreementAwardedOptionAmount>
    <ino:GrantProceedsReceived
      contextRef="i6e8d2f7132dd4ad696314336b323045a_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN183OS9mcmFnOjA4NzBhNjMwYjg4OTRlNTk4NzAwM2Q2NWZhMmI0NzVjL3RleHRyZWdpb246MDg3MGE2MzBiODg5NGU1OTg3MDAzZDY1ZmEyYjQ3NWNfNzM4OQ_60de2070-1946-4ffa-a417-0b53daf02bd8"
      unitRef="usd">230000</ino:GrantProceedsReceived>
    <ino:GrantProceedsReceived
      contextRef="ib9b1dac9eb2f4b86842d7bbf220a3ec9_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN183OS9mcmFnOjA4NzBhNjMwYjg4OTRlNTk4NzAwM2Q2NWZhMmI0NzVjL3RleHRyZWdpb246MDg3MGE2MzBiODg5NGU1OTg3MDAzZDY1ZmEyYjQ3NWNfNzQ1MA_662657eb-164f-4886-a907-6e618e990a89"
      unitRef="usd">619000</ino:GrantProceedsReceived>
    <us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
      contextRef="i6e8d2f7132dd4ad696314336b323045a_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN183OS9mcmFnOjA4NzBhNjMwYjg4OTRlNTk4NzAwM2Q2NWZhMmI0NzVjL3RleHRyZWdpb246MDg3MGE2MzBiODg5NGU1OTg3MDAzZDY1ZmEyYjQ3NWNfNzgxNw_a599da5a-5a41-4e03-8656-e404a9302ee4"
      unitRef="usd">318000</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
    <us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
      contextRef="ib9b1dac9eb2f4b86842d7bbf220a3ec9_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN183OS9mcmFnOjA4NzBhNjMwYjg4OTRlNTk4NzAwM2Q2NWZhMmI0NzVjL3RleHRyZWdpb246MDg3MGE2MzBiODg5NGU1OTg3MDAzZDY1ZmEyYjQ3NWNfNzkxMw_450b63c9-a4f3-4907-bf81-fa1b33e71a6a"
      unitRef="usd">362000</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
    <us-gaap:AccountsReceivableRelatedParties
      contextRef="iab8d55f8b4464cb1af38f6596cf6b33d_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN183OS9mcmFnOjA4NzBhNjMwYjg4OTRlNTk4NzAwM2Q2NWZhMmI0NzVjL3RleHRyZWdpb246MDg3MGE2MzBiODg5NGU1OTg3MDAzZDY1ZmEyYjQ3NWNfODAwMg_2b24c23b-ff22-4d37-a4ca-56b9ea4e5149"
      unitRef="usd">256000</us-gaap:AccountsReceivableRelatedParties>
    <us-gaap:AccountsReceivableRelatedParties
      contextRef="ie31e1b7159e7405fb6b7791df154daf6_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN183OS9mcmFnOjA4NzBhNjMwYjg4OTRlNTk4NzAwM2Q2NWZhMmI0NzVjL3RleHRyZWdpb246MDg3MGE2MzBiODg5NGU1OTg3MDAzZDY1ZmEyYjQ3NWNfODAwOQ_aea272c2-204f-4e62-94a2-8116ca63cd2c"
      unitRef="usd">425000</us-gaap:AccountsReceivableRelatedParties>
    <us-gaap:DueToRelatedPartiesCurrentAndNoncurrent
      contextRef="iab8d55f8b4464cb1af38f6596cf6b33d_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN183OS9mcmFnOjA4NzBhNjMwYjg4OTRlNTk4NzAwM2Q2NWZhMmI0NzVjL3RleHRyZWdpb246MDg3MGE2MzBiODg5NGU1OTg3MDAzZDY1ZmEyYjQ3NWNfODA4NA_074a9a65-e890-43f8-a454-3a2da899a3c1"
      unitRef="usd">768000</us-gaap:DueToRelatedPartiesCurrentAndNoncurrent>
    <us-gaap:DueToRelatedPartiesCurrentAndNoncurrent
      contextRef="ie31e1b7159e7405fb6b7791df154daf6_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN183OS9mcmFnOjA4NzBhNjMwYjg4OTRlNTk4NzAwM2Q2NWZhMmI0NzVjL3RleHRyZWdpb246MDg3MGE2MzBiODg5NGU1OTg3MDAzZDY1ZmEyYjQ3NWNfODA5MQ_b90e2c09-7901-4610-aea4-4529516fe9d0"
      unitRef="usd">643000</us-gaap:DueToRelatedPartiesCurrentAndNoncurrent>
    <ino:DeferredGrantFundingFromAffiliate
      contextRef="iab8d55f8b4464cb1af38f6596cf6b33d_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN183OS9mcmFnOjA4NzBhNjMwYjg4OTRlNTk4NzAwM2Q2NWZhMmI0NzVjL3RleHRyZWdpb246MDg3MGE2MzBiODg5NGU1OTg3MDAzZDY1ZmEyYjQ3NWNfODE1NA_b07b0b3b-5ca8-485b-a083-ea287b865898"
      unitRef="usd">76000</ino:DeferredGrantFundingFromAffiliate>
    <us-gaap:LesseeOperatingLeasesTextBlock
      contextRef="i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN184Mi9mcmFnOjhhYmI3MjAyY2NjMzQwY2M5NzJhN2FjZmVkZmRjZDQxL3RleHRyZWdpb246OGFiYjcyMDJjY2MzNDBjYzk3MmE3YWNmZWRmZGNkNDFfMjk5NQ_c6c4217e-aa93-485f-9512-9df4a52cf5bf">Leases                                                  &lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company leases approximately 82,200 square feet of office, laboratory, and manufacturing space in San Diego, California and 57,360 square feet of office space in Plymouth Meeting, Pennsylvania under various non-cancellable operating lease agreements with remaining lease terms as of March&#160;31, 2021&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; of 2.7 to 8.8 ye&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ars, which represent the non-cancellable periods of the leases. The Company has excluded the extension options from its lease terms in the calculation of future lease payments as they are not reasonably certain to be exercised. The Company's lease payments consist primarily of fixed rental payments for the right to use the underlying leased assets over the lease terms as well as payments for common area maintenance and administrative services. The Company has received customary incentives from its landlords, such as reimbursements for tenant improvements and rent abatement periods, which effectively reduce the total lease payments owed for these leases.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company performed an evaluation of its contracts with customers and suppliers in accordance with ASC Topic 842 and determined that, except for the real estate leases described above and various copier leases, none of its other contracts contain a right-of-use asset. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating lease right-of-use assets and liabilities on the condensed consolidated balance sheet represents the present value of the remaining lease payments over the remaining lease terms. Payments for additional monthly fees to cover the Company's share of certain facility expenses are not included in operating lease right-of-use assets and liabilities. The Company uses its incremental borrowing rate to calculate the present value of its lease payments, as the implicit rates in the leases are not readily determinable.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%"&gt;As of March&#160;31, 2021, the maturities of the Company's operating lease liabilities were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:85.449%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.351%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Remainder of 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,983,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,045,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,023,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,001,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,063,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,888,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Total remaining lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,003,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: present value adjustment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,168,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Total operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,835,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,396,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,439,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average remaining lease term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.2 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.5%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Lease costs included in operating expenses in the condensed consolidated statements of operations for the three months ended March 31, 2021 and 2020 were $850,000 and $834,000, respectively. Operating lease costs consisting of the fixed lease payments included in operating lease liabilities are recorded on a straight-line basis over the lease terms. Variable lease costs are recorded as incurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the fourth quarter of 2019, the Company entered into two agreements to sublease a total of approximately 13,500 square feet in its Plymouth Meeting headquarters through periods between December 31, 2022 and March 31, 2025.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the normal course of business, the Company is a party to a variety of agreements pursuant to which it may be obligated to indemnify the other party. It is not possible to predict the maximum potential amount of future payments under these types of agreements due to the conditional nature of the Company's obligations and the unique facts and circumstances involved in each particular agreement. Historically, payments made by the Company under these types of agreements have not had a material effect on its business, consolidated results of operations or financial condition.&lt;/span&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <ino:LesseeOperatingLeaseAreaofLandUnderLease
      contextRef="ie67e1db182b94da1b67c475206b65805_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN184Mi9mcmFnOjhhYmI3MjAyY2NjMzQwY2M5NzJhN2FjZmVkZmRjZDQxL3RleHRyZWdpb246OGFiYjcyMDJjY2MzNDBjYzk3MmE3YWNmZWRmZGNkNDFfMTAw_2cbaae33-33d8-42f2-a0c7-edc2243bfbf2"
      unitRef="sqft">82200</ino:LesseeOperatingLeaseAreaofLandUnderLease>
    <ino:LesseeOperatingLeaseAreaofLandUnderLease
      contextRef="ib2743077b3474815ac3d7d4bbcd3dbd9_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN184Mi9mcmFnOjhhYmI3MjAyY2NjMzQwY2M5NzJhN2FjZmVkZmRjZDQxL3RleHRyZWdpb246OGFiYjcyMDJjY2MzNDBjYzk3MmE3YWNmZWRmZGNkNDFfMTkx_4757d922-3bd7-4b8d-9e28-67f5479cf2aa"
      unitRef="sqft">57360</ino:LesseeOperatingLeaseAreaofLandUnderLease>
    <us-gaap:LesseeOperatingLeaseRemainingLeaseTerm
      contextRef="ic4e4f4221dec4206a08ffb18e83ff0e2_I20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN184Mi9mcmFnOjhhYmI3MjAyY2NjMzQwY2M5NzJhN2FjZmVkZmRjZDQxL3RleHRyZWdpb246OGFiYjcyMDJjY2MzNDBjYzk3MmE3YWNmZWRmZGNkNDFfMzUy_4ba24181-720b-441d-a3f8-1381983c049a">P2Y8M12D</us-gaap:LesseeOperatingLeaseRemainingLeaseTerm>
    <us-gaap:LesseeOperatingLeaseRemainingLeaseTerm
      contextRef="i02dc7b8bd133444db127be6bff5fedf5_I20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN184Mi9mcmFnOjhhYmI3MjAyY2NjMzQwY2M5NzJhN2FjZmVkZmRjZDQxL3RleHRyZWdpb246OGFiYjcyMDJjY2MzNDBjYzk3MmE3YWNmZWRmZGNkNDFfMzU4_999876d0-ff44-4b52-9eab-dc6c7e83bd92">P8Y9M18D</us-gaap:LesseeOperatingLeaseRemainingLeaseTerm>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN184Mi9mcmFnOjhhYmI3MjAyY2NjMzQwY2M5NzJhN2FjZmVkZmRjZDQxL3RleHRyZWdpb246OGFiYjcyMDJjY2MzNDBjYzk3MmE3YWNmZWRmZGNkNDFfMzAwMg_33a36ea9-b23e-4e4d-8197-0ba1e995db3c">&lt;div style="text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%"&gt;As of March&#160;31, 2021, the maturities of the Company's operating lease liabilities were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:85.449%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.351%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Remainder of 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,983,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,045,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,023,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,001,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,063,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,888,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Total remaining lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,003,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: present value adjustment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,168,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Total operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,835,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,396,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,439,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average remaining lease term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.2 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.5%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
      contextRef="ic36b9cedad7f41a6b9eb223b09b7186c_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN184Mi9mcmFnOjhhYmI3MjAyY2NjMzQwY2M5NzJhN2FjZmVkZmRjZDQxL3RhYmxlOjFhZmZhODk2ZTYyZjRiZGI4NTBlY2EzOTAzN2E2MmU0L3RhYmxlcmFuZ2U6MWFmZmE4OTZlNjJmNGJkYjg1MGVjYTM5MDM3YTYyZTRfMC0xLTEtMS0w_e986657f-d8aa-4e85-9241-89605835569b"
      unitRef="usd">2983000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="ic36b9cedad7f41a6b9eb223b09b7186c_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN184Mi9mcmFnOjhhYmI3MjAyY2NjMzQwY2M5NzJhN2FjZmVkZmRjZDQxL3RhYmxlOjFhZmZhODk2ZTYyZjRiZGI4NTBlY2EzOTAzN2E2MmU0L3RhYmxlcmFuZ2U6MWFmZmE4OTZlNjJmNGJkYjg1MGVjYTM5MDM3YTYyZTRfMS0xLTEtMS0w_33f04903-f7e1-4b50-ad9b-aca9a3e6feec"
      unitRef="usd">4045000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="ic36b9cedad7f41a6b9eb223b09b7186c_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN184Mi9mcmFnOjhhYmI3MjAyY2NjMzQwY2M5NzJhN2FjZmVkZmRjZDQxL3RhYmxlOjFhZmZhODk2ZTYyZjRiZGI4NTBlY2EzOTAzN2E2MmU0L3RhYmxlcmFuZ2U6MWFmZmE4OTZlNjJmNGJkYjg1MGVjYTM5MDM3YTYyZTRfMi0xLTEtMS0w_cdc7bb52-5b08-4bd9-84a9-cf57de5976ef"
      unitRef="usd">4023000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="ic36b9cedad7f41a6b9eb223b09b7186c_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN184Mi9mcmFnOjhhYmI3MjAyY2NjMzQwY2M5NzJhN2FjZmVkZmRjZDQxL3RhYmxlOjFhZmZhODk2ZTYyZjRiZGI4NTBlY2EzOTAzN2E2MmU0L3RhYmxlcmFuZ2U6MWFmZmE4OTZlNjJmNGJkYjg1MGVjYTM5MDM3YTYyZTRfMy0xLTEtMS0w_f913b585-6c81-4fb3-99d5-c0751e51e7fa"
      unitRef="usd">3001000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="ic36b9cedad7f41a6b9eb223b09b7186c_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN184Mi9mcmFnOjhhYmI3MjAyY2NjMzQwY2M5NzJhN2FjZmVkZmRjZDQxL3RhYmxlOjFhZmZhODk2ZTYyZjRiZGI4NTBlY2EzOTAzN2E2MmU0L3RhYmxlcmFuZ2U6MWFmZmE4OTZlNjJmNGJkYjg1MGVjYTM5MDM3YTYyZTRfNC0xLTEtMS0w_fa66b4ea-ee70-49f4-a5ff-c40ea15317f8"
      unitRef="usd">3063000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <ino:LesseeOperatingLeaseLiabilityToBePaidAfterYearFour
      contextRef="ic36b9cedad7f41a6b9eb223b09b7186c_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN184Mi9mcmFnOjhhYmI3MjAyY2NjMzQwY2M5NzJhN2FjZmVkZmRjZDQxL3RhYmxlOjFhZmZhODk2ZTYyZjRiZGI4NTBlY2EzOTAzN2E2MmU0L3RhYmxlcmFuZ2U6MWFmZmE4OTZlNjJmNGJkYjg1MGVjYTM5MDM3YTYyZTRfNS0xLTEtMS0w_b7f7192c-f546-4854-87c7-e4e605c9aa0a"
      unitRef="usd">9888000</ino:LesseeOperatingLeaseLiabilityToBePaidAfterYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="ic36b9cedad7f41a6b9eb223b09b7186c_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN184Mi9mcmFnOjhhYmI3MjAyY2NjMzQwY2M5NzJhN2FjZmVkZmRjZDQxL3RhYmxlOjFhZmZhODk2ZTYyZjRiZGI4NTBlY2EzOTAzN2E2MmU0L3RhYmxlcmFuZ2U6MWFmZmE4OTZlNjJmNGJkYjg1MGVjYTM5MDM3YTYyZTRfNi0xLTEtMS0w_e5b9da92-216d-41ab-b62a-f9c5de4d9fca"
      unitRef="usd">27003000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="ic36b9cedad7f41a6b9eb223b09b7186c_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN184Mi9mcmFnOjhhYmI3MjAyY2NjMzQwY2M5NzJhN2FjZmVkZmRjZDQxL3RhYmxlOjFhZmZhODk2ZTYyZjRiZGI4NTBlY2EzOTAzN2E2MmU0L3RhYmxlcmFuZ2U6MWFmZmE4OTZlNjJmNGJkYjg1MGVjYTM5MDM3YTYyZTRfNy0xLTEtMS0w_459f186b-86ed-4bd5-827d-e2c5c0329294"
      unitRef="usd">7168000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="ic36b9cedad7f41a6b9eb223b09b7186c_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN184Mi9mcmFnOjhhYmI3MjAyY2NjMzQwY2M5NzJhN2FjZmVkZmRjZDQxL3RhYmxlOjFhZmZhODk2ZTYyZjRiZGI4NTBlY2EzOTAzN2E2MmU0L3RhYmxlcmFuZ2U6MWFmZmE4OTZlNjJmNGJkYjg1MGVjYTM5MDM3YTYyZTRfOC0xLTEtMS0w_c1470a5e-a427-43a9-afed-11a243d01d74"
      unitRef="usd">19835000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="ic36b9cedad7f41a6b9eb223b09b7186c_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN184Mi9mcmFnOjhhYmI3MjAyY2NjMzQwY2M5NzJhN2FjZmVkZmRjZDQxL3RhYmxlOjFhZmZhODk2ZTYyZjRiZGI4NTBlY2EzOTAzN2E2MmU0L3RhYmxlcmFuZ2U6MWFmZmE4OTZlNjJmNGJkYjg1MGVjYTM5MDM3YTYyZTRfOS0xLTEtMS0w_824bedaf-9103-4d31-ab05-c2357a4c1c1b"
      unitRef="usd">2396000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="ic36b9cedad7f41a6b9eb223b09b7186c_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN184Mi9mcmFnOjhhYmI3MjAyY2NjMzQwY2M5NzJhN2FjZmVkZmRjZDQxL3RhYmxlOjFhZmZhODk2ZTYyZjRiZGI4NTBlY2EzOTAzN2E2MmU0L3RhYmxlcmFuZ2U6MWFmZmE4OTZlNjJmNGJkYjg1MGVjYTM5MDM3YTYyZTRfMTAtMS0xLTEtMA_1f861446-4502-45b5-823d-6078872515f0"
      unitRef="usd">17439000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="ic36b9cedad7f41a6b9eb223b09b7186c_I20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN184Mi9mcmFnOjhhYmI3MjAyY2NjMzQwY2M5NzJhN2FjZmVkZmRjZDQxL3RhYmxlOjFhZmZhODk2ZTYyZjRiZGI4NTBlY2EzOTAzN2E2MmU0L3RhYmxlcmFuZ2U6MWFmZmE4OTZlNjJmNGJkYjg1MGVjYTM5MDM3YTYyZTRfMTItMS0xLTEtMA_89c1fe95-aa2d-4920-97d5-26ef0a41d368">P7Y2M12D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="ic36b9cedad7f41a6b9eb223b09b7186c_I20210331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN184Mi9mcmFnOjhhYmI3MjAyY2NjMzQwY2M5NzJhN2FjZmVkZmRjZDQxL3RhYmxlOjFhZmZhODk2ZTYyZjRiZGI4NTBlY2EzOTAzN2E2MmU0L3RhYmxlcmFuZ2U6MWFmZmE4OTZlNjJmNGJkYjg1MGVjYTM5MDM3YTYyZTRfMTMtMS0xLTEtMA_a621a339-5b3d-4232-b3c1-a2fa6c218745"
      unitRef="number">0.085</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:LeaseCost
      contextRef="i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN184Mi9mcmFnOjhhYmI3MjAyY2NjMzQwY2M5NzJhN2FjZmVkZmRjZDQxL3RleHRyZWdpb246OGFiYjcyMDJjY2MzNDBjYzk3MmE3YWNmZWRmZGNkNDFfMjAyNw_5cd0300e-35e7-4b78-a387-545d42cc8a06"
      unitRef="usd">850000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="i03bccaa0abfb4733b1e2831ecde4e4e8_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN184Mi9mcmFnOjhhYmI3MjAyY2NjMzQwY2M5NzJhN2FjZmVkZmRjZDQxL3RleHRyZWdpb246OGFiYjcyMDJjY2MzNDBjYzk3MmE3YWNmZWRmZGNkNDFfMjE3NA_8e5b684a-9b3d-4fa8-9266-bc7fca229c8f"
      unitRef="usd">834000</us-gaap:LeaseCost>
    <ino:LesseeOperatingLeaseAreaofLandUnderLease
      contextRef="i49a24e6bc43d4cd9a7a914b19403f340_D20191001-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN184Mi9mcmFnOjhhYmI3MjAyY2NjMzQwY2M5NzJhN2FjZmVkZmRjZDQxL3RleHRyZWdpb246OGFiYjcyMDJjY2MzNDBjYzk3MmE3YWNmZWRmZGNkNDFfMjE5OTAyMzI1ODk3OA_4c64eb2f-8b2c-43f6-8f4e-cf5d68330e36"
      unitRef="sqft">13500</ino:LesseeOperatingLeaseAreaofLandUnderLease>
    <us-gaap:CollaborativeArrangementDisclosureTextBlock
      contextRef="i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN184NS9mcmFnOjE2ZTFhMGJhMzg4NjQzZWI4MzhlNGQ2ZWE5ODVjMzcwL3RleHRyZWdpb246MTZlMWEwYmEzODg2NDNlYjgzOGU0ZDZlYTk4NWMzNzBfMTMwNDM_b206af38-4dc9-495e-8432-d131c85584f9">Collaborative Agreements&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Advaccine Biopharmaceuticals Suzhou Co., Ltd. (Advaccine)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On December 31, 2020, the Company entered into a Collaboration and License Agreement (the &#x201c;Advaccine Agreement&#x201d;) with Advaccine. Under the terms of the Advaccine Agreement, the Company granted to Advaccine the exclusive right to develop, manufacture and commercialize the Company&#x2019;s vaccine candidate INO-4800 within the territories of China, Taiwan, Hong Kong and Macau (referred to collectively as &#x201c;Greater China&#x201d;). Advaccine does not have the right to grant sublicenses, other than to affiliated entities, without the Company&#x2019;s express prior written consent. As part of the collaboration, Advaccine has also granted to the Company a non-exclusive license to certain DNA vaccine manufacturing processes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the Advaccine Agreement, Advaccine made an upfront payment to the Company of $3.0&#160;million. In addition to the upfront payment, the Company is entitled to receive up to an aggregate of $108.0&#160;million upon the achievement of specified milestones related to the development, regulatory approval and commercialization of INO-4800, including the achievement of specified net sales thresholds for INO-4800 in Greater China, if approved. As of December 31, 2020 the Company had earned a $2.0&#160;million milestone payment based on the enrollment of the first subject in the Phase 2 clinical trial for the product in the Advaccine territory. The Company will also be entitled to receive a royalty equal to a high single-digit percentage of annual net sales in each region within Greater China, subject to reduction in the event of competition from biosimilar products in a particular region and in other specified circumstances. Advaccine&#x2019;s obligation to pay royalties will continue, on a licensed product-by-licensed product basis and region-by-region basis, for ten years after the first commercial sale in a particular region within Greater China or, if later, until the expiration of the last-to-expire patent covering a given licensed product in a given region.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the Advaccine Agreement, Advaccine is responsible for the development and commercialization of the licensed products at its own cost and expense and is obligated to use commercially reasonable efforts to develop, obtain and maintain regulatory approval of INO-4800, as well as the Company&#x2019;s CELLECTRA&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; device and arrays for use in connection with the administration of INO-4800, in each region in Greater China. In the event that the Company has not initiated the planned Phase 3 segment of its ongoing clinical trial of INO-4800 in the United States within one year after entering into the Advaccine Agreement, Advaccine may elect to conduct a Phase 3 clinical trial outside of Greater China at its own cost and expense for the purposes of obtaining regulatory approval in China, subject to the Company&#x2019;s right to review and approve the protocols and design of such a trial.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the Advaccine Agreement, the Company will supply Advaccine&#x2019;s clinical requirements of INO-4800 and devices, although Advaccine may manufacture INO-4800 for its clinical use and may procure alternate suppliers. Advaccine is responsible for the manufacture and supply of INO-4800 itself or through a contract manufacturer for commercial use. Upon Advaccine&#x2019;s reasonable request, the parties may negotiate a separate clinical and/or commercial supply agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Advaccine Agreement will continue in force on a region-by-region basis until Advaccine has no remaining royalty obligations in such region. Either party may terminate the Advaccine Agreement (i) in the event the other party shall have materially breached its obligations thereunder and such default shall have continued for a specified period after written notice thereof or (ii) upon the bankruptcy or insolvency of the other party. In addition, the Company may terminate the agreement, upon prior written notice, if Advaccine (i) ceases all development or commercialization activities for at least nine months, subject to certain exceptions, or (ii) challenges the validity, enforceability or scope of any of the patents licensed by the Company to Advaccine under the Advaccine Agreement, subject to certain conditions. Advaccine may terminate the Advaccine Agreement at any time for convenience upon nine months&#x2019; written notice to the Company, if such notice is provided before the first commercial sale of INO-4800 in Greater China, or 18 months&#x2019; written notice thereafter; provided that the Company may accelerate the effectiveness of such termination to the extent permitted by law.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company evaluated the terms of the Advaccine Agreement under ASC Topics 606 and 808, and determined that the contract was with a customer and therefore should be accounted for under ASC Topic 606. The license to INO-4800 in the territories was identified as the only distinct performance obligation on a standalone basis as of the inception of the Advaccine Agreement. The Company concluded that the license was distinct from potential future manufacturing and supply obligations. The Company further determined that the transaction price under the Advaccine Agreement consisted of the $3.0&#160;million upfront payment plus the initial $2.0&#160;million milestone payment which was achieved upon contract signing. The future potential milestone amounts were not included in the transaction price, as they were all determined to be fully constrained. As part of the evaluation of the development and regulatory milestones constraint, the Company determined that the achievement of such milestones is contingent upon success in future clinical trials and regulatory approvals, each of which is uncertain. Future potential milestone amounts may be recognized as revenue under the Advaccine Agreement, as well as under other collaborative research and development arrangements, if unconstrained. Reimbursable program costs will be recognized proportionately with the performance of the underlying services or delivery of drug supply and are excluded from the transaction price.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under Topic 606, the entire transaction price of $5.0&#160;million was allocated to the license performance obligation. The Company determined that as of December 31, 2020, the transfer of technology has occurred for the use and benefit of the license and accordingly, the performance obligation was fully satisfied. The Company accordingly recognized $5.0&#160;million in revenue under collaborative research and development arrangements on the consolidated statement of operations during the year ended December 31, 2020. During the three months ended March 31, 2021, no revenue was recognized from Advaccine.  As of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;March&#160;31, 2021 and &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;December 31, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2020&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, the Company had an accounts receivable balance of $0 and $7.1&#160;million, respectively, from Advaccine.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;ApolloBio Corporation &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On December&#160;29, 2017, the Company entered into an Amended and Restated License and Collaboration Agreement (the "ApolloBio Agreement"),&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;with ApolloBio Corporation ("ApolloBio"), with an effective date of March 20, 2018. Under the terms of the ApolloBio Agreement, the Company has granted to ApolloBio the exclusive right to develop and commercialize&#160;VGX-3100, its DNA immunotherapy product candidate designed to treat&#160;pre-cancers&#160;caused by HPV, within the territories of China, Hong Kong, Macao, Taiwan, and potentially Korea in the event that no patent covering&#160;VGX-3100&#160;is issued in China within the three years following the effective date of the ApolloBio Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the ApolloBio Agreement, the Company received proceeds of $19.4 million in March 2018 which comprised the upfront payment of $23.0 million less $2.2 million in foreign income taxes and $1.4 million in certain foreign non-income taxes. The foreign income taxes were recorded as a provision for income taxes and the foreign non-income taxes were recorded as a general and administrative expense, on the condensed consolidated statement of operations. The Company also incurred advisory fees of $960,000 in connection with receiving the upfront payment from ApolloBio. These fees were determined to be incremental costs of obtaining the contract. The Company applied the practical expedient that permits a company to expense incremental costs to obtain a contract when the expected amortization period is one year or less and recorded the fees in general and administrative expense during the quarter ended March 31, 2018. No additional advisory fees are due related to the ApolloBio Agreement. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition to the upfront payment, the Company is entitled to receive up to an aggregate of $20.0 million, less required income, withholding or other taxes, upon the achievement of specified milestones related to the regulatory approval of&#160;VGX-3100&#160;in the United States, China and Korea. In the event that&#160;VGX-3100 is approved for marketing, the Company will be entitled to receive royalty payments based on a tiered percentage of annual net sales, with such percentage being in the&#160;low-&#160;to&#160;mid-teens,&#160;subject to reduction in the event of generic competition in a particular territory. ApolloBio&#x2019;s obligation to pay royalties will continue for 10 years after the first commercial sale in a particular territory or, if later, until the expiration of the&#160;last-to-expire&#160;patent covering the licensed products in the specified territory. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The ApolloBio Agreement will continue in force until ApolloBio has no remaining royalty obligations. Either party may terminate the ApolloBio Agreement in the event the other party shall materially breach or default in the performance of its material obligations thereunder and such default continues for a specified period after written notice thereof. In addition, ApolloBio may terminate the ApolloBio Agreement at any time beginning one year after the effective date for any reason upon 90 days written notice to the Company.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company evaluated the terms of the ApolloBio Agreement under ASC Topic 606, and the license to VGX-3100 in the territories was identified as the only distinct performance obligation on a standalone basis as of the inception of the agreement.  The Company concluded that the license was distinct from potential future manufacturing and supply obligations. The Company further determined that the transaction price under the agreement consisted of the $23.0 million upfront payment.  The future potential milestone amounts were not included in the transaction price, as they were all determined to be fully constrained. As part of the evaluation of the development and regulatory milestones constraint, the Company determined that the achievement of such milestones is contingent upon success in future clinical trials and regulatory approvals, each of which is uncertain at this time. Future potential milestone amounts may be recognized as revenue under the ApolloBio Agreement, as &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;well as under other collaborative research and development arrangements, if unconstrained. Reimbursable program costs will be recognized proportionately with the performance of the underlying services or delivery of drug supply and are excluded from the transaction price. As of March&#160;31, 2021 there have been no significant reimbursable program costs under the ApolloBio Agreement.&lt;/span&gt;&lt;span style="color:#ee2724;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under Topic 606, the entire transaction price of $23.0 million was allocated to the license performance obligation. The Company determined that during the quarter ended June 30, 2018, the transfer of technology occurred and accordingly, the performance obligation was fully satisfied. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;AstraZeneca &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On August 7, 2015, the Company entered into a license and collaboration agreement with MedImmune, the global biologics research and development arm of AstraZeneca ("AstraZeneca"). Under the agreement, AstraZeneca acquired exclusive rights to the Company's INO-3112 immunotherapy, renamed as MEDI0457, which targets cancers caused by human papillomavirus (HPV) types 16 and 18, with the ability to sublicense those license rights. AstraZeneca made an upfront payment of $27.5 million to the Company in September 2015. AstraZeneca may be obligated to make potential future development and regulatory event-based payments to the Company totaling up to $125 million and potential future commercial event-based payments totaling up to $115 million, in each case upon the achievement of specified milestones related to MEDI0457 set forth in the license and collaboration agreement. AstraZeneca will fund all development costs associated with MEDI0457 immunotherapy. The Company is entitled to receive up to mid-single to double-digit tiered royalties on MEDI0457 product sales. Under the agreement, AstraZeneca can also request the Company to provide certain clinical manufacturing at an agreed upon price. The Company determined these options did not represent material rights at the inception of the agreement.   &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December 31, 2017, the Company had recognized all of the $27.5 million upfront payment as revenue, as all identified material performance obligations had been met with respect to that payme&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;nt. In both December 2018 and March 2019, the Company recognized as revenue $2.0&#160;million in milestone payments from AstraZeneca triggered by AstraZeneca&#x2019;s &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;initiation of the Phase 2 portion of ongoing clinical trials in the second and third major indication, respectively, under the agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Coalition for Epidemic Preparedness Innovations &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In April 2018, the Company entered into agreements with CEPI, pursuant to which the Company intends to develop vaccine candidates against Lassa fever and MERS. The goal of the collaboration between the Company and CEPI is to conduct research and development so that investigational stockpiles will be ready for clinical efficacy trial testing during potential disease outbreaks. The agreements with CEPI contemplate preclinical&#160;studies, as well as Phase 1 and Phase 2 clinical trials, occurring over multiple years. As part of the arrangement between the parties, CEPI has agreed to fund up to an aggregate of $56 million of costs over a five-year period for preclinical studies, as well as planned Phase 1 and Phase 2 clinical trials, to be conducted by the Company and collaborators, with funding from CEPI based on the achievement of identified milestones. During the three months ended March 31, 2021 and 2020, the Company received funding of $2.4 million and  $1.1 million, respectively, related to these grants and recorded those payments as contra-research and development expense. As of March&#160;31, 2021, the Company had $251,000 recorded as grant funding liability on the condensed consolidated balance sheet related to the CEPI grant. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In January 2020, CEPI awarded the Company a grant of up to $9.0 million to support preclinical and clinical development of INO-4800 through Phase 1 human testing in the United States. In April 2020, CEPI awarded the Company a grant of $6.9 million to work with the International Vaccine Institute ("IVI") and the Korea National Institute of Health ("KNIH") to conduct clinical trials of INO-4800 in South Korea, a grant of $5.0 million to accelerate development of  the Company's next-generation intradermal electroporation device, known as CELLECTRA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; 3PSP, for the intradermal delivery of INO-4800, and a grant of $1.3 million to support large-scale manufacturing of INO-4800. During each of the three months ended March 31, 2021 and 2020, the Company received funding of $2.4 million from CEPI related to these grants for INO-4800 and recorded such amounts as contra-research and development expense. As of March&#160;31, 2021, the Company had $4.0 million recorded as deferred grant funding on the condensed consolidated balance sheet related to the CEPI grants related to INO-4800.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Bill &amp;amp; Melinda Gates Foundation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2018, the Bill &amp;amp; Melinda Gates Foundation (&#x201c;Gates&#x201d;) awarded and funded the Company a grant of $2.2 million to advance the development of dMAbs to address issues in infectious disease prevention and therapy. This technology has high relevance for the control of influenza and HIV. This next-generation approach to the delivery of monoclonal antibodies would make the technology accessible to low and middle-income countries. In August 2019, Gates funded an additional $1.1 million for the project. During the three months ended March 31, 2021 and 2020, the Company recorded $0 and $134,000, respectively, as contra-research and development expense related to the Gates dMAb grant. As of March&#160;31, 2021, the Company had $660,000 recorded as deferred grant funding on the condensed consolidated balance sheet related to the grant.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2020, Gates awarded and funded the Company a grant of $5.0 million to accelerate the development of the &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;CELLECTRA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; 3PSP device for the intradermal delivery of INO-4800. During the three months ended March 31, 2021 and 2020, the Company recorded $893,000 and $64,000, respectively, as contra-research and development expense related to this Gates grant. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Department of Defense (DoD) &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2020, the Company entered into an Other Transaction Authority for Prototype Agreement (the &#x201c;OTA Agreement&#x201d;)&#160;with the DoD to fund the Company&#x2019;s efforts in developing the CELLECTRA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;3PSP device and associated arrays to be used for delivery of&#160;INO-4800 against&#160;COVID-19. Under the OTA Agreement, the Company intends to develop the CELLECTRA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; 3PSP device and arrays for use in the U.S. military population and the U.S. population as a whole, subject to approval of the device by the U.S. Food and Drug Administration (the &#x201c;FDA&#x201d;). The OTA Agreement is also expected to support large-scale manufacturing of the CELLECTRA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; 3PSP device, as well as large-scale DNA plasmid production for manufacture and supply of a specified number of doses of&#160;INO-4800&#160;in support of FDA approval of the device. The total amount of funding being made available to the Company under the OTA Agreement is approximately $54.5 million. The Company has determined that the OTA Agreement should be considered under Subtopic 958-605, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Not-for-Profit Entities-&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue Recognition&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, which is outside the scope of Topic 606, as the government agency granting the Company funds is not&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;receiving reciprocal value for their contributions. The Company will record contra-research development expense on the condensed consolidated statement of operations in the same period that the underlying expenses are incurred. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Additionally, in June 2020, the Company was awarded a fixed-price contract (the &#x201c;Procurement Contract&#x201d;) from the DoD for the purchase of the Company&#x2019;s intradermal CELLECTRA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#160;2000 device and accessories. The CELLECTRA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; 2000 devices will be used to inject&#160;INO-4800&#160;in the Company&#x2019;s planned later-stage clinical trials. The total purchase price under the Procurement Contract is approximately $16.6 million. The Company has determined that the Procurement Contract does not currently fall under the scope of ASC 606 as contingencies remain regarding INO-4800 which does not give the Company the ability to satisfy its obligations under the arrangement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three months ended March 31, 2021, the Company recorded $7.8&#160;million as contra-research and development expense related to these agreements with the DoD. As of March&#160;31, 2021 and December 31, 2020, the Company had an accounts receivable balance of $9.6&#160;million and $11.4&#160;million, respectively, on the condensed consolidated balance sheet from the DoD.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In April 2021, the Company announced that the DoD had notified the Company that it will discontinue funding for the Phase 3 segment of the Company's clinical trial of INO-4800 in the United States, while continuing to fund the completion of the ongoing Phase 2 segment.&lt;/span&gt;&lt;/div&gt;</us-gaap:CollaborativeArrangementDisclosureTextBlock>
    <ino:CollaborativeAgreementsUpfrontPaymentReceived
      contextRef="i16a0d0ea59c14de2b4879a3250ddd093_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN184NS9mcmFnOjE2ZTFhMGJhMzg4NjQzZWI4MzhlNGQ2ZWE5ODVjMzcwL3RleHRyZWdpb246MTZlMWEwYmEzODg2NDNlYjgzOGU0ZDZlYTk4NWMzNzBfMjE5OTAyMzI3OTcxNA_cda72955-d06c-4147-bab9-5d03ad5ad3f1"
      unitRef="usd">3000000.0</ino:CollaborativeAgreementsUpfrontPaymentReceived>
    <ino:CollaborationAgreementAdditionalRevenueToBeAchieved
      contextRef="i16a0d0ea59c14de2b4879a3250ddd093_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN184NS9mcmFnOjE2ZTFhMGJhMzg4NjQzZWI4MzhlNGQ2ZWE5ODVjMzcwL3RleHRyZWdpb246MTZlMWEwYmEzODg2NDNlYjgzOGU0ZDZlYTk4NWMzNzBfMjE5OTAyMzI3OTc5OA_862885f2-a51e-4730-a21c-cf6d5fbb731d"
      unitRef="usd">108000000.0</ino:CollaborationAgreementAdditionalRevenueToBeAchieved>
    <ino:CollaborationAgreementPaymentEarned
      contextRef="i16a0d0ea59c14de2b4879a3250ddd093_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN184NS9mcmFnOjE2ZTFhMGJhMzg4NjQzZWI4MzhlNGQ2ZWE5ODVjMzcwL3RleHRyZWdpb246MTZlMWEwYmEzODg2NDNlYjgzOGU0ZDZlYTk4NWMzNzBfMjE5OTAyMzI3OTcyOA_f7c26f9d-88bc-433b-9fff-eefa4aa3eac9"
      unitRef="usd">2000000.0</ino:CollaborationAgreementPaymentEarned>
    <ino:CollaborationAgreementRoyaltyPeriod
      contextRef="i16a0d0ea59c14de2b4879a3250ddd093_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN184NS9mcmFnOjE2ZTFhMGJhMzg4NjQzZWI4MzhlNGQ2ZWE5ODVjMzcwL3RleHRyZWdpb246MTZlMWEwYmEzODg2NDNlYjgzOGU0ZDZlYTk4NWMzNzBfNTQ5NzU1ODE2NTU1MQ_9870efab-3151-4461-8777-8bba10a05e23">P10Y</ino:CollaborationAgreementRoyaltyPeriod>
    <ino:CollaborativeAgreementPeriodFromEffectiveDateForTermination
      contextRef="i16a0d0ea59c14de2b4879a3250ddd093_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN184NS9mcmFnOjE2ZTFhMGJhMzg4NjQzZWI4MzhlNGQ2ZWE5ODVjMzcwL3RleHRyZWdpb246MTZlMWEwYmEzODg2NDNlYjgzOGU0ZDZlYTk4NWMzNzBfNTQ5NzU1ODE2NTU2OA_382adea3-61e3-4eb3-9d4b-7e97eefed7ed">P1Y</ino:CollaborativeAgreementPeriodFromEffectiveDateForTermination>
    <ino:CollaborativeAgreementsUpfrontPaymentReceived
      contextRef="i16a0d0ea59c14de2b4879a3250ddd093_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN184NS9mcmFnOjE2ZTFhMGJhMzg4NjQzZWI4MzhlNGQ2ZWE5ODVjMzcwL3RleHRyZWdpb246MTZlMWEwYmEzODg2NDNlYjgzOGU0ZDZlYTk4NWMzNzBfMjE5OTAyMzI3OTc0Mg_66d35f82-7062-4984-93e3-6a6536d659fc"
      unitRef="usd">3000000.0</ino:CollaborativeAgreementsUpfrontPaymentReceived>
    <ino:CollaborationAgreementPaymentEarned
      contextRef="i16a0d0ea59c14de2b4879a3250ddd093_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN184NS9mcmFnOjE2ZTFhMGJhMzg4NjQzZWI4MzhlNGQ2ZWE5ODVjMzcwL3RleHRyZWdpb246MTZlMWEwYmEzODg2NDNlYjgzOGU0ZDZlYTk4NWMzNzBfMjE5OTAyMzI3OTc1Ng_bfc0d170-8aa9-4330-a396-f8a55bb2d356"
      unitRef="usd">2000000.0</ino:CollaborationAgreementPaymentEarned>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i218a10d1c62a4a1d8cff8c3442114b71_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN184NS9mcmFnOjE2ZTFhMGJhMzg4NjQzZWI4MzhlNGQ2ZWE5ODVjMzcwL3RleHRyZWdpb246MTZlMWEwYmEzODg2NDNlYjgzOGU0ZDZlYTk4NWMzNzBfMjE5OTAyMzI3OTc3MA_78bcda29-2036-4ff6-bc92-01ac5e7233a8"
      unitRef="usd">5000000.0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i43ca7eb4e9604967b950979b7b65da58_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN184NS9mcmFnOjE2ZTFhMGJhMzg4NjQzZWI4MzhlNGQ2ZWE5ODVjMzcwL3RleHRyZWdpb246MTZlMWEwYmEzODg2NDNlYjgzOGU0ZDZlYTk4NWMzNzBfMjE5OTAyMzI3OTc4NA_442466ca-275a-4677-896f-acb7d075bbdb"
      unitRef="usd">5000000.0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iff19a2c26f364894a1393fb4bb5ed788_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN184NS9mcmFnOjE2ZTFhMGJhMzg4NjQzZWI4MzhlNGQ2ZWE5ODVjMzcwL3RleHRyZWdpb246MTZlMWEwYmEzODg2NDNlYjgzOGU0ZDZlYTk4NWMzNzBfMTA5OTUxMTY1MjczNA_9ef36836-4373-46d8-b627-e3692f52ef35"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:AccountsReceivableNet
      contextRef="i9e2527d562564d0da42bfadc4214aabf_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN184NS9mcmFnOjE2ZTFhMGJhMzg4NjQzZWI4MzhlNGQ2ZWE5ODVjMzcwL3RleHRyZWdpb246MTZlMWEwYmEzODg2NDNlYjgzOGU0ZDZlYTk4NWMzNzBfMjE5OTAyMzI3OTg2Mg_ca25634d-2a76-440b-9830-3e4caf059118"
      unitRef="usd">0</us-gaap:AccountsReceivableNet>
    <us-gaap:AccountsReceivableNet
      contextRef="ie9a3ac315bd64233b038ae99d2926ee5_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN184NS9mcmFnOjE2ZTFhMGJhMzg4NjQzZWI4MzhlNGQ2ZWE5ODVjMzcwL3RleHRyZWdpb246MTZlMWEwYmEzODg2NDNlYjgzOGU0ZDZlYTk4NWMzNzBfNTQ5NzU1ODE2NTU4NQ_c05f9e52-3761-46c1-8150-ab70877e33f4"
      unitRef="usd">7100000</us-gaap:AccountsReceivableNet>
    <ino:CollaborationAgreementTerritoryExpansionOptionPeriod
      contextRef="i4ae78b29c7ad4225be2a6e2ef791b855_D20171229-20171229"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN184NS9mcmFnOjE2ZTFhMGJhMzg4NjQzZWI4MzhlNGQ2ZWE5ODVjMzcwL3RleHRyZWdpb246MTZlMWEwYmEzODg2NDNlYjgzOGU0ZDZlYTk4NWMzNzBfNjU5_6f122f5a-255d-4cef-9ef2-04c2470860be">P3Y</ino:CollaborationAgreementTerritoryExpansionOptionPeriod>
    <ino:ProceedsFromCollaborativeAgreement
      contextRef="ifb1c860482c945d2b8d0a23ea9de9d2b_D20180301-20180331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN184NS9mcmFnOjE2ZTFhMGJhMzg4NjQzZWI4MzhlNGQ2ZWE5ODVjMzcwL3RleHRyZWdpb246MTZlMWEwYmEzODg2NDNlYjgzOGU0ZDZlYTk4NWMzNzBfNzgz_b0ac66a0-73a4-486d-9d66-7bcce6c5e323"
      unitRef="usd">19400000</ino:ProceedsFromCollaborativeAgreement>
    <ino:CollaborativeAgreementsUpfrontPaymentReceived
      contextRef="ifb1c860482c945d2b8d0a23ea9de9d2b_D20180301-20180331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN184NS9mcmFnOjE2ZTFhMGJhMzg4NjQzZWI4MzhlNGQ2ZWE5ODVjMzcwL3RleHRyZWdpb246MTZlMWEwYmEzODg2NDNlYjgzOGU0ZDZlYTk4NWMzNzBfODM5_c31f1af8-f5f8-489a-9851-479208d2b957"
      unitRef="usd">23000000.0</ino:CollaborativeAgreementsUpfrontPaymentReceived>
    <ino:CollaborativeAgreementCorporateIncomeTax
      contextRef="ic48f2b7387c740dda32316adb9b93c55_D20180301-20180331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN184NS9mcmFnOjE2ZTFhMGJhMzg4NjQzZWI4MzhlNGQ2ZWE5ODVjMzcwL3RleHRyZWdpb246MTZlMWEwYmEzODg2NDNlYjgzOGU0ZDZlYTk4NWMzNzBfODQ3_5c1e77ae-6f2b-47eb-ac3b-efe3b844b286"
      unitRef="usd">2200000</ino:CollaborativeAgreementCorporateIncomeTax>
    <ino:CollaborativeAgreementForeignNonIncomeTaxes
      contextRef="ic48f2b7387c740dda32316adb9b93c55_D20180301-20180331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN184NS9mcmFnOjE2ZTFhMGJhMzg4NjQzZWI4MzhlNGQ2ZWE5ODVjMzcwL3RleHRyZWdpb246MTZlMWEwYmEzODg2NDNlYjgzOGU0ZDZlYTk4NWMzNzBfODc4_14b09597-0d27-4ecc-a5a8-54de8d8adcdf"
      unitRef="usd">1400000</ino:CollaborativeAgreementForeignNonIncomeTaxes>
    <ino:CollaborativeAgreementAdvisoryFees
      contextRef="ifcaf1ba492eb44b08dea1762e6aae5a6_I20180331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN184NS9mcmFnOjE2ZTFhMGJhMzg4NjQzZWI4MzhlNGQ2ZWE5ODVjMzcwL3RleHRyZWdpb246MTZlMWEwYmEzODg2NDNlYjgzOGU0ZDZlYTk4NWMzNzBfMTE3NQ_994f264f-9963-40ad-ad5a-96ed5b5edf55"
      unitRef="usd">960000</ino:CollaborativeAgreementAdvisoryFees>
    <ino:CollaborationAgreementAdditionalRevenueToBeAchieved
      contextRef="ibfe7179d0c314ec8b6575735e5576485_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN184NS9mcmFnOjE2ZTFhMGJhMzg4NjQzZWI4MzhlNGQ2ZWE5ODVjMzcwL3RleHRyZWdpb246MTZlMWEwYmEzODg2NDNlYjgzOGU0ZDZlYTk4NWMzNzBfMTc2Mw_ad02e6d6-6d19-4139-b0a1-07736e73e2a7"
      unitRef="usd">20000000.0</ino:CollaborationAgreementAdditionalRevenueToBeAchieved>
    <ino:CollaborationAgreementRoyaltyPeriod
      contextRef="ibfe7179d0c314ec8b6575735e5576485_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN184NS9mcmFnOjE2ZTFhMGJhMzg4NjQzZWI4MzhlNGQ2ZWE5ODVjMzcwL3RleHRyZWdpb246MTZlMWEwYmEzODg2NDNlYjgzOGU0ZDZlYTk4NWMzNzBfMjMwNA_6547788c-fecc-4360-9e06-6a73733978ee">P10Y</ino:CollaborationAgreementRoyaltyPeriod>
    <ino:CollaborativeAgreementPeriodFromEffectiveDateForTermination
      contextRef="ibfe7179d0c314ec8b6575735e5576485_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN184NS9mcmFnOjE2ZTFhMGJhMzg4NjQzZWI4MzhlNGQ2ZWE5ODVjMzcwL3RleHRyZWdpb246MTZlMWEwYmEzODg2NDNlYjgzOGU0ZDZlYTk4NWMzNzBfMTA5OTUxMTY2MTIwMA_4f98766d-6cce-419a-ad2c-1f208a963db3">P1Y</ino:CollaborativeAgreementPeriodFromEffectiveDateForTermination>
    <ino:CollaborativeAgreementNumberofDaysWrittenNoticeBeforeTermination
      contextRef="ibfe7179d0c314ec8b6575735e5576485_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN184NS9mcmFnOjE2ZTFhMGJhMzg4NjQzZWI4MzhlNGQ2ZWE5ODVjMzcwL3RleHRyZWdpb246MTZlMWEwYmEzODg2NDNlYjgzOGU0ZDZlYTk4NWMzNzBfMTA5OTUxMTY2MTI0OQ_e9d1ee16-fe4b-4221-a612-30202cbacbe5">P90D</ino:CollaborativeAgreementNumberofDaysWrittenNoticeBeforeTermination>
    <ino:CollaborativeAgreementsUpfrontPaymentReceived
      contextRef="ibfe7179d0c314ec8b6575735e5576485_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN184NS9mcmFnOjE2ZTFhMGJhMzg4NjQzZWI4MzhlNGQ2ZWE5ODVjMzcwL3RleHRyZWdpb246MTZlMWEwYmEzODg2NDNlYjgzOGU0ZDZlYTk4NWMzNzBfMjk0Mw_06835947-65f2-4c51-8425-242aedc4b973"
      unitRef="usd">23000000.0</ino:CollaborativeAgreementsUpfrontPaymentReceived>
    <ino:CollaborativeAgreementsUpfrontPaymentReceived
      contextRef="i166171f55c2146e6a9bfc1cbda21593f_D20180401-20180630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN184NS9mcmFnOjE2ZTFhMGJhMzg4NjQzZWI4MzhlNGQ2ZWE5ODVjMzcwL3RleHRyZWdpb246MTZlMWEwYmEzODg2NDNlYjgzOGU0ZDZlYTk4NWMzNzBfNDMxMA_c91a1dae-390e-4392-8728-45ad02e7ac15"
      unitRef="usd">23000000.0</ino:CollaborativeAgreementsUpfrontPaymentReceived>
    <ino:CollaborativeAgreementsUpfrontPaymentReceived
      contextRef="i312dc53a327b4c2584c0408f7ce3c401_D20150901-20150930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN184NS9mcmFnOjE2ZTFhMGJhMzg4NjQzZWI4MzhlNGQ2ZWE5ODVjMzcwL3RleHRyZWdpb246MTZlMWEwYmEzODg2NDNlYjgzOGU0ZDZlYTk4NWMzNzBfNTI2Ng_d2af6377-4aa3-41b4-a9ea-37d8d35f97ed"
      unitRef="usd">27500000</ino:CollaborativeAgreementsUpfrontPaymentReceived>
    <ino:CollaborationAgreementAnticipatedDevelopmentandRegulatoryEventBasedPaymentReceivableMilestones
      contextRef="id271d63e442f4a9f8fb4db1a017f1090_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN184NS9mcmFnOjE2ZTFhMGJhMzg4NjQzZWI4MzhlNGQ2ZWE5ODVjMzcwL3RleHRyZWdpb246MTZlMWEwYmEzODg2NDNlYjgzOGU0ZDZlYTk4NWMzNzBfNTQzNQ_9add39e4-fd24-4fb4-a44e-83e453235ffe"
      unitRef="usd">125000000</ino:CollaborationAgreementAnticipatedDevelopmentandRegulatoryEventBasedPaymentReceivableMilestones>
    <ino:CollaborationAgreementAnticipatedCommercialEventBasedPaymentReceivableMilestones
      contextRef="id271d63e442f4a9f8fb4db1a017f1090_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN184NS9mcmFnOjE2ZTFhMGJhMzg4NjQzZWI4MzhlNGQ2ZWE5ODVjMzcwL3RleHRyZWdpb246MTZlMWEwYmEzODg2NDNlYjgzOGU0ZDZlYTk4NWMzNzBfNTUwNg_25da275e-05a0-4f3a-a060-c7598cc1b0a6"
      unitRef="usd">115000000</ino:CollaborationAgreementAnticipatedCommercialEventBasedPaymentReceivableMilestones>
    <ino:CollaborativeAgreementsUpfrontPaymentReceived
      contextRef="iab8cbd4abffa49939bca24df9e09f682_D20171231-20171231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN184NS9mcmFnOjE2ZTFhMGJhMzg4NjQzZWI4MzhlNGQ2ZWE5ODVjMzcwL3RleHRyZWdpb246MTZlMWEwYmEzODg2NDNlYjgzOGU0ZDZlYTk4NWMzNzBfNjUzNw_dc58d413-d46b-4886-876c-abace57ae1dc"
      unitRef="usd">27500000</ino:CollaborativeAgreementsUpfrontPaymentReceived>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1279cb3397f540cf8c03eff95603717f_D20181201-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN184NS9mcmFnOjE2ZTFhMGJhMzg4NjQzZWI4MzhlNGQ2ZWE5ODVjMzcwL3RleHRyZWdpb246MTZlMWEwYmEzODg2NDNlYjgzOGU0ZDZlYTk4NWMzNzBfMjE5OTAyMzI3ODEyMA_a99b7a4b-6239-4b70-9704-d70d5b5da2cb"
      unitRef="usd">2000000.0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0a00fce528054fc1b13da4166be4a7f9_D20190302-20190331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN184NS9mcmFnOjE2ZTFhMGJhMzg4NjQzZWI4MzhlNGQ2ZWE5ODVjMzcwL3RleHRyZWdpb246MTZlMWEwYmEzODg2NDNlYjgzOGU0ZDZlYTk4NWMzNzBfMjE5OTAyMzI3ODEyMA_f78fe4ea-61e3-4d60-8c7f-2534aef0a457"
      unitRef="usd">2000000.0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <ino:CollaborativeAgreementFundingToBeReceived
      contextRef="i26869d6b62d04f7b965bf3b12a74986b_D20180401-20180430"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN184NS9mcmFnOjE2ZTFhMGJhMzg4NjQzZWI4MzhlNGQ2ZWE5ODVjMzcwL3RleHRyZWdpb246MTZlMWEwYmEzODg2NDNlYjgzOGU0ZDZlYTk4NWMzNzBfNzc1Ng_9e2eb08b-3a55-4d6d-b4dd-4e19d0a3bf00"
      unitRef="usd">56000000</ino:CollaborativeAgreementFundingToBeReceived>
    <ino:CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment
      contextRef="i26869d6b62d04f7b965bf3b12a74986b_D20180401-20180430"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN184NS9mcmFnOjE2ZTFhMGJhMzg4NjQzZWI4MzhlNGQ2ZWE5ODVjMzcwL3RleHRyZWdpb246MTZlMWEwYmEzODg2NDNlYjgzOGU0ZDZlYTk4NWMzNzBfMTMwMzg_ab568341-06cd-4e04-9f5a-2bcaa4edb879">P5Y</ino:CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment>
    <ino:CollaborativeAgreementFundingReceived
      contextRef="i9e2dfcc4dad04e25a9c9b44b8901a333_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN184NS9mcmFnOjE2ZTFhMGJhMzg4NjQzZWI4MzhlNGQ2ZWE5ODVjMzcwL3RleHRyZWdpb246MTZlMWEwYmEzODg2NDNlYjgzOGU0ZDZlYTk4NWMzNzBfODA0Mg_83aefe17-1aa8-407c-8633-b5487d5a96e7"
      unitRef="usd">2400000</ino:CollaborativeAgreementFundingReceived>
    <ino:CollaborativeAgreementFundingReceived
      contextRef="id320f2073edd475b8fd5feeb871b3bb2_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN184NS9mcmFnOjE2ZTFhMGJhMzg4NjQzZWI4MzhlNGQ2ZWE5ODVjMzcwL3RleHRyZWdpb246MTZlMWEwYmEzODg2NDNlYjgzOGU0ZDZlYTk4NWMzNzBfODIzMg_fe9716f3-4518-4ad7-990c-b1e1bc46b1e8"
      unitRef="usd">1100000</ino:CollaborativeAgreementFundingReceived>
    <ino:DeferredGrantFundingCurrent
      contextRef="i7705f1893eef43a683c986157751b493_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN184NS9mcmFnOjE2ZTFhMGJhMzg4NjQzZWI4MzhlNGQ2ZWE5ODVjMzcwL3RleHRyZWdpb246MTZlMWEwYmEzODg2NDNlYjgzOGU0ZDZlYTk4NWMzNzBfODM4NQ_567b29c2-1d90-475d-b4f3-683d86af89ce"
      unitRef="usd">251000</ino:DeferredGrantFundingCurrent>
    <ino:CollaborativeAgreementFundingToBeReceived
      contextRef="i4c2c68f34809458b92b1fe442b05fe04_D20200101-20200131"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN184NS9mcmFnOjE2ZTFhMGJhMzg4NjQzZWI4MzhlNGQ2ZWE5ODVjMzcwL3RleHRyZWdpb246MTZlMWEwYmEzODg2NDNlYjgzOGU0ZDZlYTk4NWMzNzBfODU2NQ_54701191-7702-4dcf-950f-820c17fa41ec"
      unitRef="usd">9000000.0</ino:CollaborativeAgreementFundingToBeReceived>
    <ino:CollaborativeAgreementFundingToBeReceived
      contextRef="iefa41d3db8c44b3784e3e21a11b9f57b_D20200401-20200430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN184NS9mcmFnOjE2ZTFhMGJhMzg4NjQzZWI4MzhlNGQ2ZWE5ODVjMzcwL3RleHRyZWdpb246MTZlMWEwYmEzODg2NDNlYjgzOGU0ZDZlYTk4NWMzNzBfODg2Nw_d13aef93-4ddf-4eb7-8240-996fac4d6fdc"
      unitRef="usd">6900000</ino:CollaborativeAgreementFundingToBeReceived>
    <ino:CollaborativeAgreementFundingToBeReceived
      contextRef="ie8d1c12d54e14e8fadc5b66c01656f3f_D20200401-20200430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN184NS9mcmFnOjE2ZTFhMGJhMzg4NjQzZWI4MzhlNGQ2ZWE5ODVjMzcwL3RleHRyZWdpb246MTZlMWEwYmEzODg2NDNlYjgzOGU0ZDZlYTk4NWMzNzBfOTA0NQ_3ca9434f-b250-4523-844f-c7edb1b53a29"
      unitRef="usd">5000000.0</ino:CollaborativeAgreementFundingToBeReceived>
    <ino:CollaborativeAgreementFundingToBeReceived
      contextRef="i4e63edbfeb924628bea29aa126db3731_D20200401-20200430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN184NS9mcmFnOjE2ZTFhMGJhMzg4NjQzZWI4MzhlNGQ2ZWE5ODVjMzcwL3RleHRyZWdpb246MTZlMWEwYmEzODg2NDNlYjgzOGU0ZDZlYTk4NWMzNzBfOTIyNw_1dd8135b-7564-4ef2-8b34-3e16f1164b9a"
      unitRef="usd">1300000</ino:CollaborativeAgreementFundingToBeReceived>
    <ino:CollaborativeAgreementFundingReceived
      contextRef="i90e840c675604f9ea05a3d3799146d6a_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN184NS9mcmFnOjE2ZTFhMGJhMzg4NjQzZWI4MzhlNGQ2ZWE5ODVjMzcwL3RleHRyZWdpb246MTZlMWEwYmEzODg2NDNlYjgzOGU0ZDZlYTk4NWMzNzBfOTMyNw_24193cf9-7cda-4278-913d-b41db2a8bf4c"
      unitRef="usd">2400000</ino:CollaborativeAgreementFundingReceived>
    <ino:CollaborativeAgreementFundingReceived
      contextRef="i9c578a4352674268833b02f441d2630a_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN184NS9mcmFnOjE2ZTFhMGJhMzg4NjQzZWI4MzhlNGQ2ZWE5ODVjMzcwL3RleHRyZWdpb246MTZlMWEwYmEzODg2NDNlYjgzOGU0ZDZlYTk4NWMzNzBfOTMyNw_7738335e-4cfc-42a6-955f-abfc41cb6d79"
      unitRef="usd">2400000</ino:CollaborativeAgreementFundingReceived>
    <ino:DeferredGrantFundingCurrent
      contextRef="i462daba8e70241fa90cc3d9158a0e6b1_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN184NS9mcmFnOjE2ZTFhMGJhMzg4NjQzZWI4MzhlNGQ2ZWE5ODVjMzcwL3RleHRyZWdpb246MTZlMWEwYmEzODg2NDNlYjgzOGU0ZDZlYTk4NWMzNzBfOTQ5NQ_ca0875b2-4fad-427e-b691-4457759de3f7"
      unitRef="usd">4000000.0</ino:DeferredGrantFundingCurrent>
    <ino:CollaborativeAgreementFundingReceived
      contextRef="i8914061f84134527886aafd4379342b3_D20181001-20181031"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN184NS9mcmFnOjE2ZTFhMGJhMzg4NjQzZWI4MzhlNGQ2ZWE5ODVjMzcwL3RleHRyZWdpb246MTZlMWEwYmEzODg2NDNlYjgzOGU0ZDZlYTk4NWMzNzBfOTc2Mg_e692216d-a003-45a6-a317-9659460fd770"
      unitRef="usd">2200000</ino:CollaborativeAgreementFundingReceived>
    <ino:CollaborativeAgreementFundingReceived
      contextRef="id9b959950a9d4883a9e0bbc48e5b75b8_D20190801-20190830"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN184NS9mcmFnOjE2ZTFhMGJhMzg4NjQzZWI4MzhlNGQ2ZWE5ODVjMzcwL3RleHRyZWdpb246MTZlMWEwYmEzODg2NDNlYjgzOGU0ZDZlYTk4NWMzNzBfMTAxNzE_b4342e8a-e814-404d-bfa0-1e144e6f0fc1"
      unitRef="usd">1100000</ino:CollaborativeAgreementFundingReceived>
    <ino:CollaborativeAgreementFundingReceived
      contextRef="ia04b81c5769143f2ad65bc25e43bd9ed_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN184NS9mcmFnOjE2ZTFhMGJhMzg4NjQzZWI4MzhlNGQ2ZWE5ODVjMzcwL3RleHRyZWdpb246MTZlMWEwYmEzODg2NDNlYjgzOGU0ZDZlYTk4NWMzNzBfMTAyMjc_6542eeb3-8d55-498c-82c3-74c61dd2ab0e"
      unitRef="usd">0</ino:CollaborativeAgreementFundingReceived>
    <ino:CollaborativeAgreementFundingReceived
      contextRef="i091601a25e604419963010db9959837c_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN184NS9mcmFnOjE2ZTFhMGJhMzg4NjQzZWI4MzhlNGQ2ZWE5ODVjMzcwL3RleHRyZWdpb246MTZlMWEwYmEzODg2NDNlYjgzOGU0ZDZlYTk4NWMzNzBfMTAyMzQ_d262944d-d6c7-42e2-b7b1-51e40c4405f2"
      unitRef="usd">134000</ino:CollaborativeAgreementFundingReceived>
    <ino:DeferredGrantFundingCurrent
      contextRef="i870d9127e6314fc4aebaa4f4b2a7931e_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN184NS9mcmFnOjE2ZTFhMGJhMzg4NjQzZWI4MzhlNGQ2ZWE5ODVjMzcwL3RleHRyZWdpb246MTZlMWEwYmEzODg2NDNlYjgzOGU0ZDZlYTk4NWMzNzBfMTA0MTQ_148ed612-528b-4053-a6aa-c0b95eb7ef68"
      unitRef="usd">660000</ino:DeferredGrantFundingCurrent>
    <ino:CollaborativeAgreementFundingReceived
      contextRef="i752ae0ad316946429cc2310340ed7334_D20200301-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN184NS9mcmFnOjE2ZTFhMGJhMzg4NjQzZWI4MzhlNGQ2ZWE5ODVjMzcwL3RleHRyZWdpb246MTZlMWEwYmEzODg2NDNlYjgzOGU0ZDZlYTk4NWMzNzBfMTA1ODE_4afe1b67-4128-43c2-93bf-9251055ef559"
      unitRef="usd">5000000.0</ino:CollaborativeAgreementFundingReceived>
    <ino:CollaborativeAgreementFundingReceived
      contextRef="i56915aed723e478494673e49cebb3d4e_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN184NS9mcmFnOjE2ZTFhMGJhMzg4NjQzZWI4MzhlNGQ2ZWE5ODVjMzcwL3RleHRyZWdpb246MTZlMWEwYmEzODg2NDNlYjgzOGU0ZDZlYTk4NWMzNzBfMTA3MjI_82d8303a-8e7c-4967-8879-db7a8f6935b0"
      unitRef="usd">893000</ino:CollaborativeAgreementFundingReceived>
    <ino:CollaborativeAgreementFundingReceived
      contextRef="i779a998ae097423cbfecbd164c6d6a15_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN184NS9mcmFnOjE2ZTFhMGJhMzg4NjQzZWI4MzhlNGQ2ZWE5ODVjMzcwL3RleHRyZWdpb246MTZlMWEwYmEzODg2NDNlYjgzOGU0ZDZlYTk4NWMzNzBfMTA3Mjk_fdc15f22-b096-4a3f-aef0-baa53401ef9b"
      unitRef="usd">64000</ino:CollaborativeAgreementFundingReceived>
    <ino:CollaborativeAgreementFundingReceived
      contextRef="i264c6f79f8444773b5305906e6e512df_D20200601-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN184NS9mcmFnOjE2ZTFhMGJhMzg4NjQzZWI4MzhlNGQ2ZWE5ODVjMzcwL3RleHRyZWdpb246MTZlMWEwYmEzODg2NDNlYjgzOGU0ZDZlYTk4NWMzNzBfMTE4ODM_fb7cdfce-4cbf-4fd4-9d37-5960fef773a7"
      unitRef="usd">54500000</ino:CollaborativeAgreementFundingReceived>
    <ino:CollaborativeArrangementFixedPriceContractAmountAwarded
      contextRef="ic4269fc3e43a44779c7573901206998d_D20200601-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN184NS9mcmFnOjE2ZTFhMGJhMzg4NjQzZWI4MzhlNGQ2ZWE5ODVjMzcwL3RleHRyZWdpb246MTZlMWEwYmEzODg2NDNlYjgzOGU0ZDZlYTk4NWMzNzBfMTI1NDQ_f2363a30-f54f-487d-a14d-17784b1daed1"
      unitRef="usd">16600000</ino:CollaborativeArrangementFixedPriceContractAmountAwarded>
    <ino:GrantProceedsReceived
      contextRef="iccb3ccc026234192a47e7268051e1700_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN184NS9mcmFnOjE2ZTFhMGJhMzg4NjQzZWI4MzhlNGQ2ZWE5ODVjMzcwL3RleHRyZWdpb246MTZlMWEwYmEzODg2NDNlYjgzOGU0ZDZlYTk4NWMzNzBfMTI4Mjk_19fc5cf4-76cd-4da8-93e1-5b5da27d4911"
      unitRef="usd">7800000</ino:GrantProceedsReceived>
    <us-gaap:AccountsReceivableRelatedParties
      contextRef="ic1b65e61f4594842852e823b554bc0cb_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN184NS9mcmFnOjE2ZTFhMGJhMzg4NjQzZWI4MzhlNGQ2ZWE5ODVjMzcwL3RleHRyZWdpb246MTZlMWEwYmEzODg2NDNlYjgzOGU0ZDZlYTk4NWMzNzBfMTI5Nzg_3aeb3dd7-75fc-47db-91cb-06be5a91b24d"
      unitRef="usd">9600000</us-gaap:AccountsReceivableRelatedParties>
    <us-gaap:AccountsReceivableRelatedParties
      contextRef="ia71441f3bf2e4190b91ebcea736fec60_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN184NS9mcmFnOjE2ZTFhMGJhMzg4NjQzZWI4MzhlNGQ2ZWE5ODVjMzcwL3RleHRyZWdpb246MTZlMWEwYmEzODg2NDNlYjgzOGU0ZDZlYTk4NWMzNzBfMjE5OTAyMzI4MDEzMg_2fce6064-2b4c-4201-b881-5d4f7d224f11"
      unitRef="usd">11400000</us-gaap:AccountsReceivableRelatedParties>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN184OC9mcmFnOjNkY2U2NzNlYWQwMDQ4MGE5YzZhZmIzMTU3YjhkMTZlL3RleHRyZWdpb246M2RjZTY3M2VhZDAwNDgwYTljNmFmYjMxNTdiOGQxNmVfMTg1MQ_e38995e7-4f6b-444a-9714-1095f40ad735">Income Taxes The Company uses an estimated annual effective tax rate, which is based on expected annual income, statutory tax rates and tax planning opportunities available in the various jurisdictions in which the Company operates, to determine its quarterly provision for income taxes. Certain significant or unusual items are separately recognized in the quarter in which they occur and can be a source of variability in the effective tax rates from quarter to quarter.&#160;Due to the adoption of ASU 2019-12 which removes the exception under ASC 740-20-45-7 to consider all sources of income in order to determine the tax benefit resulting from a loss from continuing operations, ASC 740-20-45-7 no longer applies.On March 27, 2020, the United States enacted the Coronavirus Aid, Relief and Economic Security Act (CARES Act).&#160; The CARES Act is an emergency economic stimulus package that includes spending and tax breaks to strengthen the United States economy and fund a nationwide effort to curtail the effect of COVID-19.&#160;The CARES Act provides sweeping tax changes in response to the COVID-19 pandemic; some of the more significant provisions are removal of certain limitations on utilization of net operating losses, increasing the loss carryback period for certain losses to five years, and increasing the ability to deduct interest expense, as well as amending certain provisions of the previously enacted Tax Cuts and Jobs Act.&#160;At March&#160;31, 2021, the Company has not recorded any income tax provision/(benefit) for the impact for the CARES Act due to the Company&#x2019;s history of net operating losses generated and the maintenance of a full valuation allowance against its net deferred tax assets.</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock
      contextRef="i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN185MS9mcmFnOjBmMTk4ODlkNzI3NDQyYzQ4ODM2ZTVlMzcyODg1ZTUzL3RleHRyZWdpb246MGYxOTg4OWQ3Mjc0NDJjNDg4MzZlNWUzNzI4ODVlNTNfNzYxNg_e54b7eac-137b-4dbb-aa96-c79498aadcde">Geneos Therapeutics, Inc. &lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2016, the Company formed Geneos to develop and commercialize neoantigen-based personalized cancer therapies. Geneos was considered a variable interest entity (VIE) for which the Company was the primary beneficiary. In February 2019, Geneos completed the initial closing of a&#160;Series A preferred stock financing. The Company invested&#160;$1.2 million&#160;in the Series A preferred stock financing, which was led by an outside investor. Following this transaction, the Company held&#160;61%&#160;of the outstanding equity, on an as-converted to common stock basis, of Geneos and continued to consolidate its investment in Geneos under ASC 810, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Consolidation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. &lt;/span&gt;&lt;div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In January 2020, Geneos completed the second closing of the&#160;Series A preferred stock financing, in which the Company invested $800,000. Following this transaction, as of March 31, 2020, the Company held&#160;52%&#160;of the outstanding equity, on an as-converted to common stock basis, of Geneos and continued to consolidate its investment in Geneos.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2020, Geneos closed an additional&#160;Series A preferred stock financing round, in which the Company invested $800,000.  Following this transaction, the Company owned 47% of the outstanding equity of Geneos on an as-converted to common stock basis. This transaction triggered a VIE reconsideration, as the Company no longer held a controlling financial interest. Based on the Company&#x2019;s assessment, Geneos continued to be a VIE as it did not have sufficient equity at risk to finance its activities without additional subordinated financial support.  However, the Company was not the primary beneficiary of Geneos, as it did not have the power to direct the activities that most significantly impact Geneos&#x2019; economic performance.  Accordingly, the Company deconsolidated its investment in Geneos as of June 1, 2020, resulting in a gain of $4.1 million, of which $2.4 million related to the remeasurement of the retained noncontrolling interest investment to fair value.  The gain has been recorded separately on the Company's condensed consolidated statement of operations.  The following table shows the amounts related to the deconsolidation accounting: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:84.405%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Working capital (excluding cash) &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(59,992)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Note payable &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;171,620&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fixed assets, net of accumulated depreciation &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16,340)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Carrying value of noncontrolling interest &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,181,640&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of investment in Geneos retained&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,618,998&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gain on deconsolidation of Geneos &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,121,075)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Decrease in cash resulting from the deconsolidation of Geneos&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,774,851&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%"&gt;The details of the Company&#x2019;s 47% retained equity investment in Geneos is shown in the table below, with fair values calculated as of June 1, 2020, the date of deconsolidation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:54.178%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.973%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.562%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.119%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.392%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;Geneos Share Class&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Price per Share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Common&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,000,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.273&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;819,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Preferred&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,113,206&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.325&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,799,998&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,113,206&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,618,998&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of Geneos Series A preferred stock was based on the per share price paid by third-party investors in connection with the most recent closing of the Series A preferred stock financing for Geneos on June 1, 2020. The fair value of Geneos common stock was determined by a third-party valuation, as there is no public market for such stock. Geneos&#x2019; enterprise value, which was estimated using a market approach that derived an implied total equity value from a transaction involving its own securities, was allocated to all classes of equity using the option pricing method. Under the option pricing method, each equity class was modeled as having a call option with a distinct claim on the total value of Geneos. Each option&#x2019;s exercise price was based on the total value available for each participating security holder. The characteristics of each class of ownership determined the claim on the total value for that class of ownership.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The estimated value allocated to common stock included assumptions related to the fair value of the enterprise, expected volatility, expected term, and risk-free interest rate. Expected volatility was based on historical asset volatilities derived from daily stock price changes of guideline public companies. The estimated expected term was based on a weighted average of the estimated time to Geneo's next financing and successful exit timing assumption.  The risk-free interest rate was based on the yield of U.S. Treasury with a comparable term. Geneos&#x2019;s common stock is classified as a Level 3 financial instrument. The assumptions used in the fair value calculation as of June 1, 2020 are presented below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:8pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:78.548%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.252%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected term (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.92&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.46%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Geneos enterprise value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$4,966,531&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company applies the equity method to investments in common stock and to other investments in entities that have risk and reward characteristics that are substantially similar to an investment in the investee&#x2019;s common stock.  Since the Company&#x2019;s Series A preferred stock investment in Geneos has a substantive liquidation preference, it is not substantially similar to the Company&#x2019;s common stock investment and will therefore be recorded as an equity security under ASC 321.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of June 1, 2020, the Company accounts for its common stock investment in Geneos, in which the Company lacks control but does have the ability to exercise significant influence over operating and financial policies, using the equity method. Generally, the ability to exercise significant influence is presumed when the investor possesses more than 20% of the voting interests of the investee. This presumption may be overcome based on specific facts and circumstances that demonstrate that the ability to exercise significant influence is restricted. In applying the equity method, the Company records the investment at cost unless the initial recognition is the result of the deconsolidation of a subsidiary, in which case it is recorded at fair value. The Company's proportionate share of net loss of Geneos is recorded in&#160;equity in net earnings of Geneos in the Company's condensed consolidated statements of operations. The Company's equity method investments are reviewed for indicators of impairment at each reporting period and are written down to fair value if there is evidence of a loss in value that is other-than-temporary.&#160;Any difference between the carrying amount of the Company&#x2019;s investment and the amount of underlying equity in Geneos&#x2019; net assets is amortized into income or expense accordingly. There were no basis differences identified as of the deconsolidation date that would need to be amortized.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Upon deconsolidation, the Company recorded its Series A preferred stock investment at fair value based on the per share price paid by third party investors in connection with the preferred stock financing on June 1, 2020. The Company has determined that its Series A preferred stock investment in Geneos does not have a readily determinable fair value and has therefore elected the measurement alternative in ASC 321 to subsequently record the investment at cost, less any impairments, plus or minus changes resulting from observable price changes in orderly transactions for identical or similar investments of the same issuer.&#160;When fair value becomes determinable, from observable price changes in orderly transactions, the Company&#x2019;s investment will be marked to fair value.&#160; There have been no observable price changes or impairments identified since the deconsolidation date.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2020, Geneos completed the closing of a Series A-1 preferred stock financing. The Company invested $1.4&#160;million in the Series A-1 preferred stock financing, which was led by outside investors. The closing date of this transaction was determined to be a VIE reconsideration event; based on the Company&#x2019;s assessment, Geneos continues to be a VIE as it does not have sufficient equity at risk to finance its activities without additional subordinated financial support. The Company continues to not be the primary beneficiary of Geneos, as it does not have the power to direct the activities that most significantly impact Geneos&#x2019;s economic performance and should not consolidate Geneos. Following this transaction, the Company held approximately 36% of the outstanding equity, on an as-converted to common stock basis. Accordingly, the Company continues to account for its common stock investment in Geneos as an equity method investment under ASC 323 and its preferred stock investments as equity securities under ASC 321.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of Geneos&#x2019;s Series A-1 preferred stock was based on the per share price paid by third-party investors in connection with the closing on November 12, 2020. The Company has concluded that its Series A-1 preferred stock investment is not similar to its prior Series A preferred stock investment due to certain material rights held solely by Series A preferred stockholders. Therefore, the Company will continue to record its Series A preferred stock investment in Geneos at cost, as there have been no observable price changes or impairments identified since the deconsolidation date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s share of net losses of Geneos for the period from June 1, 2020 through December 31, 2020 was $4.6 million and for the three months ended March 31, 2021 was $1.5&#160;million; however, only $434,000 was recorded, reducing the Company's total investment in Geneos to $0. Of the total amount, $819,000 has been allocated to the equity method investment, thereby reducing the balance to $0 as of March 31, 2021. The remaining $4.2 million loss has been allocated to the Company&#x2019;s Series A and Series A-1 preferred stock investment in Geneos, on a ratable basis, thereby reducing the balance to $0 as of March 31, 2021 as shown in the table below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:84.133%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.115%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.352%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investment in Geneos upon deconsolidation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,618,998&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investment in Geneos Series A-1 preferred stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,399,999&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Share in net loss of Geneos from June 1, 2020 - December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,584,610)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Share in net loss of Geneos for the three months ended March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(434,387)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investment in Geneos as of March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company will not reduce its investment below $0 and will not record its share of further net losses of Geneos as the Company has no obligation to fund Geneos.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In February 2021, Geneos completed a second closing of the Series A-1 preferred stock financing, in which the Company did not participate. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Following this transaction, the Company held approximately 35% of the outstanding equity, on an as-converted to common stock basis.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company continues to exclusively license its SynCon&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;immunotherapy and CELLECTRA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;technology platform to Geneos to be used in the field of personalized, neoantigen-based therapy for cancer. The license agreement provides for &lt;/span&gt;&lt;/div&gt;potential royalty payments to the Company in the event that Geneos commercializes any products using the licensed technology. The Company is not obligated to use any of its assets to fund the future operations of Geneos.</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:PaymentsToAcquireAdditionalInterestInSubsidiaries
      contextRef="i12df974976054802af3d27561d6c09dd_D20190201-20190228"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN185MS9mcmFnOjBmMTk4ODlkNzI3NDQyYzQ4ODM2ZTVlMzcyODg1ZTUzL3RleHRyZWdpb246MGYxOTg4OWQ3Mjc0NDJjNDg4MzZlNWUzNzI4ODVlNTNfMzcw_6acc7fe0-6594-4459-ab27-3fe21ba4553a"
      unitRef="usd">1200000</us-gaap:PaymentsToAcquireAdditionalInterestInSubsidiaries>
    <us-gaap:MinorityInterestOwnershipPercentageByParent
      contextRef="i197c02bfa6fb453089c92b4a206b5240_I20190228"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN185MS9mcmFnOjBmMTk4ODlkNzI3NDQyYzQ4ODM2ZTVlMzcyODg1ZTUzL3RleHRyZWdpb246MGYxOTg4OWQ3Mjc0NDJjNDg4MzZlNWUzNzI4ODVlNTNfNDkw_0ed94f19-9391-4479-bf76-034edc64fefb"
      unitRef="number">0.61</us-gaap:MinorityInterestOwnershipPercentageByParent>
    <ino:StockPurchaseAgreementCommitmentOfAdditionalInvestment
      contextRef="i22e9833894df4c5d90786ba65f0c072a_I20200131"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN185MS9mcmFnOjBmMTk4ODlkNzI3NDQyYzQ4ODM2ZTVlMzcyODg1ZTUzL3RleHRyZWdpb246MGYxOTg4OWQ3Mjc0NDJjNDg4MzZlNWUzNzI4ODVlNTNfNzc0_01a0ec75-7477-4f56-bf8b-6559de23c9e7"
      unitRef="usd">800000</ino:StockPurchaseAgreementCommitmentOfAdditionalInvestment>
    <us-gaap:MinorityInterestOwnershipPercentageByParent
      contextRef="i9c60a7b844ef4b0685afab98a626ab57_I20200331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN185MS9mcmFnOjBmMTk4ODlkNzI3NDQyYzQ4ODM2ZTVlMzcyODg1ZTUzL3RleHRyZWdpb246MGYxOTg4OWQ3Mjc0NDJjNDg4MzZlNWUzNzI4ODVlNTNfODQ1_f4af2052-94bd-408d-ac10-022641caa169"
      unitRef="number">0.52</us-gaap:MinorityInterestOwnershipPercentageByParent>
    <ino:StockPurchaseAgreementCommitmentOfAdditionalInvestment
      contextRef="icf16dce9089247ddb07885bad1158a5b_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN185MS9mcmFnOjBmMTk4ODlkNzI3NDQyYzQ4ODM2ZTVlMzcyODg1ZTUzL3RleHRyZWdpb246MGYxOTg4OWQ3Mjc0NDJjNDg4MzZlNWUzNzI4ODVlNTNfMTA4Nw_a04ed559-1e51-44b6-a986-98ed6020cc51"
      unitRef="usd">800000</ino:StockPurchaseAgreementCommitmentOfAdditionalInvestment>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="i86c6d642fb404b608772c10c34c2a8fc_I20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN185MS9mcmFnOjBmMTk4ODlkNzI3NDQyYzQ4ODM2ZTVlMzcyODg1ZTUzL3RleHRyZWdpb246MGYxOTg4OWQ3Mjc0NDJjNDg4MzZlNWUzNzI4ODVlNTNfMTIwMg_abcfbc61-9365-417b-9c4a-2d19044880e0"
      unitRef="number">0.47</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:DeconsolidationGainOrLossAmount
      contextRef="i49cf08539f5f4d268c6222c435b55016_D20200601-20200601"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN185MS9mcmFnOjBmMTk4ODlkNzI3NDQyYzQ4ODM2ZTVlMzcyODg1ZTUzL3RleHRyZWdpb246MGYxOTg4OWQ3Mjc0NDJjNDg4MzZlNWUzNzI4ODVlNTNfMTgwOA_5c02a64c-1559-4492-aa12-574f916271e3"
      unitRef="usd">4100000</us-gaap:DeconsolidationGainOrLossAmount>
    <us-gaap:DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount
      contextRef="i49cf08539f5f4d268c6222c435b55016_D20200601-20200601"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN185MS9mcmFnOjBmMTk4ODlkNzI3NDQyYzQ4ODM2ZTVlMzcyODg1ZTUzL3RleHRyZWdpb246MGYxOTg4OWQ3Mjc0NDJjNDg4MzZlNWUzNzI4ODVlNTNfMTgyMQ_8a78a32d-08a2-44d6-aa6a-d153970b58f0"
      unitRef="usd">2400000</us-gaap:DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount>
    <us-gaap:EquityMethodInvestmentsTextBlock
      contextRef="i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN185MS9mcmFnOjBmMTk4ODlkNzI3NDQyYzQ4ODM2ZTVlMzcyODg1ZTUzL3RleHRyZWdpb246MGYxOTg4OWQ3Mjc0NDJjNDg4MzZlNWUzNzI4ODVlNTNfNzYxNw_fcd8cbba-b7f9-40ef-a1a6-b01354383a0b">The following table shows the amounts related to the deconsolidation accounting: &lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:84.405%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Working capital (excluding cash) &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(59,992)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Note payable &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;171,620&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fixed assets, net of accumulated depreciation &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16,340)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Carrying value of noncontrolling interest &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,181,640&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of investment in Geneos retained&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,618,998&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gain on deconsolidation of Geneos &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,121,075)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Decrease in cash resulting from the deconsolidation of Geneos&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,774,851&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%"&gt;The details of the Company&#x2019;s 47% retained equity investment in Geneos is shown in the table below, with fair values calculated as of June 1, 2020, the date of deconsolidation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:54.178%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.973%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.562%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.119%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.392%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;Geneos Share Class&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Price per Share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Common&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,000,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.273&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;819,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Preferred&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,113,206&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.325&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,799,998&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,113,206&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,618,998&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;The remaining $4.2 million loss has been allocated to the Company&#x2019;s Series A and Series A-1 preferred stock investment in Geneos, on a ratable basis, thereby reducing the balance to $0 as of March 31, 2021 as shown in the table below:&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:84.133%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.115%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.352%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investment in Geneos upon deconsolidation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,618,998&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investment in Geneos Series A-1 preferred stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,399,999&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Share in net loss of Geneos from June 1, 2020 - December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,584,610)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Share in net loss of Geneos for the three months ended March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(434,387)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investment in Geneos as of March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:EquityMethodInvestmentsTextBlock>
    <ino:WorkingCapitalExcludingCash
      contextRef="i11b75bcb273c48128928387d5ceda2d2_I20200601"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN185MS9mcmFnOjBmMTk4ODlkNzI3NDQyYzQ4ODM2ZTVlMzcyODg1ZTUzL3RhYmxlOjNmNjFhODdiNWRiNjRlMDU4MzdiOTkyMDgyYTk4Yzc1L3RhYmxlcmFuZ2U6M2Y2MWE4N2I1ZGI2NGUwNTgzN2I5OTIwODJhOThjNzVfMC0xLTEtMS0w_b2c41928-97e1-41ee-b487-d9a0e4888610"
      unitRef="usd">59992</ino:WorkingCapitalExcludingCash>
    <us-gaap:NotesPayable
      contextRef="i11b75bcb273c48128928387d5ceda2d2_I20200601"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN185MS9mcmFnOjBmMTk4ODlkNzI3NDQyYzQ4ODM2ZTVlMzcyODg1ZTUzL3RhYmxlOjNmNjFhODdiNWRiNjRlMDU4MzdiOTkyMDgyYTk4Yzc1L3RhYmxlcmFuZ2U6M2Y2MWE4N2I1ZGI2NGUwNTgzN2I5OTIwODJhOThjNzVfMS0xLTEtMS0w_cb664159-115c-4a74-9ce5-affb9670a2e0"
      unitRef="usd">171620</us-gaap:NotesPayable>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i11b75bcb273c48128928387d5ceda2d2_I20200601"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN185MS9mcmFnOjBmMTk4ODlkNzI3NDQyYzQ4ODM2ZTVlMzcyODg1ZTUzL3RhYmxlOjNmNjFhODdiNWRiNjRlMDU4MzdiOTkyMDgyYTk4Yzc1L3RhYmxlcmFuZ2U6M2Y2MWE4N2I1ZGI2NGUwNTgzN2I5OTIwODJhOThjNzVfMi0xLTEtMS0w_640a8800-bdf5-4838-859e-4eb093cdab63"
      unitRef="usd">16340</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:MinorityInterest
      contextRef="i11b75bcb273c48128928387d5ceda2d2_I20200601"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN185MS9mcmFnOjBmMTk4ODlkNzI3NDQyYzQ4ODM2ZTVlMzcyODg1ZTUzL3RhYmxlOjNmNjFhODdiNWRiNjRlMDU4MzdiOTkyMDgyYTk4Yzc1L3RhYmxlcmFuZ2U6M2Y2MWE4N2I1ZGI2NGUwNTgzN2I5OTIwODJhOThjNzVfMy0xLTEtMS0w_20bc6176-845d-423b-8a52-f214c39d2305"
      unitRef="usd">3181640</us-gaap:MinorityInterest>
    <us-gaap:RetainedInterestFairValueDisclosure
      contextRef="i11b75bcb273c48128928387d5ceda2d2_I20200601"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN185MS9mcmFnOjBmMTk4ODlkNzI3NDQyYzQ4ODM2ZTVlMzcyODg1ZTUzL3RhYmxlOjNmNjFhODdiNWRiNjRlMDU4MzdiOTkyMDgyYTk4Yzc1L3RhYmxlcmFuZ2U6M2Y2MWE4N2I1ZGI2NGUwNTgzN2I5OTIwODJhOThjNzVfNC0xLTEtMS0w_cd75162d-3438-4209-8013-ed0f1f908818"
      unitRef="usd">3618998</us-gaap:RetainedInterestFairValueDisclosure>
    <us-gaap:DeconsolidationGainOrLossAmount
      contextRef="i49cf08539f5f4d268c6222c435b55016_D20200601-20200601"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN185MS9mcmFnOjBmMTk4ODlkNzI3NDQyYzQ4ODM2ZTVlMzcyODg1ZTUzL3RhYmxlOjNmNjFhODdiNWRiNjRlMDU4MzdiOTkyMDgyYTk4Yzc1L3RhYmxlcmFuZ2U6M2Y2MWE4N2I1ZGI2NGUwNTgzN2I5OTIwODJhOThjNzVfNS0xLTEtMS0w_55cc83e7-8e95-47ca-a8b6-5f1ab300280b"
      unitRef="usd">4121075</us-gaap:DeconsolidationGainOrLossAmount>
    <us-gaap:CashDivestedFromDeconsolidation
      contextRef="i49cf08539f5f4d268c6222c435b55016_D20200601-20200601"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN185MS9mcmFnOjBmMTk4ODlkNzI3NDQyYzQ4ODM2ZTVlMzcyODg1ZTUzL3RhYmxlOjNmNjFhODdiNWRiNjRlMDU4MzdiOTkyMDgyYTk4Yzc1L3RhYmxlcmFuZ2U6M2Y2MWE4N2I1ZGI2NGUwNTgzN2I5OTIwODJhOThjNzVfNi0xLTEtMS0w_5c0aae43-d85a-4de3-9938-43870706bd7e"
      unitRef="usd">2774851</us-gaap:CashDivestedFromDeconsolidation>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="i8ac1a1cef3df4067985d61a1d1aaf9b8_I20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN185MS9mcmFnOjBmMTk4ODlkNzI3NDQyYzQ4ODM2ZTVlMzcyODg1ZTUzL3RleHRyZWdpb246MGYxOTg4OWQ3Mjc0NDJjNDg4MzZlNWUzNzI4ODVlNTNfMjEzOQ_59264192-2ac5-4573-8f15-a6ba0d61f1fa"
      unitRef="number">0.47</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:InvestmentOwnedBalanceShares
      contextRef="idc86dae1ec654c2e8eb6ba13fc81ec0b_I20200601"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN185MS9mcmFnOjBmMTk4ODlkNzI3NDQyYzQ4ODM2ZTVlMzcyODg1ZTUzL3RhYmxlOjhkNTVjMTllYjM0YzQzODlhNzVjZmIwZTMyYzkyZDgzL3RhYmxlcmFuZ2U6OGQ1NWMxOWViMzRjNDM4OWE3NWNmYjBlMzJjOTJkODNfMS0xLTEtMS0w_b1d0ba03-511e-4711-9234-af59d26b9c38"
      unitRef="shares">3000000</us-gaap:InvestmentOwnedBalanceShares>
    <us-gaap:SharePrice
      contextRef="idc86dae1ec654c2e8eb6ba13fc81ec0b_I20200601"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN185MS9mcmFnOjBmMTk4ODlkNzI3NDQyYzQ4ODM2ZTVlMzcyODg1ZTUzL3RhYmxlOjhkNTVjMTllYjM0YzQzODlhNzVjZmIwZTMyYzkyZDgzL3RhYmxlcmFuZ2U6OGQ1NWMxOWViMzRjNDM4OWE3NWNmYjBlMzJjOTJkODNfMS0zLTEtMS0w_3eb57117-97f7-47d9-8614-f964a7ccd5e0"
      unitRef="usdPerShare">0.273</us-gaap:SharePrice>
    <us-gaap:EquityMethodInvestments
      contextRef="idc86dae1ec654c2e8eb6ba13fc81ec0b_I20200601"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN185MS9mcmFnOjBmMTk4ODlkNzI3NDQyYzQ4ODM2ZTVlMzcyODg1ZTUzL3RhYmxlOjhkNTVjMTllYjM0YzQzODlhNzVjZmIwZTMyYzkyZDgzL3RhYmxlcmFuZ2U6OGQ1NWMxOWViMzRjNDM4OWE3NWNmYjBlMzJjOTJkODNfMS01LTEtMS0w_906d1395-43bf-4094-b82e-a8e4567ecfdf"
      unitRef="usd">819000</us-gaap:EquityMethodInvestments>
    <us-gaap:InvestmentOwnedBalanceShares
      contextRef="ib661d85215674c8e93c1385a9ed48322_I20200601"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN185MS9mcmFnOjBmMTk4ODlkNzI3NDQyYzQ4ODM2ZTVlMzcyODg1ZTUzL3RhYmxlOjhkNTVjMTllYjM0YzQzODlhNzVjZmIwZTMyYzkyZDgzL3RhYmxlcmFuZ2U6OGQ1NWMxOWViMzRjNDM4OWE3NWNmYjBlMzJjOTJkODNfMi0xLTEtMS0w_ca0d0b64-a45e-44b9-a5f9-b25068073e01"
      unitRef="shares">2113206</us-gaap:InvestmentOwnedBalanceShares>
    <us-gaap:SharePrice
      contextRef="ib661d85215674c8e93c1385a9ed48322_I20200601"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN185MS9mcmFnOjBmMTk4ODlkNzI3NDQyYzQ4ODM2ZTVlMzcyODg1ZTUzL3RhYmxlOjhkNTVjMTllYjM0YzQzODlhNzVjZmIwZTMyYzkyZDgzL3RhYmxlcmFuZ2U6OGQ1NWMxOWViMzRjNDM4OWE3NWNmYjBlMzJjOTJkODNfMi0zLTEtMS0w_c9da8cd6-89b5-46d8-8a4f-7e2f59e8714a"
      unitRef="usdPerShare">1.325</us-gaap:SharePrice>
    <us-gaap:EquityMethodInvestments
      contextRef="ib661d85215674c8e93c1385a9ed48322_I20200601"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN185MS9mcmFnOjBmMTk4ODlkNzI3NDQyYzQ4ODM2ZTVlMzcyODg1ZTUzL3RhYmxlOjhkNTVjMTllYjM0YzQzODlhNzVjZmIwZTMyYzkyZDgzL3RhYmxlcmFuZ2U6OGQ1NWMxOWViMzRjNDM4OWE3NWNmYjBlMzJjOTJkODNfMi01LTEtMS0w_d3c3ca68-5747-45e9-97c9-381a7fcba35e"
      unitRef="usd">2799998</us-gaap:EquityMethodInvestments>
    <us-gaap:InvestmentOwnedBalanceShares
      contextRef="i11b75bcb273c48128928387d5ceda2d2_I20200601"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN185MS9mcmFnOjBmMTk4ODlkNzI3NDQyYzQ4ODM2ZTVlMzcyODg1ZTUzL3RhYmxlOjhkNTVjMTllYjM0YzQzODlhNzVjZmIwZTMyYzkyZDgzL3RhYmxlcmFuZ2U6OGQ1NWMxOWViMzRjNDM4OWE3NWNmYjBlMzJjOTJkODNfMy0xLTEtMS0w_24bf746c-6e5c-4afc-beb0-f9cda1bf5f14"
      unitRef="shares">5113206</us-gaap:InvestmentOwnedBalanceShares>
    <us-gaap:EquityMethodInvestments
      contextRef="i11b75bcb273c48128928387d5ceda2d2_I20200601"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN185MS9mcmFnOjBmMTk4ODlkNzI3NDQyYzQ4ODM2ZTVlMzcyODg1ZTUzL3RhYmxlOjhkNTVjMTllYjM0YzQzODlhNzVjZmIwZTMyYzkyZDgzL3RhYmxlcmFuZ2U6OGQ1NWMxOWViMzRjNDM4OWE3NWNmYjBlMzJjOTJkODNfMy01LTEtMS0w_ecb6d353-82f0-44b7-aa8f-8cfb6cefbbdb"
      unitRef="usd">3618998</us-gaap:EquityMethodInvestments>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock
      contextRef="i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN185MS9mcmFnOjBmMTk4ODlkNzI3NDQyYzQ4ODM2ZTVlMzcyODg1ZTUzL3RleHRyZWdpb246MGYxOTg4OWQ3Mjc0NDJjNDg4MzZlNWUzNzI4ODVlNTNfNzYxOQ_f3c6cf88-6d76-4ff6-b14e-9867e972e66c">The assumptions used in the fair value calculation as of June 1, 2020 are presented below:&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:78.548%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.252%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected term (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.92&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.46%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Geneos enterprise value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$4,966,531&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock>
    <ino:AlternativeInvestmentMeasurementInputTerm
      contextRef="i496071670fd64b74b11100bd501df568_D20200601-20200601"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN185MS9mcmFnOjBmMTk4ODlkNzI3NDQyYzQ4ODM2ZTVlMzcyODg1ZTUzL3RhYmxlOmE0ZDM5ZDZmZWI1NTQ5MmViMTU0MzFlNjQ2OTE0NDQ5L3RhYmxlcmFuZ2U6YTRkMzlkNmZlYjU1NDkyZWIxNTQzMWU2NDY5MTQ0NDlfMC0xLTEtMS0w_8d16d941-9056-44d2-9595-162ca6b1830f">P2Y11M1D</ino:AlternativeInvestmentMeasurementInputTerm>
    <us-gaap:AlternativeInvestmentMeasurementInput
      contextRef="i521f37bfc08d4393a839105bd352f62b_I20200601"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN185MS9mcmFnOjBmMTk4ODlkNzI3NDQyYzQ4ODM2ZTVlMzcyODg1ZTUzL3RhYmxlOmE0ZDM5ZDZmZWI1NTQ5MmViMTU0MzFlNjQ2OTE0NDQ5L3RhYmxlcmFuZ2U6YTRkMzlkNmZlYjU1NDkyZWIxNTQzMWU2NDY5MTQ0NDlfMS0xLTEtMS0w_5842aa6d-4ba9-4314-94a2-f004cb77ee55"
      unitRef="number">0.70</us-gaap:AlternativeInvestmentMeasurementInput>
    <us-gaap:AlternativeInvestmentMeasurementInput
      contextRef="idf75b7fb59a640709f8bece075b171dd_I20200601"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN185MS9mcmFnOjBmMTk4ODlkNzI3NDQyYzQ4ODM2ZTVlMzcyODg1ZTUzL3RhYmxlOmE0ZDM5ZDZmZWI1NTQ5MmViMTU0MzFlNjQ2OTE0NDQ5L3RhYmxlcmFuZ2U6YTRkMzlkNmZlYjU1NDkyZWIxNTQzMWU2NDY5MTQ0NDlfMi0xLTEtMS0w_1a88ebea-600d-44f1-815e-72395c9bc158"
      unitRef="number">0.0246</us-gaap:AlternativeInvestmentMeasurementInput>
    <ino:EquityMethodInvestmentEnterpriseValue
      contextRef="i11b75bcb273c48128928387d5ceda2d2_I20200601"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN185MS9mcmFnOjBmMTk4ODlkNzI3NDQyYzQ4ODM2ZTVlMzcyODg1ZTUzL3RhYmxlOmE0ZDM5ZDZmZWI1NTQ5MmViMTU0MzFlNjQ2OTE0NDQ5L3RhYmxlcmFuZ2U6YTRkMzlkNmZlYjU1NDkyZWIxNTQzMWU2NDY5MTQ0NDlfMy0xLTEtMS0w_fc781fdf-a8a6-43f3-852c-96536bdcf4a9"
      unitRef="usd">4966531000</ino:EquityMethodInvestmentEnterpriseValue>
    <us-gaap:PaymentsToAcquireAdditionalInterestInSubsidiaries
      contextRef="i5f2d61cc6bd64875b11002017e8003ca_D20201101-20201130"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN185MS9mcmFnOjBmMTk4ODlkNzI3NDQyYzQ4ODM2ZTVlMzcyODg1ZTUzL3RleHRyZWdpb246MGYxOTg4OWQ3Mjc0NDJjNDg4MzZlNWUzNzI4ODVlNTNfMjE5OTAyMzI2NTE1Mg_e48f0f59-8126-43d0-b76d-80dd813ac16d"
      unitRef="usd">1400000</us-gaap:PaymentsToAcquireAdditionalInterestInSubsidiaries>
    <us-gaap:MinorityInterestOwnershipPercentageByParent
      contextRef="i26487b836039455e8049dc86128e27ea_I20201130"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN185MS9mcmFnOjBmMTk4ODlkNzI3NDQyYzQ4ODM2ZTVlMzcyODg1ZTUzL3RleHRyZWdpb246MGYxOTg4OWQ3Mjc0NDJjNDg4MzZlNWUzNzI4ODVlNTNfMjE5OTAyMzI2NTE2Ng_14e35b4a-d52b-45f4-813b-6d24c3650d1e"
      unitRef="number">0.36</us-gaap:MinorityInterestOwnershipPercentageByParent>
    <ino:IncomeLossFromEquityMethodInvestmentsRealizedAndAllocatedToInvestment
      contextRef="ie8cf0b8ea91645f8adbebe6fd2ff82e8_D20200601-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN185MS9mcmFnOjBmMTk4ODlkNzI3NDQyYzQ4ODM2ZTVlMzcyODg1ZTUzL3RleHRyZWdpb246MGYxOTg4OWQ3Mjc0NDJjNDg4MzZlNWUzNzI4ODVlNTNfNjgyMg_36cff4ae-9158-4af6-9059-6d6373d502c1"
      unitRef="usd">4600000</ino:IncomeLossFromEquityMethodInvestmentsRealizedAndAllocatedToInvestment>
    <ino:IncomeLossFromEquityMethodInvestmentsRealizedAndAllocatedToInvestment
      contextRef="iecead882e1cc4b15851f3a17bd9de72e_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN185MS9mcmFnOjBmMTk4ODlkNzI3NDQyYzQ4ODM2ZTVlMzcyODg1ZTUzL3RleHRyZWdpb246MGYxOTg4OWQ3Mjc0NDJjNDg4MzZlNWUzNzI4ODVlNTNfMTA5OTUxMTY0NzYwOQ_32c6f082-333c-4451-ad9f-830b453819f7"
      unitRef="usd">1500000</ino:IncomeLossFromEquityMethodInvestmentsRealizedAndAllocatedToInvestment>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="iecead882e1cc4b15851f3a17bd9de72e_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN185MS9mcmFnOjBmMTk4ODlkNzI3NDQyYzQ4ODM2ZTVlMzcyODg1ZTUzL3RleHRyZWdpb246MGYxOTg4OWQ3Mjc0NDJjNDg4MzZlNWUzNzI4ODVlNTNfNTQ5NzU1ODE1OTQ1MA_2e2f2ead-8420-4130-ad4b-d6323d28df8c"
      unitRef="usd">-434000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:EquityMethodInvestments
      contextRef="i55de06d621d74ea4af67ec695d2aeb62_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN185MS9mcmFnOjBmMTk4ODlkNzI3NDQyYzQ4ODM2ZTVlMzcyODg1ZTUzL3RleHRyZWdpb246MGYxOTg4OWQ3Mjc0NDJjNDg4MzZlNWUzNzI4ODVlNTNfNTQ5NzU1ODE1OTQ2MQ_99dbfb08-e4db-460c-bb6c-fbbe91649a99"
      unitRef="usd">0</us-gaap:EquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="ida22e72ec08c488993f6f37b0a40f441_D20200601-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN185MS9mcmFnOjBmMTk4ODlkNzI3NDQyYzQ4ODM2ZTVlMzcyODg1ZTUzL3RleHRyZWdpb246MGYxOTg4OWQ3Mjc0NDJjNDg4MzZlNWUzNzI4ODVlNTNfNjg1MA_948667f2-2309-4538-8345-d9fbfc9f2e7b"
      unitRef="usd">-819000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:EquityMethodInvestments
      contextRef="ic39b978122b34ef0b586d2c3f0a20046_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN185MS9mcmFnOjBmMTk4ODlkNzI3NDQyYzQ4ODM2ZTVlMzcyODg1ZTUzL3RleHRyZWdpb246MGYxOTg4OWQ3Mjc0NDJjNDg4MzZlNWUzNzI4ODVlNTNfNjkzNw_d73e7ab6-f831-4701-ad24-53c73f113618"
      unitRef="usd">0</us-gaap:EquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i819679aabd4442d3be1364eba1821db3_D20200601-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN185MS9mcmFnOjBmMTk4ODlkNzI3NDQyYzQ4ODM2ZTVlMzcyODg1ZTUzL3RleHRyZWdpb246MGYxOTg4OWQ3Mjc0NDJjNDg4MzZlNWUzNzI4ODVlNTNfNjk4MA_942d016d-a160-4be4-afe1-b06674855193"
      unitRef="usd">-4200000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:EquityMethodInvestments
      contextRef="ib3a8dbbd273043a2a304eb2892a14c8c_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN185MS9mcmFnOjBmMTk4ODlkNzI3NDQyYzQ4ODM2ZTVlMzcyODg1ZTUzL3RleHRyZWdpb246MGYxOTg4OWQ3Mjc0NDJjNDg4MzZlNWUzNzI4ODVlNTNfNzEwMg_c1637f68-f387-4804-9930-70efa688d7c0"
      unitRef="usd">0</us-gaap:EquityMethodInvestments>
    <us-gaap:EquityMethodInvestments
      contextRef="i11b75bcb273c48128928387d5ceda2d2_I20200601"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN185MS9mcmFnOjBmMTk4ODlkNzI3NDQyYzQ4ODM2ZTVlMzcyODg1ZTUzL3RhYmxlOjQ0Y2Q1OTY1ODRlMzQwMGFiMTVlYzRlM2MzYmJlM2Y2L3RhYmxlcmFuZ2U6NDRjZDU5NjU4NGUzNDAwYWIxNWVjNGUzYzNiYmUzZjZfMS0yLTEtMS0w_ab0f169f-df38-4a10-8450-9ee081e41b97"
      unitRef="usd">3618998</us-gaap:EquityMethodInvestments>
    <us-gaap:EquityMethodInvestments
      contextRef="i5f89255103014c46a5a9ab71646dba92_I20200601"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN185MS9mcmFnOjBmMTk4ODlkNzI3NDQyYzQ4ODM2ZTVlMzcyODg1ZTUzL3RhYmxlOjQ0Y2Q1OTY1ODRlMzQwMGFiMTVlYzRlM2MzYmJlM2Y2L3RhYmxlcmFuZ2U6NDRjZDU5NjU4NGUzNDAwYWIxNWVjNGUzYzNiYmUzZjZfMi0yLTEtMS0yODU1_4b4cf0d6-cf95-4522-8407-64529c4c2fbd"
      unitRef="usd">1399999</us-gaap:EquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="ie8cf0b8ea91645f8adbebe6fd2ff82e8_D20200601-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN185MS9mcmFnOjBmMTk4ODlkNzI3NDQyYzQ4ODM2ZTVlMzcyODg1ZTUzL3RhYmxlOjQ0Y2Q1OTY1ODRlMzQwMGFiMTVlYzRlM2MzYmJlM2Y2L3RhYmxlcmFuZ2U6NDRjZDU5NjU4NGUzNDAwYWIxNWVjNGUzYzNiYmUzZjZfMi0yLTEtMS0w_ecbecaf6-2649-4ed2-8fce-3acd8edaa3c6"
      unitRef="usd">-4584610</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="iecead882e1cc4b15851f3a17bd9de72e_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN185MS9mcmFnOjBmMTk4ODlkNzI3NDQyYzQ4ODM2ZTVlMzcyODg1ZTUzL3RhYmxlOjQ0Y2Q1OTY1ODRlMzQwMGFiMTVlYzRlM2MzYmJlM2Y2L3RhYmxlcmFuZ2U6NDRjZDU5NjU4NGUzNDAwYWIxNWVjNGUzYzNiYmUzZjZfNC0yLTEtMS0yODU1_09acded4-f77d-4df5-be72-821348e83bcb"
      unitRef="usd">-434387</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:EquityMethodInvestments
      contextRef="i55de06d621d74ea4af67ec695d2aeb62_I20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN185MS9mcmFnOjBmMTk4ODlkNzI3NDQyYzQ4ODM2ZTVlMzcyODg1ZTUzL3RhYmxlOjQ0Y2Q1OTY1ODRlMzQwMGFiMTVlYzRlM2MzYmJlM2Y2L3RhYmxlcmFuZ2U6NDRjZDU5NjU4NGUzNDAwYWIxNWVjNGUzYzNiYmUzZjZfMy0yLTEtMS0w_faaf072e-df11-49ca-982e-5a59659b7d8b"
      unitRef="usd">0</us-gaap:EquityMethodInvestments>
    <us-gaap:EquityMethodInvestments
      contextRef="i55de06d621d74ea4af67ec695d2aeb62_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN185MS9mcmFnOjBmMTk4ODlkNzI3NDQyYzQ4ODM2ZTVlMzcyODg1ZTUzL3RleHRyZWdpb246MGYxOTg4OWQ3Mjc0NDJjNDg4MzZlNWUzNzI4ODVlNTNfMzI5ODUzNDkwNDkzNg_f4e5b54b-d2e5-4a73-a2dc-ce60f5403839"
      unitRef="usd">0</us-gaap:EquityMethodInvestments>
    <us-gaap:MinorityInterestOwnershipPercentageByParent
      contextRef="i9ae4c9aeb5d247e7bef7ede5fd594691_I20210228"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN185MS9mcmFnOjBmMTk4ODlkNzI3NDQyYzQ4ODM2ZTVlMzcyODg1ZTUzL3RleHRyZWdpb246MGYxOTg4OWQ3Mjc0NDJjNDg4MzZlNWUzNzI4ODVlNTNfMTA5OTUxMTY0ODMzMw_59aa8057-cf3d-4494-9cca-23023368af29"
      unitRef="number">0.35</us-gaap:MinorityInterestOwnershipPercentageByParent>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139775257011064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover Page - shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>May 06, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar. 31,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-14888<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">INOVIO PHARMACEUTICALS, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">33-0969592<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">660 W. GERMANTOWN PIKE, SUITE 110<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">PLYMOUTH MEETING<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">PA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">19462<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">267<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">440-4200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">COMMON STOCK, $0.001 PAR VALUE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">INO<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">209,399,260<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001055726<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139775184146168">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 83,634,176<span></span>
</td>
<td class="nump">$ 250,728,118<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Short-term investments</a></td>
<td class="nump">434,969,528<span></span>
</td>
<td class="nump">160,914,935<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="nump">9,911,922<span></span>
</td>
<td class="nump">18,559,967<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableRelatedPartiesCurrent', window );">Accounts receivable from affiliated entities</a></td>
<td class="nump">346,974<span></span>
</td>
<td class="nump">503,782<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">59,572,236<span></span>
</td>
<td class="nump">40,357,456<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity', window );">Prepaid expenses and other current assets from affiliated entities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">106,432<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">588,434,836<span></span>
</td>
<td class="nump">471,170,690<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Fixed assets, net</a></td>
<td class="nump">10,930,312<span></span>
</td>
<td class="nump">11,348,144<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Investment in affiliated entities</a></td>
<td class="nump">3,629,891<span></span>
</td>
<td class="nump">4,460,366<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Investment in Geneos</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">434,387<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="nump">3,010,000<span></span>
</td>
<td class="nump">3,146,770<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">10,513,371<span></span>
</td>
<td class="nump">10,513,371<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">12,463,006<span></span>
</td>
<td class="nump">12,741,296<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">25,881,934<span></span>
</td>
<td class="nump">25,957,448<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">654,863,350<span></span>
</td>
<td class="nump">539,772,472<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Accounts payable and accrued expenses</a></td>
<td class="nump">25,974,530<span></span>
</td>
<td class="nump">21,203,808<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueToRelatedPartiesCurrent', window );">Accounts payable and accrued expenses due to affiliated entities</a></td>
<td class="nump">768,261<span></span>
</td>
<td class="nump">642,969<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_AccruedClinicalTrialExpenseCurrent', window );">Accrued clinical trial expenses</a></td>
<td class="nump">7,370,869<span></span>
</td>
<td class="nump">9,950,345<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue</a></td>
<td class="nump">15,378<span></span>
</td>
<td class="nump">46,628<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_ContractWithCustomerLiabilityAffiliatedEntityCurrent', window );">Deferred revenue from affiliated entities</a></td>
<td class="nump">39,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liability</a></td>
<td class="nump">2,395,928<span></span>
</td>
<td class="nump">2,329,394<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_DeferredGrantFundingCurrent', window );">Grant funding liability</a></td>
<td class="nump">4,975,484<span></span>
</td>
<td class="nump">7,474,310<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_DeferredGrantFundingFromAffiliateCurrent', window );">Grant funding liability from affiliated entities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">58,500<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">41,539,450<span></span>
</td>
<td class="nump">41,705,954<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Deferred revenue, net of current portion</a></td>
<td class="nump">75,501<span></span>
</td>
<td class="nump">79,214<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liability, net of current portion</a></td>
<td class="nump">17,438,841<span></span>
</td>
<td class="nump">18,063,515<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilitiesNet', window );">Deferred tax liabilities</a></td>
<td class="nump">32,046<span></span>
</td>
<td class="nump">32,046<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_DeferredGrantFundingFromAffiliateNoncurrent', window );">Grant funding liability from affiliated entity, net of current portion</a></td>
<td class="nump">37,500<span></span>
</td>
<td class="nump">37,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other liabilities</a></td>
<td class="nump">64,141<span></span>
</td>
<td class="nump">57,663<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">73,257,201<span></span>
</td>
<td class="nump">78,631,714<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract', window );"><strong>Stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock</a></td>
<td class="nump">209,333<span></span>
</td>
<td class="nump">186,851<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">1,542,261,467<span></span>
</td>
<td class="nump">1,367,406,869<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(960,598,943)<span></span>
</td>
<td class="num">(906,196,812)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(265,708)<span></span>
</td>
<td class="num">(256,150)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total Inovio Pharmaceuticals, Inc. stockholders&#8217; equity</a></td>
<td class="nump">581,606,149<span></span>
</td>
<td class="nump">461,140,758<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity</a></td>
<td class="nump">654,863,350<span></span>
</td>
<td class="nump">539,772,472<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ino_A6.50ConvertibleSeniorNotesDue2024Member', window );">6.50% Convertible Senior Notes Due 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebt', window );">Convertible debt</a></td>
<td class="nump">14,069,722<span></span>
</td>
<td class="nump">14,139,988<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ino_ConvertibleBondsMember', window );">Convertible bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebt', window );">Convertible debt</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 4,515,834<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_AccruedClinicalTrialExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued Clinical Trial Expense, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_AccruedClinicalTrialExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_ContractWithCustomerLiabilityAffiliatedEntityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying amount of consideration received or receivable from related parties as of the balance sheet date on potential earnings that were not recognized as revenue in conformity with GAAP, and which are expected to be recognized as such within one year or the normal operating cycle, if longer, including sales, license fees, and royalties, but excluding interest income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_ContractWithCustomerLiabilityAffiliatedEntityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_DeferredGrantFundingCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Grant Funding, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_DeferredGrantFundingCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_DeferredGrantFundingFromAffiliateCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Grant Funding, From Affiliate, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_DeferredGrantFundingFromAffiliateCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_DeferredGrantFundingFromAffiliateNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Grant Funding, From Affiliate, Noncurrent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_DeferredGrantFundingFromAffiliateNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amounts paid to related parties in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121593590&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121593590&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableRelatedPartiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of receivables arising from transactions with related parties due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.3(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39603-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableRelatedPartiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130532-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, carrying amount of debt identified as being convertible into another form of financial instrument (typically the entity's common stock) as of the balance sheet date, which originally required full repayment more than twelve months after issuance or greater than the normal operating cycle of the company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueToRelatedPartiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of obligations due all related parties. For classified balance sheets, represents the current portion of such liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueToRelatedPartiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8813-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNi">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=99377092&amp;loc=SL75136599-209740<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNi</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1)(g))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ino_A6.50ConvertibleSeniorNotesDue2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ino_A6.50ConvertibleSeniorNotesDue2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ino_ConvertibleBondsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ino_ConvertibleBondsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139775257852408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Operations - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 371,120<span></span>
</td>
<td class="nump">$ 1,327,274<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">39,044,418<span></span>
</td>
<td class="nump">19,111,188<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">13,881,194<span></span>
</td>
<td class="nump">7,448,354<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">52,925,612<span></span>
</td>
<td class="nump">26,559,542<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(52,554,492)<span></span>
</td>
<td class="num">(25,232,268)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestIncomeOperating', window );">Interest income</a></td>
<td class="nump">769,237<span></span>
</td>
<td class="nump">416,569<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(513,034)<span></span>
</td>
<td class="num">(2,803,755)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet', window );">Change in fair value of derivative liability</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(13,221,977)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_ChangeInValueOfInvestmentsInAffiliatedCompany', window );">Gain (loss) on investment in affiliated entities</a></td>
<td class="num">(830,475)<span></span>
</td>
<td class="nump">13,181,619<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss', window );">Net unrealized loss on available-for-sale equity securities</a></td>
<td class="num">(847,958)<span></span>
</td>
<td class="num">(5,050,092)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income (expense), net</a></td>
<td class="nump">8,978<span></span>
</td>
<td class="num">(425,500)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments', window );">Net loss before share in net loss of Geneos</a></td>
<td class="num">(53,967,744)<span></span>
</td>
<td class="num">(33,135,404)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Share in net loss of Geneos</a></td>
<td class="num">(434,387)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">(54,402,131)<span></span>
</td>
<td class="num">(33,135,404)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net loss attributable to non-controlling interest</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">594,350<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss attributable to Inovio Pharmaceuticals, Inc.</a></td>
<td class="num">$ (54,402,131)<span></span>
</td>
<td class="num">$ (32,541,054)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDilutedAbstract', window );"><strong>Net loss per share attributable to Inovio Pharmaceuticals, Inc. stockholders</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Basic and diluted (in dollars per share)</a></td>
<td class="num">$ (0.27)<span></span>
</td>
<td class="num">$ (0.26)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract', window );"><strong>Weighted average number of common shares outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Basic and diluted (in shares)</a></td>
<td class="nump">202,414,445<span></span>
</td>
<td class="nump">124,623,263<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember', window );">Revenue under collaborative research and development arrangements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 39,615<span></span>
</td>
<td class="nump">$ 71,500<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ino_LicensewithAffiliatedEntitiesMember', window );">Revenue under collaborative research and development arrangements with affiliated entities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">49,949<span></span>
</td>
<td class="nump">1,172,126<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember', window );">Other revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 281,556<span></span>
</td>
<td class="nump">$ 83,648<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_ChangeInValueOfInvestmentsInAffiliatedCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of the change in fair value of the investment in affiliated entity. This investment is measured at fair value on a recurring basis.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_ChangeInValueOfInvestmentsInAffiliatedCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDilutedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDilutedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net Increase or Decrease in the fair value of the embedded derivative or group of embedded derivatives included in earnings in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 15<br> -URI http://asc.fasb.org/subtopic&amp;trid=2229187<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=120269885&amp;loc=SL75117546-209714<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(1)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeOperating">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating interest income, including, but not limited to, amortization and accretion of premiums and discounts on securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1(e))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeOperating</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3000-108585<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_LicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ino_LicensewithAffiliatedEntitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ino_LicensewithAffiliatedEntitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139775263613144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Comprehensive Loss - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (54,402,131)<span></span>
</td>
<td class="num">$ (33,135,404)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract', window );"><strong>Other comprehensive income (loss):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation</a></td>
<td class="num">(14,419)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized gain (loss) on short-term investments, net of tax</a></td>
<td class="nump">4,861<span></span>
</td>
<td class="num">(1,929,538)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest', window );">Comprehensive loss</a></td>
<td class="num">(54,411,689)<span></span>
</td>
<td class="num">(35,064,942)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest', window );">Comprehensive loss attributable to non-controlling interest</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">594,350<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss attributable to Inovio Pharmaceuticals, Inc.</a></td>
<td class="num">$ (54,411,689)<span></span>
</td>
<td class="num">$ (34,470,592)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4613674-111683<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569643-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3000-108585<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139775263617304">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Stockholders' Equity - USD ($)<br></strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Preferred stock</div></th>
<th class="th"><div>Common stock</div></th>
<th class="th"><div>Additional paid-in capital</div></th>
<th class="th"><div>Accumulated deficit</div></th>
<th class="th"><div>Accumulated other comprehensive income (loss)</div></th>
<th class="th"><div>Non- controlling interest</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Beginning balance (in shares) at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23<span></span>
</td>
<td class="nump">101,361,034<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Dec. 31, 2019</a></td>
<td class="nump">$ 5,404,858<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 101,361<span></span>
</td>
<td class="nump">$ 742,646,785<span></span>
</td>
<td class="num">$ (739,785,655)<span></span>
</td>
<td class="nump">$ 472,608<span></span>
</td>
<td class="nump">$ 1,969,759<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock for cash, net of financing costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43,148,952<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock for cash, net of financing costs</a></td>
<td class="nump">208,241,933<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 43,149<span></span>
</td>
<td class="nump">208,198,784<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Exercise of stock options for cash and vesting of RSUs, net of tax payments (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,405,114<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Exercise of stock options for cash and vesting of RSUs, net of tax payments</a></td>
<td class="nump">3,100,703<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,405<span></span>
</td>
<td class="nump">3,099,298<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">4,001,553<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,017,761<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(16,208)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance', window );">Acquisition of non-controlling interest in Geneos</a></td>
<td class="nump">2,169,998<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,169,998<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss attributable to common stockholders</a></td>
<td class="num">(33,135,404)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(32,541,054)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(594,350)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized gain (loss) on short-term investments, net of tax</a></td>
<td class="num">(1,929,538)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,929,538)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Ending balance (in shares) at Mar. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23<span></span>
</td>
<td class="nump">145,915,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Mar. 31, 2020</a></td>
<td class="nump">187,854,103<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 145,915<span></span>
</td>
<td class="nump">957,962,628<span></span>
</td>
<td class="num">(772,326,709)<span></span>
</td>
<td class="num">(1,456,930)<span></span>
</td>
<td class="nump">3,529,199<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Beginning balance (in shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9<span></span>
</td>
<td class="nump">186,851,493<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Dec. 31, 2020</a></td>
<td class="nump">461,140,758<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 186,851<span></span>
</td>
<td class="nump">1,367,406,869<span></span>
</td>
<td class="num">(906,196,812)<span></span>
</td>
<td class="num">(256,150)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock for cash, net of financing costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,355,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock for cash, net of financing costs</a></td>
<td class="nump">162,105,030<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,355<span></span>
</td>
<td class="nump">162,084,675<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Conversion of preferred stock to common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,009,450<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Conversion of preferred stock to common stock</a></td>
<td class="nump">4,377,892<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,009<span></span>
</td>
<td class="nump">4,376,883<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Exercise of stock options for cash and vesting of RSUs, net of tax payments (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,118,093<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Exercise of stock options for cash and vesting of RSUs, net of tax payments</a></td>
<td class="num">(1,201,789)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,118<span></span>
</td>
<td class="num">(1,202,907)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">9,595,947<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,595,947<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss attributable to common stockholders</a></td>
<td class="num">(54,402,131)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(54,402,131)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized gain (loss) on short-term investments, net of tax</a></td>
<td class="nump">4,861<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,861<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation</a></td>
<td class="num">(14,419)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(14,419)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Ending balance (in shares) at Mar. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9<span></span>
</td>
<td class="nump">209,334,036<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Mar. 31, 2021</a></td>
<td class="nump">$ 581,606,149<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 209,333<span></span>
</td>
<td class="nump">$ 1,542,261,467<span></span>
</td>
<td class="num">$ (960,598,943)<span></span>
</td>
<td class="num">$ (265,708)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=120383193&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=120383193&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326096&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in noncontrolling interest from subsidiary issuance of equity interests to noncontrolling interest holders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569655-111683<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3000-108585<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The gross value of stock issued during the period upon the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21914-107793<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568740-111683<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21711-107793<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568447-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139775179105864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Stockholders' Equity (Parenthetical)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfStockholdersEquityAbstract', window );"><strong>Statement of Stockholders' Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Stock issuance costs</a></td>
<td class="nump">$ 531<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfStockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfStockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139775185455736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Cash Flows - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (54,402,131)<span></span>
</td>
<td class="num">$ (33,135,404)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">660,697<span></span>
</td>
<td class="nump">809,559<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of intangible assets</a></td>
<td class="nump">136,770<span></span>
</td>
<td class="nump">136,770<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDerivativeLiabilities', window );">Change in fair value of derivative liability</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">13,221,977<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">9,595,947<span></span>
</td>
<td class="nump">4,001,553<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_NonCashInterestIncomeExpense', window );">Non-cash interest expense</a></td>
<td class="num">(31,281)<span></span>
</td>
<td class="nump">213,559<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnInvestments', window );">Loss on short-term investments</a></td>
<td class="nump">10,151<span></span>
</td>
<td class="nump">475,490<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_SettlementOfReceivableWithSharesOfCommonStockFromEquitySecurity', window );">Settlement of receivable with shares of common stock from affiliated entity (PLS)</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(1,713,770)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_ChangeInValueOfInvestmentsInAffiliatedCompany', window );">(Gain) loss on equity investment in affiliated entities</a></td>
<td class="nump">830,475<span></span>
</td>
<td class="num">(13,181,619)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Share of net loss in Geneos</a></td>
<td class="nump">434,387<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiUnrealizedLoss', window );">Net unrealized loss on available-for-sale equity securities</a></td>
<td class="nump">847,958<span></span>
</td>
<td class="nump">5,050,092<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_OperatingLeaseNonCashLeaseExpense', window );">Non-cash lease expense</a></td>
<td class="nump">278,290<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax', window );">Unrealized transaction loss on foreign-currency denominated debt</a></td>
<td class="num">(176,927)<span></span>
</td>
<td class="num">(681,151)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="nump">8,648,045<span></span>
</td>
<td class="nump">58,430<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties', window );">Accounts receivable from affiliated entities</a></td>
<td class="nump">156,808<span></span>
</td>
<td class="nump">697,846<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="num">(19,214,780)<span></span>
</td>
<td class="num">(894,606)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity', window );">Prepaid expenses and other current assets from affiliated entities</a></td>
<td class="nump">106,432<span></span>
</td>
<td class="num">(740,469)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets', window );">Other assets</a></td>
<td class="nump">75,514<span></span>
</td>
<td class="nump">191,937<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable and accrued expenses</a></td>
<td class="nump">4,735,352<span></span>
</td>
<td class="num">(7,217,676)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_IncreaseDecreaseInAccruedClinicalTrialExpense', window );">Accrued clinical trial expenses</a></td>
<td class="num">(2,579,476)<span></span>
</td>
<td class="nump">1,011,439<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties', window );">Accounts payable and accrued expenses due to affiliated entities</a></td>
<td class="nump">125,292<span></span>
</td>
<td class="num">(466,273)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="num">(34,963)<span></span>
</td>
<td class="num">(26,297)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_IncreaseDecreaseInDeferredRevenueFromRelatedParties', window );">Deferred revenue from affiliated entities</a></td>
<td class="num">(37,500)<span></span>
</td>
<td class="num">(31,250)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet', window );">Operating lease right-of-use assets and liabilities, net</a></td>
<td class="num">(558,140)<span></span>
</td>
<td class="num">(517,949)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_IncreaseDecreaseinDeferredGrantFundingCurrent', window );">Grant funding liability</a></td>
<td class="num">(2,461,326)<span></span>
</td>
<td class="nump">7,026,212<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_IncreaseDecreaseinDeferredGrantFundingFromAffiliateCurrent', window );">Grant funding liability from affiliated entities</a></td>
<td class="num">(19,500)<span></span>
</td>
<td class="num">(49,250)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities', window );">Other liabilities</a></td>
<td class="nump">6,478<span></span>
</td>
<td class="nump">36,501<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(52,867,428)<span></span>
</td>
<td class="num">(25,452,721)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireShortTermInvestments', window );">Purchases of investments</a></td>
<td class="num">(275,408,976)<span></span>
</td>
<td class="num">(56,698,250)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfShortTermInvestments', window );">Proceeds from sale or maturity of investments</a></td>
<td class="nump">504,464<span></span>
</td>
<td class="nump">5,030,257<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of capital assets</a></td>
<td class="num">(210,824)<span></span>
</td>
<td class="num">(140,952)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(275,115,336)<span></span>
</td>
<td class="num">(51,808,945)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock, net of issuance costs</a></td>
<td class="nump">162,105,030<span></span>
</td>
<td class="nump">208,241,933<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from stock option exercises</a></td>
<td class="nump">2,632,996<span></span>
</td>
<td class="nump">5,173,534<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Taxes paid related to net share settlement of equity awards</a></td>
<td class="num">(3,834,785)<span></span>
</td>
<td class="num">(2,072,831)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromMinorityShareholders', window );">Acquisition of non-controlling interest</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,169,998<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">160,903,241<span></span>
</td>
<td class="nump">213,512,634<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Effect of exchange rate changes on cash and cash equivalents</a></td>
<td class="num">(14,419)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Increase (Decrease) in cash and cash equivalents</a></td>
<td class="num">(167,093,942)<span></span>
</td>
<td class="nump">136,250,968<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents, beginning of period</a></td>
<td class="nump">250,728,118<span></span>
</td>
<td class="nump">22,196,097<span></span>
</td>
<td class="nump">$ 22,196,097<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents, end of period</a></td>
<td class="nump">83,634,176<span></span>
</td>
<td class="nump">158,447,065<span></span>
</td>
<td class="nump">$ 250,728,118<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosures:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities', window );">Amounts accrued for purchases of property and equipment</a></td>
<td class="nump">35,370<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Interest paid</a></td>
<td class="nump">544,315<span></span>
</td>
<td class="nump">2,590,196<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_AmortizationOfOperatingLeaseRightOfUseAssets', window );">Amortization Of Operating Lease Right-Of-Use Assets</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 271,628<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_AmortizationOfOperatingLeaseRightOfUseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortization Of Operating Lease Right-Of-Use Assets</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_AmortizationOfOperatingLeaseRightOfUseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_ChangeInValueOfInvestmentsInAffiliatedCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of the change in fair value of the investment in affiliated entity. This investment is measured at fair value on a recurring basis.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_ChangeInValueOfInvestmentsInAffiliatedCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_IncreaseDecreaseInAccruedClinicalTrialExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) In Accrued Clinical Trial Expense</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_IncreaseDecreaseInAccruedClinicalTrialExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_IncreaseDecreaseInDeferredRevenueFromRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net change during the reporting period, excluding the portion taken into income, in the liability reflecting services yet to be performed by the reporting entity for which cash or other forms of consideration was received or recorded as a receivable from a related party.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_IncreaseDecreaseInDeferredRevenueFromRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) In Operating Lease, Right-Of-Use Asset (Lease Liability), Net</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net change during the reporting period in the value of prepaid expenses and other current assets from related parties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_IncreaseDecreaseinDeferredGrantFundingCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) in Deferred Grant Funding, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_IncreaseDecreaseinDeferredGrantFundingCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_IncreaseDecreaseinDeferredGrantFundingFromAffiliateCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) in Deferred Grant Funding, From Affiliate, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_IncreaseDecreaseinDeferredGrantFundingFromAffiliateCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_NonCashInterestIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Non-Cash Interest Income (Expense)</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_NonCashInterestIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_OperatingLeaseNonCashLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating Lease, Non-Cash Lease Expense</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_OperatingLeaseNonCashLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_SettlementOfReceivableWithSharesOfCommonStockFromEquitySecurity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Settlement Of Receivable With Shares Of Common Stock From Equity Security</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_SettlementOfReceivableWithSharesOfCommonStockFromEquitySecurity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiUnrealizedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized loss on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=120269885&amp;loc=SL75117546-209714<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiUnrealizedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109240200&amp;loc=d3e30690-110894<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 35<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121605123&amp;loc=d3e30226-110892<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=120253306&amp;loc=d3e28228-110885<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450222&amp;loc=d3e30840-110895<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of realized and unrealized gain (loss) on investment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27405-111563<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(c),9(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the obligations due for goods and services provided by the following types of related parties: a parent company and its subsidiaries, subsidiaries of a common parent, an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entities' management, an entity and its principal owners, management, or member of their immediate families, affiliates, or other parties with the ability to exert significant influence.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amount due to the reporting entity for good and services provided to the following types of related parties: a parent company and its subsidiaries; subsidiaries of a common parent; an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entity's management, an entity and its principal owners, management, member of their immediate families, affiliates, or other parties with the ability to exert significant influence.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDerivativeLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the period in the carrying value of derivative instruments reported as liabilities that are due to be disposed of within one year (or the normal operating cycle, if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDerivativeLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in other expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for securities or other assets acquired, which qualify for treatment as an investing activity and are to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromMinorityShareholders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from a noncontrolling interest. Includes, but is not limited to, purchase of additional shares or other increase in noncontrolling interest ownership.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromMinorityShareholders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from sales of all investments, including securities and other assets, having ready marketability and intended by management to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3000-108585<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139775179915384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Operations<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NatureOfOperations', window );">Organization and Operations</a></td>
<td class="text">Organization and Operations<div style="margin-top:5pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inovio Pharmaceuticals, Inc. (the &#8220;Company&#8221; or &#8220;INOVIO&#8221;), is a biotechnology company focused on rapidly bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases, cancer, and diseases associated with human papillomavirus ("HPV"). INOVIO's DNA medicines pipeline is comprised of three types of product candidates: DNA vaccines, DNA immunotherapies and DNA encoded monoclonal antibodies ("dMAbs"). In clinical trials, INOVIO has demonstrated that DNA medicines can be delivered directly into cells in the body through its proprietary smart device to consistently activate robust and fully functional T cell and antibody responses against targeted pathogens and cancers. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's novel DNA medicine candidates are made using its proprietary SynCon</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> technology that creates optimized plasmids, which are circular strands of DNA that instruct a cell to produce antigens to help the person&#8217;s immune system recognize and destroy cancerous or virally infected cells.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">INOVIO's patented CELLECTRA</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> smart delivery devices provide optimized uptake of its DNA medicines within the cell, overcoming a key limitation of other DNA-based technology approaches. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Human clinical trial data to date have shown a favorable safety profile of INOVIO's DNA medicines delivered directly into cells in the body using the CELLECTRA</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> smart device in more than 7,000 administrations across more than 3,000 patients.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> INOVIO's corporate strategy is to advance, protect and, once approved, commercialize its novel DNA medicines to meet urgent and emerging global health needs. The Company continues to advance and clinically validate an array of DNA medicine candidates that target HPV-associated diseases, cancer, and infectious diseases, such as COVID-19. The Company aims to advance these candidates through commercialization and continue to leverage third-party resources through collaborations and partnerships, including product license agreements. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company's partners and collaborators include ApolloBio Corporation.,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> AstraZeneca, Beijing Advaccine, The Bill &amp; Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations ("CEPI"), The U.S. Department of Defense ("DoD"), Defense Advanced Research Projects Agency ("DARPA"), GeneOne Life Science, HIV Vaccines Trial Network, the U.S. Defense Threat Reduction Agency&#8217;s Medical CBRN Defense Consortium ("MCDC"), International Vaccine Institute ("IVI"), National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Ology Bioservices, the Parker Institute for Cancer Immunotherapy, Plumbline Life Sciences, Regeneron Pharmaceuticals, Inc., Richter-Helm BioLogics, Thermo Fisher Scientific, the University of Pennsylvania, the Walter Reed Army Institute of Research, and The Wistar Institute.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company and its collaborators are currently conducting or planning clinical studies of its DNA medicines for HPV-associated precancers, including cervical, vulvar, and anal dysplasia; HPV-associated cancers, including head &amp; neck, cervical, anal, penile, vulvar, and vaginal; other HPV-associated disorders, such as recurrent respiratory papillomatosis ("RRP"); glioblastoma multiforme ("GBM"); prostate cancer; HIV; Ebola; Middle East Respiratory Syndrome ("MERS"); Lassa fever; Zika virus; and COVID-19.  </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">INOVIO was incorporated in Delaware in June 2001 and has its principal executive offices in Plymouth Meeting, Pennsylvania.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI http://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139775177927688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation, Liquidity and Risks and Uncertainties<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock', window );">Basis of Presentation, Liquidity and Risks and Uncertainties</a></td>
<td class="text">Basis of Presentation, Liquidity and Risks and Uncertainties<div style="margin-bottom:3pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Basis of Presentation</span></div><div style="margin-top:4.5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited condensed consolidated financial statements of Inovio have been prepared in accordance with U.S. generally accepted accounting principles (&#8220;U.S. GAAP&#8221;) as contained in the Financial Accounting Standards Board ("FASB") Accounting Standards Codification ("ASC") for interim financial information and with instructions to Form&#160;10-Q and Article&#160;10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. The condensed consolidated balance sheet as of March&#160;31, 2021, the condensed consolidated statements of operations, the condensed consolidated statements of comprehensive loss, the condensed consolidated statements of stockholders' equity and the condensed consolidated statements of cash flows for the three months ended March 31, 2021 and 2020 are unaudited, but include all adjustments (consisting of normal recurring adjustments) that the Company considers necessary for a fair presentation of the financial position, results of operations, cash flows and changes in stockholders' equity for the periods presented. The results of operations for the three months ended March 31, 2021 shown herein are not necessarily indicative of the results that may be expected for the year ending December&#160;31, 2021, or for any other period. These unaudited financial statements, and notes thereto, should be read in conjunction with the audited consolidated financial statements for the </span></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">year ended December&#160;31, 2020, included in the Company's Annual Report on Form&#160;10-K filed with the U.S. Securities and Exchange Commission (&#8220;SEC&#8221;) on March&#160;1, 2021. The balance sheet at December&#160;31, 2020 has been derived from the audited financial statements at that date, but does not include all of the information and footnotes required by U.S. GAAP for complete financial statements. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2020, the Company formed a wholly-owned subsidiary, Inovio Asia LLC, under the laws of South Korea, through which the Company intends to advance its corporate development projects and other functions in South Korea and other Asian countries.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These unaudited condensed consolidated financial statements include the accounts of Inovio Pharmaceuticals, Inc. and its subsidiarie</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s. As of March 31, 2021, the Company consolidated its wholly-owned subsidiary Inovio Asia LLC. On December 31, 2020, former wholly-owned subsidiaries Genetronics, Inc. and VGX Pharmaceuticals Inc. and former majority -owned subsidiary VGX Animal Health, Inc. were merged into Inovio Pharmaceuticals, Inc. All intercompany accounts and transactions were eliminated upon consolidation. As of June 1, 2020, the Company deconsolidated its former subsidiary Geneos Therapeutics, Inc. ("Geneos"), as the Company no longer held a controlling financial interest.  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Refer to Footnote 17 for further discussion.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Liquidity </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company incurred a net loss attributable to common stockholders of $54.4 million for the three months ended March 31, 2021. The Company had working capital of $546.9 million and an accumulated deficit of $960.6 million as of March&#160;31, 2021. The Company has incurred losses in each year since its inception and expects to continue to incur significant expenses and operating losses for the foreseeable future in connection with the research and preclinical and clinical development of its product candidates. The Company&#8217;s cash, cash equivalents and short-term investments of $518.6 million as of March&#160;31, 2021 are sufficient to support the Company's operations for a period of at least 12 months from the date of issuance of these financial statements. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to continue to fund future research and development activit</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ies, the Company will need to seek additional capital. This may occur through strategic alliance and licensing arrangements, grant agreements and/or future public or private debt or equity financings including use of potential future At-the-Market Equity Offering Sales Agreements (&#8220;Sales Agreements&#8221;). The Company</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> has a history of conducting debt and equity financings, including the receipt of net proceeds of $162.1&#160;million from a January 2021 underwritten public offering and net proceeds of $454.5 million under past Sales Agreements </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for the year ended December 31, 2020. However, sufficient funding may not be available in the future, or if available, may be on terms that significantly dilute or otherwise adversely affect the rights of existing stockholders. If adequate funds are not available, the Company may need to delay, reduce the scope of or put on hold one or more of its clinical and/or preclinical programs.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s ability to continue its operations is dependent upon its ability to obtain additional capital in the future and achieve profitable operations. The Company expects to continue to rely on outside sources of financing to meet its capital needs and the Company may never achieve positive cash flow. These condensed consolidated financial statements do not include any adjustments to the specific amounts and classifications of assets and liabilities, which might be necessary should Inovio be unable to continue as a going concern. The Company's condensed consolidated financial statements as of and for the three months ended March 31, 2021 have been prepared on a going concern basis, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business for the foreseeable future. The Company has evaluated subsequent events after the balance sheet date through the date it issued these condensed consolidated financial statements.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is and, from time to time,&#160;may in the future be subject to various legal proceedings and claims arising in the ordinary course of business. The Company assesses contingencies to determine the degree of probability and range of possible loss for potential accrual in its consolidated financial statements. An estimated loss contingency is accrued in the consolidated financial statements if it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated. Legal proceedings, including litigation, government investigations and enforcement actions, could result in material costs, occupy significant management resources and entail civil and criminal penalties, even if the Company ultimately prevails.&#160;Any of the foregoing consequences could result in serious harm to the Company&#8217;s business, results of operations and financial condition. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risks and Uncertainties</span></div><div style="margin-top:5pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The global pandemic resulting from COVID-19, caused by a novel strain of coronavirus, SARS-CoV-2, has caused national and global economic and financial market disruptions. The impact of this pandemic has been and will likely continue to be extensive in many aspects of society, which has resulted in and will continue to cause significant disruptions to the global economy, as well as businesses and capital markets around the world. </span></div><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company is closely monitoring the impact of the COVID-19 pandemic on its employees, collaborators and service providers. The extent to which the pandemic will continue to impact the Company's business and operations will depend on future developments, including travel restrictions and social distancing in the United States and other countries, and the </span></div>effectiveness of actions taken in the United States and other countries to contain and treat the disease, including mass vaccination efforts, that are highly uncertain as of the date the Company is issuing these financial statements.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the business description and basis of presentation concepts.  Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity.  Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI http://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139775179769608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Critical Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Critical Accounting Policies</a></td>
<td class="text">Critical Accounting Policies<div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaboration Agreements </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company assesses whether its collaboration agreements are subject to ASC Topic 808:&#160;Collaborative Arrangements&#160;(&#8220;Topic 808&#8221;) based on whether they involve joint operating activities and whether both parties have active participation in the arrangement and are exposed to significant risks and rewards. To the extent that the arrangement falls within the scope of Topic 808 and the Company concludes that its collaboration partner is not a customer, the Company presents such payments as a reduction of research and development expense. If payments from the collaboration partner to the Company represent consideration from a customer, then the Company accounts for those payments within the scope of Accounting Standards Update (&#8220;ASU&#8221;) 2014-09, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;Topic 606&#8221;). </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue Recognition </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which it expects to be entitled in exchange for those goods or services. To determine revenue recognition for contracts with customers, the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the Company satisfies its performance obligations. At contract inception, the Company assesses the goods or services agreed upon within each contract and assess whether each good or service is distinct and determine those that are</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">performance obligations. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Arrangements</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company enters into collaborative arrangements with partners that typically include payment of one or more of the following: (i) license fees; (ii) product supply services; (iii) milestone payments related to the achievement of developmental, regulatory, or commercial goals; and (iv) royalties on net sales of licensed products. Where a portion of non-refundable, upfront fees or other payments received are allocated to continuing performance obligations under the terms of a collaborative arrangement, they are recorded as deferred revenue and recognized as revenue when (or as) the underlying performance obligation is satisfied.  </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the accounting for these arrangements, the Company must develop estimates and assumptions that require judgment of management to determine the underlying stand-alone selling price for each performance obligation which determines how the transaction price is allocated among the performance obligation. The standalone selling price may include items such as forecasted revenues, development timelines, discount rates and probabilities of technical and regulatory success. The Company evaluates each performance obligation to determine if it can be satisfied at a point in time or over time. In addition, variable consideration must be evaluated to determine if it is constrained and, therefore, excluded from the transaction price.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">License Fees</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If a license to intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company will recognize revenues from non-refundable, upfront fees allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license. For licenses that are bundled with other promises, the Company will utilize judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Product Supply Services</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Arrangements that include a promise for future supply of drug product for either clinical development or commercial supply at the licensee&#8217;s discretion are generally considered as options. The Company will assess if these options provide a material right to the licensee and if so, they will be accounted for as separate performance obligations. The Company evaluates whether it is the principal or agent in the arrangement. The Company had determined that it is the principal in the current arrangements as the Company controls the product supply before it is transferred to the customer. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Milestone Payments</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the inception of each arrangement that includes milestone payments (variable consideration), the Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the Company's or its collaboration partner&#8217;s control, such as regulatory approvals, are generally not considered probable of being achieved until those approvals are received. The transaction price is then allocated to each performance obligation on a relative stand-alone selling price basis, for which the Company recognizes revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, the Company re-evaluates the probability of achieving such milestones and any related constraint, and if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect license, collaboration or other revenues and earnings in the period of adjustment.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Royalties</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and for which the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). To date, the Company has not recognized any royalty revenue resulting from any of its collaborative arrangements.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Grants</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for various grant agreements under the contributions guidance under Subtopic 958-605, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Not-for-Profit Entities-Revenue Recognition</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which is outside the scope of Topic 606, as the government agencies granting the Company funds are not receiving reciprocal value for their contributions. All contributions received from current grant agreements are recorded as a contra-expense as opposed to revenue on the condensed consolidated statement of operations. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For its long-term operating leases, the Company recognizes an operating lease right-of-use asset and an operating lease liability on its condensed consolidated balance sheets. The lease liability is determined as the present value of future lease payments using an estimated rate of interest that the Company would pay to borrow equivalent funds on a collateralized basis at the lease commencement date. The right-of-use asset is based on the liability adjusted for any prepaid or deferred rent. The Company determines the lease term at the commencement date by considering whether renewal options and termination options are reasonably assured of exercise. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fixed rent expense for the Company's operating leases is recognized on a straight-line basis over the term of the lease and is included in operating expenses on the condensed consolidated statements of operations. Variable lease payments including lease operating expenses are recorded as incurred.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development Expenses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s activities have largely consisted of research and development efforts related to developing electroporation delivery technologies, DNA vaccines, DNA immunotherapies and dMABs. Research and development expenses consist of expenses incurred in performing research and development activities including salaries and benefits, facilities and other overhead expenses, clinical trials, contract services and other outside expenses. Research and development expenses are charged to operations as they are incurred. These expenses result from the Company's independent research and development efforts as well as efforts associated with collaborations and licensing arrangements. The Company reviews and accrues clinical trial expense based on work performed, which relies on estimates of total costs incurred based on patient enrollment, completion of studies and other events. Accrued clinical trial costs are subject to revisions as trials progress. Revisions are charged to expense in the period in which the facts that give rise to the revision become known. Historically, revisions have not resulted in material changes to research and development expense; however, a modification in the protocol of a clinical trial or cancellation of a trial could result in a charge to the Company's results of operations.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Valuation of Intangible Assets and Goodwill</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets are amortized over their estimated useful lives ranging from <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18zNy9mcmFnOmE0NTZiM2ZhOTA0ZjQ0ZjNiYTUyYzg0OWE5YTIxNGRiL3RleHRyZWdpb246YTQ1NmIzZmE5MDRmNDRmM2JhNTJjODQ5YTlhMjE0ZGJfOTk1Nw_def5a8b0-cb2d-4478-a5a4-79b9dd366f59">two</span> to 18&#160;years. Acquired intangible assets are continuously being developed for the future economic viability contemplated at the time of acquisition. The Company is concurrently conducting preclinical studies and clinical trials using the acquired intangibles and has entered into licensing agreements for the use of these acquired intangibles.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">License costs are recorded based on the fair value of consideration paid and are amortized using the straight-line method over the shorter of the expected useful life of the underlying patents or the term of the related license agreement to the extent the license has an alternative future use. As of March&#160;31, 2021 and December&#160;31, 2020, the Company&#8217;s intangible assets </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">resulting from the acquisition of Inovio AS and Bioject Medical Technologies, Inc. ("Bioject"), and additional intangibles including license costs, net of accumulated amortization, totaled $3.0 million and $3.1 million, respectively.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The determination of the value of intangible assets requires management to make estimates and assumptions that affect the Company&#8217;s condensed consolidated financial statements. The Company assesses potential impairments to intangible assets when there is evidence that events or changes in circumstances indicate that the carrying amount of an asset may not be recovered. The Company&#8217;s judgments regarding the existence of impairment indicators and future cash flows related to intangible assets are based on operational performance of its acquired businesses, market conditions and other factors. If impairment is indicated, the Company will reduce the carrying value of the intangible asset to fair value. While current and historical operating and cash flow losses are potential indicators of impairment, the Company believes the future cash flows to be received from its intangible assets will exceed the intangible assets&#8217; carrying value, and accordingly, the Company has not recognized any impairment losses through March&#160;31, 2021.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill represents the excess of acquisition cost over the fair value of the net assets of acquired businesses. Goodwill is reviewed for impairment at least annually at November 30, or more frequently if an event occurs indicating the potential for impairment. During its goodwill impairment review, the Company may assess qualitative factors to determine whether it is more likely than not that the fair value of its reporting unit is less than its carrying amount, including goodwill. The qualitative factors include, but are not limited to, macroeconomic conditions, industry and market considerations, and the overall financial performance of the Company. If, after assessing the totality of these qualitative factors, the Company determines that it is not likely that the fair value of its reporting unit is less than its carrying amount, then no additional assessment is deemed necessary. Otherwise, the Company will proceed to perform the impairment test in which the fair value of the reporting unit is compared with its carrying amount, and an impairment charge will be recorded for the amount by which the carrying amount exceeds the reporting unit's fair value, if any. The Company performed its annual assessment for goodwill impairment as of November 30, 2020, identifying no impairment.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although there are inherent uncertainties in this assessment process, the estimates and assumptions the Company is using are consistent with its internal planning. If these estimates or their related assumptions change in the future, the Company may be required to record an impairment charge on all or a portion of its goodwill and intangible assets. Furthermore, the Company cannot predict the occurrence of future impairment triggering events nor the impact such events might have on its reported asset values. Future events could cause the Company to conclude that impairment indicators exist and that goodwill or other intangible assets associated with its acquired businesses are impaired. Any resulting impairment loss could have an adverse impact on the Company&#8217;s results of operations. See Note&#160;8 for further discussion of the Company&#8217;s goodwill and intangible assets.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Foreign Currency Translation</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The functional and presentation currency of the Company is the U.S. dollar. Transactions denominated in a currency other than the functional currency are recorded on the initial recognition at the exchange rate at the date of the transaction. After initial recognition monetary assets and liabilities denominated in foreign currency are translated at the end of each reporting period into the functional currency at the exchange rate at that date. The cumulative translation adjustment is included in the accumulated other comprehensive income (loss) within the statement of stockholders' equity. Exchange differences are included in general and administrative expenses in the condensed consolidated statement of operations. Non- monetary assets and liabilities measured at cost are translated at the exchange rate at the date of the transaction.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Variable Interest Entities (VIE)</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates its ownership, contractual and other interests in entities that are not wholly-owned to determine if these entities are VIEs, and, if so, whether the Company is the primary beneficiary of the VIE. In determining whether the Company is the primary beneficiary of a VIE and therefore required to consolidate the VIE, the Company applies a qualitative approach that determines whether it has both (1) the power to direct the activities of the VIE that most significantly impact the VIE&#8217;s economic performance and (2) the obligation to absorb losses of, or the rights to receive benefits from, the VIE that could potentially be significant to that VIE. The Company will continuously perform this assessment, as changes to existing relationships or future transactions may result in the consolidation or deconsolidation of a VIE.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Equity Investments</span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under ASC Topic 321, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investments - Equity Securities,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> the Company must measure equity investments (except those accounted for under the equity method, those that result in consolidation of the investee and certain other investments) at fair value and recognize any changes in fair value in the condensed consolidated statement of operations. The Company can elect a measurement alternative for equity investments that do not have readily determinable fair values and do not qualify for the practical expedient in ASC 820, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurement,</span> to estimate fair value using the net asset value per share (or its equivalent).&#160;The Company's equity investments that do not have readily determinable fair values and do not qualify for the net asset value practical expedient for estimating fair value are measured at cost, less any impairments, plus or minus changes resulting from observable price changes in orderly transactions for identifiable or similar investments of the same issuer.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139775177887656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Impact of Recently Issued Accounting Standards<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock', window );">Impact of Recently Issued Accounting Standards</a></td>
<td class="text">Impact of Recently Issued Accounting Standards <div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The recent accounting pronouncements below may have a significant effect on the Company's financial statements. Recent accounting pronouncements that are not anticipated to have an impact on or are unrelated to the Company's financial condition, results of operations, or related disclosures are not discussed. </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accounting Standards Pending Adoption</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">ASU No. 2020-06.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In August 2020, the FASB issued ASU No. 2020-06, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Debt&#8212;Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging&#8212;Contracts in Entity&#8217;s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity&#8217;s Own Equity</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;ASU 2020-06&#8221;), which simplifies the guidance on an issuer&#8217;s accounting for convertible instruments and contracts in its own equity. The standard is effective for the Company beginning in the first quarter of 2022, with early adoption permitted in the first quarter of 2021. The Company did not elect to early adopt the standard and does not expect ASU 2020-06 to have a material impact to its condensed consolidated financial statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for change in accounting principle. Includes, but is not limited to, nature, reason, and method of adopting amendment to accounting standards or other change in accounting principle.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=113356391&amp;loc=SL49131195-203048<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -URI http://asc.fasb.org/topic&amp;trid=2122394<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=113356391&amp;loc=SL49131195-203048<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section S99<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=112272810&amp;loc=SL108384541-122693<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (i)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=113356391&amp;loc=SL49131195-203048<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (j)<br> -URI http://asc.fasb.org/extlink&amp;oid=113356391&amp;loc=SL49131195-203048<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120154821&amp;loc=SL120154904-197079<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 11.M.Q2)<br> -URI http://asc.fasb.org/extlink&amp;oid=112272810&amp;loc=d3e31137-122693<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120154821&amp;loc=SL120154904-197079<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120154821&amp;loc=SL120154904-197079<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL121648383-210437<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL121648383-210437<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (e)(1)<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (e)(2)<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (e)(3)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139775179266600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue Recognition<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerTextBlock', window );">Revenue Recognition</a></td>
<td class="text">Revenue Recognition  During the three months ended March 31, 2021, the Company recognized total revenue under collaborative research and development and other agreements of $50,000 from its affiliated entity Plumbline Life Sciences, Inc. ("PLS") and $321,000 from various other contracts as a result of performance obligations being satisfied. Of the total revenue recognized during the three months ended March 31, 2021, $4,000 was in deferred revenue as of December 31, 2020.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI http://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130551-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130556-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130554-203045<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130550-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130554-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130554-203045<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130554-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130558-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130554-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139775266575816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Short-term Investments<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock', window );">Short-term Investments</a></td>
<td class="text">Short-term Investments<div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Short-term investments at March&#160;31, 2021 consisted of mutual funds, U.S. treasury securities, certificates of deposit and U.S. agency mortgage-backed securities. Short-term investments at December&#160;31, 2020 consisted of mutual funds, certificates of deposit and U.S. agency mortgage-backed securities. Short-term investments are recorded at fair value, based on current market valuations. Unrealized gains and losses on the Company's short-term debt investments are excluded from earnings and reported as a separate component of other comprehensive loss until realized. Realized gains and losses and unrealized gains and losses on available-for-sale equity securities are included in non-operating other income (expense) on the condensed consolidated statements of operations and are derived using the specific identification method for determining the cost of the securities sold. During the three months ended March 31, 2021 and 2020, the Company recorded gross realized gain on investments of $0 and $50,000, respectively, and gross realized loss on investments of $10,000 and $525,000, respectively. During the three months ended March 31, 2021 and 2020, the Company recorded net unrealized loss on available-for-sale equity securities of $(848,000) and $(5.1) million, respectively. No&#160;material balances were&#160;reclassified out of accumulated&#160;other comprehensive income (loss) for the three months ended March 31, 2021 and 2020. Interest and dividends on investments classified as available-for-sale are included in interest income in the condensed consolidated statements of operations. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of available-for-sale securities as of March&#160;31, 2021 and December&#160;31, 2020:</span></div><div style="margin-top:5pt;text-indent:27pt"><span><br/></span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:25.839%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.809%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.809%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.809%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.812%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of March 31, 2021</span></td></tr><tr style="height:21pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Contractual<br/>Maturity&#160;(in&#160;years)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross&#160;Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross&#160;Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair&#160;Market&#160;Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mutual funds</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">---</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">228,101,615&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,562,498&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(714,957)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">228,949,156&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less than 1</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200,408,976&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,404&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,380)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200,414,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less than 1</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,977,623&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,700&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,123)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,992,200&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. agency mortgage-backed securities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,646,077&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,100&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(33,005)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,614,172&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">434,134,291&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,597,702&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(762,465)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">434,969,528&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:25.839%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.809%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.809%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.809%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.812%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2020</span></td></tr><tr style="height:21pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Contractual<br/>Maturity&#160;(in&#160;years)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross&#160;Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross&#160;Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair&#160;Market&#160;Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mutual funds</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">---</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">153,177,675&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,339,639&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(644,140)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">154,873,174&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less&#160;than&#160;1</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,000,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,260&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,016,260&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. agency mortgage-backed securities</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,062,256&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(36,755)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,025,501&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">159,239,931&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,365,899&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(690,895)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">160,914,935&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*No single maturity date.</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company periodically reviews its portfolio of available-for-sale debt securities to determine if any investment is impaired due to credit loss or other potential valuation concerns. For the debt securities where the fair value of the investment is less than the amortized cost basis, the Company has assessed at the individual security level for various quantitative factors including, but not limited to, the nature of the investments, changes in credit ratings, interest rate fluctuations, industry analyst reports, and the severity of impairment. Unrealized losses on available-for-sale debt securities as of&#160;March&#160;31, 2021&#160;were primarily due to changes in interest rates, including credit spreads from perceived increased credit risks as a result of the COVID-19 global pandemic, and not due to increased credit risks associated with specific securities. The Company does not intend to sell these investments and it is not more likely than not that the Company will be required to sell the investments before recovery of their amortized cost basis, which may be at maturity. Based on the credit quality of the available-for-sale debt securities that are in an unrealized loss position, and the Company&#8217;s estimates of future cash flows to be collected from those securities, the Company believes the unrealized losses are not credit losses. Accordingly, at March&#160;31, 2021, the Company has not recorded an allowance for credit losses related to its available-for-sale debt securities.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for  investments in certain debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2209399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2324412<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI http://asc.fasb.org/topic&amp;trid=2196928<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2176304<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139775179341880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
<td class="text">Fair Value Measurements<div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The guidance regarding fair value measurements establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value. These tiers include: Level&#160;1, defined as observable inputs such as quoted prices in active markets that are accessible at the measurement date; Level&#160;2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable; and Level&#160;3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assets are classified based on the lowest level of input that is significant to the fair value measurements. The Company reviews the fair value hierarchy classification on a quarterly basis. Changes in the ability to observe valuation inputs may result in a reclassification of levels for certain securities within the fair value hierarchy. The Company does not have any liabilities measured at fair value on a recurring basis and did not have any transfer of assets or liabilities between Level 1, Level 2 and Level 3 of the fair value hierarchy during the three months ended March 31, 2021 or 2020. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the Company&#8217;s assets that were measured at fair value on a recurring basis, determined using the following inputs as of March&#160;31, 2021:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:35.796%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.541%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.541%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.737%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.689%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements at</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted Prices<br/>in Active Markets<br/>(Level&#160;1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Other Unobservable<br/>Inputs<br/>(Level&#160;2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Unobservable<br/>Inputs<br/>(Level&#160;3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Mutual funds</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">228,949,156&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">228,949,156&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S. treasury securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200,414,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200,414,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Certificates of deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,992,200&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,992,200&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S. agency mortgage-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,614,172&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,614,172&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total short-term investments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">434,969,528&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">429,363,156&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,606,372&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment in affiliated entity</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,629,891&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,629,891&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets measured at fair value</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">438,599,419&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">432,993,047&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,606,372&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the Company&#8217;s assets that were measured at fair value on a recurring basis, determined using the following inputs as of December&#160;31, 2020:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:35.796%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.541%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.541%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.737%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.689%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements at</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted Prices<br/>in Active Markets<br/>(Level&#160;1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Other Unobservable<br/>Inputs<br/>(Level&#160;2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Unobservable<br/>Inputs<br/>(Level&#160;3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S. treasury securities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,996,800&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,996,800&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Mutual funds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">154,873,174&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">154,873,174&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Certificates of deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,016,260&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,016,260&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S. agency mortgage-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,025,501&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,025,501&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total short-term investments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">160,914,935&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">154,873,174&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,041,761&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment in affiliated entities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,460,366&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,460,366&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets measured at fair value</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">225,372,101&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">219,330,340&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,041,761&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Level 1 assets at March&#160;31, 2021 consisted of mutual funds and U.S. treasury securities held by the Company that are valued at quoted market prices, as well as the Company&#8217;s investment in its affiliated entity, PLS. The Company accounts for its investment in 597,808 common shares of PLS based on the closing price of the shares on the Korea New Exchange Market on the applicable balance sheet date. Unrealized gains and losses on the Company's equity securities are reported in the condensed consolidated statement of ope</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">rations as unrealized gain (loss) on available-for-sale equity securities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">or as a gain (loss) on investment in affiliated entities.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 2 assets at March&#160;31, 2021 consisted of certificates of deposit and U.S. agency mortgage-backed securities held by the Company that are initially valued at the transaction price and subsequently valued, at the end of each reporting period, typically utilizing market observable data. The Company obtains the fair value of its Level 2 assets from a professional pricing service, which may use quoted market prices for identical or comparable instruments, or inputs other than quoted prices that are observable either directly or indirectly. The professional pricing service gathers quoted market prices and observable inputs from a variety of industry data providers. The valuation techniques used to measure the fair value of the Company's Level 2 financial instruments were derived from non-binding market consensus prices that are corroborated by observable market data, quoted market prices for similar instruments, or pricing models such as discounted cash flow techniques. The Company validates the quoted market prices provided by the primary pricing service by comparing the service's assessment of the fair values of the Company's investment portfolio balance against the fair values of the Company's investment portfolio balance obtained from an independent source.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no Level 3 assets held as of March&#160;31, 2021.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139775177902168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Intangible Assets<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock', window );">Goodwill and Intangible Assets</a></td>
<td class="text">Goodwill and Intangible Assets<div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following sets forth the goodwill and intangible assets by major asset class:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"><tr><td style="width:1.0%"/><td style="width:18.870%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.535%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.206%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.060%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.060%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.500%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.918%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr style="height:45pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average Useful<br/>Life<br/>(Yrs)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Book<br/>Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Book<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indefinite lived:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill(a)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,513,371&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,513,371&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,513,371&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,513,371&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Definite lived:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Licenses</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,323,761&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,284,039)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,722&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,323,761&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,276,852)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,909&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bioject(b)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,100,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,542,222)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,557,778&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,100,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,468,889)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,631,111&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other(c)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,050,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,637,500)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">412,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,050,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,581,250)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">468,750&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total intangible assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,473,761&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,463,761)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,010,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,473,761&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,326,991)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,146,770&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total goodwill and intangible assets</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,987,132&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,463,761)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,523,371&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,987,132&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,326,991)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,660,141&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">Goodwill was recorded from the acquisition of other companies. </span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">Bioject intangible assets represent the estimated fair value of developed technology and intellectual property which were recorded from an asset acquisition.</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">Other intangible assets represent the estimated fair value of acquired intellectual property. </span></div>Aggregate amortization expense on intangible assets for each of the three months ended March 31, 2021 and 2020 was $137,000. Estimated aggregate amortization expense is $384,000 for the remainder of fiscal year 2021, $493,000 for 2022, $276,000 for 2023, $253,000 for 2024, $253,000 for 2025 and $1.4 million for 2026 and subsequent years combined.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -URI http://asc.fasb.org/topic&amp;trid=2144416<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139775177876680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Debt<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Convertible Debt</a></td>
<td class="text">Convertible Debt<div style="margin-bottom:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Convertible Senior Notes </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 19, 2019 and March 1, 2019, the Company completed a private placement of $78.5 million aggregate principal amount of its 6.50% convertible senior notes due 2024 (the &#8220;Notes&#8221;). The Notes were sold in a private offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended. Net proceeds from the offering were approximately $75.7 million.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Notes are senior unsecured obligations of the Company and accrue interest payable in cash semi-annually in arrears on March 1 and September 1 of each year, beginning on September 1, 2019, at a rate of 6.50% per annum. The Notes will mature on March 1, 2024, unless earlier converted, redeemed or repurchased.&#160;Prior to the close of business on the business day immediately preceding November 1, 2023, the Notes will be convertible at the option of the holders only upon the satisfaction of certain circumstances. Thereafter, the Notes will be convertible at the option of the holders at any time until the close of business on the scheduled trading day immediately before the maturity date. Upon conversion, the Company will pay or deliver, as the case may be, cash, shares of its common stock or a combination of cash and shares of its common stock, at its election. The initial conversion rate will be 185.8045 shares per $1,000 principal amount of Notes (equivalent to an initial conversion price of approximately $5.38 per share), subject to adjustment upon the occurrence of specified events.  </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company may not redeem the Notes prior to March 1, 2022. On or after March 1, 2022, the Company may redeem all, or any portion, of the Notes for cash if the last reported sale price per share of the Company's common stock exceeds 130% of the conversion price on (i) each of at least 20 trading days (whether or not consecutive) during the 30 consecutive trading days ending on, and including, the trading day immediately before the Company sends the related redemption notice; and (ii) the trading day immediately before the date the Company sends such redemption notice.&#160;The redemption price will be equal to 100% of the principal amount of the Notes to be redeemed, plus accrued and unpaid interest to, but excluding, the redemption date.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluated the accounting for the issuance of the Notes and concluded that the embedded conversion features meet the requirements for a derivative scope exception for instruments that are both indexed to an entity&#8217;s own stock and classified in stockholders&#8217; equity in its condensed consolidated balance sheet, and that the cash conversion guidance applies. Therefore, the Notes issuance proceeds of $78.5 million are allocated first to the liability component based on the fair </span></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">value of non-convertible debt with otherwise identical residual terms with the residual proceeds allocated to equity for the conversion featu</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">res. The Company determined that the fair value of the non-convertible debt upon issuance of the Notes was $62.2 million and recorded this amount as a liability and the offsetting amount as a debt discount as a reduction to the carrying value of the Notes on the closing date. The debt issuance costs associated with the Notes of $2.8 million are allocated to the liability and equity component in the same proportion as the issuance proceeds. </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determined that all other features of the Notes were clearly and closely associated with a debt host and did not require bifurcation as a derivative liability, or the fair value of the feature was immaterial to the Company's condensed consolidated financial statements.</span></div><div style="margin-bottom:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determined that the expected life of the Notes was equal to the period through November 1, 2023 as this represents the point at which the Notes are initially subject to repurchase by the Company at the option of the holders. Accordingly, the total debt discount of $18.6 million, inclusive of the fair value of the embedded conversion feature derivative at issuance, is being amortized using the effective interest method through November 1, 2023.&#160;The effective interest rate of the liability component is 13.1%. </span></div><div style="margin-bottom:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">During the year ended December 31, 2020, the Company received notices for the conversion of $62.1&#160;million of principal amount of the Notes, which were settled for</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> an aggregate of 11,535,660 shares of the Company's common stock</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">. The fair value of the Notes at the date of conversion was $43.7&#160;million compared to the carrying value of $52.5&#160;million, resulting in a $8.8 million gain on extinguishment of debt. This gain was recorded in the condensed consolidated statement of operations. To measure the fair value of the converted Notes as of the conversion dates, the Company engaged a third-party valuation expert and utilized a binomial lattice model.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The balance of the Notes at March&#160;31, 2021 is as follows:</span></div><div style="margin-bottom:5pt;margin-top:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:69.617%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:28.183%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Original principal amount</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78,500,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Principal amount converted into common shares</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(62,085,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unamortized debt discount on the liability component</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,139,698)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unamortized debt issuance cost</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(294,495)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88,915&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Net carrying amount </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,069,722&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March 31, 2021 and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2020</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,&#160;the Company recognized $463,000 and $2.1 million, respectively, of interest expense related to the Notes, of which $267,000 and $1.3 million, respectively, related to the contractual interest coupon.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2021, future minimum payments due under the Notes, representing contractual amounts due, including interest based on the fixed rate of 6.5% per annum, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">are as follows:</span></div><div style="margin-bottom:5pt;margin-top:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:85.742%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.328%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Remainder of 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">534,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,067,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,067,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,948,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,616,000&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:5pt;padding-left:22.5pt"><span><br/></span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">August 2019 Convertible Bonds</span></div><div style="margin-top:5pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 1, 2019, the Company closed a private placem</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ent of the August 2019 Bonds with an aggregate principal amount of 18 billion Korean Won (KRW) (approximately USD $15.0 million based on the exchange rate on the date of issuance) issued to institutional investors led by Korea Investment Partners (KIP), a global venture capital and private equity firm based in Seoul, Korea. Net proceeds from the offering were approximately $14.5 million. </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The August 2019 Bonds, which were unsecured obligations of the Company, were issued on August 1, 2019 and accrued interest at a coupon rate of 1.00% per annum, payable quarterly. The August 2019 Bonds were scheduled to mature on July 31, 2024, unless earlier converted or repurchased. On August 3, 2020 the August 2019 Bonds were converted in full into an aggregate of 4,962,364 shares of the Company's common stock, leaving no further August 2019 Bonds outstanding. The initial conversion rate was 211.0595 shares per KRW1,000,000 in principal amount (equivalent to an initial conversion price of approximately USD $4.00 per share based on the exchange rate as of July 30, 2019), subject to adjustment upon the occurrence of specified events. The conversion rate was reset on January 2, 2020 and was subject to reset quarterly thereafter if the current </span></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">market price was lower than the conversion price then in effect. The conversion rate as of the date of conversion on August 1, 2020 was 275.6873 shares per KRW 1,000,000 in principal amount (equivalent to a conversion price of approximately USD $3.14 per share).</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluated the accounting for the issuance of the August 2019 Bonds and concluded that the embedded conversion feature was considered a derivative requiring bifurcation from the August 2019 Bonds as it did not meet the equity scope exception due to the fact that it was denominated in a currency other than the Company's functional currency. The fair value of the conversion feature at August 1, 2019 was $7.1 million, which was recorded as a reduction to the carrying value of the debt. This debt discount was being amortized to&#160;interest expense over the term of the debt using the effective interest method. The conversion option was accounted for as a derivative liability, which was revalued each reporting period with&#160;the resulting change in fair value reflected in other income (expense), net, in the condensed consolidated&#160;statements of operations.  </span></div><div style="margin-bottom:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determined that all other features of the August 2019 Bonds were clearly and closely associated with a debt host and did not require bifurcation as a derivative liability, or the fair value of the feature was immaterial to the Company's condensed consolidated financial statements.</span></div><div style="margin-bottom:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At their issuance, the Company determined that the expected life of the August 2019 Bonds was equal to the period through August 1, 2022 as this represented the point at which the August 2019 Bonds were initially subject to repurchase by the Company at the option of the holders. Accordingly, the total debt discount of $7.3 million, inclusive of the fair value of the embedded conversion feature derivative at issuance, was being amortized using the effective interest method through August 1, 2022</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. For the three months ended March 31, 2020, the Company recognized $641,000 of interest expense related to the August 2019 Bonds, of which $38,000 related to the contractual interest coupon.</span></div><div style="margin-bottom:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Immediately prior to the August 2020 conversion, the derivative liability associated with the August 2019 Bonds was revalued at $84.5 million. The change in fair value of the derivative liability was an increase of $75.7 million, which was recorded on the consolidated statement of operations for the year ended December 31, 2020. To measure the fair value of the derivative liability as of the conversion date, the Company engaged a third-party valuation expert.</span></div><div style="margin-bottom:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon conversion, a loss on extinguishment of $8.2&#160;million was recorded on the consolidated statement of operations for the year ended December 31, 2020. This loss represents the difference between (a) the calculated fair value of the derivative liability immediately prior to its derecognition plus the carrying amount of the debt component including any unamortized debt discount and issuance costs and (b) the fair value of the 4,692,364 shares of the Company's common stock issued upon conversion.</span></div><div style="margin-bottom:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">December 2019 Convertible Bonds </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December&#160;26, 2019, the Company closed a private placement of convertible promissory notes (the &#8220;December 2019 Bonds&#8221;) with an aggregate principal amount of 4.7 billion KRW (approximately USD $4.1 million based on the exchange rate on the date of issuance) issued to a Korea-based institutional investor. Net proceeds from the offering were approximately $4.0 million.  </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The December 2019 Bonds, which were unsecured obligations of the Company, were issued on December&#160;31, 2019 and accrued interest at a coupon rate of 1.00% per annum, payable quarterly. The December 2019 Bonds were scheduled to mature on December&#160;31, 2024, unless earlier converted or repurchased. On March 17, 2021, the December 2019 Bonds were converted in full into an aggregate of 1,009,450 shares of the Company's common stock, leaving no further December 2019 Bonds outstanding. The initial conversion rate was 214.7766 shares per KRW1,000,000 principal amount of Bonds (equivalent to an initial conversion price of approximately USD $4.00 per share based on the exchange rate as of December&#160;19, 2019), subject to adjustment upon the occurrence of certain events. As of the conversion date of March 17, 2021, the conversion rate had not been reset from the initial conversion rate.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluated the accounting for the issuance of the December 2019 Bonds and concluded that the embedded conversion feature does not require bifurcation from the December 2019 Bonds. Although the embedded conversion feature meets the definition of a derivative, it qualifies for the equity scope exception for instruments that are both indexed to an entity&#8217;s own stock and classified in stockholders&#8217; equity in its consolidated balance sheet. The December 2019 Bonds were denominated in a foreign currency other than the Company&#8217;s functional currency, which would typically violate the settlement provision criteria when analyzing whether the conversion option is indexed to an entity&#8217;s own stock. However, per the terms of the agreement, the functional currency rate required to be used in a conversion scenario was fixed as of the date preceding the date of issuance of the Bonds. Therefore, the fluctuation in functional currency did not impact the settlement of the conversion option. Further, as there was no cash conversion feature or beneficial conversion feature on the date of issuance, and the Bonds were not issued at a substantial premium, all of the proceeds were recorded as a liability. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determined that all other features of the December 2019 Bonds were clearly and closely associated with a debt host and did not require bifurcation as a derivative liability, or the fair value of the feature was immaterial to the Company's condensed consolidated financial statements.</span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At their issuance, the Company determined that the expected life of the December 2019 Bonds was equal to the period through December 31, 2022 as this represented the point at which the December 2019 Bonds were initially subject to repurchase by the Company at the option of the holders. The effective interest rate of the December 2019 Bonds was 6.2%</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. For the three months ended March 31, 2021 and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2020</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,&#160;the Company recognized $59,000 and $62,000, respectively, of interest expense related to the December 2019 Bonds, of which $9,000 and $10,000, respectively, related to the contractual interest coupon.</span> As of March&#160;31, 2021, all outstanding December 2019 Bonds were converted into 1,009,450 shares of the Company's common stock. Upon conversion, the $4.4&#160;million carrying value of the December 2019 Bonds was recorded to stockholders' equity.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI http://asc.fasb.org/topic&amp;trid=2208564<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139775281730632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Equity</a></td>
<td class="text">Stockholders&#8217; Equity<div style="margin-bottom:10pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of the Company's authorized and issued common and preferred stock as of March&#160;31, 2021 and December&#160;31, 2020: </span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.830%"><tr><td style="width:1.0%"/><td style="width:42.095%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.473%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.539%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.473%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.539%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.136%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.539%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.106%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Outstanding as of</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Authorized</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Issued</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common Stock, par value $0.001 per share</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">600,000,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">209,334,036&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">209,334,036&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">186,851,493&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Series&#160;C Preferred Stock, par value $0.001 per share</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,091&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,091&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Preferred Stock</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2020, 14 shares of the Company&#8217;s Series&#160;C preferred stock were converted into an aggregate of 5,147 shares of the Company&#8217;s common stock.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Common Stock</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 25, 2021, the Company closed an underwritten public offering of 20,355,000 shares of common stock at a public offering price of $8.50 per share. The net proceeds to the Company, after deducting the underwriters' discounts and commissions and other estimated offering expenses, were $162.1&#160;million. </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2018, the Company entered into a Sales Agreement with an outside placement agent (the &#8220;Placement Agent&#8221;) to sell shares of its common stock with aggregate gross proceeds of up to $100.0 million, from time to time, through an &#8220;at-the-market&#8221; equity offering program under which the Placement Agent acted as sales agent. During the first quarter of 2020, the Company and the Placement Agent entered into a first and second amendment to the Sales Agreement (the "Prior Sales Agreement") to increase the amount of common stock that may be sold under the Sales Agreement from $100.0 million to $250.0 million. As of March 31, 2020, there was no remaining capacity under the Prior Sales Agreement. On April 3, 2020, the Company and the Placement Agent entered into a new Sales Agreement (the "New Sales Agreement") to sell shares of its common stock</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 3, 2020 and May 12, 2020, the Company filed prospectus supplements pursuant to the New Sales Agreement for the offer and sale of its Common Stock for aggregate gross proceeds of up to an aggregate of $250.0 million. </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March 31, 2020, the Company sold 43,148,952 shares of its common stock under the Prior Sales Agreement. The sales were made at a weighted average price of $4.92 per share, resulting in aggregate net proceeds of $208.2 million. As of March 31, 2020, there was no remaining capacity under the Prior Sales Agreement.</span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">During the year ended December 31, 2020, the Company sold a total of 22,919,934 shares of its common stock under the New Sales Agreement. The sales were made at a weighted average price of $10.91 per share resulting in aggregate net proceeds of $246.2 million. There were no additional sales during the three months ended March 31, 2021, and as of March 31, 2021, there was no remaining capacity under the New Sales Agreement. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock Options and Restricted Stock Units</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has a stock-based incentive plan, the 2016 Omnibus Incentive Plan (as amended to date, the "2016 Incentive Plan"), pursuant to which the Company may grant stock options, restricted stock awards, restricted stock units and other stock-based awards or short-term cash incentive awards to employees, directors and consultants. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2016 Incentive Plan was originally approved by the Company's stockholders on May 13, 2016, and an amendment to the plan to increase the number of shares available for issuance was approved by the stockholders on May 8, 2019. As of March 31, 2021, the maximum number of shares of the Company&#8217;s common stock available for issuance over the term of the 2016 Incentive Plan was 20,000,000 shares. On the first business day of each calendar year, such maximum number of shares is further increased by&#160;2,000,000 shares of common stock unless the Board determines, prior to January 1 for any such calendar year, to increase such maximum amount by a fewer number of shares or not to increase the maximum amount at all for such year. On January 1, 2021, the maximum number of shares increased by 2,000,000. At March&#160;31, 2021, the Company had 5,251,776 shares of common stock available for future grant under the 2016 Incentive Plan, 2,610,130 shares underlying </span></div>outstanding but unvested restricted stock units and options outstanding to purchase 7,994,029 shares of common stock under the 2016 Incentive Plan. The awards granted and available for future grant under the 2016 Incentive Plan generally vest over three years and have a maximum contractual term of ten years. The 2016 Incentive Plan terminates by its terms on March&#160;9, 2026.The Amended and Restated 2007 Omnibus Incentive Plan (the "2007 Incentive Plan") was adopted on March&#160;31, 2007 and terminated by its terms on March&#160;31, 2017. At March&#160;31, 2021, the Company had options outstanding to purchase 2,832,443 shares of common stock under the 2007 Incentive Plan. The awards granted under the 2007 Incentive Plan generally vest over three years and have a maximum contractual term of ten years.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139775177876680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Loss Per Share</a></td>
<td class="text">Net Loss Per Share <div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net loss per share is computed by dividing the net loss for the period by the weighted average number of shares of common stock outstanding during the period. Diluted net loss per share is calculated in accordance with the treasury stock method for the outstanding stock options and restricted stock units and refle</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">cts the potential dilution that would occur if securities or other con</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">tracts to issue common stock were exercised or converted to common stock. The dilutive impact of the outstanding Notes and Bonds issued by the Company (discussed in Note 9) has been considered using the "if-converted" method. The calculation of diluted net loss per share requires that, to the extent the average market price of the underlying shares for the reporting period exceeds the exercise price of the options or other securities and the presumed exercise of such securities are dilutive to net loss per share for the period, an adjustment to the net loss used in the calculation is required to remove the change in fair value of such securities from the numerator for the period. Likewise, an adjustment to the denominator is required to reflect the related dilutive shares, if any. For the three months ended March 31, 2021 and 2020, basic and diluted net loss per share were the same, as the assumed exercise or settlement of stock options and restricted stock units and the potentially dilutive shares issuable upon conversion of the Notes and Bonds would have been anti-dilutive.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes potential shares of common stock that were excluded from the diluted net loss per share calculation because of their anti-dilutive effect for the three months ended March 31, 2021 and 2020: </span></div><div style="margin-bottom:6pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.170%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.549%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.263%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Common Stock Equivalents</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options to purchase common stock</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,826,472&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,615,986&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service-based restricted stock units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,610,130&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,667,710&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Performance-based restricted stock units</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">663,353&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible preferred stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,309&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,456&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,049,980&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,585,653&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 2019 Bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,928,859&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 2019 Bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,009,450&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,153,244&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,816,114&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139775177904408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text">Stock-Based Compensation<div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company incurs stock-based compensation expense related to restricted stock units ("RSUs") and stock options. The fair value of restricted stock is determined by the closing price of the Company's common stock reported on the Nasdaq Global Select Market on the date of grant. The Company estimates the fair value of stock options granted using the Black-Scholes option pricing model. The Black-Scholes option pricing model was developed for use in estimating the fair value of traded options, which have no vesting restrictions and are fully transferable. In addition, option valuation models require the input of subjective assumptions, including the expected stock price volatility and expected option life. The Company amortizes the fair value of the awards on a straight-line basis over the requisite vesting period of the awards. Expected volatility is based on historical volatility. The expected life of options granted is based on historical expected life. The risk-free interest rate is based on the U.S. Treasury yield in effect at the time of grant. The dividend yield is based on the fact that no dividends have been paid historically and none are currently expected to be paid in the foreseeable future. The Company recognizes forfeitures as they occur.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average assumptions used in the Black-Scholes model for option grants to employees and directors are presented below:</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  </span></div><div style="margin-bottom:5pt;margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:73.461%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.914%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.88%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.74%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected life in years</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.8</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.9</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div><span><br/></span></div><div style="margin-bottom:3pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total employee and director stock-based compensation expense recognized in the condensed consolidated statements of operations for the three months ended March 31, 2021 and 2020 was $9.2 million and $3.6 million, respectively, of which $5.2 million and $2.3 million, respectively, was included in research and development expenses, and $4.0 million and $1.3 million, respectively, was included in general and administrative expenses.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At March&#160;31, 2021, there was $22.3 million of total unrecognized compensation expense related to unvested stock options, which is expected to be recognized over a weighted-average period of 2.6 years.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average grant date fair value per share, calculated using the Black-Scholes option pricing model, was $8.34 and $5.37 for employee and director stock options granted during the three months ended March 31, 2021 and 2020, respectively. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At March&#160;31, 2021, there was $19.4 million of total unrecognized compensation expense related to unvested service-based RSUs, which is expected to be recognized over a weighted-average period of 2.3 years.  </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average grant date fair value per share was $11.42 and $8.32 for service-based RSUs granted during the three months ended March 31, 2021 and 2020, respectively.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of stock options granted to non-employees was estimated using the Black-Scholes pricing model. Total stock-based compensation expense for stock options and RSUs granted to non-employees for the three months ended March 31, 2021 and 2020 was $429,000 and $383,000, respectively. </span></div><div style="margin-bottom:5pt;text-indent:27pt"><span style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On August 28, 2020, the Company granted 663,353 performance-based RSUs to executives under the 2016 Incentive Plan. The RSUs will vest in two tranches as follows: 50% of the shares in each tranche will vest upon achievement of the predetermined performance milestones and the remaining 50% of the shares in each tranche will vest upon subsequent completion of a one-year service period. The total grant date fair value of the performance-based RSUs was $8.0&#160;million based on the grant date closing price per share of $12.06. As of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">March&#160;31, 2021</span><span style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, the underlying performance milestones of the RSUs were not probable of achievement, and no stock-based compensation expense was recognized for the performance-based RSUs for the three months then ended.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139775177876680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionDueFromToRelatedPartyAbstract', window );"><strong>Related Party Transaction, Due from (to) Related Party [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related Party Transactions</a></td>
<td class="text">Related Party Transactions<div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Plumbline Life Sciences, Inc.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company owns 597,808 shares of common stock in PLS as of March&#160;31, 2021, representing a 19.7% ownership interest, and one of the Company's directors, Dr.&#160;David B. Weiner, acts as a consultant to PLS.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue recognized from PLS consists of milestone, license and patent fees. For the three months ended March 31, 2021 and 2020, the Company recognized revenue from PLS of $50,000 and $1.1 million, respectively. At March&#160;31, 2021 and December&#160;31, 2020, the Company had an accounts receivable balance of $80,000 and $67,000, respectively, related to PLS.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The Wistar Institute</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's director Dr.&#160;David B. Weiner is a director of the Vaccine Center of The Wistar Institute ("Wistar"). Dr. Weiner is also the Executive Vice President of Wistar.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2016, the Company entered into collaborative research agreements with Wistar&#160;for preventive and therapeutic DNA-based immunotherapy applications and products developed by&#160;Dr. Weiner and Wistar for the treatment of cancers and infectious diseases. Under the terms of the agreement, the Company reimbursed Wistar for all direct and indirect costs incurred in the conduct of the collaborative research, not to exceed $3.1 million during the five-year term of the agreements. In March 2021, upon expiration of the March 2016 agreements, the Company entered into new collaborative research agreements with Wistar&#160;with the same terms. The Company has the exclusive right to in-license new intellectual property developed under the agreements.  </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2016, the Company received a&#160;$6.1 million&#160;sub-grant through Wistar to develop a DMAb against the Zika infection, with funding through June 2021. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is also a collaborator with Wistar on an Integrated Preclinical/Clinical AIDS Vaccine Development grant from the NIAID, with funding through February 2022.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2020, the Company received a $10.7&#160;million sub-grant through Wistar for the preclinical development and translational studies of DMAbs as countermeasures for COVID-19, with funding through September 2022. The sub-grant also includes an option for an additional $6.0&#160;million in funding through September 2024.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred grant funding recognized from Wistar and recorded as contra-research and development expense is related to work performed by the Company on the research sub-contract agreements. For the three months ended March 31, 2021 and 2020, the Company recorded $230,000 and $619,000, respectively, as contra-research and development expense from Wistar. </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses recorded from Wistar relate primarily to the collaborative research agreements and sub-contract agreements related to the Bill &amp; Melinda Gates Foundation and CEPI (see Note 15). Research and development expenses recorded from Wistar for the three months ended March 31, 2021 and 2020 were $318,000 and $362,000, respectively. At March&#160;31, 2021 and December&#160;31, 2020, the Company had an accounts receivable balance of $256,000 and $425,000, respectively, and an accounts payable and accrued liability balance of $768,000 and $643,000, respectively, related to Wistar. As of March&#160;31, 2021, the Company had $76,000 recorded as deferred grant funding on the condensed consolidated balance sheet related to Wistar.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionDueFromToRelatedPartyAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionDueFromToRelatedPartyAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -URI http://asc.fasb.org/topic&amp;trid=2122745<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39691-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139775177819752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Leases</a></td>
<td class="text">Leases                                                  <div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company leases approximately 82,200 square feet of office, laboratory, and manufacturing space in San Diego, California and 57,360 square feet of office space in Plymouth Meeting, Pennsylvania under various non-cancellable operating lease agreements with remaining lease terms as of March&#160;31, 2021</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of 2.7 to 8.8 ye</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ars, which represent the non-cancellable periods of the leases. The Company has excluded the extension options from its lease terms in the calculation of future lease payments as they are not reasonably certain to be exercised. The Company's lease payments consist primarily of fixed rental payments for the right to use the underlying leased assets over the lease terms as well as payments for common area maintenance and administrative services. The Company has received customary incentives from its landlords, such as reimbursements for tenant improvements and rent abatement periods, which effectively reduce the total lease payments owed for these leases.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company performed an evaluation of its contracts with customers and suppliers in accordance with ASC Topic 842 and determined that, except for the real estate leases described above and various copier leases, none of its other contracts contain a right-of-use asset. </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease right-of-use assets and liabilities on the condensed consolidated balance sheet represents the present value of the remaining lease payments over the remaining lease terms. Payments for additional monthly fees to cover the Company's share of certain facility expenses are not included in operating lease right-of-use assets and liabilities. The Company uses its incremental borrowing rate to calculate the present value of its lease payments, as the implicit rates in the leases are not readily determinable.</span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">As of March&#160;31, 2021, the maturities of the Company's operating lease liabilities were as follows:</span></div><div style="margin-bottom:5pt;margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:85.449%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.351%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Remainder of 2021</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,983,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,045,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,023,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,001,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,063,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,888,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Total remaining lease payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,003,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: present value adjustment</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,168,000)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Total operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,835,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: current portion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,396,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term operating lease liabilities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,439,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average remaining lease term</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.2 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average discount rate</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.5%</span></td></tr></table></div><div style="margin-top:8pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lease costs included in operating expenses in the condensed consolidated statements of operations for the three months ended March 31, 2021 and 2020 were $850,000 and $834,000, respectively. Operating lease costs consisting of the fixed lease payments included in operating lease liabilities are recorded on a straight-line basis over the lease terms. Variable lease costs are recorded as incurred.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the fourth quarter of 2019, the Company entered into two agreements to sublease a total of approximately 13,500 square feet in its Plymouth Meeting headquarters through periods between December 31, 2022 and March 31, 2025.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the normal course of business, the Company is a party to a variety of agreements pursuant to which it may be obligated to indemnify the other party. It is not possible to predict the maximum potential amount of future payments under these types of agreements due to the conditional nature of the Company's obligations and the unique facts and circumstances involved in each particular agreement. Historically, payments made by the Company under these types of agreements have not had a material effect on its business, consolidated results of operations or financial condition.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI http://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139775177876680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborative Agreements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">Collaborative Agreements</a></td>
<td class="text">Collaborative Agreements<div style="margin-top:5pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Advaccine Biopharmaceuticals Suzhou Co., Ltd. (Advaccine)</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 31, 2020, the Company entered into a Collaboration and License Agreement (the &#8220;Advaccine Agreement&#8221;) with Advaccine. Under the terms of the Advaccine Agreement, the Company granted to Advaccine the exclusive right to develop, manufacture and commercialize the Company&#8217;s vaccine candidate INO-4800 within the territories of China, Taiwan, Hong Kong and Macau (referred to collectively as &#8220;Greater China&#8221;). Advaccine does not have the right to grant sublicenses, other than to affiliated entities, without the Company&#8217;s express prior written consent. As part of the collaboration, Advaccine has also granted to the Company a non-exclusive license to certain DNA vaccine manufacturing processes.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Advaccine Agreement, Advaccine made an upfront payment to the Company of $3.0&#160;million. In addition to the upfront payment, the Company is entitled to receive up to an aggregate of $108.0&#160;million upon the achievement of specified milestones related to the development, regulatory approval and commercialization of INO-4800, including the achievement of specified net sales thresholds for INO-4800 in Greater China, if approved. As of December 31, 2020 the Company had earned a $2.0&#160;million milestone payment based on the enrollment of the first subject in the Phase 2 clinical trial for the product in the Advaccine territory. The Company will also be entitled to receive a royalty equal to a high single-digit percentage of annual net sales in each region within Greater China, subject to reduction in the event of competition from biosimilar products in a particular region and in other specified circumstances. Advaccine&#8217;s obligation to pay royalties will continue, on a licensed product-by-licensed product basis and region-by-region basis, for ten years after the first commercial sale in a particular region within Greater China or, if later, until the expiration of the last-to-expire patent covering a given licensed product in a given region.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Advaccine Agreement, Advaccine is responsible for the development and commercialization of the licensed products at its own cost and expense and is obligated to use commercially reasonable efforts to develop, obtain and maintain regulatory approval of INO-4800, as well as the Company&#8217;s CELLECTRA</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> device and arrays for use in connection with the administration of INO-4800, in each region in Greater China. In the event that the Company has not initiated the planned Phase 3 segment of its ongoing clinical trial of INO-4800 in the United States within one year after entering into the Advaccine Agreement, Advaccine may elect to conduct a Phase 3 clinical trial outside of Greater China at its own cost and expense for the purposes of obtaining regulatory approval in China, subject to the Company&#8217;s right to review and approve the protocols and design of such a trial.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Advaccine Agreement, the Company will supply Advaccine&#8217;s clinical requirements of INO-4800 and devices, although Advaccine may manufacture INO-4800 for its clinical use and may procure alternate suppliers. Advaccine is responsible for the manufacture and supply of INO-4800 itself or through a contract manufacturer for commercial use. Upon Advaccine&#8217;s reasonable request, the parties may negotiate a separate clinical and/or commercial supply agreement.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Advaccine Agreement will continue in force on a region-by-region basis until Advaccine has no remaining royalty obligations in such region. Either party may terminate the Advaccine Agreement (i) in the event the other party shall have materially breached its obligations thereunder and such default shall have continued for a specified period after written notice thereof or (ii) upon the bankruptcy or insolvency of the other party. In addition, the Company may terminate the agreement, upon prior written notice, if Advaccine (i) ceases all development or commercialization activities for at least nine months, subject to certain exceptions, or (ii) challenges the validity, enforceability or scope of any of the patents licensed by the Company to Advaccine under the Advaccine Agreement, subject to certain conditions. Advaccine may terminate the Advaccine Agreement at any time for convenience upon nine months&#8217; written notice to the Company, if such notice is provided before the first commercial sale of INO-4800 in Greater China, or 18 months&#8217; written notice thereafter; provided that the Company may accelerate the effectiveness of such termination to the extent permitted by law.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluated the terms of the Advaccine Agreement under ASC Topics 606 and 808, and determined that the contract was with a customer and therefore should be accounted for under ASC Topic 606. The license to INO-4800 in the territories was identified as the only distinct performance obligation on a standalone basis as of the inception of the Advaccine Agreement. The Company concluded that the license was distinct from potential future manufacturing and supply obligations. The Company further determined that the transaction price under the Advaccine Agreement consisted of the $3.0&#160;million upfront payment plus the initial $2.0&#160;million milestone payment which was achieved upon contract signing. The future potential milestone amounts were not included in the transaction price, as they were all determined to be fully constrained. As part of the evaluation of the development and regulatory milestones constraint, the Company determined that the achievement of such milestones is contingent upon success in future clinical trials and regulatory approvals, each of which is uncertain. Future potential milestone amounts may be recognized as revenue under the Advaccine Agreement, as well as under other collaborative research and development arrangements, if unconstrained. Reimbursable program costs will be recognized proportionately with the performance of the underlying services or delivery of drug supply and are excluded from the transaction price.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under Topic 606, the entire transaction price of $5.0&#160;million was allocated to the license performance obligation. The Company determined that as of December 31, 2020, the transfer of technology has occurred for the use and benefit of the license and accordingly, the performance obligation was fully satisfied. The Company accordingly recognized $5.0&#160;million in revenue under collaborative research and development arrangements on the consolidated statement of operations during the year ended December 31, 2020. During the three months ended March 31, 2021, no revenue was recognized from Advaccine.  As of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March&#160;31, 2021 and </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December 31, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2020</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the Company had an accounts receivable balance of $0 and $7.1&#160;million, respectively, from Advaccine.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ApolloBio Corporation </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December&#160;29, 2017, the Company entered into an Amended and Restated License and Collaboration Agreement (the "ApolloBio Agreement"),</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">with ApolloBio Corporation ("ApolloBio"), with an effective date of March 20, 2018. Under the terms of the ApolloBio Agreement, the Company has granted to ApolloBio the exclusive right to develop and commercialize&#160;VGX-3100, its DNA immunotherapy product candidate designed to treat&#160;pre-cancers&#160;caused by HPV, within the territories of China, Hong Kong, Macao, Taiwan, and potentially Korea in the event that no patent covering&#160;VGX-3100&#160;is issued in China within the three years following the effective date of the ApolloBio Agreement.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the ApolloBio Agreement, the Company received proceeds of $19.4 million in March 2018 which comprised the upfront payment of $23.0 million less $2.2 million in foreign income taxes and $1.4 million in certain foreign non-income taxes. The foreign income taxes were recorded as a provision for income taxes and the foreign non-income taxes were recorded as a general and administrative expense, on the condensed consolidated statement of operations. The Company also incurred advisory fees of $960,000 in connection with receiving the upfront payment from ApolloBio. These fees were determined to be incremental costs of obtaining the contract. The Company applied the practical expedient that permits a company to expense incremental costs to obtain a contract when the expected amortization period is one year or less and recorded the fees in general and administrative expense during the quarter ended March 31, 2018. No additional advisory fees are due related to the ApolloBio Agreement. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the upfront payment, the Company is entitled to receive up to an aggregate of $20.0 million, less required income, withholding or other taxes, upon the achievement of specified milestones related to the regulatory approval of&#160;VGX-3100&#160;in the United States, China and Korea. In the event that&#160;VGX-3100 is approved for marketing, the Company will be entitled to receive royalty payments based on a tiered percentage of annual net sales, with such percentage being in the&#160;low-&#160;to&#160;mid-teens,&#160;subject to reduction in the event of generic competition in a particular territory. ApolloBio&#8217;s obligation to pay royalties will continue for 10 years after the first commercial sale in a particular territory or, if later, until the expiration of the&#160;last-to-expire&#160;patent covering the licensed products in the specified territory. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The ApolloBio Agreement will continue in force until ApolloBio has no remaining royalty obligations. Either party may terminate the ApolloBio Agreement in the event the other party shall materially breach or default in the performance of its material obligations thereunder and such default continues for a specified period after written notice thereof. In addition, ApolloBio may terminate the ApolloBio Agreement at any time beginning one year after the effective date for any reason upon 90 days written notice to the Company.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluated the terms of the ApolloBio Agreement under ASC Topic 606, and the license to VGX-3100 in the territories was identified as the only distinct performance obligation on a standalone basis as of the inception of the agreement.  The Company concluded that the license was distinct from potential future manufacturing and supply obligations. The Company further determined that the transaction price under the agreement consisted of the $23.0 million upfront payment.  The future potential milestone amounts were not included in the transaction price, as they were all determined to be fully constrained. As part of the evaluation of the development and regulatory milestones constraint, the Company determined that the achievement of such milestones is contingent upon success in future clinical trials and regulatory approvals, each of which is uncertain at this time. Future potential milestone amounts may be recognized as revenue under the ApolloBio Agreement, as </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">well as under other collaborative research and development arrangements, if unconstrained. Reimbursable program costs will be recognized proportionately with the performance of the underlying services or delivery of drug supply and are excluded from the transaction price. As of March&#160;31, 2021 there have been no significant reimbursable program costs under the ApolloBio Agreement.</span><span style="color:#ee2724;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under Topic 606, the entire transaction price of $23.0 million was allocated to the license performance obligation. The Company determined that during the quarter ended June 30, 2018, the transfer of technology occurred and accordingly, the performance obligation was fully satisfied. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">AstraZeneca </span></div><div style="margin-bottom:3pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 7, 2015, the Company entered into a license and collaboration agreement with MedImmune, the global biologics research and development arm of AstraZeneca ("AstraZeneca"). Under the agreement, AstraZeneca acquired exclusive rights to the Company's INO-3112 immunotherapy, renamed as MEDI0457, which targets cancers caused by human papillomavirus (HPV) types 16 and 18, with the ability to sublicense those license rights. AstraZeneca made an upfront payment of $27.5 million to the Company in September 2015. AstraZeneca may be obligated to make potential future development and regulatory event-based payments to the Company totaling up to $125 million and potential future commercial event-based payments totaling up to $115 million, in each case upon the achievement of specified milestones related to MEDI0457 set forth in the license and collaboration agreement. AstraZeneca will fund all development costs associated with MEDI0457 immunotherapy. The Company is entitled to receive up to mid-single to double-digit tiered royalties on MEDI0457 product sales. Under the agreement, AstraZeneca can also request the Company to provide certain clinical manufacturing at an agreed upon price. The Company determined these options did not represent material rights at the inception of the agreement.   </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2017, the Company had recognized all of the $27.5 million upfront payment as revenue, as all identified material performance obligations had been met with respect to that payme</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">nt. In both December 2018 and March 2019, the Company recognized as revenue $2.0&#160;million in milestone payments from AstraZeneca triggered by AstraZeneca&#8217;s </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">initiation of the Phase 2 portion of ongoing clinical trials in the second and third major indication, respectively, under the agreement.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Coalition for Epidemic Preparedness Innovations </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2018, the Company entered into agreements with CEPI, pursuant to which the Company intends to develop vaccine candidates against Lassa fever and MERS. The goal of the collaboration between the Company and CEPI is to conduct research and development so that investigational stockpiles will be ready for clinical efficacy trial testing during potential disease outbreaks. The agreements with CEPI contemplate preclinical&#160;studies, as well as Phase 1 and Phase 2 clinical trials, occurring over multiple years. As part of the arrangement between the parties, CEPI has agreed to fund up to an aggregate of $56 million of costs over a five-year period for preclinical studies, as well as planned Phase 1 and Phase 2 clinical trials, to be conducted by the Company and collaborators, with funding from CEPI based on the achievement of identified milestones. During the three months ended March 31, 2021 and 2020, the Company received funding of $2.4 million and  $1.1 million, respectively, related to these grants and recorded those payments as contra-research and development expense. As of March&#160;31, 2021, the Company had $251,000 recorded as grant funding liability on the condensed consolidated balance sheet related to the CEPI grant. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2020, CEPI awarded the Company a grant of up to $9.0 million to support preclinical and clinical development of INO-4800 through Phase 1 human testing in the United States. In April 2020, CEPI awarded the Company a grant of $6.9 million to work with the International Vaccine Institute ("IVI") and the Korea National Institute of Health ("KNIH") to conduct clinical trials of INO-4800 in South Korea, a grant of $5.0 million to accelerate development of  the Company's next-generation intradermal electroporation device, known as CELLECTRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 3PSP, for the intradermal delivery of INO-4800, and a grant of $1.3 million to support large-scale manufacturing of INO-4800. During each of the three months ended March 31, 2021 and 2020, the Company received funding of $2.4 million from CEPI related to these grants for INO-4800 and recorded such amounts as contra-research and development expense. As of March&#160;31, 2021, the Company had $4.0 million recorded as deferred grant funding on the condensed consolidated balance sheet related to the CEPI grants related to INO-4800.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Bill &amp; Melinda Gates Foundation</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2018, the Bill &amp; Melinda Gates Foundation (&#8220;Gates&#8221;) awarded and funded the Company a grant of $2.2 million to advance the development of dMAbs to address issues in infectious disease prevention and therapy. This technology has high relevance for the control of influenza and HIV. This next-generation approach to the delivery of monoclonal antibodies would make the technology accessible to low and middle-income countries. In August 2019, Gates funded an additional $1.1 million for the project. During the three months ended March 31, 2021 and 2020, the Company recorded $0 and $134,000, respectively, as contra-research and development expense related to the Gates dMAb grant. As of March&#160;31, 2021, the Company had $660,000 recorded as deferred grant funding on the condensed consolidated balance sheet related to the grant.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2020, Gates awarded and funded the Company a grant of $5.0 million to accelerate the development of the </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CELLECTRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 3PSP device for the intradermal delivery of INO-4800. During the three months ended March 31, 2021 and 2020, the Company recorded $893,000 and $64,000, respectively, as contra-research and development expense related to this Gates grant. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Department of Defense (DoD) </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2020, the Company entered into an Other Transaction Authority for Prototype Agreement (the &#8220;OTA Agreement&#8221;)&#160;with the DoD to fund the Company&#8217;s efforts in developing the CELLECTRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;3PSP device and associated arrays to be used for delivery of&#160;INO-4800 against&#160;COVID-19. Under the OTA Agreement, the Company intends to develop the CELLECTRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 3PSP device and arrays for use in the U.S. military population and the U.S. population as a whole, subject to approval of the device by the U.S. Food and Drug Administration (the &#8220;FDA&#8221;). The OTA Agreement is also expected to support large-scale manufacturing of the CELLECTRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 3PSP device, as well as large-scale DNA plasmid production for manufacture and supply of a specified number of doses of&#160;INO-4800&#160;in support of FDA approval of the device. The total amount of funding being made available to the Company under the OTA Agreement is approximately $54.5 million. The Company has determined that the OTA Agreement should be considered under Subtopic 958-605, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Not-for-Profit Entities-</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue Recognition</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which is outside the scope of Topic 606, as the government agency granting the Company funds is not</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">receiving reciprocal value for their contributions. The Company will record contra-research development expense on the condensed consolidated statement of operations in the same period that the underlying expenses are incurred. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Additionally, in June 2020, the Company was awarded a fixed-price contract (the &#8220;Procurement Contract&#8221;) from the DoD for the purchase of the Company&#8217;s intradermal CELLECTRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;2000 device and accessories. The CELLECTRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> 2000 devices will be used to inject&#160;INO-4800&#160;in the Company&#8217;s planned later-stage clinical trials. The total purchase price under the Procurement Contract is approximately $16.6 million. The Company has determined that the Procurement Contract does not currently fall under the scope of ASC 606 as contingencies remain regarding INO-4800 which does not give the Company the ability to satisfy its obligations under the arrangement.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March 31, 2021, the Company recorded $7.8&#160;million as contra-research and development expense related to these agreements with the DoD. As of March&#160;31, 2021 and December 31, 2020, the Company had an accounts receivable balance of $9.6&#160;million and $11.4&#160;million, respectively, on the condensed consolidated balance sheet from the DoD.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2021, the Company announced that the DoD had notified the Company that it will discontinue funding for the Phase 3 segment of the Company's clinical trial of INO-4800 in the United States, while continuing to fund the completion of the ongoing Phase 2 segment.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -URI http://asc.fasb.org/topic&amp;trid=5833765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139775177807080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text">Income Taxes The Company uses an estimated annual effective tax rate, which is based on expected annual income, statutory tax rates and tax planning opportunities available in the various jurisdictions in which the Company operates, to determine its quarterly provision for income taxes. Certain significant or unusual items are separately recognized in the quarter in which they occur and can be a source of variability in the effective tax rates from quarter to quarter.&#160;Due to the adoption of ASU 2019-12 which removes the exception under ASC 740-20-45-7 to consider all sources of income in order to determine the tax benefit resulting from a loss from continuing operations, ASC 740-20-45-7 no longer applies.On March 27, 2020, the United States enacted the Coronavirus Aid, Relief and Economic Security Act (CARES Act).&#160; The CARES Act is an emergency economic stimulus package that includes spending and tax breaks to strengthen the United States economy and fund a nationwide effort to curtail the effect of COVID-19.&#160;The CARES Act provides sweeping tax changes in response to the COVID-19 pandemic; some of the more significant provisions are removal of certain limitations on utilization of net operating losses, increasing the loss carryback period for certain losses to five years, and increasing the ability to deduct interest expense, as well as amending certain provisions of the previously enacted Tax Cuts and Jobs Act.&#160;At March&#160;31, 2021, the Company has not recorded any income tax provision/(benefit) for the impact for the CARES Act due to the Company&#8217;s history of net operating losses generated and the maintenance of a full valuation allowance against its net deferred tax assets.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139775184550120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Geneos Therapeutics, Inc.<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncontrollingInterestAbstract', window );"><strong>Noncontrolling Interest [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Geneos Therapeutics, Inc.</a></td>
<td class="text">Geneos Therapeutics, Inc. <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2016, the Company formed Geneos to develop and commercialize neoantigen-based personalized cancer therapies. Geneos was considered a variable interest entity (VIE) for which the Company was the primary beneficiary. In February 2019, Geneos completed the initial closing of a&#160;Series A preferred stock financing. The Company invested&#160;$1.2 million&#160;in the Series A preferred stock financing, which was led by an outside investor. Following this transaction, the Company held&#160;61%&#160;of the outstanding equity, on an as-converted to common stock basis, of Geneos and continued to consolidate its investment in Geneos under ASC 810, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Consolidation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2020, Geneos completed the second closing of the&#160;Series A preferred stock financing, in which the Company invested $800,000. Following this transaction, as of March 31, 2020, the Company held&#160;52%&#160;of the outstanding equity, on an as-converted to common stock basis, of Geneos and continued to consolidate its investment in Geneos.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2020, Geneos closed an additional&#160;Series A preferred stock financing round, in which the Company invested $800,000.  Following this transaction, the Company owned 47% of the outstanding equity of Geneos on an as-converted to common stock basis. This transaction triggered a VIE reconsideration, as the Company no longer held a controlling financial interest. Based on the Company&#8217;s assessment, Geneos continued to be a VIE as it did not have sufficient equity at risk to finance its activities without additional subordinated financial support.  However, the Company was not the primary beneficiary of Geneos, as it did not have the power to direct the activities that most significantly impact Geneos&#8217; economic performance.  Accordingly, the Company deconsolidated its investment in Geneos as of June 1, 2020, resulting in a gain of $4.1 million, of which $2.4 million related to the remeasurement of the retained noncontrolling interest investment to fair value.  The gain has been recorded separately on the Company's condensed consolidated statement of operations.  The following table shows the amounts related to the deconsolidation accounting: </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:84.405%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.395%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Working capital (excluding cash) </span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(59,992)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Note payable </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">171,620&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed assets, net of accumulated depreciation </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16,340)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Carrying value of noncontrolling interest </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,181,640&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of investment in Geneos retained</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,618,998&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain on deconsolidation of Geneos </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,121,075)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Decrease in cash resulting from the deconsolidation of Geneos</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,774,851&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">The details of the Company&#8217;s 47% retained equity investment in Geneos is shown in the table below, with fair values calculated as of June 1, 2020, the date of deconsolidation.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:54.178%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.976%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.973%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.562%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.119%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.392%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Geneos Share Class</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Price per Share</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,000,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.273&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">819,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Preferred</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,113,206&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.325&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,799,998&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total </span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,113,206&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,618,998&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:5pt;text-indent:22.5pt"><span><br/></span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of Geneos Series A preferred stock was based on the per share price paid by third-party investors in connection with the most recent closing of the Series A preferred stock financing for Geneos on June 1, 2020. The fair value of Geneos common stock was determined by a third-party valuation, as there is no public market for such stock. Geneos&#8217; enterprise value, which was estimated using a market approach that derived an implied total equity value from a transaction involving its own securities, was allocated to all classes of equity using the option pricing method. Under the option pricing method, each equity class was modeled as having a call option with a distinct claim on the total value of Geneos. Each option&#8217;s exercise price was based on the total value available for each participating security holder. The characteristics of each class of ownership determined the claim on the total value for that class of ownership.  </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated value allocated to common stock included assumptions related to the fair value of the enterprise, expected volatility, expected term, and risk-free interest rate. Expected volatility was based on historical asset volatilities derived from daily stock price changes of guideline public companies. The estimated expected term was based on a weighted average of the estimated time to Geneo's next financing and successful exit timing assumption.  The risk-free interest rate was based on the yield of U.S. Treasury with a comparable term. Geneos&#8217;s common stock is classified as a Level 3 financial instrument. The assumptions used in the fair value calculation as of June 1, 2020 are presented below:</span></div><div style="margin-bottom:5pt;margin-top:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:78.548%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.252%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term (years)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.92</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Volatility</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.46%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Geneos enterprise value</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$4,966,531</span></td></tr></table></div><div style="margin-top:8pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company applies the equity method to investments in common stock and to other investments in entities that have risk and reward characteristics that are substantially similar to an investment in the investee&#8217;s common stock.  Since the Company&#8217;s Series A preferred stock investment in Geneos has a substantive liquidation preference, it is not substantially similar to the Company&#8217;s common stock investment and will therefore be recorded as an equity security under ASC 321.  </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June 1, 2020, the Company accounts for its common stock investment in Geneos, in which the Company lacks control but does have the ability to exercise significant influence over operating and financial policies, using the equity method. Generally, the ability to exercise significant influence is presumed when the investor possesses more than 20% of the voting interests of the investee. This presumption may be overcome based on specific facts and circumstances that demonstrate that the ability to exercise significant influence is restricted. In applying the equity method, the Company records the investment at cost unless the initial recognition is the result of the deconsolidation of a subsidiary, in which case it is recorded at fair value. The Company's proportionate share of net loss of Geneos is recorded in&#160;equity in net earnings of Geneos in the Company's condensed consolidated statements of operations. The Company's equity method investments are reviewed for indicators of impairment at each reporting period and are written down to fair value if there is evidence of a loss in value that is other-than-temporary.&#160;Any difference between the carrying amount of the Company&#8217;s investment and the amount of underlying equity in Geneos&#8217; net assets is amortized into income or expense accordingly. There were no basis differences identified as of the deconsolidation date that would need to be amortized.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">  </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon deconsolidation, the Company recorded its Series A preferred stock investment at fair value based on the per share price paid by third party investors in connection with the preferred stock financing on June 1, 2020. The Company has determined that its Series A preferred stock investment in Geneos does not have a readily determinable fair value and has therefore elected the measurement alternative in ASC 321 to subsequently record the investment at cost, less any impairments, plus or minus changes resulting from observable price changes in orderly transactions for identical or similar investments of the same issuer.&#160;When fair value becomes determinable, from observable price changes in orderly transactions, the Company&#8217;s investment will be marked to fair value.&#160; There have been no observable price changes or impairments identified since the deconsolidation date.  </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2020, Geneos completed the closing of a Series A-1 preferred stock financing. The Company invested $1.4&#160;million in the Series A-1 preferred stock financing, which was led by outside investors. The closing date of this transaction was determined to be a VIE reconsideration event; based on the Company&#8217;s assessment, Geneos continues to be a VIE as it does not have sufficient equity at risk to finance its activities without additional subordinated financial support. The Company continues to not be the primary beneficiary of Geneos, as it does not have the power to direct the activities that most significantly impact Geneos&#8217;s economic performance and should not consolidate Geneos. Following this transaction, the Company held approximately 36% of the outstanding equity, on an as-converted to common stock basis. Accordingly, the Company continues to account for its common stock investment in Geneos as an equity method investment under ASC 323 and its preferred stock investments as equity securities under ASC 321.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of Geneos&#8217;s Series A-1 preferred stock was based on the per share price paid by third-party investors in connection with the closing on November 12, 2020. The Company has concluded that its Series A-1 preferred stock investment is not similar to its prior Series A preferred stock investment due to certain material rights held solely by Series A preferred stockholders. Therefore, the Company will continue to record its Series A preferred stock investment in Geneos at cost, as there have been no observable price changes or impairments identified since the deconsolidation date.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s share of net losses of Geneos for the period from June 1, 2020 through December 31, 2020 was $4.6 million and for the three months ended March 31, 2021 was $1.5&#160;million; however, only $434,000 was recorded, reducing the Company's total investment in Geneos to $0. Of the total amount, $819,000 has been allocated to the equity method investment, thereby reducing the balance to $0 as of March 31, 2021. The remaining $4.2 million loss has been allocated to the Company&#8217;s Series A and Series A-1 preferred stock investment in Geneos, on a ratable basis, thereby reducing the balance to $0 as of March 31, 2021 as shown in the table below:</span></div><div style="margin-bottom:6pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:84.133%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.115%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.352%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment in Geneos upon deconsolidation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,618,998&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment in Geneos Series A-1 preferred stock</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,399,999&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share in net loss of Geneos from June 1, 2020 - December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,584,610)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share in net loss of Geneos for the three months ended March 31, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(434,387)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment in Geneos as of March 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:5pt;text-indent:22.5pt"><span><br/></span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company will not reduce its investment below $0 and will not record its share of further net losses of Geneos as the Company has no obligation to fund Geneos.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2021, Geneos completed a second closing of the Series A-1 preferred stock financing, in which the Company did not participate. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following this transaction, the Company held approximately 35% of the outstanding equity, on an as-converted to common stock basis.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company continues to exclusively license its SynCon</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">immunotherapy and CELLECTRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;technology platform to Geneos to be used in the field of personalized, neoantigen-based therapy for cancer. The license agreement provides for </span></div>potential royalty payments to the Company in the event that Geneos commercializes any products using the licensed technology. The Company is not obligated to use any of its assets to fund the future operations of Geneos.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncontrollingInterestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncontrollingInterestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI http://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139775257572168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation, Liquidity and Risks and Uncertainties (Policies)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><div style="margin-bottom:3pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Basis of Presentation</span></div><div style="margin-top:4.5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited condensed consolidated financial statements of Inovio have been prepared in accordance with U.S. generally accepted accounting principles (&#8220;U.S. GAAP&#8221;) as contained in the Financial Accounting Standards Board ("FASB") Accounting Standards Codification ("ASC") for interim financial information and with instructions to Form&#160;10-Q and Article&#160;10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. The condensed consolidated balance sheet as of March&#160;31, 2021, the condensed consolidated statements of operations, the condensed consolidated statements of comprehensive loss, the condensed consolidated statements of stockholders' equity and the condensed consolidated statements of cash flows for the three months ended March 31, 2021 and 2020 are unaudited, but include all adjustments (consisting of normal recurring adjustments) that the Company considers necessary for a fair presentation of the financial position, results of operations, cash flows and changes in stockholders' equity for the periods presented. The results of operations for the three months ended March 31, 2021 shown herein are not necessarily indicative of the results that may be expected for the year ending December&#160;31, 2021, or for any other period. These unaudited financial statements, and notes thereto, should be read in conjunction with the audited consolidated financial statements for the </span></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">year ended December&#160;31, 2020, included in the Company's Annual Report on Form&#160;10-K filed with the U.S. Securities and Exchange Commission (&#8220;SEC&#8221;) on March&#160;1, 2021. The balance sheet at December&#160;31, 2020 has been derived from the audited financial statements at that date, but does not include all of the information and footnotes required by U.S. GAAP for complete financial statements. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2020, the Company formed a wholly-owned subsidiary, Inovio Asia LLC, under the laws of South Korea, through which the Company intends to advance its corporate development projects and other functions in South Korea and other Asian countries.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These unaudited condensed consolidated financial statements include the accounts of Inovio Pharmaceuticals, Inc. and its subsidiarie</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s. As of March 31, 2021, the Company consolidated its wholly-owned subsidiary Inovio Asia LLC. On December 31, 2020, former wholly-owned subsidiaries Genetronics, Inc. and VGX Pharmaceuticals Inc. and former majority -owned subsidiary VGX Animal Health, Inc. were merged into Inovio Pharmaceuticals, Inc. All intercompany accounts and transactions were eliminated upon consolidation. As of June 1, 2020, the Company deconsolidated its former subsidiary Geneos Therapeutics, Inc. ("Geneos"), as the Company no longer held a controlling financial interest.  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Refer to Footnote 17 for further discussion.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Liquidity </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company incurred a net loss attributable to common stockholders of $54.4 million for the three months ended March 31, 2021. The Company had working capital of $546.9 million and an accumulated deficit of $960.6 million as of March&#160;31, 2021. The Company has incurred losses in each year since its inception and expects to continue to incur significant expenses and operating losses for the foreseeable future in connection with the research and preclinical and clinical development of its product candidates. The Company&#8217;s cash, cash equivalents and short-term investments of $518.6 million as of March&#160;31, 2021 are sufficient to support the Company's operations for a period of at least 12 months from the date of issuance of these financial statements. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to continue to fund future research and development activit</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ies, the Company will need to seek additional capital. This may occur through strategic alliance and licensing arrangements, grant agreements and/or future public or private debt or equity financings including use of potential future At-the-Market Equity Offering Sales Agreements (&#8220;Sales Agreements&#8221;). The Company</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> has a history of conducting debt and equity financings, including the receipt of net proceeds of $162.1&#160;million from a January 2021 underwritten public offering and net proceeds of $454.5 million under past Sales Agreements </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for the year ended December 31, 2020. However, sufficient funding may not be available in the future, or if available, may be on terms that significantly dilute or otherwise adversely affect the rights of existing stockholders. If adequate funds are not available, the Company may need to delay, reduce the scope of or put on hold one or more of its clinical and/or preclinical programs.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s ability to continue its operations is dependent upon its ability to obtain additional capital in the future and achieve profitable operations. The Company expects to continue to rely on outside sources of financing to meet its capital needs and the Company may never achieve positive cash flow. These condensed consolidated financial statements do not include any adjustments to the specific amounts and classifications of assets and liabilities, which might be necessary should Inovio be unable to continue as a going concern. The Company's condensed consolidated financial statements as of and for the three months ended March 31, 2021 have been prepared on a going concern basis, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business for the foreseeable future. The Company has evaluated subsequent events after the balance sheet date through the date it issued these condensed consolidated financial statements.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is and, from time to time,&#160;may in the future be subject to various legal proceedings and claims arising in the ordinary course of business. The Company assesses contingencies to determine the degree of probability and range of possible loss for potential accrual in its consolidated financial statements. An estimated loss contingency is accrued in the consolidated financial statements if it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated. Legal proceedings, including litigation, government investigations and enforcement actions, could result in material costs, occupy significant management resources and entail civil and criminal penalties, even if the Company ultimately prevails.&#160;Any of the foregoing consequences could result in serious harm to the Company&#8217;s business, results of operations and financial condition. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risks and Uncertainties</span></div><div style="margin-top:5pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The global pandemic resulting from COVID-19, caused by a novel strain of coronavirus, SARS-CoV-2, has caused national and global economic and financial market disruptions. The impact of this pandemic has been and will likely continue to be extensive in many aspects of society, which has resulted in and will continue to cause significant disruptions to the global economy, as well as businesses and capital markets around the world. </span></div><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company is closely monitoring the impact of the COVID-19 pandemic on its employees, collaborators and service providers. The extent to which the pandemic will continue to impact the Company's business and operations will depend on future developments, including travel restrictions and social distancing in the United States and other countries, and the </span></div>effectiveness of actions taken in the United States and other countries to contain and treat the disease, including mass vaccination efforts, that are highly uncertain as of the date the Company is issuing these financial statements.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementAccountingPolicy', window );">Collaboration Agreements</a></td>
<td class="text">Collaboration Agreements <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company assesses whether its collaboration agreements are subject to ASC Topic 808:&#160;Collaborative Arrangements&#160;(&#8220;Topic 808&#8221;) based on whether they involve joint operating activities and whether both parties have active participation in the arrangement and are exposed to significant risks and rewards. To the extent that the arrangement falls within the scope of Topic 808 and the Company concludes that its collaboration partner is not a customer, the Company presents such payments as a reduction of research and development expense. If payments from the collaboration partner to the Company represent consideration from a customer, then the Company accounts for those payments within the scope of Accounting Standards Update (&#8220;ASU&#8221;) 2014-09, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span> (&#8220;Topic 606&#8221;).<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue Recognition </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which it expects to be entitled in exchange for those goods or services. To determine revenue recognition for contracts with customers, the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the Company satisfies its performance obligations. At contract inception, the Company assesses the goods or services agreed upon within each contract and assess whether each good or service is distinct and determine those that are</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">performance obligations. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Arrangements</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company enters into collaborative arrangements with partners that typically include payment of one or more of the following: (i) license fees; (ii) product supply services; (iii) milestone payments related to the achievement of developmental, regulatory, or commercial goals; and (iv) royalties on net sales of licensed products. Where a portion of non-refundable, upfront fees or other payments received are allocated to continuing performance obligations under the terms of a collaborative arrangement, they are recorded as deferred revenue and recognized as revenue when (or as) the underlying performance obligation is satisfied.  </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the accounting for these arrangements, the Company must develop estimates and assumptions that require judgment of management to determine the underlying stand-alone selling price for each performance obligation which determines how the transaction price is allocated among the performance obligation. The standalone selling price may include items such as forecasted revenues, development timelines, discount rates and probabilities of technical and regulatory success. The Company evaluates each performance obligation to determine if it can be satisfied at a point in time or over time. In addition, variable consideration must be evaluated to determine if it is constrained and, therefore, excluded from the transaction price.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">License Fees</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If a license to intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company will recognize revenues from non-refundable, upfront fees allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license. For licenses that are bundled with other promises, the Company will utilize judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Product Supply Services</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Arrangements that include a promise for future supply of drug product for either clinical development or commercial supply at the licensee&#8217;s discretion are generally considered as options. The Company will assess if these options provide a material right to the licensee and if so, they will be accounted for as separate performance obligations. The Company evaluates whether it is the principal or agent in the arrangement. The Company had determined that it is the principal in the current arrangements as the Company controls the product supply before it is transferred to the customer. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Milestone Payments</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the inception of each arrangement that includes milestone payments (variable consideration), the Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the Company's or its collaboration partner&#8217;s control, such as regulatory approvals, are generally not considered probable of being achieved until those approvals are received. The transaction price is then allocated to each performance obligation on a relative stand-alone selling price basis, for which the Company recognizes revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, the Company re-evaluates the probability of achieving such milestones and any related constraint, and if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect license, collaboration or other revenues and earnings in the period of adjustment.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Royalties</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and for which the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). To date, the Company has not recognized any royalty revenue resulting from any of its collaborative arrangements.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_GrantPolicyPolicyTextBlock', window );">Grants</a></td>
<td class="text">Grants<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for various grant agreements under the contributions guidance under Subtopic 958-605, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Not-for-Profit Entities-Revenue Recognition</span>, which is outside the scope of Topic 606, as the government agencies granting the Company funds are not receiving reciprocal value for their contributions. All contributions received from current grant agreements are recorded as a contra-expense as opposed to revenue on the condensed consolidated statement of operations.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For its long-term operating leases, the Company recognizes an operating lease right-of-use asset and an operating lease liability on its condensed consolidated balance sheets. The lease liability is determined as the present value of future lease payments using an estimated rate of interest that the Company would pay to borrow equivalent funds on a collateralized basis at the lease commencement date. The right-of-use asset is based on the liability adjusted for any prepaid or deferred rent. The Company determines the lease term at the commencement date by considering whether renewal options and termination options are reasonably assured of exercise. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fixed rent expense for the Company's operating leases is recognized on a straight-line basis over the term of the lease and is included in operating expenses on the condensed consolidated statements of operations. Variable lease payments including lease operating expenses are recorded as incurred.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Expense</a></td>
<td class="text"><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development Expenses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s activities have largely consisted of research and development efforts related to developing electroporation delivery technologies, DNA vaccines, DNA immunotherapies and dMABs. Research and development expenses consist of expenses incurred in performing research and development activities including salaries and benefits, facilities and other overhead expenses, clinical trials, contract services and other outside expenses. Research and development expenses are charged to operations as they are incurred. These expenses result from the Company's independent research and development efforts as well as efforts associated with collaborations and licensing arrangements. The Company reviews and accrues clinical trial expense based on work performed, which relies on estimates of total costs incurred based on patient enrollment, completion of studies and other events. Accrued clinical trial costs are subject to revisions as trials progress. Revisions are charged to expense in the period in which the facts that give rise to the revision become known. Historically, revisions have not resulted in material changes to research and development expense; however, a modification in the protocol of a clinical trial or cancellation of a trial could result in a charge to the Company's results of operations.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock', window );">Valuation of Intangible Assets and Goodwill</a></td>
<td class="text"><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Valuation of Intangible Assets and Goodwill</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets are amortized over their estimated useful lives ranging from <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjFkMjNkMTZhNjk0ODRiNjNhYTAwN2VjNjg2ZTgwMzM3L3NlYzoxZDIzZDE2YTY5NDg0YjYzYWEwMDdlYzY4NmU4MDMzN18zNy9mcmFnOmE0NTZiM2ZhOTA0ZjQ0ZjNiYTUyYzg0OWE5YTIxNGRiL3RleHRyZWdpb246YTQ1NmIzZmE5MDRmNDRmM2JhNTJjODQ5YTlhMjE0ZGJfOTk1Nw_def5a8b0-cb2d-4478-a5a4-79b9dd366f59">two</span> to 18&#160;years. Acquired intangible assets are continuously being developed for the future economic viability contemplated at the time of acquisition. The Company is concurrently conducting preclinical studies and clinical trials using the acquired intangibles and has entered into licensing agreements for the use of these acquired intangibles.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">License costs are recorded based on the fair value of consideration paid and are amortized using the straight-line method over the shorter of the expected useful life of the underlying patents or the term of the related license agreement to the extent the license has an alternative future use. As of March&#160;31, 2021 and December&#160;31, 2020, the Company&#8217;s intangible assets </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">resulting from the acquisition of Inovio AS and Bioject Medical Technologies, Inc. ("Bioject"), and additional intangibles including license costs, net of accumulated amortization, totaled $3.0 million and $3.1 million, respectively.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The determination of the value of intangible assets requires management to make estimates and assumptions that affect the Company&#8217;s condensed consolidated financial statements. The Company assesses potential impairments to intangible assets when there is evidence that events or changes in circumstances indicate that the carrying amount of an asset may not be recovered. The Company&#8217;s judgments regarding the existence of impairment indicators and future cash flows related to intangible assets are based on operational performance of its acquired businesses, market conditions and other factors. If impairment is indicated, the Company will reduce the carrying value of the intangible asset to fair value. While current and historical operating and cash flow losses are potential indicators of impairment, the Company believes the future cash flows to be received from its intangible assets will exceed the intangible assets&#8217; carrying value, and accordingly, the Company has not recognized any impairment losses through March&#160;31, 2021.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill represents the excess of acquisition cost over the fair value of the net assets of acquired businesses. Goodwill is reviewed for impairment at least annually at November 30, or more frequently if an event occurs indicating the potential for impairment. During its goodwill impairment review, the Company may assess qualitative factors to determine whether it is more likely than not that the fair value of its reporting unit is less than its carrying amount, including goodwill. The qualitative factors include, but are not limited to, macroeconomic conditions, industry and market considerations, and the overall financial performance of the Company. If, after assessing the totality of these qualitative factors, the Company determines that it is not likely that the fair value of its reporting unit is less than its carrying amount, then no additional assessment is deemed necessary. Otherwise, the Company will proceed to perform the impairment test in which the fair value of the reporting unit is compared with its carrying amount, and an impairment charge will be recorded for the amount by which the carrying amount exceeds the reporting unit's fair value, if any. The Company performed its annual assessment for goodwill impairment as of November 30, 2020, identifying no impairment.</span></div>Although there are inherent uncertainties in this assessment process, the estimates and assumptions the Company is using are consistent with its internal planning. If these estimates or their related assumptions change in the future, the Company may be required to record an impairment charge on all or a portion of its goodwill and intangible assets. Furthermore, the Company cannot predict the occurrence of future impairment triggering events nor the impact such events might have on its reported asset values. Future events could cause the Company to conclude that impairment indicators exist and that goodwill or other intangible assets associated with its acquired businesses are impaired. Any resulting impairment loss could have an adverse impact on the Company&#8217;s results of operations.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock', window );">Foreign Currency Translation</a></td>
<td class="text"><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Foreign Currency Translation</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The functional and presentation currency of the Company is the U.S. dollar. Transactions denominated in a currency other than the functional currency are recorded on the initial recognition at the exchange rate at the date of the transaction. After initial recognition monetary assets and liabilities denominated in foreign currency are translated at the end of each reporting period into the functional currency at the exchange rate at that date. The cumulative translation adjustment is included in the accumulated other comprehensive income (loss) within the statement of stockholders' equity. Exchange differences are included in general and administrative expenses in the condensed consolidated statement of operations. Non- monetary assets and liabilities measured at cost are translated at the exchange rate at the date of the transaction.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationVariableInterestEntityPolicy', window );">Variable Interest Entities (VIE)</a></td>
<td class="text"><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Variable Interest Entities (VIE)</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates its ownership, contractual and other interests in entities that are not wholly-owned to determine if these entities are VIEs, and, if so, whether the Company is the primary beneficiary of the VIE. In determining whether the Company is the primary beneficiary of a VIE and therefore required to consolidate the VIE, the Company applies a qualitative approach that determines whether it has both (1) the power to direct the activities of the VIE that most significantly impact the VIE&#8217;s economic performance and (2) the obligation to absorb losses of, or the rights to receive benefits from, the VIE that could potentially be significant to that VIE. The Company will continuously perform this assessment, as changes to existing relationships or future transactions may result in the consolidation or deconsolidation of a VIE.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValuePolicyTextBlock', window );">Equity Investments</a></td>
<td class="text">Equity Investments<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under ASC Topic 321, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investments - Equity Securities,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> the Company must measure equity investments (except those accounted for under the equity method, those that result in consolidation of the investee and certain other investments) at fair value and recognize any changes in fair value in the condensed consolidated statement of operations. The Company can elect a measurement alternative for equity investments that do not have readily determinable fair values and do not qualify for the practical expedient in ASC 820, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurement,</span> to estimate fair value using the net asset value per share (or its equivalent).&#160;The Company's equity investments that do not have readily determinable fair values and do not qualify for the net asset value practical expedient for estimating fair value are measured at cost, less any impairments, plus or minus changes resulting from observable price changes in orderly transactions for identifiable or similar investments of the same issuer.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Issued Accounting Standards</a></td>
<td class="text"><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The recent accounting pronouncements below may have a significant effect on the Company's financial statements. Recent accounting pronouncements that are not anticipated to have an impact on or are unrelated to the Company's financial condition, results of operations, or related disclosures are not discussed. </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accounting Standards Pending Adoption</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">ASU No. 2020-06.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In August 2020, the FASB issued ASU No. 2020-06, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Debt&#8212;Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging&#8212;Contracts in Entity&#8217;s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity&#8217;s Own Equity</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;ASU 2020-06&#8221;), which simplifies the guidance on an issuer&#8217;s accounting for convertible instruments and contracts in its own equity. The standard is effective for the Company beginning in the first quarter of 2022, with early adoption permitted in the first quarter of 2021. The Company did not elect to early adopt the standard and does not expect ASU 2020-06 to have a material impact to its condensed consolidated financial statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_GrantPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Grant Policy [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_GrantPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementAccountingPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for collaborative arrangements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementAccountingPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationVariableInterestEntityPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for consolidation to describe the significant judgments and assumptions made in determining whether a variable interest held by the entity requires the variable interest entity to be consolidated and (or) disclose information about its involvement with the variable interest entity; the methodology used by the entity for determining whether or not it is the primary beneficiary of the variable interest entity; and the significant factors considered and judgments made in determining that the power to direct the activities that significantly impact the economic performance of the variable interest entity are shared (as defined).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5728-111685<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=SL6759159-111685<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2AA<br> -Subparagraph a<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=SL6759068-111685<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationVariableInterestEntityPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValuePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment in equity security without readily determinable fair value, which does not qualify for practical expedient to estimate fair value using net asset value per share. Includes, but is not limited to, information considered for determining upward and downward adjustment from observable price change.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120269885&amp;loc=SL75117539-209714<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValuePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -URI http://asc.fasb.org/topic&amp;trid=2175825<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918666-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130561-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130566-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130563-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI http://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130566-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130563-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18823-107790<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130566-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130564-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130566-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139775179778760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Short-term Investments (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock', window );">Schedule of Summary of Investments</a></td>
<td class="text"><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of available-for-sale securities as of March&#160;31, 2021 and December&#160;31, 2020:</span></div><div style="margin-top:5pt;text-indent:27pt"><span><br/></span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:25.839%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.809%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.809%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.809%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.812%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of March 31, 2021</span></td></tr><tr style="height:21pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Contractual<br/>Maturity&#160;(in&#160;years)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross&#160;Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross&#160;Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair&#160;Market&#160;Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mutual funds</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">---</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">228,101,615&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,562,498&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(714,957)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">228,949,156&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less than 1</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200,408,976&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,404&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,380)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200,414,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less than 1</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,977,623&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,700&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,123)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,992,200&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. agency mortgage-backed securities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,646,077&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,100&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(33,005)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,614,172&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">434,134,291&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,597,702&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(762,465)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">434,969,528&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:25.839%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.809%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.809%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.809%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.812%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2020</span></td></tr><tr style="height:21pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Contractual<br/>Maturity&#160;(in&#160;years)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross&#160;Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross&#160;Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair&#160;Market&#160;Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mutual funds</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">---</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">153,177,675&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,339,639&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(644,140)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">154,873,174&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less&#160;than&#160;1</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,000,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,260&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,016,260&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. agency mortgage-backed securities</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,062,256&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(36,755)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,025,501&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">159,239,931&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,365,899&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(690,895)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">160,914,935&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*No single maturity date.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139775177909416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Schedule of Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis</a></td>
<td class="text"><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the Company&#8217;s assets that were measured at fair value on a recurring basis, determined using the following inputs as of March&#160;31, 2021:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:35.796%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.541%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.541%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.737%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.689%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements at</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted Prices<br/>in Active Markets<br/>(Level&#160;1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Other Unobservable<br/>Inputs<br/>(Level&#160;2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Unobservable<br/>Inputs<br/>(Level&#160;3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Mutual funds</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">228,949,156&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">228,949,156&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S. treasury securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200,414,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200,414,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Certificates of deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,992,200&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,992,200&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S. agency mortgage-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,614,172&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,614,172&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total short-term investments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">434,969,528&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">429,363,156&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,606,372&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment in affiliated entity</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,629,891&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,629,891&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets measured at fair value</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">438,599,419&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">432,993,047&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,606,372&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the Company&#8217;s assets that were measured at fair value on a recurring basis, determined using the following inputs as of December&#160;31, 2020:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:35.796%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.541%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.541%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.737%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.689%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements at</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted Prices<br/>in Active Markets<br/>(Level&#160;1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Other Unobservable<br/>Inputs<br/>(Level&#160;2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Unobservable<br/>Inputs<br/>(Level&#160;3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S. treasury securities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,996,800&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,996,800&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Mutual funds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">154,873,174&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">154,873,174&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Certificates of deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,016,260&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,016,260&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S. agency mortgage-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,025,501&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,025,501&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total short-term investments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">160,914,935&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">154,873,174&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,041,761&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment in affiliated entities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,460,366&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,460,366&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets measured at fair value</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">225,372,101&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">219,330,340&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,041,761&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139775179131496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Intangible Assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock', window );">Schedule of Summary of Intangible Assets by Major Asset Class</a></td>
<td class="text"><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following sets forth the goodwill and intangible assets by major asset class:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"><tr><td style="width:1.0%"/><td style="width:18.870%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.535%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.206%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.060%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.060%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.500%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.918%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr style="height:45pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average Useful<br/>Life<br/>(Yrs)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Book<br/>Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Book<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indefinite lived:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill(a)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,513,371&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,513,371&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,513,371&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,513,371&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Definite lived:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Licenses</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,323,761&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,284,039)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,722&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,323,761&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,276,852)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,909&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bioject(b)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,100,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,542,222)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,557,778&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,100,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,468,889)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,631,111&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other(c)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,050,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,637,500)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">412,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,050,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,581,250)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">468,750&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total intangible assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,473,761&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,463,761)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,010,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,473,761&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,326,991)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,146,770&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total goodwill and intangible assets</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,987,132&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,463,761)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,523,371&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,987,132&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,326,991)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,660,141&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">Goodwill was recorded from the acquisition of other companies. </span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">Bioject intangible assets represent the estimated fair value of developed technology and intellectual property which were recorded from an asset acquisition.</span></div>(c)Other intangible assets represent the estimated fair value of acquired intellectual property.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of goodwill and intangible assets, which may be broken down by segment or major class.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139775179445384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Debt (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebtTableTextBlock', window );">Schedule of Convertible Debt</a></td>
<td class="text"><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The balance of the Notes at March&#160;31, 2021 is as follows:</span></div><div style="margin-bottom:5pt;margin-top:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:69.617%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:28.183%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Original principal amount</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78,500,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Principal amount converted into common shares</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(62,085,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unamortized debt discount on the liability component</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,139,698)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unamortized debt issuance cost</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(294,495)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88,915&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Net carrying amount </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,069,722&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock', window );">Schedule of Maturities of Long-term Debt</a></td>
<td class="text"><div style="margin-top:5pt;text-indent:24.75pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2021, future minimum payments due under the Notes, representing contractual amounts due, including interest based on the fixed rate of 6.5% per annum, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">are as follows:</span></div><div style="margin-bottom:5pt;margin-top:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:85.742%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.328%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Remainder of 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">534,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,067,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,067,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,948,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,616,000&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of borrowings which can be exchanged for a specified number of another security at the option of the issuer or the holder. Disclosures include, but are not limited to, principal amount, amortized premium or discount, and amount of liability and equity components.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturity and sinking fund requirement for long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139775179316056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfStockByClassTextBlock', window );">Schedule of Summary of Common and Preferred Stock Authorized, Issued and Outstanding</a></td>
<td class="text"><div style="margin-bottom:10pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of the Company's authorized and issued common and preferred stock as of March&#160;31, 2021 and December&#160;31, 2020: </span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.830%"><tr><td style="width:1.0%"/><td style="width:42.095%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.473%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.539%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.473%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.539%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.136%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.539%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.106%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Outstanding as of</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Authorized</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Issued</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common Stock, par value $0.001 per share</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">600,000,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">209,334,036&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">209,334,036&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">186,851,493&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Series&#160;C Preferred Stock, par value $0.001 per share</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,091&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,091&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockByClassTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's stock, including par or stated value per share, number and dollar amount of share subscriptions, shares authorized, shares issued, shares outstanding, number and dollar amount of shares held in an employee trust, dividend per share, total dividends, share conversion features, par value plus additional paid in capital, the value of treasury stock and other information necessary to a fair presentation, and EPS information.  Stock by class includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. Includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity. If more than one issue is outstanding, state the title of each issue and the corresponding dollar amount; dollar amount of any shares subscribed but unissued and the deduction of subscriptions receivable there from; number of shares authorized, issued, and outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=65888546&amp;loc=d3e21300-112643<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21553-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=65877616&amp;loc=d3e177068-122764<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21538-112644<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21521-112644<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21488-112644<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21506-112644<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21484-112644<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockByClassTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139775179791256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share</a></td>
<td class="text"><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes potential shares of common stock that were excluded from the diluted net loss per share calculation because of their anti-dilutive effect for the three months ended March 31, 2021 and 2020: </span></div><div style="margin-bottom:6pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.170%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.549%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.263%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Common Stock Equivalents</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options to purchase common stock</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,826,472&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,615,986&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service-based restricted stock units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,610,130&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,667,710&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Performance-based restricted stock units</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">663,353&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible preferred stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,309&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,456&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,049,980&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,585,653&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 2019 Bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,928,859&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 2019 Bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,009,450&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,153,244&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,816,114&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139775184759656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Weighted Average Assumptions</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average assumptions used in the Black-Scholes model for option grants to employees and directors are presented below:</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  </span><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:73.461%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.914%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.88%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.74%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected life in years</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.8</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.9</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139775179445384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of Future Minimum Rental Payments for Operating Leases</a></td>
<td class="text"><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">As of March&#160;31, 2021, the maturities of the Company's operating lease liabilities were as follows:</span></div><div style="margin-bottom:5pt;margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:85.449%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.351%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Remainder of 2021</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,983,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,045,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,023,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,001,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,063,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,888,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Total remaining lease payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,003,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: present value adjustment</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,168,000)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Total operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,835,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: current portion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,396,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term operating lease liabilities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,439,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average remaining lease term</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.2 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average discount rate</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.5%</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139775177785752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Geneos Therapeutics, Inc. (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncontrollingInterestAbstract', window );"><strong>Noncontrolling Interest [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentsTextBlock', window );">Schedule of Equity Method Investments</a></td>
<td class="text">The following table shows the amounts related to the deconsolidation accounting: <div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:84.405%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.395%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Working capital (excluding cash) </span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(59,992)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Note payable </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">171,620&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed assets, net of accumulated depreciation </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16,340)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Carrying value of noncontrolling interest </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,181,640&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of investment in Geneos retained</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,618,998&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain on deconsolidation of Geneos </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,121,075)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Decrease in cash resulting from the deconsolidation of Geneos</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,774,851&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">The details of the Company&#8217;s 47% retained equity investment in Geneos is shown in the table below, with fair values calculated as of June 1, 2020, the date of deconsolidation.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:54.178%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.976%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.973%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.562%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.119%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.392%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Geneos Share Class</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Price per Share</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,000,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.273&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">819,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Preferred</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,113,206&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.325&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,799,998&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total </span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,113,206&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,618,998&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div>The remaining $4.2 million loss has been allocated to the Company&#8217;s Series A and Series A-1 preferred stock investment in Geneos, on a ratable basis, thereby reducing the balance to $0 as of March 31, 2021 as shown in the table below:<table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:84.133%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.115%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.352%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment in Geneos upon deconsolidation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,618,998&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment in Geneos Series A-1 preferred stock</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,399,999&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share in net loss of Geneos from June 1, 2020 - December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,584,610)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share in net loss of Geneos for the three months ended March 31, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(434,387)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment in Geneos as of March 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock', window );">Schedule of Fair Value Measurement Inputs and Valuation Techniques</a></td>
<td class="text">The assumptions used in the fair value calculation as of June 1, 2020 are presented below:<table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:78.548%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.252%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term (years)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.92</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Volatility</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.46%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Geneos enterprise value</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$4,966,531</span></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of equity method investments including, but not limited to, name of each investee or group of investments, percentage ownership, difference between recorded amount of an investment and the value of the underlying equity in the net assets, and summarized financial information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncontrollingInterestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncontrollingInterestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139775185657016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation, Liquidity and Risks and Uncertainties (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="nump">$ 54,402,131<span></span>
</td>
<td class="nump">$ 32,541,054<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Capital', window );">Working capital</a></td>
<td class="nump">546,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Retained earnings (accumulated deficit)</a></td>
<td class="num">(960,598,943)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (906,196,812)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestments', window );">Cash, cash equivalents, and short-term investments</a></td>
<td class="nump">518,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of stock</a></td>
<td class="nump">$ 162,105,030<span></span>
</td>
<td class="nump">$ 208,241,933<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common stock | Underwritten Public Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">162,100,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common stock | Sales Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 454,500,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Capital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of total capital as defined by regulatory framework.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 948<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=6490092&amp;loc=d3e47304-110998<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 505<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=117337116&amp;loc=SL5958568-112826<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 948<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6490092&amp;loc=d3e47080-110998<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Capital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=ino_UnderwrittenPublicOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=ino_UnderwrittenPublicOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=ino_SalesAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=ino_SalesAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139775185003576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Critical Accounting Policies (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="nump">$ 3,010,000<span></span>
</td>
<td class="nump">$ 3,146,770<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Useful life (in years)</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Useful life (in years)</a></td>
<td class="text">18 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139775282381224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue Recognition (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 371,120<span></span>
</td>
<td class="nump">$ 1,327,274<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Revenue recognized from deferred revenue</a></td>
<td class="nump">4,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ino_PlumblineLifeSciencesMember', window );">Plumbline Life Sciences</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">50,000<span></span>
</td>
<td class="nump">$ 1,100,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ino_OtherCounterpartyMember', window );">Other Counterparty</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 321,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ino_PlumblineLifeSciencesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ino_PlumblineLifeSciencesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ino_OtherCounterpartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ino_OtherCounterpartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139775287247352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Short-term Investments - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain', window );">Realized gain on investments</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss', window );">Realized loss on investments</a></td>
<td class="nump">10,000<span></span>
</td>
<td class="nump">525,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss', window );">Unrealized gain (loss) on available-for-sale equity securities</a></td>
<td class="num">$ (847,958)<span></span>
</td>
<td class="num">$ (5,050,092)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of realized gain on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27357-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleRealizedGain</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of realized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27357-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=120269885&amp;loc=SL75117546-209714<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139775185752808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Short-term Investments - Summary of Available-for-sale Securities (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Debt Securities, Available-for-sale [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Cost</a></td>
<td class="nump">$ 434,134,291<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 159,239,931<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross&#160;Unrealized Gains</a></td>
<td class="nump">1,597,702<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,365,899<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross&#160;Unrealized Losses</a></td>
<td class="num">(762,465)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(690,895)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair&#160;Market&#160;Value</a></td>
<td class="nump">434,969,528<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">160,914,935<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=ino_MutualFundsMember', window );">Mutual funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Debt Securities, Available-for-sale [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Cost</a></td>
<td class="nump">228,101,615<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">153,177,675<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross&#160;Unrealized Gains</a></td>
<td class="nump">1,562,498<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,339,639<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross&#160;Unrealized Losses</a></td>
<td class="num">(714,957)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(644,140)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair&#160;Market&#160;Value</a></td>
<td class="nump">$ 228,949,156<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">154,873,174<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryBillSecuritiesMember', window );">U.S. treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_DebtSecuritiesAvailableforSaleContractualMaturity', window );">Contractual maturity (less than)</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Debt Securities, Available-for-sale [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Cost</a></td>
<td class="nump">$ 200,408,976<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross&#160;Unrealized Gains</a></td>
<td class="nump">14,404<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross&#160;Unrealized Losses</a></td>
<td class="num">(9,380)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair&#160;Market&#160;Value</a></td>
<td class="nump">$ 200,414,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember', window );">Certificates of deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_DebtSecuritiesAvailableforSaleContractualMaturity', window );">Contractual maturity (less than)</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Debt Securities, Available-for-sale [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Cost</a></td>
<td class="nump">$ 2,977,623<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross&#160;Unrealized Gains</a></td>
<td class="nump">19,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,260<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross&#160;Unrealized Losses</a></td>
<td class="num">(5,123)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(10,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair&#160;Market&#160;Value</a></td>
<td class="nump">2,992,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,016,260<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember', window );">U.S. agency mortgage-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Debt Securities, Available-for-sale [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Cost</a></td>
<td class="nump">2,646,077<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,062,256<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross&#160;Unrealized Gains</a></td>
<td class="nump">1,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross&#160;Unrealized Losses</a></td>
<td class="num">(33,005)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(36,755)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair&#160;Market&#160;Value</a></td>
<td class="nump">$ 2,614,172<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,025,501<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_DebtSecuritiesAvailableforSaleContractualMaturity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Securities, Available-for-sale contractual maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_DebtSecuritiesAvailableforSaleContractualMaturity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121558606&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121558606&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=ino_MutualFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=ino_MutualFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryBillSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryBillSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139775180095560">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Assets and Liabilities Measured at Fair Value (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities, available for sale</a></td>
<td class="nump">$ 434,969,528<span></span>
</td>
<td class="nump">$ 160,914,935<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Investment in affiliated entities</a></td>
<td class="nump">3,629,891<span></span>
</td>
<td class="nump">4,460,366<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=ino_MutualFundsMember', window );">Mutual funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities, available for sale</a></td>
<td class="nump">228,949,156<span></span>
</td>
<td class="nump">154,873,174<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryBillSecuritiesMember', window );">U.S. treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities, available for sale</a></td>
<td class="nump">200,414,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember', window );">Certificates of deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities, available for sale</a></td>
<td class="nump">2,992,200<span></span>
</td>
<td class="nump">3,016,260<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember', window );">U.S. agency mortgage-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities, available for sale</a></td>
<td class="nump">2,614,172<span></span>
</td>
<td class="nump">3,025,501<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities, available for sale</a></td>
<td class="nump">434,969,528<span></span>
</td>
<td class="nump">160,914,935<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Investment in affiliated entities</a></td>
<td class="nump">3,629,891<span></span>
</td>
<td class="nump">4,460,366<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at fair value</a></td>
<td class="nump">438,599,419<span></span>
</td>
<td class="nump">225,372,101<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Quoted Prices in Active Markets (Level&#160;1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities, available for sale</a></td>
<td class="nump">429,363,156<span></span>
</td>
<td class="nump">154,873,174<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Investment in affiliated entities</a></td>
<td class="nump">3,629,891<span></span>
</td>
<td class="nump">4,460,366<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at fair value</a></td>
<td class="nump">432,993,047<span></span>
</td>
<td class="nump">219,330,340<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Significant Other Unobservable Inputs (Level&#160;2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities, available for sale</a></td>
<td class="nump">5,606,372<span></span>
</td>
<td class="nump">6,041,761<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Investment in affiliated entities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at fair value</a></td>
<td class="nump">5,606,372<span></span>
</td>
<td class="nump">6,041,761<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Significant Unobservable Inputs (Level&#160;3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities, available for sale</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Investment in affiliated entities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Mutual funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities, available for sale</a></td>
<td class="nump">228,949,156<span></span>
</td>
<td class="nump">154,873,174<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Mutual funds | Quoted Prices in Active Markets (Level&#160;1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities, available for sale</a></td>
<td class="nump">228,949,156<span></span>
</td>
<td class="nump">154,873,174<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Mutual funds | Significant Other Unobservable Inputs (Level&#160;2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities, available for sale</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Mutual funds | Significant Unobservable Inputs (Level&#160;3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities, available for sale</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | U.S. treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents, fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">59,996,800<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities, available for sale</a></td>
<td class="nump">200,414,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | U.S. treasury securities | Quoted Prices in Active Markets (Level&#160;1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents, fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">59,996,800<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities, available for sale</a></td>
<td class="nump">200,414,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | U.S. treasury securities | Significant Other Unobservable Inputs (Level&#160;2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents, fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities, available for sale</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | U.S. treasury securities | Significant Unobservable Inputs (Level&#160;3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents, fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities, available for sale</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Certificates of deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities, available for sale</a></td>
<td class="nump">2,992,200<span></span>
</td>
<td class="nump">3,016,260<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Certificates of deposit | Quoted Prices in Active Markets (Level&#160;1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities, available for sale</a></td>
<td class="nump">0<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Certificates of deposit | Significant Other Unobservable Inputs (Level&#160;2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities, available for sale</a></td>
<td class="nump">2,992,200<span></span>
</td>
<td class="nump">3,016,260<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Certificates of deposit | Significant Unobservable Inputs (Level&#160;3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities, available for sale</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | U.S. agency mortgage-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities, available for sale</a></td>
<td class="nump">2,614,172<span></span>
</td>
<td class="nump">3,025,501<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | U.S. agency mortgage-backed securities | Quoted Prices in Active Markets (Level&#160;1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities, available for sale</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | U.S. agency mortgage-backed securities | Significant Other Unobservable Inputs (Level&#160;2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities, available for sale</a></td>
<td class="nump">2,614,172<span></span>
</td>
<td class="nump">3,025,501<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | U.S. agency mortgage-backed securities | Significant Unobservable Inputs (Level&#160;3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities, available for sale</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121558606&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNi">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=99377092&amp;loc=SL75136599-209740<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNi</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=ino_MutualFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=ino_MutualFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryBillSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryBillSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139775179328472">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Narrative (Details)<br></strong></div></th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>shares</div>
</th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common stock | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_MarketableSecuritiesAndFairValueMeasurementsTextualAbstract', window );"><strong>Marketable Securities and Fair Value Measurements (Textual) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentOwnedBalanceShares', window );">Investment owned (in shares)</a></td>
<td class="nump">597,808<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_MarketableSecuritiesAndFairValueMeasurementsTextualAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Marketable securities and fair value measurements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_MarketableSecuritiesAndFairValueMeasurementsTextualAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentOwnedBalanceShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Balance held at close of period in number of shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99383244&amp;loc=d3e12121-115841<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 320<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column B))<br> -URI http://asc.fasb.org/extlink&amp;oid=120401592&amp;loc=d3e611197-123010<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentOwnedBalanceShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139775185454872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Intangible Assets - Schedule Goodwill and Intangible Assets (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract', window );"><strong>Indefinite lived:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillGross', window );">Goodwill, gross</a></td>
<td class="nump">$ 10,513,371<span></span>
</td>
<td class="nump">$ 10,513,371<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill, net book value</a></td>
<td class="nump">10,513,371<span></span>
</td>
<td class="nump">10,513,371<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract', window );"><strong>Definite lived:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Intangible assets, gross</a></td>
<td class="nump">10,473,761<span></span>
</td>
<td class="nump">10,473,761<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Intangible assets, accumulated amortization</a></td>
<td class="num">(7,463,761)<span></span>
</td>
<td class="num">(7,326,991)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangible assets, net book value</a></td>
<td class="nump">3,010,000<span></span>
</td>
<td class="nump">3,146,770<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_GoodwillAndIntangibleAssetsGross', window );">Total goodwill and intangible assets, gross</a></td>
<td class="nump">20,987,132<span></span>
</td>
<td class="nump">20,987,132<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_GoodwillAndIntangibleAssetsNet', window );">Total goodwill and intangible assets, net book value</a></td>
<td class="nump">13,523,371<span></span>
</td>
<td class="nump">13,660,141<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember', window );">Licenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract', window );"><strong>Definite lived:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Intangible assets, gross</a></td>
<td class="nump">1,323,761<span></span>
</td>
<td class="nump">1,323,761<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Intangible assets, accumulated amortization</a></td>
<td class="num">(1,284,039)<span></span>
</td>
<td class="num">(1,276,852)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangible assets, net book value</a></td>
<td class="nump">39,722<span></span>
</td>
<td class="nump">46,909<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=ino_BiojectMember', window );">Bioject</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract', window );"><strong>Definite lived:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Intangible assets, gross</a></td>
<td class="nump">5,100,000<span></span>
</td>
<td class="nump">5,100,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Intangible assets, accumulated amortization</a></td>
<td class="num">(2,542,222)<span></span>
</td>
<td class="num">(2,468,889)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangible assets, net book value</a></td>
<td class="nump">2,557,778<span></span>
</td>
<td class="nump">2,631,111<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_OtherIntangibleAssetsMember', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract', window );"><strong>Definite lived:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Intangible assets, gross</a></td>
<td class="nump">4,050,000<span></span>
</td>
<td class="nump">4,050,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Intangible assets, accumulated amortization</a></td>
<td class="num">(3,637,500)<span></span>
</td>
<td class="num">(3,581,250)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangible assets, net book value</a></td>
<td class="nump">$ 412,500<span></span>
</td>
<td class="nump">$ 468,750<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_WeightedAverageMember', window );">Weighted Average</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract', window );"><strong>Definite lived:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Useful life (in years)</a></td>
<td class="text">11 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_WeightedAverageMember', window );">Weighted Average | Licenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract', window );"><strong>Definite lived:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Useful life (in years)</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_WeightedAverageMember', window );">Weighted Average | Bioject</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract', window );"><strong>Definite lived:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Useful life (in years)</a></td>
<td class="text">12 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_WeightedAverageMember', window );">Weighted Average | Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract', window );"><strong>Definite lived:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Useful life (in years)</a></td>
<td class="text">18 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_GoodwillAndIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Goodwill and intangible assets gross.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_GoodwillAndIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_GoodwillAndIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Goodwill and intangible assets net.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_GoodwillAndIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 928<br> -SubTopic 340<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6473545&amp;loc=d3e61844-108004<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=ino_BiojectMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=ino_BiojectMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_OtherIntangibleAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_OtherIntangibleAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_WeightedAverageMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_WeightedAverageMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139775281579448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Intangible Assets - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Aggregate amortization expense on intangible assets</a></td>
<td class="nump">$ 136,770<span></span>
</td>
<td class="nump">$ 136,770<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear', window );">Estimated aggregate amortization expense for remainder of 2021</a></td>
<td class="nump">384,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">Estimated aggregate amortization expense for 2022</a></td>
<td class="nump">493,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">Estimated aggregate amortization expense for 2023</a></td>
<td class="nump">276,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">Estimated aggregate amortization expense for 2024</a></td>
<td class="nump">253,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">Estimated aggregate amortization expense for 2025</a></td>
<td class="nump">253,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour', window );">Estimated aggregate amortization expense for 2026</a></td>
<td class="nump">$ 1,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Finite-Lived Intangible Asset, Expected Amortization, After Year Four</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139775174721592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Debt - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Aug. 03, 2020 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 26, 2019 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Aug. 01, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 01, 2019 </div>
<div>USD ($) </div>
<div>day </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Aug. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 26, 2019 </div>
<div>KRW (&#8361;)</div>
</th>
<th class="th">
<div>Aug. 01, 2019 </div>
<div>KRW (&#8361;)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Non-cash interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 513,034<span></span>
</td>
<td class="nump">$ 2,803,755<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet', window );">Change in fair value of derivative liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(13,221,977)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Debt conversion, converted instrument, shares issued (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,692,364<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ino_A6.50ConvertibleSeniorNotesDue2024Member', window );">6.50% Convertible Senior Notes Due 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Original principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">78,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Unamortized debt issuance cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">294,495<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Debt instrument, unamortized discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,139,698<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember', window );">Convertible Debt | 6.50% Convertible Senior Notes Due 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Original principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 78,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.50%<span></span>
</td>
<td class="nump">6.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfDebt', window );">Proceeds from issuance of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionRatio1', window );">Debt instrument, convertible, conversion ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.1858045<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Debt instrument, convertible conversion price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.38<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger', window );">Debt instrument, convertible, threshold percentage of stock price trigger</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">130.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdTradingDays', window );">Debt instrument, convertible, threshold trading days | day</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1', window );">Debt instrument, convertible, threshold consecutive trading days | day</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPricePercentage', window );">Debt instrument, redemption price percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent', window );">Carrying value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 62,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 52,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Unamortized debt issuance cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Debt instrument, unamortized discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Debt instrument, effective interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentAmount1', window );">Debt conversion, converted instrument principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 62,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Debt conversion, converted instrument, shares issued (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,535,660<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFairValue', window );">Fair value of date conversion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 43,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Gain on extinguishment of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Non-cash interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 463,000<span></span>
</td>
<td class="nump">2,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest expense, contractual interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 267,000<span></span>
</td>
<td class="nump">1,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember', window );">Convertible Debt | August 2019 Bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Original principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8361; 18,000,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfDebt', window );">Proceeds from issuance of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionRatio1', window );">Debt instrument, convertible, conversion ratio</a></td>
<td class="nump">0.0002756873<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Debt instrument, convertible conversion price (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 3.14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent', window );">Carrying value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Debt instrument, unamortized discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Debt conversion, converted instrument, shares issued (in shares) | shares</a></td>
<td class="nump">4,962,364<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Gain on extinguishment of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Non-cash interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">641,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest expense, contractual interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability', window );">Fair value of derivative liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 84,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet', window );">Change in fair value of derivative liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember', window );">Convertible Debt | August 2019 Bonds | Initial Conversion Price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionRatio1', window );">Debt instrument, convertible, conversion ratio</a></td>
<td class="nump">0.0002110595<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Debt instrument, convertible conversion price (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 4.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember', window );">Convertible Debt | December 2019 Bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Original principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8361; 4,700,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfDebt', window );">Proceeds from issuance of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Debt instrument, effective interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Debt conversion, converted instrument, shares issued (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,009,450<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,009,450<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Non-cash interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 59,000<span></span>
</td>
<td class="nump">62,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest expense, contractual interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,000<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfUnits', window );">Conversion of carrying value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember', window );">Convertible Debt | December 2019 Bonds | Initial Conversion Price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionRatio1', window );">Debt instrument, convertible, conversion ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0002147766<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Debt instrument, convertible conversion price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4304-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentSharesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying amount of the equity component of convertible debt which may be settled in cash upon conversion.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120520924&amp;loc=SL6031897-161870<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionPrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The price per share of the conversion feature embedded in the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120520924&amp;loc=SL6031898-161870<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionPrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of debt instrument into equity with equity shares divided by debt principal amount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21521-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21506-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Threshold period of specified consecutive trading days within which common stock price to conversion price of convertible debt instrument must exceed threshold percentage for specified number of trading days to trigger conversion feature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Minimum percentage of common stock price to conversion price of convertible debt instruments to determine eligibility of conversion.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleThresholdTradingDays">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Threshold number of specified trading days that common stock price to conversion price of convertible debt instruments must exceed threshold percentage within a specified consecutive trading period to trigger conversion feature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleThresholdTradingDays</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28551-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121572278&amp;loc=d3e13433-108611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120520924&amp;loc=SL6036836-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateEffectivePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPricePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage price of original principal amount of debt at which debt can be redeemed by the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -Subparagraph e<br> -URI http://asc.fasb.org/extlink&amp;oid=75038535&amp;loc=d3e64711-112823<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPricePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28541-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value as of the balance sheet date of the embedded derivative or group of embedded derivatives classified as a liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5624163-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net Increase or Decrease in the fair value of the embedded derivative or group of embedded derivatives included in earnings in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 15<br> -URI http://asc.fasb.org/subtopic&amp;trid=2229187<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=117329964&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117329964&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense for debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120520924&amp;loc=SL6036836-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ino_A6.50ConvertibleSeniorNotesDue2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ino_A6.50ConvertibleSeniorNotesDue2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ino_August2019ConvertibleBondsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ino_August2019ConvertibleBondsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionByUniqueDescriptionAxis=ino_InitialConversionPriceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionByUniqueDescriptionAxis=ino_InitialConversionPriceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ino_December2019ConvertibleBondsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ino_December2019ConvertibleBondsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139775184756888">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Convertible Debt - Balance of Convertible Bonds and Notes (Details) - 6.50% Convertible Senior Notes Due 2024<br></strong></div></th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Original principal amount</a></td>
<td class="nump">$ 78,500,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_DebtInstrumentConvertibleDebtConvertedAmount', window );">Principal amount converted into common shares</a></td>
<td class="num">(62,085,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Unamortized debt discount on the liability component</a></td>
<td class="num">(2,139,698)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Unamortized debt issuance cost</a></td>
<td class="num">(294,495)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_DebtInstrumentAccruedInterest', window );">Accrued interest</a></td>
<td class="nump">88,915<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Net carrying amount</a></td>
<td class="nump">$ 14,069,722<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_DebtInstrumentAccruedInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Accrued Interest</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_DebtInstrumentAccruedInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_DebtInstrumentConvertibleDebtConvertedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Convertible Debt, Converted Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_DebtInstrumentConvertibleDebtConvertedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28551-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28541-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120520924&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ino_A6.50ConvertibleSeniorNotesDue2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ino_A6.50ConvertibleSeniorNotesDue2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139775184891400">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Convertible Debt - Schedule of Maturities (Details) - 6.50% Convertible Senior Notes Due 2024 - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 01, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Net carrying amount</a></td>
<td class="nump">$ 14,069,722<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember', window );">Convertible Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear', window );">Remainder of 2021</a></td>
<td class="nump">534,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths', window );">2022</a></td>
<td class="nump">1,067,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo', window );">2023</a></td>
<td class="nump">1,067,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree', window );">2024</a></td>
<td class="nump">16,948,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Net carrying amount</a></td>
<td class="nump">$ 19,616,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="nump">6.50%<span></span>
</td>
<td class="nump">6.50%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120520924&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04.(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04.(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04.(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04.(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ino_A6.50ConvertibleSeniorNotesDue2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ino_A6.50ConvertibleSeniorNotesDue2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139775257871512">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Stockholders' Equity - Summary of Authorized and Issued Common and Preferred Stock (Details) - $ / shares<br></strong></div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract', window );"><strong>Summary of common and preferred stock authorized, issued and outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares, authorized (in shares)</a></td>
<td class="nump">600,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares, issued (in shares)</a></td>
<td class="nump">209,334,036<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares, outstanding (in shares)</a></td>
<td class="nump">209,334,036<span></span>
</td>
<td class="nump">186,851,493<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember', window );">Series C Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract', window );"><strong>Summary of common and preferred stock authorized, issued and outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">1,091<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="nump">1,091<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">9<span></span>
</td>
<td class="nump">9<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139775257133896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jan. 25, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>May 12, 2020</div></th>
<th class="th"><div>May 31, 2018</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Jan. 01, 2021</div></th>
<th class="th"><div>May 13, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Underwritten public offering, common stock (in shares)</a></td>
<td class="nump">20,355,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock, price per share (in dollars per share)</a></td>
<td class="nump">$ 8.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesForCommissionsExpenseAndTaxes', window );">Commissions and other estimated offering expenses</a></td>
<td class="nump">$ 162,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=ino_A2016IncentivePlanMember', window );">2016 Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_NumberOfPotentialSharesAuthorizedForIssuanceUnderShareBasedCompensationPlan', window );">Number of potential shares authorized for issuance under share based compensation plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_SharebasedCompensationArrangementbySharebasedPaymentAwardIncreaseInNumberofSharesAuthorized', window );">Increase in number of shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Number of shares available for grant (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,251,776<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of shares of unvested restricted stock units and options outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,610,130<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockOtherSharesOutstanding', window );">Common stock, other shares, outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,994,029<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm', window );">Maximum contractual term (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=ino_A2007IncentivePlanMember', window );">2007 Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockOtherSharesOutstanding', window );">Common stock, other shares, outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,832,443<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm', window );">Maximum contractual term (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember', window );">Series C Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Conversion of stock, shares converted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesIssued1', window );">Conversion of stock, shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,147<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common stock | Prior Sales Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_StockSalesAgreementMaximumAuthorizedAmount', window );">Maximum authorized amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_StockSalesAgreementRemainingAuthorizedAmount', window );">Remaining authorized amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_StockSaleAgreementAggregateNumberofSharesIssued', window );">Aggregate number of shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43,148,952<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_StockSaleAgreementWeightedAveragePricePerShare', window );">Stock sale agreement weighted average price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.92<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_StockSaleAgreementAggregateProceedsFromIssuanceOfStock', window );">Aggregate proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 208,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common stock | New Sales Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_StockSalesAgreementMaximumAuthorizedAmount', window );">Maximum authorized amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_StockSalesAgreementRemainingAuthorizedAmount', window );">Remaining authorized amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_StockSaleAgreementAggregateNumberofSharesIssued', window );">Aggregate number of shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,919,934<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_StockSaleAgreementWeightedAveragePricePerShare', window );">Stock sale agreement weighted average price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.91<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_StockSaleAgreementAggregateProceedsFromIssuanceOfStock', window );">Aggregate proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 246,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_NumberOfPotentialSharesAuthorizedForIssuanceUnderShareBasedCompensationPlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of potential shares authorized for issuance under a share-based compensation plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_NumberOfPotentialSharesAuthorizedForIssuanceUnderShareBasedCompensationPlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award maximum contractual term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_SharebasedCompensationArrangementbySharebasedPaymentAwardIncreaseInNumberofSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Increase In Number of Shares Authorized</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_SharebasedCompensationArrangementbySharebasedPaymentAwardIncreaseInNumberofSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_StockSaleAgreementAggregateNumberofSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Sale Agreement, Aggregate Number of Shares Issued</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_StockSaleAgreementAggregateNumberofSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_StockSaleAgreementAggregateProceedsFromIssuanceOfStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Sale Agreement, Aggregate Proceeds From Issuance Of Stock</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_StockSaleAgreementAggregateProceedsFromIssuanceOfStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_StockSaleAgreementWeightedAveragePricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Sale Agreement Weighted Average Price Per Share</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_StockSaleAgreementWeightedAveragePricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_StockSalesAgreementMaximumAuthorizedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Sales Agreement, Maximum Authorized Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_StockSalesAgreementMaximumAuthorizedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_StockSalesAgreementRemainingAuthorizedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Sales Agreement, Remaining Authorized Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_StockSalesAgreementRemainingAuthorizedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesForCommissionsExpenseAndTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying amount for commissions, taxes and other expenses that were incurred but unpaid as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.15)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesForCommissionsExpenseAndTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockOtherSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of shares of other common stock instruments held by shareholders, such as exchangeable shares. May be all or portion of the number of common shares authorized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockOtherSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesConverted1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4313-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4304-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesConverted1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=ino_A2016IncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=ino_A2016IncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=ino_A2007IncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=ino_A2007IncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=ino_PriorSalesAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=ino_PriorSalesAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=ino_NewSalesAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=ino_NewSalesAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139775185381944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share - Schedule of Anti-Dilutive Securities (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded (in shares)</a></td>
<td class="nump">17,153,244<span></span>
</td>
<td class="nump">32,816,114<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Options to purchase common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded (in shares)</a></td>
<td class="nump">10,826,472<span></span>
</td>
<td class="nump">9,615,986<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=ino_ServiceBasedRestrictedStockUnitsMember', window );">Service-based restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded (in shares)</a></td>
<td class="nump">2,610,130<span></span>
</td>
<td class="nump">2,667,710<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Performance-based restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded (in shares)</a></td>
<td class="nump">663,353<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertiblePreferredStockMember', window );">Convertible preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded (in shares)</a></td>
<td class="nump">3,309<span></span>
</td>
<td class="nump">8,456<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ino_A6.50ConvertibleSeniorNotesDue2024Member', window );">6.50% Convertible Senior Notes Due 2024 | Convertible notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded (in shares)</a></td>
<td class="nump">3,049,980<span></span>
</td>
<td class="nump">14,585,653<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ino_August2019ConvertibleBondsMember', window );">August 2019 Bonds | Convertible notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">4,928,859<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ino_December2019ConvertibleBondsMember', window );">December 2019 Bonds | Convertible notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,009,450<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=ino_ServiceBasedRestrictedStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=ino_ServiceBasedRestrictedStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ino_A6.50ConvertibleSeniorNotesDue2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ino_A6.50ConvertibleSeniorNotesDue2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertibleDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertibleDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ino_August2019ConvertibleBondsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ino_August2019ConvertibleBondsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ino_December2019ConvertibleBondsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ino_December2019ConvertibleBondsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139775180160024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Aug. 28, 2020</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,595,947<span></span>
</td>
<td class="nump">$ 4,001,553<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Total unrecognized compensation cost related to unvested stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Period over which total unrecognized compensation cost related to unvested stock options will be recognized (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 7 months 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8.34<span></span>
</td>
<td class="nump">$ 5.37<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=ino_A2016IncentivePlanMember', window );">2016 Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Allocated share-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,200,000<span></span>
</td>
<td class="nump">$ 2,300,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Allocated share-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,000,000.0<span></span>
</td>
<td class="nump">1,300,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=ino_EmployeesAndDirectorsMember', window );">Employees and Directors</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,200,000<span></span>
</td>
<td class="nump">3,600,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=ino_NonEmployeeMember', window );">Non Employee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 429,000<span></span>
</td>
<td class="nump">$ 383,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options | Employees and Directors</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.88%<span></span>
</td>
<td class="nump">0.74%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">92.00%<span></span>
</td>
<td class="nump">76.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life in years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years 9 months 18 days<span></span>
</td>
<td class="text">5 years 10 months 24 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Performance-based restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Total unrecognized compensation cost related to unvested stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Period over which total unrecognized compensation cost related to unvested stock options will be recognized (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 3 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value, restricted stock units (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11.42<span></span>
</td>
<td class="nump">$ 8.32<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Performance-based restricted stock units | 2016 Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value, restricted stock units (in dollars per share)</a></td>
<td class="nump">$ 12.06<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="nump">663,353<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodGrantDateFairValue', window );">Grant date fair value</a></td>
<td class="nump">$ 8,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Performance-based restricted stock units | 2016 Incentive Plan | Tranche One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting percentage</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Performance-based restricted stock units | 2016 Incentive Plan | Tranche Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting percentage</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period (in years)</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Fair Value</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of vesting of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=ino_A2016IncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=ino_A2016IncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=ino_EmployeesAndDirectorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=ino_EmployeesAndDirectorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=ino_NonEmployeeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=ino_NonEmployeeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139775184936152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Nov. 30, 2016</div></th>
<th class="th"><div>Mar. 31, 2016</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_RelatedPartyTransactionsTextualAbstract', window );"><strong>Related-Party Transactions (Textual) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from related parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 371,120<span></span>
</td>
<td class="nump">$ 1,327,274<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_DirectorMember', window );">Director</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_RelatedPartyTransactionsTextualAbstract', window );"><strong>Related-Party Transactions (Textual) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableRelatedParties', window );">Accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">256,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 425,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_CollaborativeAgreementExpensesToReimburse', window );">Expenses to reimburse</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_CollaborativeArrangementTerm', window );">Term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_CollaborativeAgreementAwardedAmount', window );">Awarded amount</a></td>
<td class="nump">$ 6,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_GrantProceedsReceived', window );">Contra-research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">230,000<span></span>
</td>
<td class="nump">619,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty', window );">Operating expenses related to affiliated entity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">318,000<span></span>
</td>
<td class="nump">362,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent', window );">Accounts payable/accrued liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">768,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">643,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_DeferredGrantFundingFromAffiliate', window );">Deferred grant funding, from affiliate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">76,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ino_TheWistarInstituteMember', window );">The Wistar Institute</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_RelatedPartyTransactionsTextualAbstract', window );"><strong>Related-Party Transactions (Textual) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_CollaborativeAgreementAwardedAmount', window );">Awarded amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,700,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_CollaborativeAgreementAwardedOptionAmount', window );">Awarded option amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,000,000.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ino_PlumblineLifeSciencesMember', window );">Plumbline Life Sciences</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_RelatedPartyTransactionsTextualAbstract', window );"><strong>Related-Party Transactions (Textual) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from related parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="nump">$ 1,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableRelatedParties', window );">Accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 80,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 67,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ino_PlumblineLifeSciencesMember', window );">Plumbline Life Sciences | Available-for-sale Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_RelatedPartyTransactionsTextualAbstract', window );"><strong>Related-Party Transactions (Textual) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentOwnedBalanceShares', window );">Investment owned (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">597,808<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_CollaborativeAgreementAwardedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Agreement, Awarded Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_CollaborativeAgreementAwardedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_CollaborativeAgreementAwardedOptionAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Agreement, Awarded Option Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_CollaborativeAgreementAwardedOptionAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_CollaborativeAgreementExpensesToReimburse">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Agreement, Expenses To Reimburse</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_CollaborativeAgreementExpensesToReimburse</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_CollaborativeArrangementTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Term</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_CollaborativeArrangementTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_DeferredGrantFundingFromAffiliate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Grant Funding, From Affiliate</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_DeferredGrantFundingFromAffiliate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_GrantProceedsReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Grant Proceeds Received</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_GrantProceedsReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_RelatedPartyTransactionsTextualAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Related party transactions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_RelatedPartyTransactionsTextualAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an unclassified balance sheet, amount of receivables arising from transactions with related parties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39603-107864<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of obligations due all related parties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(3),(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueToRelatedPartiesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentOwnedBalanceShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Balance held at close of period in number of shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99383244&amp;loc=d3e12121-115841<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 320<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column B))<br> -URI http://asc.fasb.org/extlink&amp;oid=120401592&amp;loc=d3e611197-123010<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentOwnedBalanceShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expenses recognized resulting from transactions (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_DirectorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_DirectorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ino_TheWistarInstituteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ino_TheWistarInstituteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ino_PlumblineLifeSciencesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ino_PlumblineLifeSciencesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InformationByCategoryOfDebtSecurityAxis=us-gaap_AvailableforsaleSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InformationByCategoryOfDebtSecurityAxis=us-gaap_AvailableforsaleSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139775179808968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Narrative (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">3 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Mar. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>ft&#178;</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Lease cost | $</a></td>
<td class="nump">$ 850<span></span>
</td>
<td class="nump">$ 834<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm', window );">Operating lease, remaining lease term</a></td>
<td class="text">2 years 8 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm', window );">Operating lease, remaining lease term</a></td>
<td class="text">8 years 9 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=ino_SanDiegoOfficeMember', window );">San Diego, California</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_LesseeOperatingLeaseAreaofLandUnderLease', window );">Area leased (in square feet)</a></td>
<td class="nump">82,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=ino_PlymouthMeetingPennsylvaniaMember', window );">Plymouth Meeting, Pennsylvania</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_LesseeOperatingLeaseAreaofLandUnderLease', window );">Area leased (in square feet)</a></td>
<td class="nump">57,360<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,500<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_LesseeOperatingLeaseAreaofLandUnderLease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Area of Land Under Lease</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_LesseeOperatingLeaseAreaofLandUnderLease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Remaining lease term of operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRemainingLeaseTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=ino_SanDiegoOfficeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=ino_SanDiegoOfficeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=ino_PlymouthMeetingPennsylvaniaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=ino_PlymouthMeetingPennsylvaniaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139775184197640">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Summary of Future Minimum Lease Payments (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear', window );">Remainder of 2021</a></td>
<td class="nump">$ 2,983,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2022</a></td>
<td class="nump">4,045,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2023</a></td>
<td class="nump">4,023,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2024</a></td>
<td class="nump">3,001,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2025</a></td>
<td class="nump">3,063,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour', window );">Thereafter</a></td>
<td class="nump">9,888,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total remaining lease payments</a></td>
<td class="nump">27,003,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: present value adjustment</a></td>
<td class="num">(7,168,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total operating lease liabilities</a></td>
<td class="nump">19,835,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Less: current portion</a></td>
<td class="num">(2,395,928)<span></span>
</td>
<td class="num">$ (2,329,394)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Long-term operating lease liabilities</a></td>
<td class="nump">$ 17,438,841<span></span>
</td>
<td class="nump">$ 18,063,515<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted-average remaining lease term</a></td>
<td class="text">7 years 2 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted-average discount rate</a></td>
<td class="nump">8.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Liability, To Be Paid, After Year Four</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139775169278536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborative Agreements (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="11">1 Months Ended</th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 29, 2017</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Apr. 30, 2020</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Jan. 31, 2020</div></th>
<th class="th"><div>Aug. 30, 2019</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Oct. 31, 2018</div></th>
<th class="th"><div>Apr. 30, 2018</div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 371,120<span></span>
</td>
<td class="nump">$ 1,327,274<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_DeferredGrantFundingCurrent', window );">Grant funding liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,975,484<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,474,310<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=ino_AdvaccineMember', window );">Advaccine | Customer Concentration Risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNet', window );">Accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,100,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember', window );">Revenue under collaborative research and development arrangements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39,615<span></span>
</td>
<td class="nump">71,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ino_AdvaccineMember', window );">Advaccine | Collaborative Arrangement, Product</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_CollaborativeAgreementsUpfrontPaymentReceived', window );">Upfront payment received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_CollaborationAgreementAdditionalRevenueToBeAchieved', window );">Additional revenue to be achieved</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">108,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_CollaborationAgreementPaymentEarned', window );">Collaboration Agreement, Payment Earned</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_CollaborationAgreementRoyaltyPeriod', window );">Royalty period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_CollaborativeAgreementPeriodFromEffectiveDateForTermination', window );">Period from effective date for termination</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ino_AdvaccineMember', window );">Advaccine | Collaborative Arrangement, Product | Revenue under collaborative research and development arrangements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ino_ApolloBioMember', window );">ApolloBio | Collaborative Arrangement, Product</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_CollaborativeAgreementsUpfrontPaymentReceived', window );">Upfront payment received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 23,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 23,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_CollaborationAgreementAdditionalRevenueToBeAchieved', window );">Additional revenue to be achieved</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_CollaborationAgreementRoyaltyPeriod', window );">Royalty period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_CollaborativeAgreementPeriodFromEffectiveDateForTermination', window );">Period from effective date for termination</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_CollaborationAgreementTerritoryExpansionOptionPeriod', window );">Territory expansion option period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_ProceedsFromCollaborativeAgreement', window );">Proceeds received in upfront payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_CollaborativeAgreementAdvisoryFees', window );">Advisory fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">960,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_CollaborativeAgreementNumberofDaysWrittenNoticeBeforeTermination', window );">Number of days written notice before termination</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">90 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ino_ApolloBioMember', window );">ApolloBio | Collaborative Arrangement, Product | Foreign Tax Authority</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_CollaborativeAgreementCorporateIncomeTax', window );">Foreign corporate income taxes reducing upfront payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_CollaborativeAgreementForeignNonIncomeTaxes', window );">Foreign non-corporate income taxes reducing upfront payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ino_AstraZenecaMember', window );">AstraZeneca</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000.0<span></span>
</td>
<td class="nump">$ 2,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ino_AstraZenecaMember', window );">AstraZeneca | Collaborative Arrangement, Product</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_CollaborativeAgreementsUpfrontPaymentReceived', window );">Upfront payment received</a></td>
<td class="nump">$ 27,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 27,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_CollaborationAgreementAnticipatedDevelopmentandRegulatoryEventBasedPaymentReceivableMilestones', window );">Anticipated development and regulatory event based payment receivable milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 125,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_CollaborationAgreementAnticipatedCommercialEventBasedPaymentReceivableMilestones', window );">Anticipated commercial event based payment receivable milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">115,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ino_CoalitionforEpidemicPreparednessInnovationsMember', window );">Coalition for Epidemic Preparedness Innovations | Collaborative Arrangement, Product</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_CollaborativeAgreementFundingToBeReceived', window );">Collaborative agreement, funding to be received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ino_CoalitionforEpidemicPreparednessInnovationsMember', window );">Coalition for Epidemic Preparedness Innovations | Collaborative Arrangement, Product | Lassa Fever and MERS Vaccine</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_CollaborativeAgreementFundingToBeReceived', window );">Collaborative agreement, funding to be received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 56,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment', window );">Collaborative agreement, period to receive funding for research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_CollaborativeAgreementFundingReceived', window );">Funding received for research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,400,000<span></span>
</td>
<td class="nump">1,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_DeferredGrantFundingCurrent', window );">Grant funding liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">251,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ino_CoalitionforEpidemicPreparednessInnovationsMember', window );">Coalition for Epidemic Preparedness Innovations | Collaborative Arrangement, Product | SARS-CoV-2/COVID-19 Vaccine</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_CollaborativeAgreementFundingToBeReceived', window );">Collaborative agreement, funding to be received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_CollaborativeAgreementFundingReceived', window );">Funding received for research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,400,000<span></span>
</td>
<td class="nump">2,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_DeferredGrantFundingCurrent', window );">Grant funding liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ino_CoalitionforEpidemicPreparednessInnovationsMember', window );">Coalition for Epidemic Preparedness Innovations | Collaborative Arrangement, Product | CELLECTRA 3PSP Proprietary Smart Device</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_CollaborativeAgreementFundingToBeReceived', window );">Collaborative agreement, funding to be received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ino_CoalitionforEpidemicPreparednessInnovationsMember', window );">Coalition for Epidemic Preparedness Innovations | Collaborative Arrangement, Product | INO-4800</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_CollaborativeAgreementFundingToBeReceived', window );">Collaborative agreement, funding to be received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ino_BillAndMelindaGatesFoundationMember', window );">Bill and Melinda Gates Foundation | Collaborative Arrangement, Product | CELLECTRA 3PSP Proprietary Smart Device</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_CollaborativeAgreementFundingReceived', window );">Funding received for research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">893,000<span></span>
</td>
<td class="nump">64,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ino_BillAndMelindaGatesFoundationMember', window );">Bill and Melinda Gates Foundation | Collaborative Arrangement, Product | DNA-Encoded Monoclonal Antibody Technology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_CollaborativeAgreementFundingReceived', window );">Funding received for research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 134,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_DeferredGrantFundingCurrent', window );">Grant funding liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">660,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ino_DepartmentOfDefenceMember', window );">Department of Defence | Collaborative Arrangement, Product</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_GrantProceedsReceived', window );">Contra-research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableRelatedParties', window );">Accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,400,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ino_DepartmentOfDefenceMember', window );">Department of Defence | Collaborative Arrangement, Product | CELLECTRA 3PSP Proprietary Smart Device</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_CollaborativeAgreementFundingReceived', window );">Funding received for research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 54,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ino_DepartmentOfDefenceMember', window );">Department of Defence | Collaborative Arrangement, Product | CELLECTRA 2000 Device</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_CollaborativeArrangementFixedPriceContractAmountAwarded', window );">Purchase price, procurement contract</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_CollaborationAgreementAdditionalRevenueToBeAchieved">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration Agreement, Additional Revenue To Be Achieved</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_CollaborationAgreementAdditionalRevenueToBeAchieved</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_CollaborationAgreementAnticipatedCommercialEventBasedPaymentReceivableMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration Agreement, Anticipated Commercial Event Based Payment Receivable Milestones</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_CollaborationAgreementAnticipatedCommercialEventBasedPaymentReceivableMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_CollaborationAgreementAnticipatedDevelopmentandRegulatoryEventBasedPaymentReceivableMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration Agreement, Anticipated Development and Regulatory Event Based Payment Receivable Milestones</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_CollaborationAgreementAnticipatedDevelopmentandRegulatoryEventBasedPaymentReceivableMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_CollaborationAgreementPaymentEarned">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration Agreement, Payment Earned</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_CollaborationAgreementPaymentEarned</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_CollaborationAgreementRoyaltyPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration Agreement, Royalty Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_CollaborationAgreementRoyaltyPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_CollaborationAgreementTerritoryExpansionOptionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration Agreement, Territory Expansion Option Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_CollaborationAgreementTerritoryExpansionOptionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_CollaborativeAgreementAdvisoryFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Agreement, Advisory Fees</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_CollaborativeAgreementAdvisoryFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_CollaborativeAgreementCorporateIncomeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Agreement, Corporate Income Tax</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_CollaborativeAgreementCorporateIncomeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_CollaborativeAgreementForeignNonIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Agreement, Non-Income Taxes</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_CollaborativeAgreementForeignNonIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_CollaborativeAgreementFundingReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Agreement, Funding Received</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_CollaborativeAgreementFundingReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_CollaborativeAgreementFundingToBeReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Agreement, Funding Received for Research and Development</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_CollaborativeAgreementFundingToBeReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_CollaborativeAgreementNumberofDaysWrittenNoticeBeforeTermination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Agreement, Number of Days Written Notice Before Termination</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_CollaborativeAgreementNumberofDaysWrittenNoticeBeforeTermination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_CollaborativeAgreementPeriodFromEffectiveDateForTermination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Agreement, Period From Effective Date For Termination</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_CollaborativeAgreementPeriodFromEffectiveDateForTermination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Agreement, Period to Receive Funding for Research and Development</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_CollaborativeAgreementsUpfrontPaymentReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Agreements, Upfront Payment Received</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_CollaborativeAgreementsUpfrontPaymentReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_CollaborativeArrangementFixedPriceContractAmountAwarded">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Fixed-Price Contract, Amount Awarded</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_CollaborativeArrangementFixedPriceContractAmountAwarded</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_DeferredGrantFundingCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Grant Funding, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_DeferredGrantFundingCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_GrantProceedsReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Grant Proceeds Received</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_GrantProceedsReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_ProceedsFromCollaborativeAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds From Collaborative Agreement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_ProceedsFromCollaborativeAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an unclassified balance sheet, amount of receivables arising from transactions with related parties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39603-107864<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=ino_AdvaccineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=ino_AdvaccineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_LicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ino_AdvaccineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ino_AdvaccineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ino_ApolloBioMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ino_ApolloBioMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ino_AstraZenecaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ino_AstraZenecaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ino_CoalitionforEpidemicPreparednessInnovationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ino_CoalitionforEpidemicPreparednessInnovationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ino_LassaFeverAndMERSVaccineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ino_LassaFeverAndMERSVaccineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ino_SARSCoV2COVID19VaccineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ino_SARSCoV2COVID19VaccineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ino_CELLECTRA3PSPProprietarySmartDeviceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ino_CELLECTRA3PSPProprietarySmartDeviceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ino_INO4800Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ino_INO4800Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ino_BillAndMelindaGatesFoundationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ino_BillAndMelindaGatesFoundationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ino_DNAEncodedMonoclonalAntibodyTechnologyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ino_DNAEncodedMonoclonalAntibodyTechnologyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ino_DepartmentOfDefenceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ino_DepartmentOfDefenceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ino_CELLECTRA2000DeviceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ino_CELLECTRA2000DeviceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139775184182232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Geneos Therapeutics, Inc. - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">7 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 01, 2020</div></th>
<th class="th"><div>Nov. 30, 2020</div></th>
<th class="th"><div>Feb. 28, 2019</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Feb. 28, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jan. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestLineItems', window );"><strong>Noncontrolling Interest [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Share of net loss in Geneos</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 434,387<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Investment in equity method investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 434,387<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=ino_SeriesAOnePreferredStockMember', window );">Series A One Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestLineItems', window );"><strong>Noncontrolling Interest [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Investment in equity method investments</a></td>
<td class="nump">$ 1,399,999<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_OwnershipAxis=ino_GeneosTherapeuticsInc.Member', window );">Geneos Therapeutics, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestLineItems', window );"><strong>Noncontrolling Interest [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByParent', window );">Noncontrolling interest, ownership percentage by parent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36.00%<span></span>
</td>
<td class="nump">61.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">52.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">47.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">47.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ino_GeneosTherapeuticsInc.Member', window );">Geneos Therapeutics, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestLineItems', window );"><strong>Noncontrolling Interest [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries', window );">Payments to acquire additional interest in subsidiaries</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,400,000<span></span>
</td>
<td class="nump">$ 1,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_StockPurchaseAgreementCommitmentOfAdditionalInvestment', window );">Stock purchase agreement, commitment of additional investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 800,000<span></span>
</td>
<td class="nump">$ 800,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeconsolidationGainOrLossAmount', window );">Gain on deconsolidation of investment</a></td>
<td class="nump">4,121,075<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount', window );">Deconsolidation gain, remeasurement of retained noncontrolling investment to fair value</a></td>
<td class="nump">2,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_IncomeLossFromEquityMethodInvestmentsRealizedAndAllocatedToInvestment', window );">Loss from equity method investment, recorded and allocated to investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,500,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,600,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Share of net loss in Geneos</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">434,387<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,584,610<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Investment in equity method investments</a></td>
<td class="nump">3,618,998<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ino_GeneosTherapeuticsInc.Member', window );">Geneos Therapeutics, Inc. | Common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestLineItems', window );"><strong>Noncontrolling Interest [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Investment in equity method investments</a></td>
<td class="nump">819,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ino_GeneosTherapeuticsInc.Member', window );">Geneos Therapeutics, Inc. | Preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestLineItems', window );"><strong>Noncontrolling Interest [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Share of net loss in Geneos</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Investment in equity method investments</a></td>
<td class="nump">$ 2,799,998<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ino_GeneosTherapeuticsInc.Member', window );">Geneos Therapeutics, Inc. | Series A One Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestLineItems', window );"><strong>Noncontrolling Interest [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Share of net loss in Geneos</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 819,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_IncomeLossFromEquityMethodInvestmentsRealizedAndAllocatedToInvestment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Income (Loss) From Equity Method Investments, Realized And Allocated to Investment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_IncomeLossFromEquityMethodInvestmentsRealizedAndAllocatedToInvestment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_StockPurchaseAgreementCommitmentOfAdditionalInvestment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Purchase Agreement, Commitment Of Additional Investment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_StockPurchaseAgreementCommitmentOfAdditionalInvestment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeconsolidationGainOrLossAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) from deconsolidation of subsidiary and derecognition of group of assets constituting transfer of business or nonprofit activity, excluding conveyance of oil and gas mineral rights and transfer of good or service in contract with customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4582445-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeconsolidationGainOrLossAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) from remeasurement to fair value of retained investment in former subsidiary and group of assets constituting business or nonprofit activity deconsolidated and derecognized, excluding conveyance of oil and gas mineral rights and transfer of product or service in contract with customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4582445-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8813-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestOwnershipPercentageByParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The parent entity's interest in net assets of the subsidiary, expressed as a percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestOwnershipPercentageByParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the purchase of noncontrolling interest during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=ino_SeriesAOnePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=ino_SeriesAOnePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=ino_GeneosTherapeuticsInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=ino_GeneosTherapeuticsInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ino_GeneosTherapeuticsInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ino_GeneosTherapeuticsInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_PreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_PreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139775184197640">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Geneos Therapeutics, Inc. - Deconsolidation Accounting (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 01, 2020</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestLineItems', window );"><strong>Noncontrolling Interest [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Fixed assets, net of accumulated depreciation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (10,930,312)<span></span>
</td>
<td class="num">$ (11,348,144)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ino_GeneosTherapeuticsInc.Member', window );">Geneos Therapeutics, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestLineItems', window );"><strong>Noncontrolling Interest [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_WorkingCapitalExcludingCash', window );">Working capital (excluding cash)</a></td>
<td class="num">$ (59,992)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayable', window );">Note payable</a></td>
<td class="nump">171,620<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Fixed assets, net of accumulated depreciation</a></td>
<td class="num">(16,340)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Carrying value of noncontrolling interest</a></td>
<td class="nump">3,181,640<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedInterestFairValueDisclosure', window );">Fair value of investment in Geneos retained</a></td>
<td class="nump">3,618,998<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeconsolidationGainOrLossAmount', window );">Gain on deconsolidation of Geneos</a></td>
<td class="num">(4,121,075)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashDivestedFromDeconsolidation', window );">Decrease in cash resulting from the deconsolidation of Geneos</a></td>
<td class="nump">$ 2,774,851<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_WorkingCapitalExcludingCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Working Capital, Excluding Cash</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_WorkingCapitalExcludingCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashDivestedFromDeconsolidation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reduction in cash due to no longer including the former subsidiary's cash in the consolidated entity's cash.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashDivestedFromDeconsolidation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeconsolidationGainOrLossAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) from deconsolidation of subsidiary and derecognition of group of assets constituting transfer of business or nonprofit activity, excluding conveyance of oil and gas mineral rights and transfer of good or service in contract with customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4582445-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeconsolidationGainOrLossAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedInterestFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of interest continued to be held by a transferor after transferring financial assets to a third party.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedInterestFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ino_GeneosTherapeuticsInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ino_GeneosTherapeuticsInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139775185344360">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Geneos Therapeutics, Inc. - Investment In Geneos (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Jun. 01, 2020</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestLineItems', window );"><strong>Noncontrolling Interest [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Fair Value</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 434,387<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ino_GeneosTherapeuticsInc.Member', window );">Geneos Therapeutics, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestLineItems', window );"><strong>Noncontrolling Interest [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentOwnedBalanceShares', window );">Shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,113,206<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Fair Value</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,618,998<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common stock | Geneos Therapeutics, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestLineItems', window );"><strong>Noncontrolling Interest [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentOwnedBalanceShares', window );">Shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Price per Share (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.273<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 819,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_PreferredStockMember', window );">Preferred stock | Geneos Therapeutics, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestLineItems', window );"><strong>Noncontrolling Interest [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentOwnedBalanceShares', window );">Shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,113,206<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Price per Share (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.325<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Fair Value</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,799,998<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8813-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentOwnedBalanceShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Balance held at close of period in number of shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99383244&amp;loc=d3e12121-115841<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 320<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column B))<br> -URI http://asc.fasb.org/extlink&amp;oid=120401592&amp;loc=d3e611197-123010<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentOwnedBalanceShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ino_GeneosTherapeuticsInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ino_GeneosTherapeuticsInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_PreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_PreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139775257189080">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Geneos Therapeutics, Inc. - Fair Value Assumptions (Details) - Geneos Therapeutics, Inc.<br></strong></div></th>
<th class="th">
<div>Jun. 01, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestLineItems', window );"><strong>Noncontrolling Interest [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_EquityMethodInvestmentEnterpriseValue', window );">Geneos enterprise value</a></td>
<td class="nump">$ 4,966,531,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ino_GeneosTherapeuticsInc.Member', window );">Expected term (years)</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestLineItems', window );"><strong>Noncontrolling Interest [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_AlternativeInvestmentMeasurementInputTerm', window );">Equity method investment, measurement input, expected term</a></td>
<td class="text">2 years 11 months 1 day<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ino_GeneosTherapeuticsInc.Member', window );">Volatility</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestLineItems', window );"><strong>Noncontrolling Interest [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AlternativeInvestmentMeasurementInput', window );">Equity method investment, measurement input</a></td>
<td class="nump">0.70<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ino_GeneosTherapeuticsInc.Member', window );">Risk-free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestLineItems', window );"><strong>Noncontrolling Interest [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AlternativeInvestmentMeasurementInput', window );">Equity method investment, measurement input</a></td>
<td class="nump">0.0246<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_AlternativeInvestmentMeasurementInputTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Alternative Investment, Measurement Input, Term</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_AlternativeInvestmentMeasurementInputTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_EquityMethodInvestmentEnterpriseValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Method Investment, Enterprise Value</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_EquityMethodInvestmentEnterpriseValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AlternativeInvestmentMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure alternative investment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AlternativeInvestmentMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ino_GeneosTherapeuticsInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ino_GeneosTherapeuticsInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139775184151272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Geneos Therapeutics, Inc. - Preferred stock Investment (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">7 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MovementInMinorityInterestRollForward', window );"><strong>Stockholders' Equity Attributable to Noncontrolling Interest [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Investment in Geneos upon deconsolidation</a></td>
<td class="nump">$ 434,387<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Share in net loss of Geneos</a></td>
<td class="num">(434,387)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Investment in Geneos as of March 31, 2021</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 434,387<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ino_GeneosTherapeuticsInc.Member', window );">Geneos Therapeutics, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MovementInMinorityInterestRollForward', window );"><strong>Stockholders' Equity Attributable to Noncontrolling Interest [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Share in net loss of Geneos</a></td>
<td class="num">(434,387)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,584,610)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Investment in Geneos as of March 31, 2021</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ino_GeneosTherapeuticsInc.Member', window );">Geneos Therapeutics, Inc. | Series A One Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MovementInMinorityInterestRollForward', window );"><strong>Stockholders' Equity Attributable to Noncontrolling Interest [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Share in net loss of Geneos</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (819,000)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8813-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MovementInMinorityInterestRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MovementInMinorityInterestRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ino_GeneosTherapeuticsInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ino_GeneosTherapeuticsInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=ino_SeriesAOnePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=ino_SeriesAOnePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>71
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M2_T W%\(H0XG^@?RO=;^?U!+ P04    " #X?JI2M=OCU70'  !#(0  &
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MYPEP?&V=SKHYW<#3[T_>?ZN#AV"6W(A;57R6:[N]FF4SM!8;OB_LO3K^(=J
M8N=OI0I3_T?'UC::H=7>6%6V@P%!*:OFDW]KB3@9 '[\ T@[@ P'L(D!M!U
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M%1P.C#. WS=*V:<'-T%W'W[]/U!+ P04    " #X?JI2 #.);4<#  !%"0
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MVC>"N^C^N&D>&-BUEUP:(M@"709G0Y1;-W=V,P&U<M?>7 %>HFY8X3N':6N
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MWXJFM<I$45_N3%G6S@-YAHA-=*W_VF4>Z4.E=SZSWH%]RB6S\#GO>M'+;T!
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M:]:(MI+GPQKIY]H,1BL,4LU7UB\ >:&5155U6N>'B<C%(!E7ZWVCVK3M@@9
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M"C"Y0YI5K8_FG/.L?-ULL)/H'\;3?6R4FT"?6[H;<3&[MF?Q3.T9N1HU!)A
MZ21M!<<7Z@P^O49U>!,E_+I%V>%Q5-+LN^I5Z?C3R0\MF;J9AE( E&!1,GEX
M,A2L))J5YI0[U7HZ4#NF1J9TS0%/%0P!G\$1,3X7SY:S15^B*&BD^%&"-N)
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M;MUA45' V($'UP:0R\:JUHM7H+<Y>U MY7$0:P=5AU<M?E@'JIM *QC)O\
MX>BJMRZDM<YV%Q ;1T@%JU8OP)8APF-.UIILW9+19ES4&B3.(* P$+1YTXT8
MHD[Y-AS"@*5"ZR8BU6E-+AC:X$%HRZ[!4SV6"-I!9HXFS6A#C+W)C?W(&HF
M]G":QHEAWG@RI& 6*B5/3@*0LPO;*X/'#B)O4&P%YF"@Z!$@!C%AW/4L%4E/
MOX\&./UM;#;!)H X)0AIL)/@FW'B,8]?J!:M#<JSEK@C1T8B*=R<]%;,>G%C
M@(( SN=C0A$.((# &:?=FZ,1T35'UDXE/S2#W@GV4@1B=*W\D+0+(LVQ%LA0
M(ZC'Q\:3-BH7I0J&OE(KTS+@1:7I>ML1X&<C"4Z%!X*W3L*FOE/M2)O=)[1"
M%6:-H &@+Z*%:#@5!FMP,L3BF,^ :'*E.[1^^ !0$<!)TQA..'?*&72^"2PA
M\T$0(F0U<T<;3ZM 8?"L03;)!L&C090+!"THYB;AT2/5+JM_2'A[BR[_#GTR
M!#PX$'@ Y4'4'T&*(&"0RG"@?!4H:00LQ006SY+8<2K3,Q(Q#*\F-4'I27O3
MML< 0%#VO1'L*(<%UO8!28<'P%+ F>[H=1WKC_@ /0*5!B^.GK]?Z4ZO328
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MW9>@<=T$J #F*O.?5#:C^]M!8;KV0V8Q<2N\XD&,=E ?MMQRA9C8MSIT"OP
MAE*H$;,RLG%#Y#93<OFHR9T79--'M9&MQ&8<70H(WY;J#JR7>-]T&5!>JSH
M^PVB/&>\3I-*WA<,NT;L^J6S^VY9_1T\R3H>!2XRTBA6,"A"JV'/BNTJGOM[
MYN9^LWV&(Q1L%BRPWV4;:B3D=VF ]<'BM32>?94"Q(8=(@+,JZ($%66+:5F,
MVE#Z)6%-;I+\$ Q_)DAC>2F[ONN@?MX8C-DWF']9R7^SMJ&F6_:UDJ\==6$
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M^1FR *(GRA?LRX<2!L0*C_,5189<O$C(G/,JBD5%]&"H&"[](@V@M#P>W+2
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M\JD=O@#?KRTXJWS  ^(_]_#R_P%02P,$%     @ ^'ZJ4B"%!%[; P  !PD
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M'\>MT3'O7#$N?GMXS&?7MU:W\:&;*+?@S_FR11;?O/73^A>#<?&AO%E>_-P
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MQ6')W*)X\,/ %%T2EY4$(E,!!+9C<8#ZFF2-1695:+<X(%6WX*/*$9A7T2Q
MQ$VE:!N)R7-5H2;H;RJ>'LF=/7YBA9\Y@>&H4DI<OWL_/CF?3FDGNO"D5[HV
ME5:T@1?PO1R)3U+?25#(UZ98BM_P'USSK4QD(P[ 1<%+O $P=?)E0.5:2.O9
M^"OX8IB9I_,,G$3;30VL5YA:K.0MDQ^V3.P!ASS/6%)V) P,0$[+ @?(Q4)G
M6B(+@;>ZUC@$MP3^?9 3ZBO$!FM%66E3B3O8;ZT*(+U TP*JX(FL:B^_)%:9
M443S"O8'&FIB <9RE;"A8MP*T=%/;%)5#<%(7+V[#')I):J!OV5E$J!1V5BO
M!E6I_3*7*2J#:,I%!6X.=K$FA>[1!?O:/YY,P5-G&6QI(J[!$M)4DTFXL;TI
MN@JK+3,ZXSU78(&XOZ8D:<!D2Z!NB1J&2\VFY^UB,,BPHLEDI4&9B4 89DN5
MZ(6&&6&D@I!2@$)4*I,18YWR,T&P0@-/306,+H%;M^ #^X80W*37]!'X 1!'
MBAS>240!J8:50 @, UU9F2RU M*+UF9 >AVMAJD7CA*5DA+!A!O.J</'E02-
ME54!ZTFQ?Q1Q*? @R!"C>BH<[U11@5)ZJO&;A:XL&<G?P?J$L^4;T% ECD0"
MGAB=J:@KC!2X#7P,I*9-.SKR/<X'K"?B4T3N'1#'"C]7@PH@1676,JO!Z_[1
MX'+H<5=@Q\("PS,U3O52@TZ!>#"&+4D_9%'@V);A0(X"N:" D17.-_5X[7=*
MJ^,N<*C;" B4&0.J4*J:]1K4.1=S;:P&WLK*;YZ6DV3O.FGP@5L650D>L:=I
M]2+15=+DMH:@BZ89>!9\BP$WM93>E$!ZCB?H3XF!X&9J731JA,*4WBFDGJ#Q
M?#WN?X?"!YM#DI@Z'.3HI$<CEBDXL37H$XQ<U,YCL%ZT-D$\WK;G(58+4Y%F
MHR'"7PT0G[G@5.HJ&!A^DTE;CVLSIB>HN37*(0%[((\FQ1*4I-C8,5/#SYB0
M[W!Y&IV$!9]B]1PVYE4[\A3;G0+1W",&> <$P7_F#B."Y==A1^2Y22F"C%GY
M&ZNBZ2'J ?>L*222HQ9 $$P6!VXS)\^/4V$]0A^&?%G':T&DN5-H?78PH+UX
M^>;-RQ>?/EQ"O)T]/GF"J\'&:!%957+-O@M)U13H"E=O4 I#CC"%O%UCUCCD
M,CL&V=<0BA^MW4%4KGM>CB,[S%]SE";GDX'AP]_LHXZ%54OOSXC]Q=*@TO1<
M5T27M_;?85J8A])?ZU48/2>:@K,$2@)Q.LH"'Q1)P8=ESL$ OTA/92"V3U53
M6YV2-^O:SBY="EZXJ4IC.=MBW4!"AS0"]K7I_8;4(:1.%:@!U)RD!AR9O..O
M#19E]"155B])Y+8!*4O>U+TV6/<C@VW*$M1_TR4&;E40%L S<-(?BY+)0)4%
M5P;.$C*WY:HGCCCA#2\B$Y'#88G&62F^@2D4I<<92*3 =(1(U*J*/?<V%])/
ML-WV.AI80^4.4L,7*B)9DGO'TBM^OZ))(R<,5 )_,1/:Y%;D/I!?D 8PK\E=
M@YK@S@JU-&1+L*!5\ 3_##P :@^[ZSG:I9<>Q_4!L79#%&H<4 Z.A$+5<.QQ
M(:&;%A>H>[G799<4M*&1HBYIFW?X+S4%6MSDFK:()90FH6W10'&@'W4C/OYE
MHFGL"OPQ%Q0Y&B6[YWF%S@PKPMIV2,(W54-*S_(&\AQT$D_EF9.24&64&T!>
MHTWJ7(ZO*L#SH2>FR0WIRH$&PD,:/)?%EZHIZV2-SS36^["99.T#5+2A3J+>
M-<!-CLG64FFM;JW#5%%@;UF+#$U ^Q26-5DGAG;4R8=0 JNHW&)6U"*#MVM1
MD,D2SM)Q5;[H@8I(E<3S4>!'@@Q6Q5)Q@ -WIV&?ZQ&X;M) .8<2KR8>V<24
M+G,,7.)<P[;A?+[N\*=36C>['=L Q1@!B.L=Q_$P-94U$5KK7#DW4(" -<A8
ML60B=CDGL*$\'3=/4B/M=(\U5K+F%B(0[%O!&FI'ZM>+H+VT&NB;G=]##&HR
MZ?B3=MF-H(^\ 59 #*T\<R 98F2@P-K;AQO/P*CV5%\I<2SQ25VS,#-YURU&
M%*A($[*)^P 7)_/+CR_$)U/JQ(JSZ1F9^?GT?.3B#Y,2[R8X\SO)J04Z>,([
MG9,@9A#'H41L,N0_;MLTA =0SM5=&-?EC41H0#^EB3$87!E8##Z'?(Q+ $T!
MGBR%? W*6>(4(=^H4E']04X;2Y549I@0N2HB\ G>93O<P;@NTX$?6#W'+/+;
M0#H#051LE0;%2 5G0U&T"W#$,;7UPMWU%DU%[F](-B"8PDI.8\&Y)??8-<$[
M0!\6T;S;& /9@$S*K+&.29KV<$]Y?K?2H,S(! <II&S<08,PQX)M\_X<0UH.
MM1/*')4'TWT8P&FS8[E7COZ^1TXIUOP.N^Z67U2M+QH,?<@">!V_WT"YG#U%
MVM"OH:*4-()HPIR]E'!(9'VT!>T_FDI;%UR79+'(/AB"*!@E(LRS;NIM^Y3Y
M9!E""]4LL R+AA(5Y\\GXM7] D /-L<<+#$@N6]L>Q5F&LV](20JUW@D1_&D
M X CDB\KS+@Y^VV9#14;\(#29'+V0'@LN0]*Y_.FLI0CPG:7E<RIOG (0Y=J
M&%!"$0J"!6^9K=N2K^,U6.1$;+9&\[2JHGP<0T*J,B"XHFB;5LTRY)-47CJ<
M&E64['Y027TY$9S@R %9-4(%F[:,P.%I9'%D65EFDA@/]+YGV/]U74E?'^4P
M/C=JR5^@W( O*ED5)C-+KF1- C5%Y9P[\<Q5''.(:PM=]X %YA%$A HQQVP]
MVF1]Z[!QDVRI%KZPZ/"[FX@FBD7<X13!";&6_H#6>9PQ"?TG6,7Z!A-5JJ6J
M7-Z<LC_'\51R*VRM;7)V(J[:@0BJ^J3'O?"6J/*MM!&7$+R/.[*\L%W2LJCO
MPE!K]WW:WB;ZVO51B+\B7,T!VSH<D\QJ+C-O&/M<G^X_GLP\DT=4,?H^QVB3
MHA)X;IYK TM!=>] E;A9=72!%,T>[VI60768,V]P_0^*!- VK/#+;CNKU\+:
M:\D(3_8>C5S?:I#$@_:=,!+H"*F;2!VJS]Q&>X%=G&_O?6U2T!>![?2_POC=
M_:^!EM?G7_]S?#PCO I$B8T5G>=-09Y7ENN -K;M+P8^G#O!/!C&J'&"<J\@
M%,G&%1*O;SZ/[F^1A=;8B/IBIFV:(:TATH#E_@;YHNR7KK!Z838P4[\I#%_:
MVH;3  :78HK(G!C[72 '[[RA;4INBU@Z>,]]4G. ?\I=*I5:;O1<3$YB-^1U
M!"H*CL&(QU?:NIR]GW+A%$=Q3I9AY(>\ZRB>%)-MA*L@+8(L7-3RJ^(D8'_6
M7=W7;OX%[,7%+[E,;&@ZRJ/0X50IAWW)E0X=\B#(J;]X'4W57VAH.LAP0"NY
M815#K[?*XX.CR >G7-,^Q!OWX@4V:X 6CE@RA2U@DK10K+G[%V?3T93KCCXH
MS"+V:M27%3L\KR:T*$*:RN]V(P$%(ACXDYE+53IP9UQL];9 B)W#C/$Q)7_(
MI%0'R^%2T1+\%@I^#[1N+@T//0H?E7@K5?C&!C "^95CWN3 #@?N(/KOL650
M!%)13D&=>$D3%+>Q[I=R'#S_:" =5]5 .$0'^\X$Z =G[(@2<["T4?UVZ:"5
M_[F]7@CSTS9($G<<Z)LZHV%/BOU4W+?QJ3%9RNB?Z@YO::*T+G2@7S#R0#U(
MB-SR4#,C=L*^P4MN()?5%X7UR@ :OJ5%ZK%0QVO;]G6EJ#4%_]WM41>4J7:*
M1LX5MS<X]S1W8UPTU^FX5JJP#^R7DKY">A[W3?NMPJ@W'/3K^YN?Q+[9] ?;
ME8&&G]><'.X%.@:UVM?KC ]8V#8$W:'DX86'H.3WP^(#ZS\ $M] P[G(8ZC;
MO=^K#C55Q/S:@U%SSP7[(U!Y#^UNM_HP-L2PZUPM=4%,[O4%!S(DHK3P75QV
M2!=3>+:VNV'9A\.3 ]0.H(2CD%A$2&'?F?UO(87R_S<^*'>@@D<[8,%_H7?_
M!] [0?3 -VC;/Q7*&RI[_@7E;4)Y@X +N6UND<X5.4G&O!<@;^!$M7VG.R7P
M(\!AQX1_.G*X-67_6P,Z=^P@D9U 8@ 1_VET\!)UZ;\@;TLDXDN7S;*!!.HQ
MT7"Z\R1T#%!VCKA&WI$4[*U*KQ%)43S=,C-SL+*YQJU@)VV'\N>X[YC$@[WH
MT]ZC&'2(&M;Q&S)QY4,/#+*]\/OOEMIHQ[/941?X0:RND#D;_=N75]?3DU/@
M#_N56E9+A>='-D"?50," !];@AJ97-[JJK'BX/7-YT>B7I=@3#/N'Z*DVU-4
MKDL-I+7GE>&)L:W*,?5=R6T[N$O*_'AR&I2Y=Y(7G.%'",P.4@2)]Z<EO]<Y
MKI;++VHS].Z(%I1(CKE,"55+CX[:0'&-1L%EX?[LJ"6Y@WZ%.-!F^%OF[TTX
M.VW+2G\>+<'#6#]:,7I- .]88]('$O35T_V&T64S>>I%@Z;<.S;!_DU::Q(^
M^<8&Y9?NZ&G7Z>PLN[&NXQ.U!(D:4#5_MM;5D&W9!62']3P$2H7D VPOP?H>
M(21W$*DG<]_^;X])^.C>R^1J!@I@C30<1L$XLM7+(IAD2M=>T"EE4I4J^>Y+
M6X<X1^#RDUU)ZN!I[#[ZCNV .$?(LC8IC(VP;Z5M,D'I KX7Y>&!VF&W;FE9
MBIBYJCWV1LT%MC+I%A(.O9F#PD1]!$17^2Z& ULO-J#:@:2GT\W6 PUMZR"^
M2!L@95LN2;O /48/0O7O#GA&$O 'T%W60IC?X,'.MM16B'>ZTD=7R+Z_$^":
MPN!ZH/4RD-1/8//@/6J/UKXL01PY9 \W%9Z54RD=0+DN"D@U603 UDO0R2R*
MW,-1L[VS1()Z\?+F>H0G.&TC^9Z%"RL='PV^+XW/ &_>Q &E68(!@86] 6<A
MQ0(&<CW]]N6'CVPH2R.#/G;=TES5=\J!EP$VQ>804(>.)#K"NC566Z=JNK@%
M17"ZB?A+;9(O)6I'E)#*=,U'F;P,H8:&_Y.U.P];XQ0@8Y<IM=X?"D \7X8'
M9A%X^.+*N2&V4C&A\A(=-O9EPEJV;E*ZX1-EYJQGW/0;OO2 1\THZ2(4 +F;
M-^ @R\RU338JJBAS[S#8'<,<,9%T!8@=&W"98L 69/3T+-@;W4P@")RD+!:@
MRF-")1PL@KR];\O=\]/W;)W+2*<$FZ?CNI'.5!YDQ/T@O\@5T'X[MU!Z$3?V
M>2'D?E_7ERC9O,,7VDV>(,J+HG:/Z_]L[<]VD6+@$;4<-Y![3-."_Y/6]0;&
M6XW&@?C#!=%F;-D_.IU1NR7N!?'M-K^Q3(>#CCN[/[X]S7>B>T X28KFI8#Q
M-PC&$A(YYBL]E'<R-"O:VVI,"FS$)5T748R@C+9$/][13-(<_Z%S8#0Z9N@/
M1WM5Y=3:.XDA6'X2>^2'4KU_-KF(Z<6;UFUJ?EWP(7!V:Y^=![X&GZOK!FST
M8._Z\_7>HP"Z<9/VG7^A'0@KO59X1AU>^>W=]6MX)W*P_;#6.V[Y$3S?BN<>
M=6@_[?(Z.CK9XVJWY"G4UWK,;2:'UH/"0D#,T2GC_05"#/@9'[ ?B2\%WD>0
M [=&CF\^WHS"P99XKA@VB&ZE8*2.-C&;' \I3(9%UM@F".5W,\-HMN H//#S
MISJ,UJ-M<PV=NWX=/\&W)!RT]"=XB9-(%6)/D?IKMEV7\5,<1:<T:D7R'$/^
M7V1>/A%O00.*5(I?*5UY!;MWM]+!4M\GM?')*&_H(2\>^+O!^"!<JO9&CES$
M+>ZP]_AD -I,>DM;[:.?B'2]O9Q;'I/2S5\Z2T%)IRX(_C>-#=E)25ERN" >
MU6>83'6/@]'M1N"=XK6][9!.&,K78(&L4<4W;C*^OO[L)NJ;+F&?J/OALFMK
M<F !)LFX\PN$S4U*@#^=.*:"GGL!@3))N"M=9X'9,L-7@*!L3*%0=&<3Z,P3
M-@[8V3)PQ/4#B\IQ7Q9QXSF.LO%%4FPN_JQ8SQKOCUW-CD\P:/9#^L,-KZ_U
MO#M4"1\D'VB89^ZTQ)]KE&W@]B4=LHB)_@[CV!Y0!NR#G<% -/ 7"1\:$WZR
M"IQ?'!/'21'.?JH>@ 4R3QV_K[ TK#U#KD"L^,K!E;EZ1$D48KOW_;H$>$)J
M#GR*4.E+"/BFPHP.>7B#-^\0/]SR<Q/O/UUN^Z$)' 74A#HC(J/]80-WWU07
MG@%>%CNE2W&\!:G<C5$N&@@/7?0Z!VU@=&7KB_>?KZ_&LXL85.KLI7>H9+,F
M?AB1&W=9*76<0(F<8]J,:6YI2H0N(^_- ^+O\:30W<IDJG,P(CXUXHP$%W;%
M$DWRRABVOBOLG5QV+\W&@GQU==G^S,6G/C?H) D":^&LT4/3I?O8U*D1XYGP
M0"34C!:"@,<!O0O??M,Q;MD7#0%.&$W]==4XL_74XV_27%UNX26S@L!=ET'A
M<^\T^0P+8^&W4F?2Q:]8<YIA]0I'<[[JG'MC^Z<G+637A1I7Y+<W&YS=&=L+
M/=0C3LG.>?F/S;RF=M3%Z?GX;'HZ$N],/096CL&^\0SX2_<S)&/QP0%N'QB&
M(YZ/VJ:FOSE,T)>_UQ8? > F_A*1@H+!QB7=#B2O%8P[M,/1J+1U>*D_P =_
M:3RH"4S'-G'PYKIBUZGGS4!OG> >=L4;'G;(N_[0<<4 ^\E<>?0CR"-J8;I%
M^*B;/]"(=_%\8H*A0&]UT]0#]+%3+/17E8ZY71B._\7&>\,7AXG<%VY <,:A
M,8K..+K$G5!UVZW0(FBTC9L;YGN$(2[V<I2]&<[-/@T9?/1&B\N1IZ[QO"<Y
MM/ZELCY)'D"BLU-C2Z?(>M5K;*YAA_VS%$/,&C#'V=GD[/O,<7#B\#M!I )%
M#5,O$'!OZ0EFA*=IZ)9?=# AT=0%RMV/+DCJNT:_@T1V&=; WZ3H]CQZ/3[J
MPZXW;A)'F'2+(G[O_8?AC.CQY+Q%O7XT!;:;D*M3Z.^Y3/%#=RDN6BUPZ7UT
M;+N?VWU/%AV;91<^ZO$2M-[@69)(T]"2D7X\U[70O:2:87%WK@]*Q/8(HT='
MG0\8^"6++ECSG;]E06$B"Q?.276BW \/:68J[K;XUHJ'@1TADZ$?@3N,?HTO
M5Y FX&\.6BX*^8?YPK?A9PTO^=?\VN'\FXB@*TM( D6F%O#J=/+X=(\[<_X#
MQ$KZ;;^YJ6N3TY\KA=X0!\#SA3&U_X +A!][?/8/4$L#!!0    ( /A^JE+*
MN?EP% 4  /T*   9    >&PO=V]R:W-H965T<R]S:&5E=#(S+GAM;)U6VV[;
M1A#]E84"! D@6S<GSL4V(,LIF@)! CM)'XH^K,BAN#6YR^Q%LO+U/3.\6&XN
M+?HB<;D[9\[,G!GNV<[YVU 217575S:<C\H8FU>32<A*JG4X=@U9[!3.USIB
MZ3>3T'C2N1C5U60^G3Z?U-K8T<69O/O@+\Y<BI6Q],&KD.I:^_TE56YW/IJ-
M^A?79E-&?C&Y.&OTAFXH?FH^>*PF TIN:K+!.*L\%>>CY>S5Y0F?EP.?#>W"
MP;/B2-;.W?+B;7X^FC(AJBB+C*#QMZ45514#@<:7#G,TN&3#P^<>_1>)';&L
M=:"5JWXW>2S/1R]&*J="IRI>N]VOU,7SC/$R5P7Y5;OV[&(Q4ED*T=6=,1C4
MQK;_^J[+PX'!B^D/#.:=P5QXMXZ$Y96.^N+,NYWR?!IH_""ABC7(&<M%N8D>
MNP9V\>*MS5Q-ZJ.^HW VB4#D]Y.LL[YLK><_L%ZH=\[&,J@W-J?\H?T$3 8Z
M\Y[.Y?RG@.^T/U:+V5C-I_/93_ 60W@+P5O\:WCJRH2L<B%Y4G\LUR%Z".+/
MG[@X&5R<B(N3_YG!_VZM/I:D5JYNM-VK%/!"6T4A&HB/<BQLTI6BHB"1LHJ(
MRF-KK':ER4IE@@@T5U [W34X=6]EQ,]8A:ACBL[O!VOVDLNJJ7#8V(UR3>-\
M3-9$P]M;;2J]K@@@*H+B5GOC4E!_)6]";J2] F^V-.)!%!@>XF.LHD.S1/+0
M,(!B4%^2]EA7>]5XMS72Y1@R'5,F1.%8K<A'C!85S,::PF3:1H5#R:8@846J
MP1 U#=1H=@4\3YG#Z:^(OF/<^7K $>2R+'F)'K!J34JKX)+/2+E"@M1K4YFX
M[U&^S7Q0A7?U (\8N\?CQX]FSZ>OKQ+Q2S;6N6MD#@%[>?,) I^]/)K-.SZ>
M:K<%G+BYRZ@]FM!5'J=7ZO1D>C2?'IT\.SIEP P)-[RGJZKC'!BXRQWX.I^W
MA.Z3SMA,?$V6"A/A,V!T<;TE"*W0'5U P,=&:K7 %>0*C[]A8AUL[(9Y-$T%
MK1R_MPHMC(#FI]+#T[&X_00IH1HW47)&5HLT6Z%X9_76>.AI:?*QNB8 %5*5
M-Z#A:I.I&T*AN!#++*HGJ^7UFQM^?-IEN>V;_BVW ?=-37Y#-MLKZF&XDU(%
M1XW.;O'% 0$=.6=5RD$KX$.7<\A]/ZSQE;L-G$1,"[(;\+7?"T?P]V)6H&3(
MI)6,89*+:-!+4K3$4JX.I,0E6[W__/;J:/:RB^5A*-(9PFU'U# WYI65&DF7
MCD,-&Y1F4%F/AA"A'03]&O*H1="\73ONE(-6&EJO;2*1(=H*Q[.N\2I3F]@*
M@.=*BFB)K[I7LL6UH5,(R+& N->14J0N"%]X%5UEVOO]&HE7.&Y<+KT^.!%#
M#J+@]MJ3]H#AA/X#JN]($7:>N-H6^L:0E(F'3, LJ!V^\OROZZZDO:.#>+N4
MX"JSY6F&N='KDK\6JQ3;P?B;6P>N15>?96P%WJ[Z+]7XP= KX=FZ*',(;<@S
M>'\PUNY)3)YTO?A4LL$8!A"(JE_>2R&_'R6=G\>/7LQGIZ^#*DV0B?Z#>BBT
M@4SAO%4VZT!SVJRV[:S3T"T2ALJGMK(8*VXGNWJ#H\@N3VP&QX6'O*>V033@
M<27\WD=T<G ED4[DBQ=4X)*-[>UD>#O<[9;ME>;^>'LQ1+XWX* J*F Z/3Y]
M-E*^O6RUB^@:N>"L7<1U21Y+W$_)\P'L%\[%?L$.AAOOQ=]02P,$%     @
M^'ZJ4OX2)9W%#@  @BX  !D   !X;"]W;W)K<VAE971S+W-H965T,C0N>&UL
MS5IK;]PV%OTKA.MV;4 >S\NOO #'3=HLVFX0I^F'Q7[@2)P1$8VHDI+'TU_?
M<R_UG)$<NYLN%FAC>X:\O(]SG^2+C;&?7:Q4+N[72>I>'L1YGCT[/75AK-;2
MC4RF4GRS-'8M<_QI5Z<NLTI&O&F=G$['X_/3M=3IP:L7_-E[^^J%*?)$I^J]
M%:Y8KZ7=OE:)V;P\F!Q4'WS0JSBG#TY?O<CD2MVJ_-?LO<5?IS652*]5ZK1)
MA57+EP?7DV>OY[2>%WS2:N-:OPN29&',9_KC7?3R8$P,J42%.5&0^'&G;E22
M$"&P\7M)\Z ^DC:V?Z^HOV79(<M".G5CDM]TE,<O#RX/1*26LDCR#V;SHRKE
M.2-ZH4D<_RLV?NWL[$"$A<O-NMP,#M8Z]3_E?:F'UH;+\<"&:;EARGS[@YC+
M[V4N7[VP9B,LK08U^H5%Y=U@3J=DE-O<XEN-??FK'U2JC!,?8V5EIHI<ARX0
M[])P].(T!WE:=!J6I%Y[4M,!4C/QLTGSV(DW::2B[OY3L%7S-JUX>SU]D.#/
MTH[$;!*(Z7@Z>8#>K)9UQO1F _1^,6D(#JU)\,T*4N;**I>+?U\O7&Z!C_\\
M<,B\/F3.A\R_AD(?)$7^^,QE,E0O#^!P3MD[=3!,'_^(ZV(%R$!?D_- Y+$2
M-V:=R70KR'M5),K-N0%P[^"0F9!I)$*S7BL;:IGH/Y3 "IGF>J72$X)[)#)E
MG4GY2ZR5::@LT<;Q6KE117,C'0C!62,H-1)2W$FKY2)10E=Z5B";;\71IW=O
MCHDCL8EU&'?X)"KT=V8UQ0BQ /&E!FMVRP*^50M;T!<0\2JHSH8 6:)R'$M[
M=:ISR"+"Q#BRLUF"FUMEP:VX!F6U5)98A&^%G\52IQ )ZT:DTYH1G=Z!9:PZ
MG(RF<#Q !C%$IWS"EXD%I6PD3X*O%UMH6B HDGY*X@;H?@LLF@UQF<<:HEN9
M.LGQJFN_6"61.)]\2\+0YT0IA^UHI_J]@%H#03$._[D3F.%.65:'8>/B&\\?
M#*H!%Q I->?-#[ND1;4\=2;1D<S!9NY*5A&%<Q*^W%7 P:VXOKT1EY-Q ":K
M/:0CMM,_95J::3H>,)-3."MJ6^FQJ@4C^\AI#'8Y'@?C\?AAY<(N.!$1!F3*
M$#/N4?G9]/]#Y5ZI1:IV- KED;.!ARC2)!EP_V45"FM@PJ^CR/96LTFQ;W[Q
M@,Y:BGBL\L@QNZ?B=[U:E7$&T035015Z9&W>-F.I$8E)L<-;58IV'BC5 LU5
MD6HD7G/D,VF;RG??7$XG%\]A0>>4<V2@%K1;!EVHDBUPH7,1Z0@,Y"*6=T!]
ML:1X1L8M%2)S8;7[3!L])QX%7*[ I+#D1N<Q--FVL2L6QD*MDK36"."*+#,6
M_/]H-@CP-M@+KL3(0(!M3!/T<<Z[0-9R^M!0N:?48C2/(<S:(-0[O4HUZ"*3
M)( 4SL=J3[Q4HR"3F;4.*;]P<0G)1^(Z#%FP5;+M,A^IEI]$P[').S:[2NW6
ML"F*-+(UUDFQ0JU*BP[GHTD5VME#O3,<3D?S.N);E<@2F<2-56LE74$_<&J)
M<JMR4%2DJTZ!42>^%J-D9:DMLF-2*)]RF)T8?"^42AG*-B*?59D$G!7TU\7A
M/QAN$0IC%8F.4N!K><T9ZG;O#<X?LVR<F-.RB\W&>XE<(QQ GSNRMC7N"^B0
MUH'",_$;2FTB%:((R &\(W4?)D7D/W+QL3@41V=7P=75]%C\8A#8,KGE4R<7
MD^!\.A9O]3UY+SPI!]Q2Q2SCA&)=>"8BA? %7/+11ZAG9O/QL;B1UF[I%-8?
M[1G2^2R87.*H.8ZJ]4WK>T%36W 6G$\NP?:E^(%!DNYIH8E?1_-@,IT$XXNS
M8_&]"M$2.4KMK( 6Y);6K'OUV5 Z%-/@XF(>7)Y-V%01L9.X"E^[\8<";,UQ
M&45ZQ4+4)"O7=8LW_((ZL8"C2@N+ )5,PE+Y?4[$(E".PC<[HM1%X&TL+?A-
M8%?_NQ/OK49$ Q;++]D:G]@:-S[4SRC)T/_0PW@TO9CAYR6J._KD?9W"IL%D
M,@NFXW-\.QG-IF=>:U=7;*V/AE!XUEK36)+!W\% Q>U0HJ1 N6AG &+?,?N9
M%T=JKNF0#FUT C^M+6"L8PR8-"W[3M8S$>' "$R3C9Y<]7"]W"3.MFE&PQ)V
MDBE)!60INV;@4$G:$8 V=](GQ-64,416+!($:B2,SW!4XL05")1,=K0;ULD!
MH27X G/3KH2A'V0= EC!TLN*I,PR:R07(L@@2./HU+FL0>9(-(<DLF^)=2\E
M^Y7LE 4P@4GN. P@G!'P4606EI-3P!Q(Q,"P"G+X X;@;$XZ*ZE[UKAZR9@J
MF9P^6BNDX6@D?N7J=W!!(!1)4E)C^GSTVD0J\;Z%?.K%#XF%D@KC1"*S0DEI
M2!"1>ET!T,N_8]Z1>$,G^?UU=%#WU,NY"JI[6&Z3DG>(,QP4R*C,-V$!XF22
M@U>I/U3#)H'4'FHA/ $:AY4<M9^L.]KJ9:74@SK0NEAG;;S1V8,RT?%L^WT:
M_LP&.B7G;4-V8 [E(1/YY%*L63=[J:WK+/1) UO8[SZ#[])1!KMTPJ5^_2$)
M%' 53V7;R=*J5HM+"1MFV2?0M0/J640*E$>)3X'-0@H#%?X9X1$LM"U%\Q:%
M^E'*LI)6!6I>&AM4+AIRJN"^O*NU#OM=9J38\.R*5(::4:X:I=3;\9,,YH&'
M B15]WDK.)$V$!)"E,7+ GYZC^(16_BKV@J>I0&E[>-TJZE4!R>_CFZQU7+=
MM:W<A 6U#%V2:"<*[40^[3RN4)%Z!Y3B)YI_B%FG^'>Y+2B#>D;;\"F(KS*)
MMK!394RNCO92IO#Y0CG"5N33[K,&&VR(HZV2UAV+Z>AJ*CXU:+D8?RL^#&@*
MY>GYMU6$WPVW*&J#J_/SX&PVZ<PS$&$37Z*K*C3Y<$56;8J',GFU=$>FQ1)#
M^6!W(0]TZL*?NP1N9=@YU$;::"]6\$I2##H8:@UI4D/X!E@2R:V%3'>*&3_3
MX:94]=IW)&XUM4U]M=)@9NTMF&+&1LT:Y$DTE%46;)Z$PE$!=4?:=U.#@O2Q
MLQ.I:A9(8QNT'#[M(AI2F=;T L166MFMCLG-&&8VG:!U&BC::@CX^MUQL*4$
M.<1,K8^!"4$BP\^N:J'% IUI9)1KND2Y\""&#NIDU&H(070)I)+%#.)-U:B4
M8:1QR SU9<B9NTG)'>AZI[>D]^")!\-VY)D%#44WL6J##,K)#'?XBI*V)9F@
M_.FXGFK<F;S=:M1U>@72<F#A#_#)?2VIU69YH7751#J':$#L(:R$>3D<TA9M
M$&$JK%PK4C 4S:ASY3]XLK3$*+(' @^/DB@<;'N5VL6,1Z!KB>?ABD1-U6R1
M)M!39^I*.U:I]O68*_MCZH4J+?6T0=[E=$13B!;F0FZH<L]^Y0GY7O_<M,4H
M(FG\02.27)4%.[6(2+"HMUVK,&Z3U&G31/%:A.04NNFL?VH'[OI:\&9[-P2W
MPRKQ;-6=5ANJ ,A3TPCVY,:"VE=0T+8R I==5K'0,":.TR9B$!&9#:)$#FQ'
M5 EW!@]"+YL"'X=%WAO)$JPHB.O7,=BPAL/_"3G"">3#>3R0OZ:YC%Z601$
MSS>J]*6P:M3]<&&HE=T)@<TT@C9P?/,P;0S4[3;(7'Z(0%QB*Q3Q!]N4TQK[
M&E6V2+HP%H? <KK$%B$ET3_H<7C4V)(&!"/*;U7),(#>J';)C2E0KZ2JF0%6
MW*!ER/8G"7V.5@ZV'I.T.H[PA&Y5/+);'>Y$>]O/>FK>;3(]?AXI4I.'.9_4
MDT<IZ+J9RN"*LF]9&O$).W'5M'+VY&O?LNMHC^QD @H(#Y3;<5Z9/,EB%((
M,\432V^.@; 7"(YZ/"ROW1%I*DL*1V@#@_BE*M-W)D%F01=Y+$"WG*=QDV7
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M6-&5XI)HK=X/Y"38+_HCS@UB%]::? O!731A#PIFYSRE; S('!C$TB;< 0=
M?T":<'U:?P2?U1!(A>E%K)'O$-XBG+,URDOP?1B<]WIE:O3KAA:!$T/TCE$$
M8FGG$*@(,ELY%#"U C7;A#UZ0#I/Q&^'!;R)\ _"TUMVE(L>?P]PE_G2K8+/
MHIC:$^>V8$. )T"TC'8-&[_6Y["G'\$ZO.01?E^"V:%P5&'L>YU(B?AI]$4
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M,CWZ")PK2QIE'4I3>4X)>U(?%8O6+"*L# .1%;ZEQL52XW'*HSLEL0L$ON#
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M.!F//**Z%:I3C%R[M64I#2Y!3JQPZP1E+^#[4F)S;Q7KH-]CY_\"4$L#!!0
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M*Z/HE).=F:Z,3&]S*3)4^@0N[FIN'N']#5L+U!_&@2$75C%(6[AY Q>_ 9?
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MN65!XQ^5#:#]M91F;]@"W1_*[!]02P,$%     @ ^'ZJ4HO3+1";!   .@H
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M[XTHI*J^J=0O1I;N=K"0ANX:;IG1Y0Z5%:#SI:3QWKQ8 ^UU<?X/4$L#!!0
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M&YDC+MM[H)UHL7:M="FT:<QNN#)W)T@;8/8K(?1V8@7\;9R_ 5!+ P04
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M0>0$@80).@9.CR7T04I'1#)>UYQ!'=(!M]<;]N\^=\IES"WTM?PM<BPZP77
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M<)%@SE39;,N)D1O7KQ;28/=SPS5>4$#9#?A^):793:R#^LHS_@U02P,$%
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MRQ*OA2ZH MT'ULC'!V 7210XMGZRN".+3Y(]""3"<_(747*[$SG3F4-$'E,
MX8RN&6?FV4)64D#_RL7O :-P.$DF:3]?TO$E_\?'M*[=E<BD[B5)>D@FH]$D
M[@<9=R#CDR!76:;J9K\ -ZDW]/A=Z#2=A$<"IUW@]&3@6WP-,JK4,Q/;$T<W
M?7=TPU&03,91]":\?U"@;*W':XT71!,.&W0-!F/D5TW];#I&5JYFK:7!"NB:
M!3XYH*P!SF\D%I:V8\M@]XC-_P%02P,$%     @ ^'ZJ4E$+WC*V @  .0@
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M\C9+YS#6'9=IL3Q"<Y'GX.;*COPFA:,5DURUED(U3F3',<O3_90$-(J" -[
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MD&99_3Q3G6BQMA_B;X76(K>'*\X67)H'X/Z=$/KIQ'S;W_Y(-OT/4$L#!!0
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MVLJ-XYNBVM9ZG%R7:M*EZ@5)$G=J:E<0!V$<1D=?[=MM:[LND*^L"]4*-OL
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M%,(J,0-G:;O\:PU93]>MA*K7),F3!;@_J-TDW?I8=K>6=,,^BN(.^E2DD(G
M,NA&T"+@G]X6M7<:]:"_5:@?-',-:A<=+R8V%G8!A]=6&)"L)0.JQ9$GFBB(
M=<LT8$$:T2)#([: +<?,N>+##^LY%IJDPF;Q:80D]J01XW!0A)"I*PFZ,NE.
MX6!U'B@)$N^5MS;>K6XE%>X/#);!V)-,'&:9CZR ]!<N;I<9[$&X-HJZ1'I&
MZ#Q!Q,F)A,XS0!PNK?\R=&OP]BZ5UH5N?V <#)TOX'&X@G_(9T*N&-/KI.-
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M1;64+LBY*8T%6M%DV50'+@LF]2"(:YK72JVP6:X^Z#/55/"T53QU2"$7$41
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M!&1\$,A9@X,_#2 3 C(Y(.2/.(!,"<CTD)!) )D1D-DA(=, \IB /#XD9!9
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MX\_+[Y.(\^*,<X(?9>Z_ %!+ P04    " #X?JI2%\C,&]L!  #1(@  $P
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M4$L! A0#%     @ ^'ZJ4@=!36*!    L0   !               ( !
M &1O8U!R;W!S+V%P<"YX;6Q02P$"% ,4    " #X?JI2#%<",NX    K @
M$0              @ &O    9&]C4')O<',O8V]R92YX;6Q02P$"% ,4
M" #X?JI2F5R<(Q &  "<)P  $P              @ ', 0  >&PO=&AE;64O
M=&AE;64Q+GAM;%!+ 0(4 Q0    ( /A^JE)5HC4[5@4  '<5   8
M      " @0T(  !X;"]W;W)K<VAE971S+W-H965T,2YX;6Q02P$"% ,4
M" #X?JI2M=OCU70'  !#(0  &               @(&9#0  >&PO=V]R:W-H
M965T<R]S:&5E=#(N>&UL4$L! A0#%     @ ^'ZJ4FH1> P&!@  &Q<  !@
M             ("!0Q4  'AL+W=O<FMS:&5E=',O<VAE970S+GAM;%!+ 0(4
M Q0    ( /A^JE( ,XEM1P,  $4)   8              " @7\;  !X;"]W
M;W)K<VAE971S+W-H965T-"YX;6Q02P$"% ,4    " #X?JI260.'80 '   @
M'P  &               @('\'@  >&PO=V]R:W-H965T<R]S:&5E=#4N>&UL
M4$L! A0#%     @ ^'ZJ4@KLZ\0G @  D@0  !@              ("!,B8
M 'AL+W=O<FMS:&5E=',O<VAE970V+GAM;%!+ 0(4 Q0    ( /A^JE*%R$:P
MG@D  !DH   8              " @8\H  !X;"]W;W)K<VAE971S+W-H965T
M-RYX;6Q02P$"% ,4    " #X?JI2*?!4EV,(  !I$@  &
M@(%C,@  >&PO=V]R:W-H965T<R]S:&5E=#@N>&UL4$L! A0#%     @ ^'ZJ
M4K6NI%&)#   X"$  !@              ("!_#H  'AL+W=O<FMS:&5E=',O
M<VAE970Y+GAM;%!+ 0(4 Q0    ( /A^JE*4:+W9IA4  /I!   9
M      " @;M'  !X;"]W;W)K<VAE971S+W-H965T,3 N>&UL4$L! A0#%
M  @ ^'ZJ4B"%!%[; P  !PD  !D              ("!F%T  'AL+W=O<FMS
M:&5E=',O<VAE970Q,2YX;6Q02P$"% ,4    " #X?JI2)(8HIL8"   R!@
M&0              @(&J80  >&PO=V]R:W-H965T<R]S:&5E=#$R+GAM;%!+
M 0(4 Q0    ( /A^JE+L[CDYQ <  #84   9              " @:=D  !X
M;"]W;W)K<VAE971S+W-H965T,3,N>&UL4$L! A0#%     @ ^'ZJ4I#XM?T+
M"   Z!8  !D              ("!HFP  'AL+W=O<FMS:&5E=',O<VAE970Q
M-"YX;6Q02P$"% ,4    " #X?JI2TF(GWLP#  #1"   &0
M@('D=   >&PO=V]R:W-H965T<R]S:&5E=#$U+GAM;%!+ 0(4 Q0    ( /A^
MJE(/18HU Q   "$Y   9              " @>=X  !X;"]W;W)K<VAE971S
M+W-H965T,38N>&UL4$L! A0#%     @ ^'ZJ4NCNH'Y(!P  910  !D
M         ("!(8D  'AL+W=O<FMS:&5E=',O<VAE970Q-RYX;6Q02P$"% ,4
M    " #X?JI2@ER;=#L%  "5#   &0              @(&@D   >&PO=V]R
M:W-H965T<R]S:&5E=#$X+GAM;%!+ 0(4 Q0    ( /A^JE(HL@QLY 8  )43
M   9              " @1*6  !X;"]W;W)K<VAE971S+W-H965T,3DN>&UL
M4$L! A0#%     @ ^'ZJ4@^C9DUQ!@  4Q$  !D              ("!+9T
M 'AL+W=O<FMS:&5E=',O<VAE970R,"YX;6Q02P$"% ,4    " #X?JI2:*Y4
MU&,'  #($0  &0              @('5HP  >&PO=V]R:W-H965T<R]S:&5E
M=#(Q+GAM;%!+ 0(4 Q0    ( /A^JE+R]0EN:1<  /A1   9
M  " @6^K  !X;"]W;W)K<VAE971S+W-H965T,C(N>&UL4$L! A0#%     @
M^'ZJ4LJY^7 4!0  _0H  !D              ("!#\,  'AL+W=O<FMS:&5E
M=',O<VAE970R,RYX;6Q02P$"% ,4    " #X?JI2_A(EG<4.  ""+@  &0
M            @(%:R   >&PO=V]R:W-H965T<R]S:&5E=#(T+GAM;%!+ 0(4
M Q0    ( /A^JE(BC2(\;Q\  !]D   9              " @5;7  !X;"]W
M;W)K<VAE971S+W-H965T,C4N>&UL4$L! A0#%     @ ^'ZJ4CDM37K" P
M)0@  !D              ("!_/8  'AL+W=O<FMS:&5E=',O<VAE970R-BYX
M;6Q02P$"% ,4    " #X?JI2R5+2. H$  #3"@  &0              @('U
M^@  >&PO=V]R:W-H965T<R]S:&5E=#(W+GAM;%!+ 0(4 Q0    ( /A^JE(3
MH0XPS ,  &((   9              " @3;_  !X;"]W;W)K<VAE971S+W-H
M965T,C@N>&UL4$L! A0#%     @ ^'ZJ4KT(U;A< P  :@<  !D
M     ("!.0,! 'AL+W=O<FMS:&5E=',O<VAE970R.2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( /A^JE*+TRT0FP0  #H*   9              "
M@5H3 0!X;"]W;W)K<VAE971S+W-H965T,S0N>&UL4$L! A0#%     @ ^'ZJ
M4K**@JJN P  H@L  !D              ("!+!@! 'AL+W=O<FMS:&5E=',O
M<VAE970S-2YX;6Q02P$"% ,4    " #X?JI2J*EZ8) "  "9!P  &0
M        @($1' $ >&PO=V]R:W-H965T<R]S:&5E=#,V+GAM;%!+ 0(4 Q0
M   ( /A^JE+H(9?,O (  "\(   9              " @=@> 0!X;"]W;W)K
M<VAE971S+W-H965T,S<N>&UL4$L! A0#%     @ ^'ZJ4C4=\,*> @  H08
M !D              ("!RR$! 'AL+W=O<FMS:&5E=',O<VAE970S."YX;6Q0
M2P$"% ,4    " #X?JI24[(7=C(%  !H%P  &0              @(&@) $
M>&PO=V]R:W-H965T<R]S:&5E=#,Y+GAM;%!+ 0(4 Q0    ( /A^JE)2T%N*
M.0<   PS   9              " @0DJ 0!X;"]W;W)K<VAE971S+W-H965T
M-# N>&UL4$L! A0#%     @ ^'ZJ4M>SM146 @  6 0  !D
M ("!>3$! 'AL+W=O<FMS:&5E=',O<VAE970T,2YX;6Q02P$"% ,4    " #X
M?JI2/T[^):T$   R%P  &0              @('&,P$ >&PO=V]R:W-H965T
M<R]S:&5E=#0R+GAM;%!+ 0(4 Q0    ( /A^JE*A>\;SS (  /X(   9
M          " @:HX 0!X;"]W;W)K<VAE971S+W-H965T-#,N>&UL4$L! A0#
M%     @ ^'ZJ4K&*-%HO"   KBT  !D              ("!K3L! 'AL+W=O
M<FMS:&5E=',O<VAE970T-"YX;6Q02P$"% ,4    " #X?JI2R;Z4#[X"  #0
M!@  &0              @($31 $ >&PO=V]R:W-H965T<R]S:&5E=#0U+GAM
M;%!+ 0(4 Q0    ( /A^JE)1"]XRM@(  #D(   9              " @0A'
M 0!X;"]W;W)K<VAE971S+W-H965T-#8N>&UL4$L! A0#%     @ ^'ZJ4N(C
MY^;P @  8PH  !D              ("!]4D! 'AL+W=O<FMS:&5E=',O<VAE
M970T-RYX;6Q02P$"% ,4    " #X?JI2IT:Z'^D%   P&P  &0
M    @($<30$ >&PO=V]R:W-H965T<R]S:&5E=#0X+GAM;%!+ 0(4 Q0    (
M /A^JE*SA,T(_ ,  ,@1   9              " @3Q3 0!X;"]W;W)K<VAE
M971S+W-H965T-#DN>&UL4$L! A0#%     @ ^'ZJ4L-+-'G5!0  =!X  !D
M             ("!;U<! 'AL+W=O<FMS:&5E=',O<VAE970U,"YX;6Q02P$"
M% ,4    " #X?JI2K#B.&[D$  "P$@  &0              @(%[70$ >&PO
M=V]R:W-H965T<R]S:&5E=#4Q+GAM;%!+ 0(4 Q0    ( /A^JE)?,9HH1P,
M "D+   9              " @6MB 0!X;"]W;W)K<VAE971S+W-H965T-3(N
M>&UL4$L! A0#%     @ ^'ZJ4H[#DIM= P  UPH  !D              ("!
MZ64! 'AL+W=O<FMS:&5E=',O<VAE970U,RYX;6Q02P$"% ,4    " #X?JI2
M6N^845,)  ! .@  &0              @(%]:0$ >&PO=V]R:W-H965T<R]S
M:&5E=#4T+GAM;%!+ 0(4 Q0    ( /A^JE( !:7>'P4  )X7   9
M      " @0=S 0!X;"]W;W)K<VAE971S+W-H965T-34N>&UL4$L! A0#%
M  @ ^'ZJ4H<2P!A* P  U0D  !D              ("!77@! 'AL+W=O<FMS
M:&5E=',O<VAE970U-BYX;6Q02P$"% ,4    " #X?JI2%@7_530#   L#
M&0              @('>>P$ >&PO=V]R:W-H965T<R]S:&5E=#4W+GAM;%!+
M 0(4 Q0    ( /A^JE(>B291N@(  #,(   9              " @4E_ 0!X
M;"]W;W)K<VAE971S+W-H965T-3@N>&UL4$L! A0#%     @ ^'ZJ4FTLM&0S
M P  "@L  !D              ("!.H(! 'AL+W=O<FMS:&5E=',O<VAE970U
M.2YX;6Q02P$"% ,4    " #X?JI2^'Z)*4\#  #L%   #0
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:+GAM;%!+!08     0P!# $P2   ^DP$    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.21.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>271</ContextCount>
  <ElementCount>395</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>80</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>7</UnitCount>
  <MyReports>
    <Report instance="ino-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="ino-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1001002 - Statement - Condensed Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/CondensedConsolidatedBalanceSheets</Role>
      <ShortName>Condensed Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="ino-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1002003 - Statement - Condensed Consolidated Statements of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/CondensedConsolidatedStatementsofOperations</Role>
      <ShortName>Condensed Consolidated Statements of Operations</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="ino-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1003004 - Statement - Condensed Consolidated Statements of Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/CondensedConsolidatedStatementsofComprehensiveLoss</Role>
      <ShortName>Condensed Consolidated Statements of Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="ino-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1004005 - Statement - Condensed Consolidated Statements of Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/CondensedConsolidatedStatementsofStockholdersEquity</Role>
      <ShortName>Condensed Consolidated Statements of Stockholders' Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="ino-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1005006 - Statement - Condensed Consolidated Statements of Stockholders' Equity (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/CondensedConsolidatedStatementsofStockholdersEquityParenthetical</Role>
      <ShortName>Condensed Consolidated Statements of Stockholders' Equity (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="ino-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>1006007 - Statement - Condensed Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows</Role>
      <ShortName>Condensed Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="ino-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>2101101 - Disclosure - Organization and Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/OrganizationandOperations</Role>
      <ShortName>Organization and Operations</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="ino-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>2102102 - Disclosure - Basis of Presentation, Liquidity and Risks and Uncertainties</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/BasisofPresentationLiquidityandRisksandUncertainties</Role>
      <ShortName>Basis of Presentation, Liquidity and Risks and Uncertainties</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="ino-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2105103 - Disclosure - Critical Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/CriticalAccountingPolicies</Role>
      <ShortName>Critical Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="ino-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2107104 - Disclosure - Impact of Recently Issued Accounting Standards</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/ImpactofRecentlyIssuedAccountingStandards</Role>
      <ShortName>Impact of Recently Issued Accounting Standards</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="ino-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2108105 - Disclosure - Revenue Recognition</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/RevenueRecognition</Role>
      <ShortName>Revenue Recognition</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="ino-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2110106 - Disclosure - Short-term Investments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/ShorttermInvestments</Role>
      <ShortName>Short-term Investments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="ino-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2114107 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/FairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="ino-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2118108 - Disclosure - Goodwill and Intangible Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/GoodwillandIntangibleAssets</Role>
      <ShortName>Goodwill and Intangible Assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="ino-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2122109 - Disclosure - Convertible Debt</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/ConvertibleDebt</Role>
      <ShortName>Convertible Debt</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="ino-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2127110 - Disclosure - Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/StockholdersEquity</Role>
      <ShortName>Stockholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="ino-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2131111 - Disclosure - Net Loss Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/NetLossPerShare</Role>
      <ShortName>Net Loss Per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="ino-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2134112 - Disclosure - Stock-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/StockBasedCompensation</Role>
      <ShortName>Stock-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="ino-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2137113 - Disclosure - Related Party Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/RelatedPartyTransactions</Role>
      <ShortName>Related Party Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="ino-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2139114 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/Leases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="ino-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2143115 - Disclosure - Collaborative Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/CollaborativeAgreements</Role>
      <ShortName>Collaborative Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="ino-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2145116 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="ino-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2146117 - Disclosure - Geneos Therapeutics, Inc.</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/GeneosTherapeuticsInc</Role>
      <ShortName>Geneos Therapeutics, Inc.</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="ino-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2203201 - Disclosure - Basis of Presentation, Liquidity and Risks and Uncertainties (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/BasisofPresentationLiquidityandRisksandUncertaintiesPolicies</Role>
      <ShortName>Basis of Presentation, Liquidity and Risks and Uncertainties (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.inovio.com/role/CriticalAccountingPolicies</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="ino-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2311301 - Disclosure - Short-term Investments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/ShorttermInvestmentsTables</Role>
      <ShortName>Short-term Investments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.inovio.com/role/ShorttermInvestments</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="ino-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2315302 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/FairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.inovio.com/role/FairValueMeasurements</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="ino-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2319303 - Disclosure - Goodwill and Intangible Assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/GoodwillandIntangibleAssetsTables</Role>
      <ShortName>Goodwill and Intangible Assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.inovio.com/role/GoodwillandIntangibleAssets</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="ino-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2323304 - Disclosure - Convertible Debt (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/ConvertibleDebtTables</Role>
      <ShortName>Convertible Debt (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.inovio.com/role/ConvertibleDebt</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="ino-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2328305 - Disclosure - Stockholders' Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/StockholdersEquityTables</Role>
      <ShortName>Stockholders' Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.inovio.com/role/StockholdersEquity</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="ino-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2332306 - Disclosure - Net Loss Per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/NetLossPerShareTables</Role>
      <ShortName>Net Loss Per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.inovio.com/role/NetLossPerShare</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="ino-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2335307 - Disclosure - Stock-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/StockBasedCompensationTables</Role>
      <ShortName>Stock-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.inovio.com/role/StockBasedCompensation</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="ino-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2340308 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/LeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.inovio.com/role/Leases</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="ino-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>2347309 - Disclosure - Geneos Therapeutics, Inc. (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/GeneosTherapeuticsIncTables</Role>
      <ShortName>Geneos Therapeutics, Inc. (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.inovio.com/role/GeneosTherapeuticsInc</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="ino-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>2404401 - Disclosure - Basis of Presentation, Liquidity and Risks and Uncertainties (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/BasisofPresentationLiquidityandRisksandUncertaintiesDetails</Role>
      <ShortName>Basis of Presentation, Liquidity and Risks and Uncertainties (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.inovio.com/role/BasisofPresentationLiquidityandRisksandUncertaintiesPolicies</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="ino-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>2406402 - Disclosure - Critical Accounting Policies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/CriticalAccountingPoliciesDetails</Role>
      <ShortName>Critical Accounting Policies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="ino-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>2409403 - Disclosure - Revenue Recognition (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/RevenueRecognitionDetails</Role>
      <ShortName>Revenue Recognition (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.inovio.com/role/RevenueRecognition</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="ino-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>2412404 - Disclosure - Short-term Investments - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/ShorttermInvestmentsNarrativeDetails</Role>
      <ShortName>Short-term Investments - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="ino-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>2413405 - Disclosure - Short-term Investments - Summary of Available-for-sale Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/ShorttermInvestmentsSummaryofAvailableforsaleSecuritiesDetails</Role>
      <ShortName>Short-term Investments - Summary of Available-for-sale Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="ino-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>2416406 - Disclosure - Fair Value Measurements - Assets and Liabilities Measured at Fair Value (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueDetails</Role>
      <ShortName>Fair Value Measurements - Assets and Liabilities Measured at Fair Value (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="ino-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>2417407 - Disclosure - Fair Value Measurements - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/FairValueMeasurementsNarrativeDetails</Role>
      <ShortName>Fair Value Measurements - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="ino-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>2420408 - Disclosure - Goodwill and Intangible Assets - Schedule Goodwill and Intangible Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/GoodwillandIntangibleAssetsScheduleGoodwillandIntangibleAssetsDetails</Role>
      <ShortName>Goodwill and Intangible Assets - Schedule Goodwill and Intangible Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="ino-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>2421409 - Disclosure - Goodwill and Intangible Assets - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/GoodwillandIntangibleAssetsNarrativeDetails</Role>
      <ShortName>Goodwill and Intangible Assets - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="ino-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>2424410 - Disclosure - Convertible Debt - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/ConvertibleDebtNarrativeDetails</Role>
      <ShortName>Convertible Debt - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="ino-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>2425411 - Disclosure - Convertible Debt - Balance of Convertible Bonds and Notes (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.inovio.com/role/ConvertibleDebtBalanceofConvertibleBondsandNotesDetails</Role>
      <ShortName>Convertible Debt - Balance of Convertible Bonds and Notes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="ino-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>2426412 - Disclosure - Convertible Debt - Schedule of Maturities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/ConvertibleDebtScheduleofMaturitiesDetails</Role>
      <ShortName>Convertible Debt - Schedule of Maturities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="ino-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>2429413 - Disclosure - Stockholders' Equity - Summary of Authorized and Issued Common and Preferred Stock (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/StockholdersEquitySummaryofAuthorizedandIssuedCommonandPreferredStockDetails</Role>
      <ShortName>Stockholders' Equity - Summary of Authorized and Issued Common and Preferred Stock (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="ino-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>2430414 - Disclosure - Stockholders' Equity - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/StockholdersEquityNarrativeDetails</Role>
      <ShortName>Stockholders' Equity - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="ino-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>2433415 - Disclosure - Net Loss Per Share - Schedule of Anti-Dilutive Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/NetLossPerShareScheduleofAntiDilutiveSecuritiesDetails</Role>
      <ShortName>Net Loss Per Share - Schedule of Anti-Dilutive Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="ino-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>2436416 - Disclosure - Stock-Based Compensation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/StockBasedCompensationDetails</Role>
      <ShortName>Stock-Based Compensation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.inovio.com/role/StockBasedCompensationTables</ParentRole>
      <Position>50</Position>
    </Report>
    <Report instance="ino-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>2438417 - Disclosure - Related Party Transactions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/RelatedPartyTransactionsDetails</Role>
      <ShortName>Related Party Transactions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.inovio.com/role/RelatedPartyTransactions</ParentRole>
      <Position>51</Position>
    </Report>
    <Report instance="ino-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>2441418 - Disclosure - Leases - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/LeasesNarrativeDetails</Role>
      <ShortName>Leases - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="ino-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>2442419 - Disclosure - Leases - Summary of Future Minimum Lease Payments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/LeasesSummaryofFutureMinimumLeasePaymentsDetails</Role>
      <ShortName>Leases - Summary of Future Minimum Lease Payments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="ino-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>2444420 - Disclosure - Collaborative Agreements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/CollaborativeAgreementsDetails</Role>
      <ShortName>Collaborative Agreements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.inovio.com/role/CollaborativeAgreements</ParentRole>
      <Position>54</Position>
    </Report>
    <Report instance="ino-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>2448421 - Disclosure - Geneos Therapeutics, Inc. - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/GeneosTherapeuticsIncNarrativeDetails</Role>
      <ShortName>Geneos Therapeutics, Inc. - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="ino-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>2449422 - Disclosure - Geneos Therapeutics, Inc. - Deconsolidation Accounting (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/GeneosTherapeuticsIncDeconsolidationAccountingDetails</Role>
      <ShortName>Geneos Therapeutics, Inc. - Deconsolidation Accounting (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="ino-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>2450423 - Disclosure - Geneos Therapeutics, Inc. - Investment In Geneos (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/GeneosTherapeuticsIncInvestmentInGeneosDetails</Role>
      <ShortName>Geneos Therapeutics, Inc. - Investment In Geneos (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="ino-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>2451424 - Disclosure - Geneos Therapeutics, Inc. - Fair Value Assumptions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/GeneosTherapeuticsIncFairValueAssumptionsDetails</Role>
      <ShortName>Geneos Therapeutics, Inc. - Fair Value Assumptions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="ino-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>2452425 - Disclosure - Geneos Therapeutics, Inc. - Preferred stock Investment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/GeneosTherapeuticsIncPreferredstockInvestmentDetails</Role>
      <ShortName>Geneos Therapeutics, Inc. - Preferred stock Investment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" original="ino-20210331.htm">ino-20210331.htm</File>
    <File>ino-20210331.xsd</File>
    <File>ino-20210331_cal.xml</File>
    <File>ino-20210331_def.xml</File>
    <File>ino-20210331_lab.xml</File>
    <File>ino-20210331_pre.xml</File>
    <File>ino-33121x10qex311.htm</File>
    <File>ino-33121x10qex312.htm</File>
    <File>ino-33121x10qex321.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>ino-20210331_g1.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy>http://fasb.org/srt/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/us-gaap/2020-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>77
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "ino-20210331.htm": {
   "axisCustom": 0,
   "axisStandard": 28,
   "contextCount": 271,
   "dts": {
    "calculationLink": {
     "local": [
      "ino-20210331_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "ino-20210331_def.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-eedm-def-2020-01-31.xml",
      "http://xbrl.fasb.org/srt/2020/elts/srt-eedm1-def-2020-01-31.xml"
     ]
    },
    "inline": {
     "local": [
      "ino-20210331.htm"
     ]
    },
    "labelLink": {
     "local": [
      "ino-20210331_lab.xml"
     ],
     "remote": [
      "https://xbrl.sec.gov/dei/2020/dei-doc-2020-01-31.xml",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-doc-2020-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "ino-20210331_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-ref-2020-01-31.xml",
      "https://xbrl.sec.gov/dei/2020/dei-ref-2020-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "ino-20210331.xsd"
     ],
     "remote": [
      "http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd",
      "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd",
      "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-parts-codification-2020-01-31.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd"
     ]
    }
   },
   "elementCount": 537,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2020-01-31": 5,
    "http://xbrl.sec.gov/dei/2020-01-31": 5,
    "total": 10
   },
   "keyCustom": 63,
   "keyStandard": 332,
   "memberCustom": 36,
   "memberStandard": 38,
   "nsprefix": "ino",
   "nsuri": "http://www.inovio.com/20210331",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20210331.htm",
      "contextRef": "i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001001 - Document - Cover Page",
     "role": "http://www.inovio.com/role/CoverPage",
     "shortName": "Cover Page",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20210331.htm",
      "contextRef": "i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20210331.htm",
      "contextRef": "i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2105103 - Disclosure - Critical Accounting Policies",
     "role": "http://www.inovio.com/role/CriticalAccountingPolicies",
     "shortName": "Critical Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20210331.htm",
      "contextRef": "i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20210331.htm",
      "contextRef": "i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2107104 - Disclosure - Impact of Recently Issued Accounting Standards",
     "role": "http://www.inovio.com/role/ImpactofRecentlyIssuedAccountingStandards",
     "shortName": "Impact of Recently Issued Accounting Standards",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20210331.htm",
      "contextRef": "i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20210331.htm",
      "contextRef": "i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2108105 - Disclosure - Revenue Recognition",
     "role": "http://www.inovio.com/role/RevenueRecognition",
     "shortName": "Revenue Recognition",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20210331.htm",
      "contextRef": "i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20210331.htm",
      "contextRef": "i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2110106 - Disclosure - Short-term Investments",
     "role": "http://www.inovio.com/role/ShorttermInvestments",
     "shortName": "Short-term Investments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20210331.htm",
      "contextRef": "i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20210331.htm",
      "contextRef": "i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2114107 - Disclosure - Fair Value Measurements",
     "role": "http://www.inovio.com/role/FairValueMeasurements",
     "shortName": "Fair Value Measurements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20210331.htm",
      "contextRef": "i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20210331.htm",
      "contextRef": "i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2118108 - Disclosure - Goodwill and Intangible Assets",
     "role": "http://www.inovio.com/role/GoodwillandIntangibleAssets",
     "shortName": "Goodwill and Intangible Assets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20210331.htm",
      "contextRef": "i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20210331.htm",
      "contextRef": "i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2122109 - Disclosure - Convertible Debt",
     "role": "http://www.inovio.com/role/ConvertibleDebt",
     "shortName": "Convertible Debt",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20210331.htm",
      "contextRef": "i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20210331.htm",
      "contextRef": "i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2127110 - Disclosure - Stockholders' Equity",
     "role": "http://www.inovio.com/role/StockholdersEquity",
     "shortName": "Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20210331.htm",
      "contextRef": "i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20210331.htm",
      "contextRef": "i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2131111 - Disclosure - Net Loss Per Share",
     "role": "http://www.inovio.com/role/NetLossPerShare",
     "shortName": "Net Loss Per Share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20210331.htm",
      "contextRef": "i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20210331.htm",
      "contextRef": "i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2134112 - Disclosure - Stock-Based Compensation",
     "role": "http://www.inovio.com/role/StockBasedCompensation",
     "shortName": "Stock-Based Compensation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20210331.htm",
      "contextRef": "i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20210331.htm",
      "contextRef": "ic36b9cedad7f41a6b9eb223b09b7186c_I20210331",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1001002 - Statement - Condensed Consolidated Balance Sheets",
     "role": "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets",
     "shortName": "Condensed Consolidated Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20210331.htm",
      "contextRef": "ic36b9cedad7f41a6b9eb223b09b7186c_I20210331",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20210331.htm",
      "contextRef": "i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2137113 - Disclosure - Related Party Transactions",
     "role": "http://www.inovio.com/role/RelatedPartyTransactions",
     "shortName": "Related Party Transactions",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20210331.htm",
      "contextRef": "i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20210331.htm",
      "contextRef": "i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2139114 - Disclosure - Leases",
     "role": "http://www.inovio.com/role/Leases",
     "shortName": "Leases",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20210331.htm",
      "contextRef": "i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20210331.htm",
      "contextRef": "i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2143115 - Disclosure - Collaborative Agreements",
     "role": "http://www.inovio.com/role/CollaborativeAgreements",
     "shortName": "Collaborative Agreements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20210331.htm",
      "contextRef": "i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20210331.htm",
      "contextRef": "i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2145116 - Disclosure - Income Taxes",
     "role": "http://www.inovio.com/role/IncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20210331.htm",
      "contextRef": "i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20210331.htm",
      "contextRef": "i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2146117 - Disclosure - Geneos Therapeutics, Inc.",
     "role": "http://www.inovio.com/role/GeneosTherapeuticsInc",
     "shortName": "Geneos Therapeutics, Inc.",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20210331.htm",
      "contextRef": "i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20210331.htm",
      "contextRef": "i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2203201 - Disclosure - Basis of Presentation, Liquidity and Risks and Uncertainties (Policies)",
     "role": "http://www.inovio.com/role/BasisofPresentationLiquidityandRisksandUncertaintiesPolicies",
     "shortName": "Basis of Presentation, Liquidity and Risks and Uncertainties (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20210331.htm",
      "contextRef": "i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20210331.htm",
      "contextRef": "i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2311301 - Disclosure - Short-term Investments (Tables)",
     "role": "http://www.inovio.com/role/ShorttermInvestmentsTables",
     "shortName": "Short-term Investments (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20210331.htm",
      "contextRef": "i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20210331.htm",
      "contextRef": "i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2315302 - Disclosure - Fair Value Measurements (Tables)",
     "role": "http://www.inovio.com/role/FairValueMeasurementsTables",
     "shortName": "Fair Value Measurements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20210331.htm",
      "contextRef": "i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20210331.htm",
      "contextRef": "i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2319303 - Disclosure - Goodwill and Intangible Assets (Tables)",
     "role": "http://www.inovio.com/role/GoodwillandIntangibleAssetsTables",
     "shortName": "Goodwill and Intangible Assets (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20210331.htm",
      "contextRef": "i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20210331.htm",
      "contextRef": "i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConvertibleDebtTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2323304 - Disclosure - Convertible Debt (Tables)",
     "role": "http://www.inovio.com/role/ConvertibleDebtTables",
     "shortName": "Convertible Debt (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20210331.htm",
      "contextRef": "i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConvertibleDebtTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20210331.htm",
      "contextRef": "i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1002003 - Statement - Condensed Consolidated Statements of Operations",
     "role": "http://www.inovio.com/role/CondensedConsolidatedStatementsofOperations",
     "shortName": "Condensed Consolidated Statements of Operations",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20210331.htm",
      "contextRef": "i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331",
      "decimals": "0",
      "lang": "en-US",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20210331.htm",
      "contextRef": "i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfStockByClassTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2328305 - Disclosure - Stockholders' Equity (Tables)",
     "role": "http://www.inovio.com/role/StockholdersEquityTables",
     "shortName": "Stockholders' Equity (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20210331.htm",
      "contextRef": "i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfStockByClassTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20210331.htm",
      "contextRef": "i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2332306 - Disclosure - Net Loss Per Share (Tables)",
     "role": "http://www.inovio.com/role/NetLossPerShareTables",
     "shortName": "Net Loss Per Share (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20210331.htm",
      "contextRef": "i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20210331.htm",
      "contextRef": "i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2335307 - Disclosure - Stock-Based Compensation (Tables)",
     "role": "http://www.inovio.com/role/StockBasedCompensationTables",
     "shortName": "Stock-Based Compensation (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20210331.htm",
      "contextRef": "i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20210331.htm",
      "contextRef": "i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2340308 - Disclosure - Leases (Tables)",
     "role": "http://www.inovio.com/role/LeasesTables",
     "shortName": "Leases (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20210331.htm",
      "contextRef": "i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20210331.htm",
      "contextRef": "i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EquityMethodInvestmentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2347309 - Disclosure - Geneos Therapeutics, Inc. (Tables)",
     "role": "http://www.inovio.com/role/GeneosTherapeuticsIncTables",
     "shortName": "Geneos Therapeutics, Inc. (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20210331.htm",
      "contextRef": "i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EquityMethodInvestmentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20210331.htm",
      "contextRef": "i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2404401 - Disclosure - Basis of Presentation, Liquidity and Risks and Uncertainties (Details)",
     "role": "http://www.inovio.com/role/BasisofPresentationLiquidityandRisksandUncertaintiesDetails",
     "shortName": "Basis of Presentation, Liquidity and Risks and Uncertainties (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20210331.htm",
      "contextRef": "ic36b9cedad7f41a6b9eb223b09b7186c_I20210331",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:Capital",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20210331.htm",
      "contextRef": "ic36b9cedad7f41a6b9eb223b09b7186c_I20210331",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IntangibleAssetsNetExcludingGoodwill",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2406402 - Disclosure - Critical Accounting Policies (Details)",
     "role": "http://www.inovio.com/role/CriticalAccountingPoliciesDetails",
     "shortName": "Critical Accounting Policies (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20210331.htm",
      "contextRef": "i2f37abb9631043cc818c2a98efb857df_D20210101-20210331",
      "decimals": null,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetUsefulLife",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20210331.htm",
      "contextRef": "i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2409403 - Disclosure - Revenue Recognition (Details)",
     "role": "http://www.inovio.com/role/RevenueRecognitionDetails",
     "shortName": "Revenue Recognition (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20210331.htm",
      "contextRef": "i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:ContractWithCustomerLiabilityRevenueRecognized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20210331.htm",
      "contextRef": "i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleRealizedGain",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2412404 - Disclosure - Short-term Investments - Narrative (Details)",
     "role": "http://www.inovio.com/role/ShorttermInvestmentsNarrativeDetails",
     "shortName": "Short-term Investments - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20210331.htm",
      "contextRef": "i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleRealizedGain",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20210331.htm",
      "contextRef": "ic36b9cedad7f41a6b9eb223b09b7186c_I20210331",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2413405 - Disclosure - Short-term Investments - Summary of Available-for-sale Securities (Details)",
     "role": "http://www.inovio.com/role/ShorttermInvestmentsSummaryofAvailableforsaleSecuritiesDetails",
     "shortName": "Short-term Investments - Summary of Available-for-sale Securities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20210331.htm",
      "contextRef": "ic36b9cedad7f41a6b9eb223b09b7186c_I20210331",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20210331.htm",
      "contextRef": "i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003004 - Statement - Condensed Consolidated Statements of Comprehensive Loss",
     "role": "http://www.inovio.com/role/CondensedConsolidatedStatementsofComprehensiveLoss",
     "shortName": "Condensed Consolidated Statements of Comprehensive Loss",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20210331.htm",
      "contextRef": "i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331",
      "decimals": "0",
      "lang": "en-US",
      "name": "us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20210331.htm",
      "contextRef": "ic36b9cedad7f41a6b9eb223b09b7186c_I20210331",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2416406 - Disclosure - Fair Value Measurements - Assets and Liabilities Measured at Fair Value (Details)",
     "role": "http://www.inovio.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueDetails",
     "shortName": "Fair Value Measurements - Assets and Liabilities Measured at Fair Value (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20210331.htm",
      "contextRef": "idc037a18dec8422896679a520fe0751f_I20210331",
      "decimals": "0",
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20210331.htm",
      "contextRef": "i0cce4e82b88342c787d49f1a7ed20009_I20210331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentOwnedBalanceShares",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2417407 - Disclosure - Fair Value Measurements - Narrative (Details)",
     "role": "http://www.inovio.com/role/FairValueMeasurementsNarrativeDetails",
     "shortName": "Fair Value Measurements - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20210331.htm",
      "contextRef": "i0cce4e82b88342c787d49f1a7ed20009_I20210331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentOwnedBalanceShares",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20210331.htm",
      "contextRef": "ic36b9cedad7f41a6b9eb223b09b7186c_I20210331",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2420408 - Disclosure - Goodwill and Intangible Assets - Schedule Goodwill and Intangible Assets (Details)",
     "role": "http://www.inovio.com/role/GoodwillandIntangibleAssetsScheduleGoodwillandIntangibleAssetsDetails",
     "shortName": "Goodwill and Intangible Assets - Schedule Goodwill and Intangible Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20210331.htm",
      "contextRef": "ic36b9cedad7f41a6b9eb223b09b7186c_I20210331",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20210331.htm",
      "contextRef": "i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AmortizationOfIntangibleAssets",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2421409 - Disclosure - Goodwill and Intangible Assets - Narrative (Details)",
     "role": "http://www.inovio.com/role/GoodwillandIntangibleAssetsNarrativeDetails",
     "shortName": "Goodwill and Intangible Assets - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20210331.htm",
      "contextRef": "ic36b9cedad7f41a6b9eb223b09b7186c_I20210331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20210331.htm",
      "contextRef": "i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InterestExpense",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2424410 - Disclosure - Convertible Debt - Narrative (Details)",
     "role": "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails",
     "shortName": "Convertible Debt - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20210331.htm",
      "contextRef": "ic05ddd45fe7a4ed3a38c628d55f5113b_D20200101-20201231",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:DebtConversionConvertedInstrumentSharesIssued1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ConvertibleDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20210331.htm",
      "contextRef": "ibf1dda891fd044098c213cc6a530fa62_I20210331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentFaceAmount",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2425411 - Disclosure - Convertible Debt - Balance of Convertible Bonds and Notes (Details)",
     "role": "http://www.inovio.com/role/ConvertibleDebtBalanceofConvertibleBondsandNotesDetails",
     "shortName": "Convertible Debt - Balance of Convertible Bonds and Notes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ConvertibleDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20210331.htm",
      "contextRef": "ibf1dda891fd044098c213cc6a530fa62_I20210331",
      "decimals": "0",
      "lang": "en-US",
      "name": "ino:DebtInstrumentConvertibleDebtConvertedAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ConvertibleDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20210331.htm",
      "contextRef": "ibf1dda891fd044098c213cc6a530fa62_I20210331",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebt",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2426412 - Disclosure - Convertible Debt - Schedule of Maturities (Details)",
     "role": "http://www.inovio.com/role/ConvertibleDebtScheduleofMaturitiesDetails",
     "shortName": "Convertible Debt - Schedule of Maturities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20210331.htm",
      "contextRef": "i334e05b1c2d349408f504085686e16e6_I20210331",
      "decimals": "0",
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfStockByClassTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20210331.htm",
      "contextRef": "ic36b9cedad7f41a6b9eb223b09b7186c_I20210331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2429413 - Disclosure - Stockholders' Equity - Summary of Authorized and Issued Common and Preferred Stock (Details)",
     "role": "http://www.inovio.com/role/StockholdersEquitySummaryofAuthorizedandIssuedCommonandPreferredStockDetails",
     "shortName": "Stockholders' Equity - Summary of Authorized and Issued Common and Preferred Stock (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfStockByClassTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20210331.htm",
      "contextRef": "ic36b9cedad7f41a6b9eb223b09b7186c_I20210331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20210331.htm",
      "contextRef": "i1105e820c10e4516b0891db1691036b2_D20210125-20210125",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2430414 - Disclosure - Stockholders' Equity - Narrative (Details)",
     "role": "http://www.inovio.com/role/StockholdersEquityNarrativeDetails",
     "shortName": "Stockholders' Equity - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20210331.htm",
      "contextRef": "i1105e820c10e4516b0891db1691036b2_D20210125-20210125",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20210331.htm",
      "contextRef": "i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2433415 - Disclosure - Net Loss Per Share - Schedule of Anti-Dilutive Securities (Details)",
     "role": "http://www.inovio.com/role/NetLossPerShareScheduleofAntiDilutiveSecuritiesDetails",
     "shortName": "Net Loss Per Share - Schedule of Anti-Dilutive Securities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20210331.htm",
      "contextRef": "i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20210331.htm",
      "contextRef": "id632c5e641ae4912873249f66ba9b746_I20191231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharesIssued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1004005 - Statement - Condensed Consolidated Statements of Stockholders' Equity",
     "role": "http://www.inovio.com/role/CondensedConsolidatedStatementsofStockholdersEquity",
     "shortName": "Condensed Consolidated Statements of Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20210331.htm",
      "contextRef": "id632c5e641ae4912873249f66ba9b746_I20191231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharesIssued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20210331.htm",
      "contextRef": "i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensation",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2436416 - Disclosure - Stock-Based Compensation (Details)",
     "role": "http://www.inovio.com/role/StockBasedCompensationDetails",
     "shortName": "Stock-Based Compensation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20210331.htm",
      "contextRef": "ic36b9cedad7f41a6b9eb223b09b7186c_I20210331",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20210331.htm",
      "contextRef": "i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2438417 - Disclosure - Related Party Transactions (Details)",
     "role": "http://www.inovio.com/role/RelatedPartyTransactionsDetails",
     "shortName": "Related Party Transactions (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20210331.htm",
      "contextRef": "iab8d55f8b4464cb1af38f6596cf6b33d_I20210331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:AccountsReceivableRelatedParties",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20210331.htm",
      "contextRef": "i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2441418 - Disclosure - Leases - Narrative (Details)",
     "role": "http://www.inovio.com/role/LeasesNarrativeDetails",
     "shortName": "Leases - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20210331.htm",
      "contextRef": "i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20210331.htm",
      "contextRef": "ic36b9cedad7f41a6b9eb223b09b7186c_I20210331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2442419 - Disclosure - Leases - Summary of Future Minimum Lease Payments (Details)",
     "role": "http://www.inovio.com/role/LeasesSummaryofFutureMinimumLeasePaymentsDetails",
     "shortName": "Leases - Summary of Future Minimum Lease Payments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20210331.htm",
      "contextRef": "ic36b9cedad7f41a6b9eb223b09b7186c_I20210331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20210331.htm",
      "contextRef": "i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2444420 - Disclosure - Collaborative Agreements (Details)",
     "role": "http://www.inovio.com/role/CollaborativeAgreementsDetails",
     "shortName": "Collaborative Agreements (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20210331.htm",
      "contextRef": "i9e2527d562564d0da42bfadc4214aabf_I20210331",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:AccountsReceivableNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20210331.htm",
      "contextRef": "i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeLossFromEquityMethodInvestments",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2448421 - Disclosure - Geneos Therapeutics, Inc. - Narrative (Details)",
     "role": "http://www.inovio.com/role/GeneosTherapeuticsIncNarrativeDetails",
     "shortName": "Geneos Therapeutics, Inc. - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20210331.htm",
      "contextRef": "i5f89255103014c46a5a9ab71646dba92_I20200601",
      "decimals": "0",
      "lang": "en-US",
      "name": "us-gaap:EquityMethodInvestments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20210331.htm",
      "contextRef": "ic36b9cedad7f41a6b9eb223b09b7186c_I20210331",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentNet",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2449422 - Disclosure - Geneos Therapeutics, Inc. - Deconsolidation Accounting (Details)",
     "role": "http://www.inovio.com/role/GeneosTherapeuticsIncDeconsolidationAccountingDetails",
     "shortName": "Geneos Therapeutics, Inc. - Deconsolidation Accounting (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20210331.htm",
      "contextRef": "i11b75bcb273c48128928387d5ceda2d2_I20200601",
      "decimals": "0",
      "lang": "en-US",
      "name": "ino:WorkingCapitalExcludingCash",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20210331.htm",
      "contextRef": "ic36b9cedad7f41a6b9eb223b09b7186c_I20210331",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EquityMethodInvestments",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2450423 - Disclosure - Geneos Therapeutics, Inc. - Investment In Geneos (Details)",
     "role": "http://www.inovio.com/role/GeneosTherapeuticsIncInvestmentInGeneosDetails",
     "shortName": "Geneos Therapeutics, Inc. - Investment In Geneos (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20210331.htm",
      "contextRef": "i11b75bcb273c48128928387d5ceda2d2_I20200601",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:InvestmentOwnedBalanceShares",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20210331.htm",
      "contextRef": "i11b75bcb273c48128928387d5ceda2d2_I20200601",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "ino:EquityMethodInvestmentEnterpriseValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2451424 - Disclosure - Geneos Therapeutics, Inc. - Fair Value Assumptions (Details)",
     "role": "http://www.inovio.com/role/GeneosTherapeuticsIncFairValueAssumptionsDetails",
     "shortName": "Geneos Therapeutics, Inc. - Fair Value Assumptions (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20210331.htm",
      "contextRef": "i11b75bcb273c48128928387d5ceda2d2_I20200601",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "ino:EquityMethodInvestmentEnterpriseValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20210331.htm",
      "contextRef": "i066bb5b0a9e84c0a878b1e800703d92b_I20201231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EquityMethodInvestments",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2452425 - Disclosure - Geneos Therapeutics, Inc. - Preferred stock Investment (Details)",
     "role": "http://www.inovio.com/role/GeneosTherapeuticsIncPreferredstockInvestmentDetails",
     "shortName": "Geneos Therapeutics, Inc. - Preferred stock Investment (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20210331.htm",
      "contextRef": "i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PaymentsOfStockIssuanceCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1005006 - Statement - Condensed Consolidated Statements of Stockholders' Equity (Parenthetical)",
     "role": "http://www.inovio.com/role/CondensedConsolidatedStatementsofStockholdersEquityParenthetical",
     "shortName": "Condensed Consolidated Statements of Stockholders' Equity (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20210331.htm",
      "contextRef": "i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PaymentsOfStockIssuanceCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20210331.htm",
      "contextRef": "i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1006007 - Statement - Condensed Consolidated Statements of Cash Flows",
     "role": "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows",
     "shortName": "Condensed Consolidated Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20210331.htm",
      "contextRef": "i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331",
      "decimals": "0",
      "lang": "en-US",
      "name": "us-gaap:Depreciation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20210331.htm",
      "contextRef": "i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NatureOfOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2101101 - Disclosure - Organization and Operations",
     "role": "http://www.inovio.com/role/OrganizationandOperations",
     "shortName": "Organization and Operations",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20210331.htm",
      "contextRef": "i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NatureOfOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20210331.htm",
      "contextRef": "i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2102102 - Disclosure - Basis of Presentation, Liquidity and Risks and Uncertainties",
     "role": "http://www.inovio.com/role/BasisofPresentationLiquidityandRisksandUncertainties",
     "shortName": "Basis of Presentation, Liquidity and Risks and Uncertainties",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20210331.htm",
      "contextRef": "i7dcba16c07f54950ac2ac843a581025a_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 80,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CoverPage"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CoverPage"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CoverPage"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CoverPage"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r566"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report",
        "terseLabel": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r567"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CoverPage"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CoverPage"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r568"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CoverPage"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CoverPage"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r568"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CoverPage"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r568"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CoverPage"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CoverPage"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r569"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r568"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r568"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r568"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r568"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CoverPage"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r564"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CoverPage"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r565"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CoverPage"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CoverPage"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "ino_A2007IncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2007 Incentive Plan [Member]",
        "label": "2007 Incentive Plan [Member]",
        "terseLabel": "2007 Incentive Plan"
       }
      }
     },
     "localname": "A2007IncentivePlanMember",
     "nsuri": "http://www.inovio.com/20210331",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_A2016IncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2016 Incentive Plan [Member]",
        "label": "2016 Incentive Plan [Member]",
        "terseLabel": "2016 Incentive Plan"
       }
      }
     },
     "localname": "A2016IncentivePlanMember",
     "nsuri": "http://www.inovio.com/20210331",
     "presentation": [
      "http://www.inovio.com/role/StockBasedCompensationDetails",
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_A6.50ConvertibleSeniorNotesDue2024Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "6.50% Convertible Senior Notes Due 2024 [Member]",
        "label": "6.50% Convertible Senior Notes Due 2024 [Member]",
        "terseLabel": "6.50% Convertible Senior Notes Due 2024"
       }
      }
     },
     "localname": "A6.50ConvertibleSeniorNotesDue2024Member",
     "nsuri": "http://www.inovio.com/20210331",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.inovio.com/role/ConvertibleDebtBalanceofConvertibleBondsandNotesDetails",
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails",
      "http://www.inovio.com/role/ConvertibleDebtScheduleofMaturitiesDetails",
      "http://www.inovio.com/role/NetLossPerShareScheduleofAntiDilutiveSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_AccruedClinicalTrialExpenseCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued Clinical Trial Expense, Current",
        "label": "Accrued Clinical Trial Expense, Current",
        "verboseLabel": "Accrued clinical trial expenses"
       }
      }
     },
     "localname": "AccruedClinicalTrialExpenseCurrent",
     "nsuri": "http://www.inovio.com/20210331",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_AdvaccineMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Advaccine",
        "label": "Advaccine [Member]",
        "terseLabel": "Advaccine"
       }
      }
     },
     "localname": "AdvaccineMember",
     "nsuri": "http://www.inovio.com/20210331",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_AlternativeInvestmentMeasurementInputTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Alternative Investment, Measurement Input, Term",
        "label": "Alternative Investment, Measurement Input, Term",
        "terseLabel": "Equity method investment, measurement input, expected term"
       }
      }
     },
     "localname": "AlternativeInvestmentMeasurementInputTerm",
     "nsuri": "http://www.inovio.com/20210331",
     "presentation": [
      "http://www.inovio.com/role/GeneosTherapeuticsIncFairValueAssumptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ino_AmortizationOfOperatingLeaseRightOfUseAssets": {
     "auth_ref": [],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortization Of Operating Lease Right-Of-Use Assets",
        "label": "Amortization Of Operating Lease Right-Of-Use Assets",
        "terseLabel": "Amortization Of Operating Lease Right-Of-Use Assets"
       }
      }
     },
     "localname": "AmortizationOfOperatingLeaseRightOfUseAssets",
     "nsuri": "http://www.inovio.com/20210331",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_ApolloBioMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ApolloBio [Member]",
        "label": "ApolloBio [Member]",
        "terseLabel": "ApolloBio"
       }
      }
     },
     "localname": "ApolloBioMember",
     "nsuri": "http://www.inovio.com/20210331",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_AstraZenecaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "AstraZeneca [Member]",
        "label": "AstraZeneca [Member]",
        "terseLabel": "AstraZeneca"
       }
      }
     },
     "localname": "AstraZenecaMember",
     "nsuri": "http://www.inovio.com/20210331",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_August2019ConvertibleBondsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "August 2019 Convertible Bonds [Member]",
        "label": "August 2019 Convertible Bonds [Member]",
        "terseLabel": "August 2019 Bonds"
       }
      }
     },
     "localname": "August2019ConvertibleBondsMember",
     "nsuri": "http://www.inovio.com/20210331",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails",
      "http://www.inovio.com/role/NetLossPerShareScheduleofAntiDilutiveSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_BillAndMelindaGatesFoundationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Bill And Melinda Gates Foundation [Member]",
        "label": "Bill And Melinda Gates Foundation [Member]",
        "terseLabel": "Bill and Melinda Gates Foundation"
       }
      }
     },
     "localname": "BillAndMelindaGatesFoundationMember",
     "nsuri": "http://www.inovio.com/20210331",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_BiojectMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Bioject [Member]",
        "label": "Bioject [Member]",
        "terseLabel": "Bioject"
       }
      }
     },
     "localname": "BiojectMember",
     "nsuri": "http://www.inovio.com/20210331",
     "presentation": [
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsScheduleGoodwillandIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_CELLECTRA2000DeviceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "CELLECTRA 2000 Device [Member]",
        "label": "CELLECTRA 2000 Device [Member]",
        "terseLabel": "CELLECTRA 2000 Device"
       }
      }
     },
     "localname": "CELLECTRA2000DeviceMember",
     "nsuri": "http://www.inovio.com/20210331",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_CELLECTRA3PSPProprietarySmartDeviceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "CELLECTRA 3PSP Proprietary Smart Device [Member]",
        "label": "CELLECTRA 3PSP Proprietary Smart Device [Member]",
        "terseLabel": "CELLECTRA 3PSP Proprietary Smart Device"
       }
      }
     },
     "localname": "CELLECTRA3PSPProprietarySmartDeviceMember",
     "nsuri": "http://www.inovio.com/20210331",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_ChangeInValueOfInvestmentsInAffiliatedCompany": {
     "auth_ref": [],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      },
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 5.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of the change in fair value of the investment in affiliated entity. This investment is measured at fair value on a recurring basis.",
        "label": "Change in Value of Investments in Affiliated Company",
        "negatedLabel": "(Gain) loss on equity investment in affiliated entities",
        "verboseLabel": "Gain (loss) on investment in affiliated entities"
       }
      }
     },
     "localname": "ChangeInValueOfInvestmentsInAffiliatedCompany",
     "nsuri": "http://www.inovio.com/20210331",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows",
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_CoalitionforEpidemicPreparednessInnovationsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Coalition for Epidemic Preparedness Innovations [Member]",
        "label": "Coalition for Epidemic Preparedness Innovations [Member]",
        "terseLabel": "Coalition for Epidemic Preparedness Innovations"
       }
      }
     },
     "localname": "CoalitionforEpidemicPreparednessInnovationsMember",
     "nsuri": "http://www.inovio.com/20210331",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_CollaborationAgreementAdditionalRevenueToBeAchieved": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration Agreement, Additional Revenue To Be Achieved",
        "label": "Collaboration Agreement, Additional Revenue To Be Achieved",
        "terseLabel": "Additional revenue to be achieved"
       }
      }
     },
     "localname": "CollaborationAgreementAdditionalRevenueToBeAchieved",
     "nsuri": "http://www.inovio.com/20210331",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_CollaborationAgreementAnticipatedCommercialEventBasedPaymentReceivableMilestones": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration Agreement, Anticipated Commercial Event Based Payment Receivable Milestones",
        "label": "Collaboration Agreement, Anticipated Commercial Event Based Payment Receivable Milestones",
        "terseLabel": "Anticipated commercial event based payment receivable milestones"
       }
      }
     },
     "localname": "CollaborationAgreementAnticipatedCommercialEventBasedPaymentReceivableMilestones",
     "nsuri": "http://www.inovio.com/20210331",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_CollaborationAgreementAnticipatedDevelopmentandRegulatoryEventBasedPaymentReceivableMilestones": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration Agreement, Anticipated Development and Regulatory Event Based Payment Receivable Milestones",
        "label": "Collaboration Agreement, Anticipated Development and Regulatory Event Based Payment Receivable Milestones",
        "terseLabel": "Anticipated development and regulatory event based payment receivable milestones"
       }
      }
     },
     "localname": "CollaborationAgreementAnticipatedDevelopmentandRegulatoryEventBasedPaymentReceivableMilestones",
     "nsuri": "http://www.inovio.com/20210331",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_CollaborationAgreementPaymentEarned": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration Agreement, Payment Earned",
        "label": "Collaboration Agreement, Payment Earned",
        "terseLabel": "Collaboration Agreement, Payment Earned"
       }
      }
     },
     "localname": "CollaborationAgreementPaymentEarned",
     "nsuri": "http://www.inovio.com/20210331",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_CollaborationAgreementRoyaltyPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration Agreement, Royalty Period",
        "label": "Collaboration Agreement, Royalty Period",
        "terseLabel": "Royalty period"
       }
      }
     },
     "localname": "CollaborationAgreementRoyaltyPeriod",
     "nsuri": "http://www.inovio.com/20210331",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ino_CollaborationAgreementTerritoryExpansionOptionPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration Agreement, Territory Expansion Option Period",
        "label": "Collaboration Agreement, Territory Expansion Option Period",
        "terseLabel": "Territory expansion option period"
       }
      }
     },
     "localname": "CollaborationAgreementTerritoryExpansionOptionPeriod",
     "nsuri": "http://www.inovio.com/20210331",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ino_CollaborativeAgreementAdvisoryFees": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Agreement, Advisory Fees",
        "label": "Collaborative Agreement, Advisory Fees",
        "terseLabel": "Advisory fees"
       }
      }
     },
     "localname": "CollaborativeAgreementAdvisoryFees",
     "nsuri": "http://www.inovio.com/20210331",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_CollaborativeAgreementAwardedAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Agreement, Awarded Amount",
        "label": "Collaborative Agreement, Awarded Amount",
        "terseLabel": "Awarded amount"
       }
      }
     },
     "localname": "CollaborativeAgreementAwardedAmount",
     "nsuri": "http://www.inovio.com/20210331",
     "presentation": [
      "http://www.inovio.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_CollaborativeAgreementAwardedOptionAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Agreement, Awarded Option Amount",
        "label": "Collaborative Agreement, Awarded Option Amount",
        "terseLabel": "Awarded option amount"
       }
      }
     },
     "localname": "CollaborativeAgreementAwardedOptionAmount",
     "nsuri": "http://www.inovio.com/20210331",
     "presentation": [
      "http://www.inovio.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_CollaborativeAgreementCorporateIncomeTax": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Agreement, Corporate Income Tax",
        "label": "Collaborative Agreement, Corporate Income Tax",
        "terseLabel": "Foreign corporate income taxes reducing upfront payment"
       }
      }
     },
     "localname": "CollaborativeAgreementCorporateIncomeTax",
     "nsuri": "http://www.inovio.com/20210331",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_CollaborativeAgreementExpensesToReimburse": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Agreement, Expenses To Reimburse",
        "label": "Collaborative Agreement, Expenses To Reimburse",
        "terseLabel": "Expenses to reimburse"
       }
      }
     },
     "localname": "CollaborativeAgreementExpensesToReimburse",
     "nsuri": "http://www.inovio.com/20210331",
     "presentation": [
      "http://www.inovio.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_CollaborativeAgreementForeignNonIncomeTaxes": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Agreement, Non-Income Taxes",
        "label": "Collaborative Agreement, Foreign Non-Income Taxes",
        "terseLabel": "Foreign non-corporate income taxes reducing upfront payment"
       }
      }
     },
     "localname": "CollaborativeAgreementForeignNonIncomeTaxes",
     "nsuri": "http://www.inovio.com/20210331",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_CollaborativeAgreementFundingReceived": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Agreement, Funding Received",
        "label": "Collaborative Agreement, Funding Received",
        "verboseLabel": "Funding received for research and development"
       }
      }
     },
     "localname": "CollaborativeAgreementFundingReceived",
     "nsuri": "http://www.inovio.com/20210331",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_CollaborativeAgreementFundingToBeReceived": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Agreement, Funding Received for Research and Development",
        "label": "Collaborative Agreement, Funding To Be Received",
        "terseLabel": "Collaborative agreement, funding to be received"
       }
      }
     },
     "localname": "CollaborativeAgreementFundingToBeReceived",
     "nsuri": "http://www.inovio.com/20210331",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_CollaborativeAgreementNumberofDaysWrittenNoticeBeforeTermination": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Agreement, Number of Days Written Notice Before Termination",
        "label": "Collaborative Agreement, Number of Days Written Notice Before Termination",
        "terseLabel": "Number of days written notice before termination"
       }
      }
     },
     "localname": "CollaborativeAgreementNumberofDaysWrittenNoticeBeforeTermination",
     "nsuri": "http://www.inovio.com/20210331",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ino_CollaborativeAgreementPeriodFromEffectiveDateForTermination": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Agreement, Period From Effective Date For Termination",
        "label": "Collaborative Agreement, Period From Effective Date For Termination",
        "terseLabel": "Period from effective date for termination"
       }
      }
     },
     "localname": "CollaborativeAgreementPeriodFromEffectiveDateForTermination",
     "nsuri": "http://www.inovio.com/20210331",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ino_CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Agreement, Period to Receive Funding for Research and Development",
        "label": "Collaborative Agreement, Period to Receive Funding for Research and Development",
        "terseLabel": "Collaborative agreement, period to receive funding for research and development"
       }
      }
     },
     "localname": "CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment",
     "nsuri": "http://www.inovio.com/20210331",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ino_CollaborativeAgreementsUpfrontPaymentReceived": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Agreements, Upfront Payment Received",
        "label": "Collaborative Agreements, Upfront Payment Received",
        "terseLabel": "Upfront payment received"
       }
      }
     },
     "localname": "CollaborativeAgreementsUpfrontPaymentReceived",
     "nsuri": "http://www.inovio.com/20210331",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_CollaborativeArrangementFixedPriceContractAmountAwarded": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Fixed-Price Contract, Amount Awarded",
        "label": "Collaborative Arrangement, Fixed-Price Contract, Amount Awarded",
        "terseLabel": "Purchase price, procurement contract"
       }
      }
     },
     "localname": "CollaborativeArrangementFixedPriceContractAmountAwarded",
     "nsuri": "http://www.inovio.com/20210331",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_CollaborativeArrangementTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Term",
        "label": "Collaborative Arrangement, Term",
        "terseLabel": "Term"
       }
      }
     },
     "localname": "CollaborativeArrangementTerm",
     "nsuri": "http://www.inovio.com/20210331",
     "presentation": [
      "http://www.inovio.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ino_ContractWithCustomerLiabilityAffiliatedEntityCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The carrying amount of consideration received or receivable from related parties as of the balance sheet date on potential earnings that were not recognized as revenue in conformity with GAAP, and which are expected to be recognized as such within one year or the normal operating cycle, if longer, including sales, license fees, and royalties, but excluding interest income.",
        "label": "Contract With Customer, Liability, Affiliated Entity, Current",
        "verboseLabel": "Deferred revenue from affiliated entities"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityAffiliatedEntityCurrent",
     "nsuri": "http://www.inovio.com/20210331",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_ConvertibleBondsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Convertible Bonds [Member]",
        "label": "Convertible Bonds [Member]",
        "terseLabel": "Convertible bonds"
       }
      }
     },
     "localname": "ConvertibleBondsMember",
     "nsuri": "http://www.inovio.com/20210331",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_DNAEncodedMonoclonalAntibodyTechnologyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "DNA-Encoded Monoclonal Antibody Technology [Member]",
        "label": "DNA-Encoded Monoclonal Antibody Technology [Member]",
        "terseLabel": "DNA-Encoded Monoclonal Antibody Technology"
       }
      }
     },
     "localname": "DNAEncodedMonoclonalAntibodyTechnologyMember",
     "nsuri": "http://www.inovio.com/20210331",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_DebtInstrumentAccruedInterest": {
     "auth_ref": [],
     "calculation": {
      "http://www.inovio.com/role/ConvertibleDebtBalanceofConvertibleBondsandNotesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Accrued Interest",
        "label": "Debt Instrument, Accrued Interest",
        "terseLabel": "Accrued interest"
       }
      }
     },
     "localname": "DebtInstrumentAccruedInterest",
     "nsuri": "http://www.inovio.com/20210331",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtBalanceofConvertibleBondsandNotesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_DebtInstrumentConvertibleDebtConvertedAmount": {
     "auth_ref": [],
     "calculation": {
      "http://www.inovio.com/role/ConvertibleDebtBalanceofConvertibleBondsandNotesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Convertible Debt, Converted Amount",
        "label": "Debt Instrument, Convertible Debt, Converted Amount",
        "negatedTerseLabel": "Principal amount converted into common shares"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleDebtConvertedAmount",
     "nsuri": "http://www.inovio.com/20210331",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtBalanceofConvertibleBondsandNotesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_DebtSecuritiesAvailableforSaleContractualMaturity": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Securities, Available-for-sale contractual maturity.",
        "label": "Debt Securities, Available-for-Sale Contractual Maturity",
        "terseLabel": "Contractual maturity (less than)"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableforSaleContractualMaturity",
     "nsuri": "http://www.inovio.com/20210331",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsSummaryofAvailableforsaleSecuritiesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ino_December2019ConvertibleBondsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "December 2019 Convertible Bonds [Member]",
        "label": "December 2019 Convertible Bonds [Member]",
        "terseLabel": "December 2019 Bonds"
       }
      }
     },
     "localname": "December2019ConvertibleBondsMember",
     "nsuri": "http://www.inovio.com/20210331",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails",
      "http://www.inovio.com/role/NetLossPerShareScheduleofAntiDilutiveSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_DeferredGrantFundingCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 7.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Grant Funding, Current",
        "label": "Deferred Grant Funding, Current",
        "terseLabel": "Grant funding liability"
       }
      }
     },
     "localname": "DeferredGrantFundingCurrent",
     "nsuri": "http://www.inovio.com/20210331",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails",
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_DeferredGrantFundingFromAffiliate": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Grant Funding, From Affiliate",
        "label": "Deferred Grant Funding, From Affiliate",
        "terseLabel": "Deferred grant funding, from affiliate"
       }
      }
     },
     "localname": "DeferredGrantFundingFromAffiliate",
     "nsuri": "http://www.inovio.com/20210331",
     "presentation": [
      "http://www.inovio.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_DeferredGrantFundingFromAffiliateCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 8.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Grant Funding, From Affiliate, Current",
        "label": "Deferred Grant Funding, From Affiliate, Current",
        "terseLabel": "Grant funding liability from affiliated entities"
       }
      }
     },
     "localname": "DeferredGrantFundingFromAffiliateCurrent",
     "nsuri": "http://www.inovio.com/20210331",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_DeferredGrantFundingFromAffiliateNoncurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Grant Funding, From Affiliate, Noncurrent",
        "label": "Deferred Grant Funding, From Affiliate, Noncurrent",
        "terseLabel": "Grant funding liability from affiliated entity, net of current portion"
       }
      }
     },
     "localname": "DeferredGrantFundingFromAffiliateNoncurrent",
     "nsuri": "http://www.inovio.com/20210331",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_DepartmentOfDefenceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Department Of Defence [Member]",
        "label": "Department Of Defence [Member]",
        "terseLabel": "Department of Defence"
       }
      }
     },
     "localname": "DepartmentOfDefenceMember",
     "nsuri": "http://www.inovio.com/20210331",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_EmployeesAndDirectorsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employees and Directors [Member]",
        "label": "Employees and Directors [Member]",
        "terseLabel": "Employees and Directors"
       }
      }
     },
     "localname": "EmployeesAndDirectorsMember",
     "nsuri": "http://www.inovio.com/20210331",
     "presentation": [
      "http://www.inovio.com/role/StockBasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_EquityMethodInvestmentEnterpriseValue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Method Investment, Enterprise Value",
        "label": "Equity Method Investment, Enterprise Value",
        "verboseLabel": "Geneos enterprise value"
       }
      }
     },
     "localname": "EquityMethodInvestmentEnterpriseValue",
     "nsuri": "http://www.inovio.com/20210331",
     "presentation": [
      "http://www.inovio.com/role/GeneosTherapeuticsIncFairValueAssumptionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Finite-Lived Intangible Asset, Expected Amortization, After Year Four",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, After Year Four",
        "terseLabel": "Estimated aggregate amortization expense for 2026"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour",
     "nsuri": "http://www.inovio.com/20210331",
     "presentation": [
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_GeneosTherapeuticsInc.Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Geneos Therapeutics, Inc. [Member]",
        "label": "Geneos Therapeutics, Inc. [Member]",
        "terseLabel": "Geneos Therapeutics, Inc."
       }
      }
     },
     "localname": "GeneosTherapeuticsInc.Member",
     "nsuri": "http://www.inovio.com/20210331",
     "presentation": [
      "http://www.inovio.com/role/GeneosTherapeuticsIncDeconsolidationAccountingDetails",
      "http://www.inovio.com/role/GeneosTherapeuticsIncFairValueAssumptionsDetails",
      "http://www.inovio.com/role/GeneosTherapeuticsIncInvestmentInGeneosDetails",
      "http://www.inovio.com/role/GeneosTherapeuticsIncNarrativeDetails",
      "http://www.inovio.com/role/GeneosTherapeuticsIncPreferredstockInvestmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_GoodwillAndIntangibleAssetsGross": {
     "auth_ref": [],
     "calculation": {
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsScheduleGoodwillandIntangibleAssetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Goodwill and intangible assets gross.",
        "label": "Goodwill and Intangible Assets Gross",
        "totalLabel": "Total goodwill and intangible assets, gross"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsGross",
     "nsuri": "http://www.inovio.com/20210331",
     "presentation": [
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsScheduleGoodwillandIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_GoodwillAndIntangibleAssetsNet": {
     "auth_ref": [],
     "calculation": {
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsScheduleGoodwillandIntangibleAssetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Goodwill and intangible assets net.",
        "label": "Goodwill and Intangible Assets Net",
        "totalLabel": "Total goodwill and intangible assets, net book value"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsNet",
     "nsuri": "http://www.inovio.com/20210331",
     "presentation": [
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsScheduleGoodwillandIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_GrantPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Grant Policy [Policy Text Block]",
        "label": "Grant Policy [Policy Text Block]",
        "terseLabel": "Grants"
       }
      }
     },
     "localname": "GrantPolicyPolicyTextBlock",
     "nsuri": "http://www.inovio.com/20210331",
     "presentation": [
      "http://www.inovio.com/role/BasisofPresentationLiquidityandRisksandUncertaintiesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ino_GrantProceedsReceived": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Grant Proceeds Received",
        "label": "Grant Proceeds Received",
        "terseLabel": "Contra-research and development expense"
       }
      }
     },
     "localname": "GrantProceedsReceived",
     "nsuri": "http://www.inovio.com/20210331",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails",
      "http://www.inovio.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_INO4800Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "INO-4800 [Member]",
        "label": "INO-4800 [Member]",
        "terseLabel": "INO-4800"
       }
      }
     },
     "localname": "INO4800Member",
     "nsuri": "http://www.inovio.com/20210331",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_IncomeLossFromEquityMethodInvestmentsRealizedAndAllocatedToInvestment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income (Loss) From Equity Method Investments, Realized And Allocated to Investment",
        "label": "Income (Loss) From Equity Method Investments, Realized And Allocated to Investment",
        "negatedLabel": "Loss from equity method investment, recorded and allocated to investment"
       }
      }
     },
     "localname": "IncomeLossFromEquityMethodInvestmentsRealizedAndAllocatedToInvestment",
     "nsuri": "http://www.inovio.com/20210331",
     "presentation": [
      "http://www.inovio.com/role/GeneosTherapeuticsIncNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_IncreaseDecreaseInAccruedClinicalTrialExpense": {
     "auth_ref": [],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 21.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (Decrease) In Accrued Clinical Trial Expense",
        "label": "Increase (Decrease) In Accrued Clinical Trial Expense",
        "terseLabel": "Accrued clinical trial expenses"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedClinicalTrialExpense",
     "nsuri": "http://www.inovio.com/20210331",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_IncreaseDecreaseInDeferredRevenueFromRelatedParties": {
     "auth_ref": [],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 24.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net change during the reporting period, excluding the portion taken into income, in the liability reflecting services yet to be performed by the reporting entity for which cash or other forms of consideration was received or recorded as a receivable from a related party.",
        "label": "Increase Decrease in Deferred Revenue From Related Parties",
        "verboseLabel": "Deferred revenue from affiliated entities"
       }
      }
     },
     "localname": "IncreaseDecreaseInDeferredRevenueFromRelatedParties",
     "nsuri": "http://www.inovio.com/20210331",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet": {
     "auth_ref": [],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 25.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (Decrease) In Operating Lease, Right-Of-Use Asset (Lease Liability), Net",
        "label": "Increase (Decrease) In Operating Lease, Right-Of-Use Asset (Lease Liability), Net",
        "terseLabel": "Operating lease right-of-use assets and liabilities, net"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet",
     "nsuri": "http://www.inovio.com/20210331",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity": {
     "auth_ref": [],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 18.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net change during the reporting period in the value of prepaid expenses and other current assets from related parties.",
        "label": "Increase Decrease in Prepaid Expenses and Other Current Assets from Affiliated Entity",
        "negatedLabel": "Prepaid expenses and other current assets from affiliated entities"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity",
     "nsuri": "http://www.inovio.com/20210331",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_IncreaseDecreaseinDeferredGrantFundingCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 26.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (Decrease) in Deferred Grant Funding, Current",
        "label": "Increase (Decrease) in Deferred Grant Funding, Current",
        "terseLabel": "Grant funding liability"
       }
      }
     },
     "localname": "IncreaseDecreaseinDeferredGrantFundingCurrent",
     "nsuri": "http://www.inovio.com/20210331",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_IncreaseDecreaseinDeferredGrantFundingFromAffiliateCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 27.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (Decrease) in Deferred Grant Funding, From Affiliate, Current",
        "label": "Increase (Decrease) in Deferred Grant Funding, From Affiliate, Current",
        "terseLabel": "Grant funding liability from affiliated entities"
       }
      }
     },
     "localname": "IncreaseDecreaseinDeferredGrantFundingFromAffiliateCurrent",
     "nsuri": "http://www.inovio.com/20210331",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_InitialConversionPriceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Initial Conversion Price [Member]",
        "label": "Initial Conversion Price [Member]",
        "terseLabel": "Initial Conversion Price"
       }
      }
     },
     "localname": "InitialConversionPriceMember",
     "nsuri": "http://www.inovio.com/20210331",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_LassaFeverAndMERSVaccineMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lassa Fever And MERS Vaccine [Member]",
        "label": "Lassa Fever And MERS Vaccine [Member]",
        "terseLabel": "Lassa Fever and MERS Vaccine"
       }
      }
     },
     "localname": "LassaFeverAndMERSVaccineMember",
     "nsuri": "http://www.inovio.com/20210331",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_LesseeOperatingLeaseAreaofLandUnderLease": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Area of Land Under Lease",
        "label": "Lessee, Operating Lease, Area of Land Under Lease",
        "terseLabel": "Area leased (in square feet)"
       }
      }
     },
     "localname": "LesseeOperatingLeaseAreaofLandUnderLease",
     "nsuri": "http://www.inovio.com/20210331",
     "presentation": [
      "http://www.inovio.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "areaItemType"
    },
    "ino_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour": {
     "auth_ref": [],
     "calculation": {
      "http://www.inovio.com/role/LeasesSummaryofFutureMinimumLeasePaymentsDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Liability, To Be Paid, After Year Four",
        "label": "Lessee, Operating Lease, Liability, To Be Paid, After Year Four",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityToBePaidAfterYearFour",
     "nsuri": "http://www.inovio.com/20210331",
     "presentation": [
      "http://www.inovio.com/role/LeasesSummaryofFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_LicensewithAffiliatedEntitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License with Affiliated Entities [Member]",
        "label": "License with Affiliated Entities [Member]",
        "terseLabel": "Revenue under collaborative research and development arrangements with affiliated entities"
       }
      }
     },
     "localname": "LicensewithAffiliatedEntitiesMember",
     "nsuri": "http://www.inovio.com/20210331",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_MarketableSecuritiesAndFairValueMeasurementsTextualAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Marketable securities and fair value measurements.",
        "label": "Marketable Securities and Fair Value Measurements (Textual) [Abstract]",
        "verboseLabel": "Marketable Securities and Fair Value Measurements (Textual) [Abstract]"
       }
      }
     },
     "localname": "MarketableSecuritiesAndFairValueMeasurementsTextualAbstract",
     "nsuri": "http://www.inovio.com/20210331",
     "presentation": [
      "http://www.inovio.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ino_MutualFundsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Mutual funds.",
        "label": "Mutual Funds [Member]",
        "terseLabel": "Mutual funds",
        "verboseLabel": "Mutual funds"
       }
      }
     },
     "localname": "MutualFundsMember",
     "nsuri": "http://www.inovio.com/20210331",
     "presentation": [
      "http://www.inovio.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueDetails",
      "http://www.inovio.com/role/ShorttermInvestmentsSummaryofAvailableforsaleSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_NewSalesAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "New Sales Agreement [Member]",
        "label": "New Sales Agreement [Member]",
        "terseLabel": "New Sales Agreement"
       }
      }
     },
     "localname": "NewSalesAgreementMember",
     "nsuri": "http://www.inovio.com/20210331",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_NonCashInterestIncomeExpense": {
     "auth_ref": [],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non-Cash Interest Income (Expense)",
        "label": "Non-Cash Interest Income (Expense)",
        "negatedTerseLabel": "Non-cash interest expense"
       }
      }
     },
     "localname": "NonCashInterestIncomeExpense",
     "nsuri": "http://www.inovio.com/20210331",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_NonEmployeeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non employee.",
        "label": "Non Employee [Member]",
        "terseLabel": "Non Employee"
       }
      }
     },
     "localname": "NonEmployeeMember",
     "nsuri": "http://www.inovio.com/20210331",
     "presentation": [
      "http://www.inovio.com/role/StockBasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_NumberOfPotentialSharesAuthorizedForIssuanceUnderShareBasedCompensationPlan": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of potential shares authorized for issuance under a share-based compensation plan.",
        "label": "Number Of Potential Shares Authorized For Issuance Under Share Based Compensation Plan",
        "terseLabel": "Number of potential shares authorized for issuance under share based compensation plan (in shares)"
       }
      }
     },
     "localname": "NumberOfPotentialSharesAuthorizedForIssuanceUnderShareBasedCompensationPlan",
     "nsuri": "http://www.inovio.com/20210331",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "ino_OperatingLeaseNonCashLeaseExpense": {
     "auth_ref": [],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating Lease, Non-Cash Lease Expense",
        "label": "Operating Lease, Non-Cash Lease Expense",
        "terseLabel": "Non-cash lease expense"
       }
      }
     },
     "localname": "OperatingLeaseNonCashLeaseExpense",
     "nsuri": "http://www.inovio.com/20210331",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_OtherCounterpartyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Counterparty [Member]",
        "label": "Other Counterparty [Member]",
        "terseLabel": "Other Counterparty"
       }
      }
     },
     "localname": "OtherCounterpartyMember",
     "nsuri": "http://www.inovio.com/20210331",
     "presentation": [
      "http://www.inovio.com/role/RevenueRecognitionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_PlumblineLifeSciencesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plumbline Life Sciences [Member]",
        "label": "Plumbline Life Sciences [Member]",
        "terseLabel": "Plumbline Life Sciences"
       }
      }
     },
     "localname": "PlumblineLifeSciencesMember",
     "nsuri": "http://www.inovio.com/20210331",
     "presentation": [
      "http://www.inovio.com/role/RelatedPartyTransactionsDetails",
      "http://www.inovio.com/role/RevenueRecognitionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_PlymouthMeetingPennsylvaniaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plymouth Meeting, Pennsylvania [Member]",
        "label": "Plymouth Meeting, Pennsylvania [Member]",
        "terseLabel": "Plymouth Meeting, Pennsylvania"
       }
      }
     },
     "localname": "PlymouthMeetingPennsylvaniaMember",
     "nsuri": "http://www.inovio.com/20210331",
     "presentation": [
      "http://www.inovio.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity": {
     "auth_ref": [],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amounts paid to related parties in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event.",
        "label": "Prepaid Expenses and Other Current Assets from Affiliated Entity",
        "verboseLabel": "Prepaid expenses and other current assets from affiliated entities"
       }
      }
     },
     "localname": "PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity",
     "nsuri": "http://www.inovio.com/20210331",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_PriorSalesAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Prior Sales Agreement [Member]",
        "label": "Prior Sales Agreement [Member]",
        "verboseLabel": "Prior Sales Agreement"
       }
      }
     },
     "localname": "PriorSalesAgreementMember",
     "nsuri": "http://www.inovio.com/20210331",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_ProceedsFromCollaborativeAgreement": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds From Collaborative Agreement",
        "label": "Proceeds From Collaborative Agreement",
        "terseLabel": "Proceeds received in upfront payment"
       }
      }
     },
     "localname": "ProceedsFromCollaborativeAgreement",
     "nsuri": "http://www.inovio.com/20210331",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_RelatedPartyTransactionsTextualAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related party transactions.",
        "label": "Related Party Transactions (Textual) [Abstract]",
        "verboseLabel": "Related-Party Transactions (Textual) [Abstract]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsTextualAbstract",
     "nsuri": "http://www.inovio.com/20210331",
     "presentation": [
      "http://www.inovio.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ino_SARSCoV2COVID19VaccineMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "SARS-CoV-2/COVID-19 Vaccine [Member]",
        "label": "SARS-CoV-2/COVID-19 Vaccine [Member]",
        "terseLabel": "SARS-CoV-2/COVID-19 Vaccine"
       }
      }
     },
     "localname": "SARSCoV2COVID19VaccineMember",
     "nsuri": "http://www.inovio.com/20210331",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_SalesAgreementsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sales Agreements [Member]",
        "label": "Sales Agreements [Member]",
        "terseLabel": "Sales Agreements"
       }
      }
     },
     "localname": "SalesAgreementsMember",
     "nsuri": "http://www.inovio.com/20210331",
     "presentation": [
      "http://www.inovio.com/role/BasisofPresentationLiquidityandRisksandUncertaintiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_SanDiegoOfficeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "San Diego Office [Member]",
        "label": "San Diego Office [Member]",
        "terseLabel": "San Diego, California"
       }
      }
     },
     "localname": "SanDiegoOfficeMember",
     "nsuri": "http://www.inovio.com/20210331",
     "presentation": [
      "http://www.inovio.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_SeriesAOnePreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series A One Preferred Stock [Member]",
        "label": "Series A One Preferred Stock [Member]",
        "terseLabel": "Series A One Preferred Stock"
       }
      }
     },
     "localname": "SeriesAOnePreferredStockMember",
     "nsuri": "http://www.inovio.com/20210331",
     "presentation": [
      "http://www.inovio.com/role/GeneosTherapeuticsIncNarrativeDetails",
      "http://www.inovio.com/role/GeneosTherapeuticsIncPreferredstockInvestmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_ServiceBasedRestrictedStockUnitsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Service-Based Restricted Stock Units",
        "label": "Service-Based Restricted Stock Units [Member]",
        "verboseLabel": "Service-based restricted stock units"
       }
      }
     },
     "localname": "ServiceBasedRestrictedStockUnitsMember",
     "nsuri": "http://www.inovio.com/20210331",
     "presentation": [
      "http://www.inovio.com/role/NetLossPerShareScheduleofAntiDilutiveSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_SettlementOfReceivableWithSharesOfCommonStockFromEquitySecurity": {
     "auth_ref": [],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Settlement Of Receivable With Shares Of Common Stock From Equity Security",
        "label": "Settlement Of Receivable With Shares Of Common Stock From Equity Security",
        "negatedLabel": "Settlement of receivable with shares of common stock from affiliated entity (PLS)"
       }
      }
     },
     "localname": "SettlementOfReceivableWithSharesOfCommonStockFromEquitySecurity",
     "nsuri": "http://www.inovio.com/20210331",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodGrantDateFairValue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Fair Value",
        "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Grant Date Fair Value",
        "terseLabel": "Grant date fair value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodGrantDateFairValue",
     "nsuri": "http://www.inovio.com/20210331",
     "presentation": [
      "http://www.inovio.com/role/StockBasedCompensationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award maximum contractual term.",
        "label": "Share based Compensation Arrangement By Share based Payment Award Maximum Contractual Term",
        "terseLabel": "Maximum contractual term (in years)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm",
     "nsuri": "http://www.inovio.com/20210331",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ino_SharebasedCompensationArrangementbySharebasedPaymentAwardIncreaseInNumberofSharesAuthorized": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Increase In Number of Shares Authorized",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Increase In Number of Shares Authorized",
        "terseLabel": "Increase in number of shares authorized (in shares)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementbySharebasedPaymentAwardIncreaseInNumberofSharesAuthorized",
     "nsuri": "http://www.inovio.com/20210331",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "ino_StockPurchaseAgreementCommitmentOfAdditionalInvestment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Purchase Agreement, Commitment Of Additional Investment",
        "label": "Stock Purchase Agreement, Commitment Of Additional Investment",
        "terseLabel": "Stock purchase agreement, commitment of additional investment"
       }
      }
     },
     "localname": "StockPurchaseAgreementCommitmentOfAdditionalInvestment",
     "nsuri": "http://www.inovio.com/20210331",
     "presentation": [
      "http://www.inovio.com/role/GeneosTherapeuticsIncNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_StockSaleAgreementAggregateNumberofSharesIssued": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Sale Agreement, Aggregate Number of Shares Issued",
        "label": "Stock Sale Agreement, Aggregate Number of Shares Issued",
        "terseLabel": "Aggregate number of shares issued (in shares)"
       }
      }
     },
     "localname": "StockSaleAgreementAggregateNumberofSharesIssued",
     "nsuri": "http://www.inovio.com/20210331",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "ino_StockSaleAgreementAggregateProceedsFromIssuanceOfStock": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Sale Agreement, Aggregate Proceeds From Issuance Of Stock",
        "label": "Stock Sale Agreement, Aggregate Proceeds From Issuance Of Stock",
        "terseLabel": "Aggregate proceeds"
       }
      }
     },
     "localname": "StockSaleAgreementAggregateProceedsFromIssuanceOfStock",
     "nsuri": "http://www.inovio.com/20210331",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_StockSaleAgreementWeightedAveragePricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Sale Agreement Weighted Average Price Per Share",
        "label": "Stock Sale Agreement, Weighted Average Price Per Share",
        "terseLabel": "Stock sale agreement weighted average price per share"
       }
      }
     },
     "localname": "StockSaleAgreementWeightedAveragePricePerShare",
     "nsuri": "http://www.inovio.com/20210331",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "ino_StockSalesAgreementMaximumAuthorizedAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Sales Agreement, Maximum Authorized Amount",
        "label": "Stock Sales Agreement, Maximum Authorized Amount",
        "terseLabel": "Maximum authorized amount"
       }
      }
     },
     "localname": "StockSalesAgreementMaximumAuthorizedAmount",
     "nsuri": "http://www.inovio.com/20210331",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_StockSalesAgreementRemainingAuthorizedAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Sales Agreement, Remaining Authorized Amount",
        "label": "Stock Sales Agreement, Remaining Authorized Amount",
        "terseLabel": "Remaining authorized amount"
       }
      }
     },
     "localname": "StockSalesAgreementRemainingAuthorizedAmount",
     "nsuri": "http://www.inovio.com/20210331",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_TheWistarInstituteMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Wistar Institute [Member]",
        "label": "The Wistar Institute [Member]",
        "terseLabel": "The Wistar Institute"
       }
      }
     },
     "localname": "TheWistarInstituteMember",
     "nsuri": "http://www.inovio.com/20210331",
     "presentation": [
      "http://www.inovio.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_UnderwrittenPublicOfferingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Underwritten Public Offering [Member]",
        "label": "Underwritten Public Offering [Member]",
        "terseLabel": "Underwritten Public Offering"
       }
      }
     },
     "localname": "UnderwrittenPublicOfferingMember",
     "nsuri": "http://www.inovio.com/20210331",
     "presentation": [
      "http://www.inovio.com/role/BasisofPresentationLiquidityandRisksandUncertaintiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_WorkingCapitalExcludingCash": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Working Capital, Excluding Cash",
        "label": "Working Capital, Excluding Cash",
        "negatedTerseLabel": "Working capital (excluding cash)"
       }
      }
     },
     "localname": "WorkingCapitalExcludingCash",
     "nsuri": "http://www.inovio.com/20210331",
     "presentation": [
      "http://www.inovio.com/role/GeneosTherapeuticsIncDeconsolidationAccountingDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r42",
      "r98"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]",
        "terseLabel": "Counterparty Name [Axis]"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails",
      "http://www.inovio.com/role/GeneosTherapeuticsIncDeconsolidationAccountingDetails",
      "http://www.inovio.com/role/GeneosTherapeuticsIncFairValueAssumptionsDetails",
      "http://www.inovio.com/role/GeneosTherapeuticsIncInvestmentInGeneosDetails",
      "http://www.inovio.com/role/GeneosTherapeuticsIncNarrativeDetails",
      "http://www.inovio.com/role/GeneosTherapeuticsIncPreferredstockInvestmentDetails",
      "http://www.inovio.com/role/RelatedPartyTransactionsDetails",
      "http://www.inovio.com/role/RevenueRecognitionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_DirectorMember": {
     "auth_ref": [
      "r166"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Director [Member]",
        "terseLabel": "Director"
       }
      }
     },
     "localname": "DirectorMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_EquityMethodInvesteeNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment, Name [Domain]",
        "terseLabel": "Investment, Name [Domain]"
       }
      }
     },
     "localname": "EquityMethodInvesteeNameDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MajorCustomersAxis": {
     "auth_ref": [
      "r165",
      "r271",
      "r277",
      "r535"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Axis]",
        "terseLabel": "Customer [Axis]"
       }
      }
     },
     "localname": "MajorCustomersAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r297",
      "r298",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r467",
      "r533",
      "r536"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CriticalAccountingPoliciesDetails",
      "http://www.inovio.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r297",
      "r298",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r467",
      "r533",
      "r536"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CriticalAccountingPoliciesDetails",
      "http://www.inovio.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_NameOfMajorCustomerDomain": {
     "auth_ref": [
      "r165",
      "r271",
      "r277",
      "r535"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Domain]",
        "terseLabel": "Customer [Domain]"
       }
      }
     },
     "localname": "NameOfMajorCustomerDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_OwnershipAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ownership [Axis]",
        "terseLabel": "Ownership [Axis]"
       }
      }
     },
     "localname": "OwnershipAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/GeneosTherapeuticsIncNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_OwnershipDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ownership [Domain]",
        "terseLabel": "Ownership [Domain]"
       }
      }
     },
     "localname": "OwnershipDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/GeneosTherapeuticsIncNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r163",
      "r271",
      "r275",
      "r468",
      "r532",
      "r534"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails",
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r163",
      "r271",
      "r275",
      "r468",
      "r532",
      "r534"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]",
        "terseLabel": "Product and Service [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails",
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r287",
      "r297",
      "r298",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r467",
      "r533",
      "r536"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CriticalAccountingPoliciesDetails",
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsScheduleGoodwillandIntangibleAssetsDetails",
      "http://www.inovio.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r287",
      "r297",
      "r298",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r467",
      "r533",
      "r536"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CriticalAccountingPoliciesDetails",
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsScheduleGoodwillandIntangibleAssetsDetails",
      "http://www.inovio.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis": {
     "auth_ref": [
      "r555",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Name of Property [Axis]",
        "terseLabel": "Name of Property [Axis]"
       }
      }
     },
     "localname": "RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain": {
     "auth_ref": [
      "r555",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Name of Property [Domain]",
        "terseLabel": "Name of Property [Domain]"
       }
      }
     },
     "localname": "RealEstateAndAccumulatedDepreciationNameOfPropertyDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]",
        "terseLabel": "Counterparty Name [Domain]"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails",
      "http://www.inovio.com/role/GeneosTherapeuticsIncDeconsolidationAccountingDetails",
      "http://www.inovio.com/role/GeneosTherapeuticsIncFairValueAssumptionsDetails",
      "http://www.inovio.com/role/GeneosTherapeuticsIncInvestmentInGeneosDetails",
      "http://www.inovio.com/role/GeneosTherapeuticsIncNarrativeDetails",
      "http://www.inovio.com/role/GeneosTherapeuticsIncPreferredstockInvestmentDetails",
      "http://www.inovio.com/role/RelatedPartyTransactionsDetails",
      "http://www.inovio.com/role/RevenueRecognitionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": {
     "auth_ref": [
      "r185"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment, Name [Axis]",
        "terseLabel": "Investment, Name [Axis]"
       }
      }
     },
     "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualAxis": {
     "auth_ref": [
      "r166",
      "r433"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Axis]",
        "terseLabel": "Title of Individual [Axis]"
       }
      }
     },
     "localname": "TitleOfIndividualAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockBasedCompensationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Domain]",
        "terseLabel": "Title of Individual with Relationship to Entity [Domain]"
       }
      }
     },
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockBasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_WeightedAverageMember": {
     "auth_ref": [
      "r443",
      "r445",
      "r448"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average [Member]",
        "terseLabel": "Weighted Average"
       }
      }
     },
     "localname": "WeightedAverageMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsScheduleGoodwillandIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]",
        "terseLabel": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r29"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.",
        "label": "Accounts Payable and Accrued Liabilities, Current",
        "verboseLabel": "Accounts payable and accrued expenses"
       }
      }
     },
     "localname": "AccountsPayableAndAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableNet": {
     "auth_ref": [
      "r16",
      "r514"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business.",
        "label": "Accounts Receivable, after Allowance for Credit Loss",
        "terseLabel": "Accounts receivable"
       }
      }
     },
     "localname": "AccountsReceivableNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r3",
      "r16",
      "r167",
      "r168"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "verboseLabel": "Accounts receivable"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableRelatedParties": {
     "auth_ref": [
      "r15",
      "r96",
      "r431",
      "r434",
      "r522"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an unclassified balance sheet, amount of receivables arising from transactions with related parties.",
        "label": "Accounts Receivable, Related Parties",
        "terseLabel": "Accounts receivable"
       }
      }
     },
     "localname": "AccountsReceivableRelatedParties",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails",
      "http://www.inovio.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableRelatedPartiesCurrent": {
     "auth_ref": [
      "r39",
      "r101",
      "r431",
      "r434"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of receivables arising from transactions with related parties due within one year or the normal operating cycle, if longer.",
        "label": "Accounts Receivable, Related Parties, Current",
        "terseLabel": "Accounts receivable from affiliated entities"
       }
      }
     },
     "localname": "AccountsReceivableRelatedPartiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesForCommissionsExpenseAndTaxes": {
     "auth_ref": [
      "r524"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The carrying amount for commissions, taxes and other expenses that were incurred but unpaid as of the balance sheet date.",
        "label": "Accrued Liabilities for Commissions, Expense and Taxes",
        "terseLabel": "Commissions and other estimated offering expenses"
       }
      }
     },
     "localname": "AccruedLiabilitiesForCommissionsExpenseAndTaxes",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r19",
      "r46",
      "r47",
      "r48",
      "r518",
      "r544",
      "r548"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "verboseLabel": "Accumulated other comprehensive loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r45",
      "r48",
      "r49",
      "r104",
      "r105",
      "r106",
      "r371",
      "r539",
      "r540"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated other comprehensive income (loss)"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Acquired Finite-Lived Intangible Assets [Line Items]",
        "terseLabel": "Acquired Finite-Lived Intangible Assets [Line Items]"
       }
      }
     },
     "localname": "AcquiredFiniteLivedIntangibleAssetsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsScheduleGoodwillandIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r17",
      "r328"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.",
        "label": "Additional Paid in Capital",
        "verboseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r104",
      "r105",
      "r106",
      "r324",
      "r325",
      "r326"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r299",
      "r301",
      "r331",
      "r332"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r301",
      "r316",
      "r330"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-based Payment Arrangement, Expense",
        "terseLabel": "Allocated share-based compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockBasedCompensationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AlternativeInvestmentMeasurementInput": {
     "auth_ref": [
      "r390"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of input used to measure alternative investment.",
        "label": "Alternative Investment, Measurement Input",
        "terseLabel": "Equity method investment, measurement input"
       }
      }
     },
     "localname": "AlternativeInvestmentMeasurementInput",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/GeneosTherapeuticsIncFairValueAssumptionsDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "auth_ref": [
      "r83",
      "r212",
      "r219"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Amortization of Intangible Assets",
        "terseLabel": "Aggregate amortization expense on intangible assets",
        "verboseLabel": "Amortization of intangible assets"
       }
      }
     },
     "localname": "AmortizationOfIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows",
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r133"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Antidilutive securities excluded (in shares)"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/NetLossPerShareScheduleofAntiDilutiveSecuritiesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r133"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/NetLossPerShareScheduleofAntiDilutiveSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/NetLossPerShareScheduleofAntiDilutiveSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r133"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name [Domain]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/NetLossPerShareScheduleofAntiDilutiveSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r95",
      "r151",
      "r155",
      "r161",
      "r186",
      "r365",
      "r376",
      "r399",
      "r491",
      "r516"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "verboseLabel": "ASSETS"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r4",
      "r5",
      "r41",
      "r95",
      "r186",
      "r365",
      "r376",
      "r399"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "verboseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "auth_ref": [
      "r386"
     ],
     "calculation": {
      "http://www.inovio.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Fair Value Disclosure",
        "totalLabel": "Total assets measured at fair value"
       }
      }
     },
     "localname": "AssetsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsFairValueDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Fair Value Disclosure [Abstract]",
        "verboseLabel": "Assets:"
       }
      }
     },
     "localname": "AssetsFairValueDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [
      "r174"
     ],
     "calculation": {
      "http://www.inovio.com/role/ShorttermInvestmentsSummaryofAvailableforsaleSecuritiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax",
        "verboseLabel": "Gross\u00a0Unrealized Gains"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsSummaryofAvailableforsaleSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [
      "r175"
     ],
     "calculation": {
      "http://www.inovio.com/role/ShorttermInvestmentsSummaryofAvailableforsaleSecuritiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax",
        "negatedLabel": "Gross\u00a0Unrealized Losses"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsSummaryofAvailableforsaleSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "auth_ref": [
      "r172",
      "r201"
     ],
     "calculation": {
      "http://www.inovio.com/role/ShorttermInvestmentsSummaryofAvailableforsaleSecuritiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Amortized Cost",
        "totalLabel": "Cost"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsSummaryofAvailableforsaleSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-sale [Abstract]",
        "verboseLabel": "Debt Securities, Available-for-sale [Abstract]"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsSummaryofAvailableforsaleSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "auth_ref": [
      "r170",
      "r173",
      "r201",
      "r498"
     ],
     "calculation": {
      "http://www.inovio.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      },
      "http://www.inovio.com/role/ShorttermInvestmentsSummaryofAvailableforsaleSecuritiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale",
        "terseLabel": "Fair\u00a0Market\u00a0Value",
        "verboseLabel": "Debt securities, available for sale"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueDetails",
      "http://www.inovio.com/role/ShorttermInvestmentsSummaryofAvailableforsaleSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableforsaleSecuritiesMember": {
     "auth_ref": [
      "r179"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Available-for-sale Securities [Member]",
        "terseLabel": "Available-for-sale Securities"
       }
      }
     },
     "localname": "AvailableforsaleSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r303",
      "r318"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockBasedCompensationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/BasisofPresentationLiquidityandRisksandUncertaintiesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock": {
     "auth_ref": [
      "r1",
      "r103",
      "r146"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the business description and basis of presentation concepts.  Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity.  Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Business Description and Basis of Presentation [Text Block]",
        "terseLabel": "Basis of Presentation, Liquidity and Risks and Uncertainties"
       }
      }
     },
     "localname": "BusinessDescriptionAndBasisOfPresentationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/BasisofPresentationLiquidityandRisksandUncertainties"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Capital": {
     "auth_ref": [
      "r512",
      "r553",
      "r554"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of total capital as defined by regulatory framework.",
        "label": "Banking Regulation, Total Capital, Actual",
        "terseLabel": "Working capital"
       }
      }
     },
     "localname": "Capital",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/BasisofPresentationLiquidityandRisksandUncertaintiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r2",
      "r25",
      "r85"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "verboseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "auth_ref": [],
     "calculation": {
      "http://www.inovio.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "terseLabel": "Cash and cash equivalents, fair value"
       }
      }
     },
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsAndShortTermInvestments": {
     "auth_ref": [
      "r25"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.",
        "label": "Cash, Cash Equivalents, and Short-term Investments",
        "terseLabel": "Cash, cash equivalents, and short-term investments"
       }
      }
     },
     "localname": "CashCashEquivalentsAndShortTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/BasisofPresentationLiquidityandRisksandUncertaintiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r79",
      "r85",
      "r90"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "Cash and cash equivalents, end of period",
        "periodStartLabel": "Cash and cash equivalents, beginning of period"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r79",
      "r404"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Increase (Decrease) in cash and cash equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashDivestedFromDeconsolidation": {
     "auth_ref": [
      "r71"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reduction in cash due to no longer including the former subsidiary's cash in the consolidated entity's cash.",
        "label": "Cash Divested from Deconsolidation",
        "terseLabel": "Decrease in cash resulting from the deconsolidation of Geneos"
       }
      }
     },
     "localname": "CashDivestedFromDeconsolidation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/GeneosTherapeuticsIncDeconsolidationAccountingDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CertificatesOfDepositMember": {
     "auth_ref": [
      "r509"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Short to medium-term investment available at banks and savings and loan institutions where a customer agrees to lend money to the institution for a certain amount of time and is paid a predetermined rate of interest. Certificates of deposit (CD) are typically Federal Deposit Insurance Corporation (FDIC) insured.",
        "label": "Certificates of Deposit [Member]",
        "terseLabel": "Certificates of deposit"
       }
      }
     },
     "localname": "CertificatesOfDepositMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueDetails",
      "http://www.inovio.com/role/ShorttermInvestmentsSummaryofAvailableforsaleSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [
      "r93",
      "r95",
      "r126",
      "r127",
      "r128",
      "r130",
      "r132",
      "r139",
      "r140",
      "r141",
      "r186",
      "r399"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.",
        "label": "Class of Stock [Domain]",
        "terseLabel": "Class of Stock [Domain]"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/BasisofPresentationLiquidityandRisksandUncertaintiesDetails",
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails",
      "http://www.inovio.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.inovio.com/role/GeneosTherapeuticsIncInvestmentInGeneosDetails",
      "http://www.inovio.com/role/GeneosTherapeuticsIncNarrativeDetails",
      "http://www.inovio.com/role/GeneosTherapeuticsIncPreferredstockInvestmentDetails",
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails",
      "http://www.inovio.com/role/StockholdersEquitySummaryofAuthorizedandIssuedCommonandPreferredStockDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Stock [Line Items]",
        "terseLabel": "Class of Stock [Line Items]",
        "verboseLabel": "Class of Stock [Line Items]"
       }
      }
     },
     "localname": "ClassOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails",
      "http://www.inovio.com/role/StockholdersEquitySummaryofAuthorizedandIssuedCommonandPreferredStockDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CollaborativeArrangementAccountingPolicy": {
     "auth_ref": [
      "r356"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for collaborative arrangements.",
        "label": "Collaborative Arrangement, Accounting Policy [Policy Text Block]",
        "terseLabel": "Collaboration Agreements"
       }
      }
     },
     "localname": "CollaborativeArrangementAccountingPolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/BasisofPresentationLiquidityandRisksandUncertaintiesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CollaborativeArrangementDisclosureTextBlock": {
     "auth_ref": [
      "r354",
      "r355",
      "r358"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.",
        "label": "Collaborative Arrangement Disclosure [Text Block]",
        "terseLabel": "Collaborative Agreements"
       }
      }
     },
     "localname": "CollaborativeArrangementDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CollaborativeArrangementMember": {
     "auth_ref": [
      "r357"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual arrangement that involves two or more parties that both: (i) actively participate in a joint operating activity and (ii) are exposed to significant risks and rewards that depend on the commercial success of the joint operating activity.",
        "label": "Collaborative Arrangement [Member]",
        "terseLabel": "Collaborative Arrangement, Product"
       }
      }
     },
     "localname": "CollaborativeArrangementMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]"
       }
      }
     },
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r104",
      "r105"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/BasisofPresentationLiquidityandRisksandUncertaintiesDetails",
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofStockholdersEquity",
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails",
      "http://www.inovio.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.inovio.com/role/GeneosTherapeuticsIncInvestmentInGeneosDetails",
      "http://www.inovio.com/role/GeneosTherapeuticsIncNarrativeDetails",
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Number of Shares, Par Value and Other Disclosures [Abstract]",
        "verboseLabel": "Summary of common and preferred stock authorized, issued and outstanding"
       }
      }
     },
     "localname": "CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquitySummaryofAuthorizedandIssuedCommonandPreferredStockDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommonStockOtherSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of shares of other common stock instruments held by shareholders, such as exchangeable shares. May be all or portion of the number of common shares authorized.",
        "label": "Common Stock, Other Shares, Outstanding",
        "terseLabel": "Common stock, other shares, outstanding (in shares)"
       }
      }
     },
     "localname": "CommonStockOtherSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquitySummaryofAuthorizedandIssuedCommonandPreferredStockDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares, authorized (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquitySummaryofAuthorizedandIssuedCommonandPreferredStockDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, shares, issued (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquitySummaryofAuthorizedandIssuedCommonandPreferredStockDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r14",
      "r241"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "terseLabel": "Common stock, shares, outstanding (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquitySummaryofAuthorizedandIssuedCommonandPreferredStockDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r14"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "verboseLabel": "Common stock"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r51",
      "r53",
      "r54",
      "r60",
      "r504",
      "r530"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofComprehensiveLoss": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive loss attributable to Inovio Pharmaceuticals, Inc."
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r51",
      "r53",
      "r59",
      "r362",
      "r363",
      "r382",
      "r503",
      "r529"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest",
        "negatedLabel": "Comprehensive loss attributable to non-controlling interest"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r51",
      "r53",
      "r58",
      "r361",
      "r382",
      "r502",
      "r528"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest",
        "totalLabel": "Comprehensive loss"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "auth_ref": [
      "r144",
      "r145",
      "r165",
      "r397",
      "r398",
      "r549"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.",
        "label": "Concentration Risk Type [Axis]",
        "terseLabel": "Concentration Risk Type [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "auth_ref": [
      "r144",
      "r145",
      "r165",
      "r397",
      "r398"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.",
        "label": "Concentration Risk Type [Domain]",
        "terseLabel": "Concentration Risk Type [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConsolidationVariableInterestEntityPolicy": {
     "auth_ref": [
      "r91",
      "r375",
      "r378",
      "r379"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for consolidation to describe the significant judgments and assumptions made in determining whether a variable interest held by the entity requires the variable interest entity to be consolidated and (or) disclose information about its involvement with the variable interest entity; the methodology used by the entity for determining whether or not it is the primary beneficiary of the variable interest entity; and the significant factors considered and judgments made in determining that the power to direct the activities that significantly impact the economic performance of the variable interest entity are shared (as defined).",
        "label": "Consolidation, Variable Interest Entity, Policy [Policy Text Block]",
        "terseLabel": "Variable Interest Entities (VIE)"
       }
      }
     },
     "localname": "ConsolidationVariableInterestEntityPolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/BasisofPresentationLiquidityandRisksandUncertaintiesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityCurrent": {
     "auth_ref": [
      "r252",
      "r253",
      "r272"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.",
        "label": "Contract with Customer, Liability, Current",
        "verboseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityNoncurrent": {
     "auth_ref": [
      "r252",
      "r253",
      "r272"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.",
        "label": "Contract with Customer, Liability, Noncurrent",
        "verboseLabel": "Deferred revenue, net of current portion"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": {
     "auth_ref": [
      "r273"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.",
        "label": "Contract with Customer, Liability, Revenue Recognized",
        "terseLabel": "Revenue recognized from deferred revenue"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityRevenueRecognized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/RevenueRecognitionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConversionOfStockSharesConverted1": {
     "auth_ref": [
      "r87",
      "r88",
      "r89"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Conversion of Stock, Shares Converted",
        "terseLabel": "Conversion of stock, shares converted (in shares)"
       }
      }
     },
     "localname": "ConversionOfStockSharesConverted1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ConversionOfStockSharesIssued1": {
     "auth_ref": [
      "r87",
      "r88",
      "r89"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Conversion of Stock, Shares Issued",
        "terseLabel": "Conversion of stock, shares issued (in shares)"
       }
      }
     },
     "localname": "ConversionOfStockSharesIssued1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ConvertibleDebt": {
     "auth_ref": [
      "r11",
      "r493",
      "r517"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Including the current and noncurrent portions, carrying amount of debt identified as being convertible into another form of financial instrument (typically the entity's common stock) as of the balance sheet date, which originally required full repayment more than twelve months after issuance or greater than the normal operating cycle of the company.",
        "label": "Convertible Debt",
        "terseLabel": "Convertible debt"
       }
      }
     },
     "localname": "ConvertibleDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConvertibleDebtMember": {
     "auth_ref": [
      "r228"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock.",
        "label": "Convertible Debt [Member]",
        "terseLabel": "Convertible Debt"
       }
      }
     },
     "localname": "ConvertibleDebtMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails",
      "http://www.inovio.com/role/ConvertibleDebtScheduleofMaturitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConvertibleDebtSecuritiesMember": {
     "auth_ref": [
      "r288"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt securities that can be exchanged for equity of the debt issuer at the option of the issuer or the holder.",
        "label": "Convertible Debt Securities [Member]",
        "verboseLabel": "Convertible notes"
       }
      }
     },
     "localname": "ConvertibleDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/NetLossPerShareScheduleofAntiDilutiveSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConvertibleDebtTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of borrowings which can be exchanged for a specified number of another security at the option of the issuer or the holder. Disclosures include, but are not limited to, principal amount, amortized premium or discount, and amount of liability and equity components.",
        "label": "Convertible Debt [Table Text Block]",
        "terseLabel": "Schedule of Convertible Debt"
       }
      }
     },
     "localname": "ConvertibleDebtTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConvertiblePreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Preferred stock that may be exchanged into common shares or other types of securities at the owner's option.",
        "label": "Convertible Preferred Stock [Member]",
        "terseLabel": "Convertible preferred stock"
       }
      }
     },
     "localname": "ConvertiblePreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/NetLossPerShareScheduleofAntiDilutiveSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CustomerConcentrationRiskMember": {
     "auth_ref": [
      "r143",
      "r165"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.",
        "label": "Customer Concentration Risk [Member]",
        "terseLabel": "Customer Concentration Risk"
       }
      }
     },
     "localname": "CustomerConcentrationRiskMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtConversionByUniqueDescriptionAxis": {
     "auth_ref": [
      "r87",
      "r89"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by description of debt issuances converted in a noncash or part noncash transaction.",
        "label": "Debt Conversion Description [Axis]",
        "terseLabel": "Debt Conversion Description [Axis]"
       }
      }
     },
     "localname": "DebtConversionByUniqueDescriptionAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtConversionConvertedInstrumentAmount1": {
     "auth_ref": [
      "r87",
      "r89"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Debt Conversion, Converted Instrument, Amount",
        "terseLabel": "Debt conversion, converted instrument principal amount"
       }
      }
     },
     "localname": "DebtConversionConvertedInstrumentAmount1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtConversionConvertedInstrumentSharesIssued1": {
     "auth_ref": [
      "r87",
      "r89"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or payments in the period.",
        "label": "Debt Conversion, Converted Instrument, Shares Issued",
        "terseLabel": "Debt conversion, converted instrument, shares issued (in shares)"
       }
      }
     },
     "localname": "DebtConversionConvertedInstrumentSharesIssued1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_DebtConversionNameDomain": {
     "auth_ref": [
      "r87",
      "r89"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name of the original debt issue that has been converted in a noncash (or part noncash) transaction during the accounting period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Debt Conversion, Name [Domain]",
        "terseLabel": "Debt Conversion, Name [Domain]"
       }
      }
     },
     "localname": "DebtConversionNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]",
        "terseLabel": "Debt Disclosure [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "auth_ref": [
      "r236"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.",
        "label": "Debt Disclosure [Text Block]",
        "terseLabel": "Convertible Debt"
       }
      }
     },
     "localname": "DebtDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebt"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r8",
      "r10",
      "r11",
      "r492",
      "r493",
      "r513"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]",
        "terseLabel": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.inovio.com/role/ConvertibleDebtBalanceofConvertibleBondsandNotesDetails",
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails",
      "http://www.inovio.com/role/ConvertibleDebtScheduleofMaturitiesDetails",
      "http://www.inovio.com/role/NetLossPerShareScheduleofAntiDilutiveSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent": {
     "auth_ref": [
      "r229"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The carrying amount of the equity component of convertible debt which may be settled in cash upon conversion.",
        "label": "Debt Instrument, Convertible, Carrying Amount of Equity Component",
        "terseLabel": "Carrying value"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentConvertibleConversionPrice1": {
     "auth_ref": [
      "r231"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The price per share of the conversion feature embedded in the debt instrument.",
        "label": "Debt Instrument, Convertible, Conversion Price",
        "terseLabel": "Debt instrument, convertible conversion price (in dollars per share)"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleConversionPrice1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_DebtInstrumentConvertibleConversionRatio1": {
     "auth_ref": [
      "r33",
      "r242",
      "r245",
      "r247"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ratio applied to the conversion of debt instrument into equity with equity shares divided by debt principal amount.",
        "label": "Debt Instrument, Convertible, Conversion Ratio",
        "terseLabel": "Debt instrument, convertible, conversion ratio"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleConversionRatio1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Threshold period of specified consecutive trading days within which common stock price to conversion price of convertible debt instrument must exceed threshold percentage for specified number of trading days to trigger conversion feature.",
        "label": "Debt Instrument, Convertible, Threshold Consecutive Trading Days",
        "terseLabel": "Debt instrument, convertible, threshold consecutive trading days"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleThresholdConsecutiveTradingDays1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minimum percentage of common stock price to conversion price of convertible debt instruments to determine eligibility of conversion.",
        "label": "Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger",
        "terseLabel": "Debt instrument, convertible, threshold percentage of stock price trigger"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentConvertibleThresholdTradingDays": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Threshold number of specified trading days that common stock price to conversion price of convertible debt instruments must exceed threshold percentage within a specified consecutive trading period to trigger conversion feature.",
        "label": "Debt Instrument, Convertible, Threshold Trading Days",
        "terseLabel": "Debt instrument, convertible, threshold trading days"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleThresholdTradingDays",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "auth_ref": [
      "r414",
      "r416"
     ],
     "calculation": {
      "http://www.inovio.com/role/ConvertibleDebtBalanceofConvertibleBondsandNotesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face (par) amount of debt instrument at time of issuance.",
        "label": "Debt Instrument, Face Amount",
        "terseLabel": "Original principal amount"
       }
      }
     },
     "localname": "DebtInstrumentFaceAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtBalanceofConvertibleBondsandNotesDetails",
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentFairValue": {
     "auth_ref": [
      "r394"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable.",
        "label": "Debt Instrument, Fair Value Disclosure",
        "terseLabel": "Fair value of date conversion"
       }
      }
     },
     "localname": "DebtInstrumentFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentInterestRateEffectivePercentage": {
     "auth_ref": [
      "r32",
      "r232",
      "r414"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.",
        "label": "Debt Instrument, Interest Rate, Effective Percentage",
        "terseLabel": "Debt instrument, effective interest rate"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateEffectivePercentage",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "auth_ref": [
      "r32"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "verboseLabel": "Stated interest rate"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails",
      "http://www.inovio.com/role/ConvertibleDebtScheduleofMaturitiesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Instrument [Line Items]",
        "terseLabel": "Debt Instrument [Line Items]"
       }
      }
     },
     "localname": "DebtInstrumentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtBalanceofConvertibleBondsandNotesDetails",
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails",
      "http://www.inovio.com/role/ConvertibleDebtScheduleofMaturitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r34"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]",
        "terseLabel": "Debt Instrument, Name [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.inovio.com/role/ConvertibleDebtBalanceofConvertibleBondsandNotesDetails",
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails",
      "http://www.inovio.com/role/ConvertibleDebtScheduleofMaturitiesDetails",
      "http://www.inovio.com/role/NetLossPerShareScheduleofAntiDilutiveSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPricePercentage": {
     "auth_ref": [
      "r510"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage price of original principal amount of debt at which debt can be redeemed by the issuer.",
        "label": "Debt Instrument, Redemption Price, Percentage",
        "terseLabel": "Debt instrument, redemption price percentage"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPricePercentage",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentTable": {
     "auth_ref": [
      "r34",
      "r99",
      "r242",
      "r246",
      "r247",
      "r248",
      "r413",
      "r414",
      "r416",
      "r511"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Schedule of Long-term Debt Instruments [Table]",
        "terseLabel": "Schedule of Long-term Debt Instruments [Table]"
       }
      }
     },
     "localname": "DebtInstrumentTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtBalanceofConvertibleBondsandNotesDetails",
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails",
      "http://www.inovio.com/role/ConvertibleDebtScheduleofMaturitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentUnamortizedDiscount": {
     "auth_ref": [
      "r413",
      "r416"
     ],
     "calculation": {
      "http://www.inovio.com/role/ConvertibleDebtBalanceofConvertibleBondsandNotesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after accumulated amortization, of debt discount.",
        "label": "Debt Instrument, Unamortized Discount",
        "negatedTerseLabel": "Unamortized debt discount on the liability component",
        "terseLabel": "Debt instrument, unamortized discount"
       }
      }
     },
     "localname": "DebtInstrumentUnamortizedDiscount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtBalanceofConvertibleBondsandNotesDetails",
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleRealizedGain": {
     "auth_ref": [
      "r180"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of realized gain on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Realized Gain",
        "terseLabel": "Realized gain on investments"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleRealizedGain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss": {
     "auth_ref": [
      "r180"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of realized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Realized Loss",
        "terseLabel": "Realized loss on investments"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleRealizedLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTable": {
     "auth_ref": [
      "r181"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale [Table]",
        "terseLabel": "Debt Securities, Available-for-sale [Table]"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsSummaryofAvailableforsaleSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeconsolidationGainOrLossAmount": {
     "auth_ref": [
      "r373"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) from deconsolidation of subsidiary and derecognition of group of assets constituting transfer of business or nonprofit activity, excluding conveyance of oil and gas mineral rights and transfer of good or service in contract with customer.",
        "label": "Deconsolidation, Gain (Loss), Amount",
        "negatedTerseLabel": "Gain on deconsolidation of Geneos",
        "verboseLabel": "Gain on deconsolidation of investment"
       }
      }
     },
     "localname": "DeconsolidationGainOrLossAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/GeneosTherapeuticsIncDeconsolidationAccountingDetails",
      "http://www.inovio.com/role/GeneosTherapeuticsIncNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount": {
     "auth_ref": [
      "r374"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) from remeasurement to fair value of retained investment in former subsidiary and group of assets constituting business or nonprofit activity deconsolidated and derecognized, excluding conveyance of oil and gas mineral rights and transfer of product or service in contract with customer.",
        "label": "Deconsolidation, Revaluation of Retained Investment, Gain (Loss), Amount",
        "terseLabel": "Deconsolidation gain, remeasurement of retained noncontrolling investment to fair value"
       }
      }
     },
     "localname": "DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/GeneosTherapeuticsIncNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredFinanceCostsNet": {
     "auth_ref": [
      "r27",
      "r415"
     ],
     "calculation": {
      "http://www.inovio.com/role/ConvertibleDebtBalanceofConvertibleBondsandNotesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.",
        "label": "Debt Issuance Costs, Net",
        "negatedTerseLabel": "Unamortized debt issuance cost",
        "terseLabel": "Unamortized debt issuance cost"
       }
      }
     },
     "localname": "DeferredFinanceCostsNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtBalanceofConvertibleBondsandNotesDetails",
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilitiesNet": {
     "auth_ref": [
      "r335",
      "r336"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.",
        "label": "Deferred Income Tax Liabilities, Net",
        "verboseLabel": "Deferred tax liabilities"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r83",
      "r223"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation",
        "verboseLabel": "Depreciation"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisaggregationOfRevenueLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Disaggregation of Revenue [Line Items]",
        "terseLabel": "Disaggregation of Revenue [Line Items]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/RevenueRecognitionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTable": {
     "auth_ref": [
      "r271",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table]",
        "terseLabel": "Disaggregation of Revenue [Table]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/RevenueRecognitionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r333"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement [Text Block]",
        "terseLabel": "Stock-Based Compensation"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockBasedCompensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Payment Arrangement [Abstract]",
        "terseLabel": "Share-based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DueToRelatedPartiesCurrent": {
     "auth_ref": [
      "r28",
      "r101",
      "r431"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of obligations due all related parties. For classified balance sheets, represents the current portion of such liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Due to Related Parties, Current",
        "verboseLabel": "Accounts payable and accrued expenses due to affiliated entities"
       }
      }
     },
     "localname": "DueToRelatedPartiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DueToRelatedPartiesCurrentAndNoncurrent": {
     "auth_ref": [
      "r101",
      "r431",
      "r499",
      "r525"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of obligations due all related parties.",
        "label": "Due to Related Parties",
        "terseLabel": "Accounts payable/accrued liabilities"
       }
      }
     },
     "localname": "DueToRelatedPartiesCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "terseLabel": "Earnings Per Share [Abstract]"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasicAndDiluted": {
     "auth_ref": [
      "r131"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic and Diluted",
        "terseLabel": "Basic and diluted (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareBasicAndDilutedAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Basic and Diluted [Abstract]",
        "terseLabel": "Net loss per share attributable to Inovio Pharmaceuticals, Inc. stockholders"
       }
      }
     },
     "localname": "EarningsPerShareBasicAndDilutedAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r133",
      "r134",
      "r135",
      "r137"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "Net Loss Per Share"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/NetLossPerShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r404"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "terseLabel": "Effect of exchange rate changes on cash and cash equivalents"
       }
      }
     },
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability": {
     "auth_ref": [
      "r384"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value as of the balance sheet date of the embedded derivative or group of embedded derivatives classified as a liability.",
        "label": "Embedded Derivative, Fair Value of Embedded Derivative Liability",
        "terseLabel": "Fair value of derivative liability"
       }
      }
     },
     "localname": "EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet": {
     "auth_ref": [
      "r385"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 4.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net Increase or Decrease in the fair value of the embedded derivative or group of embedded derivatives included in earnings in the period.",
        "label": "Embedded Derivative, Gain (Loss) on Embedded Derivative, Net",
        "terseLabel": "Change in fair value of derivative liability"
       }
      }
     },
     "localname": "EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofOperations",
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "auth_ref": [
      "r317"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount",
        "terseLabel": "Total unrecognized compensation cost related to unvested stock options"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockBasedCompensationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r317"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Period over which total unrecognized compensation cost related to unvested stock options will be recognized (in years)"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockBasedCompensationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [
      "r315"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-based Payment Arrangement, Option [Member]",
        "terseLabel": "Stock Options",
        "verboseLabel": "Options to purchase common stock"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/NetLossPerShareScheduleofAntiDilutiveSecuritiesDetails",
      "http://www.inovio.com/role/StockBasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r104",
      "r105",
      "r106",
      "r111",
      "r120",
      "r122",
      "r138",
      "r191",
      "r241",
      "r249",
      "r324",
      "r325",
      "r326",
      "r343",
      "r344",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r539",
      "r540",
      "r541"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityMethodInvestmentOwnershipPercentage": {
     "auth_ref": [
      "r185"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.",
        "label": "Equity Method Investment, Ownership Percentage",
        "terseLabel": "Ownership percentage"
       }
      }
     },
     "localname": "EquityMethodInvestmentOwnershipPercentage",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/GeneosTherapeuticsIncNarrativeDetails",
      "http://www.inovio.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EquityMethodInvestments": {
     "auth_ref": [
      "r26",
      "r152",
      "r184"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.",
        "label": "Equity Method Investments",
        "netLabel": "Fair Value",
        "periodEndLabel": "Investment in Geneos as of March 31, 2021",
        "periodStartLabel": "Investment in Geneos upon deconsolidation",
        "terseLabel": "Investment in Geneos",
        "verboseLabel": "Investment in equity method investments"
       }
      }
     },
     "localname": "EquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.inovio.com/role/GeneosTherapeuticsIncInvestmentInGeneosDetails",
      "http://www.inovio.com/role/GeneosTherapeuticsIncNarrativeDetails",
      "http://www.inovio.com/role/GeneosTherapeuticsIncPreferredstockInvestmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquityMethodInvestmentsTextBlock": {
     "auth_ref": [
      "r187"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of equity method investments including, but not limited to, name of each investee or group of investments, percentage ownership, difference between recorded amount of an investment and the value of the underlying equity in the net assets, and summarized financial information.",
        "label": "Equity Method Investments [Table Text Block]",
        "terseLabel": "Schedule of Equity Method Investments"
       }
      }
     },
     "localname": "EquityMethodInvestmentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/GeneosTherapeuticsIncTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EquitySecuritiesFvNi": {
     "auth_ref": [
      "r393"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.inovio.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).",
        "label": "Equity Securities, FV-NI",
        "verboseLabel": "Investment in affiliated entities"
       }
      }
     },
     "localname": "EquitySecuritiesFvNi",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.inovio.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss": {
     "auth_ref": [
      "r183",
      "r531"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 6.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).",
        "label": "Equity Securities, FV-NI, Unrealized Gain (Loss)",
        "terseLabel": "Net unrealized loss on available-for-sale equity securities",
        "verboseLabel": "Unrealized gain (loss) on available-for-sale equity securities"
       }
      }
     },
     "localname": "EquitySecuritiesFvNiUnrealizedGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofOperations",
      "http://www.inovio.com/role/ShorttermInvestmentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesFvNiUnrealizedLoss": {
     "auth_ref": [
      "r183"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrealized loss on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).",
        "label": "Equity Securities, FV-NI, Unrealized Loss",
        "terseLabel": "Net unrealized loss on available-for-sale equity securities"
       }
      }
     },
     "localname": "EquitySecuritiesFvNiUnrealizedLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValuePolicyTextBlock": {
     "auth_ref": [
      "r182"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for investment in equity security without readily determinable fair value, which does not qualify for practical expedient to estimate fair value using net asset value per share. Includes, but is not limited to, information considered for determining upward and downward adjustment from observable price change.",
        "label": "Equity Securities without Readily Determinable Fair Value [Policy Text Block]",
        "terseLabel": "Equity Investments"
       }
      }
     },
     "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValuePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/BasisofPresentationLiquidityandRisksandUncertaintiesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock": {
     "auth_ref": [
      "r388"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.",
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]",
        "terseLabel": "Schedule of Fair Value Measurement Inputs and Valuation Techniques"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/GeneosTherapeuticsIncTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]",
        "terseLabel": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]"
       }
      }
     },
     "localname": "FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueDetails",
      "http://www.inovio.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByBalanceSheetGroupingTable": {
     "auth_ref": [
      "r386",
      "r395",
      "r396"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities.",
        "label": "Fair Value, by Balance Sheet Grouping [Table]",
        "terseLabel": "Fair Value, by Balance Sheet Grouping [Table]"
       }
      }
     },
     "localname": "FairValueByBalanceSheetGroupingTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueDetails",
      "http://www.inovio.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r296",
      "r387",
      "r440",
      "r441",
      "r442"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueDetails",
      "http://www.inovio.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r386",
      "r387",
      "r389",
      "r390",
      "r392"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Measurement Frequency [Axis]",
        "terseLabel": "Measurement Frequency [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]",
        "terseLabel": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r391"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "verboseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/FairValueMeasurements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r288",
      "r289",
      "r294",
      "r296",
      "r387",
      "r440"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Level 1",
        "verboseLabel": "Quoted Prices in Active Markets (Level\u00a01)"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueDetails",
      "http://www.inovio.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r288",
      "r289",
      "r294",
      "r296",
      "r387",
      "r441"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "verboseLabel": "Significant Other Unobservable Inputs (Level\u00a02)"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r296",
      "r387",
      "r442"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "verboseLabel": "Significant Unobservable Inputs (Level\u00a03)"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Measurement Frequency [Domain]",
        "terseLabel": "Measurement Frequency [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r296",
      "r440",
      "r441",
      "r442"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value, Measurements, Fair Value Hierarchy [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueDetails",
      "http://www.inovio.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r391",
      "r392"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Fair Value, Recurring [Member]",
        "terseLabel": "Fair Value, Measurements, Recurring"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r176",
      "r177",
      "r196",
      "r197",
      "r198",
      "r199",
      "r200",
      "r202",
      "r203",
      "r204",
      "r205",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]",
        "terseLabel": "Financial Instrument [Axis]",
        "verboseLabel": "Financial Instrument [Axis]"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueDetails",
      "http://www.inovio.com/role/ShorttermInvestmentsSummaryofAvailableforsaleSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Finite-Lived Intangible Asset, Useful Life",
        "terseLabel": "Useful life (in years)"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CriticalAccountingPoliciesDetails",
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsScheduleGoodwillandIntangibleAssetsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "auth_ref": [
      "r218"
     ],
     "calculation": {
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsScheduleGoodwillandIntangibleAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Accumulated Amortization",
        "negatedLabel": "Intangible assets, accumulated amortization"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsScheduleGoodwillandIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": {
     "auth_ref": [
      "r220"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One",
        "terseLabel": "Estimated aggregate amortization expense for 2022"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in remainder of current fiscal year.",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year",
        "terseLabel": "Estimated aggregate amortization expense for remainder of 2021"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": {
     "auth_ref": [
      "r220"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Four",
        "verboseLabel": "Estimated aggregate amortization expense for 2025"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": {
     "auth_ref": [
      "r220"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three",
        "verboseLabel": "Estimated aggregate amortization expense for 2024"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": {
     "auth_ref": [
      "r220"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two",
        "verboseLabel": "Estimated aggregate amortization expense for 2023"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r213",
      "r214",
      "r218",
      "r221",
      "r469",
      "r476"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by major type or class of finite-lived intangible assets.",
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsScheduleGoodwillandIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsGross": {
     "auth_ref": [
      "r218",
      "r476"
     ],
     "calculation": {
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsScheduleGoodwillandIntangibleAssetsDetails": {
       "order": 2.0,
       "parentTag": "ino_GoodwillAndIntangibleAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Gross",
        "verboseLabel": "Intangible assets, gross"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsScheduleGoodwillandIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Finite-Lived Intangible Assets [Line Items]",
        "terseLabel": "Finite-Lived Intangible Assets [Line Items]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CriticalAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r213",
      "r217"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.",
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsScheduleGoodwillandIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "auth_ref": [
      "r218",
      "r469"
     ],
     "calculation": {
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsScheduleGoodwillandIntangibleAssetsDetails": {
       "order": 2.0,
       "parentTag": "ino_GoodwillAndIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Net",
        "totalLabel": "Intangible assets, net book value"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsScheduleGoodwillandIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Assets, Net [Abstract]",
        "verboseLabel": "Indefinite lived:"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsScheduleGoodwillandIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ForeignCountryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax departments of governments entitled to levy and collect income taxes from the entity outside the entity's country of domicile.",
        "label": "Foreign Tax Authority [Member]",
        "terseLabel": "Foreign Tax Authority"
       }
      }
     },
     "localname": "ForeignCountryMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ForeignCurrencyTransactionGainLossBeforeTax": {
     "auth_ref": [
      "r400",
      "r401",
      "r402",
      "r403"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.",
        "label": "Foreign Currency Transaction Gain (Loss), before Tax",
        "negatedTerseLabel": "Unrealized transaction loss on foreign-currency denominated debt"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionGainLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": {
     "auth_ref": [
      "r91",
      "r411"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.",
        "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]",
        "terseLabel": "Foreign Currency Translation"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/BasisofPresentationLiquidityandRisksandUncertaintiesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GainLossOnInvestments": {
     "auth_ref": [
      "r65",
      "r83",
      "r171"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of realized and unrealized gain (loss) on investment.",
        "label": "Gain (Loss) on Investments",
        "negatedTerseLabel": "Loss on short-term investments"
       }
      }
     },
     "localname": "GainLossOnInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainsLossesOnExtinguishmentOfDebt": {
     "auth_ref": [
      "r83",
      "r234",
      "r235"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.",
        "label": "Gain (Loss) on Extinguishment of Debt",
        "terseLabel": "Gain on extinguishment of debt"
       }
      }
     },
     "localname": "GainsLossesOnExtinguishmentOfDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r64"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "verboseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r61"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General and Administrative Expense [Member]",
        "terseLabel": "General and Administrative Expense"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockBasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Goodwill": {
     "auth_ref": [
      "r206",
      "r207",
      "r490"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 7.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsScheduleGoodwillandIntangibleAssetsDetails": {
       "order": 1.0,
       "parentTag": "ino_GoodwillAndIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill",
        "totalLabel": "Goodwill, net book value",
        "verboseLabel": "Goodwill"
       }
      }
     },
     "localname": "Goodwill",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsScheduleGoodwillandIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill and Intangible Assets Disclosure [Abstract]",
        "terseLabel": "Goodwill and Intangible Assets Disclosure [Abstract]"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r222"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for goodwill and intangible assets.",
        "label": "Goodwill and Intangible Assets Disclosure [Text Block]",
        "verboseLabel": "Goodwill and Intangible Assets"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/GoodwillandIntangibleAssets"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock": {
     "auth_ref": [
      "r91",
      "r210",
      "r215"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets.",
        "label": "Goodwill and Intangible Assets, Policy [Policy Text Block]",
        "terseLabel": "Valuation of Intangible Assets and Goodwill"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/BasisofPresentationLiquidityandRisksandUncertaintiesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GoodwillGross": {
     "auth_ref": [
      "r208",
      "r209"
     ],
     "calculation": {
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsScheduleGoodwillandIntangibleAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_Goodwill",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Gross",
        "verboseLabel": "Goodwill, gross"
       }
      }
     },
     "localname": "GoodwillGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsScheduleGoodwillandIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments": {
     "auth_ref": [
      "r100",
      "r151",
      "r154",
      "r157",
      "r160",
      "r162"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.",
        "label": "Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest",
        "totalLabel": "Net loss before share in net loss of Geneos"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromEquityMethodInvestments": {
     "auth_ref": [
      "r56",
      "r83",
      "r150",
      "r184",
      "r500",
      "r526"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      },
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) for proportionate share of equity method investee's income (loss).",
        "label": "Income (Loss) from Equity Method Investments",
        "negatedTerseLabel": "Share of net loss in Geneos",
        "terseLabel": "Share in net loss of Geneos"
       }
      }
     },
     "localname": "IncomeLossFromEquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows",
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofOperations",
      "http://www.inovio.com/role/GeneosTherapeuticsIncNarrativeDetails",
      "http://www.inovio.com/role/GeneosTherapeuticsIncPreferredstockInvestmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]",
        "terseLabel": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r225"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs, by Report Line [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockBasedCompensationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Employee Service Share-based Compensation, Allocation of Recognized Period Costs, Report Line [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockBasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "auth_ref": [
      "r338"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by tax jurisdiction.",
        "label": "Income Tax Authority [Axis]",
        "terseLabel": "Income Tax Authority [Axis]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.",
        "label": "Income Tax Authority [Domain]",
        "terseLabel": "Income Tax Authority [Domain]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]",
        "terseLabel": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r337",
      "r339",
      "r340",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
     "auth_ref": [
      "r82"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 20.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.",
        "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities",
        "verboseLabel": "Accounts payable and accrued expenses"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties": {
     "auth_ref": [
      "r82"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 22.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the obligations due for goods and services provided by the following types of related parties: a parent company and its subsidiaries, subsidiaries of a common parent, an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entities' management, an entity and its principal owners, management, or member of their immediate families, affiliates, or other parties with the ability to exert significant influence.",
        "label": "Increase (Decrease) in Accounts Payable, Related Parties",
        "verboseLabel": "Accounts payable and accrued expenses due to affiliated entities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayableRelatedParties",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r82"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 15.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Accounts receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties": {
     "auth_ref": [
      "r82"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 16.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amount due to the reporting entity for good and services provided to the following types of related parties: a parent company and its subsidiaries; subsidiaries of a common parent; an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entity's management, an entity and its principal owners, management, member of their immediate families, affiliates, or other parties with the ability to exert significant influence.",
        "label": "Increase (Decrease) in Accounts Receivable, Related Parties",
        "negatedTerseLabel": "Accounts receivable from affiliated entities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivableRelatedParties",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": {
     "auth_ref": [
      "r82"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 23.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Increase (Decrease) in Contract with Customer, Liability",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "IncreaseDecreaseInContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInDerivativeLiabilities": {
     "auth_ref": [
      "r82"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the period in the carrying value of derivative instruments reported as liabilities that are due to be disposed of within one year (or the normal operating cycle, if longer).",
        "label": "Increase (Decrease) in Derivative Liabilities",
        "terseLabel": "Change in fair value of derivative liability"
       }
      }
     },
     "localname": "IncreaseDecreaseInDerivativeLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "verboseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherAccruedLiabilities": {
     "auth_ref": [
      "r82"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in other expenses incurred but not yet paid.",
        "label": "Increase (Decrease) in Other Accrued Liabilities",
        "terseLabel": "Amounts accrued for purchases of property and equipment"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingAssets": {
     "auth_ref": [
      "r82"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 19.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in operating assets classified as other.",
        "label": "Increase (Decrease) in Other Operating Assets",
        "negatedLabel": "Other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherOperatingAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingLiabilities": {
     "auth_ref": [
      "r82"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 28.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in operating liabilities classified as other.",
        "label": "Increase (Decrease) in Other Operating Liabilities",
        "terseLabel": "Other liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherOperatingLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r82"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 17.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Indefinite-lived Intangible Assets (Excluding Goodwill) [Abstract]",
        "verboseLabel": "Definite lived:"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsScheduleGoodwillandIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InformationByCategoryOfDebtSecurityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by category of debt security, either available-for-sale or held-to-maturity.",
        "label": "Debt Security Category [Axis]",
        "terseLabel": "Debt Security Category [Axis]"
       }
      }
     },
     "localname": "InformationByCategoryOfDebtSecurityAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "auth_ref": [
      "r211",
      "r216"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.",
        "label": "Intangible Assets, Net (Excluding Goodwill)",
        "terseLabel": "Intangible assets, net",
        "verboseLabel": "Intangible assets, net"
       }
      }
     },
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.inovio.com/role/CriticalAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Intangible Assets, Net (Excluding Goodwill) [Abstract]",
        "verboseLabel": "Schedule of intangible assets by major asset class"
       }
      }
     },
     "localname": "IntangibleAssetsNetExcludingGoodwillAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsScheduleGoodwillandIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r55",
      "r149",
      "r412",
      "r415",
      "r505"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 3.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "negatedTerseLabel": "Interest expense",
        "terseLabel": "Non-cash interest expense"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofOperations",
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpenseDebt": {
     "auth_ref": [
      "r66",
      "r233"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt.",
        "label": "Interest Expense, Debt",
        "terseLabel": "Interest expense, contractual interest"
       }
      }
     },
     "localname": "InterestExpenseDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestIncomeOperating": {
     "auth_ref": [
      "r62"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating interest income, including, but not limited to, amortization and accretion of premiums and discounts on securities.",
        "label": "Interest Income, Operating",
        "terseLabel": "Interest income"
       }
      }
     },
     "localname": "InterestIncomeOperating",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPaidNet": {
     "auth_ref": [
      "r77",
      "r80",
      "r86"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "terseLabel": "Interest paid"
       }
      }
     },
     "localname": "InterestPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentOwnedBalanceShares": {
     "auth_ref": [
      "r550",
      "r551"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Balance held at close of period in number of shares.",
        "label": "Investment Owned, Balance, Shares",
        "terseLabel": "Investment owned (in shares)",
        "verboseLabel": "Shares (in shares)"
       }
      }
     },
     "localname": "InvestmentOwnedBalanceShares",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.inovio.com/role/GeneosTherapeuticsIncInvestmentInGeneosDetails",
      "http://www.inovio.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments, Debt and Equity Securities [Abstract]",
        "terseLabel": "Investments, Debt and Equity Securities [Abstract]"
       }
      }
     },
     "localname": "InvestmentsDebtAndEquitySecuritiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r181",
      "r489",
      "r508",
      "r552"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for  investments in certain debt and equity securities.",
        "label": "Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]",
        "verboseLabel": "Short-term Investments"
       }
      }
     },
     "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeaseCost": {
     "auth_ref": [
      "r424",
      "r426"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lease cost recognized by lessee for lease contract.",
        "label": "Lease, Cost",
        "terseLabel": "Lease cost"
       }
      }
     },
     "localname": "LeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]",
        "terseLabel": "Leases [Abstract]"
       }
      }
     },
     "localname": "LeasesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Lessee, Lease, Description [Line Items]",
        "terseLabel": "Lessee, Lease, Description [Line Items]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "auth_ref": [
      "r421"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about lessee's leases.",
        "label": "Lessee, Lease, Description [Table]",
        "terseLabel": "Lessee, Lease, Description [Table]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "auth_ref": [
      "r419"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.",
        "label": "Lessee, Leases [Policy Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeLeasesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/BasisofPresentationLiquidityandRisksandUncertaintiesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r425"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "terseLabel": "Schedule of Future Minimum Rental Payments for Operating Leases"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r425"
     ],
     "calculation": {
      "http://www.inovio.com/role/LeasesSummaryofFutureMinimumLeasePaymentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "totalLabel": "Total remaining lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/LeasesSummaryofFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r425"
     ],
     "calculation": {
      "http://www.inovio.com/role/LeasesSummaryofFutureMinimumLeasePaymentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/LeasesSummaryofFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r425"
     ],
     "calculation": {
      "http://www.inovio.com/role/LeasesSummaryofFutureMinimumLeasePaymentsDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/LeasesSummaryofFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r425"
     ],
     "calculation": {
      "http://www.inovio.com/role/LeasesSummaryofFutureMinimumLeasePaymentsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/LeasesSummaryofFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r425"
     ],
     "calculation": {
      "http://www.inovio.com/role/LeasesSummaryofFutureMinimumLeasePaymentsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/LeasesSummaryofFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": {
     "auth_ref": [
      "r425"
     ],
     "calculation": {
      "http://www.inovio.com/role/LeasesSummaryofFutureMinimumLeasePaymentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year",
        "terseLabel": "Remainder of 2021"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/LeasesSummaryofFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r425"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "negatedTerseLabel": "Less: present value adjustment"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/LeasesSummaryofFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseRemainingLeaseTerm": {
     "auth_ref": [
      "r420"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Remaining lease term of operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Remaining Lease Term",
        "terseLabel": "Operating lease, remaining lease term"
       }
      }
     },
     "localname": "LesseeOperatingLeaseRemainingLeaseTerm",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "auth_ref": [
      "r427"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.",
        "label": "Lessee, Operating Leases [Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeOperatingLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/Leases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r30",
      "r95",
      "r156",
      "r186",
      "r366",
      "r376",
      "r377",
      "r399"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r22",
      "r95",
      "r186",
      "r399",
      "r495",
      "r521"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders\u2019 equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "verboseLabel": "LIABILITIES AND STOCKHOLDERS\u2019 EQUITY"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r31",
      "r95",
      "r186",
      "r366",
      "r376",
      "r377",
      "r399"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "verboseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LicenseMember": {
     "auth_ref": [
      "r275"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right to use intangible asset. Intangible asset includes, but is not limited to, patent, copyright, technology, manufacturing process, software or trademark.",
        "label": "License [Member]",
        "terseLabel": "Revenue under collaborative research and development arrangements"
       }
      }
     },
     "localname": "LicenseMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails",
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LicensingAgreementsMember": {
     "auth_ref": [
      "r353"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rights, generally of limited duration, under a license arrangement (for example, to sell or otherwise utilize specified products or processes in a specified territory).",
        "label": "Licensing Agreements [Member]",
        "verboseLabel": "Licenses"
       }
      }
     },
     "localname": "LicensingAgreementsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsScheduleGoodwillandIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LongTermDebt": {
     "auth_ref": [
      "r11",
      "r230",
      "r493",
      "r517"
     ],
     "calculation": {
      "http://www.inovio.com/role/ConvertibleDebtBalanceofConvertibleBondsandNotesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.inovio.com/role/ConvertibleDebtScheduleofMaturitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt",
        "totalLabel": "Net carrying amount"
       }
      }
     },
     "localname": "LongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtBalanceofConvertibleBondsandNotesDetails",
      "http://www.inovio.com/role/ConvertibleDebtScheduleofMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": {
     "auth_ref": [
      "r102",
      "r226"
     ],
     "calculation": {
      "http://www.inovio.com/role/ConvertibleDebtScheduleofMaturitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year One",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtScheduleofMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree": {
     "auth_ref": [
      "r102",
      "r226"
     ],
     "calculation": {
      "http://www.inovio.com/role/ConvertibleDebtScheduleofMaturitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year Three",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtScheduleofMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": {
     "auth_ref": [
      "r102",
      "r226"
     ],
     "calculation": {
      "http://www.inovio.com/role/ConvertibleDebtScheduleofMaturitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year Two",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtScheduleofMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear": {
     "auth_ref": [
      "r102"
     ],
     "calculation": {
      "http://www.inovio.com/role/ConvertibleDebtScheduleofMaturitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in remainder of current fiscal year.",
        "label": "Long-Term Debt, Maturity, Remainder of Fiscal Year",
        "terseLabel": "Remainder of 2021"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtScheduleofMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "auth_ref": [
      "r34"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-term debt.",
        "label": "Long-term Debt, Type [Axis]",
        "terseLabel": "Long-term Debt, Type [Axis]"
       }
      }
     },
     "localname": "LongtermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails",
      "http://www.inovio.com/role/ConvertibleDebtScheduleofMaturitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "auth_ref": [
      "r34",
      "r227"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Long-term Debt, Type [Domain]",
        "terseLabel": "Long-term Debt, Type [Domain]"
       }
      }
     },
     "localname": "LongtermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails",
      "http://www.inovio.com/role/ConvertibleDebtScheduleofMaturitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputExpectedTermMember": {
     "auth_ref": [
      "r388"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using period financial instrument is expected to be outstanding. Excludes maturity date.",
        "label": "Measurement Input, Expected Term [Member]",
        "terseLabel": "Expected term (years)"
       }
      }
     },
     "localname": "MeasurementInputExpectedTermMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/GeneosTherapeuticsIncFairValueAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputPriceVolatilityMember": {
     "auth_ref": [
      "r388"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using rate at which price of security will increase (decrease) for given set of returns.",
        "label": "Measurement Input, Price Volatility [Member]",
        "terseLabel": "Volatility"
       }
      }
     },
     "localname": "MeasurementInputPriceVolatilityMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/GeneosTherapeuticsIncFairValueAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputRiskFreeInterestRateMember": {
     "auth_ref": [
      "r388"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using interest rate on instrument with zero risk of financial loss.",
        "label": "Measurement Input, Risk Free Interest Rate [Member]",
        "terseLabel": "Risk-free interest rate"
       }
      }
     },
     "localname": "MeasurementInputRiskFreeInterestRateMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/GeneosTherapeuticsIncFairValueAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputTypeAxis": {
     "auth_ref": [
      "r388"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Axis]",
        "terseLabel": "Measurement Input Type [Axis]"
       }
      }
     },
     "localname": "MeasurementInputTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/GeneosTherapeuticsIncFairValueAssumptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MeasurementInputTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Domain]",
        "terseLabel": "Measurement Input Type [Domain]"
       }
      }
     },
     "localname": "MeasurementInputTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/GeneosTherapeuticsIncFairValueAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MinorityInterest": {
     "auth_ref": [
      "r40",
      "r95",
      "r186",
      "r399",
      "r494",
      "r520"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).",
        "label": "Stockholders' Equity Attributable to Noncontrolling Interest",
        "terseLabel": "Carrying value of noncontrolling interest"
       }
      }
     },
     "localname": "MinorityInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/GeneosTherapeuticsIncDeconsolidationAccountingDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MinorityInterestLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Noncontrolling Interest [Line Items]",
        "terseLabel": "Noncontrolling Interest [Line Items]"
       }
      }
     },
     "localname": "MinorityInterestLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/GeneosTherapeuticsIncDeconsolidationAccountingDetails",
      "http://www.inovio.com/role/GeneosTherapeuticsIncFairValueAssumptionsDetails",
      "http://www.inovio.com/role/GeneosTherapeuticsIncInvestmentInGeneosDetails",
      "http://www.inovio.com/role/GeneosTherapeuticsIncNarrativeDetails",
      "http://www.inovio.com/role/GeneosTherapeuticsIncPreferredstockInvestmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MinorityInterestOwnershipPercentageByParent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The parent entity's interest in net assets of the subsidiary, expressed as a percentage.",
        "label": "Noncontrolling Interest, Ownership Percentage by Parent",
        "terseLabel": "Noncontrolling interest, ownership percentage by parent"
       }
      }
     },
     "localname": "MinorityInterestOwnershipPercentageByParent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/GeneosTherapeuticsIncNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_MinorityInterestTable": {
     "auth_ref": [
      "r40",
      "r63",
      "r360",
      "r372"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of noncontrolling interest disclosure which includes the name of the subsidiary, the ownership percentage held by the parent, the ownership percentage held by the noncontrolling owners, the amount of the noncontrolling interest, the location of this amount on the balance sheet (when not reported separately), an explanation of the increase or decrease in the amount of the noncontrolling interest, the noncontrolling interest share of the net Income or Loss of the subsidiary, the location of this amount on the income statement (when not reported separately), the nature of the noncontrolling interest such as background information and terms, the amount of the noncontrolling interest represented by preferred stock, a description of the preferred stock, and the dividend requirements of the preferred stock.",
        "label": "Noncontrolling Interest [Table]",
        "terseLabel": "Noncontrolling Interest [Table]"
       }
      }
     },
     "localname": "MinorityInterestTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/GeneosTherapeuticsIncDeconsolidationAccountingDetails",
      "http://www.inovio.com/role/GeneosTherapeuticsIncFairValueAssumptionsDetails",
      "http://www.inovio.com/role/GeneosTherapeuticsIncInvestmentInGeneosDetails",
      "http://www.inovio.com/role/GeneosTherapeuticsIncNarrativeDetails",
      "http://www.inovio.com/role/GeneosTherapeuticsIncPreferredstockInvestmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember": {
     "auth_ref": [
      "r288"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt securities collateralized by real estate mortgage loans (mortgages), issued by US Government Sponsored Enterprises, such as Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac).",
        "label": "Mortgage-backed Securities, Issued by US Government Sponsored Enterprises [Member]",
        "terseLabel": "U.S. agency mortgage-backed securities"
       }
      }
     },
     "localname": "MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueDetails",
      "http://www.inovio.com/role/ShorttermInvestmentsSummaryofAvailableforsaleSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MovementInMinorityInterestRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Stockholders' Equity Attributable to Noncontrolling Interest [Roll Forward]",
        "terseLabel": "Stockholders' Equity Attributable to Noncontrolling Interest [Roll Forward]"
       }
      }
     },
     "localname": "MovementInMinorityInterestRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/GeneosTherapeuticsIncPreferredstockInvestmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NatureOfOperations": {
     "auth_ref": [
      "r142",
      "r146"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.",
        "label": "Nature of Operations [Text Block]",
        "terseLabel": "Organization and Operations"
       }
      }
     },
     "localname": "NatureOfOperations",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/OrganizationandOperations"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r79"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "verboseLabel": "Cash flows from financing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r79"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash used in investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "verboseLabel": "Cash flows from investing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r79",
      "r81",
      "r84"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "verboseLabel": "Cash flows from operating activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r0",
      "r50",
      "r52",
      "r57",
      "r84",
      "r95",
      "r110",
      "r116",
      "r117",
      "r118",
      "r119",
      "r121",
      "r122",
      "r129",
      "r151",
      "r154",
      "r157",
      "r160",
      "r162",
      "r186",
      "r399",
      "r501",
      "r527"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "negatedLabel": "Net loss",
        "totalLabel": "Net loss attributable to Inovio Pharmaceuticals, Inc."
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/BasisofPresentationLiquidityandRisksandUncertaintiesDetails",
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r50",
      "r52",
      "r121",
      "r122",
      "r368",
      "r381"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest.",
        "label": "Net Income (Loss) Attributable to Noncontrolling Interest",
        "negatedLabel": "Net loss attributable to non-controlling interest"
       }
      }
     },
     "localname": "NetIncomeLossAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock": {
     "auth_ref": [
      "r108",
      "r109",
      "r112",
      "r113",
      "r123",
      "r124",
      "r125",
      "r192",
      "r193",
      "r282",
      "r283",
      "r284",
      "r285",
      "r327",
      "r345",
      "r346",
      "r347",
      "r473",
      "r474",
      "r475",
      "r543",
      "r544",
      "r545",
      "r546",
      "r548"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for change in accounting principle. Includes, but is not limited to, nature, reason, and method of adopting amendment to accounting standards or other change in accounting principle.",
        "label": "Accounting Standards Update and Change in Accounting Principle [Text Block]",
        "terseLabel": "Impact of Recently Issued Accounting Standards"
       }
      }
     },
     "localname": "NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/ImpactofRecentlyIssuedAccountingStandards"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "New Accounting Pronouncements or Change in Accounting Principle [Line Items]",
        "terseLabel": "New Accounting Pronouncements or Change in Accounting Principle [Line Items]"
       }
      }
     },
     "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/BasisofPresentationLiquidityandRisksandUncertaintiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable": {
     "auth_ref": [
      "r107",
      "r110",
      "r111",
      "r112",
      "r114",
      "r115",
      "r118",
      "r136",
      "r188",
      "r189",
      "r190",
      "r191",
      "r194",
      "r195",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r328",
      "r341",
      "r342",
      "r343",
      "r344",
      "r470",
      "r471",
      "r472",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summarization of the changes in an accounting principle or a new accounting pronouncement, including the line items affected by the change and the financial effects of the change on those particular line items.",
        "label": "Accounting Standards Update and Change in Accounting Principle [Table]",
        "terseLabel": "Accounting Standards Update and Change in Accounting Principle [Table]"
       }
      }
     },
     "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/BasisofPresentationLiquidityandRisksandUncertaintiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recently Issued Accounting Standards"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/BasisofPresentationLiquidityandRisksandUncertaintiesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NoncontrollingInterestAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Noncontrolling Interest [Abstract]",
        "terseLabel": "Noncontrolling Interest [Abstract]"
       }
      }
     },
     "localname": "NoncontrollingInterestAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance": {
     "auth_ref": [
      "r250",
      "r364",
      "r370"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in noncontrolling interest from subsidiary issuance of equity interests to noncontrolling interest holders.",
        "label": "Noncontrolling Interest, Increase from Subsidiary Equity Issuance",
        "terseLabel": "Acquisition of non-controlling interest in Geneos"
       }
      }
     },
     "localname": "NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NoncontrollingInterestMember": {
     "auth_ref": [
      "r104",
      "r105",
      "r106",
      "r249",
      "r359"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest.",
        "label": "Noncontrolling Interest [Member]",
        "terseLabel": "Non- controlling interest"
       }
      }
     },
     "localname": "NoncontrollingInterestMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonoperating Income (Expense) [Abstract]",
        "verboseLabel": "Other income (expense):"
       }
      }
     },
     "localname": "NonoperatingIncomeExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NotesPayable": {
     "auth_ref": [
      "r11",
      "r493",
      "r517"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer.",
        "label": "Notes Payable",
        "terseLabel": "Note payable"
       }
      }
     },
     "localname": "NotesPayable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/GeneosTherapeuticsIncDeconsolidationAccountingDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "verboseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r151",
      "r154",
      "r157",
      "r160",
      "r162"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r418"
     ],
     "calculation": {
      "http://www.inovio.com/role/LeasesSummaryofFutureMinimumLeasePaymentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "totalLabel": "Total operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/LeasesSummaryofFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r418"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      },
      "http://www.inovio.com/role/LeasesSummaryofFutureMinimumLeasePaymentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "negatedLabel": "Less: current portion",
        "terseLabel": "Operating lease liability"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.inovio.com/role/LeasesSummaryofFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r418"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      },
      "http://www.inovio.com/role/LeasesSummaryofFutureMinimumLeasePaymentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "netLabel": "Long-term operating lease liabilities",
        "terseLabel": "Operating lease liability, net of current portion"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.inovio.com/role/LeasesSummaryofFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r417"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 8.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Operating lease right-of-use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r423",
      "r426"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Weighted-average discount rate"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/LeasesSummaryofFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r422",
      "r426"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Weighted-average remaining lease term"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/LeasesSummaryofFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
        "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "auth_ref": [
      "r1",
      "r383"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]",
        "terseLabel": "Geneos Therapeutics, Inc."
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/GeneosTherapeuticsInc"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r27"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "verboseLabel": "Other assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": {
     "auth_ref": [
      "r43"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofComprehensiveLoss": {
       "order": 3.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax",
        "terseLabel": "Foreign currency translation"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofComprehensiveLoss",
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]",
        "terseLabel": "Other comprehensive income (loss):"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": {
     "auth_ref": [
      "r44",
      "r46"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax",
        "terseLabel": "Unrealized gain (loss) on short-term investments, net of tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofComprehensiveLoss",
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherIntangibleAssetsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Intangible assets classified as other.",
        "label": "Other Intangible Assets [Member]",
        "verboseLabel": "Other"
       }
      }
     },
     "localname": "OtherIntangibleAssetsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsScheduleGoodwillandIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r35"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 7.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r67"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 7.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "terseLabel": "Other income (expense), net"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain": {
     "auth_ref": [
      "r178"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Provides the categories of debt securities, available-for-sale or held-to-maturity, on which an entity may recognize other than temporary impairments (OTTI) for which a portion related to credit losses has been recognized in earnings and a portion related to all other factors has been recognized in other comprehensive income.",
        "label": "Other than Temporary Impairment, Credit Losses Recognized in Earnings, Categories of Investments [Domain]",
        "terseLabel": "Other than Temporary Impairment, Credit Losses Recognized in Earnings, Categories of Investments [Domain]"
       }
      }
     },
     "localname": "OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "auth_ref": [
      "r76"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security.",
        "label": "Payments of Stock Issuance Costs",
        "terseLabel": "Stock issuance costs"
       }
      }
     },
     "localname": "PaymentsOfStockIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofStockholdersEquityParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": {
     "auth_ref": [
      "r75"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.",
        "label": "Payment, Tax Withholding, Share-based Payment Arrangement",
        "negatedTerseLabel": "Taxes paid related to net share settlement of equity awards"
       }
      }
     },
     "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries": {
     "auth_ref": [
      "r69"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the purchase of noncontrolling interest during the period.",
        "label": "Payments to Acquire Additional Interest in Subsidiaries",
        "terseLabel": "Payments to acquire additional interest in subsidiaries"
       }
      }
     },
     "localname": "PaymentsToAcquireAdditionalInterestInSubsidiaries",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/GeneosTherapeuticsIncNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r70"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchases of capital assets"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireShortTermInvestments": {
     "auth_ref": [
      "r71"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for securities or other assets acquired, which qualify for treatment as an investing activity and are to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.",
        "label": "Payments to Acquire Short-term Investments",
        "negatedLabel": "Purchases of investments"
       }
      }
     },
     "localname": "PaymentsToAcquireShortTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r303",
      "r318"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockBasedCompensationDetails",
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name [Domain]"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockBasedCompensationDetails",
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company.",
        "label": "Preferred Stock [Member]",
        "terseLabel": "Preferred stock"
       }
      }
     },
     "localname": "PreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofStockholdersEquity",
      "http://www.inovio.com/role/GeneosTherapeuticsIncInvestmentInGeneosDetails",
      "http://www.inovio.com/role/GeneosTherapeuticsIncNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquitySummaryofAuthorizedandIssuedCommonandPreferredStockDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "verboseLabel": "Preferred stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquitySummaryofAuthorizedandIssuedCommonandPreferredStockDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "verboseLabel": "Preferred stock, shares issued (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquitySummaryofAuthorizedandIssuedCommonandPreferredStockDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "verboseLabel": "Preferred stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquitySummaryofAuthorizedandIssuedCommonandPreferredStockDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r13"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "terseLabel": "Preferred stock"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r4",
      "r23",
      "r24"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "verboseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r72"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from Issuance of Common Stock",
        "terseLabel": "Proceeds from issuance of common stock, net of issuance costs",
        "verboseLabel": "Proceeds from issuance of stock"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/BasisofPresentationLiquidityandRisksandUncertaintiesDetails",
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfDebt": {
     "auth_ref": [
      "r73"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt.",
        "label": "Proceeds from Issuance of Debt",
        "terseLabel": "Proceeds from issuance of debt"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromMinorityShareholders": {
     "auth_ref": [
      "r74"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from a noncontrolling interest. Includes, but is not limited to, purchase of additional shares or other increase in noncontrolling interest ownership.",
        "label": "Proceeds from Noncontrolling Interests",
        "terseLabel": "Acquisition of non-controlling interest"
       }
      }
     },
     "localname": "ProceedsFromMinorityShareholders",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleOfShortTermInvestments": {
     "auth_ref": [
      "r68"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from sales of all investments, including securities and other assets, having ready marketability and intended by management to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.",
        "label": "Proceeds from Sale of Short-term Investments",
        "verboseLabel": "Proceeds from sale or maturity of investments"
       }
      }
     },
     "localname": "ProceedsFromSaleOfShortTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r72",
      "r319"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Proceeds from Stock Options Exercised",
        "terseLabel": "Proceeds from stock option exercises"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProductAndServiceOtherMember": {
     "auth_ref": [
      "r275"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Article or substance produced by nature, labor or machinery and act of providing assistance, classified as other.",
        "label": "Product and Service, Other [Member]",
        "terseLabel": "Other revenue"
       }
      }
     },
     "localname": "ProductAndServiceOtherMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r0",
      "r50",
      "r52",
      "r78",
      "r95",
      "r110",
      "r121",
      "r122",
      "r151",
      "r154",
      "r157",
      "r160",
      "r162",
      "r186",
      "r361",
      "r367",
      "r369",
      "r381",
      "r382",
      "r399",
      "r506"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      },
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "netLabel": "Net loss attributable to common stockholders",
        "terseLabel": "Net loss",
        "totalLabel": "Net loss",
        "verboseLabel": "Net loss"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows",
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofComprehensiveLoss",
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofOperations",
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r6",
      "r7",
      "r224",
      "r523"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "negatedTerseLabel": "Fixed assets, net of accumulated depreciation",
        "verboseLabel": "Fixed assets, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.inovio.com/role/GeneosTherapeuticsIncDeconsolidationAccountingDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RelatedPartyDomain": {
     "auth_ref": [
      "r295",
      "r430",
      "r431"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Domain]",
        "terseLabel": "Related Party [Domain]"
       }
      }
     },
     "localname": "RelatedPartyDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionDueFromToRelatedPartyAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction, Due from (to) Related Party [Abstract]",
        "terseLabel": "Related Party Transaction, Due from (to) Related Party [Abstract]"
       }
      }
     },
     "localname": "RelatedPartyTransactionDueFromToRelatedPartyAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty": {
     "auth_ref": [
      "r430"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expenses recognized resulting from transactions (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.",
        "label": "Related Party Transaction, Expenses from Transactions with Related Party",
        "verboseLabel": "Operating expenses related to affiliated entity"
       }
      }
     },
     "localname": "RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Related Party Transaction [Line Items]",
        "terseLabel": "Related Party Transaction [Line Items]"
       }
      }
     },
     "localname": "RelatedPartyTransactionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "auth_ref": [
      "r295",
      "r430",
      "r434",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Axis]",
        "terseLabel": "Related Party [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "auth_ref": [
      "r428",
      "r429",
      "r431",
      "r435",
      "r436"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Related Party Transactions Disclosure [Text Block]",
        "verboseLabel": "Related Party Transactions"
       }
      }
     },
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/RelatedPartyTransactions"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r334",
      "r563"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "verboseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and Development Expense"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockBasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r91",
      "r334"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and Development Expense"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/BasisofPresentationLiquidityandRisksandUncertaintiesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "Performance-based restricted stock units"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/NetLossPerShareScheduleofAntiDilutiveSecuritiesDetails",
      "http://www.inovio.com/role/StockBasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r18",
      "r249",
      "r328",
      "r519",
      "r543",
      "r548"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "netLabel": "Accumulated deficit",
        "terseLabel": "Retained earnings (accumulated deficit)"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/BasisofPresentationLiquidityandRisksandUncertaintiesDetails",
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r104",
      "r105",
      "r106",
      "r111",
      "r120",
      "r122",
      "r191",
      "r324",
      "r325",
      "r326",
      "r343",
      "r344",
      "r539",
      "r541"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedInterestFairValueDisclosure": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of interest continued to be held by a transferor after transferring financial assets to a third party.",
        "label": "Retained Interest, Fair Value Disclosure",
        "terseLabel": "Fair value of investment in Geneos retained"
       }
      }
     },
     "localname": "RetainedInterestFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/GeneosTherapeuticsIncDeconsolidationAccountingDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue from Contract with Customer [Abstract]",
        "terseLabel": "Revenue from Contract with Customer [Abstract]"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r147",
      "r148",
      "r153",
      "r158",
      "r159",
      "r163",
      "r164",
      "r165",
      "r270",
      "r271",
      "r468"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "netLabel": "Revenues",
        "terseLabel": "Revenue from related parties",
        "verboseLabel": "Total revenues"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails",
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofOperations",
      "http://www.inovio.com/role/RelatedPartyTransactionsDetails",
      "http://www.inovio.com/role/RevenueRecognitionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "auth_ref": [
      "r92",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r286"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue from contract with customer.",
        "label": "Revenue from Contract with Customer [Policy Text Block]",
        "terseLabel": "Revenue Recognition"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/BasisofPresentationLiquidityandRisksandUncertaintiesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerTextBlock": {
     "auth_ref": [
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r274",
      "r286"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.",
        "label": "Revenue from Contract with Customer [Text Block]",
        "terseLabel": "Revenue Recognition"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/RevenueRecognition"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenuesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenues [Abstract]",
        "verboseLabel": "Revenues:"
       }
      }
     },
     "localname": "RevenuesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale of Stock [Domain]",
        "terseLabel": "Sale of Stock [Domain]"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/BasisofPresentationLiquidityandRisksandUncertaintiesDetails",
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.",
        "label": "Sale of Stock, Price Per Share",
        "terseLabel": "Sale of stock, price per share (in dollars per share)"
       }
      }
     },
     "localname": "SaleOfStockPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable": {
     "auth_ref": [
      "r213"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the major classes of acquired finite-lived intangible assets showing the amount, any significant residual value, weighted average amortization period, and other characteristics. A major class is composed of intangible assets that can be grouped together because they are similar, either by nature or by their use in the operations of the company.",
        "label": "Schedule of Acquired Finite-Lived Intangible Asset by Major Class [Table]",
        "terseLabel": "Schedule of Acquired Finite-Lived Intangible Asset by Major Class [Table]"
       }
      }
     },
     "localname": "ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsScheduleGoodwillandIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r133"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/NetLossPerShareScheduleofAntiDilutiveSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r133"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "verboseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/NetLossPerShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Securities, Available-for-sale [Line Items]",
        "terseLabel": "Debt Securities, Available-for-sale [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsSummaryofAvailableforsaleSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value.",
        "label": "Schedule of Available-for-sale Securities Reconciliation [Table Text Block]",
        "terseLabel": "Schedule of Summary of Investments"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "auth_ref": [
      "r357"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]"
       }
      }
     },
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "auth_ref": [
      "r386",
      "r387"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]",
        "verboseLabel": "Schedule of Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis"
       }
      }
     },
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": {
     "auth_ref": [
      "r213",
      "r217",
      "r469"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Schedule of Finite-Lived Intangible Assets [Table]",
        "terseLabel": "Schedule of Finite-Lived Intangible Assets [Table]"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CriticalAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock": {
     "auth_ref": [
      "r210"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of goodwill and intangible assets, which may be broken down by segment or major class.",
        "label": "Schedule of Intangible Assets and Goodwill [Table Text Block]",
        "terseLabel": "Schedule of Summary of Intangible Assets by Major Asset Class"
       }
      }
     },
     "localname": "ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": {
     "auth_ref": [
      "r226"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of maturity and sinking fund requirement for long-term debt.",
        "label": "Schedule of Maturities of Long-term Debt [Table Text Block]",
        "terseLabel": "Schedule of Maturities of Long-term Debt"
       }
      }
     },
     "localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "auth_ref": [
      "r97",
      "r432",
      "r434"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Schedule of Related Party Transactions, by Related Party [Table]",
        "terseLabel": "Schedule of Related Party Transactions, by Related Party [Table]"
       }
      }
     },
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r303",
      "r318"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockBasedCompensationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r310"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "verboseLabel": "Schedule of Weighted Average Assumptions"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "auth_ref": [
      "r36",
      "r93",
      "r139",
      "r140",
      "r237",
      "r239",
      "r240",
      "r242",
      "r243",
      "r244",
      "r246",
      "r247",
      "r248",
      "r249"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.",
        "label": "Schedule of Stock by Class [Table]",
        "terseLabel": "Schedule of Stock by Class [Table]"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails",
      "http://www.inovio.com/role/StockholdersEquitySummaryofAuthorizedandIssuedCommonandPreferredStockDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfStockByClassTextBlock": {
     "auth_ref": [
      "r12",
      "r13",
      "r14",
      "r238",
      "r239",
      "r240",
      "r242",
      "r243",
      "r244",
      "r246",
      "r247",
      "r248",
      "r249"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's stock, including par or stated value per share, number and dollar amount of share subscriptions, shares authorized, shares issued, shares outstanding, number and dollar amount of shares held in an employee trust, dividend per share, total dividends, share conversion features, par value plus additional paid in capital, the value of treasury stock and other information necessary to a fair presentation, and EPS information.  Stock by class includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. Includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity. If more than one issue is outstanding, state the title of each issue and the corresponding dollar amount; dollar amount of any shares subscribed but unissued and the deduction of subscriptions receivable there from; number of shares authorized, issued, and outstanding.",
        "label": "Schedule of Stock by Class [Table Text Block]",
        "verboseLabel": "Schedule of Summary of Common and Preferred Stock Authorized, Issued and Outstanding"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SeriesCPreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Outstanding nonredeemable series C preferred stock or outstanding series C preferred stock. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.",
        "label": "Series C Preferred Stock [Member]",
        "verboseLabel": "Series C Preferred Stock"
       }
      }
     },
     "localname": "SeriesCPreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails",
      "http://www.inovio.com/role/StockholdersEquitySummaryofAuthorizedandIssuedCommonandPreferredStockDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r82"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Noncash Expense",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows",
      "http://www.inovio.com/role/StockBasedCompensationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r304"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period",
        "terseLabel": "Award vesting period (in years)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockBasedCompensationDetails",
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r308"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockBasedCompensationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r308"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted average grant date fair value, restricted stock units (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockBasedCompensationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r307"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "terseLabel": "Number of shares of unvested restricted stock units and options outstanding (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r313"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockBasedCompensationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r312"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "terseLabel": "Expected volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockBasedCompensationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r314"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Risk-free interest rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockBasedCompensationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockBasedCompensationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "auth_ref": [
      "r305"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized",
        "terseLabel": "Number of shares authorized (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r318"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant",
        "terseLabel": "Number of shares available for grant (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r309"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted average grant date fair value (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockBasedCompensationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r300",
      "r306"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Award Type [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockBasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationAwardTrancheOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "First portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.",
        "label": "Share-based Payment Arrangement, Tranche One [Member]",
        "terseLabel": "Tranche One"
       }
      }
     },
     "localname": "ShareBasedCompensationAwardTrancheOneMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockBasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationAwardTrancheTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Second portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.",
        "label": "Share-based Payment Arrangement, Tranche Two [Member]",
        "terseLabel": "Tranche Two"
       }
      }
     },
     "localname": "ShareBasedCompensationAwardTrancheTwoMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockBasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SharePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Price of a single share of a number of saleable stocks of a company.",
        "label": "Share Price",
        "terseLabel": "Price per Share (in dollars per share)"
       }
      }
     },
     "localname": "SharePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/GeneosTherapeuticsIncInvestmentInGeneosDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": {
     "auth_ref": [
      "r304"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of vesting of award under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage",
        "terseLabel": "Vesting percentage"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockBasedCompensationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r311",
      "r329"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected life in years"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockBasedCompensationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharesIssued": {
     "auth_ref": [
      "r241"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.",
        "label": "Shares, Issued",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)"
       }
      }
     },
     "localname": "SharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShortTermInvestments": {
     "auth_ref": [
      "r9",
      "r496",
      "r497",
      "r515"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.",
        "label": "Short-term Investments",
        "verboseLabel": "Short-term investments"
       }
      }
     },
     "localname": "ShortTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r103"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "verboseLabel": "Critical Accounting Policies"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CriticalAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r12",
      "r13",
      "r14",
      "r93",
      "r95",
      "r126",
      "r127",
      "r128",
      "r130",
      "r132",
      "r139",
      "r140",
      "r141",
      "r186",
      "r241",
      "r399"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Class of Stock [Axis]",
        "terseLabel": "Class of Stock [Axis]"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/BasisofPresentationLiquidityandRisksandUncertaintiesDetails",
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails",
      "http://www.inovio.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.inovio.com/role/GeneosTherapeuticsIncInvestmentInGeneosDetails",
      "http://www.inovio.com/role/GeneosTherapeuticsIncNarrativeDetails",
      "http://www.inovio.com/role/GeneosTherapeuticsIncPreferredstockInvestmentDetails",
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails",
      "http://www.inovio.com/role/StockholdersEquitySummaryofAuthorizedandIssuedCommonandPreferredStockDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r38",
      "r104",
      "r105",
      "r106",
      "r111",
      "r120",
      "r122",
      "r138",
      "r191",
      "r241",
      "r249",
      "r324",
      "r325",
      "r326",
      "r343",
      "r344",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r539",
      "r540",
      "r541"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofOperations",
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]",
        "terseLabel": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]",
        "terseLabel": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Comprehensive Income [Abstract]",
        "terseLabel": "Statement of Comprehensive Income [Abstract]"
       }
      }
     },
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]",
        "terseLabel": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r104",
      "r105",
      "r106",
      "r138",
      "r468"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofOperations",
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": {
     "auth_ref": [
      "r37",
      "r241",
      "r242",
      "r249"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities.",
        "label": "Stock Issued During Period, Shares, Conversion of Convertible Securities",
        "terseLabel": "Conversion of preferred stock to common stock (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r13",
      "r14",
      "r241",
      "r249"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Issuance of common stock for cash, net of financing costs (in shares)",
        "verboseLabel": "Underwritten public offering, common stock (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofStockholdersEquity",
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": {
     "auth_ref": [
      "r13",
      "r14",
      "r241",
      "r249"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture",
        "terseLabel": "Exercise of stock options for cash and vesting of RSUs, net of tax payments (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": {
     "auth_ref": [
      "r38",
      "r241",
      "r249"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities.",
        "label": "Stock Issued During Period, Value, Conversion of Convertible Securities",
        "terseLabel": "Conversion of preferred stock to common stock"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueConversionOfUnits": {
     "auth_ref": [
      "r38",
      "r241",
      "r249"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit).",
        "label": "Stock Issued During Period, Value, Conversion of Units",
        "terseLabel": "Conversion of carrying value"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueConversionOfUnits",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r13",
      "r14",
      "r241",
      "r249"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period, Value, New Issues",
        "terseLabel": "Issuance of common stock for cash, net of financing costs"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": {
     "auth_ref": [
      "r13",
      "r14",
      "r249",
      "r302",
      "r309"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture",
        "terseLabel": "Exercise of stock options for cash and vesting of RSUs, net of tax payments"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r14",
      "r20",
      "r21",
      "r95",
      "r169",
      "r186",
      "r399"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "totalLabel": "Total Inovio Pharmaceuticals, Inc. stockholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r95",
      "r104",
      "r105",
      "r106",
      "r111",
      "r120",
      "r186",
      "r191",
      "r249",
      "r324",
      "r325",
      "r326",
      "r343",
      "r344",
      "r359",
      "r360",
      "r380",
      "r399",
      "r405",
      "r406",
      "r410",
      "r540",
      "r541"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.",
        "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]",
        "verboseLabel": "Stockholders\u2019 equity:"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Note [Abstract]",
        "terseLabel": "Stockholders' Equity Note [Abstract]"
       }
      }
     },
     "localname": "StockholdersEquityNoteAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r94",
      "r249",
      "r251"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "verboseLabel": "Stockholders' Equity"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]",
        "terseLabel": "Sale of Stock [Axis]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/BasisofPresentationLiquidityandRisksandUncertaintiesDetails",
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplemental disclosures:"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r176",
      "r177",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Financial Instruments [Domain]",
        "terseLabel": "Financial Instrument [Domain]",
        "verboseLabel": "Financial Instrument [Domain]"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueDetails",
      "http://www.inovio.com/role/ShorttermInvestmentsSummaryofAvailableforsaleSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r357"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_USTreasuryBillSecuritiesMember": {
     "auth_ref": [
      "r507"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This category includes information about negotiable debt securities issued by the United States Department of the Treasury which generally have maturities of one year or less, are interest bearing, and are backed by the full faith and credit of the United States government.",
        "label": "US Treasury Bill Securities [Member]",
        "terseLabel": "U.S. treasury securities"
       }
      }
     },
     "localname": "USTreasuryBillSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueDetails",
      "http://www.inovio.com/role/ShorttermInvestmentsSummaryofAvailableforsaleSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_VestingAxis": {
     "auth_ref": [
      "r318"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by vesting schedule of award under share-based payment arrangement.",
        "label": "Vesting [Axis]",
        "terseLabel": "Vesting [Axis]"
       }
      }
     },
     "localname": "VestingAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockBasedCompensationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VestingDomain": {
     "auth_ref": [
      "r318"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vesting schedule of award under share-based payment arrangement.",
        "label": "Vesting [Domain]",
        "terseLabel": "Vesting [Domain]"
       }
      }
     },
     "localname": "VestingDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockBasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).",
        "label": "Weighted Average Number of Shares Outstanding, Basic and Diluted",
        "terseLabel": "Basic and diluted (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfShareOutstandingBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Basic [Abstract]",
        "terseLabel": "Weighted average number of common shares outstanding"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasicAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "stringItemType"
    }
   },
   "unitCount": 7
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "http://asc.fasb.org/topic&trid=2122149"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(h)(1)(i))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(k)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04.(a))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21914-107793"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21930-107793"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21711-107793"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21728-107793"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(4)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=112272810&loc=d3e31137-122693"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=112272810&loc=SL108384541-122693"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "250",
   "URI": "http://asc.fasb.org/topic&trid=2122394"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1252-109256"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1278-109256"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "55",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e2626-109256"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1337-109256"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=120380238&loc=d3e3842-109258"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "http://asc.fasb.org/topic&trid=2144383"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70191-108054"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70229-108054"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "http://asc.fasb.org/topic&trid=2134479"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3)(a)(2))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8813-108599"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4647-111522"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4428-111522"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4531-111522"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121553693&loc=d3e26610-111562"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27405-111563"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27232-111563"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=SL120269820-111563"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27340-111563"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=SL6284393-111563"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27357-111563"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "http://asc.fasb.org/topic&trid=2196928"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=120269885&loc=SL75117539-209714"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=120269885&loc=SL75117546-209714"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=109237563&loc=d3e33749-111570"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(4)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919244-210447"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919249-210447"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919253-210447"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919258-210447"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919230-210447"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121558606&loc=SL82898722-210454"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922888-210455"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922895-210455"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922900-210455"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=120320667&loc=SL49117168-202975"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "((a)(1),(b))",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(2)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(3)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "350",
   "URI": "http://asc.fasb.org/topic&trid=2144416"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=6802200&loc=d3e1835-112601"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=6802200&loc=SL6230698-112601"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=109126253&loc=d3e4852-112606"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=120520924&loc=SL6031897-161870"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=120520924&loc=SL6031897-161870"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=120520924&loc=SL6031898-161870"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=120520924&loc=SL6036836-161870"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=120520924&loc=SL6036836-161870"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=117329964&loc=d3e12317-112629"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=117329964&loc=d3e12355-112629"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "http://asc.fasb.org/topic&trid=2208564"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(CFRR 211.02)",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=65877616&loc=d3e177068-122764"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=65877616&loc=d3e177068-122764"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21553-112644"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21484-112644"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21488-112644"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21521-112644"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21538-112644"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "http://asc.fasb.org/topic&trid=2208762"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121556615&loc=SL49130531-203044"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121556615&loc=SL49130532-203044"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130551-203045"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.12)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130556-203045"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130558-203045"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130561-203045"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130563-203045"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130563-203045"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130564-203045"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130543-203045"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130545-203045"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130549-203045"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130549-203045"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130550-203045"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=113356391&loc=SL49131195-203048"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=113356391&loc=SL49131195-203048"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(i)(2)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=113356391&loc=SL49131195-203048"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(j)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=113356391&loc=SL49131195-203048"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "http://asc.fasb.org/topic&trid=49130388"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118257860&loc=d3e4179-114921"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121326096&loc=d3e4534-113899"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=SL79508275-113901"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(5))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120383193&loc=d3e11149-113907"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120383193&loc=d3e11178-113907"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "http://asc.fasb.org/topic&trid=2228938"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e31917-109318"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e31931-109318"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32705-109319"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32718-109319"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32809-109319"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32857-109319"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "740"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "740"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "740"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330215-122817"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "http://asc.fasb.org/topic&trid=2144680"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=121598580&loc=d3e5419-128473"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "808",
   "URI": "http://asc.fasb.org/topic&trid=5833765"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4568447-111683"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.28,29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4568740-111683"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569643-111683"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4613674-111683"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569655-111683"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-30)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4582445-111684"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4582445-111684"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2AA",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "a",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=SL6759068-111685"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5728-111685"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=SL6759159-111685"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4I",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4590271-111686"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "http://asc.fasb.org/topic&trid=2197479"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624163-113959"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "15",
   "Topic": "815",
   "URI": "http://asc.fasb.org/subtopic&trid=2229187"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.3(a)(2))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=SL6742756-110258"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=99377092&loc=SL75136599-209740"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13433-108611"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13467-108611"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13476-108611"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13531-108611"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13537-108611"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=120253306&loc=d3e28228-110885"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=121605123&loc=d3e30226-110892"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=109240200&loc=d3e30690-110894"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450222&loc=d3e30840-110895"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "830",
   "URI": "http://asc.fasb.org/topic&trid=2175825"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28541-108399"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28551-108399"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28555-108399"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918666-209980"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(1)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918673-209980"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918673-209980"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918701-209980"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121568110&loc=SL77918982-209971"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/subtopic&trid=77888251"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "850",
   "URI": "http://asc.fasb.org/topic&trid=2122745"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(i)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(ii)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)(i)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e637-108580"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(5)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(6)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(7)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(b)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "http://asc.fasb.org/extlink&oid=119991564&loc=SL119991595-234733"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e681-108580"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(f)(1)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(f)(2)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(f)(3)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "340",
   "Topic": "928",
   "URI": "http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61929-109447"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61929-109447"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62059-109447"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669686-108580"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62059-109447"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62395-109447"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62395-109447"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62479-109447"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62479-109447"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=SL6807758-109447"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=SL6807758-109447"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(1)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61872-109447"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(2)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61872-109447"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "940",
   "URI": "http://asc.fasb.org/subtopic&trid=2176304"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL34724394-108580"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(4))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(5))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.15(3),(4))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6801-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(13)(f))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(24))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(25))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120252992&loc=d3e62557-112803"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/subtopic&trid=2209399"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "405",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=116652737&loc=d3e64164-112818"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Subparagraph": "e",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "505",
   "Subparagraph": "(c)(1)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=117337116&loc=SL5958568-112826"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(5))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(1)(g))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(24))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(3))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.15)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.17)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(10))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(20))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(21))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(3)(d))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121643868&loc=SL117782755-158439"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117783719-158441"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117783719-158441"
  },
  "r536": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117819544-158441"
  },
  "r537": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r538": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r539": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e557-108580"
  },
  "r540": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r541": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r542": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r543": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r544": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r545": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r546": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iv)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r547": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r548": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r549": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=99380617&loc=SL75241803-196195"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r550": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "210",
   "Subparagraph": "(c)",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=99383244&loc=d3e12121-115841"
  },
  "r551": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r552": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "946",
   "URI": "http://asc.fasb.org/subtopic&trid=2324412"
  },
  "r553": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "948",
   "URI": "http://asc.fasb.org/extlink&oid=6490092&loc=d3e47080-110998"
  },
  "r554": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "948",
   "URI": "http://asc.fasb.org/extlink&oid=6490092&loc=d3e47304-110998"
  },
  "r555": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r556": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r557": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r558": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r559": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(12))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r560": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r561": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r562": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r563": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r564": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r565": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r566": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a"
  },
  "r567": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r568": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r569": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(22))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(23))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.1(e))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.19)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7(c),9(a))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.8)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3179-108585"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3367-108585"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3000-108585"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3521-108585"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3044-108585"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4297-108586"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4304-108586"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4313-108586"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4332-108586"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(2))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=SL98516268-108586"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18823-107790"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(k)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(k))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(e),(f))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>78
<FILENAME>0001055726-21-000040-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001055726-21-000040-xbrl.zip
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M*!<\,G"B!MMRWK'%^ULHCD^&$#?0>4#W8H[^3#&$5\4'B#L][/'CPG=@8S"
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ME0;'CRO9WUT*7$^K22 2K:43A J#D 1PW/&\D81GUIL:6<T5+)?'6B+\+.7
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MTJ4=B"TPR724BDDE(HE.,)]<1 >6"N=\JK;GU'*G_7)S-!CVNU .OE]D]]:
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M#1CP2)DI3\'@;\3_5"KRS6?.(A#[>0?=W,[-CAL,=M/^L!_>WPY2=+O]WOA
M3133*T6CD8Q*I44P8'F@'.FZA2@,9S^7M9PG%%Z7D* L(=8)#<(JHJG2)"$U
M]5IX2BDA/B(%BDDJ4P,:-.O_%KC!J!P+::=W-AI^OHW9[3.V/YU!&$(\@/);
M&Y379"A?/!E#PY*X]BD0$P6WW!EN4=@^<LF28JN19D[8?5T6 ?[J=]RPZ&#O
MU<3<Q(1,72<OK5.":&*3\1" X*]4TQA7Z)@/.O+>C"]*@)W<7A@,]U";:P(1
MF1@Z"B&HO&^GR<#  2F7: =#" _3R@?T<C]L6LUX2>7& OH=FT;3^>1:L"Q
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MK<EK//[?N?,7]>QOC7=?"[XM0(Y7T<_&BYU7VXWV[OKT/1XN7+0]CNN_*#J
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M88,[PP(/<^HW='#&IE&%X>MW_[$SOS_F\:6<UNI-33[XT+818PF#P?2?5]@
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M'*PW#DY@ -,FNQ(:<;)("&*CV\>O:=3!YQ>]1O;<&K>S%QHG4$+1NWF724?
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M00.DE0 480(,9P(0JBD7@C&IEU?>?L6*OF2(6$$VF 'C*0!CDG*)*.<]-11
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MP!!E7!%"F1GI>-;OU=+O>1+9+;Z[\<B,=EG3GU#39_8V*-4X0K8&DEH5U_!
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M(7<EB>-$$1J*A'#A>811#@ G$DIZ<F,KBMQ1Q.)[JF&^1HA]8-Q[@[@#XSX
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M==-<H5G@#I% W[UH'P NQ@>@2PO.\M\?=D(WW#:G(PHUPZ'_$_<(&R9/X$%
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M_)0BPE='5J^88Y;]M#D:."*5L$;VW^; 7:7Q)_X/7YNQ."  0 GX/]?KXS%
M&^T^!B[?0?U!=UOC*T/55VHUUVHI"R"8<0"_+ $M3F4TC&B2J"1SJ62QE'"_
MVKCL/=>"YP5E,.9N*L- Q7Y*/>&"UA.Q@+F9Z[,HCJ)+XT+I(UJM:O&)(96K
MI*=;&RY;%-<ZBK:GL&!C0$=G13G#&,X>FOJ_#H8%R%8::HQSA&>C+NJ@Y6K=
M"@F?.LFK2L,Z"RJ/7NTT<!(^[L 8*]G-R;0 >6:73$3;VC3\!9H%<2A-9&A7
M3*^4S/K,AA\HO T8D(6J'A#M_9 E]/'TEKW&QHG$TX4[VJ(,FH1S#MAC?$$
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M4__8F*.NB6_3V8-72S@.\*#%45=-H$UG1%VHH*=DD8)48WZ!P42Z9 1>50F
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M?ME9.YL+/)GDL]KAJV^P$8\"J,J@]M2FFUQACEDV&ZEO?#PW<9SSM ()A@,
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M'COKGQ^HT]I#XS*'[$W$W^5'Z\WQVR6506Y:C2->YVH<P4^OQG'4PJB%*@=
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M),#YL:EH< #O-=V/W5%35RTK3:X95F#30D3+(Y.%TC!/+1A:<NV_;]/9-15
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MWHWGDU27/,+B9,Z1R'5D9U,TX]W;HXV7MZYM$-* !0 R(@;J=:08YU("7,E
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MGY.4,YG&"0F9I(1*UR4\# .2L80#3E,J]<3&U@KD>>LJ@$$J!. _GF8IC8,
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ME6N=")/A7>B(--$2:8N3I0Z^$S6\2]JF0JY02Z)&K%=1K$_CH!_L\* )NZR
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MJ\GRKT"-CFK][;LP#[#6@(1NWHP![9N-SMJ@S_9PIF>]9&"-#<$C+F7;@"^
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MR%;-D&UB,X-#<V@_EY#/,'MX7?CWQ25\6_*\S(VF=6$S^WH309PWT2=5?7Z
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M)3318E-C+J9/SLS\7R1'-!>:R?4J_13_,P9+IQMKN\7V%KT&;O=U4M3-30\
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MYU88UX$1X* 59XS?9\.>XY'G;!MXMGV\I[@A6%H/6*'!51*6(W"=+-("!YG
M20'LV'BY #GF^> \P\1>J/WH]N1XA^^.\R>UYKN!H3Y5CD-XTG"2R5=.1A=5
M>5@[#L"* %._EE?\5 %2W?#AV?A?\);A&'#NTN,G?MIN&<+9=S5 3DWNF$."
MV0)8+2WZY]EXBZIL8@,YZOP*=U[M<;"%@>D=V+\L=Y-C&!G.,0J22Z-% !_$
MYKX1UVC+1;[4S$X#7G#QS/5OMXZZX^$DA!4*OXY[1[8*LW#6J-\&UW:4[;%Y
M49ECN>*R?L]^GMN]7'V+.N93-D6HZR-]/M,QR^XT>[>:!(S/TS:3#^0HTZG<
M.HDFY.A'R)_,V3$IEGC-L'48XVA"T'*>)XM';4U;D*@2Y,\@-O3]HUALXIKF
M^8+J3)Z&]<NR40UT!AL<J/DM#Z$XS'!!-3K)>PI$_0H._?'4Q"[C!4-].-TT
MJ#^?Q#LF-V0,R8$)^+:. ^25&M:S*:=:"YV<[19Z# ]@/C6VGLV_N 5S<]\?
MPTWY8O#6N]59@":CX'Q\YHS&9_L-S1[J.N 8O/MX3SNBF5>@'Y30B(,:1XYC
MAI)W5JK$.:B5[^ZBYKVD;K?OZ]-OU:"@4>U=5M95W<R6>=>]W\N^OLO!RVGP
MK9R5N\6!MPD4<+JIRM'+?GUV\T51[B" OQY7870PK2LP=^,$U_#L%NM +,:C
MJV^YU [ZD1"/R L$FOMY,)B.Y@C4,G*#:+^@$C%X8;O'V8'YY3S* Z!?H.'%
MZ5^='79-9LUW,V4N9-:X%&FBV@AF*7=<&2Y];E9-.%&4"?&]S)KSNNF1%N;L
MC">(!9H/3P= &[#M .'+N?+C*A\QRHHS5PD #3*L0K'WXN!P6%]7:Y;)YV=
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MU7ECCU0=L/!N'8*Y;%Q-;/[1;(\_Y]G.P/RV8<9@%>A0(ZP-/'.UME%)%7#
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M8]%;;$DT<KEH7U<:W$&LO_X&8SX@4D0P%@02A!+$?1!(Z\!0"@XK%KA4,3Q
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M*52@\2]WEP17=/"JY &L9/EJ^/-*A,O67> *M,[;;P\B5D:$G">G02KPZ,#
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M.7_  $_9TZ%H]))"F'/$XESOM9Q$';_&@>_D-(+^8*J],]PQT[JW&-#5[,$
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M/"M8&E6MXCKL<XT<)%H9XA-1FD4>O-,@%37X!)%8KXT-J]D_ZP#XLQ&!TWE
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M;*:N1H646 'F(-@&@7(7F":6!LT"LSH8K<V:"I^8"O?Y[ML#RYTF2KA\Z$-
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M&D%DBB;DEF;\-MW_9K)9QS[NUM4E=/-&R#,1'3EH,@Y<EN#)FRILF8W:K91
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M->-"57F_\FR.RN3@8'EHU:MLAW6DM'2I2',KLE1DW"96\51[90UHN%PI[5<
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M0"LG)@$]PNG<^:QX]B);U<'G?@W12'5/SQ2K*A%1[L9+=#\&52Y2Y1)E&<U
M9^>I-"9%5$*>.)LS5N6%L(W#\9ZO$C:F/^+*.ZHSX-@4<<F828EDVA.9"IH(
MX;P0ZX4PEQA5^-8&4/1J0%'Q^ %%GR! Z";H_:-![S*1X,:A[X<S]028>$*!
M#$F9XWG!0;CD\$H:IS6SW-W U-N8 W<A5UC[R_Y1D=J")4R1PN4&K$"0,$61
M2V)UK@J?229T\NQ%(=ER%6U=6S#/I9*R ,5"YCQE1GMGM*49V)PV4U1L;,&?
M=_A?C[PU%,P]L  3F1&NF"=8RD[ 0!*@YU'GI0;]_'Y-P>ZH5&-_)$_[,06
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M2N[!WI<L8"3FDFB?9R1AW%F3<>\\%L M(BC]5SS>R@4-E#)64:EW<,'',>:
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M*B84CH7.R[.[-C/]V<FH5MQ]W#*0A.IXNBGUS^&_2&+QJOPWL#&@C08[Q=T
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M,P[AX%%;V/FZ&SMEKUS)LNG,!37J*>"6G7=[O1A3!):"2&#39J\XK7YU<'7
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M1V8.UQ2^U*N.8X4 V6H%^8'+G?(T$/AGO<D(;RM,$%Y463US70,&\)3AM["
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ME S!E8Q9"5A7"^1=E8[^Y]R<_7[KE=/#"=;M(ADO*>Q76 TX0$REY6VPKB[
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MPO<1Y27N>9KO3(WD&DAGQP085BH9"[\&@ZX?"I-CN4[S]W1OR>_WOD?(DL9
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MG<!>J67"UB*65=WRO22FG7X?":Z<!DS[%5(F3<C_("5C-X0*ZRVT%F_(<)Q
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M%+! HH<;.CBJ>W\T6G"ZC.,1^#5L)VS-KCA@6>;5DH5\^$RDC8-TCL1(N:1
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MAY6/Q'\_!\!.2CL9TIH6!9%SP&4H=C&0;.8T90+I@XGI.YFXVB*GZ(OK4*I
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M<B*6H__(RL!:"\:->=4@YI5VJZNZ6)$+:$=)> -XA\E8@5<,F?R#KP_W#Z0
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M.;Y^8WYI/>A+U^?+Q[P^!VW*XUN(MV42$Y#CP\K3?*XDB!>\Y16="G]^_NH
M38(W5I[%H2(<LY*<^_/!_G,+V6]\F6?,.RB/L:SI>$7AV^@9ID(2I1AC8;VY
M*1"XKMFEZ(6F_O>2NZ&SOY@+")[=:4G=WG@4<&-YC\_@9>(N?5 ;1IBSO]8>
MKJ7D79*NY,J%_(LG(H["U)J[N!#1 T4SDIJ="G!\\<'9>8WUZ,-/GQYAO?G6
MVV43Q!CL7YY?\"$VTK6/=XN5))FOYZ\9 B.[:&"+O=X_N,L>X[5)FT#6YA<N
M2(Y5Z0/3NCUW)&$"A=>7%B:F%?.#6EHJ :KP@@WE_2YD&)G39_NOXBCH'2W[
M%?H?A=@)(T3WU=A:G@%7>;'_C1O*,HX [<Z<.7YRR>&&1X2;+Q>8(F$ID]EY
M\B>(S9>4%IY_^/3!(#;2?INUW#2$V;,RFLS>07\)V.3H!8R 7%;-\Z%OV*)!
M<4+Y'S:NF,/]UV%[\6+0BPCH#75%6PMAK7<6Q\\__/?>\X,-R_HPUGV,A]W6
MI&:^J]FLR5=<X^JL5UGO>YM;+O0M1*O03H;S.DNZ8O 4WR3;@O;_N::WF,67
M,_]W;?)].(?_F$>G.&L-$J=,IQ@#ZV+KC84DO'2XLN;&0RR&^N!Y',;;^ L=
MB_XRFON',NAQ"?+J>.5>BT?@S]\\?P;/4#T.<<,PF*XNR! P_O0/@HY@T(;D
M61DTX[9(L/HZN+R)$[_-U<]=TB)C[_(P/%=\<[L_-TS;0W5VI&L8Q%VYC;"/
M>&TV;H5'N!=NZ43]L+FSYG&X43=XP "T#-S(6JD:\KH$?DOS2<?@/T-NKJ#0
MGDY]YKE1I2?!\*W2KX;M_?KVV[OOL;W:?_%@^]MMA TN%$?8;!5O>#B^VNA.
MS?-S+D38H0@?S@U@!Z0LG]:*.7E@C:9MSURNI+;4I6:'^0\T$+1L2C7I$X9F
MZQ_14PB<S#S,]Y]?OW@)R]4Q"$?M.?/\'3X[>"U\AI9+QF^^J\JI%HRZ@Y:,
M#$[2Y]_P#7;H%+VEY?BT85T\K+G8]%1AM=+R40#7=*1U.3G]I2$B2+ (%WG!
M<S9O<ZN?9<S+KFPN3:2Y@X\0]L.E$NFCJ99!?*-+[=25G4E;&$F69,<)81;S
M;%_W!K=/0$@:Y[4[)7%Z/X\XBO18WA^=SI1TAE9OBSP)>2.=KQ_&G$[W5.?[
M^0SG=7Z3;BKRZY^E]SBX^3VV](C&D^RS <&B70RF:J.!S&RWR\KCV592G;AR
M_%H)XC>\6!KYD#SC(P7ZWW+GFQ(T#UVU>.!\9>=A;I-4X4WQZNO7:J8[A_.+
M@U>W2GIV#^:KK!DX9$W6Q#QFK;[K7\^RN0@RS88A4.@)XC/QB:8MP<\</@!^
M9N E9[-[>TDQ!E..2'$8_#M"+4G<_#_9HWF6$6V2V?_[I__K^@+3JS_]?Y^%
M77[&Y;*55!*S+^&]>Y0F4H^>1V(C;^]"P$B^/'@^;"0/[Y#GZ)9#;A?!^,I'
MT7VMF. *O$XE\IW@+\U+9D&!\A X@_BF[^4GO:K@'[4/$U]MK&LC?%@(3;=@
MG$V(!2T;( RO&#QKS7[XDF#.71*CK+:\C1X2/C9!).(>NZC!2^Z>^B;/&:[(
MD_([N25_!&3YEIOQ. :)B4-/5HO9W=E#G!<JQS'8:/7@,&SLF,DM7N/FNU%V
M^,'SZ-VCWR6T8CN!FOX"#/XWC17'R=.I()ML#<[R#&A@Z9>5/"J4X4)W=3;\
M^,)'!)FH8M;6TCX54WK3_,P8RQ?&_]D(V"JWJ$RDR,N.1*'7E_PL8C+=AQ7/
M#<,;0D2 FV?DM8'9BK,/,9RSWO=\RC56:*4JW=(JO8&:D:%A]%MQC.*S@$M6
M06<))'%1:-(M@9[@Z##(3"[HI,02("=&0U^^K(;7VNU273)/ W,+,YZ[V+E=
M5F5WK/C.K?">W63,=C^H^H'QPG]A<J:_CO#^P>EG''$?B/# *!%.F[@G3D2^
M5HFQ"HD4%4P)=HLW9OJ:'W[Z)'1Q(*G2--JSVV%/NC[*#1\&G1:NUT2?!G4+
MY4*5)\-;(X?I3.9MG!_7DB8^@K$ !+^ Z1Z8_$%TLVD3:&M4$4-=>RC8:G$4
M-HPG6N^;]'V3)!>WG0C@K9B$H3"_03[RGQ6Y:E@Z05#TG5PO6XE-M,BUN>"&
M2DFE 4+S129KM-%:[?QV?\_DU24-ZQPF4-9[:;IH\WR/5M0>.NIT\IN@[/KP
M.[^\^\/?)7L)._#B&^&SYZS@2U_,[]83O=K@'7;^[B^M3Q=*"<K39(:4[475
M/"R-P&<S+,,/QXX5)XJQVQENCX^&/W]ES(5.5]$<,*A[<T;";(>Z$/_!FC2_
M2WCSI7#:;QXSG/:GI)'S6!LY/UHCY^/;$=L53B!_*XS^8V7-Y:P^BXY(+(RF
MT]AQPNPP"!"V@48C.Z4C;4[Y&I+/*+/,!-"@<2*?YKK&O(;:FMN]LA"L6Q5[
M?_0);2W\/P#E1Z81(84JM!T7;Z5$KG)FTGN7K/\*P3(VB)N;MGN&FI&Q'&8I
M!ST_LF(H\,\HS6AHNQM;SD?#7_.+LOC8@N<7"UMAQQ;]];2RO#S&M^JWYG,W
MZ;86SEX=->OWQJ=>?!TK^D.UE(/.1?[\XO!U!+QU#W'9!%9[3]ZG6V9A^)OU
MDF]XC:EWN(>=CG3(AJ%0*W5\-N^AH13;=1P!'7:!L4/Y(0](2Q%<(QV<P@WL
MU##A+B,06,/@!M52?T^@,L8.%L(5V]@L@ZMP>]98T2.F .,>;>?,PS&OJ^_G
MU=6N'8 <6V!36#-B)']V1Y1D]KNHUC\?OHS[\@[.>A=(<+-GN?E]DOX/YT/*
M#B9#%#%58ZD2M )1*NU!TF>(8"]+4(F6@UZ/#%<$U6MI8+YVFY0O6U;EGABA
M*;?%F_&T2QQZRFX+GZX?DYA;!;9_ .'(#$7<8EI,._!Z:4A7;*N\XM@9--'D
M7"I1=Y".YDF(_$UC!W(']WX"YQ^ ;<J[F:LU.";TZ3!EX?4VXEW""+[V.)4O
MB3U=(#D.W]R>:5LG62BQMI#\C7)+72SAGU^]?M6'?A6K?/$H85^_@RFY>;'A
MFNW[W,/TY7=?OH=?'Q[(=-QM_W[3W;Z])1XW'^H?7"T:7NJKCN=R@SI.-]/X
MY1L@29Y<O_FZD*SKEK]9/5]/DG:&_GAUVAK"!R3'>H,D>#\1:V0>V42P=P'?
MZZ^TL2E.P:D!RQH(J^#FY:N5T.L).0B\'^LH )9!F@8C,T>LOO*UNZ[AO,A;
MBT:W)69FLWL._Y_8>!(TT?,_%$WTY6FH73U*9$\.>:6'KYR1TI3OP=U::C:X
MI9_!;"Y@[$ZX%TNNR X74 Z>%C,EDFR$TW((G;=LZ=ZJZDCV5S6+N*A\!WV2
M1S1ARAH&3F>MI ],&IG]7BQ!IOGW#":VS)I'\&P,T!,++,U**"Y_?F<39AU@
M"M9]YN/QS0F A!]P6[A_@XXAM9R\#AY?7/SJ!:/)FJ9%$X-@]S"D@-W?^=4>
MRXH_=<F8ERY]=D.^1Q1PQ\]?2F?)%N@5TPKUOAWJK^1QOGS&I0VY1(P9;>&-
M0\'#A EY$89'R^OF*Z%9;RW!!TVGI@ET:1*2&&O1-#Y$<,TH*H1+<\99\]#X
MU".MO#Z@<9/^: @7@T;1P3>87[@;.)08[5^.CH295&O<;\6-/K4Q^@13<62F
M(F )>[\7=[ ,[>[+>29T,JR'X;[X(?S^2'X/8N'Y?-L2DFN?GS.%S0KB&DT3
M+1-]@^)[L )08.Y( \1D%<+NS/\=!Q>7'E1YGQ)B5F-JVD3/*F8T\D=V7F9T
M5;5S)LWF1$2PLF#75TV,65$WJT$01#HM=,UI2"/0%V4==@;=]ZQ:HU_KE 12
M,MJ,JQ?\>&>*N/#N?O=%XGDQ<$_6; N3T=_2.AF'+]UD=) @UT3.$17RXOGX
MX,4WX]<O#]WZV'"R=9\4$);PG,EAABZ^9]_XL.W[RKC"I1<(LX?^R0@4B[(C
MDVR90<S+;E\TW?M?ZP'=\(1X4,5HT[UX/MZT4FE@K[H.140<T]^&+85X*HO^
MRKO>'.RS[@+6,RXPS42.@")<Y ]97Y7=J)9V8+M4CGAV5_D@7YG?-/!DP6?#
MDE:9M@W%CG1M;39(Z1XX%5-\<&AHU/#4I8^D_[@W2&Z;FD^("23O-1Z=\1:V
M7;S(?BL6[6+@Y64UQ(TY]*0#%N*SVJ-APG*8@\/#\>N#E^/7SU]<;PXVC<\V
MD_#B:V\2CI+*7,SKH7F^@P&]J9T8?*[-IN+QD]<[N_Z0>)MKXZQ'"777G.2H
MBBHI%E>/7KXZ''_S\M6FA0XG-?^-E6H;;0+9L+(C#_NAKRV(%Q,^U4E/KK+?
M1J%8@AJ*JX+PY06PE*8)/W[ZF_6!"@W--X/G_V->)X-"BX]ZG;Q^]F)\\.KY
MEZ\3R9<?_I$KY#!FOG8M8?3[21N;./2PNK&4?G()HU'_X"ELH%D#M9C/B>,O
MY8#^74%<WU%-KH6@FUO+H\";!,5<E_$/<IW"M94]?)[,2VT[-R,DU2@H"HWW
M3@ZY3A2VT6XR$_4?D!E%H>^0D?K^S1'D;22"'5:.QPE=0KF-GXN%?: TPS(H
MR=.I2EN\GK3;L+SCA=T\GP:5>*%*L^(Q$.H35@%>03NQF$A'#07%Z->V"3JC
M:W"R%"URZ+JA^$&F4_41G*QEY#=WG(](;C0=#^Z*G$M3?_/=+K\P]F]>Y)=Y
M[&^RBOEU@"*9CZ!1;C)"&&45^NN"I!)8'@S.:C2GM;;2K.)O](^KG!4=U0['
M5B>)*#WQR8VKR(\F97@ZF^U]IRT"G] B<.3(-G?,S'%W7#&%(!%0F#T\,KO^
MP#&;*A5ML6F%+T0)0?XJ_Q4IE;VT?R)E*$6[U,R(AU&>:*VZH/KIODOUT]OC
M78):87T<*X:4^;E/S^;%^6-E]+VIW[^KOC=K]G*Z<I6)S1_@/Q*G1SNK+>?!
M"(O7XQ<O?=J;QT'5,[]J.NF*AVYAJ8-<J>;"MTD.N,59Q<49$^N&,PT\51+9
MWB-]OH$84LI\^H8):/QGR'MLDSU[8([QPX/'W!1Q\OGMN]'S??%D^__[7W\[
M^NGD\]'GDY_?CH[>OQG1S^\_VR_>G'PZ_NGTT]\^OOTT.OKN]&^?1^^./O[G
MV\^CCR>?_O,N@WYPL'_X2 QVRBCQD=T3%GW9,5NMM1WH*;J^(YRNJK&(R +.
MX2);>R6L#=(=!G6)36A)SR(G@.%9SAA2; 7K;,H=SWG2)QFN:!:F0F^..M\H
M*NCISVY\](]_6U8F:^G>+M;(Z=I/2!^/]'GQ/POI\T##B/"-&X0YSQ*7<2J4
M%7J7ZZ";%>2E0KO4A./#E:Y>I\REZARS><NG</C*P#45!1FPDQ:[#M[ ;PW9
MW>K#0R%$B;C2KFK9;>K,P_MG#]ZHIOLDE,Q# __"@3OC_HX,%G3=O\%I\'&H
M"1&-70#1 CGJWMM?V5U/K  [(&(7P,)1=;ZJLR46A"+OQ;)?0&VR6:Z-@;"2
M]64B:"1#@^A?>\TPY@VGP^8%^49 3^6SC/%4;(_&B7&2&,9AJ/BW>![^ZKF\
M7_PR7S7"QHH$(7I>9Z"4CVW2HS<1%.1"^8C("E6@H:8H_A;KE:D1K;@L-; @
M.)(?3'DQ"ZJ1@HR8]?LL8U=O617!Q1Q8Q%(NCZLKKJU<A:BN853HOLNN)1&E
MN\NO4J4_\NV(8P.2*^PFL#.-F99S5OR6"RL+CV/3GOU=DXC;#4A_I+9[N0/U
MJ(/G]UN9OJ67]CTODI^Q.MX)Y^DNYEL^)PWZPTT:PYNPVU%>797D;%T4RX1*
M(S!<E X(SV:=55*$7P/A%3)P[D'HGA[ OY7((LWOM(WE"7KD&PP4WU"VR"S_
M%[D[+#EH;$V)".1&UHX;F82#%^P&<B:U/-^;Y[/'M[CUK#VVL_:F4<B+_4>T
MN$U:7FL:T]1=YVGL"XXN*LX;,Z&U*93>H,6U(R:#ZE3/2YMR-IW5@5GM#<IH
M\W5L-Y=3:9JZ/-Z[Z+D_L-_>ZCJH2_Z;]K-CH8NVZ19=Z(M\COSGIZJE"\C:
M#AJI-(L5EG_>_4PY^L5UA6@%(;HO@5FG0YL3*.6;FUZ[#!3CEA/;,+0#_F-O
MW"[RZ;EX.-&AXVX_!@;M7 _9L<YMLF*[LY8L^\YX*!N!L2YT9V \>MO6%7WD
M._;J:-E\J."!"I=%F9$'5H[>V/!+42YYEG/(A7'5BYWFJLQ7C #>T%:V:<W%
M9U6/GSZH&WB?CA&9?H.P1^J9)K_VCE)N"DZ,"[&&N>Y=\4B0GA=Y?^RKNCC7
MA^<>[KDO2NL^!-HGTV3&N,.C9RF.@)\4G51M$A#]7RY:7H ,P"4WMM+T(TER
M1:'VB+E<*M8G3J-$^[I%<%>:RL7'N+P96#-V\21P,=YU\:*4O)<4[4A^AL$/
MG/Z1Y:,7RLOS3**,5 S!S M=X@)$8^1=-XTP_&%XP\<#N8?DDRG$@K>B]QHP
M10\S=N+VW3T1_>+1)Z)?;$Q$'Y^^__SQE-Q&SD)_^'AZ_/8-YYUWJ 2(MWR;
MG,U<*)F+7X':8*7T%1\8>3-E1HQ=W-\,@<11.(VO-_&OMPRO9PZ(G#1<G9+,
M+L46@5"U2*1L 3 P6E6]@2L9(W)H#%_+6Y[.E$61X-ICHW"(&(Y$<>W@]?,7
MJ$0#AL]U;96_J/$#GIM.+_IGTR[X(/^G1N A8F&_SZB1^52R4CG;L (<1OK7
M3V^/OVJDQ"T+7#B4ZT5("#+,N87>3WQ_>AR/\;',><L$*(XW91%J<MZC@'+?
M19'/Z+UI#&!/3QG?D=? ;1^_/95[RX=BJ2[YT/>G,D*,AR%W!JHS%5=4JRN\
M,G>IT;LVJD,6I8=UYN*BN"%/P*-:WB>EKE/C@W%P'1[?FRSY.#M16D4]KIM\
MO:P40$2GVI50:]-G5>\M"P @7J63K+2V1@J7(?>1-57)+4]C')U6Q. II;LB
M>,># +L$9XPN&^K<US\>=O*"@N_144 G<7!5^'&[R5NFRWA4YKSSQ'46YN)H
M"&@ILD--V][DZN$+Q(F1C$6SVCO+RWQ6J)PE+U!.DC _2-4T8$^__LF,UIW?
M!0WR%-@TZX8EY9')L"_-FXIWJZ1:"F%5$0I@"P)YQ!<*Z\S.R-N77&SQ:SXO
M+JIJ*HE]<#6SXJVK%-2 FK$!I+70F3A^'GTZX-V J)-'R":TKR\1<-%8@724
M*<Z8,TFL(\,B(N9,[QT]TV]5\P?]5.%-N6IXE@/D1@9C2O/")H%^DRF=A??D
MP[5"H\@T9RR\9H&6<VUZY>C9Z@+\2;? ^'Y(!!7@7MH??1=O)<P3/$"T!I"7
MCUG0S!Y9IXOV(7F#D7E5*Y5Y77,U@X* .FNGN%M%%K<.B=8S80WG(&#7DL[?
M&2%N%K<'+\BLKH5=;Z6<9*O(!>[X)R<\_1+Z#&JYC]TAV[1+EI0-&)"0#P$[
M"5=0?'YBRWGU]E2.)#YV.K^0S +;/N,=R5;C_AO@$)57&-_01H_^DJ+1/M(Q
M+:?TP?-L[^#E7_*_QD/[X.74_^K&CL9?%:&-B!+XUDW 8J-GC];;[?HY8W)O
M=I)RLO/1>,+'T2P 9E$*)@@[%'8F^A\?C8K^J:[OZ_HOG_2 'L>S_)%Z0(_*
M&Q:(8<B:@V:6'1!WY$M-4_?WQ.]OGV4SJ0D!J4^0-IOZ?+\U3F]FLU0(D^3K
MZ4RR3!T\#?9*@_5<BY.U%O! YPOCVSWQ%L.[R4Y<4VC]ES1E7V\V9;=)<+WZ
MT[T;P!L!EO[X<1T^8S]PT'%RLC\Z1:[^)&82[CNC^?J/2&@^?_;H$YH'&Q.:
M/[W]X>@GR62^?7/R_H>=2V4Z]_8G03$-K:L-$9&5W&M<\/7C.=+0J<^%9.O5
M'X/$IM;\'D +7$U@ZM%YQI3A$PFB.'KEQ.=X]&[RAF$*T]$ELW]4ET4U^D!?
M6V23O%TQ4S%%OR?E9!]!QW_LC_ZC:O+EQ>@_BX7(O0HSP&!=_ WS%W-OV3&K
MK07T^]NLX?,J_IDA%GE9-NOY9586V7A49B#X:INAFVY-#$HD1.=N%M2DYME5
MTQ8KSA?DYY:ZNM)JNSM19_2J(OM+H?8\EZJ*"[EC=A!AF6LNY,1*4*CGMSP^
M_?GDS=[!:W,IE%;()1/Y+S344?S:\BRS? H.:$<0R2^@+)>8LV)&86*>_\J)
MD)BI#17+:;;(^#TKSKE<9/-9"(S;E92E="F4TOO);:Z2T6BL3S ( ,?PUD=S
M9*KJ,E\WVD)!S\R9IE.5=F#^'EF*DLGBJ<^6@-C!&2K;?#[ZA7M*LT4C/!JU
MQ),\Z/$=<465DPJ\'N_J_?A=H])(4#UN::?+2$ 8&L-7LF":[H*A6W[*EROM
MKSD8O*T,G!24W5YC/)#LM?'HJ)S6M,/_=U[2C<)S"JN.9NN_\$'?A'^'RR\J
M+"8:45IHG"Z*8QF:738\ B^6]^0UXK5?&JD[#<;W^5D-[JV#KQV%A,XJZI-8
M1%QRJ$6+0$&@G#D9:QMNN4Y^&1_=%E#OR4T'CN]B4LTW^)K>4'[0^@8C9/].
M:WB2ZZ/3"R_0#;@HG.*2\L<(:P;6\?-GRJ/1EZ?CQZ+7*F[V5!!>JS0G8HP;
M_J+!BK^V,>[-[@IRDG127.5.Q4YG3Q\K$R7ULKH::3F+XX"U#,H'6PK=YV1[
M)0:!31#:K:QX,Q4('7W@+.<J-(T+V<E#?<I=RR<&DJ##9]>=E:[0[W;I=_D%
M@YSYH,1!Q$VA\_U[/P7Q#I$Y7 MO_)2J3M^S#<FI1QNAM@2Z?%M/&-T(Z%QO
M4ODQ$!;)>3GM))Y51/!ZSZ+S&!0E0^B%150J/7'B"W#Q("OFVM%N-!#)H8.4
M9\N+*$G7(M3M9F4C2'_)0 GNS9%=T(V4O_A<;1NO&"L*+"I:@_)H/!9?]D]%
M&M:U,E!C;5W0XM)AA,H$CET$Q>HD9#SUJXM)A871-S1\I>#/.0\BF2%:?X(N
MXMP'6^2U5=W8=O!@A:(:TS^/YE5YGDN#51YIG?C9W9E_&.WF07S3JZK'O+QE
MAVD7ZWULI4F&TA5=Z:2AA<);^#NRWZO*=C$>_TU^F=79KQ7M(_OUI6WU??SX
M^2)Y7ME<7+3GYESE,6\*,EY9'?97,SC!*-#P-O/-)5MWM'^Z>'"C=,<7XH49
MO(8A"Y'%*^K$L3$_Z"_+Q)V*\%4_94RHZ^HG.KS,'D@3N#6*>!.O$N.P(/L:
M[ZO#5#2V2W9C1^S>F8AE\"J>B*J,??UQ^'V^HOG3T_!Q'X9NN]AQ>.V6K9H@
M49@L3#<8LGQ\G'+XRF\G'2%=92:U'*X4JHR];K2)$%8+VDA\1ML&=!$*S_AE
M^ <F:-FU-?>+]!*50$/(3#EZ':Y_7Q;G55VUS?S&^^G1I)E^_N&_3^Z08'HD
M4V/'N:?1C$&V[2'=%;*#(]WTA[D*Y;VC^YQ7M"G7_)ER11&(W\NCC*4D:+/P
M6+G<DDGZ_E3,\M$GIO'AD(W_C**(_EEA)=5YCDV#/>0NQ-1#QDW./EA>&^RF
MT8_!K0W5&\P7]T^X1!"GWR<7N0CX@=ER[4C(;=<NNJ9%7,=I3D:DSL@2K0/
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MH5RXS,O, WP#SQ9G4^7)U^$B@<=6E*OV1]^;U!LXN!)ATTD$@B;ZLN(!J%X
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MU:K(@MAN)*9(/1&PG$2ZCJ%[/ZV0^UHAVCMYEDD>2RH2TF]63K.:15QBL64
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M^YV<N@G=[=8_F)YO=$YF7&>B2#96FS$4J*H(2'DJQ01N<XAU=Z\(M-DC\4*
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M;/P,Q$.T58MIRP"LX8@"Y;Z!ZQGQ<N=R _,1ZG"!-L'AF*1!WY5H#0$L4-W
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MD<)$W3D=417?M M<.^$PM4)"G%#FYY7B.A$%AZ)]Y_+^'$73*,U,0'YIF@+
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MDB5<IZCPT&^QBR&I5KH'@$EBW,TS'3OEGFO/4E_>\14IR7:ZPBG?H^/7.M=
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ML+-F6$J',X3S)A>V^)CH3^JQJ9%!]5?WA5)AU%[>1]!.72YDZU6#TKOXMTJ
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M.*7\_RX'_+P;_,#D2F[/(88#LZ.,\'5JDP>LATXER87T-7?GX\1D:9FE"\5
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MU:X5Z9^+U@DJ LAM1=[1^EW&,+?&B;;0(%J5A'YK[[FK&QL."AI=YK#BN+M
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MC).EU _M=_X 467<7.H&(B^IZ4W04M:%,M 76MUR3 K=2-1/-Q&XGZ\#<KA
MJ2&IRT?/M2@HPB^8"8<+@WBF#H0.77"*K6!=]7ZPF),+PD9XJ4'SB82- 1M6
MI7IHHD(=E.T]=DB[!\7_+@KNZ?/\1M>\6702RUL^F;>N-?@S.2_X6KHNBK4W
MYL"'/L; E 4"FLYIH'VDE9T35P.G!J)J90+*/.I8.X()/9,1Y6([P.E&'W^0
M]Z-F9ZUV#-YS<"6Y<8I],ZYIB$:4N8'7@O;;^%'G.);S )W/"T]^:@2PY1TQ
M4&M>-%RD_6)Z/=#H%N@U*Y65)T2-)J'.G$#3+(C&=<ST0W0\E!^VY:@(Z'UA
M_&Z.F'J]UT5,8EF,HA0Q%3@6H";C*O0"YQM:F,G20JTN@>7V]:ZO*R&/,PGX
MI.E"!#5#G,B$'3Y+%2+"0&"%PR,KB'%!P(61 SJ3-MSUW:IG\M+(:UO_5) F
M9;[5J-*^('U+LS]E 8\3+D3[[G -RE@MJXZKFC3QB6&72#4P:T>KP4E@$U\I
M;\,<^JG>_%1+-"T$T#)U8($MYZ)01=HOG [VP/L54%\[&-$%'QA:1"%0%OI9
M.4W1 QVU?8PS(_L!>5F%]M%I=4(DF-SI*<W])YZUP3>M<<6-3V/<'4+'(FO
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M/>!VXHJZL]-RLIAY$H_7SH;0*$V:PPJ#G2;HZ9U7+#J9"%\(>()+(+2B^<0
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M!A8JE-816S1G$"T*13WI,.PG<X-L%^Y,+4V>@W(\E8ZTVG.,N9-LWTIX6YT
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M;G0!9TK)_R++4BU<CC.OZ>15_3ACV87K1,5",N > A[ZCQ_BFET_:%<-4,<
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MEZ!6"];CLL@\Z"?L.Y17R9M%"^,"5#MFSEWU)$MYV=.'%X2K1,FU]J5CFH
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M+D=8&^NK:MO05>^?5!$Z]=P%SUSP=$YR3O!S_Z6AM>JAQ/U6Z9NTHBG!0FX
MARJ =^1H01NC^S[Q'9\N\A1OE==ZIL)HV<(.98(Q!_0PXS(%*\!OF8'&\\89
ME()\5+#D+3?3?ITK1D 3DRP<JYI,+ +I5<-]?E'3TTBMI4@N-ER$#)!/_(Z
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M9SV Y,FX3)?N_\Z:V?1__C]02P,$%     @ ^'ZJ4C%: @I($P  U=   !
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M99,U#XZ5JHM>WIZ,!+<L2H'&=C!H>ZO(B7.@B?12"(^\8*9)@=G["!N"ZFR
MG#TVRO[R.<96N73]=KFO]XAY;7+(AAC.'/IPBI8>AH)X TD'$4*PX<@XNH74
M/=5OVWR AX%6#2%6J5)UQQ&T@K^3!I>>&;$B,"*9B\0EI0@#L%0+M#),[F=O
M;M$VAUN<*Z*C95H8;XA7,A&)I@^:0OB!.B0,0J*1-S4[!Z- JXOX-NMS?[X?
M0U>N-;BCPEL>2:"E(@,:5<1)EXF2EH'-H$R;+CTU3M@'-D/[ Z2J=.HU =\X
M3=E&[B$$DE)I<!%2)#9'_)(&2Z/S4=@FV-CNH/;5>YE)H:,!XCP>&M*5[D61
M):*R59EYQQ-/_Q)ZKY><[]9Q^_"X8:S\CLA4A8CY/J,W#<2UC9X_FTT_ UI?
M8973= "CKH]0X1W773157O#!T?#MXU1??(NH][4I*FR6^T:LSI:C;HI?_*34
MRIGE2]__939-)9/GC]FBU[/( V>JSM##UE@I*>G5;/JAE(\KA(RB<<9+:TAD
MS!*IT,KRRGK";'"&ANRA30;%92+ZVB1EC)?3^:([*Q>@+WP$]''/IHL1'K/6
M>A>(,IFC'1D<">"@Y(9"]EED+YO<]-]&T) LE8-1<-U:J<+]:H;V56K^G/I-
MLG!)9UB2Q:GDF5M)@L8%RRA"Z3BA"56A&%,VV]"D4-R]E TJ3-4('GT%4A$G
MJWK;JQHW4%+)E_$WS:R)R3!T!S,2X[@B)8Q DO74V)2#YHW0L96>016@JHB)
M_LRO$HV\"LYU,RYT":"#^6($WB@MI2,BN4).=NB#B41H5H$&"C13>X_%<>\D
M0RH#U5N^=5G:0,+7S+#UE\N8^%(3!<D-LXJ@OZUPS<D3IZ,E5D)T)?=5N%VZ
M:.PSYR[R/UI+]@8 J,CQAL&-:U1NLG%F^7>_Z/U\>X_!JSL:.Z^DA6]AE4LB
M@B4.'$7AXHYWW)4^3<"D%I(I:%+SN:9O<7FL"Q:^A4_K*HFO\YMN/(WC3W[R
M%D[]&'G8O<XOT+;QD_\&WXU*'X480B)<"(%+QPV%&D^CB:,2"X8YI9LSX1#"
M!^NK[(.JZX;'4:59S5;=@^J7TS]P)[__ I//\/MLNO@X'T54XC'82)ADF4B3
M& D1$O'1.:I\-/)Z![NC _ FU4.XJGI(]/64X\- K^R0]U]FHXR\<89S8@W@
M)HG<$9M*=C_XD(,*X$R3L,LAQ [I <;# .T0J3T@OA P,))":Y=,)M2KTAK9
MH=F(W"+4:2I39"GH)J\G#R-WL#[><3&VM^0:&OS+8NKKLL.K%TH'&/9;!JE0
M:^D>RGI7K[HQ_N'5SVX;J@47FE0^NS'+156KL\7'65?BE.62>%FC<=6[ ;]\
MTZWC5\N_[U'7J^;T+7A>BQOUY52C/MW]@[;@:=N[U#]@48KBO(%5D?X#V')]
MA/X\N).FR@L^6)=M'Z?ZXEMHL6M37(1\3J:+\?/QY*R@K48=P@,GJL[$@U98
M10?=;!!RH-ZYI=-(?UUS#X5MN-#/@KAMN%8<:69)W)BIY^%TZWBM.--DXZS[
MR+SQ'1IQG<>IXJ'--&X=JD;UY5VH;,6+/A6I[QZQ'6>:@.55:4U\"!_6?]A_
MN=LHJ+.J@[7DE3^OM<(66G U<@7;_):!:JV]K0V^FN/<=WIQMCCKX/?Q='QZ
M=KK\V:;#5E_^[#%%+<X=NJI:UXLPGP-<]"PO\VZJNWT[)^ ,1A&XS-9(DE-V
MY5XYD9 5)5GHH"P%E663M[V[$M@[;KK+/-NOL)R7R94\/&]4B?,Z3ZS/I9%K
MX,92+WRCV.G!) _J*K(% F_$5H\CW7I1_!V9<N-.R]@0J,LELZ2\=LU)D: C
M?F#)\>123FVR[0XE>%#7DH-!8E_)'AV'FRNO%"-+BELB'"@B4R@=*ZDD@D<C
M; H<6)/'>'O2.:@[RB&A[A Y/@S85G=?--#L+"=2V+(G1+G[HI90),]'9Z-@
M38K3[TWIH"XL!P>XO67Y()![,3OK1M8*3I7@)//RUIESW!C<2V*85TSX*++2
M#XVX0NB>6;#_6H#;6Y)5$J?OI/#][!?T]\;I)"^@.Z<1/=0@,_!RTN/&4%X3
M"S824,%GK;AQXMIQNC5]>O^9=X&/_A[@<P3!5%-6MU X0JXZ$54D)ADDAEM$
M,H G7$&2B2FGH$G=H%OH:;3,9V==AY(>^9@X+PR7.I:L/9&(U9J3*"/7/*08
MVN3"W4W6D#SJ&CBYKEXK"J7U?OAC-HT;LC(-C.9,4BQ]EW#]Q.FDB?+ O9:>
MYGA,K%Q0-B2W]XAP.5 T3=^I3!!9LU7P^N0#&J*'=G^Y;:0:+U!VH+%_S8"M
MD_1YI'/G@,W8TJ97\A0_+3VQ#KINNOS7_==]*RV]JTG#%&;S]Q]QZWZ"L\4X
MSG&J Y:[?9P*16;NIZ\)"PZO.'[':(W8T:3*^+:):I0HVFG<1HQJ7-1_VY3/
M(<ZF\]EDG%9'_7F'\LHLO'>>1BS=;WU-6'S13O?E=/4+E7E[^P2-F+KCBIIP
M\[P;QLD<C<E//1-K]IZB$4=W7E43GIXG=\]+PMB%="OS];YI&O%VK]5=YN_:
MIB\? GH,__C;_P=02P,$%     @ ^'ZJ4K]DRHE7>0  HB<% !0   !I;F\M
M,C R,3 S,S%?9&5F+GAM;.R]6Y-;-Y(N^CZ_PL?S>M#&_=(Q/3MDR^ZM"-E2
M2/+T/D^,!)"0N)M%:DB6;,VO/PFRKKQ4D5P+9(G5$6ZWI)+7^I#Y+2 SD9?_
M^%]_7HR^^X+3V7 R_MOWXB_\^^]PG"9Y./[XM^]___ +\]__K__\MW_[C_^'
ML?_SX[O7W[V<I,L+',^_^VF*,,?\W1_#^:?O_I%Q]L_ORG1R\=T_)M-_#K\
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MJGQ67-A89&90!U#I7#MAI929L^!#RMSSV*0RZQZ*XQF%/6IFK9'4H6+MN3/
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M=-9"L2)"9EJB9,!#8CY:KJ5(7*DF)_@I:Y"/R9(#1=VBB'#;[-';1C3_FR1
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M\G\/<4HO^?3U-7[!T=+JM";'P&G#=MK1\2_K-6FI\9:4I<XIN#:%B[O!.]_
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MOLUHU7LH3N"5-%#5I"\Y-U3Z(#E?BD/'W,(16F:1UA$]BGY"3A+(T.0BYAK
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M (I%FW)6$(K631K;;L!RK!YP[;W?_45[ZB9NU^MX/1E_)-/M8E%71?_-HE6
M(/=,^=K_4$19>YZ08$H.3%@@P\TF;WB3"\)-8$[5/Z:S@E=+X;L*ND6?A!5,
M5V7 NZ!JV>5E,ZS3-'/IKK9'>-!!YL=C!.I YI#BS*7:'=/7Y/8L:G=,7Y**
M$C$W\8B.R81'6JT<BPC[B+H! 5:J0:\;/1B?97&6&:7)FO'2D"L/@B6=(V (
MJ'23?-N-:(YO2?:AJDG?<FY>OKA@.+H2M4Z226MJ78+US&?Z%4>>4ZHSY],1
M<OK/R1#H*.3FM69W^H'L@JNE(; -V&E,@:Z*>Y '':7>X"38BB\+0>BD8B4#
M,)U4JMU3-4,=023CI%%'2)4_<>>U8Y%A'V'W2(+:Z^F%_8OA=\ZI]S@>3J:_
M3>8X>WF)I"1]W3#5(J(@[SF3&50#_9J.0"F8RSQ83P>DD2N]EC:VT-KU?:>.
M)!VJG4ECT?;<)NW%Y<?+V;PVA+H#],?).%]W=;(E*)<+V2FQ#@6KQ6(A^,"X
MMT%"!.Y6+]$VJ_V1]YR#NOL49<]?^4M,"PP/H ,?S"*MA[8W9%K6SLHQ(4-N
M@U<\!,7]#HI^_$UGH.J>Q=G(VKL-5?_X]??Q\+\OR0F9I>EP436S.,P<.3'!
MF,) U2)VZY%%+XF;G@XR"<I+;);E^RBZ<W(%^E5%HWX"MR#O?"*[X&KM'6P"
M=CKOH&==/LB6CHIHY#!LQ%<@TW9::OH'*5)#C"P ;7V)1R@JD'E3CK"7/ &'
MX43\V$?^/5L7KZID8;32Z>+J(-0! +WAY";90,9M(5PB*2:+='0^RA3R+@;D
M0^\XC47170N3!B)L$#!<M-!:U$763K)7;2461/9DQV0CR6 2=3Q;@$R4EIX%
M2^8L%+)N79.4RJV(SL5FZ$?D#;K'W,5S1?E=$+6T$-8AG<8VZ$EGJU<(_0B\
MQ272.C*-Q/F CG:F0DX/:,VBH-TO9+2%9Z5*:K(?'(L"CYS^1V/ /G)N<GUX
M<3$9+P!=G5!%>@DV<9:A3M)1(!AYT()A<K(X*;-I4VRQAN3XID!7]:Q=&7:1
M[=;3O\>^ZBN7FC_"J);"3\IJ( 3&>1GK[*OE\LYOZKL5\V%+7&G1[.JT:6V-
M#UIKX6W0LNA$NG-%(P]\];)XYY<V:MU<2DAH HL\6]JQ7"'#)2:6=<PA)(%V
M-1SX;;9N5E;1WQ:!B5#'QR=;R+8VBMF@N%6B_J/;K_-)MF[>@P$[MV[>1]P]
M7W5L[?%RZ\S5*8%+G,(;I\!S)C7*FMEKF(^^@@W"<HT8O7AD]]KWG=^VYIM*
MN/G%]Z:&'5EZ'<EO9T7)4"/X=5*XM P$[>&^* ,BMM\9GG;'E-ZVB*X*:'*%
MLKG73\P0@W9DV*F:$"9=9$%ETJ0361CA74J->/'4&RMU8D-W8?=X+;*^F[U(
M:7JYF+"T*($<E%P(AT$&M0I-UZN]B%G3L@/(PKFC?6SO V+E)=^V:ON588-8
M5DWX_'"5\#F@G47DY F+KUT#A10L2 S,1BG!@5;TPU;)S]<@OFU]=Q9K\X;#
MR[BL]F!<=:"EC(:VE$C@,@\,G2_6 T:;CY#9]C1JHWH[O_<7[5.IC=J0XP?)
M"4PR,X^&G)2@%2.G/;$"X#UPG8(Z@N_[U.XS]E+NX^G0^PCYF(FON^!ZUNG0
M>RENUPS80Z1^3%9(2-YJX1BW&IC6CI,O4B23GBN-3G&01^C,^P2R&XY!AGV$
M?:IT: -. 9V2K'@"JITV9,5RRZ0E=.!-T@@[V/_?8#KT7MHY)!UZ']&>X,+C
M??J$^7*$D_(KS"^G]/ >[S@>>GC?UQH[+V3E)L.[*#V0&YX]Z,1Y<)8L>2^\
M,KE$;E=O,AYZ3Z/+"U10+"HF4ZJQ1>E8C$Z3<1N@-B3R,1PA=-?;Y<5=C^I6
MA._P,WRM[YF]*6^GPW$:?H;1.ZS?*'T(;\HOPUF"T?^',!W(HC,(E\B]KE$4
MCI)Y+BQ3"5(,-@>NF]S+=P5^ZEWO,$8]Y! W5U^#_*\]\+\:_T:;Q8<_</0%
M?R5_[=-L(*QS1MK"C)=U4!I(%FORFC?:2%<RE^74W%M'_>R(UU%QC9H4[ R^
M?B8?_I@,?))6Q>@9VB0J9F"@2V':5D.48&O7) GY$+#/D&.'J*G!S<[^F(DK
M.- \I1R+9KE(68>G.>:S\@Q2T@)-*3$V214X#.YSI=?>JFI037,O!&XSY\+9
MRFZT]0HKL9"U9DZ&B&0]1^Z:A Z>Z,U"3V382ZS-QV@^.'$:LBL)(M28::I[
M7.TD4T<%D:/LO)<15G-)GO$0\ [T:*22(UU+6>6MQFR929:,?)2>C'R;&!E?
M:*'>T^ 1>K \C6NIWDBPOVB?RK74QDY4N680HY=,*?!,^UCCKDHQP3$7;A5J
MT\R7>LHM^_92\"XM^_81]/$:M.V"ZEFW[-M+;;MU:CM$YL=CA',9R)8E3+:V
MW<_:T*\X_39SFR$*<&T&VC[UEGT-B+"/J(_6LD]&K:UTCO13R)@IAHQ@B(45
MY\G^16>!JQ;Z?]HM^_92U4XM^_:1\W%:]CF0#I4U3*@0R,,UP()S@24AC;'.
M1<!GF*/2Q1#H*.1CMNS;!=>SSE'92W&[IB4<(O5CYJA@DB((390/]"]M,F?@
MO6%6.:0=J^C8)H7UJ>>H-"'#/L(^58X*1BZ<LY:094>[H:=3BPXKQH.Q2J<<
M$ZQ, 3B7')6]M'-(CLH^HCU&CLJB8/C39$2/GRT'E!^0B[+A(9US3AX#MI);
M$CV/P1:!243M)(]T9L>0R+R2-KB$@X<Q=A/9PH8X)(EGZZ,:B&\3R!4AEBBC
MXH9L(4]VJR0!AB!]]L(6'FF_VR#$=;S=1/G^\N("IE\GY<7E_--D6NNZ8)R7
M,U66)>[TV[?3JZJ?9?'\P3E4O;Z^@<KZ$L:*FB'*)% 7$"IJXT,L(N04K30E
M2Z?R!C5W0-)?LY#;0&\,,4:0P#+/A=PJARS2YLRX2H'V@9!D:#*R=2.:'KMB
M_'99#PEZP6)P[EM8#CA[,<YOYI]P6@L<1Y/9)?WH1:3#"])\4"S)(0C)K*YU
M,E9%%G,4S$D#&**3TC3)6.L"^K2]-@YCT0/M-MHJK4%4X YV0OMFNKSE6J!^
MB]/%,@;1ENP4)Q-%A%)+[#+S*04F(U@E8_2IM/G"'L=V OH<3=G;6=:+IMKV
M]%G*Y/:$&!BN8Q;HF:J?E8Y1LEB282&8:%1"$@MO3*)53,^3/)TTTR! M09M
M:4D,C(R6<VV828OIX$G6UG>&D44:<_%:A]@DY64+GN=,E@,TTB A:@W6F\OY
M;$ZVYG#\<9"4-+[>[RNK%=.N..87U?[&"D,.2T3>)#_F(5#/F3*'ZJ9!EM5]
M5V3KV>EET)Y'PTHVD6E/*$.N^:2N%."\A(A-QEWN!N\9<:F!OAJD7]U'N7:H
M"A^#%9:S3+XTTSD  _#(#)<0R-VNLSG:L^D96SP]ZF>=/;8%>ZY.6<>]1QX\
MRTK54<":/%%A-?.(P(5PULLFWM9V2,^<-0?H99TQK@5C[AZRGMO:6R$R'@20
M%4_4!CI;F7!DPBO- V_3;^(17,^<.X=J:)U OG,']JL*VJO0UX]?%X&P9<J#
MR#Z:6!3SHNZ&BM<^L^ 8^)*]K3Z@:9("] "F8^4/]Q\.[$O03R6+>'M':BL!
M'%=$9E';+UIEF,^)++)"YKXT)L<VPUZ?7.O^WE2^<PO_?41_G+[MNR!ZWBW\
M]]+9XPW<#Q'X<:@@$SKT1;+"B>A:H6>@=&!&< @8C;.K?4V^+0H<W,*_9P;L
M(^<&FG^/TR'.?KIO]US/*;0>@U2"E:0L+==F!D%Y9JU,VM F2"9SDZ-A.Z8G
MT=9_+Y6MG@8]R?LTN42_P70*\^$7[#-'8^VA#3(O'@:^DD^!-H,V05IOLC9.
M1)^=\@I"--FHN"F?8NWY+;(D2C(Q)9]9"3XQ72>(!HZ:56LV9>T<YVUR ]ID
M25Q/N+IZ\M+9NND.+@:!6W"EEO/&^CDXYUA(PM-7%[GV)I@,C6:)/(+LJ>0[
M[,.'S>4-?8F_25+#1H#+0(X8Z)RS$:[.VXZ::5[J'LP54UEYX;.DS[1AP<LV
M6&?,C$,$W\)>J8B66%Y>3H?CCV_I0)WD)<;?\(_%CV8#X7DI!0L=H%;727F2
M14B1\20U/32FPK&)Z;(3O'.@20-%-$A,> \W#OUBD.+-S1.4A+9$PI4X+=T;
MR3R"8CDX:4$X8723"/TV0&=!B3Z$W2#IX*K=_.LAQ.%HT3?FE\FTAIB'L[K-
MS7[^\S-YA36F_ '^),X&0&4R=ZS4#J9:9D[+YY9A4E&X#%:Z)H;'GCC/@3(M
M5=-C&D(M"5F>A43QV8N/4US$!GZ%/X<7EQ>W5Y)7(VT*=REDPYFLI-<".//.
M<N9D\M&H0$[$+O4VN[_Q6Z9"0]GVF#*P!>6R3R.=?FLX%41C=.$,<E),J]I2
M'T'0GI>)P#*3S;3+N.-]WGF&+.A'OCU>_M_#>0/SQ4?ZU4>8X_*V<E+NW3HK
M@R%+HQCM4#5/P9$HA%*,Q^2+52[2QK4/%79[[=FPH8&4>[S;WPSU'SC\^*G.
M."-7"C[B?7-(<^-C/;5<J&/?0XR,K.3 DD]2D54,,LF#^/#06\^/#KW)N,>+
M^D>(^W8Z28AY]@L)J]*VCKBZDM# U.-+T<$6K<O+J'*4Q%^KT%EI191<=]LE
M'GC[^;&C=YFOLR1T]DXK57^$V:+FKAJZL)3Y%,8?%XOX\>OM7WF[['3YX@^8
MYOM),7=2XC"78 Q8)M$@N=LZLYAM8DYYP*(C1-ND#U#O*_F6"?DTU+LA^-9I
M;.HUJ+>3.>$<PF@5'7ENU]_7[[5U^>;EOQW!N,:690)B4DJ2C'A#7Z 7X%F)
M$FS,R#.8'?:Z'B%]RWP[I78VL*Q33XL%K/C -Q._WOZ5N]_,JW&:(OWAJ_%]
MZ_!ND50,L61#Y@#6FWN#Y#*$K)D4EEAE ,$_=GO9&.*WSL*GHKT-K.P>2NYI
M-_\"PU%-*J,/\N_TW\X'@M<6#5(RPTU-+E-DCD0163"I.&.L$*)-!EZC!7W+
M)'Y2RM[ XLZQ\(,7MLQSN&VR,UOD7W_X!.,WG^LC9K_5>\,9^6-+$0QD"%YR
M#\P77EOOD.0]'2 L6&LR&A&\:9+,?K05/FN>-Z7#!N)WKB"\4U*P@+J>VZ]R
M+EQA9*D.%]?:UYZ!7M41=E)+Y7)43<8Z/(KL'(C6K_@W$*1S,>#!G\+B7_]%
M7+^Y!!>#8C@'VM@9\GKC&2P9*[2$FDLC<S16:O>T_/ -BS@'VIU,J1L8VNW.
MX="%7-VC_309+ZJC+F%4)V<,E*/5@ E$)!O)#@G(((A0BZ1$U,+Y9':ZD^@7
MUK=,N5-K:0/C.A<L/E030Z<W'>4A,Z&R(6PE,9\%_=8E ?232$?ZLZHWZ[1/
M]23HIU]OYH(!:WS- ")>ZR(3@Z(+2U[;!#H%GMN<C-]2O=E>*M^YWFP?T1^G
MR&@71,^[WFPOG3U>;72(P(]#!9-SYB9)EI7)3'/E6>3D*2IABJ*CSAAHTUOL
MJ=>;]<R ?>1\Y'JSB)('1[MG31=E.@G)8E"D-,=3T#Q9&]M8%$^\WFPOE>U1
M;[:/O-NVK;P"1(O,6=7^/TK42;-)L""S8"#(D$+IG,ZMV\6=B=J[R;;%=W\9
M9\,\A.G7.UGBB_TM^&BU)+/90LW4L=82,&N8,8C"*(+KFV1;;T5T=@9A+Z)O
M6YQ16_:_*1_(3YZ1^TMBNOH&=D'8TD!\'.*)#,9^=+J]@*-/A;383AY'ZDN(
M*@?Z6KRN&UXQ#)2"JFDGT(7@51.#\E24><S /!5C]M%#SP-2WDZ'D^E*6<'5
M:9A0)5E;.'FW:.( M&99&*]W$"H*@7$E"K$Q_+GU!<<W(/K6Q*1O,?9H02X2
MGO"/C9 D>C)HB+XVTOFH,7GF;>&$BZ-7.3NS6B2_.;5L\^//2J]]B+#!WEYS
MT.I2%YM3<8 Z:L,X[5*$A1<6C54L M>VE$4U6(M=_"Z(<S,(#Q9P@]K,:RQ7
M5-X%34M[[SZ<T]AVAZMGBYX[R+;AYWV%2GLI@LN%B<@#TQ$C"\EH%H74T?F<
MM6TRROH8FG[$)&NEZ'U$VO=(.LF%?35.-0?Y"U9<UY9"$#+$K%DQM8.>Y9)%
M;P-+*1;CHDBT[!V.Y6W//_ZYW$7FDYX%UK-I19BXVX0IDZ6ARN+0B8KI8,C0
M2"FS6*POZ*V7JQUYMBEQX_._925V%]C6+[''CEZ_X?SU9#:[J0F\]^J=VG>M
M/J%SKZX'(:TTYM*0,R<=B2BTSDJ"S63XU(HMF<% &CR KH.8#AX'N/DY?8ML
MAT& *=I +D'FRA7M:K/K6+*S'G)$37]M57#=I@"N/.S:C)V4%_1]O!R.+NM7
M\A[3Y731\>'P7G('OJAO!1RTP!4-N0(V.,L3)PU%RT&#DS)QP4W42>.JAG9]
M9\?.*?3LO/;LG_],HTN"7BLJ:Y[3Y7R1YO2F_ S36JM_ _+U36Y,MED7%2)S
MWM'.JJ&.)K*"Y:BM-BH#Q"8U#GTMH',+FFXXKGH>I(@<A4)630-&#"'ST*%@
MW"91B#36MZD4Z07]\4_WD[!WK</-T37?X*KV-A+1<3G+X(6"&+QQB645@&E'
M#H_G)3-EE=68B@V-JI1[7<:QL@V?!(U/R("GDM.X8:)\(:$%3G(4H&(M3#3D
MI"7'!+D-(7"O5$PMB+P.Y?0QRN/S8M*K?AJ$NK:.I=\%5\LPYS9@IPEX=E7<
M@SSH*/5CLL(5GEP*R(QWHM:7 (N1TW9M(<;B+4!JDO]V7#8\$A0]%AGV$7;?
M05+[%\.O.BT/:==[C^/A9/K;9$YNVR62DO15^*B4 %)X9-KGS+1$K%9?88E;
MHT%DH>(N;3)V?=_Q+?1^M#-I+-J^PZN7'R]G<\E%N /TQ\DXSZZP&0P.@DC,
M)V\JWP6+61OF@ OKLC>A[-(Z\+'WG(.Z^Q1ESU_Y2TP+# ^@XR('6K=E/'&L
M";B1@4B9 7*'J%1RQ>Z@Z,??= :J[EF<#=(9.QK /W[=_(#%$9BM=9*322YR
MI.TJ.5DO$I YI4!+0U+,36Y)&Z[I7Q[+DV',T3Z&._O +OA:ND"/ 3R-*_1D
M&+$34SNJLX%O]2A.S3%&+2PKD4X>'>B@ *T6 V%]4%9XJXX80C^QK_7-LFT?
M+39@V<\7GT>3KXC+=B:+?C?7([RXX1J29L*9A75CF#>^VILA>&V=,J[) /JM
MB)[*K<NARINTD'S/#MU[G'X9IF53AW=(-N\PS:\J[7XG:5^;IT)G;A <RYI+
MIJ'Z(C9R1DY)3;0WG/YD!VM_M[>=B=X;B;?!GK )V;OWOU\G FFAI0?.!*^)
M0"D6YG-)K(#6M4VUUKY)9>.#J,Z$(_UKH($]?,=EW5B+FZ*5V=!RDS6&:1W(
M=PU:D.]J%.%V)?.&P^ZVXCHSBO2IA0;)\'?@U?C)[?*O.6RB]$("BV19,2TM
M+5W109=0:Y *0,:&0^^VXCI?DG36PM891'V/:5UK.G5 .MV6!_4SCO41@*L)
MBS:"##J3"0=:0 ;K59T4I@UPZ[D?/(ZUNP@/SOM\\'&-Q+E#%J@U5MIHLY$Q
MZ1Q"5"'F7$1V@7L(N$6HW9)!-S^SX_S@K<]K)-Q=,CA-D89\C=J:36H3#$0=
M<DP2BX5DD6^1;C^)F@<WGGM]DQVD)!=>*\TB#YZV3*?K5&O:0;U,(5DM?&DS
M,K,S])-U_OP%AM/_@M$EOIC-+B^6?6_?#6?__&6*^&H\QRE9I.]@CH-BG?61
M3,[H:@>.7'OXI$ >*D?K.)2D\M.2[:XK.T$]['&9WEM#T29<:9'JV><"Z_C&
MZI#]UV1$CQD-YU\72Y0U*,.1%L:YJC?P]:*.[#2K/-<EEIR@S?#5]FO[UP=Q
M8KZT:#;RV%2+'[=,M7AHB;6_JQCP2.9!RH)I#/0OHSD+PGD6BTL6-(!9G1+9
MXY?09$G/\P,X/3M:]&=J\6F_''X99K*;%Q\VEY),>T]R-S$Q;=VBHW9AZ K/
MJMB8]?_?WI?NMI4D:_Z?I[@O$'=R7X#! "K;U3#@*ALN=S?F_A%RB2QS6B(]
M).4NWZ>?2(J298H4#\E,4HL!PU76PO-EQ'<R(S*V+M>BW5?V,M^"1\.5#G=S
MZQ=X;DP,P;D(Y*.Z.G4T0_3!@97&"!&Y")UZ5JZ%\Y-VNVNEX9CPV^O)B\7/
M8%X/;SG4_-S(0+:\#""3([,F:P]1. 2G<F(V.H_8Q0P>!N_%<:F#UAH.(+\7
M ;^.BJ['>CM\9R&>V:?)/%S<_?ZKR6S^^V3^?W#^$=/DS_%BP)KC')6EO34(
M)T!%)L!7N\,K9I'YF)3E/>C8;44OCL&/@QL-IZUW7]CU:)=?)]/EE^K/\7,5
ME<@,R;:0@EYQ52]CA,] -GSF(I-^.F?Q'&69/U^/Q\.BA@/I#Q;V<H#;8E[A
M[.WX>G$KP]87WWQ-A^6M^7YN?-;!T6F8<S*@A*V)_8F!\[QP[4H1JQV>3NS+
M[;?.%_?6/&8>W7]MW.,=D+FK(*P2.EDZ9)';.H:Y6 @8&!@17(G"6B,?UPRY
MUA+X^:H]">[=?PG]4WD)S[D5)N3"(:N0:]9PU99E@,EY8[SQ@G69^7FL!?Y\
MA1X#<];$I-K$:?<).]R=;/FQ[@.UGJ.V+J2=X#PZ=+X.'$PE*O+SR'"-VAH(
MR11E>)'6=;D#Z+*:ETG^DW)B#=/;A%];S7 E?RS'Y!EX7Q>CHH:0A0/+K:4W
MVO'0)Q&_Y2)>)J]/P8 U=-X[JGK0?-@=3Z=U%EW6!J.JR= H04GZ*_*:Y(Z%
MV5A8B'8EV-!VX._!*W@QK']"1%GS?AP>:/T^]6";$&:;I+ LS8^84-=+!*DB
M.3&,030I0LJ2H9&!L3[7N,U6<*P.@Z?>WD^B\<?25O :/OWPHFQ:%8;1)0G<
MU!XF1C,ZG6P$C+0TC;[DTF7>R0\H3M^:XZA$6(T#[ZV07KF'>PGB^S+&>;7/
M_8 U=9VJUV%1)^K7L3]7=K5QCZ7HIT+BDK567$K(@M,K[G@!IZ(''[70DAGM
M3Y1$_FC(NZW[Q^/F[B[Z/6J/CZBEL77J5D97Y_+2V>:BL>!2P"A#8CP^]QX?
MIU?XX+X@NVBK0SG-PTT)F&>,ZUI%'!@Y7%Q$B,X5,%%P)XI.9$V_@+80CXY.
M[;36<&>:3>?GGT;S:AZ_'>>:&GT5+A9[M]'!+O)+L& !E32M4@0/UM@@M9 L
MJ2&I%_2 .Q2B?ZW29R."E^DPM%%(P\*-M8#^.9I__H@7"WG,/H^^?)J\&<]'
M\V_+UV0(U!U\@?TX]##&XYKVC;3Z$$<ZJ*3W/K,%<M$R%:8,9&8<*.$1@J>_
M<N$Z%T.+T4,ZDSP=]FRPK4]/GETTT;CC\8T1-J/#^/5HBHE^]*9I2DDEB5!K
M=HJM65TZ@K.9@>8VV&BY9WHET6)M^.&!1QS/;.FNEDE[F;:>OCT9WR!;@@G)
M^^"\ 6&DJ?,J9:V(X/3N1G11,&_$D-F0]S[X>:KU,/EU<'??CM/DDMRG,%]8
M2^_J+U0I+ZX&#/>)95?CI)X6&1!B% 6D-R%*B:93\[H',+U,@[.ULCJ426Z
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MAN7_FP_1:URU!?&;4C M4I+#''^=3&N&WFB\6,RY],P8F0)8X1S4>;X0>.:
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M4LY\B#7X%*BR:Z"S/U-V$?XQ YU<)<L\2\ ,G98J:@M>" U.HE(YE:3#D,+
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M7V+B71S-1]^5IC$#=I%SXZ-_RS!--&3T"%MJ2HBC3<]9""D%0&LRFN2=CW'
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M;+>TJEVID&LZN]>J69Q)7[N%2G#:%'__RM.+>(WK(;YR*XGA5ZGY4(0H%;9
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MN:1N;=8Y^!MUZ<>/38@**;_Z +94$I'I21[2>T=38S?#!OEFM\-]/8(!PC*
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M!I?<*$][ $MAVN6_%%=[R.-UO;/7!E-6GA\^DW3J@I/1*>4WXFJ[Z&;T7;M
MUJY3 />FDN,Z188T. ? O!S"UB3\N_;PN,F247N8/'QP8"P8Y&S_)=)_FX6H
MHU6?+A'G'=_Y&/9\.4.D6+IK6#-=[-MI4,J[!"(8[1Q\WJV@ .E-&+#XS_9%
M:9GF6?^E].:Y7Q2-_Y#;LW]Q#=;R-FO&K:YW>?LQK?@&\]7G=O&_1%>5<8GQ
MLOLH\_K1X(%\?XM,5L(CUSNII>III;C-=TG_<]/\OSH]4L%)ULV7R4QSI\0-
M.CXU(OV=UM!U1%6OY'&CL*0M>=._R1X$IVOXHXJ$.3M#(FRW,BO]_JGBXG>K
MQX9"O$,I@O%O;HU)RYC,$V1'#^^&))@99 *48QA;=@T<@R=G/5U\X-W1$BB8
M51GK[Z="RTCPMLG%>_N#9#*C8CBP8QC$UZ,0WE/9.5J;"10T=1K9<0"SN)R7
MT^'3JT]TCY)ELL:30^D$]?=Y7-<Z#7GH!C!'.FI\T3*U/R]9?:Y;9QUA$.^2
M1Y)'T_[</>OGEQI-1;<5))/^(G-SM_:O[_ZWOXJ1,DZ*;OQ&O#+&,P/?%EDR
M)OZ>\A2U$!ZU4NJ,U^#\)_=I!1SGWQG5;AQZ&YW%LA><EZ,O*5VVV?7./K1M
MT)D!J:3_@P]^0IN5Z$OWDTA?#)[S3TY-A$+/S<TOH#Z.3'0KWF='40N.":TE
MB^D<6J^1FOK]O[MRZ/QT,7= =N!U:7(I'AS%QJLO[J5/#3Y]W1LIH-+;XUM%
M=^=P8+#C'%5$,9X:LK+5L#;))6\KN]2@@PM2;YKS^I%'$<@5\Z)HW093EVGN
MN<ND:H6[@<9U!;2M^Q$C43P,L_,JQGDR!8=MRS9A1R-$-K,M"*!0 G!B.[/9
M'M,Q<Y5(\E'MV*RE7$; P)8C_]=/]JQW^V-[L]*IP[?N82PCPQ-;@[W$F>&"
M/"&+9@4=<ZSR[F4M3DM.E7BW2G6YF8AS>1)WY1&+S$'S"?DD.2ULEGU]2J>U
MC>FL+\K.0@B!DX7ZQS[W]U[?#U/C<"R+*(]'QKKS9,$D$?SN)9MF4 L?8=>M
MYN:;G<P LKNE[ Q[DNU )0[GJQOTW )7YIU'S(@Z$<S-I^"IWMV&"]W2C'%2
M/@KY6^?+GL"3 \@S8&C"_CIW+<EK2=; 9<ED,G'CQ+3WKNZ6H%E"ZE#*)]"2
M-TS6[=+NY];21J*"(-/38!V9\SDV#@=.Q:.A7H2[P9RI8L1E* \=#,+P+CI)
M?'AKZ.I]0QKGN=O%([X5!U;H0X:&ZV\W@?.3.]"]U&G7\D0;2^9\U:N>MD.#
M\ALT'^LR[-CYP8N*Z6> ]2();=L-U&/OQGZBSN[H-*2Y";2'N2OHVTU>_"LE
M4Z'/HBL6Q/)K,LX$D]5JT_5T)OSQJ0]D-+BL<"[]- []9JM9]<:XYYB<@ ("
M!40$9$==+L5$K>3Q?KF 5:V^D%;LP)JIX/0[[N@<K!*^RG;-[VPX8C( (:@E
MSI4M:'*5UTDHRN9-WUUO+D9=4A#5:ZDY1) WY<LZWG,90+H:C5Y+ZF9M/\F2
MG$PT9%JVR/*L5A$.&UJ6B-KUR<%]89)<43<-"Y)ITYFIK=N<T"LKO+:IH*-+
M67)6JC)($I<X]_2_X.!+2=IW.5FIP)/EM%&";!4CL+7KYEJ&V.#31:4'\!K[
M8<B@I?N]UT^_L3!2T%H8QSSRL) \2D>OF;C V?<:KW8]H-(/G3ZP>IOF^58%
MSO8<=\ZC4J6C0WA0QG!$^G.*-!PF?-?\%;\A@J;7D9OKE.QPJER*P7>X%?$=
M'L+R@/O6P+7X:.+B^)@CO+;.4[T[\+6$F8?-=>202\[R8H!+\FRHW+A)YYYT
M/A&,H&1TMF >3VZ9IZL.VN0V]!"90]%1NUA6ZK10_-WF=>2OZA_U=[-#G@IX
MUA5!L!XCHAL+*29KC=M)#7SH#T%+-^;XQF"""@\I+0FK:Q(E$J,4$?TAW6M7
M6,!6,?(SX)3!EQ<3<QSB&O,4.3@Y11(+L1[EYGQ4I7.T#/[*]YK-'!PK@H7T
MH;\E#YO"(A&<M1$_V(IXJA7^X+%.IDK*>V8YSMG$=U&3KGA0<3F[:32Z)>'&
MN6EJ:F1KS!4>*8'_EBVKI%%=<O=BG *[?N4R0M?/HI6)>;/8OLJNW.LX<=!N
MRNHQY2XG;5Y@@,GGW&>K]T[K]42CX;3BE2!8N#GA9*4*GE_#^*6NTJF@[$9[
MOU@%,1==;(,1/G<QAQIXU#4&Z&<0^\\M95B!HLP=S,T9/J;HGA/(?1K:5.$3
MX.#@:$MD&LIO:HRLHI%6.S8WKXNS$!:1E>*T?6@3:X\>ZND^M@?+.\OP:Z^$
M]@C"=DGIWLC-76A/UF_0?RVW+DEGU)SD/+*@CK":"C:,3C2GRXY&5L3:-C1C
M+R;(P+I@J0WJ%TL_*CW-B!72TBB6^V['XN9%/;(?\M;'P$;/;B+G8\: Y@B6
MG>,KD=F+*GCT'^-1('%0HD 4(=B:Z?,GPPJ?[(%J^DZ1@HW9 92L9X#4Q2#<
M,.WVL);A31I/P77$B/S&^)P!3\ZY_(/#=/O[,R'#W_L77?5N[^HJ>DFKHO5W
M-:0$KD\SREOFC:B9.N;0&WHTO0F)(N1=LB<W)0V8IU4%H6OA?;>;,%04E"Y&
MXQ:5 ?[^W_>U=173Y1U^5%PV_3C;B\QA=-9KSG2;X]$OJ>VW9V1RK+0;4$CP
M[2XE3O,F<IV]*E +?ZM.W4(=M];D71F;<1Y[P,!#WV0.<+$>:$'?F?<(>V02
MB,[:X+E^^%Y3X'#%) (\:ANAC[[3R2Q]C+$@H-/:,"L7 ,9<H>ODL),;)=5P
MI]4OZS^Y#*IF#C> O7WWZPXJ9TUSRJWF78;&2QYM/9-\QN;TVQX+R^YYC89S
MM\2N6 J? ;*OC&Y@J-\V:U?!-/UJ37R<N-?._#UL)F-K]##M\UOL$:-L8MG_
MLNTX<[[K&=!J\U;N;VXWG862?=IUG@%/E,^ 1RYXF>NH9T"\5=ONQM.3695'
MJ#>-T=&$FD]>2#(>^E)W&W;Y]5YAVX2$?$A)*[W/$<;+).M$(B=$(%>:!\P\
MGT*03V.0N"%^B-UKV"8)T_GK"W!I@H/+DZ5N*\9[:8F,!/ 1/1@U<=.P#N%I
MG9N:''XNE;<IH:*UHNU(!.TI._L*=^010W&9*6F_57Q9Y6+#8?"60$CXW(Q$
M-Y;N%MVF]%SQ>"MJFKCR/C:6)'9Q9-.V*;HNSN^$L:EO:,C^B./3OHY'4('@
M0F]Q27U3N$%;K9#^65>M,P:<6/0C#NZGX9UC G/HA8/!JXVI2V^LX4BP @ON
MB_?P)AZ;<#U\6]O"02)/YSOWN6:9LWI"T\@NK8>Q1MI3B4)^?E13&I3>[_6I
M(WG0Y$>F\B&K"+M(]>.5XFB*1X;]-X:X\1<-KFN0SJXV=*<(YK'S2R$;(E-C
M,['&>9X-_=CSRC-F:\6T%-K;X@JZS!:#Z'2UR@:]#+;50W0/I3:%22O-C17R
M<-O2O*[,1"\<JUNH^O)IC(+PCS0S_7QD-:B/"Q.7 K+E,$&1^5F,_&1NDB'-
MUTGP!RX2^8W)=P,F:V]P''&_L==A8'2CWY*B7=&GE!9@H')M\EH$J.S%,("\
M8V'LBT96:)IPW$+KFP06?%IPZ',OR\K&Z%3023/J2+LT#]&BI;0/39[04-AG
M _M2;,(ANELVT3@Q*&=1R:E)HO8V"HDVRJV%WPFV4RK\W"Q!%+M3?DDT3>/+
M]LS@LE"XX<%I<X[SLN/Z\-)3EH8U*':OO^M7;B7I*<^A5J*I+412VT-HM!F*
MALP)H:S6A['$\*&MX)2X1"XBKA5[P@>3TPO& "[]$M2<TG.*9(U3/3%Z?"O9
M)I>5Q4HV*P,]^QAK%=4TSX:1=R&)%-1]Q_U+N5?DHP?R+A43@=/*3V:#Z[GT
MQ,E#G'GP]B16J0D$PE\2<@,(^!,V ARV_#[?>>UQ/(0_M"4^#9Z[&^G$9>8=
M0-=6%#6Y*K.I0VGLN-O/1_ _G."G&$8V>N35A<4J9#&.\Y;3(]*%#0GD1\:'
MVK)D[6]N\!^6R:K$>'EP584NL^OUR'17V[Z?7=K["29/Z#Q Y[ J7>?0@.EB
MD>\4LM*;JY+<M#U97<P5D-$=TH]%JXC]0@IFI[![ZP05=9D6JIVF8&LX,"0/
MG4[\%KR9=E/^=5(552L_ACS?.*!68A[-6_PQ"LPP'SW+2%(<RE%6=".QKB"H
MD#.3T&"<+*=NC2OUH"D:\7"J4+>Y0E%:6'N]K,$GZRQ_%/A%F!5T%A&HZ>G&
M.-IK0Z+>'?HD]99-:<A/#Z)]RW:W3V)ONB,75Y+7.4#-()T"PXI*P1-8X[U@
M"=C1/K 3^)K<W?=FOJ_#3<<_]%M(*WG5:'PEI:'DU5[?SV> ^&&SVWR ,#.D
MZ:4NW0N<K[VGTG!X<CJ, U$,9Y^U43=F[9BNZ1.X*:KX:6TP<":>L&/CTAQ#
MO7NFUY>EJZ<I5*WG DN_JGPE)1<,,[A[J0!)2ZLE%WG[R?E5UQXVSK5Y2IIN
MG*_.N2?N>.0_?F?=M7>?EA*Q)8GT"4/W+]%OR\24&ES:V3Y!.2.HSD38*U.I
MT@K0B'X&$'Q1F/,XK-MS_G3'_93J=E ^Z%*#+M8E1$]6?=X\Q]HD3F]O[[=!
MP?C48-6J%:_ ++6\TG)+3W];FAUL8;'JX.HICR9XT8L))C$]7MZFAD#-;UV=
M)^?(S^SFJ@TTZ[1XX1X5CQ!4<X'7MU"7B#CGSSZ'EZ%./%%.=2AO)X5JZ\%U
M;S;V4I85EW(*NHM>/27HY[7QCQ69N@[G=Q\9TCEG"LN:M*WP/ /4FUD9!K*Y
MP(LD(8J=#]-<Q@)UL9YSF^DK 5O/@'NOI8=D%TW$NH3#F=.!VFUK!G=Q +EG
MF@Z" T9&(ET]MZXH%'^?CS!"428L.*AAAN9H+5M2;O075\C&W:\,YL@[CG2&
M9X "8;_K7B!%7?YV[KE3W7W:QJ/9Q-Q,O&HX\[)/\\UO@EBU#['V+'KT@3T#
M78L.)Z6&V;?WMQ;V(B+0F(%T]!6!XH,X4.8X+VFS0B?11NERQYS+SM!M$OM5
M7W+S+ )24OU:GQO$KD[R>FW5,R%!(B4OM0V:^/DPS/UH:G4AF353NC53.$ ,
MIU<(HR>^G)5D!RPBJ/4,2$P??P84:3?@&MEE>K#,F3?S5J$GC->B!K#Z60O-
MVQJQ$K"U_I!'/R>M6=MJ[I,*5"7+@A( "]^B'XFD=&_O$SP#;$W*IUMP!-QX
MD[5BE-"Z'R+X^.51YZ@LSC4I_ 05UHZ\!>>Y*_+W,<$6&D18;EB1/4-6O)N:
M;>,:K\3'ZHL5)@E^)X"%Q1:@2#H47*QAA0G3O8\%-,E9U,MA-__V_8Q&9YM-
ME7U[2B!LP\W=HOKD>V(?91D2-P0+"H-1/'-S\W./^GJZHG&W9\"PPY<FOJYN
MHRV?UIDFH)YC[8':[EP*547,-XA)?IP;<7*13TJ%IL'C.A7D38 JN<PW/FV=
MI2FX2M<F==NY;/?F&I;Q"BZY>'/RY**%4BHQD^;L.R*J) P.BBC_A='E5?<_
M_V6E"O6'O64#=Y.34T\>GSX;O=V/NPAA/J)/?*K$,[0.6PW\"*>;:VO=R[H?
M2&*E:,-NW)L%.*JJZIB>%%>H84TU;-B&22%=(%K5S_VDGP\_T)HSO3=1V%P7
M/90_VCP\/&QSQF\9,\A9,;+C%J#P'AS-'(,CMJ%5E9DQ<=?8V&\W2"Q.1M[N
MN7%6!#FZ'8Y545'H$,+E_I_[@].V&#I\*-3<W (*=7GQ_=;2RXY);CDY9]V3
MW'%/M+)8\,H=PF-X8/Y0E+D-@NL LW=I9;/ZG<.L/\I/LMF92P^G!C2\?L>"
M8*B-T@P-O8Y]LB8I+7#4R'/[X=H0JFC5NW6'B1.<83F_*?^TVJ_/J /X3>!K
M3L?VR@*_/7XM-6#-[9\R0['7(=,\;^1 L&S3E/*@=W=6B20  @;%JFS9\"HQ
M0A:)0!4X,H>WEW(QY3P5M"H"[:9XFPG2:P$<*5;RU &$W2,R9E%)-"'O\"$<
M47WOX706@^>2TU?\O0P[O=+6YH<K)W25.H%]W5IKI ]9G5,@H9CU$?$A_\'R
MGSPH[Q)5WDT5PID8  2!"7W_S4$_RRXQ@X2&[A$QU_3=1S6^&.Q28'DD7V-0
M=-1?PA/]MW3&?SIFNXFKN#XI$'$WGNQ_8_<O?OU[0M.*D3O%.\3,2"38(QE!
M3Z+*GC M]AK<0JR1A0]EH*\QE_[F1Y2\-""&_1(R)\3E_X>[MPR*(UK;14D(
M1$@@!/?@$"RX0P+!+;A#L"'HH(-#"![<99#@#H'!!@8(P3TX S/X0)#!!Y>3
M_=W]W=K[W'.JOG/N/7_NJNJNM;JJU^I^NU<_SROK;7,.X9SBF'++.WFD/;%]
MG[8AU,U[5Z_VY2UQL@;O(]<0_R+KT7V@7YD 6FTYNNB0RXJLR>!L5E3>%G=L
MZ>C/=D7I<!TUKX="PH@(Q ^;H$Q7JO8ED#PB@MG+[SVH 4'S&[IK-*ZU--A%
M'<%LHNHFJ4I#EG@9I-,SYU+&,OK3=R1?L#XV%+\KA/\MJ36:>=F\:4&URJK!
M44CPS)*5;<E>7<=CXU4SYYJAS[I[VZ2J1 =?=<7&V(VQU2O<+X$3-)M4;5 "
M2?^T0@E:4N=\1_QT.U=B_U<HF+B0C!V?5VM(</IL+34KVN/]2ZJ^'R0OZ0:B
MA9/Y^7VN8>UW0:S#PR?C,R?FD_\#24;W:,PZ40<BXO=C) N#I$0L:)4NO0#.
M%#?W6+ OQ]%Y*TUYNJ@G"A1_J<Z'V O2PJ]#QFY!95PXAJ+GTFT[TM.F4U_W
M!&%P5D!Y8RL:?C./MH.EB?'9VK*XIC/C*$;E@ ?GD=!5* J>_5Q?CMX@=\?Y
MMS!%)&@3Y0+RLH)F3\Y 02#GO"<GN3^X;X['/D:V\1^:[?L)4R&Z.H5$=G]]
M8C]6E<[",/.P@+:J;W6XI&7]\L+=47G!H'=R,NR1Y0CW]O"QX\%">E @>2!M
M,RM7?V=B#T0X+YT6,_!]GQ7YZP'CR.>!T<4%@E ^UK\PH%U>%]-[M3?P1%=.
MB"Y!H<U\KIWB3C+I'@M42X!0^D>3_![+>*[>+.@>Z\4[F:_LL74(8+L,_JI4
M3,(B@@[?&+]66MKNB'L4M;5OHLV,J.[ S&?S9@&V%.N$*^P5?82WXH(Q%8T!
M)>>=^HI'^ZSO/NRP4XV<*Y\%E\ZN?\?_$Z$-U9P6,[DDQ&]^_?1$L$3*O^<=
M([OB8I%5H$)N_C@(:PD!E&IL;/U]%7"7'Y'.<QSMX__RO!6<!/R^<[P3E/_*
M%?ME(BCW^WP[,/(>*\<#4-5W-"[567(B2 7?WLJC37#M?GDRWI:V%:=O@/BJ
MO#DQ'Z>\>7-(%"P#[$^^YGN;GGQ]8?UX(W+L_SFCQ#F_S]/"%S.;6*D^HW4#
M8U]RF^/9]3-_381=A1WI&QG]KL.0:4[;3T&2,Y1?N3A%__G28 ZXNQT53_*]
MN!W_.5R"IHJQS?VI8,4<XK::B8+$NH%YY5D#_2MON%<'ZJ1EJ4-$KMU;?8'Z
MZY8C=OY+_)(QF9F_-KD10JO./BO6AU%#%!)Y&24O$[P#\VUJ&D'JLT#2B@F*
MMR-V+]ZG3L%?KW[KXT.D]OWDY?46=H"T&V.R,[,K3<-[W4"V;$AXSI?YV*'C
M2EVX7Z?]QS?SU7-=3_N'Y:\@ZMA1\<DN/A(/CGO[P8.V%#:P[ ^NN0H<\W3V
M7GG*#MDZAM7T>;T[U-:P0+N^A:=+1"!;;ZZN88/BSQ1W?EH;'PVC;HHCZ08?
MP ?^7X+(OUGG:Y7+&I><CLZAG;9O[K![OK_5_ ^T)_[WZ%$%K42S;?,2'L=[
MK.:=@Y5S_=?<9__#_A^^$?_3\=J3%9[#?#$8I].G+_KOUOM_919F--![+)GC
M2#P^+TFOR-25X@:CI7LLW?F(KM^7T6[\)*U'V![;8'>J9M/6%7R#J*>(/?W-
M$(P*#B"K-]JX73Q9/XN#!)6$1X**\V8-'1+-SR*B8,ABQYG_JEA$*#)B&ODB
M-//2QDUJ-_=04=A*HPD\#;*,=VE O\-L@KSO/M<EMG23@B#2/_0R;T0@;S]H
MK!KS-O'*&FWP?GA47_!_&,49_#HJUXA$S_R4 ZDKRK_7F"_K'CW-OI8LEL;7
MU?G]3W UHVK-VPY<C*^[#.I3'2H<@@E[2D_>-M-9'=]CQ62F/ K[KX\,<\OG
M:(X(X$Y8-.2C- 9N][>T!>OD-F!V%2V*WY)FT]QCH6#SQ!]-<J$>#?/9:IE<
M#TYPVD2VC8>Q>TPT@HO657@TATI?109< PI'N< ;H>;MHNVM\NR=9H,0@NK=
M^2Q/[INVU(_&9=79>_5*P$&UCUKUBY3&9?H4*LYMCF 6.M/=&]KT7I.Q'8D.
M<9SP_MXUY"#*^;U\[.=+@&U:;TB<$"/KITBQ5E1"N$A/3*A9*[(Z@+&:L'2C
M,6+!$2?'/3&R* Q#JKO1O6VP0>:R6TP%V>1_R-1SQUJQ7J$L13';;,_O_FSO
M+ IQ.[D$^[G9+&TPF'"HM!1.F9!BP"G2!CY=.WIM(0^KFLR@Z78@0^$_=$A^
M$BUL:M%$A4-&*UQC')3>FU.(;[R#X[W* N1Q50S23M>!Q+?7EJE[_+F>,4(&
M, [I6VMT&K"CXXV"QII,\P3,91I=@3%BL_J"1O("'CNTVS8V8EOI@G!!O=FY
M^,Z=(3(-B%8(DAK28.O3=+E?/O]"L]:M\4B[$U(JL-Z4_;.;#F;AVS+^;&;"
M=@>4S.7%:!ORVN>&.V,1IU+K@3-.:* Y-]7XSEUG.O@:J0C@=_2XD904J8CO
M_U/T.*%#PP^<+KUU&R0X6K[-J>HX(K+P','O,QU\ [X[E,ZJH#R//1FNU]M0
M$.8."+B)G@H((#V&I/JG#7(E&9-LZ4\(4B_2P*$'#$N=AA[['4K2<AQ,6?%[
MU4FFZ?F4";/ JCO4V:>R)3,4,^9TG^<JA.:.77_G'LO!_'V#,ZUY0=]'H2"_
M1@/C\3AI&:[CP,GIZB-0K8EXTJ4Q[CW6/O.-F@KKUQH_=*K9K:^(4I!.\>T'
MQR[M'>'C._-AE+D999ZAH@18K12P54EB('IIL1NV'%]+$7W=<EN;ON,O'I#G
MHN5V2+,3?^P-POUT6U='W(>^FB38K2V2T)_:FO3<F#EQ"2V\Q]+JY[DJ*2QS
MD?J>[))#ZK4]SJ9TI_TU_B#K;<FS/,. 2/9K6&<Z'O,!")3MX^OSI&@=06K)
MEG-7Z-EWS.]ZW"E[:V'"2M_HTVH":\!_1W>UT$.*'5_98WT<';0<0W,G?\Y9
M(TRQ?2GY9K@T\RPVZ;CD3EFH3/ANR-J]ZD]6FM0^0N52WV>.3NBIOTF%NY(_
M:LBS@81L]ENR='(SYST6*_4]%L\I3S$)*YDKO2M]X!.EG$CS'7%I_/&K&Y<.
M&/%=/68Q^28H_B:HF]%Q5*5UN5;G'HM[]\BT0W6?*Q--W^*+:[ QT=HO6=K'
M9TG9R$.=,7FVH&#GJK<PQN?""&",LT^28[PE)V*OV+M>[BK_XTU\SJ@Z,RV8
M.6\SLCV.1Y;V:9OTB(#LTR*%O9G!8!^5R,#@8(:\D#,QCJQF@/>; . )5V$X
M3'^NP5#A%%2:K.;J<+WD?G)D9)8GWS92[-SJ+D.895H4FQP*\UPSH\DV2ZZR
MF= QNCO-ODL,G0S(99&IC]QO===_HL8#$3GG"8,O-]4L.L>\OE+1G,V][IM4
M"VG_*X,MAVON33XK1W$5UO U1[=I/\&\_#'1,6$BSBJ40VW_\P2U%Y%,27@O
ME:A_&X2.L:^D,5(PI%&\[U,LCNF-$V6D?RMD268)T":"N[=ON0CXZ/;MTMV-
M"9PZ3J0T115,8]X9AC[KT!S-A[U&8+J3OBH5GQD 9;LNTOJ_2/YPV7?I7^,T
MSU=#TY6NEB]^6[;EJ,N3DGOJ.U1N73K3,IOHY<]U]P<_)_'-D0B$X-0S/DVZ
M^"U)NH70E:BUI91_]N>:?9UQ+LE%EPH.M_F=N(#*9GRU)?2+&D]4,B:6O] Y
M+?SW[TX>O/ '0S4*S'3@I[Y]AL=>C,FEU0LH;^O5/]@<//OFWD*Q(WO[K3-7
M1,(X54O2&H:5LH0@_LK4_#+(@T.S1V[D<!-6W^HTJ.%6L^%FB>YJO:L1;[@"
M9<OV"T%\*@H-B@?$P5JD#[,4=M)Z-C28P=I4E]EG5=1-+,(G[$RL7IZ5?C87
MU7*MW#E%VZ*IU@H&VD/-C*1_C(U_50]E%(NAF&X6)186 F#0LVPQ=5HQ[_Y@
M&BI\2GF0D*.G]]C0\8^#FJM<:JI0%)5]2F%[\F:AT[FZ4.FPV)5_P,)3 G6;
M!6$0?<5D<K.4:S>GNZK$/=9B.#_9597Z^,8NM2OKVMI@AR9AD/1U[4W[,*<[
MQJB7*G5YM*120GU9-XZ/5GKLQU]0!^>P,[*>'%ZL[T;[--\%;>IK7,?Z-C#^
M0E@5%I-(F 81:060\8>7ELQ%T]R=:*8E2C;_R<Y%+F$4/LP$IH:Y7\_#/>:7
M:V9[F>^V3R\SP^:3'0]VJ])X%*RRPT?W$(W?0+0EI8JASJ8M[T9/!1U\1_;&
M?R9&8B?48037!  )_2N\(GLL;UIT^];*N^13L$9[/'?[)B)XNCT559%: V;3
M2:**ZAOJ!X9Y"M=DL<FZ^]:37]+TPCEPIQ4S.]Q5F.T/-Y[])?DU2JX-,MK
M[[A8QW:Q<1/1_+7>@K'=_E[]6?4QM/J$N^9%.I.[>MSJDJ))E2@._GJ^@\;>
M6TL/]^L9KIKS+S=T9BS<@&I6B@W[.:A<34V5?4"O_I#VP$EU'L>"YK&V<7>^
M[O(D;H^(/;)B$,]E<K51DD)EX>00:,GYCFOOM)E6,B)0H_P*'+R:,U- XA'P
M&B%\D]@(%R+;Y-P'!9,1_(R-\?1[.&9RB)0SO' 6RXMG7<U)F5L)5TCON0*B
M;]]T;J\NM=[Y!?I1+7_S\,G"_]Y!,L?S!VE\5]R\HB^L8W@HJ3QUZ0M+W4)=
M!>U8QVFDPF&MTA]N LRH4G^<*RQCJM2YYSIG7:=MMX;'^ZJ)LZ^YUZ]X$I$=
MA6U<7I0+TD342R8G)A&82S+@:=!&[3T6'/+1GZ,YBXREIW?W2D%]8<?VE>51
MG2!!>;9AV.56KEQF1T&F9!G;4C4MLLTPTSAH+$XB_0"5OD]_ *B\*]4L[QA+
M2S^Q]3??7V+;;_B@^[)!'L<K/X#GNO2L3OH@:RCI(N^RZB_"1%S1F!:VXVT'
M(:4;?>ZQ_&=UTGONL48C_B.M@08<?$-2%G01<H]U.DW"NB![IUMRCU48?WV9
MUK1/_\,&0M8UB&"<H]B,,8_#B>L0&([G]A]$WMSI:ZOG*[1XK3FPGAUEW^[&
M:)M4:GR3OI:M"JHUN<?R0]3YO[A[/!4TO7V/U?+UQE&=5]X-?-I/3AQN(GZ(
MQ?WA!D]4^CGB<&3_;M/6\YH;AARI+;-3T_#)*][>WIMIXNXD*)TY:@)L]0"_
MKQ?F=OZ^)1MH\'78RG[=-J89?YIEON!$JI+&%_1H>=\XZP1T-S%.?5:T?<0I
M,<OTQ_EQ3\Z0[+:M%XBV,# -=>%,E>XI8?I39)S,Q#EU7UK,;E18.X\@'1C*
MEVG88N=S1M[Q'+6^OM7.:8Z1<A%MEIV*]_HK-*X[5QO+/(4VHBF6PXV_$UI
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M"MU4OTSY9Q,7\QZBK"QRB]:W1K3['MV($C!VPSC/P/MYC3+B%+&-=5+R6$>
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M8MMAG]GY%W"777R,5O6L)Y]OK=!)#C9MBN?*8RD=FH!,S/&Z[S(L=+:< DX
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MV(/6^$-\DZOAWWR1S/*3#B.E?N^#S#4D&VD/T3/2;F>00:^!VRQF J%QAYU
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MLPLVC,$==_OUS,> >QS.9$6GVXQ*[WL<J-#(Z\"61N75U::;\[O>LMU_0UW
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MU<C^!'1,Z<IJMMCOACKKSKG19.M]#.!>>\R6['Q7*\8I#\;+TPABM2VW")Q
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MFX8:A&,9PMH(?(JPDL(Y9;EPU9DX.T!A"?5NCF@M]0VFM+0\+E3MXCS.&0^
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MB8U-PA@S_+;B35<9H^'4]@Y:_U*E^XM[Q>F\JJL5I;X3H/6IA'.#A:*]SX^
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M135R-9&_TJP&7%!>+O?V'_8&[53*)EK($W%*9<PA*T8:<4H2G">". "@0.>
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M[LH4US+]D1XU/).GE<B1I,M'"AKZ2"&W]IT!U98]1"F@85>,_GLEOT9 =G[
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M5"44,FHU,8#"WYOVI-S]Y='YPV%$X!PEV.]YM&>#94^!3<N6%^ZU!TJ9Y0<
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M*F;C0AQGK)-;?Q'W62_L)99=6WM],UK@O7\O0E=BAVH]#+F\650UG&SF4L8
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MF1^HYN/&+3%#AP/H]![7BYBZB9OM4"K>_"<OBKJF."@+BH\LSRMEB+&/)ZQ
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M#V5NH]\REP7L<]923#Y+9:D-;BJL.?- ^4_K"U,6/XZ71D38I,2\=5<&0RL
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M(#V*JC0(7TV--;(JX$%KT_-.B@67C:66<AMR9>W))0990Q>SK \66Z"L#=8
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M-#FZA G0IJ(8?KM::I.\0GS>K8_&U6"!R(\RS,1'=QZM[^Y9+0L$1)>^78J
M+7-EDY^X;:\A+(#7_!5RU>,?\>Y7V6SBH&<24O52$^6;-AQ; B.6)NB7%P-4
M VEGEQ3?/1R0?1)U>^L-F*:UKE4QZ2;-RCD^\@W7J >T&@V=@>@I9%C6\F;7
M8=ZL%[^7O+5Z9W2NO0"^';6<V5P"1T2J LBCJ?*L&!ZK[U9>*.O6]GMK>A<
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M#!4<C@O>V!L&)PMZUW61RX*/ZL"B$1+8L#*'I(K$'[G-@'$]72@74)^B1EB
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M]O?4RN)4+Y%+Q^!R$?F-A?C$O1YY)18A:3Y2_OK$A=9E3;Z[B)L; 82E3+D
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M,;9XJ;%O7/Y[63(#TH3IFX[&2SAQ'O0:RL4@_1]>0"* ]<X-OI^.D*=7%\-
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M5P0@JLX;(^.>#)52YKC1N,BWW9*W)WW5GIY.%JNWRSV^AL--/K#M\?WG<VB
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MAEPRJ_26;U/S%0QNN\RD=)T6A=!??B"6FJ0,6L<AN9I$OX-/&7;HJKEE1_2
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M!UM1N5]S<^.C6Q>0>[%M#OA3"V;%?+KJD^D.!+0,'UDE.CIG@=,L?7C %TK
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M1:TPM5KCL,G(7[HF&2C[38KZ>JS4O(I3?>7^GN>5NR0/7KPB1:-\_]_\?2S
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M%\'#JXP0E"0 :KV&BML3>762=?J E[3_\3OAR-23=W"7Q<"C!]A9X,*__WC
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MP>4"U*-LF_]7RA[]J_B5H\, [MPU;X#3K+M-<63KBQ\VVFHV./)Y2&ZIU')
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M>7C.MY!>;2S+=,;WB2Q&)_EKIJF4%':H+G+^1<W,PF&T,[;^CJ&3^@!FOPF
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M"-:F-M/8\GF77,.>=\Z:[_SB&%!M6XO*XLZUL_$YP?IT(@!-+9[X/*;2NPN
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MYVAM[5_NZ^OKWP63;Q8VD7B]V=*=^=5^>-QC[,"RY2SL2T#?59QR',^OP73
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MP\(<9B4U\K[F%0H$\?!WA<QI6"U1W#COL"""4N1,7F!Z"+9T\NOF>GB]U *
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M-P1CIV$(0INA<VIGV.2/-'ZY70^>(CY>63<K'AC+L?J0"LC2=I_5,(/"JAB
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M7_E]?D^7\RUWO&^\OK#3-E5=MQ6/&(X;[H?LR2,"U+H@V[Q+*3&9H]AYV]+
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M;JM\];ZA)T-:N3U:8-# I6W_T^=ITZQ!IN;601S 7!%>2\8PGJ)'/,@&+<=
MLHSOG\L[0FARO]S[TS]@7,BZND$?,'#-X^G"&6Q<+QW-1H:ZO\RTX&AT!I>E
M+7I-"!JKJ")J!E+__*6Z7/9PU]!TL^T:_SR:9<MUY^AL'W7"G3:-\OD4>WB(
M_U62>16^/.M,RUG0FO8^GI,=J9.=(F<D.JHGQ!U;*AL"<1M71EPUD*N*W<CM
M#^-0\^G;_-%#Q;]PU'N@K&\AM_F-0\<X;AR+:H.(Q13TO3G#)5)BZ"9TRYA+
MG/C6:/O.?.,N<N^SG 7XS>E!\TBIRT+R7+VPZ8'G_=+UAPC?#^>X#5"QBGB8
M606;G;/@^PT!V)2%G2K=B_C36GJY8;CC>Z.$23-!XL.C49132@.,0O7+-9:S
M9QM<*FJLS9;&BC-_Q/PS52Q\BIR-M>GCM>%@9N[WFF=GFBZ#N6\G*EY,V;Z-
M9&29[EB8FW;%K@WT3!BCN C?=QD5U-&WM8I>$Y\*\0MC3:2^#Q#>Y@G3@NFQ
M B*+.-DP#>NL43'BED?/15GRM@L<3^.=6,UX-1=+P/LSJ><WDD9!C0?GU?;%
MKY&6VIK/[0E8%NVYR\I*A;98%P5N+PZX(X)U[(:-/JQ4X0KLP*@)I5^X_<)]
MQP/#Y<'\&X+HX"OJCPP8?PTR< P.#B)FY$P>,)PR9/[G1Z9P:]Q1.$L+.+Z%
M639%%87WD"CP=O/S8?XQG'J=I)D\'A$J/1YF>;RJMKO? 5N9P91_% B[H>UO
M@&1FC+^7YK,'_K@5*'+JFX]H<8Q4^Y"E<.Q_"'[IY!06I+D,TYOX/.I"DD)X
M?H"EA]#$72>:KF)LQ1;CRY&['PQ;/';Q)UX;]*?UV[;Q#SFIAO$<""Z.Z-!0
MOZKT6NG/&$M7S\RS[Y+D6K&18GTY$[-Z6!?X#4+#SM5#V$^=*C^RNJ>=\4=)
MR1WPZ-=#\3[JMFS_W7<X].*(!!O.P1LM*ZXP**.V[+3 -?" <:D(=Y\\'5BH
MUQ[J?@]'Q(:<GL=/6H>0]W+V/V"D?2ECIM6NO4SK2M<1>U/B40!9RDZPUMNF
MDMC0,7]V@ ![4\H8@W\?3.':"%[AS9UEMCY@2-WC3/]$5:_S?G#+"J435.1,
MJ7UQ-+W-(SZU;Y1V&?_\**'1(Y]6?7\-%$+9:M#-8M8#562_"Q'O+)TPKQ+C
MA3%YRC,EJ1-%U*D3I7K .*SAU'5*^*S42=D\GSYA/^(CA(CQE4FQZSCPZL+8
MG*Y,TH^T;ZIZ.468SA?8Y)M&!19D#>:)M)/339O-#UB9AYIW('->JWD+^8QS
MR_T',]7HW(U)2=)<74FJ=^]3W]VRGZ\- 3((9D_@JRS)J:R_=_>HK]YE8,^S
M1C*2DZ4[)^^+S7(*'LY.C&T(W,L)^U,) $0I-*">[11.[W]J4A*DP)+[;(1#
ME)2",MP#VTXZ\:FGK9H/?(ZEG[H%/3<*-%K,>OM9&&7V@F+^-H('KL^Q)!K?
MK*U,2UU'$@<./VS,Q*%N*-==E8H2-]30S?#/)'A.$,II?^2EXQV<NMVW:$@<
M:\I,:=IN[)9CQ?6E=-GE^0H\ >?PZ'M0^H KNR-G=:!W7)I7.:_IZIK9F-DI
M$U(GW/D<:=_!*N>>9?4D>OSR:.5.ATBFZ9E:1("1LD*C^^78$>H8@7P5V)=[
MBQ0STY+66Q!C9AO6SD%=I&ZPLBG?VK#,N:[/<'01Q6@!/UBF#_ H,W5B<T6'
M/"+RRML[3_HMBL]-9;!#(U9*^;,XGKI$NS@PI5=*3O>'>((/DG;#81+M<XTX
MB(MU'M<=-TV?X6XP=4O=X.[BT= \5H2!95I:#5]WL;>7,E/4P)J3Q>I>T!S0
MA7)-6M :72L2E0DL_/8E3&_R.Q16?'5QF2E>*F1BWM^EXN?XS03*).X/.]_S
MG7?5*[:G'YMP>TE<"5SET_TQ,U_+!V*0=>6F?$\I&IP<&O[,?)&#8+V8!N>7
M),,P.E3FFMEC;H</\&,N-$Y,D_6^Y_=9 LFI"=/M8)_QZ[L!\LR;TK&:&YG%
M&>IB![?<6!_Z"C-!U$8#OYL,WOIM3CUA&!AOA$MM0/("U&%KZ:6,,%MO+<SN
MZ]IG!HZY#Y5QU(%'%3F!=@A@Q>LK;WF?.WLJ%/G*9:G"RLZ0?Q5:["72T$%=
M00%U0&O%XP+CV0Y1HH>W%R94D4MNLNO&$*&G&<D,KJIYO=[67C<IQIM\BN5[
M&RON+?V L4.PL <)E4G8J0,U=%,C"@+Y1O%*RQP$#><":E=>%D*[AUL-V;B[
MLA87?\3RWH9<RR.H5+I..%)F-+9$>MFG/'6/>XEBMN?JS1]GVXN4'SP]6&JJ
M].HTEW5NQF(OL1CZQ8Q;_:/?/(;ZYQJ+2ZPNSX>Z>W:M]-O'[_N#CFD;C%K[
MWNICHW$(]<@V:Q-P!P>[N_F$< >'4']K2XR\Z^ BCVT&7P96#P9?],+"E:]O
MJ-"?9L+[@/&'^PTUVSF[1$/BXH].KTD%ALULDCU2=YL#F8=L4EPTK9N!>K\3
MS RJ%N^SFTQR6GL'L\7[BQ%C;PA5.W_';*8_8-"@KCT%W6*7N'>@]^P,-S@^
M)I!V"*1 \+Y2P:N^M;RYB7IY<$]5Q8HE?K^@<7]W=8Q,D*UL?)OXKS[C$F*"
M2(6U>%"G.3+T5G>T@VJ_A[GX%&#NS]<4X$D51F1U6JM.1ZPU>GF%9N/J.EAG
M+N,5UY!?AR?T6N&S$N6YDA"LVI(KRH\>UT\D]^6$)'PE7S048OG.U!&44;;$
M="V@D^"3,NL7B+T49 %NR^=?VE5T1JZ?)VQ K1%<JT>UVE5FN0:1SYOH8YKL
M'K4\<T0"+2/I727_$OXI9PPZ!IA=,ZR?!)X%&^_W1S P7/[WC"?S?DPQ,3&^
MAC_7U9\F)B:5T@ &T:+O&/Z*S4719*LZ^5II63KV'"V?\.45C5=W]UC$(=0Y
MX J2E-FEY+Y3=4=@)K.J)U:),;*L!DQ52TL6,\5-@'G]J51ZRT'GVW&3C+ 0
M?\GL/C\>FP))JA^]J74?^C%!.M*D@?$2F.(]9X3_F(\F@;NO/4^7PVWO+(J#
MW\L[BM;\.3%);7,A3.<6B1L2C,<EBZT[F O+4^CNIC/74:3\>;PNYE]]_-)<
M(G(B(].,.@^'595=08$KCT,[A_41*R#4TNQKC-[*S!H?N:VMCYL@=\'V4.("
MT <R]M+3P%(UZV4LB28KH5A#KF<>2R#_^DI_)(Q*74",OL>4Y!>]QYUX]?A_
MVCE#_FA! MZ[A2>4,TGIKT#M@D7IR>8TG^$?4\3,'8%_;\:!8L1E[&Y5I<?D
M:^6C9W=<@LQ*'%/N230+[XA/_)*[_JRE2"E%;%.C,+JR/;![&V(![\BVH3KN
M\7^-FZ&"X5O3MLLY.]\>WS#Y\K.>31$;KV@L=R"G;;*'G=D\FDF  ;W0V_'F
M@%2T[GB/U.%(;N0G[\[$/^*3K7V>[*(""]NRK-00CQ!?8_H!WDS P:/N\)X&
MPWKB5FPA2BI.'2(J+[H1#PPY6D(5Z<CM&5.X:3:.AIU:.K1?S^XX:W%<,8:!
MW-YR[!+N5T%UQN?5J<ITX>PF\<YK%:[2TZ/ \'A%EK 7\V]81%$8?X,B&NSB
M^!<HHC]LS#U*^1^]P?^"NGHOL'WO'.DPI>V<,%*B;02 ,SH6ON?+71;<4_0L
M:U^Q\D7,-(5L=Z*H#5JX,O=TG0ZN)Q<%:WX;\$@:1>;WHXH(N %J<9<[O6KS
MT$[1IR,((7%_S^YO]-A_3_,[>E4;37(38;KT1PT)/>7>\U0'C]/A;4M(16[M
M.#5[$@%?K:6[=236Z&D8?STW8&;E9CTWO+0-9?WK.CBID<>^JG*N\D78Z'2O
M7960T7*#VV+G=%9I(I>PB^A^SOHM6!R4SSW0E[8S4?T;]D+VE$>!*&$'HQ9\
ME1GX[/^+D.G_5FW-+-1.G>"$K\:[))_0;[7'(>?LY?)M(/]*OZ&#F=K^T)#B
ME\L-1)ZD?.TO;:P.3^4@ FC OB!M4I]F["!!2@-YET&,#B6!I,8BNQ*3.GJ*
M95%C."Q^XE\^FL[G>;'*V?1-!W$>.LR<,=X^GI/N%]/ .,.(#/_E' :PF&<W
MA =*[7^"-2 O]D,@X>?<U;<%1 %'Y8P3$VQR'!V*%[SS]:Z&^)24T0+=ZF'K
M8IIA@M/Y/UK._U]+WOUSMPP<F.#[>1.8%C<PVFC:&.^ 2M[F",+;M:\<ZL_(
M&B02RK"H;T P1GTE7'.!Z)/%5V75P;!PK/)*QX5OIP3OZ3@U.F7)4\LL(V7B
M6GH=D&S&4=\:C/RB<S38"OB L+M5C3*)1>YIO?M!A_JSMW6.LANVZ:9\J6DY
M ZU>EPW+-0@X+52^[<Y,QH?]])TS'W\A0/A?OZB<'!98YO;,2=JE<FRJ2<_/
M:;+A\9<79Y7(1$!X#_'G:!@_;YCRB[!=]XSHV(8&=I#OQXLP_84AT6E.:0 %
M&$=3S_4+P[*ET[XH+X7%B$Y"7\!2^>OZIC47=A/!U,>.LV$R&8C:YE)OOC;6
M]ZM-&ED=+&("7^NG[&?P_Z;).4Q9V0+R<EN4=N8J74?%B2G(J1MJJ4B2+.DL
MAY'3G.C1IB8RGM6RU*J5\8D,P<RB?+RTP^EAUNV/R2IZQIEU4_./.;HGJ)NB
M.&!D9O];8!CC7/F8C]&S62RQ3?>?KYGWE]>1JDC0M9!5HS[:?>DP)RW#S1NV
M)=^-Q26:$]%DC_]R28"OFJ@'B(R%OQ#2:F(V[+);BF80?'574W&6F__U>KB9
MTZ=X=R%\(8XH:]3P:*LF)2PF[1!H4_=UH(O)8+=)BY7,?W-Z*VEMYU$=#L)(
MQFY=H.8@^%SQO?-4]>#FD*;N]OK;9C-*86([+GU!^S?6]I1\?A.N2/<Z(RUT
MCO+/SH"G>#Y!=&O%Y5M'/6TC=U:E,CR!T(!;@Z:7-<9G'C7%/A=! WPIBQ-I
MOD=T7T(2G ZJJ=:L/5UIP$!;YK,T@4.0X2\?M$>XV;:446 *0@@H?F?VW=;U
MX %C[?@!(S/X4D!/-$1T[>G&MG]HYI4IADTW=R[3\ A"K.'.=NWNN7.% 6@Q
M)I3__)XJ%/4N_="'XQHYHGK99<R]4I="($MID5\T[7]=N73GN-X//E/NM<LC
M3E7-4#-M5P+Z^:32]87-I1_VF:>SL!Z[DQOL4B)X@G&_'%R9IYLD$+3PX=;)
M6KK^U9XBQV>PC+;#+/NU\?KS1C(N/<":2*S/<O@G4S!'1^W$=O)V3HB$A"3M
M_LT]E?>N/_141[3F2M X](D@E*LFC0MQX+5O:[;D4[+H3+42GSOO;*A'T6*W
M/=N/ )6.B7O!MUM]H 01'(/=A+$8#5ZQSZ XHH)K4*K 0Q>>;0Y TI3NU\WA
M7L%>K#<N\T)XGB06==^&!_?W#HFD=*ZH<+PX/+O.,1?F._-**_@%U&C1]K'+
MBOILA0)/<&Q[7(Y&\')\U(Y %8L5;W,#,Z9B')LJ'W4S<=)GQ//OJ--5- XF
MD%6.9H$T,ZY W0&!;+$N^5NSJMZO@&%06?J43T(9*>#LS8O->?9*%;<T43WU
M^6$RA3=1-EWV>Z\U$=YH7?ZI(>5>Y=+MN.0.1R!_,3DS",U43.EJ79;JLR#L
M638NO(?T:U6\)*.:"U6BDI^V*YR\)O_PL<@'D-[[TBDDX%O*E<A;5<$W2Q'B
MQ_N_^QD; GE2#M](GW=W\%D(N$92[,%ZM)I8<2>:<(5.)TM2T%&*8MH1.HG0
ME#1#)SD3D<>1M&-%&]T9_H7^N&&8\2;7,%BG.7?Y T;E_M\"!JHK)RACZI.>
M"(=X/F# 4@VC'C#VX?!:\=OB/:D^QN/-ZXV&#8(A$1V V8N\V[IJM)/0I; Y
M#H=]$&F=4 C5$=BPWH%\!6EM=;[;#-8VA6BTOA8)&:CV"+[25FL?<1P^Q6N8
M!=JEH!VVJ^1]6C5CQJ]#T(%?7M\],^JWIF<K6_TA$HS;D&E0V^6L407"#A+]
MX@,]P$1"NI,#11/H7P%K+-9A]NVAT4\Q279;%)D$^O*,+R*>91SK#SOB'ZN\
M#>BP?/DK8@P$4G7KOF/GXPOL+.3.9$7<=NHF+8?B-BZ0.[Z)'1C<Z;0Y2A#7
M[XJ9.OKN=.XL8LA5-C-PI6<<Y;?$KG5!-['V@)%4K6D?M M2E.Q(46$O;2L"
MA^3N\*IH>%!EB@432?6?4:%<R_]H;HOH8^8[\IW0U4[@X@'ZC'P8=&I>]8 1
MD^88'+JV_/'UZ0-&@NRZ\A^6Y$X*T%IS,LGK$$U;;W*9'YVLT&M4E(@5=%+A
MD39KYZE3YA]7L:#64N "6--SH'81.Y.%$F4K%7KMYWN&Z:)GY9.1JH).TQE9
MPH[(FF<YXR/\$3PPW'<>2M;T?\GMCKB[;.%O"I^?E;GH;;P/[VWGP7D9J#E-
MX:0_ZIXA1;;;DEH[4E9,LE(4MRC^-FB_-;<KV:ZI6G"M70(+#X7J5YF!P<G)
M>%7F8XE-B7<0)D(:<T;H"".S4_0S39>5!;+=N0_LQM).>W4U/BW[#QA!^68&
M%RF7\BJJM3?9D"I,6[?N&N^J=Q)#$WY'"9-JD5JC+8ZF?)VTY&2'2SSV6:S#
MAL BBGB>WO&,"D7+P(:2/R(QJ&;+<RW:+X%=;Q BQAMT8<J%\'Z^W G3E0<C
M3-TO+,&N[45H$16-GQ\_(N,^L)4Y4]0,:TYIA]2G;#]@>"@S)1&1/3O_KSE&
MUN/N_ J9_Y:W?F3_G$.7 R=OV<KQ<]"ZOCO1Q)$"YL:+P7M:5T3&4&$?J-YG
MT&FS S==L*/M9+()5\]A-M+HW'$::!,.\_^UEH5=D!3%%&/05YC,1TZ"Y>[C
M$T*&_)5CFE2P,9FMV YJ#>;<H]I,,3E#+%^SR1A+JC)2.HVY^SD'RE=(T7H9
MCD(#6JO/IE/0R9?5$.7@S>8V7R-XO5]7%3=UT.Z5'V(;#$IYP)@E#Y4JGY<:
M@+[N6%K4^;J8LE C.(UFGLAR:)P2/!%RBX%^(1HP4GPEQ#)=$<FQ*]RO/E0G
MQ.SN$I_C_)F=YY= GWQ>YJ]7\HQ>B= ],?]#F0>,U]"^!XRF@V/])46D>Y.X
M2H,[AYZ.EZ]9<K7JWJ1UR%YBR&[AI3"8G%*THW(+9&DNRIW L?R P::X/\P]
MQ6NJ<YLWILX].I,;G=MJ^\>^/-DX3SV^<+L80?&S:XU254D,]L8#%9K9=8">
M9L/VM1Z ^$XYS)Y\GB]1IM/X;T%L"7$1#(Y-O:)GWVHH%:=L* S:E)8^/6 T
M/F#0@_L1-]GH#<12-Q<"OE<HA,6-=S82^8"A"=V^\H!*6(4?>5?:KZWKE>JX
MIJO:>//-%:=INGJHG@!!$.$!3MAR70ORE'-@<WZGKKII=][YSY, M\UB&B3<
M#QK J0JH1D!H]N:PB[Y92;@;:QDGOTJG]DFJLGT_DZIF (N!O;WDRFPAH<)7
M9%1?R)]!WZ::[!\4827EPVK QK[4H7(\UF=I8TG9B[\85VK'%12&A^=[KS)R
M.TJ.Z-+?D^+C4.EV%!"OH0"NMZ''YC]L*^J _#OM8RFG<&JMU'&JVW"B7B:%
M!PRM#-.[G0^C$ODMH23V*(7;K>HJU )">V[%]'DQN%=0I><NP$NBK33!J-/8
M[2?\0^FH"FFG[?U"^P-&)U&L6:Y:YX+&H>D-THK)7STPN5<K(T"3JH3AL_K4
MHXV*[R5P#&L;_%*4==[MN!#-$\:H!&'K62[R/&-0J?^>1@AGMB S.UFE\C4;
M:YXBFTW2O4YB7S[:.\-8=?ISD,#AYV7!!PP^;> ZC8BS+.96I:?B+W=^/IO9
MR@MV"%2:5K!IR;[%W25\*P6O=/_Y!+D9U<L;M_(U2U_B;,IB'G3 "LX=M3-H
M(%7 L6]>C#\N"DIU@HAUV[TATZ0XK/Y$J4-U>JO7.4FAV^73#&%#1F,K*]\Z
MJZXN+J@Q!W'#KE&INX;/"<ISQU(94LZ !ZF6R($FKCVF=VM#P!^+:CU[9T'9
MMTM7U:;?^,]+)L^#517L*X<+ZI KPA8\Z36XBG .$LW'-D\\UKX"\@RN7)$
MO;M9R<V]Z#'&%Z5%GS\81[?%G]?5^D\E9EYY)D?LT;[*G,F,PJ)^>]IP0YTD
MHDC@!P[BPI'5!C?/41XJVU@"-ZV]]6C??/X\+O%82U-1LUN/I320DPZ+TC@N
MGPXH&238X&3BN"V<)SBBVW]-^ZG8-$T*F@(27EO3PCL_J=*M*%HY3)#0T]SM
MXLW6$O1>UJ7PKLRUU3)_8Z_=AF"^3CP182@^<B &!O;_.&-?F:53VNZ MI*1
MZW1K4N9G00Q!N)1O1*C3N;"?Y!$CNN/S)BCF2/A:Y64F5A*)L-)APM]?:YAP
M-; I60,T "XH.4U$"C0; NU8 ET_8*R;^PJD-85,9B.K##L"]J*K%B >]AQS
M8 =/$=LFA\$>3X,Z\0AM=?Z2/V(%92VW?P OTF&AWG?[FB^L,=%QI8]EZF*Z
MQ,0LQDQ1W:_BF;Z ;AEO;#>Q98[5!SV]/]&N*Y[1<'BKN58/M()^/W:^>[Z"
MO!NY1F3,79-N;750@B;\G7PP'\4W@8;67?1[5^M2"_V=33M<I&.>,3Q=R>Q#
MI"3.6T0*BI0D"ULEPIG9>GD\4K2 EF@VY6(*&.=<2B!3\O;<)DC/:;H,_"+%
MU;O>U'C).MFL!F7#ZDMGL1M_MY_.J!2A R^Q)UP7Z-1F%8;3E3I27:9UN9V'
MWP, N'KB[R*UDGM 3WK?Z/33]IMRE]A9N+?L"KXI>L'CER7 DS$K4$A1H?U=
MIMW;?J*&\)#GEU&C5C<ASMN(CUU_1'TM#H2UEH7[H^!QYV,5G-D& 29_9]ML
M(%9VIG;$N]>Z23-Q=11^K64)T4OAK U^L$K3W$4%D%30QR.LT_5"A%S^YJVD
M0YW^AZJ44./4U3MG]Y@:KZP2P@4VD0-QM_644R.)L[-F9W8IVU((W@.&+7(\
M$ZH>SO Z<?K_'IU6\OO/B8'?';%]TC3EE&]\[,RJ7M?)6^;V:71D,)$?OUZ/
ME 7";G.49R8?!6KOZE8USN-I%E3QM*QX,+U@29K/FV+Y_610O1H,V/&O._EY
M3 [MM9?+!"H9?TRN/@C% HP8P;;NQN'(=:</B5NY"N[R_4%4'O8VW0NUEDN_
MRU%%R0E:@44#^F3'H?3L#/\ZMP8IMP<,>W/#[S^:&YC%_%J0P:HE&?VMR7%E
M1M0+].B9JPJW[84H+-#;#KLV.<<DTAB]SKQ!JBU?9^_]C*G4G/[:&6%KJ %>
M-[+V!%J!_I$"YAS*(M;@(<+&]7E):8+3O7)P52J )]XLF:Y#(VST/:G,[(R=
M!\HSHC<AS4_\^0%#Q3TCA>\*+"[&=T4O.?:?=./4+(4LV2OT;LVS(-_7P8:4
MF2AO;S_>$BX?I2\<):KLWDL'\NEN/%I+OJ2?6?@T;YWOE*?2(3K%99SW9O*-
M-&>VGFVB97B''R,;(,]>O8<QYG5$4;*,#^$C#U: [0>BO<#9Y\&_YTW5*U'^
M1M4J.]U?P_5#RJ=%.;=;,@*PL[L8RC$!=IG9)4/15]N\?/0\5?\:UC:?FR^H
MS]C2-JZQV6Z5:#""^E[&F80/U2J81R3U$4+K]Q2 /ARU*5%][A$:LDB$T_.Q
ME]J1.*1Q7:L[<28N+'$FWL]7$$ !MB[2Y030"2O%&ADCJP<O*GH^=T'?O"6P
M03^O8,$)2"='O&7*?XSIUKTJ:R66&(T '5&OEL7%O+>@?]37/27+'R:H_,[_
M/]2C_BDPTG#[GVJ_A14R_*L78&FA5XHX77+A#.M 3323&:_CWP[_'<[P$[7[
MZV#]P_A;F[(Z;T$LC:U*34U0K:>V^,Z5T&:4IQ8$<@7Q K=^,?FEQ=T.TI+4
M#Q&2F4M)B2QR\N7:/^@EIXSO>G9C(H4AO/[4U?-M P'#X"8NX]\I9Y@N!5BM
MQ.W.O>&2L+PN3VO%BO>/I2"Q8=[8X?\PM'"OX*)'6R:Y[SF>!YW%5%:'OU\Y
MNBY\XSP^,1\TL@3#!-6K#?+96+YB=5^5QL>I^$3/]3\"&OA?T'U>D'MC9#YQ
M$4N0A&$1R_.MCICRZH1YEC)75CLD*+,C*Q\+1TP,VK?+T3WITF0XHD2GT6#M
M ^=@[.Z0T(Q+;3GA8NF>K1Z^,S\+S3+-+KXZHIG/CJ=^OO5W\@<NB("TP[EL
ML*%9*1%\IXH9H&^[EL$X\CZ0_N".(^W6 ''?+[J9=GH(OM/;8U='G;GHUH^<
MT;8?#8S<F#[#2P"VU\25\H9 $KY[(DY,19N#6M9.Y(@0:#AH$SGS?RIB[W_[
MB<?%'C!J9WT]&JLUE1QBXAPID^)RU/RH^+GD^S_TC:;-+.(THE>5K%U977X4
M644J,W*MRSV%ADSD9@G@CSOB7$MI8>3\YC/JM;8@>9F9(S>F\N(X370F-U(_
M1JE2=D_".'&Z?#V$1,EOO\9B#E[GPQC@Y941O2@JFD"^9CHV4_J(H3 H+&#;
M("2OH=<ZZ_4RE%",\+0;( FHHI*@N\!\!^"O=F4KY3NUZ5VO13)_3RH6PG<S
MB)[+2R&G3Z>4[G(XZ97'BSF6%V?24GJ\[';ZCW4]_> COF>1/[-GHZFS,JR\
MV:<U.6%@UOSR:E VGW=*LEI&[+U8!]"[AK'&SC GK['9(OV$BJ?= "^XQ%VT
M06V!:CH(9E%GIODJB^2:<FLN%A1P83\(-YOT."_(XJ4U\6-%AA0=0&3!Z*J<
MB9JX(76.F] ?' HB;8.\&@:.KN,O B*!6G7*@_2#E**_([YX?&N $QG5F"=R
ME<=N6'I,ND[6!*1%<>FT/M9S,*IZK6XVY/_3.M*/!1@C8IG.2Q+_CA63V)+<
M)T1_]/]IG#')PK_U63[QN/\GN(9_<.(_PS'HTNK^DT_S&Q/;OR?\0M_WFZ_7
MV.(>K]#A=^W(U8^O>'^B;$.?4A?K;2<[2Z1DO,MQ-!3R9S.B%_KN6W1;H>Z$
M_T'_JZ$S@4G_>'W98$_=9##Q.A "JQZ+6)OU'A;K=0]F)AM=&_E5P5(VZN5?
MD353HWN8:EY4< VK'GK9?Z: ]>IKGWD/>LN@%UWGL_X]N7<^JF*NV*.U11WW
M=SX^$]-B4"#7<"]UCWNF.V61_N<#L?WF7E<!QDE1J\DC*E!LB=9DGL(S][:2
M=OH#,D91-:ZC@:7?1S-ZH<39H"]BJCJ1D:G&*=\\ _3YDL9G8TE]L;)@&F?'
M%.T1(319R>"^>VL2:<9 [RH9#VD *Z5%^CL6UO9;$KA!P+Y0MJJN]11H[(@Z
M)9<W6&1E9D9N:;J.V[M3^1CAO&/[PBVMS7ND,)?$&>E@+'\_V,'(C/0[.$F
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MZGO0'FSP?C67/BXQB9KC!TM$_1!!'Y-#LK=@"[F[R;8]=>V$IQ#OI;N:^<J
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MQ5;O W_R:N$V[3BFG?V-$;4%<&/B@JK%_FYE10CG&)O4-]-=.L*?I^S-!>\
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M].L<F+S90O.+ 5]7M=&J5?[,2A=S:=<P7::^>986OP<XJB>3=VHT0%^EPT[
MUSC=B0SM+?0N%0RJ&U;E=-$*:I/?DXTRJ7EM/%MF!,&^43"+^B$XY8CU0V)V
M0T[W#J/QBBYQ\I=8Z)S#F(MU?I;0D*AXFZZ^A\+H-[PMTKDAD<R T(S@#!H"
MYP/.LD _3$//DC: 8]QFJ5V%N_:"C9YAZU:[<76<<T+N>29)Y"_.!AK9P:_U
MK7F&3;F;[?"=!!-!AP2($\0HLME^JRQX"^4>I]CL1>!0-4.&GVV\#[?.Z].M
MM5QO+7G]IHYHRX+QR*0[[?991P,-XQM4[<P%\WHA+R).:,]]<&/YA?.&;'QV
M[.>XMH;0O?RVX?H!5QU[";-^H0&O/G<R!]:Z0A_[D,7'(V+Y4*^BG>QAOM]G
M@\]-Y_],FTCBO7<ET%:ZZ.%6* X)3QD3H%ZZP3V>_XB0E+=#!K:TYN0P: U2
M " RMA <(]@GD9":N:-B9R+>.LXUWN=RP"C)BC =MD%VM5']*1F<(])V]E50
M*C;:I_139O'9JX.%W1NUW .>QI6:^""1CJ_!5:;VA'-="&)WYHU><7EJ4\(8
MLQJ^CE6*;NF?'PG^TB5.2TC:%4N!ZYR#8F#J-]@'%RW>1C1V,F:MBFD"0XKT
MIZ@G*<;8^-5XH<8*##O4E3JXTIC=RFEP)4?(1".N08AX"_A;S]2 CJ-7&(UN
M:)C^!(F\*X=>R[N)*WH$HTP7J*MR2 MQ0+W/LJM;(56?2B&FL5J8K&'S/4E%
MH=K]&:GK:[M0DA/R5/IH^LX',(7D&FDC<=+ZD/?_DA^D0U *Q-,LIV+%+VMF
M@D7VJ0<^"(\?@/TH,-QD7:4VZ,[2P0QZ'+R09,,00=:?FIU9_/!P9I_CEW9Z
MQWZ2 -BN.<TIB.^6,H.25-3BVY3MX(.-X80!B3"X:M_7\)3'3XH(GK-9ME#D
MQ<XL%$F4N8R.2+VWY+ HQQ.3PE9Q^JF%Y7]9FKCPJMHGBY*A2[#)K?GO# YS
MK7U4:8NJUO9)*R95DPDSQ[@^-O+B2R).1*_'.X_X(.^?*=*>L??O7:OBVF)U
M17R0T1L931?T=ZYO2!WWV)#0G2+3?4E9'1X_G<^N[>(>FMJ2EQ<5--WTY*8+
M^P9H<.]$.R:GZ-=%.?$KC++(+O,2LRWM"%WS+YE/CZ8KGH=[\CU4P_;U$_9_
MC?7/\AI\-MJB>>Z=>O:,IK/Q-*OL'\UN6T]Y_[Z).6Z6S(]>FN\OO_<[Z2J)
M>[_XI^9_R:_OA##'SD^F7HZ?U"5Q-^DRN+J;FB=%'(7'UQ)^/R5TV6/<0VSX
MN\P**Z.#6"ZKO]YA^.C9?QF5656#TB1#U/L]KUJ+E7QN(=EILTSQ!3LS]C,_
M#:;W5+$>K'/\'%1S%OUUPS'9Y;K9^6#BKR.P')5;7;N,VM39<<PVFM3XZ.GF
MNH.67[K#*%R+HMAQ6=;2CM3-'K_LAW1"DS7FD%LVB^)W&%G.,[P@[_;\WPAU
MTI.6?>(_S/O!!M@\>.V;?2KJR'EHQ9-O2F(%_. \=0$54SW5ZX4&XVY.*=UN
M@-4+<X[;L>E^[GGV#/ 93E^Z0+^WURCA@3<)!#GZ7=5"TX-7WT8THI"?BN+^
M+G=V;T83?3A'+I\L43[3JP_H&V5'3E>ZL4G[2/2_QU'A7.(+5@!MP@;"?D3M
M+BE.S''4ALZE=W>,NC5G&%WT(VN$[X&W4=N@FA&<V[&O(=D-W;7P__-N^E/D
MDD[!GW)=WI.R_G6D?ZYEEE<B7_6Q:I*DP7_QU/V7=UD,B?=_S]E 1/6G7!:V
MC/,_Q37];2;_,7*IA/T?,UUH&3/_9?7\+9YWE;O3L!LV(#NW&#*LPERB4%*=
M^'GIE/I5N6']PI$LYV9JKPS%U6]=Z:G2KRMMMAG"T@]_Y.2A1H;V]@_ _HF-
M* -&(DTHPKN%1F$9TJS/&>LS9&E?EU9$HL_]J^Y O8/[^J6Q4("QJ+B*%8TN
M-6[Q>@']$69%/WWIPV=_#]UY5@Y9.D4P:@=%C=G9%8(_&7/@IM:9=D^O/2N<
M)+&B)V1[7HMORB004_A)E=SE28>D\*Y\N]=,P1?=HB\*=%E/&-*>Y/"&Z0)#
M%N0+P]Z A9!A;PFCWH"Y><Q^[[&/F/T):DQP!P0N\>Y/"J4= YZ^1G*O<@>;
MX3EQ&YY8[FZRTBX8CR&6*4XWQO#*B*DMK34[=Q='\7\RHFA;?#Q].7S1%[^$
MO^U#._?VM7W2-?-:)7P Y]6:M<P MN@\3L2IC21<:J@V.%V0$SY7QK5\LZ#<
M?9(U]3Y[1+=/=X?[_KGTI'[?]F4-0$*Q:1A3Y20F&8NF;#QUL= :?BZ!UVBT
M2]Y&_6QT,#,+J)2L8FB;G.INTHPD0G:T95FL+%=7@;3KZJYQ(A(AHJ:P=WX0
M57A54:FZSX1)&=ESEE+^,U4M6YS>PF$5;9?YO<RA!DDS/Z]R>$8A-R;JPQ=B
MYB\M;[HH^=?"2+L9(AXU@;$0$K"=RNP.G^SZV\3%"XEXM*_6A.U.)"B CNCQ
M6TGN".WQ"+,F<](JF1=QBC7RF[,$NLB7@\J#ZBX)^9=-[XPL%D\=&A:%3TL>
MVN$3?@\)%29LQV$?AD'_*(<KR'F'P<!9,W;)(M:8ED>6_S&1H=\"=194+Z1W
MS<TI5E*IG_S%=NJ5=)_9T,:2#,:+ $8CVL;*ZNE:I+U48$] $KD!OO:'RD>,
ML_LPVAY<VY^4"1'J,7VD#PB'V:)5V;NFG1UW57X\M[]-HD1X-6:MV-K&9-G#
MNN)_DC,JBY*#,SY/+8N H^SKQE-QRS]Q/Z&R=5.0-68&(<FI:3+0]C!(&NE'
MP;,]!2>+B9V2@M<;,TO#O?5,+TM>DG1RX; /-IG$DSR:Z&N^E86<&2CS;RY"
MIGON,%A>;$S&@:)U'?! 6>-F6^,<QNAATZ3'##[!VDYT05T#3CE9VF4Z3S@%
M?LT\,;IFSKH.I'U\T=65X$0/M9Q;LSVQ#K>I:)](*7DH[0MD%U.HHL ;2YC=
MEQ.;7W>Z99QAC+^=&! G290]=128/FY*TLY+M6=<1&6>R09"E^&YO)%J)JP=
M7C[8T5^[4DA'TR)$O39OU;2P[.8=9F8RHXMZ52^R,T"/'X=@/\;F#OG]#8'<
MIV<?ZAP:[N+S_/WAVD_UE"E+_1;2!C3@4P]@ IZ63I4%C\]!1+5R\%C\;?5"
M&&B8W8^9SR6F3'B46^,<V@;<G%#B%(M-)[,_ID4,R#+ZC+J!H).:N8Q$&YMU
MGB;R[_ \<'G7.(>WEOW#&%6<+P<LE-_>*!]:?C6H0"1^OQ0M"&9H3(F(G/,D
MZ=O^5E]2(9IW^&GYR:.%>N =1JW7L)H39ZZC0<H2W$2>1;5CM2L'?,67'INY
MP-8<=N-#).@HEBJFG^%I%SQQZ_2DWJ\09?-Y.0GQT03W]'KVB=EVJHU !D<-
MC4S5:@&%"]5[;W<57G\&_:D+V+MNU6VRN2.[%@9^^]F!SDI/KF%\7 1\ZVK]
M->WZ.879MCYL*X3>VW/XX01\P!:7EX-.+#S-2R&KIWP#DS4T/RO@.,N<B%)=
M 2?U7>!X=)DTQZI0G=]B-A4.[M3F*#0G.)G%/S9]V #F E@#O+6-)A#1$WT6
M7<$2TU/H7+%[G_UPXM!;T(K'O&=M:Y#E"R]XA_1M:R))K34A-*8UJ8F2)79P
M,>M6]N=LA;%B,L>@QGPUFTX8*4*AD"].)8;8E=XOF]^S!= ]N]6%XI]?,['T
M*0W?;8#Q&@*$+ 75*P?Z"F=E!U1,UH21+4LLW<:<UG4#+986RT:K:+:@VXQ,
M*Z;KV8=M%&!Z &Y]ZM62J-!\M\D2F*PL^@[C%,1UAT&2>.Z&.6[+CG,O,8;!
MHRS#)3',)2-0J;MG-4Y6R RT+9YL<R\_PB0JUXF)L_XDDE7HB#&R$4TQ>H-S
MAX'F(EE\]DM9_X--;M9+VB3>M?S5!&/A1_/S\W,!F;^OMK*76(F7>W(N1Z7S
M!C0LN ;J<9MA$8L)@CL)BVKJB[6+#E>%S918EN[D2B,,)!D5/#/]'8RJC/7#
M:TF%ZA%?_$0Q'_;@1_P@+I,?Z<4Y@@)(VTE^'%SL&U'O[\-QAN/PIW1+*+!+
M:8'W[C 2V:3((B_6GI&56=I1ZIB!\".8 ?QOFTO3!1K%8?H9/,WQ/$4^LJ^2
MUFLTX;"DTS!"TFC%J^R^DNFI0UCL6QI*EYT!JDFJW&C)@P(<RZ8 ;I$E+%4+
M?3GP8]Y'TYS/MM"U//6W/"AA9PX3AM?1L&Z<;Z/D0@(B4:D.B5T^Y8]'V:BJ
MZE_%(2[].%0:CV4X*Q=^)BVV(OTHI]IE;4LK%GJ&G W$PUXAZD:=Y P7*Y7;
M:S:6+0PM28*,M?!9?OT;JD=T-:.^WV% :&QMO>4@:&4E)YS44'2/39J&9^32
M:6.!5P2H-C33UI02<O"]$3I=1LOSF;3YW,;+83[UQ>I:Q[R?3$QI,9?>\![D
M0L8](5N^1^!,(4M,2KQ<GZ._[=V+2</R&M4)'H/6-HZS,".+!<4RZ0_NS>!%
MCZ?*^1/GCUEBZ++U32IHCZD\*7HJ"CO?NO/$@7Y56J:(/"EKU7>T(';\,?8:
M]_C+S>^77HZ2\QEZL<E@!N7)Q@OOMW!0]3IM@I7:">S+:\QER0&!.W$:]&!B
M?&JO-])ZJ4UC_F_\9RS'$4]7<'P)E<LP(PL8$U"<BU9^TKDM,)K*Q4K]U?/U
M2NZH_<)E01_%5>AIY#M/=X%<Y$"T]E4I:T0VD]VD'ZJZ"F)1P!F:W]PG<H<A
M<WG0[ YP$?*+:'1W!Q$?TQ^C*79]J@XN=V/M]KUQ;50JY)[L\T$ICH?> ^XP
ME/;7701/OESC)9MDUS0>3&E/HFQQ+%O=B+]5%U+#J T_'I9$ 7N<29B_9$#Z
MV3IY89.4DX*:L6_4$S]XS@F=KJ\(N\ZSCJA]24"SO=-63:YB)]YVXH2!(0Z<
MF3-]G2VB2",P4D5H:KCG[=P4);IA_O2*VZY*8+CQ8#7M/$D&++EG4ND.%?"
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M[&MM1+2 R'!2B%$3!2Y.=:,BI<NCV]<'7EDZ-'(OH[, FKR:NR9Y0 +"L&%
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MM^,0DOP<!XU%A[M<KN0Q0SQJ4KVVF,KDB98'PF O:W G7M"XU/BK%>45Y<8
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MS.KNIS8_^BGW>?L26)Z-W!]5*VT@"S\DWG^UHL0V,[%#?1A?:RID$&86EU=
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M>TVZ#&Z45*UJUFONR8RZM]@LV)+0H1%9%]O!F@1>0=D);X3? D"UPB(.E?<
M,S4?4WOB=V+[Q._GDG!WRJ0&LG1&;^.<Y?;:[,0FCMCDQ#$XY!@%_SI_D1=6
M@5#\4;<%YC#6K'(9IUV?,5LGLO&& +MS*0T^LTL<H^@*<+ <[@^+YB=RW+\Z
M?UUTID<.+[H'^O-CO5\<D\=#J)#I7P/)!YN)W4B4Z :2 J,D>K?O#,6T;<%,
M##,^!HA\(X>%/V@17%XIO)N[$LY_T.A;9/TX8GQ>IJX.O;:L*K@9SMM&=B2P
M^H@K%4S=:4'Q4%9#(,[\:)6BX^_S*KJG77?-%[V;>SMA-?WZ76_>PIY2OFB>
M[QP"&H_)^-?WCI$U/6,_XRBZ3*41U*M>=TM'-G!O@G27&FIT @U2G0GJ$\-%
M D,'<P\82[3642ABMYWUK8WV*^, @L^YYU8"I8/^9 9J$XGLKRM *12.CE'.
M)B25(5>HSP9VJ)R17Q07U<<H-=N RJ$]/<D&)ST0UCD)+K^(N0QH^M,OX_<^
MEF?Q7!E?"?JL0K"'ZD<M)17LNUAT@3\GB57$4P?7(%]L^G9<6K"]*ZO%QD4\
MF2QM53V<9M--8E\3;W)NMR=96Q"ZTGLAZ(8*^0N7YKG)14M_WI^6V+9Y/YC8
M=V3/21D*AI$K&2?%XO(+@%QQNXD6&4 0<0B64?^XQ<:.5'GOMRO?S4'UQ OE
M#!@-T] (_:IB7>).MD+'^$ PD*6NE4E6>)G>P@/QGO%VPLBB+A<NFH0R_ROU
M7XO*8^U$8BQZ'L&/*5:/</04A=(#I&1Q)/!)OQI,MBA\)R]S&-SIDA8 $SA-
MVU%VO8K1UY2'<PF+4=* \ 6@_Z*Y?MH-^<M:Q6GN<P]8_,"AQBK\%LOOA6K*
MAYQ A\R'H)"Y76+>,UYYE3Y%I0*0BGBF7X&KM3 51NN)?A6CFOX(EVZ-B'3_
MNW%E=%J-/J<M"5I+^F<KTNSP880Z$\)G4<AI!#G5E"%\3G9;):A_%#XZR.0Q
M2#?*Y'@Z73G(D$360O9F@]M=&,"I]&5C<WY;27_["EHXAL[/\7)UFXN;O3_I
M(JEX4"K#WX+=V+9CE&=.4KYX1D#6H3Z_$,;;+"T3)?[I/T:?RIL"TZR+N_9'
M9'<LUEP**KI8^5Q^47:3RX!*>HFWQ+F(W03T.][$T<S.V]&:4?M$?NR"B3NI
MPG\"4Y?LC3Y($!LWJ!^9;B?,BQJ(QNW F;63L_2IA-%F;/CI"2O,7<0L '@_
M'C(A$JP_=:/D6258XW6#/S%N!WLK%Z026]";8YG'*PJB942\DE?(6 K!7/O[
M%;LPM.E>46P>V)$SK)>>WVEM':=B+^[4]:'/JB3L0SM_KE)_5-N,&YX' *H3
MW(WNT5SYUI@\GI3V6<9"=ML":F%I-+M#SKGR8"C6^$!ULJ9%6"$T$WG(_F-*
M9"_ZFN-PD$\ HW8NLF7[\4WO>\%M]F<!KE5].%/X3"3_Z53)U-F'TBYHQZA!
M$-%K@/O<BV.J^&+I.T1QP;\0\&@7-YJ=2RZ)W4(!&V]7M]X:>/:U(M>7PXX/
M4;4TLE!BMOMK[UL 2_#OI/*V!(M*53W24X _,NI150GWX"G\?+I&VA?.:+8A
MK'-.]#=6T2O6KM%+8G"8\Z+5PS^VK@2]^1IBL2_J%S]W^X+H5(B^HC/F@$+6
M227I^0M:3$]7^CX+4:"F,S4I(:,\[CG$ZH6KM!N1'-&[1'DI,M?O;F[REEUH
M.&<)23]!_H7(H>OEKW[\L;.'UIE3 %F:]$3T$7LF@< R=Q^;RPKU-!$W'AI&
M+I=[ZL<:609ZGY>2'P""_^FL\G]'A4%YX)43WPU\W"!XA)QS-4UM^\,?M'I^
MGD;\65S$Z&Z@<#3"#0$ P#3Q>5>T9/VNOH"GEA%B6M\+ 4( "G;DBH9*],#6
M6OSMK4)>3KUS_^^/(BW7WUZ6_LNZ%A*V-JGS 8*N-MRHW]0&<<7P ;W%0WEF
M[4,^*,,1(+W:9UGB2418+D>L0V)I09X:,T[?$8<=PX*<#>06)8740>Y86P==
MJBC_;&Z8. /9^=;7>>KAH?\6DO'_VRP_#EHILVM8^=;%Y;/Y)065A\DVS.?,
MZ?$L2Z\%6#*UT[5U-#:I_ K>/UJ:PN.W[R'7)7R<5#,S+: "*#Y9WX%WC;UO
M&T0[/;). S"P/CH"@QA>O,C^^T; ^;J?^:BH%9^Z0MHRV*1"^K]S7@IG([+U
MNT9$FC1;%$>ZA]V.N]8.V.^?V(F'73<YV+K.3%76"LI1EI,$2D[C 9IP!VZ\
MZPYL@&0^-F=>'TTDB<(XB3I;/S[[B-$^0CW2-7HW@N"8^0_,[/\V$O+?/,9J
M"53;0>AS\66>I>8]ZS)FZE4Z7$39;>,LD#0NG K@71+=,?+&T@'+]<,KS8CV
MJ(8! .\;DKUK!J=S7RGAI"G]V)#FD5GJB>EV5>MS+,Q@+&HQ(NLJ<VZL_?G7
M%CEM"4.XD\K-0BV8OB9>;<)5WP+4B^VE24-+]ET-?NCS3S>GRQ<E85DNA;&X
M7 [SD=@1M;*^G:2.Q0YG?;?3H*]+EXI5(& 3K$>52?SQK_"=SQVK:Q6=$25(
M'2]/^]3Z Y<KO8V-Y3]B^%\6F!AX6+WBY>GPN<$P*W%^7#]LQ*QT#]<P-#;[
MEUGXI\T-"A^(5ACC<5?W*,);@)^/9=JE-0==5(E%-D>-U!Y['A6JRSX!U?Z4
MV=":FD]<L5## UQG!4B;T;IA-\?C"XN_;N@JVSP*/WX;P.1;/7N@=+1HPV1)
M/>DC+$M#D3NXF+!PJFT3'UZ FY#5NY\!4Q4[C6_!,3#)^-I@_]\CV_^4^/[F
M<GC]7LQR[UNRF[V1>C'GAXTC^ 8_+5PW;G ARZHDI):XU@W^7*5?1%@#]OSQ
M.&GY,3=I$':MW7$15P<7=FK2?30H#NB]O*8HWC_(*^+%4:>G$,I.=ZL#)(FC
M3U,CCRQZ5>P63\P$Q=2=;1[/3[I65X..6=:1MU'EZP,J7C  \UX@ETM>H,$G
MF.C0\496=@:<'&%7WERSZ\R+<GPL^+W+;<S3_096BPFYS%&;@$T'Y@B1[KN@
M_);GK/9BGIYKQ?:&F9WJ%3Y)"K/&'2?$?0#XJ9R='&X/"]TNYS8*:P!5R_OL
M<)ADZ@3;\I0_==).S(9056#I-9B/EAD5U#QS?>*A&&BDBL8J]P$RS^!P'W:-
M3K,^6'D)SYE*60"?OWY:M2SATYD1FB],L(2CF =R0ZJ_5A4CDEL!GA[?_4$C
MLR-13IQVM\_OQQ#X?(ML57<JHE-1S\ZJZNU52I'[<G?A9RN(8*K8T=3F2Y+.
M\LELO1XFDDNAWQP3E!29=-M-7 U(7!"]^O#(^EP(RF_X]6B5!A!TB((9!9EE
M_.".?I_G1X"[$$O44Y0J=Y?02]06AN)OUINIYQMK/K<Z>7R7,3'M._1+G/[6
M<30Z0($\HWF_+/B&:SF]#?&Z\QO_4W.IZ5X:J,5"@?,70PN"Y E]"[2NKC%V
M?AS9]@PR__F=1LZ[Z;/S'8TQGL0$/VG@HSW#K&@13WF3KJZ/CYM1D4T:2/.&
ME_ZP:?=8D_ A9QFPL"2V4U1JSQD<8.C@WFC",ZDE=:W'@=K3:\Q.],K5_^(_
MXE1=G%F?8Q;X\';J9@XWN9LF1\1)+]U@M*L-HG+W-B*R1U'"<[6Y^\LYQ;O,
M&FV[*A:LYK:?D]B9L2A3E4$7M)M6JP\^M9C5%QX!KT+$)AO.& OTKF+F.);-
MYR*_4\J]7)$9/LT^TA)MY\NG!>??8.69(P]C%C3V8!F\AD+^%8I!';.2VK/7
M^$ZR#/E.*JDSOD-3 (_0BO'UV@"G_H;WK"*<2Z9!8A8-R<T<8[#!Y(1#-8O1
MJ@E<XCTGC&(N/G-/%Q@!?>4"E^?F<E(]_A;I:,9RYIB:3D,_Q] @K;HLI.^N
M(P\VQ4L&+6"_A!:1!#$[;)4%OGR15 \GG/J9J-NL>]&PJ%[./G:GP*3[!TV0
M<A@;X#+:S=\"1JPR)/FEY1 FZ]?FO(@<0@/UL^QNUUTR:N=L'VCM:581*UDO
MMQ14Z;=)(I(A:ES/U&79+F0MJ5=9ZFZCG J3G-H3C0R<ZY0V_/F;="9H?N>#
M1*^/(^<?WF[JA'_2G?61;Z'\_D7+NPXQL)HG4GG%9+I!$)A3XI^4*^$A0U;-
MSDQY70.+<X7$L!G!)F]B2 T7>KCUS)WDTI\'?4F0=-7JD6 1]N <U:%Y<RD0
MKS#9=Z:&ZRU3LV]85_'TBQ9;!PQPO]B>NZ)>ZS,5!R\O[G@.KO+^7FC*Y+/@
M,>1Z;,0QFO,'#6?S2 95(I"-L_?:2UDN.O78%J>Y3V :ZJCF[L*33_#RJA**
MYB#TOKOHCFW>)5Q=)^)%N[7MN:B(0E)"GG#MLF&H(X%DT2)D]LG@W8RS[M/H
M:-;9$-H]]+6>9P>0ID]Q'%0"9V-#HSC#RP%]".(5>..L?KAZ$C3M>_R O,#-
M\JV7_4UYE0'A9T$OS]@& 0M"K[WGVW/XW6OYA3T?-K:,1)7%&=1F'IJ"W*#^
M5#_V23P3M"D*THRMFN]EH6;$U?J:4:$:6:N\'2:Z7?TO5],&,2F],N;@-*=*
MF)KMYN::C!56(]M\6<D_LJZWPZ&O+3,#+^[;H;D.#M=W3F4K 2ESIT/JZOW[
MN[_LV9-<B.L;RWR]VPZ4N_NCI\O>;CM(6O[2*=5R<[VCG[=YUV5._XS^^<A'
M2:3D1V4X+2VB%@L B02<(%&0*O/VGVL'ORPP1UN&3X>%:_EYV/FI#[M!3>W9
M[7#$_8))26M3/1<PSN:A=N9\<,/2>NHP9!3_I.=VE TXFSDLOWZA'@INSJC6
ML;B*K8J@VPKI&7IZ%37.7Z(R0T,)8>%D3UVM&DN(SCT:VK^[,FI4M#Z! ?S%
MZ3K@[E&W[@T<FXR)KR*B*A*__A>S/3!T CY4W;,(A<LX%2GHK?59;,\L_$"W
MV6])3/4'DK1%BW_T*)\:6&#<VA[@F$J6UDN/;?UK;U/D15Y0@@"0>^5'E_[^
MUTYGEVE@S.ESCH268=63P]W;^I7E@6D*)A75QKRFD!^JR,-]$J<E;&Q9E2UU
M)38FZ]"E@6"SH+24;REYF8<YU6F"-O'2$NTHZ,\0B[N_'!*Z/(RJ;E59AX?5
M+^.J]&YOYT[D.0W/C0W<W?MTL -J._W?:1CA,:?A"^SN9^CQU?\N[RN 7EN1
M>(6(&;;5GM/MS=4LV@@L/$"@%0U\69/>*S4A'GS.Y"'EDA14TC[87)UT)3&K
M2R0)Q(M<NXM$V2U [2'REG&B=I9OW7N5=+I[YBZZB]YM ;:A(=15JD^"Q;RM
M]^/GA7;B6P2M *F2--P,<P\+Z"ZFBP&C4Z3?DG\-ESGL#;*/S$=48^ +$[@V
MEG;;D^))F)(H<B]<#OS:M$[5E>1.Y HL;B+HN1YPC*T_<5@:79H05!#".%T<
MJO?^C=(XVV!MUSLVLXHK _V(17%? ,C&/V[]RJ.T=:+4&8%@_Y[7XU^ST!)F
MK8L0UAAH]*\[9ZD:ZJDH;^85E) 4<TQ,/9(.72]Y:P?D%R_^5,>694$$5\29
MPVC=3FX$[207'94!;S4=\NG4"0<Z;7Y;,4L$$7L6R\;$G[(8Y5F3>K!BLB^[
M+%2[23&ZP9<_6B(@32P'Y0F,]8MVQ3FCO! 5+Q6Q47P-NZJYS_>\\]34-V)J
M9.S1R\8C?C[5&$LZME6\N0G]>566KN]VVIYT\RL+/H]P_H@ \,,=,5LZ"M@O
M9'[W#3=&5C U#CD:E7S>-IQ;9^29VQH;VJ>R-&0-L2%< 40EFVP49@8UAS[,
M'G$N('8C^7)KR^JUZO8_W##0"[[R,KC/5 ZT)X6/0X)FIIOD<\."WK97EVXB
MJM</AWI:A@L]4K.G3^+8WUA6+$VE18)'P4/*#?S<=P0V$*(6U^FUUT=\;3*T
MOU< KA0$0T(A9Q\Z=BS-DF"#"^;GD[>RT[9W36'Z]-9'(R1Y#->E*ZE-E]O?
MM9IN.I.%$8\#X*F\UB4-)WAA6!8[:HMK!O.3!9GW=I'PC2 W[_J!]7;8Q%P*
M>,$[M+>W-K*!38H[K(>-[-<#MZSYJ1(IK#V6VYHSJ%)R[#*U[WW<?<V"IE/#
MB!I!U?B=@Q#J30RH.;.C'5?S;-N YIVK23D0A3IKB"@\#W((#[1J)UP$]@Z3
MRRE'IZTTO9XC[[ 'W5ZCQ!(H'@9R]:Y<NVM;UJT6E*%]_')!G<+V6PZG9QF2
MQ%S-PZPH84QQFI\PV-:C<GN[L!S;]WK^BUEWEF HZ3DY@D#[BGK-#063B0Z(
MFHH34T7VC?Q!XQ!G*_-2:RZQ/7ND;36_*IYP3P*'?#F3R^S_#AO'K=@5!4[U
MT5THS\U'F(1Q>9JK-[62]T(AH31I"O9.7)7,V&=O]%CT;5@-SW\U^*$G])%B
M^[P+3?\VN)QE:NUEELJ32^IM(^JFEW1APPNI$$K[K'^CV+NSZ72S/!WKCB+?
M,!(]W] ]CC:1DXGJGVJ<"#1:;<5UCHP!FZVD+6++W;AV5.!HJ;*G7AKIQ873
M2S_9^G5]T,Z:Y^$7I<"NP.5^X7\/_8/FYX>H!4,;,Z&.33I.B@T!:J$02=:K
ME$&,^=_;>IG^JKHN&1$?4J$6;NI:32."%:GD^9Z@PLCL@C]H7^YY@"O!%J)Z
M/SQX7[K4OLL0J*VSXGI"!(4,\ZD1S#'IQ-P$IC7PO#[<Z3[2?3#0^03IU^WQ
M_X.FB!Q[M-%S?GBR7B6KM6-A809EJ2.822G1+7-IQ-,,F3YE("FBH\V=E74(
M/' ?U(DPU"D29Z$SX4G2J*$6.>QO1+2\=5>Z33)A#Q&W]K31^$115CNIVL6Z
M2\?@0#-&EH8FHHI<"0PD).-G1[8.A(=[_JV&CXT-D#P[-]S&YEI8V 7YZ/BH
M=J19YXVT2CWSQ RJZ&XZ./^#5A>5,TVBW\B@O115(Q=NWV[0PW4?9M>SJ+.W
MGFXL&=<3M!<1L3JZ/!T_MWZ+A_GT)O[2,-+<*':OE6=H?E!6/3J9#H/V>MGY
MN#@S$.RHGSLANY*8F'-XB#A[=(=\G=6]B1Y. U&]CV97J>B_8'VC%-=/'@RD
MK$927 6QA%;YB,4\;TUZN^C&ZB?O]+ITJ<KBNX!NAQ?M3)4I+RM>NB! )+Z_
M!!FBX2+[Q-P%^%R/W)'O,W[_*)?%*87TYH35YJ:5TTE2> +_X_3OY#]HB_.U
MB^2QNJ=J1T/JJ*8=$RC8>8":.NS5K_\)K9G7;]./#]5]5'F[R-O&2M 1K'SI
M%DUD"A(DBR'X4;K,VC7Y;M> 66URV2DYD S.9%3]N<"]71-B!^2;M Z+\<S]
M9&?R.,09/3J2F"J"=99LL9GFWA[IY_H+IYO\5WG/AJCJU\)$CE=()'QEU]K3
M^.^"!$_8R4>S"W-E@(7ZGI=A<>@U#HT$9O%WYM^%GXC<L#@>(VL5 VM!]%>Z
MJU18">(5?<Q;V :CI%?,8QCE20KZRWKY$.T1VG5>/TYY[DX1V14S5NZO"L3\
MX^D@5!3J(08J*=%*ZEK,&V)%6;62SWO.V3_5Z[A-.=*BZXMY1]1>"K>5VJKA
MX=B!P]<L[_YS,,_)_H^'R^PB QW@9U_ND%%Z2N<\9O<WE)\U]T5"/JFET%M[
M$?K[L^D0J6V9 4E/WT#0W^I--5C?3R^I=,P(3<Y)Y% 2"FY6O'UQ=V7>[=M(
M#?)P1RX,*!G241%3,#_R/!)'JW)\K+SRW=&^1.3(NC7$#RS5^EXFW0D3'(ZX
MSZ=WR/K0QP\7M87F%NIE9,13TOV#L!SN>7ZW OR:M+)G/,K6[ >):?&$CGX;
M?ZPI=W.4['W5Y##V!^V#1EK% E4N'6%5LMKT5&=<+?$WZ3/N5C!C[5$8<IX$
MVZYV0<ECD?6HS?XNE]I21%7@_@U@C4EAF.O%7+_2@1CVK8P-E1U"5H%V1W/\
M/Y\N_5-=3YOR7]47N!&B(_>8N.N&OD^C(_ZU($B0%Q%*4??>:YJRG7/?,IGO
M^M]VX_^=H0)%/QA1_CHL_O%F=S?S.S;5R<K8IT\P-$&_!]CK04#0-;>'I0=.
MP&TF\1F8PX01?= NV^+[D#P2OKT_]V-@[Q9]^ )7S+JRY&BS$\_+FO#C9YQ_
M&9;P6(>*5\&\R>C.42M5F'=X;"&G)7H<E@2YE7_ZJ#JVO85\=#B1?MZ'TSX]
M;GU")#)J8<=B]?-F)-N'*#U]#::(K4[Z!EK+)<<(Q1>&0,[&NG:PG_LU>.1V
M0PD;&PWOX*G@BN])8VF84]OT)%P,=QT81$J##STK_I4[_ZU:II^YCI_,JN2L
M9 \.8%WV+>9?B7&D%7*Q47"4C()_J^8U08</[E>N]49&_3U8,K#EUF?RM'N'
MN7W\WN]WN8\$ D>1?<^,@:/;.\AA0WB0NNZ("2R]Z?:8S7='8^I\;"<K)A*H
M>[[><GO1ASI!/,A^]$_^EW_5&$;4%CSBK[(Z=5%8=-JAKM0J8GWI4MMT!V &
MI<XCB-L'59%I%1;L._%,0-_8D6H>U5G_QI<K$CS/,[>AI4&CG[\>CTK[\4UJ
MMJW321%'7R%#_X'/_E_'7?[[K#:\NKT\VS:#O"Y4**RC:1MJN-Y_).T+XS(7
M5=?^8.:6^=;<?PV;>!3_M4QH+$LX6^S<ML@31C(WM$&RKQ*TUJRFILH;'_]6
M-T;RB)86W@-''G:A&^0SA1_K'EV(UHY2U$\F#^^@?S(R$_+XP8&M8&5#R- /
M[I_FVN!0Y%8 I?<Q5BC1F)LLDLA84_S#E.3N_O)D_6L9KXC&GWD&CKQ%1U5Z
M4>4J)=R>1O.7!-0_^'>8=ACVDGA!X<-C^<IA8GRYQ0;OG=5H#ZM<YG$D@O!]
M<]0(W>#"='$0G"'"O:%/BR7 ENAXW6#U<RP:+CR;<YO-PO10A/&!$4*TS?98
M+-7[#%<_M?F7W"LA$"GQ"YQ?GJ;AHG&ARZ!I8)*P&E$M+W:V5G0;H-+]"<WO
M__/X(\?KKU5JA;&XYRP-,MU0OM(Q[#2*X;=FZYZ$'.Z"G$D0<?#/I*;QUG+>
M0>\7!<X3PN"F WZ<RPZ3<Q:O.SEO-]&:)23(0V 645J:2_:EJ69/5$WX;9,:
M6_>FKW2+&; C<2M:H 35/]+F'TP]>F\(NS-Z&'KPQC7W!T3 M)$#L-ZM!8[]
MQ ^O1<,?&\!!988PY :L$F)2D%>G8L-5<XTWS7JZL6_Q)95$X[FGGQ?B+*,+
M+\B6MD:#C-5Q\T)]-=WDM[=VHSHE M3TY"ORMICMQA&P[W?;+L7UY0O9=S%9
M>U[#6VLWZS))RA>K@QLNKEZ$[]E?%MU *MM6J*8K5[VU_'JJ?!G-Z:26MIFZ
M/,6S5M>4VIC"2J=."YKTND?3>J$!C[ 0_;BU>&D9,O";OX4C?Q6),M?YS"1+
M[J8]"T;MZ"*(%Y7]2RV6'IS!05XPM\PK]>\^"0/FU"M 9,<$*$F1J?%O]?R<
MKA38JW)Q"IL"\(Y6I>,:V]SR0?[0G2LI.>]Q"T@J[ZPL>RU))A_1&:^JA!<P
M-VPGM?'=M]5P.U.HJ3QE.DH.F!:NLGL\LVPDMZD](>2%G<=,^8%@-[Y!S"X\
M5D0B9T:1J-DR4*A//!C)8]@LTDB</IW1O8+K<!?'6M&9P\OA7#T:)!LV!OF4
M>;Y+N5B=49-1Y&!,;4>$=;N0 G= &5$:<'1[/QB:#&F"V/)RI[U16GK.5AR?
M^S5"6XN;?$=X6:1'X*BL\RS7N"3AVR3W[I/\<[_[G49^^7>7C#:'#H;UKR4O
M>&*(CZ<MS+9;S\]C')_@:GI;SW#S(27]ZU/ZPS<*%_^@Z1]D>YB>"2UIV[.I
M""9<^/.F-MD7!=8=)#-MPK7[+=:VP%'3#EJ5R\!.?)^Z#1<[5(#$CE1<JK/+
MZ5E 8-"Y)NSU/<]&M]V^S^R64H&'>:^Z1F"YMFYEX\ ?-#X>I9T(I0C1?'-P
MC5J?JE%+Y<H"JC%$T (3M:<;&;RR\I ],8W!IH)1\C.3A<(_8K4#L[0!NTFD
MMD<CQ9&-P=4+/^*TA=NY(&K:N9M'&^BYYE#5_7.V 5X.WS?'$M'-&UI-U7^_
MM9O3VKSCTC]#[\S>S-P70,VZA63K'_K57EGTH]\.P2?''\]O%A5+2>[,YBOE
M>4:T-Q[L]UQU=(L*'WJ+RF(B7H#O&5W,%KS/BN5.#>D;^:7"5U8G$6\+&BMU
M27[>.[]EMGLN>IT'H)17Y'*3Y6[0=\8^&7EW^^5!M->O48]QF#E Z S>;ZT%
M/EY\;>"/-Q_+.NL-B2A<5_$!5*N5*_2E5]TY$YU-X?:I! H?R1H%"$H6\$>8
M(@)#_!]+H,-ACW_0'K'WS*O:AUTW?S8?Z(F$P,;MQLM$[Q-/D"+]VI5NBBK#
M3;03)XA;*(N48[BKV+)9)@O)KFCFG%=_8>%7H?H5[++<G/@\Q9G*R#BRR+L^
M:VN^M3Z!W,&B)GL^3&E;_<""@B\YZ"K:@6DI/V]:DXOKS$5Q>(>YI&>!\Z[
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M^5G@>_ #X>B:WY)/LSZ!7FOAY%UYL5NAF//Z^,P[0_F6AQ>#\=U&GL^]@,6
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MY1YVOR<O)09S#]M:+IZ55A2?DX>DH6R@;7]I<O _YD$&G':BF\7'K<]$&Y#
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MD=6=O4-C.QA=HUB68P?EAZDJ1!#^/?'8G F(:FYGB.OO6SIQGKY3F+O8HY]
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MM*@"9/WW+TMP$SIL,.M5H: OV0'U1(%IC)$3[E2?20#>'WL9]  " 'C->;V
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M;F*C@RE[GZ:&XO3WFS07^()R/5MTHK33<P(X60UIJR6XAOWRV&$4CWJQHOZ
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MSXPP-T%>DX9Y^'Y2FX:!5O4U34@98ML5RU6]1R9.)S6:9ZY6N7.1W:V3/CK
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M\('I=K7L'U\B\][HR(GMB"G'5<P9MK(QF!?W;CRQ#EL,,^[C*4+ 'T()2QA
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M"E7DK#XR,B<FM<:0VKX%,]L1^%J9&9:1:D5>E _T>.\:%8B%BK(,#;>V'$G
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MW_5DPXHY<9%DB<R?@4+A@*E+S/FEQ#NE=<0/HT&LU][J4O&$FD-S)SW>WAV
MT]AWJIB"4ZDB3*2C<BL?U< 5N+TSN([V[@SIH$]2$VJZ+H<K1E0<M/X3<9SH
M6Q+_M@G7-.&<[#"9>5]!#FF6+"]N))UO8T4WH2M*_# !3JX9+$J=\21:  ;C
MKPCR9O/_KJ&9.L\ 27=8JC51T&.K#I/"X4Q_S(9KCN8;9&$%TG'Z,> K$Z\Z
M$&F^CRMRHH">WA+^CMEQ8QKHJ6*7JY%B18Z3RUV.* FOGOJG=BDCL*?QKU(*
M0R9%@FDT*H8[3$QO332GIRU-$^.V"S;;LC3C*^:+,#C-9G[RX3.\1C_,%SH@
MD[_J9,^? ^^5FK.]V'HPEKYDNY ?3.MZ3?:$4KG7BDY-F5I^:NP.$.2GMGTS
M/=QA;[2VL_K&9"&,G5!YBDL6O+M#STO.MO63K,Z%I9Z:U\#\,<0.%"=,&%VA
M^G!$;RO-1Q63YA-3G&EKS29JG:;M)9"D]"3N'=OJ0';D7%[JKB%BLEQ"ES6.
MU1/3BLA8O-VX(0E$OX'1$BSU9^5+OWEUJ6X?-V%C0K[C!/G0!:[;=FKX>#&S
M:9WFT%3=IMD+S2S*YLJJ8 A8BE7Q[V2S@LT*MAMB3):H=E%U,GRQ&?/0(,SE
M'V!I7%]M6[@287 ',#Z_ P 5+I]9G:IB,17-A6^\3?"BD\;(1UXB[6C:W8]/
MGXH&Y/N'[A$:J/<FUM'YDF\;0,TS(BRH?-=PMT8ENL[_ IQ[N;CJ,H-L^'K-
M7VE%#B$0H;LS S1$[1F+R.N\(63>;&\'JZVO6H<ZV,&^TYJ7L77=HT[-W2WV
M?5YZJVV?X6\,93'YI#9.R;DEV%]TNR<G8:MMB,=#K@/EB*W) J-2!3.G3S;T
MNCL:7]N *ND#C<_C4%>FW<?<-H.@(\+<P/PC>-[-Q!U N5YRV8MR\T]D8S[:
MFO7FLJY<= F$5%$[P/'D2:;B[=)-<6N@G%+&R>3PW6JK$E, AB[1V?!3#<<]
M$TA!9T;%G+>M41Z?S^7@?EG)+)Y96WI!G"[QT72X5IFV#]26J/]Y]:O^<,<U
M&YSJS5EVK9-;*FV'M6[?N$5,!S(QVFBPZ6;!>D;%EJ7-IU9<9VE!.)K*)/WK
MF(.&/7O]+.7!WK/&,GDCOUF/!0G=*XEVL<;BY-QTA@FO(-ZRPS?+:?M-U[=>
MXZCC(MY;&\\@KPF3Y"^(%;Z+-MLM?=YI-*\=WU 3>4$\CR!18IJ#WQ0U9\ZW
M1]?ZO[_ILVWL&R^['=SOGS&#1CN>F#ZC*6VH7MG"TX_I$ZE9X8DUUFD]M9OZ
MO<)Z@?1Y&/*F,(G?>S5.\\6WAY\+]7?YEKD(Z-"7\GIHO(M4S^XL[K)!*3M"
MG7ZP@,H"QE94;H_>L7CH:K\$YYU>N:=M&T1G!VG4^KJ.;?K0:$%LMUD-.X%R
MG#BQJ%/VOHVCENXHDU==7/1<FASDOP-LZ<8ASPBG?N=10S6)\&^8@E13<HSY
MG)D](,3')U(JH@T*H_/@'Z8RK6):9Z2[-!Y"!$I_U3.ADA?%UU[/MUV?!^.E
M@7A$EG+51;W 32#,2640J;<GJJY\+*][QO75[$T9FNIV;?ADX=E6X\DEUXQ9
MQ2O0XC%7\AV@XIQB2L T/PF5.R$1>4+Y/\A[RZ@XNFY;F#@$"P[!@D-P=P@0
M(+AK(PG2N$/CD 2"T[A;<&VLL4:#TVAP&F@(#HV[DYOGG/<=XWWN=^XX9YPK
M?[Y=56/LJA\ENVKO6GNNM>8<,^W7FID;*)=*(PO '/D$T>_XUL*'-2;^KI'^
M%2%)[F,;JL*RI*)X*N!GAA!A>BQM]B>&'[W?--)A!BH_ME^NZE?ZC9;_&XVH
M?:=,6+N;CMAY(*]GD:/(Q((^P<5745PP*F^-88E'18&QP3 [@*ZK9CIQ)<;"
M4)5$08]^7L6Q>/"F*'VAV:8R5"NM2E/:>/\[Z(ED^<GQ+_<"\\P1%<+3_J@*
M1H'UK]5>"7!"M@F*)2QES6$\#-+WSSAQT!PIZ^,/-I:V&;VH'3WH*X='3V2E
M/2-#'?W [Z*7AQ[&)&FO!L;Z^G-2 F0)$8/%&PL.'F-)!XDP2_H+![[L!8%T
M.35<E>8YUK=%0V^6!CVZM(("<:P9F_T$N2)D3()#[]K+ULESBP^L%V=D5&U3
M35]D]L()#;",3T@==817(GK8Z8U@@I$FUE8O'/7S8E5R0BUG-.W8]-IJB22[
MGP06_D:S27:C>NL2M3JU0E]()K\4E<_0:DG<J,KNH2*>CHJQ=W90L]()+X:J
MXJMY(/D;/5 Q'315<M)&COXN8=1Y<"VGWVC*G _?$+ZXN2> G+*:&U:9IV1(
ME<2(O2F7.,,J_>(8:EU (P6PD9X(\:OTZ61L8H4:A<5JSX/2M,6:CEL#XBVJ
MDJ=VB''JD]&;C,PMICISTEY!QGD%]@4>KQN'"9NW#@YUR=,C!\OO4U0A[>%^
MJD0L@7MM&/0/ICK*2RD'9/L$"6_L2-OHOA"X7&\ZZ?2M8IGF<76JCPX/2YP0
MAT6W(KX,P8$2BSX"/A%6$2KFL#G;-[_1QG=VHA@6PZ^A;K_63R;77L"OG9QP
M[E6Z;R6EYP-,(S)%HQJANKTIG>H;B9=7#C'D LNK%Z:\5KTK[-)]\3T-DCN$
MMDI;YV#)[E+](0+GY<IV%1&!$P'I9(G"UF]PX_2W[JPJKHN5JL,CE+:=;'T'
MJL/#:*H'>XNBY4,.3OF'U4UZ$<8RQ,4SIWU[JL)^]\,Z!#0KG8-%&6SOBX9-
MQF7Y8=_CVL(_"2T&%]I9BPI88S_2?VL-(2_FZ^&.#/+##2]6-;>BBF>!R)-4
MC-%G._%!1^BA!'&#<A:JQQ?U^W2%DR04%,JM<,A$4FMJW5UZ\L7B@\TD;L*5
MPTU@Z#4EY<RT=@#>$OR!W+?&-"+C[B4CR/% 81D)]V+7GU3[SI4@F:UEC!TE
M.PHF6UR9C"'8BEQ"LCMFH:]OI6[0F#'6J%ETR.=;G;'.PNU@]HZ5/H)@/:P1
M]7Z;#Y8O4#M!RMWB18VX>FKZP%KA#YO; 9_ +"];U)I/OH\R'[<83R66?SO^
MT9^BQHHALCG;98 ]>-F\PX Q:]1FMY#;9K/('AX#70>-^._Z;W0,4KYI!Q3-
M]EP+L3W#,A:YNK-\FXHBHB5].YYK^#IQ5QJKZ]4LQ(@NA/2S0;!YU--G?T&M
M_B8DB1I8!0L.#0N^#3<-RZ#E<F#?5UK.S_\=Z)I(]7!D;V).W#1\,=.=DO3>
M])79J1J%GSQ5;I\>$/)QP#\Y@2D\6+YPCF*,A*_BA"*^J?-Q^V\TAZ716,?L
M>5MCVN,^ PQ4_1UA<;>X_85HAA#\_?(-N1)SF_!0LEFY;<_[!XJ0,6D[HH(0
M!9ITG@AK"R%@A)1+/$L>$U@_RCBM9XW[#0W(RHS$RM'@T=6_QR&/+>T]3$0W
M *!?!A:SOO_8&G;O^\Z;T/WUM;#!RLO9+<]?K\4<W]G.)\N K,NB$U!K<7Z/
MU0X;9YV8G&8"XQZ*9]_9Q\I2W<\A"P/3@9,?JXQR>L=V+OQY2_0S_61:HM#[
M(+/ M;B!-=6L1HED)_WX8;9U]32QX/\ SZUV:U6KJSIEGX=(Y4 DOV0,/+'9
M%UC=FVAP8L5:>WKLNK^_ANIU8GQX>)[0H7"/\4C/Y-QDPG2$''1RJ#H6\WGB
MS8W>RW'XJEYLR1C+Q@G>\0^Q%%=Y-C4NZ%62C29./NGG;$&2$_9N7N\.:M:6
MEHY9SP!CY(.>IV=@TK7IQ#_P<H?;6%_^Y,)%S/E+&N,8W%Q4J]=)K##&N<0'
M,9$Q,LG:PZA^'V2XT$67K_X)R5JIM)$+7NQG#+*_F(-=Y2SN:1]+LI")HC<.
M'@Q7N2#/$4V@1MNSI<QL+HJ1,&K^DG7B (L12^.*N6](1&8H-69G9/B-3-E;
M*1JT :L!LK+_5LS_O_JT*L[_IC+P3B/NGX')3@=KU.%*U(XW09=%E,KQ(4M_
MV_U?<&;'MZ&RTDP=!<TY&9BIQ$7+EU14@EVBNTCI&YGN:J+QG3XM):ML)--0
M94?HL01!8_$2[<N+/>M 1@Y]\T.-UIVKMN*O+O@9*;Z$;V07\,.A7GW$6Y#*
M\>?97$ 4:QV+J"361_=J?"L@Z/3/%E@VMCGZ^>3?KBXFZK;^L'6B1W;@O6\[
M_QO-Z8F2)=LYRO\)D;+V"%N%UCH7#BX5"2W;^Q.E7[T8YNPY=6OB^H5IO0<R
MLZH>26T1MZHF\RK=G:CY#98UN4_]*!&-HX>.XH,/CV+#I)!I>S/$F&>F)5XP
M73Q::XO$#YC'>5?-3AJ:0VLEEBX-YC P?!(2$-VD &;EV^\B9E4C$XQ[6CWP
MG/,$6GO[X?^E]D"-78.IC2VY2B-LQ-1A5=3Y_92S=J$ "=SJ(#@(7/3D3),K
M5L%U(+2.SQ:0MBA-RSTHJYI])3'[&VWDA6ER0H_^,5]E4+8/-X4%PW,UC=@Z
M;_O/9Z?3E"2H'AVF .&0O?%3HAK:QTR\B%T88-8U351S"6X!073$M@A[C#GN
MP\&]Y?@)]W@C?*$TOAGQ*W^1!L/_R63F"O)!^(%7=AWX\[F_!M1D#\Z4\OUZ
MZB!#.3-AR:-9W72W2QV#21S>_&W=J^]5(+%^[\7C[2SJF,DY/Q-,(K29OI5M
MG;[Q2JQA;IUB="ET;UY!-C2DZO!B"N=)V6\T3T(0X&VB&Z FZ4NZ4095SD2>
M_9Z4=&OE=6LD;R/.+/LW'R)XZP_FQ5.7VF$!YO]"-,*_TB,E^>C(5IXZQ;2-
MW KK'5$Q//H:]F]M7:#7K+<3N2"Y?]-R)3X]*)(8<:EXS^UK==^A%_BB&?;(
ML^X_/#V>QK+L\9-2B>$=SCYEUR(>V-C?R)/^(57QK_1(@_&#^^+CRZ_266]K
MKH GCQ7^XTB _T[U5?'2&'+C[N>QIN/SV*(-R!%?S J6OPL51"ND0H+I*TVW
M6%JFNYEE]#9C_/HS#K$0;W^IW)(=S,BF!*'8. P,WG ,S*;8V 3><$QH#294
MJ$54E!=:BZ H?[3\#(D\$KOT='H_'OCU0'5B5UG\@W$_N:T3[92'6703.+I4
MR+X)O7JFD=5T)3=]7/J9;]P_D^;,5+?:CY_WPV6L/2 SKWD2NG-/B0L$S^WP
MX0,[&:YI!-@V'T:.:@FJ]22O>0=I"_!F'0+?.7+T<$A+[TE+J]+3<P[$QK:\
MBFWYZZ8BH:*BHF\$Y&E# E 21YN+%>^LHXU=<DP^E@F6&]6P>C57X1D]]0^,
M_U4P-$'\<3"4$?0DGVE*ECVWBA?]?\KA\?V;XZG2=%GG&"/S5KQ0$D='^^<_
M&M2$O#EG)V AIN8ZL$]Y,'_P[WZIQ*??_M,^7.49\%!(6]Z8BA<(-#A%I#UK
MVSLWRY4C$=A:W <Y@@$C/Q;]>J>M71.;/$_6EBH>+1O$^HK&%6^[#:C_/-N#
MNHYV<\B+9F.0@X7QO8[/D<CEX0^4&?"IUT"7I=]HG.4G@9P/];ZMW!-^E123
M(AZUY1R!DB*W]FHW^!%W$9BKH,;-8X'RV4(]O?=ZW?#^(ACGJ$O&W6A:.I.5
M$:_&9/K.9)_>W7%<([8^ #7$]^6IB5&CV BSM^OBO:YQ5EQY=\>?YQQQ;I,L
M_=6SBRV>!-4XG.VR/"9CL<:*)E]\+;C2[)$NCV]]!XPRWW7AR/9>029O%<]R
M\C?UI^MT@>3$Q7?D../%0<86J\UU[38>XA0<^8XJCFK6,M[P.]KDA9L.C[I;
MI\E<[\I)?TA=E15VY>3Y7C (&ON1^:,[*)D,W=YBW^PX"14YY_4YHH@QZ*EE
M;*LT=ZBV1ZYK([".2972H_*<:@7E5UDW(YA#DSDT. FHF="8K<)RF#2))D7?
M.%?V%[H*R9+BL?X"<Q5655 [<'I^9)LU-WW-;E?!09G1N,$$T>J).[Y2MLYH
M,Y)[2Q"0?F;[I+H1:P*1M@&S+FP4J\T9GQ\IGP($E;HTD[__Z8N(BB/).)?7
M3-+W\C40*_SRQ-8+]7GU5-7^7LY%+YBAW@S=HMO+8^6!$\?,."/#TG6T&;]%
MDL.!60MW@TG'+7FQKGO?0' &4>GM0&1$DWY,$E/K,=Q\-B+ ZUY:AJK$:&2\
M[[68.+1HD1;/):E%;6Y<7E";U\OMH,I>T\G.[&:[VK@*;EI=B6)$XUOO;=3*
M'QQ]?T+S%6VS%[;(JNL(=26O &GL514)A"IH3S3;O@ YLFV<-#R5>#5JJ?S4
M:F Y]BF@I-E/Y'P-+R3K([B5MHLBA7#/8&Y(9:\A,>99"%Y+2O-/Q%0S6/\Q
M*VPQ5G[BA"0MR\_?BN4)&?BX$)S)0]W('EXQE\%-9'+LU*O$O[ DP)KD8TQP
MT^0155M,E>T_E+]A[)>>,Q>Y&;^5H%%M0G)EI_HMJMA,UPI)#8$6M!:R9Y3A
MKG6<))C:0!(VE *QA@:9)0Z!AV_]6_(YD-M*_H:_T7BU0QD2*\Q^HW$W#>$)
M$G#SDJA^;R.,TI]+2RUY=YB0FB_XG=@\@'2E F(J4$$AY+9@M\LT0:3;CFP8
MJF)W-@:@%N9?:6;FD[S9-1R5>,Z?9L"[7EG?L:]H"GIE4INPG6(YW9"7H3_^
MI_,L:= HQ"+:6MKWN7FG9GTB$BM[C2@"? N/DVE!.YF(.;?D7$'F)^7$]).4
M,R$=I'X6I(,C+&'0ZL9W1\-+*NMW@@-+F[_1=DU#GKSDSV?5_1 %'QC>8&)A
MB$4.C,K$+0X/9 VL,[G2>M)Z,GEJ>B ;YW .SJT6-%!"C)"&YH C['Y&H1P=
MTR_S\IWJ CN>^=1HB/(X BXY!SE8?2F#2,JAXJ1[)<ZX)0M<NLQ\+,Y-:70(
M'H]PH+Q,2HA7+RJXJ"1G8L\7?:E28>L30XK:I0J^JW343@@PYI<]F$PI,&O;
MM6HX\4\^X!:=;<YH*3@_O_$MK"IQRR^9LSFK?+UH?XSR/2_\Y>I)$Y=5\$,C
M7=":EFM[$$!E/!CM_1P):3*5Q LOEX;8:I=W:V8)T4)T(5Y=S*RSGU\+?0IY
M T1?B^!^A4;\"0\(!%J>Z;Q>&Q4:G(46I\0NLH*/>OO5O,PGVU&LC7P;$[J(
M6K<42U*Y5]$]OP[P^\:KRWOZ(I#T!XT6A1X9'@E7LJ!@05ON<U?7!$[,P9XE
MQ#W$&<";>_*ZD6O-;%8BO_AHA.Y9U*:CUW#9SZ EF5?5E)$-I$:VDR$VD2.?
ME70GSVYK#\O)J6  _PNYYO*()<W,;+@?_KG#7EZC0T&&@%A%V7:E)X#_Y6YD
MYA9'!'<$LN,N'K7\/H/VL(.U+B"R=\<:=&#T/'.J>4MSBO;SR56ZL$%=P$L;
M*A8HEQ*0#"=$];B?W5ZTF]Z5+TZ_67I%_[EAWXZ?D'K%24HU$FM1$'NZ/T.0
MRN3P-&!^723#P*I^M&!HEUW/ZX2L%0GG-*GUBW(YEQRUG8Y&SK_4SCU"351*
M#!.M@B64FZ-JF6JM+/?ZSG?+?.0)-2>Z)JP/45$#<INDF<R*G4PAJDL$ZZXX
MO7ID>!V-@N&?NCZ\51WYV8ZS4J%*\G.#HCR%W6.(2>1:497*7"E-APK59%]>
MA*>HJU3%F6:N&N^20P0\9H3J<F07)=I',4>!EK@UD<*2T#'QS J'ICYQJJ/P
MF%8I6Q*2C^D8:V^X&%%/HGI[>C(VK$A C!HVS;X@+ZS>=)EIU+T*,+CUR$E_
M9)#$YD5,=I?,2ER,TE7<.127;<3]X4*B:TZ%N\A]LVY<*(P[=410C;P0FEC:
M.TFZ%AQ22< JJ>1W\D,_D7MF?^ATEPJJL,ESE-97W99WYKS<\_S=HU8_ Y@H
MU%=6TQ4OU7@A%!0U+PS(]C$H .V8,07*/SX&24 BL88MF6<MMK1W,TPL=:7V
MX1(FF:,</*:D!B2[-;3R./=TPJLFDUKJEVO-P5/)1[48YPLYZ8T=P,(CIGZ8
M9WN#<NZ:0*CWR>HUSW9AWOF,G"[U-_3HKPU94\E*GRDBN?GT,^NR*3REN?+=
M[_U_99_7Z!:R'._=01M33M:0#\FG5J=ZB@=\AQ]3 -.E4-^$!&_^;)&6D.@Q
M9%:VL5Y$L?&ZF"R<D0-63\Q1QZ-*($RVX5*364 'C YG?[?$[R7U6J=Y-$F/
M7<F7MX8UIL6THK8DPIC5^*"2U?9F@;!<2SW-RRGL>M'E,*7U0D=_>3X@-B'0
M]YQZZ9;3VZ$M=1Q/)\'[OSA':%X&>;JI6ML_E]="54#L)0A('JG8;J1X;H5X
M@E_^#**XY-!G/"J;*"><@2BO87L5Q :;SBPYK$\V/U&Q] "6#?1&=:V^.:Y0
MHXLQBB>H\T!I1P^8C"PD)'J4Z;[83?=&>P$VGH\QAK5XV?H?3CGY7*M$3LSM
M6&(+%JYE1K0Q4R#3]R]P4BN!%7W=NP)A'^R@-Q")U&=+!H+=@=BN_+N+&4FD
MA IL45G)^_LCZQK-\WJ*H@+S+F7LJC:-Z :EQVJ$T\5ZM8K#:46H\H!PT"G;
M0ME7_Q1Y@08P7%%C_^$HX,18MHV,E=3GF02Y8^D"!G>JP"8KF2ND/RAARA'_
M%2*G#U6C1K6<6N)B="=\*+5;2)9\HJ[S(M[M%75"#@_3S6=V.,$#5')V!69D
MQUEB7H*D':$_6)(:BW4[\!8Z=8J; X2"UA;'!G?)DXMJG>C[-M7.30< -QI.
MSI%^48O^>GK%TC]=W.]LC[G?1I.>L^>35OFHY;EEMHS"]UOW$EQ3^O-8+T#&
M"$_%NW#8J%IY0.0$MW$^T7:*[#6TO:[P!WQH.,1CUW7O$7GUF"!\RJJ33VIL
MV_QZ[?C^%0!^+<?IQ-<XPH%7;P03\=%5+A28$N2JP-_(ZR',FV4L7I.WZDFE
M]>3<YAWL&OO5S=:&E\*T=XV@<^$'QDS??BD^2D!,W' \JHFK4WE#.?'8O(WX
M-6-4#@TC8P;177&P"J7AZK"<%L'[I0:!80/%:/*FN+,3W"%)]L.5=NA=)'MT
M7$P"13I+,\<@H.@W&J,+:-QB5TNAPS>^%Z.T.UV<VF,\CW_5*.J>5Y":Q\2\
M!VHC#6-Y:VEDL;HQF+YE!.]S\I_WGYCK:/_AT!XUT2SS(FSA1G_>4)EY%AI^
MQ=YE.&MG&"*<#R>J<6,+OLQ_DPTX56"[R$R72809#Y>S+,(6"HX;NBWY_9>'
M3^%L&?ZQ]:R8,JPU(W:*F?$MKO@=.A5O/#SXJJPHR0DHF;^.V&4N^G<A?.1*
M$R)36!985) FR@M.;\OI%YU<D_='U3QL'9H6R/H]&PYVG%->K=EZ$5J:N_;A
MO.4I$_577DWA]^6 NSMO-P9%-0#V"!D]&SS=V]?,8ISKC*7] XNM<RK-=]%@
MJ#O^3[OG'#&68_S@*'HQ*<SSA:C"OM1!*]E=E70V4ZQC1MV$#%40Q35[D7'V
M7?+, U*7?I8?Q!%O_-I7D8,WRJ+V]5*T7&ZT(X>R,*I!5#+*\M+JQ0YS>^G%
MF4UOW?G82BT-Z''YITR&%V]<XC)Q6!XMJ@JC-;VA871YPVB&;V4%!($T<Y .
M"Q?&N5/8N><.^0]6AA&_T;0%"KWI*1G2ZO;)C<.;<[J[+>BW[2O>B1,5@>!A
MT*2M#/K;E=L63&RSBU-K$8XI8%S1;.I;=5]^!@G2>AUF,R=@:^$$8CN8,C^Q
MG?CD<;OYTW?J&V5"*<\XY5/$) $N!S>_T:Y9+X-2_M@](5,I_'K]\?.7JGMB
M)>PWXLT +5N/,4? FTD7Y\SO.P(@CMS.](F&AKM0"8N+ .,Z^+E#0,&$2Z;G
M$H%*4:9W=$3]%H8YACE7O/!3"_ '.%@8#1&&A67<\_G;7/ W9'A65DZH:2TD
MQFW6*S$.K@3DWU_=C7K>_GG,.*O=EU2T>D<4JJRLQO=F[522+C&;[;%7H]=@
MNQA3K6L>A547F2&C?Y.P4H"I3X;F/!FAP#5[:, M/_/!(F/ABVE'HP>R53%_
M/9R*5ALG,D@Q]F62+CVL/&7$:?PBT3!^>_3[LD/4I&],8>V\I(Z&79-?FVN(
M',G'>DV0U;D]6*([G$@YFLS'JM2";$GXQ5>"J(*H4N[YTUK&TKEHPROE,1-Y
MU74<!;Z&8M(>NTW;)QB4OF@X^UJ<"M'Y;<JI[Z_(=7Q0@^(D?<9D\TS0RB0D
M.[>G@NV=LVD?8%7?$OBJ+;*#-'5FT&RO*6ZR ] C /YH90Y6L!OFF4FW5K,_
M:NRY U/#UW/XYQU.U9@H/9P3%/QIH^<5YPH2UYJC?QK%SRO"N@''F-UW_FY$
M?8I<@\&&1;.[R&M=^T9GAS/_%4YO=]>H$BW-_3W_O8"\R=D*<U[2#/7E_N5\
M%AG;Z ',2I9?L?ZYH !9Q/63QT(%^(]I6#T\K2YCQY<HE';V/WAP9R0$5W#&
M%5*/LJ+>NO ^V:H^)J$=W>BVY!Y7H/F9F:Z.5VC6H?*Q10MD-"U*7D$_^3H<
M?, S%FZNBA+:3>3CO9KAR*Y>+P"W2U>](6.S&W:=XHF0<RL'5IRZ5XJRQ'>O
MN]QD**\[F/'JE^.9]*];*Q[-E]K2FCUY3$WW^!3C4UP$.1YAK#[X@T4\3Z.8
M3:>/$_%.DK%*4HMQ /"YOYT_K/E$K2Z+-V"_7LEFEF]><4"HN;&+ I#391A5
M#:43C-A;;RAM7PKO/1RLB-C%%-S(! &:ZH:GSK);1!K(G=U-MB:^=#74=F9G
M#@_0LN,!S\83YVZ?J^PG9:3:0;07VY*KOE70+M:<ZMR"Q'^C#?U&LW3E0!H7
MNU 6MS"C!CAD]<A:1-7U(9YNN .\EMQ-@$<Q4\+#3-"U; D'R80!?=C[9T.4
M"1$5!%=)_IKK4SU003V8&,.-CJ&R,^_*VU.^\KW.6OS=-N>-1JH!_@D/$?;@
MMYF>4?FF\LV6*<UW?FGRG,2V@SQFE5'YQ_Y,Q"U]M@JPWKU)?W_<+@-AC[0L
MI&B/X1-_ :A>39W+*K\#<9VJY2N?$%7AH^OGB3\^MW)J=H@.4"KW8?U2EE;E
M_-9:!0EJGW:<J#65,43:C,!VUC]ETC.B5J[691=2K':<^.FVS&1H(X\W&RMO
M[(OLUC _O=WL$(+GKS0D;.S0Y[!>*7!Z7HI'=SLK\J //)O"1T\E\ U32/VV
M<(ZX-JWM->E> !M"K2].A5E:&^QM_(SM)H2Y"=.P+$%])HE7EX0S92J"U'2D
M%>5&=5/.A=%Q 6(/2!* <D>6]@9&(&F\*I5B<UEE#**A2;\#HU<A\#D>GM?8
MN_\=K.N9<ON5XT@'5T:5';]B2V_0[+%:"2H5$XLFS2:5GTAJ!P^8,E-8E1#7
M! (-1M;$7051CA#:7$(N[-A[YY4[U2LN^)_'H:9)U=$'MG*F:"6_N1QQG5@R
M[ $0I+1XG*_7=<Q/MBK>%<QS/C:"BGI#&]GV#T"!;E7,_VYWI3QL<DS$Y'M*
MU=5?SXL1MU?.]>_26N^B7F:YK=C[W@!FTO;-QN+6"QK5,W^\860-@S@UM4+*
MB,M-\LT44VSTOVZ(JJ<H3T-F8JT@9K2GJQ\8T1*I0X$TCCJWM[1.YPZC"Q#.
MBEROD#XU:E++C^'7+]/*<M)<IV5A3*_ 9UIBM&JSOPA53?Z8</3_'^Q06ZU]
MLB[#%M('R6-6G5AU?\J 71R-7$O1V*#YVB<%VRI8IM::9FYIS!1H\WGQZP?"
MH+_NXEISP?])&7_A ;IS:@O!9.4!K9YK/%0J(I=:+T6G-;C^E^?*/!=OXGW8
M4,036P=Y3][X <L3K:0*L.9^1?3M\X,M\2$H921^0DO+K>N X^)M1LBE\^>K
M?Y#G@!\>_$<.WRDTNB\#JS9#6X1:]-YX.XLP_)H6-GEOPN*@DY7S3$ZUP<6E
M)B&*38&@QFO:&A&-" [KVE5\>_O]EK_AZ[R/,"#ICNVBA9F?XWT4!5,,);VX
MT$O&GN'55^JQE5R2J6-QM0==FZL\)?\MJ!WS7Q4C=L5U_S5CZ">AQ3^;%W#;
MU+^JV;_0_OU^)U2+/K?Q;[O_BVL<_48S72S96C)&:#3DNYWHHXC E+PEYOXR
M10K?TM'+#-.EVB*C.U.?'0NF?WC^',A<HA3# R3K7#HN$Q"=N&62V'%(.@RR
MBTHO5X1MG=U60X=LRD/O2L/P3P*O53\/<.&*^=%@XW-FA4._*%B8&&=E(?X4
M9%;XG^4O.?N1K!PXX@YQE^7U[Q_'LXR66%$+[$$"^PM0-W^KD>Y)NH"-4B@T
MFF6I3^TEO=J^BK3O"Y],E7TB,G8T7AFIM(KW]6/6V+XI$XA6D_P?BV(!5I@@
MK!"1Q8"KBG?^TGV<>T-8T<.Z;P2\MCZOA\@Y\UBUZUD$3))&S_^<RS(/]UJ-
M'VA3[A.RM*'OWMQ]ZA1(+KB=MN9-EPTCQU!3[ 6P(7E?/F'X/X=^_V=5%P<G
M"'>Z&U[\&-"A5X8@K-"<)A8FS-5K K$>-+!@"O2MCGG,#B=K^@R-XQ7"6U[*
M6G@C4.Y47!A9QVW'_HEH6#4;+P"8;]J-?@*; =Y0![V!DFKQ7@3@0U5N&,#"
M7S0+_Y('',A"+H9E#81E7;O2!GP(R_KKP)^RG.*11%E[J[$AZ&FR46^YE?P:
MQU)&=4WY)I3H"X0M.]\TAL:.H(9H:)UMV)--I;^:&VKVCQP\S(8&.JM:WR\5
M[A=1W>'B^U)Q$;$#=+.H^E15W\OHMB6BEZ\0,-84Z/@3Z.VL9KF4Y^L+%3]'
M:KH6LO0L$BA$@%R1;_R87E_( C?8-:Y&4%U ]TQ%]_&):WF,]Y=!S,\'3W?V
M Y!F9R&9G3M^;!)5$3_,=LRL^S>F46??T9\K**2U*A&XB\TP<#K:K,=K>?(R
M!8#^"WWK_P?T6_]X.U,=TICJ*KK#W/H0( OK7)405O78TQ_'0UCCY*\4"&OB
MGL:E-J42A/-"6S@=7A&V' H?/.18\Q, W>^]+1>04A_;,5-*-MEPWBUNI#RR
MAV?.XSWWYB9FX&4E"E$\2=,O<U4AMC-3/7"0>&&T,]R0-%5G/O )RI]=W[S5
M3> L0T]L!^]N)4;IHT.TJZD6B3]%J%]\27I]:W4A/[JW!&TL.HEFJ# .35Y*
M'VEU?+7I(F[?R93RA@3E\<TOZ1/3$=,.]V;K$=F7\'^*/N!HY9XWZ*D N=.#
MGH'L0>:XKJQ7"S])E.LKN@XG5$Y>D<*ZQ=Z/41PIL.&'R])$(M>JJ1TJ5,]L
MT _#I=1T5A^_;*YZB;./:L12R.M05[@IZ%UO%68H"YCL?C.BJ>=M!Z,D20D$
M6>U3ES24ZZW5!V1DG,K*'W&NK<>_*T[O'?@(.M9+E8C F.=B'OOZML'\ZZ+T
MB;38EVH%$GF0^_Z+8D])!7/^@+3:R?%V'&+6.,R%WG7:3^?#)M+< 9]@ZO#4
MX+1T?55R]7.]&JS0)>;_Z\(8_W/U+61I)]E&,,_+1)Y3=R(]H"42>DRMG<9J
M_&1($'I=6+CN[5A*"4.9 2-:1\7_#-4PJXV[CI03#WKC0PMU)[!\>8C-V5)&
MJE#@3R^!CZ=.<?,?Z$]N,B4'\V?J@OC\.0_7ALY_HZ5@%DA03I(Y7\2F_$:S
M6I,<F2;^C0;>XA=3TZP*\[ 3V3O'2KZ].+5L/!*189<)#>0LO^LP,'\0R =,
MT1! G?6P_,>Z^6@=?Z/5+9&W=*1,&WBF]75PKM>$VM9EFVO85@#IU'[6)(Y8
MGN!K]8V74;HAH-; 1Y_6!M">1MAL2M!^1=](-T//Y[&_8'<I B',HVC0#X45
M2OJX3,X*&6_H$ST=ZN(!4+-?I:HWO*V0#:=Q8P_Z1L<A<[.O"AX.@RSTS7?$
MFQ^VLS SI]-:@>#Q.40M8K%NS:107PCH>0DW&^[M\;#1P0'6VYJA?PQ3E.%T
M$Q\1?79!\&,O.<U'G=! 12_I8XX62CXFG$-U>)20F3M2 8 MNU!4&$B;KH:_
MD>R]28-#@IQ$7H8C[)\LM*$0XH&9%=@ET,_B4H;XW%G5^D$"NY%DAE+A>Q^0
MSQ(:T1<RWYN7/K-AT-[MXR0NK "P2SYV?&W,>UG4&#E:BUNP@;BGPG92<=H7
MAZ1OZO2UR*[(?YO>GJJH*"GG)\]OS6Q(&9]*T>_]C99DLV^18GGN?.F=>5=+
MVUFYY-_D3$Y3H,;MD3> $LN)U%+<Z8OKLZ]\)Y^2W2]S%6OFLB<EH+A<.\Q)
MJ:^R/U_Y[.6.H8F<HZQ0:KWB[F%Z9?-J\Z#:V@YIKQ/+H(H<GJJF+4NM\<A(
M.54Y9[-M<UEDXA8'G'-U82\>V3"AT! W:;S9MDH(,E438'VI4W4@\;W,Z7/?
M(">?4%FPT]/F4%;25Z(ZE3)OU"OD7L2UD/>(Z7U=K-$:S <,&@UL01N!;8GP
MA9K$@77' 5>#-I^I4'Y8(>,+L^SAHK[U>S0V-KH)+-IE-6W4O50E/[&6ONU>
M,$QLR00.:'-ULI!M^SD-(>$@*M6.#FD3&3^F>/4YR(-$@\3CPFYON>0R05][
M/-V(ZF5-M<$8$"PHXD4A\Z&3?X%"J"Z9X2(O5R5,=2/EHV.JM+=91RM&I[X8
M2^$"2"6IO+5#5)+'F.Z _:YYP6@P_7*^:7_,?IDWAF\-?2);;(UME''J4_$O
M.<?*0(ZRM>V""[?DL93A=-2"7WTO1PL3$^(^K(5D\W)6%QL]VQX4WCV ;UMQ
MQO'8679=8Y4;J6QOX!<I>B6NT:K#RC<+W,I#9T.:.@G<8A=RI8X(%]<<F1TU
M^<1I]*M7C([K5:&?1;JJ:BK0=/"H\!6YJ;%03'YP)2,X H^U/"NZ&%-<XPM(
M*IKF]OKI2<<1VAC;POG,B2DN%8UJY#:>E^*4@)>7S[F'>S:$M+LY2?I8IB?C
M*HC78\0D)X:%3=EST@.Q[(HL]HB<+"NCUJ-<%MNR:A7]1>&/B<,O*V>@*\=)
MN][2_F!$OKO1>[A<L=&Z<6F.3\O<&@OFAO"#.=7,7 T6I^>XFZ+$6879DFX9
MQSLULX0B[ @&U&Y>16%<.7[(^4),"[+*%W3$F84Y7,Z>6F'.L-JP*<%EY%8*
M2:)1YC!<<CI'#K^3-.\G,PYX@CI>XGI4$CI&ZV/9UQ)+AQ W30?BJ([9HFH2
M98^DFW@/V8PQ[<3WSKG,WE22S\R$#8_"*4"U%>,D2N:F?2&-7B[:B_ >BVW/
MTY5F^1C!P(V#4SV]'S%8[4'2,[QV"[R,'8>&6]2^Y*\# X&-T0B\W>-OV/+Y
MM0-EA6M680>N]P1!')8C0_;?;PQL;UN*9YIS A7T&P$GO>U*7R80R@=Z! 5U
M2&$>LL6-.9>Y&^=[HDBM:UYAEQ[G+BRWN=2V,-9>MLU]"HM]D$E75@RW*'=N
MZ0ZJBK)U8QF7I@Q*2\F4-)SJPA1RN!_]DNU0C1S#_YGS,7:V=Q%/I\0VU8\)
M:S_)4\49PF;^HJ*2Y:<:4%SE>2LU?3RNJ."%2HH&XTQ@Q_H+PWR]_ E\_C%\
M)[(FC4!P .-#_("/"5'&+S.#\QFI6Y@!%]+=KHU/$D0- K$8',KJ,+1?\:\,
M3M3H.FI[C@W&"+9=E)89@ZX-K.0Y]66LW?UVCAQ&%A9!%9.(+/[D,& _\'BF
MIJ&S-S*LHD>C[O.2D0)&TPC!"9)'[NFB*&\9^<'F'& 2UJ:0?\KM8H<7"_]5
M]4@0FU6*OK[5^<2QA+US'-@:-3PAQ:<94ZN\^Q&_/-#?<5B W&2%_YNUCZT=
MEE&U$1?QIRMSM/-?<1N@$W,HN%%VU>U7X;D=I5@=0W_.#PXZ=UL2F\F4Z<V9
M_5+!!3HJ#K64E3'YU(UC#YE?#2-7I077J?5 6=^K28T,I3L=B*S@W9"W< #%
MB?]@ M"907,DHFALVL2&AL/_X#@C1K*Q_V'H=!(6!29@B!E>Y=#OVZ@1M+-P
M27L9NC*?'Y#9:08I.W'>XY'APOI\,,JQUHF!V2+I>\B!G3LRPHK)M0AFQ>YO
M@7S)C6MO@<FN2DJR1187YI\G(8.B8U&)B?EU>1,V10WQ-F=VS3:0=+I6H\TU
MC$.H+6?^WF\TJ-45.68+1-1K:CFKOC"UGL&KOC+G]9R_&[B2"ETVV=IX97#Z
MRZAT#%EV!%V+LL^Z-0.YNY@"3F+(B6;]A*<%J!M:LP )G=*$,PVW6W^?O)FH
MA@EEOT2F_D;;X$3W*X!^R<Q@>.(.2Z1QK7#$=<ZZ8!YOPTXUJS'1WZHR8][Z
MZJ5L$6)M22Q4&/'.$X,NGH?@R0L7&D8:3RNCWVC'H9]GPDL;WX-^C&QV$*P
MD-YSRZ<\\>N_T?A%)AT5E3.O  "#U(?3&U3#MQS)*>A]7?:?'W7A3LT^+6VX
M2NI_:I1RRC/%5RFV129O1=0KQJH I]/62;]7F: O&6RE:_W%),+-0L\#>O6(
ME@EH>=!2AO#<!NV^)0H"\K7-D*>AY[94[NLFS1LV[4@5]>]T.0=^//DJ%4C[
M]-[AW5OIU6,+W.C\("_=>ROU_.<QGL-^LX"&X[PPATT YV91HNYN-EP:HYC>
MK!YBTLIFQ\.V.]@0+(A F"\G8QXO@"Y\914![K2WK;NMQ)MGJ-K<;S5LHI[%
M]A0^/L4*LD>]-;L1#@H^/!?92K2'5#P83TVR)4.9NZ;+%=^>(*H>M0IE9>LY
M"5[6.9P'P"0'EC8O6R13)).&VM'=8W!IO''O<P0OLMH;X></4)&;9E$98HWB
M&I;87A)86AML/9!G97F19GW3Y-(32.W6XBXO]?/X[,Z6RWE7O2C5M==]2:VU
MHE:!PXZ)?4/8'E:PL#-.Y!0F],7)$6B99<DP?+NW/O4)7;X2[IA/M$/4XLLX
M6N?LZDGKZ1DHZ'GJ^6<-\#^\/T^]#[FEL!*$FJS5@=D+RZ.C^QZ*1ZJAO4&=
M[TTE:_9=F4 (KO'>V1W.UWOCB15$-/5B0AOF'Q;$@DEO^-F,&D$]_-:3Y7AC
MMLAR?"P=U&PP:4&Z]P97!&EG9M2P;$:\I7_[?G:/>X.,T]N5#3"9!]!A96@7
M*TSH@^8&#A[I<>RP6(WY48WH5 FM&M[0KAX@S5'9,M<+TM_QO9HZ>7)L<*L<
M'Q?X?<($^#X!(#112*4]J5FK'JDJ=FO?2I#/KGLUY'EF.&7?H%3,XWNBG9-?
M4]R.S"6SG]Q8YF@(M7*_^/9G1D]=5'-L?B2DR/VS6!T &>6B8DB?"A[5A0 $
MA0\,T@8! @S)!A_"D-,RHA.BKQ2@AG,>Q%FE*PZ;5?7T3>.1*3%J6]@%-9YH
M*A,CE 9/Z5M" HKO!F=8G"6^,_'_3%$"?9N+>KZQ@S43.94T[P>T+>_9I.44
M9W5Y-:+$H+P\RIK(_E37;H!C:<K_V3#0[)RW.^?5"9^*UDZRZI U/(4C]P43
M"P!#!8Z<OIV=9E$<$+A,/@V*UU6(_XU&[FSYNB&'31Y=VJ/?S\ ^OE)1E-G=
MF#5=D4?!O@UAOXC/S.*RP:DS:+Z5#+GAG8493KL=[>DTZDIEUY?04PMM?'7&
M,.,^Q7@4N6[I>K WNJASF?+^B<5FB+A'D3160$4!UOA-9PNIUIA.9+:_&CN%
M&OU7MC7=*T#I4+"+ H-,8Q#P_/FTG=%H\-3QL1N9:+VO_5-^UZO2#SG4*<73
MAQ"?Y^8[&TMM7[)+6X:,9AG^C%X="&3.K!#$MYALSZ=1Q[Z!LY?YX^C'O43+
M0**/H7$D"5U@G_C4#]-.L^5VW9PO"BIQPXT(8GINE-E[D]S@E1T%.]=X=LF]
M0BPBF3E7%6$GD 6C9&:5LZC$LIQ0(YU +-3DCQ$M,'N"!X",J97"LC;>M$K)
MJ=C$6EC6PZ;\"EK%"A'P!1V)'*J8\3NF-Y,<P9KC%HN%COK8C*+J*^1&U9X-
M)F E06:94"$]FG(F9BWL;J@;)NTMX]A$MDK-X!6^-695]CZ-1%,=YKI)M3([
MH#%J/VJ-K$M1/5XS*F\R*I^AV:8RFG^:'TE5/QBG'Z'/%"'\*YTWY,\<(YXE
M+]:(/D)_)(P>_(Z)X(D5/HD+(\C34GGI%/P#) #0!!=/$A6PUT]Y8I1QX2F<
M<J:D@C4[];?BL?R&>QGQ7>F<L!AR6;"2?K'JB1H'-OM^"IKQ\64O/&= =_52
M1@HSK[,,CTS2RW<^C4NA5$=4,?>;%89=)=>GYF7CD]$]=CCM!DL,_.1=B\.Q
MXW;8" &*^+.72B1$^!--.VYH9R,WGD\QT6FL!>#TSU07Q]@JSI6*L-MY&LWO
MW?O!]A)GX0H<UOFF'-+E)A&B'E%Y4(RG*VR,&B.$XP0*6$<#.$P4-1^>O"%-
M("4-CZSA%07(-.>T*GLJ89^2E^_WD<<4EYVRQ;OWW)3COGC_*:U28B!;KH..
MRK9.>?'#2@ 7*5NBQV[X D&M8Z!9?<^\+\V:\23L<?I2_%@L@6Q2'S<N?X6H
MX#O+FO8W>@.S)+]RNAK)O8C-=[8S<0J'=EK[6/5L !-KO*D C:5^9*41!4&0
M4"RY(#:#+QYATEXG$S<"PO93D1Z?0'Q\C8KXQ^H^;0MS;:.P[N'DR<0M0?PN
MQMF6SDBOGK^*F[2&2O\PA+; .08/> 2&B"F7C&U#:W0\- ,RSER<BOFTMHI\
M]YG;&M>3-[OK]-GG2!HV27SYW+WUQ5Z*Y./S[Z#V)?"%J01I75)DRW[X*7I%
M%0?Q72&&RD,P=N T\\7F4=M61O?3=151%!DU/&5)PH0JLW^Z7$&;UCXSG)]9
MD;W/V241$*G<TD0V;3%I(DL0G00@$E+ES%>[2?>GS]&'\TW8Y%.+JH*L)FYK
M"EQ?R^AH']L"2.*3MO7EZ4+@<F.H-".+=8850(7CZ.J>NN&W]5)'%I0:'Y,"
M>,(_W0,$1R'<*\M">R$?BU/4MMX\OA+5,/LJ]ZI>9VB47 ,K3CZ^/Z/US#Y%
MGE<OOKZ<!.41+5XNRK)CO#P!JFLHKMSKZ1=@XC0ROU)[%K_M$DH7D]B+B#*>
ML]>3L$,&E6&BO=M;8[K26LV:QY$NVF)U']IJF^:HS7.R/(L@V:5/R<"9Z768
ML.4Q?!&V1+FVFSJ&C.)E#=)&C+,43NN87SEUT+=TJ074.(A06M;4HBFX4?/5
M%Z>WE84XI\DSE1E7\8M.PQ<>*J?PATP^!HCDL=#1N A:X@)*ZV?<D>VAJ.3@
M@H?R3PLC38';!**\O(IL2VIG/+BIUS7H8TS6V%^G 8(5'-9(P).X%[QF)\?=
M;%XC4I&"JQ1@$9E=$I+3B&DGPLU<:PN(* R=;*WRU_9K@PBM1ST$LYF4491I
MBZ9+HZ-+9F8/'QVZ(QNU1-JOR-PM=4QT^78;RG>C5AQ\^2U$FO@NEBU;VV9G
MV.%\V=OE%-P]:9FB&>R2$@+>% <XO(<D[0N0&Y9"1!7(1<%C>XJI^0$;1N)4
M-KJ\;#DOFM6@>[;1!9:B*V1)*3-8&\C8;B7S.B'K;,UJZQN9D3!6%O_8)IO>
M.UAYL^+!JU5IH\@3>=!14SDB40K)T;;/.F!:I!VUUY4@PZU4UE7]$'X'^P1?
M<X'E.CY;U/<>(%%30K^=,T# O#-T*LZ</%@4\CRH:(:V/(X #O%AWIY6\4OD
MK(J34-_4;S5)3V$@IHV,F$]7M>E;)!%7K-1A]8H3""5:P<#KB/*V/W\:ZI6Y
MQ2:) W]1\@NBNM]H/XTM6:^D J3P"+WL<_]WT&N28WHSLW=F??2C]/3#J](J
MG1B\)_]&N/6@NJ2VWE'W3H.W50;JO1^P:ZM,R-7JI1Q\6,*'N#Z3H'XKSZMK
M%>ABSN&SQ(] PM?*L0ZZ>#\WX+$Z7RY>V%Z7+@SZK%&^T#670K X"J'!$)/"
M5*FUW F-SP]C&OAJ\5I@3YV?OS,4%)[KR_]G'/MC3WQ0_)6@NM5%-XWE?&7N
MXRD1'SK03@QW3.7XQF[/P=Z]7HWS;/U*HY9@I^L &H=;FMZ^VWWI8A08/#6'
MK1?.@P7.'M(<TMEAPGVU,XJ?90ZZ87;HFM"N(7/%GTW7+R"(&C#"CF!N/K3Q
MY"6OJ!M]H;.R05:3'D2BQJ(>G)HI/45'(\64(#1B*"]R04=#1IO-0A>+UA/L
M^_>6,Y)T]A@55?YX<A/)R:O7]XE[YL2S*$ \8FI%>&,M!>A&@Q-+!2A9E,_A
M>^;:<B6J*'99=S!C;K7Y]J-(AA8729QA&AB+Z,G-D=2N-\:W.UA-#$V M)0M
MBF-RZ7X!;C=B6E(/UL^9]<#1G7F_BG)]&:M$5R_"!?.^(F2)(ES9"O7ZA<]I
M U\N_R>5D\N<*;3F +QM$\WLG-A46WMM+*T\-D[\A&32[%91>>RG(.:/OB?7
M;N+;,B5&S1EXTY6^T:+\[2]D+05)Z #= [NLN&JO3I[PQ>VT&A62*^,\S#U7
M8Q2PW/EE:#C-HD_"%2_XD4FNWFL%+)3W",S\V1S,1?P*_8?^.S1 "!X>$(\8
M^*>8UOXW!47^[R47_:F^!'K"0.\=&A85>)O2QXB39N.10^/6_1%7=\MAO,!C
ME8EAKB]*'UWY<D]P]>K9^!%K!9\(-5B/+R;V>F5 %[>"!?97ZNOTP94[=\'?
M>X\< PI<B46&.BA5'@T<ZFX'U< 5>S^3F+F <C<K)F 4Q%ITWX:FDL%:!* ^
M21K53R[Q]8/QB;P]RGN+9ZD="H*U'U?-!Q)$GL3\NW<@?G3/9('' :<)W*[K
MZH!79OD5G!^]F,E]09YZ?'WUI36U9,"!Z( \C;M6V60JZ1?1:^O/"#S-1:U>
MPJ,/!#)\G]AXWTN[*!%^[:>(2VT)_Q)4\RBR*;9%5!1ZTO;-%&>3:@D[.9?X
M)ZHE#\$F"[P.;P-:N0VL?L0_=K\FS+X5\@I6>\UF<6HN4BZ'!^83LWOQ_?]-
MTM';-L]IT"_[WLMY;'Z[<K*([#:(E2W)!8?E=^X:I>>,8Z<#W!8_%]OZJPUP
M];X\>$OKVN@>\N_#GX]MST(BTNEF1=)9"<_V'7/I^J6[QYW4$3%?@2&A^M%<
M2:D.ZR^9$6!2AU;MHD9'._PALYZ)N1JQ6C7Q\'7AXFSOZ/5TFXVX005@LC0+
M0RQ\>#@L?#$+^6CW'ZX:T=]H!Y_AC@-9&:ZB-575/CQ!<"SB#=^T\G&N<W,N
MPD%!^)*5P!L;?7HP1+7F#>M,V1<,C!;QB[JBI/Y?QZEW HP5VBZIS1['9V^E
M1\=G2S5I0M"#4CQ!Z#\ )9E1R_$\?V9T$:/;COVXC:_QZB4<,SK+SWOX#P%@
MZZN:B,X8[=1,K=-]6;;Q 03K\>W3&::(NJZM]\:%(_^E45S#KG5A[= M8%3G
M[D6X7N'?M-O529G_/>WP[XQ[^:5_=X[%DOC^AZ=_1$3Y-VUVULS+<;]W*#6H
MB-)Q D5IU#]>;8N:NV</8\3#7@!9:RG;ORJWOZ'/^C_J9#4+M ^ ZV.OCL^<
MC7Z4:YMKWM^Y&^CK-\=,(1V@J:,02DPJW.KLT*J0F[:B6;<D+8ADPWM4N>4E
M$"/^_9P#H&!K&U"8WH4X]W7AC>M^$XM5OS^5^%4P.VEPBS(]X0PW\NEG55KC
M=^*VE1E+=G,X[4<[-8,K="'8@<5V'ZX 3U=> 5EX,R=V;B=2L+B'K>B;=H93
M;8T%=T%5P*&RCQ;'R=8(J.*^=YE1L9EM TH_*J_&<,3[)=GN&!Z4T$V&F=#U
M$:]0:HNH]QMQPG\\S]//ESX7&_"]=@C9EB@)']#VPZ]I4J]ER!Q9,\WP>/1#
M* -XJ[2'PA^4$ZFIJC9=\'4_75[/W&VN-< .%X0%9F71Q+RZG8XN^#JMQ!U5
M/4+6N/T! V8%I EX/Z?\ 6 4GT&U$W!T^9-,'W2JO[0F:\6!]NF$^,, 7SMP
ML>UQ/U.&;#!\[ UVK8 U=X.14V:L-FO?#X _R<GSOS3D]_;^XMT<'=O\8X%=
M@$ZMG#A(SOY?YS>5.OFW26HOM;I7B-,%.M7=9W?8%:S'");99+BJ3<[@38>6
MR" ^,L,7RJ0]H]@D9)";O]&8IAY,:=/:?Z.U<1S9BC=,/988:97PQ1;+=-G7
M:)$[YT*MC24/F#!:@79V/($!>:LOCR[OEP(UW,V[V.H#L7>T3%(/4D[< 9;8
M?AT)2+]T9OG(>=&0^E+']ND'6U]//3U,O?O[#H+&6CR^&L+H,V6.PXVM(=[?
M:!GP#J=OY[XYE$%U13.B"4]\#BI(/$'$GN+MTS]H#X=XSS/"JA_"%@W2D B7
M"O]-9GC.XB^5!\MM3R#P!67'@I9%3F&DKHP"#!@H!F&=BW.D^-8Z>(HI*DE[
MT$/[?A@W?4U1N"[+$+,MW207=U0_A>'>:K;S_>YP>HJUY4XMX(YH1G*EIIJ!
M(&EZ8:PUW<WI;$9/S[8URJN5BJIES'$X:M/BO0P%D9TTUHDAS-$5W*98':XD
M=O+THUA'"E])'FB42 ?#P#(^BK42SS5SBS&?M(_5DT6A+EX)M#30/K- *J>5
MF?@)'::H:2/''8$<5#E38&AQRI,WO:C8EREJ")5;KP<7I6:_SCM:<TD:%1BP
MXIF0LU0CB,'X@%9A\,:3!2OD]4^L!GO2;HSF_)FKPX#2)6S+V)GYANZL#,L5
M\^U'*9U7;-KO'THC^OKVV"F]GL2GF\2E[^=G[\>+$J1Q>,__1JL'YRUGV?O$
ML)-I=*ZI3HO3?39WC<$-3__D&=]]_DHI92"8J&A(/Z:()YYYMXO=L$[U7N;K
M9)I1GQ)EX5F[0)^Y>'(MX?'<O!FN^)#<Z!HIX3=";CG:'M>Y&C;^W1XF\7"S
M8*R^:R^EE6B1YW0C(W^^SP\ K:0+E5X9G"Q8%EZ&7[E%8BT[4A;N6K3[-;&T
M(Z*=#EENT:\TZ8T40W&KJPPB#H<V%5G<//WJ]98K]UD42DZB*^9;'WZA_'2#
MQ^M?SYBRTX7%>40;ZN0YEGLK1_U@0EW=:+C1GS2U)#1)H</-O/)$JT"">]'%
M G;RTY/Z0GV^DUZ@<V+GM1U8]E"K/:]1SG"V$*WCQUQET^YB[7=D$9KI!C[%
M+9/5(":+,U@W37?"C'=G2%_):*3'(T4T"6(Z8ED*5]F0[\9JZ*EU#15P_B$*
MPKAN$VDB[^.87@,[O58VX4$1$[$;_E83RYK (15WVY*+HH:.T3$;1>XR^Z/B
M;I$S94N/8ZTI3O"%PAZ2.T7/R'+6N^,XP919MJD7%H<GU=,NK-Z_M+_T]-:\
M&""S(]I&_JV<I>/]D1!%L]4COE"3OH^]UT>'QM856MW<F$VJO$LK?1E/82L+
MK/4A+X!G DIZFP.,F<8EOUS8' 5XTQ!KL3OF'S^9T9 <%=2X@DA>UGVO^7AE
M?;<]7>Z1[&F$LF^OG=;+H4L?,?1MW#]K=0X70N\WK*"71YV5]M!H9H%XCKZ'
M<*%XK'BR[UX=39Y5:D[QLBZK]=2X2FM<NIZ8UR7YZTX45<;#Q*<6H@$*HL)F
MN,2M4B%QH6]MTPT\.PNA1E,S-VY^VELS_'<B0^Y3@FNOW?#Y:5AY6^(D&=<M
M-ET_/(SCQ;F^?Z\V9:%Z<'#WETAB&M6.:I<:C.QX<02@;CG^VG4'C/\M#+DZ
MY0-.S#^=P'<,=R$5?M\*O.B;T7Y<WO*,-4XAV#BVA14HV&(T/=$TFUZ4TR_N
MV]S(2R!XE_3-^X.)D *B\R1-/L2VZ0<CC8VA'?"%24'79?#/UY@$A=6I;:)?
M"G%$<4,*GTM2*C[Z!'XYW?GY!2HN)6V(QM5UT(H-+&>AQG6ULVHVZ;*4$ 1$
MP/A_H_FIXB[U]J7O-]\*FC3+'.KI7KB[E;V7_]48.CDVX+.4CXT*ONRKM"M,
MECWS]^TJGC&)AUH?3#$1I-+2%EBVO&R\O_(OKJY%3BQH*:)S ED-KXM&D)YF
M?F\H#5!F);(3O]%R>,S%(XG?(])?NN@$8%5B=O/Y5_NJF@F$OK/B;S#HTLQ_
MI=MCCESN'=IR[ B*[.NBW;.8U \D'@]J+%</0<+0::IHHO'W46P-I6.;'J"\
M.D]>X<7HS#Y-1,LM"*)X$MO'.19J0KQ=I?DH(.QM+Q9>6#]II'X,FA>.-RQ^
MNE(3+("9R'R0A' -0<XL=(6IJ-I!,\LCE\2VO]U9K-G6[7'F%16"%"/3MQ>9
MM4QR(!8I; $8"I <5I$,?Y>]XY]UPTO#\3-,O]%:V=D<SB51Z[_1D.9!_>?)
MGQPA CF8+((YW]B(7VQ<$O2IW3Q0%!_\1I-G)5AB<*YQF&?Q(W]O\ 5T7A5R
M+V%S;CKC)_,EZR]Q/"?)>X2)7E-CO47S;S1KLTEA.TLK#8>1+S_4Z O&^"&2
MK(0WKN,MMT =%%^J6VQSQ/\@[RVCX@J6?]&)$@($$CP0$MPAZ. D$-R".P1W
MA\$A(;CK#$Z X*Z#$V30 8*[,Q!DD,%EAI=S_^?<=<Y:3^ZZ]]WWY?7>^T-_
MV7NO[NJN^E7UKTH&%HV251OU4SW?0%NPHH>S\N*<H&-/M&"A8=B5/R R%L'+
MZ9Q4\WR9>$6(.3W;Z_!WI:\(.Y7L8WZ]=$W)RJ\B\W*P3:>2C_8<Z%$!OD$>
M.2GJ-V)75L%SYXFI)FJT%E:85KS$=;SF&]Q$RYI+[?7/+A<^0VYY$+X=X]N+
MS?Z/C<B]#6[8"/YA9'EY?O"6NIJKH53-K$WM)S*5H4LD"';YRI.0EM;Z[&N4
MX$OA.AZ>UE8>IO-5QW.EF,5=RZ+DF0;7>6O#WN,;/>QSXM\);2N"V_T1FTP#
M\ ,DE22M8D16)EF:>7T[!2?_&"L^R5V9J(F4>D/!"83.F$V[O*#6J!R%L)S\
MY'W8V))_,Z/\7F6K.7WY#J+VZ:66I[LHS?-N%"P/M.%+)<UE-'7M7(R+\7_5
M(4Z*5T*/[Y;,&5 CGL%;<:0C5>I[[KE))[5GE7<,.$0_BIQT&_TB3OMRAWO^
M&\^E(*$460*0G2RN^B=:^%<E=3NS"E6TQJT_(PTVQJ5H-#,06TH\H=3"ZUOA
MS(66KIWA76D!]"B')C#2@51<2AH'C6S_4?&2W&XW=X\J-KW)C]C%T7"U6(=K
M"1NHG0#,P65'<> XM7D&L&/C9A24IBJE9>6F)U/M[,PS,3^(F]UE0+3E#*=4
M3Q_LEHE#TXIDCK,5.]^BYP,MMSD"&-<YIBS$+VR-,5,=0^R!VKZV1V_J3NB7
M1=W[NKO@WK>J0 7A5M^79_W3PYT-D\-0W*,>'F#!W17%X!'>S*Q1(/7.8>?E
M\D^G,^Z+_OE.8<<6\*N 3FU?XT[([<NMG,BFX48&R7N ;<$](.I6*4BVF"\2
M>=Y)9.#W9G*ZLOLAWH91T.\SG#A<2<OZML[:I0QH.')8\/@3;.6U>GM</0DP
MEJ^_"@JA3>XVX:@!<MP)BA(D-%\*?XMP00QS=M\#+)&&['NCD_;7@EL]]P!P
MNG$;2J'/7PC?SJ7.[AY@"KGM:&'';!P6EP9"EV_T*Q2_\MS82=D^WQP?GJX
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M_:1/R/255=W[>4,7I&Z!R_62D20.N(SXP%(K*]K_QBU.0\M6+SPWF]")T5(
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M?=/2DG%>V[ZW?!["I0\NENH&7;HX^]2]5! O1"6?"O@%*_&)A&"'VJ+"_F2
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M'>%Z^%Z-^YKSM41_-CWX!%P;+<1?D+V__@+!2\TV#<#JKHH9T,MLN6N.R$D
MF=I0'DD>I;16_>S\ 6I$M"F'QTI6I$[%DT\/[FV;.">V<SMFD"%%/AV-X1,?
M5'UH&S.*>*//!^W-P7,]#Z N]*K9*F)\58*P4!)G25-G5KM$^])KV&C.DHX
M6_VJHP^B)[O\C*494DP[]$<S=EZ7Q"W6\DOI-%Y)*<V/,!["'):;8#M ;U+_
M%#]<R!D#7*\D>?1[EF)?LQ6.5R9=T"<2EB]2\VM#"%H7KZT.#(=01#.NB>-
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MSFB6;-A3Z_DS?3\[6!<!OGIH WUPC4T0)\"TF5*2+>H@Y=^5S;X\USJ=X6B
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M0\9OC(S"P]^%/19[L.YA9$WS566XDGTE9-+6*Y?ZHL47)*# 9,Q4X=#F/1(
M@1$U [XS8SJ\E&;^ 9+[5PN%^7T98"A_(2R>FZZN0?7P<6[(?., KW(PAT5Q
MBY7M,.8;?>KY)/HB2$FL'N6]>Y<R^!/A2O4K7BM%_-!IHTCW*XIHDT!7.N18
MQM]Q)+Y_MP&L1[]MZTH*0*2G6[FK"2,RE_P<;8JGQG3W$$V!/ROMOT0V4Y*F
M"@J*N1"X!LTGZ"'7<\WFD4I&0CSPUEV7S%'1W*AN71400O&"]>A>?UC'&E]I
M%BP6,2CKPBW:_L&P'A P2N#$??G"GA("<;[\;Q)-<-UTTU@^%CK6LP9N0+:M
MSEZX*6'F94WCY>%&$4\.<ZV5JW5MT,>8^F!NR7'M]B:JXS>4<O2K8SDVRS?C
M"$GH"%<LA*W3&9D/)Q1,7N1YL[>!UT$8(1GTILQ5,;!N]PWC+Y&A:KXX-]+%
MNYI8MX#&LZ-G)/TG T,XXF$FT>7_'?3T&VGIMP[T_SKWUG?]U[TZ'+[\!?N8
MS1,Q,?L.=^-<P$-EO'>\5*B?^ZPUD>V"H_-#A;S0UB')>W^HC!B24IN+H7'&
M8/TA8CKID#[@+56@F)7 4&O0C"%*4,C"M*W"\8%0[J9!.-;@7#VS"HS;ACMF
M*=_T*NCUKXMA<MG=!C]Y[( "4MVQVK1**!_70C5]C++#QC#$1LE[$M9G^N P
M-+LY*U[A36Y2Y:1M>?SZ4#+6M70O;47J0 <]3**#IP@O?.(-/<GP5]!^HKBH
M^K72AT-]V+#-?T(=/VO&K;9W:>LQK>@&"Z=,[D_UDLWI=7VKV:>GEUV_V%7^
M$3F\T&NY1PX/L\=6+1^4AGIIU?^I?8&"]>I_>?T7GP [+13.]'/IM#?]D>H]
M6@+'63<_)S--G1+7Z034B/Z)MT,R=HZ#%?$?9Q^XW%1U]/,; &NXDCX04?2E
MS[*"_QWR_B]? [P@=%VV2M&))#;XPAK!D?!F^F01Z2G;--"4V"XJ40(]W:DX
MQLIWSI >IN@PN/:K7;12)Q&@PI:#KH^PE#78# NL*_"1@"A%=]H(LJ'?&\W.
M;I= !*(*=:6)- _.CI:]XOQC=0P\.K49[$RH&>?VV[I_#3R7U*8B@&JL,?T$
MC-*3^4+99+R:U'NV5+LX022&/87./_Y\9-MI^Q&,+H..^J-MKNOOKA_TOQ9/
M7<E=_LG!LNGIR7-S/O_T\664^8?\ <CLDKSM=A]'OK8AL.V!C1"%>J7R33N>
MKF\2%MLH%3*F+A*AVQ[[[!NWW1Z<[@8*WB\@!YXCK3)PSJE.D>6'XND*Y/!R
M[3)^]&@X^J^COVMZ>B*_NB0HKBCFX)*&YY'/,8XU2ZB'8BDGR5]K>?:=8OC<
M#;I)?\BLTV:!B?>;B%T9(*:$$0^8>'1UK5JG2!?K[SD66_C?M-6UV/[-;/B?
ML?AW-V&5S7^77G\A%O._[5;2L169-'*>AD[J @2(9$,F9SUFK>#$Y7 2K5_\
MNMV.$+K(*34*F*8!Z6H%GBJ7 W,CCZOSW9CG7AISJ1*!%L,P;MC\U[2/<2:$
M.VOC%G?<7F:O&>KZZ8G^.J:XI^$\)U;9/$6VX)$MWAF@I3!&!@IZ1FK_H)2:
MO1VQ\Z)8CRCE^]N'==JHE.H=5P=;S+8P;*>S%BF1A0\G3\](#ZU6MW8ELLN-
MLTKZ6OG?$ @VB?S)%*E?4Y.7EEW=(*:<MHWXTN >A./\!$R>-H@,-8I0>"G3
MLIA#5K685QJQ_=!26^_DTCG,4:8_OCN@].FFMW^HQ.GL[#O^\*V6Y<&NC7<:
M5&4YA7.^^#014_XE2TXF56*R0JMNS;6\CQ9I&NTY\+ JX<P1D=XB7GL/SZZL
MH3OA2 9&Y'%N*7=]EQ=2F8C4,4S #FT1G[3NIP2@JW0Y$$8[S-29E#@T7J)]
M:"6! 7 ]YA;@Z9E[L/O,3'JMN0.4>4[AT?EFCH*<)..!7N"*C1BIEX-X>C>[
M5OUZXXF""_6E9YJ7PK#&<3L]>L] Z[WDR;IJQ]1W0I@R&F7N7#Z3_<8S$MZ1
MGVU^XVM$ENQ)K::B81#]25^!IYH<0>Z-EU[L8X%(WU"5DE:0AE/B"#1S1*U[
MK#ZV;RXP091<TZ.V5)LW\ETUDX2:=@5'8K0TWF=5(M$Z283*=M/+&E-QK\M=
MW6(U\=\7&],%Y@=N%5)G;:;(9L(.K*Y6MS[ON)#I]O(EBZ;.H-/O9#&/LP_W
M=!8FK$LC&WK#\FFDRQR<Z5RL$E?C<X/DI51N\=VE231A9 OATQGO7C%/E?A'
M6Z&*AQ5,/[RM<^.ZY8?Q-3_EB]X_2CHVO3X9V8F7UATNLTY=>0K0F]'EV&I8
MG#@$2QB,[:0Q>%W7J$1HGS9VF2[OI#&>BX"!BX8+U:(;=UX#F3JB.J5+:[8Q
MWZNFE=FB>RR\ ')Z"8Y<8'1OD0B(+0&\?S"/?S9]%A3N.6QA# G]X"N;2QF.
MFG*@[P\@,:HQE-!LFW$MV3X3P936-/WL>>;F&^+?@4-)A$(<9?:I;E8VN8=
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M&.<53&![WR4=[8HEU2CE:AMAZR(P+"S=0DZIZK?AZ[HK=V^%*ALQ,(^2AYI
M2_S\X^3=54 ZM:A,OY2MR1"B=<S5;#-Y8?')NJF0%WA2GEGK8G1 =V7>7\Z7
MQFAFOR1\R)B^LP?%37!MT#;9!==S)-Y1ET&+1<<HOR6(,&N5?D]%;;XSR/<F
MD!30GI9+"Z4K+NR[#D\\L;>H&V!S'6#ID>VN<G.TV^LK'&#UK2PR6N67AX4]
MY37FU=A;<$_(IAQ?8L;#=QZ>@-)[#3@@1U>@M#2MG/3>MSAM.8%?T$"+O3G_
M=9AJ'Q=&Z'@W.XS#;K9LWN7SY%]+AD8*+.[?'LYYU_RRTR\ZV"[I-K,HKT75
MW)S1!*'@IZ4%0?"U^:=Y*S2I\!ASZU?:PEI_+*K,W(^\-YZ14#T_F.%Z/M4D
M%]K-0&+%XM@V*N,;*"]9F<6V*A%H"Q%&D;'MW<S\O4G,&V4*K#TJ8FO'E%++
MHT5?+L1HE"#%3=1=1NC;$Y@XT^"1\1.80\$=S]R'T19GVX8H3H2<\'Q S/RL
ME.(P>TIX\\: %W1UVB"YK.= X- /K6GAC&;R^T>*V[S<F@5$I;-#M\?AN?7O
M1H-,8^%J#X*MR1J_;>Z[?5#RXSB0=\T#8] +PS5]#>MIGU$4VC5T57.D<O!P
M^^CF8:#W<Y TR[+_C5!_"\0]B$-3-^MPI-)6'I^GGX0TLS,!(3O7U<'G*CQZ
M)V39'M&V6C#(P=4N3BY7)<F2JFD6GQW*L!:1MEWM,!3^2#5" QMX.J/U '?I
MIWR?3V_HL !3,6=7;#KC)S7HEVR7^2L[W?7>46A&?KJYVQX\5XU[,=+)&>SI
ML+89D#M"AK- K:+:4\IX/]8SYT7GX^>G(1K6Z'QE,![U=FU0?2I#;^TI*GC=
M6.T@)_6,\F&;YLC#28D%8C[H)*'NFN'[?V/7_!TW8*:1VX?;)F^ E$%([RDJ
MNEH3OSVU*[Y *T6H&M-KDW1(+P'5:-._=#J7Z>PDN"FQ;",@_1\[UG]W.\\]
MI*=G]L\]#O^87J$=Y*JM7TAX-+MF8^+Q:+_G]>&$3TQ^=*C"PB18C?11A$FM
MXG[GK!SZ.N-W04L@.*EY"AH_[E0#NSH'R/S'3=U]"&].\QI(?J<:[U'%,MVL
MU :H: >GG<X5\0, _&E<W22^"@=K8G\WFA7=0F27YU/3:]T-=37L+#AGKTC"
M7W8**W0S8D8:%+ST>BD>7?8]:S,Y$B7PZY8 4J;A7KF9/;V%:>\VUP(P)C.K
MU('1F2S]E 9",*@:R5 Y285R=@I>#V1JZX ?K!T*"&"_9"?P_\>6-"GQO)K'
MG\.>P,F&"<I1E6^G4&U?7!?3VFAH,$=54YKLTN:NU<P5>4&*M/VY2=F^RAY@
M+CSBH46U?:%_$SS?M\%"3@H!(](.YI.2ZTQ/Z:('<W3\=68EDW22BSF6N^<5
MS&#YD")2DS3&.-U\57]5KB=S?K,2W]_?@^ -%"G3,OM]#X#^B$J5,YX-C>%_
M(6TNZ_"'Y.;C2\+XA,? 1D'%!F!F'G=1CV281\4F#XGO8I6[#R$-Q(&CWL-7
M?H4ZO-1V:G4$(F @($6%\F)4?Y0T9?#+H3!)J12L/7.&LR:KA4Y(WO"CM<HW
MQDR1T4:0)^"L1^PU1IK_*#&@<_*LM-D]GLJ78260/?0#"#4KE.-;)$,V >IZ
M^.NDSTBO_25TDB23D^M,#OX+V?C?:[[]S__@.6R=77_;="?HB7']SJV011C.
MD?K7MQD_CC]))\?T:K-7WW4MB%9;/\/\,PTFL]:/3LX8Y-)!YZLB0!8/@9;<
MGBX."*;M0:N["5KY^9"T"M-5N6*>J'[[ZM*ZZYAD-"FZ50CFO-9P[7KL,LSG
M5H[A03!5,7^/AIQ 2/<9F4RUKH+HFT,EC -?I[^O0(?*H6>1+KFA2!Y,5.!3
MR%VCC!+3&#0T6ALVL&XMJT89V?SV"S@]*3-/QC2XJ2O@838U.IK$.'R8$\=.
MY-V_(#C-QH9[.!>Q.)A4X$_&, A</&!+RS^;WV?1OQV->O;!.VM++JTI5K^+
MRVG(](HQ3E/W:[V=U^NRDX9L+''1_$H-AUG/-&332+&T#!K<+A\FAR'[OE<C
M).4#E-PX(=W<]@.O,$K=S,R,R)8_PDP<'M51S^Y4+W]"!7*MM=E+0#'F&\WA
MT4F]Q(GF740EKTQ(?P<RL/8R?R>2>+V+[41H)C(^+^YT<?$Q2L9XK5D[B;I9
M85&<-KCN<X^Z0]Q=AES"Z\R8/;/0+D]%7=GOE#'WE__7T6AO7F9I/#/F/&S)
M]WBQLI2HTB3?6*5,C0\HD)@W)/[FPA\=#-6U-,[,ZK.%-*=/"@BZ>HKPOJQP
MH?3^[MN$_1+02J/<WP=&O.\D)ID86,?CZ&<,%I8%=-Y/GA-GN'!GA#,ED2+U
MKFJG%N]O7G[U.]N,/EF4BZ08C,+"H3,Q?YW3E\S=DJV'#CUF/+81@AESOYG<
M>">DPWWAC%E1O$TRLY#YSA.2GIPF]TGRO*_$I#OI$(4RDK+4H);'C2@Y-="6
M+<9MM37Q[,EPYU]9G'ES^S<]Z2&B=^96I.B60CA%?0O&S5/437/%#,>W/!%[
M33,QF_$E%)4R7&= -B^N@S^;P(&+$MO,Q50+\ZCJZ"3,LKRSB$=1>\3N?'*1
M+CR-CI0K-&G^<]>T"+_5%1(%E$O($Z; (D9$4Z:S!8ORFB"=]^&R_XI@\9*.
M$+?\4&(A]+J/*$IY.H.U?&@Y4MH!'?''Q+1(4V8-BD6HHS#B[9V">S/TX^P_
M\_;_&R)=-%[(XI+JZ75D.S?0^N.4 1WO/R!DJN;Q5@6#N6<DVZGE]J-2E<D<
MK0:MW; %T<.[QAOAJ3ZTYJS_Y?5#(^_8@DEEK\QDO3E!\1SQPQ[_!EC_,TO^
M1TA:/4'+XBCRQG_,$!'5R1>-H_3?9$'_ D9Z@EC"D#@&7X7F4,K<%5L52]I#
M+,^Q82+Y^>_1RMOIM8CJ>G\&SSHH#+UVZFD8-!9NB-$.U:8/I_-U'2;Z'?=1
M9C/TBUVL %)R5UM[GX)LFHS^7Y/QC?K"L=31?:I%-;*E(I^F!>_UUP6^O+4A
M4%ZEXZ6<*^.03D@!<57L=]-H-_>."Y,$*YXF*R2)M7\!YW<O[2&4+CB$1CB$
M]I1TWA)_-_82FMI#O'7F,C,T:CUR&SM;4S _L31/$\HIVOOF;$;VZS#,5DM]
MK*VDDT"(T)D184FX)'=V-:J#^BX5 88,>Y_K,6.GDIDQU<A3.O4S21.Z@7^K
M;(!V,DH:MGKQQA+K;R K/Y*R8_D8<G#"^_0P(G:R[QL7:NFXW)V@.O$KN<7L
MV1@V*D$1=SJY]FO,U4CT#D(&DK.A(B2AN3\3TD;Z)&G&7_P(.?HWQGN]S[_)
M__^S#>'?Y?T_17WZ=T;\5QR\_X/P875,F6]'RIB&TP9^Y<\-_4I$G<#XND=F
M(SSY'WC^/Z. B"=HG 4T%UMGP#R7,O(,AY8U@2G6V%+;-.X>-%Z.\Q.\J/4,
MOR,:\CK2 FUX"#X]F@@+N)=I-R1Z0I25P*P)0^8(K<\._$((U1)+-HH4W,W(
MYGE'IQC-5CG[2#B  O%UY /Y*V8Q5;; -!_(SXS2Z^+.UH2F>=Q[Y[Q;:U\;
M-L&$Q2);FXETFV[MC>IA^M4=2_ZCVBJ;P+.\WFN3?<+]?N'8!$2#+'@MIM1*
M?MGBRYK+.;FU=UTK2>TAH/8:H33BD&\9E8SA)N(W,.MZHGO898$7R8(AK*9*
M?TGE[?W#H1HD9,_?6*^';LY_(2!+8G U>0 LY,72S<!E'E]J0PA86^A+C97/
MP$$2J86,=Z] ?FP*,D;]:J8$(+MJI&:==?L]/26)=<&K73@-9R>-II6V_^)?
M61W^MXBF*\-6X%?<\-XA=.WD6U,M1_V)DSH_V4K\!31[GG<"!2TBUS1/4YJT
M8P53EDI?$YGCLC]M0;<DW3I;J>7@_FDF:/;%URMWCN)5JR>;:<2R)=-P.9'P
MN1<##(!I@"?OZ"Y%A\5N]S6:9B>/)X-?CXEOKYW*XF3"YUO;-("PGAZ8=GW#
MF$C0X!TDS;6E\[IDUXJ8TL? <B&&-W]LBFGM_$:;Q*@Q943Q;6^@IS'- [^E
M#B7UV]=+S8SBE.MX=JK1/46-J0U$AT/3 LTNA7D6G/6-& (_L)OUO/B__,X.
MR^($-*E77/Z@\"<.BDZ1Y^30KN"(!YV4M1^$EVA>%WY=#<E=[K>F)1Q,C"'-
M?9?=LCCIP+\L<*E6JM%.5P+F9 LAHU?)WZW(8"G4(8IW5)_0FYR^5DTU2'"D
MUP.-]5@J-_%ZXBJM/5#$'L($3**'+4Q2Q/XV&#BFJ1RDB=QFKOSK7:DDKD_&
MQ@9 &Q(R]L"=)@T-N9<]!;EKYJ3T[GPE!A"Z(-6]3UM<XK(_DP.M#6B[F$VT
M!]LK.*9ZZY31$P/1&0^ZYVKYFAK6B;/*;7BL/0# 29U?2 QV_/QAYXH3;@+A
MA[,02^WY1QR\Z_R0C:@IJFHAPNCYB-(.\Q*!P/$42-)HQ\J?3K& [][YYEE@
M.9T<'TLK31-'&+C]G#:,<U H\DQ&Z>PZ4H26A8WPP@ _U6Q3ZQ+J-Z^=-+[$
M"BRM:#@J+W"R*TM9=FY(#?;\</+DGB _78W*)^EX%WH ++(&<M=X[9<<,M[)
M>9;OQ8T?(!/8ND"Y[(:6%."7Q/O_\)=1MZO[@@WBLQJ>T/;*&A6 VR9"$E=N
MQ%J8R$=P-L]=T-JZURD)5C)[R\4@QN2?JHRJ':0_6/6!]MH[:NGV*G;\BQON
M*34TNFT9YXSC0/@W-8GM[IF12@J,I9 YVG?[X?D"(J$<H4N*3V_?+R_'+,B<
MWMPM<.0=G,:,:*'-+W71(=1/Z,3W^$5T;D]AIO3"8ZR96$0&_&G&)(GL,[SA
M'.N,0CE#-.MMYV=\]<L/BUS/2)O;A\8\K$#-/9+ILDF(W!9(-+8VJ7^>SYL,
M7B^G%8GM[?EIRB^K1'#]0+, '7\-.Y0">UCDF+4?QU9IXXL:I:[8V$?]K(&]
MY)LU-"H<OO9Y5]FG4.NF#F5^+KL/ S/AP<:?UMG$ZZRD.U9)D1LW\2KV$I1L
M^JV/^F+U%D,.-A;K.4[7KFP^35RG@B/L30OBN]T/V$\GG!NI]:B7V O9LJ#
M@YJMFIF=^I:CON2CS=(>Z=R+R<;L/WOE>XH6VL3(>+^>6.EE,H.X<>QLSAMU
M=B7+9,2/>@(%>2FIRVD%#A;9!IJPNS](OG]E+_62Q+Z'&;OW Q<J$A(,%0F-
M/3B,"XWKK\$V]S6#>4TOPO!KWTB?]^/Y$ONRZY2ZUWQ!T,',J^R6_OYC 8]Q
M&P09V6C!A-U.YV\;?7:599NTK;OA?L]MEN5^&_PQBB+*Y;+YC</Y'NN6%S/#
MV>YS<">[1"%HDZ/% U$C7_0M@<&%Y_F@46]_AHK;TJ'-O#ANU?S+K_OAL)#(
M3^6]D3E'3W1J7'8]I?1$J$$CJ"7ZL71Q08%EZM; N/4R PO0[W6S2O<HOJ0I
MM_O7+FSI?8M#)B5R1T_"C>>D(4G #+'WU.9%$JS4!JAK@72H:\A$^7/G/[U3
M4UF 5,3KW^03264]:K;XCU*6L^^X:8IO@8+&F0UC!#=3/143Y60LCO,/?UK
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M*F\.&_8GO.^ISDF7=%U62B+G&Y1(WPC2HQA]6^T-(RQ\O<_6&=Q:+1Q"'DM
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MG6#@ MY#(?!*5Z$%OON/!P.E^C< :Z#B[$FITB#H-)9Y$QX$Q>/7-O?[4F\
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M#X^WIB].=?0#:-D8_7(+<G/"0,4+1[\64%>>D"NHU41AX^J((E\4TG;$4B&
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MV=:O'KIVQ9IO"].J!>\I)-P!/7B0CIJ4=*X<;E'DQ[(LAT=CD<C]\-?9Z!O
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M!/:-:A ^*<OT')7W\@#?AX":[)G2OR4%I7]+D [M)[8Z[YTG&K[L2,7?  :
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MX)#@9 -9WM[HK6<NU]R'U6/0,;&+P]7H2SM3M$OS/7VFK0EP0C^Q^^V-S;>
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M)]7=H?YGC5(I' 2)(RY(Y7]I8:D&0>/FR7@/IL<7'?%*37NWIR _-'M/Z&$
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MX0]T9NV=-^<AU:QY92)I3-5A(<(@CA+J-VCYZZNQ!1T8R(2$;O*6/AL<!+-
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M&V^#M_CFA\?65B=KR"&K3/*L*+ZW3K[L:_)RB-^V/F6_?;8,_Y-G3+#D%RZ
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MQ%- =#G<0OR@L>$*C?8T0&].->YMAW.I$EL<I<8KW)W5[OSZ\UQ4VT3O NN
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M%$QN0#3%4X!/4I<Q1L9(QDC>-((02 B\B1GI$@BJ>1@G9VRCKH$'>'&I@=_
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M*J_?:CU^'4''@_[?MB-$//Q"<9N<WW8 O#@2_N[:]CE3S9F*Z_ )'H^(1;8
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MNOH1S>WH8VXWB(D[0/8Y(BU;P;S:4R )CTM.W]$,+:XM=,1LS\73>OL\R:+
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MA[S4EL_Z%<.95=WP\I\2/^Q^]3>]]:<^(U>_X#8+=6PH>IX_ECU08*T$.6[
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M6^87')>9;62+=EUE\8 5>\KQ',65?18#JU2A/%%<P5OM(C]*,,KQ=).FQTJ
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MN_+/03LM"F:C4LJFF8,G'T9E,U,7?U^9F:V+BT_C$Q>0"ABHM$] 59S3A!,
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MKY489)R]ILW7'Q?&Y0^%X[W8'8]LIS>(+JT^;.CPX.#DN6P(]8Q/OM[Z:N:
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M=2.._TP!VA;9ZQY-^2+-9U8\90*_\OL#<ZZQ@DFE*M;I"0W<AZ,:KZD[X7=
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MD]H9=51APZ<_H&HI^:)"1B-_7W,Q"17;N&3]M7WV=KQZR Y;ET4$*BC+;SZ
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M(S^J%+S8VDU3C^*FX>9M .."]R8OD'V,U?\."CIMZA,A,\6S9-&/>Y;,$V_
M%?.EB M]O&?ZP+4THEB%<%LT3OR)Q&^T0/)9[4,"5O82J9TOIDS9CU*V/:M[
M!F*1)M[E!X)$I-*E_^ &2A[[)]%9&M3+ID? CXU'0(/(?M5]\L9_X%Q^*YA\
MTDLSZR7H\"XX..KR-%2IU%7\,]3E-5W7V(\;IPMQ>%;1G=1DJ>V32=_=76^!
M6\H+Q8\^U/MJ]4B_>D84]\L,-T?SUHD%[<2%874R%[9Z 7+*$F,HV9P0=3$E
MFF6J%HH.GBA[H\J@\@%1E<8 7"W9WSTO7!G7LGS0<\*T'EG%IJ"M)XM-U2)]
M7"W#4W'RU#EC=!5^\<H8;.6N,ZQ,FG+P^O"!.-$+^^7\16D7K/+72-56W1A-
M.!\M&N4DKUXAZW'&*GS71$^CRB/-\U) $*C.#;)5OQZ8&OB@0X'MN>#;GZIR
M(N9YQF8*:2?)G5:[H$<D0NLP'6N6=\V93D%#!C9\Y<91W<?KY[S/?8T9"ZHK
MQ>YY*ST8R.>:I;?>$.86)A5A>P89D]E-SIO1!@YLVC>F$9QH1@@=:#37L=[1
MZAT"J26-*QP3&W#GPSQ_?NXUWAY!3**\$U,\>49: &L#NIEGC:4;^BTNX5JE
M>4AK8;62.$6>IADKJ>.1E6</2A'C/VTB(.^F?64 ^YC3\G$3:L3U:5K+WRL-
M-N=";TH^%,Z/Z\52=Y,D,\E'\>&='GVY<?NLX:1&V"G1^[?)*#AF2BEK5Y*Q
M&CUSL9TR/:@+\H5+-L#RFFE<C3WF6L'#U,F4^<9/='J!62RR5[>Q-=\4\>R[
M!<//!E[XXXLS9'!)D56FH),'_GLHU6<[L_("EGL)G%X)U^3)H_AW\,!+V,9_
M05^$= ;Z"\)E\JJNXX9#1/IAT*=_260MW?X'_GQ("*XL;2PDWP,Q%V-4 2*V
M5F1TFGC!CO2!.:@+>.:'@7\\<L?7:/$"H0Q+JGW8LP7#&MZ[NB2M'@C)V:J\
M:.'8=B&0/-< #"S-_U%+6P$JL[Y_-@4AHL8+8R=85%OF:-SY6H?K<6[RZ7P/
M43G=J+R'Q[F=E=U&3T5#0X/H8Q[Y+?]"-5XHB1:&;N3+%\70L;+?@(S9AH"]
M%LJW91/OJCXCOK^9T0ZR18UQO17]1!$N0+6/7C4_\7H*7(G5(@*L1Z7&=ZV(
MK>?AK'OOU]0-R2TUW/GB72^N;UZ?KNX<GF7FO&=1QZHY$""W.X0CWQ?E@><X
MU=P64PGS&NCZ_&0[Y%_F2/_U*0>L3K$'=?]^^'QTO5?9 O<_>**.$?$GHDUM
M3MY.5Y4)6N)_YHDR'LN[^5"G>"'<\/"<QW]RY"]$-N\4.O_S%R)#+^-MWQR0
M4Y<X1\X0%)=P'UHI:E*]JB3BXE_@WY/O&UC)81;@PQD=_+5W04EB-\I4[50;
ML6H/51P+'9O7186\7# .YBNX33M0?BB2Q<J@#(F^?A;/50T]M)*)=G<-PQ9H
MN]T(B&*',/L@#C'5(2(YD/P6Q;A^E4#O7!^J0L<&C_BV:H2]3C52<,G/AZ"L
MPWC=%2@23>?8E1:7UL3GS8O-.+L@YP>5=^&#?GX6:]V;KPH=:YYX"W&<*W_6
M\AT#3%=$(E2+.$Q,QBR%4J82!>EV\A ;/ J0[],)#<\W<TIQY)"+_#3+!K:W
MUUE1AU_H$7N\(RA7E&7:ZQSP'JI!.TS[;$/Z9RE(E*>6B:5"N!4%P:K>?2X4
M&\+1:JJ@LC/AUC1R^4OR2=^(&R&DZM]LUQBZERT_B%BGO)Q6E2WY(Z?&.;1A
M.3SOQ]!=^@UVS&2VK=&O"@NK'5%LJ/&S.^K]L1(-C:/LLVR4D;[>VO,^ H!Y
M/QLCV4HX"+^]C5;<9%YW2M%)8'L*!\M\N7)],Q=Y;?N^@6$K(@KS60:(29;%
MXVO"E?\<Y=X;MU=11ZN'=G53ZX+RL^-7_>(?5_> DMJ?\QU:*1L[D,\ZZ,HF
MSK>2/%6!/<9<88''IQ_ /=;,> <VS[<:UQ;V0S$P,&\SI#^D! ;-S0:F_EZX
MGCHWAT1W/TF^HU5=5;<W,<.OJ/-]SSK!,&SFAI/)[*6NO!^C<>R./S)OWMMD
M+#%0S8.DO7%(U#8S7#3Z^S+]0N7<(\#7.6MW=TFHHH;7J,Y-UO*3,[&@I$RQ
M%V<'^ZVR/.FM"W0Z-JKE>SS[,&A(I8,!RP]>X\%$=2-$?LX+XSN0/L-I[A^F
MZS_XE&$3RQBRC8U4A&CH("C)ITB5"&[RP7I;4B/<WHF4%H9?K36AB6RAQ29+
M&E?AV.*52!\V):O4 X:FG:+\T*@0-&;FZF"V%67F[!6G<43B)\)_!@NOKG#Y
MN^N.I1>S,JX[CXP0KM\@P)/;A[!)V^VQ(I NLK5/PM'])C6:11IG$M?N1_P6
MMY: 9V6N%K=^UBO'+H4$OF6 P\P;$)#[OIW7[NKM1+C(C[]G%30*%Z)K?3"-
M7>/U#EN_TEWQ2>S="G!4]'.G,N?EDY,1D%1_8'[MQN4!<[^39_ANGB:K;H@6
M0]0T^\=+3]T6F+;6X73J'!GM:?+3FG/3H7USJ]G]0BO=?2V7Y3Q0+N$N4YJ5
M IX$H;KJM+>LC[#&9@QUD?^.=FZC1Z9%"0]=U:2KS';.U-Q=;\'P/!65QVGC
M8E!$YL9S-A'L,DWV0/VH$#%VL"$J>+4(@_?0$\XF8N[S(PW9SK1$=2^EBKJ$
M9W&9: "%A$^!S.W4I8P#B%GGZE!8L$9H(>R5;"%#;.#O:M-SQM %0K=2#Z&L
MT&-8]2?J@?!_"43E_QJAW2_&CH='<&H(!JN1GTD"G[:&S),=7IA98GD&N-GV
MX60ZF9U8VEQD"U!^H79$^J$)G]L\E>QT0MI8[2+\J.HY1&T[^;M&3GAX,W)3
M>U>Z30XDG$@3\JW(?3)6^[!+U W?7I1^QQU\X21*V6OTH$ #;YU_S5WO%N?*
MW_8-N-&PH&K+"$G*&)U-EM-,8C3"2HH<? 1\3P.=/67*CF()J7Z*Z2C%XQ?-
M)$XM5QCG6>T0B&D074 Z^[Z:1.K]A7^'JE-+KLVG7JO@0 $!YU97.T*DQ/3"
M8/M.LY1=:<5I!&J.!<57DKCG,XM^-4=?O1?FA6I6K&Y5,YJ5+#+AI2 (3V'5
MFDQ66WN/8R]>+R-%)R9).#D/G&L(ERRI7+U3A?>;3Q&[]806,S>D?, "WDJM
M9&B=R#R=/6C,U6#U951-L([DC)C9IG+/U<=J"8HRW%4O1.8XZ.3F^@BP'E(W
MQXY?N)_N<>[52L:DZ/K8E.O!H95.S)S2(AN>8'Q*H3JL"B-#V:"(5C[00N\5
MZ(@A[OQ_KVK)EI[Z-S#T2F/<C>SVMN]O+#3?H8G?,L]<V_J1J'?^GEV[L[HS
M:S)\Y<0MIW7\K'[U+5/3LV?Y*UM+/X1R8<([O\(!&^&6,96DQH4]ZL"\6EZ[
MEPJ3ZNRO3QPX9B8;P@D=3#73-+Y?;[#Q6"",2YPM>2OX!XFD1<1?8T0+/V"D
M+F17[&S7-QW7@CQE=9>Q*UN^V.UCX0@4[V*OA(U4M[?8&^9&3XZ:!V@94!'@
M'?_!5#4UVH6+BS\]^DTM=AX:=@ZH()ECVTV]#(6L(K"7HB<U*=/5X;=\[93@
M4=W%I(5-9L+V+3)'D5#NMUKP.(L)_O[>?-0."?:>]7;5 W/-C:7DA7#:N0FO
M&N$#92].X^.90?)2A_,&IT'SYE$)>2F)KR)&'H;0M2WS;EU634%3"AQI$\,4
MP.)#>,1NBVGXI,8GD"^&9ZLL=GJ?RJ"1(P\-L>5*[Z:5E&UBTRDN-0TODRQ9
M9;P'/^G;S?Y_JB'T+T?Y1V@5<S #GJA&*(_;U.4J.5O]U368:+.QU*EYLM#:
MV(@87%IXD)DI$4ND(U=LM!5($V:Q1ENX01E;[=B3GFPM[X@8Q%^$.78T)[$L
MUC/.UMMV1^_07%A_H)D@O<Z O'\X-]&706Z6J$_WI?EQX\5P<88S+&$E_S&J
M.<?9\>V^Q4!ME'$)%0,\D1"2E59D(K$?%/']2A[/A.4SJ 5I-30H(W,N-75I
M:04"MN-S\W7BXFO;9\D2#J=P4_Q),SNZG5SD@$!M7,Y6GE2XL!3DJR0A(-(]
M2R(M 9]T5$@)97ZP?V\8I>E8:_@ZP^&\+),(E@)L':TI-,>FS;&=3K*AB#B8
M)@UFP.M%RF./G_&H')<G%8Q]E3N@*(Y,*GDRI+14S\S9L;]C1-Y)!'?Q=%DM
M!A&5JI5BJ96J^Z'R&U0 L.R[7A@,X?6\,*(DPF0/P<3DXN)$7GK_'C7*^^&J
M?1&W?LGJ:C115P%F[-O*SH>,N-1ZX-I25\WAE;GYL_JF95X6I&)\K&'%[?[#
M'3&"LV[^5^U@Z?]7HIO:#5YVGV1M+Q?;]!_>F";%PO\=:ZM$(6'SY<SR(4XW
MZCX8^@@(' ;7LK&4O(IRO3(O$S$F3^@SK84D]6PR34Q'&D5)*1E9Z'S>7/0V
MY+81TN;=2*/GSXM2,D;:CVCOBZ5T>]*-WJ3ZYT3 @X=NX[W(;D5K&>%#"]*2
M^?_T^ZT*N$ I>A7,JX5$SA<LR+(@!.FSA6(C/C>[YYCL9#%#.'!X#W',Z<CB
M]=N;WX;#+6SH*S#U,$9XX]^:=OU/@IM^<WV[0?>,JM[3/$<W#1+F4^IL?\+(
MY/PGW[I-X L&(#?F_0;':W8.(^0G9L^?_Q9J,7.E='5U=3.S)=P-P:;PSK\(
MJKMU=,,5Q93A,&]Q*75N 668$,M2!([J?XE(2=,S=:B,@D!#1J2HDQC%U*D.
M]EGC58Y6%G*ET!9P?:RDGHF_'-969WN&?+HD("\"J:84J=$13'IE09X=;";B
MQ(?UE1+)5E\\P,VDQS5@49?(T4]E6EN53N-=G@-CU3R;ZEIG@B@A.2?^!@_8
MU8U5X^L?/>,TG*11_;4E%&.ATR+(KB,+9M0.X6Q!,T3$3QNO-Y8FDJS?/6U/
MCM?,Q<H 8CIB#T23M<X$_J]DS\$B..)' +RTYWZZN\ Y$_BX#_TF71VJ J%8
ME5MF?<.RA#1TCX#S,?UJ/8U?3CV[(:&9C[9L$+\@@U%XUB>&3F&?BG>_[&BU
M+L)3TZOR)]\</F/8$_ML7:M[O+PO#O2$#E%3P]K.0HO\@Y'C]<8Q^A#WB"N?
M\B1OW=TG<R*[7M8?-5A'YK-UR9CY^- <N,B?)QA/NP_3/_46TO2W3>(,F%D=
M:(,<C>-SER\VLEB305N\V[6UWHI4MK:O]V2&/822:[,INQ!&5W#."=F)L&W#
MAUES*)_Y\OM)LK%&$6$$_=_/5/X/ &/\"N'T<?/V%C^12&[KUY2/KT%8V.)J
MIB^-98WVSWK\!A83YW6]HJ#(SCVA W-Q(FDI5(%&7WS$1U.QO30%7N?;,7E.
M>R'+,DIN<]&JM-RYBI6=52C7HVN4.F86A9&^+.M@2' 2%:1SD'WA_\[@/<W(
MR(%:O>^*X_GRX,U>K7!TL='(@%5&4, $R#.JPWQH,@]$/R8@0/9VO0B@1Y<(
M W_XXQQ]ZPOSJ5Y?JL)3K\2Y%B*<V^S40??6H=OJ](3C5"8[??-S8=#$P*OG
MB^VLI%Z>DR-'.&\6.YC3%"PV&?:U,\Z.R=1,.J?#XIG.PE0C-N*X?G,"T869
MY_$70,PC\\+,32,@T@5AHL1429S$5#&2[R@YC SXZJA*ZG/=5AP7]@J^S@T/
M#50?H89U=VO :^O1!QV<H:Q,$#G%TIWY= Q\4+"*Y!I9<J?E=1&J6S+]?E+Q
M/^J?Y,R;.SIB*?A68KHM^-@RN617+TVJU[;K_NN!?M<5C^PDRNS-G[E.IO-P
M_P*@^-W]3'W9T_7FOPDX]*A?::D*M_#\\X60/U:8]#S)'P%RVY6W$6:/ -(S
ME1*2FOJO/%#[V5?CGJV';FSAG1-"62,S4=/:E*JD>A\&0>831$^LXL6)AT3)
M(&,8 @V2X*YQ%#CJ<)XNX]TIS.G&=TS?6X/MWM-7L'SQ(?M,?06$^0C0\SNL
M^1]_WS?/S5C6$B,?^GFRR9?/"+W98[4;[##'^"5H.-<B/RPS-8H_HU^\F\/
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MS$I9:G3,ZGB6>/VD:?CG>^=%NU.OI$? 'JC"^9T-^EU=FPGN0=:&;_QB_2-
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M&5[!7L:26$GUM3?@8_&S[K>F3DG?>R?PC,APPVDKV15-WF,*OY(C#W@OOE
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M;I;W;U;II8"SQ'6*<9QZ"HKW%#2?+4]:EJFO8("R$^9"T.6]PX9#3RF_4[V
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MY7"6^?'*?X02B=16U/G-@L5VZN4]6<\"TYU0:JWT-Y"JW$>'=78L=7C;2.8
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M-@.$6Y7V 57!66V.N 7LS6Z>,1+B,G5<EZH'T76>W_-+K,C*9^8S=0,R3"S
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M;H'N4?#'9KI_1H<<K%J)'>\2-DA@\ONXMN/<'!Q,BAZFADN<M3S%M.NACR$
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M4@B7\E3^'_.S;P&41D?D(DZ5VE%X2Q%\/Q.!'$JL'"R99P=%0-M>.%<L%XZ
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M7$LB-V&1?AAWVMW#EM_>0SIN]5D'JFC/5+9LBQ58&1$77)@4C4-,NQ;9-BR
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M71PM.VCH3#>SW.TSGFVZ<Y# \IT6T)(6J"L-585T]LD$?5=-7G<X]PF@<\@
M-8W]CXP[I<_VC;D2U_# M.,*CQ5^G>AFSOR,:>1&+%R<T81 P.+K? B_"=JQ
M@#D?X2K:,1<]_C%(%P0(NZ[O 0.!MT)Y50EM/ M%L9"\9:7!>8D"YY^B;XS;
MTJ65-<;KDAF-5U\< =3+YHW"]OH(1QU&$_<V69&+.UX]@&AO@!^804+#/!RJ
M2(>96<Z4?F*/)L;K@1#4L)F9T/BV%,)_R#T[@CL? B!1^FM13F*!\^O5AX["
MBV[EJ\+J;F^14;])L_QAS%O6MZPD4>=^$UGMF>/,=D5Q7K^+LRS_5L[R'%JS
M[S-P>H^RDJ=M1?X?BOSE_TRE)>KSRJ8%^8N2$^\#2Q-&283P!Z8GG;9Z71RC
M/Y[VK6!3'0SG#NXP,/3P)O?R.&A^;)Q8+E-<X2;GJUSQ,/X@^7\TR_C??.SV
MDTE.-O'%X7WUADCTK(TDAB25-\?W*.)W2IZ:G9T+IT4)=JXG7D,>#%N;F3'$
M'/'YQ2&;^<71'O8^-YRC4A2C/;<U[/./'13'1(Z5N! ^[ NCE +/J"FYA8W]
M!";O1@FN EI2+_^B9?.OND=QC<DQ=:BJ&<>?%JNNL#$6TLZ:Q$Z-UR9_/+?<
M_6,A=P<KG[,UHUGY2J3TYASJD"$SBI3=_#^WGE:&723$?>O \B*$ +R7D&M:
M<$-"I \=,%LV7DKE2\P0H@GG8RN+X\! P#FD&0:JHV2AHMJ-[D*LT5.ID<])
MV8_?_'2,3_Z\/401V[MH^3DJV:R^"(+O5:] K=@5/C-K,(,:)(;D$.NQBH;K
M=C6!/1ISZ[U:=:$]I%]6N8BL6E #WADHH^E<@;**EGY4XLE3!E?V>"U*1)H+
M/'*J6.F@%'SRA[D9%U\\%Q_FT"E1B]2ZG]N*0%Y(-4>?4!K:Z'2Q 5?F9 I%
M-$VY 95 _I=+"\N5R*%Y6$I6HL;#O8L3.X"40XI:_T;%L>U&:-6M<B'DC'I-
MH/&-WV'%[ NK0^V!RE[A>1LBV8H/K-TJRJKKX6/<B$?X=L/PS=,0/]Q<[DP2
MNH)3-E^XZYLZ%B%MMK4CC34_QF*-J(9T4<]$SS7'4E74N*'"[^6D<2&];,LQ
M,D"*2L6(^:'5@#R@IWF)L\D;W"%=JORS&1: MSI#-&<,<W$_=CI\L(?EJU,V
MRXEC*8T@3+YJ>KX2?E@UGW3(CA_4SBNO 2_#L3C'?M^C<U;>7ROO,;G:]-/?
M^%"U?X1Y^6!9-2(IY.P!-+:+LC_@[[!;D)\G?]*$W)P/);C(+DZLS:TB^ >'
MKH>M (8;&Z3FO(B#"*ECL?N/,0*8R*JA=<OVM>?%:K!N\[^M8^KQ.8+.T8O?
M>"KR%%9R<]5ASC,=PCX**U6[<UP^TQ#KL#ZS&:1](6UR4\LZ\:C#:,6$%MZ'
M0PSUWA4B532L '$VAE:K<U[-F<^5K<]&*L=/IGDP,'W1[!-[:><@D,>,X?]A
MN/-59#"A5.![CA-\@R&#-FAPF'Z8; HT& :#S?VM)M0Y@!4)%G^!VD.)^:67
M%@V-1=1(8474Y!<O%-^#LOUACX+L*(SQFO[167M=;G)7,W/MT5PX#:(#>]/E
M9Y%+?>-1_)R\QFO-G>-_$JUDP[[2(O_J<8EKF7./PQ-G1;(=(QL3O6,;=V6U
M+3LQ"?6M9HF4,:\T?#MZ$:'\(WP.S[<W +RN71XESLR2)E=8MGE>KCT?H]UT
M)C6E[RW2>X;/_8R$CQX#Q$WN+CNP2LKM?#P)\#+D9=&G$L90F[!RA%$FI"L6
M!W_KG38EW%?)%_E $]:+805B.VET;Y5J5E#:VVYZCE@RB:1BZ:*Z_#JM\B:6
M+X*G@-Q'(!44IMA$Y$1HPZG@RPW3)FIBJ,H'9LDU5DF#PZMU8E1V%"O[E3@^
MCT]YZ7*P/MD4%H@Z14LMS>R4(N2Z!AWA.YTF)P?G^)F6:_13\NDAV1TR8J=C
M>3)(&M-<"HV=3':@-IA8O\B.?7PT8(3R'=LP Y%_']%GU+#81EY5DV/7<O0(
MN7G=+P<C*^J5K_R7X2E9930<RW#9M)$A:-K"<+4"&>&[6?$0SB]UH"]M>C#8
M)1 /M ,$'MN3U?DY;YSPH:M\( _WBE<9?\Z_E9\U^.&Y@/OJC^:9GA!W=XO5
M$'>&\\8CM!.>(^?Z*^Z'T&90+N/%9ME\F TZZ>'(AVZL'K:A$>%[%':OT;O;
M;WR/8;!S=$, P!%Q-??A;V;@'2W[)74A$H;6)';C+BK6S-][E*7@9P8SKL<C
MRE)I<3&DEX<]I)?7,-0&+E"CKZUO8.@43^*>W7!J1 B(I:6B_8/S9F&0*&U3
MMX4];3LA1DJ\JW]\(V>(_<^6A'*S4I)7R2=3WR;FLKX&61!N;]TRIQ3'Q$&5
M.R4O;U4T'X;',7E<3@Y^A!'GKMTQ8 ]83X='HB@98XH[C-!S!)(<W;32#DW<
MM*8=W=DWYSPN!UA?Z9'LE\TN,%B_21;*:E,8DQ;0Q)U\NV=$ST&$3N-*,W[A
MONTH@E9&0&7"%!H[0&J_I&X_G;HO4 36QI(M/!90E"IP'O>X%-RP/XW,U+F9
M9V$!E>O%::\9H1(N1XUT!% ],7JR@H*Z$G$1)X:_EA%<;[&6D5+/L)PVLNX.
MLG#P;@1S.2-[*681/M]A2,TZXB2\;%?AK'[K#/6,RIVZ='SR1EBSLX$ YW(O
M5:D.RAE2OY;E99'48$V)%(D;4\3>[(GW^7&U7H+SR.<LFYHS8+C,M,XJ5FR9
M]K,Q@(!BKBNT)ZIOA]?RT@/Y]:*)I8J_BUPO#&C)R^EN=RYKNV^.>+A:C89I
MMR,/68UX;W.SIFZW<W,=(TNJMB;^Y%:"8)5K (V F*>R J_2@U-N@?D3T6V7
M<$P>-MC':RZ^KDM9;=]"GAPW)G1)IPTY:<-!4+IR L_$(&L:7.::&-JAC@WH
M%>=QPIG(.3/OU2[\]Z]=_GMI#-GEZ:+*09!P=\J027E'>9U)7=Q'DXCI3,YP
M#X80:<;U$,NP[$2F1P&BU"^ !""#'4H>ZRL)LO[$1CX;"3C6XZCD,X"N68,3
M$N]BZ)N;4'><9W7N,*$2"^OJ4\2VO#0[Z?O(9*8-;QXFLBMXZ8KN><65LDNU
MKY_8;B2/PEWBQ,QE9<I'_3;3:.MCOJ]?",C4D5-? KH CG4CJA,J6OX=6M T
M%7=O9;>-8D1^ Z^KAMZ>!7>T'GV_W1XX%=R#_Z.M&HJMBJA\J!:CMFS869Z1
M_11;R,VYHOTQ2X)E]@/V+[BHO,*_5XH[+7SX#_*_/VFBI9>FH9+PM^M,N_-]
MVQ^S!O^PXT%MO[KWM\;A/$16O6=45Z"T3!DV:[;#-@&T+YWEH>ATU85>>3FD
MO=N\22;J (E>?%57R;WGR]AD2_?JW7^7KS+_OQVZBL"YU@L9/4V,H6FC2TS.
M^D3'4*<O1X(,_R,$0__)R1F&P.ZZ626AGR8#2Y_&J46(A7$9E\?-X*%4P6=;
MLQ...VH^X-Z(Z2&Z)"4;85@8YI-]ZKWC4;(\4"M[S=48=9F:7S^QC8IZ) 93
M+@^KY5 EK,D["XM9TNQ@C?&=!)HR&6LJ%PYW)[=.',#E[!5<:?@Z,'ZNM!<J
M*T'W(;<R=$"<Q4-?,\ SC&D'$ZLBSC*OT%H$"S'.9'!&/IH(8,#$7Z'RF1QX
MZNWA[HUTL$02L87/8PGA:Q0(@I==>/2L=X0XOB0R1"PK"B41#GOA-W@0_5B1
M<S?%#;G5?1/Q$#4WUU=-_ 5&D#\]=@^U"92]\P@._J-B!,#'35A_2SB&[1SD
MG+G@0")^MH.,-'-&JQF;\1RA"BF#U_%6C/.8]^I#P=@//+W,W9^H<EV<.76Q
MO%KSW[)X^CB:$P_]'*<1IQ6[\P"Y=O,+>R;\&$25V8U&WHU7EW5I]BR%BBB[
M<*L_3S8=NPZ;=M8H&C.A&)SQT308U$:X0,F,5<IE4[]KQV0OP8RC";,A/18.
M"AC@LYR :D!*/D_9C#EV)P:75&2:KM42'^YA7OA>>HC"^-1#!LNKDPM8K.CG
MW< #[-(4')*X,^46DJJ]%0D#?8:6-#<O74H&<N$S7TPTRT=IB3;\9)(S)9-<
M#DXR]D$O4#E0PY+C>=V6SR44S?PV;B4"6O=O-I-Z9J_PU^]1OFF)N'BV3CCP
MZ;S9+"<M':<UIKR5P.6].^2JNO)(SRCQ!I@BX3W@QL8;"OM?@3PMX&:7Q5!R
M0>I4M^_2@1;MC-YMW7(JNVEVJM!-8VIVJM[UQ$VL&$(J-;J.."97,,SO:\YR
MC_?T9'>>NK;I:U_),M@MS&8C6TW2WK%"A>NGZ[<=1;.M((;A?UP;2CX?B]-H
M&L)A;98R/G*:?>;IH@F+(Y-CS_6H-!C(3^0+['8 IS:FJ16\L/@HN.0\V\[U
M4IKV[C'2,/BTCU0JJJ.9T&[ >6+^.?2G1H!V1M,,1>BJ DA78X/S@=B7P0UG
M2C]I(M(6Z8NL)/*?<V N@J2D-)&DI'HG#R8) O:7'-+[^QZK*.ZK\P,1?((?
MLZZ_\7J#0DX@URQ6[Q!2V?13WKFQ475A;X@-Z?(/5=.<H>P)4^^-9*%/4YIT
M3FP[&5WH/,W)0U_7@S9/\J^E[*LU#[P8EDI3QD !.K=O]39[=W75<[=?G [I
M>_HS?NF&8O)C"K-Y$&OK+I-(_U3$ HZB(O1K>=+P[;53;3399E+7YQ+SXKH:
MDUA(!BSF!]1P1ZPG/[_+S80>R7*/X<K2!MGOW37<F<5*I?]1:VJ^-R-9.VUA
M;W]M<)&Y]1[EP_@Y\!S;(=_*V\V9<%!R]J%]M/*0]Y<2#LWO/4,83_%:$CKE
MM*X;6H @RVX=C=?& >*.63POO\CB?"(3BO>FW47N3_/[-,[9OHK<RQY4)!$1
MK5L]F+E'>4E3FS$\[TO58WS8YLM3S)E&&LFJDP-B&WKLR0L_UW"WM"(? *A'
MS\WS<:Q730$%N\&3B=]"2$,*)Q+3-L_6"4TCC7K>?\[N6MHZD)+'TZAV&;#8
MGJL';KD[GNLA1<QO:8[Y:K7>7ZA182FG-EO%13\]-2BO?X\5\+%;DN8!L:,\
M3PK'C'7F<X97NUR0UY7IQWW<D?])+<>_;&+HH]UYT=SFN4DW3^MDD93POA8$
MY4TU@%5-5YJ+>6[X3'(S)XA((5KV$H8VK.UD!=_J24$/2#2HB"1G!7*?Q_M$
M;/E/?;E4\IVX1\D7\K\^A!M>O"LMW;I'<3>QIS#W*9^<978Z2N5B31RQ&7B;
M^?6*@2F]?S60C!?]:21AJ6+&N)?)H+O.\-OVE^_'*]']WZ=I>V(NAWNH_"\J
M7>+BH@8)53;6\<KX.;6B[;4L&)W*2@M^&(C5ZMK1L^)3EEWEX27W(MH1Y'_X
M\KT96M.2\.-DBS(@KCH!9.1[=F3%U!')JP:7%5M 'YT^1WW"6N]*UORR.I9:
M0,&EETHM9-IZ&$^(O3&,8FAR Q>UX+B:(;MU]MS> )H$^C%5_%T_AZ_?[DPU
MI*C$$=7UHE/A6:)=PX7[$VP<WG0O_24">F#H?.=/@5LJGT.O5M2,,6U>($.W
M=3JOLM+:6^TKO=1$BU)F-A:#@7CIE:ZU_9&XA? 6-C\ETR.(>?;7[_)T<A;;
MJ9GB)02O^W]QM;'IBA=2-(Y[<!P  %!;_Y.88;D1,^OG1M@]RMZ[QW>A;DCG
M6BF;!83O\&S&9W C%60Z_7*7/3G]L1567]3G83E7FUXS)-61I)+R2&M?W18)
M&?0V)M>%!G%8\S%+2(F0*F9QW\ER'1_]TI.<+&LH*XL;+8OG0M[BC;V2*-I5
MC@GK[3E(]Y.E.R8(4(XC+I19LR(=DVA:&<;\(HEV_;C//'WMR\T%D-,7_9,#
MO87^^/?KO&O.[2K33EOA*75Z9_K=T3K=J#Z @(CB;*+,$*Q%F3U^80N+^ZU7
M0F17+T>=UY0+$;/,\F2/";-R?*]V?+07\V@V681:$N;>ZDMIQ. >8G!XYT,-
M>MTN)&3M*UW^F;+&:I'RB+2\5I>AE J%R\V)&^F$,VXM]@!@=3XC&.ZY0][<
MY,5L[WJ66G)RLH>!Y9^W-WSZIJZ!OV@8.?+\0"7@2<9<TO*58+U?47WX0\,>
MLU8)98WYMY=8!_."PL]J69RM2FO*37D^?H(^,:TM/'V,:?=VC.NTR^09/W/'
M@HSA:ST^WBJ$$+P4U@E>EO$6M5LG<GOCCYDZ_F%$N' RCI^?@*<JQ;F2G!!S
M-5KV]?;53+BJ(JE+ADFZCOKKWG\U^5X';F.[X]HLC,^V.IS>3>B,3KB1$RB;
M<2>6D.DF]JU0]1HO]7YDS3,KY 5@I)IFD;C0%&0GFY<3R>-+8V>Y3CQ9:+A'
M2<!$ F]=8'ZM/HHWHKH"7U!+@$??,TKN4<J\V<_W"UN7K^H(LL_G93(0A1"=
M"(S2$B,'^^>0R1JNV?"%]%K[.S9,\V>.)M4+]*5SU1P@EF"Y4;W>?M7W00%G
M)B?BJA*D;..]_QP] LA_\8-MVVD;K.IQ+7TB;P43GK.H2=3DMK53\Y($3/F5
M(Y[PZ!_=6LVA'< C#JQ>M(P"DP@R6E7]'C6F88ZHSQ_2CM)O"W_UX8UZOEK7
M>O#%ME82K3JFW^4L_U8 @;X8O7*/TB%E'"/36>>G?Z8Y"8@JY5-F_^:2,B05
MU+8]SWA%PY UT!79T^5.YZ<JZZLOELO=WFYRT^D?GE\H8Y[Y+$G:$S4GDGQ\
MZS<;,E?]\MM7P^-7J^Y\AKI+50!I?D6;^E]#J&7<0U/"\TK/WP0B7#H(=%KV
MJGY+#7^C]RQI&8-#RAKJ-$A/Q1TPZ%#IAD/<[?>::';D:K/J'L7W*NW"/^M_
M-?YA3R_?#T_Y30LE79]/+$(?@U/^K^^DO'->&Q:H:ML*'"J;O35D>VTGF^VZ
MYA%94B>O-M^5D8R )15E%'-O*7,KO0@\E5=]8++F];'>\_$?P1V';/O1N>X>
MA?50S<]9"7O.67;<A/&W%V[JVY :98&(GJ$8.Y[,CB8>^G:K9D6S/:]NC:?$
M H7MZ(&DY;M8-"AD2GY,([-9)YL5%+Z B'N4I_@#KJ(V%8C%K010\AA)Q#<>
M>S5-A-[,$'-I=5E.;Z>$ALUE^9 $>D9V?/TK1EL[<[FCN;AF[0?5+K.E3P>7
M.+6"GN22?=[ZYQG .+MOC< BL-+_/ 70)$OEO]D093(_B=:E/0XFU2AIAV',
MV&@J06P23;]S?V(#T+H5S53,S$T3/U'2Q%>5"\.RHOBZB52^<IG!;B7KND<)
M^OQO$"H\\FL,_W[B4A0N[.:EJS#6Z#8[Z:-U;B47NA\E\&XKO>[/0\"J \7L
M8<W:\!YS"I'<ZJ;3O:5^ST,>'QV2V*'/I3%,=!A47*1EU)3/R!N/&ELAY591
MH?60*W2:W$.=D.[B,=@,<N<:9@LB*C+:D[48E %B!$[PZ4!_B+]YLAK.Y\X0
MIP5+*S)602VE^;>9ZI-U=^-.</>"W6#S>^MLII9YQ,8T^.*B,MW'D)<D_%;(
M9'6$8C"A?C738[W^W+G&\,?#XR ]4:E;!/5(3V.BA0.[^Q61[]^BWL VACOM
MWJ(-EEJ-P%#-,'**NBRBS=I60X/5*75BIG"S,K5WA4U#T&/)%500K64:0\8X
M?$9;8&N!1?A.2')RY29?Q-IO/+/-YV*/_896EW4452IS>U':H?IYUUG@7,;4
M%'$6D'V[F<:=RY1)3=':SL9;@-N3C"\9*K;SRCG-*?@[1U3QP<ML4Z;WTHV*
ME$2]J)BU>?\BT?!P6\=Y&;/O>*+.\WS#/G>H$W&>-(=DB)XL=V J.6FI[M]A
M$19.+$C4"K?-2[ 3R7&3451834B#V?J4JX5D*O;;N@C9A.KDZ/FJ94%$MD>,
MA/\</M;$?Y$PE3^$K\_TJ(,^(E9KTR1*':QN$O/&G&T$.-U=(4U1-R];N;WN
M4=2M&Q2E%W3Q GL5EU:/$RBKSSC4O>QEC*BMOA$BY.E_ YBEN9@:'1<MX[UM
MI&8 U%H!7YHFX(Q"(*8XOD<W7)1QD*'0F>G;EW3,T*3GVI\O0.N3A@#3*QJ?
MK--V@SZDO=I[VPW[T2$CIM%4'_5LZ<%FR<&W?GQ.>S_S5W'?G3A>-KEIF6X5
MQH0$6ZY&LGJ$8>G<YC2_$IXBQI=7VX8;Q,T+*BB9&PQ'C5PEFFAY]9K8$/NI
M376F\PYJ*>F<.&OK_*SDXKGT8" 47MCK;2RO,6?<PY^U*24BY2)%=WF__;&9
M5#."8C1(NZI(RX9,A$FSF=&S%GMC\+I!,]3^8Q;<?_01D1STEL;D@=^7$*WY
M>Y0FZ%[S%+V?"_@.7#I[_6FF' C15J3/G6UN'!XR34P=5I.VVDU<6[_*6(#/
M'%4-K^WM(9D!C:W"YUII:7M2B"]?$C;J8?NVYE^S"@==URWU%W-#YQ]VPQV'
MUGO(%6Y<-OS':YH$N+SGTTYO$A>G]UXBW':Q@)<+9[NE/SR:1 )R3GU)&QH6
M:DL\V-E[Q_C=*BZ=Z]E(ZC&JA(554O.!S171*E0<G.,)&TO!GU-@>9[H<"6X
M4^?QQK#_^'=ZU0H162U__1;Q1%Z_?0&NDIP9@VZ2Y@89'&3WC$TI\.7&:)<W
M>MZ1VC+\*ME+7HCEC=&JKV&H%2?U79_CR,^/]L)SPUT 0$[XPW$2S5H/HN(W
MW/A.7GS*X[44$I4/(;U.JU:]LBG03" ]" A<-YM]J$U@SBZ979U94ZFQL&0P
M1B*;/QA4\I'FXZET*>.[MRE%5C>4-:\%WMZY,:^=LC(QM[X(E@^8Q[9;:">/
MRK<8BH;$3' MV>U9U']K<[3V\>8RLQZM_L5R':]4Z2,4WV=$\_>3@$WWUE\?
M4D[UBI%%X X8O13]\WF[!]34U'\\:$?]"U;#:N,QN!P'ASJY'!?D3_[,Y<4R
M#[.D(OQJU7S.-9U/# IA13I _9W=U"0B915K?1L9'CWG5SO-WWK5NY!E.D%J
MKY8@C)"/434>.5%KR;DN;D'30EAW$T>=+(:\S5D]79&K.Y<5<,WM70)RCSNS
MTA'2XQ[6D<:$JG]^L@]U?/Y[M1!2^1M/=VJW(%;<A(Z(FE'EOK5X2+'!@+']
MSX(SBR<;_,759S2>.4_,*6,*0KA QC[V'VYQE*:<)%X:/K.M]U )^A4 9U,:
M&AZ'9@H;441[;$8;QK@S YTI>2+O/G!!LDY'S.]N3_D.445^1\D:%^J'6B/K
M$@#M>Q2],\/]134_'+S?L18#R/E?UXLV$ENB%?)A%#/.>BBD0&KDS4@)9+N?
M%%!;?5I3!L4>X%-[HV2@-+A'-\#[SJ[UNV?]F1Z&ED-(4"=VU9%$GFO-MPD+
MA3'T#RJS_?-CJR1?#6BB G.9'T5BGIH1^/(243_(;L3;<@?YMJ=S[3:;UJ4%
M4@I:N/;0J,F:TO(:[X;UH.H(IDT+8_1R.@X+*2 !K@<E5##-QGS3&NEDM=FA
MRK$&,2@*-HU2Q/S([,',#&VOM5YUTNES)9 IKS<19D9*W^>9')!VSF] G<?@
MRY[=VB*4R[>QL+6%)0OA'Q(QE=G.$.0^#?DV>3'8!N](5"CI5S]HP%!1/;42
M\B!^8!O1KX]V)$$1+S0\^A_8]^]9JF*,8ZTC_>F9P<+'[N4]\F^S\#(,JF\N
MQ#K$5USOK0<SM3@UP6_]J RTF8'<]*EY$ZF8^M]357I)EYDT<8H996ECX43_
MBM.B?__:-=6LT\6<L%2K!'\Q!=$8%!.RX<E_$.YU1A4K)_ ]E?H/D1=E[).@
MX*[YA(?>3EX4O])6NGKMF[*V'7UPIUV>CG3O2O5&PP1Q*T7BN 92ECNIPI4"
M^P>/)._)+:='"UKF@LSRD^+>DY*@*%6 !B_*CX<Z,NL"UVIWZ6</]WN<_):I
M#^Y"^:S=[U'._HY424_\NY]#=9D2YO239LGJAV=ZYH:VL,I_$C-SV."QIAQJ
M.#=HRIDX:F,0]NU]^&YO^W%J2Y&.R4XEWT*NBVA$M:GL?8CR#TJ>P[/A$U.
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M&87.D> K36QN)*T3\$VT:OB+V$?U1K'?PR*U/Z^B^R;>CO[U'U)Q6^28R=8
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M1^#"7' 1,;@8''YSY3_N41S*0WDH#^6A/)2'\O]+FGUD_!U02P,$%     @
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MZ0VA4'Q%@X A)B./FAQWGA]JFL>>]XW,U4XE.UI9 M#E\@^;L T#V V\8\[
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M"<1IC*&/$4*^[Z7(K&;VN8$FQXB5K* 15GU\6EP%*5@+;-XVI1/?;C9SB=K
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M]CE?\A4K;_.O(G_.F*CR($+&.6$XALQ/*41I@B%-%.(\1-3GB4<)-SJZ.#7
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M"R%*"(&$D@"R("0)]5,6<VKE"!M5_*D1]N>F/_FSR,&WAXP]@,J@JYQL:T4
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M6".6Y)#%V&OYVSG:W/BG5M Z&#F(=;H!=F.;8+"-S#+>B/F+#[H@$52#L'/
M::4(77P_421TNFBP$'J]BOZDVS5M=0W<V_5VMRVKWLH*R*9"[E#!(6#,M19
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MH13R^M:$.H1X9P;ZP:Q"=WLK7,L$Q0HQH)1M:2SM22<C", 4LEP)Q1*>7'<
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M7%@=N'[Z<V4"HN_%X^&P]<WS9U8^"'FF&92)!+F0&4!<,<!B9<OF&4\X)EA
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M6'DO/T);.3?VJLVTZX#:P@'K@.!3Z1'3O^8$S3\^+_^(FDFN?+V)/O=/]K
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M0?RBTIX1YQ>/6@NC]2J2+PVW.?S5VMP^K[XU/-VHDTSP)$%F!0"A60OD=AF
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MLB7L<F-^M:]>+ZSIGMG,3G/@1C+!D1V8;EKV@H\M2%\( @1,<?:!*&C*L]/
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M,<ID#N,H(1!A@B')N( \T^8]G"0THL*K'-)UY*D][?MWT-/E[AA7@NY&!8-
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M_VBG4]R>XT^-*_;&-B+$5M>'*\!J@WLUR76>C6Y^&0'C@?GGP/IVP]L6[DV
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M'\TF?<YVT"HM\E3BNFH*<X)EGF<$9HF(K.JZA%00#:G6J18)3W&B?//F1I[
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M7)@?1350J;7R7/UW?_3$D*$=(@F,LL@LTV2<0)IE&*:Y(%F:226I].KKXFG
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M\+R'KR\SB6]:IIO$QH55]"(+'K PZSUGVF7/O!0D*2$Y*B$@Z#(8;!X@8B?
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M=KK2:$LZ4N(=G+H\ZL3=.%(4#A4F%YGFFG97DQ7S-F8FDE*\9BV,W])VMW'
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M;B_[]&R:ON-LN=;W!'QM]Y,M0^$*TRYAW7F(1:.A9!Z=+8UF9N]-Z[CM?#M
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M(+Z9%F!8R 278($KRSE@:5+-UX*9<6^DG!C)HZ.A@Y3BSTAO3M--E4THR>3
M%<M@!'FZDEQH ;2R$6WV!7TQ35**-XD8UY:.#XGY0/KIP]Y^JJFF_UQ37WO=
MKF#VH9;+/ELND2(K>F<QP3@&0=?FD,JS$%5@V09 88)O=&GT<;+&M8'=(7!
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MI]>._68Q!G""UZIJDWQAVAA@,7K+A$*7HQ?.\Q.9U6WD]=94^41F]&A-=8K
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MXO-JRQ4MH=I^F[AF%)45'< 7S&8PI&VCH+NVN"/![FCM=!D?W\Z"WDPLB6A
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ML1>- -I47?\X![6T4F%Z=JISVLNWC71,NY79$U2NH%?.AL0(4X7VZ*08&;C
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MBD>N$?SM?'4.9R_.9_FRP#$;\JMSJ+<D;:[E'$2\B84YXWSR2LET]Y+]UNK
M>P\>%S/CZ7<^E+"[J)WYX]U["IR6YXMO/TW/SJ[WC@M^A"[)1YM8$D Q5(F:
MQ513]SG04L2@G&QR(O(X6>-F6D:'7@/==; IUP/M=:?:5179S_AYOIRN+ECA
M"9W(D3.W#N7)?V'1<4V1?;$EZ"(!FMSM>H2F<3,MW6!P**UU ,#?YHO5!_B
M/T'Z.^;KY;1IM?'3MS_>_3HGTSNKHGOW>3Y;SHG&7]:EXXOI\OI" >2@ DB6
MBBE,:_#D7^O"BG<HM8/(^2Z=_?;&ZC#DCSM#HAM8CX"%#E; +D?LKZZG(P05
M@XN>2:2M14-MN%;G#W$MN9)!AX!-DCQ[43ER&6WC>+R=PD8.8QX07-DP=UE
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MGU![B"P;6E:6-F]#@4!6Q)M/',WM9I;3M\\X:ION\?:K_83>'79N]'"0AI8
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MNXO,.P#./9?#-@B+TFC@TM.^S70 ;ZV'Q(76QMH8L*>$BZ->8!VR0QTHZN[
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MM=UY\#3[US$A<9@L.W#"WR[2\I1BB7"VV<C?U3^H^MG$V(;[Q+*CR+I>!(F
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M9,LC\SEHQ?E?=,7UC*GGO.1>__M\?O;C>IKI^OW95UQ]_AH6>PK.*J&3)6<
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M>/^!6N5K54=/WZBS"R6)'(T!916M2J\CA1/% C'D!0M,*M4D AM,X30>U[%
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M:M9,[9CAQFZB']$%;%^W=,O#V':OF2^^C%S'].1[6M4U[<;@<>J<1!22"V[
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M0>^;#-]ZF*2)G9]15#X 1WO(OT,DO?[K&Z:+=/S3K7'-TDAK;&TFD3-9;)/
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MN25K;-:I3H>4/E$EYD\4V52\SQ#_SQ[J1P^];??VN/=F>LOJXDN1U4P#/^%
M.EPLV4*G:X-U.56<$3O+)*3LX@Z2BHYNV-7"ENZ\WARQ]7\[U^&T#0NPE?&[
MF\*I[:NC!0MN_"SI@;:I$9>^>BIU^.QK$([#1[#R'=0<O\%7\R$\1A!7;G7(
M Y].U=?P(9?_I.STOU!+ P04    " #X?JI2LE>;(%H(  "()P  %@   &EN
M;RTS,S$R,7@Q,'%E>#,Q,BYH=&WE6EMSV[82?N^O0)5I8\_H1DFN(MGQ3&H[
M4T\O\4E\)G.>.A"Q%#$&"18 )>O\^K,+4!?K4LMC)_%Q\Z"8!+#8R[??+DB>
M?'_^X>SZ/U<7+'698E?__OFWRS-6:[1:G[MGK=;Y]3G[Y?KWWUBOV8[8M>&Y
ME4[JG*M6Z^*/&JNESA7#5FLZG3:GW:8VX];UQQ:)ZK64UA::PHG:Z0G=P5_@
MXO2[D^\;#7:NXS*#W+'8 '<@6&EE/F:?!=@;UFA4L\YT,3-RG#K6:7<B]EF;
M&SGA8=Q)I^!T+N>D%:Y/6GZ3DY$6L],3(2=,BK<UV>^_2:)H$(ENDO1^&L";
M?G_4[0RB3G*40$\<_1FADBV<'M98-U/PMI;)O)$"[3_L=9K]H\(=3Z5PZ3!J
MMW^H^:FG)XG.'>YG<'WX,XC9$.;@UC6XDN-\Z$VJA:7SX5@K;8:OVO[?,8TT
M$IY)-1N^OI896/8'3-E'G?'\==UB&!H6C$S"1"O_"Z@3JN<OIT'E/LI1,H>Y
M"5&'E+ZX3>5(NA]?13^UC[M1L\/NZKUJ/C=C](#3Q7" LE<,B-'C8+Z1!6=@
MG$QDS F(3"?L[/T'=E4:6W)4QNG=!CT7"SY!7!K,(Y1X<1NG/!\#>Q<[]K%4
M8$-DHBYO1$<'<,AX+EAT)*JK9V\;M^R=T 6E]/];3 A/55ZT.P0LEP+[Q,V(
MYV ;'VX5S'R8<*33;N^=.%_<H-Y6@R[K[ K0G^Q7Q%F=Q3YK9F@3Q^0_>G.\
ME_J])I%>P85 =FXH2-RPTPM,Z ,G<X%!&S8Z'9KXC2R-FB%JF[^7+.438 8F
M$J:(2)=*R_XJN4&_J!G>+[3!>.;LO399E7CMQK\HPI>YGDC-KE)N,AY#Z9!P
M%/KQ,H]QNZ/!"_)?9Z?_?N86O8;^R6;L)M=3!6(,]>#&RGE"HR*YQD*.^W"9
M(U_-6)D[4P+:@:7=5WET*&<97AG)%4LX99%A.I.>'/R\C0DYQ& M-S.:DO$;
M\/FXD&GQGD!E<$OE6X0J86-IL"7 :3DN1TT$IL TE7'*;$D_R_53,% )(0,R
M:17V#M2&3*5+T4!;("G0[B2W0-6T0#,GN$RPT6S5#2\,$=V'(P)8(G/T.85O
MZ>.Z+U\:A\W*N,P3S+=0OV4>JU*@3(SCBD/KB %).5I@& A!A"REEA"IHF/7
MMD84"M^AUFE&J7 "XD)C\/QVUNL3<YNR1.FIG8/&P%A:9ZA8<;H9]$8MZRNQ
MMW-E-K1]8>'O[0S_]1U?O;95:*OB0JFC$VS-\!;Y[Y)Q SY2Z'DY4D >98#P
M&"EI4YI.TS*D#:(.NA;2QDK;$M<1H1BM0L@*HV,0>-NR XR0  QY",.]'52X
MO--&A:Y*4KN1!]#03HQ2>P5+(;:DU<.V3#:W3'!+LGT=:SB#*M2C"G*OW^P\
M+_SPPUWX.0>+G1YZT7/Q_<&N4YF(>6GW7T)\/0(,5[53J "Z-"@ \W@BK6<'
MG 6YET,=T9)75KG)@.(^_E4)6$:N7O$6#4KD&-3%:B6%/\K:<F2ED-SXQDN&
M0N79,B=)I:7BX1/'^DKCN03/RJB0\Z>".BNP19%QJ3A1()KEE5@6(5P12MIJ
M)<:_1D 3D:5P/8A'L=+S0]5H3U3MG=8;X-J?$/;&&.)R(@5!AUN=<^) ;A%V
MU)T0GK@1\]@BVB0?227=C,K2MFT)Z1X&/L*+ _"VRANH]K8RJ"A-@0BSOHS&
ML3;"*^#[G#'D6!T5 @U'P)_<: KV< %,B'19>(Y[47"*=\+I8L)5Z3.9? U)
M0D?#"7K);ND7L ;NP4GA<GOSX'&#"Y%/;&A11KITN_?>AS7Y8C90_Y7<W\&R
MT;RS\ZD P0?^1$QAIPU>3.C%;B8)OMV,$9UJJJ+O1]8@\ #FH&JCX[@T%(,5
M:K\C+]/6X1UZ(H)2+!X]Y\=6=K Q.4$ 81ZOS:O4Q%X7_/&+3F9YN=#E,&B2
M<KNH?<0 'G @/#5ZZRO:FN$AZP94=19;FU]_A$,>#:_GUSX?/5G[[)]>B#DF
MZ\L<)<I8Q<@R72G6#ZB &YT-*L6QKW':V$6Y\3=06(;G=0>PE01'&DL9C0B)
M.OGE!X@AY!Q+G(;_4U\U!SO\54I4V<.[S/V3-WOXC^F"Z2!+G8-_BHV*T=$B
MEH#!J4K%HAN= K\A[@^5V[._[SG\TY/YH?9!(:\:QW PVY+<7.!""XO<W@*/
MJD?!R1AI;"7JH?18K#NVS#!,Z"1O1L6=6P_^+["L[&Y0J7HD!M.HCNX'G_,8
M0/_0J8IT/="QS"=:38 X.>?CZMF9J6@"LD+I&>#H--6!&_@='&'<'UF>FGN_
M#;H3BWYGX?0MK\(6K\F>+""]O>(1?'^?02/MG,Z&!*45$Q?(6GLUX7P+7TD8
M(?C!-- <Q0L+P_D?QTC9A>*SH<R]5G[1\818'BMT)1)W6;Y-;+;#&T6'OG-B
M+K\:;OJAEA.;8[UFMSW8.=IN1CO'_E9JMQD-WCR]V &*[>XEMN4=$9R!7K4%
MS]_6NK7Y@@I\PTYQRZ*[D?+O5M=]'6+\]6G!!_4<4]R7M@42*^L?9A@EVK.R
MZW<^8U&[[E_-?T'3=F9L>Z7O^ZHO$+>[X\=7O?ZQ];^[RL#5W$U/JE]_+_4N
MKB\^?I'M]W0/^_4;&G]Y\6E73';]KGW-\0!2:A.\:\\_S?=SW9HW=MM4%4,J
MGF@2\X]#V5R])TC^+Y[G@_N^$_#^6+Y3W[.Q^%HTM5#?"QQ*AYO%>QATEDI(
MV/M%+_BA.H$^P;^#J_#P$*4NY5/+_V[Y?+':[G!7OK5\\[312OY=F[E];.[H
MM0^Z"AV^:!N&A_T3V/C$:PGP$,_E$CY"E)=N<\D]7X55O^$;-?^UW.G_ %!+
M P04    " #X?JI2@!I@^VD&  !H(@  %@   &EN;RTS,S$R,7@Q,'%E>#,R
M,2YH=&WM6FU3VS@0_GZ_0A?F*,PD?HM)R$N9X4(ZI2TE!^ET[M.-8LNQIH[E
M2C(A]^MO)=DD) 1"#P[HP3 >QY)6N\^^:+WK[J]'I[WAGX,^BN4D08,OOW\Z
M[J%*S;:_UGNV?30\0N^')Y^0;SDN&G*<"BHI2W%BV_W/%52)I<S:MCV=3JUI
MW6)\; _/;$7*MQ/&!+%"&58.NNH)7 D.#W[I_EJKH2,6Y!.22A1P@B4)42YH
M.D9?0R*^H5JMF-5CV8S3<2R1YW@N^LKX-WJ!S;BD,B$')9VN;7YW;;U)=\3"
MV4$WI!>(AF\KU&_M8[^)W2#R G^_X8V<P&M%WK[?;#2<UK[_EPM,VC#=K!%R
MEI"WE0E-:S%1^[=]SVKN9;(SI:&,VZ[C_%;14P^Z$4LE[,=AO;DU9%:(27(I
M:SBAX[2M1:J8I>5PP!+&VUN._NNHD5J$)S29M=\,Z80(])E,T1F;X/1-58 :
M:H)P&IF)@OY-@"=@3_^<&I:;0">A*2E%<#W%=/\RIB,JM[?<AM.I>Y:+KO.]
M*#[F8T! LJS= MH+ @2 ..%/)$&/<$DC&F!EB&B0<Y%CX$*R]9(\%];=??3%
M.K=Z%CHG@6+?J,&M[SG5Y\_]H4"'(<N4M[XHU*]AW7(:B$5(Q@2=8S["*1&U
MT\N$S-!A(-6(YSC>_7R"IB&(U_9\'2(>74C_1B&/4Q2P-#6BHBF5L9;Q>XXY
M()_,$"<9XUK"XY1=4(8&,>83')!<@B\EH@K/ POMJ%7;6_N>YW1Z;)+A=*9_
MN9U=!(3?,3XIC-:I_8$BQA>W020-51@_P3R(4=VMZKA=15B@B"9@-U=\@4YR
M#D<) (#3$/4O@QBG8P(1?S*A0B@9X%_-#.%X0#'A!#A?9.Y,RU/R5D4$PY:%
M9G/0"!=@>"2L(FKH!#C#P7S'1>J@0!5.@+\12=BTJK<;S5!@(@T!;+(%@[_5
MBT%47#C)XIK[VV 5QK%>&U.!OJ5L"@".R?;6WGYG(_OT+75@93A4*JDE)'IJ
M$]UQ=]$09#::0U&>@%D&8&.)4LJ5:7#R/:><J%-=*#"60-[!N^863,_=VPG+
M7]&R75W95 &JVZK[@%ZKH_7_,A'T#((T!<>;F ,0O%YBF!F6AE["BZER^XP3
MH9#4?H"3!,$RV!PG@+/( %I1U:LBFN(T4,^!8*B3/(T3S,H3HPB6$:[W%*7U
M%@'"6D7S@?'Q-X+'6,)=FATQ*=FDK52[H.N]-1F.Q*.$E!1&C$-@J8$X"<X$
M:9<WG9"*+,&S-DTU5WI1YT*%#PBM!4G8I4@?6RW+:[14!BDA;91A2;Y(+BV=
M7-HR7!WSK;K?6COJ6.[:L5NI-BRWN?<X9!L;D;4U$ 8, %6 5;VMU"OE@L(%
MVUYVB=SKBM*Y]#+41L7_O9/JUX(C<# =I:\,L9#^?H*I</.LY#K!,^0ZYDA_
M1-&>-(&\6?+M+;_9$?IJ0LSJ]8.%/I2@/"B+S8TX/#WO#]X_ROX;0H0^/J'T
MQR?KU++NNO2N?H\0Y"ACKOPT3KT$QWJABJ-/'94@$Q(LH2$J^7L)OMZZZUU1
MXZ'\F F2Q>@CG3S=F^T5LYI@FTK8+-B _0&D:U2]C591+Z8D@B08$F))+P@Z
MC2(*+S0ZJ3N"_#J0C&^8*CFF]O5LI=X9< JY:P;)ZXJ\N^M=O>2[I&7R^@=S
M_Q^=^IH+/?^P^9H+W9(+#9XP%>@/^V?_WSRH?_Z:"+TF0@^2" V(JN=^I$2\
MO"S(I#[OKBI:12KP\V4[<Q%55G<8!"Q/I2K WY7\V+I"M5*ONZ&/N;;W\7A^
MNA:/FZM^JB :,4[&3$D>7.L.4H%&1#V.<IY2$9-0.2Q1==%_59S7> /QE,D?
MZ&Q@@3)L>C%JQ5)/A7'=1$#P%H*Y:D^$5 0)$SF'V[)MOK _& /C&>.F@:$:
M/1'A) U4F1B$P^E,L:A N*OWH]LFRT+,J^=UT]V _4/55V$K4V^JN%]?0WE1
M=589.LQ0S(U)2CB8\%P.A5$"A'(,M*[5MT4>Q(4T%CI$IL4#G% P3""A 058
MIL"0)#!= B@:KZ*IH %:47>,E9G _(P#.L"H,HJ%^K9&>TJ3!&8!I8(=H+0\
M9VYE!8%-VEP<42D4JU&$\@R>*%Z)D&NKZK=[Z=('"QDS7VRT.4FP@GWE$X;Y
MP6;"WWP)'H&SY')UR1U?/117\PV&_AKDX!]02P$"% ,4    " #X?JI2R'>[
MH9FP @"AB!@ $               @ $     :6YO+3(P,C$P,S,Q+FAT;5!+
M 0(4 Q0    ( /A^JE(Q6@(*2!,  -70   0              "  <>P @!I
M;F\M,C R,3 S,S$N>'-D4$L! A0#%     @ ^'ZJ4LO7:B-E)   OWT! !0
M             ( !/<0" &EN;RTR,#(Q,#,S,5]C86PN>&UL4$L! A0#%
M  @ ^'ZJ4K]DRHE7>0  HB<% !0              ( !U.@" &EN;RTR,#(Q
M,#,S,5]D968N>&UL4$L! A0#%     @ ^'ZJ4L$@5?$>*08 AP4' !,
M         ( !76(# &EN;RTR,#(Q,#,S,5]G,2YJ<&=02P$"% ,4    " #X
M?JI2<GN%QZP! 0".?0H %               @ &LBPD :6YO+3(P,C$P,S,Q
M7VQA8BYX;6Q02P$"% ,4    " #X?JI2>,N,^:V:  !5XP8 %
M    @ &*C0H :6YO+3(P,C$P,S,Q7W!R92YX;6Q02P$"% ,4    " #X?JI2
M<"SAJU((  "M)@  %@              @ %I* L :6YO+3,S,3(Q>#$P<65X
M,S$Q+FAT;5!+ 0(4 Q0    ( /A^JE*R5YL@6@@  (@G   6
M  "  >\P"P!I;F\M,S,Q,C%X,3!Q97@S,3(N:'1M4$L! A0#%     @ ^'ZJ
M4H :8/MI!@  :"(  !8              ( !?3D+ &EN;RTS,S$R,7@Q,'%E
>>#,R,2YH=&U02P4&      H "@"1 @  &D +

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
